METHODS 0
Ten 0
healthy 0
volunteers 0
were 0
enrolled 0
in 0
a 0
randomized 0
, 0
double-blinded 0
, 0
placebo-controlled 0
, 0
crossover 0
trial 0
in 0
which 0
they 0
received 0
an 0
infusion 0
of 0
saline 0
, 0
remifentanil 0
, 0
or 0
alfentanil 0
for 0
120 0
min 0
. 0

The 0
age- 0
and 0
weight-adjusted 0
infusions 0
( 0
determined 0
with 0
STANPUMP 0
, 0
a 0
computer 0
modeling 0
software 0
package 0
) 0
were 0
given 0
to 0
achieve 0
three 0
predicted 0
constant 0
plasma 0
levels 0
for 0
40 0
min 0
each 0
of 0
remifentanil 0
( 0
0.75 0
, 0
1.5 0
, 0
and 0
3 0
ng/ml 0
) 0
and 0
alfentanil 0
( 0
16 0
, 0
32 0
, 0
and 0
64 0
ng/ml 0
) 0
. 0

Mood 0
forms 0
and 0
psychomotor 0
tests 0
were 0
completed 0
, 0
and 0
miosis 0
was 0
assessed 0
, 0
during 0
and 0
after 0
the 0
infusions 0
. 0

In 0
addition 0
, 0
analgesia 0
was 0
tested 0
at 0
each 0
dose 0
level 0
using 0
a 0
cold-pressor 0
test 0
. 0

RESULTS 0
Remifentanil 0
had 0
prototypic B-MENTAL
micro-like I-MENTAL
opioid I-MENTAL
subjective I-MENTAL
effects I-MENTAL
, 0
impaired B-MENTAL
psychomotor I-MENTAL
performance I-MENTAL
, 0
and 0
produced 0

A 0
double-blind 0
placebo 0
controlled 0
trial 0
of 0
piracetam 0
added 0
to 0
risperidone 0
in 0
patients 0
with 0
autistic 0
disorder 0
. 0

It 0
has 0
been 0
reported 0
that 0
autism 0
is 0
a 0
hypoglutamatergic 0
disorder 0
. 0

Therefore 0
, 0
it 0
was 0
of 0
interest 0
to 0
assess 0
the 0
efficacy 0
of 0
piracetam 0
, 0
a 0
positive 0
modulator 0
of 0
AMPA-sensitive 0
glutamate 0
receptors 0
in 0
autistic 0
disorder 0
. 0

About 0
40 0
children 0
between 0
the 0
ages 0
three 0
and 0
11 0
years 0
( 0
inclusive 0
) 0
with 0
a 0
DSM 0
IV 0
clinical 0
diagnosis 0
of 0
autism 0
and 0
who 0
were 0
outpatients 0
from 0
a 0
specialty 0
clinic 0
for 0
children 0
were 0
recruited 0
. 0

The 0
children 0
presented 0
with 0
a 0
chief 0
complaint 0
of 0
severely 0
disruptive 0
symptoms 0
related 0
to 0
autistic 0
disorder 0
. 0

Patients 0
were 0
randomly 0
allocated 0
to 0
piracetam 0
+ 0
risperidone 0
( 0
Group 0
A 0
) 0
or 0
placebo 0
+ 0
risperidone 0
( 0
Group 0
B 0
) 0
for 0
a 0
10-week 0
, 0
double-blind 0
, 0
placebo-controlled 0
study 0
. 0

The 0
dose 0
of 0
risperidone 0
was 0
titrated 0
up 0
to 0
2 0
mg/day 0
for 0
children 0
between 0
10 0
and 0
40 0
kg 0
and 0
3 0
mg/day 0
for 0
children 0
weighting 0
above 0
40 0
kg 0
. 0

The 0
dose 0
of 0
piracetam 0
was 0
titrated 0
up 0
to 0
800 0
mg/day 0
. 0

Patients 0
were 0
assessed 0
at 0
baseline 0
and 0
after 0
2 0
, 0
4 0
, 0
6 0
, 0
8 0
and 0
10 0
weeks 0
of 0
starting 0
medication 0
. 0

The 0
measure 0
of 0
the 0
outcome 0
was 0
the 0
Aberrant B-OTHER
Behavior I-OTHER
Checklist-Community I-OTHER
( I-OTHER
ABC-C I-OTHER
) I-OTHER
Rating I-OTHER
Scale 0
( 0
total 0
score 0
) 0
. 0

The 0
ABC-C B-OTHER
Rating I-OTHER
Scale I-OTHER
scores 0
improved 0
with 0
piracetam 0
. 0

The 0
difference 0
between 0
the 0
two 0
protocols 0
was 0
significant 0
as 0
indicated 0
by 0
the 0
effect 0
of 0
group 0
, 0
the 0
between 0
subjects 0
factor 0
( 0
F 0
= 0
5.85 0
, 0
d.f 0
. 0

= 0
1 0
, 0
P 0
= 0
0.02 0
) 0
. 0

The 0
changes 0
at 0
the 0
endpoint 0
compared 0
with 0
baseline 0
were 0
: 0
-11.90 0
+/- 0
3.79 0
( 0
mean 0
+/- 0
SD 0
) 0
and 0
-5.15 0
+/- 0
3.04 0
for 0
group 0
A 0
and 0
B 0
respectively 0
. 0

A 0
significant 0
difference 0
was 0
observed 0
on 0
the 0
change 0
in 0
scores B-OTHER
in I-OTHER
the I-OTHER
ABC-C I-OTHER
Rating I-OTHER
Scale I-OTHER
in 0
week 0
10 0
compared 0
with 0
baseline 0
in 0
the 0
two 0
groups 0
( 0
t 0
= 0
6.017 0
, 0
d.f 0
. 0

= 0
38 0
, 0
P 0
< 0
0.0001 0
) 0
. 0

The 0
results 0
suggest 0
that 0
a 0
combination 0
of 0
atypical 0
antipsychotic 0
medications 0
and 0
a 0
glutamate 0
agent 0
such 0
as 0
piracetam 0
, 0
might 0
have 0
increase 0
synergistic 0
effects 0
in 0
the 0
treatment 0
of 0
autism 0
. 0

Use 0
of 0
an 0
inspiratory 0
impedance 0
threshold 0
device 0
on 0
a 0
facemask 0
and 0
endotracheal 0
tube 0
to 0
reduce 0
intrathoracic B-PHYSICAL
pressures I-PHYSICAL
during 0
the 0
decompression 0
phase 0
of 0
active 0
compression-decompression B-PHYSICAL
cardiopulmonary I-PHYSICAL
resuscitation I-PHYSICAL
. 0

INTRODUCTION 0
Use 0
of 0
an 0
inspiratory 0
impedance 0
threshold 0
device 0
( 0
ITD 0
) 0
significantly 0
increases 0
coronary 0
perfusion 0
pressures 0
and 0
survival 0
in 0
patients 0
ventilated 0
with 0
an 0
endotracheal 0
tube 0
( 0
ETT 0
) 0
during 0
active 0
compression-decompression 0
cardiopulmonary 0
resuscitation 0
. 0

We 0
tested 0
the 0
hypothesis 0
that 0
the 0
ITD 0
could 0
lower 0
intratracheal 0
pressures 0
when 0
attached 0
to 0
either 0
a 0
facemask 0
or 0
ETT 0
. 0

METHODS 0
An 0
active 0
and 0
sham 0
ITD 0
were 0
randomly 0
applied 0
first 0
to 0
a 0
facemask 0
and 0
then 0
to 0
an 0
ETT 0
during 0
active 0
compression-decompression 0
cardiopulmonary 0
resuscitation 0
in 0
13 0
out-of-hospital 0
cardiac 0
arrest 0
patients 0
in 0
a 0
randomized 0
, 0
double-blinded 0
, 0
prospective 0
clinical 0
trial 0
. 0

The 0
compression-to-bag-valve 0
ventilation 0
ratio 0
was 0
15:2 0
. 0

Airway 0
pressures 0
( 0
surrogate 0
for 0
intrathoracic 0
pressure 0
) 0
were 0
measured 0
with 0
a 0
pressure 0
transducer 0
. 0

A 0
sham 0
and 0
an 0
active 0
ITD 0
were 0
used 0
for 0
1 0
min 0
each 0
in 0
a 0
randomized 0
order 0
, 0
first 0
on 0
a 0
facemask 0
and 0
then 0
on 0
an 0
ETT 0
. 0

Statistical 0
analyses 0
were 0
made 0
using 0
Friedman 0
's 0
and 0
Wilcoxon 0
's 0
rank-sum 0
tests 0
. 0

RESULTS 0
For 0
the 0
primary 0
end 0
point 0
, 0
mean 0
+/- B-PHYSICAL
sd I-PHYSICAL
maximum I-PHYSICAL
negative 0
intrathoracic B-PHYSICAL
pressures B-PHYSICAL
( 0
mm 0
Hg 0
) 0
during 0
the 0
decompression 0
phase 0
of 0
cardiopulmonary B-PHYSICAL
resuscitation I-PHYSICAL
were 0
-1.0 0
+/- 0
0.73 0
mm 0
Hg 0
with 0
a 0
sham 0
vs. 0
-4.6 0
+/- 0
3.7 0
mm 0
Hg 0
with 0
an 0
active 0
ITD 0
on 0
the 0
facemask 0
( 0
p 0
= 0
.003 0
) 0
and 0
-1.3 0
+/- 0
1.3 0
mm 0
Hg 0
with 0
a 0
sham 0
ITD 0
vs. 0
-7.3 0
+/- 0
4.5 0
mm 0
Hg 0
with 0
an 0
active 0
ITD 0
on 0
an 0
ETT 0
( 0
p 0
= 0
.0009 0
) 0
. 0

Decompression B-PHYSICAL
phase 0

Effect 0
of 0
spinal 0
versus 0
general 0
anesthesia 0
on 0
bladder B-PHYSICAL
compliance I-PHYSICAL
and 0
intraabdominal B-PHYSICAL
pressure I-PHYSICAL
during 0
transurethral 0
procedures 0
. 0

STUDY 0
OBJECTIVE 0
To 0
evaluate 0
the 0
influence 0
of 0
spinal 0
versus 0
general 0
anesthesia 0
on 0
bladder B-PHYSICAL
compliance I-PHYSICAL
and 0
intraabdominal B-PHYSICAL
pressure I-PHYSICAL
in 0
elderly 0
males 0
undergoing 0
elective 0
transurethral 0
resection 0
of 0
the 0
prostate 0
. 0

DESIGN 0
Prospective 0
, 0
randomized 0
, 0
open-label 0
study 0
. 0

SETTING 0
Teaching 0
hospital 0
. 0

PATIENTS 0
21 0
ASA 0
physical 0
status 0
I 0
, 0
II 0
, 0
and 0
III 0
patients 0
at 0
least 0
18 0
years 0
of 0
age 0
, 0
undergoing 0
transurethral 0
surgery 0
. 0

INTERVENTIONS 0
According 0
to 0
a 0
computer-generated 0
randomization 0
schedule 0
, 0
patients 0
were 0
allocated 0
to 0
one 0
of 0
two 0
groups 0
. 0

In 0
Group 0
Spinal 0
( 0
S 0
) 0
, 0
10 0
mg 0
of 0
hyperbaric 0
tetracaine 0
was 0
administered 0
intrathecally 0
. 0

In 0
Group 0
General 0
Anesthesia 0
( 0
GA 0
) 0
, 0
patients 0
received 0
, 0
fentanyl 0
intravenous 0
( 0
i.v 0
. 0

1 0
to 0
2 0
micrograms/kg 0
and 0
propofol 0
i.v 0
. 0

1.0 0
to 0
2.0 0
mg/kg 0
for 0
induction 0
of 0
anesthesia 0
. 0

Thereafter 0
, 0
a 0
laryngeal 0
mask 0
airway 0
was 0
inserted 0
and 0
, 0
with 0
spontaneous 0
ventilation 0
, 0
anesthesia 0
was 0
maintained 0
by 0
administering 0
isoflurane 0
( 0
end-tidal 0
0.7 0
% 0
to 0
1.2 0
% 0
) 0
and 0
70 0
% 0
nitrous 0
oxide 0
( 0
N2O 0
) 0
in 0
oxygen 0
. 0

Intraabdominal 0
pressure 0
and 0
bladder 0
compliance 0
were 0
recorded 0
prior 0
to 0
the 0
induction 0
of 0
anesthesia 0
and 0
immediately 0
before 0
the 0
onset 0
of 0
the 0
surgical 0
procedure 0
. 0

MEASUREMENTS 0
AND 0
MAIN 0
RESULTS 0
The 0
two 0
groups 0
were 0
demographically 0
comparable 0
. 0

In 0
Group 0
S 0
, 0
mean 0
bladder 0
compliance 0
was 0
significantly 0
( 0
p 0
= 0
0.003 0
) 0
higher 0
and 0
mean 0
intraabdominal B-PHYSICAL
pressure I-PHYSICAL
significantly 0
lower 0
( 0
p 0
= 0
0.007 0
) 0
when 0
compared 0
to 0
baseline 0
preanesthetic 0
values 0
. 0

In 0
Group 0
GA 0
, 0
mean 0
intraabdominal B-PHYSICAL
pressure I-PHYSICAL
significantly 0
( 0
p 0
= 0
0.006 0
) 0
decreased 0
when 0
compared 0
to 0
baseline 0
preanesthetic 0
recordings 0
. 0

Following 0
the 0
induction 0
of 0
general 0
anesthesia 0
, 0
a 0
small 0
change 0
in 0
bladder B-PHYSICAL
compliance I-PHYSICAL
was 0
noted 0
. 0

However 0
, 0
statistical 0
significance 0
was 0
not 0
reached 0
. 0

Data 0
were 0
analyzed 0
and 0
compared 0
using 0
Student 0
's 0
t-test 0
( 0
p 0
< 0
0.05 0
was 0
considered 0
statistically 0
significant 0
) 0
. 0

CONCLUSION 0
Both 0
spinal 0
and 0
general 0
anesthesia 0
induced 0
a 0
significant 0
decrease 0
in 0
intraabdominal 0
pressure 0
. 0

While 0
both 0
techniques 0
were 0
associated 0
with 0
an 0
increase 0
in 0
bladder 0
compliance 0
, 0
statistical 0
significance 0
was 0
demonstrated 0
only 0
in 0
the 0
spinal 0
anesthesia 0
treatment 0
group 0
. 0

The 0
effects 0
of 0
a 0
24-h 0
psychological 0
training 0
program 0
on 0
attitudes B-MENTAL
, 0
communication B-MENTAL
skills I-MENTAL
and 0
occupational B-MENTAL
stress I-MENTAL
in 0
oncology 0
: 0
a 0
randomised 0
study 0
. 0

The 0
usefulness 0
of 0
psychological 0
training 0
programs 0
( 0
P.T.P 0
. 0
) 0

in 0
health 0
care 0
settings 0
devoted 0
to 0
cancer 0
care 0
is 0
beginning 0
to 0
be 0
recognised 0
but 0
their 0
content 0
, 0
form 0
and 0
effectiveness 0
need 0
further 0
investigation 0
. 0

Seventy-two 0
oncology 0
nurses 0
were 0
randomly 0
assigned 0
to 0
a 0
24-h 0
P.T.P 0
. 0

or 0
to 0
a 0
waiting 0
list 0
period 0
. 0

Attitudes B-MENTAL
were 0
assessed 0
by 0
a 0
semantic B-MENTAL
differential I-MENTAL
questionnaire 0
, 0
occupational B-MENTAL
stress I-MENTAL
was 0
assessed 0
by 0
the 0
Nursing B-MENTAL
Stress 0
Scale B-MENTAL
and 0
communication B-MENTAL
skills I-MENTAL
were 0
assessed 0
by 0
standardised 0
videotaped 0
role-playing B-MENTAL
exercises B-MENTAL
. 0

These 0
were 0
used 0
to 0
compare 0
trained 0
( 0
T.S 0
. 0
) 0

and 0
control 0
subjects 0
( 0
C.S. 0
) 0
. 0

The 0
results 0
show 0
a 0
significant 0
training 0
effect 0
on 0
attitudes B-MENTAL
( 0
P 0
= 0
0.05 0
) 0
, 0
especially 0
on 0
those 0
related 0
to 0

Surgery 0
of 0
aphakic 0
retinal 0
detachment 0
. 0

In 0
a 0
prospective 0
study 0
84 0
patients 0
with 0
aphakic 0
retinal 0
detachment 0
were 0
treated 0
either 0
by 0
local 0
scleral 0
buckling 0
alone 0
or 0
combined 0
with 0
an 0
encirclement 0
. 0

The 0
rate 0
of B-PHYSICAL
surgical I-PHYSICAL
reattachment I-PHYSICAL
of I-PHYSICAL
the I-PHYSICAL

Correlation 0
between 0
in 0
vivo 0
humoral 0
and 0
in 0
vitro 0
cellular 0
immune 0
responses 0
following 0
immunization 0
with 0
hepatitis 0
B 0
surface 0
antigen 0
( 0
HBsAg 0
) 0
vaccines 0
. 0

To 0
study 0
the 0
regulation 0
of 0
the 0
human 0
immune 0
response 0
to 0
hepatitis 0
B 0
surface 0
antigen 0
( 0
HBsAg 0
) 0
we 0
have 0
carefully 0
monitored 0
the 0
in 0
vivo 0
humoral 0
and 0
in 0
vitro 0
cellular 0
immune 0
responses 0
to 0
HBsAg 0
in 0
50 0
subjects 0
receiving 0
four 0
doses 0
of 0
hepatitis 0
B 0
vaccine 0
according 0
to 0
a 0
0 0
, 0
1 0
, 0
2 0
, 0
12 0
month 0
vaccination 0
scheme 0
. 0

Twenty-three 0
subjects 0
were 0
given 0
a 0
plasma-derived 0
vaccine 0
( 0
Hevac 0
B 0
) 0
and 0
27 0
received 0
a 0
recombinant 0
HBsAg 0
vaccine 0
( 0
yeast-derived 0
; 0
Engerix-B 0
) 0
. 0

The 0
humoral 0
and 0
cellular 0
immune 0
responses 0
were 0
measured 0
before 0
vaccination 0
( 0
day 0
0 0
) 0
; 0
6 0
days 0
after 0
the 0
second 0
dose 0
( 0
day 0
36 0
) 0
; 0
6 0
days 0
( 0
day 0
66 0
) 0
, 0
2 0
months 0
( 0
day 0
120 0
) 0
and 0
10 0
months 0
( 0
day 0
365 0
) 0
after 0
the 0
third 0
dose 0
and 0
1 0
month 0
after 0
the 0
fourth 0
dose 0
( 0
day 0
395 0
) 0
. 0

Based 0
on 0
the 0
kinetics 0
of 0
the 0
humoral 0
immune 0
responses 0
, 0
the 0
vaccinees 0
could 0
be 0
classified 0
into 0
fast 0
, 0
intermediate 0
and 0
slow/non-responders 0
. 0

Based 0
on 0
the 0
magnitude 0
of 0
the 0
immune 0
response 0
( 0
anti-HBs 0
titre 0
) 0
on 0
day 0
395 0
, 0
the 0
vaccinees 0
could 0
be 0
divided 0
into 0
high 0
( 0
> 0
or 0
= 0
2000 0
U 0
l-1 0
) 0
and 0
low 0
( 0
< 0
or 0
= 0
2000 0
U 0
l-1 0
) 0
responders 0
. 0

A 0
close 0
correlation 0
between 0
the 0
kinetics 0
and 0
the 0
magnitude 0
of 0
the 0
humoral B-PHYSICAL
immune I-PHYSICAL
response I-PHYSICAL
was 0
observed 0
. 0

The 0
in 0
vivo B-PHYSICAL
anti-HBs I-PHYSICAL
response I-PHYSICAL
was 0
measured 0
using 0
commercially 0
available 0
immunoradiometric 0
assays 0
. 0

The 0
in 0
vitro B-PHYSICAL
cellular I-PHYSICAL
immune I-PHYSICAL
response I-PHYSICAL
was 0
measured 0
using 0
an 0
HBsAg-specific 0
lymphoproliferation 0
assay 0
. 0

Because 0
of 0
interassay 0
variability 0
the 0
results 0
were 0
considered 0
as 0
dichotomous B-OTHER
variables I-OTHER
( 0
proliferation 0
versus 0
non-proliferation 0
) 0
for 0
further 0
data 0
analysis 0
. 0

A 0
statistically 0
significant 0
correlation 0
was 0
observed 0
between 0
the 0
kinetics 0
and 0
magnitude 0
of 0
the 0
humoral 0
immune 0
response 0
on 0
the 0
one 0
hand 0
and 0
the 0
in 0
vitro 0
anti-HBs 0
response 0
on 0
the 0
other 0
hand 0
. 0
( 0

ABSTRACT 0
TRUNCATED 0
AT 0
250 0
WORDS 0
) 0

Salmeterol 0
plus 0
fluticasone 0
propionate 0
versus 0
fluticasone 0
propionate 0
plus 0
montelukast 0
: 0
a 0
randomised 0
controlled 0
trial 0
investigating 0
the 0
effects 0
on 0
airway B-PHYSICAL
inflammation I-PHYSICAL
in 0
asthma 0
. 0

BACKGROUND 0
Few 0
studies 0
have 0
compared 0
treatment 0
strategies 0
in 0
patients 0
with 0
asthma 0
poorly 0
controlled 0
on 0
low 0
dose 0
inhaled 0
corticosteroids 0
, 0
and 0
little 0
is 0
known 0
about 0
the 0
effects 0
of 0
different 0
treatments 0
on 0
airway 0
inflammation 0
. 0

In 0
this 0
double-blind 0
, 0
placebo-controlled 0
, 0
parallel 0
group 0
study 0
, 0
we 0
compared 0
the 0
effects 0
of 0
salmeterol 0
plus 0
fluticasone 0
propionate 0
( 0
FP 0
) 0
( 0
Seretide 0
; 0
SFC 0
) 0
and 0
FP 0
plus 0
montelukast 0
( 0
FP/M 0
) 0
on 0
sputum B-PHYSICAL
inflammatory I-PHYSICAL
markers I-PHYSICAL
, 0
airway B-PHYSICAL
responsiveness I-PHYSICAL
, 0
lung B-PHYSICAL
function I-PHYSICAL
, 0
and 0
symptoms B-PHYSICAL
in 0
adult 0
asthmatics 0
. 0

METHODS 0
Sixty-six 0
subjects 0
were 0
randomised 0
to 0
SFC 0
or 0
FP/M 0
for 0
12 0
weeks 0
. 0

The 0
primary 0
outcome 0
was 0
changes 0
in 0
neutrophil 0
, 0
eosinophil 0
, 0
macrophage 0
, 0
lymphocyte 0
, 0
and 0
epithelial 0
cell 0
levels 0
in 0
induced 0
sputum 0
. 0

Additional 0
outcomes 0
included 0
the 0
change 0
in 0
other 0
sputum 0
markers 0
of 0
airway B-PHYSICAL
inflammation I-PHYSICAL
, 0
airway B-PHYSICAL
responsiveness I-PHYSICAL
, 0
symptom B-PHYSICAL
control I-PHYSICAL
, 0
and 0
lung B-PHYSICAL
function I-PHYSICAL
. 0

RESULTS 0
Both 0
treatments 0
had 0
no 0
significant 0
effect 0
on 0
induced 0
sputum B-PHYSICAL
inflammatory I-PHYSICAL
cells 0
, 0
although 0
there 0
was 0
a 0
trend 0
for 0
a 0
reduction 0
in 0
sputum B-PHYSICAL
eosinophils I-PHYSICAL
. 0

Both 0
treatments 0
significantly 0
improved 0
airway B-PHYSICAL
responsiveness I-PHYSICAL
, 0
whereas 0
SFC 0
generally 0
led 0
to 0
greater 0
improvements 0
in 0
symptom B-PHYSICAL
control I-PHYSICAL
and 0
lung B-PHYSICAL
function I-PHYSICAL
than 0
FP/M 0
. 0

FP/M 0
led 0
to 0
significantly 0
greater 0
reductions 0
in 0
sputum B-PHYSICAL
cysteinyl I-PHYSICAL
leukotrienes I-PHYSICAL
than 0
SFC 0
( 0
treatment 0
ratio 0
1.80 0
; 0
95 0
% 0
CI 0
1.09 0
, 0
2.94 0
) 0
. 0

CONCLUSION 0
Both 0
treatments 0
led 0
to 0
similar 0
control 0
of 0
eosinophilic B-PHYSICAL
airway I-PHYSICAL
inflammation I-PHYSICAL
, 0
although 0
PEF 0
and 0
symptom 0
control 0
were 0
better 0
with 0
SFC 0
. 0

STUDY 0
NUMBER 0
: 0
SAM40030 0
( 0
SOLTA 0
) 0
. 0

The 0
value-congruence 0
model 0
of 0
memory 0
for 0
emotional B-MENTAL
experiences I-MENTAL
: 0
an 0
explanation 0
for 0
cultural 0
differences 0
in 0
emotional 0
self-reports 0
. 0

In 0
3 0
studies 0
, 0
the 0
authors 0
found 0
support 0
for 0
the 0
value-congruence 0
model 0
that 0
accounts 0
for 0
cultural 0
variations 0
in 0
memory 0
for 0
emotional B-MENTAL
experiences I-MENTAL
. 0

In 0
Study 0
1 0
, 0
the 0
authors 0
found 0
that 0
in 0
the 0
made-in-the-U.S. 0
scenario 0
condition 0
, 0
European 0
Americans 0
were 0
more 0
accurate 0
than 0
were 0
Asian 0
Americans 0
in 0
their 0
retrospective B-MENTAL
frequency 0
judgments B-MENTAL
of I-MENTAL
emotions B-MENTAL
. 0

However 0
, 0
in 0
the 0
made-in-Japan 0
scenario 0
condition 0
, 0
European 0
Americans 0
were 0
less 0
accurate 0
than 0
were 0
Asian 0
Americans 0
. 0

In 0
Study 0
2 0
, 0
the 0
authors 0
demonstrated 0
that 0
value 0
orientation 0
mediates 0
the 0
CulturexType B-MENTAL
of B-MENTAL
Event 0
congruence B-MENTAL
effect 0
. 0

In 0
Study 0
3 0
( 0
a 0
daily 0
event 0
sampling 0
study 0
) 0
, 0
the 0
authors 0
showed 0
that 0
the 0

Randomized 0
clinical 0
trial 0
comparing 0
laparoscopic 0
and 0
open 0
surgery 0
in 0
patients 0
with 0
rectal 0
cancer 0
. 0

BACKGROUND 0
The 0
laparoscopic 0
treatment 0
of 0
rectal 0
cancer 0
is 0
controversial 0
. 0

This 0
study 0
compared 0
surgical 0
outcomes 0
after 0
laparoscopic 0
and 0
open 0
approaches 0
for 0
mid 0
and 0
low 0
rectal 0
cancers 0
. 0

METHODS 0
Some 0
204 0
patients 0
with 0
mid 0
and 0
low 0
rectal 0
adenocarcinomas 0
were 0
allocated 0
randomly 0
to 0
open 0
( 0
103 0
) 0
or 0
laparoscopic 0
( 0
101 0
) 0
surgery 0
. 0

The 0
surgical 0
team 0
was 0
the 0
same 0
for 0
both 0
procedures 0
. 0

Most 0
patients 0
had 0
stage 0
II 0
or 0
III 0
disease 0
, 0
and 0
received 0
neoadjuvant 0
therapy 0
with 0
oral 0
capecitabine 0
and 0
50-54 0
Gy 0
external 0
beam 0
radiotherapy 0
. 0

RESULTS 0
Sphincter-preserving 0
surgery 0
was 0
performed 0
in 0
78.6 0
and 0
76.2 0
per 0
cent 0
of 0
patients 0
in 0
the 0
open 0
and 0
laparoscopic 0
groups 0
respectively 0
. 0

Blood B-ADVERSE-EFFECTS
loss I-ADVERSE-EFFECTS
was 0
significantly 0
greater 0
for 0
open 0
surgery 0
( 0
P 0
< 0
0.001 0
) 0
and 0
operating B-OTHER
time I-OTHER
was 0
significantly 0
greater 0
for 0
laparoscopic 0
surgery 0
( 0
P 0
= 0
0.020 0
) 0
, 0
and 0
return 0
to 0
diet 0
and 0
hospital B-OTHER
stay I-OTHER
were 0
longer 0
for 0
open 0
surgery 0
. 0

Complication B-ADVERSE-EFFECTS
rates I-ADVERSE-EFFECTS
, 0
and 0

[ 0
Improving 0
wound B-PHYSICAL
healing I-PHYSICAL
after 0
nose 0
surgery 0
by 0
combined 0
administration 0
of 0
xylometazoline 0
and 0
dexpanthenol 0
] 0
. 0

BACKGROUND 0
The 0
aim 0
of 0
this 0
study 0
was 0
the 0
examination 0
of 0
efficacy 0
and 0
tolerability B-OTHER
of 0
an 0
application-form 0
of 0
the 0
new 0
combination 0
of 0
Xylometazoline 0
with 0
Dexpanthenol 0
( 0
Nasic 0
) 0
versus 0
Xylometazoline 0
alone 0
. 0

PATIENTS 0
AND 0
METHODS 0
Randomized 0
verum 0
controlled 0
parallel-group-comparison 0
of 0
two 0
weeks 0
treatment 0
of 0
a 0
nasal-spray 0
. 0

61 0
inpatients 0
with 0
the 0
diagnosis 0
Rhinitis 0
following 0
nasal 0
operation 0
were 0
included 0
in 0
this 0
study 0
and 0
30 0
patients 0
were 0
treated 0
with 0
verum 0
and 0
placebo 0
each 0
. 0

The 0
assessment 0
of 0
nasal-breathing-resistance B-PHYSICAL
according B-OTHER
to I-OTHER
scores I-OTHER
was 0
defined 0
as 0
target-parameter 0
. 0

Confirmatory 0
statistical 0
analysis 0
was 0
carried 0
out 0
according 0
to 0
Wilcoxon-Mann-Whitney-U 0
two-sided 0
at 0
alpha 0
< 0
or 0
= 0
0.05 0
. 0

MAIN 0
OUTCOME 0
MEASURE 0
The 0
superiority 0
of 0
the 0
combination 0
of 0
Xylometazoline-Dexpanthenol 0
nasal-spray 0
versus 0
Xylometazoline 0
nasal 0
spray 0
could 0
be 0
proven 0
for 0
the 0
target-parameter 0
as 0
clinically 0
relevant 0
and 0
statistically 0
significant 0
. 0

The 0
clinically B-OTHER
proven I-OTHER
efficacy I-OTHER
is 0
emphasized 0
by 0
good 0
tolerability B-OTHER
of 0
both 0
treatments 0
. 0

Due 0
to 0
easy 0
handling 0
of 0
the 0
nasal-spray 0
a 0
good 0
compliance B-OTHER
was 0
confirmed 0
. 0

CONCLUSION 0
Distinct 0
improvement B-PHYSICAL
of I-PHYSICAL
symptoms I-PHYSICAL
in 0
patients 0
following 0
nasal 0
operations 0
underlines 0
the 0
efficacy 0
of 0
both 0
medications 0
. 0

With 0
respect 0
to 0
the 0
tolerability B-OTHER
therapy 0
with 0
the 0
combination 0
is 0
more 0
beneficial 0
in 0
comparison 0
to 0
the 0
alternative 0
therapy 0
. 0

The 0
result 0
of 0
this 0
controlled 0
clinical 0
study 0
confirms 0
that 0
the 0
combination 0
Xylometazoline-Dexpanthenol 0
is 0
an 0
enlargement B-OTHER
and 0
improvement B-OTHER
of I-OTHER
effective I-OTHER
medicinal 0
treatment 0
of 0
rhinitis 0
following 0
nasal 0
operation 0
in 0
comparison 0
to 0
therapy 0
with 0
Xylometazoline 0
alone 0
. 0

RESPECT-PTSD 0
: 0
re-engineering 0
systems 0
for 0
the 0
primary 0
care 0
treatment 0
of 0
PTSD 0
, 0
a 0
randomized 0
controlled 0
trial 0
. 0

BACKGROUND 0
Although 0
collaborative 0
care 0
is 0
effective 0
for 0
treating 0
depression 0
and 0
other 0
mental 0
disorders 0
in 0
primary 0
care 0
, 0
there 0
have 0
been 0
no 0
randomized 0
trials 0
of 0
collaborative 0
care 0
specifically 0
for 0
patients 0
with 0
Posttraumatic 0
stress 0
disorder 0
( 0
PTSD 0
) 0
. 0

OBJECTIVE 0
To 0
compare 0
a 0
collaborative 0
approach 0
, 0
the 0
Three 0
Component 0
Model 0
( 0
3CM 0
) 0
, 0
with 0
usual 0
care 0
for 0
treating 0
PTSD 0
in 0
primary 0
care 0
. 0

DESIGN 0
The 0
study 0
was 0
a 0
two-arm 0
, 0
parallel 0
randomized 0
clinical 0
trial 0
. 0

PTSD 0
patients 0
were 0
recruited 0
from 0
five 0
primary 0
care 0
clinics 0
at 0
four 0
Veterans 0
Affairs 0
healthcare 0
facilities 0
and 0
randomized 0
to 0
receive 0
usual 0
care 0
or 0
usual 0
care 0
plus 0
3CM 0
. 0

Blinded 0
assessors 0
collected 0
data 0
at 0
baseline 0
and 0
3-month 0
and 0
6-month 0
follow-up 0
. 0

PARTICIPANTS 0
Participants 0
were 0
195 0
Veterans 0
. 0

Their 0
average 0
age 0
was 0
45 0
years 0
, 0
91 0
% 0
were 0
male 0
, 0
58 0
% 0
were 0
white 0
, 0
40 0
% 0
served 0
in 0
Iraq 0
or 0
Afghanistan 0
, 0
and 0
42 0
% 0
served 0
in 0
Vietnam 0
. 0

INTERVENTION 0
All 0
participants 0
received 0
usual 0
care 0
. 0

Participants 0
assigned 0
to 0
3CM 0
also 0
received 0
telephone 0
care 0
management 0
. 0

Care 0
managers 0
received 0
supervision 0
from 0
a 0
psychiatrist 0
. 0

MAIN 0
MEASURES 0
PTSD B-PHYSICAL
symptom I-PHYSICAL
severity I-PHYSICAL
was 0
the 0
primary 0
outcome 0
. 0

Depression B-PHYSICAL
, 0
functioning B-PHYSICAL
, 0
perceived B-PHYSICAL
quality I-PHYSICAL
of I-PHYSICAL
care I-PHYSICAL
, 0
utilization B-OTHER
, 0
and 0
costs B-OTHER
were 0
secondary 0
outcomes 0
. 0

KEY 0
RESULTS 0
There 0
were 0
no 0
differences 0
between 0
3CM 0
and 0
usual 0
care 0
in 0
symptoms 0
or 0
functioning 0
. 0

Participants 0
assigned 0
to 0
3CM 0
were 0
more 0
likely 0
to 0
have 0
a 0
mental B-MENTAL
health I-MENTAL
visit I-MENTAL
, 0
fill 0
an 0
antidepressant 0
prescription 0
, 0
and 0
have 0
adequate B-OTHER
antidepressant I-OTHER
refills I-OTHER
. 0

3CM 0
participants 0
also 0
had 0
more 0
mental B-MENTAL
health I-MENTAL
visits I-MENTAL
and 0
higher 0
outpatient B-OTHER
pharmacy I-OTHER
costs I-OTHER
. 0

CONCLUSIONS 0
Results 0
suggest 0
the 0
need 0
for 0
careful 0
examination 0
of 0
the 0
way 0
that 0
collaborative 0
care 0
models 0
are 0
implemented 0
for 0
treating 0
PTSD 0
, 0
and 0
for 0
additional 0
supports 0
to 0
encourage 0
primary 0
care 0
providers 0
to 0
manage 0
PTSD 0
. 0

Comparison 0
of 0
non-invasive 0
methods 0
for 0
the 0
assessment 0
of 0
haemodynamic 0
drug 0
effects 0
in 0
healthy 0
male 0
and 0
female 0
volunteers 0
: 0
sex 0
differences 0
in 0
cardiovascular 0
responsiveness 0
. 0

1 0
. 0

The 0
study 0
was 0
performed 0
to 0
determine 0
the 0
sensitivity 0
and 0
short-term 0
and 0
day-to-day 0
variability 0
of 0
a 0
novel 0
technique 0
based 0
on 0
laser 0
interferometry 0
of 0
ocular 0
fundus 0
pulsations 0
and 0
of 0
non-invasive 0
methods 0
for 0
the 0
quantification 0
of 0
haemodynamic 0
drug 0
effects 0
. 0

An 0
additional 0
aim 0
was 0
to 0
assess 0
sex 0
differences 0
in 0
haemodynamic 0
responsiveness 0
to 0
cardiovascular 0
drugs 0
in 0
male 0
and 0
female 0
healthy 0
volunteers 0
. 0

2 0
. 0

Ten 0
males 0
and 0
nine 0
females 0
( 0
age 0
range 0
20-33 0
years 0
) 0
were 0
studied 0
in 0
a 0
double-blind 0
, 0
randomized 0
, 0
cross-over 0
trial 0
. 0

Simultaneous B-PHYSICAL
measurements I-PHYSICAL
from 0
systemic 0
haemodynamics 0
, 0
laser 0
interferometry 0
of 0
ocular 0
fundus 0
pulsations 0
, 0
systolic 0
time 0
intervals 0
from 0
mechanocardiography 0
, 0
a/b 0
ratio 0
from 0
oxymetric 0
fingerplethysmography 0
and 0
Doppler 0
sonography 0
of 0
the 0
radial 0
artery 0
were 0
used 0
to 0
describe 0
the 0
haemodynamic 0
effects 0
of 0
cumulative 0
, 0
stepwise 0
increasing 0
intravenous 0
doses 0
of 0
phenylephrine 0
, 0
isoprenaline 0
, 0
sodium 0
nitroprusside 0
and 0
of 0
placebo 0
. 0

3 0
. 0

Laser 0
interferometry 0
detected 0
the 0
isoprenaline-effects 0
at 0
the 0
lowest 0
dose 0
level 0
of 0
0.1 0
micrograms 0
min-1 0
with 0
a 0
high 0
signal-to-noise 0
ratio 0
. 0

The 0
reproducibility 0
of 0
measurements 0
under 0
baseline 0
was 0
high 0
, 0
no 0
changes 0
were 0
observed 0
after 0
systemically 0
effective 0
doses 0
of 0
phenylephrine 0
or 0
sodium 0
nitroprusside 0
. 0

Systolic 0
time 0
intervals 0
were 0
sensitive 0
and 0
specific 0
for 0
isoprenaline-induced 0
effects 0
, 0
PEP 0
and 0
QS2c-measurements 0
had 0
high 0
reproducibility 0
. 0

Fingerplethysmography 0
proved 0
a 0
sensitive 0
measurement 0
for 0
the 0
detection 0
of 0
the 0
vasodilating 0
effects 0
of 0
sodium 0
nitroprusside 0
, 0
but 0
was 0
not 0
specific 0
, 0
and 0
showed 0
low 0
reproducibility 0
. 0

Measurements 0
from 0
Doppler 0
sonography 0
had 0
lower 0
reproducibility 0
and 0
sensitivity B-OTHER
compared 0
with 0
the 0
other 0
applied 0
methods 0
. 0

4 0
. 0

There 0
was 0
a 0
significant 0
sex 0
difference 0
for 0
several 0
of 0
the 0
haemodynamic 0
parameters 0
under 0
baseline 0
conditions 0
; 0
however 0
, 0
the 0
responsiveness 0
to 0
the 0
drugs 0
under 0
study 0
was 0
not 0
different 0
, 0
when 0
drug 0
effects 0
were 0
expressed 0
as 0
% 0
-change 0
from 0
the 0
baseline 0
. 0

5 0
. 0

Laser 0
interferometry 0
is 0
a 0
valuable 0
non-invasive 0
, 0
highly 0
sensitive 0
and 0
specific 0
approach 0
for 0
the 0
detection 0
of 0
pulse 0
pressure 0
changes 0
. 0

A 0
battery 0
of 0
non-invasive 0
tests 0
appears 0
useful 0
for 0
the 0
characterization 0
of 0
cardiovascular 0
drugs 0
. 0

Gender 0
differences 0
may 0
not 0
pose 0
a 0
relevant 0
problem 0
for 0
the 0
study 0
of 0
acute 0
haemodynamic 0
effects 0
of 0
cardiovascular 0
drugs 0
. 0

Prehydration 0
alone 0
is 0
sufficient 0
to 0
prevent 0
contrast-induced 0
nephropathy 0
after 0
day-only 0
angiography 0
procedures 0
-- 0
a 0
randomised 0
controlled 0
trial 0
. 0

BACKGROUND 0
Contrast 0
agents 0
used 0
in 0
angiography 0
procedures 0
for 0
patients 0
with 0
cardiovascular 0
disease 0
are 0
known 0
to 0
cause 0
contrast-induced 0
nephropathy 0
( 0
CIN 0
) 0
, 0
which 0
may 0
be 0
partially 0
due 0
to 0
the 0
production 0
of 0
nephrotoxic 0
oxygen-free 0
radicals 0
. 0

It 0
is 0
uncertain 0
whether 0
administration 0
of 0
intravenous 0
( 0
IV 0
) 0
anti-oxidant 0
, 0
N-acetylcysteine 0
( 0
NAC 0
) 0
, 0
can 0
prevent 0
reduction 0
in 0
renal 0
function 0
and 0
whether 0
this 0
is 0
a 0
cost-effective 0
approach 0
. 0

METHODS 0
Sixty-five 0
day-only 0
patients 0
with 0
renal 0
impairment 0
( 0
mean 0
serum 0
creatinine 0
concentration 0
0.16+/-0.03 0
mmol/l 0
) 0
due 0
to 0
undergo 0
coronary 0
or 0
peripheral 0
angiography 0
and/or 0
stenting 0
were 0
randomly 0
assigned 0
to 0
IV 0
NAC 0
300 0
or 0
600 0
mg 0
immediately 0
before 0
and 0
after 0
the 0
procedure 0
or 0
IV 0
fluid 0
alone 0
. 0

RESULTS 0
Of 0
the 0
60 0
patients 0
with 0
complete 0
data 0
, 0
none 0
had 0
acute 0
CIN 0
( 0
increase 0
in 0
serum 0
creatinine 0
concentration 0
> 0
or 0
= 0
0.044 0
mmol/l 0
, 0
48 0
h 0
after 0
administration 0
of 0
contrast 0
agent 0
) 0
. 0

Eight 0
patients 0
( 0
13 0
% 0
) 0
have 0
demonstrated 0
an 0
increase 0
in 0
their 0
serum B-PHYSICAL
creatinine I-PHYSICAL
concentration I-PHYSICAL
> 0
or 0
= 0
0.044 0
mmol/l 0
30 0
days 0
after 0
administration 0
of 0
contrast 0
agent 0
: 0
2/19 0
( 0
11 0
% 0
) 0
in 0
the 0
control 0
group 0
, 0
2/21 0
( 0
10 0
% 0
) 0
in 0
the 0
600 0
mg 0
NAC 0
group 0
and 0
4/20 0
( 0
20 0
% 0
) 0
the 0
300 0
mg 0
NAC 0
group 0
( 0
p 0
= 0
0.66 0
) 0
. 0

The 0
mean 0
volumes B-OTHER
of I-OTHER
contrast 0
agent B-OTHER
used 0
and 0
prehydration 0
given 0
for 0
each 0
of 0
the 0
three 0
groups 0
did 0
not 0
differ 0
significantly 0
( 0
p 0
> 0
0.83 0
) 0
. 0

There 0
was 0
significant 0
improvement 0
in 0
creatinine B-PHYSICAL

Incidence 0
of 0
puberty B-PHYSICAL
in 0
beef 0
heifers 0
fed 0
high- 0
or 0
low-starch 0
diets 0
for 0
different 0
periods 0
before 0
breeding 0
. 0

Spring-born 0
Hereford 0
x 0
Angus 0
heifers 0
( 0
n 0
= 0
206 0
) 0
were 0
used 0
to 0
determine 0
effects 0
of 0
energy 0
supplementation 0
programs 0
and 0
amount 0
of 0
starch 0
in 0
the 0
diet 0
on 0
incidence 0
of 0
puberty B-OTHER
. 0

In 0
Exp 0
. 0

1 0
, 0
heifers 0
( 0
205 0
+/- 0
5 0
kg 0
; 0
n 0
= 0
68 0
) 0
grazing 0
dormant 0
native 0
pasture 0
were 0
fed 0
0.9 0
kg/d 0
( 0
as-fed 0
basis 0
) 0
of 0
a 0
42 0
% 0
CP 0
supplement 0
from 0
November 0
until 0
February 0
14 0
. 0

Heifers 0
were 0
stratified 0
by 0
weaning 0
weight 0
and 0
allotted 0
randomly 0
to 0
treatment 0
before 0
breeding 0
( 0
May 0
to 0
July 0
) 0
. 0

Treatments 0
were 0
1 0
) 0
0.9 0
kg 0
( 0
as-fed 0
basis 0
) 0
of 0
a 0
42 0
% 0
CP 0
supplement/d 0
and 0
pasture 0
( 0
control 0
) 0
; 0
2 0
) 0
a 0
high-starch 0
( 0
HS 0
) 0
diet 0
( 0
73 0
% 0
corn 0
; 0
53 0
% 0
starch 0
) 0
fed 0
in 0
a 0
drylot 0
for 0
60 0
d 0
( 0
HS-60 0
) 0
; 0
3 0
) 0
a 0
HS 0
diet 0
fed 0
in 0
drylot 0
for 0
30 0
d 0
( 0
HS-30 0
) 0
; 0
or 0
4 0
) 0
a 0
low-starch 0
( 0
LS 0
) 0
diet 0
( 0
49 0
% 0
corn 0
; 0
37 0
% 0
starch 0
) 0
self-fed 0
on 0
pasture 0
for 0
30 0
d 0
( 0
LS-30 0
) 0
. 0

The 0
HS-60 0
and 0
HS-30 0
heifers 0
were 0
limited-fed 0
to 0
gain 0
0.9 0
kg/d 0
, 0
and 0
the 0
LS-30 0
heifers 0
had 0
ad 0
libitum 0
access 0
to 0
the 0
diet 0
. 0

High-starch-60 0
and 0
LS-30 0
heifers 0
were 0
heavier B-PHYSICAL
( 0
P 0
< 0
0.05 0
) 0
than 0
control 0
and 0
HS-30 0
heifers 0
at 0
the 0
beginning 0
of 0
the 0
breeding 0
season 0
. 0

Thirty-one 0
, 0
25 0
, 0
and 0
26 0
% 0
more 0
HS-60 0
heifers 0
were 0
pubertal 0
( 0
P 0
< 0
0.05 0
) 0
on 0
May 0
1 0
compared 0
with 0
LS-30 0
, 0
HS-30 0
, 0
and 0
control 0
heifers 0
, 0
respectively 0
. 0

At 0
puberty 0
, 0
HS-60 0
heifers 0
were 0
24 0
and 0
22 0
d 0
younger 0
( 0
P 0
< 0
0.05 0
) 0
than 0
LS-30 0
and 0
control 0
heifers 0
, 0
and 0
31 0
kg 0
lighter 0
( 0
P 0
< 0
0.01 0
) 0
than 0
LS-30 0
heifers 0
. 0

In 0
Exp 0
. 0

2 0
, 0
heifers 0
grazed 0
dormant 0
pasture 0
and 0
were 0
fed 0
0.9 0
kg 0
( 0
as-fed 0
basis 0
) 0
of 0
a 0
42 0
% 0
CP 0
supplement/d 0
from 0
weaning 0
in 0
October 0
to 0
late 0
February 0
; 0
then 0
heifers 0
were 0
assigned 0
randomly 0
to 0
treatments 0
for 0
60 0
d 0
before 0
the 0
breeding 0
season 0
. 0

In 0
two 0
years 0
, 0
control 0
heifers 0
( 0
n 0
= 0
46 0
) 0
grazed 0
pasture 0
and 0
received 0
0.9 0
kg 0
of 0
SBM 0
supplement/d 0
; 0
LS 0
( 0
n 0
= 0
46 0
) 0
heifers 0
were 0
self-fed 0
a 0
distiller 0
's 0
grain 0
and 0
soybean 0
hull-based 0
diet 0
in 0
drylot 0
; 0
and 0
HS 0
heifers 0
( 0
n 0
= 0
46 0
) 0
were 0
limited-fed 0
a 0
corn-based 0
diet 0
in 0
drylot 0
. 0

During 0
treatment 0
, 0
HS 0
and 0
LS 0
heifers 0
had 0
greater 0
weight 0
gains B-PHYSICAL
than 0
control 0
heifers 0
. 0

Pubertal B-PHYSICAL
BW I-PHYSICAL
( 0
313 0
+/- 0
6 0
kg 0
) 0
was 0
not 0
influenced 0
by 0
treatment 0
, 0
but 0
HS 0
and 0
LS 0
heifers 0
were 0
younger 0
( 0
P 0
< 0
0.03 0
) 0
than 0
control 0
heifers 0
at 0
puberty 0
. 0

During 0
a 0
60-d 0
breeding 0
period 0
, 0
the 0
incidence 0
of 0
puberty B-PHYSICAL
was 0
greater 0
( 0
P 0
< 0
0.05 0
) 0
for 0
HS 0
and 0
LS 0
heifers 0
than 0
for 0
control 0
heifers 0
and 0
was 0
greater 0
( 0
P 0
< 0
0.05 0
) 0
in 0
HS 0
than 0
in 0
LS 0
heifers 0
in 0
Year 0
1 0
. 0

Feeding 0
a 0
LS 0
or 0
a 0
HS 0
diet 0
for 0
30 0
d 0
before 0
breeding 0
may 0
be 0
inadequate 0
to 0
stimulate 0
puberty B-PHYSICAL
in 0
beef 0
heifers 0
, 0
but 0
feeding 0
a 0
diet 0
with 0
a 0
greater 0
amount 0
of 0
starch 0
for 0
60 0
d 0
before 0
breeding 0
may 0
increase 0
the 0
incidence 0
of 0
puberty B-PHYSICAL
during 0
breeding 0
of 0
heifers 0
that 0
have 0
inadequate 0
yearling 0
weight 0
. 0

Conduit 0
artery 0
structure 0
and 0
function 0
in 0
lowlanders 0
and 0
native 0
highlanders 0
: 0
relationships 0
with 0
oxidative 0
stress 0
and 0
role 0
of 0
sympathoexcitation 0
. 0

Research 0
detailing 0
the 0
normal 0
vascular 0
adaptions 0
to 0
high 0
altitude 0
is 0
minimal 0
and 0
often 0
confounded 0
by 0
pathology 0
( 0
e.g. 0
, 0
chronic 0
mountain 0
sickness 0
) 0
and 0
methodological 0
issues 0
. 0

We 0
examined 0
vascular 0
function 0
and 0
structure 0
in 0
: 0
( 0
1 0
) 0
healthy 0
lowlanders 0
during 0
acute 0
hypoxia 0
and 0
prolonged 0
( 0
?2 0
weeks 0
) 0
exposure 0
to 0
high 0
altitude 0
, 0
and 0
( 0
2 0
) 0
high-altitude 0
natives 0
at 0
5050 0
m 0
( 0
highlanders 0
) 0
. 0

In 0
12 0
healthy 0
lowlanders 0
( 0
aged 0
32 0
? 0

7 0
years 0
) 0
and 0
12 0
highlanders 0
( 0
Sherpa 0
; 0
33 0
? 0

14 0
years 0
) 0
we 0
assessed 0
brachial 0
endothelium-dependent 0
flow-mediated 0
dilatation 0
( 0
FMD 0
) 0
, 0
endothelium-independent 0
dilatation 0
( 0
via 0
glyceryl 0
trinitrate 0
; 0
GTN 0
) 0
, 0
common 0
carotid 0
intima-media 0
thickness 0
( 0
CIMT 0
) 0
and 0
diameter 0
( 0
ultrasound 0
) 0
, 0
and 0
arterial 0
stiffness 0
via 0
pulse 0
wave 0
velocity 0
( 0
PWV 0
; 0
applanation 0
tonometry 0
) 0
. 0

Cephalic 0
venous 0
biomarkers 0
of 0
free 0
radical-mediated 0
lipid 0
peroxidation 0
( 0
lipid 0
hydroperoxides 0
, 0
LOOH 0
) 0
, 0
nitrite 0
( 0
NO2- 0
) 0
and 0
lipid 0
soluble 0
antioxidants 0
were 0
also 0
obtained 0
at 0
rest 0
. 0

In 0
lowlanders 0
, 0
measurements 0
were 0
performed 0
at 0
sea 0
level 0
( 0
334 0
m 0
) 0
and 0
between 0
days 0
3-4 0
( 0
acute 0
high 0
altitude 0
) 0
and 0
12-14 0
( 0
chronic 0
high 0
altitude 0
) 0
following 0
arrival 0
to 0
5050 0
m. 0
Highlanders 0
were 0
assessed 0
once 0
at 0
5050 0
m. 0
Compared 0
with 0
sea 0
level 0
, 0
acute 0
high 0
altitude 0
reduced 0
lowlanders 0
' 0
FMD 0
( 0
7.9 0
? 0

0.4 0
vs. 0
6.8 0
? 0

0.4 0
% 0
; 0
P 0
= 0
0.004 0
) 0
and 0
GTN-induced 0
dilatation 0
( 0
16.6 0
? 0

0.9 0
vs. 0
14.5 0
? 0

0.8 0
% 0
; 0
P 0
= 0
0.006 0
) 0
, 0
and 0
raised 0
central 0
PWV 0
( 0
6.0 0
? 0

0.2 0
vs. 0
6.6 0
? 0

0.3 0
m 0
s 0
( 0
-1 0
) 0
; 0
P 0
= 0
0.001 0
) 0
. 0

These 0
changes 0
persisted 0
at 0
days 0
12-14 0
, 0
and 0
after 0
allometrically 0
scaling 0
FMD 0
to 0
adjust 0
for 0
altered 0
baseline 0
diameter 0
. 0

Compared 0
to 0
lowlanders 0
at 0
sea 0
level 0
and 0
high 0
altitude 0
, 0
highlanders 0
had 0
a 0
lower 0
carotid B-PHYSICAL
wall I-PHYSICAL
: 0
lumen B-PHYSICAL
ratio B-PHYSICAL
( 0
?19 0
% 0
, 0
P 0
? 0

0.04 0
) 0
, 0
attributable 0
to 0
a 0
narrower 0
CIMT 0
and 0
wider 0
lumen 0
. 0

Although 0
both 0
LOOH B-PHYSICAL
and 0

The 0
impact 0
of 0
schizophrenic 0
patient 0
functionality 0
on 0
service B-OTHER
utilization I-OTHER
and 0
cost B-OTHER
. 0

Based 0
on 0
a 0
presentation 0
by 0
Sandra 0
L. 0
Tunis 0
, 0
PhD 0
. 0

With 0
the 0
advent 0
of 0
atypical 0
agents 0
in 0
the 0
treatment 0
of 0
schizophrenia 0
, 0
physicians 0
and 0
policy 0
makers 0
must 0
consider 0
the 0
costs 0
that 0
may 0
accompany 0
greater 0
clinical 0
efficacy 0
. 0

Analyses 0
reveal 0
that 0
olanzapine 0
shows 0
a 0
greater 0
clinical B-OTHER
cost I-OTHER
effectiveness I-OTHER
, 0
as 0
well 0
as 0
a 0
greater 0
functional B-OTHER
cost I-OTHER
effectiveness I-OTHER
, 0
than 0
haloperidol 0
, 0
and 0
that 0
functional 0
outcomes 0
, 0
in 0
particular 0
, 0
show 0
promise 0
as 0
important 0
measures 0
of 0
effectiveness 0
. 0

Functional 0
outcomes 0
can 0
help 0
differentiate 0
medications 0
and 0
can 0
be 0
used 0
to 0
help 0
demonstrate 0
the 0
cost B-OTHER
effectiveness I-OTHER
of 0
atypical 0
agents 0
. 0

Mental B-MENTAL
health I-MENTAL
and 0
physical B-PHYSICAL
health I-PHYSICAL
functioning I-PHYSICAL
, 0
as 0
well 0
as 0
work B-MENTAL
status I-MENTAL
, 0
are 0
all 0
measures 0
of 0
functioning 0
that 0
have 0
been 0
used 0
to 0
evaluate 0
treatment 0
strategies 0
. 0

When 0
comparing 0
olanzapine 0
with 0
haloperidol 0
, 0
cost B-OTHER
savings I-OTHER
are 0
seen 0
throughout 0
the 0
treatment 0
period 0
( 0
1 0
year 0
) 0
, 0
with 0
physical B-PHYSICAL
functioning I-PHYSICAL
most 0
highly 0
affected 0
over 0
time 0
. 0

Functional 0
outcomes 0
can 0
therefore 0
serve 0
2 0
purposes 0
: 0
to 0
enhance 0
compliance 0
by 0
improving 0
health-related B-OTHER
quality I-OTHER
of I-OTHER
life I-OTHER
and 0
to 0
assist 0
in 0
making 0
both 0
treatment 0
and 0
formulary 0
decisions 0
. 0

Efficacy 0
and 0
safety 0
of 0
10 0
% 0
HES 0
130/0.4 0
versus 0
10 0
% 0
HES 0
200/0.5 0
for 0
plasma 0
volume 0
expansion 0
in 0
cardiac 0
surgery 0
patients 0
. 0

AIM 0
Hydroxyethyl 0
starch 0
( 0
HES 0
) 0
solutions 0
are 0
frequently 0
used 0
for 0
perioperative 0
volume 0
replacement 0
. 0

Whereas 0
older 0
HES 0
specimen 0
tended 0
to 0
accumulate 0
in 0
the 0
plasma 0
and 0
to 0
cause 0
negative 0
effects 0
on 0
hemostasis 0
, 0
more 0
recent 0
products 0
, 0
e.g. 0
, 0
HES 0
130/0.4 0
, 0
are 0
characterised 0
by 0
improved 0
pharmacological 0
properties 0
. 0

The 0
present 0
study 0
was 0
designed 0
to 0
compare 0
the 0
efficacy 0
and 0
safety B-OTHER
of 0
10 0
% 0
HES 0
130/0.4 0
and 0
10 0
% 0
HES 0
200/0.5 0
. 0

METHODS 0
In 0
this 0
post-hoc 0
analysis 0
of 0
a 0
prospective 0
, 0
randomised 0
, 0
double-blind 0
, 0
multi-center 0
therapeutic 0
equivalence 0
trial 0
, 0
76 0
patients 0
undergoing 0
elective 0
on-pump 0
cardiac 0
surgery 0
received 0
perioperative 0
volume 0
replacement 0
using 0
either 0
10 0
% 0
HES 0
130/0.4 0
( 0
N.=37 0
) 0
or 0
10 0
% 0
HES 0
200/0.5 0
( 0
N.=39 0
) 0
up 0
to 0
a 0
maximum 0
dose 0
of 0
20 0
mL 0
kg-1 0
. 0

RESULTS 0
Equivalent B-OTHER
volumes I-OTHER
of I-OTHER
investigational I-OTHER
medication I-OTHER
were 0
infused 0
until 0
24 0
hours 0
after 0
the 0
first 0
administration 0
( 0
1577 0
vs. 0
1540 0
mL 0
; 0
treatment 0
difference 0
37 0
[ 0
-150 0
; 0
223 0
] 0
mL 0
; 0
P 0
< 0
0.0001 0
for 0
equivalence 0
) 0
. 0

Whereas 0
standard 0
laboratory 0
tests 0
of 0
coagulation 0
were 0
comparable 0
between 0
groups 0
, 0
von B-PHYSICAL
Willebrand I-PHYSICAL
factor 0
activity B-PHYSICAL
on 0
the 0
first 0
postoperative 0
morning 0
tended 0
to 0
be 0
higher 0
following 0
treatment 0
with 0
10 0
% 0
HES 0
130/0.4 0
as 0
compared 0
to 0
10 0
% 0
HES 0
200/0.5 0
( 0
P=0.025 0
) 0
with 0
this 0
difference 0
being 0
statistically 0
significant 0
only 0
in 0
the 0
per-protocol 0
analysis 0
( 0
P=0.02 0
) 0
. 0

Treatment 0
groups 0
were 0
comparable 0
concerning 0
other 0
safety B-OTHER
parameters I-OTHER
and 0
the 0
incidence 0
of 0
adverse B-ADVERSE-EFFECTS
drug I-ADVERSE-EFFECTS
reactions B-ADVERSE-EFFECTS
. 0

In 0
particular 0
, 0

Over 0
time 0
relationships 0
between 0
early 0
adolescent 0
and 0
peer B-MENTAL
substance I-MENTAL
use 0
. 0

Peer 0
and 0
adolescent 0
substance 0
use 0
are 0
highly 0
correlated 0
, 0
but 0
this 0
relationship 0
is 0
not 0
fully 0
understood 0
. 0

In 0
particular 0
, 0
the 0
relative 0
contributions 0
of 0
selection 0
and 0
socialization 0
to 0
substance 0
use 0
progression 0
have 0
not 0
been 0
established 0
. 0

Students 0
( 0
n=2453 0
) 0
in 0
the 0
seven 0
middle 0
schools 0
in 0
one 0
school 0
district 0
were 0
assessed 0
at 0
school 0
at 0
the 0
beginning 0
and 0
end 0
of 0
the 0
sixth 0
, 0
seventh 0
, 0
eighth 0
grade 0
and 0
beginning 0
of 0
the 0
9th 0
grade 0
. 0

Self-reported B-MENTAL
smoking I-MENTAL
and I-MENTAL
drinking I-MENTAL
and 0
the 0
number 0
of 0
substance 0
using 0
friends 0
were 0
assessed 0
5 0
times 0
over 0
3 0
years 0
. 0

The 0
relationship 0
between 0
peer B-MENTAL
and 0
adolescent B-MENTAL
substance I-MENTAL
use I-MENTAL
were 0
assessed 0
in 0
parallel 0
processes 0
as 0
part 0
of 0
an 0
autoregressive 0
latent 0
trajectory 0
model 0
. 0

Substance B-MENTAL
use I-MENTAL
and 0
the 0
number B-MENTAL
of I-MENTAL
substance I-MENTAL
using 0
friends 0
increased 0
in 0
linear 0
fashion 0
from 0
T1 0
to 0
T5 0
. 0

Initial 0
substance 0
use 0
predicted 0
an 0
increase 0
in 0
the 0
number B-MENTAL
of I-MENTAL
substance I-MENTAL
using I-MENTAL
friends I-MENTAL
over I-MENTAL
time I-MENTAL
, 0
indicating 0
an 0
effect 0
of 0
selection 0
, 0
and 0
the 0
initial 0
number 0
of 0
substance 0
using 0
friends 0
predicted 0
substance B-MENTAL
use I-MENTAL
progression 0
, 0
providing 0
evidence 0
of 0
socialization 0
. 0

The 0
magnitudes 0
of 0
these 0
relationships 0
were 0
similar 0
. 0

Bivariate 0
, 0
lagged 0
autoregressive 0
analyses 0
of 0
the 0
successive 0
relationships 0
from 0
one 0
assessment 0
to 0
the 0
next 0
showed 0
consistent 0
, 0
significant 0
associations 0
from 0
peer B-MENTAL
use I-MENTAL
to I-MENTAL
adolescent I-MENTAL
substance I-MENTAL
use I-MENTAL
. 0

The 0
association 0
from 0
adolescent B-MENTAL
to I-MENTAL
peer I-MENTAL
use I-MENTAL
was 0
significant 0
only 0
from 0
7th 0
to 0
8th 0
grade 0
. 0

The 0
findings 0
provide 0
evidence 0
of 0
reciprocal 0
influences 0
, 0
but 0
socialization 0
was 0
a 0
more 0
consistent 0
influence 0
than 0
selection 0
. 0

Why 0
the 0
prone 0
position 0
is 0
a 0
risk 0
factor 0
for 0
sudden 0
infant 0
death 0
syndrome 0
. 0

INTRODUCTION 0
The 0
laryngeal 0
chemoreflex 0
may 0
explain 0
why 0
prone 0
sleeping 0
increases 0
the 0
risk 0
of 0
sudden 0
infant 0
death 0
syndrome 0
( 0
SIDS 0
) 0
. 0

Swallowing 0
and 0
arousal 0
are 0
crucial 0
to 0
prevent 0
laryngeal 0
chemoreflex 0
stimulation 0
. 0

Our 0
aim 0
was 0
to 0
examine 0
these 0
reflexes B-PHYSICAL
and 0
breathing B-PHYSICAL
responses I-PHYSICAL
in 0
healthy 0
neonates 0
after 0
pharyngeal 0
infusion 0
of 0
water 0
in 0
the 0
supine 0
versus 0
the 0
prone 0
position 0
, 0
controlling 0
for 0
sleep 0
state 0
. 0

METHODS 0
A 0
total 0
of 0
10 0
term 0
infants 0
were 0
recruited 0
after 0
parental 0
consent 0
and 0
ethics 0
approval 0
. 0

Polygraphic 0
recordings 0
included 0
sleep B-PHYSICAL
state I-PHYSICAL
( 0
active B-PHYSICAL
and 0
quiet B-PHYSICAL
sleep I-PHYSICAL
by I-PHYSICAL
electroencephalogram I-PHYSICAL
, 0
eye B-PHYSICAL
movements I-PHYSICAL
, 0
breathing B-PHYSICAL
, 0
and 0

Brief 0
Report 0
: 0
Randomized 0
test 0
of 0
the 0
efficacy 0
of 0
picture 0
exchange 0
communication 0
system 0
on 0
highly 0
generalized B-OTHER
picture I-OTHER
exchanges I-OTHER
in 0
children 0
with 0
ASD 0
. 0

A 0
randomized 0
control 0
trial 0
comparing 0
two 0
social-communication 0
interventions 0
in 0
young 0
children 0
with 0
autism 0
examined 0
far-transfer 0
of B-MENTAL
the 0
use B-MENTAL
of I-MENTAL
picture I-MENTAL
exchange I-MENTAL
to B-MENTAL
communicate I-MENTAL
. 0

Thirty-six 0
children 0
were 0
randomly 0
assigned 0
to 0
one 0
of 0
two 0
treatment 0
conditions 0
, 0
one 0
of 0
which 0
was 0
the 0
Picture 0
Exchange 0
Communication 0
System 0
( 0
PECS 0
) 0
. 0

All 0
children 0
had 0
access 0
to 0
picture 0
symbols 0
during 0
assessments 0
. 0

Post-treatment 0
measurement 0
of 0
the 0
number B-MENTAL
of I-MENTAL
picture I-MENTAL
exchanges I-MENTAL
in I-MENTAL
a I-MENTAL
far-transfer I-MENTAL
, 0
assessment 0
context 0
favored 0
the 0
PECS 0
intervention 0
. 0

These 0
findings 0
were 0
interpreted 0
as 0
support 0
for 0
the 0
hypothesis 0
that 0
the 0
PECS 0
curriculum 0
can 0
successfully 0
teach 0
a 0
generalized 0
means 0
of 0
showing 0

Women 0
's 0
responses 0
to 0
information 0
on 0
mammographic 0
breast 0
density 0
. 0

The 0
objective 0
of 0
this 0
study 0
was 0
to 0
determine 0
the 0
negative 0
and 0
positive 0
outcomes 0
of 0
providing 0
mammographic 0
breast 0
density 0
( 0
MBD 0
) 0
information 0
to 0
participants 0
of 0
a 0
screening 0
program 0
. 0

A 0
randomized 0
experiment 0
was 0
conducted 0
with 0
a 0
sample 0
of 0
618 0
women 0
50 0
years 0
or 0
older 0
with 0
MBD 0
greater 0
than 0
50 0
% 0
of 0
breast 0
volume 0
. 0

The 0
intervention 0
consisted 0
of 0
reporting 0
the 0
presence 0
of 0
MBD 0
in 0
the 0
screening 0
mammography 0
results 0
letter 0
that 0
was 0
sent 0
along 0
with 0
an 0
information 0
pamphlet 0
. 0

Compared 0
to 0
the 0
controls 0
, 0
more 0
women 0
in 0
the 0
intervention 0
group 0
described 0
the 0
term 0
breast B-PHYSICAL
density I-PHYSICAL
correctly 0
and 0
recognized 0
it 0
as 0
a 0
risk 0
factor 0
for 0
breast 0
cancer 0
. 0

Although 0
at 0
the 0
4-week 0
follow-up 0
the 0
intervention 0
group 0
indicated 0
that 0
they 0
were 0
very 0
likely 0
to 0
have 0
an 0
annual 0
clinical 0
breast 0
examination 0
more 0
frequently 0
than 0
controls 0
, 0
no 0
differences 0
were 0
detected 0
at 0
6 0
months 0
. 0

There 0
were 0
no 0
significant 0
differences 0
on 0
other 0
behavioural B-MENTAL
or I-MENTAL
psychological I-MENTAL
measures I-MENTAL
, 0
although 0
at 0
the 0
4-week 0
follow-up 0
the 0
control 0
group 0
perceived 0
their 0
risk 0
for 0
breast 0
cancer 0
, 0
relative 0
to 0
other 0
women 0
their 0
age 0
, 0
as 0
a 0
lot 0
lower 0
than 0
did 0
women 0
in 0
the 0
intervention 0
group 0
. 0

The 0
results 0
demonstrate 0
a 0
feasible 0
and 0
non-threatening 0
way 0
to 0
provide 0
women 0
with 0
important 0
personalized 0
information 0
about 0
breast B-PHYSICAL
cancer I-PHYSICAL
risk I-PHYSICAL
. 0

The 0
6 0
minute 0
walk 0
in 0
idiopathic 0
pulmonary 0
fibrosis 0
: 0
longitudinal 0
changes 0
and 0
minimum 0
important 0
difference 0
. 0

RATIONALE 0
The 0
response 0
characteristics 0
of 0
the 0
6 0
minute 0
walk 0
test 0
( 0
6MWT 0
) 0
in 0
studies 0
of 0
idiopathic 0
pulmonary 0
fibrosis 0
( 0
IPF 0
) 0
are 0
only 0
poorly 0
understood 0
, 0
and 0
the 0
change 0
in 0
walk 0
distance 0
that 0
constitutes 0
the 0
minimum 0
important 0
difference 0
( 0
MID 0
) 0
over 0
time 0
is 0
unknown 0
. 0

OBJECTIVES 0
To 0
examine 0
changes 0
over 0
time B-MENTAL
in I-MENTAL
distance 0
walked B-MENTAL
( 0
ie 0
, 0
6MWD 0
) 0
during 0
the 0
6MWT 0
and 0
to 0
estimate 0
the 0
change 0
in 0
distance 0
that 0
constitutes 0
the 0
MID 0
in 0
patients 0
with 0
IPF 0
. 0

METHODS 0
Data 0
from 0
a 0
recently 0
completed 0
trial 0
that 0
included 0
subjects 0
with 0
IPF 0
who 0
completed 0
the 0
6MWT 0
, 0
Saint 0
George 0
's 0
Respiratory 0
Questionnaire 0
( 0
SGRQ 0
) 0
and 0
forced 0
vital 0
capacity 0
( 0
FVC 0
) 0
at 0
6 0
and 0
12 0
months 0
were 0
used 0
to 0
examine 0
longitudinal 0
changes 0
in 0
6MWD 0
. 0

Both 0
anchor- 0
and 0
distribution-based 0
approaches 0
as 0
well 0
as 0
linear 0
regression 0
analyses 0
were 0
used 0
to 0
determine 0
the 0
MID 0
for 0
6MWD 0
. 0

The 0
SGRQ B-OTHER
Total 0
score 0
and 0

Motion 0
aftereffects 0
with 0
horizontally 0
moving 0
sound 0
sources 0
in 0
the 0
free 0
field 0
. 0

A 0
horizontally 0
moving 0
sound 0
was 0
presented 0
to 0
an 0
observer 0
seated 0
in 0
the 0
center 0
of 0
an 0
anechoic 0
chamber 0
. 0

The 0
sound 0
, 0
either 0
a 0
500-Hz 0
low-pass 0
noise 0
or 0
a 0
6300-Hz 0
high-pass 0
noise 0
, 0
repeatedly 0
traversed 0
a 0
semicircular 0
arc 0
in 0
the 0
observer 0
's 0
front 0
hemifield 0
at 0
ear 0
level 0
( 0
distance 0
: 0
1.5 0
m 0
) 0
. 0

At 0
10-sec 0
intervals 0
this 0
adaptor 0
was 0
interrupted 0
, 0
and 0
a 0
750-msec 0
moving 0
probe 0
( 0
a 0
500-Hz 0
low-pass 0
noise 0
) 0
was 0
presented 0
from 0
a 0
horizontal 0
arc 0
1.6 0
m 0
in 0
front 0
of 0
the 0
observer 0
. 0

During 0
a 0
run 0
, 0
the 0
adaptor 0
was 0
presented 0
at 0
a 0
constant 0
velocity 0
( 0
-200 0
degrees 0
to 0
+200 0
degrees/sec 0
) 0
, 0
while 0
probes 0
with 0
velocities 0
varying 0
from 0
-10 0
degrees 0
to 0
+10 0
degrees/sec 0
were 0
presented 0
in 0
a 0
random 0
order 0
. 0

Observers 0
judged 0
the 0
direction 0
of 0
motion 0
( 0
left 0
or 0
right 0
) 0
of 0
each 0
probe 0
. 0

As 0
in 0
the 0
case 0
of 0
stimuli 0
presented 0
over 0
headphones 0
( 0
Grantham 0
& 0
Wightman 0
, 0
1979 0
) 0
, 0
an 0
auditory B-PHYSICAL
motion I-PHYSICAL
aftereffect I-PHYSICAL
( I-PHYSICAL
MAE I-PHYSICAL
) I-PHYSICAL
occurred 0
: 0
subjects 0
responded 0
left 0
to 0
probes 0
more 0
often 0
when 0
the 0
adaptor 0
moved 0
right 0
than 0
when 0
it 0
moved 0
left 0
. 0

When 0
the 0
adaptor 0
and 0
probe 0
were 0
spectrally 0
the 0
same 0
, 0
the 0
MAE B-PHYSICAL
was 0
greater 0
than 0
when 0
they 0
were 0
from 0
different 0
spectral 0
regions 0
; 0
the 0
magnitude 0
of 0
this 0
difference 0
depended 0
on 0
adaptor 0
speed 0
and 0
was 0
subject-dependent 0
. 0

It 0
is 0
proposed 0
that 0
there 0
are 0
two 0
components 0
underlying 0
the 0
auditory 0
MAE B-PHYSICAL
: 0
( 0
1 0
) 0
a 0
generalized 0
bias 0
to 0
respond 0
that 0
probes 0
move 0
in 0
the 0
direction 0
opposite 0
to 0
that 0
of 0
the 0
adaptor 0
, 0
independent 0
of 0
their 0
spectra 0
; 0
and 0
( 0
2 0
) 0
a 0
loss 0
of 0
sensitivity 0
to 0
the 0
velocity 0
of 0
moving 0
sounds 0
after 0
prolonged 0
exposure 0
to 0
moving 0
sounds 0
having 0
the 0
same 0
spectral 0
content 0
. 0

Dietary 0
sodium 0
intake 0
modulates 0
myocardial B-PHYSICAL
relaxation I-PHYSICAL
responsiveness I-PHYSICAL
to 0
angiotensin 0
II 0
. 0

Dietary 0
sodium 0
alters 0
renovascular 0
responsiveness 0
to 0
angiotensin 0
II 0
( 0
Ang 0
II 0
) 0
in 0
normal 0
subjects 0
. 0

Evidence 0
supports 0
a 0
connection 0
among 0
dietary 0
sodium 0
, 0
the 0
rennin-angiotensin 0
system 0
, 0
and 0
myocardial 0
function 0
. 0

The 0
authors 0
hypothesized 0
that 0
a 0
similar 0
relationship 0
would 0
exist 0
in 0
the 0
heart 0
, 0
and 0
that 0
the 0
pattern 0
of 0
responses 0
would 0
be 0
qualitatively 0
similar 0
to 0
the 0
renal 0
vasculature 0
. 0

Thirteen 0
healthy 0
volunteers 0
( 0
aged 0
38.6 0
+/- 0
4 0
years 0
) 0
entered 0
a 0
2 0
week 0
crossover 0
design 0
study 0
( 0
week 0
1 0
, 0
high 0
sodium 0
diet 0
[ 0
HS 0
] 0
> 0
200 0
mmol 0
Na/day 0
; 0
week 0
2 0
, 0
low 0
sodium 0
diet 0
[ 0
LS 0
] 0
, 0
< 0
10 0
mmol 0
Na/day 0
) 0
to 0
investigate 0
the 0
influence 0
of 0
dietary 0
sodium 0
and 0
Ang 0
II 0
on 0
myocardial 0
relaxation 0
and 0
renal B-PHYSICAL
blood I-PHYSICAL
flow I-PHYSICAL
( I-PHYSICAL
RBF I-PHYSICAL
) I-PHYSICAL
. 0

At 0
the 0
end 0
of 0
each 0
study 0
week 0
, 0
the 0
authors 0
assessed 0
diastolic B-PHYSICAL
function I-PHYSICAL
( 0
myocardial B-PHYSICAL
relaxation I-PHYSICAL
velocities I-PHYSICAL
[ 0
E 0
' 0
] 0
using 0
tissue 0
Doppler 0
imaging 0
) 0
and 0
RBF B-PHYSICAL
( 0
para-aminohippurate 0
clearance 0
) 0
at 0
baseline 0
and 0
after 0
infusion 0
of 0
Ang 0
II 0
( 0
3 0
ng/kg/min 0
x 0
45 0
min 0
) 0
. 0

On 0
HS 0
diet 0
, 0
E 0
' 0
and 0
RBF B-PHYSICAL
were 0
higher 0
than 0
on 0
LS 0
diet 0
( 0
E 0
' 0
14.0 0
+/- 0
1.2 0
vs 0
12.6 0
+/- 0
1.0 0
cm/s 0
, 0
P 0
= 0
0.02 0
; 0
RBF 0
596 0
+/- 0
24 0
vs 0
563 0
+/- 0
26 0
mL/min 0
, 0
P 0
= 0
0.02 0
) 0
. 0

Dietary 0
sodium 0
significantly 0
modulated 0
E B-PHYSICAL
' 0
and 0
RBF B-PHYSICAL
responsiveness I-PHYSICAL
to 0
Ang 0
II 0
infusion 0
in 0
like 0
manner 0
. 0

HS 0
was 0
associated 0
with 0
increased 0
responsiveness 0
compared 0
with 0
a 0
blunted 0
LS B-PHYSICAL
response I-PHYSICAL
( 0
HS 0
DeltaE 0
' 0
-1.4 0
+/- 0
0.4 0
cm/s 0
vs 0
LS 0
DeltaE 0
' 0
-0.1 0
+/- 0
0.3 0
cm/s 0
, 0
P 0
= 0
0.02 0
; 0
HS 0
DeltaRBF 0
-135.2 0
+/- 0
13.2 0
vs 0
LS 0
DeltaRBF 0
-62.5 0
+/- 0
10.1 0
mL/min 0
, 0
P 0
< 0
0.01 0
) 0
. 0

The 0
authors 0
describe 0
for 0
the 0
first 0
time 0
that 0
dietary 0
sodium 0
modulates 0
myocardial B-PHYSICAL
relaxation I-PHYSICAL
and I-PHYSICAL
responsiveness I-PHYSICAL
to 0
Ang 0
II 0
. 0

It 0
is 0
important 0
to 0
consider 0
dietary 0
sodium 0
intake 0
when 0
assessing 0
diastolic B-PHYSICAL
function I-PHYSICAL
. 0

Ang 0
II 0
may 0
play 0
a 0
role 0
in 0
the 0
interaction 0
between 0
dietary 0
sodium 0
and 0
myocardial B-PHYSICAL
relaxation I-PHYSICAL
. 0

Future 0
research 0
will 0
investigate 0
whether 0
abnormalities 0
in 0
these 0
mechanisms 0
play 0
a 0
role 0
in 0
disorders 0
of 0
diastolic 0
function 0
. 0

The 0
effect 0
of 0
HCG 0
supplementation 0
after 0
combined 0
GnRH 0
agonist/HMG 0
treatment 0
in 0
an 0
IVF 0
programme 0
. 0

The 0
necessity 0
of 0
luteal-phase 0
supplementation 0
in 0
an 0
IVF 0
programme 0
is 0
of 0
continuing 0
interest 0
. 0

After 0
ovarian 0
stimulation 0
with 0
clomiphene 0
and 0
human 0
menopausal 0
gonadotrophin 0
( 0
HMG 0
) 0
, 0
the 0
beneficial 0
effect 0
of 0
supporting 0
the 0
luteal 0
phase 0
has 0
never 0
been 0
scientifically 0
demonstrated 0
. 0

After 0
ovarian 0
stimulation 0
with 0
GnRH 0
agonist/HMG 0
, 0
the 0
luteal 0
phase 0
seems 0
to 0
be 0
inadequate 0
, 0
but 0
in 0
a 0
previous 0
study 0
we 0
did 0
not 0
find 0
evidence 0
to 0
support 0
the 0
need 0
for 0
oral 0
progesterone 0
supplementation 0
. 0

To 0
evaluate 0
the 0
beneficial 0
effect 0
of 0
human 0
chorionic 0
gonadotrophin 0
( 0
HCG 0
) 0
supplementation 0
, 0
we 0
performed 0
a 0
multicentre 0
, 0
double-blind 0
, 0
randomized 0
study 0
with 0
HCG 0
( 0
193 0
transfers 0
) 0
against 0
placebo 0
( 0
194 0
transfers 0
) 0
. 0

The 0
ongoing B-PHYSICAL
pregnancy I-PHYSICAL
rate I-PHYSICAL
per I-PHYSICAL
transfer I-PHYSICAL
cycle I-PHYSICAL
was 0
significantly 0
better 0
with 0
HCG 0
( 0
18.7 0
versus 0
9.3 0
) 0
. 0

This 0
is 0
the 0
first 0
truly 0
objective 0
( 0
randomized 0
) 0
study 0
demonstrating 0
the 0
beneficial 0
effect 0
of 0
supporting 0
the 0
luteal 0
phase 0
in 0
an 0
IVF 0
programme 0
. 0

Corticosteroid-induced 0
osteopenia B-PHYSICAL
and 0
vitamin B-PHYSICAL
D I-PHYSICAL
metabolism I-PHYSICAL
. 0

Effect 0
of 0
vitamin 0
D2 0
, 0
calcium 0
phosphate 0
and 0
sodium 0
fluoride 0
administration 0
. 0

Thirty-one 0
patients 0
scheduled 0
for 0
long-term 0
( 0
24 0
weeks 0
) 0
treatment 0
with 0
prednisone 0
in 0
comparatively 0
high 0
doses 0
were 0
randomly 0
allocated 0
to 0
two 0
further 0
treatment 0
groups 0
. 0

Group 0
A 0
received 0
prednisone 0
plus 0
'triple-treatment 0
' 0
( 0
vitamin 0
D2 0
45000 0
iu 0
twice 0
weekly 0
, 0
sodium 0
fluoride 0
50 0
mg 0
and 0
calcium 0
phosphate 0
4.5 0
g 0
daily 0
) 0
, 0
group 0
B 0
received 0
only 0
prednisone 0
. 0

The 0
study 0
was 0
undertaken 0
in 0
order 0
to 0
evaluate 0
the 0
effect 0
of 0
prednisone- 0
and 0
triple-treatment 0
upon 0
bone B-PHYSICAL
mineral I-PHYSICAL
content I-PHYSICAL
( I-PHYSICAL
BMC I-PHYSICAL
) I-PHYSICAL
and 0
vitamin B-PHYSICAL
D I-PHYSICAL
metabolism I-PHYSICAL
. 0

The 0
groups 0
were 0
comparable 0
with 0
regard 0
to 0
age 0
, 0
sex 0
and 0
prednisone 0
dose 0
. 0

BMC B-PHYSICAL
fell 0
rapidly 0
and 0
similarly 0
in 0
both 0
groups 0
, 0
demonstrating 0
that 0
the 0
triple-treatment 0
has 0
no 0
preventive 0
effect 0
on 0
corticosteroid 0
induced 0
osteopenia 0
. 0

Serum B-PHYSICAL
concentrations I-PHYSICAL
of I-PHYSICAL
25OHD2 I-PHYSICAL
, I-PHYSICAL
25OHD3 I-PHYSICAL
and I-PHYSICAL
1,25 I-PHYSICAL
( I-PHYSICAL
OH I-PHYSICAL
) I-PHYSICAL
2D I-PHYSICAL
were 0
unchanged 0
in 0
group 0
B 0
( 0
without 0
triple-treatment 0
) 0
, 0
whereas 0
in 0
group 0
A 0
25OHD2 B-PHYSICAL
increased 0
enormously 0
, 0
25OHD3 B-PHYSICAL
was 0
suppressed 0
possibly 0
by 0
substrate 0
competition 0
for 0
hydroxylation 0
in 0
the 0
liver 0
and 0
1,25 0
( B-PHYSICAL
OH I-PHYSICAL
) I-PHYSICAL
2D I-PHYSICAL
was 0
halved 0
. 0

The 0
suppression 0
of 0
1,25 0
( B-PHYSICAL
OH I-PHYSICAL
) I-PHYSICAL
2D I-PHYSICAL
may 0
be 0
an 0
effect 0
of 0
raised 0
25OHD2 0
alone 0
, 0
or 0
in 0
combination 0
with 0
corticosteroid 0
excess 0
. 0

Citalopram 0
for 0
post-stroke 0
pathological 0
crying 0
. 0

Post-stroke 0
pathological 0
crying 0
is 0
a 0
distressing 0
condition 0
in 0
which 0
episodes 0
occur 0
in 0
response 0
to 0
minor 0
stimuli 0
without 0
associated 0
mood 0
changes 0
. 0

There 0
is 0
preliminary 0
evidence 0
of 0
disturbed 0
serotoninergic 0
neurotransmission 0
in 0
such 0
cases 0
. 0

We 0
investigated 0
the 0
effect 0
of 0
the 0
selective B-PHYSICAL
serotonin I-PHYSICAL
reuptake I-PHYSICAL
inhibitor I-PHYSICAL
citalopram I-PHYSICAL
on 0
uncontrolled B-MENTAL
crying I-MENTAL
in 0
stroke 0
patients 0
in 0
a 0
double-blind 0
placebo-controlled 0
crossover 0
study 0
. 0

16 0
consecutive 0
patients 0
( 0
median 0
age 0
58.5 0
years 0
, 0
range 0
40-83 0
) 0
entered 0
the 0
9-week 0
study 0
a 0
median 0
of 0
168 0
days 0
( 0
range 0
6-913 0
) 0
post 0
stroke 0
and 0
were 0
treated 0
with 0
citalopram 0
10-20 0
mg 0
daily 0
for 0
3 0
weeks 0
. 0

Crying B-MENTAL
history I-MENTAL
was 0
determined 0
from 0
semistructured 0
interviews 0
and 0
from 0
diaries 0
kept 0
by 0
the 0
patients 0
. 0

Psychiatric B-MENTAL
assessment I-MENTAL
was 0
made 0
with 0
the 0
Hamilton B-MENTAL
depression I-MENTAL
scale I-MENTAL
( 0
HDS 0
) 0
, 0
and 0
unwanted B-ADVERSE-EFFECTS
effects I-ADVERSE-EFFECTS
were 0
measured 0
with 0
the 0
UKU B-ADVERSE-EFFECTS
side-effect I-ADVERSE-EFFECTS
scale I-ADVERSE-EFFECTS
. 0

In 0
13 0
patients 0
in 0
whom 0
frequency 0
of 0
crying B-MENTAL
could 0
be 0
assessed 0
, 0
the 0
number 0
of 0
daily B-MENTAL
crying I-MENTAL
episodes I-MENTAL
decreased 0
by 0
at 0
least 0
50 0
% 0
in 0
all 0
cases 0
during 0
citalopram 0
treatment 0
vs 0
2 0
patients 0
during 0
placebo 0
treatment 0
( 0
p 0
< 0
0.005 0
, 0
McNemar 0
's 0
test 0
) 0
, 0
the 0
effect 0
being 0
rapid 0
( 0
1-3 0
days 0
) 0
and 0
pronounced 0
in 0
11 0
( 0
73 0
% 0
) 0
. 0

There 0
was 0
a 0
concomitant 0
significant 0
decrease 0
in 0
depression B-MENTAL
rating I-MENTAL
from 0
HDS 0
8.9 0
to 0
5.3 0
( 0
p 0
< 0
0.005 0
, 0
Wilcoxon 0
's 0
test 0
) 0
. 0

Citalopram 0
was 0
well 0
tolerated 0
, 0
the 0
few 0
side-effects 0
being 0
mild 0
and 0
transient 0
. 0

We 0
conclude 0
that 0
serotoninergic 0
neurotransmission 0
plays 0
an 0
important 0
part 0
in 0
post-stroke 0
pathological 0
crying 0
and 0
that 0
citalopram 0
is 0
an 0
effective 0
and 0
well-tolerated 0
treatment 0
. 0

Acute 0
prolactin 0
and 0
oxytocin 0
responses 0
and 0
milk B-PHYSICAL
yield I-PHYSICAL
to 0
infant 0
suckling 0
and 0
artificial B-OTHER
methods I-OTHER
of I-OTHER
expression I-OTHER
in 0
lactating 0
women 0
. 0

Breast-feeding 0
is 0
today 0
the 0
major 0
form 0
of 0
infant 0
nutrition 0
in 0
the 0
immediate 0
postpartum 0
period 0
. 0

Despite 0
this 0
, 0
recent 0
trends 0
in 0
modern 0
life-styles 0
have 0
raised 0
obstacles 0
to 0
successful 0
lactation 0
. 0

These 0
include 0
infant 0
illness 0
and 0
maternal 0
responsibilities 0
outside 0
the 0
home 0
, 0
both 0
requiring 0
separation 0
from 0
the 0
mother 0
. 0

While 0
the 0
hormonal 0
dynamics 0
of 0
infant 0
suckling 0
are 0
understood 0
, 0
little 0
is 0
known 0
about 0
the 0
effects 0
of 0
artificial 0
methods 0
of 0
milk B-OTHER
expression I-OTHER
. 0

A 0
variety 0
of 0
breast 0
pumps 0
exist 0
in 0
the 0
current 0
US 0
market 0
which 0
vary 0
considerably 0
in 0
price 0
and 0
effectiveness 0
. 0

To 0
understand 0
better 0
the 0
ability 0
of 0
these 0
pumps 0
to 0
assist 0
women 0
in 0
the 0
maintenance 0
of 0
lactation 0
, 0
the 0
current 0
study 0
was 0
undertaken 0
to 0
evaluate 0
their 0
effects 0
on 0
milk 0
yield 0
and 0
prolactin 0
and 0
oxytocin B-OTHER
release I-OTHER
when 0
compared 0
to 0
natural 0
infant 0
suckling 0
. 0

Twenty-three 0
women 0
who 0
were 0
exclusively 0
breast-feeding 0
their 0
infants 0
were 0
randomly 0
assigned 0
to 0
serially 0
use 0
several 0
pumping 0
methods 0
, 0
as 0
well 0
as 0
infant 0
suckling 0
, 0
with 0
blood 0
being 0
taken 0
at 0
10-minute 0
intervals 0
to 0
determine 0
the 0
hormonal 0
responses 0
. 0

The 0
results 0
reveal 0
variability 0
in 0
the 0
prolactin B-OTHER
responses I-OTHER
to 0
the 0
artificial 0
pumping 0
methods 0
, 0
with 0
the 0
greatest 0
responses 0
found 0
with 0
an 0
electric 0
pulsatile 0
pump 0
; 0
these 0
responses 0
compare 0
favorably 0
with 0
those 0
of 0
natural 0
infant 0
suckling 0
. 0

Other 0
methods 0
were 0
less 0
successful 0
in 0
causing 0
prolactin B-OTHER
elevations I-OTHER
. 0

No 0
differences 0
were 0
seen 0
among 0
the 0
methods 0
in 0
the 0
oxytocin B-OTHER
response I-OTHER
. 0

The 0
results 0
of 0
this 0
study 0
demonstrate 0
striking 0
differences 0
in 0
the 0
ability 0
of 0
breast-pumping 0
methods 0
to 0
produce 0
an 0
acute B-OTHER
and I-OTHER
sustained I-OTHER
prolactin I-OTHER
rise I-OTHER
in 0
breast-feeding 0
mothers 0
. 0

The 0
large 0
discrepancies 0
found 0
suggest 0
the 0
need 0
for 0
further 0
studies 0
in 0
to 0
enable 0
women 0
and 0
health 0
care 0
providers 0
to 0
choose 0
the 0
most 0
appropriate 0
method 0
for 0
milk 0
expression 0
. 0
( 0

ABSTRACT 0
TRUNCATED 0
AT 0
250 0
WORDS 0
) 0

Yoga 0
effects 0
on 0
mood B-MENTAL
and 0
quality 0
of 0
life 0
in 0
Chinese 0
women 0
undergoing 0
heroin 0
detoxification 0
: 0
a 0
randomized 0
controlled 0
trial 0
. 0

BACKGROUND 0
Yoga 0
, 0
as 0
a 0
mind-body 0
therapy 0
, 0
is 0
effective 0
in 0
improving 0
quality 0
of 0
life 0
for 0
patients 0
with 0
chronic 0
diseases 0
, 0
yet 0
little 0
is 0
known 0
about 0
its 0
effectiveness 0
in 0
female 0
heroin 0
addicts 0
. 0

OBJECTIVES 0
The 0
aim 0
of 0
this 0
study 0
was 0
to 0
evaluate 0
the 0
effects 0
of 0
yoga 0
on 0
mood 0
status 0
and 0
quality 0
of 0
life 0
among 0
women 0
undergoing 0
detoxification 0
for 0
heroin 0
dependence 0
in 0
China 0
. 0

METHOD 0
This 0
study 0
was 0
a 0
randomized 0
controlled 0
trial 0
. 0

Seventy-five 0
women 0
aged 0
20-37 0
years 0
undergoing 0
detoxification 0
for 0
heroin 0
dependence 0
at 0
AnKang 0
Hospital 0
were 0
allocated 0
randomly 0
into 0
an 0
intervention 0
or 0
a 0
control 0
group 0
. 0

Women 0
in 0
the 0
intervention 0
group 0
received 0
a 0
6-month 0
yoga 0
intervention 0
in 0
addition 0
to 0
hospital 0
routine 0
care 0
, 0
and 0
women 0
in 0
the 0
control 0
group 0
received 0
hospital 0
routine 0
care 0
only 0
. 0

Mood 0
status 0
and 0
quality 0
of 0
life 0
were 0
assessed 0
using 0
the 0
Profile B-MENTAL
of I-MENTAL
Mood I-MENTAL
States I-MENTAL
and 0
Medical B-MENTAL
Outcomes I-MENTAL
Study I-MENTAL
36-item I-MENTAL
Short-Form I-MENTAL
Health I-MENTAL
Survey I-MENTAL
at 0
baseline 0
and 0
following 0
3 0
and 0
6 0
months 0
of 0
treatment 0
. 0

Repeated-measures 0
analysis 0
of 0
variance 0
was 0
used 0
to 0
evaluate 0
treatment 0
and 0
time 0
effects 0
on 0
mood 0
and 0
quality 0
of 0
life 0
. 0

RESULTS 0
Most 0
female 0
heroin 0
addicts 0
were 0
young 0
and 0
single 0
, 0
with 0
a 0
low 0
education 0
level 0
. 0

Most 0
had 0
used 0
heroin 0
by 0
injection 0
. 0

Mood 0
state 0
and 0
quality 0
of 0
life 0
of 0
female 0
heroin 0
addicts 0
were 0
poor 0
. 0

The 0
intervention 0
group 0
showed 0
a 0
significant 0
improvement 0
in 0
mood 0
status 0
and 0
quality 0
of 0
life 0
over 0
time 0
compared 0
with 0
their 0
counterparts 0
in 0
the 0
control 0
group 0
. 0

CONCLUSION 0
Yoga 0
may 0
improve 0
mood 0
status 0
and 0
quality 0
of 0
life 0
for 0
women 0
undergoing 0
detoxification 0
for 0
heroin 0
dependence 0
. 0

Yoga 0
can 0
be 0
used 0
as 0
an 0
auxiliary 0
treatment 0
with 0
traditional 0
hospital 0
routine 0
care 0
for 0
these 0
women 0
. 0

Assessing 0
drug 0
use 0
prevalence 0
in 0
the 0
workplace 0
: 0
a 0
comparison 0
of 0
self-report 0
methods 0
and 0
urinalysis 0
. 0

A 0
random 0
sample 0
of 0
800 0
employees 0
of 0
a 0
steel 0
manufacturing 0
company 0
were 0
randomly 0
assigned 0
to 0
one 0
of 0
four 0
self-report 0
methods 0
of 0
assessing 0
illicit 0
drug 0
use 0
: 0
1 0
) 0
Individual 0
interview 0
in 0
the 0
workplace 0
, 0
2 0
) 0
group-administered 0
questionnaire 0
in 0
the 0
workplace 0
, 0
3 0
) 0
telephone 0
interview 0
, 0
and 0
4 0
) 0
individual 0
interview 0
off 0
the 0
worksite 0
. 0

All 0
621 0
subjects 0
participating 0
in 0
the 0
research 0
were 0
also 0
tested 0
by 0
urinalysis 0
. 0

Rates 0
of 0
drug B-MENTAL
use I-MENTAL
self-report I-MENTAL
were 0
highest 0
in 0
the 0
workplace 0
interview 0
condition 0
and 0
lowest 0
in 0
the 0
overall 0
group 0
questionnaire 0
condition 0
. 0

Although 0
the 0
overall B-OTHER
prevalence 0
rates B-OTHER
produced 0
by 0
self-reports 0
and 0
urinalysis 0
were 0
similar 0
, 0
there 0
was 0
little 0
concordance 0
between 0
urinalysis B-OTHER
positives 0
and 0
self-report B-MENTAL
positives 0
. 0

The 0
results 0
indicated 0
that 0
self-reports 0
and 0
urinalysis 0
are 0
complementary 0
methods 0
of 0

Hemolytic 0
streptococcus 0
preparation 0
OK-432 0
; 0
beneficial 0
adjuvant 0
therapy 0
in 0
recurrent 0
gastric 0
carcinoma 0
. 0

The 0
administration 0
of 0
a 0
hemolytic 0
streptococcus 0
preparation 0
, 0
OK-432 0
, 0
is 0
thought 0
to 0
be 0
of 0
therapeutic 0
value 0
in 0
the 0
treatment 0
of 0
cancer 0
patients 0
through 0
a 0
stimulatory 0
effect 0
on 0
the 0
immune 0
system 0
. 0

In 0
order 0
to 0
evaluate 0
any 0
beneficial 0
effect 0
of 0
such 0
an 0
administration 0
, 0
a 0
group 0
of 0
patients 0
with 0
recurrent 0
gastric 0
cancer 0
was 0
studied 0
. 0

This 0
group 0
was 0
randomly 0
subdivided 0
into 0
3 0
groups 0
: 0
1 0
) 0
Intradermal 0
group 0
( 0
ID 0
Group 0
) 0
, 0
42 0
patients 0
given 0
an 0
intradermal 0
injections 0
of 0
OK-432 0
. 0

2 0
) 0
Intramuscular 0
group 0
( 0
IM 0
Group 0
) 0
, 0
40 0
patients 0
given 0
an 0
intramuscular 0
injections 0
of 0
OK-432 0
. 0

3 0
) 0
Control 0
group 0
( 0
C 0
Group 0
) 0
, 0
39 0
patients 0
not 0
given 0
injections 0
. 0

Each 0
group 0
was 0
studied 0
in 0
regards 0
to 0
the 0
length B-MORTALITY
of I-MORTALITY
survival I-MORTALITY
, 0
the 0
host B-PHYSICAL
immune I-PHYSICAL
response I-PHYSICAL
and 0
the 0
incidence 0
of 0
side B-ADVERSE-EFFECTS
effects I-ADVERSE-EFFECTS
. 0

When 0
compared 0
to 0
the 0
IM 0
and 0
C 0
Groups 0
, 0
the 0
ID 0
Group 0
showed 0
improved 0
survival B-MORTALITY
. 0

Accompanying 0
this 0
improved 0
survival 0
, 0
the 0
ID 0
Group 0
also 0
had 0
greater 0
white B-PHYSICAL
cell I-PHYSICAL
and I-PHYSICAL
lymphocyte I-PHYSICAL
counts I-PHYSICAL
, 0
a 0
greater 0
number 0
of 0
T 0
cells B-PHYSICAL
, 0
and 0
a 0
more 0
dramatic B-PHYSICAL
skin I-PHYSICAL
reaction I-PHYSICAL
to 0
the 0
extracted 0
cell 0
wall 0
polysaccharide 0
of 0
hemolytic 0
streptococcus 0
Su-strain 0
( 0
Su-PS 0
) 0
. 0

The 0
ID 0
Group 0
, 0
following 0
OK-432 0
injection 0
, 0
had 0
a 0
4.8 0
% 0
incidence 0
of 0
fever B-PHYSICAL
and 0
a 0
52.4 0
% 0
incidence 0
of 0
local B-PHYSICAL
abscess I-PHYSICAL
formation I-PHYSICAL
at 0
the 0
injection 0
site 0
. 0

90 0
% 0
of 0
the 0
IM 0
Group 0
developed 0
fever B-PHYSICAL
but 0
abscess B-PHYSICAL
formation I-PHYSICAL
was 0
absent 0
in 0
all 0
patients 0
. 0

From 0
these 0
results 0
, 0
it 0
was 0
concluded 0
that 0
in 0
the 0
patients 0
tested 0
, 0
intradermal 0
injection 0
of 0
OK-432 0
appears 0
to 0
be 0
clinically 0
superior 0
to 0
intramuscular 0
injection 0
. 0

Is 0
the 0
effect 0
of 0
mobile 0
phone 0
radiofrequency 0
waves 0
on 0
human 0
skin 0
perfusion 0
non-thermal 0
? 0

OBJECTIVE 0
To 0
establish 0
whether 0
SkBF B-PHYSICAL
can 0
be 0
modified 0
by 0
exposure 0
to 0
the 0
radiofrequency 0
waves 0
emitted 0
by 0
a 0
mobile 0
phone 0
when 0
the 0
latter 0
is 0
held 0
against 0
the 0
jaw 0
and 0
ear 0
. 0

METHODS 0
Variations B-PHYSICAL
in I-PHYSICAL
SkBF I-PHYSICAL
and 0
Tsk 0
in 0
adult 0
volunteers 0
were 0
simultaneously 0
recorded 0
with 0
a 0
thermostatic 0
laser 0
Doppler 0
system 0
during 0
a 0
20-minute 0
radiofrequency 0
exposure 0
session 0
and 0
a 0
20-minute 0
sham 0
session 0
. 0

The 0
skin 0
microvessels 0
' 0
vasodilatory 0
reserve 0
was 0
assessed 0
with 0
a 0
heat 0
challenge 0
at 0
the 0
end 0
of 0
the 0
protocol 0
. 0

RESULTS 0
During 0
the 0
radiofrequency 0
exposure 0
session 0
, 0
SkBF B-PHYSICAL
increased 0
( 0
vs. 0
baseline 0
) 0
more 0
than 0
during 0
the 0
sham 0
exposure 0
session 0
. 0

The 0
sessions 0
did 0
not 0
differ 0
significant 0
in 0
terms 0
of 0
the 0
Tsk B-OTHER
time-course I-OTHER
response I-OTHER
. 0

The 0
skin B-PHYSICAL
microvessels I-PHYSICAL
' 0
vasodilatory B-PHYSICAL
ability B-PHYSICAL
was 0
found 0
to 0
be 0
greater 0
during 0
radiofrequency 0
exposure 0
than 0
during 0
sham 0
exposure 0
. 0

CONCLUSIONS 0
Our 0
results 0
reveal 0
the 0
existence 0
of 0
a 0
specific 0

Vitamin 0
A 0
supplementation 0
for 0
extremely-low-birth-weight 0
infants 0
. 0

National 0
Institute 0
of 0
Child 0
Health 0
and 0
Human 0
Development 0
Neonatal 0
Research 0
Network 0
. 0

BACKGROUND 0
Vitamin 0
A 0
supplementation 0
may 0
reduce 0
the 0
risk 0
of 0
chronic 0
lung 0
disease 0
and 0
sepsis 0
in 0
extremely-low-birth-weight 0
infants 0
. 0

The 0
results 0
of 0
our 0
pilot 0
study 0
suggested 0
that 0
a 0
dose 0
of 0
5000 0
IU 0
administered 0
intramuscularly 0
three 0
times 0
per 0
week 0
for 0
four 0
weeks 0
was 0
more 0
effective 0
than 0
the 0
lower 0
doses 0
given 0
in 0
past 0
trials 0
. 0

METHODS 0
We 0
performed 0
a 0
multicenter 0
, 0
blinded 0
, 0
randomized 0
trial 0
to 0
assess 0
the 0
effectiveness 0
and 0
safety B-OTHER
of 0
this 0
regimen 0
as 0
compared 0
with 0
sham 0
treatment 0
in 0
807 0
infants 0
in 0
need 0
of 0
respiratory 0
support 0
24 0
hours 0
after 0
birth 0
. 0

The 0
mean 0
birth B-PHYSICAL
weight I-PHYSICAL
was 0
770 0
g 0
in 0
the 0
vitamin 0
A 0
group 0
and 0
769 0
g 0
in 0
the 0
control 0
group 0
, 0
and 0
the 0
respective 0
gestational 0
ages 0
were 0
26.8 0
and 0
26.7 0
weeks 0
. 0

RESULTS 0
By 0
36 0
weeks 0
' 0
postmenstrual 0
age 0
, 0
59 0
of 0
the 0
405 0
infants 0
( 0
15 0
percent 0
) 0
in 0
the 0
vitamin 0
A 0
group 0
and 0
55 0
of 0
the 0
402 0
infants 0
( 0
14 0
percent 0
) 0
in 0
the 0
control 0
group 0
had 0
died 0
. 0

The 0
primary 0
outcome 0
- 0
death B-MORTALITY
or I-MORTALITY
chronic I-MORTALITY
lung I-MORTALITY
disease I-MORTALITY
at 0
36 0
weeks 0
' 0
postmenstrual 0
age 0
- 0
occurred 0
in 0
significantly 0
fewer 0
infants 0
in 0
the 0
vitamin 0
A 0
group 0
than 0
in 0
the 0
control 0
group 0
( 0
55 0
percent 0
vs. 0
62 0
percent 0
; 0
relative 0
risk 0
, 0
0.89 0
; 0
95 0
percent 0
confidence 0
interval 0
, 0
0.80 0
to 0
0.99 0
) 0
. 0

Overall 0
, 0
1 0
additional 0
infant 0
survived 0
without 0
chronic B-MORTALITY
lung I-MORTALITY
disease I-MORTALITY
for 0
every 0
14 0
to 0
15 0
infants 0
who 0
received 0
vitamin 0
A 0
supplements 0
. 0

The 0
proportions 0
of 0
infants 0
in 0
the 0
vitamin 0
A 0
group 0
and 0
the 0
control 0
group 0
who 0
had 0
signs 0
of 0
potential B-PHYSICAL
vitamin I-PHYSICAL
A I-PHYSICAL
toxicity I-PHYSICAL
were 0
similar 0
. 0

The 0
proportion B-PHYSICAL
of I-PHYSICAL
infants I-PHYSICAL
with I-PHYSICAL
serum 0
retinol 0
values 0
below 0
20 0
microg 0
per 0
deciliter 0
( 0
0.70 0
micromol 0
per 0
liter 0
) 0
was 0
lower 0
in 0
the 0
vitamin 0
A 0
group 0
than 0
in 0
the 0
control 0
group 0
( 0
25 0
percent 0
vs. 0
54 0
percent 0
, 0
P 0
< 0
0.001 0
) 0
. 0

CONCLUSIONS 0
Intramuscular 0
administration 0
of 0
5000 0
IU 0
of 0
vitamin 0
A 0
three 0
times 0
per 0
week 0
for 0
four 0
weeks 0
reduced 0
biochemical 0
evidence 0
of 0
vitamin 0
A 0
deficiency 0
and 0
slightly 0
decreased 0
the 0
risk 0
of 0
chronic B-MORTALITY
lung I-MORTALITY
disease I-MORTALITY
in 0
extremely-low-birth-weight 0
infants 0
. 0

Uncomplicated 0
moderate 0
coronary 0
artery 0
dissections 0
after 0
balloon 0
angioplasty 0
: 0
good 0
outcome 0
without 0
stenting 0
. 0

OBJECTIVE 0
To 0
study 0
the 0
relation 0
between 0
moderate 0
coronary 0
dissections 0
, 0
coronary 0
flow 0
velocity 0
reserve 0
( 0
CFVR 0
) 0
, 0
and 0
long 0
term 0
outcome 0
. 0

METHODS 0
523 0
patients 0
undergoing 0
balloon 0
angioplasty 0
and 0
sequential 0
intracoronary 0
Doppler 0
measurements 0
were 0
examined 0
as 0
part 0
of 0
the 0
DEBATE 0
II 0
trial 0
( 0
Doppler 0
endpoints 0
balloon 0
angioplasty 0
trial 0
Europe 0
) 0
. 0

After 0
successful 0
balloon 0
angioplasty 0
, 0
patients 0
were 0
randomised 0
to 0
stenting 0
or 0
no 0
further 0
treatment 0
. 0

Dissections 0
were 0
graded 0
at 0
the 0
core 0
laboratory 0
by 0
two 0
observers 0
and 0
divided 0
into 0
four 0
categories 0
: 0
none 0
, 0
mild 0
( 0
type 0
A-B 0
) 0
, 0
moderate 0
( 0
type 0
C 0
) 0
, 0
severe 0
( 0
types 0
D 0
to 0
F 0
) 0
. 0

Patients 0
with 0
severe 0
dissections 0
( 0
n 0
= 0
128 0
) 0
or 0
without 0
available 0
reference 0
vessel 0
CFVR 0
( 0
n 0
= 0
139 0
) 0
were 0
excluded 0
. 0

The 0
remaining 0
256 0
patients 0
were 0
divided 0
into 0
two 0
groups 0
according 0
to 0
the 0
presence 0
( 0
group 0
A 0
, 0
n 0
= 0
45 0
) 0
or 0
absence 0
( 0
group 0
B 0
, 0
n 0
= 0
211 0
) 0
of 0
moderate 0
dissection 0
. 0

RESULTS 0
Following 0
balloon 0
angioplasty 0
, 0
there 0
was 0
no 0
difference 0
in 0
CFVR B-PHYSICAL
between 0
the 0
two 0
groups 0
. 0

At 0
12 0
months 0
follow 0
up 0
, 0
a 0
higher 0
rate 0
of 0
major B-ADVERSE-EFFECTS
adverse I-ADVERSE-EFFECTS
cardiac I-ADVERSE-EFFECTS
events I-ADVERSE-EFFECTS
was 0
observed 0
overall 0
in 0
group 0
A 0
than 0
in 0
group 0
B 0
( 0
10 0
( 0
22 0
% 0
) 0
v 0
23 0
( 0
11 0
% 0
) 0
, 0
p 0
= 0
0.041 0
) 0
. 0

However 0
, 0
the 0
risk 0
of 0
major B-ADVERSE-EFFECTS
adverse I-ADVERSE-EFFECTS
events I-ADVERSE-EFFECTS
was 0
similar 0
in 0
the 0
subgroups 0
receiving 0
balloon 0
angioplasty 0
( 0
group 0
A 0
, 0
6 0
( 0
19 0
% 0
) 0
v 0
group 0
B 0
, 0
16 0
( 0
16 0
% 0
) 0
, 0
NS 0
) 0
. 0

Among 0
group 0
A 0
patients 0
, 0
the 0
adverse B-ADVERSE-EFFECTS
events I-ADVERSE-EFFECTS
risk I-ADVERSE-EFFECTS
was 0
greater 0
in 0
those 0
randomised 0
to 0
stenting 0
( 0
odds 0
ratios 0
6.603 0
v 0
1.197 0
, 0
p 0
= 0
0.046 0
) 0
, 0
whereas 0
there 0
was 0
no 0
difference 0
in 0
risk 0
if 0
the 0
group 0
was 0
analysed 0
according 0
to 0
whether 0
the 0
CFVR 0
was 0
< 0
2.5 0
or 0
> 0
/= 0
2.5 0
after 0
balloon 0
angioplasty 0
. 0

CONCLUSIONS 0
Moderate 0
dissections 0
left 0
untreated 0
result 0
in 0
no 0
increased 0
risk 0
of 0
major B-ADVERSE-EFFECTS
adverse I-ADVERSE-EFFECTS
cardiac I-ADVERSE-EFFECTS
events I-ADVERSE-EFFECTS
. 0

Additional 0
stenting 0
does 0
not 0
improve 0
the 0
long 0
term 0
outcome 0
. 0

Pharmacokinetics B-OTHER
and I-OTHER
relative I-OTHER
bioavailability I-OTHER
of 0
prajmalium 0
bitartrate 0
after 0
single 0
oral 0
dosing 0
. 0

Pharmacokinetics B-PHYSICAL
and 0
relative B-PHYSICAL
bioavailability I-PHYSICAL
of 0
the 0
marketed 0
prajmalium 0
bitartrate 0
tablet 0
( 0
Neo-Gilurytmal 0
, 0
CAS 0
2589-47-1 0
) 0
compared 0
to 0
an 0
oral 0
solution 0
were 0
investigated 0
in 0
an 0
open 0
, 0
randomized 0
, 0
single-dose 0
two-fold 0
crossover 0
study 0
in 0
20 0
healthy 0
male 0
volunteers 0
. 0

One 0
subject 0
was 0
identified 0
to 0
be 0
a 0
poor B-OTHER
metabolizer I-OTHER
. 0

In 0
the 0
study 0
population 0
with 0
normal 0
metabolic 0
status 0
the 0
two 0
oral 0
formulations 0
proved 0
to 0
be 0
bioequivalent 0
with 0
regard 0
to 0
the 0
pharmacokinetic B-PHYSICAL
parameters I-PHYSICAL
Cmax I-PHYSICAL
, 0
AUC B-PHYSICAL
( I-PHYSICAL
0-Tlast I-PHYSICAL
) I-PHYSICAL
, 0
AUC B-PHYSICAL
( I-PHYSICAL
0-infinity I-PHYSICAL
) I-PHYSICAL
and 0
Ae B-PHYSICAL
( I-PHYSICAL
24h I-PHYSICAL
) I-PHYSICAL
. 0

tmax B-PHYSICAL
was 0
prolonged 0
after 0
administration 0
of 0
the 0
tablets 0
. 0

The 0
relative B-PHYSICAL
bioavailability I-PHYSICAL
of 0
prajmalium 0
bitartrate 0
from 0
the 0
tablet 0
amounted 0
to 0
112 0
% 0
. 0

The 0
poor 0
metabolizer 0
demonstrated 0
in 0
both 0
oral 0
formulations 0
high B-PHYSICAL
plasma I-PHYSICAL
concentrations I-PHYSICAL
, 0
increased B-PHYSICAL
AUCs I-PHYSICAL
and I-PHYSICAL
prolonged I-PHYSICAL
terminal I-PHYSICAL
half-lives I-PHYSICAL
as I-PHYSICAL
well I-PHYSICAL
as I-PHYSICAL
increased I-PHYSICAL
renal I-PHYSICAL
excretion I-PHYSICAL
of I-PHYSICAL
prajmalium I-PHYSICAL

Evaluation 0
of 0
the 0
effect 0
of 0
acetazolamide 0
on 0
cystoid 0
macular 0
oedema 0
in 0
patients 0
with 0
Behcet 0
's 0
disease 0
. 0

AIM 0
To 0
study 0
the 0
effect 0
of 0
acetazolamide 0
on 0
cystoid 0
macular 0
oedema 0
( 0
CMO 0
) 0
in 0
patients 0
with 0
Behcet 0
's 0
disease 0
. 0

PATIENTS 0
AND 0
METHODS 0
A 0
total 0
of 0
67 0
eyes 0
of 0
35 0
Behcet 0
's 0
patients 0
with 0
chronic 0
, 0
but 0
well-controlled 0
uveitis 0
, 0
and 0
CMO 0
were 0
randomised 0
into 0
a 0
double-masked 0
, 0
crossover 0
trial 0
comparing 0
the 0
effect 0
of 0
acetazolamide 0
vs 0
placebo 0
. 0

The 0
patients 0
received 0
an 0
initial 0
4-week 0
course 0
of 0
either 0
250 0
mg 0
acetazolamide 0
twice 0
daily 0
( 0
b.i.d 0
. 0
) 0

or 0
placebo 0
, 0
followed 0
by 0
a 0
4-week 0
washout 0
period 0
. 0

They 0
then 0
received 0
a 0
4-week 0
course 0
of 0
the 0
reverse 0
study 0
medication 0
. 0

An 0
improvement 0
in 0
visual B-PHYSICAL
acuity I-PHYSICAL
and 0
fundus B-PHYSICAL
fluorescein I-PHYSICAL
angiographic I-PHYSICAL
findings I-PHYSICAL
was 0
assessed 0
. 0

RESULTS 0
In 0
total 0
, 0
29 0
patients 0
( 0
55 0
eyes 0
) 0
completed 0
the 0
trial 0
and 0
were 0
available 0
for 0
analysis 0
. 0

Of 0
the 0
29 0
, 0
16 0
men 0
and 0
13 0
were 0
women 0
. 0

The 0
age 0
range 0
was 0
13-50 0
years 0
( 0
mean 0
33.6 0
years 0
) 0
. 0

Patients 0
on 0
acetazolamide 0
showed 0
a 0
slightly 0
better 0
improvement 0
of 0
angiographic B-PHYSICAL
signs I-PHYSICAL
( 0
at 0
least 0
by 0
one 0
grade 0
improvement 0
) 0
over 0
that 0
of 0
placebo 0
( 0
12 0
vs 0
five 0
eyes 0
) 0
. 0

They 0
also 0
had 0
less 0
deterioration 0
of 0
angiographic B-PHYSICAL
signs I-PHYSICAL
over 0
that 0
of 0
placebo 0
( 0
three 0
vs 0
seven 0
eyes 0
) 0
. 0

However 0
, 0
these 0
findings 0
were 0
not 0
statistically 0
significant 0
( 0
P=0.99 0
) 0
. 0

Acetazolamide 0
had 0
no 0
statistically 0
significant 0
effect 0
( 0
P=0.53 0
) 0
on 0
the 0
improvement 0
of 0
visual B-PHYSICAL
acuity I-PHYSICAL
of 0
patients 0
over 0
that 0
of 0
placebo 0
( 0
13 0
vs 0
eight 0
eyes 0
) 0
, 0
nor 0
on 0
the 0
deterioration 0
of 0
visual B-PHYSICAL
acuity I-PHYSICAL
( 0
three 0
vs 0
11 0
eyes 0
) 0
. 0

CONCLUSION 0
Despite 0
seemingly 0
favourable 0
results 0
, 0
the 0
4-week 0
course 0
of 0
acetazolamide 0
( 0
250 0
mg 0
b.i.d 0
. 0
) 0

has 0
no 0
statistically 0
significant 0
effect 0
on 0
the 0
improvement 0
of 0
the 0
visual B-PHYSICAL
acuity I-PHYSICAL
and 0
the 0
fluorescein B-PHYSICAL
angiographic I-PHYSICAL
findings I-PHYSICAL
in 0
Behcet 0
's 0
patients 0
with 0
CMO 0
. 0

CDP571 0
, 0
a 0
humanized 0
monoclonal 0
antibody 0
to 0
tumour 0
necrosis 0
factor-alpha 0
, 0
for 0
steroid-dependent 0
Crohn 0
's 0
disease 0
: 0
a 0
randomized 0
, 0
double-blind 0
, 0
placebo-controlled 0
trial 0
. 0

BACKGROUND 0
More 0
than 0
50 0
% 0
of 0
patients 0
with 0
Crohn 0
's 0
disease 0
become 0
either 0
steroid 0
resistant 0
or 0
dependent 0
. 0

Accordingly 0
, 0
development 0
of 0
new 0
treatments 0
for 0
steroid-dependent 0
Crohn 0
's 0
disease 0
is 0
a 0
research 0
priority 0
. 0

AIM 0
To 0
evaluate 0
CDP571 0
, 0
a 0
humanized 0
antibody 0
to 0
tumour 0
necrosis 0
factor-alpha 0
, 0
for 0
the 0
treatment 0
of 0
steroid-dependent 0
Crohn 0
's 0
disease 0
. 0

METHODS 0
Patients 0
with 0
steroid-dependent 0
Crohn 0
's 0
disease 0
( 0
n 0
= 0
271 0
) 0
were 0
enrolled 0
in 0
a 0
36-week 0
, 0
double-blind 0
, 0
placebo-controlled 0
trial 0
. 0

Steroid 0
dependence 0
was 0
defined 0
as 0
use 0
of 0
prednisolone 0
or 0
prednisone 0
( 0
15-40 0
mg/day 0
) 0
or 0
budesonide 0
( 0
9 0
mg/day 0
) 0
for 0
> 0
or 0
=8 0
weeks 0
, 0
a 0
previous 0
failed 0
attempt 0
to 0
decrease 0
or 0
discontinue 0
steroids 0
within 0
8 0
weeks 0
of 0
screening 0
, 0
and 0
a 0
Crohn 0
's 0
Disease 0
Activity 0
Index 0
score 0
of 0
< 0
or 0
=150 0
points 0
. 0

Patients 0
were 0
randomized 0
to 0
receive 0
intravenous 0
CDP571 0
10 0
mg/kg 0
or 0
placebo 0
8-weekly 0
through 0
to 0
week 0
32 0
. 0

Steroids 0
were 0
then 0
tapered 0
using 0
a 0
defined 0
schedule 0
. 0

The 0
primary 0
efficacy 0
endpoint 0
was 0
the 0
percentage 0
of 0
patients B-PHYSICAL
with I-PHYSICAL
steroid I-PHYSICAL
sparing I-PHYSICAL
, 0
defined 0
as 0
discontinuation 0
of 0
steroid 0
therapy 0
without 0
a 0
disease 0
flare 0
( 0
Crohn 0
's 0
Disease 0
Activity 0
Index 0
score 0
> 0
or 0
=220 0
points 0
) 0
at 0
week 0
36 0
. 0

RESULTS 0
Steroid B-PHYSICAL
sparing I-PHYSICAL
occurred 0
in 0
53 0
of 0
181 0
( 0
29.3 0
% 0
) 0
CDP571 0
patients 0
and 0
33 0
of 0
90 0
( 0
36.7 0
% 0
) 0
placebo 0
patients 0
( 0
P 0
= 0
0.24 0
) 0
. 0

Adverse B-ADVERSE-EFFECTS
events I-ADVERSE-EFFECTS
occurred 0
at 0
similar 0
frequencies 0
in 0
both 0
treatment 0
groups 0
. 0

CONCLUSIONS 0
CDP571 0
was 0
ineffective 0
for 0
sparing B-ADVERSE-EFFECTS
steroids I-ADVERSE-EFFECTS
in 0
patients 0
with 0
steroid-dependent 0
Crohn 0
's 0
disease 0
. 0

CDP571 0
was 0
well 0
tolerated 0
. 0

Letrozole 0
in 0
the 0
neoadjuvant 0
setting 0
: 0
the 0
P024 0
trial 0
. 0

Neoadjuvant 0
chemotherapy 0
trials 0
have 0
consistently 0
reported 0
lower 0
response 0
rates B-OTHER
in 0
hormone 0
receptor-positive 0
( 0
HR+ 0
) 0
breast 0
cancer 0
when 0
compared 0
with 0
HR- 0
cases 0
. 0

Preoperative 0
endocrine 0
therapy 0
has 0
therefore 0
become 0
a 0
logical 0
alternative 0
and 0
has 0
gained 0
considerable 0
momentum 0
from 0
the 0
finding 0
that 0
aromatase 0
inhibitors 0
( 0
AIs 0
) 0
are 0
more 0
effective 0
than 0
tamoxifen 0
for 0
HR+ 0
breast 0
cancer 0
in 0
both 0
the 0
neoadjuvant 0
and 0
adjuvant 0
settings 0
. 0

The 0
most 0
convincing 0
neoadjuvant 0
trial 0
to 0
demonstrate 0
the 0
superiority 0
of 0
an 0
AI 0
versus 0
tamoxifen 0
was 0
the 0
P024 0
study 0
, 0
a 0
large 0
multinational 0
double-blind 0
trial 0
in 0
postmenopausal 0
women 0
with 0
HR+ 0
breast 0
cancer 0
ineligible 0
for 0
breast-conserving 0
surgery 0
. 0

The 0
overall B-OTHER
response 0
rate B-OTHER
( I-OTHER
ORR I-OTHER
) B-OTHER
was 0
55 0
% 0
for 0
letrozole 0
and 0
36 0
% 0
for 0
tamoxifen 0
( 0
P 0
< 0
0.001 0
) 0
. 0

Significantly 0
more 0
letrozole-treated 0
patients 0
underwent B-OTHER
breast-conserving B-OTHER
surgery I-OTHER
( 0
45 0
vs. 0
35 0
% 0
, 0
respectively 0
; 0
P=0.022 0
) 0
. 0

In 0
addition 0
, 0
ORR B-OTHER
was 0
significantly 0
higher 0
with 0
letrozole 0
than 0
tamoxifen 0
in 0
the 0
human 0
epidermal 0
growth 0
factor 0
receptor 0
HER1/HER2+ 0
subgroup 0
( 0
P=0.0004 0
) 0
. 0

The 0
clinical B-OTHER
efficacy I-OTHER
of 0
letrozole 0
in 0
HER2+ 0
breast 0
cancer 0
was 0
confirmed 0
by 0
fluorescent 0
in 0
situ 0
hybridization 0
analysis 0
and 0
was 0
found 0
to 0
be 0
comparable 0
to 0
that 0
of 0
HER2- 0
cases 0
( 0
ORR 0
71 0
% 0
in 0
both 0
subsets 0
) 0
. 0

Biomarker B-OTHER
studies I-OTHER
confirmed 0
the 0
superiority 0
of 0
letrozole 0
in 0
centrally 0
assessed 0
estrogen 0
receptor-positive 0
( 0
ER+ 0
) 0
tumors 0
and 0
found 0
a 0
strong 0
relationship 0
with 0
the 0
degree B-OTHER
of I-OTHER

Effects 0
of 0
a 0
low-salt 0
diet 0
and 0
of 0
acute 0
salt 0
loading 0
on 0
blood B-PHYSICAL
pressure I-PHYSICAL
and 0
intralymphocytic B-PHYSICAL
sodium I-PHYSICAL
concentration I-PHYSICAL
in 0
young 0
subjects 0
with 0
borderline 0
hypertension 0
. 0

1 0
. 0

Three 0
groups 0
of 0
young 0
patients 0
with 0
borderline 0
hypertension 0
were 0
studied 0
for 0
a 0
12 0
months 0
period 0
. 0

The 0
first 0
was 0
on 0
a 0
free 0
sodium 0
diet 0
while 0
the 0
second 0
was 0
on 0
a 0
low-salt 0
diet 0
. 0

The 0
third 0
group 0
of 0
patients 0
underwent 0
acute 0
salt 0
loading 0
. 0

2 0
. 0

After 0
12 0
months 0
the 0
group 0
on 0
free 0
diet 0
showed 0
a 0
significant 0
increase 0
of 0
intralymphocytic B-PHYSICAL
sodium I-PHYSICAL
but 0
no 0
change 0
in 0
blood B-PHYSICAL
pressure I-PHYSICAL
was 0
noted 0
. 0

Five 0
patients 0
who 0
were 0
re-checked 0
after 0
24 0
months 0
also 0
had 0
a 0
significant 0
increase 0
in 0
blood B-PHYSICAL
pressure I-PHYSICAL
. 0

3 0
. 0

Patients 0
treated 0
with 0
a 0
low-salt 0
diet 0
showed 0
a 0
significant 0
decrease 0
of 0
both 0
intralymphocytic B-PHYSICAL
sodium I-PHYSICAL
concentration I-PHYSICAL
and 0
blood B-PHYSICAL
pressure I-PHYSICAL
. 0

4 0
. 0

After 0
acute 0
salt 0
loading 0
, 0
borderline 0
subjects 0
with 0
high 0
intralymphocytic 0
sodium 0
showed 0
a 0
significant 0
greater 0
natriuresis B-PHYSICAL
whereas 0
intralymphocytic B-PHYSICAL
sodium I-PHYSICAL
increased 0
only 0
in 0
those 0
subjects 0
in 0
whom 0
it 0
was 0
initially 0
normal 0
. 0

Marginal 0
zone 0
B 0
cell 0
lymphoma 0
of 0
the 0
parotid 0
glands 0
: 0
results 0
of 0
a 0
randomised 0
trial 0
comparing 0
radiotherapy 0
to 0
combined 0
therapy 0
. 0

39 0
patients 0
with 0
marginal 0
zone 0
B 0
cell 0
lymphoma 0
( 0
MZBCL 0
) 0
of 0
the 0
parotid 0
glands 0
( 0
stages 0
I 0
or 0
II 0
) 0
were 0
studied 0
. 0

They 0
were 0
randomized 0
to 0
be 0
treated 0
with 0
either 0
radiotherapy 0
alone 0
( 0
extended 0
fields 0
, 0
4500 0
cGy 0
) 0
or 0
radiotherapy 0
( 0
the 0
same 0
schedule 0
) 0
plus 0
adjuvant 0
chemotherapy 0
( 0
cyclophosphamide 0
, 0
vincristine 0
and 0
prednisone 0
) 0
. 0

The 0
end B-PHYSICAL
points I-PHYSICAL
were 0
survival 0
and 0
time 0
to 0
treatment 0
failure 0
( 0
TTF 0
) 0
. 0

Patients 0
who 0
received 0
radiotherapy 0
alone 0
had 0
a 0
complete B-PHYSICAL
remission I-PHYSICAL
rate I-PHYSICAL
of 0
100 0
% 0
, 0
the 0
TTF B-OTHER
was 0
90 0
% 0
at 0
5 0
years 0
and 0
overall B-MORTALITY
survival I-MORTALITY
at 0
5 0
years 0
was 0
90 0
% 0
with 0
no 0
statistical 0
difference 0
when 0
compared 0
with 0
patients 0
who 0
received 0
combined 0
therapy 0
[ 0
100 0
, 0
80 0
and 0
95 0
% 0
, 0
respectively 0
( 0
P 0
= 0
0.5 0
) 0
] 0
. 0

Although 0
adjuvant 0
chemotherapy 0
was 0
well 0
tolerated B-OTHER
, 0
the 0
use 0
of 0
this 0
therapeutic 0
approach 0
in 0
patients 0
with 0
early 0
stage 0
MZBCL 0
did 0
not 0
offer 0
any 0
advantage 0
over 0
radiotherapy 0
alone 0
as 0
the 0
initial 0
treatment 0
. 0

Until 0
now 0
, 0
radiotherapy 0
was 0
considered 0
the 0
treatment 0
of 0
choice 0
in 0
this 0
clinical 0
setting 0
of 0
patients 0
. 0

A 0
placebo-controlled 0
, 0
fixed-dose 0
study 0
of 0
aripiprazole 0
in 0
children 0
and 0
adolescents 0
with 0
irritability 0
associated 0
with 0
autistic 0
disorder 0
. 0

OBJECTIVE 0
To 0
evaluate 0
the 0
short-term 0
efficacy 0
and 0
safety B-OTHER
of 0
aripiprazole 0
in 0
the 0
treatment 0
of 0
irritability 0
in 0
children 0
and 0
adolescents 0
with 0
autistic 0
disorder 0
. 0

METHOD 0
Two 0
hundred 0
eighteen 0
children 0
and 0
adolescents 0
( 0
aged 0
6-17 0
years 0
) 0
with 0
a 0
diagnosis 0
of 0
autistic 0
disorder 0
, 0
and 0
with 0
behaviors 0
such 0
as 0
tantrums 0
, 0
aggression 0
, 0
self-injurious 0
behavior 0
, 0
or 0
a 0
combination 0
of 0
these 0
symptoms 0
, 0
were 0
randomized 0
1:1:1:1 0
to 0
aripiprazole 0
( 0
5 0
, 0
10 0
, 0
or 0
15 0
mg/day 0
) 0
or 0
placebo 0
in 0
this 0
8-week 0
double-blind 0
, 0
randomized 0
, 0
placebo-controlled 0
, 0
parallel-group 0
study 0
. 0

Efficacy 0
was 0
evaluated 0
using 0
the 0
caregiver-rated 0
Aberrant B-MENTAL
Behavior I-MENTAL
Checklist I-MENTAL
Irritability I-MENTAL
subscale I-MENTAL
( I-MENTAL
primary I-MENTAL
efficacy 0
measure B-MENTAL
) B-MENTAL
and 0
the 0
clinician-rated B-MENTAL
Clinical B-MENTAL
Global B-MENTAL
Impressions-Improvement B-MENTAL
score 0
. 0

Safety B-OTHER
and 0
tolerability B-OTHER
were 0
also 0
assessed 0
. 0

RESULTS 0
At 0
week 0
8 0
, 0
all 0
aripiprazole 0
doses 0
produced 0
significantly 0
greater 0
improvement B-OTHER
than 0
placebo 0
in 0
mean 0
Aberrant B-MENTAL
Behavior I-MENTAL
Checklist B-MENTAL
Irritability I-MENTAL
subscale B-MENTAL
scores 0
( 0
5 0
mg/day 0
, 0
-12.4 0
; 0
10 0
mg/day 0
, 0
-13.2 0
; 0
15 0
mg/day 0
, 0
-14.4 0
; 0
versus 0
placebo 0
, 0
-8.4 0
; 0
all 0
p 0
< 0
.05 0
) 0
. 0

All 0
aripiprazole 0
doses 0
demonstrated 0
significantly 0
greater 0
improvements B-MENTAL
in B-MENTAL
mean 0
Clinical B-MENTAL
Global B-MENTAL
Impressions-Improvement B-MENTAL
score 0
than 0
placebo 0
at 0
week 0
8 0
. 0

Discontinuation 0
rates 0
due 0
to 0
adverse B-ADVERSE-EFFECTS
events I-ADVERSE-EFFECTS
were 0
as 0
follows 0
: 0
placebo 0
7.7 0
% 0
, 0
aripiprazole 0
5 0
mg/day 0
9.4 0
% 0
, 0
10 0
mg/day 0
13.6 0
% 0
, 0
and 0
15 0
mg/day 0
7.4 0
% 0
. 0

The 0
most 0
common 0

Haemodynamic 0
profile 0
of 0
angiotensin 0
II 0
antagonism 0
in 0
essential 0
hypertensive 0
patients 0
. 0

1 0
. 0

The 0
haemodynamic 0
response 0
to 0
antagonistic 0
( 0
10 0
microgram 0
min-1 0
kg-1 0
) 0
and 0
agonistic 0
( 0
40 0
microgram 0
min-1 0
kg-1 0
) 0
doses 0
of 0
saralasin 0
was 0
studied 0
in 0
young 0
essential 0
hypertensive 0
patients 0
. 0

Blood B-PHYSICAL
pressure I-PHYSICAL
behaviour I-PHYSICAL
alone 0
was 0
thought 0
to 0
be 0
inadequate 0
to 0
describe 0
the 0
response 0
pattern 0
. 0

2 0
. 0

Pre-saralasin 0
setting 0
of 0
the 0
renin-angiotensin 0
axis 0
was 0
varied 0
with 0
salt 0
intake 0
( 0
15 0
and 0
290 0
mmol 0
of 0
Na+/day 0
) 0
each 0
for 0
10 0
days 0
. 0

This 0
failed 0
to 0
influence 0
blood B-PHYSICAL
pressure I-PHYSICAL
or 0
plasma B-PHYSICAL
volume I-PHYSICAL
. 0

3 0
. 0

Antagonist 0
blockade 0
after 0
low 0
salt 0
lowered 0
blood B-PHYSICAL
pressure I-PHYSICAL
in 0
three 0
patients 0
with 0
the 0
highest 0
plasma 0
renin 0
values 0
. 0

Cardiac B-PHYSICAL
output I-PHYSICAL
rose 0
in 0
two 0
of 0
these 0
, 0
but 0
it 0
dropped 0
in 0
all 0
others 0
. 0

4 0
. 0

Decreases 0
in 0
cardiac B-PHYSICAL
output I-PHYSICAL
occurred 0
with 0
both 0
doses 0
of 0
saralasin 0
and 0
even 0
with 0
suppression 0
of 0
the 0
renin-angiotensin 0
axis 0
. 0

This 0
response 0
is 0
therefore 0
unlikely 0
to 0
be 0
due 0
to 0
removal 0
of 0
myocardial B-PHYSICAL
or I-PHYSICAL
venous I-PHYSICAL
angiotensin I-PHYSICAL
effects I-PHYSICAL
. 0

5 0
. 0

The 0
renin-angiotensin 0
system 0
played 0
a 0
part 0
in 0
maintenance 0
of 0
blood B-PHYSICAL
pressure I-PHYSICAL
only 0
with 0
severe 0
salt 0
restriction 0
and 0
in 0
a 0
small 0
proportion 0
of 0
cases 0
. 0

6 0
. 0

No 0
heart B-PHYSICAL
rate I-PHYSICAL
effect 0
was 0
seen 0
with 0
sarcalasin 0
. 0

7 0
. 0

Blood B-PHYSICAL
pressure I-PHYSICAL
and I-PHYSICAL
total 0
peripheral B-PHYSICAL
resistance I-PHYSICAL
responses B-PHYSICAL
were 0
dependent 0
on 0
pre- 0
( 0
antagonist/agonist 0
) 0
setting 0
, 0
but 0
heart B-PHYSICAL
rate I-PHYSICAL
and 0

A 0
randomized 0
trial 0
of 0
a 0
health 0
care 0
program 0
for 0
first-time 0
adolescent 0
mothers 0
and 0
their 0
infants 0
. 0

To 0
test 0
the 0
effectiveness 0
of 0
a 0
special 0
health 0
care 0
program 0
for 0
adolescent 0
mothers 0
( 0
17 0
years 0
old 0
or 0
younger 0
) 0
and 0
their 0
infants 0
, 0
243 0
mother-infant 0
pairs 0
were 0
randomly 0
assigned 0
to 0
one 0
of 0
two 0
groups 0
. 0

All 0
of 0
the 0
mothers 0
were 0
unwed 0
, 0
on 0
Medicaid 0
, 0
and 0
black 0
. 0

The 0
control 0
group 0
received 0
routine 0
well-baby 0
care 0
. 0

The 0
experimental 0
group 0
received 0
routine 0
care 0
and 0
services 0
that 0
included 0
rigorous 0
follow-up 0
, 0
discussions 0
with 0
the 0
mother 0
about 0
her 0
plans 0
for 0
return 0
to 0
school 0
and 0
use 0
of 0
family 0
planning 0
methods 0
, 0
and 0
extra 0
health 0
teaching 0
. 0

The 0
dropout 0
rate 0
in 0
the 0
experimental 0
group 0
( 0
60 0
% 0
) 0
was 0
significantly 0
less 0
after 0
18 0
months 0
than 0
the 0
control 0
group 0
( 0
82 0
% 0
) 0
. 0

In 0
spite 0
of 0
the 0
high 0
dropout 0
rate 0
, 0
91 0
% 0
of 0
the 0
mothers 0
were 0
located 0
for 0
the 0
18 0
month 0
follow-up 0
interview 0
. 0

The 0
repeat B-PHYSICAL
pregnancy I-PHYSICAL
rate I-PHYSICAL
in 0
the 0
experimental 0
group 0
was 0
12 0
% 0
after 0
18 0
months 0
, 0
and 0
28 0
% 0
in 0
the 0
control 0
group 0
. 0

There 0
was 0
no 0
significant 0
difference 0
in 0
the 0
percentage B-MENTAL
returning I-MENTAL
to I-MENTAL
school I-MENTAL
. 0

After 0
12 0
months 0
, 0
the 0
infants 0
in 0
the 0
experimental 0
group 0
were 0
more 0
likely 0
to 0
be 0
fully B-PHYSICAL
immunized I-PHYSICAL
( 0
33 0
% 0
) 0
than 0
the 0
infants 0
in 0
the 0
control 0
group 0
( 0
18 0
% 0
) 0
. 0

Mothers 0
in 0
the 0
special 0
care 0
program 0
who 0
continued 0
to 0
attend 0
clinic 0
used 0
the B-OTHER
emergency I-OTHER
room I-OTHER
less 0
than 0
the 0
mothers 0
who 0
continued 0
to 0
attend 0
in 0
the 0
control 0
group 0
. 0

These 0
results 0
suggest 0
that 0
a 0
comprehensive 0
health 0
care 0
program 0
is 0
one 0
way 0
to 0
bring 0
about 0
better 0
outcomes 0
for 0
both 0
adolescent 0
mothers 0
and 0
their 0
infants 0
. 0

Hypotensive 0
effects 0
and 0
influence 0
on 0
serum B-PHYSICAL
lipids I-PHYSICAL
of 0
SQ29,852 0
, 0
a 0
new 0
angiotensin 0
converting 0
enzyme 0
inhibitor 0
, 0
in 0
patients 0
with 0
essential 0
hypertension 0
: 0
a 0
comparison 0
with 0
atenolol 0
. 0

The 0
effects 0
of 0
SQ29,852 0
( 0
n 0
= 0
24 0
) 0
, 0
a 0
new 0
angiotensin 0
converting 0
enzyme 0
inhibitor 0
, 0
and 0
atenolol 0
( 0
n 0
= 0
22 0
) 0
, 0
monotherapies 0
were 0
compared 0
in 0
46 0
patients 0
with 0
mild 0
to 0
moderate 0
essential 0
hypertension 0
. 0

Both 0
SQ29,852 0
( 0
mean 0
dose 0
15.0 0
+/- 0
5.1 0
mg/day 0
) 0
and 0
atenolol 0
( 0
mean 0
dose 0
37.5 0
+/- 0
18.5 0
mg/day 0
) 0
significantly 0
decreased 0
both 0
systolic B-PHYSICAL
and I-PHYSICAL
diastolic I-PHYSICAL
blood I-PHYSICAL
pressures I-PHYSICAL
. 0

There 0
were 0
no 0
significant 0
changes 0
in 0
serum B-PHYSICAL
lipids I-PHYSICAL
, 0
apolipoproteins B-PHYSICAL
, 0
lipoproteins B-PHYSICAL
or 0
atherosclerotic B-PHYSICAL
indices I-PHYSICAL
after 0
both 0
SQ29,852 0
and 0
atenolol 0
. 0

There 0
were 0
also 0
no 0
significant B-OTHER
inter-group I-OTHER
differences I-OTHER
. 0

There 0
were 0
no 0
serious B-ADVERSE-EFFECTS
side I-ADVERSE-EFFECTS
effects I-ADVERSE-EFFECTS
or I-ADVERSE-EFFECTS
abnormal I-ADVERSE-EFFECTS
laboratory I-ADVERSE-EFFECTS
tests I-ADVERSE-EFFECTS
in 0
both 0
treatment 0
groups 0
. 0

It 0
is 0
concluded 0
that 0
SQ29,852 0
is 0
an 0
effective 0
antihypertensive 0
drug 0
without 0
adverse B-ADVERSE-EFFECTS
effect 0
on 0
lipid 0
metabolism 0
. 0

Prediction 0
of 0
metabolic 0
and 0
cardiopulmonary 0
responses 0
to 0
maximum 0
cycle 0
ergometry 0
: 0
a 0
randomised 0
study 0
. 0

All 0
of 0
the 0
most 0
widely-cited 0
studies 0
for 0
the 0
prediction 0
of 0
maximum B-PHYSICAL
exercise I-PHYSICAL
responses I-PHYSICAL
have 0
utilized 0
either 0
volunteers 0
or 0
referred 0
subjects 0
. 0

Therefore 0
, 0
selection 0
bias 0
, 0
with 0
overestimation 0
of 0
the 0
reference 0
values 0
, 0
is 0
a 0
likely 0
consequence 0
. 0

In 0
order 0
to 0
establish 0
a 0
set 0
of 0
predictive 0
equations 0
for 0
the 0
gas B-PHYSICAL
exchange I-PHYSICAL
, 0
ventilatory B-PHYSICAL
and 0
cardiovascular B-PHYSICAL
responses I-PHYSICAL
to 0
maximum 0
ramp-incremental 0
cycle 0
ergometry 0
, 0
this 0
study 0
prospectively 0
evaluated 0
120 0
sedentary 0
individuals 0
( 0
60 0
males 0
, 0
60 0
females 0
, 0
aged 0
20-80 0
) 0
, 0
randomly-selected 0
from 0
> 0
8,000 0
subjects 0
. 0

Regular 0
physical B-PHYSICAL
activity I-PHYSICAL
pattern I-PHYSICAL
by I-PHYSICAL
questionnaire 0
, 0
body B-PHYSICAL
composition I-PHYSICAL
by I-PHYSICAL
anthropometry I-PHYSICAL
and I-PHYSICAL
dual I-PHYSICAL
energy I-PHYSICAL
X-ray I-PHYSICAL
absorptiometry I-PHYSICAL
( 0
n B-PHYSICAL
= I-PHYSICAL
75 I-PHYSICAL
) 0
and B-PHYSICAL
knee I-PHYSICAL
strength I-PHYSICAL
by I-PHYSICAL
isokinetic I-PHYSICAL
dynamometry B-PHYSICAL
were 0
also 0
assessed 0
. 0

Previously 0
reported 0
equations 0
typically 0
overestimated 0
the 0
subjects 0
' 0
peak 0
oxygen B-PHYSICAL
uptake I-PHYSICAL
( 0
p 0
< 0
0.05 0
) 0
. 0

Prediction 0
linear 0
equations 0
for 0
the 0
main 0
variables 0
of 0
clinical 0
interest 0
were 0
established 0
by 0
backward 0
stepwise 0
regression 0
analysis 0
including 0
: 0
sex 0
, 0
age 0
, 0
knee 0
extensor 0
peak 0
torque 0
, 0
bone-free 0
lean 0
leg 0
mass 0
, 0
total 0
and 0
lean 0
body 0
mass 0
, 0
height 0
, 0
and 0
physical 0
activity 0
scores 0
. 0

Reference B-PHYSICAL
intervals I-PHYSICAL
( 0
95 0
% 0
confidence 0
limits 0
) 0
were 0
calculated 0
: 0
some 0
of 0
these 0
values 0
differed 0
markedly 0
from 0
those 0
formerly 0
recommended 0
. 0

The 0
results 0
therefore 0
might 0
provide 0
a 0
more 0
appropriate 0
frame 0
of 0
reference 0
for 0
interpretation 0
of 0
the 0

Comparison 0
of 0
alfentanil 0
, 0
fentanyl 0
and 0
sufentanil 0
for 0
total 0
intravenous 0
anaesthesia 0
with 0
propofol 0
in 0
patients 0
undergoing 0
coronary 0
artery 0
bypass 0
surgery 0
. 0

We 0
have 0
studied 0
the 0
pharmacokinetics B-PHYSICAL
and 0
pharmacodynamics B-PHYSICAL
of 0
alfentanil 0
, 0
fentanyl 0
and 0
sufentanil 0
together 0
with 0
propofol 0
in 0
patients 0
undergoing 0
coronary 0
artery 0
bypass 0
graft 0
surgery 0
( 0
CABG 0
) 0
. 0

Sixty 0
patients 0
( 0
age 0
40-73 0
yr 0
, 0
56 0
male 0
) 0
were 0
assigned 0
randomly 0
to 0
receive 0
alfentanil 0
, 0
fentanyl 0
or 0
sufentanil 0
and 0
propofol 0
. 0

Plasma B-PHYSICAL
concentrations I-PHYSICAL
of 0
these 0
drugs 0
and 0
times B-OTHER
for I-OTHER
the I-OTHER
plasma I-OTHER
concentration 0
to B-OTHER
decrease 0
by B-OTHER
50 B-OTHER
% B-OTHER
( 0
t50 0
) 0
and 0
80 0
% 0
( 0
t80 0
) 0
after 0
cessation 0
of 0
the 0
infusion 0
were 0
determined 0
. 0

Times 0
were 0
recorded 0
to 0
awakening 0
and 0
tracheal 0
extubation 0
. 0

Total 0
dose B-PHYSICAL
and 0
plasma B-PHYSICAL
concentrations I-PHYSICAL
of 0
propofol 0
were 0
similar 0
in 0
all 0
groups 0
. 0

Mean 0
total 0
doses B-OTHER
of 0
alfentanil 0
, 0
fentanyl 0
and 0
sufentanil 0
were 0
443 0
, 0
45 0
and 0
4.4 0
micrograms 0
kg-1 0
, 0
respectively 0
. 0

Time B-PHYSICAL
to B-PHYSICAL
awakening B-PHYSICAL
did 0
not 0
differ 0
significantly 0
. 0

In 0
patients 0
receiving 0
fentanyl 0
, 0
the 0
trachea B-PHYSICAL
was 0
extubated B-PHYSICAL
on 0
average 0
2 0
h 0
later 0
than 0
in 0
those 0
receiving 0
sufentanil 0
and 0
3 0
h 0
later 0
than 0
in 0
those 0
receiving 0
alfentanil 0
( 0
P 0
< 0
0.05 0
) 0
. 0

The 0
t80 B-PHYSICAL
of 0
fentanyl 0
was 0
longer 0
( 0
P 0
< 0
0.05 0
) 0
than 0
that 0
of 0
alfentanil 0
or 0
sufentanil 0
, 0
and 0
there 0
was 0
a 0
linear 0
correlation 0
between 0
the 0
t80 B-PHYSICAL
of 0
the 0
opioid 0
and 0
the 0
time B-OTHER
to I-OTHER
tracheal I-OTHER
extubation B-OTHER
( 0
r 0
= 0
0.51 0
; 0
P 0
< 0
0.01 0
) 0
. 0

However 0
, 0
the 0

Famotidine 0
treatment 0
of 0
children 0
with 0
autistic 0
spectrum 0
disorders 0
: 0
pilot 0
research 0
using 0
single 0
subject 0
research 0
design 0
. 0

Using 0
single 0
subject 0
research 0
design 0
, 0
we 0
performed 0
pilot 0
research 0
to 0
evaluate 0
the 0
safety 0
and 0
efficacy 0
of 0
famotidine 0
for 0
the 0
treatment 0
of 0
children 0
with 0
autistic 0
spectrum 0
disorders 0
. 0

We 0
studied 0
9 0
Caucasian 0
boys 0
, 0
3.8-8.1 0
years 0
old 0
, 0
with 0
a 0
DSM-IV 0
diagnosis 0
of 0
a 0
pervasive 0
developmental 0
disorder 0
, 0
living 0
with 0
their 0
families 0
, 0
receiving 0
no 0
chronic 0
medications 0
, 0
and 0
without 0
significant 0
gastrointestinal 0
symptoms 0
. 0

The 0
dose 0
of 0
oral 0
famotidine 0
was 0
2 0
mg/kg/day 0
( 0
given 0
in 0
two 0
divided 0
doses 0
) 0
; 0
the 0
maximum 0
total 0
daily 0
dose 0
was 0
100 0
mg 0
. 0

Using 0
single-subject 0
research 0
analysis 0
and 0
medication 0
given 0
in 0
a 0
randomized 0
, 0
double-blind 0
, 0
placebo-controlled 0
, 0
cross-over 0
design 0
, 0
4 0
of 0
9 0
children 0
randomized 0
( 0
44 0
% 0
) 0
had 0
evidence 0
of 0
behavioral B-MENTAL
improvement I-MENTAL
. 0

Primary 0
efficacy 0
was 0
based 0
on 0
data 0
kept 0
by 0
primary 0
caregivers 0
, 0
including 0
a 0
daily 0
diary 0
; 0
daily 0
visual 0
analogue 0
scales 0
of 0
affection 0
, 0
reciting 0
, 0
or 0
aspects 0
of 0
social 0
interaction 0
; 0
Aberrant B-PHYSICAL
Behavior I-PHYSICAL
Checklists I-PHYSICAL
( 0
ABC B-PHYSICAL
, 0
Aman B-PHYSICAL
) 0
; 0
and 0

Five-year 0
outcome 0
of 0
surgical 0
treatment 0
of 0
migraine B-PAIN
headaches I-PAIN
. 0

BACKGROUND 0
This 0
study 0
was 0
designed 0
to 0
assess 0
the 0
long-term 0
efficacy 0
of 0
surgical 0
deactivation 0
of 0
migraine B-PHYSICAL
headache I-PHYSICAL
trigger 0
sites 0
. 0

METHODS 0
One 0
hundred 0
twenty-five 0
volunteers 0
were 0
randomly 0
assigned 0
to 0
the 0
treatment 0
( 0
n 0
= 0
100 0
) 0
or 0
control 0
group 0
( 0
n 0
= 0
25 0
) 0
after 0
examination 0
by 0
the 0
team 0
neurologist 0
to 0
ensure 0
a 0
diagnosis 0
of 0
migraine B-PAIN
headache I-PAIN
. 0

Patients 0
were 0
asked 0
to 0
complete 0
the 0
Medical B-PHYSICAL
Outcomes I-PHYSICAL
Study I-PHYSICAL
36-Item I-PHYSICAL
Short I-PHYSICAL
Form I-PHYSICAL
Health I-PHYSICAL
Survey I-PHYSICAL
, 0
Migraine-Specific B-OTHER
Quality I-OTHER
of I-OTHER
Life I-OTHER
, 0
and 0
Migraine B-PHYSICAL
Disability I-PHYSICAL
Assessment I-PHYSICAL
questionnaires I-PHYSICAL
before 0
treatment 0
and 0
at 0
12- 0
and 0
60-month 0
postoperative 0
follow-up 0
. 0

The 0
treatment 0
group 0
received 0
botulinum 0
toxin 0
to 0
confirm 0
the 0
trigger 0
sites 0
; 0
controls 0
received 0
saline 0
injections 0
. 0

Treated 0
patients 0
underwent 0
surgical 0
deactivation 0
of 0
trigger 0
site 0
( 0
s 0
) 0
. 0

Results 0
were 0
analyzed 0
at 0
1 0
year 0
( 0
previously 0
published 0
) 0
and 0
5 0
years 0
postoperatively 0
( 0
the 0
subject 0
of 0
this 0
report 0
) 0
. 0

RESULTS 0
Eighty-nine 0
of 0
100 0
patients 0
in 0
the 0
treatment 0
group 0
underwent 0
surgery 0
, 0
and 0
79 0
were 0
followed 0
for 0
5 0
years 0
. 0

Ten 0
patients 0
underwent 0
deactivation 0
of 0
additional 0
( 0
different 0
) 0
trigger 0
sites 0
during 0
the 0
follow-up 0
period 0
and 0
were 0
not 0
included 0
in 0
the 0
data 0
analysis 0
. 0

The 0
final 0
outcome 0
with 0
or 0
without 0
inclusion 0
of 0
these 0
10 0
patients 0
was 0
not 0
statistically 0
different 0
. 0

Sixty-one 0
( 0
88 0
percent 0
) 0
of 0
69 0
patients 0
have 0
experienced 0
a 0
positive 0
response B-PHYSICAL
to 0
the 0
surgery 0
after 0
5 0
years 0
. 0

Twenty 0
( 0
29 0
percent 0
) 0
reported 0
complete B-OTHER
elimination 0
of B-OTHER
migraine I-OTHER
headache B-OTHER
, 0
41 0
( 0
59 0
percent 0
) 0
noticed 0
a 0
significant 0
decrease 0
, 0
and 0
eight 0
( 0
12 0
percent 0
) 0
experienced 0
no 0
significant 0
change 0
. 0

When 0
compared 0
with 0
the 0
baseline 0
values 0
, 0
all 0
measured 0
variables 0
at 0
60 0
months 0
improved 0
significantly 0
( 0
p 0
< 0
0.0001 0
) 0
. 0

CONCLUSION 0
Based 0
on 0
the 0
5-year 0
follow-up 0
data 0
, 0
there 0
is 0
strong 0
evidence 0
that 0
surgical 0
manipulation 0
of 0
one 0
or 0
more 0
migraine 0
trigger 0
sites 0
can 0
successfully 0
eliminate B-OTHER
or B-OTHER
reduce I-OTHER

Neridronate 0
prevents 0
bone B-PHYSICAL
loss I-PHYSICAL
in 0
patients 0
receiving 0
androgen 0
deprivation 0
therapy 0
for 0
prostate 0
cancer 0
. 0

UNLABELLED 0
Today 0
, 0
androgen 0
deprivation 0
therapy 0
is 0
a 0
cornerstone 0
of 0
treatment 0
for 0
advanced 0
prostate 0
cancer 0
, 0
although 0
it 0
presents 0
important 0
complications 0
such 0
as 0
osteoporosis B-PHYSICAL
. 0

Neridronate 0
, 0
a 0
relatively 0
new 0
bisphosphonate 0
, 0
is 0
able 0
to 0
prevent 0
bone B-PHYSICAL
loss I-PHYSICAL
in 0
patients 0
with 0
prostate 0
cancer 0
during 0
androgen 0
ablation 0
. 0

INTRODUCTION 0
Androgen-deprivation 0
therapy 0
( 0
ADT 0
) 0
is 0
a 0
cornerstone 0
of 0
treatment 0
for 0
advanced 0
prostate 0
cancer 0
. 0

This 0
therapy 0
has 0
iatrogenic 0
complications 0
, 0
such 0
as 0
osteoporosis 0
. 0

The 0
aim 0
of 0
our 0
study 0
was 0
to 0
evaluate 0
the 0
efficacy 0
of 0
neridronate 0
, 0
a 0
relatively 0
new 0
bisphosphonate 0
, 0
to 0
prevent 0
bone 0
loss 0
during 0
androgen 0
ablation 0
. 0

MATERIALS 0
AND 0
METHODS 0
Forty-eight 0
osteoporotic 0
patients 0
with 0
prostate 0
cancer 0
, 0
treated 0
with 0
3-month 0
depot 0
triptorelina 0
, 0
were 0
enrolled 0
and 0
randomly 0
assigned 0
to 0
two 0
different 0
treatment 0
groups 0
: 0
group 0
A 0
( 0
n 0
= 0
24 0
) 0
was 0
treated 0
with 0
a 0
daily 0
calcium 0
and 0
cholecalciferol 0
supplement 0
( 0
500 0
mg 0
of 0
elemental 0
calcium 0
and 0
400 0
IU 0
cholecalciferol 0
) 0
, 0
and 0
group 0
B 0
( 0
n 0
= 0
24 0
) 0
received 0
in 0
addition 0
to 0
the 0
same 0
daily 0
calcium 0
and 0
cholecalciferol 0
supplement 0
, 0
25 0
mg 0
of 0
neridronate 0
given 0
intramuscularly 0
every 0
month 0
. 0

All 0
patients 0
also 0
received 0
bicalutamide 0
for 0
4 0
weeks 0
. 0

Lumbar B-PHYSICAL
and I-PHYSICAL
femoral I-PHYSICAL
BMD I-PHYSICAL
was 0
evaluated 0
by 0
DXA 0
at 0
baseline 0
and 0
after 0
1 0
year 0
of 0
therapy 0
; 0
moreover 0
, 0
deoxypyridinoline 0
( 0
DPD 0
) 0
and 0
bone 0
alkaline 0
phosphatase 0
( 0
BALP 0
) 0
were 0
determined 0
at 0
the 0
beginning 0
, 0
midway 0
through 0
, 0
and 0
at 0
the 0
end 0
of 0
the 0
study 0
. 0

RESULTS 0
After 0
6 0
and 0
12 0
months 0
, 0
whereas 0
patients 0
treated 0
only 0
with 0
calcium 0
and 0
cholecalciferol 0
( 0
group 0
A 0
) 0
showed 0
a 0
marked B-PHYSICAL
bone I-PHYSICAL
loss I-PHYSICAL
, 0
with 0
increased 0
levels B-PHYSICAL
of I-PHYSICAL
DPD I-PHYSICAL
and I-PHYSICAL
BALP I-PHYSICAL
compared 0
with 0
baseline 0
values 0
, 0
patients 0
treated 0
also 0
with 0
neridronate 0
( 0
group 0
B 0
) 0
had 0
substantially 0
unchanged 0
levels 0
of 0
these 0
markers 0
. 0

After 0
1 0
year 0
of 0
treatment 0
, 0
lumbar B-PHYSICAL
and 0
total 0
hip B-PHYSICAL
BMD I-PHYSICAL
decreased I-PHYSICAL
significantly 0
in 0
patients 0
treated 0
only 0
with 0
calcium 0
and 0
cholecalciferol 0
( 0
group 0
A 0
) 0
, 0
whereas 0
it 0
did 0
not 0
change B-OTHER
significantly I-OTHER
at 0
any 0
skeletal 0
site 0
in 0
patients 0
treated 0
also 0
with 0
neridronate 0
( 0
group 0
B 0
) 0
. 0

No 0
relevant B-ADVERSE-EFFECTS
side I-ADVERSE-EFFECTS
effects I-ADVERSE-EFFECTS
were 0
recorded 0
during 0
our 0
study 0
. 0

CONCLUSIONS 0
Neridronate 0
is 0
an 0
effective 0
treatment 0
in 0
preventing 0
bone B-PHYSICAL
loss I-PHYSICAL
in 0
the 0
hip 0
and 0
lumbar 0
spine 0
in 0
men 0
receiving 0
ADT 0
for 0
prostate 0
cancer 0
. 0

[ 0
The 0
effect 0
of 0
indobufen 0
on 0
aortocoronary 0
bypass 0
patency 0
after 0
1 0
week 0
and 0
after 0
1 0
year 0
] 0
. 0

A 0
randomized 0
clinical 0
study 0
was 0
conducted 0
to 0
compare 0
the 0
effect 0
of 0
conventional 0
antiaggregation 0
therapy 0
( 0
ASA 0
plus 0
dipyridamole 0
) 0
versus 0
indobufen 0
in 0
patients 0
after 0
aortocoronary 0
bypass 0
( 0
ACB 0
) 0
surgery 0
. 0

The 0
patency 0
of 0
venous 0
ACB 0
using 0
coronary 0
DSA 0
one 0
week 0
and 0
one 0
year 0
after 0
surgery 0
was 0
evaluated 0
in 0
52 0
patients 0
divided 0
into 0
two 0
groups 0
. 0

The 0
study 0
included 0
only 0
ACB 0
's 0
with 0
intraoperative 0
blood 0
flow 0
rates 0
< 0
or 0
= 0
40 0
ml/min 0
as 0
it 0
is 0
just 0
these 0
ACB 0
's 0
which 0
are 0
at 0
the 0
highest 0
risk 0
of 0
early 0
and 0
late 0
occlusions 0
. 0

While 0
, 0
in 0
the 0
ASA 0
plus 0
dipyridamole-treated 0
group 0
, 0
occlusions B-PHYSICAL
were 0
found 0
in 0
11 0
of 0
the 0
39 0
reconstructions 0
( 0
28.2 0
% 0
) 0
, 0
the 0
proportion 0
was 0
nine 0
out 0
of 0
37 0
procedures 0
( 0
24.3 0
% 0
) 0
in 0
the 0
indobufen 0
group 0
. 0

One 0
year 0
after 0
surgery 0
, 0
occlusion B-PHYSICAL
was 0
found 0
in 0
14 0
out 0
of 0
32 0
ACB 0
's 0
( 0
43.7 0
% 0
) 0
in 0
the 0
ASA 0
plus 0
dipyridamole 0
group 0
compared 0
to 0
14 0
occlusions 0
in 0
31 0
ACB 0
's 0
( 0
45.2 0
% 0
) 0
in 0
the 0
indobufen 0
group 0
. 0

The 0
difference 0
in 0
the 0
number B-PHYSICAL
of I-PHYSICAL
occlusions I-PHYSICAL
between 0
the 0
two 0
groups 0
was 0
not 0
statistically 0
significant 0
. 0

Because 0
of 0
some 0
benefits 0
of 0
indobufen 0
compared 0
to 0
ASA 0
( 0
shorter 0
time 0
of 0
effect 0
, 0
superior 0
tolerance 0
in 0
patients 0
with 0
ulceration 0
) 0
, 0
the 0
former 0
drug 0
can 0
be 0
recommended 0
for 0
use 0
in 0
some 0
indicated 0
cases 0
. 0

Local B-MENTAL
contextual I-MENTAL
processing I-MENTAL
in 0
major 0
depressive 0
disorder 0
. 0

OBJECTIVE 0
The 0
study 0
investigated 0
local B-MENTAL
contextual I-MENTAL
processing I-MENTAL
in 0
patients 0
with 0
major 0
depressive 0
disorder 0
( 0
MDD 0
) 0
. 0

This 0
was 0
defined 0
as 0
the 0
ability 0
to 0
utilize 0
predictive 0
contextual 0
information 0
to 0
facilitate 0
detection 0
of 0
predictable 0
versus 0
random 0
targets 0
. 0

METHOD 0
We 0
recorded 0
EEG 0
in 0
15 0
MDD 0
patients 0
and 0
14 0
age-matched 0
controls 0
. 0

Recording 0
blocks 0
consisted 0
of 0
targets 0
preceded 0
by 0
randomized 0
sequences 0
of 0
standards 0
and 0
by 0
sequences 0
of 0
standards 0
that 0
included 0
a 0
predictive 0
sequence 0
signaling 0
the 0
occurrence 0
of 0
a 0
subsequent 0
target 0
event 0
. 0

RESULTS 0
Both 0
MDD 0
patients 0
and 0
age-matched 0
controls 0
demonstrated 0
a 0
significant B-PHYSICAL
reaction 0
time 0
( 0
RT 0
) 0
and 0
P3b B-MENTAL
latency I-MENTAL
differences B-PHYSICAL
between 0
predicted 0
and 0
random 0
targets 0
. 0

However 0
, 0
patients 0
demonstrated 0
a 0
specific B-PHYSICAL
prolongation B-MENTAL
of 0
these 0
measures 0
during 0
processing 0
of 0
predicted 0
targets 0
, 0
as 0
well 0
as 0
an 0
attenuation 0
of 0
P3b B-MENTAL
amplitudes I-MENTAL
for 0
the 0
predictive 0
sequence 0
. 0

In 0
addition 0
, 0
patients 0
target 0
N1 B-MENTAL
amplitudes I-MENTAL
were 0
attenuated B-PHYSICAL
compared 0
with 0
controls 0
. 0

CONCLUSION 0
MDD 0
patients 0
were 0
able 0
to 0
utilize B-MENTAL
predictive I-MENTAL
context I-MENTAL
in 0
order 0
to 0
facilitate 0
processing 0
of 0
deterministic 0
targets 0
, 0
however 0
, 0
this 0
ability B-PHYSICAL
was 0
limited B-ADVERSE-EFFECTS
compared 0
to 0
controls 0
, 0
as 0
demonstrated 0
by 0
context-dependent 0
P3b 0
deficits 0
. 0

SIGNIFICANCE 0
These 0
findings 0
suggest 0
that 0
patients 0
with 0
major 0
depression 0
have 0
altered B-MENTAL
processing I-MENTAL
of I-MENTAL
local I-MENTAL
contextual I-MENTAL
processing I-MENTAL
. 0

Low 0
intensity 0
physical 0
training 0
in 0
older 0
subjects 0
. 0

BACKGROUND 0
This 0
study 0
was 0
designed 0
to 0
evaluate 0
the 0
effects 0
of 0
a 0
low 0
intensity 0
general 0
training 0
program 0
( 0
< 0
50 0
% 0
of 0
heart 0
rate 0
reserve 0
) 0
on 0
physical 0
fitness 0
of 0
healthy 0
older 0
subjects 0
, 0
by 0
comparing 0
maximal 0
and 0
submaximal 0
indices 0
of 0
training 0
response 0
. 0

METHODS 0
Twenty-two 0
volunteers 0
over 0
60 0
years 0
of 0
age 0
participated 0
in 0
the 0
present 0
study 0
. 0

The 0
sample 0
was 0
randomly 0
divided 0
in 0
an 0
experimental 0
group 0
of 0
13 0
older 0
subjects 0
( 0
3 0
men 0
and 0
10 0
women 0
, 0
mean 0
age 0
63.5 0
+/- 0
3 0
years 0
) 0
while 0
the 0
remaining 0
9 0
subjects 0
( 0
3 0
men 0
and 0
6 0
women 0
, 0
mean 0
age 0
64.2 0
+/- 0
4 0
years 0
) 0
served 0
as 0
inactive 0
control 0
group 0
. 0

After 0
medical 0
screening 0
all 0
participants 0
were 0
evaluated 0
before 0
and 0
after 0
12 0
weeks 0
in 0
which 0
the 0
experimental 0
subjects 0
underwent 0
a 0
low 0
intensity 0
training 0
. 0

Each 0
subjects-either 0
inactive 0
or 0
active-performed 0
two 0
treadmill 0
tests 0
at 0
two-days 0
interval 0
, 0
to 0
measure 0
maximal 0
and 0
submaximal 0
responses 0
to 0
exercise 0
, 0
respectively 0
. 0

Heart 0
rate 0
( 0
HR 0
) 0
, 0
oxygen B-PHYSICAL
uptake I-PHYSICAL
( I-PHYSICAL
VO2 I-PHYSICAL
) I-PHYSICAL
and 0
pulmonary B-PHYSICAL
ventilation I-PHYSICAL
( I-PHYSICAL
VE I-PHYSICAL
) I-PHYSICAL
were 0
measured 0
using 0
a 0
telemetric 0
apparatus 0
. 0

RESULTS 0
The 0
major 0
finding 0
of 0
the 0
study 0
was 0
the 0
significant 0
improvement 0
in 0
submaximal B-PHYSICAL
response 0
to B-PHYSICAL
exercise I-PHYSICAL
of I-PHYSICAL
experimental I-PHYSICAL
subjects B-PHYSICAL
, 0
expressed 0
by 0
the 0
reduction 0
in 0
HR B-PHYSICAL
, 0
VO2 B-PHYSICAL
VE 0
while 0
VO2 B-PHYSICAL
max 0
did 0
not 0
change 0
. 0

CONCLUSIONS 0
Thus 0
, 0
it 0
appears 0
that 0
a 0
low 0
intensity 0
general 0
training 0
similar 0
to 0
that 0
followed 0
in 0
the 0
present 0
study 0
may 0
represent 0
a 0
good 0
means 0
to 0
improve 0
physical B-PHYSICAL
fitness I-PHYSICAL
in 0
healthy 0
elderly 0
people 0
. 0

Similarly 0
, 0
this 0
study 0
supports 0
the 0
effectiveness 0
of 0
evaluation 0
tests 0
based 0
on 0

Virtual 0
patients 0
design 0
and 0
its 0
effect 0
on 0
clinical B-MENTAL
reasoning I-MENTAL
and 0
student B-OTHER
experience I-OTHER
: 0
a 0
protocol 0
for 0
a 0
randomised 0
factorial 0
multi-centre 0
study 0
. 0

BACKGROUND 0
Virtual 0
Patients 0
( 0
VPs 0
) 0
are 0
web-based 0
representations 0
of 0
realistic 0
clinical 0
cases 0
. 0

They 0
are 0
proposed 0
as 0
being 0
an 0
optimal 0
method 0
for 0
teaching 0
clinical 0
reasoning 0
skills 0
. 0

International 0
standards 0
exist 0
which 0
define 0
precisely 0
what 0
constitutes 0
a 0
VP 0
. 0

There 0
are 0
multiple 0
design 0
possibilities 0
for 0
VPs 0
, 0
however 0
there 0
is 0
little 0
formal 0
evidence 0
to 0
support 0
individual 0
design 0
features 0
. 0

The 0
purpose 0
of 0
this 0
trial 0
is 0
to 0
explore 0
the 0
effect 0
of 0
two 0
different 0
potentially 0
important 0
design 0
features 0
on 0
clinical B-MENTAL
reasoning I-MENTAL
skills I-MENTAL
and 0
the 0
student B-OTHER
experience I-OTHER
. 0

These 0
are 0
the 0
branching 0
case 0
pathways 0
( 0
present 0
or 0
absent 0
) 0
and 0
structured 0
clinical 0
reasoning 0
feedback 0
( 0
present 0
or 0
absent 0
) 0
. 0

METHODS/DESIGN 0
This 0
is 0
a 0
multi-centre 0
randomised 0
2 0
x 0
2 0
factorial 0
design 0
study 0
evaluating 0
two 0
independent 0
variables 0
of 0
VP 0
design 0
, 0
branching 0
( 0
present 0
or 0
absent 0
) 0
, 0
and 0
structured 0
clinical 0
reasoning 0
feedback 0
( 0
present 0
or 0
absent 0
) 0
.The 0
study 0
will 0
be 0
carried 0
out 0
in 0
medical 0
student 0
volunteers 0
in 0
one 0
year 0
group 0
from 0
three 0
university 0
medical 0
schools 0
in 0
the 0
United 0
Kingdom 0
, 0
Warwick 0
, 0
Keele 0
and 0
Birmingham 0
. 0

There 0
are 0
four 0
core 0
musculoskeletal 0
topics 0
. 0

Each 0
case 0
can 0
be 0
designed 0
in 0
four 0
different 0
ways 0
, 0
equating 0
to 0
16 0
VPs 0
required 0
for 0
the 0
research 0
. 0

Students 0
will 0
be 0
randomised 0
to 0
four 0
groups 0
, 0
completing 0
the 0
four 0
VP 0
topics 0
in 0
the 0
same 0
order 0
, 0
but 0
with 0
each 0
group 0
exposed 0
to 0
a 0
different 0
VP 0
design 0
sequentially 0
. 0

All 0
students 0
will 0
be 0
exposed 0
to 0
the 0
four 0
designs 0
. 0

Primary 0
outcomes 0
are 0
performance 0
for 0
each 0
case B-MENTAL
design I-MENTAL
in I-MENTAL
a I-MENTAL
standardized I-MENTAL
fifteen I-MENTAL
item I-MENTAL
clinical I-MENTAL
reasoning I-MENTAL
assessment I-MENTAL
, 0
integrated 0
into 0
each 0
VP 0
, 0
which 0
is 0
identical 0
for 0
each 0
topic 0
. 0

Additionally 0
a 0
15-item B-OTHER
self-reported I-OTHER
evaluation I-OTHER
is 0
completed 0
for 0
each 0
VP 0
, 0
based 0
on 0
a 0
widely 0
used 0
EViP 0
tool 0
. 0

Student 0
patterns 0
of 0
use 0
of 0
the 0
VPs 0
will 0
be 0
recorded.In 0
one 0
centre 0
, 0
formative 0
clinical 0
and 0
examination 0
performance 0
will 0
be 0
recorded 0
, 0
along 0
with 0
a 0
self 0
reported 0
pre 0
and 0
post-intervention 0
reasoning 0
score 0
, 0
the 0
DTI 0
. 0

Our 0
power 0
calculations 0
indicate 0
a 0
sample 0
size 0
of 0
112 0
is 0
required 0
for 0
both 0
primary 0
outcomes 0
. 0

DISCUSSION 0
This 0
trial 0
will 0
provide 0
robust 0
evidence 0
to 0
support 0
the 0
effectiveness 0
of 0
different 0
designs 0
of 0
virtual 0
patients 0
, 0
based 0
on 0
student B-MENTAL
performance I-MENTAL
and 0
evaluation B-OTHER
. 0

The 0
cases 0
and 0
all 0
learning 0
materials 0
will 0
be 0
open 0
access 0
and 0
available 0
on 0
a 0
Creative 0
Commons 0
Attribution-Share-Alike 0
license 0
. 0

Chronic 0
fatigue 0
syndrome 0
versus 0
neuroendocrineimmune 0
dysfunction 0
syndrome 0
: 0
differential 0
attributions 0
. 0

Since 0
1988 0
, 0
when 0
the 0
term 0
chronic 0
fatigue 0
syndrome 0
( 0
CFS 0
) 0
was 0
coined 0
, 0
considerable 0
discussion 0
has 0
occurred 0
about 0
stigma 0
associated 0
with 0
this 0
diagnostic 0
term 0
. 0

In 0
particular 0
, 0
patients 0
with 0
CFS 0
have 0
felt 0
that 0
this 0
term 0
trivializes 0
the 0
serious 0
nature 0
of 0
this 0
disorder 0
. 0

A 0
Name 0
Change 0
Work 0
group 0
, 0
appointed 0
by 0
the 0
CFS 0
Coordinating 0
Committee 0
, 0
developed 0
an 0
umbrella 0
term 0
: 0
chronic 0
neuroendocrineimmune 0
dysfunction 0
syndrome 0
( 0
CNDS 0
) 0
, 0
and 0
proposed 0
that 0
there 0
would 0
be 0
sub-types 0
under 0
this 0
term 0
, 0
one 0
being 0
CFS 0
. 0

The 0
present 0
study 0
examined 0
attributions B-OTHER
of 0
this 0
new 0
umbrella 0
term 0
when 0
compared 0
with 0
CFS 0
. 0

Nurses 0
and 0
physician 0
assistants 0
( 0
PAs 0
) 0
were 0
presented 0
a 0
case 0
study 0
of 0
a 0
patient 0
with 0
symptoms 0
of 0
CFS 0
. 0

They 0
were 0
told 0
that 0
the 0
patient 0
had 0
either 0
chronic 0
fatigue 0
syndrome 0
, 0
chronic 0
neuroendocrineimmune 0
dysfunction 0
syndrome 0
, 0
or 0
chronic 0
neuroendocrineimmune 0
dysfunction 0
syndrome 0
, 0
which 0
had 0
formerly 0
been 0
called 0
chronic 0
fatigue 0
syndrome 0
. 0

The 0
different 0
terms 0
led 0
to 0
different 0
attributions 0
, 0
with 0
PA 0
respondents 0
rating 0
the 0
CNDS 0
label 0
as 0
more 0
severe 0
. 0

Results 0
suggest 0
that 0
a 0
more 0
medical B-OTHER
sounding I-OTHER
term I-OTHER
( 0
CNDS 0
) 0
may 0
lead 0
to 0
attributions B-OTHER
that 0
this 0
syndrome 0
is 0
a 0
more 0
serious 0
, 0
disabling 0
illness 0
. 0

The 0
policy 0
implications 0
of 0
these 0
findings 0
are 0
discussed 0
. 0

Detection 0
of 0
traumatic 0
arthrotomy 0
of 0
the 0
knee 0
using 0
the 0
saline 0
solution 0
load 0
test 0
. 0

BACKGROUND 0
The 0
saline 0
solution 0
load 0
test 0
helps 0
to 0
determine 0
if 0
a 0
wound 0
extends 0
into 0
the 0
knee 0
joint 0
. 0

Little 0
is 0
known 0
about 0
the 0
volume 0
of 0
injected 0
intra-articular 0
saline 0
solution 0
that 0
is 0
needed 0
to 0
effectively 0
rule 0
in 0
or 0
rule 0
out 0
a 0
traumatic 0
arthrotomy 0
of 0
the 0
knee 0
. 0

The 0
purpose 0
of 0
the 0
present 0
study 0
was 0
to 0
determine 0
the 0
appropriate B-OTHER
volume I-OTHER
and 0
needle B-OTHER
location I-OTHER
for 0
the 0
diagnosis 0
of 0
a 0
traumatic 0
knee 0
arthrotomy 0
and 0
to 0
assess 0
the 0
effect 0
of 0
associated 0
variables 0
, 0
including 0
knee 0
circumference 0
, 0
body 0
mass 0
index 0
, 0
and 0
sex 0
. 0

METHODS 0
Fifty-six 0
consecutive 0
patients 0
scheduled 0
for 0
knee 0
arthroscopy 0
were 0
enrolled 0
. 0

A 0
standard 0
inferolateral 0
arthroscopic 0
portal 0
was 0
made 0
with 0
a 0
single 0
stab 0
incision 0
with 0
use 0
of 0
a 0
number-11 0
blade 0
. 0

Injection 0
sites 0
were 0
randomized 0
to 0
either 0
a 0
superomedial 0
or 0
inferomedial 0
location 0
. 0

The 0
injection 0
of 0
normal 0
saline 0
solution 0
at 0
a 0
rate 0
of 0
5 0
mL/sec 0
through 0
an 0
18-gauge 0
needle 0
was 0
continued 0
while 0
the 0
knee 0
was 0
moved 0
through 0
a 0
range 0
of 0
motion 0
until 0
fluid 0
extravasated 0
from 0
the 0
iatrogenic 0
laceration 0
. 0

The 0
volume 0
of 0
injected 0
fluid 0
was 0
recorded 0
. 0

RESULTS 0
The 0
study 0
group 0
included 0
thirty-one 0
female 0
patients 0
and 0
twenty-five 0
male 0
patients 0
with 0
a 0
combined 0
average 0
age 0
of 0
fifty 0
years 0
and 0
an 0
average 0
body B-PHYSICAL
mass I-PHYSICAL
index I-PHYSICAL
of 0
30.9 0
. 0

In 0
order 0
to 0
effectively 0
diagnose B-OTHER
50 I-OTHER
% I-OTHER
of I-OTHER
the I-OTHER
arthrotomies I-OTHER
, 0
75 0
mL 0
of 0
injected 0
fluid 0
was 0
needed 0
; 0
the 0
volumes 0
that 0
were B-OTHER
needed I-OTHER
in I-OTHER
order I-OTHER
to I-OTHER
effectively I-OTHER
diagnose I-OTHER
75 0
% 0
, 0
90 0
% 0
, 0
95 0
% 0
, 0
and 0
99 0
% 0
of 0
the 0
arthrotomies 0
were 0
110 0
, 0
145 0
, 0
155 0
, 0
and 0
175 0
mL 0
, 0
respectively 0
. 0

The 0
mean 0
volumes B-PHYSICAL
of I-PHYSICAL
injected I-PHYSICAL
fluid I-PHYSICAL
needed I-PHYSICAL
for I-PHYSICAL
a I-PHYSICAL
positive 0
result B-PHYSICAL
at I-PHYSICAL
the I-PHYSICAL
inferomedial I-PHYSICAL
and I-PHYSICAL
superomedial I-PHYSICAL
needle I-PHYSICAL
locations B-PHYSICAL
were 0
64.0 0
and 0
95.2 0
mL 0
, 0
respectively 0
; 0
this 0
difference 0
was 0
significant 0
( 0
p 0
= 0
0.01 0
) 0
. 0

There 0
was 0
no 0
correlation 0
between 0
necessary 0
injection 0
volume 0
and 0
sex 0
, 0
body 0
mass 0
index 0
, 0
or 0
knee 0
circumference 0
. 0

CONCLUSIONS 0
In 0
order 0
to 0
detect 0
95 0
% 0
of 0
1-cm 0
inferolateral 0
arthrotomies 0
of 0
the 0
knee 0
with 0
use 0
of 0
the 0
saline 0
solution 0
load 0
test 0
, 0
155 0
mL 0
must 0
be 0
injected 0
. 0

An 0
inferomedial 0
injection 0
location 0
requires 0

Bright 0
light 0
therapy 0
in 0
Parkinson 0
's 0
disease 0
: 0
a 0
pilot 0
study 0
. 0

Several 0
observations 0
suggest 0
a 0
beneficial 0
effect 0
of 0
melatonin 0
antagonism 0
for 0
Parkinson 0
's 0
disease 0
( 0
PD 0
) 0
. 0

Although 0
bright 0
light 0
therapy 0
( 0
BLT 0
) 0
suppresses 0
melatonin 0
release 0
and 0
is 0
an 0
established 0
treatment 0
for 0
depression 0
and 0
sleep 0
disturbances 0
, 0
it 0
has 0
not 0
been 0
evaluated 0
in 0
PD 0
. 0

We 0
examined 0
effects 0
of 0
BLT 0
on 0
motor B-MENTAL
symptoms I-MENTAL
, 0
depression B-MENTAL
, 0
and 0
sleep B-MENTAL
in 0
PD 0
in 0
a 0
randomized 0
placebo-controlled 0
double-blind 0
study 0
in 0
36 0
PD 0
patients 0
, 0
using 0
Parkinson 0
's 0
Disease 0
Rating 0
Scale 0
( 0
UPDRS 0
) 0
I-IV 0
, 0
Beck 0
's 0
Depression 0
Inventory 0
, 0
and 0
Epworth B-MENTAL
Sleepiness I-MENTAL
Scale I-MENTAL
. 0

All 0
patients 0
received 0
BLT 0
for 0
15 0
days 0
in 0
the 0
morning 0
, 0
30 0
min 0
daily 0
. 0

Illuminance B-MENTAL
was 0
7.500 0
lux 0
in 0
the 0
active 0
treatment 0
group 0
and 0
950 0
lux 0
in 0
the 0
placebo 0
group 0
. 0

Although 0
group 0
differences 0
were 0
small 0
, 0
BLT 0
led 0
to 0
significant 0
improvement 0
of 0
tremor B-MENTAL
, 0
UPDRS B-MENTAL
I I-MENTAL
, 0
II B-MENTAL
, 0
and 0

Effect 0
of 0
dietary 0
supplementation 0
with 0
n-3 0
fatty 0
acids 0
on 0
coronary 0
artery 0
bypass 0
graft 0
patency 0
. 0

Epidemiologic 0
and 0
experimental 0
data 0
suggest 0
that 0
a 0
high 0
dietary 0
intake 0
of 0
long-chain 0
polyunsaturated 0
n-3 0
fatty 0
acids 0
may 0
reduce 0
the 0
risk 0
of 0
atherothrombotic 0
disease 0
. 0

In 0
a 0
randomized 0
, 0
controlled 0
study 0
, 0
610 0
patients 0
undergoing 0
coronary 0
artery 0
bypass 0
grafting 0
were 0
assigned 0
either 0
to 0
a 0
fish 0
oil 0
group 0
, 0
receiving 0
4 0
g/day 0
of 0
fish 0
oil 0
concentrate 0
, 0
or 0
to 0
a 0
control 0
group 0
. 0

All 0
patients 0
received 0
antithrombotic 0
treatment 0
, 0
either 0
aspirin 0
or 0
warfarin 0
. 0

Their 0
diet 0
and 0
serum 0
phospholipid 0
fatty 0
acid 0
profiles 0
were 0
monitored 0
. 0

The 0
primary 0
end 0
point 0
was 0
1-year 0
graft B-PHYSICAL
patency I-PHYSICAL
, 0
which 0
was 0
assessed 0
by 0
angiography 0
in 0
95 0
% 0
of 0
patients 0
. 0

Vein B-PHYSICAL
graft I-PHYSICAL
occlusion I-PHYSICAL
rates I-PHYSICAL
per I-PHYSICAL
distal I-PHYSICAL
anastomoses I-PHYSICAL
were 0
27 0
% 0
in 0
the 0
fish 0
oil 0
group 0
and 0
33 0
% 0
in 0
the 0
control 0
group 0
( 0
odds 0
ratio 0
0.77 0
, 0
95 0
% 0
confidence 0
interval 0
, 0
0.60 0
to 0
0.99 0
, 0
p 0
= 0
0.034 0
) 0
. 0

In 0
the 0
fish 0
oil 0
group 0
, 0
43 0
% 0
of 0
the 0
patients 0
had 0
> 0
or 0

Safety 0
of 0
intravitreous 0
fomivirsen 0
for 0
treatment 0
of 0
cytomegalovirus 0
retinitis 0
in 0
patients 0
with 0
AIDS 0
. 0

PURPOSE 0
To 0
report 0
data 0
regarding 0
the 0
safety 0
of 0
intravitreous 0
fomivirsen 0
for 0
treatment 0
of 0
cytomegalovirus 0
( 0
CMV 0
) 0
retinitis 0
in 0
patients 0
with 0
acquired 0
immunodeficiency 0
syndrome 0
( 0
AIDS 0
) 0
. 0

DESIGN 0
Critical 0
review 0
of 0
safety 0
data 0
from 0
three 0
randomized 0
controlled 0
clinical 0
trials 0
with 0
supplemental 0
information 0
from 0
an 0
expanded 0
drug 0
access 0
program 0
. 0

METHODS 0
Adverse 0
ocular 0
events 0
reported 0
by 0
clinician 0
investigators 0
were 0
listed 0
using 0
terms 0
modified 0
from 0
the 0
COSTART 0
dictionary 0
. 0

Data 0
for 0
two 0
doses 0
( 0
165-microg/injection 0
[ 0
35 0
eyes 0
, 0
30 0
patients 0
] 0
and 0
330-microg/injection 0
[ 0
153 0
eyes 0
, 0
120 0
patients 0
] 0
) 0
and 0
two 0
330-microg/injection 0
dose 0
schedules 0
of 0
different 0
intensity 0
were 0
pooled 0
to 0
calculate 0
incidence 0
rates 0
for 0
each 0
event 0
. 0

Rates 0
were 0
calculated 0
as 0
events/patient-year 0
( 0
based 0
on 0
total 0
cumulative 0
reported 0
events 0
and 0
duration 0
of 0
treatment 0
) 0
for 0
events 0
that 0
could 0
recur 0
during 0
treatment 0
. 0

Rates 0
were 0
calculated 0
as 0
patients 0
with 0
events/person-year 0
for 0
the 0
following 0
events 0
: 0
retinal 0
detachment 0
, 0
cataract 0
, 0
visual 0
field 0
disturbance 0
, 0
and 0
retinal 0
pigment 0
epitheliopathy 0
. 0

To 0
assess 0
the 0
ability 0
to 0
manage 0
events 0
, 0
we 0
reviewed 0
treatments 0
given 0
for 0
two 0
events 0
( 0
anterior 0
chamber 0
inflammation 0
, 0
increased 0
intraocular 0
pressure 0
) 0
in 0
one 0
trial 0
. 0

We 0
also 0
report 0
an 0
analysis 0
comparing 0
the 0
proportion 0
of 0
eyes 0
that 0
developed 0
one 0
or 0
more 0
key 0
events 0
to 0
the 0
cumulative 0
number 0
of 0
injections 0
. 0

RESULTS 0
Incidence 0
rates 0
were 0
dose 0
and 0
schedule 0
dependent 0
( 0
165 0
microg/injection 0
, 0
4.06 0
events/patient-year 0
; 0
330 0
microg/injection 0
, 0
6.58 0
events/patient-year 0
[ 0
less 0
intense 0
regimen 0
] 0
and 0
8.35 0
events/patient-year 0
[ 0
more 0
intense 0
regimen 0
] 0
) 0
. 0

The 0
most 0
frequently 0
reported 0
events 0
were 0
anterior B-ADVERSE-EFFECTS
chamber I-ADVERSE-EFFECTS
inflammation I-ADVERSE-EFFECTS
and 0
increased 0
intraocular B-ADVERSE-EFFECTS
pressure I-ADVERSE-EFFECTS
. 0

We 0
found 0
no 0
evidence 0
that 0
the 0
proportion 0
of 0
patients B-OTHER
with I-OTHER
events I-OTHER
increased 0
as 0
the 0
number B-OTHER
of I-OTHER
injections I-OTHER
increased 0
. 0

CONCLUSIONS 0
Intravitreous 0
fomivirsen 0
is 0
well B-OTHER
tolerated I-OTHER
with I-OTHER
an I-OTHER
acceptable I-OTHER
safety I-OTHER
profile I-OTHER
. 0

Adverse B-ADVERSE-EFFECTS
ocular I-ADVERSE-EFFECTS
events I-ADVERSE-EFFECTS
associated 0
with 0
doses 0
and 0
schedules 0
used 0
clinically 0
can 0
be 0
managed 0
successfully 0
with 0
medical 0
therapy 0
. 0

Clinical B-PHYSICAL
pharmacology I-PHYSICAL
of 0
methadone 0
in 0
dogs 0
. 0

OBJECTIVE 0
To 0
investigate 0
the 0
pharmacokinetics B-PHYSICAL
and 0
effects 0
of 0
methadone 0
on 0
behaviour B-MENTAL
and 0
plasma B-PHYSICAL
concentrations I-PHYSICAL
of I-PHYSICAL
cortisol I-PHYSICAL
and I-PHYSICAL
vasopressin I-PHYSICAL
in 0
healthy 0
dogs 0
. 0

STUDY 0
DESIGN 0
Randomized 0
, 0
cross-over 0
, 0
experimental 0
trial 0
. 0

ANIMALS 0
Nine 0
adult 0
dogs 0
( 0
beagle 0
and 0
beagle 0
cross 0
breeds 0
) 0
, 0
four 0
males 0
and 0
five 0
females 0
. 0

METHODS 0
Methadone 0
hydrochloride 0
, 0
0.4 0
mg 0
kg 0
( 0
-1 0
) 0
, 0
was 0
administered 0
intravenously 0
( 0
IV 0
) 0
and 0
subcutaneously 0
( 0
SC 0
) 0
with 0
a 0
crossover 0
design 0
. 0

Drug 0
and 0
hormone 0
analyses B-PHYSICAL
in I-PHYSICAL
plasma I-PHYSICAL
were 0
performed 0
using 0
Liquid 0
Chromatography-Electrospray 0
Ionization-Tandem 0
Mass 0
Spectrometry 0
and 0
radioimmunoassay 0
respectively 0
. 0

Behavioural B-MENTAL
data I-MENTAL
were 0
collected 0
using 0
a 0
standardized 0
protocol 0
. 0

RESULTS 0
After 0
IV 0
administration 0
, 0
the 0
plasma B-PHYSICAL
concentration 0
of B-PHYSICAL
methadone B-PHYSICAL
at 0
10 0
minutes 0
was 0
82.1 0
+/- 0
9.2 0
ng 0
mL 0
( 0
-1 0
) 0
( 0
mean 0
+/- 0
SD 0
) 0
, 0
the 0
terminal 0
half-life 0
was 0
3.9 0
+/- 0
1.0 0
hours 0
, 0
the 0
volume 0
of 0
distribution 0
9.2 0
+/- 0
3.3 0
L 0
kg 0
( 0
-1 0
) 0
and 0
plasma 0
clearance 0
27.9 0
+/- 0
7.6 0
mL 0
minute 0
( 0
-1 0
) 0
kg 0
( 0
-1 0
) 0
. 0

After 0
SC 0
administration 0
, 0
time 0
to 0
maximal 0
plasma 0
concentration 0
was 0
1.26 0
+/- 0
1.04 0
hours 0
and 0
maximal B-PHYSICAL
plasma B-PHYSICAL
concentration 0
of B-PHYSICAL
methadone B-PHYSICAL
was 0
23.9 0
+/- 0
14.4 0
ng 0
mL 0
( 0
-1 0
) 0
, 0
the 0
terminal 0
half-life 0
was 0
10.7 0
+/- 0
4.3 0
hours 0
and 0
bioavailability B-PHYSICAL
was 0
79 0
+/- 0
22 0
% 0
. 0

Concentrations 0
of 0
both 0
cortisol B-PHYSICAL
and 0
vasopressin B-PHYSICAL
were 0
increased 0
for 0
an 0
hour 0
following 0
IV 0
methadone 0
. 0

The 0
observed 0
behavioural 0
effects 0
of 0
methadone 0
were 0
decreased 0
licking B-MENTAL
and 0
swallowing B-MENTAL
and 0
an 0
increase 0
in 0
whining B-MENTAL
after 0
SC 0
administration 0
. 0

The 0
latter 0
finding 0
is 0
notable 0
as 0
it 0
can 0
be 0
misinterpreted 0
as 0
pain B-PAIN
when 0
methadone 0
is 0
used 0
as 0
an 0
analgesic 0
. 0

CONCLUSION 0
AND 0
CLINICAL 0
RELEVANCE 0
When 0
methadone 0
was 0
administered 0
by 0
the 0
SC 0
route 0
, 0
the 0
half-life 0
was 0
longer 0
, 0
but 0
the 0
individual 0
variation 0
in 0

Physician-pharmacist 0
cooperation 0
program 0
for 0
blood 0
pressure 0
control 0
in 0
patients 0
with 0
hypertension 0
: 0
a 0
randomized-controlled 0
trial 0
. 0

BACKGROUND 0
The 0
aim 0
of 0
the 0
trial 0
was 0
to 0
evaluate 0
the 0
effectiveness 0
of 0
a 0
program 0
of 0
cooperation 0
between 0
physician 0
and 0
pharmacist 0
to 0
reduce 0
cardiovascular 0
risk 0
factors 0
in 0
patients 0
with 0
mild 0
to 0
moderate 0
hypertension 0
by 0
promoting 0
better 0
blood 0
pressure 0
( 0
BP 0
) 0
control 0
, 0
appropriate 0
changes 0
in 0
antihypertensive 0
medications 0
, 0
and 0
beneficial 0
changes 0
in 0
lifestyle 0
. 0

METHODS 0
The 0
132 0
subjects 0
in 0
this 0
randomized 0
, 0
controlled 0
trial 0
were 0
in 0
the 0
age 0
range 0
of 0
40-79 0
years 0
. 0

The 0
inclusion 0
criteria 0
were 0
: 0
systolic B-PHYSICAL
BP I-PHYSICAL
( I-PHYSICAL
SBP I-PHYSICAL
) I-PHYSICAL
ranging 0
from 0
140-179 0
mm 0
Hg 0
and/or 0
diastolic B-PHYSICAL
BP I-PHYSICAL
( I-PHYSICAL
DBP I-PHYSICAL
) I-PHYSICAL
ranging 0
from 0
90-99 0
mm 0
Hg 0
and 0
treatment-naive 0
( 0
untreated 0
for 0
hypertension 0
) 0
; 0
or 0
on 0
a 0
regimen 0
of 0
medication 0
for 0
hypertension 0
. 0

Of 0
these 0
132 0
subjects 0
, 0
124 0
( 0
94 0
% 0
) 0
were 0
already 0
receiving 0
treatment 0
with 0
antihypertensive 0
medications 0
. 0

Equal 0
numbers 0
of 0
subjects 0
were 0
randomly 0
assigned 0
to 0
one 0
of 0
two 0
groups 0
: 0
a 0
physician-pharmacist 0
intervention 0
group 0
( 0
n 0
= 0
66 0
) 0
and 0
a 0
control 0
group 0
( 0
n 0
= 0
66 0
) 0
. 0

RESULTS 0
The 0
6-month 0
follow-up 0
rate 0
was 0
97 0
% 0
in 0
both 0
groups 0
. 0

At 0
6 0
months 0
, 0
the 0
mean 0
decrease 0
in 0
SBP/DBP B-PHYSICAL
, 0
as 0
measured 0
at 0
home 0
in 0
the 0
morning 0
, 0
was 0
2.9/3.3 0
mm 0
Hg 0
in 0
the 0
intervention 0
group 0
relative 0
to 0
baseline 0
( 0
P 0
= 0
0.02 0
and 0
P 0
< 0
0.0001 0
for 0
SBP 0
and 0
DBP 0
, 0
respectively 0
) 0
. 0

The 0
mean 0
decrease 0
in 0
home B-PHYSICAL
morning I-PHYSICAL
SBP I-PHYSICAL
in 0
the 0
intervention 0
group 0
was 0
not 0
significantly 0
greater 0
than 0
in 0
the 0
control 0
group 0
. 0

However 0
, 0
the 0
DBP B-PHYSICAL
decline 0
was 0
significantly 0
greater 0
in 0
the 0
intervention 0
than 0
control 0
groups 0
, 0
which 0
showed 0
a 0
mean 0
decrease 0
of 0
2.8 0
mm 0
Hg 0
( 0
confidence 0
interval 0
: 0
-5.5 0
to 0
-0.1 0
; 0
P 0
= 0
0.04 0
) 0
. 0

The 0
percentage 0
of 0
patients 0
in 0
whom 0
control 0
of 0
home B-PHYSICAL
morning I-PHYSICAL
BP I-PHYSICAL
was 0
achieved 0
was 0
53 0
% 0
in 0
the 0
intervention 0
group 0
and 0
47 0
% 0
in 0
the 0
control 0
group 0
( 0
P 0
= 0
0.40 0
) 0
. 0

A 0
higher 0
percentage 0
of 0
patients 0
in 0
the 0
intervention 0
group 0
, 0
relative 0
to 0
the 0
control 0
group 0
, 0
were 0
able 0
to 0
reduce 0
the 0
use 0
of 0
antihypertensive B-OTHER
medications I-OTHER
( 0
31 0
vs. 0
8 0
% 0
, 0
P 0
< 0
0.0001 0
) 0
, 0
and 0
fewer 0
patients 0
in 0
this 0
group 0
required 0
additional B-PHYSICAL
medications I-PHYSICAL
or 0
increases 0
in 0
dosage 0
relative 0
to 0
the 0
controls 0
( 0
11 0
vs. 0
28 0
% 0
, 0
P 0
= 0
0.03 0
) 0
. 0

Patients 0
of 0
the 0
intervention 0
group 0
were 0
more 0
likely 0
to 0
show 0
reduction 0
in 0
body 0
mass 0
index 0
and 0
sodium B-MENTAL
intake I-MENTAL
and 0
to 0
stop B-MENTAL
smoking I-MENTAL
, 0
as 0
compared 0
with 0
the 0
control 0
group 0
. 0

CONCLUSIONS 0
A 0
program 0
of 0
cooperation 0
between 0
physician 0
and 0
pharmacist 0
was 0
successful 0
in 0
reducing 0
cardiovascular 0
risk 0
factors 0
in 0
patients 0
with 0
mild 0
to 0
moderate 0
hypertension 0
by 0
promoting 0
better 0
blood 0
pressure 0
( 0
BP 0
) 0
control 0
, 0
appropriate 0
changes 0
in 0
antihypertensive 0
medications 0
, 0
and 0
beneficial 0
changes 0
in 0
lifestyle 0
. 0

The 0
instruction 0
to 0
refrain 0
from 0
blinking 0
affects 0
auditory B-PHYSICAL
P3 I-PHYSICAL
and 0
N1 B-PHYSICAL
amplitudes I-PHYSICAL
. 0

Often 0
subjects 0
have 0
been 0
instructed 0
to 0
refrain 0
from 0
blinking 0
lest 0
their 0
evoked 0
EEG 0
potentials 0
should 0
be 0
distorted 0
. 0

We 0
studied 0
whether 0
these 0
very 0
instructions 0
have 0
any 0
impact 0
on 0
P3 B-PHYSICAL
amplitude 0
. 0

Two 0
tones 0
were 0
presented 0
in 0
random 0
order 0
, 0
and 0
subjects 0
had 0
to 0
count 0
the 0
high-pitched 0
tones 0
. 0

Half 0
the 0
subjects 0
were 0
instructed 0
not 0
to 0
blink 0
, 0
whereas 0
this 0
instruction 0
was 0
omitted 0
for 0
the 0
other 0
subjects 0
. 0

Target 0
tones 0
evoked 0
larger 0
P3s B-PHYSICAL
than 0
non-targets 0
in 0
the 0
latter 0
group 0
but 0
not 0
in 0
the 0
former 0
, 0
in 0
particular 0
not 0
in 0
those 0
subjects 0
that 0
actually 0
blinked 0
rarely 0
. 0

The 0
groups 0
also 0
differed 0
in 0
their 0
N1 B-PHYSICAL
amplitudes I-PHYSICAL
. 0

These 0
findings 0
might 0
be 0
relevant 0
to 0
P3 0
studies 0
working 0
with 0
patients 0
and 0
controls 0
: 0
the 0
harder 0
some 0
frequently 0
blinking 0
subjects 0
try 0
to 0
refrain 0
from 0
blinking 0
, 0
the 0
smaller 0
might 0
become 0
their 0
P3 B-PHYSICAL
amplitudes I-PHYSICAL
. 0

Omitting 0
the 0
instruction 0
and 0
using 0
off-line 0
blink 0
subtraction 0
procedures 0
seems 0
a 0
viable 0
alternative 0
. 0

This 0
study 0
was 0
actually 0
motivated 0
by 0
discrepant 0
findings 0
on 0
the 0
effects 0
of 0
the 0
preceding 0
tone 0
sequence 0
on 0
P3 0
. 0

These 0
discrepancies 0
could 0
be 0
largely 0
resolved 0
by 0
the 0
instructional 0
variable 0
, 0
in 0
conjunction 0
with 0
different 0
tone B-PHYSICAL
intensities I-PHYSICAL
. 0

It 0
is 0
suggested 0
that 0
subjects 0
who 0
are 0
discouraged 0
from 0
blinking 0
try 0
to 0
protect 0
themselves 0
against 0
the 0
arousing 0
effects 0
of 0
stimuli 0
. 0

Cirrhosis 0
and 0
bleeding 0
: 0
the 0
need 0
for 0
very 0
early 0
management 0
. 0

BACKGROUND/AIMS 0
Retrospective 0
studies 0
suggest 0
that 0
the 0
prognosis 0
of 0
patients 0
with 0
cirrhosis 0
and 0
variceal 0
hemorrhage 0
has 0
improved 0
in 0
more 0
recent 0
decades 0
. 0

In 0
a 0
prospective 0
cohort 0
study 0
in 0
which 0
the 0
choice 0
of 0
prophylactic 0
therapy 0
was 0
left 0
to 0
each 0
practitioner 0
, 0
we 0
followed 0
cirrhotic 0
patients 0
with 0
medium/large 0
varices 0
to 0
determine 0
factors 0
predictive 0
of 0
bleeding 0
and 0
death 0
. 0

METHODS 0
Three 0
hundred 0
fourteen 0
patients 0
with 0
grades 0
2 0
or 0
3 0
esophageal 0
varices 0
( 0
Child 0
A 0
and 0
B/C 0
: 0
218 0
and 0
96 0
) 0
were 0
enrolled 0
. 0

One 0
hundred 0
seventy-three 0
patients 0
had 0
no 0
previous 0
history 0
of 0
variceal 0
bleeding 0
. 0

Only 0
245 0
patients 0
( 0
100 0
% 0
of 0
patients 0
with 0
prior 0
variceal 0
hemorrhage 0
, 0
61 0
% 0
of 0
patients 0
without 0
prior 0
hemorrhage 0
) 0
were 0
receiving 0
some 0
form 0
of 0
prophylactic 0
therapy 0
. 0

The 0
median 0
follow-up 0
was 0
18 0
months 0
. 0

RESULTS 0
There 0
were 0
76 0
bleeding B-PHYSICAL
events I-PHYSICAL
and 0
14 0
related B-MORTALITY
deaths I-MORTALITY
( 0
18 0
% 0
) 0
; 0
nine 0
of 0
these 0
deaths 0
occurred 0
within 0
24 0
h 0
of 0
bleeding B-PHYSICAL
onset 0
( 0
two 0
at 0
home 0
, 0
two 0
during 0
hospital 0
transfer 0
, 0
and 0
five 0
in 0
hospital 0
, 0
a 0
mean 0
of 0
2.5 0
h 0
after 0
onset 0
; 0
six 0
involved 0
Child 0
C 0
patients 0
) 0
. 0

Twenty-five 0
deaths B-MORTALITY
were 0
not 0
due 0
to 0
bleeding 0
but 0
were 0
closely 0
related 0
to 0
cirrhosis 0
. 0

In 0
a 0
Cox 0
model 0
, 0
the 0
presence 0
of 0
tense 0
ascites 0
( 0
relative 0
risk 0
3.4 0
, 0
95 0
% 0
confidence 0
interval 0
, 0
CI 0
2.5-5.9 0
) 0
and 0
a 0
prior 0
history 0
of 0
hemorrhage 0
( 0
relative 0
risk 0
4.4 0
, 0
95 0
% 0
CI 0
2.6-7.5 0
) 0
were 0
independent 0
predictors 0
of 0
variceal B-PHYSICAL
hemorrhage I-PHYSICAL
. 0

In 0
patients 0
without 0
a 0
prior 0
history 0
of 0
bleeding 0
, 0
bleeding 0
risk 0
was 0
higher 0
with 0
more 0
prolonged 0
prothrombin 0
time 0
and 0
lower 0
when 0
patients 0
were 0
receiving 0
propranolol 0
. 0

CONCLUSIONS 0
Despite 0
the 0
advent 0
of 0
effective 0
drugs 0
and 0
endoscopic 0
therapy 0
for 0
variceal 0
bleeding 0
, 0
about 0
a 0
quarter 0
of 0
deaths B-MORTALITY
occur 0
very 0
early 0
after 0
bleeding 0
onset 0
, 0
confirming 0
the 0
need 0
for 0
rapid 0
specific 0
management 0
. 0

Effect 0
of 0
supplementary 0
antioxidant 0
vitamin 0
intake 0
on 0
carotid B-PHYSICAL
arterial I-PHYSICAL
wall I-PHYSICAL
intima-media I-PHYSICAL
thickness I-PHYSICAL
in 0
a 0
controlled 0
clinical 0
trial 0
of 0
cholesterol 0
lowering 0
. 0

BACKGROUND 0
There 0
is 0
accumulating 0
experimental 0
, 0
epidemiological 0
, 0
and 0
clinical 0
evidence 0
of 0
an 0
association 0
between 0
anti-oxidant 0
vitamin 0
intake 0
and 0
reduced 0
risk 0
of 0
coronary 0
heart 0
disease 0
. 0

Using 0
data 0
from 0
the 0
Cholesterol 0
Lowering 0
Atherosclerosis 0
Study 0
( 0
CLAS 0
) 0
, 0
we 0
explored 0
the 0
association 0
of 0
self-selected 0
supplementary 0
antioxidant 0
vitamin 0
intake 0
on 0
the 0
rate 0
of 0
progression 0
of 0
early 0
preintrusive 0
atherosclerosis 0
. 0

METHODS 0
AND 0
RESULTS 0
CLAS 0
was 0
an 0
arterial 0
imaging 0
trial 0
in 0
which 0
nonsmoking 0
40- 0
to 0
59-year-old 0
men 0
with 0
previous 0
coronary 0
artery 0
bypass 0
graft 0
surgery 0
were 0
randomized 0
to 0
colestipol/niacin 0
plus 0
diet 0
or 0
placebo 0
plus 0
diet 0
. 0

The 0
rate 0
of 0
progression 0
of 0
early 0
preintrusive 0
atherosclerosis B-PHYSICAL
was 0
determined 0
in 0
146 0
subjects 0
using 0
high-resolution 0
B-mode 0
ultrasound 0
quantification 0
of 0
the 0
distal 0
common 0
carotid 0
artery 0
far 0
wall 0
intima-media 0
thickness 0
( 0
IMT 0
) 0
. 0

From 0
the 0
nutritional 0
supplement 0
database 0
, 0
22 0
subjects 0
had 0
an 0
on-trial 0
average 0
supplementary 0
vitamin 0
E 0
intake 0
of 0
> 0
or 0
= 0
100 0
IU 0
per 0
day 0
( 0
high 0
users 0
) 0
and 0
29 0
subjects 0
had 0
an 0
average 0
on-trial 0
supplementary 0
vitamin 0
C 0
intake 0
of 0
> 0
or 0
= 0
250 0
mg 0
per 0
day 0
( 0
high 0
users 0
) 0
. 0

Within 0
the 0
placebo 0
group 0
, 0
less 0
carotid B-PHYSICAL
IMT I-PHYSICAL
progression I-PHYSICAL
was 0
found 0
for 0
high 0
supplementary 0
vitamin 0
E 0
users 0
when 0
compared 0
with 0
low 0
vitamin 0
E 0
users 0
( 0
0.008 0
versus 0
0.023 0
mm/y 0
, 0
P 0
= 0
.03 0
) 0
. 0

No 0
effect 0
of 0
vitamin B-PHYSICAL
E 0
within 0
the 0
drug 0
group 0
was 0
found 0
. 0

No 0
effect 0
of 0
vitamin 0
C 0
within 0
the 0
drug 0
or 0
placebo 0
group 0
was 0
found 0
. 0

CONCLUSIONS 0
Supplementary 0
vitamin 0
E 0
intake 0
appears 0
to 0
be 0
effective 0
in 0
reducing 0
the 0
progression B-PHYSICAL
of I-PHYSICAL
atherosclerosis I-PHYSICAL
in 0
subjects 0
not 0
treated 0
with 0
lipid-lowering 0
drugs 0
while 0
the 0
process 0
is 0
still 0
confined 0
to 0
the 0
arterial 0
wall 0
( 0
early 0
preintrusive 0
atherosclerosis 0
) 0
. 0

Noradrenergic B-PHYSICAL
response I-PHYSICAL
to 0
intravenous 0
yohimbine 0
in 0
patients 0
with 0
depression 0
and 0
comorbidity 0
of 0
depression 0
and 0
panic 0
. 0

Adrenergic B-PHYSICAL
response I-PHYSICAL
following 0
infusions 0
of 0
yohimbine 0
or 0
normal 0
saline 0
was 0
evaluated 0
in 0
9 0
control 0
subjects 0
, 0
8 0
patients 0
suffering 0
from 0
a 0
major 0
depressive 0
episode 0
( 0
MDE 0
) 0
, 0
and 0
12 0
patients 0
suffering 0
from 0
concurrent 0
MDE 0
and 0
panic 0
disorder 0
( 0
MDE 0
+ 0
P 0
) 0
. 0

Blood 0
was 0
drawn 0
at 0
-20 0
, 0
0 0
, 0
5 0
, 0
10 0
, 0
20 0
, 0
45 0
, 0
and 0
90 0
min 0
following 0
the 0
infusions 0
, 0
and 0
assayed 0
for 0
norepinephrine 0
( 0
NE 0
) 0
and 0
3-methoxy-4-hydroxy-phenyl 0
glycol 0
( 0
MHPG 0
) 0
. 0

Although 0
the 0
patient 0
groups 0
exhibited 0
higher 0
baseline 0
NE B-PHYSICAL
concentrations I-PHYSICAL
, 0
and 0
a 0
greater 0
NE B-PHYSICAL
area 0
under B-PHYSICAL
the I-PHYSICAL
plasma I-PHYSICAL
concentration 0
versus B-PHYSICAL
time B-PHYSICAL
curve 0
( 0
AUC0-90 0
) 0
during 0
the 0
yohimbine 0
infusion 0
, 0
the 0
differences 0
were 0
not 0
statistically 0
significant 0
. 0

Baseline 0

Clomipramine 0
versus 0
haloperidol 0
in 0
the 0
treatment 0
of 0
autistic 0
disorder 0
: 0
a 0
double-blind 0
, 0
placebo-controlled 0
, 0
crossover 0
study 0
. 0

Clomipramine 0
, 0
haloperidol 0
, 0
and 0
placebo 0
were 0
compared 0
with 0
baseline 0
in 0
the 0
treatment 0
of 0
autism 0
, 0
and 0
overall B-MENTAL
outcome I-MENTAL
, 0
specific B-MENTAL
symptoms I-MENTAL
, 0
and 0
side 0
effects 0
were 0
examined 0
. 0

It 0
was 0
hypothesized 0
that 0
clomipramine 0
would 0
be 0
better 0
tolerated 0
than 0
haloperidol 0
and 0
prove 0
superior 0
on 0
a 0
measure 0
of 0
stereotypy 0
. 0

Individuals 0
with 0
a 0
DSM-IV 0
diagnosis 0
of 0
autistic 0
disorder 0
( 0
mean 0
age 0
, 0
16.3 0
years 0
; 0
range 0
, 0
10-36 0
years 0
) 0
were 0
randomly 0
assigned 0
, 0
by 0
using 0
a 0
Latin 0
square 0
design 0
, 0
to 0
the 0
following 0
7-week 0
trials 0
: 0
placebo 0
, 0
clomipramine 0
( 0
mean 0
daily 0
dose 0
, 0
128.4 0
mg 0
; 0
range 0
, 0
100-150 0
mg 0
) 0
, 0
or 0
haloperidol 0
( 0
mean 0
daily 0
dose 0
, 0
1.3 0
mg 0
; 0
range 0
, 0
1-1.5 0
mg 0
) 0
. 0

Data 0
on 0
36 0
subjects 0
were 0
analyzed 0
and 0
taken 0
together 0
; 0
the 0
results 0
favored 0
haloperidol 0
. 0

In 0
those 0
patients 0
who 0
were 0
able 0
to 0
complete 0
a 0
full 0
therapeutic 0
trial 0
, 0
clomipramine 0
proved 0
comparable 0
to 0
haloperidol 0
in 0
terms 0
of 0
improvement B-PHYSICAL
compared 0
with 0
baseline 0
. 0

However 0
, 0
significantly 0
fewer 0
individuals 0
receiving 0
clomipramine 0
versus 0
haloperidol 0
were 0
able 0
to 0
complete 0
the 0
trial 0
( 0
37.5 0
% 0
vs. 0
69.7 0
% 0
, 0
respectively 0
) 0
for 0
reasons 0
related 0
to 0
both 0
side 0
effects 0
and 0
efficacy 0
or 0
behavior B-MENTAL
problems I-MENTAL
. 0

In 0
the 0
intent-to-treat 0
sample 0
, 0
which 0
is 0
perhaps 0
more 0
clinically 0
relevant 0
, 0
only 0
haloperidol 0
proved 0
superior 0
to 0
baseline 0
on 0
a 0
global 0
measure 0
of 0
autistic B-MENTAL
symptom I-MENTAL
severity I-MENTAL
, 0
as 0
well 0
as 0
specific 0
measures 0
for 0
irritability B-MENTAL
and 0
hyperactivity B-MENTAL
. 0

Clomipramine 0
did 0
not 0
seem 0
more 0
effective 0
on 0
a 0
measure 0
of 0
stereotypy 0
, 0
nor 0
was 0
it 0
better 0
tolerated 0
. 0

Anxiety 0
disorders 0
in 0
typically 0
developing 0
youth 0
: 0
autism 0
spectrum 0
symptoms 0
as 0
a 0
predictor 0
of 0
cognitive-behavioral 0
treatment 0
. 0

Symptoms 0
of 0
autism 0
spectrum 0
disorder 0
( 0
ASD 0
) 0
were 0
assessed 0
( 0
Social 0
Responsiveness 0
Scale-Parent 0
( 0
SRS-P 0
) 0
; 0
coded 0
in-session 0
behavior 0
) 0
in 0
typically-developing 0
, 0
anxiety-disordered 0
children 0
( 0
N 0
= 0
50 0
) 0
treated 0
with 0
cognitive-behavioral 0
therapy 0
( 0
CBT 0
) 0
. 0

Study 0
1 0
: 0
children 0
with 0
moderate 0
autistic 0
symptomology 0
( 0
per 0
SRS-P 0
) 0
were 0
significantly 0
more 0
likely 0
to 0
improve 0
from 0
family 0
CBT 0
( 0
FCBT 0
) 0
than 0
individual 0
CBT 0
( 0
ICBT 0
; 0
OR 0
= 0
8.67 0
) 0
. 0

Coded 0
behavior 0
did 0
not 0
predict 0
outcome 0
. 0

Study 0
2 0
: 0
CBT 0
components 0
were 0
compared 0
by 0
treatment 0
and 0
ASD 0
symptom 0
status 0
. 0

At-home 0
exposure 0
completion 0
was 0
greater 0
in 0
FCBT 0
and 0
there 0
was 0
an 0
interaction 0
in 0
child 0
involvement 0
for 0
treatment 0
and 0
ASD 0
status 0
. 0

Though 0
both 0
treatments 0
reduced 0
anxiety B-MENTAL
, 0
FCBT 0
outperformed 0
ICBT 0
for 0
children 0
with 0
moderate 0
ASD 0
symptoms 0
, 0
a 0
benefit 0
potentially 0
linked 0
to 0
more 0
at-home 0
exposures 0
and 0
greater 0
child 0
involvement 0
in 0
FCBT 0
. 0

Enhancing 0
antiepileptic 0
drug 0
adherence 0
: 0
a 0
randomized 0
controlled 0
trial 0
. 0

Suboptimal 0
adherence 0
to 0
antiepileptic 0
drug 0
( 0
AED 0
) 0
treatment 0
is 0
commonplace 0
, 0
and 0
increases 0
the 0
risk 0
of 0
status 0
epilepticus 0
and 0
sudden 0
unexplained 0
death 0
in 0
epilepsy 0
. 0

This 0
randomized 0
controlled 0
trial 0
was 0
designed 0
to 0
demonstrate 0
whether 0
an 0
implementation 0
intention 0
intervention 0
involving 0
the 0
completion 0
of 0
a 0
simple 0
self-administered 0
questionnaire 0
linking 0
the 0
intention 0
of 0
taking 0
medication 0
with 0
a 0
particular 0
time 0
, 0
place 0
, 0
and 0
other 0
activity 0
can 0
improve 0
AED 0
treatment 0
schedule 0
adherence 0
. 0

Of 0
the 0
81 0
patients 0
with 0
epilepsy 0
who 0
were 0
randomized 0
, 0
69 0
completed 0
a 0
1-month 0
monitoring 0
period 0
with 0
an 0
objective 0
measure 0
of 0
tablet 0
taking 0
( 0
electronic 0
registration 0
of 0
pill 0
bottle 0
openings 0
, 0
Medication 0
Event 0
Monitoring 0
System 0
[ 0
MEMS 0
] 0
) 0
. 0

Intervention 0
participants 0
showed 0
improved B-MENTAL
adherence I-MENTAL
relative I-MENTAL
to I-MENTAL
controls I-MENTAL
on 0
all 0
three 0
outcomes 0
: 0
doses B-OTHER
taken I-OTHER
in I-OTHER
total 0
( 0
93.4 0
% 0
vs. 0
79.1 0
% 0
) 0
, 0
days 0
on 0
which 0
correct B-OTHER
dose I-OTHER
was I-OTHER
taken I-OTHER
( 0
88.7 0
% 0
vs. 0
65.3 0
% 0
) 0
, 0
and 0
doses B-OTHER
taken I-OTHER
on I-OTHER
schedule I-OTHER
( 0
78.8 0
% 0
vs. 0
55.3 0
% 0
) 0
( 0
P 0
< 0
0.01 0
) 0
. 0

The 0
implementation 0
intention 0
intervention 0
may 0
be 0
an 0
easy-to-administer 0
and 0
effective 0
means 0
of 0
promoting 0
AED 0
adherence 0
. 0

RAB-plate 0
versus 0
sliding 0
hip 0
screw 0
for 0
unstable 0
trochanteric 0
hip 0
fractures 0
: 0
stability 0
of 0
the 0
fixation 0
and 0
modes 0
of 0
failure 0
-- 0
radiographic 0
analysis 0
of 0
218 0
fractures 0
. 0

BACKGROUND 0
The 0
sliding 0
hip 0
screw 0
has 0
gained 0
considerable 0
acceptance 0
in 0
the 0
treatment 0
of 0
unstable 0
trochanteric 0
fractures 0
. 0

However 0
, 0
the 0
new 0
type 0
of 0
120 0
degrees 0
fixed 0
angle 0
blade-plate 0
with 0
a 0
buttress 0
rod 0
( 0
RAB-plate 0
) 0
showed 0
encouraging 0
clinical 0
results 0
. 0

The 0
purpose 0
of 0
this 0
study 0
was 0
to 0
assess 0
stability 0
of 0
fixation 0
and 0
analyze 0
modes 0
of 0
failure 0
in 0
unstable 0
trochanteric 0
hip 0
fractures 0
treated 0
with 0
these 0
devices 0
. 0

METHODS 0
A 0
retrospective 0
radiographic 0
review 0
of 0
218 0
unstable 0
fractures 0
was 0
performed 0
. 0

Linear 0
and 0
angular 0
displacements 0
of 0
the 0
major 0
fragments 0
and 0
implant B-PHYSICAL
migration I-PHYSICAL
into I-PHYSICAL
the I-PHYSICAL
femoral I-PHYSICAL
head I-PHYSICAL
during 0
healing 0
were 0
assessed 0
. 0

Additionally 0
, 0
adequacy 0
of 0
the 0
reduction 0
and 0
the 0
location 0
of 0
the 0
implant 0
within 0
the 0
femoral 0
head 0
as 0
predictors 0
of 0
fixation 0
failure 0
were 0
evaluated 0
. 0

RESULTS 0
The 0
postreduction 0
neck-shaft 0
angle 0
was 0
maintained 0
in 0
the 0
majority 0
of 0
the 0
fractures 0
in 0
both 0
groups 0
. 0

However 0
, 0
there 0
was 0
a 0
significantly 0
higher 0
incidence 0
of 0
varus 0
angulation 0
by 0
10 0
degrees 0
or 0
more 0
by 0
the 0
completion 0
of 0
healing 0
among 0
fractures 0
treated 0
with 0
the 0
sliding 0
hip 0
screw 0
( 0
p 0
= 0
0.04 0
) 0
. 0

There 0
was 0
no 0
statistically 0
significant 0
difference 0
in 0
vertical B-PHYSICAL
migration I-PHYSICAL
of I-PHYSICAL
the I-PHYSICAL
device I-PHYSICAL
into I-PHYSICAL
the I-PHYSICAL
femoral I-PHYSICAL
head I-PHYSICAL
between 0
the 0
implants 0
used 0
( 0
p 0
= 0
0.3 0
) 0
. 0

There 0
was 0
a 0
significant 0
relationship 0
between 0
failure 0
of 0
the 0
fixation 0
and 0
varus 0
reduction 0
( 0
p 0
= 0
0.04 0
) 0
as 0
well 0
as 0
screw/neck 0
angle 0
deviation 0
more 0
than 0
20 0
degrees 0
in 0
the 0
lateral 0
projection 0
( 0
p 0
= 0
0.005 0
) 0
or 0
if 0
the 0
implant 0
was 0
in 0
a 0
superior 0
or 0
posterior 0
position 0
( 0
p 0
= 0
0.02 0
) 0
. 0

CONCLUSION 0
The 0
RAB-plate 0
provided 0
a 0
more 0
stable 0
fixation 0
, 0
especially 0
with 0
regard 0
to 0
maintained 0
postoperative 0
alignment 0
. 0

However 0
, 0
positive 0
predictors 0
for 0
fixation B-PHYSICAL
failure I-PHYSICAL
were 0
identical 0
for 0
both 0
devices 0
. 0

Here 0
, 0
the 0
screw/neck 0
angle 0
deviation 0
has 0
had 0
the 0
strongest 0
significance 0
for 0
prediction 0
of 0
fixation 0
failure 0
. 0

Randomized 0
clinical 0
trial 0
of 0
balance-based 0
torso 0
weighting 0
for 0
improving 0
upright B-PHYSICAL
mobility I-PHYSICAL
in 0
people 0
with 0
multiple 0
sclerosis 0
. 0

BACKGROUND 0
Torso 0
weighting 0
has 0
sometimes 0
been 0
effective 0
for 0
improving 0
upright B-PHYSICAL
mobility I-PHYSICAL
in 0
people 0
with 0
multiple 0
sclerosis 0
, 0
but 0
parameters B-PHYSICAL
for I-PHYSICAL
weighting I-PHYSICAL
have 0
been 0
inconsistent 0
. 0

OBJECTIVE 0
To 0
determine 0
whether 0
balance-based 0
torso 0
weighting 0
( 0
BBTW 0
) 0
has 0
immediate 0
effects 0
on 0
upright 0
mobility 0
in 0
people 0
with 0
multiple 0
sclerosis 0
. 0

METHODS 0
This 0
was 0
a 0
2-phase 0
randomized 0
clinical 0
trial 0
. 0

In 0
phase 0
1 0
, 0
36 0
participants 0
were 0
randomly 0
assigned 0
to 0
experimental 0
and 0
control 0
groups 0
. 0

In 0
phase 0
2 0
, 0
the 0
control 0
group 0
was 0
subsequently 0
randomized 0
into 0
2 0
groups 0
with 0
alternate 0
weight-placement 0
. 0

Tests 0
of 0
upright B-PHYSICAL
mobility I-PHYSICAL
included 0
: 0
timed B-PHYSICAL
up I-PHYSICAL
and I-PHYSICAL
go I-PHYSICAL
( I-PHYSICAL
TUG I-PHYSICAL
) I-PHYSICAL
, 0
sharpened B-PHYSICAL
Romberg I-PHYSICAL
, 0
360-degree B-PHYSICAL
turns I-PHYSICAL
, 0
25-foot B-PHYSICAL
walk I-PHYSICAL
, 0
and 0
computerized B-PHYSICAL
platform I-PHYSICAL
posturography I-PHYSICAL
. 0

Participants 0
were 0
tested 0
at 0
baseline 0
and 0
again 0
with 0
weights 0
placed 0
according 0
to 0
group 0
membership 0
. 0

In 0
both 0
phases 0
, 0
a 0
physical 0
therapist 0
assessed 0
balance 0
for 0
the 0
BBTW 0
group 0
and 0
then 0
placed 0
weights 0
to 0
decrease 0
balance B-PHYSICAL
loss I-PHYSICAL
. 0

In 0
phase 0
1 0
, 0
the 0
control 0
group 0
had 0
no 0
weights 0
placed 0
. 0

In 0
phase 0
2 0
, 0
the 0
alternate 0
treatment 0
group 0
received 0
standard 0
weight 0
placement 0
of 0
1.5 0
% 0
body 0
weight 0
. 0

RESULTS 0
People 0
with 0
BBTW 0
showed 0
a 0
significant 0
improvement 0
in 0
the 0
25-foot B-PHYSICAL
walk I-PHYSICAL
( 0
P 0
= 0
.01 0
) 0
over 0
those 0
with 0
no 0
weight 0
, 0
and 0
the 0
TUG B-PHYSICAL
( 0
P 0
= 0
.01 0
) 0
over 0
those 0
with 0
standard 0
weight 0
placement 0
. 0

BBTW 0
participants 0
received 0
an 0
average 0
of 0
0.5 0
kg 0
, 0
less 0
than 0
1.5 0
% 0
of 0
any 0
participant 0
's 0
body 0
weight 0
. 0

CONCLUSION 0
BBTW 0
can 0
have 0
immediate 0
advantages 0
over 0
a 0
nonweighted 0
condition 0
for 0
gait B-PHYSICAL
velocity I-PHYSICAL
and 0
over 0
a 0
standardized 0
weighted 0
condition 0
for 0
a 0
functional B-PHYSICAL
activity I-PHYSICAL
in 0
people 0
with 0
multiple 0
sclerosis 0
( 0
MS 0
) 0
who 0
are 0
ambulatory 0
but 0
have 0
balance 0
and 0
mobility 0
abnormalities 0
. 0

Peritoneovenous 0
shunting 0
as 0
compared 0
with 0
medical 0
treatment 0
in 0
patients 0
with 0
alcoholic 0
cirrhosis 0
and 0
massive 0
ascites 0
. 0

Veterans 0
Administration 0
Cooperative 0
Study 0
on 0
Treatment 0
of 0
Alcoholic 0
Cirrhosis 0
with 0
Ascites 0
. 0

The 0
optimal 0
management 0
of 0
severe 0
ascites 0
in 0
patients 0
with 0
alcoholic 0
cirrhosis 0
has 0
not 0
been 0
defined 0
. 0

in 0
a 0
5 0
1/2-year 0
study 0
, 0
we 0
randomly 0
assigned 0
299 0
men 0
with 0
alcoholic 0
cirrhosis 0
, 0
who 0
had 0
persistent 0
or 0
recurrent 0
severe 0
ascites 0
despite 0
a 0
standard 0
medical 0
regimen 0
, 0
to 0
receive 0
either 0
intensive 0
medical 0
treatment 0
or 0
peritoneovenous 0
( 0
LeVeen 0
) 0
shunting 0
. 0

We 0
identified 0
three 0
risk 0
groups 0
: 0
Group 0
1 0
had 0
normal 0
or 0
mildly 0
abnormal 0
results 0
on 0
liver-function 0
tests 0
, 0
Group 0
2 0
had 0
more 0
severe 0
liver 0
dysfunction 0
or 0
previous 0
complications 0
, 0
and 0
Group 0
3 0
had 0
severe 0
prerenal 0
azotemia 0
without 0
kidney 0
disease 0
. 0

For 0
the 0
patients 0
who 0
received 0
the 0
medical 0
treatment 0
and 0
those 0
who 0
received 0
the 0
surgical 0
treatment 0
combined 0
, 0
the 0
median 0
survival 0
times 0
were 0
1093 0
days 0
in 0
Group 0
1 0
, 0
222 0
days 0
in 0
Group 0
2 0
, 0
and 0
37 0
days 0
in 0
Group 0
3 0
( 0
P 0
less 0
than 0
or 0
equal 0
to 0
0.01 0
) 0
for 0
all 0
comparisons 0
) 0
. 0

For 0
all 0
the 0
groups 0
combined 0
, 0
the 0
median 0
time 0
to 0
the 0
resolution 0
of 0
ascites 0
was 0
5.4 0
weeks 0
for 0
medical 0
patients 0
and 0
3.0 0
weeks 0
for 0
surgical 0
patients 0
( 0
P 0
less 0
than 0
0.01 0
) 0
. 0

Within 0
each 0
risk 0
group 0
, 0
mortality B-MORTALITY
during 0
the 0
initial 0
hospitalization 0
and 0
median 0
long-term B-MORTALITY
survival I-MORTALITY
were 0
similar 0
among 0
patients 0
receiving 0
either 0
treatment 0
. 0

However 0
, 0
the 0
median 0
time 0
to 0
the 0
recurrence B-PHYSICAL
of I-PHYSICAL
ascites I-PHYSICAL
in 0
Group 0
1 0
was 0
4 0
months 0
in 0
medical 0
patients 0
, 0
as 0
compared 0
with 0
18 0
months 0
in 0
surgical 0
patients 0
( 0
P 0
= 0
0.01 0
) 0
; 0
in 0
Group 0
2 0
it 0
was 0
3 0
months 0
in 0
medical 0
patients 0
as 0
compared 0
with 0
12 0
months 0
in 0
surgical 0
patients 0
( 0
P 0
= 0
0.04 0
) 0
. 0

The 0
median 0
duration B-OTHER
of I-OTHER
hospitalization I-OTHER
was 0
longer 0
in 0
medical 0
patients 0
than 0
in 0
surgical 0
patients 0
( 0
6.1 0
vs. 0
2.4 0
weeks 0
in 0
Group 0
1 0
[ 0
P 0
less 0
than 0
0.001 0
] 0
and 0
5.0 0
vs. 0
3.1 0
weeks 0
in 0
Group 0
2 0
[ 0
P 0
less 0
than 0
0.01 0
] 0
) 0
. 0

Group 0
3 0
was 0
too 0
small 0
to 0
permit 0
a 0
meaningful 0
comparison 0
. 0

During 0
the 0
initial 0
hospitalization 0
, 0
the 0
incidence 0
of 0
infections B-ADVERSE-EFFECTS
, 0
gastrointestinal B-ADVERSE-EFFECTS
bleeding I-ADVERSE-EFFECTS
, 0
and 0

Effect 0
of 0
ischaemic 0
preconditioning 0
, 0
cardiopulmonary 0
bypass 0
and 0
myocardial 0
ischaemic/reperfusion 0
on 0
free B-PHYSICAL
radical I-PHYSICAL
generation I-PHYSICAL
in 0
CABG 0
patients 0
. 0

OBJECTIVE 0
To 0
investigate 0
the 0
free 0
radicals 0
( 0
FR 0
) 0
generation 0
after 0
ischaemic 0
preconditioning 0
and 0
cardiopulmonary 0
bypass 0
and 0
during 0
reperfusion 0
in 0
CABG 0
patients 0
, 0
and 0
the 0
role 0
of 0
ischaemic 0
preconditioning 0
. 0

METHODS 0
Forty-three 0
CABG 0
patients 0
were 0
randomised 0
into 0
an 0
ischaemic 0
preconditioning 0
and 0
a 0
control 0
group 0
. 0

The 0
protocol 0
for 0
ischaemic 0
preconditioning 0
was 0
two 0
cycles 0
of 0
2-min 0
ischaemia 0
followed 0
by 0
3-min 0
reperfusion 0
. 0

Free B-PHYSICAL
radicals I-PHYSICAL
were 0
measured 0
using 0
electron 0
spin 0
resonance 0
spectroscopy 0
. 0

Global B-PHYSICAL
and I-PHYSICAL
right I-PHYSICAL
heart I-PHYSICAL
functions I-PHYSICAL
were 0
collected 0
. 0

RESULTS 0
The 0
free B-PHYSICAL
radicals I-PHYSICAL
generation I-PHYSICAL
in I-PHYSICAL
coronary I-PHYSICAL
sinus I-PHYSICAL
blood I-PHYSICAL
in 0
the 0
ischaemic 0
preconditioning 0
group 0
was 0
9.7 0
and 0
16.6 0
% 0
after 0
the 0
ischaemic 0
preconditioning 0
protocol 0
and 0
10 0
min 0
after 0
declamping 0
, 0
6.8 0
and 0
13.3 0
% 0
in 0
the 0
controls 0
. 0

The 0
free B-PHYSICAL
radicals I-PHYSICAL
in I-PHYSICAL
arterial I-PHYSICAL
samples I-PHYSICAL
were 0
, 0
respectively 0
, 0
21 0
, 0
14 0
, 0
10 0
and 0
9 0
% 0
at 0
10 0
min 0
, 0
1 0
, 0
2 0
and 0
24 0
h 0
after 0
reperfusion 0
. 0

Cardiac B-PHYSICAL
index 0
( B-PHYSICAL
CI I-PHYSICAL
) B-PHYSICAL
and 0
right B-PHYSICAL
ventricular I-PHYSICAL
ejection I-PHYSICAL
fraction I-PHYSICAL
( I-PHYSICAL
RVEF B-PHYSICAL
) I-PHYSICAL
were 0
improved 0
by 0
ischaemic 0
preconditioning 0
. 0

CONCLUSION 0
Both 0
ischaemic 0
preconditioning 0
and 0
cardiopulmonary 0
bypass 0
induced 0
free B-PHYSICAL
radicals I-PHYSICAL
generation I-PHYSICAL
. 0

Although 0
ischaemic 0
preconditioning 0
had 0
no 0
effect 0
on 0

A 0
comparison 0
of 0
the 0
effect 0
of 0
short-term 0
aromatase 0
inhibitor 0
( 0
letrozole 0
) 0
and 0
GnRH 0
agonist 0
( 0
triptorelin 0
) 0
versus 0
case 0
control 0
on 0
pregnancy B-PHYSICAL
rate I-PHYSICAL
and 0
symptom B-PHYSICAL
and 0
sign B-PHYSICAL
recurrence I-PHYSICAL
after 0
laparoscopic 0
treatment 0
of 0
endometriosis 0
. 0

PURPOSE 0
To 0
compare 0
the 0
role 0
of 0
an 0
aromatase 0
inhibitor 0
( 0
letrozole 0
) 0
with 0
a 0
GnRH 0
agonist 0
( 0
triptorelin 0
) 0
versus 0
case 0
control 0
on 0
the 0
pregnancy B-PHYSICAL
rate I-PHYSICAL
and 0
recurrence 0
of 0
symptoms B-PHYSICAL
and 0
signs B-PHYSICAL
in 0
patients 0
with 0
endometriosis 0
. 0

METHODS 0
In 0
a 0
prospective 0
randomized 0
clinical 0
trial 0
, 0
after 0
treatment 0
of 0
144 0
infertile 0
women 0
in 0
their 0
reproductive 0
age 0
by 0
laparoscopy 0
( 0
whose 0
endometriosis 0
was 0
confirmed 0
by 0
prior 0
laparoscopy 0
) 0
, 0
they 0
were 0
divided 0
into 0
3 0
groups 0
: 0
group 0
1 0
( 0
47 0
cases 0
) 0
who 0
received 0
letrozole 0
for 0
2 0
months 0
, 0
group 0
2 0
( 0
40 0
patients 0
) 0
who 0
were 0
prescribed 0
triptorelin 0
for 0
2 0
months 0
and 0
group 0
3 0
who 0
were 0
57 0
patients 0
in 0
the 0
control 0
group 0
and 0
did 0
not 0
receive 0
any 0
medication 0
. 0

We 0
followed 0
up 0
each 0
group 0
at 0
least 0
for 0
12 0
months 0
after 0
their 0
restoration 0
of 0
regular 0
cycle 0
. 0

RESULTS 0
Pregnancy B-PHYSICAL
rate I-PHYSICAL
was 0
23.4 0
% 0
in 0
group 0
1 0
, 0
27.5 0
% 0
in 0
group 0
2 0
, 0
and 0
28.1 0
% 0
in 0
group 0
3 0
. 0

The 0
results 0
did 0
not B-OTHER
show I-OTHER
significant I-OTHER
differences I-OTHER
among 0
the 0
3 0
groups 0
. 0

Recurrence B-PHYSICAL
rate I-PHYSICAL
of I-PHYSICAL
endometriosis I-PHYSICAL
was 0
6.4 0
% 0
in 0
group 0
1 0
, 0
5 0
% 0
group 0
2 0
and 0
5.3 0
% 0
in 0
group 0
3 0
, 0
which 0
was 0
not 0
statistically B-OTHER
significantly I-OTHER
different I-OTHER
as 0
well 0
. 0

CONCLUSION 0
Pregnancy B-PHYSICAL
rate I-PHYSICAL
and 0
endometriosis B-PHYSICAL
recurrence I-PHYSICAL
rate I-PHYSICAL
are 0
comparable 0
among 0
the 0
3 0
groups 0
. 0

Standardized 0
preoperative 0
corticosteroid 0
treatment 0
in 0
neonates 0
undergoing 0
cardiac 0
surgery 0
: 0
results 0
from 0
a 0
randomized 0
trial 0
. 0

OBJECTIVE 0
A 0
heightened 0
inflammatory 0
response 0
occurs 0
after 0
cardiac 0
surgery 0
. 0

The 0
perioperative 0
use 0
of 0
glucocorticoids 0
has 0
been 0
advocated 0
as 0
a 0
method 0
to 0
improve 0
postoperative 0
outcomes 0
. 0

Randomized 0
prospective 0
studies 0
to 0
quantify 0
the 0
effect 0
of 0
methylprednisolone 0
on 0
perioperative 0
outcomes 0
in 0
neonatal 0
cardiac 0
surgery 0
have 0
not 0
been 0
performed 0
. 0

We 0
sought 0
to 0
determine 0
whether 0
preoperative 0
methylprednisolone 0
would 0
improve 0
postoperative 0
recovery 0
in 0
neonates 0
requiring 0
cardiac 0
surgery 0
. 0

METHODS 0
Neonates 0
scheduled 0
for 0
cardiac 0
surgery 0
were 0
randomly 0
assigned 0
to 0
receive 0
either 0
2-dose 0
( 0
8 0
hours 0
preoperatively 0
and 0
operatively 0
, 0
n 0
= 0
39 0
) 0
or 0
single-dose 0
( 0
operatively 0
, 0
n 0
= 0
37 0
) 0
methylprednisolone 0
( 0
30 0
mg/kg 0
per 0
dose 0
) 0
in 0
a 0
prospective 0
double-blind 0
trial 0
. 0

The 0
primary 0
outcome 0
was 0
the 0
incidence 0
of 0
low 0
cardiac 0
output 0
syndrome 0
( 0
standardized 0
score 0
) 0
or 0
death 0
36 0
hours 0
postoperatively 0
. 0

Secondary 0
outcomes 0
were 0
death 0
at 0
30 0
days 0
, 0
interleukin-6 0
levels 0
, 0
inotropic 0
score 0
, 0
fluid 0
balance 0
, 0
serum 0
creatinine 0
, 0
and 0
intensive 0
care 0
unit 0
and 0
hospital 0
stay 0
. 0

RESULTS 0
Preoperative 0
plasma 0
levels 0
of 0
the 0
inflammatory 0
cytokine 0
interleukin-6 0
were 0
reduced 0
by 0
2-fold 0
( 0
P 0
< 0
.001 0
) 0
in 0
the 0
2-dose 0
methylprednisolone 0
group 0
, 0
consistent 0
with 0
the 0
anti-inflammatory 0
effects 0
of 0
methylprednisolone 0
. 0

However 0
, 0
the 0
incidence 0
of 0
low 0
cardiac 0
output 0
syndrome 0
was 0
46 0
% 0
( 0
17/37 0
) 0
in 0
the 0
single-dose 0
and 0
38 0
% 0
( 0
15/39 0
) 0
in 0
the 0
2-dose 0
methylprednisolone 0
groups 0
( 0
P 0
= 0
.51 0
) 0
. 0

Two-dose 0
methylprednisolone 0
was 0
associated 0
with 0
a 0
higher 0
serum B-PHYSICAL
creatinine I-PHYSICAL
( 0
0.61 0
? 0

0.18 0
mg/dL 0
vs 0
0.53 0
? 0

0.12 0
mg/dL 0
, 0
P 0
= 0
.03 0
) 0
and 0
poorer 0
postoperative 0
diuresis 0
( 0
-96 0
? 0

49 0
mL 0
, 0
P 0
= 0
.05 0
) 0
. 0

Inotropic 0
requirement 0
, 0
duration 0
of 0
mechanical 0
ventilation 0
, 0
intensive 0
care 0
unit 0
, 0
and 0
hospital 0
stay 0
did 0
not 0
differ 0
between 0
the 0
2 0
groups 0
. 0

CONCLUSIONS 0
Combined 0
preoperative 0
and 0
intraoperative 0
use 0
of 0
glucocorticoids 0
in 0
neonatal 0
cardiac 0
surgery 0
does 0
not 0
favorably 0
affect 0
early 0
clinical 0
outcomes 0
and 0
may 0
exacerbate 0
perioperative 0
renal 0
dysfunction 0
. 0

Temporal 0
expectation 0
in 0
focal 0
hand 0
dystonia 0
. 0

Patients 0
with 0
writer 0
's 0
cramp 0
present 0
sensory 0
and 0
representational 0
abnormalities 0
relevant 0
to 0
motor 0
control 0
, 0
such 0
as 0
impairment 0
in 0
the 0
temporal 0
discrimination 0
between 0
tactile 0
stimuli 0
and 0
in 0
pure 0
motor 0
imagery 0
tasks 0
, 0
like 0
the 0
mental 0
rotation 0
of 0
corporeal 0
and 0
inanimate 0
objects 0
. 0

However 0
, 0
only 0
limited 0
information 0
is 0
available 0
on 0
the 0
ability 0
of 0
patients 0
with 0
dystonia 0
to 0
process 0
the 0
time-dependent 0
features 0
( 0
e.g 0
. 0

speed 0
) 0
of 0
movement 0
in 0
real 0
time 0
. 0

The 0
processing 0
of 0
time-dependent 0
features 0
of 0
movement 0
has 0
a 0
crucial 0
role 0
in 0
predicting 0
whether 0
the 0
outcome 0
of 0
a 0
complex 0
motor 0
sequence 0
, 0
such 0
as 0
handwriting 0
or 0
playing 0
a 0
musical 0
passage 0
, 0
will 0
be 0
consistent 0
with 0
its 0
ultimate 0
goal 0
, 0
or 0
results 0
instead 0
in 0
an 0
execution 0
error 0
. 0

In 0
this 0
study 0
, 0
we 0
sought 0
to 0
evaluate 0
the 0
implicit 0
ability 0
to 0
perceive 0
the 0
temporal 0
outcome 0
of 0
different 0
movements 0
in 0
a 0
group 0
of 0
patients 0
with 0
writer 0
's 0
cramp 0
. 0

Fourteen 0
patients 0
affected 0
by 0
writer 0
's 0
cramp 0
in 0
the 0
right 0
hand 0
and 0
17 0
age- 0
and 0
gender-matched 0
healthy 0
subjects 0
were 0
recruited 0
for 0
the 0
study 0
. 0

Subjects 0
were 0
asked 0
to 0
perform 0
a 0
temporal 0
expectation 0
task 0
by 0
predicting 0
the 0
end 0
of 0
visually 0
perceived 0
human 0
body 0
motion 0
( 0
handwriting 0
, 0
i.e 0
. 0

the 0
action 0
performed 0
by 0
the 0
human 0
body 0
segment 0
specifically 0
affected 0
by 0
writer 0
's 0
cramp 0
) 0
or 0
inanimate 0
object 0
motion 0
( 0
a 0
moving 0
circle 0
reaching 0
a 0
spatial 0
target 0
) 0
. 0

Videos 0
representing 0
movements 0
were 0
shown 0
in 0
full 0
before 0
experimental 0
trials 0
; 0
the 0
actual 0
tasks 0
consisted 0
of 0
watching 0
the 0
same 0
videos 0
, 0
but 0
interrupted 0
after 0
a 0
variable 0
interval 0
( 0
'pre-dark 0
' 0
) 0
from 0
its 0
onset 0
by 0
a 0
dark 0
interval 0
of 0
variable 0
duration 0
. 0

During 0
the 0
'dark 0
' 0
interval 0
, 0
subjects 0
were 0
asked 0
to 0
indicate 0
when 0
the 0
movement 0
represented 0
in 0
the 0
video 0
reached 0
its 0
end 0
by 0
clicking 0
on 0
the 0
space 0
bar 0
of 0
the 0
keyboard 0
. 0

We 0
also 0
included 0
a 0
visual B-MENTAL
working I-MENTAL
memory I-MENTAL
task I-MENTAL
. 0

Performance 0
on 0
the 0
timing 0
task 0
was 0
analysed 0
measuring 0
the 0
absolute 0
value 0
of 0
timing 0
error 0
, 0
the 0
coefficient 0
of 0
variability 0
and 0
the 0
percentage 0
of 0
anticipation 0
responses 0
. 0

Patients 0
with 0
writer 0
's 0
cramp 0
exhibited 0
greater 0
absolute 0
timing 0
error 0
compared 0
with 0
control 0
subjects 0
in 0
the 0
human 0
body 0
motion 0
task 0
( 0
whereas 0
no 0
difference 0
was 0
observed 0
in 0
the 0
inanimate 0
object 0
motion 0
task 0
) 0
. 0

No 0
effect 0
of 0
group 0
was 0
documented 0
on 0
the 0
visual 0
working 0
memory 0
tasks 0
. 0

Absolute B-MENTAL
timing I-MENTAL
error I-MENTAL
on 0
the 0
human 0
body 0
motion 0
task 0
did 0
not 0
significantly 0
correlate 0
with 0
symptom 0
severity 0
, 0
disease 0
duration 0
or 0
writing 0
speed 0
. 0

Our 0
findings 0
suggest 0
an 0
alteration 0
of 0
the 0
writing 0
movement 0
representation 0
at 0
a 0
central 0
level 0
and 0
are 0
consistent 0
with 0
the 0
view 0
that 0
dystonia 0
is 0
not 0
a 0
purely 0
motor 0
disorder 0
, 0
but 0
it 0
also 0
involves 0
non-motor 0
( 0
sensory 0
, 0
cognitive 0
) 0
aspects 0
related 0
to 0
movement 0
processing 0
and 0
planning 0
. 0

Stepwise 0
hook 0
extension 0
technique 0
for 0
radiofrequency 0
ablation 0
therapy 0
of 0
hepatocellular 0
carcinoma 0
. 0

OBJECTIVE 0
Our 0
study 0
was 0
designed 0
to 0
examine 0
the 0
efficacy 0
of 0
stepwise 0
hook 0
extension 0
technique 0
for 0
radiofrequency 0
ablation 0
( 0
RFA 0
) 0
therapy 0
of 0
hepatocellular 0
carcinoma 0
in 0
a 0
randomized 0
controlled 0
study 0
. 0

METHOD 0
Twenty 0
patients 0
with 0
hepatocellular 0
carcinoma 0
measuring 0
< 0
25 0
mm 0
were 0
divided 0
randomly 0
into 0
two 0
equal 0
groups 0
. 0

RFA 0
was 0
applied 0
using 0
our 0
new 0
stepwise 0
hook 0
extension 0
technique 0
in 0
patients 0
of 0
group 0
1 0
, 0
and 0
the 0
full 0
extension 0
method 0
in 0
group 0
2 0
. 0

The 0
10-hook 0
electrode 0
of 0
LeVeen 0
needle 0
was 0
deployed 0
in 0
four 0
steps 0
to 0
full 0
extension 0
during 0
ablation 0
in 0
group 0
1 0
, 0
and 0
full 0
extension 0
at 0
start 0
of 0
treatment 0
in 0
group 0
2 0
. 0

RESULTS 0
Roll-off B-PHYSICAL
was 0
achieved 0
in 0
all 0
10 0
patients 0
of 0
group 0
1 0
, 0
indicative 0
of 0
sufficient 0
tumor 0
coagulation 0
, 0
but 0
only 0
in 0
3 0
of 0
10 0
patients 0
of 0
group 0
2 0
. 0

The 0
median 0
time B-OTHER
to I-OTHER
completion I-OTHER
of I-OTHER
treatment I-OTHER
was 0
6 0
min 0
and 0
55 0
s 0
( 0
range 0
3 0
min 0
to 0
14 0
min 0
and 0
3 0
s 0
) 0
and 0
15 0
min 0
( 0
6-15 0
min 0
) 0
, 0
respectively 0
. 0

The 0
total 0
power 0
output B-OTHER
used 0
for 0
RF 0
was 0
lower 0
in 0
group 0
1 0
than 0
in 0
group 0
2 0
( 0
median 0
271 0
vs. 0
1,045 0
W.m 0
) 0
. 0

The 0
diameters 0
of 0
RFA-induced B-PHYSICAL
lesions I-PHYSICAL
were 0
not 0
significantly 0
different 0
between 0
the 0
groups 0
( 0
group 0
1 0
: 0
27 0
, 0
range 0
23-37 0
mm 0
; 0
group 0
2 0
: 0
23 0
, 0
0-42 0
mm 0
) 0
. 0

CONCLUSIONS 0
Application 0
of 0
RFA 0
using 0
stepwise 0
hook 0
extension 0
technique 0
is 0
superior 0
to 0
the 0
full 0
extension 0
method 0
since 0
it 0
produces 0
the 0
same 0
therapeutic B-OTHER
effects I-OTHER
within 0
a 0
short 0
period 0
using 0
a 0
lower 0
energy 0
. 0

Active 0
warming 0
, 0
not 0
passive 0
heat 0
retention 0
, 0
maintains 0
normothermia B-PHYSICAL
during 0
combined 0
epidural-general 0
anesthesia 0
for 0
hip 0
and 0
knee 0
arthroplasty 0
. 0

STUDY 0
OBJECTIVE 0
to 0
compare 0
passive 0
heat 0
retention 0
by 0
low-flow 0
anesthesia 0
, 0
alone 0
and 0
with 0
additional 0
thermal 0
insulation 0
by 0
reflective 0
blankets 0
, 0
with 0
forced-air 0
warming 0
preventing 0
intraoperative 0
hypothermia 0
during 0
combined 0
epidural-general 0
anesthesia 0
. 0

DESIGN 0
Randomized 0
, 0
controlled 0
study 0
. 0

SETTING 0
Inpatient 0
anesthesia 0
at 0
a 0
university 0
department 0
of 0
orthopedic 0
surgery 0
. 0

PATIENTS 0
30 0
ASA 0
physical 0
status 0
I 0
and 0
II 0
patients 0
, 0
who 0
were 0
scheduled 0
for 0
elective 0
hip 0
or 0
knee 0
arthroplasty 0
and 0
were 0
free 0
from 0
systemic 0
disease 0
. 0

INTERVENTIONS 0
Patients 0
received 0
epidural 0
block 0
up 0
to 0
T10 0
by 0
alkalinized 0
lidocaine 0
2 0
% 0
, 0
and 0
then 0
were 0
administered 0
standard 0
general 0
anesthesia 0
by 0
means 0
of 0
low-flow 0
rebreathing 0
system 0
( 0
fresh 0
gas 0
flow 0
= 0
1 0
L/min 0
) 0
. 0

All 0
procedures 0
started 0
between 0
8 0
and 0
10 0
AM 0
, 0
and 0
operating 0
room 0
( 0
OR 0
) 0
temperature 0
was 0
maintained 0
between 0
21 0
degrees 0
and 0
23 0
degrees 0
C 0
, 0
with 0
relative 0
humidity 0
ranging 0
between 0
40 0
% 0
and 0
45 0
% 0
. 0

For 0
heat 0
retention 0
or 0
warming 0
therapy 0
, 0
patients 0
received 0
either 0
low-flow 0
anesthesia 0
only 0
( 0
control 0
, 0
n 0
= 0
10 0
) 0
, 0
low-flow 0
anesthesia 0
with 0
additional 0
reflective 0
blankets 0
( 0
blanket 0
, 0
n 0
= 0
10 0
) 0
, 0
or 0
low-flow 0
anesthesia 0
with 0
active 0
forced-air 0
warming 0
( 0
forced-air 0
, 0
n 0
= 0
10 0
) 0
. 0

Tympanic B-PHYSICAL
temperature I-PHYSICAL
was 0
measured 0
at 0
OR 0
arrival 0
( 0
baseline 0
) 0
; 0
immediately 0
following 0
general 0
anesthesia 0
induction 0
; 0
30 0
, 0
60 0
, 0
90 0
, 0
and 0
120 0
minutes 0
from 0
general 0
anesthesia 0
induction 0
; 0
and 0
at 0
the 0
end 0
of 0
surgery 0
. 0

MEASUREMENTS 0
AND 0
MAIN 0
RESULTS 0
Duration B-PHYSICAL
of I-PHYSICAL
anesthesia I-PHYSICAL
, 0
invasiveness B-PHYSICAL
of I-PHYSICAL
surgery I-PHYSICAL
, 0
and 0
baseline 0

A 0
double-blind 0
, 0
randomized 0
, 0
controlled 0
, 0
multicenter 0
study 0
to 0
assess 0
the 0
safety B-OTHER
and 0
cardiovascular B-ADVERSE-EFFECTS
effects I-ADVERSE-EFFECTS
of 0
skeletal 0
myoblast 0
implantation 0
by 0
catheter 0
delivery 0
in 0
patients 0
with 0
chronic 0
heart 0
failure 0
after 0
myocardial 0
infarction 0
. 0

BACKGROUND 0
We 0
sought 0
to 0
determine 0
the 0
safety B-OTHER
and 0
preliminary 0
efficacy 0
of 0
transcatheter 0
intramyocardial 0
administration 0
of 0
myoblasts 0
in 0
patients 0
with 0
heart 0
failure 0
( 0
HF 0
) 0
. 0

METHODS 0
MARVEL 0
is 0
a 0
randomized 0
placebo-controlled 0
trial 0
of 0
image-guided 0
, 0
catheter-based 0
intramyocardial 0
injection 0
of 0
placebo 0
or 0
myoblasts 0
( 0
400 0
or 0
800 0
million 0
) 0
in 0
patients 0
with 0
class 0
II 0
to 0
IV 0
HF 0
and 0
ejection 0
fraction 0
< 0
35 0
% 0
. 0

Primary 0
end 0
points 0
were 0
frequency 0
of 0
serious B-ADVERSE-EFFECTS
adverse I-ADVERSE-EFFECTS
events I-ADVERSE-EFFECTS
( 0
safety B-PHYSICAL
) 0
and 0
changes B-PHYSICAL
in I-PHYSICAL
6-minute I-PHYSICAL
walk I-PHYSICAL
test I-PHYSICAL
and 0
Minnesota B-OTHER
Living I-OTHER
With I-OTHER
HF I-OTHER
score 0
( 0
efficacy 0
) 0
. 0

Of 0
330 0
patients 0
intended 0
for 0
enrollment 0
, 0
23 0
were 0
randomized 0
( 0
MARVEL-1 0
) 0
before 0
stopping 0
the 0
study 0
for 0
financial 0
reasons 0
. 0

RESULTS 0
At 0
6 0
months 0
, 0
similar 0
numbers 0
of 0
events 0
occurred 0
in 0
each 0
group 0
: 0
8 0
( 0
placebo 0
) 0
, 0
7 0
( 0
low 0
dose 0
) 0
, 0
and 0
8 0
( 0
high 0
dose 0
) 0
, 0
without 0
deaths 0
. 0

Ventricular B-PHYSICAL
tachycardia I-PHYSICAL
responsive I-PHYSICAL
to I-PHYSICAL
amiodarone I-PHYSICAL
was 0
more 0
frequent 0
in 0
myoblast-treated 0
patients 0
: 0
1 0
( 0
placebo 0
) 0
, 0
3 0
( 0
low 0
dose 0
) 0
, 0
and 0
4 0
( 0
high 0
dose 0
) 0
. 0

A 0
trend 0
toward 0
improvement 0
in 0
functional B-MENTAL
capacity I-MENTAL
was 0
noted 0
in 0
myoblast-treated 0
groups 0
( 0
?6-minute 0
walk 0
test 0
of 0
-3.6 0
vs 0
+95.6 0
vs 0
+85.5 0
m 0
[ 0
placebo 0
vs 0
low 0
dose 0
vs 0
high 0
dose 0
; 0
P 0
= 0
.50 0
] 0
) 0
without 0
significant 0
changes 0
in 0
Minnesota 0
Living 0
With 0
HF 0
scores 0
. 0

CONCLUSIONS 0
In 0
HF 0
patients 0
with 0
chronic 0
postinfarction 0
cardiomyopathy 0
, 0
transcatheter 0
administration 0
of 0
myoblasts 0
in 0
doses 0
of 0
400 0
to 0
800 0
million 0
cells 0
is 0
feasible 0
and 0
may 0
lead 0
to 0
important 0
clinical 0
benefits 0
. 0

Ventricular 0
tachycardia 0
may 0
be 0
provoked 0
by 0
myoblast 0
injection 0
but 0
appears 0
to 0
be 0
a 0
transient 0
and 0
treatable 0
problem 0
. 0

A 0
large-scale 0
outcome 0
trial 0
of 0
myoblast 0
administration 0
in 0
HF 0
patients 0
with 0
postinfarction 0
cardiomyopathy 0
is 0
feasible 0
and 0
warranted 0
. 0

Oral B-PHYSICAL
estrogen I-PHYSICAL
antagonizes I-PHYSICAL
the I-PHYSICAL
metabolic I-PHYSICAL
actions I-PHYSICAL
of I-PHYSICAL
growth I-PHYSICAL
hormone I-PHYSICAL
in I-PHYSICAL
growth I-PHYSICAL
hormone-deficient I-PHYSICAL
women I-PHYSICAL
. 0

We 0
have 0
determined 0
whether 0
oral 0
estrogen 0
reduces 0
the 0
biological 0
effects 0
of 0
growth 0
hormone 0
( 0
GH 0
) 0
in 0
GH-deficient 0
( 0
GHD 0
) 0
women 0
compared 0
with 0
transdermal 0
estrogen 0
treatment 0
. 0

In 0
two 0
separate 0
studies 0
, 0
eight 0
GHD 0
women 0
randomly 0
received 0
either 0
oral 0
or 0
transdermal 0
estrogen 0
for 0
8 0
wk 0
before 0
crossing 0
over 0
to 0
the 0
alternate 0
route 0
of 0
administration 0
. 0

The 0
first 0
study 0
assessed 0
the 0
effects 0
of 0
incremental 0
doses 0
of 0
GH 0
( 0
0.5 0
, 0
1.0 0
, 0
2.0 0
IU/day 0
for 0
1 0
wk 0
each 0
) 0
on 0
insulin-like 0
growth 0
factor 0
I 0
( 0
IGF-I 0
) 0
levels 0
during 0
each 0
estrogen 0
treatment 0
phase 0
. 0

The 0
second 0
study 0
assessed 0
the 0
effects 0
of 0
GH 0
( 0
2 0
IU/day 0
) 0
on 0
lipid 0
oxidation 0
and 0
on 0
protein 0
metabolism 0
using 0
the 0
whole 0
body 0
leucine 0
turnover 0
technique 0
. 0

Mean 0
IGF-I 0
level 0
was 0
significantly 0
lower 0
during 0
oral 0
estrogen 0
treatment 0
( 0
P 0
< 0
0.05 0
) 0
and 0
rose B-PHYSICAL
dose I-PHYSICAL
dependently I-PHYSICAL
during I-PHYSICAL
GH I-PHYSICAL
administration I-PHYSICAL
by 0
a 0
lesser 0
magnitude 0
( 0
P 0
< 0
0.05 0
) 0
compared 0
with 0
transdermal 0
treatment 0
. 0

Postprandial B-PHYSICAL
lipid I-PHYSICAL
oxidation I-PHYSICAL
was I-PHYSICAL
significantly I-PHYSICAL
lower 0
with B-PHYSICAL
oral I-PHYSICAL
estrogen B-PHYSICAL
treatment 0
, 0
both 0
before 0
( 0
P 0
< 0
0.05 0
) 0
and 0
during 0
( 0
P 0
< 0
0.05 0
) 0
GH 0
administration 0
, 0
compared 0
with 0
transdermal 0
treatment 0
. 0

Protein B-PHYSICAL
synthesis I-PHYSICAL
was 0
lower 0
during 0
oral 0
estrogen 0
both 0
before 0
and 0
during 0
GH 0
administration 0
( 0
P 0
< 0
0.05 0
) 0
. 0

Oral 0
estrogen 0
antagonizes B-PHYSICAL
several I-PHYSICAL
of I-PHYSICAL
the B-PHYSICAL
metabolic I-PHYSICAL
actions I-PHYSICAL
of I-PHYSICAL
GH I-PHYSICAL
. 0

It 0
may 0
aggravate 0

Safety 0
and 0
efficacy 0
of 0
sitaxsentan 0
50 0
and 0
100 0
mg 0
in 0
patients 0
with 0
pulmonary 0
arterial 0
hypertension 0
. 0

OBJECTIVE 0
To 0
assess 0
safety 0
and 0
efficacy 0
of 0
sitaxsentan 0
50 0
and 0
100 0
mg 0
in 0
patients 0
with 0
pulmonary 0
arterial 0
hypertension 0
( 0
PAH 0
) 0
. 0

BACKGROUND 0
Sitaxsentan 0
is 0
a 0
highly 0
selective 0
endothelin-A 0
receptor 0
antagonist 0
that 0
was 0
recently 0
withdrawn 0
by 0
the 0
manufacturer 0
because 0
of 0
a 0
pattern 0
of 0
idiosyncratic 0
liver 0
injury 0
. 0

METHODS 0
Before 0
sitaxsentan 0
withdrawal 0
, 0
this 0
18-week 0
double-blind 0
, 0
placebo-controlled 0
study 0
randomized 0
patients 0
with 0
PAH 0
to 0
receive 0
placebo 0
or 0
sitaxsentan 0
50 0
or 0
100 0
mg 0
once 0
daily 0
. 0

The 0
primary 0
efficacy 0
endpoint 0
was 0
change 0
from 0
baseline 0
in 0
6-min 0
walk 0
distance 0
( 0
6MWD 0
) 0
at 0
week 0
18 0
. 0

Changes 0
in 0
World 0
Health 0
Organization 0
( 0
WHO 0
) 0
functional 0
class 0
and 0
time 0
to 0
clinical 0
worsening 0
( 0
TTCW 0
) 0
were 0
secondary 0
endpoints 0
. 0

The 0
primary 0
efficacy 0
analysis 0
was 0
powered 0
for 0
sitaxsentan 0
100 0
mg 0
versus 0
placebo 0
. 0

RESULTS 0
Of 0
98 0
randomized 0
patients 0
, 0
61 0
% 0
were 0
WHO 0
functional 0
class 0
II 0
at 0
baseline 0
. 0

Improvement 0
from 0
baseline 0
to 0
week 0
18 0
in 0
6MWD 0
occurred 0
with 0
sitaxsentan 0
100 0
but 0
not 0
50 0
mg 0
; 0
a 0
strong 0
placebo 0
effect 0
was 0
observed 0
. 0

At 0
week 0
18 0
, 0
WHO 0
functional 0
class 0
was 0
improved 0
or 0
maintained 0
in 0
more 0
patients 0
receiving 0
sitaxsentan 0
100 0
mg 0
than 0
placebo 0
( 0
P 0
= 0
0.038 0
) 0
; 0
0 0
% 0
versus 0
12 0
% 0
of 0
patients 0
deteriorated 0
, 0
respectively 0
. 0

TTCW B-PHYSICAL
was 0
not 0
significantly 0
different 0
for 0
100-mg 0
sitaxsentan 0
patients 0
than 0
placebo 0
( 0
P 0
= 0
0.090 0
) 0
. 0

Adverse 0
events 0
( 0
AEs 0
) 0
occurring 0
more 0
frequently 0
with 0
sitaxsentan 0
( 0
50 0
or 0
100 0
mg 0
) 0
included 0
headache B-ADVERSE-EFFECTS
, 0
peripheral B-ADVERSE-EFFECTS
edema I-ADVERSE-EFFECTS
, 0
dizziness B-ADVERSE-EFFECTS
, 0
nausea B-ADVERSE-EFFECTS
, 0
extremity B-ADVERSE-EFFECTS
pain I-ADVERSE-EFFECTS
, 0
and 0

Dual-task-related 0
gait 0
changes 0
in 0
transitionally 0
frail 0
older 0
adults 0
: 0
the 0
type 0
of 0
the 0
walking-associated 0
cognitive 0
task 0
matters 0
. 0

BACKGROUND 0
Changes 0
in 0
gait 0
patterns 0
due 0
to 0
a 0
simultaneously 0
performed 0
cognitive 0
task 0
have 0
been 0
reported 0
previously 0
and 0
associated 0
with 0
an 0
increased 0
falling 0
risk 0
among 0
older 0
adults 0
. 0

Little 0
is 0
known 0
whether 0
the 0
type 0
of 0
cognitive 0
task 0
performed 0
while 0
walking 0
is 0
important 0
concerning 0
possible 0
gait 0
interference 0
in 0
older 0
fall-prone 0
individuals 0
. 0

OBJECTIVE 0
To 0
quantify 0
and 0
compare 0
the 0
effects 0
of 0
two 0
different 0
cognitive 0
tasks 0
on 0
gait 0
in 0
transitionally 0
frail 0
older 0
adults 0
. 0

MEASUREMENTS 0
Gait 0
was 0
tested 0
in 0
30 0
transitionally 0
frail 0
older 0
adults 0
( 0
mean 0
age 0
82.6 0
+/- 0
7.1 0
years 0
, 0
90 0
% 0
female 0
) 0
while 0
either 0
walking B-MENTAL
alone I-MENTAL
, 0
performing B-MENTAL
a I-MENTAL
simple I-MENTAL
arithmetic I-MENTAL
task I-MENTAL
, 0
or 0
performing 0
a 0
task 0
of 0
verbal 0
fluency 0
. 0

Walking 0
time 0
in 0
seconds 0
, 0
number B-MENTAL
of I-MENTAL
steps I-MENTAL
, 0
frequency 0
of 0
lateral B-MENTAL
line I-MENTAL
stepping-over I-MENTAL
, 0
and 0

The 0
effects 0
of 0
delay 0
in 0
standard 0
treatment 0
due 0
to 0
induction 0
chemotherapy 0
in 0
two 0
randomized 0
prospective 0
studies 0
. 0

It 0
is 0
often 0
suggested 0
that 0
tumors 0
will 0
respond 0
to 0
induction 0
chemotherapy 0
and 0
result 0
in 0
improved 0
survival B-MORTALITY
for 0
patients 0
with 0
squamous 0
cell 0
carcinoma 0
of 0
the 0
head 0
and 0
neck 0
. 0

Two 0
regimens 0
of 0
induction 0
chemotherapy 0
were 0
studied 0
in 0
separate 0
randomized 0
, 0
prospective 0
trials 0
over 0
the 0
last 0
6 0
years 0
. 0

Eighty-three 0
patients 0
with 0
advanced 0
disease 0
were 0
entered 0
into 0
the 0
first 0
study 0
( 0
43/chemotherapy 0
; 0
40/control 0
) 0
, 0
and 0
60 0
into 0
the 0
second 0
( 0
27/chemotherapy 0
; 0
33/control 0
) 0
. 0

Patient 0
randomization 0
was 0
stratified 0
by 0
stage 0
( 0
III/IV 0
) 0
and 0
site 0
( 0
oral 0
cavity 0
, 0
oropharynx 0
, 0
nasopharynx 0
, 0
hypopharynx 0
, 0
larynx 0
, 0
paranasal 0
sinuses 0
) 0
. 0

The 0
first 0
study 0
utilized 0
bleomycin 0
, 0
Cytoxan 0
, 0
methotrexate 0
and 0
5-fluorouracil 0
in 0
two 0
cycles 0
( 0
one 0
cycle 0
if 0
no 0
tumor 0
response 0
) 0
, 0
followed 0
by 0
standard 0
treatment 0
which 0
consisted 0
of 0
combined 0
irradiation 0
and 0
surgery 0
or 0
, 0
in 0
some 0
instances 0
, 0
primary 0
irradiation 0
alone 0
. 0

The 0
second 0
study 0
utilized 0
cisplatin 0
and 0
5-fluorouracil 0
in 0
three 0
cycles 0
prior 0
to 0
standard 0
treatment 0
. 0

An 0
objective B-OTHER
tumor I-OTHER
response I-OTHER
to 0
chemotherapy 0
was 0
observed 0
in 0
68 0
% 0
in 0
the 0
first 0
study 0
and 0
85 0
% 0
in 0
the 0
second 0
. 0

The 0
patient B-MORTALITY
survival I-MORTALITY
in 0
both 0
studies 0
( 0
at 0
24 0
months 0
in 0
the 0
first 0
; 0
at 0
19 0
in 0
the 0
second 0
) 0
was 0
better 0
in 0
the 0
control 0
than 0
that 0
in 0
the 0
experimental 0
groups 0
( 0
43 0
% 0
to 0
31 0
% 0
; 0
69 0
% 0
to 0
46 0
% 0
) 0
. 0

In 0
the 0
second 0
study 0
, 0
the 0
average 0
length 0
of B-OTHER
delay I-OTHER
of I-OTHER
standard I-OTHER
treatment B-OTHER
was 0
longer 0
than 0
in 0
the 0
first 0
study 0
( 0
95 0
days 0
vs. 0
66 0
days 0
; 0
P 0
less 0
than 0
.02 0
) 0
. 0

Results 0
combining 0
the 0
P-values 0
of 0
both 0
studies 0
indicate 0
that 0
the 0
relative 0
risk 0
of 0
having 0
persistent 0
disease 0
was 0
2.9 0
times 0
greater 0
for 0
patients 0
who 0
received 0
chemotherapy 0
. 0

While 0

MRI 0
signal 0
hyperintensities 0
in 0
geriatric 0
depression 0
. 0

OBJECTIVE 0
The 0
authors 0
rated 0
periventricular 0
and 0
subcortical 0
signal 0
hyperintensities 0
on 0
magnetic 0
resonance 0
imaging 0
( 0
MRI 0
) 0
scans 0
in 0
elderly 0
patients 0
with 0
depression 0
and 0
in 0
normal 0
subjects 0
with 0
similar 0
demographic 0
features 0
to 0
examine 0
whether 0
such 0
changes 0
discriminate 0
patients 0
with 0
depression 0
from 0
normal 0
subjects 0
and 0
whether 0
they 0
are 0
associated 0
with 0
any 0
clinical 0
variables 0
. 0

METHOD 0
Two 0
established 0
hyperintensity 0
rating 0
systems 0
were 0
used 0
to 0
compare 0
the 0
MRI 0
brain 0
scans 0
of 0
48 0
elderly 0
patients 0
with 0
depression 0
diagnosed 0
according 0
to 0
DSM-III-R 0
with 0
the 0
scans 0
of 0
39 0
normal 0
elderly 0
subjects 0
. 0

RESULTS 0
Elderly 0
depressed 0
patients 0
manifested 0
significantly 0
more 0
severe 0
hyperintensity B-PHYSICAL
ratings I-PHYSICAL
in 0
the 0
subcortical 0
gray 0
matter 0
than 0
age-matched 0
comparison 0
subjects 0
. 0

Significant 0
differences 0
were 0
not 0
identified 0
between 0
patients 0
with 0
similar 0
current 0
ages 0
and 0
cerebrovascular 0
disease 0
risk 0
who 0
had 0
early-onset 0
or 0
late-onset 0
depression 0
. 0

CONCLUSIONS 0
These 0
findings 0
support 0
those 0
of 0
neuroimaging 0
studies 0
implicating 0
the 0
basal 0
ganglia 0
in 0
depression 0
and 0
geriatric 0
depression 0
. 0

The 0
data 0
suggest 0
that 0
the 0
relationship 0
observed 0
in 0
some 0
reports 0
between 0
late-onset 0
depression 0
and 0
MRI 0
hyperintensities 0
is 0
most 0
likely 0
a 0
function 0
of 0
cerebrovascular 0
disease 0
risk 0
and 0
age 0
. 0

A 0
pilot 0
randomised 0
control 0
trial 0
of 0
a 0
parent 0
training 0
intervention 0
for 0
pre-school 0
children 0
with 0
autism 0
. 0

Preliminary 0
findings 0
and 0
methodological 0
challenges 0
. 0

Few 0
attempts 0
have 0
been 0
made 0
to 0
conduct 0
randomised 0
control 0
trials 0
( 0
RCTs 0
) 0
of 0
interventions 0
for 0
pre-school 0
children 0
with 0
autism 0
. 0

We 0
report 0
findings 0
of 0
a 0
pilot 0
RCT 0
for 0
a 0
parent 0
training 0
intervention 0
with 0
a 0
focus 0
on 0
the 0
development 0
of 0
joint 0
attention 0
skills 0
and 0
joint 0
action 0
routines 0
. 0

Twenty-four 0
children 0
meeting 0
ICD-10 0
criteria 0
for 0
childhood 0
autism 0
( 0
mean 0
age 0
= 0
23 0
months 0
) 0
were 0
identified 0
using 0
the 0
CHAT 0
screen 0
and 0
randomised 0
to 0
the 0
parent 0
training 0
group 0
or 0
to 0
local 0
services 0
only 0
. 0

A 0
follow-up 0
was 0
conducted 0
12 0
months 0
later 0
( 0
mean 0
age 0
= 0
35 0
months 0
) 0
. 0

There 0
was 0
some 0
evidence 0
that 0
the 0
parent 0
training 0
group 0
made 0
more 0
progress 0
in 0
language B-MENTAL
development I-MENTAL
than 0
the 0
local 0
services 0
group 0
. 0

However 0
, 0
the 0
present 0
pilot 0
study 0
was 0
compromised 0
by 0
several 0
factors 0
: 0
a 0
reliance 0
on 0
parental 0
report 0
to 0
measure 0
language 0
, 0
non-matching 0
of 0
the 0
groups 0
on 0
initial 0
IQ 0
, 0
and 0
a 0
lack 0
of 0
systematic 0
checking 0
regarding 0
the 0
implementation 0
of 0
the 0
parent 0
training 0
intervention 0
. 0

Furthermore 0
, 0
three 0
parents 0
in 0
the 0
local 0
services 0
group 0
commenced 0
intensive 0
, 0
home-based 0
behavioural 0
intervention 0
during 0
the 0
course 0
of 0
the 0
study 0
. 0

The 0
difficulties 0
encountered 0
in 0
the 0
conduct 0
of 0
RCTs 0
for 0
pre-school 0
children 0
with 0
autism 0
are 0
discussed 0
. 0

Methodological 0
challenges 0
and 0
strategies 0
for 0
future 0
well-designed 0
RCTs 0
for 0
autism 0
interventions 0
are 0
highlighted 0
. 0

Further 0
evaluation 0
of 0
docosahexaenoic 0
acid 0
in 0
patients 0
with 0
retinitis 0
pigmentosa 0
receiving 0
vitamin 0
A 0
treatment 0
: 0
subgroup 0
analyses 0
. 0

OBJECTIVE 0
To 0
determine 0
whether 0
docosahexaenoic 0
acid 0
will 0
slow 0
the 0
course 0
of 0
retinal 0
degeneration 0
in 0
subgroups 0
of 0
patients 0
with 0
retinitis 0
pigmentosa 0
who 0
are 0
receiving 0
vitamin 0
A 0
. 0

DESIGN 0
A 0
cohort 0
of 0
208 0
patients 0
with 0
retinitis 0
pigmentosa 0
, 0
aged 0
18 0
to 0
55 0
years 0
, 0
were 0
randomly 0
assigned 0
to 0
1200 0
mg 0
of 0
docosahexaenoic 0
acid 0
plus 0
15 0
000 0
IU/d 0
of 0
vitamin 0
A 0
given 0
as 0
retinyl 0
palmitate 0
( 0
DHA 0
+ 0
A 0
group 0
) 0
or 0
control 0
fatty 0
acid 0
plus 0
15 0
000 0
IU/d 0
of 0
vitamin 0
A 0
( 0
control 0
+ 0
A 0
group 0
) 0
and 0
followed 0
up 0
over 0
4 0
years 0
. 0

Seventy 0
percent 0
of 0
the 0
patients 0
in 0
each 0
group 0
were 0
taking 0
vitamin 0
A 0
, 0
15 0
000 0
IU/d 0
, 0
prior 0
to 0
entry 0
. 0

We 0
compared 0
rates 0
of 0
decline 0
in 0
ocular 0
function 0
in 0
the 0
DHA 0
+ 0
A 0
vs 0
control 0
+ 0
A 0
groups 0
among 0
the 0
subgroups 0
defined 0
by 0
use 0
or 0
nonuse 0
of 0
vitamin 0
A 0
prior 0
to 0
entry 0
. 0

We 0
also 0
determined 0
whether 0
decline 0
in 0
ocular 0
function 0
was 0
related 0
to 0
red 0
blood 0
cell 0
phosphatidylethanolamine 0
docosahexaenoic 0
acid 0
level 0
, 0
dietary 0
omega-3 0
fatty 0
acid 0
intake 0
, 0
or 0
duration 0
of 0
vitamin 0
A 0
use 0
. 0

Main 0
outcome 0
measures 0
were 0
Humphrey B-PHYSICAL
Field I-PHYSICAL
Analyzer I-PHYSICAL
visual I-PHYSICAL
field I-PHYSICAL
sensitivity I-PHYSICAL
, 0
30-Hz B-OTHER
electroretinogram I-OTHER
amplitude I-OTHER
, 0
and 0
visual B-PHYSICAL
acuity I-PHYSICAL
. 0

RESULTS 0
Among 0
patients 0
not 0
taking 0
vitamin 0
A 0
prior 0
to 0
entry 0
, 0
those 0
in 0
the 0
DHA 0
+ 0
A 0
group 0
had 0
a 0
slower 0
decline 0
in 0
field B-PHYSICAL
sensitivity I-PHYSICAL
and 0
electroretinogram B-OTHER
amplitude I-OTHER
than 0
those 0
in 0
the 0
control 0
+ 0
A 0
group 0
over 0
the 0
first 0
2 0
years 0
( 0
P 0
=.01 0
and 0
P 0
=.03 0
, 0
respectively 0
) 0
; 0
these 0
differences 0
were 0
not 0
observed 0
in 0
years 0
3 0
and 0
4 0
of 0
follow-up 0
or 0
among 0
patients 0
taking 0
vitamin 0
A 0
prior 0
to 0
entry 0
. 0

In 0
the 0
entire 0
cohort 0
, 0
red 0
blood 0
cell 0
phosphatidylethanolamine 0
docosahexaenoic 0
acid 0
level 0
was 0
inversely 0
related 0
to 0
rate 0
of 0
decline 0
in 0
total 0
field B-PHYSICAL
sensitivity I-PHYSICAL
over 0
4 0
years 0
( 0
test 0
for 0
trend 0
, 0
P 0
=.05 0
) 0
. 0

This 0
was 0
particularly 0
evident 0
over 0
the 0
first 0
2 0
years 0
among 0
those 0
not 0
on 0
vitamin 0
A 0
prior 0
to 0
entry 0
( 0
test 0
for 0
trend 0
, 0
P 0
=.003 0
) 0
. 0

In 0
the 0
entire 0
control 0
+ 0
A 0
group 0
, 0
dietary 0
omega-3 0
fatty 0
acid 0
intake 0
was 0
inversely 0
related 0
to 0
loss 0
of 0
total 0
field B-PHYSICAL
sensitivity I-PHYSICAL
over 0
4 0
years 0
( 0
intake 0
, 0
< 0
0.20 0
vs 0
> 0
or 0
=0.20 0
g/d 0
; 0
P 0
=.02 0
) 0
. 0

The 0
duration B-PHYSICAL
of I-PHYSICAL
vitamin I-PHYSICAL
A I-PHYSICAL
supplementation I-PHYSICAL
prior 0
to 0
entry 0
was 0
inversely 0
related 0
to 0
rate 0
of 0
decline 0
in 0
electroretinogram 0
amplitude 0
( 0
P 0
=.008 0
) 0
. 0

CONCLUSIONS 0
For 0
patients 0
with 0
retinitis 0
pigmentosa 0
beginning 0
vitamin 0
A 0
therapy 0
, 0
addition 0
of 0
docosahexaenoic 0
acid 0
, 0
1200 0
mg/d 0
, 0
slowed 0
the 0
course 0
of 0
disease 0
for 0
2 0
years 0
. 0

Among 0
patients 0
on 0
vitamin 0
A 0
for 0
at 0
least 0
2 0
years 0
, 0
a 0
diet 0
rich 0
in 0
omega-3 0
fatty 0
acids 0
( 0
> 0
or 0
=0.20 0
g/d 0
) 0
slowed 0
the 0
decline 0
in 0
visual 0
field 0
sensitivity 0
. 0

A 0
comparison 0
of 0
acupuncture 0
with 0
advice 0
and 0
exercises 0
on 0
the 0
symptomatic B-PHYSICAL
treatment I-PHYSICAL
of 0
osteoarthritis 0
of 0
the 0
hip 0
-- 0
a 0
randomised 0
controlled 0
trial 0
. 0

Acupuncture 0
is 0
becoming 0
a 0
common 0
technique 0
within 0
the 0
physiotherapy 0
profession 0
as 0
a 0
treatment 0
modality 0
for 0
pain B-PAIN
relief I-PAIN
; 0
however 0
, 0
few 0
randomised 0
controlled 0
trials 0
have 0
been 0
undertaken 0
to 0
assess 0
the 0
effectiveness 0
of 0
acupuncture 0
, 0
particularly 0
in 0
the 0
treatment 0
of 0
osteoarthritis 0
( 0
OA 0
) 0
of 0
the 0
hip 0
. 0

Therefore 0
, 0
a 0
randomised 0
trial 0
to 0
compare 0
the 0
effectiveness 0
of 0
acupuncture 0
with 0
advice 0
and 0
exercises 0
on 0
the 0
symptomatic 0
treatment 0
of 0
OA 0
of 0
the 0
hip 0
was 0
carried 0
out 0
. 0

Thirty-two 0
patients 0
awaiting 0
a 0
total 0
hip 0
arthroplasty 0
were 0
randomly 0
allocated 0
to 0
either 0
the 0
experimental 0
group 0
, 0
( 0
A 0
) 0
, 0
to 0
have 0
six 0
sessions 0
of 0
acupuncture 0
each 0
lasting 0
up 0
to 0
25 0
minutes 0
, 0
or 0
the 0
control 0
group 0
, 0
( 0
B 0
) 0
, 0
to 0
be 0
given 0
advice 0
and 0
exercises 0
for 0
their 0
hip 0
over 0
a 0
six 0
week 0
period 0
. 0

Group 0
A 0
consisted 0
of 0
three 0
men 0
and 0
13 0
women 0
, 0
and 0
group 0
B 0
consisted 0
of 0
four 0
men 0
and 0
eight 0
women 0
. 0

The 0
average 0
age 0
in 0
group 0
A 0
was 0
66 0
years 0
and 0
in 0
group 0
B 0
it 0
was 0
68 0
years 0
. 0

Patients 0
were 0
assessed 0
for 0
pain 0
and 0
functional 0
ability 0
, 0
using 0
a 0
modified 0
version 0
of 0
the 0
WOMAC B-OTHER
questionnaire 0
, 0
pre-treatment 0
, 0
immediately 0
post-treatment 0
and 0
at 0
eight 0
weeks 0
post-treatment 0
. 0

The 0
pre-treatment 0
WOMAC B-OTHER
scores I-OTHER
in 0
the 0
two 0
groups 0
were 0
similar 0
( 0
p=0.85 0
) 0
. 0

There 0
was 0
a 0
significant 0
improvement 0
in 0
group 0
A 0
( 0
decrease 0
in 0
WOMAC B-OTHER
score I-OTHER
) 0
immediately 0
post-treatment 0
( 0
p=0.002 0
) 0
and 0
this 0
was 0
maintained 0
at 0
the 0
eight-week 0
follow-up 0
( 0
p=0.03 0
) 0
. 0

There 0
were 0
no 0
significant 0
changes 0
in 0
group 0
B 0
. 0

When 0
the 0
changes 0
in 0
WOMAC B-OTHER
scores I-OTHER
were 0
compared 0
between 0
groups 0
, 0
a 0
significantly 0
greater 0
improvement 0
was 0
found 0
between 0
pre-treatment 0
and 0
immediately 0
post-treatment 0
in 0
group 0
A 0
, 0
compared 0
with 0
group 0
B 0
( 0
p=0.02 0
) 0
. 0

The 0
changes 0
between 0
pre-treatment 0
and 0
the 0
eight-week 0
follow-up 0
also 0
showed 0
a 0
significant 0
improvement 0
in 0
group 0
A 0
compared 0
with 0
group 0
B 0
( 0
p=0.03 0
) 0
. 0

In 0
conclusion 0
, 0
this 0
trial 0
supports 0
the 0
hypothesis 0
that 0
acupuncture 0
is 0
more 0
effective 0
than 0
advice 0
and 0
exercises 0
in 0
the 0
symptomatic 0
treatment 0
of 0
OA 0
of 0
the 0
hip 0
. 0

The 0
long-term 0
effect 0
of 0
oxandrolone 0
on 0
hepatic 0
acute 0
phase 0
proteins 0
in 0
severely 0
burned 0
children 0
. 0

BACKGROUND 0
Acute 0
phase 0
protein 0
production 0
is 0
a 0
hallmark 0
of 0
severe 0
burns 0
. 0

We 0
wondered 0
whether 0
anabolic 0
treatment 0
with 0
oxandrolone 0
would 0
affect 0
these 0
proteins 0
. 0

METHODS 0
Thirty-five 0
children 0
with 0
> 0
or 0
=40 0
% 0
total 0
body 0
surface 0
area 0
burns 0
were 0
randomized 0
to 0
receive 0
either 0
placebo 0
or 0
oxandrolone 0
( 0
0.1 0
mg/kg 0
by 0
mouth 0
twice 0
daily 0
) 0
from 0
postoperative 0
day 0
5 0
to 0
1 0
year 0
postburn 0
. 0

Levels 0
of 0
constitutive 0
proteins 0
and 0
acute 0
phase 0
proteins 0
were 0
measured 0
at 0
admission 0
; 0
at 0
discharge 0
; 0
and 0
at 0
6 0
, 0
9 0
, 0
and 0
12 0
months 0
after 0
burn 0
. 0

Total 0
albumin B-PHYSICAL
supplementation I-PHYSICAL
and 0
hepatic B-PHYSICAL
transaminases I-PHYSICAL
were 0
also 0
assessed 0
. 0

RESULTS 0
Constitutive B-PHYSICAL
proteins I-PHYSICAL
such I-PHYSICAL
as I-PHYSICAL
albumin I-PHYSICAL
, I-PHYSICAL
prealbumin I-PHYSICAL
, I-PHYSICAL
and I-PHYSICAL
retinol-binding I-PHYSICAL
protein I-PHYSICAL
levels I-PHYSICAL
increased 0
( 0
p 0
< 0
0.05 0
) 0
, 0
and 0
acute B-PHYSICAL
phase 0
proteins B-PHYSICAL
such I-PHYSICAL
as I-PHYSICAL
alpha I-PHYSICAL
1-acid I-PHYSICAL
glycoprotein I-PHYSICAL
, I-PHYSICAL
C3 I-PHYSICAL
complement I-PHYSICAL
, I-PHYSICAL
alpha I-PHYSICAL
2-macroglobulin I-PHYSICAL
, I-PHYSICAL
and I-PHYSICAL
fibrinogen I-PHYSICAL
levels B-PHYSICAL
significantly 0
decreased 0
in 0
the 0
oxandrolone 0
group 0
compared 0
with 0
placebo 0
( 0
p 0
< 0
0.05 0
) 0
. 0

Albumin B-PHYSICAL
supplementation I-PHYSICAL
during B-PHYSICAL
the I-PHYSICAL
acute B-PHYSICAL
hospitalization I-PHYSICAL
was 0
reduced 0
in 0
the 0
oxandrolone 0
group 0
. 0

Randomised 0
multicentre 0
trial 0
of 0
circular 0
stapling 0
devices 0
. 0

PURPOSE 0
In 0
a 0
register 0
study 0
, 0
the 0
risk 0
of 0
anastomotic B-PHYSICAL
leakage I-PHYSICAL
correlated 0
to 0
the 0
choice 0
of 0
circular 0
stapling 0
device 0
with 0
a 0
4 0
% 0
difference 0
between 0
the 0
two 0
brands 0
used 0
. 0

Based 0
on 0
those 0
data 0
, 0
a 0
randomised 0
multicentre 0
study 0
was 0
started 0
to 0
explore 0
the 0
risk 0
of 0
an 0
anastomotic B-PHYSICAL
leakage I-PHYSICAL
based 0
upon 0
the 0
surgical 0
device 0
. 0

METHODS 0
Patients 0
above 0
18 0
years 0
with 0
a 0
rectal 0
cancer 0
, 0
able 0
to 0
give 0
informed 0
consent 0
, 0
and 0
scheduled 0
for 0
an 0
anterior 0
resection 0
were 0
eligible 0
for 0
the 0
study 0
. 0

Perioperative 0
randomisation 0
was 0
to 0
Ethicon? 0
PROXIMATE? 0
ILS? 0
or 0
Autosuture? 0
Premium 0
Plus 0
CEEA? 0
. 0

Anastomotic 0
leakage 0
was 0
defined 0
as 0
a 0
clinically 0
manifest 0
leak 0
. 0

RESULTS 0
Five 0
hundred 0
twenty-nine 0
patients 0
were 0
randomised 0
( 0
58 0
% 0
male 0
) 0
. 0

A 0
leak 0
occurred 0
in 0
8.3 0
% 0
. 0

The 0
anastomoses 0
created 0
by 0
PROXIMATE? 0
ILS? 0
leaked 0
in 0
25/265 0
( 0
9.4 0
% 0
) 0
anastomoses 0
, 0
and 0
the 0
Premium 0
Plus 0
CEEA? 0
leaked 0
in 0
19/260 0
( 0
7.3 0
% 0
) 0
, 0
p 0
= 0
.419 0
. 0

CONCLUSION 0
No 0
difference 0
in 0
the 0
leak 0
rate 0
could 0
be 0
revealed 0
. 0

Several 0
centres 0
replaced 0
one 0
of 0
the 0
staplers 0
by 0
a 0
new 0
product 0
, 0
and 0
the 0
study 0
was 0
ended 0
before 0
the 0
stipulated 0
number 0
of 0
patients 0
was 0
reached 0
. 0

In 0
the 0
future 0
, 0
surgical 0
devices 0
may 0
have 0
to 0
prove 0
superiority 0
in 0
randomised 0
trials 0
or 0
be 0
monitored 0
in 0
quality 0
registers 0
before 0
they 0
can 0
be 0
introduced 0
into 0
day 0
to 0
day 0
surgical 0
practice 0
. 0

The 0
study 0
was 0
registered 0
at 0
ClinicalTrials.gov 0
: 0
NCT00399009 0
. 0

Laser 0
therapy 0
combined 0
with 0
brachytherapy 0
for 0
the 0
palliation 0
of 0
malignant 0
dysphagia 0
. 0

BACKGROUND/AIM 0
OF 0
STUDY 0
Laser 0
therapy 0
is 0
effective 0
in 0
relieving 0
malignant B-PHYSICAL
dysphagia I-PHYSICAL
, 0
but 0
repeated 0
treatments 0
at 0
4 0
to 0
6 0
week 0
intervals 0
are 0
usually 0
required 0
. 0

This 0
prospective 0
randomised 0
trial 0
is 0
designed 0
to 0
determine 0
if 0
addition 0
of 0
brachytherapy 0
offers 0
any 0
advantages 0
over 0
laser 0
therapy 0
alone 0
. 0

METHODS 0
Patients 0
with 0
inoperable 0
carcinoma 0
of 0
the 0
oesophagus 0
were 0
randomised 0
to 0
receive 0
either 0
endoscopic 0
Nd 0
: 0
YAG 0
laser 0
therapy 0
alone 0
, 0
or 0
laser 0
followed 0
by 0
brachytherapy 0
. 0

Patients 0
who 0
developed 0
worsening 0
dysphagia 0
during 0
follow-up 0
were 0
offered 0
further 0
treatment 0
as 0
appropriate 0
. 0

RESULTS 0
Fourteen 0
patients 0
were 0
randomised 0
to 0
receive 0
laser 0
only 0
, 0
and 0
12 0
to 0
receive 0
laser 0
followed 0
by 0
brachytherapy 0
. 0

Of 0
these 0
12 0
, 0
one 0
was 0
lost 0
to 0
follow-up 0
and 0
four 0
did 0
not 0
receive 0
brachytherapy 0
because 0
they 0
were 0
unfit 0
, 0
had 0
extension 0
into 0
the 0
cardia 0
or 0
had 0
mainly 0
extrinsic 0
compression 0
. 0

These 0
4 0
are 0
included 0
on 0
an 0
'intention-to-treat 0
' 0
basis 0
. 0

The 0
mean 0
therapeutic B-PHYSICAL
interval I-PHYSICAL
for 0
the 0
brachytherapy 0
group 0
was 0
significantly 0
longer 0
, 0
83 0
days 0
compared 0
to 0
36 0
days 0
for 0
the 0
laser 0
group 0
( 0
p 0
= 0
0.026 0
) 0
. 0

There 0
were 0
no 0
differences 0
in 0
the 0
degree 0
of 0
dysphagia B-PHYSICAL
relief I-PHYSICAL
, 0
number 0
of 0
endoscopic B-OTHER
procedures I-OTHER
or 0
survival B-MORTALITY
times I-MORTALITY
. 0

CONCLUSION 0
The 0
preliminary 0
results 0
of 0
this 0
trial 0
suggest 0
that 0
brachytherapy 0
in 0
addition 0
to 0
laser 0
therapy 0
prolongs 0
the 0
first 0
therapeutic B-PHYSICAL
interval I-PHYSICAL
. 0

However 0
, 0
no 0
long-term 0
advantages 0
have 0
been 0
shown 0
. 0

JobTIPS 0
: 0
a 0
transition 0
to 0
employment 0
program 0
for 0
individuals 0
with 0
autism 0
spectrum 0
disorders 0
. 0

This 0
study 0
evaluated 0
the 0
effectiveness 0
of 0
an 0
internet B-OTHER
accessed I-OTHER
training I-OTHER
program I-OTHER
that 0
included 0
Theory 0
of 0
Mind-based 0
guidance 0
, 0
video 0
models 0
, 0
visual 0
supports 0
, 0
and 0
virtual 0
reality 0
practice 0
sessions 0
in 0
teaching 0
appropriate 0
job 0
interview 0
skills 0
to 0
individuals 0
with 0
high 0
functioning 0
Autism 0
Spectrum 0
Disorders 0
. 0

In 0
a 0
randomized 0
study 0
, 0
twenty-two 0
youth 0
, 0
ages 0
16-19 0
, 0
were 0
evaluated 0
during 0
two 0
employment 0
interviews 0
. 0

Half 0
received 0
a 0
training 0
intervention 0
following 0
the 0
initial 0
interview 0
and 0
the 0
half 0
who 0
served 0
as 0
a 0
contrast 0
group 0
did 0
not 0
. 0

Their 0
performance 0
pre 0
and 0
post 0
intervention 0
was 0
assessed 0
by 0
four 0
independent 0
raters 0
using 0
a 0
scale 0
that 0
included 0
evaluation 0
of 0
both 0
Content B-OTHER
and 0
Delivery B-OTHER
. 0

Results 0
suggest 0
that 0
youth 0
who 0
completed 0
the 0
JobTIPS 0
employment 0
program 0
demonstrated 0
significantly B-MENTAL
more I-MENTAL
effective I-MENTAL
verbal I-MENTAL
content I-MENTAL
skills I-MENTAL
than 0
those 0
who 0
did 0
not 0
. 0

In 0
vivo 0
effect 0
of 0
clarithromycin 0
on 0
multiple 0
cytochrome 0
P450s 0
. 0

The 0
in 0
vivo 0
effects 0
of 0
oral 0
clarithromycin 0
administration 0
on 0
the 0
in 0
vivo 0
activity 0
of 0
cytochrome 0
P450 0
1A2 0
, 0
2C9 0
, 0
and 0
2D6 0
were 0
determined 0
. 0

The 0
cytochrome 0
P450 0
probes 0
caffeine 0
( 0
CYP1A2 0
) 0
, 0
tolbutamide 0
( 0
CYP2C9 0
) 0
, 0
and 0
dextromethorphan 0
( 0
CYP2D6 0
) 0
were 0
administered 0
as 0
an 0
oral 0
cocktail 0
prior 0
to 0
and 0
7 0
days 0
after 0
oral 0
clarithromycin 0
( 0
500 0
mg 0
twice 0
daily 0
) 0
administration 0
to 0
12 0
healthy 0
male 0
subjects 0
. 0

Blood B-PHYSICAL
and 0
urine B-PHYSICAL
samples I-PHYSICAL
were 0
collected 0
and 0
assayed 0
for 0
each 0
of 0
the 0
compounds 0
and 0
their 0
metabolites 0
using 0
high-performance 0
liquid 0
chromatography 0
. 0

The 0
CYP1A2 B-PHYSICAL
indices I-PHYSICAL
, 0
oral B-PHYSICAL
caffeine I-PHYSICAL
clearance I-PHYSICAL
( 0
6.2 0
+/- 0
3.3 0
l/h 0
before 0
and 0
5.7 0
+/- 0
4.2 0
l/h 0
after 0
, 0
p 0
> 0
0.05 0
) 0
and 0
the 0
6-h B-PHYSICAL
paraxanthine I-PHYSICAL
to I-PHYSICAL
caffeine I-PHYSICAL
serum I-PHYSICAL
concentration 0
ratio B-PHYSICAL
( 0
0.49 0
+/- 0
0.3 0
before 0
and 0
0.44 0
+/- 0
0.3 0
after 0
, 0
p 0
> 0
0.05 0
) 0
, 0
were 0
unchanged 0
following 0
clarithromycin 0
dosing 0
. 0

Neither 0
the 0
tolbutamide B-PHYSICAL
oral I-PHYSICAL
clearance I-PHYSICAL
( 0
0.77 0
+/- 0
0.28 0
l/h 0
before 0
and 0
0.72 0
+/-0.24 0
l/h 0
after 0
, 0
p 0
> 0
0.05 0
) 0
nor 0
the 0
tolbutamide B-PHYSICAL
urinary B-PHYSICAL
metabolic I-PHYSICAL
ratio I-PHYSICAL
( 0
779 0
+/- 0
294 0
before 0
and 0
681 0
+/- 0
416 0
after 0
, 0
p 0
> 0
0.05 0
) 0
indices 0
of 0
CYP2C9 0
were 0
altered 0
by 0
clarithromycin 0
administration 0
. 0

In 0
the 0
case 0
of 0
CYP2D6 0
, 0
the 0
dextromethorphan B-PHYSICAL
to 0
dextrorphan B-PHYSICAL
urinary I-PHYSICAL
ratio I-PHYSICAL
was 0
not 0

Simulating 0
a 0
memory 0
impairment 0
: 0
can 0
amnesics 0
implicitly 0
outperform 0
simulators 0
? 0

OBJECTIVES 0
The 0
purpose 0
of 0
this 0
study 0
was 0
to 0
examine 0
the 0
effectiveness 0
of 0
a 0
variety 0
of 0
tests 0
in 0
differentiating 0
simulating B-MENTAL
test I-MENTAL
performances I-MENTAL
from 0
genuine 0
memory-impaired B-MENTAL
and 0
normal 0
( 0
control 0
) 0
test 0
performances 0
. 0

DESIGN 0
A 0
simulation 0
design 0
was 0
implemented 0
, 0
based 0
on 0
an 0
analogue 0
design 0
in 0
which 0
normal 0
participants 0
were 0
given 0
experimental 0
instructions 0
to 0
feign 0
a 0
mental 0
impairment 0
and 0
are 0
compared 0
to 0
( 0
a 0
) 0
other 0
normal 0
participants 0
with 0
instructions 0
to 0
perform 0
honestly 0
, 0
and 0
( 0
b 0
) 0
a 0
comparison 0
group 0
, 0
for 0
example 0
, 0
acquired 0
brain-injured 0
persons 0
, 0
with 0
similar 0
instructions 0
. 0

METHOD 0
Forty 0
individuals 0
comprised 0
the 0
simulating 0
and 0
control 0
group 0
and 0
all 0
participants 0
were 0
randomly 0
assigned 0
to 0
the 0
simulating 0
and 0
control 0
groups 0
. 0

Twenty 0
memory-impaired 0
patients 0
, 0
all 0
of 0
whom 0
had 0
been 0
diagnosed 0
as 0
suffering 0
from 0
a 0
memory 0
impairment 0
following 0
acquired 0
brain 0
damage 0
, 0
participated 0
as 0
the 0
memory-impaired 0
control 0
group 0
. 0

The 0
simulation 0
group 0
was 0
directed 0
to 0
imitate 0
a 0
person 0
with 0
a 0
memory 0
impairment 0
. 0

The 0
primary 0
outcome 0
measure 0
involved 0
identifying B-MENTAL
those I-MENTAL
tests I-MENTAL
, I-MENTAL
if I-MENTAL
any I-MENTAL
, I-MENTAL
where I-MENTAL
simulators I-MENTAL
were I-MENTAL
significantly I-MENTAL
different I-MENTAL
from I-MENTAL
normal I-MENTAL
and I-MENTAL
memory-impaired I-MENTAL
participants I-MENTAL
. 0

RESULTS 0
On 0
5 0
of 0
the 0
15 0
tasks 0
administered 0
, 0
simulators B-MENTAL
performed I-MENTAL
significantly I-MENTAL
differently I-MENTAL
from I-MENTAL
normal I-MENTAL
and I-MENTAL
memory-impaired I-MENTAL
participants I-MENTAL
. 0

Of 0
these 0
5 0
tasks 0
, 0
the 0
coin-in-the-hand 0
, 0
when 0
administered 0
in 0
conjunction 0
with 0
the 0
autobiographical 0
interview 0
, 0
identified 0
95 0
per 0
cent 0
of 0
the 0
simulators 0
without 0
misclassifying 0
any 0
of 0
the 0
memory-impaired 0
or 0
normal 0
participants 0
. 0

CONCLUSION 0
It 0
is 0
suggested 0
that 0
these 0
two 0
tests 0
, 0
when 0
administered 0
jointly 0
, 0
might 0
be 0
of 0
use 0
in 0
clinical 0
settings 0
to 0
assist 0
in 0
the 0
detection 0
of 0
malingerers 0
. 0

The 0
cognitive B-PHYSICAL
, 0
subjective B-PHYSICAL
, 0
and 0

Tramadol 0
suppository 0
versus 0
placebo 0
for 0
the 0
relief 0
of 0
perineal B-PAIN
pain I-PAIN
after 0
perineorrhaphy 0
: 0
a 0
randomized 0
controlled 0
trial 0
in 0
Thailand 0
. 0

OBJECTIVE 0
This 0
randomized 0
double-blinded 0
control 0
trial 0
was 0
conducted 0
to 0
compare 0
the 0
effectiveness 0
of 0
tramodol 0
and 0
placebo 0
rectal 0
suppository 0
for 0
the 0
management 0
of 0
postpartum B-PAIN
perineal I-PAIN
pain I-PAIN
after 0
perineorrhaphy 0
. 0

MATERIAL 0
AND 0
METHOD 0
One 0
hundred 0
women 0
who 0
gave 0
birth 0
vaginally 0
with 0
episiotomy 0
and 0
a 0
second- 0
or 0
third-degree 0
tear 0
, 0
were 0
randomly 0
assign 0
to 0
receive 0
two 0
tablets 0
oftramadol 0
50 0
mg 0
or 0
two 0
tablets 0
ofplacebo 0
, 0
the 0
pill 0
were 0
physically 0
similar 0
to 0
the 0
real 0
drug 0
. 0

Pain B-PAIN
ratings I-PAIN
were 0
recorded 0
immediately 0
after 0
perineorrhaphy 0
, 0
30 0
minutes 0
, 0
and 0
1 0
, 0
2 0
, 0
6 0
, 0
12 0
and 0
24 0
hours 0
after 0
first 0
dose 0
on 0
a 0
10-cm 0
visual 0
analogue 0
scale 0
. 0

Side B-ADVERSE-EFFECTS
effects I-ADVERSE-EFFECTS
and I-ADVERSE-EFFECTS
overall I-ADVERSE-EFFECTS
opinion I-ADVERSE-EFFECTS
were 0
assessed 0
. 0

RESULTS 0
Tramadol 0
and 0
placebo 0
had 0
no 0
statistical 0
significances 0
in 0
analgesic B-PAIN
properties I-PAIN
, 0
assessed 0
by 0
the 0
means 0
of 0
pain B-PAIN
rating I-PAIN
at 0
the 0
different 0
time 0
intervals 0
. 0

There 0
were 0
no 0
serious B-ADVERSE-EFFECTS
adverse I-ADVERSE-EFFECTS
events I-ADVERSE-EFFECTS
reported 0
. 0

CONCLUSION 0
No 0
differences 0
were 0
found 0
in 0
between 0
Tramadol 0
and 0
placebo 0
in 0
relief 0
perineal 0
pain 0
after 0
perineorrhaphy 0

Preoperative 0
lanreotide 0
treatment 0
in 0
acromegalic 0
patients 0
with 0
macroadenomas 0
increases 0
short-term B-PHYSICAL
postoperative I-PHYSICAL
cure I-PHYSICAL
rates I-PHYSICAL
: 0
a 0
prospective 0
, 0
randomised 0
trial 0
. 0

OBJECTIVE 0
To 0
investigate 0
whether 0
4-month 0
preoperative 0
lanreotide 0
treatment 0
would 0
improve 0
the 0
surgical B-OTHER
cure I-OTHER
rate I-OTHER
of 0
newly 0
diagnosed 0
acromegalic 0
patients 0
with 0
macroadenomas 0
. 0

DESIGN 0
A 0
prospective 0
, 0
randomised 0
study 0
. 0

METHODS 0
After 0
a 0
baseline 0
evaluation 0
, 0
patients 0
were 0
randomly 0
assigned 0
to 0
4-month 0
preoperative 0
treatment 0
with 0
lanreotide 0
( 0
starting 0
with 0
30 0
mg/2 0
weeks 0
i.m 0
. 0

and 0
increasing 0
to 0
30 0
mg/week 0
i.m 0
. 0

at 0
week 0
8 0
if 0
mean 0
GH 0
> 0
2.5 0
microg/l 0
on 0
GH 0
day 0
curves 0
; 0
pretreatment 0
group 0
, 0
Group 0
1 0
) 0
or 0
to 0
transsphenoidal 0
surgery 0
( 0
direct 0
surgery 0
group 0
, 0
Group 0
2 0
) 0
. 0

Cure B-OTHER
was 0
evaluated 0
4 0
months 0
postoperatively 0
primarily 0
by 0
fasting 0
IGF1 0
less 0
than 0
or 0
equal 0
to 0
age-adjusted 0
upper 0
limit 0
of 0
normal 0
. 0

RESULTS 0
A 0
pool 0
of 0
108 0
patients 0
was 0
randomly 0
divided 0
into 0
two 0
groups 0
. 0

Five 0
patients 0
in 0
each 0
group 0
were 0
lost 0
to 0
follow-up 0
during 0
the 0
study 0
period 0
, 0
so 0
49 0
patients 0
in 0
each 0
group 0
were 0
analysed 0
. 0

At 0
baseline 0
, 0
no 0
difference 0
was 0
observed 0
between 0
the 0
two 0
groups 0
. 0

Cure B-OTHER
was 0
established 0
in 0
24 0
of 0
49 0
( 0
49.0 0
% 0
, 0
95 0
% 0
confidence 0
interval 0
( 0
CI 0
) 0
, 0
35.0-63.0 0
% 0
) 0
pretreated 0
patients 0
( 0
Group 0
1 0
) 0
versus 0
9 0
of 0
49 0
( 0
18.4 0
% 0
, 0
95 0
% 0
CI 0
, 0
7.6-29.2 0
% 0
) 0
direct 0
surgery 0
patients 0
( 0
Group 0
2 0
; 0
P=0.001 0
) 0
. 0

Surgical B-PHYSICAL
morbidity I-PHYSICAL
was 0
recorded 0
in 0
12 0
patients 0
( 0
12.2 0
% 0
) 0
and 0
was 0
similar 0
in 0
Group 0
1 0
and 0
2 0
patients 0
( 0
14.3 0
and 0
10.2 0
% 0
respectively 0
; 0
P=0.538 0
) 0
. 0

The 0
postoperative B-OTHER
hospital I-OTHER
stay I-OTHER
was 0
similar 0
between 0
groups 0
: 0
being 0
4.5+/-1.6 0
days 0
in 0
Group 0
1 0
vs 0
4.8+/-1.9 0
days 0
in 0
Group 0
2 0
( 0
P=0.328 0
) 0
. 0

CONCLUSIONS 0
Pretreatment 0
with 0
lanreotide 0
before 0
transsphenoidal 0
surgery 0
improves 0
surgical B-OTHER
cure I-OTHER
rates I-OTHER
in 0
patients 0
with 0
GH-secreting 0
pituitary 0
macroadenomas 0
. 0

Pretreatment 0
does 0
not 0
affect 0
surgical B-ADVERSE-EFFECTS
complications I-ADVERSE-EFFECTS
or 0
duration 0
of 0
hospital B-OTHER
stay I-OTHER
( 0
ClinicalTrials.gov 0
number 0
, 0
NCT00993356 0
) 0
. 0

Oral 0
S-adenosylmethionine 0
in 0
the 0
symptomatic 0
treatment 0
of 0
intrahepatic B-PHYSICAL
cholestasis I-PHYSICAL
. 0

A 0
double-blind 0
, 0
placebo-controlled 0
study 0
. 0

Parenteral 0
S-adenosylmethionine 0
proved 0
to 0
be 0
effective 0
in 0
reversing 0
intrahepatic B-PHYSICAL
cholestasis I-PHYSICAL
in 0
pregnant 0
women 0
. 0

Based 0
on 0
these 0
findings 0
, 0
a 0
prospective 0
multicenter 0
, 0
double-blind 0
, 0
placebo-controlled 0
trial 0
was 0
planned 0
to 0
assess 0
whether 0
oral 0
S-adenosylmethionine 0
is 0
effective 0
in 0
cholestatic B-PHYSICAL
patients I-PHYSICAL
with 0
chronic 0
liver 0
disease 0
. 0

Accordingly 0
, 0
220 0
inpatients 0
( 0
26 0
% 0
chronic 0
active 0
hepatitis 0
, 0
68 0
% 0
cirrhosis 0
, 0
6 0
% 0
primary 0
biliary 0
cirrhosis 0
) 0
with 0
stable 0
( 0
1 0
month 0
or 0
more 0
) 0
at 0
least 0
twofold 0
increases 0
in 0
serum B-PHYSICAL
total 0
and 0
conjugated B-PHYSICAL
bilirubin I-PHYSICAL
and I-PHYSICAL
alkaline I-PHYSICAL
phosphatase I-PHYSICAL
volunteered 0
for 0
the 0
trial 0
. 0

Serum B-PHYSICAL
markers I-PHYSICAL
of I-PHYSICAL
cholestasis I-PHYSICAL
significantly 0
( 0
P 0
less 0
than 0
0.01 0
) 0
decreased 0
after 0
oral 0
S-adenosylmethionine 0
administration 0
( 0
1600 0
mg/day 0
) 0
, 0
and 0
their 0
values 0
were 0
significantly 0
( 0
P 0
less 0
than 0
0.01 0
) 0
lower 0
than 0
the 0
corresponding 0
values 0
in 0
the 0
placebo 0
group 0
. 0

S-adenosylmethionine 0
significantly 0
( 0
P 0
less 0
than 0
0.01 0
) 0
improved 0
subjective B-PHYSICAL
symptoms I-PHYSICAL
such I-PHYSICAL
as I-PHYSICAL
pruritus I-PHYSICAL
, 0
fatigue B-PHYSICAL
, 0
and 0
feeling 0
of 0

Effect 0
of 0
entacapone 0
, 0
a 0
peripherally 0
acting 0
catechol-O-methyltransferase 0
inhibitor 0
, 0
on 0
the 0
motor B-PHYSICAL
response 0
to B-PHYSICAL
acute I-PHYSICAL
treatment 0
with B-PHYSICAL
levodopa B-PHYSICAL
in 0
patients 0
with 0
Parkinson 0
's 0
disease 0
. 0

Catechol-O-methyltransferase 0
( 0
COMT 0
) 0
inhibitors 0
may 0
be 0
useful 0
in 0
the 0
treatment 0
of 0
Parkinson 0
's 0
disease 0
by 0
improving 0
the 0
bioavailability B-OTHER
of 0
levodopa 0
and 0
by 0
prolonging 0
its 0
effects 0
. 0

Entacapone 0
( 0
OR-611 0
) 0
, 0
a 0
novel 0
COMT 0
inhibitor 0
, 0
which 0
does 0
not 0
cross 0
the 0
blood 0
brain 0
barrier 0
, 0
was 0
assessed 0
in 0
12 0
patients 0
with 0
Parkinson 0
's 0
disease 0
and 0
motor 0
fluctuations 0
in 0
a 0
randomised 0
, 0
double-blind 0
, 0
cross-over 0
, 0
single 0
dose 0
study 0
. 0

The 0
magnitude 0
and 0
duration 0
of 0
the 0
therapeutic 0
response 0
to 0
a 0
single 0
dose 0
of 0
200 0
mg 0
levodopa/50 0
mg 0
carbidopa 0
was 0
evaluated 0
after 0
concomitant 0
placebo 0
, 0
or 0
200 0
or 0
800 0
mg 0
entacapone 0
. 0

A 0
significant 0
increase 0
in 0
the 0
duration 0
of 0
the 0
motor B-PHYSICAL
response 0
to B-PHYSICAL
levodopa I-PHYSICAL
was 0
seen 0
when 0
200 0
mg 0
entacapone 0
was 0
given 0
with 0
levodopa/carbidopa 0
. 0

Pretreatment 0
with 0
thiopental 0
for 0
prevention 0
of 0
pain B-PAIN
associated I-PAIN
with I-PAIN
propofol I-PAIN
injection I-PAIN
. 0

UNLABELLED 0
Propofol 0
causes 0
pain 0
on 0
IV B-PAIN
injection I-PAIN
in 0
28 0
% 0
-90 0
% 0
of 0
patients 0
. 0

A 0
number 0
of 0
techniques 0
have 0
been 0
tried 0
to 0
minimize 0
propofol-induced 0
pain 0
, 0
with 0
variable 0
results 0
. 0

We 0
compared 0
the 0
efficacy 0
of 0
pretreatment 0
with 0
thiopental 0
0.25 0
mg/kg 0
and 0
0.5 0
mg/kg 0
and 0
lidocaine 0
40 0
mg 0
after 0
venous 0
occlusion 0
for 0
prevention 0
of 0
propofol-induced B-PAIN
pain I-PAIN
. 0

One-hundred-twenty-four 0
adult 0
patients 0
, 0
ASA 0
physical 0
status 0
I-II 0
, 0
undergoing 0
elective 0
surgery 0
were 0
randomly 0
assigned 0
into 0
4 0
groups 0
of 0
31 0
each 0
. 0

Group 0
I 0
received 0
normal 0
saline 0
, 0
group 0
II 0
received 0
lidocaine 0
2 0
% 0
( 0
40 0
mg 0
) 0
, 0
and 0
groups 0
III 0
and 0
IV 0
received 0
thiopental 0
0.25 0
mg/kg 0
and 0
0.5 0
mg/kg 0
, 0
respectively 0
. 0

All 0
pretreatment 0
drugs 0
were 0
made 0
in 0
2 0
mL 0
and 0
were 0
accompanied 0
by 0
manual 0
venous 0
occlusion 0
for 0
1 0
min 0
. 0

Propofol 0
was 0
administered 0
after 0
release 0
of 0
venous 0
occlusion 0
. 0

Pain B-PHYSICAL
was 0
assessed 0
with 0
a 0
four-point 0
scale 0
: 0
0 0
= 0
no 0
pain 0
, 0
1 0
= 0
mild 0
pain 0
, 0
2 0
= 0
moderate 0
pain 0
, 0
and 0
3 0
= 0
severe 0
pain 0
at 0
the 0
time 0
of 0
propofol 0
injection 0
. 0

Twenty-four 0
patients 0
( 0
77 0
% 0
) 0
complained 0
of 0
pain B-PHYSICAL
in 0
the 0
group 0
pretreated 0
with 0
normal 0
saline 0
as 0
compared 0
with 0
12 0
( 0
39 0
% 0
) 0
, 0
10 0
( 0
32 0
% 0
) 0
, 0
and 0
1 0
( 0
3 0
% 0
) 0
in 0
the 0
groups 0
pretreated 0
with 0
lidocaine 0
40 0
mg 0
, 0
thiopental 0
0.25 0
mg/kg 0
, 0
and 0
thiopental 0
0.5 0
mg/kg 0
, 0
respectively 0
( 0
P 0
< 0
0.05 0
) 0
. 0

Thiopental 0
0.5 0
mg/kg 0
was 0
the 0
most 0
effective 0
treatment 0
. 0

We 0
therefore 0
suggest 0
routine 0
pretreatment 0
with 0
thiopental 0
0.5 0
mg/kg 0
along 0
with 0
venous 0
occlusion 0
for 0
1 0
min 0
for 0
prevention 0
of 0
pain B-PHYSICAL
associated 0
with 0
propofol 0
injection 0
. 0

IMPLICATIONS 0
Pain B-PHYSICAL
associated 0
with 0
IV 0
injection 0
of 0
propofol 0
is 0
seen 0
in 0
28 0
% 0
-90 0
% 0
patients 0
. 0

Pretreatment 0
with 0
thiopental 0
0.25 0
mg/kg 0
and 0
0.5 0
mg/kg 0
after 0
manual 0
venous 0
occlusion 0
for 0
1 0
min 0
effectively 0
attenuated 0
pain B-PHYSICAL
associated 0
with 0
propofol 0
injection 0
. 0

Thiopental 0
0.5 0
mg/kg 0
was 0
the 0
most 0
effective 0
in 0
prevention 0
of 0
propofol B-PAIN
pain I-PAIN
and 0
can 0
be 0
used 0
routinely 0
. 0

Riluzole 0
as 0
an 0
adjunctive 0
therapy 0
to 0
risperidone 0
for 0
the 0
treatment 0
of 0
irritability B-MENTAL
in 0
children 0
with 0
autistic 0
disorder 0
: 0
a 0
double-blind 0
, 0
placebo-controlled 0
, 0
randomized 0
trial 0
. 0

BACKGROUND 0
A 0
hyperglutamatergic 0
state 0
has 0
been 0
shown 0
to 0
play 0
a 0
possible 0
role 0
in 0
the 0
pathophysiology 0
of 0
autistic 0
disorders 0
. 0

Riluzole 0
is 0
a 0
glutamate-modulating 0
agent 0
with 0
neuroprotective 0
properties 0
, 0
which 0
has 0
been 0
shown 0
to 0
have 0
positive 0
effects 0
in 0
many 0
neuropsychiatric B-PHYSICAL
disorders I-PHYSICAL
. 0

OBJECTIVE 0
The 0
aim 0
of 0
this 0
study 0
was 0
to 0
assess 0
the 0
efficacy 0
and 0
tolerability B-OTHER
of 0
riluzole 0
as 0
an 0
adjunctive 0
to 0
risperidone 0
in 0
the 0
treatment 0
of 0
irritability 0
in 0
autistic 0
children 0
who 0
were 0
not 0
optimally 0
responding 0
to 0
previous 0
medications 0
. 0

STUDY 0
DESIGN 0
This 0
was 0
a 0
10-week 0
, 0
randomized 0
, 0
double-blind 0
, 0
parallel-group 0
, 0
placebo-controlled 0
trial 0
. 0

PARTICIPANTS 0
The 0
study 0
enrolled 0
male 0
and 0
female 0
outpatients 0
aged 0
5-12 0
years 0
with 0
a 0
diagnosis 0
of 0
autistic 0
disorder 0
based 0
on 0
the 0
DSM-IV-TR 0
criteria 0
and 0
a 0
score 0
of 0
?12 0
on 0
the 0
Aberrant 0
Behavior 0
Checklist-Community 0
( 0
ABC-C 0
) 0
irritability 0
subscale 0
who 0
had 0
discontinued 0
other 0
medications 0
because 0
of 0
a 0
lack 0
of 0
efficacy 0
. 0

INTERVENTIONS 0
Subjects 0
received 0
riluzole 0
( 0
titrated 0
to 0
50 0
or 0
100 0
mg/day 0
based 0
on 0
bodyweight 0
) 0
or 0
placebo 0
in 0
addition 0
to 0
risperidone 0
( 0
titrated 0
up 0
to 0
2 0
or 0
3 0
mg/day 0
based 0
on 0
bodyweight 0
) 0
for 0
10 0
weeks 0
. 0

OUTCOME 0
Patients 0
were 0
assessed 0
at 0
baseline 0
, 0
week 0
5 0
, 0
and 0
week 0
10 0
. 0

The 0
primary 0
outcome 0
measure 0
was 0
the 0
difference 0
in 0
the 0
change 0
in 0
the 0
ABC-C 0
irritability 0
subscale 0
score 0
from 0
baseline 0
to 0
week 0
10 0
between 0
the 0
two 0
groups 0
. 0

We 0
also 0
compared 0
changes 0
in 0
other 0
ABC-C 0
subscale 0
scores 0
and 0
Clinical 0
Global 0
Impressions-Improvement 0
( 0
CGI-I 0
) 0
scale 0
scores 0
between 0
the 0
two 0
groups 0
. 0

RESULTS 0
Forty-nine 0
patients 0
were 0
enrolled 0
in 0
the 0
study 0
, 0
and 0
forty 0
children 0
completed 0
the 0
trial 0
( 0
dropouts 0
: 0
placebo 0
= 0
4 0
, 0
riluzole 0
= 0
5 0
) 0
. 0

A 0
significantly 0
greater 0
improvement 0
in 0
the 0
study 0
primary 0
outcome 0
( 0
the 0
ABC-C 0
irritability 0
subscale 0
score 0
) 0
was 0
achieved 0
by 0
the 0
riluzole-treated 0
children 0
compared 0
with 0
the 0
placebo 0
group 0
( 0
P 0
= 0
0.03 0
) 0
. 0

Patients 0
in 0
the 0
riluzole 0
group 0
also 0
showed 0
significantly 0
greater 0
improvement 0
on 0
the 0
lethargy/social 0
withdrawal 0
( 0
P 0
= 0
0.02 0
) 0
, 0
stereotypic 0
behavior 0
( 0
P 0
= 0
0.03 0
) 0
, 0
and 0
hyperactivity/non-compliance 0
subscales 0
( 0
P 0
= 0
0.005 0
) 0
, 0
but 0
not 0
on 0
the 0
inappropriate 0
speech 0
subscale 0
( 0
P 0
= 0
0.20 0
) 0
than 0
patients 0
in 0
the 0
placebo 0
group 0
. 0

Eleven 0
patients 0
in 0
the 0
riluzole 0
group 0
and 0
five 0
patients 0
in 0
the 0
placebo 0
group 0
were 0
classified 0
as 0
responders 0
based 0
on 0
their 0
CGI-I 0
scores 0
[ 0
? 0
( 0

2 0
) 0
( 0
1 0
) 0
= 0
3.750 0
, 0
P 0
= 0
0.05 0
] 0
. 0

Children 0
in 0
the 0
riluzole 0
group 0
experienced 0
significantly 0
more 0
increases 0
in 0
their 0
appetite 0
and 0
bodyweight 0
than 0
children 0
in 0
the 0
placebo 0
group 0
by 0
the 0
end 0
of 0
the 0
study 0
. 0

CONCLUSION 0
Riluzole 0
add-on 0
therapy 0
shows 0
several 0
therapeutic 0
outcomes 0
, 0
particularly 0
for 0
improving 0
irritability 0
, 0
in 0
children 0
with 0
autism 0
. 0

However 0
, 0
its 0
add-on 0
to 0
risperidone 0
also 0
results 0
in 0
significantly 0
increased 0
appetite 0
and 0
weight 0
gain 0
. 0

The 0
evaluation 0
of 0
pulmonary 0
hypertension 0
using 0
right 0
ventricular 0
myocardial 0
isovolumic 0
relaxation 0
time 0
. 0

Right 0
ventricular 0
( 0
RV 0
) 0
blood 0
pool-derived 0
isovolumic 0
relaxation 0
time 0
( 0
IVRT 0
) 0
correlates 0
well 0
with 0
systolic 0
pulmonary 0
arterial 0
pressure 0
( 0
PAP 0
) 0
. 0

However 0
, 0
because 0
of 0
complex 0
parameter 0
derivation 0
, 0
the 0
method 0
is 0
rarely 0
used 0
. 0

The 0
aim 0
of 0
this 0
study 0
was 0
to 0
validate 0
the 0
measurement 0
of 0
myocardial 0
velocity 0
imaging-derived 0
RV 0
IVRT 0
( 0
IVRT 0
' 0
) 0
against 0
invasively 0
measured 0
PAP 0
. 0

Transthoracic 0
echocardiography 0
with 0
myocardial 0
velocity 0
imaging 0
and 0
right 0
heart 0
catheterization 0
were 0
performed 0
in 0
33 0
patients 0
with 0
pulmonary 0
hypertension 0
. 0

Blood B-PHYSICAL
pool I-PHYSICAL
IVRT I-PHYSICAL
and 0
myocardial B-PHYSICAL
IVRTs I-PHYSICAL
for I-PHYSICAL
the I-PHYSICAL
tricuspid I-PHYSICAL
valve I-PHYSICAL
annulus I-PHYSICAL
ring I-PHYSICAL
, 0
basal B-PHYSICAL
and 0
apical B-PHYSICAL
RV I-PHYSICAL
free I-PHYSICAL
wall I-PHYSICAL
segments I-PHYSICAL
were 0
measured 0
and 0
compared 0
with 0
data 0
from 0
33 0
age- 0
and 0
sex-matched 0
control 0
subjects 0
. 0

Measured B-PHYSICAL
IVRTs I-PHYSICAL
were 0
significantly 0
longer 0
in 0
patients 0
with 0
pulmonary 0
hypertension 0
than 0
in 0
control 0
subjects 0
. 0

The 0
strongest 0
correlation 0
( 0
R 0
= 0
0.74 0
, 0
P 0
< 0
.0001 0
) 0
was 0
found 0
between 0
systolic B-PHYSICAL
PAP I-PHYSICAL
and 0
the B-PHYSICAL
heart I-PHYSICAL
rate-corrected I-PHYSICAL
IVRT I-PHYSICAL
' 0
derived 0
from 0
the 0
basal 0
RV 0
free 0
wall 0
segment 0
. 0

The 0
basal B-PHYSICAL
segment I-PHYSICAL
IVRT I-PHYSICAL
' 0
corrected 0
for 0
heart B-PHYSICAL
rate I-PHYSICAL
correlates 0
well 0
with 0
the 0
invasive 0
PAP 0
measurement 0
and 0
, 0
therefore 0
, 0
can 0
be 0
used 0
to 0
predict 0
systolic B-PHYSICAL
PAP I-PHYSICAL
. 0

It 0
can 0
even 0
be 0
considered 0
as 0
an 0
alternative 0
to 0
tricuspid 0
regurgitation-derived 0
PAP 0
systolic 0
when 0
tricuspid 0
regurgitation 0
is 0
nonrecordable 0
. 0

A 0
proposed 0
method 0
to 0
derive 0
systolic 0
PAP 0
should 0
be 0
used 0
while 0
screening 0
the 0
patients 0
at 0
risk 0
for 0
pulmonary 0
hypertension 0
, 0
monitoring 0
the 0
disease 0
progression 0
and 0
the 0
effect 0
of 0
treatment 0
. 0

Adjvant 0
treatment 0
of 0
tongue 0
and 0
floor 0
of 0
the 0
mouth 0
cancers 0
. 0

Since 0
January 0
1974 0
, 0
95 0
patients 0
with 0
anterior 0
tongue 0
and 0
floor 0
of 0
the 0
mouth 0
cancers 0
were 0
included 0
in 0
a 0
randomized 0
trial 0
. 0

After 0
stratification 0
according 0
to 0
staging 0
and 0
initial 0
treatment 0
, 0
one-third 0
of 0
the 0
patients 0
received 0
chemotherapy 0
for 0
2 0
years 0
( 0
methotrexate 0
400 0
mg 0
followed 0
by 0
citrovorum 0
factor 0
100 0
mg 0
+ 0
bleomycin 0
60 0
mg/week 0
, 0
during 0
the 0
first 0
15 0
weeks 0
) 0
, 0
one-third 0
of 0
the 0
patients 0
received 0
immunotherapy 0
with 0
weekly 0
C. 0
parvum 0
injections 0
during 0
2 0
years 0
, 0
while 0
the 0
remaining 0
third 0
did 0
not 0
receive 0
any 0
treatment 0
. 0

If 0
adjuvant 0
treatment 0
seems 0
to 0
delay B-OTHER
recurrence I-OTHER
it 0
did 0
not 0
significantly 0
decrease 0
the 0
recurrence B-OTHER
rate I-OTHER
. 0

Survival B-MORTALITY
is 0
also 0
not 0
signigicantly 0
modified 0
by 0
adjuvant 0
treatment 0
and 0
was 0
better 0
for 0
patients 0
with 0
small 0
tumors 0
. 0

Patients 0
who 0
previously 0
received 0
radiotherapy 0
did 0
not 0
benefit 0
from 0
adjuvant 0
therapy 0
. 0

Getting 0
a 0
high 0
response 0
rate 0
of 0
sexual 0
behavior 0
survey 0
among 0
the 0
general 0
population 0
in 0
Japan 0
: 0
three 0
different 0
methods 0
of 0
survey 0
on 0
sexual 0
behavior 0
. 0

The 0
purpose 0
of 0
this 0
study 0
was 0
to 0
specify 0
the 0
most 0
accurate 0
, 0
reliable 0
and 0
valid 0
technique 0
for 0
a 0
general 0
sexual 0
behavioral 0
survey 0
in 0
Japan 0
. 0

This 0
pilot 0
study 0
was 0
conducted 0
to 0
assure 0
a 0
high 0
response 0
rate 0
and 0
to 0
keep 0
respondents 0
' 0
privacy 0
confidential 0
by 0
using 0
an 0
anonymous 0
questionnaire 0
survey 0
technique 0
. 0

The 0
sample 0
( 0
360 0
potential 0
respondents 0
) 0
was 0
selected 0
randomly 0
from 0
basic 0
resident 0
registers 0
in 0
two 0
geographically 0
different 0
areas 0
. 0

From 0
the 0
registries 0
, 0
90 0
residents 0
, 0
aged 0
20 0
to 0
49 0
years 0
old 0
, 0
were 0
randomly 0
selected 0
to 0
represent 0
each 0
sex 0
from 0
each 0
area 0
. 0

The 0
subjects 0
were 0
randomly 0
assigned 0
to 0
three 0
groups 0
each 0
having 0
a 0
different 0
procedure 0
of 0
requesting 0
the 0
completion 0
of 0
the 0
survey 0
and 0
providing 0
the 0
questionnaires 0
: 0
( 0
1 0
) 0
Postal 0
Group 0
, 0
( 0
2 0
) 0
Telephone 0
Group 0
, 0
and 0
( 0
3 0
) 0
Face-to-face 0
Group 0
. 0

The 0
survey 0
was 0
carried 0
out 0
from 0
October 0
1995 0
to 0
February 0
1996 0
. 0

Effective B-OTHER
response 0
rates B-OTHER
for 0
the 0
above 0
mentioned 0
three 0
groups 0
were 0
69.2 0
% 0
, 0
69.2 0
% 0
and 0
55.8 0
% 0
, 0
respectively 0
. 0

It 0
is 0
difficult 0
to 0
determine 0
the 0
best 0
method 0
when 0
only 0
considering 0
the 0

Sequential 0
therapy 0
versus 0
standard 0
triple-drug 0
therapy 0
for 0
Helicobacter 0
pylori 0
eradication 0
: 0
a 0
randomized 0
study 0
. 0

BACKGROUND 0
Antimicrobial 0
resistance 0
has 0
decreased 0
eradication 0
rates 0
for 0
Helicobacter 0
pylori 0
infection 0
worldwide 0
. 0

A 0
sequential 0
treatment 0
schedule 0
has 0
been 0
reported 0
to 0
be 0
effective 0
, 0
but 0
studies 0
published 0
to 0
date 0
were 0
performed 0
in 0
Italy 0
. 0

We 0
undertook 0
this 0
study 0
to 0
determine 0
whether 0
these 0
results 0
could 0
be 0
replicated 0
in 0
India 0
. 0

METHODS 0
A 0
randomized 0
, 0
open-labeled 0
, 0
prospective 0
controlled 0
trial 0
comparing 0
sequential 0
vs. 0
standard 0
triple-drug 0
therapy 0
was 0
carried 0
out 0
at 0
Lokmanya 0
Tilak 0
Municipal 0
General 0
Hospital 0
, 0
Mumbai 0
. 0

Two 0
hundred 0
and 0
thirty-one 0
patients 0
with 0
dyspepsia 0
were 0
randomized 0
to 0
a 0
10-day 0
sequential 0
regimen 0
( 0
40 0
mg 0
of 0
pantoprazole 0
, 0
1 0
g 0
of 0
amoxicillin 0
, 0
each 0
administered 0
twice 0
daily 0
for 0
the 0
first 0
5 0
days 0
, 0
followed 0
by 0
40 0
mg 0
of 0
pantoprazole 0
, 0
500 0
mg 0
of 0
clarithromycin 0
, 0
and 0
500 0
mg 0
of 0
tinidazole 0
, 0
each 0
administered 0
twice 0
daily 0
for 0
the 0
remaining 0
5 0
days 0
) 0
or 0
to 0
standard 0
14-day 0
therapy 0
( 0
40 0
mg 0
of 0
pantoprazole 0
, 0
500 0
mg 0
of 0
clarithromycin 0
, 0
and 0
1 0
g 0
of 0
amoxicillin 0
, 0
each 0
administered 0
twice 0
daily 0
) 0
. 0

RESULTS 0
The 0
eradication B-OTHER
rate I-OTHER
achieved 0
with 0
the 0
sequential 0
regimen 0
was 0
significantly 0
greater 0
than 0
that 0
obtained 0
with 0
the 0
triple 0
therapy 0
. 0

Per-protocol B-OTHER
eradication I-OTHER
rate I-OTHER
of 0
sequential 0
therapy 0
was 0
92.4 0
% 0
( 0
95 0
% 0
CI 0
85.8-96.1 0
% 0
) 0
vs. 0
81.8 0
% 0
( 0
95 0
% 0
CI 0
73.9-87.8 0
% 0
) 0
( 0
p 0
= 0
0.027 0
) 0
for 0
standard 0
drug 0
therapy 0
. 0

Intention-to-treat 0
eradication 0
rates 0
were 0
88.2 0
% 0
( 0
95 0
% 0
CI 0
80.9-93.0 0
% 0
) 0
vs. 0
79.1 0
% 0
( 0
95 0
% 0
CI 0
71.1-85.4 0
% 0
) 0
, 0
p 0
= 0
0.029 0
, 0
respectively 0
. 0

The 0
incidence 0
of 0
major 0
and 0
minor 0
side 0
effects 0
between 0
therapy 0
groups 0
was 0
not 0
significantly 0
different 0
( 0
14.6 0
% 0
in 0
the 0
triple 0
therapy 0
group 0
vs. 0
23.5 0
% 0
in 0
sequential 0
group 0
, 0
p 0
= 0
0.12 0
) 0
. 0

Follow 0
up 0
was 0
incomplete 0
in 0
3.3 0
% 0
and 0
4.7 0
% 0
patients 0
in 0
standard 0
and 0
sequential 0
therapy 0
groups 0
, 0
respectively 0
. 0

Sequential 0
therapy 0
includes 0
one 0
additional 0
antibiotic 0
( 0
tinidazole 0
) 0
that 0
is 0
not 0
contained 0
in 0
standard 0
therapy 0
. 0

CONCLUSIONS 0
Sequential 0
therapy 0
was 0
significantly 0
better 0
than 0
standard 0
therapy 0
for 0
eradicating 0
H. 0
pylori 0
infection 0
. 0

Moisture-vapour-permeable 0
film 0
as 0
an 0
outpatient 0
burn 0
dressing 0
. 0

This 0
study 0
compares 0
a 0
moisture-vapour-permeable 0
film 0
( 0
MVPF 0
) 0
with 0
silver 0
sulphadiazine 0
in 0
a 0
randomized 0
prospective 0
manner 0
for 0
the 0
treatment 0
of 0
outpatient 0
burns 0
. 0

The 0
two 0
treatment 0
groups 0
were 0
closely 0
matched 0
in 0
age 0
, 0
sex 0
, 0
per 0
cent 0
of 0
BSA 0
burned 0
, 0
and 0
in 0
burn 0
severity 0
and 0
locations 0
. 0

The 0
MVPF 0
group 0
demonstrated 0
a 0
39.0 0
per 0
cent 0
greater 0
reduction 0
in 0
pain B-PAIN
after 0
application 0
of 0
the 0
dressing 0
over 0
the 0
silver 0
sulphadiazine 0
group 0
. 0

Patients 0
in 0
the 0
MVPF 0
film 0
group 0
also 0
reported 0
significantly 0
less 0
difficulty 0
in 0
wound B-OTHER
care I-OTHER
and 0
in 0
dressing B-OTHER
interference I-OTHER
with I-OTHER
their I-OTHER
daily I-OTHER
functions I-OTHER
. 0

The 0
clinical B-ADVERSE-EFFECTS
infection I-ADVERSE-EFFECTS
rate I-ADVERSE-EFFECTS
and 0
time B-OTHER
to I-OTHER
healing I-OTHER
were 0
similar 0
in 0
both 0
groups 0
. 0

In 0
the 0
management B-OTHER
of 0
outpatient 0
burns 0
, 0
MVPF 0
was 0
found 0
to 0
be 0
superior 0
to 0
silver 0
sulphadiazine 0
. 0

Specific 0
immunoglobulin 0
for 0
treatment 0
of 0
whooping 0
cough 0
. 0

Immunoglobulin 0
treatment 0
for 0
whooping 0
cough 0
( 0
pertussis 0
) 0
is 0
widely 0
believed 0
to 0
be 0
ineffective B-OTHER
although 0
there 0
are 0
sound 0
reasons 0
for 0
regarding 0
the 0
condition 0
as 0
a 0
toxin-induced 0
disease 0
. 0

We 0
wondered 0
whether 0
the 0
lack B-OTHER
of I-OTHER
success I-OTHER
with 0
pertussis 0
immunoglobulins 0
might 0
be 0
attributable 0
to 0
inadequate 0
dose 0
, 0
so 0
we 0
designed 0
a 0
randomised 0
, 0
double-blind 0
, 0
placebo-controlled 0
trial 0
of 0
two 0
immunoglobulin 0
preparations 0
. 0

The 0
study 0
was 0
conducted 0
at 0
three 0
Swedish 0
hospitals 0
. 0

We 0
enrolled 0
73 0
children 0
aged 0
less 0
than 0
36 0
months 0
who 0
were 0
admitted 0
with 0
a 0
clinical 0
diagnosis 0
of 0
whooping 0
cough 0
. 0

On 0
admission 0
they 0
were 0
assigned 0
to 0
one 0
of 0
three 0
groups 0
: 0
( 0
a 0
) 0
monocomponent 0
pertussis 0
toxoid 0
vaccine 0
; 0
( 0
b 0
) 0
two-component 0
acellular 0
vaccine 0
also 0
containing 0
filamentous 0
haemagglutinin 0
; 0
or 0
( 0
c 0
) 0
20 0
% 0
albumin 0
solution 0
( 0
placebo 0
) 0
. 0

The 0
immunoglobulins 0
had 0
a 0
high 0
antitoxin 0
content 0
and 0
had 0
been 0
raised 0
with 0
acellular 0
pertussis 0
vaccines 0
. 0

Diagnosis 0
of 0
pertussis 0
was 0
confirmed 0
by 0
laboratory 0
tests 0
and 0
the 0
follow-up 0
was 0
completed 0
in 0
67 0
children 0
. 0

The 0
main 0
study 0
group 0
consisted 0
of 0
47 0
children 0
with 0
less 0
than 0
or 0
equal 0
to 0
14 0
days 0
of 0
disease 0
before 0
therapy 0
. 0

Duration 0
of 0
whoops B-PHYSICAL
post-treatment I-PHYSICAL
was 0
8.7 0
days 0
( 0
95 0
% 0
Cl 0
4.8 0
, 0
12.6 0
) 0
in 0
the 0
33 0
children 0
receiving 0
immunoglobulin 0
vs 0
20.6 0
( 0
95 0
% 0
Cl 0
11.9 0
, 0
29.3 0
) 0
in 0
the 0
14 0
receiving 0
placebo 0
( 0
p 0
= 0
0.0041 0
) 0
. 0

Mean 0
number B-PHYSICAL
of I-PHYSICAL
whoops I-PHYSICAL
during 0
the 0
first 0
week 0
of 0
follow-up 0
was 0
also 0
significantly 0
reduced 0
( 0
p 0
= 0
0.0196 0
) 0
. 0

We 0
found 0
that 0
early 0
treatment 0
was 0
important 0
, 0
since 0
the 0
effect 0
on 0
duration B-PHYSICAL
of I-PHYSICAL
whoops I-PHYSICAL
was 0
most 0
pronounced 0
when 0
disease 0
duration 0
before 0
treatment 0
was 0
less 0
than 0
or 0
equal 0
to 0
7 0
days 0
. 0

There 0
were 0
no 0
significant 0
differences B-PHYSICAL
between 0
the 0
two 0
immunoglobulin 0
preparations 0
. 0

High-dose 0
specific 0
pertussis 0
immunoglobulin 0
with 0
a 0
high 0
antitoxin 0
concentration 0
has 0
a 0
beneficial B-OTHER
effect 0
in 0
the 0
treatment 0
of 0
whooping 0
cough 0
. 0

The 0
Finnish 0
Diabetes 0
Prevention 0
Study 0
. 0

The 0
aim 0
of 0
the 0
Finnish 0
Diabetes 0
Prevention 0
Study 0
is 0
to 0
assess 0
the 0
efficacy 0
of 0
an 0
intensive 0
diet-exercise 0
programme 0
in 0
preventing 0
or 0
delaying 0
type 0
2 0
diabetes B-PHYSICAL
in 0
individuals 0
with 0
impaired 0
glucose 0
tolerance 0
( 0
IGT 0
) 0
and 0
to 0
evaluate 0
the 0
effect 0
of 0
the 0
programme 0
on 0
the 0
risk 0
factors 0
of 0
atherosclerotic 0
vascular 0
diseases 0
and 0
the 0
incidence 0
of 0
cardiovascular 0
events 0
. 0

In 0
this 0
ongoing 0
study 0
, 0
a 0
total 0
of 0
523 0
overweight 0
subjects 0
with 0
IGT 0
based 0
on 0
two 0
oral 0
glucose 0
tolerance 0
tests 0
were 0
randomized 0
to 0
either 0
an 0
intervention 0
group 0
or 0
a 0
control 0
group 0
. 0

The 0
main 0
measure 0
in 0
the 0
intervention 0
group 0
is 0
individual B-OTHER
dietary I-OTHER
advice I-OTHER
aimed 0
at 0
reducing 0
weight 0
and 0
intake 0
of 0
saturated 0
fat 0
and 0
increasing 0
intake 0
of 0
dietary 0
fibre 0
. 0

The 0
intervention 0
subjects 0
are 0
individually 0
guided 0
to 0
increase 0
their 0
level 0
of 0
physical 0
activity 0
. 0

The 0
control 0
group 0
receives 0
general 0
information 0
about 0
the 0
benefits 0
of 0
weight 0
reduction 0
, 0
physical 0
activity 0
and 0
healthy 0
diet 0
in 0
the 0
prevention 0
of 0
diabetes 0
. 0

A 0
pilot 0
study 0
began 0
in 0
1993 0
, 0
and 0
recruitment 0
ended 0
in 0
1998 0
. 0

By 0
the 0
end 0
of 0
April 0
1999 0
there 0
were 0
65 0
new 0
cases 0
of 0
diabetes 0
, 0
34 0
drop-outs 0
and 0
one 0
death B-MORTALITY
. 0

The 0
weight 0
reduction B-PHYSICAL
was 0
greater 0
( 0
-4.6 0
kg 0
) 0
at 0
1 0
year 0
in 0
the 0
intervention 0
group 0
( 0
n 0
= 0
152 0
) 0
than 0
in 0
the 0
control 0
group 0
( 0
n 0
= 0
143 0
, 0
-0.9 0
kg 0
, 0
P 0
< 0
0.0001 0
) 0
, 0
and 0
this 0
difference 0
was 0
sustained 0
in 0
the 0
second 0
year 0
of 0
follow-up 0
. 0

At 0
1 0
year 0
43.4 0
% 0
and 0
at 0
2 0
years 0
41.8 0
% 0
of 0
the 0
intervention 0
subjects 0
had 0
achieved 0
a 0
weight 0
reduction B-PHYSICAL
of 0
at 0
least 0
5 0
kg 0
, 0
while 0
the 0
corresponding 0
figures 0
for 0
the 0
control 0
subjects 0
were 0
14.0 0
and 0
12.0 0
% 0
( 0
P 0
< 0
0.001 0
between 0
the 0
groups 0
) 0
. 0

At 0
1 0
year 0
the 0
intervention 0
group 0
showed 0
significantly 0
greater 0
reductions 0
in 0
2 0
h B-PHYSICAL
glucose I-PHYSICAL
, 0
fasting B-PHYSICAL
and I-PHYSICAL
2 I-PHYSICAL
h I-PHYSICAL
insulin I-PHYSICAL
, 0
systolic B-PHYSICAL
and I-PHYSICAL
diastolic I-PHYSICAL
blood I-PHYSICAL
pressure I-PHYSICAL
, 0
and 0
serum B-PHYSICAL
triglycerides I-PHYSICAL
. 0

Most 0
of 0
the 0
beneficial 0
changes 0
in 0
cardiovascular B-PHYSICAL
risk 0
factors B-PHYSICAL
were 0
sustained 0
for 0
2 0
years 0
. 0

These 0
interim 0
results 0
of 0
the 0
ongoing 0
Finnish 0
Diabetes 0
Prevention 0
Study 0
demonstrate 0
the 0
efficacy 0
and 0

A 0
study 0
of 0
a 0
Self-Care 0
Rehabilitation 0
Program 0
in 0
pediatric 0
asthma 0
. 0

The 0
Self-Care 0
Rehabilitation 0
in 0
Pediatric 0
Asthma 0
( 0
SCRPA 0
) 0
project 0
was 0
designed 0
to 0
ascertain 0
the 0
level 0
to 0
which 0
children 0
with 0
asthma 0
are 0
able 0
to 0
acquire 0
the 0
asthma 0
knowledge 0
and 0
skills 0
presented 0
in 0
a 0
self-management 0
training 0
program 0
conducted 0
by 0
the 0
American 0
Lung 0
Association 0
of 0
Utah 0
and 0
the 0
effect 0
of 0
such 0
training 0
on 0
the 0
asthma 0
experience 0
. 0

The 0
preschool 0
SCRPA 0
Curriculum 0
( 0
ages 0
2-5 0
) 0
consisted 0
of 0
six 0
1-hour 0
classes 0
scheduled 0
twice 0
a 0
week 0
for 0
3 0
weeks 0
. 0

The 0
first 0
and 0
last 0
classes 0
were 0
for 0
one 0
or 0
both 0
parents 0
only 0
, 0
and 0
the 0
middle 0
four 0
sessions 0
were 0
for 0
the 0
child 0
and 0
parent 0
( 0
s 0
) 0
. 0

The 0
school-age 0
SCRPA 0
curriculum 0
( 0
ages 0
6-14 0
) 0
consisted 0
of 0
eight 0
90-minute 0
classes 0
for 0
both 0
child 0
and 0
parent 0
( 0
s 0
) 0
scheduled 0
twice 0
a 0
week 0
for 0
4 0
weeks 0
. 0

Private 0
physicians 0
referred 0
21 0
preschool 0
children 0
and 0
38 0
school-age 0
children 0
into 0
the 0
program 0
. 0

The 0
school-age 0
children 0
were 0
randomly 0
assigned 0
to 0
a 0
study 0
or 0
control 0
group 0
, 0
and 0
the 0
preschool 0
children 0
served 0
as 0
their 0
own 0
controls 0
. 0

A 0
comparison 0
of 0
asthma 0
episodes 0
during 0
the 0
3 0
months 0
before 0
and 0
after 0
training 0
showed 0
a 0
statistically 0
significant 0
decrease 0
in 0
the B-MENTAL
number I-MENTAL
of I-MENTAL
episodes I-MENTAL
but 0
no 0
change 0
in 0
severity B-MENTAL
in 0
the 0
preschool 0
, 0
school 0
study 0
, 0
and 0
school 0
control 0
groups 0
. 0

The 0
decrease 0
in 0
episodes B-MENTAL
for 0
the 0
control 0
groups 0
suggest 0
that 0
the 0
family 0
record 0
keeping 0
required 0
of 0
all 0
subjects 0
may 0
have 0
a 0
beneficial 0
effect 0
, 0
a 0
phenomenon 0
worth 0
further 0
investigation 0
. 0

Also 0
, 0
the 0
school-age 0
group 0
, 0
in 0
pre- 0
and 0
posttesting 0
, 0
demonstrated 0
that 0
the 0
SCRPA 0
curriculum 0
increased 0
knowledge B-MENTAL
and 0
skills B-MENTAL
in 0
the 0
study 0
group 0
, 0
changes 0
not 0
found 0
in 0
the 0
control 0
group 0
. 0

Randomised 0
clinical 0
trial 0
of 0
physiotherapy 0
after 0
open 0
abdominal 0
surgery 0
in 0
high 0
risk 0
patients 0
. 0

Postoperative 0
physiotherapy 0
has 0
been 0
shown 0
to 0
reduce B-OTHER
the I-OTHER
incidence I-OTHER
of 0
postoperative 0
pulmonary 0
complications 0
after 0
open 0
abdominal 0
surgery 0
. 0

This 0
study 0
aimed 0
to 0
determine 0
if 0
the 0
addition 0
of 0
deep 0
breathing 0
exercises 0
and 0
secretion 0
clearing 0
techniques 0
to 0
a 0
standardised 0
physiotherapist-directed 0
program 0
of 0
early 0
mobilisation 0
improved 0
clinical 0
outcomes 0
in 0
patients 0
undergoing 0
open 0
abdominal 0
surgery 0
. 0

Fifty-six 0
patients 0
undergoing 0
open 0
abdominal 0
surgery 0
, 0
at 0
high 0
risk 0
of 0
developing 0
postoperative 0
pulmonary 0
complications 0
, 0
were 0
randomised 0
before 0
operation 0
to 0
an 0
early 0
mobilisation-only 0
group 0
or 0
an 0
early 0
mobilisation-plus-deep 0
breathing 0
and 0
coughing 0
group 0
. 0

Mobility B-PHYSICAL
duration I-PHYSICAL
, 0
frequency 0
and 0
intensity 0
of 0
breathing B-PHYSICAL
interventions I-PHYSICAL
were 0
quantified 0
for 0
both 0
groups 0
. 0

All 0
outcomes 0
were 0
assessed 0
by 0
a 0
blinded 0
outcomes 0
researcher 0
using 0
a 0
standardised 0
outcomes 0
measurement 0
tool 0
developed 0
specifically 0
for 0
this 0
population 0
. 0

Outcomes 0
included 0
incidence 0
of 0
clinically 0
significant 0
postoperative B-PHYSICAL
pulmonary I-PHYSICAL
complications I-PHYSICAL
, 0
fever B-PHYSICAL
, 0
length B-OTHER
of I-OTHER
stay I-OTHER
, 0
and 0
restoration B-PHYSICAL
of I-PHYSICAL
mobility I-PHYSICAL
. 0

There 0
were 0
no 0
significant 0
differences 0
between 0
groups 0
in 0
mean 0
age 0
, 0
anaesthetic B-OTHER
time I-OTHER
, 0
perioperative B-PHYSICAL
morbidity I-PHYSICAL
, 0
or 0

[ 0
Clinical 0
study 0
of 0
the 0
efficacy 0
of 0
and 0
tolerance 0
to 0
nimesulide 0
in 0
suppository 0
formulation 0
in 0
pain-inflammatory 0
pathologies 0
of 0
the 0
ear 0
, 0
nose 0
, 0
and 0
throat 0
] 0
. 0

The 0
efficacy 0
and 0
tolerability B-OTHER
of 0
a 0
new 0
pharmaceutical 0
form 0
of 0
the 0
non-steroid 0
anti-inflammatory 0
drug 0
. 0

Nimesulide 0
have 0
been 0
studied 0
in 0
a 0
double 0
blind 0
study 0
compared 0
with 0
flurbiprofen 0
, 0
in 0
98 0
patients 0
aged 0
between 0
18 0
and 0
75 0
suffering 0
from 0
pain-inflammatory 0
pathologies 0
of 0
ENT 0
nature 0
. 0

Both 0
drugs 0
, 0
administered 0
in 0
a 0
dose 0
of 0
one 0
suppository 0
twice 0
a 0
day 0
for 0
7 0
days 0
, 0
showed 0
marked 0
anti-inflammatory B-PHYSICAL
, 0
analgesic B-PHYSICAL
and 0
antipyretic B-PHYSICAL
activity I-PHYSICAL
and 0
produced 0
a 0
significant 0
, 0
progressive 0
improvement 0
in 0
the 0
typical 0
symptoms 0
of 0
the 0
inflammatory B-PHYSICAL
state I-PHYSICAL
up 0
to 0
their 0
complete 0
remission 0
. 0

Nimesulide 0
evidenced 0
greater 0
speed B-PHYSICAL
and 0
duration 0
of 0
therapeutic B-PHYSICAL
action I-PHYSICAL
. 0

Assessment 0
on 0
the 0
effectiveness 0
and 0
tolerability B-OTHER
as 0
expressed 0
separately 0
by 0
the 0
physician 0
and 0
patient 0
were 0
positive 0
in 0
almost 0
all 0
cases 0
of 0
both 0
treatments 0
. 0

Superior 0
visual 0
search 0
in 0
adults 0
with 0
autism 0
. 0

Recent 0
studies 0
have 0
suggested 0
that 0
children 0
with 0
autism 0
perform 0
better 0
than 0
matched 0
controls 0
on 0
visual 0
search 0
tasks 0
and 0
that 0
this 0
stems 0
from 0
a 0
superior 0
visual B-MENTAL
discrimination I-MENTAL
ability I-MENTAL
. 0

This 0
study 0
assessed 0
whether 0
these 0
findings 0
generalize 0
from 0
children 0
to 0
adults 0
with 0
autism 0
. 0

Experiments 0
1 0
and 0
2 0
showed 0
that 0
, 0
like 0
children 0
, 0
adults 0
with 0
autism 0
were 0
superior 0
to 0
controls 0
at 0
searching B-MENTAL
for I-MENTAL
targets I-MENTAL
. 0

Experiment 0
3 0
showed 0
that 0
increases 0
in 0
target-distractor B-MENTAL
similarity 0
slowed B-MENTAL
the I-MENTAL
visual I-MENTAL
search I-MENTAL
performance B-MENTAL
of 0
the 0
control 0
group 0
significantly 0
more 0
than 0
that 0
of 0
the 0
autism 0
group 0
, 0
suggesting 0
that 0
the 0
adults 0
with 0
autism 0
have 0
a 0
superior B-PHYSICAL
visual I-PHYSICAL
discrimination I-PHYSICAL

Hepatorenal 0
syndrome 0
. 0

Studies 0
of 0
the 0
effect 0
of 0
vascular 0
volume 0
and 0
intraperitoneal 0
pressure 0
on 0
renal B-PHYSICAL
and I-PHYSICAL
hepatic I-PHYSICAL
function I-PHYSICAL
. 0

Eleven 0
patients 0
with 0
well-documented 0
hepatorenal 0
syndrome 0
were 0
studied 0
by 0
measurement 0
of 0
blood B-PHYSICAL
volume I-PHYSICAL
, 0
glomerular B-PHYSICAL
filtration I-PHYSICAL
rate I-PHYSICAL
, 0
renal B-PHYSICAL
plasma I-PHYSICAL
flow I-PHYSICAL
, 0
plasma B-PHYSICAL
aldosterone I-PHYSICAL
concentration I-PHYSICAL
, 0
renin B-PHYSICAL
substrate I-PHYSICAL
concentration I-PHYSICAL
, 0
and 0
plasma B-PHYSICAL
renin I-PHYSICAL
activity I-PHYSICAL
. 0

They 0
were 0
then 0
given 0
750 0
ml 0
of 0
stored 0
plasma 0
, 0
750 0
ml 0
of 0
fresh 0
frozen 0
plasma 0
, 0
and 0
then 0
an 0
infusion 0
of 0
angiotensin 0
II 0
, 0
in 0
random 0
order 0
on 0
successive 0
days 0
. 0

Infusion 0
of 0
fresh 0
frozen 0
plasma 0
improved 0
function 0
more 0
than 0
did 0
stored 0
plasma 0
and 0
in 0
addition 0
returned 0
a 0
very 0
low 0
filtration 0
fraction 0
toward 0
normal 0
. 0

Angiotensin 0
II 0
infusion 0
increased 0
filtration B-PHYSICAL
fraction I-PHYSICAL
, 0
but 0
decreased 0
glomerular B-PHYSICAL
filtration I-PHYSICAL
rate I-PHYSICAL
, 0
renal B-PHYSICAL
plasma I-PHYSICAL
flow I-PHYSICAL
, 0
and 0
urine B-PHYSICAL
flow I-PHYSICAL
sharply 0
. 0

Patients 0
were 0
then 0
given 0
a 0
daily 0
infusion 0
of 0
1,000 0
ml 0
of 0
fresh 0
frozen 0
plasma 0
for 0
seven 0
to 0
18 0
days 0
to 0
expand 0
the 0
blood 0
volume 0
to 0
supranormal 0
levels 0
as 0
assayed 0
by 0
serial 0
measurement 0
of 0
blood 0
volume 0
. 0

Plasma B-PHYSICAL
aldosterone I-PHYSICAL
levels I-PHYSICAL
decreased 0
to 0
a 0
normal 0
range 0
, 0
glomerular B-PHYSICAL
filtration I-PHYSICAL
rate I-PHYSICAL
and 0
renal B-PHYSICAL
plasma I-PHYSICAL
flow I-PHYSICAL
both 0
increased 0
, 0
and 0
urinary B-PHYSICAL
excretion I-PHYSICAL
of I-PHYSICAL
sodium I-PHYSICAL
and 0
potassium B-PHYSICAL
both 0
returned 0
toward 0
normal 0
. 0

The 0
effect 0
of 0
intraperitoneal 0
pressure 0
was 0
then 0
studied 0
by 0
measuring 0
glomerular B-PHYSICAL
filtration I-PHYSICAL
rate I-PHYSICAL
, 0
renal B-PHYSICAL
plasma I-PHYSICAL
flow I-PHYSICAL
, 0
pressure B-PHYSICAL
in I-PHYSICAL
the I-PHYSICAL
vena I-PHYSICAL
cava I-PHYSICAL
, 0
hepatic B-PHYSICAL
vein I-PHYSICAL
free I-PHYSICAL
flow I-PHYSICAL
, 0
and 0
hepatic B-PHYSICAL
vein I-PHYSICAL
wedged I-PHYSICAL
pressure I-PHYSICAL
before 0
, 0
during 0
, 0
and 0
after 0
paracentesis 0
to 0
reduce 0
the 0
intraperitoneal 0
pressure 0
from 0
30 0
to 0
40 0
cm 0
H2O 0
to 0
12 0
to 0
17 0
cm 0
H2O 0
. 0

Venous B-PHYSICAL
pressures I-PHYSICAL
moved 0
parallel 0
to 0
ascitic B-PHYSICAL
fluid I-PHYSICAL
pressures I-PHYSICAL
, 0
and 0
glomerular B-PHYSICAL
filtration I-PHYSICAL
rate I-PHYSICAL
, 0
renal B-PHYSICAL
plasma I-PHYSICAL
flow I-PHYSICAL
, 0
and 0
urine B-PHYSICAL
flow I-PHYSICAL
all 0
improved 0
sharply 0
; 0
then 0
, 0
as 0
ascitic 0
fluid 0
continued 0
to 0
form 0
, 0
reducing 0
vascular B-PHYSICAL
volume I-PHYSICAL
, 0
urine 0
flow 0
, 0
glomerular 0
filtration 0
rate 0
, 0
and 0
renal B-PHYSICAL
plasma I-PHYSICAL
flow I-PHYSICAL
all 0
decreased 0
slowly 0
. 0

Six 0
patients 0
then 0
underwent 0
placement 0
of 0
a 0
LeVeen 0
shunt 0
. 0

Improvement 0
in 0
glomerular B-PHYSICAL
filtration I-PHYSICAL
rate I-PHYSICAL
and 0
renal B-PHYSICAL
plasma I-PHYSICAL
flow I-PHYSICAL
and 0
clinical B-PHYSICAL
condition I-PHYSICAL
was 0
dramatic 0
. 0

During 0
postoperative 0
observation 0
of 0
up 0
to 0
two 0
years 0
, 0
progressive 0
improvement 0
in 0
hepatic B-PHYSICAL
function I-PHYSICAL
has 0
occurred 0
. 0

Capsular 0
contracture 0
around 0
saline-filled 0
fine 0
textured 0
and 0
smooth 0
mammary 0
implants 0
: 0
a 0
prospective 0
7.5-year 0
follow-up 0
. 0

In 0
a 0
previous 0
prospective 0
randomized 0
clinical 0
study 0
comparing 0
in 0
the 0
same 0
patient 0
textured 0
and 0
smooth 0
saline-filled 0
mammary 0
implants 0
( 0
Biocell 0
) 0
with 0
large 0
pore 0
size 0
( 0
300 0
to 0
600 0
microm 0
) 0
, 0
we 0
saw 0
no 0
difference 0
in 0
capsular 0
contracture 0
. 0

This 0
study 0
was 0
undertaken 0
in 0
a 0
similar 0
way 0
to 0
compare 0
capsular 0
contracture 0
around 0
smooth 0
and 0
textured 0
saline-filled 0
prostheses 0
with 0
pores 0
of 0
small 0
size 0
. 0

During 0
a 0
period 0
of 0
7.5 0
years 0
, 0
the 0
breast 0
hardness 0
was 0
followed 0
up 0
, 0
and 0
at 0
the 0
end 0
of 0
the 0
study 0
patient 0
satisfaction 0
was 0
evaluated 0
. 0

Twenty 0
healthy 0
women 0
with 0
a 0
mean 0
age 0
of 0
30 0
years 0
were 0
operated 0
on 0
for 0
breast 0
augmentation 0
. 0

Two 0
surgeons 0
performed 0
all 0
operations 0
in 0
a 0
standardized 0
way 0
. 0

Each 0
patient 0
received 0
subglandularly 0
a 0
Siltex 0
textured 0
saline-filled 0
prosthesis 0
with 0
a 0
pore 0
size 0
of 0
30 0
to 0
70 0
microm 0
in 0
one 0
breast 0
, 0
and 0
a 0
smooth 0
saline-filled 0
prosthesis 0
in 0
the 0
other 0
. 0

The 0
hardness B-PHYSICAL
of I-PHYSICAL
the I-PHYSICAL
breasts I-PHYSICAL
was 0
evaluated 0
after 0
0.5 0
, 0
1 0
, 0
and 0
7.5 0
years 0
using 0
Baker B-OTHER
grading I-OTHER
and I-OTHER
applanation I-OTHER
tonometry I-OTHER
. 0

Eighteen 0
patients 0
completed 0
1-year 0
and 0
7.5-year 0
follow-up 0
. 0

Two 0
breasts 0
with 0
smooth 0
prostheses 0
were 0
contracted 0
after 0
6 0
months 0
( 0
Baker 0
III 0
or 0
IV 0
) 0
. 0

After 0
1 0
year 0
, 0
four 0
patients 0
with 0
smooth 0
prostheses 0
and 0
one 0
with 0
a 0
textured 0
prosthesis 0
had 0
capsular B-PHYSICAL
contracture I-PHYSICAL
( 0
p 0
= 0
0.34 0
) 0
. 0

Seven 0
and 0
one-half 0
years 0
after 0
surgery 0
, 0
six 0
patents 0
with 0
smooth 0
and 0
four 0
with 0
textured 0
implants 0
had 0
contracture B-PHYSICAL
( 0
p 0
= 0
0.66 0
) 0
. 0

On 0
two 0
patients 0
with 0
smooth 0
prostheses 0
and 0
one 0
patient 0
with 0
a 0
textured 0
prosthesis 0
, 0
the 0
capsule 0
around 0
the 0
implant 0
hardened 0
between 0
6 0
and 0
12 0
months 0
. 0

Between 0
1 0
year 0
and 0
7.5 0
years 0
, 0
three 0
breasts 0
with 0
smooth B-OTHER
and 0
textured B-OTHER
implants I-OTHER
contracted I-OTHER
and 0
one 0
with 0
a 0
textured 0
implant 0
softened.The 0
patients 0
reported 0
on 0
a 0
Visual 0
Analogue 0
Scale 0
( 0
1 0
to 0
10 0
) 0
the 0
impact 0
of 0
the 0
augmentation 0
on 0
their 0
quality 0
of 0
life 0
to 0
be 0
9 0
+/- 0
1 0
. 0

Four 0
patients 0
preferred 0
the 0
breast 0
with 0
the 0
smooth 0
prosthesis 0
, 0
three 0
preferred 0
the 0
breast 0
with 0
the 0
textured 0
prosthesis 0
, 0
and 0
the 0
others 0
found 0
both 0
breasts 0
equal 0
. 0

This 0
study 0
showed 0
no 0
significant B-OTHER
difference I-OTHER
of 0
contracture B-PHYSICAL
with 0
smooth 0
versus 0
fine 0
textured 0
implants 0
. 0

The 0
majority 0
of 0
the 0
patients 0
preferred 0
the 0
smooth 0
implants 0
. 0

The 0
patients 0
reported 0
that 0
the 0
breast 0
augmentation 0
had 0
had 0
an 0
extremely 0
high 0
impact 0
on 0
their 0
quality 0
of 0
life 0
. 0

A 0
prospective 0
randomized 0
treatment 0
study 0
comparing 0
three 0
treatment 0
options 0
for 0
chalazia 0
: 0
triamcinolone 0
acetonide 0
injections 0
, 0
incision 0
and 0
curettage 0
and 0
treatment 0
with 0
hot 0
compresses 0
. 0

BACKGROUND 0
Three 0
methods 0
of 0
treating 0
chalazia 0
were 0
compared 0
: 0
intralesional 0
triamcinolone 0
acetonide 0
injections 0
( 0
0.2 0
mL 0
of 0
10 0
mg/mL 0
) 0
, 0
incision 0
and 0
curettage 0
and 0
advice 0
regarding 0
the 0
application 0
of 0
hot 0
compresses 0
to 0
the 0
affected 0
eyelid 0
. 0

METHODS 0
This 0
was 0
a 0
single 0
centre 0
randomized 0
treatment 0
study 0
. 0

Patients 0
with 0
a 0
chalazion 0
underwent 0
either 0
of 0
the 0
three 0
treatment 0
options 0
. 0

Chalazion B-OTHER
resolution I-OTHER
, 0
pain B-PAIN
, 0
satisfaction B-OTHER
and 0
inconvenience B-PAIN
experienced I-PAIN
because I-PAIN
of I-PAIN
treatments I-PAIN
were 0
the 0
outcomes 0
assessed 0
via 0
a 0
telephone 0
interview 0
at 0
3 0
weeks 0
. 0

RESULTS 0
136 0
consecutive 0
patients 0
were 0
enrolled 0
into 0
the 0
study 0
. 0

At 0
the 0
3-week 0
follow 0
up 0
, 0
the 0
resolution B-OTHER
rates I-OTHER
in 0
the 0
triamcinolone 0
acetonide 0
injection 0
and 0
surgical 0
treatment 0
groups 0
were 0
not 0
significantly 0
different 0
from 0
each 0
other 0
at 0
84 0
% 0
( 0
47/56 0
) 0
and 0
87 0
% 0
( 0
39/45 0
) 0
, 0
respectively 0
( 0
P 0
< 0
0.001 0
) 0
, 0
but 0
was 0
significantly 0
lower 0
in 0
the 0
conservative 0
treatment 0
group 0
at 0
46 0
% 0
( 0
16/35 0
) 0
( 0
P 0
< 0
0.001 0
) 0
. 0

Pain B-PAIN
scores I-PAIN
were 0
higher 0
in 0
the 0
surgical 0
treatment 0
group 0
compared 0
with 0
the 0
triamcinolone 0
injection 0
group 0
( 0
P 0
< 0
0.003 0
) 0
. 0

Inconvenience B-PHYSICAL
experienced I-PHYSICAL
by I-PHYSICAL
patients I-PHYSICAL
was 0
reported 0
as 0
significantly 0
less 0
in 0
the 0
triamcinolone 0
group 0
compared 0
with 0
the 0
conservative 0
and 0
surgical 0
treatment 0
groups 0
( 0
P 0
< 0
0.001 0
) 0
. 0

Patient B-OTHER
satisfaction I-OTHER
scores I-OTHER
were 0
lower 0
in 0
the 0
conservative 0
treatment 0
group 0
compared 0
with 0
each 0
of 0
the 0
other 0
two 0
groups 0
which 0
in 0
turn 0
, 0
were 0
no 0
different 0
from 0
each 0
other 0
regarding 0
this 0
outcome 0
( 0
P 0
< 0
0.001 0
) 0
. 0

CONCLUSIONS 0
To 0
our 0
knowledge 0
, 0
this 0
is 0
the 0
first 0
prospective 0
randomized 0
study 0
comparing 0
the 0
three 0
methods 0
of 0
chalazia 0
treatment 0
. 0

Results 0
suggest 0
that 0
a 0
single 0
triamcinolone 0
acetonide 0
injection 0
followed 0
by 0
lid 0
massage 0
is 0
almost 0
as 0
effective 0
as 0
incision 0
and 0
curettage 0
in 0
the 0
treatment 0
of 0
chalazia 0
and 0
with 0
similar 0
patient B-OTHER
satisfaction I-OTHER
and 0
less 0
pain B-PAIN
and 0
patient B-ADVERSE-EFFECTS
inconvenience I-ADVERSE-EFFECTS
. 0

[ 0
Clinilal 0
study 0
of 0
medical 0
ozone 0
therapy 0
in 0
chronic 0
hepatitis 0
B 0
of 0
20 0
patients 0
] 0
. 0

OBJECTIVE 0
To 0
study 0
the 0
effect 0
of 0
medical 0
ozone 0
in 0
the 0
treatment 0
of 0
chronic 0
hepatitis 0
B 0
. 0

METHODS 0
42 0
patients 0
with 0
chronic 0
hepatitis 0
B 0
were 0
divided 0
randomly 0
into 0
two 0
groups 0
. 0

22 0
patients 0
treated 0
with 0
basic 0
therapy 0
were 0
as 0
a 0
control 0
group 0
. 0

20 0
patients 0
treated 0
with 0
basic 0
therapy 0
plus 0
ozone 0
therapy 0
were 0
taken 0
as 0
a 0
treatment 0
group 0
. 0

Index 0
of 0
biochemistry B-PHYSICAL
and 0
virology B-PHYSICAL
were 0
studied 0
at 0
initial 0
and 0
post-treatment 0
8 0
weeks 0
. 0

RESULTS 0
After 0
the 0
treatment 0
, 0
liver 0
function 0
of 0
the 0
treatment 0
group 0
and 0
the 0
control 0
group 0
had 0
more 0
significant 0
improvement 0
. 0

The 0
treatment 0
group 0
complete B-OTHER
effective I-OTHER
and 0
partial B-OTHER
effective I-OTHER
were 0
10 0
% 0
and 0
35 0
% 0
difference 0
. 0

The 0
control 0
group 0
complete 0
effective 0
and 0
partial 0
effective 0
were 0
4.6 0
% 0
and 0
13.6 0
% 0
( 0
P 0
< 0
0.05 0
) 0
. 0

CONCLUSION 0
Treatment 0
of 0
medical 0
ozone 0
on 0
patients 0
with 0
chronic 0
hepatitis 0
B 0
is 0
effective 0
. 0

Late 0
patient-reported 0
toxicity 0
after 0
preoperative 0
radiotherapy 0
or 0
chemoradiotherapy 0
in 0
nonresectable 0
rectal 0
cancer 0
: 0
results 0
from 0
a 0
randomized 0
Phase 0
III 0
study 0
. 0

PURPOSE 0
Preoperative 0
chemoradiotherapy 0
( 0
CRT 0
) 0
is 0
superior 0
to 0
radiotherapy 0
( 0
RT 0
) 0
in 0
locally 0
advanced 0
rectal 0
cancer 0
, 0
but 0
the 0
survival B-MORTALITY
gain I-MORTALITY
is 0
limited 0
. 0

Late 0
toxicity B-ADVERSE-EFFECTS
is 0
, 0
therefore 0
, 0
important 0
. 0

The 0
aim 0
was 0
to 0
compare 0
late B-PHYSICAL
bowel I-PHYSICAL
, I-PHYSICAL
urinary I-PHYSICAL
, 0
and 0
sexual B-PHYSICAL
functions I-PHYSICAL
after 0
CRT 0
or 0
RT 0
. 0

METHODS 0
AND 0
MATERIALS 0
Patients 0
( 0
N 0
= 0
207 0
) 0
with 0
nonresectable 0
rectal 0
cancer 0
were 0
randomized 0
to 0
preoperative 0
CRT 0
or 0
RT 0
( 0
2 0
Gy 0
? 0

25 0
? 0

5-fluorouracil/leucovorin 0
) 0
. 0

Extended 0
surgery 0
was 0
often 0
required 0
. 0

Self-reported 0
late 0
toxicity 0
was 0
scored 0
according 0
to 0
the 0
LENT 0
SOMA 0
criteria 0
in 0
a 0
structured 0
telephone 0
interview 0
and 0
with 0
questionnaires 0
European 0
Organisation 0
for 0
Research 0
and 0
Treatment 0
of 0
Cancer 0
( 0
EORTC 0
) 0
Quality 0
of 0
Life 0
Questionnaire 0
( 0
QLQ-C30 0
) 0
, 0
International 0
Index 0
of 0
Erectile 0
Function 0
( 0
IIEF 0
) 0
, 0
and 0
sexual 0
function-vaginal 0
changes 0
questionnaire 0
( 0
SVQ 0
) 0
. 0

RESULTS 0
Of 0
the 0
105 0
patients 0
alive 0
in 0
Norway 0
and 0
Sweden 0
after 0
4 0
to 0
12 0
years 0
of 0
follow-up 0
, 0
78 0
( 0
74 0
% 0
) 0
responded 0
. 0

More 0
patients 0
in 0
the 0
CRT 0
group 0
had 0
received 0
a 0
stoma 0
( 0
73 0
% 0
vs. 0
52 0
% 0
, 0
p 0
= 0
0.09 0
) 0
. 0

Most 0
patients 0
without 0
a 0
stoma 0
( 0
7 0
of 0
12 0
in 0
CRT 0
group 0
and 0
9 0
of 0
16 0
in 0
RT 0
group 0
) 0
had 0
incontinence 0
for 0
liquid 0
stools 0
or 0
gas 0
. 0

No 0
stoma 0
and 0
good 0
anal 0
function 0
were 0
seen 0
in 0
5 0
patients 0
( 0
11 0
% 0
) 0
in 0
the 0
CRT 0
group 0
and 0
in 0
11 0
( 0
30 0
% 0
) 0
in 0
the 0
RT 0
group 0
( 0
p 0
= 0
0.046 0
) 0
. 0

Of 0
44 0
patients 0
in 0
the 0
CRT 0
group 0
, 0
12 0
( 0
28 0
% 0
) 0
had 0
had 0
bowel 0
obstruction 0
compared 0
with 0
5 0
of 0
33 0
( 0
15 0
% 0
) 0
in 0
the 0
RT 0
group 0
( 0
p 0
= 0
0.27 0
) 0
. 0

One-quarter 0
of 0
the 0
patients 0
reported 0
urinary 0
incontinence 0
. 0

The 0
majority 0
of 0
men 0
had 0
severe 0
erectile 0
dysfunction 0
. 0

Few 0
women 0
reported 0
sexual 0
activity 0
during 0
the 0
previous 0
month 0
. 0

However 0
, 0
the 0
majority 0
did 0
not 0
have 0
concerns 0
about 0
their 0
sex 0
life 0
. 0

CONCLUSIONS 0
Fecal 0
incontinence 0
and 0
erectile 0
dysfunction 0
are 0
frequent 0
after 0
combined 0
treatment 0
for 0
locally 0
advanced 0
rectal 0
cancer 0
. 0

There 0
was 0
a 0
clear 0
tendency 0
for 0
the 0
problems 0
to 0
be 0
more 0
common 0
after 0
CRT 0
than 0
after 0
RT 0
. 0

Combined 0
delivery 0
approach 0
of 0
bone 0
marrow 0
mononuclear 0
stem 0
cells 0
early 0
and 0
late 0
after 0
myocardial 0
infarction 0
: 0
the 0
MYSTAR 0
prospective 0
, 0
randomized 0
study 0
. 0

BACKGROUND 0
Combined 0
intracoronary 0
and 0
intramyocardial 0
administration 0
might 0
improve 0
outcomes 0
for 0
bone-marrow-derived 0
stem 0
cell 0
therapy 0
for 0
acute 0
myocardial 0
infarction 0
( 0
AMI 0
) 0
. 0

We 0
compared 0
the 0
safety B-OTHER
and 0
feasibility B-OTHER
of 0
early 0
and 0
late 0
delivery 0
of 0
stem 0
cells 0
with 0
combined 0
therapy 0
approaches 0
. 0

METHODS 0
Patients 0
with 0
left 0
ventricular 0
ejection 0
fraction 0
less 0
than 0
45 0
% 0
after 0
AMI 0
were 0
randomly 0
assigned 0
stem 0
cell 0
delivery 0
via 0
intramyocardial 0
injection 0
and 0
intracoronary 0
infusion 0
3-6 0
weeks 0
or 0
3-4 0
months 0
after 0
AMI 0
. 0

Primary 0
end 0
points 0
were 0
changes 0
in 0
infarct B-PHYSICAL
size I-PHYSICAL
and 0
left B-PHYSICAL
ventricular I-PHYSICAL
ejection I-PHYSICAL
fraction I-PHYSICAL
3 I-PHYSICAL
months I-PHYSICAL
after I-PHYSICAL
therapy I-PHYSICAL
. 0

RESULTS 0
A 0
total 0
of 0
60 0
patients 0
were 0
treated 0
. 0

The 0
mean 0
changes 0
in 0
infarct B-PHYSICAL
size 0
at B-PHYSICAL
3 I-PHYSICAL
months B-PHYSICAL
were 0
-3.5 0
+/- 0
5.1 0
% 0
( 0
95 0
% 0
CI 0
-5.5 0
% 0
to 0
-1.5 0
% 0
, 0
P 0
= 0
0.001 0
) 0
in 0
the 0
early 0
group 0
and 0
-3.9 0
+/- 0
5.6 0
% 0
( 0
95 0
% 0
CI 0
-6.1 0
% 0
to 0
-1.6 0
% 0
, 0
P 0
= 0
0.002 0
) 0
in 0
the 0
late 0
group 0
, 0
and 0
changes 0
in 0
ejection B-PHYSICAL
fraction I-PHYSICAL
were 0
3.5 0
+/- 0
5.6 0
% 0
( 0
95 0
% 0
CI 0
1.3-5.6 0
% 0
, 0
P 0
= 0
0.003 0
) 0
and 0
3.4 0
+/- 0
7.0 0
% 0
( 0
95 0
% 0
CI 0
0.7-6.1 0
% 0
, 0
P 0
= 0
0.017 0
) 0
, 0
respectively 0
. 0

At 0
9-12 0
months 0
after 0
AMI 0
, 0
ejection B-PHYSICAL
fraction I-PHYSICAL
remained 0
significantly 0
higher 0
than 0
at 0
baseline 0
in 0
both 0
groups 0
. 0

In 0
the 0
early 0
and 0
late 0
groups 0
, 0
a 0
mean 0
of 0
200.3 0
+/- 0
68.7 0
x 0
10 0
( 0
6 0
) 0
and 0
194.8 0
+/- 0
60.4 0
x 0
10 0
( 0
6 0
) 0
stem B-PHYSICAL
cells I-PHYSICAL
, 0
respectively 0
, 0
were 0
delivered 0
to 0
the 0
myocardium 0
, 0
and 0
1.30 0
+/- 0
0.68 0
x 0
10 0
( 0
9 0
) 0
and 0
1.29 0
+/- 0
0.41 0
x 0
10 0
( 0
9 0
) 0
cells 0
, 0
respectively 0
, 0
were 0
delivered 0
into 0
the 0
artery 0
. 0

A 0
high 0
number B-PHYSICAL
of I-PHYSICAL
cells I-PHYSICAL
was 0
required 0
for 0
significant 0
improvements 0
in 0
the 0
primary 0
end 0
points 0
. 0

CONCLUSIONS 0
Combined 0
cardiac 0
stem 0
cell 0
delivery 0
induces 0
a 0
moderate 0
but 0
significant 0
improvement 0
in 0
myocardial B-PHYSICAL
infarct I-PHYSICAL
size I-PHYSICAL
and 0

The 0
Low 0
Energy 0
Safety 0
Study 0
( 0
LESS 0
) 0
: 0
rationale 0
, 0
design 0
, 0
patient 0
characteristics 0
, 0
and 0
device 0
utilization 0
. 0

BACKGROUND 0
A 0
10-J 0
energy 0
safety 0
margin 0
has 0
traditionally 0
been 0
used 0
in 0
programming 0
implantable 0
cardioverter 0
defibrillators 0
( 0
ICDs 0
) 0
. 0

The 0
Low 0
Energy 0
Safety 0
Study 0
( 0
LESS 0
) 0
tests 0
the 0
hypothesis 0
that 0
programming 0
shocks 0
to 0
lower 0
energy 0
margins 0
is 0
safe 0
and 0
effective 0
. 0

METHODS 0
Patients 0
with 0
standard 0
ICD 0
indications 0
undergo 0
defibrillation 0
threshold 0
testing 0
( 0
DFT 0
) 0
at 0
the 0
time 0
of 0
ICD 0
implant 0
, 0
with 0
reconfirmation 0
of 0
lowest 0
successful 0
energy 0
twice 0
( 0
DFT++ 0
) 0
. 0

Patients 0
are 0
randomized 0
to 0
2 0
groups 0
: 0
the 0
first 0
has 0
the 0
initial 0
2 0
shocks 0
for 0
ventricular 0
fibrillation 0
conversion 0
programmed 0
at 0
2 0
energy 0
steps 0
above 0
DFT++ 0
( 0
typically 0
4-6 0
J 0
, 0
maximum 0
10 0
J 0
) 0
with 0
subsequent 0
shocks 0
at 0
maximum 0
energy 0
, 0
and 0
the 0
second 0
has 0
all 0
shocks 0
programmed 0
at 0
maximum 0
energy 0
. 0

Patients 0
are 0
followed 0
up 0
every 0
3 0
months 0
for 0
2 0
years 0
to 0
assess 0
shock B-PHYSICAL
conversion I-PHYSICAL
efficacy 0
of B-PHYSICAL
spontaneous I-PHYSICAL
arrhythmias B-PHYSICAL
. 0

In 0
a 0
subgroup 0
of 0
patients 0
, 0
there 0
is 0
a 0
second 0
randomization 0
to 0
energy 0
levels 0
of 0
0 0
, 0
1 0
, 0
2 0
, 0
3 0
, 0
or 0
4 0
steps 0
above 0
implant 0
DFT++ 0
for 0
conversion 0
testing 0
of 0
3 0
induced 0
ventricular 0
fibrillation 0
episodes 0
at 0
prehospital 0
discharge 0
, 0
3 0
months 0
, 0
and 0
12 0
months 0
after 0
implant 0
. 0

RESULTS 0
Enrollment 0
is 0
complete 0
( 0
702 0
patients 0
) 0
, 0
but 0
follow-up 0
results 0
are 0
pending 0
. 0

There 0
were 0
no 0
significant 0
variations 0
in 0
implant B-PHYSICAL
indications I-PHYSICAL
and 0
baseline 0
antiarrhythmic B-PHYSICAL
drug I-PHYSICAL
use I-PHYSICAL
over 0
the 0
3-year 0
enrollment 0
period 0
, 0
although 0
an 0
increase 0
in 0
the 0
percentage 0
of 0
dual-chamber B-PHYSICAL
ICDs I-PHYSICAL
implanted I-PHYSICAL
occurred 0
, 0
with 0
the 0
majority 0
( 0
65 0
% 0
) 0
of 0
implanted 0
ICDs 0
being 0
dual-chamber 0
devices 0
by 0
the 0
end 0
of 0
the 0
enrollment 0
period 0
. 0

CONCLUSION 0
The 0
results 0
of 0
LESS 0
should 0
facilitate 0
the 0
development 0
of 0
algorithms 0
for 0
programming 0
ICD 0

Using 0
dietetic 0
assistants 0
to 0
improve 0
the 0
outcome 0
of 0
hip 0
fracture 0
: 0
a 0
randomised 0
controlled 0
trial 0
of 0
nutritional 0
support 0
in 0
an 0
acute 0
trauma 0
ward 0
. 0

OBJECTIVE 0
To 0
examine 0
how 0
improved 0
attention 0
to 0
nutritional B-PHYSICAL
status I-PHYSICAL
and 0
dietary B-MENTAL
intake I-MENTAL
, 0
achieved 0
through 0
the 0
employment 0
of 0
dietetic 0
assistants 0
( 0
DAs 0
) 0
, 0
will 0
affect 0
postoperative B-OTHER
clinical I-OTHER
outcome I-OTHER
among 0
elderly 0
women 0
with 0
hip 0
fracture 0
. 0

DESIGN 0
Open 0
prospective 0
randomised 0
controlled 0
trial 0
, 0
comparing 0
conventional 0
nursing 0
care 0
with 0
the 0
additional 0
nutritional 0
support 0
provided 0
by 0
DA 0
. 0

SETTING 0
Thirty-eight 0
bedded 0
acute 0
trauma 0
ward 0
in 0
a 0
teaching 0
hospital 0
. 0

PARTICIPANTS 0
All 0
but 0
11 0
of 0
344 0
consecutive 0
admissions 0
with 0
acute 0
nonpathological 0
hip 0
fracture 0
were 0
approached 0
. 0

Three 0
hundred 0
and 0
eighteen 0
( 0
93 0
% 0
) 0
agreed 0
to 0
inclusion 0
. 0

Sixteen 0
were 0
ineligible 0
as 0
they 0
were 0
immediately 0
transferred 0
to 0
another 0
acute 0
ward 0
, 0
were 0
managed 0
conservatively 0
or 0
died 0
preoperatively 0
. 0

PRIMARY 0
OUTCOME 0
MEASURE 0
Postoperative B-MORTALITY
mortality I-MORTALITY
in 0
the 0
acute 0
trauma 0
unit 0
. 0

SECONDARY 0
OUTCOME 0
MEASURES 0
Postoperative B-MORTALITY
mortality I-MORTALITY
at I-MORTALITY
4 I-MORTALITY
months I-MORTALITY
after I-MORTALITY
fracture I-MORTALITY
, 0
length B-OTHER
of I-OTHER
stay I-OTHER
, 0
energy B-MENTAL
intake I-MENTAL
and 0
nutritional B-PHYSICAL
status I-PHYSICAL
. 0

RESULTS 0
DA-supported 0
participants 0
were 0
less 0
likely B-MORTALITY
to I-MORTALITY
die I-MORTALITY
in 0
the 0
acute 0
ward 0
( 0
4.1 0
versus 0
10.1 0
% 0
, 0
P 0
= 0
0.048 0
) 0
. 0

This 0
effect 0
was 0
still 0
apparent 0
at 0
4 0
month 0
follow-up 0
( 0
13.1 0
versus 0
22.9 0
% 0
, 0
P 0
= 0
0.036 0
) 0
. 0

DA-supported 0
subjects 0
had 0
significantly 0
better 0
mean 0
daily B-MENTAL
energy I-MENTAL
intake I-MENTAL
( 0
1,105 0
kcal 0
versus 0
756 0
kcal/24 0
h 0
, 0
95 0
% 0
CI 0
259-440 0
kcal/24 0
h 0
, 0
P 0
< 0
0.001 0
) 0
, 0
significantly 0
smaller 0
reduction 0
in 0
mid-arm 0
circumference 0
during 0
their 0
inpatient 0
stay 0
( 0
0.39 0
cm 0
, 0
P 0
= 0
0.002 0
) 0
and 0
nonsignificantly 0
favourable 0
results 0
for 0
other 0
anthropometric B-OTHER
and 0
laboratory B-OTHER
measurements I-OTHER
. 0

CONCLUSION 0
Dietetic 0
or 0
nutrition 0
assistants 0
are 0
being 0
introduced 0
in 0
units 0
across 0
the 0
UK 0
. 0

This 0
, 0
the 0
largest 0
ever 0
study 0
of 0
nutritional 0
support 0
after 0
hip 0
fracture 0
, 0
shows 0
that 0
their 0
employment 0
significantly 0
reduced 0
patients B-MORTALITY
' 0
risk 0

Zinc B-PHYSICAL
and 0
copper B-PHYSICAL
balances I-PHYSICAL
in 0
preterm 0
infants 0
. 0

Preterm 0
infants 0
are 0
at 0
risk 0
for 0
copper 0
and 0
zinc 0
depletion 0
if 0
sufficient 0
quantities 0
of 0
these 0
nutrients 0
are 0
not 0
provided 0
in 0
a 0
bioavailable 0
form 0
in 0
postnatal 0
life 0
. 0

The 0
purpose 0
of 0
this 0
study 0
was 0
to 0
determine 0
whether 0
the 0
use 0
of 0
a 0
whey-predominant 0
, 0
50 0
% 0
medium 0
chain 0
triglyceride 0
formula 0
with 0
relatively 0
high 0
concentrations 0
of 0
zinc 0
and 0
copper 0
would 0
promote 0
the 0
achievement 0
of 0
the 0
in 0
utero B-PHYSICAL
accretion I-PHYSICAL
rate I-PHYSICAL
for I-PHYSICAL
zinc I-PHYSICAL
and I-PHYSICAL
copper I-PHYSICAL
in 0
the 0
preterm 0
infant 0
. 0

Two 0
groups 0
of 0
five 0
preterm 0
infants 0
were 0
fed 0
a 0
diet 0
containing 0
12.5 0
mg/L 0
of 0
zinc 0
and 0
either 0
0.9 0
mg/L 0
or 0
2.1 0
mg/L 0
of 0
copper 0
. 0

Seventy-two-hour 0
metabolic 0
balance 0
studies 0
were 0
performed 0
at 0
an 0
average 0
postconceptual 0
age 0
of 0
34 0
weeks 0
and 0
an 0
average 0
weight 0
of 0
1,549 0
g. 0
All 0
infants 0
were 0
in 0
positive 0
zinc B-PHYSICAL
balance I-PHYSICAL
and 0
nine 0
of 0
ten 0
achieved 0
the 0
in 0
utero B-PHYSICAL
accretion I-PHYSICAL
rate I-PHYSICAL
for I-PHYSICAL
zinc I-PHYSICAL
for 0
a 0
34-week 0
gestation 0
fetus 0
( 0
greater 0
than 0
or 0
equal 0
to 0
0.432 0
mg/d 0
) 0
. 0

Three 0
infants 0
receiving 0
the 0
high 0
copper 0
formula 0
and 0
two 0
receiving 0
the 0
lower 0
copper 0
formula 0
were 0
in 0
positive 0
copper B-PHYSICAL
balance I-PHYSICAL
. 0

Two 0
infants 0
from 0
each 0
group 0
achieved 0
the 0
in 0
utero B-PHYSICAL
accretion I-PHYSICAL
rate I-PHYSICAL
for I-PHYSICAL
copper I-PHYSICAL
for 0
a 0
34-week 0
gestation 0
fetus 0
( 0
0.088 0
mg/d 0
) 0
. 0

A 0
formula 0
that 0
provides 0
12.5 0
mg/L 0
of 0
zinc 0
permits 0
positive 0
zinc B-PHYSICAL
balance I-PHYSICAL
and 0
zinc B-PHYSICAL
retention I-PHYSICAL
similar 0
to 0
in 0
utero 0
rates 0
. 0

A 0
formula 0
that 0
provides 0
as 0
much 0
as 0
2.1 0
mg/L 0
of 0
copper 0
, 0
however 0
, 0
may 0
not 0
always 0
permit 0
positive 0
copper B-PHYSICAL
balance I-PHYSICAL
. 0

Oxidative 0
DNA 0
damage 0
measured 0
in 0
human 0
lymphocytes 0
: 0
large 0
differences 0
between 0
sexes 0
and 0
between 0
countries 0
, 0
and 0
correlations 0
with 0
heart 0
disease 0
mortality 0
rates 0
. 0

The 0
'antioxidant 0
hypothesis 0
' 0
proposes 0
that 0
vitamin 0
C 0
, 0
vitamin 0
E 0
, 0
carotenoids 0
, 0
and 0
other 0
antioxidants 0
occurring 0
in 0
fruit 0
and 0
vegetables 0
afford 0
protection 0
against 0
heart 0
disease 0
and 0
cancer 0
by 0
preventing 0
oxidative 0
damage 0
to 0
lipids 0
and 0
to 0
DNA 0
, 0
respectively 0
. 0

To 0
test 0
elements 0
of 0
this 0
hypothesis 0
, 0
we 0
have 0
measured 0
blood 0
levels 0
of 0
dietary 0
antioxidants 0
, 0
and 0
8-oxodeoxyguanosine 0
( 0
8-oxo-dG 0
) 0
concentrations 0
in 0
lymphocyte 0
DNA 0
, 0
in 0
healthy 0
men 0
and 0
women 0
from 0
five 0
European 0
countries 0
: 0
France 0
, 0
Ireland 0
, 0
The 0
Netherlands 0
, 0
Spain 0
, 0
and 0
the 0
U.K 0
. 0

Volunteers 0
, 0
aged 0
25 0
45 0
, 0
all 0
nonsmokers 0
, 0
gave 0
blood 0
samples 0
before 0
and 0
after 0
a 0
12-wk 0
carotenoid 0
supplementation 0
regime 0
. 0

Vitamin 0
C 0
was 0
measured 0
in 0
plasma 0
and 0
vitamin 0
E 0
and 0
carotenoids 0
were 0
measured 0
in 0
serum 0
by 0
high-performance 0
liquid 0
chromatography 0
( 0
HPLC 0
) 0
. 0

8-oxo-dG 0
was 0
assayed 0
by 0
HPLC 0
( 0
with 0
coulometric 0
detection 0
) 0
in 0
DNA 0
isolated 0
from 0
lymphocytes 0
from 0
the 0
same 0
blood 0
samples 0
. 0

Mean 0
values 0
were 0
calculated 0
for 0
groups 0
of 0
volunteers 0
at 0
each 0
sampling 0
time 0
according 0
to 0
country 0
, 0
sex 0
, 0
and 0
supplementation 0
( 0
between 0
9 0
and 0
24 0
individual 0
samples 0
contributing 0
to 0
each 0
mean 0
) 0
. 0

We 0
found 0
that 0
8-oxo-dG 0
levels 0
in 0
lymphocyte 0
DNA 0
vary 0
significantly 0
according 0
to 0
sex 0
and 0
country 0
. 0

A 0
low 0
mean 0
8-oxo-dG B-PHYSICAL
concentration I-PHYSICAL
is 0
seen 0
in 0
DNA 0
of 0
women 0
from 0
all 0
five 0
countries 0
, 0
and 0
of 0
men 0
from 0
France 0
and 0
Spain 0
. 0

8-oxo-dG B-PHYSICAL
is 0
significantly 0
higher 0
( 0
up 0
to 0
about 0
threefold 0
) 0
in 0
lymphocyte 0
DNA 0
from 0
men 0
in 0
Ireland 0
and 0
the 0
U.K. 0
Oxidative B-PHYSICAL
DNA I-PHYSICAL
damage I-PHYSICAL
is 0
not 0
significantly 0
affected 0
by 0
carotenoid 0
supplementation 0
; 0
nor 0
is 0
there 0
any 0
association 0
with 0
mean 0
baseline 0
levels B-PHYSICAL
of I-PHYSICAL
antioxidants I-PHYSICAL
, 0
which 0
are 0
generally 0
similar 0
in 0
the 0
five 0
countries 0
. 0

The 0
five 0
countries 0
sampled 0
lie 0
on 0
an 0
axis 0
from 0
northern 0
to 0
southern 0
Europe 0
with 0
a 0
steep 0
gradient 0
in 0
terms 0
of 0
premature 0
heart 0
disease 0
. 0

There 0
is 0
a 0
strong 0
association 0
between 0
premature B-MORTALITY
coronary I-MORTALITY
heart I-MORTALITY
disease I-MORTALITY
mortality I-MORTALITY
in 0
men 0
and 0
the 0
mean 0
levels 0
of 0
8-oxo-dG 0
for 0
the 0
five 0
countries 0
( 0
r 0
= 0
0.95 0
, 0
P 0
< 0
0.01 0
) 0
. 0

Women 0
have 0
low 0
coronary B-MORTALITY
heart I-MORTALITY
disease I-MORTALITY
mortality I-MORTALITY
rates I-MORTALITY
, 0
which 0
do 0
not 0
correlate 0
with 0
8-oxo-dG 0
. 0

In 0
terms 0
of 0
cancer 0
deaths 0
, 0
only 0
colorectal 0
cancer 0
in 0
men 0
shows 0
a 0
significant B-OTHER
positive 0
correlation B-OTHER
( 0
r 0
= 0
0.91 0
, 0
P 0
< 0
0.05 0
) 0
, 0
and 0

[ 0
Local 0
application 0
of 0
anti-cancer 0
drugs 0
for 0
the 0
treatment 0
of 0
malignant 0
pleural 0
and 0
pericardial 0
effusion 0
] 0
. 0

Pleural 0
effusion 0
is 0
a 0
common 0
complication 0
in 0
patients 0
with 0
malignant 0
neoplasm 0
. 0

A 0
randomized 0
controlled 0
study 0
of 0
intrapleural 0
instillation 0
of 0
Adriamycin 0
( 0
control 0
group 0
, 0
30 0
patients 0
) 0
and 0
Adriamycin 0
Nocardia 0
rubra 0
cell 0
wall 0
skeleton 0
( 0
N-CWS 0
group 0
, 0
26 0
patients 0
) 0
with 0
tube 0
thoracostomy 0
was 0
performed 0
in 0
55 0
patients 0
with 0
malignant 0
pleural 0
effusion 0
due 0
to 0
primary 0
lung 0
cancer 0
. 0

The 0
response 0
rates 0
for 0
control 0
of 0
pleural B-PHYSICAL
effusion I-PHYSICAL
were 0
73.4 0
% 0
in 0
the 0
N-CWS 0
group 0
and 0
46.1 0
% 0
in 0
the 0
N-CWS 0
group 0
. 0

These 0
results 0
suggest 0
that 0
intrapleural 0
instillation 0
using 0
a 0
combination 0
of 0
anti-cancer 0
agent 0
and 0
immunopotentiator 0
is 0
an 0
effective 0
treatment 0
for 0
malignant 0
pleurisy 0
. 0

Cardiac 0
tamponade 0
secondary 0
to 0
cancer 0
is 0
a 0
life-threatening 0
complication 0
requiring 0
immediate 0
treatment 0
. 0

Twenty-four 0
patients 0
with 0
malignant 0
pericardial 0
effusion 0
were 0
treated 0
by 0
intrapericardial 0
instillation 0
of 0
anti-cancer 0
drugs 0
, 0
such 0
as 0
Carbazilquinone 0
, 0
Mitomycin-C 0
or 0
ACNU 0
, 0
with 0
pericardial 0
drainage 0
. 0

The 0
range 0
of 0
survival B-MORTALITY
time I-MORTALITY
from 0
the 0
instillation 0
of 0
anti-cancer 0
drug 0
was 0
3-365 0
days 0
( 0
average 0
days 0
) 0
. 0

In 0
only 0
4 0
patients 0
, 0
reaccumulation 0
of 0
pericardial B-PHYSICAL
effusion I-PHYSICAL
was 0
recognized 0
. 0

There 0
were 0
no 0
serious 0
complications 0
with 0
this 0
procedure 0
. 0

It 0
was 0
considered 0
that 0
local 0
instillation 0
of 0
anti-cancer 0
agents 0
with 0
pericardial 0
drainage 0
was 0
a 0
useful 0
therapeutic 0
modality 0
for 0
malignant 0
pericarditis 0
. 0

Pregabalin 0
versus 0
naltrexone 0
in 0
alcohol 0
dependence 0
: 0
a 0
randomised 0
, 0
double-blind 0
, 0
comparison 0
trial 0
. 0

Pregabalin 0
( 0
PRE 0
) 0
acts 0
as 0
a 0
presynaptic 0
inhibitor 0
of 0
the 0
release 0
of 0
excessive 0
levels 0
of 0
excitatory 0
neurotransmitters 0
by 0
selectively 0
binding 0
to 0
the 0
alpha 0
( 0
2 0
) 0
-delta 0
subunit 0
of 0
voltage-gated 0
calcium 0
channels 0
. 0

In 0
this 0
randomised 0
, 0
double-blind 0
comparison 0
trial 0
with 0
naltrexone 0
( 0
NAL 0
) 0
, 0
we 0
aimed 0
to 0
investigate 0
the 0
efficacy 0
of 0
PRE 0
on 0
alcohol B-MENTAL
drinking I-MENTAL
indices I-MENTAL
. 0

Craving B-MENTAL
reduction I-MENTAL
and 0
improvement 0
of 0
psychiatric B-MENTAL
symptoms I-MENTAL
were 0
the 0
secondary 0
endpoints 0
. 0

Seventy-one 0
alcohol-dependent 0
subjects 0
were 0
detoxified 0
and 0
subsequently 0
randomised 0
into 0
two 0
groups 0
, 0
receiving 0
50 0
mg 0
of 0
NAL 0
or 0
150-450 0
mg 0
of 0
PRE 0
. 0

Craving B-MENTAL
( I-MENTAL
VAS 0
; 0
OCDS B-MENTAL
) I-MENTAL
, 0
withdrawal B-OTHER
( B-OTHER
CIWA-Ar I-OTHER
) I-OTHER
and 0
psychiatric B-MENTAL
symptoms I-MENTAL
( B-MENTAL
SCL-90-R I-MENTAL
) I-MENTAL
rating B-MENTAL
scales 0
were 0
applied 0
. 0

Alcohol B-MENTAL
drinking B-MENTAL
indices B-MENTAL
and 0
craving B-MENTAL
scores I-MENTAL
were 0
not 0
significantly 0
different 0
between 0
groups 0
. 0

Compared 0
with 0
NAL 0
, 0
PRE 0
resulted 0
in 0
greater 0
improvement 0
of 0
specific 0
symptoms 0
in 0
the 0
areas 0
of 0
anxiety B-MENTAL
, 0

Ceftriaxone 0
versus 0
ampicillin 0
and 0
chloramphenicol 0
for 0
treatment 0
of 0
bacterial B-PHYSICAL
meningitis I-PHYSICAL
in 0
children 0
. 0

78 0
patients 0
with 0
bacterial 0
meningitis 0
were 0
evaluated 0
in 0
a 0
prospective 0
, 0
randomised 0
study 0
comparing 0
twice-daily 0
ceftriaxone 0
as 0
single-drug 0
therapy 0
with 0
ampicillin 0
and 0
chloramphenicol 0
given 0
every 0
6 0
h. 0
The 0
groups 0
were 0
comparable 0
in 0
age 0
, 0
sex 0
, 0
days 0
of 0
illness 0
before 0
admission 0
, 0
and 0
bacterial 0
colony 0
counts 0
in 0
cerebrospinal 0
fluid 0
( 0
CSF 0
) 0
. 0

The 0
pathogens 0
were 0
Haemophilus 0
influenzae 0
type 0
b 0
( 0
54 0
cases 0
) 0
, 0
streptococci 0
( 0
9 0
cases 0
) 0
, 0
meningococci 0
( 0
9 0
cases 0
) 0
, 0
and 0
unknown 0
( 0
6 0
cases 0
) 0
. 0

In 0
40 0
CSF 0
specimens 0
obtained 0
4-12 0
h 0
after 0
initiation 0
of 0
therapy 0
, 0
cultures B-OTHER
were I-OTHER
negative 0
in 0
57 0
% 0
of 0
the 0
ceftriaxone 0
patients 0
and 0
in 0
42 0
% 0
of 0
the 0
others 0
. 0

The 0
mean 0
falls B-OTHER
in I-OTHER
the I-OTHER
CSF I-OTHER
bacterial I-OTHER
colony I-OTHER
counts I-OTHER
were 0
4.7 0
and 0
5.0 0
log10 0
colony-forming 0
units/ml 0
, 0
respectively 0
. 0

Mean 0
bactericidal B-PHYSICAL
activity I-PHYSICAL
in I-PHYSICAL
CSF I-PHYSICAL
was 0
significantly 0
greater 0
in 0
the 0
ceftriaxone 0
than 0
in 0
the 0
conventional 0
treatment 0
group 0
at 0
the 0
beginning 0
and 0
end 0
of 0
therapy 0
. 0

There 0
were 0
no 0
significant 0
differences 0
in 0
clinical B-PHYSICAL
responses I-PHYSICAL
or 0
in 0
frequency 0
of 0
complications B-ADVERSE-EFFECTS
, 0
except 0
for 0
mild B-PHYSICAL
diarrhoea I-PHYSICAL
, 0
which 0
occurred 0
in 0
16 0
ceftriaxone 0
patients 0
and 0
in 0
8 0
in 0
the 0
other 0
group 0
( 0
p 0
less 0
than 0
0.05 0
) 0
. 0

Efficacy 0
of 0
dose-intensified 0
MEC 0
( 0
methotrexate 0
, 0
epirubicin 0
and 0
cisplatin 0
) 0
chemotherapy 0
for 0
advanced 0
urothelial 0
carcinoma 0
: 0
a 0
prospective 0
randomized 0
trial 0
comparing 0
MEC 0
and 0
M-VAC 0
( 0
methotrexate 0
, 0
vinblastine 0
, 0
doxorubicin 0
and 0
cisplatin 0
) 0
. 0

Japanese 0
Urothelial 0
Cancer 0
Research 0
Group 0
. 0

BACKGROUND 0
To 0
evaluate 0
the 0
antitumor B-OTHER
activity I-OTHER
in 0
patients 0
with 0
T3b 0
, 0
T4 0
or 0
metastatic 0
urothelial 0
carcinoma 0
treated 0
with 0
MEC 0
or 0
M-VAC 0
chemotherapy 0
, 0
by 0
performing 0
a 0
multi-center 0
randomized 0
prospective 0
study 0
. 0

METHODS 0
From 0
1991 0
to 0
1995 0
, 0
89 0
patients 0
with 0
T3b 0
, 0
T4 0
or 0
metastatic 0
urothelial 0
carcinoma 0
were 0
randomly 0
allocated 0
to 0
a 0
methotrexate 0
, 0
epirubicin 0
and 0
cisplatin 0
chemotherapy 0
group 0
( 0
arm 0
1 0
: 0
S-MEC 0
therapy 0
; 0
n 0
= 0
29 0
) 0
, 0
a 0
dose-intensified 0
MEC 0
therapy 0
combined 0
with 0
G-CSF 0
group 0
( 0
arm 0
2 0
: 0
I-MEC 0
therapy 0
; 0
n 0
= 0
30 0
) 0
or 0
a 0
methotrexate 0
, 0
vinblastine 0
, 0
doxorubicin 0
and 0
cisplatin 0
chemotherapy 0
( 0
arm 0
3 0
: 0
M-VAC 0
therapy 0
; 0
n 0
= 0
30 0
) 0
. 0

At 0
the 0
registration 0
center 0
, 0
the 0
patients 0
were 0
stratified 0
into 0
previously 0
untreated 0
patients 0
and 0
patients 0
with 0
recurrence 0
after 0
radical 0
operation 0
and 0
then 0
randomly 0
allocated 0
to 0
the 0
treatment 0
groups 0
. 0

In 0
each 0
arm 0
, 0
two 0
or 0
more 0
courses 0
of 0
chemotherapy 0
( 0
4-week 0
cycles 0
) 0
were 0
performed 0
. 0

RESULTS 0
Of 0
the 0
88 0
eligible 0
patients 0
, 0
four 0
treated 0
with 0
S-MEC 0
therapy 0
and 0
two 0
treated 0
with 0
I-MEC 0
therapy 0
showed 0
CR 0
. 0

The 0
response 0
rates B-OTHER
( 0
CR 0
+ 0
PR 0
) 0
were 0
52 0
% 0
( 0
15/29 0
) 0
with 0
S-MEC 0
therapy 0
, 0
76 0
% 0
( 0
22/29 0
) 0
with 0
I-MEC 0
therapy 0
and 0
47 0
% 0
( 0
14/30 0
) 0
with 0
M-VAC 0
therapy 0
. 0

The 0
response 0
rate 0
with 0
I-MEC B-OTHER
therapy I-OTHER
was 0
significantly 0
higher 0
than 0
that 0
with 0
M-VAC 0
therapy 0
( 0
P 0
= 0
0.02 0
) 0
. 0

Although 0
the 0
incidence 0
of 0
leukopenia 0
was 0
low 0
with 0
I-MEC B-OTHER
therapy I-OTHER
, 0
the 0
incidence 0
of 0
thrombocytopenia B-PHYSICAL
was 0
high 0
with 0
this 0
therapy 0
. 0

CONCLUSION 0
MEC 0
therapy 0
used 0
in 0
this 0
study 0
is 0
promising 0
in 0
terms 0
of 0
the 0
antitumor B-OTHER
effects I-OTHER
. 0

Budesonide 0
and 0
beclomethasone 0
dipropionate 0
in 0
hay 0
fever 0
- 0
a 0
single 0
blind 0
comparison 0
. 0

93 0
patients 0
with 0
seasonal 0
allergic 0
rhinitis 0
took 0
part 0
in 0
a 0
single 0
blind 0
randomized 0
clinical 0
comparison 0
of 0
budesonide 0
and 0
beclomethasone 0
dipropionate 0
( 0
Becotide 0
Nasal 0
) 0
. 0

All 0
patients 0
were 0
sensitive 0
to 0
either 0
birch 0
or 0
grass 0
pollen 0
, 0
their 0
sensitivity 0
being 0
confirmed 0
by 0
a 0
skin 0
prick 0
test 0
. 0

The 0
total 0
daily 0
dose 0
was 0
400 0
micrograms 0
for 0
both 0
drugs 0
. 0

Budesonide 0
was 0
administered 0
twice 0
a 0
day 0
and 0
Becotide 0
Nasal 0
four 0
times 0
a 0
day 0
. 0

Symptoms 0
were 0
assessed 0
over 0
a 0
four-week 0
period 0
starting 0
with 0
a 0
run-in 0
period 0
of 0
one 0
week 0
. 0

There 0
was 0
no 0
placebo 0
control 0
group 0
. 0

Daily B-PHYSICAL
pollen I-PHYSICAL
counts I-PHYSICAL
were 0
measured 0
throughout 0
the 0
trial 0
. 0

The 0
patients 0
' 0
diary 0
cards 0
revealed 0
that 0
both 0
drugs 0
had 0
a 0
beneficial 0
therapeutic 0
effect 0
, 0
and 0
that 0
budesonide 0
was 0
significantly 0
more 0
active 0
than 0
Becotide 0
Nasal 0
. 0

The 0
side 0
effects 0
of 0
both 0
drugs 0
were 0
few 0
and 0
transient 0
. 0

The 0
immediate B-OTHER
efficacy I-OTHER
of 0
adjunctive 0
doxycycline 0
in 0
treatment 0
of 0
localized 0
juvenile 0
periodontitis 0
. 0

A 0
randomized 0
, 0
double-blind 0
, 0
placebo-controlled 0
study 0
on 0
the 0
immediate B-OTHER
clinical I-OTHER
and I-OTHER
microbiological I-OTHER
efficacy I-OTHER
of 0
doxycycline 0
( 0
100 0
mg 0
for 0
14 0
days 0
) 0
was 0
carried 0
out 0
to 0
determine 0
the 0
benefit 0
of 0
adjunctive 0
medication 0
in 0
16 0
patients 0
with 0
localized 0
juvenile 0
periodontitis 0
. 0

Measurements 0
of 0
gingival B-PHYSICAL
fluid I-PHYSICAL
flow I-PHYSICAL
, 0
probing B-PHYSICAL
depths I-PHYSICAL
, 0
bleeding B-PHYSICAL
on I-PHYSICAL
probing I-PHYSICAL
and 0
suppuration B-PHYSICAL
were 0
determined 0
at 0
2 0
periodontal 0
sites 0
with 0
and 0
2 0
without 0
radiographic 0
attachment 0
loss 0
, 0
at 0
weeks 0
0 0
, 0
1 0
, 0
3 0
and 0
8 0
. 0

Subgingival B-PHYSICAL
bacterial I-PHYSICAL
samples I-PHYSICAL
were 0
taken 0
with 0
curettes 0
from 0
the 0
same 0
sites 0
. 0

Spirochaetes 0
were 0
searched 0
for 0
by 0
dark-field 0
microscopy 0
. 0

Actinobacillus 0
actinomycetemcomitans 0
, 0
pigmented 0
and 0
non-pigmented 0
Bacteroides 0
spp. 0
, 0
Capnocytophaga 0
, 0
Fusobacterium 0
and 0
Actinomyces 0
spp 0
. 0

were 0
cultured 0
on 0
various 0
selective 0
and 0
non-selective 0
media 0
. 0

Bacterial 0
species 0
found 0
at 0
least 0
in 0
50 0
% 0
of 0
the 0
patients 0
and 0
comprising 0
on 0
average 0
5 0
% 0
or 0
more 0
of 0
the 0
cultivable 0
flora 0
were 0
included 0
in 0
the 0
analysis 0
. 0

Neither 0
short-term B-OTHER
clinical I-OTHER
nor I-OTHER
microbiological I-OTHER
efficacy I-OTHER
beyond 0
that 0
of 0
a 0
course 0
of 0
mechanical 0
debridement 0
alone 0
was 0
found 0
by 0
using 0
systemic 0
medication 0
with 0
doxycycline 0
in 0
patients 0
with 0
localized 0
juvenile 0
periodontitis 0
. 0

Blood B-PHYSICAL
purification I-PHYSICAL
for 0
critical 0
care 0
medicine 0
: 0
endotoxin 0
adsorption 0
. 0

Many 0
kinds 0
of 0
blood 0
purifying 0
technologies 0
have 0
been 0
applied 0
to 0
the 0
treatment 0
of 0
critically 0
ill 0
patients 0
since 0
1979 0
when 0
plasma 0
exchange 0
with 0
hollow-fiber 0
membranes 0
was 0
developed 0
. 0

These 0
technologies 0
have 0
been 0
applied 0
not 0
only 0
to 0
the 0
removal 0
of 0
toxic 0
substances 0
, 0
but 0
also 0
to 0
the 0
treatment 0
of 0
objective 0
diseases 0
and 0
the 0
removal 0
of 0
the 0
factors 0
relating 0
to 0
the 0
associated 0
inflammation 0
. 0

This 0
article 0
summarizes 0
these 0
methods 0
and 0
their 0
efficacies 0
for 0
critically 0
ill 0
patients 0
, 0
especially 0
those 0
with 0
severe 0
sepsis 0
. 0

Attempts 0
have 0
been 0
made 0
to 0
remove 0
endotoxin 0
, 0
the 0
main 0
cause 0
of 0
sepsis 0
, 0
from 0
the 0
circulation 0
using 0
polymyxin 0
B 0
immobilized 0
fiber 0
, 0
charcoal 0
hemoperfusion 0
, 0
and 0
plasma 0
or 0
whole 0
blood 0
exchange 0
. 0

Attempts 0
have 0
also 0
been 0
made 0
to 0
remove 0
proinflammatory 0
cytokines 0
, 0
eicosanoides 0
, 0
and 0
coagulative 0
factors 0
from 0
the 0
circulation 0
in 0
the 0
human 0
body 0
. 0

Continuous 0
hemofiltration 0
or 0
hemodiafiltration 0
is 0
the 0
representative 0
technology 0
. 0

The 0
efficacy 0
of 0
these 0
methods 0
has 0
been 0
established 0
, 0
but 0
several 0
issues 0
remain 0
unresolved 0
. 0

All 0
methods 0
of 0
the 0
treatment 0
of 0
severe 0
sepsis 0
are 0
discussed 0
with 0
reference 0
to 0
treatment 0
indications B-OTHER
, 0
efficacy 0
, 0
and 0
outcome 0
parameters 0
. 0

In 0
particular 0
, 0
the 0
clinical 0
results 0
of 0
endotoxin 0
removal 0
with 0
polymyxin 0
B 0
immobilized 0
fiber 0
are 0
summarized 0
in 0
this 0
article 0
. 0

In 0
vitro 0
biocompatibility 0
tests 0
of 0
glass 0
ionomer 0
cements 0
impregnated 0
with 0
collagen 0
or 0
bioactive 0
glass 0
to 0
fibroblasts 0
. 0

AIM 0
AND 0
DESIGN 0
To 0
evaluate 0
the 0
biocompatibility 0
of 0
glass 0
ionomer 0
cement 0
( 0
GIC 0
) 0
impregnated 0
with 0
collagen 0
or 0
bioactive 0
glass 0
to 0
BHK-21 0
fibroblasts 0
in 0
vitro 0
. 0

Mineral 0
Trioxide 0
Aggregate 0
was 0
used 0
as 0
the 0
standard 0
for 0
comparison 0
. 0

Human 0
maxillary 0
central 0
incisors 0
( 0
n 0
= 0
70 0
) 0
were 0
instrumented 0
with 0
a 0
rotary 0
NiTi 0
system 0
and 0
filled 0
. 0

Following 0
resection 0
of 0
the 0
apical 0
3mm 0
, 0
root 0
end 0
cavities 0
were 0
prepared 0
and 0
restored 0
with 0
conventional 0
GIC 0
( 0
group 0
1 0
) 0
or 0
GIC 0
with 0
0.01 0
% 0
, 0
0.1 0
% 0
or 0
1 0
% 0
collagen 0
( 0
groups 0
2 0
, 0
3 0
, 0
4 0
respectively 0
) 0
or 0
, 0
10 0
% 0
, 0
30 0
% 0
or 0
50 0
% 0
bioactive 0
glass 0
( 0
groups 0
5 0
, 0
6 0
, 0
7 0
respectively 0
) 0
, 0
or 0
Mineral 0
Trioxide 0
Aggregate 0
( 0
group 0
8 0
) 0
. 0

The 0
root 0
slices 0
were 0
incubated 0
in 0
tissue 0
culture 0
plates 0
with 0
BHK-21 0
fibroblast 0
cell 0
line 0
. 0

Phase 0
contrast 0
and 0
scanning 0
electron 0
microscopes 0
were 0
used 0
to 0
score 0
cell B-OTHER
quantity I-OTHER
, 0
morphology B-OTHER
and 0
cell B-OTHER
attachment I-OTHER
. 0

The 0
data 0
were 0
statistically 0
analyzed 0
by 0
one 0
way 0
ANOVA 0
with 0
Post B-OTHER
Hoc I-OTHER
Tukey I-OTHER
HSD I-OTHER
test I-OTHER
( 0
p 0
= 0
0.05 0
) 0
. 0

RESULTS 0
AND 0
CONCLUSIONS 0
Group 0
5 0
showed 0
the 0
highest 0
scores 0
which 0
was 0
significantly 0
higher 0
than 0
all 0
other 0
groups 0
( 0
p 0
< 0
0.05 0
) 0
except 0
group 0
8 0
, 0
with 0
which 0
there 0
was 0
no 0
significant 0
difference 0
( 0
p 0
> 0
0.05 0
) 0
. 0

Glass 0
ionomer 0
cement 0
with 0
10 0
% 0
bioactive 0
glass 0
showed 0
better B-OTHER
adhesion I-OTHER
and 0
spreading B-OTHER
of I-OTHER
cells I-OTHER
than 0
glass 0
ionomer 0
cement 0
with 0
0.01 0
% 0
collagen 0
. 0

The 0
biocompatibility 0
of 0
collagen B-OTHER
and 0
bioactive B-OTHER
glass I-OTHER
was 0
concentration 0
dependent 0
. 0

The 0
addition 0
of 0
bioactive 0
glass 0
improved 0
the 0
biocompatibility 0
of 0
glass 0
ionomer 0
cement 0
to 0
fibroblasts 0
better 0
than 0
addition 0
of 0
collagen 0
. 0

Osteoporosis 0
and 0
gait 0
and 0
balance 0
disturbances 0
in 0
older 0
sarcopenic 0
obese 0
New 0
Zealanders 0
. 0

UNLABELLED 0
Bone 0
, 0
muscle 0
, 0
and 0
fat 0
may 0
affect 0
gait 0
and 0
balance 0
in 0
older 0
adults 0
. 0

Osteoporosis 0
was 0
prevalent 0
in 0
low 0
muscle 0
mass 0
participants 0
and 0
related 0
to 0
gait 0
and 0
balance 0
deficits 0
. 0

Low 0
muscle 0
combined 0
with 0
high 0
fat 0
mass 0
had 0
more 0
functional 0
deficits 0
and 0
poorer 0
bone 0
health 0
, 0
which 0
has 0
implications 0
for 0
falls 0
risk 0
and 0
fractures 0
. 0

INTRODUCTION 0
Decreasing 0
bone 0
density 0
and 0
muscle 0
mass 0
and 0
increasing 0
fat 0
mass 0
may 0
act 0
synergistically 0
to 0
affect 0
gait 0
and 0
balance 0
in 0
older 0
adults 0
. 0

METHODS 0
One 0
hundred 0
eighty-three 0
older 0
adults 0
( 0
age 0
72.7 0
+/- 0
6 0
years 0
, 0
range 0
56-93 0
; 0
body 0
mass 0
index 0
28.2 0
+/- 0
4.9 0
, 0
range 0
16.6-46.0 0
) 0
were 0
recruited 0
from 0
a 0
New 0
Zealand 0
falls 0
prevention 0
intervention 0
trial 0
. 0

Total 0
and 0
appendicular B-PHYSICAL
skeletal I-PHYSICAL
muscle I-PHYSICAL
mass I-PHYSICAL
( I-PHYSICAL
ASM I-PHYSICAL
) I-PHYSICAL
, 0
percent B-PHYSICAL
fat I-PHYSICAL
, 0
and 0
bone B-PHYSICAL
mineralization I-PHYSICAL
were 0
assessed 0
by 0
dual 0
energy 0
X-ray 0
absorptiometry 0
and 0
used 0
to 0
characterize 0
normal 0
lean 0
( 0
NL 0
, 0
n 0
= 0
51 0
) 0
, 0
sarcopenic 0
( 0
SS 0
, 0
n 0
= 0
18 0
) 0
, 0
sarcopenic 0
obese 0
( 0
SO 0
, 0
n 0
= 0
29 0
) 0
, 0
and 0
obese 0
( 0
OO 0
, 0
n 0
= 0
85 0
) 0
phenotypes 0
. 0

Functional 0
performance 0
was 0
assessed 0
using 0
timed 0
up 0
and 0
go 0
, 0
chair 0
stand 0
, 0
single 0
leg 0
stand 0
, 0
and 0
step 0
test 0
. 0

Regression 0
models 0
were 0
adjusted 0
for 0
age 0
, 0
sex 0
, 0
medications 0
, 0
and 0
physical 0
activity 0
. 0

RESULTS 0
Femoral B-PHYSICAL
neck I-PHYSICAL
osteoporosis I-PHYSICAL
was 0
present 0
in 0
22 0
% 0
SS 0
, 0
17 0
% 0
SO 0
, 0
12 0
% 0
NL 0
, 0
and 0
7 0
% 0
OO 0
. 0

Femoral 0
neck 0
osteoporosis 0
with 0
low 0
ASM B-PHYSICAL
predicted 0
poor 0
chair B-PHYSICAL
stand I-PHYSICAL
performance I-PHYSICAL
( 0
beta 0
-3.3 0
, 0
standard 0
error 0
1.6 0
, 0
p 0
= 0
0.04 0
) 0
. 0

SO 0
scored 0
lowest 0
on 0
the 0
chair 0
stand 0
( 0
p 0
= 0
0.03 0
) 0
and 0
step 0
test 0
( 0
p 0
= 0
0.03 0
) 0
. 0

Higher B-PHYSICAL
ASM I-PHYSICAL
predicted 0
faster 0
timed 0
up 0
and 0
go 0
performance 0
( 0
p 0
= 0
0.001 0
) 0
. 0

CONCLUSIONS 0
Osteoporosis 0
was 0
prevalent 0
in 0
low 0
ASM 0
groups 0
( 0
SS 0
and 0
SO 0
) 0
and 0
related 0
to 0
gait 0
and 0
balance 0
deficits 0
, 0
particularly 0
in 0
the 0
SO 0
. 0

This 0
has 0
implications 0
for 0
falls 0
risk 0
, 0
fractures 0
, 0
and 0
interventions 0
. 0

[ 0
Efficacy 0
of 0
paliperidone 0
extended-release 0
tablets 0
in 0
the 0
improvement 0
of 0
social B-MENTAL
functions I-MENTAL
in 0
schizophrenics 0
: 0
a 0
randomized 0
and 0
controlled 0
study 0
] 0
. 0

OBJECTIVE 0
To 0
explore 0
the 0
efficacy 0
of 0
paliperidone 0
extended-release 0
tablets 0
in 0
the 0
improvement 0
of 0
social B-MENTAL
functions I-MENTAL
in 0
schizophrenics 0
. 0

METHODS 0
A 0
total 0
of 0
81 0
schizophrenics 0
were 0
randomly 0
divided 0
into 0
study 0
group 0
with 0
paliperidone 0
extended-release 0
tablets 0
and 0
control 0
group 0
with 0
risperidone 0
for 0
a 0
12-week 0
treatment 0
. 0

They 0
were 0
assessed 0
and 0
analyzed 0
by 0
positive 0
and 0
negative 0
symptoms 0
scales 0
( 0
PANSS 0
) 0
, 0
social 0
disability 0
screening 0
schedule 0
( 0
SDSS 0
) 0
and 0
treatment 0
emergent 0
symptom 0
scale 0
( 0
TESS 0
) 0
at 0
baseline 0
, 0
6 0
( 0
th 0
) 0
weekend 0
and 0
12 0
( 0
th 0
) 0
weekend 0
. 0

RESULTS 0
In 0
study 0
group 0
, 0
the 0
factors 0
and 0
total 0
scores 0
of 0
PANSS 0
in 0
the 0
12 0
( 0
th 0
) 0
weekend 0
of 0
treatment 0
[ 0
( 0
12.0 0
? 0

2.8 0
) 0
, 0
( 0
12.1 0
? 0

3.6 0
) 0
, 0
( 0
26.2 0
? 0

5.0 0
) 0
, 0
( 0
50.2 0
? 0

8.7 0
) 0
] 0
were 0
all 0
significantly 0
lower 0
than 0
those 0
at 0
baseline 0
[ 0
( 0
24.7 0
? 0

5.3 0
) 0
, 0
( 0
23.8 0
? 0

3.6 0
) 0
, 0
( 0
45.0 0
? 0

2.9 0
) 0
, 0
( 0
93.5 0
? 0

6.8 0
) 0
] 0
( 0
t 0
= 0
9.60-16.78 0
, 0
P 0
< 0
0.05 0
) 0
. 0

In 0
study 0
group 0
, 0
the 0
positive 0
factor 0
, 0
negative 0
factor 0
and 0
total 0
scores 0
of 0
PANSS 0
in 0
the 0
12 0
( 0
th 0
) 0
weekend 0
of 0
treatment 0
[ 0
( 0
12.0 0
? 0

2.8 0
) 0
, 0
( 0
12.1 0
? 0

3.6 0
) 0
, 0
( 0
50.2 0
? 0

8.7 0
) 0
] 0
were 0
all 0
significantly 0
lower 0
than 0
those 0
in 0
the 0
6 0
( 0
th 0
) 0
weekend 0
of 0
treatment 0
[ 0
( 0
14.2 0
? 0

1.8 0
) 0
, 0
( 0
14.6 0
? 0

2.4 0
) 0
, 0
( 0
56.5 0
? 0

6.4 0
) 0
] 0
( 0
t 0
= 0
2.58-4.26 0
, 0
P 0
< 0
0.05 0
) 0
. 0

In 0
the 0
12 0
( 0
th 0
) 0
weekend 0
of 0
treatment 0
, 0
the 0
factors 0
and 0
total 0
scores 0
of 0
PANSS 0
in 0
study 0
group 0
[ 0
( 0
12.0 0
? 0

2.8 0
) 0
, 0
( 0
12.1 0
? 0

3.6 0
) 0
, 0
( 0
26.2 0
? 0

5.0 0
) 0
, 0
( 0
50.2 0
? 0

8.7 0
) 0
] 0
were 0
all 0
significantly 0
lower 0
than 0
those 0
in 0
control 0
group 0
[ 0
( 0
16.9 0
? 0

4.9 0
) 0
, 0
( 0
18.7 0
? 0

5.3 0
) 0
, 0
( 0
32.5 0
? 0

5.1 0
) 0
, 0
( 0
68.1 0
? 0

13.0 0
) 0
] 0
( 0
t 0
= 0
-4.28 0
-- 0
5.67 0
, 0
P 0
< 0
0.05 0
) 0
. 0

In 0
study 0
group 0
, 0
the 0
total 0
scores 0
of 0
SDSS 0
in 0
the 0
12 0
( 0
th 0
) 0
weekend 0
of 0
treatment 0
( 0
5.93 0
? 0

2.78 0
) 0
were 0
significantly 0
lower 0
than 0
those 0
at 0
baseline 0
( 0
13.9 0
? 0

3.4 0
) 0
( 0
t 0
= 0
10.83 0
, 0
P 0
< 0
0.05 0
) 0
. 0

In 0
study 0
group 0
, 0
the 0
total 0
scores 0
of 0
SDSS 0
in 0
the 0
12 0
( 0
th 0
) 0
weekend 0
of 0
treatment 0
( 0
5.9 0
? 0

2.8 0
) 0
were 0
significantly 0
lower 0
than 0
those 0
in 0
the 0
6 0
( 0
th 0
) 0
weekend 0
of 0
treatment 0
( 0
7.6 0
? 0

2.9 0
) 0
( 0
t 0
= 0
5.21 0
, 0
P 0
< 0
0.05 0
) 0
. 0

But 0
there 0
was 0
no 0
significant 0
improvement 0
in 0
control 0
group 0
( 0
t 0
= 0
1.88 0
, 0
P 0
> 0
0.05 0
) 0
. 0

In 0
the 0
12 0
( 0
th 0
) 0
weekend 0
of 0
treatment 0
, 0
the 0
total 0
scores 0
of 0
SDSS 0
in 0
study 0
group 0
( 0
5.9 0
? 0

2.8 0
) 0
were 0
significantly 0
lower 0
than 0
those 0
in 0
control 0
group 0
( 0
8.8 0
? 0

2.9 0
) 0
( 0
t 0
= 0
-4.49 0
, 0
P 0
< 0
0.05 0
) 0
. 0

No 0
severe 0
adverse 0
effect 0
was 0
reported 0
in 0
either 0
group 0
. 0

CONCLUSION 0
Paliperidone 0
extended-release 0
tablets 0
are 0
effective 0
to 0
improve 0
social 0
functions 0
and 0
psychiatric 0
symptoms 0
of 0
schizophrenics 0
. 0

Ursodeoxycholic 0
acid 0
has 0
no 0
influence 0
on 0
function 0
after 0
restorative 0
proctocolectomy B-PHYSICAL
in 0
ulcerative 0
colitis 0
. 0

BACKGROUND 0
Poor 0
pouch 0
function 0
is 0
associated 0
with 0
impaired 0
bile 0
acid 0
absorption 0
and 0
increased 0
faecal 0
loss 0
of 0
bile 0
acids 0
. 0

Bile 0
acid 0
replacement 0
therapy 0
might 0
therefore 0
be 0
of 0
clinical 0
benefit 0
, 0
provided 0
that 0
diarrhoea 0
is 0
not 0
aggravated 0
by 0
therapy 0
. 0

AIM 0
To 0
investigate 0
the 0
role 0
of 0
exogenous 0
bile 0
acid 0
therapy 0
in 0
patients 0
with 0
poor 0
pouch 0
function 0
after 0
restorative 0
proctocolectomy 0
for 0
ulcerative 0
colitis 0
. 0

PATIENTS 0
AND 0
METHODS 0
Twenty 0
ulcerative 0
colitis 0
patients 0
with 0
poor 0
pouch 0
function 0
( 0
score 0
> 0
4 0
on 0
a 0
12-point 0
score 0
) 0
were 0
recruited 0
for 0
inclusion 0
to 0
a 0
prospective 0
, 0
randomized 0
, 0
double-blind 0
crossover 0
, 0
placebo-controlled 0
trial 0
of 0
ursodeoxycholic 0
acid 0
( 0
10 0
mg/kg 0
per 0
day 0
in 0
two 0
divided 0
doses 0
for 0
1 0
month 0
) 0
. 0

RESULTS 0
A 0
total 0
of 0
16 0
patients 0
completed 0
the 0
study 0
. 0

There 0
was 0
no 0
significant 0
difference 0
in 0
the 0
functional B-PHYSICAL
score 0
or B-PHYSICAL
bowel I-PHYSICAL
frequency B-PHYSICAL
following 0
treatment 0
irrespective 0
of 0
whether 0
the 0
active 0
treatment 0
was 0
given 0
before 0
or 0
after 0
placebo 0
. 0

CONCLUSIONS 0
We 0
conclude 0
that 0
ursodeoxycholic 0
acid 0
given 0
over 0
4 0
weeks 0
had 0
no 0
influence 0
on 0
functional B-PHYSICAL
score 0

Environmental 0
enrichment 0
as 0
an 0
effective 0
treatment 0
for 0
autism B-PHYSICAL
: 0
a 0
randomized 0
controlled 0
trial 0
. 0

Enriched 0
sensorimotor 0
environments 0
enable 0
rodents 0
to 0
compensate 0
for 0
a 0
wide 0
range 0
of 0
neurological 0
challenges 0
, 0
including 0
those 0
induced 0
in 0
animal 0
models 0
of 0
autism 0
. 0

Given 0
the 0
sensorimotor 0
deficits 0
in 0
most 0
children 0
with 0
autism 0
, 0
we 0
attempted 0
to 0
translate 0
that 0
approach 0
to 0
their 0
treatment 0
. 0

In 0
a 0
randomized 0
controlled 0
trial 0
, 0
3-12 0
year-old 0
children 0
with 0
autism 0
were 0
assigned 0
to 0
either 0
a 0
sensorimotor 0
enrichment 0
group 0
, 0
which 0
received 0
daily 0
olfactory/tactile 0
stimulation 0
along 0
with 0
exercises 0
that 0
stimulated 0
other 0
paired 0
sensory 0
modalities 0
, 0
or 0
to 0
a 0
control 0
group 0
. 0

We 0
administered 0
tests 0
of 0
cognitive 0
performance 0
and 0
autism 0
severity 0
to 0
both 0
groups 0
at 0
the 0
initiation 0
of 0
the 0
study 0
and 0
after 0
6 0
months 0
. 0

Severity B-PHYSICAL
of I-PHYSICAL
autism I-PHYSICAL
, 0
as 0
assessed 0
with 0
the 0
Childhood B-OTHER
Autism I-OTHER
Rating I-OTHER
Scale 0
, 0
improved 0
significantly 0
in 0
the 0
enriched 0
group 0
compared 0
to 0
controls 0
. 0

Indeed 0
, 0
42 0
% 0
of 0
the 0
enriched 0
group 0
and 0
only 0
7 0
% 0
of 0
the 0
control 0
group 0
had 0
what 0
we 0
considered 0
to 0
be 0
a 0
clinically 0
significant 0
improvement 0
of 0
5 0
points 0
on 0
that 0
scale 0
. 0

Sensorimotor 0
enrichment 0
also 0
produced 0
a 0
clear B-OTHER
improvement I-OTHER
in I-OTHER
cognition I-OTHER
, 0
as 0
determined 0
by 0
their 0
Leiter-R 0
Visualization 0
and 0
Reasoning 0
scores 0
. 0

At 0
6 0
months 0
, 0
the 0
change 0
in 0
average 0
scores 0
for 0
the 0
enriched 0
group 0
was 0
11.3 0
points 0
higher 0
than 0
that 0
for 0
the 0
control 0
group 0
. 0

Finally 0
, 0
69 0
% 0
of 0
parents 0
in 0
the 0
enriched 0
group 0
and 0
31 0
% 0
of 0
parents 0
in 0
the 0
control 0
group 0
reported 0
improvement 0
in 0
their 0
child 0
over 0
the 0
6-month 0
study 0
. 0

Environmental 0
enrichment 0
therefore 0
appears 0
to 0
be 0
effective 0
in 0
ameliorating 0
some 0
of 0
the 0
symptoms 0
of 0
autism 0
in 0
children 0
. 0

Safety 0
and 0
efficacy 0
of 0
dalcetrapib 0
on 0
atherosclerotic 0
disease 0
using 0
novel 0
non-invasive 0
multimodality 0
imaging 0
( 0
dal-PLAQUE 0
) 0
: 0
a 0
randomised 0
clinical 0
trial 0
. 0

BACKGROUND 0
Dalcetrapib 0
modulates 0
cholesteryl 0
ester 0
transfer 0
protein 0
( 0
CETP 0
) 0
activity 0
to 0
raise 0
high-density 0
lipoprotein 0
cholesterol 0
( 0
HDL-C 0
) 0
. 0

After 0
the 0
failure 0
of 0
torcetrapib 0
it 0
was 0
unknown 0
if 0
HDL 0
produced 0
by 0
interaction 0
with 0
CETP 0
had 0
pro-atherogenic 0
or 0
pro-inflammatory 0
properties 0
. 0

dal-PLAQUE 0
is 0
the 0
first 0
multicentre 0
study 0
using 0
novel 0
non-invasive 0
multimodality 0
imaging 0
to 0
assess 0
structural 0
and 0
inflammatory 0
indices 0
of 0
atherosclerosis 0
as 0
primary 0
endpoints 0
. 0

METHODS 0
In 0
this 0
phase 0
2b 0
, 0
double-blind 0
, 0
multicentre 0
trial 0
, 0
patients 0
( 0
aged 0
18-75 0
years 0
) 0
with 0
, 0
or 0
with 0
high 0
risk 0
of 0
, 0
coronary 0
heart 0
disease 0
were 0
randomly 0
assigned 0
( 0
1:1 0
) 0
to 0
dalcetrapib 0
600 0
mg/day 0
or 0
placebo 0
for 0
24 0
months 0
. 0

Randomisation 0
was 0
done 0
with 0
a 0
computer-generated 0
randomisation 0
code 0
and 0
was 0
stratified 0
by 0
centre 0
. 0

Patients 0
and 0
investigators 0
were 0
masked 0
to 0
treatment 0
. 0

Coprimary 0
endpoints 0
were 0
MRI-assessed B-OTHER
indices I-OTHER
( 0
total 0
vessel B-OTHER
area 0
, 0
wall B-OTHER
area 0
, 0
wall B-OTHER
thickness I-OTHER
, 0
and 0
normalised B-OTHER
wall I-OTHER
index I-OTHER
[ 0
average 0
carotid 0
] 0
) 0
after 0
24 0
months 0
and 0
( 0
18 0
) 0
F-fluorodeoxyglucose 0
( 0
( 0
18 0
) 0
F-FDG 0
) 0
PET/CT 0
assessment 0
of 0
arterial 0
inflammation 0
within 0
an 0
index 0
vessel 0
( 0
right 0
carotid 0
, 0
left 0
carotid 0
, 0
or 0
ascending 0
thoracic 0
aorta 0
) 0
after 0
6 0
months 0
, 0
with 0
no-harm 0
boundaries 0
established 0
before 0
unblinding 0
of 0
the 0
trial 0
. 0

Analysis 0
was 0
by 0
intention 0
to 0
treat 0
. 0

This 0
trial 0
is 0
registered 0
at 0
ClinicalTrials.gov 0
, 0
NCT00655473 0
. 0

FINDINGS 0
189 0
patients 0
were 0
screened 0
and 0
130 0
randomly 0
assigned 0
to 0
placebo 0
( 0
66 0
patients 0
) 0
or 0
dalcetrapib 0
( 0
64 0
patients 0
) 0
. 0

For 0
the 0
coprimary 0
MRI 0
and 0
PET/CT 0
endpoints 0
, 0
CIs 0
were 0
below 0
the 0
no-harm 0
boundary 0
or 0
the 0
adverse 0
change 0
was 0
numerically 0
lower 0
in 0
the 0
dalcetrapib 0
group 0
than 0
in 0
the 0
placebo 0
group 0
. 0

MRI-derived B-OTHER
change I-OTHER
in I-OTHER
total 0

Atrial 0
natriuretic 0
factor 0
inhibits 0
metoclopramide 0
stimulated 0
aldosterone B-PHYSICAL
release I-PHYSICAL
in 0
man 0
. 0

1 0
. 0

Atrial 0
natriuretic 0
factor 0
( 0
ANF 0
) 0
has 0
an 0
inhibitory 0
effect 0
on 0
angiotensin B-PHYSICAL
II I-PHYSICAL
and 0
ACTH B-PHYSICAL
stimulated I-PHYSICAL
aldosterone I-PHYSICAL
secretion I-PHYSICAL
in 0
man 0
. 0

The 0
selectivity 0
of 0
this 0
aldosterone 0
suppressing 0
effect 0
of 0
ANF 0
is 0
unclear 0
in 0
man 0
. 0

The 0
present 0
study 0
investigated 0
the 0
effect 0
of 0
ANF 0
on 0
the 0
increase 0
in 0
plasma B-PHYSICAL
aldosterone I-PHYSICAL
due 0
to 0
metoclopramide B-OTHER
in 0
man 0
. 0

2 0
. 0

Eight 0
normal 0
male 0
volunteers 0
were 0
studied 0
on 0
three 0
occasions 0
. 0

Metoclopramide 0
( 0
10 0
mg 0
slow 0
i.v 0
. 0
) 0

was 0
given 0
on 0
all 0
study 0
days 0
and 0
each 0
volunteer 0
was 0
randomised 0
to 0
receive 0
45 0
min 0
infusion 0
of 0
either 0
5 0
% 0
D-glucose 0
( 0
placebo 0
) 0
or 0
ANF 0
( 0
99-126 0
) 0
3 0
or 0
15 0
pmol 0
kg-1 0
min-1 0
. 0

3 0
. 0

Metoclopramide 0
increased 0
plasma B-PHYSICAL
aldosterone I-PHYSICAL
to 0
approximately 0
170 0
% 0
of 0
baseline 0
levels 0
( 0
P 0
less 0
than 0
0.01 0
) 0
. 0

Concomitant 0
infusion 0
of 0
ANF 0
3 0
pmol 0
kg-1 0
min-1 0
and 0
15 0
pmol 0
kg-1 0
min-1 0
significantly 0
attenuated 0
this 0
rise 0
in 0
plasma 0
aldosterone 0
to 0
approximately 0
130 0
% 0
( 0
P 0
less 0
than 0
0.05 0
) 0
and 0
110 0
% 0
( 0
P 0
less 0
than 0
0.01 0
) 0
of 0
baseline 0
values 0
respectively 0
. 0

4 0
. 0

It 0
is 0
suggested 0
, 0
in 0
the 0
light 0
of 0
previous 0
findings 0
, 0
that 0
the 0
inhibitory 0
effect 0
of 0
ANF 0
represents 0
a 0
non-selective 0
action 0
of 0
ANF 0
on 0
aldosterone B-PHYSICAL
release I-PHYSICAL
. 0

Determination 0
of 0
vital 0
status 0
at 0
the 0
end 0
of 0
the 0
DIG 0
trial 0
. 0

The 0
Digitalis 0
Investigation 0
Group 0
( 0
DIG 0
) 0
trial 0
was 0
a 0
randomized 0
, 0
double-blind 0
placebo-controlled 0
trial 0
whose 0
primary 0
objective 0
was 0
to 0
determine 0
whether 0
digoxin 0
had 0
beneficial 0
, 0
harmful 0
, 0
or 0
no 0
effect 0
on 0
total 0
mortality 0
in 0
patients 0
with 0
heart 0
failure 0
who 0
were 0
in 0
sinus 0
rhythm 0
and 0
whose 0
ejection 0
fraction 0
was 0
< 0
/=0.45 0
. 0

The 0
study 0
was 0
designed 0
as 0
a 0
large 0
simple 0
trial 0
with 0
a 0
large 0
number 0
of 0
centers 0
( 0
302 0
) 0
in 0
the 0
United 0
States 0
and 0
Canada 0
, 0
many 0
of 0
which 0
were 0
inexperienced 0
in 0
research 0
. 0

To 0
ensure 0
that 0
the 0
results 0
of 0
the 0
trial 0
would 0
be 0
reported 0
accurately 0
without 0
possible 0
bias 0
due 0
to 0
missing 0
data 0
, 0
the 0
study 0
leadership 0
decided 0
that 0
no 0
outcome 0
results 0
would 0
be 0
reported 0
until 0
the 0
vital 0
status 0
at 0
the 0
end 0
of 0
the 0
study 0
was 0
known 0
for 0
at 0
least 0
97 0
% 0
of 0
the 0
study 0
participants 0
. 0

Planning 0
for 0
closeout 0
of 0
the 0
study 0
began 0
a 0
year 0
prior 0
to 0
the 0
common 0
end 0
date 0
of 0
December 0
31 0
, 0
1995 0
and 0
included 0
plans 0
for 0
obtaining 0
vital 0
status 0
on 0
December 0
31 0
, 0
1995 0
. 0

Participants 0
were 0
given 0
postcards 0
at 0
their 0
final 0
study 0
visit 0
to 0
be 0
completed 0
and 0
mailed 0
on 0
or 0
after 0
January 0
1 0
, 0
1996 0
. 0

Of 0
5602 0
postcards 0
distributed 0
, 0
5070 0
( 0
90.5 0
% 0
) 0
were 0
completed 0
and 0
returned 0
. 0

A 0
contract 0
search 0
agency 0
was 0
hired 0
to 0
locate 0
the 0
remaining 0
participants 0
. 0

Of 0
the 0
total 0
7788 0
participants 0
entered 0
into 0
the 0
DIG 0
trial 0
, 0
only 0
97 0
participants 0
( 0
1.2 0
% 0
) 0
could 0
not 0
have 0
their 0
vital B-PHYSICAL
status I-PHYSICAL
as 0
of 0
December 0
31 0
, 0
1995 0
determined 0
. 0

It 0
is 0
recommended 0
that 0
investigators 0
having 0
an 0
outcome 0
measure 0
with 0
a 0
common 0
end 0
date 0
include 0
plans 0
in 0
their 0
protocols 0
for 0
obtaining 0
their 0
measures 0
and 0
activate 0
those 0
plans 0
as 0
early 0
as 0
possible 0
during 0
the 0
course 0
of 0
the 0
study 0
. 0

Effect 0
of 0
CX516 0
, 0
an 0
AMPA-modulating 0
compound 0
, 0
on 0
cognition B-MENTAL
and 0
behavior B-MENTAL
in 0
fragile 0
X 0
syndrome 0
: 0
a 0
controlled 0
trial 0
. 0

A 0
Phase 0
II 0
, 0
4-week 0
randomized 0
, 0
double-blind 0
, 0
placebo-controlled 0
clinical 0
trial 0
was 0
conducted 0
to 0
evaluate 0
the 0
safety 0
and 0
efficacy 0
of 0
the 0
Ampakine 0
compound 0
CX516 0
as 0
a 0
potential 0
treatment 0
for 0
the 0
underlying 0
disorder 0
in 0
fragile 0
X 0
syndrome 0
( 0
FXS 0
) 0
. 0

After 0
baseline 0
screening 0
, 0
subjects 0
with 0
FXS 0
( 0
n 0
= 0
49 0
) 0
underwent 0
a 0
1-week 0
placebo 0
lead-in 0
and 0
then 0
were 0
randomized 0
to 0
study 0
drug 0
or 0
placebo 0
for 0
a 0
4-week 0
period 0
. 0

Cognitive B-MENTAL
and 0
behavioral B-MENTAL
outcome 0
measures 0
were 0
administered 0
prior 0
to 0
treatment 0
, 0
at 0
the 0
end 0
of 0
treatment 0
, 0
and 0
2 0
weeks 0
posttreatment 0
. 0

There 0
were 0
minimal B-ADVERSE-EFFECTS
side I-ADVERSE-EFFECTS
effects I-ADVERSE-EFFECTS
, 0
no 0
significant B-OTHER
changes I-OTHER
in I-OTHER
safety I-OTHER
parameters I-OTHER
, 0
and 0
no 0
serious B-ADVERSE-EFFECTS
adverse I-ADVERSE-EFFECTS
events I-ADVERSE-EFFECTS
. 0

There 0
was 0
a 0
12.5 0
% 0
frequency 0
of 0
allergic B-PHYSICAL
rash I-PHYSICAL
in 0
the 0
CX516 0
group 0
and 0
1 0
subject 0
developed 0
a 0
substantial B-ADVERSE-EFFECTS
rash I-ADVERSE-EFFECTS
. 0

There 0
was 0
also 0
no 0
significant B-MENTAL
improvement I-MENTAL
in 0
memory B-MENTAL
, 0
the 0
primary 0
outcome 0
measure 0
, 0
or 0
in 0
secondary 0
measures 0
of 0
language B-MENTAL
, I-MENTAL
attention/executive I-MENTAL
function I-MENTAL
, I-MENTAL
behavior I-MENTAL
, I-MENTAL
and I-MENTAL
overall I-MENTAL
functioning I-MENTAL
in 0
CX516-treated 0
subjects 0
compared 0
to 0
placebo 0
. 0

This 0
study 0
did 0
demonstrate 0
that 0
many 0
outcome 0
measures B-OTHER
were 0
reproducible 0
in 0
this 0
test-retest 0
setting 0
for 0
the 0
FXS 0
population 0
, 0
yet 0
some 0
were 0
too 0
difficult 0
or 0
variable 0
. 0

Adult 0
subjects 0
with 0
FXS 0
were 0
able 0
to 0
complete 0
an 0
intensive 0
clinical 0
trial 0
, 0
and 0
some 0
valid 0
outcome 0
measures 0
were 0
identified 0
for 0
future 0
FXS 0
trial 0
design 0
. 0

Problems 0
with 0
potency 0
of 0
CX516 0
in 0
other 0
studies 0
have 0
suggested 0
dosing 0
may 0
have 0
been 0
inadequate 0
for 0
therapeutic 0
effect 0
and 0
thus 0
it 0
remains 0
unclear 0
whether 0
modulation 0
of 0
AMPA-mediated 0
neurotransmission 0
is 0
a 0
viable B-OTHER
therapeutic I-OTHER
strategy I-OTHER
for 0
the 0
treatment 0
of 0
FXS 0
. 0

Topiramate 0
improves 0
health-related B-PHYSICAL
quality I-PHYSICAL
of I-PHYSICAL
life I-PHYSICAL
when 0
used 0
to 0
prevent 0
migraine 0
. 0

OBJECTIVE 0
To 0
assess 0
changes 0
in 0
health-related B-PHYSICAL
quality 0
of 0
life 0
( B-PHYSICAL
HRQoL B-PHYSICAL
) B-PHYSICAL
measures I-PHYSICAL
among 0
patients 0
receiving 0
topiramate 0
( 0
TPM 0
) 0
100 0
mg/d 0
in 0
two 0
divided 0
doses 0
for 0
migraine 0
prevention 0
in 0
three 0
randomized 0
, 0
double-blind 0
, 0
placebo-controlled 0
, 0
26-week 0
trials 0
with 0
similar 0
protocols 0
and 0
study 0
populations 0
. 0

BACKGROUND 0
Migraine 0
substantially 0
impairs 0
HRQoL B-PHYSICAL
and 0
work B-OTHER
productivity I-OTHER
before 0
, 0
during 0
, 0
and 0
after 0
attacks 0
. 0

Approximately 0
50 0
% 0
of 0
patients 0
with 0
migraine 0
could 0
be 0
recommended 0
for 0
preventive 0
therapies 0
, 0
yet 0
only 0
3 0
% 0
to 0
5 0
% 0
of 0
patients 0
receive 0
them 0
. 0

TPM 0
is 0
an 0
effective B-OTHER
and B-OTHER
generally B-OTHER
well-tolerated B-OTHER
migraine 0
prophylactic 0
( 0
preventive 0
) 0
therapy 0
for 0
adults 0
, 0
as 0
demonstrated 0
in 0
several 0
randomized 0
, 0
double-blind 0
, 0
placebo-controlled 0
trials 0
. 0

The 0
most 0
common 0
adverse 0
events 0
in 0
double-blind 0
, 0
placebo-controlled 0
studies 0
of 0
TPM 0
in 0
migraine 0
prevention 0
are 0
paresthesia B-ADVERSE-EFFECTS
, 0
fatigue B-ADVERSE-EFFECTS
, 0
anorexia B-ADVERSE-EFFECTS
, 0
nausea B-ADVERSE-EFFECTS
, 0
taste B-ADVERSE-EFFECTS
alteration I-ADVERSE-EFFECTS
, 0
and 0
diarrhea B-ADVERSE-EFFECTS
. 0

DESIGN 0
AND 0
METHODS 0
The 0
Migraine-Specific B-PHYSICAL
Questionnaire 0
( B-PHYSICAL
MSQ B-PHYSICAL
, 0
version 0
2.1 0
) 0
was 0
used 0
to 0
assess 0
the 0
effect 0
of 0
TPM 0
100 0
mg/d 0
on 0
the 0
functionality 0
and 0
HRQoL 0
of 0
randomized 0
intent-to-treat 0
( 0
ITT 0
) 0
and 0
study-completer 0
populations 0
pooled 0
from 0
three 0
randomized 0
, 0
double-blind 0
, 0
placebo-controlled 0
trials 0
. 0

MSQ B-PHYSICAL
scores I-PHYSICAL
( 0
0 0
to 0
100 0
, 0
higher 0
score 0
indicates 0
better 0
functioning 0
) 0
were 0
assessed 0
for 0
the 0
following 0
three 0
domains 0
: 0
role 0
restriction 0
( 0
examines 0
the 0
degree 0
to 0
which 0
performance 0
of 0
daily 0
activities 0
is 0
limited 0
by 0
migraine 0
) 0
, 0
role 0
prevention 0
( 0
examines 0
the 0
degree 0
to 0
which 0
performance 0
of 0
daily 0
activities 0
is 0
interrupted 0
by 0
migraine 0
) 0
, 0
and 0
emotional B-MENTAL
function I-MENTAL
( 0
examines 0
feelings 0
of 0
frustration 0
and 0
helplessness 0
due 0
to 0
migraine 0
) 0
. 0

Between-group 0
differences 0
from 0
baseline 0
in 0
mean 0
MSQ B-PHYSICAL

Activator 0
protein-1 0
( 0
AP-1 0
) 0
signalling 0
in 0
human 0
atherosclerosis 0
: 0
results 0
of 0
a 0
systematic 0
evaluation 0
and 0
intervention 0
study 0
. 0

Animal 0
studies 0
implicate 0
the 0
AP-1 0
( 0
activator 0
protein-1 0
) 0
pro-inflammatory 0
pathway 0
as 0
a 0
promising 0
target 0
in 0
the 0
treatment 0
of 0
atherosclerotic 0
disease 0
. 0

It 0
is 0
, 0
however 0
, 0
unclear 0
whether 0
these 0
observations 0
apply 0
to 0
human 0
atherosclerosis 0
. 0

Therefore 0
we 0
evaluated 0
the 0
profile 0
of 0
AP-1 0
activation 0
through 0
histological 0
analysis 0
and 0
tested 0
the 0
potential 0
benefit 0
of 0
AP-1 0
inhibition 0
in 0
a 0
clinical 0
trial 0
. 0

AP-1 0
activation 0
was 0
quantified 0
by 0
phospho-c-Jun 0
nuclear 0
translocation 0
( 0
immunohistochemistry 0
) 0
on 0
a 0
biobank 0
of 0
aortic 0
wall 0
samples 0
from 0
organ 0
donors 0
. 0

The 0
effect 0
of 0
AP-1 B-PHYSICAL
inhibition I-PHYSICAL
on 0
vascular 0
parameters 0
was 0
tested 0
through 0
a 0
double 0
blind 0
placebo-controlled 0
cross-over 0
study 0
of 0
28 0
days 0
doxycycline 0
or 0
placebo 0
in 0
patients 0
with 0
symptomatic 0
peripheral 0
artery 0
disease 0
. 0

Vascular 0
function 0
was 0
assessed 0
by 0
brachial 0
dilation 0
as 0
well 0
as 0
by 0
plasma 0
samples 0
analysed 0
for 0
hs-CRP 0
( 0
high-sensitivity 0
C-reactive 0
protein 0
) 0
, 0
IL-6 0
( 0
interleukin-6 0
) 0
, 0
IL-8 0
, 0
ICAM-1 0
( 0
intercellular 0
adhesion 0
molecule-1 0
) 0
, 0
vWF 0
( 0
von 0
Willebrand 0
factor 0
) 0
, 0
MCP-1 0
( 0
monocyte 0
chemoattractant 0
protein-1 0
) 0
, 0
PAI-1 0
( 0
plasminogen 0
activator 0
inhibitor-1 0
) 0
and 0
fibrinogen 0
. 0

Histological 0
evaluation 0
of 0
human 0
atherosclerosis 0
showed 0
minimal 0
AP-1 0
activation 0
in 0
non-diseased 0
arterial 0
wall 0
( 0
i.e 0
. 0

vessel 0
wall 0
without 0
any 0
signs 0
of 0
atherosclerotic 0
disease 0
) 0
. 0

A 0
gradual 0
increase 0
of 0
AP-1 0
activation 0
was 0
found 0
in 0
non-progressive 0
and 0
progressive 0
phases 0
of 0
atherosclerosis 0
respectively 0
( 0
P 0
< 0
0.044 0
) 0
. 0

No 0
significant 0
difference 0
was 0
found 0
between 0
progressive 0
and 0
vulnerable 0
lesions 0
. 0

The 0
expression 0
of 0
phospho-c-Jun 0
diminished 0
as 0
the 0
lesion 0
stabilized 0
( 0
P 0
< 0
0.016 0
) 0
and 0
does 0
not 0
significantly 0
differ 0
from 0
the 0
normal 0
aortic 0
wall 0
( 0
P 0
< 0
0.33 0
) 0
. 0

Evaluation 0
of 0
the 0
doxycycline 0
intervention 0
only 0
revealed 0
a 0
borderline-significant 0
reduction 0
of 0
circulating 0
hs-CRP 0
levels 0
( 0
-0.51 0
?g/ml 0
, 0
P=0.05 0
) 0
and 0
did 0
not 0
affect 0
any 0
of 0
the 0
other 0
markers 0
of 0
systemic 0
inflammation 0
and 0
vascular 0
function 0
. 0

Our 0
studies 0
do 0
not 0
characterize 0
AP-1 0
as 0
a 0
therapeutic 0
target 0
for 0
progressive 0
human 0
atherosclerotic 0
disease 0
. 0

Efficacy 0
of 0
chlorhexidine 0
gluconate 0
use 0
in 0
the 0
prevention 0
of 0
perirectal 0
infections 0
in 0
patients 0
with 0
acute 0
leukemia 0
. 0

The 0
frequency 0
of 0
rectal B-PHYSICAL
infections I-PHYSICAL
is 0
increased 0
in 0
patients 0
with 0
acute 0
leukemia 0
. 0

Complications 0
associated 0
with 0
rectal 0
lesions 0
may 0
be 0
severe 0
enough 0
to 0
cause 0
life-threatening 0
septicemia 0
. 0

Clinical 0
research 0
evaluating 0
the 0
effects 0
of 0
preventive 0
perirectal 0
skin 0
care 0
is 0
scarce 0
. 0

This 0
study 0
's 0
purpose 0
was 0
to 0
determine 0
whether 0
using 0
chlorhexidine 0
gluconate 0
( 0
CHG 0
) 0
in 0
a 0
prophylactic 0
perirectal 0
skin-care 0
regimen 0
decreases 0
perirectal 0
infections 0
and 0
whether 0
it 0
produces 0
more 0
skin 0
irritation 0
than 0
a 0
nonmedicated 0
skin 0
cleanser 0
. 0

The 0
sample 0
consisted 0
of 0
40 0
patients 0
, 0
16 0
of 0
whom 0
were 0
randomized 0
to 0
use 0
chlorhexidine 0
and 0
24 0
of 0
whom 0
were 0
randomized 0
to 0
use 0
nonmedicated 0
skin 0
cleanser 0
. 0

Chi-square 0
and 0
t-tests 0
were 0
used 0
to 0
analyze 0
the 0
incidence 0
of 0
skin B-PHYSICAL
breakdown I-PHYSICAL
and 0
rectal B-PHYSICAL
infections I-PHYSICAL
; 0
the 0
correlation 0
between 0
the 0
two 0
factors 0
; 0
a 0
positive 0
history 0
of 0
rectal 0
infections 0
, 0
fissures 0
, 0
or 0
hemorrhoids 0
; 0
presence 0
of 0
hemorrhoids 0
; 0
severity 0
of 0
diarrhea 0
; 0
and 0
duration 0
and 0
severity 0
of 0
granulocytopenia 0
. 0

A 0
positive 0
relationship 0
was 0
found 0
between 0
the 0
severity B-PHYSICAL
of I-PHYSICAL
granulocytopenia I-PHYSICAL
and 0
the 0
incidence 0
of 0
rectal B-PHYSICAL
infections I-PHYSICAL
( 0
p 0
= 0
0.02 0
) 0
. 0

No 0
significant 0
difference 0
was 0
seen 0
in 0
the 0
occurrence 0
of 0
perirectal B-PHYSICAL
infections I-PHYSICAL
( 0
p 0
= 0
0.35 0
) 0
or 0
skin B-PHYSICAL
breakdown I-PHYSICAL
( 0
p 0
= 0
0.18 0
) 0
between 0
the 0
two 0
groups 0
. 0

The 0
data 0
suggest 0
that 0
CHG 0
does 0
not 0
offer 0
increased 0
protection 0
against 0
perirectal 0
infections 0
in 0
patients 0
undergoing 0
intensive 0
chemotherapy 0
, 0
nor 0
is 0
it 0
more 0
irritating 0
than 0
a 0
nonmedicated 0
skin 0
cleanser 0
. 0

Further 0
studies 0
are 0
needed 0
to 0
examine 0
the 0
efficacy 0
of 0
hygienic 0
measures 0
such 0
as 0
using 0
skin 0
disinfectants 0
to 0
prevent 0
infections 0
in 0
patients 0
who 0
are 0
immunocompromised 0
. 0

[ 0
Triple 0
therapy 0
regimens 0
involving 0
H2 0
blockaders 0
for 0
therapy 0
of 0
Helicobacter B-PHYSICAL
pylori I-PHYSICAL
infections I-PHYSICAL
] I-PHYSICAL
. 0

Comparison B-OTHER
of 0
ranitidine 0
and 0
lansoprazole 0
in 0
short-term 0
low-dose 0
triple 0
therapy 0
for 0
Helicobacter 0
pylori 0
infection 0
. 0

To 0
evaluate 0
the 0
efficacy 0
and 0
safety 0
of 0
two 0
1-week 0
low-dose 0
triple-therapy 0
drug 0
regimens 0
involving 0
antisecretory 0
drugs 0
for 0
Helicobacter 0
pylori 0
infection 0
, 0
99 0
patients 0
with 0
H. 0
pylori 0
infection 0
were 0
treated 0
with 0
either 0
lansoprazole 0
( 0
LPZ 0
) 0
or 0
ranitidine 0
( 0
RNT 0
) 0
used 0
together 0
with 0
clarithromycin 0
( 0
CAM 0
) 0
and 0
metrinidazole 0
( 0
MTZ 0
) 0
. 0

The 0
drug 0
combination 0
and 0
administration 0
periods 0
in 0
the 0
PPI 0
group 0
were 0
LPZ 0
30 0
mg 0
, 0
CAM 0
400 0
mg 0
, 0
MTZ 0
500 0
mg 0
( 0
LCM 0
group 0
) 0
. 0

The 0
ranitidine 0
group 0
received 0
RNT 0
300 0
mg 0
, 0
CAM 0
400 0
mg 0
, 0
MTZ 0
500 0
mg 0
( 0
RCM 0
group 0
) 0
. 0

The 0
cure B-OTHER
rate I-OTHER
of I-OTHER
H. 0
pylori B-PHYSICAL
infection I-PHYSICAL
was 0
88 0
% 0
in 0
the 0
LCM 0
group 0
; 0
95 0
% 0
CI 0
79-97 0
and 0
92 0
% 0
in 0
the 0
RCM 0
group 0
; 0
95 0
% 0
CI 0
84-99 0
. 0

[ 0
Intravenous 0
treatment 0
of 0
postpartum 0
anemia 0
with 0
trivalent 0
ferrum 0
preparation 0
] 0
. 0

AIM 0
OF 0
THE 0
STUDY 0
To 0
assess 0
the 0
effectivity 0
and 0
safeness B-OTHER
of 0
intravenous 0
treatment 0
of 0
pospartal 0
anemia 0
with 0
trivalent 0
ferrum 0
preparation 0
. 0

TYPE 0
OF 0
THE 0
STUDY 0
Prospective 0
randomized 0
study 0
. 0

SETTING 0
Department 0
of 0
Obstetric 0
and 0
Gynecology 0
2nd 0
Medical 0
Faculty 0
Charles 0
University 0
and 0
Teaching 0
Hospital 0
Motol 0
, 0
Prague 0
, 0
and 0
Department 0
of 0
Obstetric 0
and 0
Gynecology 0
1st 0
Medical 0
Faculty 0
and 0
Teaching 0
Hospital 0
Bulovka 0
, 0
Prague 0
. 0

METHODS 0
500 0
mg 0
of 0
sacharose 0
ferric 0
oxide 0
( 0
Venofer 0
) 0
was 0
intravenously 0
administered 0
in 0
two 0
days 0
regimen 0
to 0
50 0
women 0
with 0
clinical 0
and 0
lab 0
signs 0
of 0
postpartal 0
anemia 0
. 0

The 0
effect 0
of 0
administered 0
drug 0
was 0
determined 0
by 0
comparsion 0
of 0
values 0
of 0
red 0
blood 0
count 0
recovered 0
before 0
the 0
treatment 0
, 0
2nd 0
or 0
3rd 0
day 0
post 0
administration 0
and 0
two 0
weeks 0
later 0
. 0

The 0
serum 0
values 0
of 0
soluble 0
transferrin 0
receptors 0
and 0
ferritin 0
were 0
observed 0
as 0
markers 0
of 0
iron B-PHYSICAL
cell I-PHYSICAL
saturation I-PHYSICAL
and 0
body B-PHYSICAL
iron I-PHYSICAL
reserves I-PHYSICAL
, 0
too 0
. 0

Integral 0
part 0
of 0
the 0
study 0
was 0
the 0
monitoring 0
of 0
adverse B-ADVERSE-EFFECTS
events I-ADVERSE-EFFECTS
during 0
the 0
treatment 0
. 0

RESULTS 0
Venofer 0
came 0
in 0
sight 0
as 0
effective 0
drug 0
in 0
the 0
treatment 0
of 0
pospartal B-PHYSICAL
anemia I-PHYSICAL
and 0
could 0
become 0
as 0
the 0
alternative 0
to 0
blood 0
transfusion 0
in 0
mid-severe 0
cases 0
. 0

It 0
should 0
be 0
emphasized 0
that 0
we 0
have 0
not 0
encountered 0
any 0
serious B-ADVERSE-EFFECTS
adverse I-ADVERSE-EFFECTS
event I-ADVERSE-EFFECTS
with 0
intravenous 0
trivalent 0
saccharose 0
ferric 0
oxide 0
treatment 0
. 0

The 0
role 0
of 0
somatostatin 0
( 0
octreotide 0
) 0
in 0
the 0
regulation 0
of 0
melatonin B-PHYSICAL
secretion I-PHYSICAL
in 0
healthy 0
volunteers 0
and 0
in 0
patients 0
with 0
primary 0
hypothyroidism 0
. 0

Somatostatin 0
has 0
been 0
found 0
in 0
the 0
pineal 0
gland 0
of 0
several 0
animal 0
species 0
, 0
which 0
suggests 0
that 0
it 0
may 0
be 0
involved 0
in 0
the 0
regulation 0
of 0
melatonin B-PHYSICAL
secretion I-PHYSICAL
. 0

Whether 0
somatostatin 0
has 0
regulatory 0
influence 0
on 0
melatonin B-PHYSICAL
secretion I-PHYSICAL
in 0
man 0
has 0
never 0
been 0
unequivocally 0
shown 0
. 0

We 0
studied 0
the 0
nocturnal B-PHYSICAL
melatonin I-PHYSICAL
secretion I-PHYSICAL
in 0
8 0
healthy 0
volunteers 0
, 0
and 0
6 0
women 0
with 0
untreated 0
primary 0
hypothyroidism 0
, 0
a 0
disease 0
state 0
that 0
is 0
associated 0
with 0
increased 0
nocturnal 0
secretion 0
of 0
melatonin 0
. 0

The 0
participants 0
were 0
given 0
subcutaneous 0
injections 0
at 0
18:00 0
h 0
and 0
23:00 0
h 0
of 0
either 0
saline 0
or 0
octreotide 0
( 0
Sandostatin 0
; 0
each 0
injection 0
50 0
microg 0
) 0
. 0

During 0
the 0
nights 0
when 0
the 0
healthy 0
volunteers 0
were 0
given 0
octreotide 0
, 0
melatonin B-PHYSICAL
secretion I-PHYSICAL
was 0
similar 0
to 0
that 0
recorded 0
during 0
administration 0
of 0
saline 0
. 0

Also 0
the 0
urinary B-PHYSICAL
excretion I-PHYSICAL
of I-PHYSICAL
melatonin I-PHYSICAL
was 0
of 0
similar 0
magnitude 0
at 0
these 0
two 0
occasions 0
. 0

By 0
contrast 0
, 0
the 0
GH B-PHYSICAL
secretion I-PHYSICAL
was 0
significantly 0
lower 0
the 0
nights 0
the 0
healthy 0
controls 0
were 0
given 0
octreotide 0
( 0
GH 0
AUC 0
22.6+/-5.4 0
mU/l 0
x 0
h 0
during 0
octreotide 0
and 0
126.6+/-21.9 0
mU/l 0
x 0
h 0
during 0
saline 0
; 0
p 0
< 0
0.01 0
) 0
. 0

The 0
patients 0
with 0
hypothyroidism 0
also 0
showed 0
similar 0
nocturnal B-PHYSICAL
melatonin I-PHYSICAL
secretion I-PHYSICAL
during 0
octreotide 0
and 0
saline 0
. 0

Urinary B-PHYSICAL
excretion I-PHYSICAL
of I-PHYSICAL
melatonin I-PHYSICAL
also 0
remained 0
unchanged 0
, 0
as 0
did 0
GH B-PHYSICAL
secretion I-PHYSICAL
. 0

The 0
total 0
nocturnal B-PHYSICAL
secretion I-PHYSICAL
of I-PHYSICAL
TSH I-PHYSICAL
was 0
, 0
however 0
, 0
significantly 0
reduced 0
by 0
octreotide 0
( 0
TSH 0
AUC 0
562+/-136 0
mU/l 0
x 0
h 0
during 0
octreotide 0
and 0
851+/-185 0
mU/l 0
x 0
h 0
during 0
saline 0
; 0
p 0
< 0
0.05 0
) 0
, 0
thus 0
suggesting 0
that 0
100 0
microg 0
of 0
octreotide 0
should 0
be 0
sufficient 0
to 0
inhibit 0
also 0
the 0
pinealocytes 0
if 0
their 0
function 0
were 0
regulated 0
by 0
somatostatin 0
. 0

Since 0
exogenous 0
somatostatin 0
-- 0
in 0
the 0
form 0
of 0
octreotide 0
-- 0
fails 0
to 0
influence 0
nocturnal B-PHYSICAL
secretion I-PHYSICAL
and 0
urinary B-PHYSICAL
excretion I-PHYSICAL
of I-PHYSICAL
melatonin I-PHYSICAL
in 0
normal 0
subjects 0
and 0
in 0
patients 0
with 0
primary 0
hypothyroidism 0
, 0
it 0
is 0
reasonable 0
to 0
assume 0
that 0
endogenous 0
somatostatin 0
may 0
not 0
be 0
an 0
important 0
regulator 0
of 0
melatonin 0
secretion 0
in 0
man 0
. 0

Is 0
anti-Pseudomonas 0
therapy 0
warranted 0
in 0
acute 0
respiratory B-PHYSICAL
exacerbations I-PHYSICAL
in 0
children 0
with 0
cystic 0
fibrosis 0
? 0

A 0
controlled 0
study 0
was 0
designed 0
to 0
clarify 0
the 0
indications 0
for 0
antibiotic 0
therapy 0
in 0
children 0
with 0
advanced 0
cystic 0
fibrosis 0
hospitalized 0
with 0
respiratory 0
exacerbations 0
. 0

Twenty-two 0
children 0
with 0
severe 0
CF 0
and 0
signs 0
of 0
acute 0
lower 0
respiratory 0
infection 0
were 0
randomly 0
assigned 0
to 0
receive 0
either 0
cloxacillin 0
or 0
carbenicillin 0
plus 0
gentamicin 0
administered 0
intravenously 0
for 0
ten 0
days 0
. 0

Other 0
aspects 0
of 0
therapy 0
were 0
constant 0
. 0

The 0
groups 0
were 0
comparable 0
in 0
all 0
respects 0
and 0
Pseudomonas 0
aeruginosa 0
was 0
the 0
predominant 0
sputum 0
pathogen 0
in 0
most 0
patients 0
. 0

Clinical B-PHYSICAL
improvement I-PHYSICAL
, 0
chest B-PHYSICAL
radiograph I-PHYSICAL
changes I-PHYSICAL
, 0
evidence B-PHYSICAL
of I-PHYSICAL
airway I-PHYSICAL
obstruction I-PHYSICAL
, 0
and 0

Placebo-controlled 0
acute 0
dosage 0
naltrexone 0
study 0
in 0
young 0
autistic 0
children 0
. 0

In 0
a 0
double-blind 0
, 0
placebo-controlled 0
crossover 0
trial 0
23 0
autistic 0
children 0
were 0
treated 0
with 0
a 0
single 0
40-mg 0
dose 0
of 0
the 0
opiate 0
antagonist 0
naltrexone 0
. 0

Drug 0
effects 0
were 0
monitored 0
by 0
detailed 0
playroom 0
observations 0
, 0
actometers 0
, 0
and 0
parents 0
' 0
checklist 0
ratings 0
( 0

Infliximab 0
in 0
ankylosing 0
spondylitis 0
: 0
alone 0
or 0
in 0
combination 0
with 0
methotrexate 0
? 0

A 0
pharmacokinetic 0
comparative 0
study 0
. 0

INTRODUCTION 0
Methotrexate 0
( 0
MTX 0
) 0
has 0
been 0
shown 0
to 0
modify 0
infliximab 0
pharmacokinetics 0
in 0
rheumatoid 0
arthritis 0
. 0

However 0
, 0
its 0
combination 0
with 0
infliximab 0
in 0
the 0
treatment 0
of 0
ankylosing 0
spondylitis 0
( 0
AS 0
) 0
is 0
not 0
recommended 0
. 0

The 0
objective 0
of 0
this 0
study 0
was 0
to 0
examine 0
the 0
influence 0
of 0
MTX 0
on 0
infliximab 0
exposure 0
in 0
patients 0
with 0
AS 0
. 0

METHODS 0
Patients 0
with 0
AS 0
patients 0
who 0
had 0
predominantly 0
axial 0
symptoms 0
were 0
randomised 0
to 0
receive 0
infliximab 0
alone 0
( 0
infusions 0
of 0
5 0
mg/kg 0
at 0
weeks 0
0 0
, 0
2 0
, 0
6 0
, 0
12 0
and 0
18 0
) 0
or 0
infliximab 0
combined 0
with 0
MTX 0
( 0
10 0
mg/week 0
) 0
. 0

Infliximab B-PHYSICAL
concentrations I-PHYSICAL
were 0
measured 0
before 0
and 0
2 0
hours 0
after 0
each 0
infusion 0
and 0
at 0
1 0
, 0
3 0
, 0
4 0
, 0
5 0
, 0
8 0
, 0
10 0
, 0
14 0
and 0
18 0
weeks 0
. 0

We 0
estimated 0
individual 0
cumulative 0
area 0
under 0
the 0
concentration 0
versus 0
time 0
curves 0
( 0
AUC 0
) 0
for 0
infliximab B-PHYSICAL
concentration I-PHYSICAL
between 0
baseline 0
and 0
week 0
18 0
( 0
AUC 0
( 0
0-18 0
) 0
) 0
. 0

Clinical 0
and 0
laboratory 0
evaluations 0
were 0
performed 0
at 0
each 0
visit 0
. 0

The 0
Bath B-OTHER
Ankylosing I-OTHER
Spondylitis I-OTHER
Disease I-OTHER
Activity I-OTHER
Index 0
( B-OTHER
BASDAI I-OTHER
) B-OTHER
score 0
was 0
the 0
primary 0
end 0
point 0
for 0
clinical 0
response 0
. 0

RESULTS 0
Twenty-six 0
patients 0
were 0
included 0
( 0
infliximab 0
group 0
: 0
n 0
= 0
12 0
, 0
infliximab 0
+ 0
MTX 0
group 0
: 0
n 0
= 0
14 0
) 0
, 0
and 0
507 0
serum 0
samples 0
were 0
available 0
for 0
measurement 0
of 0
infliximab B-PHYSICAL
concentration B-PHYSICAL
. 0

The 0
two 0
groups 0
did 0
not 0
differ 0
with 0
regard 0
to 0
AUC B-OTHER
( B-PHYSICAL

Comparative B-PHYSICAL
bioavailability I-PHYSICAL
of 0
two 0
formulations 0
of 0
terbinafine 0
. 0

Data 0
from 0
a 0
cross-over 0
, 0
randomised 0
, 0
open-label 0
bioequivalence 0
study 0
in 0
healthy 0
volunteers 0
. 0

An 0
open-label 0
, 0
randomised 0
, 0
cross-over 0
single 0
dose 0
study 0
, 0
using 0
2 0
periods 0
x 0
2 0
sequences 0
, 0
with 0
a 0
minimum 0
washout 0
period 0
of 0
21 0
days 0
, 0
was 0
conducted 0
in 0
order 0
to 0
assess 0
the 0
comparative B-PHYSICAL
bioavailability I-PHYSICAL
of 0
two 0
formulations 0
of 0
terbinafine 0
( 0
CAS 0
78628-80-5 0
) 0
250 0
mg 0
tablets 0
. 0

Plasma B-PHYSICAL
samples I-PHYSICAL
were 0
obtained 0
at 0
baseline 0
, 0
+0.333 0
; 0
0.667 0
; 0
1.00 0
; 0
1.33 0
; 0
1.67 0
; 0
2.00 0
; 0
2.33 0
; 0
2.67 0
; 0
3.00 0
; 0
3.50 0
; 0
4.00 0
; 0
6.00 0
; 0
8.00 0
; 0
12.0 0
; 0
24.0 0
; 0
36.0 0
; 0
48.0 0
and 0
72.0 0
h 0
post-administration 0
. 0

Terbinafine B-PHYSICAL
levels I-PHYSICAL
were 0
determined 0
by 0
high B-PHYSICAL
pressure I-PHYSICAL
liquid I-PHYSICAL
chromatography I-PHYSICAL
with 0
tandem 0
mass 0
detection 0
( 0
HPLC-MS/MS 0
) 0
and 0
the 0
lower 0
limit 0
of 0
quantification 0
was 0
set 0
at 0
9.99 0
ng/mL 0
. 0

The 0
pharmacokinetic B-OTHER
parameters I-OTHER
used 0
for 0
the 0
bioequivalence B-MENTAL
assessment I-MENTAL
( 0
AUClast B-MENTAL
, 0
AUCinf B-MENTAL
and 0
Cmax B-MENTAL
) 0
were 0
determined 0
from 0
the 0
terbinafine 0
concentration 0
data 0
using 0
non-compartmental 0
analysis 0
. 0

Bilateral 0
transversus 0
abdominis 0
plane 0
block 0
does 0
not 0
decrease 0
postoperative 0
pain 0
after 0
laparoscopic 0
cholecystectomy 0
when 0
compared 0
with 0
local 0
anesthetic 0
infiltration 0
of 0
trocar 0
insertion 0
sites 0
. 0

BACKGROUND 0
AND 0
OBJECTIVES 0
Transversus 0
abdominis 0
plane 0
( 0
TAP 0
) 0
block 0
has 0
been 0
shown 0
to 0
reduce 0
pain 0
and 0
analgesic 0
requirements 0
after 0
abdominal 0
surgery 0
. 0

Our 0
hypothesis 0
was 0
that 0
bilateral 0
TAP 0
blocks 0
decrease 0
pain 0
after 0
laparoscopic 0
cholecystectomy 0
when 0
compared 0
with 0
local 0
anesthetic 0
infiltration 0
of 0
trocar 0
insertion 0
sites 0
. 0

METHODS 0
Eighty 0
patients 0
undergoing 0
laparoscopic 0
cholecystectomy 0
were 0
randomized 0
to 0
receive 0
either 0
bilateral 0
TAP 0
blocks 0
or 0
local 0
anesthetic 0
infiltration 0
of 0
trocar 0
insertion 0
sites 0
with 0
ropivacaine 0
0.5 0
% 0
. 0

Postoperative B-PAIN
pain I-PAIN
scores 0
and 0
analgesic 0
use 0
for 0
the 0
first 0
24 0
hrs 0
were 0
recorded 0
. 0

RESULTS 0
Eighty 0
patients 0
were 0
enrolled 0
in 0
the 0
study 0
. 0

After 0
exclusions 0
, 0
data 0
were 0
analyzed 0
on 0
39 0
patients 0
in 0
group 0
T 0
( 0
bilateral 0
TAP 0
block 0
) 0
and 0
35 0
patients 0
in 0
group 0
I 0
( 0
infiltration 0
) 0
. 0

There 0
was 0
no 0
statistically 0
significant 0
difference B-PHYSICAL
in 0
pain B-PAIN
scores I-PAIN
on I-PAIN
the I-PAIN
numeric I-PAIN
analog I-PAIN
scale 0
( 0
0-10 0
) 0
between 0
the 0
groups 0
at 0
4 0
hrs 0
after 0
surgery 0
( 0
P 0
= 0
0.18 0
) 0
or 0
during 0
the 0
24 0
hrs 0
after 0
surgery 0
( 0
P 0
= 0
0.23 0
) 0
. 0

The 0
time B-OTHER
interval I-OTHER
from I-OTHER
anesthesia I-OTHER
start I-OTHER
to I-OTHER
surgery I-OTHER
start I-OTHER
was 0
greater 0
in 0
group 0
T 0
than 0
group 0
I 0
( 0
48 0
vs 0
35 0
mins 0
, 0
P 0
< 0
0.001 0
) 0
. 0

There 0
was 0
no 0
significant B-PHYSICAL
difference I-PHYSICAL
found 0
in 0
analgesic B-OTHER
use I-OTHER
during 0
the 0
first 0
24 0
hrs 0
after 0
surgery 0
. 0

CONCLUSIONS 0
Bilateral 0
ultrasound-guided 0
TAP 0
block 0
is 0
equivalent 0
to 0
local 0
anesthetic 0
infiltration 0
of 0
trocar 0
insertion 0
sites 0
for 0
overall 0
postoperative B-PAIN
pain I-PAIN
in 0
a 0
heterogeneous 0
group 0
of 0
patients 0
undergoing 0
laparoscopic 0
cholecystectomy 0
. 0

Oral 0
ganciclovir 0
dosing 0
in 0
transplant 0
recipients 0
and 0
dialysis 0
patients 0
based 0
on 0
renal 0
function 0
. 0

BACKGROUND 0
An 0
oral 0
formulation 0
of 0
ganciclovir 0
( 0
GCV 0
) 0
was 0
recently 0
approved 0
for 0
the 0
prevention 0
of 0
cytomegalovirus 0
disease 0
in 0
solid 0
organ 0
transplant 0
recipients 0
. 0

This 0
study 0
was 0
designed 0
to 0
determine 0
the 0
bioavailability 0
of 0
GCV 0
and 0
to 0
test 0
a 0
dosing 0
algorithm 0
in 0
transplant 0
and 0
dialysis 0
patients 0
with 0
different 0
levels 0
of 0
renal 0
function 0
. 0

METHODS 0
Pharmacokinetic 0
studies 0
were 0
carried 0
out 0
in 0
23 0
patients 0
who 0
were 0
either 0
a 0
recipient 0
of 0
an 0
organ 0
transplant 0
or 0
on 0
hemodialysis 0
. 0

Drug 0
dosing 0
was 0
established 0
by 0
the 0
following 0
algorithm 0
based 0
on 0
calculated 0
creatinine 0
clearance 0
( 0
CrCl 0
) 0
: 0
CrCl 0
= 0
[ 0
( 0
140-age 0
) 0
x 0
body 0
weight 0
] 0
/ 0
( 0
72 0
x 0
Cr 0
) 0
x 0
0.85 0
for 0
women 0
that 0
is 0
, 0
CrCl 0
> 0
50 0
ml/min 0
, 0
1000 0
mg 0
every 0
8 0
hr 0
; 0
CrCl 0
of 0
25-50 0
ml/min 0
, 0
1000 0
mg 0
every 0
24 0
hr 0
; 0
CrCl 0
of 0
10-24 0
ml/ 0
min 0
, 0
500 0
mg 0
every 0
day 0
; 0
CrCl 0
< 0
10 0
ml/min 0
( 0
or 0
on 0
dialysis 0
) 0
, 0
500 0
mg 0
every 0
other 0
day 0
after 0
dialysis 0
. 0

GCV 0
was 0
taken 0
within 0
30 0
min 0
after 0
a 0
meal 0
. 0

The 0
patients 0
received 0
oral 0
GCV 0
for 0
between 0
12 0
days 0
and 0
14 0
weeks 0
. 0

Serum 0
specimens 0
( 0
or 0
plasma 0
from 0
patients 0
on 0
hemodialysis 0
) 0
obtained 0
at 0
steady 0
state 0
were 0
analyzed 0
for 0
GCV 0
concentrations 0
by 0
high-performance 0
liquid 0
chromatography 0
. 0

In 0
nine 0
of 0
the 0
transplant 0
recipients 0
, 0
absolute B-PHYSICAL
bioavailability I-PHYSICAL
was 0
determined 0
by 0
comparing 0
GCV B-PHYSICAL
levels I-PHYSICAL
after 0
single 0
oral 0
and 0
intravenous 0
doses 0
of 0
GCV 0
. 0

RESULTS 0
The 0
following 0
GCV B-PHYSICAL
concentrations I-PHYSICAL
( 0
mean 0
+/-SD 0
) 0
were 0
determined 0
: 0
with 0
CrCl 0
of 0
> 0
or 0
=70 0
ml/min 0
, 0
the 0
minimum 0
steady-state 0
concentration 0
( 0
Cmin 0
) 0
and 0
maximum 0
concentration 0
( 0
Cmax 0
) 0
were 0
0.78+/-0.46 0
microg/ml 0
and 0
1.42+/-0.37 0
microg/ml 0
, 0
respectively 0
, 0
with 0
a 0
24-hr 0
area 0
under 0
the 0
concentration 0
time 0
curve 0
( 0
AUC0-24 0
) 0
of 0
24.7+/-7.8 0
microg 0
x 0
hr/ml 0
; 0
with 0
CrCl 0
of 0
50-69 0
ml/min 0
, 0
the 0
Cmin 0
and 0
Cmax 0
were 0
1.93+/-0.48 0
and 0
2.57+/-0.39 0
microg/ml 0
, 0
respectively 0
, 0
with 0
an 0
AUC0-24 0
of 0
52.1+/-10.1 0
microg 0
x 0
hr/ml 0
; 0
with 0
CrCl 0
of 0
25-50 0
ml/min 0
, 0
the 0
Cmin 0
and 0
Cmax 0
were 0
0.41+/-0.27 0
and 0
1.17+/-0.32 0
microg/ml 0
, 0
respectively 0
, 0
with 0
an 0
AUC0-24 0
of 0
14.6+/-7.4 0
microg 0
x 0
hr/ml 0
. 0

For 0
one 0
patient 0
with 0
a 0
CrCl 0
of 0
23.8 0
ml/min 0
, 0
the 0
Cmin 0
and 0
Cmax 0
were 0
0.32 0
and 0
0.7 0
microg/ml 0
, 0
respectively 0
, 0
with 0
an 0
AUC0-24 0
of 0
10.7 0
microg 0
x 0
hr/ml 0
. 0

With 0
CrCl 0
of 0
< 0
10 0
ml/min 0
, 0
the 0
mean 0
Cmin 0
and 0
Cmax 0
were 0
0.75+/-0.42 0
and 0
1.59+/-0.55 0
microg/ml 0
, 0
respectively 0
, 0
with 0
a 0
mean 0
AUC0-24 0
of 0
64.6+/-18.8 0
microg 0
x 0
hr/ml 0
. 0

Absolute B-PHYSICAL
bioavailability I-PHYSICAL
, 0
for 0
the 0
nine 0
patients 0
so 0
analyzed 0
, 0
was 0
7.2+/-2.4 0
% 0
. 0

For 0
those 0
patients 0
with 0
end-stage 0
renal 0
failure 0
, 0
GCV B-PHYSICAL
concentrations I-PHYSICAL
fell 0
during 0
dialysis 0
from 0
a 0
mean 0
of 0
1.47+/-0.48 0
microg/ml 0
before 0
dialysis 0
to 0
0.69+/-0.38 0
microg/ml 0
after 0
dialysis 0
. 0

CONCLUSIONS 0
The 0
bioavailability 0
of 0
oral 0
GCV 0
in 0
transplant 0
patients 0
was 0
similar 0
to 0
that 0
observed 0
in 0
human 0
immunodeficiency 0
virus-infected 0
patients 0
. 0

However 0
, 0
levels 0
between 0
0.5 0
and 0
1 0
microg/ml 0
( 0
within 0
the 0
IC50 0
of 0
most 0
cytomegalovirus 0
isolates 0
) 0
could 0
be 0
achieved 0
with 0
tolerable 0
oral 0
doses 0
. 0

The 0
proposed 0
dosing 0
algorithm 0
resulted 0
in 0
adequate 0
levels 0
for 0
patients 0
with 0
CrCl 0
greater 0
than 0
50 0
ml/min 0
and 0
for 0
patients 0
on 0
dialysis 0
. 0

For 0
patients 0
with 0
CrCl 0
between 0
10 0
and 0
50 0
ml/min 0
, 0
the 0
levels 0
achieved 0
were 0
low 0
and 0
these 0
patients 0
would 0
likely 0
benefit 0
from 0
increased 0
doses 0
. 0

The 0
effect 0
of 0
aging 0
on 0
circulating 0
levels 0
of 0
proinflammatory 0
cytokines 0
during 0
septic 0
shock 0
. 0

Norasept 0
II 0
Study 0
Investigators 0
. 0

BACKGROUND 0
As 0
the 0
proportion 0
of 0
the 0
population 0
that 0
is 0
older 0
continues 0
to 0
rise 0
, 0
infection 0
in 0
older 0
people 0
has 0
become 0
an 0
important 0
healthcare 0
problem 0
. 0

Although 0
aging 0
is 0
associated 0
with 0
multiple 0
abnormalities 0
in 0
immune 0
function 0
, 0
the 0
effect 0
of 0
aging 0
on 0
the 0
production 0
of 0
proinflammatory B-PHYSICAL
cytokines 0
has 0
not 0
been 0
well 0
studied 0
under 0
conditions 0
of 0
clinical 0
stress 0
. 0

OBJECTIVES 0
The 0
aim 0
of 0
this 0
study 0
was 0
to 0
examine 0
the 0
effect 0
of 0
aging 0
on 0
circulating 0
levels 0
of 0
the 0
proinflammatory 0
cytokines 0
in 0
a 0
large 0
cohort 0
of 0
septic 0
shock 0
patients 0
. 0

We 0
hypothesized 0
that 0
aging 0
would 0
be 0
associated 0
with 0
a 0
diminished 0
proinflammatory 0
cytokine 0
response 0
to 0
sepsis 0
. 0

DESIGN 0
Patients 0
with 0
septic 0
shock 0
who 0
were 0
enrolled 0
in 0
the 0
placebo 0
limb 0
of 0
the 0
North 0
American 0
Sepsis 0
Trial 0
( 0
NORASEPT 0
II 0
) 0
study 0
were 0
analyzed 0
. 0

SETTING 0
The 0
intensive 0
care 0
units 0
of 0
105 0
hospitals 0
in 0
the 0
United 0
States 0
and 0
Canada 0
. 0

PARTICIPANTS 0
Nine 0
hundred 0
and 0
thirty 0
patients 0
presenting 0
to 0
hospital 0
within 0
12 0
hours 0
of 0
the 0
onset 0
of 0
septic 0
shock 0
. 0

MEASUREMENTS 0
Interleukin-6 B-PHYSICAL
( I-PHYSICAL
IL-6 I-PHYSICAL
) I-PHYSICAL
, 0
tumor B-PHYSICAL
necrosis I-PHYSICAL
factor-alpha I-PHYSICAL
( I-PHYSICAL
TNF-alpha I-PHYSICAL
) I-PHYSICAL
, 0
soluble B-PHYSICAL
tumor I-PHYSICAL
necrosis I-PHYSICAL
factor-receptor-55 I-PHYSICAL
( I-PHYSICAL
sTNF-R55 I-PHYSICAL
) I-PHYSICAL
, 0
and 0
soluble B-PHYSICAL
tumor I-PHYSICAL
necrosis I-PHYSICAL
factor-receptor-75 I-PHYSICAL
( I-PHYSICAL
sTNF-R75 I-PHYSICAL
) I-PHYSICAL
concentrations I-PHYSICAL
were 0
measured 0
at 0
enrollment 0
. 0

The 0
study 0
population 0
was 0
broken 0
down 0
into 0
five 0
age 0
groups 0
as 0
follows 0
: 0
less 0
than 0
50 0
years 0
( 0
group 0
one 0
) 0
, 0
50 0
to 0
64 0
years 0
( 0
group 0
two 0
) 0
, 0
65 0
to 0
74 0
years 0
( 0
group 0
three 0
) 0
, 0
75 0
to 0
84 0
years 0
( 0
group 0
four 0
) 0
, 0
and 0
85 0
or 0
older 0
( 0
group 0
five 0
) 0
. 0

Clinical B-OTHER
, 0
demographic B-OTHER
, 0
and 0

Perceptual B-MENTAL
learning I-MENTAL
of I-MENTAL
speech I-MENTAL
under 0
optimal 0
and 0
adverse 0
conditions 0
. 0

Humans 0
have 0
a 0
remarkable 0
ability 0
to 0
understand 0
spoken 0
language 0
despite 0
the 0
large 0
amount 0
of 0
variability 0
in 0
speech 0
. 0

Previous 0
research 0
has 0
shown 0
that 0
listeners 0
can 0
use 0
lexical 0
information 0
to 0
guide 0
their 0
interpretation 0
of 0
atypical 0
sounds 0
in 0
speech 0
( 0
Norris 0
, 0
McQueen 0
, 0
& 0
Cutler 0
, 0
2003 0
) 0
. 0

This 0
kind 0
of 0
lexically 0
induced 0
perceptual B-MENTAL
learning I-MENTAL
enables 0
people 0
to 0
adjust 0
to 0
the 0
variations 0
in 0
utterances 0
due 0
to 0
talker-specific 0
characteristics 0
, 0
such 0
as 0
individual 0
identity 0
and 0
dialect 0
. 0

The 0
current 0
study 0
investigated 0
perceptual B-MENTAL
learning I-MENTAL
in 0
two 0
optimal 0
conditions 0
: 0
conversational 0
speech 0
( 0
Experiment 0
1 0
) 0
versus 0
clear 0
speech 0
( 0
Experiment 0
2 0
) 0
, 0
and 0
three 0
adverse 0
conditions 0
: 0
noise 0
( 0
Experiment 0
3a 0
) 0
versus 0
two 0
cognitive 0
loads 0
( 0
Experiments 0
4a 0
and 0
4b 0
) 0
. 0

Perceptual B-MENTAL
learning I-MENTAL
occurred 0
in 0
the 0
two 0
optimal 0
conditions 0
and 0
in 0
the 0
two 0
cognitive 0
load 0
conditions 0
, 0
but 0
not 0
in 0
the 0
noise 0
condition 0
. 0

Furthermore 0
, 0
perceptual B-MENTAL
learning I-MENTAL
occurred 0
only 0
in 0
the 0
first 0
of 0
two 0
sessions 0
for 0
each 0
participant 0
, 0
and 0
only 0
for 0
atypical 0
/s/ 0
sounds 0
and 0
not 0
for 0
atypical 0
/f/ 0
sounds 0
. 0

This 0
pattern 0
of 0
learning 0
and 0
nonlearning 0
reflects 0
a 0
balance 0
between 0
flexibility 0
and 0
stability 0
that 0
the 0
speech 0
system 0
must 0
have 0
to 0
deal 0
with 0
speech 0
variability 0
in 0
the 0
diverse 0
conditions 0
that 0
speech 0
is 0
encountered 0
. 0

Oesophageal 0
intubation 0
can 0
be 0
undetected 0
by 0
auscultation 0
of 0
the 0
chest 0
. 0

Prompt 0
detection 0
of 0
oesophageal 0
intubation 0
is 0
a 0
primary 0
concern 0
in 0
anaesthetic 0
practice 0
. 0

This 0
blind 0
, 0
randomised 0
study 0
evaluates 0
three 0
widely 0
used 0
tests 0
of 0
intubation 0
. 0

Forty 0
patients 0
had 0
both 0
their 0
trachea 0
and 0
oesophagus 0
intubated 0
, 0
each 0
patient 0
was 0
studied 0
twice 0
. 0

Auscultation B-OTHER
of I-OTHER
the I-OTHER
epigastrium I-OTHER
, 0
right 0
and 0
left 0
axilla 0
is 0
more 0
reliable 0
than 0
auscultation 0
of 0
the 0
chest 0
, 0
and 0
the 0
anaesthetist 0
's 0
feeling 0
when 0
he 0
squeezes 0
the 0
bag 0
. 0

P 0
= 0
0.001 0
and 0
P 0
= 0
0.048 0
, 0
respectively 0
. 0

The 0
tests 0
were 0
carried 0
out 0
after 0
gastric 0
distension 0
with 0
gas 0
had 0
occurred 0
. 0

We 0
conclude 0
that 0
auscultation 0
of 0
epigastrium 0
, 0
right 0
and 0
left 0
axilla 0
, 0
are 0
recommended 0
. 0

The 0
use 0
of 0
adrenocorticotrophic 0
hormone 0
( 0
4-9 0
) 0
analog 0
ORG 0
2766 0
in 0
autistic 0
children 0
: 0
effects 0
on 0
the 0
organization 0
of 0
behavior 0
. 0

In 0
a 0
double-blind 0
placebo-controlled 0
crossover 0
trial 0
, 0
14 0
autistic 0
children 0
were 0
treated 0
with 0
the 0
neuropeptide 0
ORG 0
2766 0
, 0
a 0
synthetic 0
analog 0
of 0
adrenocorticotrophic 0
hormone 0
( 0
ACTH 0
) 0
( 0
4-9 0
) 0
. 0

ORG 0
2766 0
treatment 0
( 0
20 0
mg 0
per 0
day 0
during 0
4 0
weeks 0
) 0
was 0
associated 0
with 0
an 0
increased 0
amount 0
and 0
an 0
improved 0
quality 0
of 0
the 0
social 0
interaction 0
of 0
the 0
autistic 0
children 0
with 0
a 0
familiar 0
experimenter 0
. 0

These 0
changes 0
in 0
interaction 0
were 0
clinically 0
relevant 0
. 0

Following 0
treatment 0
with 0
ORG 0
2766 0
gaze 0
and 0

Randomized 0
study 0
of 0
chlorambucil 0
( 0
CB 0
) 0
compared 0
to 0
interferon 0
( 0
alfa-2b 0
) 0
combined 0
with 0
CB 0
in 0
low-grade 0
non-Hodgkin 0
's 0
lymphoma 0
: 0
an 0
interim 0
report 0
of 0
a 0
randomized 0
study 0
. 0

Non-Hodgkin 0
's 0
Lymphoma 0
Cooperative 0
Study 0
Group 0
. 0

Alpha 0
interferon 0
has 0
shown 0
initial 0
promise 0
in 0
the 0
treatment 0
of 0
low-grade 0
non-Hodgkin 0
's 0
lymphoma 0
( 0
NHL 0
) 0
, 0
especially 0
with 0
the 0
nodular 0
form 0
of 0
the 0
disease 0
. 0

The 0
present 0
study 0
enrolled 0
70 0
NHL 0
patients 0
who 0
received 0
either 0
chlorambucil 0
( 0
CB 0
; 0
10 0
mg/day 0
) 0
or 0
CB 0
plus 0
interferon 0
alfa-2b 0
( 0
5 0
million 0
units 0
( 0
MU 0
) 0
/m2 0
subcutaneously 0
three 0
times 0
a 0
week 0
) 0
. 0

Among 0
63 0
evaluable 0
patients 0
, 0
similar 0
response 0
rates 0
( 0
62.1 0
% 0
and 0
64.7 0
% 0
respectively 0
) 0
were 0
recorded 0
for 0
the 0
treatment 0
arms 0
. 0

In 0
patients 0
receiving 0
no 0
maintenance 0
therapy 0
, 0
those 0
who 0
received 0
interferon 0
alfa-2b 0
during 0
the 0
induction 0
phase 0
showed 0
a 0
favourable 0
trend 0
in 0
terms 0
of 0
incidence 0
of 0
relapse B-PHYSICAL
compared 0
to 0
those 0
who 0
had 0
received 0
chlorambucil 0
alone 0
. 0

During 0
maintenance 0
therapy 0
with 0
interferon 0
alfa-2b 0
, 0
no 0
significant 0
differences 0
in 0
the 0
occurrence B-PHYSICAL
of I-PHYSICAL
relapse I-PHYSICAL
have 0
yet 0
been 0
seen 0
compared 0
to 0
patients 0
on 0
no 0
maintenance 0
therapy 0
. 0

A 0
longer 0
observation 0
period 0
is 0
needed 0
to 0
make 0
a 0
definitive 0
conclusion 0
about 0
the 0
usefulness 0
of 0
interferon 0
maintenance 0
therapy 0
and 0
to 0
evaluate 0
further 0
the 0
effects 0
of 0
the 0
combined 0
schedule 0
of 0
chlorambucil 0
and 0
interferon 0
induction 0
on 0
the 0
duration 0
of 0
remission 0
. 0

Local 0
injection 0
of 0
bupivacaine 0
after 0
rubber 0
band 0
ligation 0
of 0
hemorrhoids 0
: 0
prospective 0
, 0
randomized 0
study 0
. 0

PURPOSE 0
The 0
aim 0
of 0
this 0
study 0
was 0
to 0
determine 0
if 0
local 0
injection 0
of 0
bupivacaine 0
after 0
hemorrhoidal 0
banding 0
causes 0
a 0
decrease 0
in B-PAIN
pain I-PAIN
and I-PAIN
in I-PAIN
the I-PAIN
incidence 0
of B-PAIN
associated B-PAIN
symptoms B-PAIN
. 0

METHODS 0
After 0
hemorrhoidal 0
banding 0
, 0
patients 0
were 0
randomly 0
assigned 0
to 0
receive 0
a 0
local 0
injection 0
of 0
bupivacaine 0
with 0
1:200,000 0
epinephrine 0
, 0
an 0
injection 0
of 0
normal 0
saline 0
, 0
or 0
no 0
injection 0
, 0
just 0
superior 0
to 0
each 0
band 0
. 0

Pain B-PAIN
was 0
graded 0
by 0
the 0
patient 0
and 0
by 0
the 0
study 0
nurse 0
within 0
30 0
minutes 0
, 0
and 0
any 0
associated B-PHYSICAL
symptoms I-PHYSICAL
were 0
recorded 0
. 0

At 0
intervals 0
6 0
, 0
24 0
, 0
and 0
48 0
hours 0
postbanding 0
, 0
the 0
patient 0
recorded 0

[ 0
Rilmenidine 0
sympatholytic 0
activity 0
preserves 0
mental B-MENTAL
and I-MENTAL
orthostatic I-MENTAL
sympathetic I-MENTAL
response I-MENTAL
and 0
epinephrine B-PHYSICAL
secretion I-PHYSICAL
] I-PHYSICAL
. 0

BACKGROUND 0
Heightened 0
central 0
sympathetic 0
nervous 0
outflow 0
is 0
common 0
in 0
essential 0
hypertension 0
, 0
contributing 0
to 0
hypertension 0
development 0
and 0
perhaps 0
also 0
to 0
complications 0
. 0

Acute 0
sympathetic 0
nervous 0
activation 0
is 0
a 0
proven 0
trigger 0
for 0
adverse B-ADVERSE-EFFECTS
cardiovascular I-ADVERSE-EFFECTS
events I-ADVERSE-EFFECTS
. 0

Accordingly 0
, 0
antihypertensive 0
drugs 0
inhibiting 0
sympathetic 0
outflow 0
represent 0
a 0
theoretically 0
attractive 0
therapeutic 0
option 0
. 0

OBJECTIVES 0
To 0
study 0
the 0
sympatholytic 0
and 0
blood B-PHYSICAL
pressure I-PHYSICAL
lowering I-PHYSICAL
activity I-PHYSICAL
of 0
the 0
imidazoline 0
binding 0
agent 0
rilmenidine 0
at 0
rest 0
and 0
during 0
reflex 0
sympathetic 0
activation 0
. 0

DESIGN 0
AND 0
METHODS 0
The 0
HERA 0
study 0
( 0
Hyperium 0
Effect 0
on 0
the 0
sympathetic 0
Reflex 0
activation 0
and 0
Adrenaline 0
) 0
is 0
a 0
randomised 0
, 0
double-blind 0
, 0
6-week 0
cross-over 0
trial 0
, 0
with 0
a 0
1-week 0
placebo 0
run-in 0
period 0
, 0
two 0
2-week 0
active 0
treatment 0
intervals 0
( 0
rilmenidine 0
1 0
mg 0
bid 0
, 0
placebo 0
) 0
and 0
intervening 0
one 0
week 0
placebo 0
wash-out 0
. 0

In 0
15 0
hypertensive 0
patients 0
, 0
noradrenaline B-PHYSICAL
and I-PHYSICAL
adrenaline I-PHYSICAL
plasma I-PHYSICAL
kinetics I-PHYSICAL
and I-PHYSICAL
intra-arterial I-PHYSICAL
blood I-PHYSICAL
pressure I-PHYSICAL
measurements I-PHYSICAL
were 0
performed 0
at 0
rest 0
, 0
after 0
mental 0
stress 0
( 0
difficult 0
mental 0
arithmetic 0
) 0
and 0
during 0
head-up 0
tilting 0
, 0
at 0
the 0
end 0
of 0
the 0
2-week 0
dosing 0
periods 0
. 0

RESULTS 0
The 0
noradrenaline 0
spillover 0
rate 0
, 0
indicative 0
of 0
whole 0
body 0
sympathetic 0
activity 0
, 0
was 0
reduced 0
35 0
% 0
by 0
rilmenidine 0
at 0
rest 0
( 0
p 0
< 0
0.01 0
) 0
and 0
remained 0
significantly 0
lower 0
during 0
mental 0
stress 0
and 0
tilting 0
, 0
although 0
the 0
increases 0
in 0
noradrenaline B-PHYSICAL
spillover I-PHYSICAL
with 0
both 0
stimuli 0
were 0
preserved 0
. 0

The 0
effects 0
on 0
intraarterial B-PHYSICAL
blood I-PHYSICAL
pressure I-PHYSICAL
ran 0
in 0
parallel 0
, 0
a 0
fall 0
in 0
supine 0
resting 0
pressure 0
, 0
but 0
no 0
reduction 0
in 0
BP B-PHYSICAL
rise I-PHYSICAL
during 0
mental 0
stress 0
and 0
a 0
lack 0
of 0
fall 0
in 0
BP B-PHYSICAL
with 0
tilting 0
. 0

On 0
placebo 0
, 0
adrenaline B-PHYSICAL
secretion I-PHYSICAL
was 0
162 0
+/- 0
27 0
ng/min 0
( 0
mean 0
, 0
SE 0
) 0
at 0
rest 0
, 0
increased 0
by 0
77 0
+/- 0
42 0
ng/min 0
with 0
mental 0
stress 0
( 0
p=0.019 0
) 0
and 0
was 0
unchanged 0
with 0
tilting 0
. 0

Rilmenidine 0
left 0
adrenaline B-PHYSICAL
secretion I-PHYSICAL
untouched 0
under 0
all 0
conditions 0
. 0

CONCLUSIONS 0
This 0
study 0
confirms 0
a 0
sympatholytic 0
effect 0
of 0
rilmenidine 0
during 0
supine 0
rest 0
but 0
demonstrates 0
that 0
sympathetic B-PHYSICAL
responses I-PHYSICAL
during 0
mental 0
stress 0
and 0
tilting 0
are 0
preserved 0
, 0
the 0
latter 0
underlying 0
a 0
perhaps 0
surprising 0
absence 0
of 0
postural 0
hypotension 0
on 0
the 0
drug 0
. 0

The 0
absence 0
of 0
suppression 0
of 0
reflexive 0
sympathetic 0
responses 0
contrasts 0
with 0
the 0
effects 0
of 0
rilmenidine 0
in 0
experimental 0
animals 0
, 0
and 0
emphasises 0
the 0
previously 0
demonstrated 0
unique 0
importance 0
in 0
humans 0
of 0
suprabulbar 0
noradrenergic 0
neuronal 0
projections 0
from 0
the 0
brainstem 0
, 0
which 0
are 0
inhibited 0
by 0
imidazoline 0
binding 0
agents 0
, 0
in 0
regulating 0
tonic B-PHYSICAL
sympathetic I-PHYSICAL
activity I-PHYSICAL
in 0
essential 0
hypertension 0
. 0

Sympathetic 0
nervous 0
inhibition 0
with 0
rilmenidine 0
contrasted 0
with 0
an 0
absence 0
of 0
suppression 0
of 0
the 0
secretion 0
of 0
adrenaline 0
affirming 0
that 0
here 0
, 0
as 0
elsewhere 0
, 0
sympathetic B-MENTAL
nervous I-MENTAL
and 0
adrenal B-PHYSICAL
medullary I-PHYSICAL
function I-PHYSICAL
can 0
be 0
disconnected 0
. 0

A 0
randomized 0
effectiveness 0
trial 0
of 0
collaborative 0
care 0
for 0
patients 0
with 0
panic 0
disorder 0
in 0
primary 0
care 0
. 0

BACKGROUND 0
Effectiveness 0
studies 0
have 0
tested 0
interventions 0
to 0
improve 0
quality B-OTHER
of I-OTHER
care I-OTHER
for 0
depression 0
in 0
primary 0
care 0
, 0
but 0
none 0
, 0
to 0
our 0
knowledge 0
, 0
have 0
been 0
completed 0
for 0
panic 0
disorder 0
( 0
PD 0
) 0
in 0
this 0
setting 0
. 0

This 0
study 0
sought 0
to 0
test 0
the 0
clinical B-OTHER
effectiveness I-OTHER
of 0
PD 0
pharmacotherapy 0
embedded 0
in 0
a 0
disease 0
management 0
framework 0
of 0
collaborative 0
care 0
( 0
CC 0
) 0
. 0

METHODS 0
One 0
hundred 0
fifteen 0
patients 0
with 0
PD 0
from 0
3 0
primary 0
care 0
clinics 0
were 0
randomized 0
to 0
CC 0
or 0
usual 0
care 0
( 0
UC 0
) 0
. 0

Patients 0
in 0
CC 0
( 0
n 0
= 0
57 0
) 0
received 0
educational 0
videotapes 0
and 0
pamphlets 0
; 0
pharmacotherapy 0
with 0
the 0
selective 0
serotonin 0
reuptake 0
inhibitor 0
paroxetine 0
; 0
2 0
psychiatrist 0
visits 0
and 0
2 0
telephone 0
calls 0
in 0
the 0
first 0
8 0
weeks 0
; 0
and 0
up 0
to 0
5 0
telephone 0
calls 0
between 0
3 0
and 0
12 0
months 0
' 0
follow-up 0
. 0

Usual 0
care 0
patients 0
( 0
n 0
= 0
58 0
) 0
were 0
treated 0
by 0
their 0
primary 0
care 0
physician 0
. 0

Telephone 0
assessments 0
of 0
panic B-MENTAL
, 0
anxiety B-MENTAL
sensitivity I-MENTAL
, 0
depression B-MENTAL
, 0
and 0
disability B-MENTAL
variables I-MENTAL
were 0
performed 0
at 0
3 0
, 0
6 0
, 0
9 0
, 0
and 0
12 0
months 0
' 0
follow-up 0
. 0

Adequacy B-OTHER
of I-OTHER
pharmacotherapy I-OTHER
was 0
assessed 0
with 0
an 0
algorithm 0
based 0
on 0
a 0
review 0
of 0
efficacy 0
studies 0
. 0

RESULTS 0
Patients 0
in 0
CC 0
were 0
more 0
likely 0
to 0
receive 0
adequate B-OTHER
( 0
type 0
, 0

Safety 0
of 0
injectable 0
opioid 0
maintenance 0
treatment 0
for 0
heroin 0
dependence 0
. 0

BACKGROUND 0
There 0
is 0
a 0
growing 0
debate 0
about 0
injectable 0
opioid 0
treatment 0
programs 0
in 0
many 0
Western 0
countries 0
. 0

This 0
is 0
the 0
first 0
placebo-controlled 0
study 0
of 0
the 0
safety 0
of 0
injectable 0
opioids 0
in 0
a 0
controlled 0
treatment 0
setting 0
. 0

METHODS 0
Twenty-five 0
opioid-dependent 0
patients 0
on 0
intravenous 0
( 0
IV 0
) 0
heroin 0
or 0
IV 0
methadone 0
maintenance 0
treatment 0
were 0
randomly 0
assigned 0
to 0
either 0
their 0
individual 0
prescribed 0
IV 0
maintenance 0
dose 0
or 0
placebo 0
. 0

Acute B-OTHER
drug I-OTHER
effects I-OTHER
were 0
recorded 0
, 0
focusing 0
on 0
electrocardiography B-OTHER
, 0
respiratory B-PHYSICAL
movements I-PHYSICAL
, 0
arterial B-PHYSICAL
blood I-PHYSICAL
oxygen I-PHYSICAL
saturation I-PHYSICAL
, 0
and 0
electroencephalography B-PHYSICAL
( I-PHYSICAL
EEG I-PHYSICAL
) I-PHYSICAL
. 0

RESULTS 0
After 0
heroin 0
injection 0
, 0
marked 0
respiratory B-PHYSICAL
depression I-PHYSICAL
progressing 0
to 0
a 0
Cheyne-Stokes B-PHYSICAL
pattern I-PHYSICAL
occurred 0
. 0

Peripheral B-PHYSICAL
arterial I-PHYSICAL
blood I-PHYSICAL
oxygenation I-PHYSICAL
decreased 0
to 0
78.9 0
+/- 0
8.7 0
% 0
( 0
mean 0
+/- 0
SD 0
) 0
ranging 0
from 0
52 0
% 0
-90 0
% 0
. 0

During 0
hypoxia B-PHYSICAL
, 0
7 0
of 0
the 0
16 0
subjects 0
experienced 0
intermittent 0
and 0
somewhat 0
severe 0
bradycardia B-PHYSICAL
. 0

Five 0
subjects 0
exhibited 0
paroxysmal B-PHYSICAL
EEG I-PHYSICAL
patterns I-PHYSICAL
. 0

After 0
methadone 0
injection 0
, 0
respiratory B-PHYSICAL
depression I-PHYSICAL
was 0
less 0
pronounced 0
than 0
after 0
heroin 0
injection 0
. 0

No 0
relevant 0
bradycardia B-PHYSICAL
was 0
noted 0
. 0

CONCLUSIONS 0
Opioid 0
doses 0
commonly 0
prescribed 0
in 0
IV 0
opioid 0
treatment 0
induce 0
marked 0
respiratory B-PHYSICAL
and I-PHYSICAL
circulatory I-PHYSICAL
depression I-PHYSICAL
, 0
as 0
well 0
as 0
occasionally 0
irregular B-PHYSICAL
paroxysmal I-PHYSICAL
EEG I-PHYSICAL
activity I-PHYSICAL
. 0

Further 0
studies 0
are 0
needed 0
to 0
optimize 0
the 0
clinical 0
practice 0
of 0
IV 0
opioid 0
treatment 0
to 0
prevent 0
serious 0
complications 0
. 0

Moreover 0
, 0
the 0
extent 0
of 0
the 0
observed 0
effects 0
raises 0
questions 0
about 0
the 0
appropriateness 0
of 0
IV 0
opioid 0
treatment 0
in 0
the 0
present 0
form 0
. 0

Phosphate 0
binder 0
impact 0
on 0
bone B-PHYSICAL
remodeling I-PHYSICAL
and 0
coronary B-PHYSICAL
calcification I-PHYSICAL
-- 0
results 0
from 0
the 0
BRiC 0
study 0
. 0

BACKGROUND 0
AND 0
AIMS 0
Calcium-containing 0
phosphate 0
binders 0
have 0
been 0
shown 0
to 0
increase 0
the 0
progression 0
of 0
vascular B-PHYSICAL
calcification I-PHYSICAL
in 0
hemodialysis 0
patients 0
. 0

This 0
is 0
a 0
prospective 0
study 0
that 0
compares 0
the 0
effects 0
of 0
calcium 0
acetate 0
and 0
sevelamer 0
on 0
coronary B-PHYSICAL
calcification I-PHYSICAL
( 0
CAC 0
) 0
and 0
bone B-PHYSICAL
histology I-PHYSICAL
. 0

METHODS 0
101 0
hemodialysis 0
patients 0
were 0
randomized 0
for 0
each 0
phosphate 0
binder 0
and 0
submitted 0
to 0
multislice 0
coronary 0
tomographies 0
and 0
bone 0
biopsies 0
at 0
entry 0
and 0
12 0
months 0
. 0

RESULTS 0
The 0
71 0
patients 0
who 0
concluded 0
the 0
study 0
had 0
similar 0
baseline 0
characteristics 0
. 0

On 0
follow-up 0
, 0
the 0
sevelamer 0
group 0
had 0
higher 0
levels 0
of 0
intact B-PHYSICAL
parathyroid I-PHYSICAL
hormone I-PHYSICAL
( 0
498 0
+/- 0
352 0
vs. 0
326 0
+/- 0
236 0
pg/ml 0
, 0
p 0
= 0
0.017 0
) 0
, 0
bone B-PHYSICAL
alkaline I-PHYSICAL
phosphatase I-PHYSICAL
( 0
38 0
+/- 0
24 0
vs. 0
28 0
+/- 0
15 0
U/l 0
, 0
p 0
= 0
0.03 0
) 0
and 0
deoxypyridinoline B-PHYSICAL
( 0
135 0
+/- 0
107 0
vs. 0
89 0
+/- 0
71 0
nmol/l 0
, 0
p 0
= 0
0.03 0
) 0
and 0
lower B-PHYSICAL
LDL I-PHYSICAL
cholesterol I-PHYSICAL
( 0
74 0
+/- 0
21 0
vs. 0
91 0
+/- 0
28 0
mg/dl 0
, 0
p 0
= 0
0.015 0
) 0
. 0

Phosphorus B-PHYSICAL
( 0
5.8 0
+/- 0
1.0 0
vs. 0
6 0
+/- 0
1.0 0
mg/dl 0
, 0
p 0
= 0
0.47 0
) 0
and 0
calcium B-PHYSICAL
( 0
1.27 0
+/- 0
0.07 0
vs. 0
1.23 0
+/- 0
0.08 0
mmol/l 0
, 0
p 0
= 0
0.68 0
) 0
levels 0
did 0
not 0
differ 0
between 0
groups 0
. 0

CAC B-PHYSICAL
progression I-PHYSICAL
( 0
35 0
vs. 0
24 0
% 0
, 0
p 0
= 0
0.94 0
) 0
and 0
bone B-PHYSICAL
histological I-PHYSICAL
diagnosis I-PHYSICAL
at 0
baseline 0
and 0
12 0
months 0
were 0
similar 0
in 0
both 0
groups 0
. 0

Patients 0
of 0
the 0
sevelamer 0
group 0
with 0
a 0
high 0
turnover 0
at 0
baseline 0
had 0
an 0
increase 0
in 0
bone B-PHYSICAL
resorption I-PHYSICAL
( 0
eroded 0
surface 0
, 0
ES/BS 0
= 0
9.0 0
+/- 0
5.9 0
vs. 0
13.1 0
+/- 0
9.5 0
% 0
, 0
p 0
= 0
0.05 0
) 0
, 0
whereas 0
patients 0
of 0
both 0
groups 0
with 0
low 0
turnover 0
at 0
baseline 0
had 0
an 0
improvement 0
in 0
bone B-PHYSICAL
formation I-PHYSICAL
rate I-PHYSICAL
( 0
BFR/BS 0
= 0
0.015 0
+/- 0
0.016 0
vs. 0
0.062 0
+/- 0
0.078 0
, 0
p 0
= 0
0.003 0
for 0
calcium 0
and 0
0.017 0
+/- 0
0.016 0
vs. 0
0.071 0
+/- 0
0.084 0
microm 0
( 0
3 0
) 0
/microm 0
( 0
2 0
) 0
/day 0
, 0
p 0
= 0
0.010 0
for 0
sevelamer 0
) 0
. 0

CONCLUSIONS 0
There 0
was 0
no 0
difference 0
in 0
CAC B-PHYSICAL
progression I-PHYSICAL
or 0
changes 0
in 0
bone B-PHYSICAL
remodeling I-PHYSICAL
between 0
the 0
calcium 0
and 0
the 0
sevelamer 0
groups 0
. 0

An 0
analysis 0
of 0
the 0
radiation 0
related 0
morbidity B-MENTAL
observed 0
in 0
a 0
randomized 0
trial 0
of 0
neutron 0
therapy 0
for 0
bladder 0
cancer 0
. 0

This 0
report 0
is 0
an 0
analysis 0
of 0
the 0
morbidity B-PHYSICAL
in 0
the 0
bladder 0
and 0
bowel 0
observed 0
in 0
a 0
randomized 0
trial 0
of 0
d 0
( 0
15 0
) 0
+Be 0
neutrons 0
versus 0
megavoltage 0
photons 0
in 0
the 0
treatment 0
of 0
bladder 0
cancer 0
. 0

Acute B-PHYSICAL
reactions I-PHYSICAL
in 0
the 0
bladder 0
and 0
bowel 0
were 0
significantly 0
worse 0
after 0
photon 0
therapy 0
. 0

Of 0
the 0
patients 0
treated 0
with 0
photons 0
45.7 0
% 0
had 0
severe 0
reactions B-PHYSICAL
in I-PHYSICAL
the I-PHYSICAL
bladder I-PHYSICAL
compared 0
with 0
10.6 0
% 0
after 0
neutron 0
therapy 0
( 0
p 0
less 0
than 0
0.001 0
) 0
. 0

Severe B-PHYSICAL
acute I-PHYSICAL
bowel I-PHYSICAL
reactions I-PHYSICAL
were 0
observed 0
in 0
8.5 0
% 0
of 0
the 0
patients 0
after 0
photon 0
therapy 0
compared 0
with 0
3.8 0
% 0
after 0
neutron 0
therapy 0
( 0
p 0
less 0
than 0
0.05 0
) 0
. 0

Late B-PHYSICAL
reactions I-PHYSICAL
were 0
significantly 0
worse 0
after 0
neutrons 0
. 0

Severe B-PHYSICAL
late I-PHYSICAL
reactions I-PHYSICAL
in I-PHYSICAL
the I-PHYSICAL
bladder I-PHYSICAL
were 0
seen 0
in 0
58.5 0
% 0
of 0
patients 0
after 0
neutron 0
therapy 0
and 0
in 0
40.5 0
% 0
after 0
photon 0
therapy 0
( 0
p 0
less 0
than 0
0.05 0
) 0
. 0

In 0
the 0
bowel 0
they 0
were 0
observed 0
in 0
53.3 0
% 0
of 0
patients 0
after 0
neutron 0
therapy 0
compared 0
with 0
8 0
% 0
after 0
photon 0
therapy 0
( 0
p 0
less 0
than 0
0.0001 0
) 0
. 0

The 0
disparity 0
in 0
the B-MENTAL
degree I-MENTAL
of I-MENTAL
early I-MENTAL
and I-MENTAL
late I-MENTAL
complications I-MENTAL
makes 0
assessment 0
of 0
RBE B-MORTALITY
values I-MORTALITY
difficult 0
. 0

It 0
is 0
estimated 0
that 0
for 0
bladder B-PHYSICAL
morbidity I-PHYSICAL
the 0
RBE B-PHYSICAL
value I-PHYSICAL
, 0
for 0
photon 0
dose 0
fractions 0
of 0
2.75 0
Gy 0
, 0
is 0
less 0
than 0
3.3 0
for 0
early 0
reactions 0
and 0
equal 0
to 0
3.4 0
for 0
late 0
effects 0
. 0

The 0
respective 0
RBE B-PHYSICAL
values I-PHYSICAL
for 0
early 0
and 0
late 0
effects 0
in 0
the 0
bowel 0
are 0
less 0
than 0
3.4 0
and 0
3.8 0
. 0

The 0
response 0
of 0
neuropathic B-PAIN
pain I-PAIN
and 0
pain B-PAIN
in 0
complex B-PAIN
regional I-PAIN
pain B-PAIN
syndrome I-PAIN
I 0
to 0
carbamazepine 0
and 0
sustained-release 0
morphine 0
in 0
patients 0
pretreated 0
with 0
spinal 0
cord 0
stimulation 0
: 0
a 0
double-blinded 0
randomized 0
study 0
. 0

Forty-three 0
patients 0
with 0
peripheral 0
neuropathic 0
pain 0
, 0
exclusively 0
pain 0
reduced 0
by 0
spinal 0
cord 0
stimulation 0
( 0
SCS 0
) 0
, 0
were 0
switched 0
into 0
a 0
painful 0
state 0
after 0
SCS 0
inactivation 0
. 0

This 0
mode 0
was 0
used 0
to 0
assess 0
the 0
pain-relieving 0
effect 0
of 0
carbamazepine 0
( 0
CMZ 0
) 0
and 0
opioids 0
in 0
a 0
double-blinded 0
, 0
placebo-controlled 0
trial 0
. 0

In 0
Phase 0
1 0
, 0
the 0
patients 0
were 0
randomly 0
allocated 0
to 0
receive 0
either 0
CMZ 0
( 0
600 0
mg/d 0
) 0
or 0
placebo 0
during 0
an 0
SCS-free 0
period 0
of 0
8 0
days 0
. 0

In 0
Phase 0
2 0
, 0
after 0
a 0
CMZ 0
elimination 0
interval 0
of 0
7 0
days 0
, 0
38 0
patients 0
received 0
either 0
sustained-release 0
morphine 0
( 0
90 0
mg/d 0
) 0
or 0
placebo 0
for 0
8 0
days 0
. 0

In 0
cases 0
of 0
intolerable B-PAIN
pain I-PAIN
, 0
the 0
patients 0
were 0
authorized 0
to 0
reactivate 0
their 0
SCS 0
. 0

The 0
pain B-PAIN
intensity I-PAIN
was 0
rated 0
on 0
a 0
numeric B-OTHER
analog I-OTHER
scale I-OTHER
. 0

In 0
38 0
patients 0
who 0
completed 0
Phase 0
1 0
, 0
significant 0
delay B-PAIN
in I-PAIN
pain I-PAIN
increase 0
was 0
observed 0
in 0
the 0
CMZ 0
group 0
as 0
compared 0
with 0
placebo 0
( 0
P 0
= 0
0.038 0
) 0
. 0

In 0
Phase 0
2 0
, 0
the 0
trend 0
observed 0
with 0
morphine 0
was 0
insignificant 0
( 0
P 0
= 0
0.41 0
) 0
. 0

Two 0
CMZ 0
patients 0
and 0
one 0
morphine 0
patient 0
showed 0
complete B-PAIN
pain I-PAIN

Fadrozole 0
HCL 0
( 0
CGS-16949A 0
) 0
versus 0
megestrol 0
acetate 0
treatment 0
of 0
postmenopausal 0
patients 0
with 0
metastatic 0
breast 0
carcinoma 0
: 0
results 0
of 0
two 0
randomized 0
double 0
blind 0
controlled 0
multiinstitutional 0
trials 0
. 0

BACKGROUND 0
Breast 0
cancer 0
patients 0
with 0
prior 0
response 0
to 0
endocrine 0
therapy 0
achieve 0
subsequent 0
benefit 0
from 0
additional 0
endocrine 0
therapies 0
. 0

The 0
efficacy 0
and 0
safety 0
of 0
an 0
aromatase 0
inhibitor 0
, 0
fadrozole 0
HCL 0
, 0
were 0
compared 0
with 0
megestrol 0
acetate 0
in 0
post 0
menopausal 0
patients 0
who 0
had 0
disease 0
progression 0
after 0
receiving 0
antiestrogen 0
therapy 0
either 0
for 0
metastatic 0
disease 0
or 0
as 0
adjuvant 0
therapy 0
. 0

METHODS 0
In 0
2 0
multiinstitutional 0
prospective 0
trials 0
, 0
683 0
postmenopausal 0
patients 0
were 0
randomized 0
to 0
receive 0
either 0
fadrozole 0
HCL 0
, 0
1 0
mg 0
twice 0
daily 0
, 0
or 0
megestrol 0
acetate 0
, 0
40 0
mg 0
4 0
times 0
daily 0
, 0
in 0
a 0
double 0
blind 0
fashion 0
after 0
progression 0
on 0
first-line 0
hormonal 0
therapy 0
. 0

Objective B-PHYSICAL
response 0
rates B-PHYSICAL
, 0
time B-PHYSICAL
to B-PHYSICAL
progression B-PHYSICAL
, 0
survival B-MORTALITY
and 0
safety B-OTHER
of 0
the 0
two 0
regimens 0
were 0
compared 0
. 0

RESULTS 0
Results 0
of 0
intent-to-treat 0
analyses 0
are 0
presented 0
in 0
this 0
study 0
. 0

No 0
significant 0
differences 0
were 0
detected 0
between 0
the 0
two 0
treatment 0
groups 0
in 0
time B-PHYSICAL
to I-PHYSICAL
progression B-PHYSICAL
, 0
objective B-PHYSICAL
response 0
rates B-PHYSICAL
, 0
duration B-PHYSICAL
of I-PHYSICAL
response B-PHYSICAL
, 0
and 0
survival B-MORTALITY
in 0
either 0
trial 0
. 0

There 0
were 0
no 0
clinically 0
meaningful 0
differences 0
between 0
the 0
treatment 0
groups 0
in 0
the 0
incidence 0
and 0
severity 0
of 0
adverse B-ADVERSE-EFFECTS
experiences B-ADVERSE-EFFECTS
, 0
except 0
that 0
weight 0
gain B-ADVERSE-EFFECTS
, 0
fluid B-ADVERSE-EFFECTS
retention B-ADVERSE-EFFECTS
, 0
and 0
dyspnea B-ADVERSE-EFFECTS
were 0
observed 0
in 0
more 0
patients 0
in 0
the 0
megestrol 0
acetate 0
group 0
compared 0
with 0
those 0
receiving 0
fadrozole 0
HCL 0
, 0
whereas 0
nausea B-ADVERSE-EFFECTS
and 0
vomiting B-ADVERSE-EFFECTS
were 0
observed 0
in 0
more 0
patients 0
in 0
the 0
fadrozole 0
HCL 0
group 0
compared 0
with 0
those 0
receiving 0
megestrol 0
acetate 0
. 0

CONCLUSIONS 0
Fadrozole 0
HCL 0
was 0
as 0
efficacious B-PHYSICAL
as 0
megestrol 0
acetate 0
in 0
postmenopausal 0
patients 0
with 0
metastatic 0
breast 0
carcinoma 0
after 0
one 0
hormonal 0
therapy 0
. 0

Adverse 0
experiences 0
were 0
mild 0
with 0
both 0
therapies 0
, 0
but 0
megestrol 0
acetate 0
was 0
associated 0
wiht 0
a 0
higher 0
frequency 0
of 0
weight 0

Microbial 0
protein 0
synthesis 0
, 0
nitrogen 0
capture 0
efficiency 0
and 0
nutrient 0
utilisation 0
in 0
sheep 0
fed 0
on 0
finger 0
millet 0
straw 0
( 0
Eleucine 0
coracana 0
) 0
-based 0
diet 0
with 0
different 0
rumen-degradable 0
nitrogen 0
levels 0
. 0

BACKGROUND 0
Microbial 0
protein 0
synthesised 0
in 0
the 0
rumen 0
is 0
a 0
very 0
important 0
protein 0
source 0
for 0
ruminants 0
. 0

It 0
is 0
essential 0
to 0
provide 0
an 0
adequate 0
amount 0
of 0
rumen-degradable 0
nitrogen 0
( 0
RDN 0
) 0
for 0
optimum 0
microbial 0
protein 0
synthesis 0
in 0
the 0
rumen 0
on 0
straw-based 0
diets 0
. 0

The 0
objective 0
of 0
this 0
study 0
was 0
to 0
determine 0
the 0
RDN 0
requirement 0
for 0
optimum 0
microbial 0
protein 0
synthesis 0
( 0
MPS 0
) 0
, 0
nitrogen 0
capture 0
efficiency 0
( 0
NCE 0
) 0
and 0
nutrient 0
utilisation 0
in 0
Nellore 0
rams 0
fed 0
on 0
a 0
finger 0
millet 0
straw 0
( 0
FMS 0
) 0
-based 0
diet 0
. 0

RESULTS 0
Thirty-six 0
Nellore 0
sheep 0
were 0
randomly 0
divided 0
into 0
four 0
groups 0
of 0
nine 0
animals 0
each 0
using 0
a 0
balanced 0
, 0
completely 0
randomised 0
design 0
. 0

The 0
animals 0
in 0
group 0
1 0
( 0
RDN0 0
) 0
were 0
fed 0
with 0
ad 0
libitum 0
FMS 0
. 0

Those 0
in 0
groups 0
2 0
, 0
3 0
and 0
4 0
( 0
RDN1 0
, 0
RDN2 0
and 0
RDN3 0
) 0
were 0
supplemented 0
with 0
groundnut 0
cake 0
to 0
provide 0
RDN B-PHYSICAL
levels I-PHYSICAL
of 0
14 0
, 0
18 0
and 0
23 0
g 0
RDN 0
kg?? 0
digestible 0
organic 0
matter 0
intake 0
( 0
DOMI 0
) 0
or 0
21 0
, 0
27 0
and 0
35 0
g 0
RDN 0
kg?? 0
digestible 0
organic 0
matter 0
apparently 0
digested 0
in 0
the 0
rumen 0
( 0
DOMR 0
) 0
respectively 0
along 0
with 0
FMS 0
. 0

The 0
digestibility 0
coefficients 0
of 0
all 0
nutrients 0
and 0
MPS 0
increased 0
( 0
P 0
< 0
0.05 0
) 0
quadratically 0
with 0
increasing 0
level 0
of 0
RDN 0
supplementation 0
. 0

NCE 0
decreased 0
linearly 0
( 0
P 0
< 0
0.05 0
) 0
as 0
the 0
level 0
of 0
RDN 0
increased 0
. 0

CONCLUSION 0
The 0
results 0
suggest 0
that 0
12 0
g 0
RDN 0
kg?? 0
DOMI 0
or 0
19 0
g 0
RDN 0
kg?? 0
DOMR 0
may 0
be 0
adequate 0
for 0
optimum 0
MPS 0
, 0
NCE 0
and 0
digestibility 0
of 0
nutrients 0
in 0
sheep 0
fed 0
on 0
an 0
FMS-based 0
diet 0
. 0

Sustained 0
oral B-PHYSICAL
health I-PHYSICAL
improvement I-PHYSICAL
and 0
use 0
of 0
toothbrushes 0
and 0
dentifrice 0
by 0
previous 0
users 0
of 0
traditional 0
materials 0
in 0
a 0
rural 0
population 0
in 0
Andhra 0
Pradesh 0
, 0
India 0
. 0

AIM 0
To 0
follow-up 0
, 0
one 0
year 0
later 0
, 0
a 0
double-blind 0
, 0
randomised 0
study 0
, 0
which 0
investigated 0
the 0
effect 0
of 0
regular 0
brushing 0
with 0
dentifrices 0
on 0
the 0
oral 0
health 0
of 0
an 0
economically 0
disadvantaged 0
rural 0
population 0
in 0
Andhra 0
Pradesh 0
, 0
India 0
who 0
were 0
primarily 0
users 0
of 0
traditional 0
materials 0
. 0

SUBJECTS 0
150 0
of 0
the 0
original 0
study 0
population 0
. 0

METHOD 0
Examination 0
to 0
determine 0
whether 0
the 0
improvements 0
in 0
oral B-PHYSICAL
health I-PHYSICAL
status I-PHYSICAL
and 0
oral B-PHYSICAL
health I-PHYSICAL
behaviour I-PHYSICAL
( 0
use 0
of 0
toothbrush 0
and 0
dentifrice 0
) 0
, 0
being 0
unsupported 0
, 0
had 0
been 0
sustained 0
since 0
completion 0
of 0
the 0
original 0
study 0
. 0

RESULTS 0
Data 0
analysis 0
showed 0
sustained 0
, 0
statistically 0
significant 0
improvements 0
in 0
gingival B-PHYSICAL
health I-PHYSICAL
as I-PHYSICAL
measured I-PHYSICAL
by I-PHYSICAL
gingival I-PHYSICAL
bleeding I-PHYSICAL
and I-PHYSICAL
plaque I-PHYSICAL
indices I-PHYSICAL
( 0
GBI B-PHYSICAL
and I-PHYSICAL
PI I-PHYSICAL
) 0
comparing 0
users 0
and 0
non-users 0
of 0
toothbrushes 0
and 0
dentifrice 0
in 0
the 0
original 0
study 0
( 0
PI 0
: 0
p 0
= 0
0.04 0
; 0
GBI 0
: 0
p 0
= 0
0.03 0
) 0
and 0
sustained B-OTHER
use I-OTHER
of I-OTHER
toothbrushes I-OTHER
and 0
dentifrice B-OTHER
by 0
60 0
% 0
of 0
the 0
subjects 0
at 0
follow-up 0
one 0
year 0
later 0
. 0

CONCLUSIONS 0
This 0
study 0
shows 0
a 0
beneficial B-PHYSICAL
effect 0
on B-PHYSICAL
oral I-PHYSICAL

Investigation 0
of 0
erosion B-PHYSICAL
and 0
abrasion B-PHYSICAL
on 0
enamel B-PHYSICAL
and 0
dentine B-PHYSICAL
: 0
a 0
model 0
in 0
situ 0
using 0
toothpastes 0
of 0
different 0
abrasivity 0
. 0

BACKGROUND 0
Studies 0
in 0
vitro 0
suggest 0
that 0
abrasion B-PHYSICAL
and 0
erosion B-PHYSICAL
may 0
act 0
synergistically 0
to 0
produce 0
wear 0
of 0
enamel B-PHYSICAL
and 0
dentine B-PHYSICAL
. 0

Methods 0
in 0
situ 0
are 0
recently 0
available 0
to 0
study 0
separately 0
erosion B-PHYSICAL
and 0
abrasion B-PHYSICAL
of 0
dental B-PHYSICAL
tissues I-PHYSICAL
. 0

The 0
aim 0
of 0
this 0
study 0
was 0
to 0
combine 0
two 0
in 0
situ 0
protocols 0
to 0
study 0
the 0
interplay 0
between 0
erosion B-PHYSICAL
and 0
abrasion B-PHYSICAL
of 0
enamel B-PHYSICAL
and 0
dentine B-PHYSICAL
. 0

METHOD 0
The 0
study 0
was 0
a 0
single-blind 0
, 0
randomised 0
, 0
five-treatment 0
cross-over 0
design 0
involving 0
15 0
healthy 0
volunteers 0
. 0

During 0
each 0
10-day 0
study 0
period 0
, 0
subjects 0
wore 0
from 0
0900 0
to 0
1700 0
h 0
an 0
upper 0
removable 0
acrylic 0
appliance 0
holding 0
one 0
polished 0
enamel 0
and 0
one 0
polished 0
dentine 0
specimen 0
. 0

The 0
specimen 0
treatment 0
regimens 0
were 0
: 0
1 0
. 0

Drinking 0
water 0
and 0
brushing 0
with 0
toothpaste 0
A 0
. 0

2 0
. 0

Drinking 0
water 0
and 0
brushing 0
with 0
toothpaste 0
B 0
. 0

3 0
. 0

Drinking 0
orange 0
juice 0
. 0

4 0
. 0

Drinking 0
orange 0
juice 0
and 0
brushing 0
with 0
toothpaste 0
A 0
. 0

5 0
. 0

Drinking 0
orange 0
juice 0
and 0
brushing 0
with 0
toothpaste 0
B 0
. 0

Drinking 0
and 0
brushing 0
times 0
were 0
around 0
0900 0
, 0
1100 0
, 0
1300 0
and 0
1500 0
h. 0
Drinks 0
were 0
consumed 0
as 0
250 0
ml 0
over 0
10 0
min 0
and 0
brushing 0
ex 0
vivo 0
for 0
1 0
min 0
to 0
each 0
specimen 0
. 0

Measurement 0
of 0
tissue B-PHYSICAL
loss I-PHYSICAL
was 0
made 0
on 0
days 0
5 0
and 0
10 0
of 0
each 0
period 0
using 0
a 0
profilometer 0
. 0

RESULTS 0
All 0
treatments 0
produced 0
increasing 0
tissue B-PHYSICAL
loss I-PHYSICAL
over I-PHYSICAL
time I-PHYSICAL
, 0
which 0
was 0
considerably 0
greater 0
for 0
dentine 0
than 0
enamel 0
. 0

For 0
enamel 0
, 0
the 0
data 0
at 0
days 0
5 0
and 0
10 0
showed 0
a 0
significant 0
effect 0
for 0
erosion B-PHYSICAL
( 0
i.e 0
. 0

orange 0
juice 0
was 0
significantly 0
more 0
erosive 0
than 0
water 0
) 0
, 0
but 0
no 0
significant 0
effect 0
for 0
abrasion B-PHYSICAL
( 0
i.e 0
. 0

no 0
significant 0
difference 0
between 0
the 0
two 0
toothpaste 0
treatments 0
) 0
. 0

The 0
combined 0
orange 0
juice 0
and 0
toothpaste 0
effects 0
were 0
directional 0
for 0
synergy 0
but 0
did 0
not 0
reach 0
significance 0
. 0

For 0
dentine 0
at 0
day 0
10 0
, 0
many 0
specimens 0
exceeded 0
the 0
50 0
microm 0
set 0
limit 0
of 0
the 0
profilometer 0
and 0
only 0
day 0
5 0
data 0
were 0
considered 0
. 0

There 0
were 0
significant 0
effects 0
for 0
erosion B-PHYSICAL
( 0
orange 0
juice 0
produced 0
significantly 0
more 0
erosion 0
than 0
water 0
) 0
and 0
for 0
abrasion B-PHYSICAL
( 0
paste 0
A 0
was 0
significantly 0
more 0
abrasive 0
to 0
dentine 0
than 0
paste 0
B 0
) 0
. 0

The 0
synergy 0
effect 0
could 0
not 0
be 0
examined 0
for 0
dentine 0
due 0
to 0
the 0
truncation 0
effect 0
as 0
the 0
set 0
limit 0
of 0
the 0
profilometer 0
was 0
exceeded 0
. 0

CONCLUSIONS 0
Erosion 0
increases 0
the 0
susceptibility B-PHYSICAL
of I-PHYSICAL
enamel I-PHYSICAL
to 0
toothpaste B-PHYSICAL
abrasion I-PHYSICAL
. 0

Dentine 0
is 0
considerably 0
more 0
susceptible 0
than 0
enamel 0
to 0
erosion B-PHYSICAL
and 0
abrasion B-PHYSICAL
alone 0
or 0
combined 0
. 0

Dentine B-PHYSICAL
loss I-PHYSICAL
appears 0
to 0
correlate 0
with 0
toothpaste 0
abrasivity 0
( 0
RDA 0
value 0
) 0
. 0

Analysis 0
of 0
prevention 0
program 0
effectiveness 0
with 0
clustered 0
data 0
using 0
generalized 0
estimating 0
equations 0
. 0

Experimental 0
studies 0
of 0
prevention 0
programs 0
often 0
randomize 0
clusters 0
of 0
individuals 0
rather 0
than 0
individuals 0
to 0
treatment 0
conditions 0
. 0

When 0
the 0
correlation 0
among 0
individuals 0
within 0
clusters 0
is 0
not 0
accounted 0
for 0
in 0
statistical 0
analysis 0
, 0
the 0
standard 0
errors 0
are 0
biased 0
, 0
potentially 0
resulting 0
in 0
misleading 0
conclusions 0
about 0
the 0
significance 0
of 0
treatment 0
effects 0
. 0

This 0
study 0
demonstrates 0
the 0
generalized 0
estimating 0
equations 0
( 0
GEE 0
) 0
method 0
, 0
focusing 0
specifically 0
on 0
the 0
GEE-independent 0
method 0
, 0
to 0
control 0
for 0
within-cluster 0
correlation 0
in 0
regression 0
models 0
with 0
either 0
continuous B-OTHER
or 0
binary B-OTHER
outcomes I-OTHER
. 0

The 0
GEE-independent 0
method 0
yields 0
consistent B-OTHER
and 0
robust B-OTHER
variance 0

Timing B-MORTALITY
of I-MORTALITY
death I-MORTALITY
and 0
myocardial B-PHYSICAL
infarction I-PHYSICAL
in 0
patients 0
with 0
non-ST 0
elevation 0
acute 0
coronary 0
syndromes 0
: 0
insights 0
from 0
randomized 0
clinical 0
trials 0
. 0

BACKGROUND 0
Adverse 0
events 0
occur 0
following 0
non-ST 0
elevation 0
acute 0
coronary 0
syndromes 0
( 0
NSTE 0
ACS 0
) 0
. 0

However 0
, 0
the 0
timing 0
of 0
these 0
events 0
in 0
relation 0
to 0
index 0
event 0
is 0
less 0
clear 0
. 0

METHODS 0
Accordingly 0
, 0
we 0
evaluated 0
26,466 0
NSTE 0
ACS 0
patients 0
from 0
the 0
Global 0
Use 0
of 0
Strategies 0
to 0
Open 0
Occluded 0
Arteries 0
in 0
Acute 0
Coronary 0
Syndromes 0
( 0
GUSTO-IIb 0
) 0
, 0
Platelet 0
Glycoprotein 0
IIb/IIIa 0
in 0
Unstable 0
Angina 0
: 0
Receptor 0
Suppression 0
Using 0
Integrilin 0
Therapy 0
( 0
PURSUIT 0
) 0
, 0
and 0
Platelet 0
IIb/IIIa 0
Antagonism 0
for 0
the 0
Reduction 0
of 0
Acute 0
Coronary 0
Syndrome 0
Events 0
in 0
a 0
Global 0
Organization 0
Network 0
( 0
PARAGON 0
) 0
A 0
and 0
B 0
trials 0
to 0
ascertain 0
the 0
timing 0
of 0
adverse 0
events 0
. 0

Outcomes 0
of 0
interest 0
were 0
death B-MORTALITY
, 0
myocardial B-PHYSICAL
infarction I-PHYSICAL
( I-PHYSICAL
MI I-PHYSICAL
) I-PHYSICAL
, 0
and 0
death B-MORTALITY
or 0
MI 0
at 0
180 B-PHYSICAL
days I-PHYSICAL
. 0

Logistic 0
regression 0
modeling 0
for 0
death 0
was 0
used 0
to 0
categorize 0
patients 0
into 0
low- 0
, 0
medium- 0
, 0
and 0
high-risk 0
groups 0
. 0

RESULTS 0
At 0
6 0
months 0
, 0
6.2 0
% 0
of 0
patients 0
died B-MORTALITY
, 0
12.1 0
% 0
had 0
MI B-PHYSICAL
, 0
and 0
15.7 0
% 0
suffered 0
death B-MORTALITY
or 0
MI B-PHYSICAL
. 0

From 0
15 0
% 0
to 0
40 0
% 0
of 0
these 0
events 0
occurred 0
beyond 0
30 0
days 0
. 0

At 0
6 0
months 0
, 0
3 0
% 0
, 0
4 0
% 0
, 0
and 0
13 0
% 0
of 0
patients 0
died 0
in 0
low- 0
, 0
medium- 0
, 0
and 0
high-risk 0
groups 0
, 0
respectively 0
. 0

However 0
, 0
the 0
proportion 0
of 0
patients B-MORTALITY
dying I-MORTALITY
beyond 0
30 0
days 0
was 0
similar 0
in 0
the 0
three 0
groups 0
( 0
44 0
% 0
, 0
43 0
% 0
, 0
and 0
41 0
% 0
of 0
death 0
, 0
respectively 0
) 0
. 0

Similarly 0
, 0
whereas 0
death B-MORTALITY
or 0
MI B-MORTALITY
increased 0
with 0
higher 0
risk 0
( 0
11 0
% 0
, 0
14 0
% 0
, 0
and 0
23 0
% 0
, 0
respectively 0
) 0
, 0
the 0
proportion B-PHYSICAL
of I-PHYSICAL
patients I-PHYSICAL
with 0
this 0
event 0
beyond 0
30 0
days 0
did 0
not 0
differ 0
in 0
the 0
three 0
strata 0
( 0
22 0
% 0
, 0
20 0
% 0
, 0
and 0
25 0
% 0
, 0
respectively 0
) 0
. 0

CONCLUSIONS 0
Our 0
study 0
provides 0
important 0
insights 0
into 0
the 0
timing 0
of 0
adverse 0
events 0
and 0
suggests 0
that 0
the 0
substantial 0
proportion 0
of 0
patients 0
suffer 0
subsequent 0
adverse 0
events 0
after 0
their 0
index 0
NSTE 0
ACS 0
. 0

Thus 0
, 0
these 0
data 0
call 0
for 0
continuous 0
surveillance 0
for 0
these 0
events 0
and 0
efforts 0
beyond 0
the 0
acute 0
phase 0
at 0
increasing 0
adherence 0
to 0
evidence-based 0
therapies 0
to 0
improve 0
the 0
outcomes 0
of 0
these 0
patients 0
. 0

A 0
randomised 0
comparison 0
of 0
UK 0
genetic 0
risk 0
counselling 0
services 0
for 0
familial 0
cancer 0
: 0
psychosocial B-MENTAL
outcomes I-MENTAL
. 0

The 0
aim 0
of 0
the 0
study 0
was 0
to 0
compare 0
psychosocial B-MENTAL
outcomes I-MENTAL
for 0
50 0
new 0
clinic 0
attendees 0
, 0
referred 0
for 0
cancer 0
genetic 0
counselling 0
to 0
five 0
UK 0
centres 0
. 0

The 0
centres 0
represented 0
England 0
, 0
Scotland 0
and 0
Wales 0
, 0
and 0
were 0
randomly 0
selected 0
from 0
groups 0
ranked 0
by 0
different 0
levels 0
of 0
clinical 0
activity 0
in 0
cancer 0
genetics 0
practice 0
. 0

Questionnaires 0
assessed 0
demographic B-OTHER
data I-OTHER
, 0
risk 0
perception 0
, 0
mental 0
health 0
and 0
use 0
of 0
health B-OTHER
services I-OTHER
pre-consultation I-OTHER
and 0
at 0
1 0
and 0
12 0
months 0
follow-up 0
. 0

Satisfaction B-OTHER
was 0
measured 0
for 0
attendees 0
and 0
referring 0
doctors 0
at 0
follow-up 0
. 0

A 0
total 0
of 0
256 0
unaffected 0
adults 0
fulfilled 0
the 0
study 0
criteria 0
. 0

The 0
five 0
centres 0
varied 0
widely 0
with 0
respect 0
to 0
service 0
organisation 0
and 0
activity 0
, 0
but 0
all 0
had 0
a 0
greater 0
proportion 0
of 0
unaffected 0
attendees 0
with 0
a 0
breast 0
cancer 0
risk 0
( 0
61-91 0
% 0
) 0
than 0
either 0
a 0
bowel 0
cancer 0
risk 0
( 0
0-33 0
% 0
) 0
or 0
ovarian 0
cancer 0
risk 0
( 0
3-25 0
% 0
) 0
. 0

There 0
were 0
no 0
significant 0
differences 0
in 0
the 0
psychosocial B-MENTAL
data I-MENTAL
between 0
centres 0
pre-counselling 0
. 0

No 0
significant 0
change 0
over 0
time 0
occurred 0
for 0
any 0
of 0
the 0
centres 0
for 0
risk 0
perception B-OTHER
or 0
general B-MENTAL
psychological I-MENTAL
distress I-MENTAL
. 0

There 0
were 0
significant 0
differences 0
between 0
centres 0
in 0
reduction 0
of 0
cancer B-PHYSICAL
worry 0
from 0
baseline 0
to 0
12 0
months 0
and 0
with 0
the 0
number 0
of 0
women 0
who 0
were 0
recommended 0
to 0
have 0
mammographic 0
surveillance 0
who 0
had 0
not 0
received 0
this 0
. 0

Overall 0
, 0
one-third 0
of 0
women 0
for 0
whom 0
mammography 0
had 0
been 0
recommended 0
had 0
not 0
been 0
screened 0
within 0
1 0
year 0
of 0
follow-up 0
. 0

Subsequent 0
attendance 0
at 0
the 0
GP 0
, 0
but 0
not 0
at 0
a 0
hospital 0
, 0
was 0
associated 0
with 0
risk 0
level 0
, 0
but 0
differences 0
between 0
centres 0
could 0
not 0
be 0
analysed 0
. 0

Satisfaction B-OTHER
differed 0
significantly 0
between 0
centres 0
for 0
4 0
: 0
14 0
aspects 0
of 0
service 0
provision 0
and 0
with 0
3 0
: 0
17 0
items 0
concerning 0
communication 0
; 0
satisfaction 0
was 0
high 0
overall 0
. 0

Over 0
90 0
% 0
of 0
referring 0
doctors 0
were 0
moderately/very 0
satisfied 0
with 0
the 0
service 0
, 0
but 0
23 0
% 0
were 0
dissatisfied 0
with 0
waiting 0
times 0
and 0
19 0
% 0
with 0
access 0
to 0
preventive 0
treatment 0
. 0

Results 0
differed 0
significantly 0
between 0
centres 0
for 0
doctor 0
's 0
satisfaction 0
with 0
the 0
provision 0
of 0
referral 0
criteria 0
and 0
prescribing 0
information 0
. 0

In 0
conclusion 0
, 0
there 0
were 0
relatively 0
few 0
significant 0
differences 0
in 0
psychosocial B-MENTAL
outcomes I-MENTAL
between 0
centres 0
, 0
considering 0
the 0
wide 0
variation 0
in 0
service 0
organisation 0
and 0
activity 0
. 0

These 0
significant 0
differences 0
were 0
not 0
consistent 0
across 0
the 0
centres 0
, 0
therefore 0
, 0
differences 0
could 0
not 0
be 0
linked 0
to 0
specific 0
aspects 0
of 0
service 0
provision 0
. 0

Dronabinol 0
versus 0
megestrol 0
acetate 0
versus 0
combination 0
therapy 0
for 0
cancer-associated 0
anorexia 0
: 0
a 0
North 0
Central 0
Cancer 0
Treatment 0
Group 0
study 0
. 0

PURPOSE 0
To 0
determine 0
whether 0
dronabinol 0
administered 0
alone 0
or 0
with 0
megestrol 0
acetate 0
was 0
more 0
, 0
less 0
, 0
or 0
equal 0
in 0
efficacy 0
to 0
single-agent 0
megestrol 0
acetate 0
for 0
palliating 0
cancer-associated 0
anorexia 0
. 0

PATIENTS 0
AND 0
METHODS 0
Four 0
hundred 0
sixty-nine 0
assessable 0
advanced 0
cancer 0
patients 0
were 0
randomized 0
to 0
( 0
1 0
) 0
oral 0
megestrol 0
acetate 0
800 0
mg/d 0
liquid 0
suspension 0
plus 0
placebo 0
, 0
( 0
2 0
) 0
oral 0
dronabinol 0
2.5 0
mg 0
twice 0
a 0
day 0
plus 0
placebo 0
, 0
or 0
( 0
3 0
) 0
both 0
agents 0
. 0

Eligible 0
patients 0
acknowledged 0
that 0
loss 0
of 0
appetite 0
or 0
weight 0
was 0
a 0
problem 0
and 0
reported 0
the 0
loss 0
of 0
5 0
pounds 0
or 0
more 0
during 0
2 0
months 0
and/or 0
a 0
daily 0
intake 0
of 0
less 0
than 0
20 0
calories/kg 0
of 0
body 0
weight 0
. 0

RESULTS 0
Groups 0
were 0
comparable 0
at 0
baseline 0
in 0
age 0
, 0
sex 0
, 0
tumor 0
type 0
, 0
weight 0
loss 0
, 0
and 0
performance 0
status 0
. 0

A 0
greater 0
percentage 0
of 0
megestrol 0
acetate-treated 0
patients 0
reported 0
appetite B-PHYSICAL
improvement I-PHYSICAL
and 0
weight 0
gain B-PHYSICAL
compared 0
with 0
dronabinol-treated 0
patients 0
: 0
75 0
% 0
versus 0
49 0
% 0
( 0
P 0
=.0001 0
) 0
for 0
appetite 0
and 0
11 0
% 0
versus 0
3 0
% 0
( 0
P 0
=.02 0
) 0
for 0
> 0
or 0
= 0
10 0
% 0
baseline 0
weight 0
gain 0
. 0

Combination 0
treatment 0
resulted 0
in 0
no 0
significant 0
differences 0
in 0
appetite B-PHYSICAL
or 0
weight B-PHYSICAL
compared 0
with 0
megestrol 0
acetate 0
alone 0
. 0

The 0
Functional 0
Assessment 0
of 0
Anorexia/Cachexia 0
Therapy 0
questionnaire 0
, 0
which 0
emphasizes 0
anorexia-related 0
questions 0
, 0
demonstrated 0
an 0
improvement 0
in 0
quality 0
of 0
life 0
( B-OTHER
QOL I-OTHER
) I-OTHER
among 0
megestrol 0
acetate-treated 0
and 0
combination-treated 0
patients 0
. 0

The 0
single-item 0
Uniscale 0
, 0
a 0
global 0
QOL B-OTHER
instrument 0
, 0
found 0
comparable 0
scores 0
. 0

Toxicity B-ADVERSE-EFFECTS
was 0
also 0
comparable 0
, 0
with 0
the 0
exception 0
of 0
an 0
increased 0
incidence 0
of 0
impotence B-PHYSICAL
among 0
men 0
who 0
received 0
megestrol 0
acetate 0
. 0

CONCLUSION 0
In 0
the 0
doses 0
and 0
schedules 0
we 0
studied 0
, 0
megestrol 0
acetate 0
provided 0
superior 0
anorexia 0
palliation 0
among 0
advanced 0
cancer 0
patients 0
compared 0
with 0
dronabinol 0
alone 0
. 0

Combination 0
therapy 0
did 0
not 0
appear 0
to 0
confer 0
additional 0
benefit 0
. 0

Bevacizumab 0
compared 0
with 0
macular 0
laser 0
grid 0
photocoagulation 0
for 0
cystoid 0
macular 0
edema 0
in 0
branch 0
retinal 0
vein 0
occlusion 0
. 0

INTRODUCTION 0
To 0
evaluate 0
the 0
outcome 0
of 0
cystoid 0
macular 0
edema 0
treated 0
with 0
intravitreal 0
injections 0
of 0
bevacizumab 0
and 0
macular 0
grid 0
laser 0
photocoagulation 0
( 0
GLP 0
) 0
, 0
in 0
patients 0
with 0
perfused 0
branch 0
retinal 0
vein 0
occlusion 0
. 0

METHODS 0
Thirty 0
eyes 0
of 0
30 0
consecutive 0
patients 0
with 0
cystoid 0
macular 0
edema 0
secondary 0
to 0
nonischemic 0
branch 0
retinal 0
vein 0
occlusion 0
were 0
assigned 0
to 0
either 0
GLP 0
group 0
or 0
to 0
intravitreal 0
bevacizumab 0
( 0
IB 0
) 0
group 0
. 0

Complete B-PHYSICAL
ophthalmologic I-PHYSICAL
examinations I-PHYSICAL
were 0
performed 0
just 0
before 0
GLP 0
and 0
IB 0
injection 0
at 0
1 0
, 0
3 0
, 0
6 0
, 0
and 0
12 0
months 0
after 0
treatment 0
. 0

Changes 0
in 0
logarithm 0
of B-PHYSICAL
minimum I-PHYSICAL
angle I-PHYSICAL
of I-PHYSICAL
resolution I-PHYSICAL
( I-PHYSICAL
logMAR I-PHYSICAL
) I-PHYSICAL
best-corrected I-PHYSICAL
visual I-PHYSICAL
acuity I-PHYSICAL
( I-PHYSICAL
BCVA I-PHYSICAL
) B-PHYSICAL
, 0
central B-PHYSICAL
macular I-PHYSICAL
thickness I-PHYSICAL
( I-PHYSICAL
CMT I-PHYSICAL
) I-PHYSICAL
shown I-PHYSICAL
by I-PHYSICAL
optical B-PHYSICAL
coherence 0
tomography-3 B-PHYSICAL
were 0
evaluated 0
. 0

RESULTS 0
Baseline 0
BCVA 0
( 0
logMAR 0
) 0
and 0
CMT 0
were 0
, 0
respectively 0
, 0
0.89 0
+/- 0
0.13 0
and 0
650 0
+/- 0
140 0
microm 0
for 0
the 0
GLP 0
group 0
, 0
0.87 0
+/- 0
0.16 0
and 0
690 0
+/- 0
120 0
microm 0
for 0
the 0
IB 0
group 0
. 0

After 0
the 0
treatment 0
, 0
at 0
1 0
, 0
3 0
, 0
6 0
, 0
and 0
12 0
months 0
in 0
the 0
GLP 0
group 0
, 0
BCVA B-PHYSICAL
had 0
improved 0
by 0
0.19 0
, 0
0.22 0
, 0
0.21 0
, 0
and 0
0.20 0
logMAR 0
, 0
CMT B-PHYSICAL
had 0
decreased 0
by 0
40 0
% 0
, 0
41.3 0
% 0
, 0
40.5 0
% 0
, 0
and 0
42 0
% 0
. 0

In 0
the 0
IB 0
group 0
, 0
BCVA B-PHYSICAL
had 0
improved 0
by 0
0.31 0
, 0
0.32 0
, 0
0.30 0
, 0
and 0
0.31 0
logMAR B-PHYSICAL
and 0
CMT B-PHYSICAL
had 0
decreased 0
by 0
59.5 0
% 0
, 0
59 0
% 0
, 0
60 0
% 0
, 0
and 0
60.3 0
% 0
. 0

The 0
group 0
receiving 0
bevacizumab 0
had 0
better 0
BCVA B-PHYSICAL
and 0
lower 0
CMT B-PHYSICAL
values 0
at 0
all 0
time 0
points 0
( 0
P 0
< 0
0.05 0
) 0
. 0

CONCLUSION 0
Intravitreal 0
bevacizumab 0
injection 0
improves 0

Effects 0
of 0
a 0
caregiver 0
intervention 0
on 0
negative 0
caregiver 0
appraisals 0
of 0
behavior 0
problems 0
in 0
patients 0
with 0
Alzheimer 0
's 0
disease 0
: 0
results 0
of 0
a 0
randomized 0
trial 0
. 0

Behavioral 0
problems 0
are 0
among 0
the 0
most 0
challenging 0
aspects 0
of 0
caring 0
for 0
a 0
person 0
with 0
Alzheimer 0
's 0
disease 0
. 0

A 0
sample 0
of 0
406 0
spouses-caregivers 0
of 0
patients 0
with 0
Alzheimer 0
's 0
disease 0
was 0
randomized 0
to 0
an 0
active 0
multicomponent 0
counseling 0
and 0
support 0
intervention 0
condition 0
or 0
to 0
a 0
usual 0
care 0
condition 0
. 0

Caregivers 0
reported 0
on 0
the 0
frequency 0
of 0
troublesome B-MENTAL
patient I-MENTAL
behaviors I-MENTAL
and I-MENTAL
their I-MENTAL
reactions I-MENTAL
to I-MENTAL
them 0
at 0
baseline 0
and 0
at 0
regular 0
follow-up 0
interviews 0
. 0

Random-effects 0
regression 0
models 0
over 0
the 0
first 0
4 0
years 0
after 0
randomization 0
revealed 0
that 0
, 0
although 0
the 0
intervention 0
did 0
not 0
affect 0
the 0
frequency 0
of 0
patient 0
behavioral 0
problems 0
, 0
it 0
did 0
significantly 0
reduce 0
caregivers B-MENTAL
' 0
reaction B-MENTAL

Etanercept 0
treatment 0
in 0
adults 0
with 0
established 0
rheumatoid 0
arthritis 0
: 0
7 0
years 0
of 0
clinical 0
experience 0
. 0

OBJECTIVE 0
To 0
evaluate 0
safety B-OTHER
and 0
efficacy 0
of 0
longterm 0
etanercept 0
treatment 0
in 0
patients 0
with 0
disease 0
modifying 0
antirheumatic 0
drug 0
( 0
DMARD 0
) 0
refractory 0
rheumatoid 0
arthritis 0
( 0
RA 0
) 0
. 0

METHODS 0
Safety 0
results 0
are 0
reported 0
for 0
714 0
patients 0
who 0
received 0
etanercept 0
in 0
one 0
of 0
7 0
initial 0
trials 0
or 0
a 0
longterm 0
extension 0
. 0

Efficacy 0
results 0
are 0
reported 0
for 0
581 0
patients 0
who 0
enrolled 0
in 0
the 0
extension 0
. 0

RESULTS 0
Of 0
the 0
714 0
patients 0
enrolled 0
in 0
the 0
initial 0
trials 0
, 0
581 0
( 0
81 0
% 0
) 0
enrolled 0
in 0
the 0
extension 0
, 0
and 0
388 0
( 0
54 0
% 0
) 0
patients 0
are 0
continuing 0
to 0
receive 0
etanercept 0
therapy 0
. 0

The 0
longest 0
individual 0
treatment 0
was 0
8.2 0
years 0
, 0
with 0
3139 0
total 0
patient-years 0
of 0
etanercept 0
exposure 0
. 0

Rates 0
of 0
serious B-ADVERSE-EFFECTS
adverse I-ADVERSE-EFFECTS
events I-ADVERSE-EFFECTS
( 0
overall 0
rate=14.8 0
events/100 0
patient-yrs 0
) 0
, 0
serious B-ADVERSE-EFFECTS
infections I-ADVERSE-EFFECTS
( 0
overall 0
rate=4.2 0
events/100 0
patient-yrs 0
) 0
, 0
cancer B-PHYSICAL
( 0
overall 0
rate=1.0 0
events/100 0
patient-yrs 0
) 0
, 0
and 0
deaths B-MORTALITY
( 0
overall 0
rate=0.7 0
events/100 0
patient-yrs 0
) 0
were 0
stable 0
each 0
year 0
, 0
through 0
8 0
years 0
of 0
etanercept 0
exposure 0
. 0

For 0
356 0
patients 0
who 0
completed 0
6 0
years 0
of 0
etanercept 0
treatment 0
, 0
response 0
rates B-OTHER
were 0
ACR20=73 0
% 0
, 0
ACR50=52 0
% 0
, 0
ACR70=27 0
% 0
, 0
DAS28 0
CRP 0
good 0
response=52 0
% 0
, 0
and 0
DAS28 0
CRP 0
remission=37 0
% 0
of 0
patients 0
. 0

Similar 0
responses 0
occurred 0
in 0
167 0
patients 0
who 0
completed 0
Year 0
7 0
. 0

Doses B-OTHER
of 0
concomitant 0
methotrexate 0
or 0
corticosteroids 0
were 0
reduced 0
in 0
many 0
patients 0
who 0
maintained 0
clinical 0
responses 0
. 0

CONCLUSION 0
The 0
safety B-OTHER
profile I-OTHER
of 0
etanercept 0
was 0
consistent 0
over 0
time 0
, 0
with 0
rates 0
of 0
adverse B-ADVERSE-EFFECTS
events I-ADVERSE-EFFECTS
similar 0
to 0
those 0
reported 0
for 0
patients 0
with 0
RA 0
in 0
general 0
. 0

Durable 0
clinical 0
responses 0
were 0
observed 0
in 0
some 0
patients 0
for 0
7 0
years 0
or 0
more 0
. 0

The 0
benefit-to-risk 0
ratio 0
for 0
longterm 0
etanercept 0
treatment 0
remains 0
highly 0
favorable 0
. 0

Hypoxic 0
exercise 0
training 0
reduces 0
senescent B-PHYSICAL
T-lymphocyte I-PHYSICAL
subsets I-PHYSICAL
in I-PHYSICAL
blood I-PHYSICAL
. 0

The 0
integration 0
and 0
control 0
of 0
systemic 0
immune 0
responses 0
depends 0
on 0
the 0
regulated 0
trafficking 0
of 0
T-lymphocytes 0
. 0

This 0
study 0
elucidates 0
how 0
various 0
exercises 0
regimens 0
with/without 0
hypoxia 0
affect 0
phenotypic B-PHYSICAL
characteristics I-PHYSICAL
of I-PHYSICAL
T-lymphocyte I-PHYSICAL
subsets I-PHYSICAL
in I-PHYSICAL
blood I-PHYSICAL
. 0

Fifty 0
sedentary 0
males 0
were 0
randomly 0
divided 0
into 0
five 0
groups 0
. 0

Each 0
group 0
( 0
n=10 0
) 0
received 0
one 0
of 0
five 0
interventions 0
: 0
normoxic 0
( 0
21 0
% 0
O? 0
) 0
resting 0
( 0
N-C 0
) 0
, 0
hypoxic 0
( 0
15 0
% 0
O? 0
) 0
resting 0
( 0
H-C 0
) 0
, 0
normoxic 0
exercise 0
( 0
50 0
% 0
W 0
( 0
max 0
) 0
under 0
21 0
% 0
O? 0
, 0
N-T 0
) 0
, 0
hypoxic-relative 0
exercise 0
( 0
50 0
% 0
maximal 0
heart 0
rate 0
reserve 0
under 0
15 0
% 0
O? 0
, 0
H-RT 0
) 0
, 0
or 0
hypoxic-absolute 0
exercise 0
( 0
50 0
% 0
W 0
( 0
max 0
) 0
under 0
15 0
% 0
O? 0
, 0
H-AT 0
) 0
for 0
30 0
min/day 0
, 0
5 0
days/week 0
for 0
4 0
weeks 0
. 0

Before 0
the 0
intervention 0
, 0
strenuous 0
exercise 0
up 0
to 0
exhaustion 0
increased 0
the 0
mobilization 0
of 0
CD3 0
, 0
CD4 0
, 0
CD8 0
, 0
or 0
CD8 0
( 0
bright 0
) 0
lymphocytes 0
expressing 0
activated 0
( 0
CD11a 0
) 0
or 0
senescent 0
( 0
KLRG1 0
) 0
molecules 0
into 0
the 0
peripheral 0
blood 0
compartment 0
. 0

The 0
H-AT 0
for 0
4 0
weeks 0
up-regulated 0
co-stimulatory 0
molecule 0
CD28 0
expression 0
and 0
was 0
accompanied 0
by 0
depressed 0
KLRG1 0
level 0
on 0
CD3 0
, 0
CD4 0
, 0
CD8 0
, 0
or 0
CD8 0
( 0
bright 0
) 0
lymphocytes 0
at 0
rest 0
or 0
following 0
exercise 0
. 0

Simultaneously 0
, 0
this 0
intervention 0
increased 0
interferon-? 0
( 0
IFN-? 0
) 0
level 0
and 0
unchanged 0
interleukin-4 0
level 0
, 0
as 0
well 0
as 0
, 0
decreased 0
myeloperoxidase 0
( 0
MPO 0
) 0
and 0
interleukin-6 0
levels 0
in 0
plasma 0
. 0

However 0
, 0
no 0
significant 0
changes 0
in 0
resting 0
and 0
exercise-induced 0
mobilizations 0
of 0
various 0
T-lymphocyte 0
subsets 0
and 0
productions 0
of 0
cytokines 0
and 0
MPO 0
occurred 0
following 0
the 0
N-C 0
, 0
H-C 0
, 0
N-T 0
, 0
and 0
H-RT 0
interventions 0
. 0

Therefore 0
, 0
we 0
conclude 0
that 0
4-week 0
H-AT 0
intervention 0
reduced 0
senescent 0
T-lymphocyte 0
subsets 0
with 0
increasing 0
IFN-? 0
level 0
in 0
blood 0
, 0
which 0
responses 0
are 0
accompanied 0
by 0
depressed 0
oxidative 0
stress 0
and 0
pro-inflammatory 0
cytokine 0
production 0
. 0

These 0
findings 0
can 0
help 0
to 0
determine 0
an 0
effective 0
hypoxic 0
exercise 0
regimen 0
to 0
minimize 0
immune 0
dysfunction 0
by 0
retarding 0
T-lymphocyte 0
senescence 0
. 0

Should 0
insertion 0
of 0
intramedullary 0
nails 0
for 0
tibial 0
fractures 0
be 0
with 0
or 0
without 0
reaming 0
? 0

A 0
prospective 0
, 0
randomized 0
study 0
with 0
3.8 0
years 0
' 0
follow-up 0
. 0

OBJECTIVE 0
To 0
determine 0
if 0
any 0
differences 0
exist 0
in 0
healing B-PHYSICAL
and 0
complications 0
between 0
reamed 0
and 0
unreamed 0
nailing 0
in 0
patients 0
with 0
tibial 0
shaft 0
fractures 0
. 0

DESIGN 0
Prospective 0
, 0
randomized 0
. 0

SETTING 0
Level 0
1 0
trauma 0
center 0
. 0

PATIENTS 0
Forty-five 0
patients 0
with 0
displaced 0
closed 0
and 0
open 0
Gustilo 0
type 0
I-IIIA 0
fractures 0
of 0
the 0
central 0
two 0
thirds 0
of 0
the 0
tibia 0
. 0

INTERVENTION 0
Stabilization 0
of 0
tibial 0
fractures 0
either 0
with 0
a 0
slotted 0
, 0
stainless 0
steel 0
reamed 0
nail 0
or 0
a 0
solid 0
, 0
titanium 0
unreamed 0
nail 0
. 0

MAIN 0
OUTCOME 0
MEASUREMENTS 0
Nonunions B-PHYSICAL
, 0
time B-OTHER
to I-OTHER
fracture I-OTHER
healing I-OTHER
, I-OTHER
and I-OTHER
rate I-OTHER
of I-OTHER
malunions I-OTHER
. 0

RESULTS 0
The 0
average 0
time B-OTHER
to I-OTHER
fracture I-OTHER
healing I-OTHER
was 0
16.7 0
weeks 0
in 0
the 0
reamed 0
group 0
and 0
25.7 0
weeks 0
in 0
the 0
unreamed 0
group 0
. 0

The 0
difference 0
was 0
statistically 0
significant 0
( 0
P 0
= 0
0.004 0
) 0
. 0

There 0
were 0
three 0
nonunions B-PHYSICAL
, 0
all 0
in 0
the 0
unreamed 0
nail 0
group 0
. 0

Two 0
of 0
these 0
fractures 0
healed 0
after 0
dynamization B-PHYSICAL
by I-PHYSICAL
removing I-PHYSICAL
static I-PHYSICAL
interlocking I-PHYSICAL
screws I-PHYSICAL
. 0

The 0
third 0
nonunion 0
did 0
not 0
heal B-PHYSICAL
despite 0
exchange 0
reamed 0
nailing 0
2 0
years 0
after 0
the 0
primary 0
surgery 0
and 0
dynamization 0
with 0
a 0
fibular 0
osteotomy 0
after 0
an 0
additional 0
1 0
year 0
. 0

There 0
were 0
two 0
malunions B-PHYSICAL
in 0
the 0
reamed 0
group 0
and 0
four 0
malunions B-PHYSICAL
in 0
the 0
unreamed 0
group 0
. 0

There 0
were 0
no 0
differences 0
for 0
all 0
other 0
outcome 0
measurements 0
. 0

CONCLUSION 0
Unreamed 0
nailing 0
in 0
patients 0
with 0
tibial 0
shaft 0
fractures 0
may 0
be 0
associated 0
with 0
higher 0
rates 0
of 0
secondary B-OTHER
operations I-OTHER
and 0
malunions B-OTHER
compared 0
with 0
reamed 0
nailing 0
. 0

The 0
time B-OTHER
to I-OTHER
fracture I-OTHER
healing I-OTHER
was 0
significantly 0
longer 0
with 0
unreamed 0
nails 0
. 0

Dofequidar 0
fumarate 0
( 0
MS-209 0
) 0
in 0
combination 0
with 0
cyclophosphamide 0
, 0
doxorubicin 0
, 0
and 0
fluorouracil 0
for 0
patients 0
with 0
advanced 0
or 0
recurrent 0
breast 0
cancer 0
. 0

PURPOSE 0
To 0
evaluate 0
the 0
efficacy 0
and 0
tolerability B-OTHER
of 0
dofequidar 0
plus 0
cyclophosphamide 0
, 0
doxorubicin 0
, 0
and 0
fluorouracil 0
( 0
CAF 0
) 0
therapy 0
in 0
comparison 0
with 0
CAF 0
alone 0
, 0
in 0
patients 0
with 0
advanced 0
or 0
recurrent 0
breast 0
cancer 0
. 0

Dofequidar 0
is 0
a 0
novel 0
, 0
orally 0
active 0
quinoline 0
derivative 0
that 0
reverses 0
multidrug 0
resistance 0
. 0

PATIENTS 0
AND 0
METHODS 0
In 0
this 0
randomized 0
, 0
double-blind 0
, 0
placebo-controlled 0
trial 0
, 0
patients 0
were 0
treated 0
with 0
six 0
cycles 0
of 0
CAF 0
therapy 0
: 0
28 0
days/cycle 0
, 0
with 0
doxorubicin 0
( 0
25 0
mg/m2 0
) 0
and 0
fluorouracil 0
( 0
500 0
mg/m2 0
) 0
administered 0
on 0
days 0
1 0
and 0
8 0
and 0
cyclophosphamide 0
( 0
100 0
mg 0
orally 0
[ 0
PO 0
] 0
) 0
administered 0
on 0
day 0
1 0
through 0
14 0
. 0

Patients 0
received 0
dofequidar 0
( 0
900 0
mg 0
PO 0
) 0
30 0
minutes 0
before 0
each 0
dose 0
of 0
doxorubicin 0
. 0

Primary 0
end 0
point 0
was 0
overall B-PHYSICAL
response 0
rate B-PHYSICAL
( I-PHYSICAL
ORR I-PHYSICAL
; 0
partial B-PHYSICAL
or I-PHYSICAL
complete B-PHYSICAL
response 0
) B-PHYSICAL
. 0

In 0
total 0
, 0
221 0
patients 0
were 0
assessable 0
. 0

RESULTS 0
ORR B-PHYSICAL
was 0
42.6 0
% 0
for 0
CAF 0
compared 0
with 0
53.1 0
% 0
for 0
dofequidar 0
+ 0
CAF 0
, 0
a 0
24.6 0
% 0
relative 0
improvement 0
and 0
10.5 0
% 0
absolute 0
increase 0
( 0
P 0
= 0
.077 0
) 0
. 0

There 0
was 0
a 0
trend 0
for 0
prolonged B-ADVERSE-EFFECTS
progression-free B-ADVERSE-EFFECTS
survival B-ADVERSE-EFFECTS
( I-ADVERSE-EFFECTS
PFS I-ADVERSE-EFFECTS
; 0
median 0
241 0
days 0
for 0
CAF 0
v 0
366 0
days 0
for 0
dofequidar 0
+ 0
CAF 0
; 0
P 0
= 0
.145 0
) 0
. 0

In 0
retrospectively 0
defined 0
subgroups 0
, 0
significant 0
improvement 0
in 0

A 0
controlled 0
trial 0
of 0
cisapride 0
in 0
anorexia 0
nervosa 0
. 0

To 0
determine 0
the 0
efficacy 0
of 0
cisapride 0
, 0
10 0
mg 0
three 0
times 0
daily 0
, 0
in 0
improving 0
gastric B-PHYSICAL
emptying I-PHYSICAL
, 0
reducing 0
distress B-MENTAL
during I-MENTAL
meals I-MENTAL
, 0
and 0
facilitating 0
weight 0
gain B-MENTAL
in 0
anorexia 0
nervosa 0
, 0
we 0
conducted 0
an 0
8-week 0
, 0
randomized 0
, 0
double-blind 0
, 0
placebo-controlled 0
trial 0
on 0
29 0
inpatients 0
. 0

Measures 0
included 0
scintigraphic 0
gastric 0
emptying 0
studies 0
at 0
0 0
, 0
2 0
, 0
4 0
, 0
and 0
8 0
weeks 0
; 0
subjective B-MENTAL
distress I-MENTAL
during I-MENTAL
meals I-MENTAL
measured 0
by 0
visual B-OTHER
analogue I-OTHER
scales I-OTHER
; 0
self-rating B-OTHER
of I-OTHER
degree I-OTHER
of I-OTHER
global I-OTHER
improvement I-OTHER
in I-OTHER
symptoms I-OTHER
associated 0
with B-OTHER
eating B-OTHER
at 0
end 0
of 0
study 0
; 0
and 0
weight 0
measured 0
weekly 0
. 0

Gastric B-PHYSICAL
emptying B-PHYSICAL
improved 0
significantly 0
but 0
equally 0
in 0
both 0
groups 0
over 0
the 0
study 0
period 0
. 0

Yet 0
subjective 0
measures 0
were 0
better 0
in 0
the 0
cisapride 0
group 0
; 0
they 0
rated 0
themselves 0
as 0
more 0
hungry B-MENTAL
( 0
p 0
= 0
.02 0
) 0
and 0
more 0
improved 0
on 0
the 0
global 0
measure 0
of 0
change B-OTHER
in B-OTHER
symptoms I-OTHER
( 0
p 0
= 0
.02 0
) 0
. 0

Even 0
so 0
, 0
the 0
cisapride 0
group 0
did 0
not 0
gain 0
more 0
weight 0
. 0

The 0
correlation 0
between 0

TEN 0
versus 0
TPN 0
following 0
major 0
abdominal 0
trauma 0
-- 0
reduced 0
septic 0
morbidity 0
. 0

Recent 0
animal 0
models 0
suggest 0
that 0
enteral 0
feeding 0
( 0
TEN 0
) 0
compared 0
to 0
parenteral 0
nutrition 0
( 0
TPN 0
) 0
improves 0
resistance 0
to 0
infection 0
. 0

This 0
prospective 0
clinical 0
trial 0
examined 0
the 0
impact 0
of 0
early 0
TEN 0
vs. 0
TPN 0
in 0
the 0
critically 0
injured 0
. 0

Seventy-five 0
patients 0
with 0
an 0
abdominal 0
trauma 0
index 0
( 0
ATI 0
) 0
greater 0
than 0
15 0
and 0
less 0
than 0
40 0
were 0
randomized 0
at 0
initial 0
laparotomy 0
to 0
receive 0
either 0
TEN 0
( 0
Vivonex 0
TEN 0
) 0
or 0
TPN 0
( 0
Freamine 0
HBC 0
6.9 0
% 0
and 0
Trophamine 0
6 0
% 0
) 0
; 0
both 0
regimens 0
contained 0
2.5 0
% 0
fat 0
, 0
33 0
% 0
branched 0
chain 0
amino 0
acids 0
, 0
and 0
had 0
a 0
calorie 0
to 0
nitrogen 0
ratio 0
of 0
150:1 0
. 0

TEN 0
was 0
delivered 0
via 0
a 0
needle 0
catheter 0
jejunostomy 0
. 0

Nutritional 0
support 0
was 0
initiated 0
within 0
12 0
hours 0
postoperatively 0
in 0
both 0
groups 0
, 0
and 0
infused 0
at 0
a 0
rate 0
sufficient 0
to 0
render 0
the 0
patients 0
in 0
positive 0
nitrogen 0
balance 0
. 0

The 0
study 0
groups 0
( 0
TEN 0
= 0
29 0
vs 0
TPN 0
= 0
30 0
) 0
were 0
comparable 0
in 0
age 0
, 0
injury 0
severity 0
and 0
initial 0
metabolic 0
stress 0
. 0

Jejunal 0
feeding 0
was 0
tolerated B-OTHER
unconditionally 0
in 0
25 0
( 0
86 0
% 0
) 0
of 0
the 0
TEN 0
group 0
. 0

Nitrogen B-PHYSICAL
balance I-PHYSICAL
remained 0
equivalent 0
throughout 0
the 0
study 0
period 0
, 0
at 0
day 0
5 0
TEN 0
= 0
-0.3 0
+/- 0
1.0 0
vs. 0
TPN 0
0.1 0
+/- 0
0.8 0
gm/day 0
. 0

Traditional 0
nutritional B-PHYSICAL
protein I-PHYSICAL
markers I-PHYSICAL
( 0
albumin B-PHYSICAL
, 0
transferrin B-PHYSICAL
, 0
and 0

Evaluation 0
of 0
prostaglandin 0
E1 0
for 0
prevention 0
of 0
respiratory 0
failure 0
in 0
high 0
risk 0
trauma 0
patients 0
: 0
a 0
prospective 0
clinical 0
trial 0
and 0
correlation 0
with 0
plasma 0
suppressive 0
factors 0
for 0
neutrophil 0
activation 0
. 0

A 0
group 0
of 0
48 0
critically 0
injured 0
patients 0
were 0
entered 0
into 0
a 0
prospective 0
, 0
double-blind 0
, 0
placebo-controlled 0
trial 0
to 0
evaluate 0
the 0
efficacy 0
of 0
early 0
infusion 0
of 0
PGE1 0
for 0
reducing 0
the 0
incidence 0
of 0
severe B-PHYSICAL
respiratory I-PHYSICAL
failure I-PHYSICAL
and 0
mortality B-MORTALITY
. 0

Secondary 0
assessments 0
examined 0
the 0
effects 0
of 0
the 0
PGE1 0
infusion 0
on 0
plasma 0
mediated 0
suppression 0
of 0
PMN 0
superoxide 0
production 0
and 0
loss 0
of 0
PMN 0
granule 0
enzyme 0
content 0
. 0

The 0
incidence 0
of 0
severe B-PHYSICAL
respiratory I-PHYSICAL
failure I-PHYSICAL
was 0
lower 0
in 0
the 0
PGE1 0
group 0
-- 0
13 0
% 0
versus 0
32 0
% 0
, 0
but 0
this 0
did 0
not 0
reach 0
significance 0
. 0

The 0
overall 0
morality 0
was 0
equivalent 0
between 0
the 0
two 0
groups 0
-- 0
26 0
% 0
( 0
PGE1 0
) 0
versus 0
28 0
% 0
( 0
placebo 0
) 0
. 0

The 0
suppressive 0
activity 0
of 0
the 0
patient 0
plasma 0
was 0
assayed 0
by 0
measurement 0
of 0
normal 0
PMN 0
superoxide 0
production 0
relative 0
to 0
normal 0
control 0
plasma 0
( 0
ratio 0
P 0
: 0
C 0
) 0
. 0

The 0
baseline 0
ratio 0
P 0
: 0
C 0
was 0
62 0
+/- 0
5 0
% 0
in 0
the 0
PGE1 0
group 0
versus 0
60 0
+/- 0
5 0
% 0
in 0
the 0
placebo 0
group 0
. 0

The 0
day 0
1 0
plasma 0
samples 0
showed 0
significant 0
reversal 0
of 0
plasma B-PHYSICAL
suppressive I-PHYSICAL
activity I-PHYSICAL
in 0
the 0
PGE1 0
group 0
-- 0
ratio 0
P 0
: 0
C 0
88 0
+/- 0
5 0
% 0
versus 0
67 0
+/- 0
5 0
% 0
in 0
the 0
placebo 0
group 0
( 0
P 0
less 0
than 0
0.02 0
) 0
. 0

In 0
patients 0
who 0
received 0
the 0
full 0
7 0
days 0
of 0
infusion 0
, 0
the 0
plasma B-PHYSICAL
suppressive I-PHYSICAL
activity I-PHYSICAL
remained 0
significantly 0
diminished 0
in 0
the 0
PGE1 0
group 0
-- 0
ratio 0
P 0
: 0
C 0
77 0
+/- 0
4 0
% 0
versus 0
61 0
+/- 0
5 0
% 0
( 0
P 0
less 0
than 0
0.04 0
) 0
. 0

The 0
baseline 0
lysozyme 0
content 0
of 0
patient 0
PMN 0
's 0
relative 0
to 0
that 0
of 0
normal 0
control 0
PMNs 0
( 0
ratio 0
P 0
: 0
C 0
) 0
was 0
119 0
+/- 0
14 0
% 0
in 0
the 0
PGE1 0
group 0
. 0

A 0
significant 0
loss 0
of 0
lysozyme 0
content 0
was 0
observed 0
in 0
the 0
PGE1 0
group 0
on 0
day 0
1 0
of 0
the 0
infusion 0
-- 0
ratio 0
P 0
: 0
C 0
79 0
+/- 0
8 0
% 0
( 0
P 0
less 0
than 0
0.03 0
) 0
, 0
and 0
was 0
associated 0
with 0
a 0
reduction 0
in 0
the 0
plasma 0
suppressive 0
activity 0
. 0
( 0

ABSTRACT 0
TRUNCATED 0
AT 0
250 0
WORDS 0
) 0

Does 0
surface 0
preparation 0
alter 0
ALA B-OTHER
uptake I-OTHER
in 0
superficial 0
non-melanoma 0
skin 0
cancer 0
in 0
vivo 0
? 0

BACKGROUND/PURPOSE 0
Photodynamic 0
therapy 0
( 0
PDT 0
) 0
using 0
aminolaevulinic 0
acid 0
( 0
ALA 0
) 0
is 0
widely 0
used 0
in 0
the 0
treatment 0
of 0
non-melanoma 0
skin 0
cancer 0
. 0

Surface 0
preparation 0
of 0
the 0
lesion 0
is 0
commonly 0
performed 0
before 0
application 0
of 0
ALA 0
but 0
the 0
extent 0
of 0
the 0
preparation 0
varies 0
from 0
centre 0
to 0
centre 0
and 0
there 0
has 0
been 0
no 0
study 0
of 0
its 0
effects 0
. 0

The 0
purpose 0
of 0
this 0
study 0
was 0
to 0
examine 0
the 0
effects 0
of 0
surface 0
preparation 0
on 0
the 0
local 0
uptake B-OTHER
of I-OTHER
ALA I-OTHER
by 0
recording 0
fluorescence 0
from 0
accumulated 0
protoporphyrin 0
IX 0
( 0
PPIX 0
) 0
. 0

METHODS 0
The 0
study 0
was 0
performed 0
on 0
16 0
lesions 0
, 0
either 0
superficial 0
basal 0
cell 0
carcinoma 0
( 0
BCC 0
) 0
or 0
Bowen 0
's 0
disease 0
( 0
BD 0
) 0
. 0

Each 0
half 0
of 0
the 0
lesion 0
was 0
randomly 0
assigned 0
to 0
( 0
a 0
) 0
no 0
surface 0
preparation 0
or 0
( 0
b 0
) 0
surface 0
preparation 0
( 0
randomly 0
allocated 0
to 0
gentle 0
curettage 0
or 0
abrasion 0
with 0
a 0
spatula 0
) 0
. 0

ALA 0
was 0
left 0
for 0
4 0
h 0
( 0
BCC 0
) 0
or 0
6 0
h 0
( 0
BD 0
) 0
. 0

PPIX B-OTHER
fluorescence I-OTHER
was 0
measured 0
using 0
an 0
excitation 0
wavelength 0
of 0
405+/-5 0
nm 0
and 0
emission 0
spectrum 0
recorded 0
using 0
a 0
photodiode 0
array 0
. 0

Spectra 0
were 0
measured 0
( 0
a 0
) 0
before 0
and 0
( 0
b 0
) 0
after 0
surface 0
preparation 0
, 0
( 0
c 0
) 0
immediately 0
before 0
and 0
( 0
d 0
) 0
after 0
laser 0
irradiation 0
at 0
630 0
nm 0
. 0

RESULTS 0
The 0
ratio 0
of 0
fluorescence B-OTHER
after I-OTHER
incubation I-OTHER
to 0
that 0
before 0
incubation 0
was 0
6.1+/-1.2 0
in 0
the 0
non-prepared 0
section 0
. 0

This 0
increased 0
slightly 0
but 0
not 0
significantly 0
to 0
6.8 0
+/-1.8 0
in 0
the 0
prepared 0
section 0
( 0
P 0
< 0
0.1 0
) 0
. 0

There 0
was 0
no 0
significant 0
difference 0
between 0
curettage B-OTHER
and 0
abrasion B-OTHER
. 0

There 0
was 0
also 0
no 0
significant 0
difference 0
in 0
outcome 0
after 0
PDT 0
. 0

CONCLUSIONS 0
The 0
clinical 0
assessment 0
agrees 0
with 0
the 0
fluorescence 0
data 0
as 0
no 0
significant 0
difference 0
was 0
seen 0
between 0
prepared 0
and 0
unprepared 0
halves 0
of 0
the 0
lesion 0
12 0
months 0
after 0
PDT 0
. 0

Overall 0
our 0
data 0
seem 0
to 0
suggest 0
that 0
for 0
most 0
BCC 0
and 0
BD 0
lesions 0
, 0
surface 0
preparation 0
did 0
not 0
increase 0
ALA B-OTHER
uptake I-OTHER
. 0

A 0
comparison 0
of 0
live 0
and 0
videotape 0
ratings 0
: 0
clomipramine 0
and 0
haloperidol 0
in 0
autism 0
. 0

This 0
study 0
compared 0
live 0
ratings 0
with 0
ratings 0
of 0
videotapes 0
and 0
compared 0
response 0
to 0
clomipramine 0
with 0
response 0
to 0
haloperidol 0
in 0
8 0
subjects 0
, 0
mean 0
age 0
5.62 0
years 0
, 0
who 0
met 0
criteria 0
for 0
autism 0
. 0

They 0
were 0
consecutive 0
admissions 0
to 0
a 0
pilot 0
study 0
of 0
clomipramine 0
( 0
n 0
= 0
4 0
) 0
or 0
a 0
double-blind 0
, 0
placebo 0
controlled 0
study 0
of 0
haloperidol 0
( 0
n 0
= 0
4 0
) 0
. 0

Live 0
ratings 0
were 0
performed 0
by 0
two 0
raters 0
at 0
the 0
end 0
of 0
the 0
pre-treatment 0
placebo 0
baseline 0
period 0
and 0
at 0
the 0
end 0
of 0
the 0
drug 0
treatment 0
period 0
on 0
the 0
CPRS 0
and 0
the 0
CGI 0
and 0
were 0
videotaped 0
. 0

Employing 0
the 0
same 0
instruments 0
, 0
these 0
videotapes 0
were 0
rated 0
by 0
two 0
raters 0
who 0
did 0
not 0
know 0
the 0
subjects 0
and 0
were 0
blind 0
to 0
study 0
design 0
, 0
treatment 0
, 0
and 0
study 0
phase 0
. 0

Ratings B-OTHER
of I-OTHER
videotapes I-OTHER
significantly 0
differed 0
from 0
live B-OTHER
ratings I-OTHER
. 0

A 0
treatment 0
effect 0
for 0
haloperidol 0
was 0
detected 0
only 0
on 0
live B-OTHER
ratings I-OTHER
and 0
not 0
on 0
ratings B-OTHER
of I-OTHER
videotapes I-OTHER
. 0

No 0
treatment 0
effect 0
was 0
detected 0
for 0
clomipramine 0
in 0
either 0
live B-OTHER
or 0
videotape B-OTHER
ratings I-OTHER
. 0

Rapid 0
injection 0
of 0
propofol 0
reduces 0
vascular 0
pain 0
and 0
facilitates 0
Laryngeal 0
Mask 0
Airway 0
insertion 0
. 0

STUDY 0
OBJECTIVE 0
To 0
compare 0
the 0
clinical 0
efficacy 0
of 0
a 0
rapid 0
injection 0
of 0
propofol 0
in 0
regard 0
to 0
pain 0
and 0
ability 0
to 0
facilitate 0
Laryngeal 0
Mask 0
Airway 0
( 0
LMA 0
) 0
insertion 0
. 0

DESIGN 0
Randomized 0
, 0
single-blinded 0
, 0
placebo-controlled 0
study 0
. 0

SETTING 0
University 0
hospital 0
. 0

PATIENTS 0
120 0
ASA 0
physical 0
status 0
1 0
and 0
2 0
patients 0
undergoing 0
elective 0
orthopedic 0
surgeries 0
. 0

INTERVENTIONS 0
Patients 0
were 0
randomly 0
allocated 0
to 0
one 0
of 0
4 0
groups 0
. 0

Group 0
A 0
patients 0
were 0
pretreated 0
with 0
normal 0
saline 0
followed 0
by 0
propofol 0
2.0 0
mg/kg 0
at 0
3.3 0
mg/sec 0
. 0

Group 0
B 0
patients 0
were 0
pretreated 0
with 0
lidocaine 0
0.5 0
mg/kg 0
followed 0
by 0
propofol 0
2.0 0
mg/kg 0
at 0
3.3 0
mg/sec 0
. 0

In 0
Group 0
C 0
, 0
patients 0
were 0
pretreated 0
with 0
lidocaine 0
1.0 0
mg/kg 0
followed 0
by 0
propofol 0
2.0 0
mg/kg 0
at 0
3.3 0
mg/sec 0
. 0

In 0
Group 0
D 0
, 0
patients 0
were 0
pretreated 0
with 0
normal 0
saline 0
followed 0
by 0
propofol 0
2.0 0
mg/kg 0
at 0
50 0
mg/sec 0
. 0

MEASUREMENTS 0
Pain 0
on 0
injection 0
was 0
measured 0
using 0
a 0
4-point 0
scale 0
. 0

Scale 0
and 0
success 0
rate 0
of 0
smooth 0
LMA 0
insertion 0
also 0
were 0
recorded 0
. 0

MAIN 0
RESULTS 0
Rapid 0
injection 0
was 0
less 0
painful B-PAIN
than 0
after 0
pretreatment 0
with 0
lidocaine 0
0.5 0
mg/kg 0
, 0
but 0
was 0
similar 0
to 0
slow 0
injection 0
after 0
pretreatment 0
with 0
lidocaine 0
1.0 0
mg/kg 0
. 0

Rapid 0
injection 0
facilitated 0
LMA B-OTHER
insertion I-OTHER
, 0
unlike 0
slow 0
injection 0
with 0
lidocaine 0
0.5 0
mg/kg 0
pretreatment 0
, 0
and 0
was 0
similarly 0
successful 0
to 0
slow 0
injection 0
after 0
pretreatment 0
with 0
lidocaine 0
1.0 0
mg/kg 0
. 0

CONCLUSIONS 0
The 0
rapid 0
administration 0
of 0
propofol 0
reduces 0
pain 0
and 0
facilitates 0
LMA 0
insertion 0
versus 0
slow 0
administration 0
of 0
propofol 0
. 0

Evaluation 0
of 0
the 0
effects 0
of 0
human 0
leukocyte 0
IFN-alpha 0
on 0
the 0
immune B-PHYSICAL
response 0
to B-PHYSICAL
the I-PHYSICAL
HBV I-PHYSICAL
vaccine B-PHYSICAL
in 0
healthy 0
unvaccinated 0
individuals 0
. 0

HBV 0
vaccine 0
needs 0
3 0
injections 0
over 0
6 0
months 0
to 0
induce 0
immunity 0
. 0

Thus 0
, 0
the 0
use 0
of 0
adjuvants 0
capable 0
of 0
inducing 0
earlier 0
immune 0
protection 0
would 0
be 0
highly 0
desirable 0
. 0

Most 0
adjuvants 0
may 0
act 0
by 0
inducing 0
cytokines 0
, 0
and 0
among 0
them 0
, 0
type 0
I 0
interferons 0
( 0
IFNs 0
) 0
, 0
deserve 0
a 0
special 0
attention 0
in 0
view 0
of 0
the 0
potent 0
immunomostimulatory 0
activity 0
observed 0
in 0
mouse 0
models 0
and 0
on 0
dendritic 0
cell 0
functions 0
. 0

The 0
aim 0
of 0
the 0
present 0
trial 0
was 0
to 0
evaluate 0
the 0
effects 0
of 0
IFN-alpha 0
administered 0
as 0
an 0
adjuvant 0
of 0
HBV 0
vaccine 0
in 0
healthy 0
unvaccinated 0
individuals 0
. 0

No 0
significant 0
enhancing 0
effect 0
on 0
the 0
antibody B-PHYSICAL
response I-PHYSICAL
was 0
observed 0
, 0
in 0
spite 0
of 0
an 0
early 0
and 0
transient 0
upregulation 0
of 0
costimulatory 0
molecule 0
expression 0
on 0

Take 0
a 0
walk 0
in 0
the 0
park 0
? 0

A 0
cross-over 0
pilot 0
trial 0
comparing 0
brisk 0
walking 0
in 0
two 0
different 0
environments 0
: 0
park 0
and 0
urban 0
. 0

OBJECTIVE 0
The 0
objective 0
of 0
the 0
present 0
study 0
is 0
to 0
investigate 0
whether 0
differences 0
exist 0
between 0
a 0
30 0
minute 0
brisk 0
walk 0
taken 0
in 0
two 0
different 0
environments 0
in 0
order 0
to 0
determine 0
which 0
environment 0
best 0
facilitates 0
current 0
physical 0
activity 0
guidelines 0
: 0
park 0
or 0
urban 0
. 0

METHODS 0
In 0
this 0
randomised 0
cross-over 0
pilot 0
study 0
, 0
participants 0
performed 0
a 0
self-timed 0
30 0
minute 0
brisk 0
walk 0
in 0
two 0
different 0
environments 0
, 0
park 0
and 0
urban 0
, 0
in 0
Glasgow 0
, 0
Scotland 0
( 0
October 0
2009 0
to 0
January 0
2010 0
) 0
. 0

Cadence B-PHYSICAL
, 0
recorded 0
using 0
the 0
activPAL? 0
activity 0
monitor 0
, 0
was 0
used 0
to 0
measure 0
intensity 0
. 0

Outcome 0
measures 0
were 0
: 0
mean 0
cadence 0
; 0
moderate-to-vigorous 0
physical 0
activity 0
time 0
accumulated 0
in 0
bouts 0
lasting 0
? 0

10 0
min 0
; 0
number 0
of 0
walking 0
breaks 0
; 0
and 0
duration 0
. 0

RESULTS 0
A 0
convenience 0
sample 0
of 0
40 0
healthy 0
adults 0
was 0
recruited 0
: 0
16 0
males 0
, 0
24 0
females 0
, 0
mean 0
age 0
22.9 0
( 0
5.5 0
) 0
years 0
. 0

The 0
mean 0
cadence 0
for 0
the 0
whole 0
walk 0
was 0
higher 0
in 0
the 0
park 0
: 0
119.3 0
( 0
8.3 0
) 0
vs. 0
110.9 0
( 0
8.9 0
) 0
steps/min 0
. 0

Participants 0
accumulated 0
more 0
moderate-to-vigorous 0
physical 0
activity 0
in 0
? 0

10 0
minute 0
bouts 0
during 0
park 0
walks 0
: 0
25.5 0
( 0
9.6 0
) 0
[ 0
median 0
( 0
interquartile 0
range 0
) 0
] 0
vs. 0
14.0 0
( 0
20.3 0
) 0
min 0
. 0

There 0
was 0
no 0
difference 0
in 0
self-timed 0
duration 0
between 0
locations 0
. 0

CONCLUSION 0
Participants 0
accumulated 0
more 0
moderate-to-vigorous 0
physical 0
activity 0
in 0
bouts 0
? 0

10 0
min 0
in 0
duration 0
on 0
park 0
walks 0
due 0
to 0
the 0
lack 0
of 0
interruptions 0
in 0
walking 0
. 0

Hence 0
the 0
park 0
environment 0
better 0
facilitated 0
the 0
achievement 0
of 0
current 0
physical 0
activity 0
guidelines 0
. 0

Further 0
research 0
involving 0
a 0
larger 0
, 0
more 0
heterogeneous 0
sample 0
is 0
recommended 0
. 0

Profound 0
luteinizing 0
hormone 0
suppression 0
after 0
stopping 0
the 0
gonadotropin-releasing 0
hormone-agonist 0
leuprolide 0
acetate 0
. 0

OBJECTIVE 0
To 0
compare 0
levels 0
of 0
serum 0
LH 0
during 0
continued 0
use 0
of 0
leuprolide 0
acetate 0
( 0
LA 0
) 0
with 0
levels 0
during 0
the 0
first 0
week 0
after 0
discontinuing 0
LA 0
. 0

DESIGN 0
Prospective 0
controlled 0
study 0
. 0

SETTING 0
Clinical 0
assisted 0
conception 0
program 0
. 0

PATIENTS 0
Women 0
undergoing 0
controlled 0
ovarian 0
stimulation 0
for 0
assisted 0
conception 0
were 0
randomized 0
to 0
receive 0
LA 0
according 0
to 0
short 0
or 0
ultrashort 0
protocols 0
. 0

The 0
alternative 0
protocol 0
was 0
used 0
then 0
in 0
a 0
second 0
cycle 0
. 0

Each 0
patient 0
was 0
thus 0
her 0
own 0
control 0
. 0

MAIN 0
OUTCOME 0
MEASURES 0
Serum B-PHYSICAL
LH I-PHYSICAL
over I-PHYSICAL
time I-PHYSICAL
. 0

RESULTS 0
When 0
LA 0
was 0
stopped 0
after 0
5 0
days 0
of 0
administration 0
, 0
LH B-PHYSICAL
levels I-PHYSICAL
fell 0
profoundly 0
when 0
compared 0
with 0
levels 0
when 0
LA 0
was 0
continued 0
. 0

CONCLUSION 0
Loss 0
of 0
LH B-MENTAL
after 0
stopping 0
LA 0
is 0
likely 0
to 0
be 0
clinically 0
important 0
in 0
ovarian 0
stimulation 0
regimens 0
that 0
use 0
pure 0
FSH 0
with 0
LA 0
in 0
ultrashort 0
protocols 0
. 0

The 0
fall 0
in 0
LH B-PHYSICAL
lasts 0
at 0
least 0
1 0
week 0
and 0
may 0
be 0
explainable 0
by 0
persistent 0
suppression 0
of 0
endogenous 0
GnRH 0
by 0
LA 0
during 0
this 0
time 0
. 0

Hitting 0
the 0
target 0
: 0
relatively 0
easy 0
, 0
yet 0
absolutely 0
difficult 0
. 0

It 0
is 0
generally 0
agreed 0
that 0
absolute-direction 0
judgments 0
require 0
information 0
about 0
eye 0
position 0
, 0
whereas 0
relative-direction 0
judgments 0
do 0
not 0
. 0

The 0
source 0
of 0
this 0
eye-position 0
information 0
, 0
particularly 0
during 0
monocular 0
viewing 0
, 0
is 0
a 0
matter 0
of 0
debate 0
. 0

It 0
may 0
be 0
either 0
binocular 0
eye 0
position 0
, 0
or 0
the 0
position 0
of 0
the 0
viewing-eye 0
only 0
, 0
that 0
is 0
crucial 0
. 0

Using 0
more 0
ecologically 0
valid 0
stimulus 0
situations 0
than 0
the 0
traditional 0
LED 0
in 0
the 0
dark 0
, 0
we 0
performed 0
two 0
experiments 0
. 0

In 0
experiment 0
1 0
, 0
observers 0
threw 0
darts 0
at 0
targets 0
that 0
were 0
fixated 0
either 0
monocularly 0
or 0
binocularly 0
. 0

In 0
experiment 0
2 0
, 0
observers 0
aimed 0
a 0
laser 0
gun 0
at 0
targets 0
while 0
fixating 0
either 0
the 0
rear 0
or 0
the 0
front 0
gunsight 0
monocularly 0
, 0
or 0
the 0
target 0
either 0
monocularly 0
or 0
binocularly 0
. 0

We 0
measured 0
the 0
accuracy 0
and 0
precision 0
of 0
the 0
observers 0
' 0
absolute- 0
and 0
relative-direction 0
judgments 0
. 0

We 0
found 0
that 0
( 0
a 0
) 0
relative-direction 0
judgments 0
were 0
precise 0
and 0
independent 0
of 0
phoria 0
, 0
and 0
( 0
b 0
) 0
monocular 0
absolute-direction 0
judgments 0
were 0
inaccurate B-OTHER
, 0
and 0
the 0
magnitude 0
of 0
the 0
inaccuracy B-MENTAL
was 0
predictable 0
from 0
the 0
magnitude 0
of 0
phoria 0
. 0

These 0
results 0
confirm 0
that 0
relative-direction 0
judgments 0
do 0
not 0
require 0
information 0
about 0
eye 0
position 0
. 0

Moreover 0
, 0
they 0
show 0
that 0
binocular 0
eye-position 0
information 0
is 0
crucial 0
when 0
judging 0
the 0
absolute 0
direction 0
of 0
both 0
monocular 0
and 0
binocular 0
targets 0
. 0

The 0
effects 0
of 0
strength 0
training 0
on 0
central B-PHYSICAL
arterial I-PHYSICAL
compliance I-PHYSICAL
in 0
middle-aged 0
and 0
older 0
adults 0
. 0

BACKGROUND 0
Contrary 0
to 0
aerobic 0
exercise 0
, 0
strength 0
training 0
( 0
ST 0
) 0
is 0
associated 0
with 0
decreased 0
central B-PHYSICAL
arterial I-PHYSICAL
compliance I-PHYSICAL
in 0
young 0
men 0
. 0

It 0
is 0
unknown 0
whether 0
ST 0
, 0
with 0
or 0
without 0
concurrent 0
endurance 0
training 0
, 0
would 0
have 0
a 0
similar 0
effect 0
in 0
older 0
adults 0
with 0
reduced 0
baseline 0
arterial B-PHYSICAL
compliance I-PHYSICAL
. 0

OBJECTIVE 0
The 0
primary 0
aim 0
of 0
this 0
study 0
was 0
to 0
determine 0
the 0
effect 0
of 0
a 0
ST 0
program 0
on 0
central B-PHYSICAL
arterial I-PHYSICAL
compliance I-PHYSICAL
in 0
middle-aged 0
and 0
older 0
adults 0
. 0

DESIGN 0
Randomized 0
, 0
controlled 0
intervention 0
study 0
in 0
which 0
37 0
healthy 0
, 0
sedentary 0
men 0
and 0
women 0
( 0
52+/-2 0
years 0
) 0
performed 0
13 0
weeks 0
of 0
ST 0
( 0
n=13 0
) 0
, 0
ST+aerobic 0
exercise 0
( 0
n=12 0
) 0
or 0
stretching 0
exercises 0
as 0
a 0
control 0
group 0
( 0
n=12 0
) 0
. 0

METHODS 0
Participants 0
were 0
rigorously 0
screened 0
for 0
cardiovascular 0
disease 0
and 0
underwent 0
pre-post 0
testing 0
for 0
carotid B-PHYSICAL
arterial I-PHYSICAL
compliance I-PHYSICAL
( 0
via 0
simultaneous 0
ultrasound 0
and 0
applanation 0
tonometry 0
) 0
, 0
carotid-femoral 0
pulse 0
wave 0
velocity 0
, 0
plasma 0
endothelin-1 0
and 0
angiotensin B-PHYSICAL
II I-PHYSICAL
concentrations I-PHYSICAL
and 0
carotid B-PHYSICAL
artery I-PHYSICAL
vasoreactivity I-PHYSICAL
( 0
cold 0
pressor 0
test 0
) 0
. 0

RESULTS 0
ST 0
performed 0
alone 0
, 0
or 0
in 0
conjunction 0
with 0
aerobic 0
exercise 0
, 0
improved 0
maximal B-PHYSICAL
muscle I-PHYSICAL
strength I-PHYSICAL
and I-PHYSICAL
increased 0
total 0
lean B-PHYSICAL
body B-PHYSICAL
mass I-PHYSICAL
( 0
both 0
P 0
< 0
0.01 0
) 0
. 0

No 0
significant 0
changes 0
were 0
observed 0
in 0
carotid B-OTHER
artery I-OTHER
compliance I-OTHER
or 0
carotid-femoral B-PHYSICAL
pulse I-PHYSICAL
wave I-PHYSICAL
velocity I-PHYSICAL
following 0
ST B-OTHER
or I-OTHER
ST+aerobic I-OTHER
exercise B-OTHER
. 0

Carotid B-PHYSICAL
artery B-PHYSICAL
compliance I-PHYSICAL
increased 0
significantly 0
( 0
23 0
% 0
) 0
following 0
stretching 0
which 0
may 0
be 0
attributed 0
to 0
a 0
reduction 0
in 0
carotid 0
pulse 0
pressure 0
. 0

No 0
significant 0
changes 0
were 0
observed 0
in 0
plasma B-PHYSICAL
vasoconstrictor I-PHYSICAL
hormones I-PHYSICAL
or 0

[ 0
Plasma 0
separation 0
combined 0
with 0
CVVHF 0
in 0
septic 0
and 0
SIRS 0
patients 0
] 0
. 0

In 0
a 0
prospective 0
non-randomized 0
trial 0
, 0
59 0
patients 0
with 0
sepsis 0
( 0
n 0
= 0
43 0
) 0
and 0
SIRS 0
( 0
n 0
= 0
16 0
) 0
were 0
treated 0
on 0
a 0
surgical 0
intensive 0
care 0
unit 0
. 0

In 0
22 0
patients 0
plasmapheresis 0
in 0
combination 0
with 0
continuous 0
venovenous 0
hemofiltration 0
( 0
CVVHF 0
) 0
was 0
administered 0
. 0

Lethality B-ADVERSE-EFFECTS
was 0
56 0
% 0
in 0
the 0
sepsis B-PHYSICAL
group I-PHYSICAL
; 0
in 0
the 0
therapy B-MENTAL
group I-MENTAL
lethality B-MORTALITY
was 0
significantly B-MENTAL
lower 0
in B-MENTAL
patients I-MENTAL
with I-MENTAL
plasmapheresis B-MENTAL
, 0
even 0
though 0
in 0
this 0
population 0
the 0
organic 0
failure 0
rate 0
was 0
higher 0
. 0

Finally 0
the 0
dependency 0
of 0
lethality B-MENTAL
and B-MENTAL
age 0
was B-MENTAL
similar I-MENTAL
in I-MENTAL
both I-MENTAL
groups I-MENTAL
. 0

Intranasal 0
recombinant 0
alfa-2b 0
interferon 0
treatment 0
of 0
naturally B-PHYSICAL
occurring I-PHYSICAL
common I-PHYSICAL
colds I-PHYSICAL
. 0

In 0
a 0
double-blind 0
, 0
placebo-controlled 0
study 0
, 0
patients 0
with 0
naturally 0
occurring 0
common 0
colds 0
of 0
less 0
than 0
or 0
equal 0
to 0
48 0
h 0
duration 0
were 0
randomly 0
assigned 0
to 0
receive 0
nasal 0
sprays 0
of 0
recombinant 0
alfa-2b 0
interferon 0
at 0
10 0
or 0
20 0
MU/day 0
or 0
placebo 0
four 0
times 0
per 0
day 0
for 0
5 0
days 0
. 0

The 0
10-MU 0
( 0
n 0
= 0
74 0
) 0
, 0
20-MU 0
( 0
n 0
= 0
74 0
) 0
, 0
and 0
placebo 0
( 0
n 0
= 0
72 0
) 0
groups 0
had 0
comparable 0
frequencies 0
of 0
documented 0
rhinovirus 0
colds 0
( 0
50 0
to 0
65 0
% 0
) 0
and 0
mean 0
durations 0
of 0
pretreatment B-PHYSICAL
symptoms I-PHYSICAL
( 0
26 0
to 0
27 0
h 0
) 0
. 0

The 0
median 0
duration B-PHYSICAL
of I-PHYSICAL
colds I-PHYSICAL
tended 0
to 0
be 0
longer 0
in 0
the 0
20-MU 0
group 0
( 0
10 0
days 0
) 0
than 0
the 0
10-MU 0
group 0
( 0
8 0
days 0
) 0
or 0
placebo 0
group 0
( 0
8 0
days 0
) 0
( 0
P 0
= 0
0.06 0
) 0
. 0

In 0
those 0
with 0
proven 0
rhinovirus 0
colds 0
treated 0
within 0
24 0
h 0
, 0
the 0
median 0
duration B-PHYSICAL
was 0
significantly 0
longer 0
in 0
the 0
20-MU 0
group 0
( 0
9 0
days 0
) 0
than 0
in 0
the 0
placebo 0
group 0
( 0
6 0
days 0
) 0
. 0

No 0
differences 0
favoring 0
interferon 0
treatment 0
were 0
found 0
in 0
respiratory 0
symptom 0
scores 0
or 0
resolution 0
of 0
specific 0
symptoms 0
. 0

On 0
days 0
5 0
and 0
7 0
, 0
nasal 0
washings 0
from 0
compliant 0
subjects 0
with 0
proven 0
rhinovirus 0
colds 0
yielded 0
rhinoviruses 0
more 0
often 0
in 0
placebo 0
( 0
47 0
and 0
48 0
% 0
, 0
respectively 0
) 0
than 0
in 0
interferon 0
( 0
15 0
and 0
16 0
% 0
, 0
respectively 0
) 0
recipients 0
( 0
P 0
less 0
than 0
0.02 0
) 0
, 0
but 0
no 0
differences 0
in 0
new 0
respiratory B-PHYSICAL
illness I-PHYSICAL
occurrence I-PHYSICAL
were 0
observed 0
in 0
household 0
contacts 0
. 0

Interferon 0
recipients 0
had 0
significantly 0
higher 0
frequencies 0
of 0
blood 0
in 0
nasal B-ADVERSE-EFFECTS
mucus I-ADVERSE-EFFECTS
( 0
16 0
to 0
18 0
% 0
) 0
than 0
did 0
placebo 0
recipients 0
( 0
4 0
% 0
) 0
during 0
treatment 0
. 0

Antibiotics B-PHYSICAL
for 0
presumed 0
secondary 0
infections 0
were 0
given 0
more 0
often 0
in 0
the 0
20-MU 0
group 0
( 0
11 0
% 0
) 0
than 0
in 0
the 0
placebo 0
group 0
( 0
0 0
% 0
) 0
( 0
P 0
less 0
than 0
0.01 0
) 0
. 0

Nasal 0
sprays 0
of 0
recombinant 0
alfa-2b 0
interferon 0
were 0
not 0
an 0
effective B-PHYSICAL
treatment 0
for B-PHYSICAL
natural I-PHYSICAL
colds B-PHYSICAL
and 0
were 0
associated 0
with 0

Age 0
and 0
autonomic 0
effects 0
on 0
interrelationships 0
between 0
lung 0
volume 0
and 0
heart 0
rate 0
. 0

To 0
determine 0
effects 0
of 0
aging 0
and 0
autonomic 0
input 0
on 0
interrelationships 0
between 0
respiratory 0
and 0
heart 0
rate 0
variability 0
, 0
we 0
collected 0
5 0
min 0
of 0
lung 0
volume 0
of 0
R-R 0
interval 0
data 0
from 0
7 0
young 0
[ 0
27 0
+/- 0
3 0
( 0
SD 0
) 0
yr 0
] 0
and 0
10 0
older 0
( 0
69 0
+/- 0
6 0
yr 0
) 0
healthy 0
supine 0
humans 0
before 0
and 0
after 0
double 0
pharmacological 0
autonomic 0
blockade 0
with 0
propranolol 0
( 0
0.2 0
mg/kg 0
iv 0
) 0
and 0
atropine 0
( 0
0.04 0
mg/kg 0
iv 0
) 0
. 0

Estimates 0
of 0
respiratory 0
and 0
heart 0
rate 0
power 0
spectra 0
and 0
linear 0
transfer 0
functions 0
between 0
the 0
two 0
groups 0
were 0
generated 0
by 0
Fourier 0
analysis 0
. 0

Age 0
, 0
double 0
blockade 0
effects 0
, 0
the 0
age-drug 0
interactions 0
were 0
determined 0
by 0
analysis 0
of 0
variance 0
for 0
repeated 0
measures 0
. 0

Basal 0
R-R 0
intervals 0
were 0
unaffected 0
by 0
age 0
. 0

Double 0
blockade 0
decreased 0
R-R B-PHYSICAL
intervals I-PHYSICAL
and 0
variability 0
in 0
both 0
age 0
groups 0
( 0
P 0
< 0
0.0001 0
) 0
, 0
but 0
R-R 0
intervals 0
decreased 0
less 0
in 0
older 0
than 0
in 0
young 0
subjects 0
( 0
P 0
< 0
0.0001 0
) 0
. 0

In 0
contrast 0
, 0
basal B-PHYSICAL
respiratory I-PHYSICAL
intervals I-PHYSICAL
and 0
standard 0
deviation 0
were 0
greater 0
in 0
older 0
subjects 0
( 0
P 0
= 0
0.05 0
) 0
and 0
were 0
unaffected 0
by 0
double 0
blockade 0
in 0
young 0
and 0
older 0
subjects 0
. 0

Lung B-PHYSICAL
volume-to-heart I-PHYSICAL
rate I-PHYSICAL
spectral I-PHYSICAL
coherence I-PHYSICAL
was 0
highest 0
at 0
frequencies 0
associated 0
with 0
respiration 0
and 0
greater 0
in 0
young 0
than 0
in 0
older 0
subjects 0
( 0
P 0
< 0
0.07 0
) 0
. 0

Double 0
blockade 0
decreased 0
lung B-PHYSICAL
volume-to-heart I-PHYSICAL
rate I-PHYSICAL
variability 0
transfer 0
function 0
magnitude B-PHYSICAL
( 0
P 0
< 0
0.007 0
) 0
and 0
increased 0
phase 0
angle B-PHYSICAL
( 0
P 0
< 0
0.02 0
) 0
without 0
age 0
effects 0
or 0
age-drug 0
interactions 0
. 0

In 0
conclusion 0
, 0
heart B-PHYSICAL
rate B-PHYSICAL
, 0
respiration B-PHYSICAL
, 0
and 0

Prognosis 0
of 0
advanced 0
hepatocellular 0
carcinoma 0
: 0
comparison 0
of 0
three 0
staging 0
systems 0
in 0
two 0
French 0
clinical 0
trials 0
. 0

OBJECTIVE 0
The 0
objective 0
of 0
this 0
study 0
was 0
to 0
assess 0
the 0
performance 0
of 0
three 0
staging 0
systems 0
[ 0
Okuda 0
, 0
Cancer 0
of 0
the 0
Liver 0
Italian 0
Program 0
( 0
CLIP 0
) 0
and 0
Barcelona 0
Clinic 0
Liver 0
Cancer 0
group 0
( 0
BCLC 0
) 0
] 0
, 0
for 0
predicting 0
survival B-MORTALITY
in 0
patients 0
with 0
hepatocellular 0
carcinoma 0
( 0
HCC 0
) 0
and 0
to 0
explore 0
how 0
to 0
improve 0
prognostic 0
classification 0
among 0
French 0
patients 0
with 0
HCC 0
whose 0
main 0
etiology 0
is 0
alcoholic 0
cirrhosis 0
. 0

METHODS 0
We 0
have 0
pooled 0
two 0
randomized 0
clinical 0
trials 0
in 0
palliative 0
condition 0
from 0
the 0
F?d?ration 0
Francophone 0
de 0
Cancerologie 0
Digestive 0
. 0

They 0
had 0
included 0
416 0
and 0
122 0
patients 0
. 0

Performances 0
of 0
Okuda 0
, 0
CLIP 0
and 0
BCLC 0
scores 0
have 0
been 0
compared 0
using 0
Akaike 0
information 0
criterion 0
, 0
discriminatory 0
ability 0
( 0
Harrell 0
's 0
C 0
and 0
the 0
Royston 0
's 0
D 0
statistics 0
) 0
, 0
monotonicity 0
of 0
gradients 0
and 0
predictive 0
accuracy 0
( 0
Schemper 0
statistics 0
Vs 0
) 0
. 0

To 0
explore 0
how 0
to 0
improve 0
classifications 0
, 0
univariate 0
and 0
multivariate 0
Cox 0
model 0
analyses 0
were 0
carried 0
out 0
. 0

RESULTS 0
The 0
pooled 0
database 0
included 0
538 0
patients 0
. 0

The 0
median 0
survival 0
was 0
5.3 0
months 0
( 0
95 0
% 0
confidence 0
interval 0
4.6-6.2 0
) 0
. 0

For 0
all 0
statistics 0
CLIP 0
staging 0
system 0
had 0
a 0
better 0
prognostic 0
ability 0
. 0

Performances 0
of 0
all 0
staging 0
systems 0
were 0
rather 0
disappointing 0
. 0

World 0
Health 0
Organization 0
performance 0
status 0
( 0
WHO 0
PS 0
) 0
for 0
CLIP 0
or 0
alpha-fetoprotein 0
for 0
BCLC 0
allowed 0
a 0
significant 0
improvement 0
of 0
prognostic 0
information 0
. 0

CONCLUSION 0
Our 0
results 0
indicate 0
that 0
CLIP 0
staging 0
seems 0
to 0
be 0
most 0
adapted 0
to 0
palliative 0
setting 0
and 0
that 0
it 0
could 0
be 0
better 0
by 0
associating 0
WHO 0
PS 0
. 0

Parenteral 0
nutrition 0
and 0
protein 0
sparing 0
after 0
surgery 0
: 0
do 0
we 0
need 0
glucose 0
? 0

Although 0
capable 0
of 0
inducing 0
an 0
anabolic 0
state 0
after 0
surgery 0
, 0
parenteral 0
nutrition 0
, 0
including 0
glucose 0
, 0
leads 0
to 0
hyperglycemia 0
. 0

Even 0
moderate 0
increases 0
in 0
blood 0
glucose 0
are 0
associated 0
with 0
poor 0
surgical 0
outcome 0
. 0

We 0
examined 0
the 0
hypothesis 0
that 0
amino 0
acids 0
, 0
in 0
the 0
absence 0
of 0
glucose 0
supply 0
, 0
spare 0
protein 0
while 0
preventing 0
hyperglycemia 0
. 0

In 0
this 0
prospective 0
study 0
, 0
14 0
patients 0
with 0
colonic 0
cancer 0
were 0
randomly 0
assigned 0
to 0
undergo 0
a 0
6-hour 0
stable 0
isotope 0
infusion 0
study 0
( 0
3 0
hours 0
of 0
fasting 0
followed 0
by 0
3-hour 0
infusions 0
of 0
amino 0
acids 0
, 0
Travasol 0
[ 0
Baxter 0
, 0
Montreal 0
, 0
Canada 0
] 0
10 0
% 0
at 0
0.02 0
mL.kg 0
( 0
-1 0
) 0
.min 0
( 0
-1 0
) 0
, 0
with 0
or 0
without 0
glucose 0
at 0
4 0
mg.kg 0
( 0
-1 0
) 0
.min 0
( 0
-1 0
) 0
) 0
on 0
the 0
second 0
day 0
after 0
colorectal 0
surgery 0
. 0

Protein B-PHYSICAL
breakdown I-PHYSICAL
, 0
protein B-PHYSICAL
oxidation I-PHYSICAL
, 0
protein B-PHYSICAL
balance I-PHYSICAL
, 0
and 0
glucose B-PHYSICAL
production I-PHYSICAL
were 0
assessed 0
by 0
stable 0
isotope 0
tracer 0
kinetics 0
using 0
l- 0
[ 0
1- 0
( 0
13 0
) 0
C 0
] 0
leucine 0
and 0
[ 0
6,6- 0
( 0
2 0
) 0
H2 0
] 0
glucose 0
. 0

Circulating B-PHYSICAL
concentrations I-PHYSICAL
of I-PHYSICAL
glucose I-PHYSICAL
, 0
cortisol B-PHYSICAL
, 0
insulin B-PHYSICAL
, 0
and 0
glucagon B-PHYSICAL
were 0
determined 0
. 0

The 0
administration 0
of 0
amino 0
acids 0
increased 0
protein B-PHYSICAL
balance I-PHYSICAL
from 0
-16+/-4 0
micromol.kg 0
( 0
-1 0
) 0
.h 0
( 0
-1 0
) 0
in 0
the 0
fasted 0
state 0
to 0
16+/-3 0
micromol.kg 0
( 0
-1 0
) 0
.h 0
( 0
-1 0
) 0
. 0

Combined 0
infusion 0
of 0
amino 0
acids 0
and 0
glucose 0
increased 0
protein B-PHYSICAL
balance I-PHYSICAL
from 0
-17+/-7 0
to 0
7+/-5 0
micromol.kg 0
( 0
-1 0
) 0
.h 0
( 0
-1 0
) 0
. 0

The 0
increase 0
in 0
protein B-PHYSICAL
balance I-PHYSICAL
during 0
nutrition 0
was 0
comparable 0
in 0
the 0
2 0
groups 0
( 0
P=.07 0
) 0
. 0

Combined 0
administration 0
of 0
amino 0
acids 0
and 0
glucose 0
decreased 0
endogenous B-PHYSICAL
glucose I-PHYSICAL
production I-PHYSICAL
( 0
P=.001 0
) 0
and 0
stimulated 0
insulin B-PHYSICAL
secretion I-PHYSICAL
( 0
P=.001 0
) 0
to 0
a 0
greater 0
extent 0
than 0
the 0
administration 0
of 0
amino 0
acids 0
alone 0
. 0

Hyperglycemia B-PHYSICAL
( 0
blood 0
glucose 0
, 0
10.1+/-1.9 0
micromol/L 0
) 0
occurred 0
only 0
in 0
the 0
presence 0
of 0
glucose 0
infusion 0
. 0

In 0
summary 0
, 0
excluding 0
glucose 0
from 0
a 0
short-term 0
feeding 0
protocol 0
does 0
not 0
diminish 0
the 0
protein-sparing B-PHYSICAL
effect 0
of 0
amino 0
acids 0
and 0
avoids 0
hyperglycemia B-PHYSICAL
. 0

Variations 0
in 0
EEG B-PHYSICAL
discharges I-PHYSICAL
predict 0
ADHD 0
severity 0
within 0
individual 0
Smith-Lemli-Opitz 0
patients 0
. 0

OBJECTIVE 0
We 0
sought 0
to 0
examine 0
the 0
prevalence 0
of 0
EEG 0
abnormalities 0
in 0
Smith-Lemli-Opitz 0
syndrome 0
( 0
SLOS 0
) 0
as 0
well 0
as 0
the 0
relationship 0
between 0
interictal 0
epileptiform 0
discharges 0
( 0
IEDs 0
) 0
and 0
within-subject 0
variations 0
in 0
attentional 0
symptom 0
severity 0
. 0

METHODS 0
In 0
the 0
context 0
of 0
a 0
clinical 0
trial 0
for 0
SLOS 0
, 0
we 0
performed 0
cross-sectional 0
and 0
repeated-measure 0
observational 0
studies 0
of 0
the 0
relationship 0
between 0
EEG 0
findings 0
and 0
cognitive/behavioral 0
factors 0
on 0
23 0
children 0
( 0
aged 0
4-17 0
years 0
) 0
. 0

EEGs 0
were 0
reviewed 0
for 0
clinical 0
abnormalities 0
, 0
including 0
IEDs 0
, 0
by 0
readers 0
blinded 0
to 0
participants 0
' 0
behavioral 0
symptoms 0
. 0

Between-group 0
differences 0
in 0
baseline 0
characteristics 0
of 0
participants 0
with 0
and 0
without 0
IEDs 0
were 0
analyzed 0
. 0

Within-subject 0
analyses 0
examined 0
the 0
association 0
between 0
the 0
presence 0
of 0
IEDs 0
and 0
changes 0
in 0
attention-deficit/hyperactivity B-PHYSICAL
disorder I-PHYSICAL
( I-PHYSICAL
ADHD I-PHYSICAL
) I-PHYSICAL
symptoms I-PHYSICAL
. 0

RESULTS 0
Of 0
85 0
EEGs 0
, 0
43 0
( 0
51 0
% 0
) 0
were 0
abnormal B-PHYSICAL
, 0
predominantly 0
because 0
of 0
IEDs 0
. 0

Only 0
one 0
subject 0
had 0
documented 0
clinical B-ADVERSE-EFFECTS
seizures I-ADVERSE-EFFECTS
. 0

IEDs 0
clustered 0
in 0
13 0
subjects 0
( 0
57 0
% 0
) 0
, 0
whereas 0
9 0
subjects 0
( 0
39 0
% 0
) 0
had 0
EEGs 0
consistently 0
free 0
of 0
IEDs 0
. 0

While 0
there 0
were 0
no 0
significant 0
group 0
differences 0
in 0
sex 0
, 0
age 0
, 0
intellectual 0
disability 0
, 0
language 0
level 0
, 0
or 0
baseline 0
ADHD 0
symptoms 0
, 0
autistic 0
symptoms 0
tended 0
to 0
be 0
more 0
prevalent 0
in 0
the 0
IED 0
group 0
( 0
according 0
to 0
Autism B-MENTAL
Diagnostic I-MENTAL
Observation I-MENTAL
Schedule-2 I-MENTAL
criteria I-MENTAL
) I-MENTAL
. 0

Within 0
individuals 0
, 0
the 0
presence 0
of 0
IEDs 0
on 0
a 0
particular 0
EEG 0
predicted 0
, 0
on 0
average 0
, 0
a 0
27 0
% 0
increase 0
in 0
ADHD B-MENTAL
symptom I-MENTAL
severity I-MENTAL
. 0

CONCLUSIONS 0
Epileptiform 0
discharges 0
are 0
common 0
in 0
SLOS 0
, 0
despite 0
a 0
relatively 0
low 0
prevalence 0
of 0
epilepsy 0
. 0

Fluctuations 0
in 0
the 0
presence 0
of 0
epileptiform 0
discharges 0
within 0
individual 0
children 0
with 0
a 0
developmental 0
disability 0
syndrome 0
may 0
be 0
associated 0
with 0
fluctuations 0
in 0
ADHD 0
symptomatology 0
, 0
even 0
in 0
the 0
absence 0
of 0
clinical 0
seizures 0
. 0

Cyclosporin 0
A 0
increases 0
somatomedin B-ADVERSE-EFFECTS
C I-ADVERSE-EFFECTS
insulin-like I-ADVERSE-EFFECTS
growth I-ADVERSE-EFFECTS
factor 0
I B-ADVERSE-EFFECTS
levels B-ADVERSE-EFFECTS
in 0
chronic 0
rheumatic 0
diseases 0
. 0

OBJECTIVE 0
To 0
determine 0
whether 0
anabolic 0
hormones 0
that 0
affect 0
the 0
musculoskeletal 0
system 0
and 0
active 0
on 0
the 0
immune 0
cells 0
changed 0
during 0
cyclosporin 0
A 0
( 0
CysA 0
) 0
therapy 0
. 0

METHODS 0
We 0
carried 0
out 0
a 0
randomized 0
study 0
of 0
patients 0
with 0
rheumatic 0
disease 0
attending 0
the 0
outpatient 0
clinic 0
for 0
rheumatic 0
diseases 0
. 0

Twenty-four 0
patients 0
with 0
chronic 0
arthritis 0
[ 0
20 0
with 0
rheumatoid 0
arthritis 0
( 0
RA 0
) 0
and 0
4 0
with 0
psoriatic 0
arthritis 0
( 0
PsA 0
) 0
] 0
were 0
divided 0
into 0
2 0
groups 0
( 0
10 0
RA 0
, 0
2 0
PsA 0
) 0
and 0
randomly 0
given 0
CysA 0
5 0
mg/kg 0
daily 0
or 0
hydroxychloroquine 0
( 0
OH-Chlor 0
) 0
6 0
mg/kg 0
daily 0
in 0
divided 0
doses 0
. 0

RESULTS 0
A 0
significant 0
increase 0
of 0
insulin-like B-PHYSICAL
growth I-PHYSICAL
factor 0
I 0
( 0
IGF-I 0
) 0
( 0
somatomedin 0
C 0
) 0
levels 0
and 0
of 0

Effectiveness 0
of 0
a 0
clinical 0
intervention 0
in 0
improving 0
pain 0
control 0
in 0
outpatients 0
with 0
cancer 0
treated 0
by 0
radiation 0
therapy 0
. 0

PURPOSE 0
To 0
determine 0
the 0
effectiveness 0
of 0
a 0
multicomponent 0
clinical 0
intervention 0
to 0
reduce 0
pain 0
in 0
outpatients 0
with 0
cancer 0
. 0

METHODS 0
AND 0
MATERIALS 0
Sixty-four 0
patients 0
were 0
randomly 0
assigned 0
to 0
receive 0
either 0
a 0
clinical 0
intervention 0
including 0
an 0
information 0
session 0
, 0
the 0
use 0
of 0
a 0
pain 0
diary 0
, 0
and 0
the 0
possibility 0
to 0
contact 0
a 0
physician 0
to 0
adjust 0
the 0
pain 0
medication 0
, 0
or 0
the 0
usual 0
treatment 0
of 0
pain 0
by 0
the 0
staff 0
radiation 0
oncologist 0
. 0

All 0
patients 0
reported 0
their 0
average 0
and 0
worst 0
pain B-PAIN
levels I-PAIN
at 0
baseline 0
and 0
2 0
and 0
3 0
weeks 0
after 0
the 0
start 0
of 0
the 0
intervention 0
. 0

RESULTS 0
The 0
study 0
groups 0
were 0
similar 0
with 0
respect 0
to 0
their 0
baseline 0
characteristics 0
and 0
pain 0
levels 0
at 0
randomization 0
. 0

After 0
3 0
weeks 0
, 0
the 0
average 0
and 0
worst 0
pain 0
experienced 0
by 0
patients 0
randomized 0
to 0
the 0
clinical 0
intervention 0
group 0
was 0
significantly 0
inferior 0
to 0
the 0
average 0
pain 0
experienced 0
by 0
patients 0
in 0
the 0
control 0
group 0
( 0
2.9/10 0
vs. 0
4.4/10 0
and 0
4.2/10 0
vs. 0
5.5/10 0
, 0
respectively 0
) 0
. 0

Results 0
showed 0
that 0
the 0
experimental 0
group 0
patients 0
decreased 0
their 0
pain 0
levels 0
more 0
than 0
the 0
control 0
group 0
patients 0
did 0
over 0
time 0
. 0

CONCLUSION 0
An 0
intervention 0
including 0
patient 0
education 0
, 0
a 0
pain B-PAIN
diary I-PAIN
, 0
and 0
defining 0
a 0
procedure 0
for 0
therapeutic 0
adjustments 0
can 0
be 0
effective 0
to 0
improve B-PAIN
pain I-PAIN
relief I-PAIN
in 0
outpatients B-PHYSICAL
with I-PHYSICAL
cancer I-PHYSICAL
. 0

A 0
randomised 0
, 0
controlled 0
study 0
of 0
dietary 0
intervention 0
in 0
autistic 0
syndromes 0
. 0

Impaired 0
social 0
interaction 0
, 0
communication 0
and 0
imaginative 0
skills 0
characterize 0
autistic 0
syndromes 0
. 0

In 0
these 0
syndromes 0
urinary 0
peptide 0
abnormalities 0
, 0
derived 0
from 0
gluten 0
, 0
gliadin 0
, 0
and 0
casein 0
, 0
are 0
reported 0
. 0

They 0
reflect 0
processes 0
with 0
opioid 0
effect 0
. 0

The 0
aim 0
of 0
this 0
single 0
blind 0
study 0
was 0
to 0
evaluate 0
effect 0
of 0
gluten 0
and 0
casein-free 0
diet 0
for 0
children 0
with 0
autistic 0
syndromes 0
and 0
urinary 0
peptide 0
abnormalities 0
. 0

A 0
randomly 0
selected 0
diet 0
and 0
control 0
group 0
with 0
10 0
children 0
in 0
each 0
group 0
participated 0
. 0

Observations B-OTHER
and 0
tests B-OTHER
were 0
done 0
before 0
and 0
after 0
a 0
period 0
of 0
1 0
year 0
. 0

The 0
development B-OTHER
for 0
the 0
group 0
of 0
children 0
on 0
diet 0
was 0
significantly 0
better 0
than 0
for 0
the 0
controls 0
. 0

A 0
comparison 0
of 0
urinary B-PHYSICAL
and I-PHYSICAL
sexual I-PHYSICAL
outcomes I-PHYSICAL
in 0
women 0
experiencing 0
vaginal 0
and 0
Caesarean 0
births 0
. 0

OBJECTIVE 0
To 0
evaluate 0
the 0
urinary B-PHYSICAL
and I-PHYSICAL
sexual I-PHYSICAL
consequences I-PHYSICAL
of 0
vaginal 0
delivery 0
compared 0
with 0
Caesarean 0
section 0
. 0

METHODS 0
We 0
performed 0
a 0
cohort 0
analysis 0
of 0
data 0
from 0
a 0
randomized 0
controlled 0
trial 0
of 0
episiotomy 0
conducted 0
in 0
3 0
Montreal 0
hospitals 0
in 0
1990-1991 0
. 0

Of 0
the 0
999 0
trial 0
participants 0
for 0
whom 0
follow-up 0
data 0
were 0
available 0
, 0
135 0
delivered 0
by 0
Caesarean 0
section 0
( 0
CS 0
) 0
, 0
and 0
864 0
had 0
a 0
vaginal 0
birth 0
( 0
VB 0
) 0
. 0

After 0
stratifying 0
for 0
parity 0
, 0
we 0
compared 0
rates 0
of 0
urinary B-PHYSICAL
incontinence I-PHYSICAL
( I-PHYSICAL
UI I-PHYSICAL
) I-PHYSICAL
and 0
sexual B-PHYSICAL
functioning I-PHYSICAL
at 0
3 0
months 0
postpartum 0
in 0
women 0
who 0
had 0
a 0
VB 0
with 0
the 0
rates 0
in 0
women 0
who 0
had 0
a 0
CS 0
. 0

RESULTS 0
Primiparous 0
women 0
reported 0
unspecified 0
UI B-PHYSICAL
at 0
3 0
months 0
postpartum 0
more 0
often 0
( 0
17.9 0
% 0
) 0
in 0
the 0
VB 0
group 0
than 0
in 0
the 0
CS 0
group 0
( 0
6.4 0
% 0
) 0
. 0

This 0
difference 0
remained 0
significant 0
whether 0
or 0
not 0
there 0
was 0
a 0
prior 0
history 0
of 0
UI 0
. 0

Multiparous 0
women 0
showed 0
no 0
difference 0
in 0
rates B-PHYSICAL
of 0
UI 0
( 0
VB 0
17.1 0
% 0
vs. 0
CS 0
16.0 0
% 0
) 0
, 0
whether 0
there 0
was 0
a 0
prior 0
history 0
of 0
UI 0
or 0
not 0
. 0

Stress 0
incontinence B-PHYSICAL
was 0
greater 0
among 0
primiparous 0
women 0
in 0
the 0
VB 0
group 0
( 0
VB 0
34.5 0
% 0
vs. 0
CS 0
12.8 0
% 0
) 0
regardless 0
of 0
prior 0
UI 0
history 0
, 0
but 0
the 0
proportion 0
of 0
women 0
whose 0
UI B-PHYSICAL
was 0
severe 0
enough 0
to 0
wear 0
a 0
pad 0
was 0
similar 0
in 0
primiparous 0
women 0
( 0
VB 0
16.0 0
% 0
, 0
CS 0
15.4 0
% 0
) 0
and 0
multiparous 0
women 0
( 0
VB 0
23.8 0
% 0
, 0
CS 0
25.0 0
% 0
) 0
. 0

Women B-MENTAL
's 0
sexual B-MENTAL
dissatisfaction I-MENTAL
was 0
greater 0
among 0
primiparous 0
women 0
who 0
had 0
a 0
vaginal 0
birth 0
( 0
VB 0
70.1 0
% 0
, 0
CS 0
54.5 0
% 0
) 0
, 0
but 0
in 0
multiparous 0
women 0
, 0
the 0
rates 0
of 0
sexual B-PHYSICAL
dissatisfaction I-PHYSICAL
were 0
similar 0
( 0
VB 0
64.2 0
% 0
, 0
CS 0
71.4 0
% 0
) 0
. 0

The 0
frequency 0
of 0
dyspareunia B-PHYSICAL
for 0
each 0
mode 0
of 0
delivery 0
was 0
similar 0
in 0
primiparous 0
women 0
( 0
VB 0
30.7 0
% 0
, 0
CS 0
31.6 0
% 0
) 0
. 0

Overall 0
, 0
both 0
primiparous 0
and 0
multiparous 0
women 0
who 0
had 0
intact 0
perineums 0
after 0
VB 0
had 0
less 0
dyspareunia B-PHYSICAL
than 0
those 0
undergoing 0
CS 0
( 0
VB 0
26.2 0
, 0
CS 0
40.7 0
% 0
) 0
. 0

However 0
, 0
the 0
proportion 0
of 0
women 0
experiencing 0
dyspareunia B-PHYSICAL
was 0
greatest 0
among 0
those 0
who 0
had 0
an 0
episiotomy 0
with 0
or 0
without 0
forceps 0
. 0

Music 0
or 0
guided 0
imagery 0
for 0
women 0
undergoing 0
colposcopy 0
: 0
a 0
randomized 0
controlled 0
study 0
of 0
effects 0
on 0
anxiety B-PAIN
, 0
perceived B-PAIN
pain I-PAIN
, 0
and 0
patient B-OTHER
satisfaction I-OTHER
. 0

OBJECTIVE 0
It 0
was 0
hypothesized 0
that 0
music 0
or 0
guided 0
imagery 0
versus 0
usual 0
care 0
would 0
result 0
in 0
less 0
anxiety B-MENTAL
and 0
perceived B-PAIN
pain I-PAIN
for 0
colposcopy 0
patients 0
. 0

MATERIALS 0
AND 0
METHODS 0
Patients 0
were 0
randomized 0
to 0
music 0
, 0
guided 0
imagery 0
, 0
or 0
usual 0
care 0
after 0
completing 0
a 0
baseline 0
questionnaire 0
. 0

All 0
patients 0
completed 0
a 0
postprocedure 0
questionnaire 0
. 0

RESULTS 0
Study 0
participants 0
( 0
N=170 0
) 0
had 0
a 0
mean 0
age 0
of 0
28.4 0
years 0
( 0
SD=9.6 0
; 0
range 0
18-60 0
) 0
and 0
formed 0
a 0
racially 0
diverse 0
group 0
. 0

Education/income 0
levels 0
were 0
low 0
. 0

No 0
between-group 0
differences 0
were 0
found 0
for 0
postprocedure B-PAIN
anxiety I-PAIN
or 0
pain B-PAIN
rating I-PAIN
. 0

CONCLUSIONS 0
Mind-body 0
interventions 0
had 0
no 0
statistically 0
significant 0
impact 0
on 0
reported 0
anxiety B-MENTAL
, 0
perceived B-PAIN
pain I-PAIN
, 0
or 0
satisfaction B-OTHER
with I-OTHER
care I-OTHER
, 0
even 0
for 0
those 0
who 0
anticipated 0
the 0
most 0
pain 0
or 0
started 0
with 0
high 0
anxiety 0
. 0

Cone 0
biopsy 0
: 0
has 0
endocervical 0
sampling 0
a 0
role 0
? 0

OBJECTIVE 0
To 0
investigate 0
the 0
sensitivity 0
, 0
specificity 0
and 0
predictive 0
value 0
of 0
endocervical 0
sampling 0
in 0
women 0
with 0
abnormal 0
cervical 0
smears 0
. 0

DESIGN 0
A 0
randomized 0
study 0
of 0
two 0
methods 0
of 0
endocervical 0
sampling 0
. 0

SETTING 0
Colposcopy 0
clinic 0
at 0
Aberdeen 0
Royal 0
Infirmary 0
. 0

SUBJECTS 0
100 0
women 0
with 0
abnormal 0
cervical 0
smears 0
selected 0
for 0
cone 0
biopsy 0
according 0
to 0
current 0
colposcopy 0
criteria 0
. 0

INTERVENTIONS 0
53 0
women 0
were 0
randomized 0
to 0
have 0
endocervical 0
sampling 0
with 0
the 0
Kevorkian 0
curette 0
and 0
47 0
to 0
have 0
sampling 0
with 0
the 0
Medscand 0
endocervical 0
brush 0
. 0

MAIN 0
OUTCOME 0
MEASURES 0
Cytology B-OTHER
and 0
histology B-OTHER
results I-OTHER
from I-OTHER
endocervical I-OTHER
sampling I-OTHER
compared 0
with 0
cone B-OTHER
biopsy I-OTHER
histology I-OTHER
. 0

RESULTS 0
The 0
overall 0
sensitivity 0
of 0
endocervical B-OTHER
sampling I-OTHER
was 0
56 0
% 0
, 0
with 0
a 0
false 0
negative 0
rate B-OTHER
of 0
44 0
% 0
and 0
a 0
negative 0
predictive B-OTHER
value I-OTHER
of 0
26 0
% 0
. 0

CONCLUSIONS 0
Endocervical 0
sampling 0
should 0
not 0
influence 0
management 0
when 0
colposcopy 0
is 0
unsatisfactory 0
. 0

Ciprofloxacin/dexamethasone 0
drops 0
decrease 0
the 0
incidence 0
of 0
physician 0
and 0
patient 0
outcomes 0
of 0
otorrhea B-PHYSICAL
after 0
tube 0
placement 0
. 0

OBJECTIVE 0
To 0
evaluate 0
ciprofloxacin 0
0.3 0
% 0
/dexamethasone 0
0.1 0
% 0
( 0
CIPRODEX 0
, 0
Alcon 0
, 0
Ft. 0
Worth 0
, 0
TX 0
) 0
for 0
the 0
prevention 0
of 0
early 0
post-operative 0
otorrhea 0
following 0
TT 0
placement 0
. 0

METHODS 0
This 0
was 0
a 0
single-center 0
, 0
randomized 0
, 0
evaluator-blinded 0
, 0
parallel-group 0
study 0
. 0

Two 0
hundred 0
children 0
undergoing 0
bilateral 0
TT 0
placement 0
were 0
categorized 0
as 0
having 0
unilateral 0
( 0
wet/dry 0
) 0
, 0
bilateral 0
( 0
wet/wet 0
) 0
, 0
or 0
no 0
( 0
dry/dry 0
) 0
effusion 0
at 0
the 0
time 0
of 0
surgery 0
. 0

All 0
patients 0
received 0
Ciprodex 0
or 0
no 0
treatment 0
for 0
5 0
days 0
post-operatively 0
and 0
returned 0
at 0
2 0
weeks 0
. 0

RESULTS 0
Physician-observed B-PHYSICAL
otorrhea I-PHYSICAL
was 0
reported 0
in 0
5 0
( 0
4.95 0
% 0
) 0
patients 0
receiving 0
Ciprodex 0
and 0
39 0
( 0
39.39 0
% 0
) 0
patients 0
receiving 0
no 0
treatment 0
( 0
p 0
< 0
0.0001 0
) 0
. 0

Treatment 0
decreased 0
otorrhea B-PHYSICAL
in 0
all 0
groups 0
, 0
while 0
the 0
greatest 0
benefit 0
was 0
observed 0
in 0
patients 0
with 0
bilateral 0
effusion 0
( 0
93 0
% 0
reduction 0
) 0
. 0

Ciprodex 0
treatment 0
also 0
decreased 0
the 0
rate 0
of 0
clinically B-PHYSICAL
diagnosed I-PHYSICAL
otitis I-PHYSICAL
media I-PHYSICAL
( I-PHYSICAL
OM I-PHYSICAL
) I-PHYSICAL
and 0
effusion B-PHYSICAL
following 0
TT 0
placement 0
( 0
p 0
< 0
or 0
=0.0006 0
) 0
. 0

CONCLUSION 0
Ciprodex 0
reduced 0
early B-PHYSICAL
post-operative I-PHYSICAL
otorrhea I-PHYSICAL
, 0
clinically B-PHYSICAL
diagnosed I-PHYSICAL
OM I-PHYSICAL
and 0
effusion B-PHYSICAL
following 0
TT 0
insertion 0
. 0

The 0
greatest 0
reduction 0
in 0
otorrhea B-PHYSICAL
was 0
observed 0
in 0
patients 0
with 0
bilateral 0
effusion 0
at 0
the 0
time 0
of 0
surgery 0
. 0

Bronchial B-PHYSICAL
matrix I-PHYSICAL
and I-PHYSICAL
inflammation I-PHYSICAL
respond 0
to 0
inhaled 0
steroids 0
despite 0
ongoing 0
allergen 0
exposure 0
in 0
asthma 0
. 0

BACKGROUND 0
Inflammatory B-PHYSICAL
and 0
structural 0
changes 0
of B-PHYSICAL
the I-PHYSICAL
airway I-PHYSICAL
mucosa I-PHYSICAL
are 0
chronic 0
features 0
of 0
asthma 0
. 0

The 0
mechanisms 0
underlying 0
these 0
changes 0
and 0
their 0
modulation 0
by 0
steroid 0
prophylaxis 0
have 0
not 0
been 0
clarified 0
. 0

OBJECTIVE 0
We 0
postulated 0
that 0
asymptomatic 0
ongoing 0
allergen 0
exposure 0
could 0
drive 0
airway 0
inflammation 0
as 0
well 0
as 0
changes 0
in 0
the 0
extracellular 0
matrix 0
( 0
ECM 0
) 0
, 0
and 0
that 0
inhaled 0
steroids 0
could 0
prevent 0
this 0
. 0

METHODS 0
Therefore 0
, 0
we 0
exposed 0
patients 0
with 0
mild 0
asthma 0
to 0
2 0
weeks 0
of 0
repeated 0
low-dose 0
allergen 0
, 0
with 0
concomitant 0
inhaled 0
steroid 0
or 0
placebo 0
treatment 0
. 0

Bronchial 0
biopsies 0
, 0
which 0
were 0
taken 0
before 0
and 0
after 0
this 0
exposure 0
, 0
were 0
stained 0
and 0
digitally 0
analysed 0
. 0

The 0
ECM 0
proteins 0
in 0
asthmatics 0
were 0
also 0
compared 0
with 0
a 0
normal 0
control 0
group 0
. 0

RESULTS 0
Low-dose 0
allergen 0
exposure 0
alone 0
resulted 0
in 0
a 0
significant 0
increase 0
of 0
bronchial B-PHYSICAL
epithelial I-PHYSICAL
macrophages I-PHYSICAL
. 0

Despite 0
ongoing 0
allergen 0
exposure 0
, 0
inhaled 0
steroids 0
reduced 0
the 0
numbers B-PHYSICAL
of I-PHYSICAL
mucosal I-PHYSICAL
eosinophils I-PHYSICAL
, 0
neutrophils B-PHYSICAL
and 0
T B-PHYSICAL
lymphocytes I-PHYSICAL
. 0

At 0
baseline 0
, 0
the 0
mean 0
density 0
of 0
the 0
proteoglycans B-PHYSICAL
( 0
PGS B-PHYSICAL
) 0
biglycan B-PHYSICAL
and 0
decorin B-PHYSICAL
were 0
, 0
respectively 0
, 0
higher 0
and 0
lower 0
in 0
the 0
bronchial 0
mucosa 0
of 0
asthmatics 0
as 0
compared 0
with 0
normal 0
controls 0
. 0

Steroid 0
treatment 0
, 0
during 0
allergen 0
exposure 0
, 0
increased 0
the 0
mean 0
density 0
of 0
the 0
PGS B-PHYSICAL
biglycan I-PHYSICAL
and 0
versican B-PHYSICAL
. 0

CONCLUSION 0
We 0
conclude 0
that 0
chronic 0
allergen 0
exposure 0
induces 0
inflammatory 0
changes 0
in 0
the 0
bronchial 0
mucosa 0
. 0

Despite 0
ongoing 0
allergen 0
exposure 0
, 0
steroid 0
treatment 0
decreases 0
mucosal B-PHYSICAL
inflammatory I-PHYSICAL
cells I-PHYSICAL
while 0
altering 0
PG 0
density 0
. 0

The 0
latter 0
observation 0
highlights 0
the 0
need 0
to 0
examine 0
steroid-induced B-OTHER
changes I-OTHER
closely 0
in 0
the 0
airway 0
structure 0
in 0
patients 0
with 0
asthma 0
. 0

Failure 0
of 0
lithium 0
to 0
reduce 0
period 0
of 0
neutropenia 0
during 0
induction 0
therapy 0
of 0
acute 0
myeloid 0
leukemia 0
. 0

Fifty-four 0
patients 0
treated 0
with 0
daunorubicin 0
, 0
cytosine 0
arabinoside 0
and 0
thioquanine 0
for 0
acute 0
myeloid 0
leukemia 0
were 0
randomly 0
assigned 0
to 0
receive 0
oral 0
lithium 0
carbonate 0
1200 0
mg 0
daily 0
or 0
no 0
lithium 0
. 0

The 0
duration B-PHYSICAL
of I-PHYSICAL
neutropenia I-PHYSICAL
( 0
less 0
than 0
0.5 0
x 0
10 0
( 0
9 0
) 0
/L 0
) 0
was 0
similar 0
between 0
controls 0
( 0
median 0
22.5 0
days 0
) 0
and 0
patients 0
treated 0
with 0
lithium 0
( 0
median 0
24 0
days 0
) 0
. 0

The 0
number B-PHYSICAL
of I-PHYSICAL
remissions I-PHYSICAL
, 0
relapse-free B-MORTALITY
survival I-MORTALITY
and 0
survival B-MORTALITY
were 0
similar 0
for 0
the 0
lithium 0
treated 0
and 0
control 0
groups 0
of 0
patients 0
. 0

There 0
was 0
no 0
apparent 0
clinical B-OTHER
efficacy I-OTHER
in 0
the 0
use 0
of 0
lithium 0
to 0
reduce 0
the 0
period 0
of 0
neutropenia 0
in 0
patients 0
undergoing 0
remission 0
induction 0
therapy 0
for 0
acute 0
myeloid 0
leukemia 0
. 0

Low-dose 0
angiotensin 0
II 0
receptor 0
antagonists 0
and 0
angiotensin 0
II-converting 0
enzyme 0
inhibitors 0
alone 0
or 0
in 0
combination 0
for 0
treatment 0
of 0
primary 0
glomerulonephritis 0
. 0

OBJECTIVE 0
The 0
renin-angiotensin 0
system 0
is 0
thought 0
to 0
be 0
involved 0
in 0
the 0
progression 0
of 0
chronic 0
renal 0
diseases 0
of 0
both 0
diabetic 0
and 0
non-diabetic 0
origin 0
. 0

It 0
has 0
been 0
confirmed 0
that 0
angiotensin-converting 0
enzyme 0
inhibitors 0
( 0
ACEIs 0
) 0
and 0
angiotensin 0
II 0
receptor 0
blockers 0
( 0
ARBs 0
) 0
reduce 0
urinary 0
protein 0
excretion 0
and 0
attenuate 0
the 0
development 0
of 0
renal 0
injury 0
. 0

Clinical 0
data 0
comparing 0
the 0
renal 0
effects 0
of 0
ACEIs 0
and 0
ARBs 0
, 0
either 0
singly 0
or 0
in 0
combination 0
, 0
are 0
scarce 0
and 0
usually 0
concern 0
the 0
use 0
of 0
standard 0
or 0
high 0
doses 0
. 0

MATERIAL 0
AND 0
METHODS 0
This 0
was 0
a 0
prospective 0
, 0
randomized 0
, 0
9-month 0
study 0
of 0
the 0
effects 0
of 0
low 0
doses 0
of 0
losartan 0
( 0
25 0
mg 0
; 0
n 0
= 0
18 0
) 0
versus 0
enalapril 0
( 0
10 0
mg 0
; 0
n 0
= 0
18 0
) 0
versus 0
the 0
combination 0
of 0
losartan 0
( 0
25 0
mg 0
) 0
and 0
enalapril 0
( 0
10 0
mg 0
) 0
( 0
n 0
= 0
16 0
) 0
on 0
proteinuria B-PHYSICAL
, 0
kidney B-PHYSICAL
function I-PHYSICAL
and 0
metabolic B-PHYSICAL
profile I-PHYSICAL
in 0
54 0
patients 0
with 0
biopsy-proven 0
chronic 0
glomerulonephritis 0
, 0
hypertension 0
and 0
normal 0
or 0
slightly 0
impaired 0
kidney 0
function 0
. 0

The 0
clinical B-PHYSICAL
evaluation I-PHYSICAL
and I-PHYSICAL
laboratory I-PHYSICAL
tests I-PHYSICAL
were 0
performed 0
before 0
treatment 0
( 0
baseline 0
) 0
and 0
after 0
3 0
and 0
9 0
months 0
of 0
therapy 0
. 0

RESULTS 0
After 0
3 0
months 0
, 0
significant 0
decreases 0
in 0
proteinuria B-PHYSICAL
were 0
observed 0
in 0
all 0
groups 0
: 0
losartan 0
, 0
22.6 0
% 0
( 0
p 0
= 0
0.02 0
) 0
; 0
enalapril 0
, 0
43 0
% 0
( 0
p 0
= 0
0.012 0
) 0
; 0
and 0
combined 0
therapy 0
, 0
63 0
% 0
( 0
p 0
= 0
0.001 0
) 0
. 0

This 0
anti-proteinuric B-PHYSICAL
effect 0
was 0
even 0
greater 0
after 0
9 0
months 0
of 0
therapy 0
: 0
losartan 0
, 0
44.2 0
% 0
( 0
p 0
= 0
0.02 0
) 0
; 0
enalapril 0
, 0
49.6 0
% 0
( 0
p 0
= 0
0.02 0
) 0
; 0
and 0
combined 0
therapy 0
, 0
51 0
% 0
( 0
p 0
= 0
0.003 0
) 0
. 0

There 0
was 0
no 0
significant 0
difference 0
between 0
losartan 0
and 0
enalapril 0
with 0
respect 0
to 0
their 0
impact 0
on 0
proteinuria B-PHYSICAL
level 0
. 0

Proteinuria B-PHYSICAL
reduction I-PHYSICAL
was 0
significantly 0
greater 0
in 0
patients 0
receiving 0
combined 0
therapy 0
in 0
comparison 0
with 0
losartan 0
treatment 0
after 0
3 0
months 0
of 0
therapy 0
( 0
p 0
= 0
0.02 0
) 0
. 0

Creatinine B-PHYSICAL
clearance I-PHYSICAL
and 0
serum B-PHYSICAL
creatinine I-PHYSICAL
were 0
stable 0
during 0
the 0
entire 0
study 0
period 0
in 0
all 0
patients 0
. 0

No 0
significant 0
changes 0
in 0
lipids B-PHYSICAL
, I-PHYSICAL
serum I-PHYSICAL
uric I-PHYSICAL
acid I-PHYSICAL
or I-PHYSICAL
protein I-PHYSICAL
levels I-PHYSICAL
were 0
observed 0
. 0

CONCLUSIONS 0
These 0
results 0
indicate 0
that 0
proteinuria 0
is 0
reduced 0
by 0
low 0
doses 0
of 0
losartan 0
or 0
enalapril 0
. 0

The 0
combination 0
of 0
these 0
drugs 0
seems 0
to 0
be 0
beneficial 0
and 0
may 0
offer 0
an 0
additional 0
renoprotective 0
effect 0
. 0

This 0
needs 0
to 0
be 0
confirmed 0
in 0
a 0
study 0
with 0
a 0
larger 0
sample 0
size 0
. 0

[ 0
The 0
comparison 0
of 0
the 0
effect 0
of 0
enalapril 0
and 0
indapamide 0
on 0
the 0
peripheral B-PHYSICAL
blood I-PHYSICAL
pressure I-PHYSICAL
and 0
central B-PHYSICAL
blood I-PHYSICAL
pressure I-PHYSICAL
through 0
pulse 0
wave 0
analysis 0
] 0
. 0

OBJECTIVES 0
The 0
purpose 0
of 0
this 0
study 0
was 0
to 0
evaluate 0
the 0
effects 0
of 0
the 0
angiotensin-converting 0
enzyme 0
( 0
ACE 0
) 0
inhibitor 0
enalapril 0
and 0
diuretic 0
indapamide 0
on 0
the 0
peripheral B-PHYSICAL
blood I-PHYSICAL
pressure I-PHYSICAL
and 0
the B-PHYSICAL
central I-PHYSICAL
blood I-PHYSICAL
pressure I-PHYSICAL
in 0
Chinese 0
patients 0
with 0
essential 0
hypertension 0
. 0

METHODS 0
This 0
study 0
was 0
a 0
double 0
blind 0
, 0
randomized 0
study 0
. 0

Informed 0
consent 0
were 0
given 0
by 0
all 0
patients 0
. 0

After 0
2 0
weeks 0
of 0
placebo 0
run-in 0
period 0
, 0
105 0
patients 0
with 0
mild 0
or 0
moderate 0
essential 0
hypertension 0
were 0
randomized 0
to 0
receive 0
either 0
enalapril 0
( 0
10 0
mg 0
per 0
day 0
) 0
or 0
indapamide 0
( 0
2.5 0
mg 0
per 0
day 0
) 0
for 0
8 0
weeks 0
. 0

Radial 0
pulse 0
wave 0
recordings 0
were 0
performed 0
in 0
all 0
the 0
patients 0
before 0
the 0
active 0
treatments 0
were 0
given 0
and 0
at 0
the 0
end 0
of 0
the 0
study 0
. 0

Only 0
those 0
patients 0
who 0
have 0
finished 0
8 0
weeks 0
of 0
active 0
treatment 0
in 0
both 0
groups 0
were 0
included 0
into 0
the 0
final 0
analysis 0
. 0

RESULTS 0
One 0
hundred 0
one 0
patients 0
( 0
51 0
in 0
enalapril 0
group 0
and 0
50 0
in 0
indapamide 0
group 0
) 0
completed 0
the 0
study 0
. 0

No 0
significant 0
difference 0
( 0
all 0
P 0
values 0
> 0
0.05 0
) 0
was 0
found 0
in 0
baseline 0
data 0
between 0
the 0
two 0
groups 0
. 0

After 0
8 0
weeks 0
of 0
treatment 0
, 0
all 0
the 0
parameters 0
of 0
pulse B-PHYSICAL
wave I-PHYSICAL
( 0
except 0
heart 0
rates 0
in 0
both 0
groups 0
and 0
augmentation 0
index 0
in 0
indapamide 0
group 0
) 0
decreased 0
significantly 0
. 0

Comparison 0
of 0
the 0
2 0
groups 0
showed 0
that 0
there 0
were 0
no 0
significant 0
differences 0
( 0
all 0
P 0
values 0
> 0
0.05 0
) 0
in 0
all 0
the 0
parameters 0
of 0
pulse 0
wave 0
except 0
that 0
the 0
central B-PHYSICAL
systolic I-PHYSICAL
blood I-PHYSICAL
pressure I-PHYSICAL
, 0
augmentation B-PHYSICAL
and 0
augmentation B-PHYSICAL
index I-PHYSICAL
were 0
significantly 0
lower 0
in 0
enalapril 0
group 0
than 0
in 0
indapamide 0
group 0
. 0

In 0
enalapril 0
group 0
, 0
the 0
reduced 0
values 0
of 0
systolic B-PHYSICAL
blood I-PHYSICAL
pressure I-PHYSICAL
and 0
pulse B-PHYSICAL
pressure I-PHYSICAL
in I-PHYSICAL
central I-PHYSICAL
aorta I-PHYSICAL
were 0
significantly 0
larger 0
than 0
those 0
in 0
brachial 0
artery 0
. 0

However 0
, 0
the 0
difference B-PHYSICAL
was 0
not 0
observed 0
in 0
indapamide 0
group 0
. 0

CONCLUSIONS 0
Enalapril 0
and 0
indapamide 0
are 0
both 0
similarly 0
effective 0
in 0
reducing 0
peripheral B-PHYSICAL
arterial I-PHYSICAL
blood I-PHYSICAL
pressure I-PHYSICAL
. 0

Moreover 0
, 0
enalapril 0
is 0
more 0
effective 0
in 0
reducing 0
central B-PHYSICAL
systolic I-PHYSICAL
pressure I-PHYSICAL
and I-PHYSICAL
augmentation I-PHYSICAL
index I-PHYSICAL
than 0
indapamide 0
. 0

The 0
difference 0
is 0
probably 0
due 0
to 0
the 0
reduction 0
of 0
wave B-PHYSICAL
reflection I-PHYSICAL
caused 0
by 0
enalapril 0
. 0

Sustained 0
ventricular 0
arrhythmias 0
and 0
mortality 0
among 0
patients 0
with 0
acute 0
myocardial 0
infarction 0
: 0
results 0
from 0
the 0
GUSTO-III 0
trial 0
. 0

BACKGROUND 0
In 0
many 0
patients 0
, 0
ventricular 0
arrhythmias 0
will 0
develop 0
early 0
after 0
acute 0
myocardial 0
infarction 0
. 0

We 0
studied 0
the 0
incidence 0
, 0
timing 0
, 0
and 0
outcomes 0
of 0
such 0
arrhythmias 0
in 0
the 0
international 0
Global 0
Utilization 0
of 0
Streptokinase 0
and 0
TPA 0
( 0
alteplase 0
) 0
for 0
Occluded 0
Coronary 0
Arteries 0
( 0
GUSTO 0
) 0
-III 0
trial 0
. 0

METHODS 0
We 0
identified 0
independent 0
predictors 0
of 0
inhospital 0
ventricular 0
fibrillation 0
( 0
VF 0
) 0
and 0
ventricular 0
tachycardia 0
( 0
VT 0
) 0
and 0
compared 0
30-day 0
and 0
1-year 0
mortality 0
rates 0
of 0
patients 0
who 0
did 0
( 0
n 0
= 0
1121 0
) 0
and 0
did 0
not 0
( 0
n 0
= 0
13,921 0
) 0
have 0
these 0
arrhythmias 0
during 0
the 0
index 0
hospitalization 0
. 0

RESULTS 0
Significant 0
independent 0
predictors 0
of 0
inhospital 0
VF 0
were 0
higher 0
Killip B-PHYSICAL
class I-PHYSICAL
, 0
lower B-PHYSICAL
baseline 0
systolic B-PHYSICAL
pressure B-PHYSICAL
, 0
intravenous B-OTHER
preenrollment I-OTHER
lidocaine B-OTHER
use B-OTHER
, 0
shorter 0
time 0
to 0
thrombolysis B-PHYSICAL
, 0
and 0
beta-blocker 0
use 0
< 0
2 0
weeks 0
before 0
enrollment 0
; 0
independent 0
predictors 0
of 0
inhospital 0
VT 0
were 0
lower 0
baseline 0
systolic B-PHYSICAL
pressure I-PHYSICAL
, 0
intravenous B-PHYSICAL
lidocaine I-PHYSICAL
use 0
before 0
enrollment 0
, 0
higher 0
Killip 0
class 0
, 0
faster 0
baseline 0
heart B-PHYSICAL
rate I-PHYSICAL
, 0
and 0
advanced 0
age 0
. 0

The 0
30-day B-MORTALITY
mortality I-MORTALITY
rate I-MORTALITY
was 0
31 0
% 0
in 0
patients 0
with 0
VF 0
, 0
24 0
% 0
in 0
those 0
with 0
VT 0
, 0
44 0
% 0
in 0
those 0
with 0
both 0
, 0
and 0
6 0
% 0
in 0
those 0
with 0
neither 0
( 0
P 0
=.001 0
) 0
. 0

The 0
corresponding 0
1-year B-MORTALITY
mortality I-MORTALITY

Clinical 0
description 0
of 0
encephalopathic 0
syndromes 0
and 0
risk 0
factors 0
for 0
their 0
occurrence 0
and 0
outcome 0
during 0
melarsoprol 0
treatment 0
of 0
human 0
African 0
trypanosomiasis 0
. 0

Encephalopathies 0
are 0
the 0
most 0
feared 0
complications 0
of 0
sleeping 0
sickness 0
treatment 0
with 0
melarsoprol 0
. 0

To 0
investigate 0
the 0
existence 0
of 0
risk 0
factors 0
, 0
the 0
incidence 0
of 0
encephalopathic 0
syndromes 0
and 0
the 0
relationship 0
between 0
the 0
development 0
of 0
different 0
types 0
of 0
encephalopathies 0
and 0
the 0
clinical 0
outcome 0
was 0
studied 0
in 0
a 0
clinical 0
trial 0
with 0
588 0
patients 0
under 0
treatment 0
with 0
melarsoprol 0
. 0

The 0
38 0
encephalopathy 0
cases 0
were 0
classified 0
into 0
three 0
types 0
according 0
to 0
the 0
leading 0
clinical 0
picture 0
: 0
coma 0
type 0
, 0
convulsion 0
type 0
and 0
psychotic 0
reactions 0
. 0

Nine 0
patients 0
were 0
attributed 0
to 0
the 0
convulsion 0
type 0
, 0
defined 0
as 0
a 0
transient 0
event 0
of 0
short 0
duration 0
with 0
convulsions 0
followed 0
by 0
a 0
post-ictal 0
phase 0
, 0
without 0
signs 0
of 0
a 0
generalized 0
disease 0
. 0

None 0
of 0
these 0
patients 0
died 0
from 0
the 0
reaction 0
. 0

Febrile B-PHYSICAL
reactions I-PHYSICAL
in 0
the 0
48 0
h 0
preceding 0
the 0
reaction 0
were 0
generally 0
not 0
observed 0
in 0
this 0
group 0
. 0

Twenty-five 0
patients 0
were 0
attributed 0
to 0
the 0
coma 0
type 0
, 0
which 0
is 0
a 0
progredient 0
coma 0
lasting 0
several 0
days 0
. 0

Those 0
patients 0
often 0
had 0
signs 0
of 0
a 0
generalized 0
disease 0
such 0
as 0
fever B-PHYSICAL
( 0
84 0
% 0
) 0
, 0
headache B-PHYSICAL
( 0
72 0
% 0
) 0
or 0
bullous 0
skin 0
( 0
8 0
% 0
) 0
reactions 0
. 0

The 0
risk 0
of 0
mortality B-MORTALITY
was 0
high 0
in 0
this 0
group 0
( 0
52 0
% 0
) 0
. 0

About 0
14/16 0
patients 0
with 0
encephalopathic 0
syndrome 0
of 0
the 0
coma 0
type 0
were 0
infected 0
with 0
malaria 0
. 0

Patients 0
with 0
psychotic 0
reactions 0
or 0
abnormal 0
psychiatric 0
behaviour 0
( 0
3/38 0
) 0
and 0
one 0
patient 0
who 0
died B-MORTALITY
after 0
alcohol 0
intake 0
were 0
excluded 0
from 0
the 0
analysis 0
. 0

The 0
overall B-PHYSICAL
rate I-PHYSICAL
of I-PHYSICAL
encephalopathic I-PHYSICAL
syndromes I-PHYSICAL
in 0
the 0
cases 0
analysed 0
( 0
n=34 0
) 0
was 0
5.8 0
% 0
, 0
of 0
which 0
38.2 0
% 0
died 0
. 0

We 0
did 0
not 0
find 0
any 0
parameters 0
of 0
predictive 0
value 0
for 0
the 0
risk 0
of 0
developing B-PHYSICAL
an I-PHYSICAL
encephalopathic I-PHYSICAL
syndrome I-PHYSICAL
based 0
on 0
the 0
symptoms 0
and 0
signs 0
before 0
treatment 0
initiation 0
. 0

The 0
appearance 0
during 0
treatment 0
of 0
febrile B-PHYSICAL
reactions I-PHYSICAL
( 0
RR 0
11.5 0
) 0
, 0
headache B-PHYSICAL
( 0
RR 0
2.5 0
) 0
, 0
bullous B-PHYSICAL
eruptions I-PHYSICAL
( 0
RR 0
4.5 0
) 0
and 0
systolic B-PHYSICAL
hypotension I-PHYSICAL
( 0
RR 0
2.6 0
) 0
were 0
associated 0
with 0
an 0
increased 0
risk 0
for 0
the 0
occurrence 0
of 0
encephalopathic 0
syndromes 0
especially 0
of 0
the 0
coma 0
type 0
. 0

Oral 0
6-mercaptopurine 0
versus 0
oral 0
6-thioguanine 0
and 0
veno-occlusive 0
disease 0
in 0
children 0
with 0
standard-risk 0
acute 0
lymphoblastic 0
leukemia 0
: 0
report 0
of 0
the 0
Children 0
's 0
Oncology 0
Group 0
CCG-1952 0
clinical 0
trial 0
. 0

The 0
Children 0
's 0
Cancer 0
Group 0
1952 0
( 0
CCG-1952 0
) 0
clinical 0
trial 0
studied 0
the 0
substitution 0
of 0
oral 0
6-thioguanine 0
( 0
TG 0
) 0
for 0
6-mercaptopurine 0
( 0
MP 0
) 0
and 0
triple 0
intrathecal 0
therapy 0
( 0
ITT 0
) 0
for 0
intrathecal 0
methotrexate 0
( 0
IT-MTX 0
) 0
in 0
the 0
treatment 0
of 0
standard-risk 0
acute 0
lymphoblastic 0
leukemia 0
. 0

After 0
remission 0
induction 0
, 0
2027 0
patients 0
were 0
randomized 0
to 0
receive 0
MP 0
( 0
n 0
= 0
1010 0
) 0
or 0
TG 0
( 0
n 0
= 0
1017 0
) 0
and 0
IT-MTX 0
( 0
n 0
= 0
1018 0
) 0
or 0
ITT 0
( 0
n 0
= 0
1009 0
) 0
. 0

The 0
results 0
of 0
the 0
thiopurine 0
comparison 0
are 0
as 0
follows 0
. 0

The 0
estimated 0
7-year 0
event-free B-MORTALITY
survival I-MORTALITY
( I-MORTALITY
EFS I-MORTALITY
) I-MORTALITY
for 0
subjects 0
randomized 0
to 0
TG 0
was 0
84.1 0
% 0
( 0
+/- 0
1.8 0
% 0
) 0
and 0
to 0
MP 0
was 0
79.0 0
% 0
( 0
+/- 0
2.1 0
% 0
; 0
P 0
= 0
.004 0
log 0
rank 0
) 0
, 0
although 0
overall B-MORTALITY
survival I-MORTALITY
was 0
91.9 0
% 0
( 0
+/- 0
1.4 0
% 0
) 0
and 0
91.2 0
% 0
( 0
+/- 0
1.5 0
% 0
) 0
, 0
respectively 0
( 0
P 0
= 0
.6 0
log 0
rank 0
) 0
. 0

The 0
TG 0
starting 0
dose 0
was 0
reduced 0
from 0
60 0
to 0
50 0
mg/m 0
( 0
2 0
) 0
per 0
day 0
after 0
recognition 0
of 0
hepatic B-PHYSICAL
veno-occlusive I-PHYSICAL
disease I-PHYSICAL
( I-PHYSICAL
VOD I-PHYSICAL
) I-PHYSICAL
. 0

A 0
total 0
of 0
257 0
patients 0
on 0
TG 0
( 0
25 0
% 0
) 0
developed 0
VOD B-PHYSICAL
or 0
disproportionate B-PHYSICAL
thrombocytopenia I-PHYSICAL
and 0
switched 0
to 0
MP 0
. 0

Once 0
portal B-PHYSICAL
hypertension I-PHYSICAL
occurred 0
, 0
all 0
subjects 0
on 0
TG 0
were 0
changed 0
to 0
MP 0
. 0

The 0
benefit 0
of 0
randomization 0
to 0
TG 0
over 0
MP 0
, 0
as 0
measured 0
by 0
EFS 0
, 0
was 0
evident 0
primarily 0
in 0
boys 0
who 0
began 0
TG 0
at 0
60 0
mg/m 0
( 0
2 0
) 0
( 0
relative 0
hazard 0
rate 0
[ 0
RHR 0
] 0
0.65 0
, 0
P 0
= 0
.002 0
) 0
. 0

The 0
toxicities 0
of 0
TG 0
preclude 0
its 0
protracted 0
use 0
as 0
given 0
in 0
this 0
study 0
. 0

This 0
study 0
is 0
registered 0
at 0
http 0
: 0
//clinicaltrials.gov 0
as 0
NCT00002744 0
. 0

Effects 0
of 0
two 0
types 0
of 0
social 0
support 0
and 0
education 0
on 0
adaptation 0
to 0
early-stage 0
breast 0
cancer 0
. 0

A 0
Roy 0
adaptation 0
model-based 0
support 0
and 0
education 0
intervention 0
for 0
women 0
with 0
early-stage 0
breast 0
cancer 0
was 0
tested 0
in 0
a 0
three-group 0
, 0
three-phase 0
randomized 0
clinical 0
trial 0
of 0
a 0
sample 0
of 0
125 0
women 0
. 0

The 0
experimental 0
group 0
received 0
13 0
months 0
of 0
combined 0
individual 0
telephone 0
and 0
in-person 0
group 0
support 0
and 0
education 0
, 0
Control 0
Group 0
1 0
received 0
13 0
months 0
of 0
telephone-only 0
individual 0
support 0
and 0
education 0
, 0
and 0
Control 0
Group 0
2 0
received 0
one-time 0
mailed 0
educational 0
information 0
. 0

The 0
experimental 0
group 0
and 0
Control 0
Group 0
1 0
reported 0
less 0
mood B-MENTAL
disturbance I-MENTAL
at 0
the 0
end 0
of 0
all 0
three 0
phases 0
, 0
less B-MENTAL
loneliness I-MENTAL
at 0
the 0
end 0
of 0
Phases 0
II 0
and 0
III 0
, 0
and 0
a 0
higher-quality B-MENTAL
relationship I-MENTAL
with I-MENTAL
a I-MENTAL
significant I-MENTAL
other 0
at 0
the 0
end 0
of 0
Phase 0
II 0
than 0
did 0
Control 0
Group 0
2 0
. 0

No 0
group 0
differences 0
were 0
found 0
for 0
cancer-related B-PHYSICAL
worry I-PHYSICAL
or I-PHYSICAL
well-being I-PHYSICAL
. 0

The 0
findings 0
suggest 0
that 0
individual 0
telephone 0
support 0
may 0
provide 0
an 0
effective 0
alternative 0
to 0
in-person 0
support 0
groups 0
. 0

Further 0
study 0
of 0
telephone 0
interventions 0
is 0
recommended 0
using 0
ethnically 0
and 0
economically 0
heterogeneous 0
samples 0
. 0

Efficiency 0
of 0
slush 0
nitrogen 0
vitrification 0
of 0
human 0
oocytes 0
vitrified 0
with 0
or 0
without 0
cumulus 0
cells 0
in 0
relation 0
to 0
survival B-MORTALITY
rate I-MORTALITY
and 0
meiotic B-PHYSICAL
spindle I-PHYSICAL
competence I-PHYSICAL
. 0

OBJECTIVE 0
To 0
evaluate 0
the 0
efficiency 0
of 0
slush 0
nitrogen 0
vitrification 0
of 0
human 0
oocytes 0
with 0
or 0
without 0
cumulus 0
cells 0
in 0
terms 0
of 0
survival B-MORTALITY
rate I-MORTALITY
and 0
maintenance 0
of 0
meiotic B-PHYSICAL
spindle I-PHYSICAL
. 0

DESIGN 0
Randomized 0
, 0
comparative 0
study 0
. 0

SETTING 0
Medical 0
center 0
. 0

PATIENT 0
( 0
S 0
) 0
A 0
total 0
of 0
274 0
oocytes 0
obtained 0
from 0
46 0
couples 0
undergoing 0
infertility 0
treatment 0
. 0

INTERVENTION 0
( 0
S 0
) 0
Metaphase 0
II 0
oocytes 0
were 0
divided 0
into 0
groups 0
A 0
and 0
B 0
, 0
vitrified 0
with 0
and 0
without 0
cumulus 0
cells 0
, 0
respectively 0
. 0

MAIN 0
OUTCOMES 0
MEASURE 0
( 0
S 0
) 0
Survival B-MORTALITY
rates I-MORTALITY
and 0
maintenance 0
of 0
meiotic B-OTHER
spindle I-OTHER
observed I-OTHER
immediately I-OTHER
after I-OTHER
warming I-OTHER
and I-OTHER
3 I-OTHER
hours I-OTHER
after I-OTHER
incubation I-OTHER
. 0

RESULT 0
( 0
S 0
) 0
No 0
statistically 0
significant 0
difference 0
was 0
detected 0
between 0
the 0
two 0
groups 0
in 0
terms 0
of 0
survival B-MORTALITY
rate I-MORTALITY
, 0
but 0
a 0
significantly 0
higher 0
percentage 0
of 0
detectable B-PHYSICAL
spindle I-PHYSICAL
was 0
observed 0
in 0
group 0
B 0
( 0
completely 0
denuded 0
oocytes 0
) 0
, 0
either 0
immediately 0
after 0
warming 0
or 0
3 0
hours 0
after 0
incubation 0
. 0

CONCLUSION 0
( 0
S 0
) 0
Complete 0
denudation 0
of 0
oocytes 0
before 0
slush 0
nitrogen 0
vitrification 0
does 0
not 0
influence 0
survival B-MORTALITY
rates I-MORTALITY
but 0
positively 0
affects 0
oocyte 0
meiotic B-PHYSICAL
spindle I-PHYSICAL
competence I-PHYSICAL
. 0

These 0
data 0
support 0
the 0
hypothesis 0
that 0
cumulus 0
cells 0
during 0
vitrification 0
represent 0
an 0
obstacle 0
to 0
cryoprotectant 0
penetration 0
more 0
than 0
having 0
a 0
protective 0
role 0
for 0
the 0
oocyte 0
. 0

Beneficial 0
effects 0
of 0
a 0
soy-based 0
dietary 0
supplement 0
on 0
lipid B-PHYSICAL
levels I-PHYSICAL
and 0
cardiovascular B-PHYSICAL
risk 0
markers B-PHYSICAL
in 0
type 0
2 0
diabetic 0
subjects 0
. 0

OBJECTIVE 0
Consumption 0
of 0
soy 0
protein 0
has 0
recently 0
been 0
shown 0
to 0
improve 0
the 0
blood B-PHYSICAL
lipid I-PHYSICAL
levels B-PHYSICAL
in 0
nondiabetic 0
subjects 0
. 0

The 0
purpose 0
of 0
this 0
study 0
was 0
to 0
evaluate 0
if 0
a 0
dietary 0
supplement 0
of 0
soy 0
protein 0
, 0
isoflavones 0
, 0
and 0
cotyledon 0
fiber 0
( 0
Abalon 0
) 0
affects 0
cardiovascular B-PHYSICAL
risk 0
markers B-PHYSICAL
, 0
blood B-PHYSICAL
glucose I-PHYSICAL
, 0
and 0
insulin B-PHYSICAL
levels B-PHYSICAL
in 0
type 0
2 0
diabetic 0
subjects 0
. 0

RESEARCH 0
DESIGN 0
AND 0
METHODS 0
Twenty 0
type 0
2 0
diabetic 0
subjects 0
participated 0
in 0
a 0
crossover 0
trial 0
. 0

They 0
were 0
randomized 0
to 0
double-blind 0
supplementation 0
for 0
6 0
weeks 0
with 0
Abalon 0
( 0
soy 0
protein 0
[ 0
50 0
g/day 0
] 0
with 0
high 0
levels 0
of 0
isoflavones 0
[ 0
minimum 0
165 0
mg/day 0
] 0
and 0
cotyledon 0
fiber 0
[ 0
20 0
g/day 0
] 0
) 0
or 0
placebo 0
( 0
casein 0
[ 0
50 0
g/day 0
] 0
and 0
cellulose 0
[ 0
20 0
g/day 0
] 0
) 0
, 0
separated 0
by 0
a 0
3-week 0
wash-out 0
period 0
. 0

RESULTS 0
The 0
results 0
are 0
expressed 0
as 0
means 0
+/- 0
SD 0
. 0

The 0
percentage 0
mean 0
treatment 0
difference 0
between 0
Abalon 0
and 0
placebo 0
demonstrated 0
significantly 0
lower 0
mean 0
values 0
after 0
Abalon 0
for 0
LDL B-PHYSICAL
cholesterol B-PHYSICAL
( 0
10 0
+/- 0
15 0
% 0
, 0
P 0
< 0
0.05 0
) 0
, 0
LDL/UHDL B-PHYSICAL
ratio I-PHYSICAL
( 0
12 0
+/- 0
18 0
% 0
, 0
P 0
< 0
0.05 0
) 0
, 0
apolipoprotein B-PHYSICAL
( 0
apo 0
) 0
B100 0
( 0
30 0
+/- 0
38 0
% 0
, 0
P 0
< 0
0.01 0
) 0
, 0
triglycerides B-PHYSICAL
( 0
22 0
+/- 0
10 0
% 0
, 0
P 0
< 0
0.05 0
) 0
, 0
and 0
homocysteine B-PHYSICAL
( 0
14 0
+/- 0
21 0
% 0
, 0
P 0
< 0
0.01 0
) 0
, 0
whereas 0
the 0
total 0
cholesterol B-PHYSICAL
value I-PHYSICAL
tended 0
to 0
be 0
less 0
significant 0
but 0
still 0
lower 0
( 0
8 0
+/- 0
15 0
% 0
, 0
P 0
< 0
0.08 0
) 0
. 0

No 0
change 0
occurred 0
in 0
HDL B-PHYSICAL
cholesterol B-PHYSICAL
, 0
apo B-PHYSICAL
B100/apo B-PHYSICAL
A1 B-PHYSICAL
ratio B-PHYSICAL
, 0
plasminogen B-PHYSICAL
activator B-PHYSICAL
inhibitor I-PHYSICAL

Theta 0
burst 0
stimulation 0
in 0
the 0
rehabilitation 0
of 0
the 0
upper 0
limb 0
: 0
a 0
semirandomized 0
, 0
placebo-controlled 0
trial 0
in 0
chronic 0
stroke 0
patients 0
. 0

BACKGROUND 0
Noninvasive 0
cortical 0
stimulation 0
could 0
represent 0
an 0
add-on 0
treatment 0
to 0
enhance 0
motor B-PHYSICAL
recovery I-PHYSICAL
after 0
stroke 0
. 0

However 0
, 0
its 0
clinical 0
value 0
, 0
including 0
anticipated 0
size 0
and 0
duration 0
of 0
the 0
treatment 0
effects 0
, 0
remains 0
largely 0
unknown 0
. 0

OBJECTIVE 0
The 0
authors 0
designed 0
a 0
small 0
semi-randomized 0
clinical 0
trial 0
to 0
explore 0
whether 0
long-lasting 0
clinically 0
important 0
gains 0
can 0
be 0
achieved 0
by 0
adding 0
theta 0
burst 0
stimulation 0
( 0
TBS 0
) 0
, 0
a 0
form 0
of 0
repetitive 0
transcranial 0
magnetic 0
stimulation 0
( 0
TMS 0
) 0
, 0
to 0
a 0
rehabilitation 0
program 0
for 0
the 0
hand 0
. 0

METHODS 0
A 0
total 0
of 0
41 0
chronic 0
stroke 0
patients 0
received 0
excitatory 0
TBS 0
to 0
the 0
ipsilesional 0
hemisphere 0
or 0
inhibitory 0
TBS 0
to 0
the 0
contralesional 0
hemisphere 0
in 0
2 0
centers 0
; 0
each 0
active 0
group 0
was 0
compared 0
with 0
a 0
group 0
receiving 0
sham 0
TBS 0
. 0

TBS 0
was 0
followed 0
by 0
physical 0
therapy 0
for 0
10 0
working 0
days 0
. 0

Patients 0
and 0
therapists 0
were 0
blinded 0
to 0
the 0
type 0
of 0
TBS 0
. 0

Primary 0
outcome 0
measures 0
( 0
9-hole 0
Peg 0
Test 0
[ 0
9HPT 0
] 0
, 0
Jebsen 0
Taylor 0
Test 0
[ 0
JTT 0
] 0
, 0
and 0
grip 0
and 0
pinch-grip 0
dynamometry 0
) 0
were 0
assessed 0
4 0
, 0
30 0
, 0
and 0
90 0
days 0
post 0
treatment 0
. 0

The 0
clinically 0
important 0
difference 0
was 0
defined 0
as 0
10 0
% 0
of 0
the 0
maximum 0
score 0
. 0

RESULTS 0
There 0
were 0
no 0
differences 0
between 0
the 0
active 0
treatment 0
and 0
sham 0
groups 0
in 0
any 0
of 0
the 0
outcome 0
measures 0
. 0

All 0
patients 0
achieved 0
small 0
sustainable 0
improvements B-PHYSICAL
-- I-PHYSICAL
9HPT I-PHYSICAL
, 0
5 B-PHYSICAL
% I-PHYSICAL
of I-PHYSICAL
maximum I-PHYSICAL
( 0
confidence 0
interval 0
[ 0
CI 0
] 0
= 0
3 0
% 0
-7 0
% 0
) 0
; 0
JTT B-PHYSICAL
, 0
5.7 0
% 0
( 0
CI 0
= 0
3 0
% 0
-8 0
% 0
) 0
; 0
and 0
grip B-PHYSICAL
strength I-PHYSICAL
, 0
6 0
% 0
( 0
CI 0
= 0
2 0
% 0
-10 0
% 0
) 0
-- 0
all 0
below 0
the 0
defined 0
clinically 0
important 0
level 0
. 0

CONCLUSIONS 0
Cortical 0
stimulation 0
did 0
not 0
augment 0
the 0
gains 0
from 0
a 0
late 0
rehabilitation 0
program 0
. 0

The 0
effect 0
size 0
anticipated 0
by 0
the 0
authors 0
was 0
overestimated 0
. 0

These 0
results 0
can 0
improve 0
the 0
design 0
of 0
future 0
work 0
on 0
therapeutic 0
uses 0
of 0
TMS 0
. 0

Promoting 0
social 0
skill 0
development 0
in 0
children 0
with 0
pervasive 0
developmental 0
disorders 0
: 0
a 0
feasibility 0
and 0
efficacy 0
study 0
. 0

A 0
randomized 0
controlled 0
design 0
was 0
employed 0
to 0
evaluate 0
a 0
social 0
skills 0
intervention 0
for 0
children 0
with 0
pervasive 0
developmental 0
disorders 0
. 0

Aims 0
included 0
evaluating 0
the 0
acceptability 0
of 0
the 0
program 0
and 0
gathering 0
preliminary 0
evidence 0
on 0
efficacy 0
. 0

Forty-four 0
children 0
, 0
ages 0
8-11 0
years 0
, 0
were 0
randomly 0
assigned 0
to 0
treatment 0
or 0
wait 0
list 0
. 0

Treatment 0
consisted 0
of 0
a 0
16-week 0
group 0
intervention 0
designed 0
to 0
teach 0
appropriate 0
social 0
behavior 0
. 0

Between 0
group 0
comparisons 0
showed 0
that 0
children 0
in 0
treatment 0
were 0
rated 0
as 0
improved 0
on 0
the 0
primary 0
outcome 0
measure 0
, 0
( 0
unblinded B-MENTAL
parent I-MENTAL
report I-MENTAL
) 0
, 0
but 0
not 0
on 0
the 0
secondary 0
outcome 0
measure 0
, 0
a 0
parent B-MENTAL
questionnaire 0
. 0

Parents 0
reported 0
a 0
high 0
level B-OTHER
of I-OTHER
satisfaction I-OTHER
with 0
the 0
intervention 0
. 0

The 0
study 0
supports 0
the 0
feasibility 0
of 0
this 0
intervention 0
to 0
families 0
and 0
highlights 0
challenges 0
for 0
future 0
research 0
in 0
social 0
skills 0
intervention 0
. 0

Pilot 0
study 0
of 0
a 0
moderate 0
dose 0
multivitamin/mineral 0
supplement 0
for 0
children 0
with 0
autistic 0
spectrum 0
disorder 0
. 0

OBJECTIVE 0
Determine 0
the 0
effect 0
of 0
a 0
moderate 0
dose 0
multivitamin/mineral 0
supplement 0
on 0
children 0
with 0
autistic 0
spectrum 0
disorder 0
. 0

DESIGN 0
Randomized 0
, 0
double-blind 0
, 0
placebo-controlled 0
3-month 0
study 0
. 0

SUBJECTS 0
Twenty 0
( 0
20 0
) 0
children 0
with 0
autistic 0
spectrum 0
disorder 0
, 0
ages 0
3-8 0
years 0
. 0

RESULTS 0
A 0
Global 0
Impressions 0
parental 0
questionnaire 0
found 0
that 0
the 0
supplement 0
group 0
reported 0
statistically 0
significant 0
improvements B-OTHER
in 0
sleep B-PHYSICAL
and I-PHYSICAL
gastrointestinal I-PHYSICAL
problems I-PHYSICAL
compared 0
to 0
the 0
placebo 0
group 0
. 0

An 0
evaluation 0
of 0
vitamin B-PHYSICAL
B I-PHYSICAL
( I-PHYSICAL
6 I-PHYSICAL
) I-PHYSICAL
levels I-PHYSICAL
prior 0
to 0
the 0
study 0
found 0
that 0
the 0
autistic 0
children 0
had 0
substantially 0
elevated 0
levels 0
of 0
B6 0
compared 0
to 0
a 0
control 0
group 0
of 0
typical 0
children 0
( 0
75 0
% 0
higher 0
, 0
p 0
< 0
0.0000001 0
) 0
. 0

Vitamin B-PHYSICAL
C I-PHYSICAL
levels I-PHYSICAL
were 0
measured 0
at 0
the 0
end 0
of 0
the 0
study 0
, 0
and 0
the 0
placebo 0
group 0
had 0
levels 0
that 0
were 0
significantly 0
below 0
average 0
for 0
typical 0
children 0
, 0
whereas 0
the 0
supplement 0
group 0
had 0
near-average 0
levels 0
. 0

DISCUSSION 0
The 0
finding 0
of 0
high B-PHYSICAL
vitamin I-PHYSICAL
B I-PHYSICAL
( I-PHYSICAL
6 I-PHYSICAL
) I-PHYSICAL
levels I-PHYSICAL
is 0
consistent 0
with 0
recent 0
reports 0
of 0
low 0
levels B-PHYSICAL
of I-PHYSICAL
pyridoxal-5-phosphate I-PHYSICAL
and 0
low 0
activity 0
of 0
pyridoxal B-PHYSICAL
kinase I-PHYSICAL
( 0
i.e. 0
, 0
pyridoxal 0
is 0
only 0
poorly 0
converted 0
to 0
pyridoxal-5-phosphate 0
, 0
the 0
enzymatically 0
active 0
form 0
) 0
. 0

This 0
may 0
explain 0
the 0
functional 0
need 0
for 0
high-dose 0
vitamin 0
B 0
( 0
6 0
) 0
supplementation 0
in 0
many 0
children 0
and 0
adults 0
with 0
autism 0
. 0

Maternal B-PHYSICAL
erythropoietin I-PHYSICAL
in 0
singleton 0
pregnancies 0
: 0
a 0
randomized 0
trial 0
on 0
the 0
effect 0
of 0
oral 0
hematinic 0
supplementation 0
. 0

OBJECTIVE 0
Our 0
purpose 0
was 0
to 0
study 0
the 0
effect 0
of 0
hematinic 0
supplementation 0
on 0
the 0
maternal B-PHYSICAL
erythropoietin I-PHYSICAL
response I-PHYSICAL
during 0
singleton 0
pregnancy 0
. 0

STUDY 0
DESIGN 0
In 0
a 0
randomized 0
, 0
double-blind 0
trial 0
97 0
patients 0
with 0
a 0
first-trimester 0
hemoglobin 0
level 0
> 0
or 0
= 0
14.0 0
gm/dl 0
received 0
either 0
iron 0
and 0
folic 0
acid 0
( 0
hematinic 0
group 0
, 0
n 0
= 0
53 0
) 0
or 0
a 0
placebo 0
( 0
n 0
= 0
44 0
) 0
. 0

Serial B-PHYSICAL
hemoglobin I-PHYSICAL
, 0
hematocrit B-PHYSICAL
, 0
and 0
serum B-PHYSICAL
erythropoietin I-PHYSICAL
were 0
recorded 0
from 0
maternal 0
blood 0
and 0
from 0
cord 0
blood 0
on 0
delivery 0
. 0

Serum B-PHYSICAL
ferritin I-PHYSICAL
was 0
measured 0
in 0
the 0
first 0
trimester 0
, 0
at 0
36 0
weeks 0
' 0
gestation 0
, 0
and 0
in 0
cord 0
blood 0
. 0

RESULTS 0
In 0
both 0
groups 0
( 0
1 0
) 0
the 0
mean 0
hemoglobin B-PHYSICAL
was 0
lower 0
( 0
p 0
< 0
0.01 0
) 0
at 0
40 0
weeks 0
' 0
gestation 0
than 0
when 0
first 0
examined 0
and 0
( 0
2 0
) 0
the 0
mean 0
serum 0
erythropoietin 0
was 0
higher 0
( 0
p 0
< 0
0.01 0
) 0
. 0

The 0
mean 0
serum B-PHYSICAL
ferritin I-PHYSICAL
was 0
lower 0
( 0
p 0
< 0
0.001 0
) 0
in 0
both 0
groups 0
at 0
36 0
weeks 0
' 0
gestation 0
than 0
at 0
presentation 0
but 0
higher 0
( 0
p 0
= 0
0.04 0
) 0
in 0
the 0
hematinic 0
group 0
than 0
in 0
the 0
placebo 0
group 0
. 0

The 0
mean 0
hemoglobin B-PHYSICAL
and 0
hematocrit B-PHYSICAL
were 0
similar 0
in 0
the 0
two 0
groups 0
until 0
the 0
third 0
trimester 0
but 0
thereafter 0
were 0
higher 0
( 0
p 0
< 0
0.05 0
) 0
in 0
the 0
hematinic 0
group 0
. 0

The 0
mean 0
maternal B-PHYSICAL
serum I-PHYSICAL
erythropoietin I-PHYSICAL
was 0
higher 0
( 0
p 0
< 0
0.05 0
) 0
in 0
the 0
placebo 0
group 0
than 0
in 0
the 0
hematinic 0
group 0
after 0
24 0
weeks 0
' 0
gestation 0
. 0

The 0
mean 0
cord B-PHYSICAL
blood 0
hematologic 0
values 0
were 0
similar 0
in 0
the 0
two 0
groups 0
. 0

CONCLUSION 0
Maternal B-PHYSICAL
serum I-PHYSICAL
erythropoietin I-PHYSICAL
increased 0
during 0
pregnancy 0
, 0
but 0
this 0
response 0
was 0
reduced 0
in 0
the 0
third 0
trimester 0
in 0
the 0
hematinic-supplemented 0
group 0
. 0

Activation 0
and 0
intermuscular 0
coherence 0
of 0
distal 0
arm 0
muscles 0
during 0
proximal 0
muscle 0
contraction 0
. 0

In 0
the 0
human 0
upper 0
extremity 0
( 0
UE 0
) 0
, 0
unintended 0
effects 0
of 0
proximal 0
muscle 0
activation 0
on 0
muscles 0
controlling 0
the 0
hand 0
could 0
be 0
an 0
important 0
aspect 0
of 0
motor 0
control 0
due 0
to 0
the 0
necessary 0
coordination 0
of 0
distal 0
and 0
proximal 0
segments 0
during 0
functional 0
activities 0
. 0

This 0
study 0
aimed 0
to 0
elucidate 0
the 0
effects 0
of 0
concurrent 0
activation 0
of 0
elbow 0
muscles 0
on 0
the 0
coordination 0
between 0
hand 0
muscles 0
performing 0
a 0
grip 0
task 0
. 0

Eleven 0
healthy 0
subjects 0
performed 0
precision 0
grip 0
tasks 0
while 0
a 0
constant 0
extension 0
or 0
flexion 0
moment 0
was 0
applied 0
to 0
their 0
elbow 0
joints 0
, 0
inducing 0
a 0
sustained 0
submaximal 0
contraction 0
of 0
elbow 0
muscles 0
to 0
counter 0
the 0
applied 0
torque 0
. 0

Activation 0
of 0
four 0
hand 0
muscles 0
was 0
measured 0
during 0
each 0
task 0
condition 0
using 0
surface 0
electromyography 0
( 0
EMG 0
) 0
. 0

When 0
concurrent 0
activation 0
of 0
elbow 0
muscles 0
was 0
induced 0
, 0
significant 0
changes 0
in 0
the 0
activation 0
levels 0
of 0
the 0
hand 0
muscles 0
were 0
observed 0
, 0
with 0
greater 0
effects 0
on 0
the 0
extrinsic 0
finger 0
extensor 0
( 0
23.2 0
% 0
increase 0
under 0
30 0
% 0
elbow 0
extensor 0
activation 0
; 0
p 0
= 0
0.003 0
) 0
than 0
extrinsic 0
finger 0
flexor 0
( 0
14.2 0
% 0
increase 0
under 0
30 0
% 0
elbow 0
flexor 0
activation 0
; 0
p 0
= 0
0.130 0
) 0
. 0

Elbow B-PHYSICAL
muscle I-PHYSICAL
activation I-PHYSICAL
also 0
induced 0
involuntary 0
changes 0
in 0
the 0
intrinsic B-PHYSICAL
thumb I-PHYSICAL
flexor I-PHYSICAL
activation I-PHYSICAL
( 0
44.6 0
% 0
increase 0
under 0
30 0
% 0
elbow 0
extensor 0
activation 0
; 0
p 0
= 0
0.005 0
) 0
. 0

EMG-EMG 0
coherence 0
analyses 0
revealed 0
that 0
elbow B-PHYSICAL
muscle I-PHYSICAL
activation I-PHYSICAL
significantly 0
reduced 0
intermuscular B-PHYSICAL
coherence 0
between B-PHYSICAL
distal I-PHYSICAL
muscle I-PHYSICAL

Stepping 0
Stones 0
Triple 0
P 0
: 0
an 0
RCT 0
of 0
a 0
parenting 0
program 0
with 0
parents 0
of 0
a 0
child 0
diagnosed 0
with 0
an 0
autism 0
spectrum 0
disorder 0
. 0

Whilst 0
the 0
Triple 0
P 0
Positive 0
Parenting 0
Program 0
has 0
a 0
large 0
evidence 0
base 0
( 0
Sanders 0
, 0
Clinical 0
Child 0
and 0
Family 0
Psychology 0
Review 0
2:71-90 0
, 0
1999 0
; 0
Sanders 0
, 0
Journal 0
of 0
Consulting 0
and 0
Clinical 0
Psychology 0
68:624-640 0
, 0
2000 0
) 0
and 0
preliminary 0
evidence 0
indicates 0
that 0
Stepping 0
Stones 0
Triple 0
P 0
is 0
also 0
efficacious 0
( 0
Roberts 0
, 0
Journal 0
of 0
Clinical 0
Child 0
and 0
Adolescent 0
Psychology 0
, 0
35 0
( 0
2 0
) 0
:180-193 0
, 0
2006 0
) 0
, 0
to 0
date 0
Stepping 0
Stones 0
has 0
not 0
been 0
evaluated 0
with 0
the 0
ASD 0
population 0
. 0

Fifty-nine 0
families 0
with 0
a 0
child 0
with 0
ASD 0
aged 0
between 0
2 0
and 0
9 0
participated 0
in 0
this 0
randomized 0
controlled 0
trial 0
. 0

The 0
results 0
demonstrate 0
significant 0
improvements 0
in 0
parental B-MENTAL
reports I-MENTAL
of I-MENTAL
child I-MENTAL
behaviour I-MENTAL
and 0
parenting B-MENTAL
styles I-MENTAL
with I-MENTAL
the I-MENTAL
treatment 0
effects B-MENTAL
for I-MENTAL
child I-MENTAL
behaviour B-MENTAL
, 0
parental B-MENTAL
over B-MENTAL
reactivity I-MENTAL
and 0
parental B-MENTAL
verbosity I-MENTAL
being 0
maintained 0
at 0
follow-up 0
6 0
months 0
later 0
. 0

Further 0
, 0
the 0
results 0
suggest 0
significant 0
improvements 0
in 0
parental B-MENTAL
satisfaction I-MENTAL
and 0
conflict B-MENTAL
about I-MENTAL

Growth 0
hormone 0
effects 0
on 0
cortical B-PHYSICAL
bone I-PHYSICAL
dimensions I-PHYSICAL
in 0
young 0
adults 0
with 0
childhood-onset 0
growth 0
hormone 0
deficiency 0
. 0

UNLABELLED 0
Growth 0
hormone 0
( 0
GH 0
) 0
treatment 0
in 0
young 0
adults 0
with 0
childhood-onset 0
GH 0
deficiency 0
has 0
beneficial 0
effects 0
on 0
bone B-PHYSICAL
mass I-PHYSICAL
. 0

The 0
present 0
study 0
shows 0
that 0
cortical 0
bone 0
dimensions 0
also 0
benefit 0
from 0
GH 0
treatment 0
, 0
with 0
endosteal 0
expansion 0
and 0
increased 0
cortical 0
thickness 0
leading 0
to 0
improved B-PHYSICAL
bone I-PHYSICAL
strength I-PHYSICAL
. 0

INTRODUCTION 0
In 0
young 0
adults 0
with 0
childhood-onset 0
growth 0
hormone 0
deficiency 0
( 0
CO 0
GHD 0
) 0
, 0
GH 0
treatment 0
after 0
final 0
height 0
is 0
reached 0
has 0
been 0
shown 0
to 0
have 0
beneficial 0
effects 0
on 0
spine 0
and 0
hip 0
bone 0
mineral 0
density 0
. 0

The 0
objective 0
of 0
the 0
study 0
was 0
to 0
evaluate 0
the 0
influence 0
of 0
GH B-PHYSICAL
on 0
cortical B-PHYSICAL
bone I-PHYSICAL
dimensions I-PHYSICAL
. 0

METHODS 0
Patients 0
( 0
n 0
= 0
160 0
; 0
mean 0
age 0
, 0
21.2 0
years 0
; 0
63 0
% 0
males 0
) 0
with 0
CO 0
GHD 0
were 0
randomised 0
2:1 0
to 0
GH 0
or 0
no 0
treatment 0
for 0
24 0
months 0
. 0

Cortical 0
bone 0
dimensions 0
were 0
evaluated 0
by 0
digital 0
x-ray 0
radiogrammetry 0
of 0
the 0
metacarpal 0
bones 0
every 0
6 0
months 0
. 0

RESULTS 0
After 0
24 0
months 0
, 0
cortical 0
thickness 0
was 0
increased 0
compared 0
with 0
the 0
controls 0
( 0
6.43 0
% 0
, 0
CI 0
3.34 0
to 0
9.61 0
% 0
; 0
p 0
= 0
0.0001 0
) 0
and 0
metacarpal 0
index 0
( 0
MCI 0
) 0
( 0
6.14 0
% 0
, 0
CI 0
3.95 0
to 0
8.38 0
% 0
; 0
p 0
< 0
0.0001 0
) 0
, 0
while 0
the 0
endosteal 0
diameter 0
decreased 0
( 0
-4.64 0
% 0
, 0
CI 0
-7.15 0
to 0
-2.05 0
; 0
p 0
< 0
0.001 0
) 0
. 0

Total 0
bone 0
width 0
did 0
not 0
change 0
significantly 0
( 0
0.68 0
% 0
, 0
CI 0
-1.17 0
to 0
2.57 0
% 0
; 0
not 0
significant 0
( 0
NS 0
) 0
) 0
. 0

A 0
gender 0
effect 0
was 0
seen 0
on 0
bone 0
width 0
( 0
p 0
< 0
0.0001 0
) 0
, 0
endosteal 0
diameter 0
( 0
p 0
< 0
0.01 0
) 0
and 0
cortical 0
thickness 0
( 0
p 0
< 0
0.01 0
) 0
, 0
but 0
not 0
with 0
MCI 0
( 0
NS 0
) 0
. 0

CONCLUSIONS 0
Cortical 0
bone 0
reacts 0
promptly 0
to 0
reinstitution 0
of 0
GH 0
beyond 0
the 0
attainment 0
of 0
final 0
height 0
by 0
increasing 0
the 0
cortical 0
thickness 0
through 0
endosteal 0
bone 0
growth 0
. 0

This 0
leads 0
to 0
a 0
higher 0
peak 0
bone 0
mass 0
and 0
may 0
reduce 0
the 0
risk 0
of 0
cortical 0
bone 0
fragility 0
later 0
in 0
life 0
. 0

Effects 0
of 0
oral 0
Lactobacillus 0
GG 0
on 0
enteric B-PHYSICAL
microflora I-PHYSICAL
in 0
low-birth-weight 0
neonates 0
. 0

BACKGROUND 0
Colonization 0
patterns 0
, 0
especially 0
by 0
anaerobic 0
flora 0
, 0
may 0
play 0
an 0
important 0
role 0
in 0
neonatal 0
gut 0
function 0
. 0

Probiotics 0
could 0
affect 0
disease B-PHYSICAL
risk I-PHYSICAL
either 0
directly 0
through 0
colonization 0
or 0
indirectly 0
by 0
promoting 0
changes 0
in 0
gut 0
microbial 0
ecology 0
. 0

METHODS 0
To 0
study 0
the 0
ability 0
of 0
Lactobacillus 0
GG 0
( 0
LGG 0
) 0
to 0
colonize 0
the 0
neonatal B-PHYSICAL
gut I-PHYSICAL
and I-PHYSICAL
modify I-PHYSICAL
its I-PHYSICAL
microbial I-PHYSICAL
ecology I-PHYSICAL
, 0
a 0
prospective 0
, 0
randomized 0
study 0
was 0
performed 0
in 0
71 0
preterm 0
infants 0
of 0
less 0
than 0
2000 0
g 0
birth 0
weight 0
. 0

Infants 0
less 0
than 0
1500 0
g 0
( 0
24 0
treated 0
, 0
15 0
control 0
) 0
received 0
10 0
( 0
9 0
) 0
LGG 0
orally 0
twice 0
daily 0
for 0
21 0
days 0
. 0

Those 0
infants 0
weighing 0
1500 0
to 0
1999 0
g 0
( 0
23 0
treated 0
, 0
9 0
control 0
) 0
were 0
treated 0
for 0
8 0
days 0
. 0

Stools 0
were 0
collected 0
before 0
treatment 0
and 0
on 0
day 0
7 0
to 0
8 0
( 0
and 0
day 0
14 0
and 0
21 0
, 0
in 0
the 0
infants 0
weighing 0
less 0
than 0
1500 0
g 0
) 0
for 0
quantitative B-PHYSICAL
aerobic I-PHYSICAL
and I-PHYSICAL
anaerobic I-PHYSICAL
cultures I-PHYSICAL
. 0

RESULTS 0
Colonization 0
with 0
LGG B-PHYSICAL
occurred I-PHYSICAL
in 0
5 0
of 0
24 0
( 0
21 0
% 0
) 0
infants 0
who 0
weighed 0
less 0
than 0
1500 0
g 0
versus 0
11 0
of 0
23 0
( 0
47 0
% 0
) 0
in 0
larger 0
infants 0
. 0

Colonization B-PHYSICAL
was 0
limited 0
to 0
infants 0
who 0
were 0
not 0
on 0
antibiotics 0
within 0
7 0
days 0
of 0
treatment 0
with 0
LGG 0
. 0

There 0
was 0
a 0
paucity 0
of 0
bacterial 0
species 0
at 0
baseline 0
, 0
although 0
larger 0
infants 0
had 0
more 0
bacterial B-PHYSICAL
species I-PHYSICAL
( 0
1.59 0
+/- 0
0.13 0
( 0
SEM 0
) 0
vs 0
1.11 0
+/- 0
0.12 0
; 0
P 0
< 0
0.03 0
) 0
and 0
higher 0
mean 0
log B-PHYSICAL
colony I-PHYSICAL
forming I-PHYSICAL
units I-PHYSICAL
( 0
CFU B-PHYSICAL
) 0
( 0
8.79 0
+/- 0
0.43 0
vs 0
7.22 0
+/- 0
0.63 0
; 0
P 0
< 0
0.05 0
) 0
compared 0
with 0
infants 0
weighing 0
less 0
than 0
1500 0
g 0
LGG 0
. 0

Treatment 0
in 0
infants 0
weighing 0
less 0
than 0
1500 0
g 0
resulted 0
in 0
a 0
significant 0
increase 0
in 0
species B-PHYSICAL
number I-PHYSICAL
by I-PHYSICAL
day I-PHYSICAL
7 I-PHYSICAL
, I-PHYSICAL
with I-PHYSICAL
further I-PHYSICAL
increases I-PHYSICAL
by I-PHYSICAL
day I-PHYSICAL
21 I-PHYSICAL
. 0

This 0
increase 0
was 0
mainly 0
the 0
result 0
of 0
increased 0
Gram 0
( 0
+ 0
) 0
and 0
anaerobic 0
species 0
. 0

No 0
difference 0
in 0
species B-PHYSICAL
number I-PHYSICAL
was 0
noted 0
in 0
controls 0
. 0

Mean 0
log B-PHYSICAL
CFU I-PHYSICAL
of I-PHYSICAL
Gram I-PHYSICAL
( I-PHYSICAL
- I-PHYSICAL
) I-PHYSICAL
bacteria I-PHYSICAL
did 0
not 0
change 0
in 0
treated 0
infants 0
weighing 0
less 0
than 0
1500 0
g. 0
However 0
, 0
Gram B-PHYSICAL
( I-PHYSICAL
+ I-PHYSICAL
) I-PHYSICAL
mean 0
log B-PHYSICAL
CFU B-PHYSICAL
showed 0
a 0
significant 0
increase 0
on 0
day 0
21 0
( 0
6.1 0
+/- 0
0.9 0
) 0
compared 0
with 0
day 0
0 0
( 0
3.5 0
+/- 0
0.9 0
) 0
( 0
P 0
< 0
0.05 0
) 0
. 0

No 0
significant 0
changes 0
in 0
species B-PHYSICAL
number I-PHYSICAL
or I-PHYSICAL
quantitative I-PHYSICAL
counts B-PHYSICAL
were 0
noted 0
after 0
LGG 0
treatment 0
in 0
the 0
infants 0
weighing 0
1500 0
to 0
1999 0
g 0
LGG B-OTHER
was I-OTHER
well I-OTHER
tolerated I-OTHER
in 0
all 0
infants 0
. 0

CONCLUSION 0
The 0

Short-term 0
metabolic 0
effects 0
of 0
prednisone 0
administration 0
in 0
healthy 0
subjects 0
. 0

AIMS 0
Supraphysiologic 0
glucocorticoid 0
activity 0
is 0
well 0
established 0
to 0
cause 0
impaired 0
glucose B-PHYSICAL
tolerance 0
and 0
insulin B-PHYSICAL
resistance I-PHYSICAL
, 0
yet 0
no 0
study 0
has 0
evaluated 0
dose-dependent 0
effects 0
of 0
low-dose 0
prednisone 0
during 0
short-term 0
oral 0
administration 0
. 0

METHODS 0
The 0
objective 0
of 0
this 0
study 0
was 0
to 0
quantify 0
the 0
effects 0
of 0
daily 0
10 0
or 0
25 0
mg 0
prednisone 0
administration 0
for 0
one 0
week 0
on 0
insulin 0
sensitivity 0
by 0
employing 0
a 0
two-step 0
hyperinsulinemic 0
euglycemic 0
glucose 0
clamp 0
( 0
Step 0
1 0
: 0
insulin 0
infusion 0
= 0
20 0
mU/m?/min 0
; 0
Step 0
2 0
: 0
insulin 0
infusion 0
= 0
80 0
mU/m?/min 0
) 0
in 0
healthy 0
, 0
lean 0
males 0
. 0

The 0
amount 0
of 0
glucose 0
infused 0
at 0
steady-state 0
to 0
maintain 0
stable 0
blood 0
glucose 0
[ 0
90 0
mg/dl 0
( 0
4.95 0
mmol/l 0
) 0
] 0
was 0
used 0
to 0
calculate 0
several 0
indices 0
of 0
insulin 0
sensitivity 0
. 0

RESULTS 0
During 0
Step 0
1 0
of 0
the 0
clamp 0
, 0
whole 0
body 0
glucose 0
disposal 0
( 0
M 0
) 0
was 0
reduced 0
by 0
35 0
% 0
( 0
p 0
= 0
0.003 0
) 0
and 0
M/I 0
was 0
reduced 0
by 0
29 0
% 0
( 0
p 0
= 0
0.025 0
) 0
for 0
25 0
mg 0
prednisone 0
compared 0
to 0
placebo 0
. 0

No 0
appreciable 0
effect 0
of 0
10 0
mg 0
prednisone 0
was 0
observed 0
. 0

During 0
Step 0
2 0
, 0
M 0
was 0
reduced 0
by 0
33 0
% 0
( 0
p 0
= 0
0.001 0
) 0
and 0
15 0
% 0
( 0
p 0
= 0
0.006 0
) 0
for 0
25 0
and 0
10 0
mg 0
prednisone 0
compared 0
to 0
placebo 0
; 0
and 0
M/I 0
ratio 0
was 0
reduced 0
by 0
31 0
% 0
( 0
p 0
< 0
0.001 0
) 0
and 0
13 0
% 0
( 0
p 0
= 0
0.026 0
) 0
, 0
respectively 0
. 0

The 0
insulin 0
sensitivity 0
index 0
, 0
Si 0
, 0
calculated 0
as 0
the 0
quotient 0
of 0
augmentation 0
of 0
M/I 0
between 0
Step 0
1 0
and 0
2 0
, 0
was 0
reduced 0
by 0
35.3 0
% 0
( 0
p 0
< 0
0.01 0
) 0
and 0
23.5 0
% 0
( 0
p 0
< 0
0.05 0
) 0
for 0
25 0
and 0
10 0
mg 0
prednisone 0
, 0
respectively 0
. 0

CONCLUSION 0
Administration 0
of 0
relatively 0
low 0
pharmacological 0
doses 0
of 0
prednisone 0
for 0
one 0
week 0
impaired 0
insulin 0
sensitivity 0
in 0
a 0
dose-dependent 0
manner 0
in 0
healthy 0
males 0
. 0

These 0
observed 0
changes 0
in 0
insulin 0
sensitivity 0
are 0
likely 0
to 0
be 0
clinically 0
relevant 0
, 0
especially 0
in 0
individuals 0
predisposed 0
to 0
develop 0
glucose 0
intolerance 0
. 0

The 0
limit 0
to 0
exercise 0
tolerance 0
in 0
humans 0
: 0
mind 0
over 0
muscle 0
? 0

In 0
exercise 0
physiology 0
, 0
it 0
has 0
been 0
traditionally 0
assumed 0
that 0
high-intensity 0
aerobic 0
exercise 0
stops 0
at 0
the 0
point 0
commonly 0
called 0
exhaustion 0
because 0
fatigued 0
subjects 0
are 0
no 0
longer 0
able 0
to 0
generate 0
the 0
power 0
output 0
required 0
by 0
the 0
task 0
despite 0
their 0
maximal 0
voluntary 0
effort 0
. 0

We 0
tested 0
the 0
validity 0
of 0
this 0
assumption 0
by 0
measuring 0
maximal B-PHYSICAL
voluntary I-PHYSICAL
cycling I-PHYSICAL
power I-PHYSICAL
before 0
( 0
mean 0
+/- 0
SD 0
, 0
1,075 0
+/- 0
214 0
W 0
) 0
and 0
immediately 0
after 0
( 0
731 0
+/- 0
206 0
W 0
) 0
( 0
P 0
< 0
0.001 0
) 0
exhaustive 0
cycling 0
exercise 0
at 0
242 0
+/- 0
24 0
W 0
( 0
80 0
% 0
of 0
peak 0
aerobic 0
power 0
measured 0
during 0
a 0
preliminary 0
incremental 0
exercise 0
test 0
) 0
in 0
ten 0
fit 0
male 0
human 0
subjects 0
. 0

Perceived B-PHYSICAL
exertion I-PHYSICAL
during 0
exhaustive 0
cycling 0
exercise 0
was 0
strongly 0
correlated 0
( 0
r 0
= 0
-0.82 0
, 0
P 0
= 0
0.003 0
) 0
with 0
time B-PHYSICAL
to I-PHYSICAL
exhaustion I-PHYSICAL
( 0
10.5 0
+/- 0
2.1 0
min 0
) 0
. 0

These 0
results 0
challenge 0
the 0
long-standing 0
assumption 0
that 0
muscle 0
fatigue 0
causes 0
exhaustion 0
during 0
high-intensity 0
aerobic 0
exercise 0
, 0
and 0
suggest 0
that 0
exercise 0
tolerance 0
in 0
highly 0
motivated 0
subjects 0
is 0
ultimately 0
limited 0
by 0
perception 0
of 0
effort 0
. 0

Ropivacaine-clonidine 0
combination 0
for 0
caudal 0
blockade 0
in 0
children 0
. 0

BACKGROUND 0
Adding 0
clonidine 0
to 0
weak 0
ropivacaine 0
solutions 0
( 0
< 0
0.2 0
% 0
) 0
could 0
potentially 0
enhance B-OTHER
analgesia I-OTHER
as 0
well 0
as 0
further 0
reduce 0
the 0
risk 0
for B-PHYSICAL
unwanted I-PHYSICAL
motor I-PHYSICAL
blockade I-PHYSICAL
. 0

The 0
aim 0
of 0
the 0
present 0
study 0
was 0
to 0
compare 0
the 0
postoperative 0
pain-relieving B-PAIN
quality I-PAIN
of 0
a 0
ropivacaine 0
0.1 0
% 0
-clonidine 0
mixture 0
to 0
that 0
of 0
plain 0
ropivacaine 0
0.2 0
% 0
following 0
caudal 0
administration 0
in 0
children 0
. 0

METHODS 0
In 0
a 0
prospective 0
, 0
observer-blinded 0
fashion 0
, 0
40 0
ASA 0
1 0
paediatric 0
patients 0
undergoing 0
subumbilical 0
surgery 0
were 0
randomly 0
allocated 0
to 0
receive 0
a 0
caudal 0
injection 0
of 0
either 0
plain 0
ropivacaine 0
0.2 0
% 0
( 0
1 0
ml/kg 0
) 0
( 0
R0.2 0
) 0
or 0
a 0
mixture 0
of 0
ropivacaine 0
0.1 0
% 0
with 0
clonidine 0
2 0
microg/kg 0
( 0
1 0
ml/kg 0
) 0
( 0
R0.1C 0
) 0
. 0

Objective 0
pain 0
scale 0
score 0
and 0
need 0
for 0
supplemental 0
analgesia 0
were 0
used 0
to 0
evaluate 0
analgesia 0
during 0
the 0
first 0
24 0
h 0
postoperatively 0
. 0

Residual 0
postoperative B-PHYSICAL
sedation I-PHYSICAL
was 0
also 0
assessed 0
. 0

RESULTS 0
A 0
significantly 0
higher 0
number 0
of 0
patients 0
in 0
the 0
R0.1C 0
group 0
( 0
18/20 0
) 0
could 0
be 0
managed 0
without 0
supplemental B-PHYSICAL
analgesia I-PHYSICAL
during 0
the 0
first 0
24 0
h 0
postoperatively 0
compared 0
to 0
the 0
R0.2 0
group 0
( 0
11/20 0
) 0
( 0
P=0.034 0
) 0
. 0

Both 0
the 0
degree B-PHYSICAL
and 0
the B-PHYSICAL
duration I-PHYSICAL
of I-PHYSICAL
postoperative I-PHYSICAL
sedation I-PHYSICAL
was 0
similar 0
in 0
both 0
groups 0
. 0

No 0
signs 0
of 0
postoperative B-PHYSICAL
motor I-PHYSICAL
blockade I-PHYSICAL
were 0
observed 0
. 0

CONCLUSIONS 0
The 0
combination 0
of 0
clonidine 0
( 0
2 0
microg/kg 0
) 0
and 0
ropivacaine 0
0.1 0
% 0
is 0
associated 0
with 0
an 0
improved 0
quality B-OTHER
of I-OTHER
postoperative I-OTHER
analgesia I-OTHER
compared 0
to 0
plain 0
0.2 0
% 0
ropivacaine 0
. 0

The 0
improved B-OTHER
analgesic I-OTHER
quality I-OTHER
of 0
the 0
clonidine-ropivacaine 0
mixture 0
is 0
achieved 0
without 0
causing 0
any 0
significant 0
degree 0
of 0
postoperative 0
sedation 0
. 0

Randomized 0
controlled 0
trial 0
of 0
entecavir 0
prophylaxis 0
for 0
rituximab-associated 0
hepatitis 0
B 0
virus 0
reactivation 0
in 0
patients 0
with 0
lymphoma 0
and 0
resolved 0
hepatitis 0
B 0
. 0

PURPOSE 0
The 0
role 0
of 0
antiviral 0
prophylaxis 0
in 0
preventing 0
hepatitis 0
B 0
virus 0
( 0
HBV 0
) 0
reactivation 0
before 0
rituximab-based 0
chemotherapy 0
in 0
patients 0
with 0
lymphoma 0
and 0
resolved 0
hepatitis 0
B 0
is 0
unclear 0
. 0

PATIENTS 0
AND 0
METHODS 0
Eighty 0
patients 0
with 0
CD20 0
( 0
+ 0
) 0
lymphoma 0
and 0
resolved 0
hepatitis 0
B 0
were 0
randomly 0
assigned 0
to 0
receive 0
either 0
prophylactic 0
entecavir 0
( 0
ETV 0
) 0
before 0
chemotherapy 0
to 0
3 0
months 0
after 0
completing 0
chemotherapy 0
( 0
ETV 0
prophylactic 0
group 0
, 0
n 0
= 0
41 0
) 0
or 0
to 0
receive 0
therapeutic 0
ETV 0
at 0
the 0
time 0
of 0
HBV 0
reactivation 0
and 0
hepatitis 0
B 0
surface 0
antigen 0
( 0
HBsAg 0
) 0
reverse 0
seroconversion 0
since 0
chemotherapy 0
( 0
control 0
group 0
, 0
n 0
= 0
39 0
) 0
. 0

RESULTS 0
Fifty-eight 0
patients 0
( 0
72.5 0
% 0
) 0
were 0
positive 0
for 0
hepatitis 0
B 0
surface 0
antibody 0
, 0
and 0
HBV 0
DNA 0
was 0
undetectable 0
in 0
50 0
patients 0
( 0
62.5 0
% 0
) 0
. 0

During 0
a 0
mean 0
18-month 0
follow-up 0
period 0
, 0
one 0
patient 0
( 0
2.4 0
% 0
) 0
in 0
the 0
ETV 0
prophylactic 0
group 0
and 0
seven 0
patients 0
( 0
17.9 0
% 0
) 0
in 0
the 0
control 0
group 0
developed 0
HBV 0
reactivation 0
( 0
P 0
= 0
.027 0
) 0
. 0

The 0
cumulative B-PHYSICAL
HBV I-PHYSICAL
reactivation I-PHYSICAL
rates I-PHYSICAL
at 0
months 0
6 0
, 0
12 0
, 0
and 0
18 0
after 0
chemotherapy 0
were 0
8 0
% 0
, 0
11.2 0
% 0
, 0
and 0
25.9 0
% 0
, 0
respectively 0
, 0
in 0
the 0
control 0
group 0
, 0
and 0
0 0
% 0
, 0
0 0
% 0
, 0
and 0
4.3 0
% 0
in 0
the 0
ETV 0
prophylactic 0
group 0
( 0
P 0
= 0
.019 0
) 0
. 0

Four 0
patients 0
( 0
50 0
% 0
) 0
in 0
the 0
control 0
group 0
had 0
HBsAg B-PHYSICAL
reverse I-PHYSICAL
seroconversion I-PHYSICAL
after 0
HBV 0
reactivation 0
. 0

The 0
cumulative B-PHYSICAL
HBsAg I-PHYSICAL
reverse I-PHYSICAL
seroconversion I-PHYSICAL
rates I-PHYSICAL
at 0
months 0
6 0
, 0
12 0
, 0
and 0
18 0
since 0
chemotherapy 0
were 0
0 0
% 0
, 0
6.4 0
% 0
, 0
and 0
16.3 0
% 0
in 0
the 0
control 0
group 0
, 0
respectively 0
, 0
which 0
were 0
significantly 0
higher 0
than 0
those 0
in 0
the 0
ETV 0
prophylactic 0
group 0
( 0
P 0
= 0
.032 0
) 0
. 0

Patients 0
with 0
detectable 0
or 0
undetectable 0
viral 0
load 0
could 0
develop 0
HBV B-PHYSICAL
reactivation I-PHYSICAL
and 0
HBsAg B-PHYSICAL
reverse I-PHYSICAL
seroconversion I-PHYSICAL
. 0

CONCLUSION 0
Undetectable 0
HBV 0
viral 0
load 0
before 0
chemotherapy 0
did 0
not 0
confer 0
reactivation-free 0
status 0
. 0

Antiviral 0
prophylaxis 0
can 0
potentially 0
prevent 0
rituximab-associated 0
HBV 0
reactivation 0
in 0
patients 0
with 0
lymphoma 0
and 0
resolved 0
hepatitis 0
B 0
. 0

Single 0
nucleotide 0
polymorphism 0
in 0
the 0
hypoxia-inducible 0
factor-1alpha 0
gene 0
in 0
colorectal 0
carcinoma 0
. 0

Colorectal 0
carcinoma 0
is 0
one 0
of 0
the 0
most 0
common 0
malignancies 0
in 0
the 0
world 0
, 0
and 0
its 0
incidence 0
has 0
increased 0
in 0
recent 0
years 0
. 0

We 0
have 0
reported 0
that 0
expression 0
of 0
hypoxia-inducible 0
factor 0
( 0
HIF 0
) 0
-1alpha 0
correlates 0
with 0
expression 0
of 0
vascular 0
endothelial 0
growth 0
factor 0
( 0
VEGF 0
) 0
, 0
tumor 0
stage 0
, 0
lymphatic 0
invasion 0
, 0
venous 0
invasion 0
, 0
and 0
liver 0
metastasis 0
. 0

It 0
has 0
also 0
been 0
reported 0
that 0
a 0
single 0
nucleotide 0
polymorphism 0
( 0
SNP 0
) 0
in 0
exon 0
12 0
of 0
HIF-1alpha 0
gene 0
is 0
present 0
in 0
renal 0
cell 0
carcinoma 0
and 0
head 0
and 0
neck 0
squamous 0
cell 0
carcinoma 0
patients 0
. 0

We 0
investigated 0
the 0
C1772T 0
polymorphism 0
in 0
colorectal 0
cancer 0
patients 0
and 0
healthy 0
control 0
subjects 0
to 0
clarify 0
the 0
mechanism 0
of 0
HIF-1alpha 0
activation 0
in 0
colorectal 0
carcinoma 0
. 0

The 0
exon 0
12 0
genotype 0
was 0
not 0
associated 0
with 0
sex 0
or 0
age 0
. 0

The 0
distribution 0
of 0
HIF-1alpha B-PHYSICAL
genotypes I-PHYSICAL
in 0
controls 0
was 0
89 0
C/C 0
( 0
89 0
% 0
) 0
, 0
11 0
C/T 0
( 0
11 0
% 0
) 0
, 0
and 0
0 0
T/T 0
( 0
0 0
% 0
) 0
. 0

The 0
distribution 0
of 0
HIF-1alpha B-PHYSICAL
genotypes I-PHYSICAL
in 0
colorectal 0
cancer 0
patients 0
was 0
100 0
C/C 0
( 0
100 0
% 0
) 0
, 0
0 0
C/T 0
( 0
0 0
% 0
) 0
, 0
and 0
0 0
T/T 0
( 0
0 0
% 0
) 0
. 0

The 0
difference 0
in 0
genotype 0
distribution 0
between 0
patients 0
and 0
control 0
subjects 0
was 0
significant 0
( 0
p 0
< 0
0.0005 0
) 0
. 0

These 0
results 0
suggest 0
that 0
the 0
C1772T B-PHYSICAL
polymorphism I-PHYSICAL
in 0
HIF-1alpha 0
is 0
not 0
involved 0
in 0
progression 0
or 0
metastasis 0
of 0
colorectal 0
carcinoma 0
. 0

Is 0
a 0
2-week 0
duration 0
sufficient 0
for 0
stenting 0
in 0
endopyelotomy 0
? 0

PURPOSE 0
Internal 0
stenting 0
is 0
an 0
integral 0
part 0
of 0
endopyelotomy 0
. 0

Studies 0
in 0
animals 0
show 0
good 0
healing 0
after 0
1 0
to 0
2 0
weeks 0
of 0
ureterotomy 0
. 0

Inherent 0
stent 0
related 0
problems 0
warrant 0
a 0
minimum 0
possible 0
duration 0
of 0
stenting 0
without 0
compromising 0
the 0
results 0
of 0
endopyelotomy 0
. 0

We 0
performed 0
a 0
prospective 0
randomized 0
trial 0
to 0
evaluate 0
the 0
optimum B-OTHER
duration I-OTHER
of I-OTHER
stenting I-OTHER
after 0
endopyelotomy 0
. 0

MATERIALS 0
AND 0
METHODS 0
A 0
total 0
of 0
57 0
consecutive 0
patients 0
with 0
primary 0
ureteropelvic 0
junction 0
obstruction 0
were 0
randomized 0
to 0
undergo 0
7/14Fr 0
internal 0
endopyelotomy 0
stent 0
placement 0
for 0
2 0
( 0
group 0
1 0
) 0
and 0
4 0
( 0
group 0
2 0
) 0
weeks 0
. 0

A 0
symptom 0
based 0
questionnaire 0
was 0
administered 0
to 0
all 0
patients 0
at 0
stent 0
removal 0
. 0

Followup 0
was 0
done 0
with 0
diuretic 0
scanning 0
at 0
3 0
, 0
6 0
, 0
9 0
and 0
12 0
months 0
and 0
then 0
yearly 0
, 0
and 0
thereafter 0
with 0
diuretic 0
renography 0
. 0

RESULTS 0
In 0
each 0
group 0
26 0
patients 0
were 0
available 0
for 0
evaluation 0
. 0

The 0
2 0
groups 0
were 0
comparable 0
in 0
terms 0
of 0
age 0
, 0
sex 0
, 0
symptoms B-PHYSICAL
and 0
ipsilateral B-PHYSICAL
glomerular I-PHYSICAL
filtration I-PHYSICAL
rate I-PHYSICAL
. 0

Mean 0
followup 0
was 0
22.3 0
( 0
range 0
12 0
to 0
36 0
) 0
and 0
21.3 0
months 0
( 0
range 0
12 0
to 0
35 0
) 0
in 0
groups 0
1 0
and 0
2 0
, 0
respectively 0
. 0

At 0
the 0
end 0
of 0
1 0
year 0
24 0
group 0
1 0
( 0
92.3 0
% 0
) 0
and 0
23 0
group 0
2 0
( 0
90.3 0
% 0
) 0
patients 0
had 0
an 0
improved 0
drainage B-OTHER
pattern I-OTHER
. 0

This 0
difference 0
was 0
not 0
significant 0
. 0

Stent B-PHYSICAL
related I-PHYSICAL
symptoms I-PHYSICAL
were 0
present 0
in 0
a 0
good 0
proportion 0
of 0
patients 0
in 0
groups 0
1 0
and 0
2 0
but 0
there 0
was 0
a 0
significant 0
difference 0
in 0
the 0
incidence 0
of 0
urinary B-ADVERSE-EFFECTS
tract I-ADVERSE-EFFECTS
infections I-ADVERSE-EFFECTS
( 0
11.5 0
% 0
versus 0
38.1 0
% 0
, 0
p 0
= 0
0.04 0
) 0
. 0

Of 0
the 0
group 0
2 0
patients 0
64 0
% 0
preferred 0
2 0
weeks B-OTHER
of I-OTHER
stenting I-OTHER
. 0

CONCLUSIONS 0
Two 0
weeks 0
seems 0
to 0
be 0
a 0
sufficient 0
duration 0
to 0
allow 0
functional 0
restoration 0
across 0
the 0
ureteropelvic 0
junction 0
after 0
endopyelotomy 0
and 0
decrease 0
stent B-ADVERSE-EFFECTS
related I-ADVERSE-EFFECTS
complications I-ADVERSE-EFFECTS
. 0

Short-term 0
aerobic 0
exercise 0
training 0
in 0
obese 0
humans 0
with 0
type 0
2 0
diabetes 0
mellitus 0
improves 0
whole-body 0
insulin 0
sensitivity 0
through 0
gains 0
in 0
peripheral 0
, 0
not 0
hepatic 0
insulin 0
sensitivity 0
. 0

CONTEXT 0
Short-term 0
aerobic 0
exercise 0
training 0
can 0
improve 0
whole-body B-PHYSICAL
insulin I-PHYSICAL
sensitivity I-PHYSICAL
in 0
humans 0
with 0
type 0
2 0
diabetes 0
mellitus 0
; 0
however 0
, 0
the 0
contributions 0
of 0
peripheral 0
and 0
hepatic 0
tissues 0
to 0
these 0
improvements 0
are 0
not 0
known 0
. 0

OBJECTIVE 0
Our 0
objective 0
was 0
to 0
determine 0
the 0
effect 0
of 0
7-d 0
aerobic 0
exercise 0
training 0
on 0
peripheral 0
and 0
hepatic 0
insulin 0
sensitivity 0
during 0
isoglycemic/hyperinsulinemic 0
clamp 0
conditions 0
. 0

DESIGN 0
Subjects 0
were 0
randomly 0
assigned 0
to 0
one 0
of 0
two 0
groups 0
. 0

The 0
energy 0
balance 0
group 0
consumed 0
an 0
isocaloric 0
diet 0
consisting 0
of 0
50 0
% 0
carbohydrate 0
, 0
30 0
% 0
fat 0
, 0
and 0
20 0
% 0
protein 0
for 0
15 0
d. 0
The 0
energy 0
balance 0
plus 0
exercise 0
group 0
consumed 0
a 0
similar 0
diet 0
over 0
the 0
15 0
d 0
and 0
performed 0
50-min 0
of 0
treadmill 0
walking 0
at 0
70 0
% 0
of 0
maximum 0
oxygen 0
consumption 0
maximum 0
during 0
the 0
second 0
7 0
d 0
of 0
the 0
15-d 0
study 0
period 0
. 0

Each 0
subject 0
underwent 0
an 0
initial 0
isoglycemic/hyperinsulinemic 0
clamp 0
after 0
1-wk 0
dietary 0
control 0
and 0
a 0
second 0
clamp 0
after 0
completing 0
the 0
study 0
. 0

SETTING 0
The 0
study 0
was 0
performed 0
at 0
Ohio 0
State 0
University 0
's 0
General 0
Clinical 0
Research 0
Center 0
. 0

PARTICIPANTS 0
There 0
were 0
18 0
obese 0
, 0
mildly 0
diabetic 0
humans 0
included 0
in 0
the 0
study 0
. 0

INTERVENTION 0
Aerobic 0
exercise 0
training 0
was 0
performed 0
for 0
7 0
d. 0
MAIN 0
OUTCOME 0
MEASURES 0
Whole-body B-PHYSICAL
, 0
peripheral B-PHYSICAL
, 0
and 0

In 0
high 0
risk 0
hypertensive 0
subjects 0
with 0
incidental 0
and 0
unilateral 0
renal 0
artery 0
stenosis 0
percutaneous 0
revascularization 0
with 0
stent 0
improves 0
blood B-PHYSICAL
pressure I-PHYSICAL
control I-PHYSICAL
but 0
not 0
glomerular B-PHYSICAL
filtration I-PHYSICAL
rate I-PHYSICAL
. 0

AIM 0
In 0
high-risk 0
hypertensive 0
subjects 0
( 0
HTs 0
) 0
with 0
incidental 0
unilateral 0
renal 0
artery 0
stenosis 0
( 0
RAS 0
) 0
, 0
the 0
effectiveness 0
of 0
percutaneous 0
revascularization 0
with 0
stent 0
( 0
PR-STENT 0
) 0
on 0
blood B-PHYSICAL
pressure I-PHYSICAL
( 0
BP 0
) 0
and 0
glomerular B-PHYSICAL
filtration I-PHYSICAL
rate I-PHYSICAL
( I-PHYSICAL
GFR I-PHYSICAL
) I-PHYSICAL
is 0
not 0
established 0
. 0

METHODS 0
Eighteen 0
HTs 0
aged 0
65.7 0
? 0

9.2 0
years 0
with 0
angiographically 0
diagnosed 0
unilateral 0
RAS 0
( 0
? 0

60 0
% 0
) 0
were 0
randomized 0
to 0
receive 0
PR-STENT 0
( 0
N=9 0
) 0
or 0
to 0
NO-STENT 0
( 0
N=9 0
) 0
. 0

BP 0
( 0
mercury 0
sphygmomanometer 0
) 0
and 0
GFR 0
( 0
99mTc-DTPA 0
clearances 0
during 0
renal 0
scintigraphy 0
) 0
were 0
evaluated 0
yearly 0
for 0
three 0
years 0
. 0

Echo-Doppler 0
of 0
renal 0
arteries 0
was 0
performed 0
to 0
verify 0
the 0
anatomic 0
patency 0
and 0
flow 0
velocities 0
of 0
the 0
reperfused 0
artery 0
. 0

Analysis 0
of 0
variance 0
compared 0
BP 0
and 0
GFR 0
values 0
changes 0
from 0
baseline 0
to 0
the 0
follow-up 0
; 0
differences 0
for 0
continuous 0
variables 0
were 0
evaluated 0
between 0
groups 0
with 0
the 0
Tukey 0
's 0
post 0
hoc 0
test 0
after 0
adjustment 0
for 0
age 0
, 0
change 0
of 0
BP 0
between 0
baseline 0
and 0
at 0
the 0
follow-up 0
, 0
GFR 0
and 0
body 0
mass 0
index 0
( 0
BMI 0
) 0
. 0

RESULTS 0
Baseline 0
systolic 0
BP 0
and 0
GFR 0
values 0
were 0
not 0
different 0
between 0
groups 0
. 0

The 0
significantly 0
greater 0
GFR 0
increase 0
observed 0
in 0
PR-STENT 0
than 0
in 0
NO-STENT 0
at 0
univariate 0
analysis 0
at 0
the 0
end 0
of 0
follow-up 0
( 0
62.5 0
? 0

19.2 0
vs. 0
42.24 0
? 0

17.6 0
, 0
P 0
< 0
0.02 0
) 0
disappeared 0
after 0
adjustment 0
for 0
confounding 0
factors 0
. 0

However 0
, 0
systolic 0
BP 0
remained 0
significantly 0
lower 0
in 0
PR-STENT 0
than 0
in 0
NO-STENT 0
( 0
140.1 0
? 0

4.6 0
vs. 0
170.0 0
? 0

8.3 0
, 0
P 0
< 0
0.0001 0
) 0
also 0
after 0
adjustment 0
for 0
age 0
, 0
GFR 0
and 0
BMI 0
. 0

CONCLUSION 0
PR-STENT 0
reduces 0
systolic 0
BP 0
without 0
improving 0
GFR 0
. 0

Due 0
to 0
the 0
strong 0
association 0
between 0
high 0
BP 0
and 0
renal 0
damage 0
, 0
this 0
study 0
raises 0
the 0
question 0
on 0
whether 0
PR-STENT 0
should 0
be 0
performed 0
in 0
all 0
HTs 0
with 0
unilateral 0
and 0
incidental 0
RAS 0
. 0

Perceptual B-OTHER
wind-up I-OTHER
in 0
the 0
human 0
oesophagus 0
is 0
enhanced 0
by 0
central 0
sensitisation 0
. 0

BACKGROUND 0
Oesophageal 0
acid 0
infusion 0
induces 0
enhanced 0
pain 0
hypersensitivity 0
in 0
non-acid 0
exposed 0
upper 0
oesophagus 0
( 0
secondary 0
hyperalgesia 0
) 0
in 0
patients 0
with 0
non-cardiac 0
chest 0
pain 0
, 0
thus 0
suggesting 0
central 0
sensitisation 0
contributes 0
to 0
visceral 0
pain 0
hypersensitivity 0
in 0
functional 0
gut 0
disorders 0
( 0
FGD 0
) 0
. 0

Perceptual 0
wind-up 0
( 0
increased 0
pain 0
perception 0
to 0
constant 0
intensity 0
sensory 0
stimuli 0
at 0
frequencies 0
> 0
or=0.3 0
Hz 0
) 0
is 0
used 0
as 0
a 0
proxy 0
for 0
central 0
sensitisation 0
to 0
investigate 0
pain 0
syndromes 0
where 0
pain 0
hypersensitivity 0
is 0
important 0
( 0
for 0
example 0
, 0
fibromyalgia 0
) 0
. 0

AIMS 0
Wind-up 0
in 0
central 0
sensitisation 0
induced 0
human 0
visceral 0
pain 0
hypersensitivity 0
has 0
not 0
been 0
explored 0
. 0

We 0
hypothesised 0
that 0
if 0
wind-up 0
is 0
a 0
proxy 0
for 0
central 0
sensitisation 0
induced 0
human 0
visceral 0
pain 0
hypersensitivity 0
, 0
then 0
oesophageal 0
wind-up 0
should 0
be 0
enhanced 0
by 0
secondary 0
hyperalgesia 0
. 0

METHODS 0
In 0
eight 0
healthy 0
volunteers 0
( 0
seven 0
males 0
; 0
mean 0
age 0
32 0
years 0
) 0
, 0
perception 0
at 0
pain 0
threshold 0
to 0
a 0
train 0
of 0
20 0
electrical 0
stimuli 0
applied 0
to 0
the 0
hand 0
and 0
upper 0
oesophagus 0
( 0
UO 0
) 0
at 0
either 0
0.1 0
Hz 0
( 0
control 0
) 0
or 0
2 0
Hz 0
was 0
determined 0
before 0
and 0
one 0
hour 0
after 0
a 0
30 0
minute 0
lower 0
oesophageal 0
acid 0
infusion 0
. 0

RESULTS 0
Wind-up B-OTHER
occurred 0
only 0
with 0
the 0
2 0
Hz 0
train 0
in 0
the 0
UO 0
and 0
hand 0
( 0
both 0
p=0.01 0
) 0
. 0

Following 0
acid 0
infusion 0
, 0
pain B-PAIN
threshold I-PAIN
decreased 0
( 0
17 0
( 0
4 0
) 0
% 0
; 0
p=0.01 0
) 0
in 0
the 0
UO 0
, 0
suggesting 0
the 0
presence 0
of 0
secondary 0
hyperalgesia 0
. 0

Wind-up B-OTHER
to I-OTHER
the I-OTHER
2 I-OTHER
Hz I-OTHER
train I-OTHER
increased 0
in 0
the 0
UO B-PHYSICAL
( 0
wind-up 0
ratio 0
1.4 0
( 0
0.1 0
) 0
to 0
1.6 0
( 0
0.1 0
) 0
; 0
p=0.03 0
) 0
but 0
not 0
in 0
the 0
hand 0
( 0
wind-up 0
ratio 0
1.3 0
( 0
0.1 0
) 0
and 0
1.3 0
( 0
0.1 0
) 0
; 0
p=0.3 0
) 0
CONCLUSION 0
Enhanced 0
wind-up 0
after 0
secondary 0
oesophageal 0
hyperalgesia 0
suggests 0
that 0
visceral 0
pain 0
hypersensitivity 0
induced 0
by 0
central 0
sensitisation 0
results 0
from 0
increased 0
central 0
neuronal 0
excitability 0
. 0

Wind-up 0
may 0
offer 0
new 0
opportunities 0
to 0
investigate 0
the 0
contribution 0
of 0
central 0
neuronal 0
changes 0
to 0
symptoms 0
in 0
FGD 0
. 0

Treatment 0
outcome 0
of 0
appliance 0
therapy 0
in 0
temporomandibular 0
disorder 0
patients 0
with 0
myofascial B-PAIN
pain I-PAIN
after 0
6 0
and 0
12 0
months 0
. 0

AIM 0
To 0
compare 0
the 0
long-term 0
effect 0
of 0
treatment 0
with 0
a 0
stabilization 0
appliance 0
( 0
group 0
T 0
) 0
and 0
treatment 0
with 0
a 0
control 0
appliance 0
( 0
group 0
C 0
) 0
in 0
temporomandibular 0
disorder 0
( 0
TMD 0
) 0
patients 0
with 0
myofascial 0
pain 0
. 0

METHODS 0
In 0
this 0
controlled 0
trial 0
, 0
60 0
patients 0
( 0
mean 0
age 0
29 0
years 0
) 0
with 0
myofascial 0
pain 0
were 0
evaluated 0
after 0
10 0
weeks 0
of 0
treatment 0
with 0
either 0
a 0
stabilization 0
appliance 0
or 0
a 0
control 0
appliance 0
. 0

All 0
60 0
patients 0
were 0
then 0
assigned 0
to 0
1 0
of 0
3 0
groups 0
according 0
to 0
demand 0
for 0
treatment 0
. 0

Seventeen 0
patients 0
from 0
group 0
C 0
requested 0
another 0
appliance 0
and 0
were 0
given 0
a 0
stabilization 0
appliance 0
, 0
thus 0
creating 0
a 0
mixed 0
group 0
( 0
group 0
M 0
) 0
. 0

RESULTS 0
A 0
significant 0
difference 0
in 0
improvement 0
of 0
overall B-PHYSICAL
subjective I-PHYSICAL
symptoms I-PHYSICAL
in 0
an 0
intent-to-treat 0
analysis 0
between 0
groups 0
T 0
and 0
C 0
was 0
found 0
at 0
the 0
follow-ups 0
. 0

In 0
a 0
survival 0
analysis 0
of 0
treatment 0
compliance 0
, 0
a 0
significant 0
difference 0
was 0
found 0
between 0
groups 0
T 0
and 0
C. 0
At 0
the 0
6- 0
and 0
12-month 0
follow-ups 0
, 0
a 0
significant 0
reduction 0
in 0
myofascial B-PAIN
pain 0
, 0
as 0
measured 0
on 0
a 0
visual 0
analog 0
scale 0
, 0
was 0
found 0
in 0
all 0
three 0
groups 0
. 0

A 0
significant 0
decrease 0
in 0
frequency 0
and 0
intensity 0
of 0
myofascial B-PAIN
pain I-PAIN
was 0
found 0
in 0
group 0
T 0
at 0
the 0
follow-ups 0
. 0

A 0
significant 0
decrease 0
in 0
number 0
of 0
tender B-PHYSICAL
sites I-PHYSICAL
on I-PHYSICAL
the I-PHYSICAL
masticatory I-PHYSICAL
muscles I-PHYSICAL
was 0
found 0
in 0
group 0
T 0
at 0
the 0
follow-ups 0
. 0

CONCLUSION 0
The 0
results 0
support 0
the 0
conclusion 0
that 0
the 0
positive 0
treatment 0
outcome 0
obtained 0
by 0
use 0
of 0
a 0
stabilization 0
appliance 0
to 0
alleviate 0
the 0
signs 0
and 0
symptoms 0
in 0
patients 0
with 0
myofascial 0
pain 0
persisted 0
after 0
6 0
and 0
12 0
months 0
. 0

Most 0
patients 0
in 0
groups 0
T 0
and 0
M 0
reported 0
positive 0
changes 0
in 0
overall B-PHYSICAL
subjective I-PHYSICAL
symptoms I-PHYSICAL
in 0
this 0
trial 0
. 0

We 0
therefore 0
recommend 0
use 0
of 0
the 0
stabilization 0
appliance 0
in 0
the 0
treatment 0
of 0
TMD 0
patients 0
with 0
myofascial B-PAIN
pain I-PAIN
. 0

Local 0
warming 0
and 0
insertion 0
of 0
peripheral 0
venous 0
cannulas 0
: 0
single 0
blinded 0
prospective 0
randomised 0
controlled 0
trial 0
and 0
single 0
blinded 0
randomised 0
crossover 0
trial 0
. 0

OBJECTIVE 0
To 0
determine 0
whether 0
local 0
warming 0
of 0
the 0
lower 0
arm 0
and 0
hand 0
facilitates 0
peripheral B-PHYSICAL
venous I-PHYSICAL
cannulation I-PHYSICAL
. 0

DESIGN 0
Single 0
blinded 0
prospective 0
randomised 0
controlled 0
trial 0
and 0
single 0
blinded 0
randomised 0
crossover 0
trial 0
. 0

SETTING 0
Neurosurgical 0
unit 0
and 0
haematology 0
ward 0
of 0
university 0
hospital 0
. 0

PARTICIPANTS 0
100 0
neurosurgical 0
patients 0
and 0
40 0
patients 0
with 0
leukaemia 0
who 0
required 0
chemotherapy 0
. 0

INTERVENTIONS 0
Neurosurgical 0
patients 0
' 0
hands 0
and 0
forearms 0
were 0
covered 0
for 0
15 0
minutes 0
with 0
a 0
carbon 0
fibre 0
heating 0
mitt 0
. 0

Patients 0
were 0
assigned 0
randomly 0
to 0
active 0
warming 0
at 0
52 0
degrees 0
C 0
or 0
passive 0
insulation 0
( 0
heater 0
not 0
activated 0
) 0
. 0

The 0
same 0
warming 0
system 0
was 0
used 0
for 0
10 0
minutes 0
in 0
patients 0
with 0
leukaemia 0
. 0

They 0
were 0
assigned 0
randomly 0
to 0
active 0
warming 0
or 0
passive 0
insulation 0
on 0
day 0
1 0
and 0
given 0
alternative 0
treatment 0
during 0
the 0
subsequent 0
visit 0
. 0

MAIN 0
OUTCOME 0
MEASURES 0
PRIMARY 0
: 0
success B-OTHER
rate I-OTHER
for I-OTHER
insertion I-OTHER
of I-OTHER
18 I-OTHER
gauge I-OTHER
cannula I-OTHER
into I-OTHER
vein I-OTHER
on I-OTHER
back I-OTHER
of I-OTHER
hand I-OTHER
. 0

SECONDARY 0
: 0
time B-OTHER
required I-OTHER
for I-OTHER
successful I-OTHER
cannulation I-OTHER
. 0

RESULTS 0
In 0
neurosurgical 0
patients 0
, 0
it 0
took 0
36 0
seconds 0
( 0
95 0
% 0
confidence 0
interval 0
31 0
to 0
40 0
seconds 0
) 0
to 0
insert B-OTHER
a I-OTHER
cannula I-OTHER
in 0
the 0
active 0
warming 0
group 0
and 0
62 0
( 0
50 0
to 0
74 0
) 0
seconds 0
in 0
the 0
passive 0
insulation 0
group 0
( 0
P=0.002 0
) 0
. 0

Three 0
( 0
6 0
% 0
) 0
first 0
attempts 0
failed B-OTHER
in 0
the 0
active 0
warming 0
group 0
compared 0
with 0
14 0
( 0
28 0
% 0
) 0
in 0
the 0
passive 0
insulation 0
group 0
( 0
P=0.008 0
) 0
. 0

The 0
crossover 0
study 0
in 0
patients 0
with 0
leukaemia 0
showed 0
that 0
insertion B-OTHER
time I-OTHER
was 0
reduced 0
by 0
20 0
seconds 0
( 0
8 0
to 0
32 0
, 0
P=0.013 0
) 0
with 0
active 0
warming 0
and 0
that 0
failure B-OTHER
rates I-OTHER
at I-OTHER
first I-OTHER
attempt I-OTHER
were 0
6 0
% 0
with 0
warming 0
and 0
30 0
% 0
with 0
passive 0
insulation 0
( 0
P 0
< 0
0.001 0
) 0
. 0

CONCLUSIONS 0
Local 0
warming 0
facilitates 0
the 0
insertion 0
of 0
peripheral B-OTHER
venous I-OTHER
cannulas I-OTHER
, 0
reducing 0
both 0
time B-OTHER
and I-OTHER
number I-OTHER
of I-OTHER
attempts I-OTHER
required I-OTHER
. 0

This 0
may 0
decrease 0
the 0
time 0
staff 0
spend 0
inserting B-OTHER
cannulas I-OTHER
, 0
reduce 0
supply B-OTHER
costs I-OTHER
, 0
and 0
improve 0
patient 0
satisfaction 0
. 0

[ 0
Opiate 0
hypothesis 0
in 0
infantile 0
autism 0
? 0

Therapeutic 0
trials 0
with 0
naltrexone 0
] 0
. 0

The 0
opioid 0
hypothesis 0
suggests 0
that 0
childhood 0
autism 0
may 0
result 0
from 0
excessive 0
brain 0
opioid 0
activity 0
during 0
neonatal 0
period 0
which 0
may 0
constitutionally 0
inhibit 0
social 0
motivation 0
, 0
yielding 0
autistic 0
isolation 0
and 0
aloofness 0
( 0
Panksepp 0
, 0
1979 0
) 0
. 0

This 0
hypothesis 0
has 0
now 0
received 0
strong 0
support 0
and 0
is 0
currently 0
based 0
on 0
three 0
types 0
of 0
arguments 0
: 0
( 0
1 0
) 0
similarity 0
between 0
autistic 0
symptomatology 0
and 0
abnormal 0
behaviors 0
induced 0
in 0
young 0
animals 0
by 0
injections 0
of 0
exogenous 0
opioids 0
, 0
such 0
as 0
increasing 0
social 0
aloofness 0
and 0
decreasing 0
social 0
vocalization 0
; 0
( 0
2 0
) 0
direct 0
biochemical 0
evidence 0
of 0
abnormalities 0
of 0
peripheral 0
endogenous 0
opioids 0
being 0
reported 0
in 0
autism 0
and 0
( 0
3 0
) 0
therapeutic 0
effects 0
of 0
the 0
long 0
lasting 0
opioid 0
receptor 0
blocking 0
agent 0
naltrexone 0
in 0
autism 0
. 0

In 0
this 0
article 0
, 0
we 0
give 0
description 0
of 0
open 0
and 0
double-blind 0
studies 0
of 0
naltrexone 0
in 0
autism 0
. 0

Naltrexone 0
has 0
been 0
tested 0
in 0
several 0
open 0
studies 0
. 0

We 0
performed 0
an 0
open 0
trial 0
with 0
naltrexone 0
in 0
2 0
autistic 0
girls 0
, 0
displaying 0
serious 0
self-injurious 0
behavior 0
, 0
reduced 0
crying 0
and 0
a 0
marked 0
preference 0
for 0
salty 0
and 0
spicy 0
foods 0
, 0
symptoms 0
that 0
could 0
be 0
related 0
to 0
a 0
dysfunction 0
of 0
the 0
opioid 0
system 0
. 0

With 0
dosages 0
of 0
1 0
mg/kg/day 0
, 0
we 0
observed 0
an 0
immediate 0
reduction 0
of 0
hyperactivity B-MENTAL
, 0
self-injurious B-MENTAL
behavior I-MENTAL
and 0
aggressiveness B-MENTAL
, 0
while B-MENTAL
attention I-MENTAL
improved 0
. 0

In 0
addition 0
, 0
social B-MENTAL
behaviors I-MENTAL
, 0
smiling B-MENTAL
, 0
social B-MENTAL
seeking I-MENTAL
behaviors I-MENTAL
and 0
play B-MENTAL
interactions I-MENTAL
increased 0
( 0
Leboyer 0
, 0
Bouvard 0
et 0
Dugas 0
, 0
1988 0
) 0
. 0

Campbell 0
et 0
al 0
. 0
( 0

1988 0
) 0
has 0
also 0
reported 0
a 0
tranquilizing B-MENTAL
and I-MENTAL
a I-MENTAL
stimulating I-MENTAL
effect 0
in 0
6 0
out 0
of 0
8 0
children 0
with 0
autism 0
. 0

We 0
did 0
confirm 0
these 0
preliminary 0
results 0
in 0
a 0
double-blind 0
study 0
performed 0
on 0
4 0
children 0
with 0
autism 0
. 0

In 0
a 0
cross-over 0
double-blind 0
study 0
, 0
three 0
dosages 0
of 0
naltrexone 0
( 0
0.5 0
, 0
1 0
and 0
2 0
mg/kg/day 0
) 0
and 0
placebo 0
were 0
compared 0
. 0
( 0

ABSTRACT 0
TRUNCATED 0
AT 0
250 0
WORDS 0
) 0

Effects 0
of 0
mecamylamine 0
on 0
human 0
cigarette 0
smoking 0
and 0
subjective 0
ratings 0
. 0

Multiple 0
measures 0
of 0
cigarette 0
smoking 0
, 0
subjective 0
effect 0
and 0
physiological 0
effect 0
were 0
collected 0
during 0
90-min 0
test 0
sessions 0
in 0
normal 0
volunteers 0
. 0

Before 0
sessions 0
subjects 0
received 0
oral 0
doses 0
of 0
mecamylamine 0
( 0
2.5 0
, 0
5.0 0
, 0
10 0
, 0
20 0
mg 0
) 0
or 0
placebo 0
. 0

Each 0
dose 0
and 0
placebo 0
was 0
given 0
three 0
times 0
in 0
a 0
randomized 0
block 0
sequence 0
. 0

Mecamylamine 0
increased 0
several 0
measures 0
of 0
cigarette 0
smoking 0
, 0
including 0
number B-PHYSICAL
of I-PHYSICAL
cigarettes I-PHYSICAL
, 0
number 0
of 0
puffs B-PHYSICAL
per I-PHYSICAL
cigarette I-PHYSICAL
, 0
and 0
expired B-PHYSICAL
air I-PHYSICAL
carbon I-PHYSICAL
monoxide I-PHYSICAL
level I-PHYSICAL
. 0

Mecamylamine 0
also 0
produced 0
modest 0
, 0
dose-related 0
decreases 0
in 0
standing 0
blood B-PHYSICAL
pressure I-PHYSICAL
and 0
increases 0
in 0
standing B-PHYSICAL
heart I-PHYSICAL
rate I-PHYSICAL
. 0

The 0
subjective 0
effects 0
produced 0
by 0
mecamylamine 0
were 0
not 0
characteristic 0
of 0
those 0
of 0
psychoactive 0
drugs 0
. 0

Mecamylamine 0
appears 0
to 0
have 0
increased 0
cigarette 0
smoking 0
by 0
decreasing 0
the 0
effective 0
dose 0
level 0
of 0
nicotine 0
available 0
from 0
cigarette 0
smoking 0
. 0

Monitoring 0
acute 0
effects 0
on 0
athletic 0
performance 0
with 0
mixed 0
linear 0
modeling 0
. 0

UNLABELLED 0
There 0
is 0
a 0
need 0
for 0
a 0
sophisticated 0
approach 0
to 0
track 0
athletic 0
performance 0
and 0
to 0
quantify 0
factors 0
affecting 0
it 0
in 0
practical 0
settings 0
. 0

PURPOSE 0
To 0
demonstrate 0
the 0
application 0
of 0
mixed 0
linear 0
modeling 0
for 0
monitoring 0
athletic 0
performance 0
. 0

METHODS 0
Elite 0
sprint 0
and 0
middle-distance 0
swimmers 0
( 0
three 0
females 0
and 0
six 0
males 0
; 0
aged 0
21-26 0
yr 0
) 0
performed 0
6-13 0
time 0
trials 0
in 0
training 0
and 0
competition 0
in 0
the 0
9 0
wk 0
before 0
and 0
including 0
Olympic-qualifying 0
trials 0
, 0
all 0
in 0
their 0
specialty 0
event 0
. 0

We 0
included 0
a 0
double-blind 0
, 0
randomized 0
, 0
diet-controlled 0
crossover 0
intervention 0
, 0
in 0
which 0
the 0
swimmers 0
consumed 0
caffeine 0
( 0
5 0
mg 0
x 0
kg 0
( 0
-1 0
) 0
body 0
mass 0
) 0
or 0
placebo 0
. 0

The 0
swimmers 0
also 0
knowingly 0
consumed 0
varying 0
doses 0
of 0
caffeine 0
in 0
some 0
time 0
trials 0
. 0

We 0
used 0
mixed 0
linear 0
modeling 0
of 0
log-transformed 0
swim 0
time 0
to 0
quantify 0
effects B-OTHER
on I-OTHER
performance I-OTHER
in 0
training 0
versus 0
competition 0
, 0
in 0
morning 0
versus 0
evening 0
swims 0
, 0
and 0
with 0
use 0
of 0
caffeine 0
. 0

Predictor 0
variables 0
were 0
coded 0
as 0
0 0
or 0
1 0
to 0
represent 0
absence 0
or 0
presence 0
, 0
respectively 0
, 0
of 0
each 0
condition 0
and 0
were 0
included 0
as 0
fixed 0
effects 0
. 0

The 0
date 0
of 0
each 0
performance 0
test 0
was 0
included 0
as 0
a 0
continuous 0
linear 0
fixed 0
effect 0
and 0
interacted 0
with 0
the 0
random 0
effect 0
for 0
the 0
athlete 0
to 0
represent 0
individual 0
differences 0
in 0
linear 0
trends 0
in 0
performance 0
. 0

RESULTS 0
Most 0
effects 0
were 0
clear 0
, 0
owing 0
to 0
the 0
high 0
reliability 0
of 0
performance 0
times 0
in 0
training 0
and 0
competition 0
( 0
typical 0
errors 0
of 0
0.9 0
% 0
and 0
0.8 0
% 0
, 0
respectively 0
) 0
. 0

Performance B-OTHER
time I-OTHER
improved 0
linearly 0
by 0
0.8 0
% 0
per 0
4 0
wk 0
. 0

The 0
swimmers 0
performed B-OTHER
substantially I-OTHER
better I-OTHER
in 0
evenings 0
versus 0
mornings 0
and 0
in 0
competition 0
versus 0
training 0
. 0

A 0
100-mg 0
dose 0
of 0
caffeine 0
enhanced 0
performance 0
in 0
training B-OTHER
and 0
competition B-OTHER
by 0
approximately 0
1.3 0
% 0
. 0

There 0
were 0
substantial 0
but 0
unclear 0
individual 0
responses 0
to 0
training 0
and 0
caffeine 0
( 0
SD 0
of 0
0.3 0
% 0
and 0
0.8 0
% 0
, 0
respectively 0
) 0
. 0

CONCLUSIONS 0
Mixed 0
linear 0
modeling 0
can 0
be 0
applied 0
successfully 0
to 0
monitor 0
factors 0
affecting 0
performance 0
in 0
a 0
squad 0
of 0
elite 0
athletes 0
. 0

Bradykinin-induced 0
cough 0
reflex 0
markedly 0
increases 0
in 0
patients 0
with 0
cough 0
associated 0
with 0
captopril 0
and 0
enalapril 0
. 0

We 0
studied 0
the 0
effects 0
of 0
angiotensin 0
converting 0
enzyme 0
( 0
ACE 0
) 0
inhibitors 0
on 0
cough B-ADVERSE-EFFECTS
responses I-ADVERSE-EFFECTS
to 0
bradykinin 0
( 0
BK 0
) 0
, 0
substance 0
P 0
( 0
SP 0
) 0
and 0
citric 0
acid 0
in 0
a 0
double 0
blind 0
, 0
random 0
study 0
on 0
10 0
hypertensive 0
patients 0
receiving 0
ACE 0
inhibitors 0
. 0

Of 0
these 0
patients 0
, 0
five 0
had 0
reported 0
cough 0
with 0
ACE 0
inhibitors 0
. 0

Cough 0
responses 0
to 0
citric 0
acid 0
were 0
similar 0
between 0
patients 0
with 0
and 0
without 0
cough 0
, 0
and 0
SP 0
up 0
to 0
10 0
( 0
-5 0
) 0
M 0
did 0
not 0
cause 0
cough 0
in 0
any 0
of 0
the 0
subjects 0
. 0

BK 0
caused 0
cough B-ADVERSE-EFFECTS
at 0
13.4 0
+/- 0
1.2 0
( 0
-log 0
M 0
) 0
in 0
5 0
patients 0
with 0
cough 0
associated 0
with 0
ACE 0
inhibitors 0
, 0
but 0
it 0
did 0
not 0
cause 0
cough B-ADVERSE-EFFECTS
at 0
concentrations 0
up 0
to 0
10 0
( 0
-5 0
) 0
M 0
in 0
other 0
5 0
patients 0
. 0

One 0
month 0
after 0
the 0
withdrawal 0
of 0
ACE 0
inhibitors 0
, 0
5 0
patients 0
were 0
free 0
from 0
cough B-PHYSICAL
symptoms I-PHYSICAL
, 0
and 0
BK 0
did 0
not 0
cause 0
cough B-PHYSICAL
up 0
to 0
10 0
( 0
-5 0
) 0
M 0
in 0
these 0
patients 0
, 0
except 0
for 0
one 0
who 0
coughed 0
at 0
10 0
( 0
-9 0
) 0
M 0
, 0
without 0
changes 0
in 0
responses 0
to 0
citric 0
acid 0
. 0

BK 0
caused 0
cough B-PHYSICAL
at 0
14.3 0
+/- 0
0.7 0
( 0
-log 0
M 0
) 0
although 0
BK1-7 0
, 0
a 0
major 0
metabolite 0
of 0
BK 0
by 0
ACE 0
, 0
caused 0
cough B-PHYSICAL
at 0
5.7 0
+/- 0
0.7 0
( 0
-log 0
M 0
) 0
in 0
another 0
3 0
patients 0
with 0
cough 0
associated 0
with 0
ACE 0
inhibitor 0
. 0

These 0
results 0
suggest 0
that 0
impaired 0
metabolism 0
of 0
BK 0
induced 0
by 0
ACE 0
inhibitors 0
may 0
relate 0
to 0
the 0
manifestation 0
of 0
cough 0
in 0
hypertensive 0
patients 0
receiving 0
ACE 0
inhibitors 0
. 0

Marimastat 0
as 0
maintenance 0
therapy 0
for 0
patients 0
with 0
advanced 0
gastric 0
cancer 0
: 0
a 0
randomised 0
trial 0
. 0

This 0
randomised 0
, 0
double-blind 0
, 0
placebo-controlled 0
study 0
was 0
designed 0
to 0
evaluate 0
the 0
ability 0
of 0
the 0
orally 0
administered 0
matrix 0
metalloproteinase 0
inhibitor 0
, 0
marimastat 0
, 0
to 0
prolong 0
survival B-MORTALITY
in 0
patients 0
with 0
non-resectable 0
gastric 0
and 0
gastro-oesophageal 0
adenocarcinoma 0
. 0

Three 0
hundred 0
and 0
sixty-nine 0
patients 0
with 0
histological 0
proof 0
of 0
adenocarcinoma 0
, 0
who 0
had 0
received 0
no 0
more 0
than 0
a 0
single 0
regimen 0
of 0
5-fluorouracil-based 0
chemotherapy 0
, 0
were 0
randomised 0
to 0
receive 0
either 0
marimastat 0
( 0
10 0
mg 0
b.d 0
. 0
) 0

or 0
placebo 0
. 0

Patients 0
were 0
treated 0
for 0
as 0
long 0
as 0
was 0
tolerable 0
. 0

The 0
primary 0
endpoint 0
was 0
overall B-MORTALITY
survival I-MORTALITY
with 0
secondary 0
endpoints 0
of 0
time 0
to 0
disease B-PHYSICAL
progression I-PHYSICAL
and 0
quality 0
of 0
life 0
. 0

At 0
the 0
point 0
of 0
protocol-defined 0
study 0
completion 0
( 0
85 0
% 0
mortality 0
in 0
the 0
placebo 0
arm 0
) 0
there 0
was 0
a 0
modest 0
difference 0
in 0
survival 0
in 0
the 0
intention-to-treat 0
population 0
in 0
favour 0
of 0
marimastat 0
( 0
P=0.07 0
log-rank 0
test 0
, 0
hazard 0
ratio=1.23 0
( 0
95 0
% 0
confidence 0
interval 0
0.98-1.55 0
) 0
) 0
. 0

This 0
survival B-MORTALITY
benefit I-MORTALITY
was 0
maintained 0
over 0
a 0
further 0
2 0
years 0
of 0
follow-up 0
( 0
P=0.024 0
, 0
hazard 0
ratio=1.27 0
( 0
1.03-1.57 0
) 0
) 0
. 0

The 0
median 0
survival B-MORTALITY
was 0
138 0
days 0
for 0
placebo 0
and 0
160 0
days 0
for 0
marimastat 0
, 0
with 0
2-year 0
survival 0
of 0
3 0
% 0
and 0
9 0
% 0
respectively 0
. 0

A 0
significant B-MORTALITY
survival I-MORTALITY
benefit I-MORTALITY
was 0
identified 0
at 0
study 0
completion 0
in 0
the 0
pre-defined 0
sub-group 0
of 0
123 0
patients 0
who 0
had 0
received 0
prior 0
chemotherapy 0
( 0
P=0.045 0
, 0
hazard 0
ratio=1.53 0
( 0
1.00-2.34 0
) 0
) 0
. 0

This 0
benefit 0
increased 0
with 0
2 0
years 0
additional 0
follow-up 0
( 0
P=0.006 0
, 0
hazard 0
ratio=1.68 0
( 0
1.16-2.44 0
) 0
) 0
, 0
with 0
2-year B-MORTALITY
survival I-MORTALITY
of 0
5 0
% 0
and 0
18 0
% 0
respectively 0
. 0

Progression-free B-MORTALITY
survival I-MORTALITY
was 0
also 0
significantly 0
longer 0
for 0
patients 0
receiving 0
marimastat 0
compared 0
to 0
placebo 0
( 0
P=0.009 0
, 0
hazard 0
ratio=1.32 0
( 0
1.07-1.63 0
) 0
) 0
. 0

Marimastat 0
treatment 0
was 0
associated 0
with 0
the 0
development 0
of 0
musculoskeletal B-PAIN
pain I-PAIN
and I-PAIN
inflammation I-PAIN
. 0

Events B-PHYSICAL
of I-PHYSICAL
anaemia I-PHYSICAL
, 0
abdominal B-PHYSICAL
pain I-PHYSICAL
, 0
jaundice B-PHYSICAL
and 0
weight 0
loss B-PHYSICAL
were 0
more 0
common 0
in 0
the 0
placebo 0
arm 0
. 0

This 0
is 0
one 0
of 0
the 0
first 0
demonstrations 0
of 0
a 0
therapeutic 0
benefit 0
for 0
a 0
matrix 0
metalloproteinase 0
inhibitor 0
in 0
cancer 0
patients 0
. 0

The 0
greatest 0
benefit 0
was 0
observed 0
in 0
patients 0
who 0
had 0
previously 0
received 0
chemotherapy 0
. 0

A 0
further 0
randomised 0
study 0
of 0
marimastat 0
in 0
these 0
patients 0
is 0
warranted 0
. 0

Aerobic 0
and 0
strength 0
training 0
reduces 0
adiposity B-PHYSICAL
in 0
overweight 0
Latina 0
adolescents 0
. 0

PURPOSE 0
To 0
date 0
, 0
no 0
study 0
has 0
examined 0
the 0
synergistic 0
effects 0
of 0
a 0
nutrition 0
and 0
combination 0
of 0
aerobic 0
and 0
strength 0
training 0
( 0
CAST 0
) 0
on 0
both 0
adiposity B-PHYSICAL
and 0
metabolic B-PHYSICAL
parameters I-PHYSICAL
in 0
overweight 0
Latina 0
adolescent 0
females 0
. 0

The 0
goal 0
was 0
to 0
assess 0
if 0
a 0
16-wk 0
nutrition 0
plus 0
CAST 0
pilot 0
study 0
had 0
stronger 0
effects 0
on 0
reducing 0
adiposity B-PHYSICAL
and 0
on 0
improving 0
glucose/insulin B-PHYSICAL
indices I-PHYSICAL
compared 0
with 0
control 0
( 0
C 0
) 0
, 0
nutrition 0
only 0
( 0
N 0
) 0
, 0
and 0
a 0
nutrition 0
plus 0
strength 0
training 0
( 0
N 0
+ 0
ST 0
) 0
groups 0
. 0

METHODS 0
In 0
a 0
16-wk 0
randomized 0
trial 0
, 0
41 0
overweight 0
Latina 0
girls 0
( 0
15.2 0
+/- 0
1.1 0
yr 0
) 0
were 0
randomly 0
assigned 0
to 0
C 0
( 0
n 0
= 0
7 0
) 0
, 0
N 0
( 0
n 0
= 0
10 0
) 0
, 0
N 0
+ 0
ST 0
( 0
n 0
= 0
9 0
) 0
, 0
or 0
N 0
+ 0
CAST 0
( 0
n 0
= 0
15 0
) 0
. 0

All 0
intervention 0
groups 0
received 0
modified 0
carbohydrate 0
nutrition 0
classes 0
( 0
once 0
a 0
week 0
) 0
, 0
whereas 0
the 0
N 0
+ 0
ST 0
also 0
received 0
strength 0
training 0
( 0
twice 0
a 0
week 0
) 0
and 0
the 0
N 0
+ 0
CAST 0
received 0
a 0
combination 0
of 0
strength 0
and 0
aerobic 0
training 0
( 0
twice 0
a 0
week 0
) 0
. 0

The 0
following 0
were 0
measured 0
before 0
and 0
after 0
intervention 0
: 0
strength B-PHYSICAL
by 0
one 0
repetition 0
maximum 0
, 0
physical B-MENTAL
activity I-MENTAL
by I-MENTAL
the I-MENTAL
7-d I-MENTAL
accelerometry I-MENTAL
and 0
the 0
3-d B-MENTAL
physical I-MENTAL
activity I-MENTAL
recall I-MENTAL
, 0
dietary B-MENTAL
intake I-MENTAL
by 0
3-d 0
records 0
, 0
body B-PHYSICAL
composition I-PHYSICAL
by 0
dual-energy 0
x-ray 0
absorptiometry 0
( 0
DEXA 0
) 0
, 0
glucose/insulin B-PHYSICAL
indices I-PHYSICAL
by 0
oral 0
glucose 0
tolerance 0
test 0
, 0
and 0
intravenous 0
glucose 0
tolerance 0
test 0
with 0
minimal 0
modeling 0
. 0

Across 0
intervention 0
group 0
, 0
effects 0
were 0
tested 0
using 0
ANCOVA 0
with 0
post 0
hoc 0
pairwise 0
comparisons 0
. 0

RESULTS 0
There 0
were 0
significant 0
overall 0
intervention 0
effects 0
for 0
all 0
adiposity B-PHYSICAL
measures 0
( 0
weight 0
, 0
body 0
mass 0
index 0
[ 0
BMI 0
] 0
, 0
BMI 0
z-scores B-PHYSICAL
, 0
and 0
DEXA B-PHYSICAL
total 0
body B-PHYSICAL
fat B-PHYSICAL
) 0
, 0
with 0
a 0
decrease 0
of 0
3 0
% 0
in 0
the 0
N 0
+ 0
CAST 0
group 0
compared 0
with 0
a 0
3 0
% 0
increase 0
in 0
the 0
N 0
+ 0
ST 0
group 0
( 0
P 0
< 0
or 0
= 0
0.05 0
) 0
. 0

There 0
was 0
also 0
an 0
intervention 0
effect 0
for 0
fasting B-PHYSICAL
glucose I-PHYSICAL
with 0
the 0
N 0
group 0
increasing 0
by 0
3 0
% 0
and 0
the 0
N 0
+ 0
CAST 0
group 0
decreasing 0
by 0
4 0
% 0
( 0
P 0
< 0
or 0
= 0
0.05 0
) 0
. 0

CONCLUSION 0
The 0
CAST 0
was 0
more 0
effective 0
than 0
nutrition 0
alone 0
or 0
nutrition 0
plus 0
strength 0
training 0
for 0
reducing 0
multiple B-PHYSICAL
adiposity I-PHYSICAL
outcomes B-PHYSICAL
and 0
fasting B-PHYSICAL
glucose I-PHYSICAL
in 0
overweight 0
Latina 0
girls 0
. 0

However 0
, 0
further 0
research 0
investigating 0
and 0
identifying 0
intervention 0
approaches 0
that 0
improve 0
both 0

Lack 0
of 0
effect 0
of 0
warfarin 0
on 0
the 0
restenosis B-PHYSICAL
rate I-PHYSICAL
or 0
on 0
clinical 0
outcome 0
after 0
balloon 0
coronary 0
angioplasty 0
. 0

Between 0
September 0
1985 0
and 0
April 0
1987 0
, 0
110 0
consecutive 0
patients 0
who 0
had 0
successful 0
coronary 0
angioplasty 0
were 0
included 0
in 0
a 0
randomised 0
prospective 0
controlled 0
evaluation 0
of 0
the 0
effects 0
of 0
warfarin 0
on 0
restenosis 0
. 0

The 0
warfarin 0
( 0
n 0
= 0
56 0
) 0
and 0
the 0
control 0
( 0
n 0
= 0
54 0
) 0
groups 0
were 0
not 0
different 0
in 0
terms 0
of 0
age 0
, 0
sex 0
, 0
previous 0
coronary 0
bypass 0
surgery 0
or 0
coronary 0
balloon 0
angioplasty 0
, 0
severity 0
of 0
symptoms 0
, 0
and 0
frequency 0
of 0
multivessel 0
disease 0
or 0
of 0
total 0
coronary 0
occlusions 0
. 0

Warfarin 0
was 0
started 0
on 0
the 0
day 0
of 0
the 0
procedure 0
and 0
the 0
dosage 0
was 0
adjusted 0
to 0
maintain 0
the 0
thromboplastin 0
international 0
normalised 0
ratio 0
greater 0
than 0
or 0
equal 0
to 0
2.5 0
. 0

One 0
hundred 0
and 0
five 0
( 0
96 0
% 0
) 0
of 0
the 0
patients 0
were 0
given 0
verapamil 0
and 0
other 0
antianginal 0
drugs 0
were 0
prescribed 0
as 0
needed 0
. 0

Low 0
molecular 0
weight 0
dextran 0
and 0
heparin 0
were 0
given 0
during 0
the 0
procedure 0
and 0
heparin 0
was 0
continued 0
for 0
24 0
hours 0
in 0
all 0
patients 0
. 0

One 0
hundred 0
and 0
eight 0
( 0
98 0
% 0
) 0
of 0
patients 0
were 0
followed 0
up 0
clinically 0
after 0
a 0
median 0
of 0
five 0
months 0
( 0
range 0
1-20 0
) 0
. 0

Eighty 0
five 0
( 0
77 0
% 0
) 0
had 0
follow 0
up 0
angiography 0
at 0
five 0
months 0
. 0

In 0
the 0
warfarin 0
group 0
symptoms B-PHYSICAL
improved B-OTHER
in 0
46 0
( 0
85 0
% 0
) 0
patients 0
by 0
at 0
least 0
1 0
angina 0
class 0
and 0
31 0
( 0
57 0
% 0
) 0
were 0
symptom B-OTHER
free I-OTHER
; 0
the 0
exercise 0
test 0
remained 0
positive 0
in 0
20 0
( 0
36 0
% 0
) 0
patients 0
and 0
the 0
angiographic B-PHYSICAL
restenosis I-PHYSICAL
rate I-PHYSICAL
was 0
25 0
% 0
per 0
lesion 0
and 0
29 0
% 0
per 0
patient 0
. 0

There 0
were 0
no 0
major B-ADVERSE-EFFECTS
bleeding I-ADVERSE-EFFECTS
complications I-ADVERSE-EFFECTS
. 0

In 0
the 0
control 0
group 0
46 0
( 0
85 0
% 0
) 0
patients 0
were 0
improved 0
by 0
at 0
least 0
1 0
angina 0
class 0
and 0
31 0
( 0
57 0
% 0
) 0
were 0
symptom 0
free 0
; 0
the 0
exercise B-OTHER
test I-OTHER
was 0
positive 0
in 0
11 0
( 0
21 0
% 0
) 0
patients 0
and 0
the 0
angiographic B-PHYSICAL
restenosis I-PHYSICAL
rate I-PHYSICAL
was 0
33 0
% 0
per 0
lesion 0
and 0
37 0
% 0
per 0
patient 0
. 0

Although 0
the 0
incidence 0
of 0
angiographic 0
restenosis 0
tended 0
to 0
be 0
lower 0
with 0
warfarin 0
, 0
none 0
of 0
these 0
differences 0
was 0
significant 0
. 0

These 0
data 0
suggest 0
that 0
the 0
combination 0
of 0
verapamil 0
and 0
warfarin 0
, 0
in 0
the 0
absence 0
of 0
aspirin 0
, 0
is 0
not 0
significantly 0
better 0
than 0
verapamil 0
alone 0
in 0
preventing 0
symptom 0
recurrence 0
or 0
angiographic B-PHYSICAL
restenosis I-PHYSICAL
after 0
coronary 0
angioplasty 0
. 0

Rational-emotive 0
therapy 0
and 0
the 0
reduction 0
of 0
interpersonal B-MENTAL
anxiety I-MENTAL
in 0
junior 0
high 0
school 0
students 0
. 0

This 0
study 0
evaluated 0
the 0
effectiveness 0
of 0
rational-emotive 0
therapy 0
and 0
rational-emotive 0
imagery 0
. 0

Fifty-nine 0
junior 0
high 0
school 0
students 0
who 0
volunteered 0
to 0
participate 0
in 0
treatment 0
for 0
interpersonal B-MENTAL
anxiety I-MENTAL
were 0
randomly 0
assigned 0
to 0
rational-emotive 0
therapy 0
without 0
imagery 0
( 0
RET 0
) 0
, 0
rational-emotive 0
therapy 0
with 0
imagery 0
( 0
REI 0
) 0
, 0
relationship-oriented 0
counseling 0
( 0
ROC 0
) 0
, 0
and 0
waiting-list 0
control 0
( 0
WLC 0
) 0
groups 0
. 0

Groups 0
met 0
for 0
seven 0
50-minute 0
treatment 0
sessions 0
during 0
a 0
three-week 0
period 0
. 0

Assessments 0
were 0
conducted 0
at 0
pretreatment 0
, 0
posttreatment 0
, 0
and 0
three-week 0
follow-up 0
. 0

Both 0
self-report B-OTHER
and I-OTHER
sociometric I-OTHER
measures I-OTHER
were 0
used 0
to 0
evaluate 0
treatment 0
outcome 0
. 0

At 0
postassessment 0
, 0
both 0
the 0
RET 0
and 0
REI 0
groups 0
were 0
rated 0
on 0
sociometric B-MENTAL
measures I-MENTAL
as 0
significantly 0
less 0
interpersonally 0
anxious B-OTHER
than 0
the 0
WLC 0
group 0
. 0

Mean 0
scores 0
favored 0
the 0
RET 0
and 0
REI 0
groups 0
, 0
but 0
no 0
significant 0
differences 0
between 0
these 0
groups 0
and 0
the 0
ROC 0
group 0
were 0
obtained 0
. 0

The 0
self-report B-OTHER
measure I-OTHER
did 0
not 0
significantly 0
differentiate 0
between 0
groups 0
, 0
but 0
the 0
REI 0
group 0
demonstrated 0
significant 0
pre- 0
to 0
follow-up 0
changes 0
. 0

Both 0
the 0
RET 0
and 0
REI 0
groups 0
yielded 0
greater 0
reductions 0
in 0
irrational B-MENTAL
thinking I-MENTAL
than 0
did 0
the 0
ROC 0
and 0
WLC 0
groups 0
. 0

In 0
addition 0
, 0
the 0
pattern 0
of 0
the 0
results 0
supported 0
the 0
use 0
of 0
rational-emotive 0
imagery 0
as 0
a 0
component 0
of 0
rational-emotive 0
therapy 0
. 0

The 0
practical 0
implications 0
of 0
these 0
findings 0
are 0
discussed 0
. 0

A 0
randomized 0
clinical 0
trial 0
of 0
treatment 0
of 0
clomiphene 0
citrate-resistant 0
anovulation 0
with 0
the 0
use 0
of 0
oral 0
contraceptive 0
pill 0
suppression 0
and 0
repeat 0
clomiphene 0
citrate 0
treatment 0
. 0

OBJECTIVE 0
The 0
purpose 0
of 0
this 0
study 0
was 0
to 0
evaluate 0
the 0
effectiveness 0
and 0
endocrine B-PHYSICAL
response I-PHYSICAL
of 0
oral 0
contraceptive 0
ovarian 0
suppression 0
followed 0
by 0
clomiphene 0
citrate 0
in 0
patients 0
who 0
previously 0
were 0
clomiphene 0
citrate 0
resistant 0
. 0

STUDY 0
DESIGN 0
Forty-eight 0
patients 0
from 0
a 0
private 0
tertiary 0
infertility 0
clinic 0
were 0
assigned 0
randomly 0
prospectively 0
to 0
either 0
group 0
1 0
( 0
oral 0
contraceptive/clomiphene 0
citrate 0
) 0
, 0
which 0
received 0
continuous 0
oral 0
contraceptives 0
followed 0
by 0
clomiphene 0
citrate 0
, 0
or 0
to 0
group 0
2 0
( 0
control 0
) 0
received 0
no 0
treatment 0
in 0
the 0
cycle 0
before 0
clomiphene 0
citrate 0
treatment 0
. 0

On 0
day 0
3 0
, 0
17 0
beta-estradiol B-OTHER
, 0
follicle-stimulating B-OTHER
hormone I-OTHER
, 0
luteinizing B-OTHER
hormone I-OTHER
, 0
and 0

[ 0
The 0
application 0
of 0
naphcon 0
eye 0
drops 0
during 0
Lasik 0
surgery 0
] 0
. 0

PURPOSE 0
To 0
evaluate 0
the 0
effects 0
of 0
Naphcon 0
eye 0
drops 0
for 0
preventing 0
conjunctival 0
bleeding 0
during 0
Lasik 0
surgery 0
. 0

METHODS 0
One 0
hundred 0
cases 0
( 0
200 0
eyes 0
) 0
were 0
divided 0
into 0
treating 0
group 0
and 0
control 0
group 0
randomly 0
according 0
to 0
using 0
and 0
not 0
using 0
Naphcon 0
eye 0
drops 0
before 0
Lasik 0
surgery 0
. 0

Treating 0
group 0
patients 0
received 0
three 0
times 0
Naphcon 0
eye 0
drops 0
during 0
15 0
minutes 0
before 0
surgery 0
. 0

RESULTS 0
The 0
incidence 0
of 0
conjunctival B-PHYSICAL
bleeding I-PHYSICAL
from 0
treating 0
and 0
control 0
group 0
were 0
8 0
% 0
and 0
15 0
% 0
respectively 0
. 0

There 0
was 0
significant 0
statistical 0
difference 0
between 0
them 0
. 0

CONCLUSION 0
Naphcon 0
eye 0
drop 0
is 0
an 0
effective 0
agent 0
to 0
prevent 0
conjunctival 0
bleeding 0
. 0

Enhanced 0
inotropic 0
state 0
of 0
the 0
failing 0
left 0
ventricle 0
by 0
cardiac 0
contractility 0
modulation 0
electrical 0
signals 0
is 0
not 0
associated 0
with 0
increased 0
myocardial B-PHYSICAL
oxygen I-PHYSICAL
consumption I-PHYSICAL
. 0

BACKGROUND 0
Previous 0
studies 0
in 0
patients 0
and 0
in 0
dogs 0
with 0
experimentally 0
induced 0
heart 0
failure 0
( 0
HF 0
) 0
showed 0
that 0
electrical 0
signals 0
applied 0
to 0
the 0
failing 0
myocardium 0
during 0
the 0
absolute 0
refractory 0
period 0
improved 0
left B-PHYSICAL
ventricular I-PHYSICAL
( I-PHYSICAL
LV I-PHYSICAL
) I-PHYSICAL
function I-PHYSICAL
. 0

We 0
examined 0
the 0
effects 0
these 0
same 0
cardiac 0
contractility 0
modulating 0
( 0
CCM 0
) 0
electrical 0
signals 0
on 0
myocardial B-PHYSICAL
oxygen I-PHYSICAL
consumption I-PHYSICAL
( 0
MVO B-PHYSICAL
( 0
2 B-PHYSICAL
) 0
) 0
in 0
both 0
patients 0
and 0
dogs 0
with 0
chronic 0
HF 0
. 0

METHODS 0
AND 0
RESULTS 0
Six 0
dogs 0
with 0
microembolizations-induced 0
HF 0
and 0
9 0
HF 0
patients 0
underwent 0
CCM 0
leads 0
and 0
generator 0
( 0
OPTIMIZER 0
II 0
) 0
implantation 0
. 0

After 0
baseline 0
measurements 0
, 0
CCM 0
signals 0
were 0
delivered 0
continuously 0
for 0
2 0
hours 0
in 0
dogs 0
and 0
for 0
30 0
minutes 0
in 0
patients 0
. 0

MVO B-PHYSICAL
( 0
2 B-PHYSICAL
) 0
was 0
measured 0
before 0
and 0
after 0
CCM 0
therapy 0
. 0

In 0
dogs 0
, 0
CCM 0
therapy 0
increased 0
LV B-PHYSICAL
ejection I-PHYSICAL
fraction I-PHYSICAL
at 0
2 0
hours 0
( 0
26 0
+/- 0
1 0
versus 0
31 0
+/- 0
2 0
% 0
, 0
P 0
= 0
.001 0
) 0
without 0
increasing 0
MVO B-PHYSICAL
( 0
2 B-PHYSICAL
) 0
( 0
257 0
+/- 0
41 0
versus 0
180 0
+/- 0
34 0
micromol/min 0
) 0
. 0

In 0
patients 0
, 0
CCM 0
therapy 0
increased 0
LV B-PHYSICAL
peak 0
+dP/dt B-PHYSICAL
by 0
10.1 0
+/- 0
1.5 0
% 0
. 0

As 0
with 0
dogs 0
, 0
the 0
increase 0
in 0
LV B-PHYSICAL
function I-PHYSICAL
after 0
30 0
minutes 0
of 0
CCM 0
therapy 0
was 0
not 0
associated 0
with 0
increased 0
MVO B-PHYSICAL
( 0

Randomised 0
trial 0
of 0
efficacy 0
and 0
safety 0
of 0
oral 0
ganciclovir 0
in 0
the 0
prevention 0
of 0
cytomegalovirus 0
disease 0
in 0
liver-transplant 0
recipients 0
. 0

The 0
Oral 0
Ganciclovir 0
International 0
Transplantation 0
Study 0
Group 0
[ 0
corrected 0
] 0
. 0

BACKGROUND 0
Cytomegalovirus 0
( 0
CMV 0
) 0
disease 0
is 0
a 0
frequent 0
cause 0
of 0
serious 0
morbidity 0
after 0
solid-organ 0
transplantation 0
. 0

The 0
prophylactic 0
regimens 0
used 0
to 0
prevent 0
CMV 0
infection 0
and 0
disease 0
have 0
shown 0
limited 0
benefit 0
in 0
seronegative 0
recipients 0
. 0

We 0
studied 0
the 0
safety 0
and 0
efficacy 0
of 0
oral 0
ganciclovir 0
in 0
the 0
prevention 0
of 0
CMV 0
disease 0
following 0
orthotopic 0
liver 0
transplantation 0
. 0

METHODS 0
Between 0
December 0
, 0
1993 0
, 0
and 0
April 0
, 0
1995 0
, 0
304 0
liver-transplant 0
recipients 0
were 0
randomised 0
to 0
receive 0
oral 0
ganciclovir 0
1000 0
mg 0
or 0
matching 0
placebo 0
three 0
times 0
a 0
day 0
. 0

Seronegative 0
recipients 0
of 0
seronegative 0
livers 0
were 0
excluded 0
. 0

Study 0
drug 0
was 0
administered 0
as 0
soon 0
as 0
the 0
patient 0
was 0
able 0
to 0
take 0
medication 0
by 0
mouth 0
( 0
no 0
later 0
than 0
day 0
10 0
) 0
until 0
the 0
98th 0
day 0
after 0
transplantation 0
. 0

Patients 0
were 0
assessed 0
at 0
specified 0
times 0
throughout 0
the 0
first 0
6 0
months 0
after 0
surgery 0
for 0
evidence 0
of 0
CMV B-OTHER
infection I-OTHER
, 0
CMV B-OTHER
disease I-OTHER
, 0
rejection B-OTHER
, 0
opportunistic B-OTHER
infections I-OTHER
, 0
and 0

Alternative 0
voice 0
after 0
laryngectomy 0
using 0
a 0
sound-producing 0
voice 0
prosthesis 0
. 0

OBJECTIVE 0
To 0
improve 0
the 0
voice 0
quality 0
of 0
female 0
laryngectomees 0
and/or 0
laryngectomees 0
with 0
a 0
hypotonic 0
pharyngoesophageal 0
( 0
PE 0
) 0
segment 0
by 0
means 0
of 0
a 0
pneumatic B-PHYSICAL
artificial I-PHYSICAL
source I-PHYSICAL
of I-PHYSICAL
voice I-PHYSICAL
incorporated I-PHYSICAL
in I-PHYSICAL
a I-PHYSICAL
regular I-PHYSICAL
tracheoesophageal I-PHYSICAL
( 0
TE B-PHYSICAL
) 0
shunt B-PHYSICAL
valve B-PHYSICAL
. 0

STUDY 0
DESIGN 0
Experimental 0
, 0
randomized 0
, 0
crossover 0
trial 0
. 0

METHODS 0
The 0
new 0
sound 0
source 0
consists 0
of 0
a 0
single 0
silicone 0
lip 0
, 0
which 0
performs 0
an 0
oscillatory 0
movement 0
driven 0
by 0
expired 0
pulmonary 0
air 0
flowing 0
along 0
the 0
outward-striking 0
lip 0
through 0
the 0
TE 0
shunt 0
valve 0
. 0

A 0
prototype 0
of 0
this 0
pneumatic 0
sound 0
source 0
is 0
evaluated 0
in 0
vitro 0
and 0
in 0
six 0
laryngectomees 0
. 0

In 0
vivo 0
evaluation 0
includes 0
speech 0
rate 0
, 0
maximal 0
phonation 0
time 0
, 0
perceptual 0
voice 0
evaluation 0
of 0
read-aloud 0
prose 0
by 0
an 0
expert 0
listener 0
, 0
speech 0
intelligibility 0
measurements 0
with 0
12 0
listeners 0
, 0
and 0
self-assessment 0
by 0
the 0
patients 0
. 0

Moreover 0
, 0
extensive B-OTHER
acoustical I-OTHER
and 0
aerodynamic B-PHYSICAL
in B-PHYSICAL
vivo I-PHYSICAL
registrations I-PHYSICAL
are 0
performed 0
using 0
a 0
newly B-OTHER
developed I-OTHER
data 0
acquisition B-OTHER
system I-OTHER
. 0

RESULTS 0
The 0
current 0
prototype 0
seems 0
beneficial 0
in 0
female 0
laryngectomees 0
with 0
a 0
hypotonic 0
PE 0
segment 0
only 0
. 0

For 0
them 0
the 0
sound-producing 0
voice 0
prosthesis 0
improves B-PHYSICAL
voice I-PHYSICAL
quality I-PHYSICAL
and I-PHYSICAL
increases 0
the B-PHYSICAL
average 0
pitch B-PHYSICAL
of I-PHYSICAL
voice I-PHYSICAL
, 0
without B-PHYSICAL
decreasing I-PHYSICAL
intelligibility 0
or B-PHYSICAL
necessitating I-PHYSICAL
other B-PHYSICAL

[ 0
Supplementary 0
treatment 0
with 0
Esberitox 0
of 0
female 0
patients 0
undergoing 0
curative 0
adjuvant 0
irradiation 0
following 0
breast 0
cancer 0
] 0
. 0

1 0
. 0

The 0
study 0
was 0
supposed 0
to 0
investigate 0
a 0
possible 0
prevention B-PHYSICAL
or 0
reduction B-PHYSICAL
of I-PHYSICAL
the I-PHYSICAL
toxicity I-PHYSICAL
of 0
radiotherapy 0
by 0
an 0
additional 0
treatment 0
with 0
Esberitox 0
. 0

This 0
question 0
arose 0
when 0
performing 0
an 0
investigation 0
about 0
the 0
effect 0
of 0
Esberitox 0
in 0
a 0
combined 0
chemo-radiotherapy 0
. 0

Whereas 0
the 0
latter 0
induces 0
above 0
all 0
a 0
systemic 0
damage 0
to 0
the 0
hemopoietic 0
system 0
, 0
radiotherapy 0
is 0
a 0
regional 0
noxa 0
. 0

2 0
. 0

The 0
present 0
prospective 0
, 0
randomized 0
study 0
was 0
conducted 0
with 0
50 0
patients 0
submitted 0
to 0
curative 0
adjuvant 0
irradiation 0
following 0
surgery 0
for 0
mammary 0
carcinoma 0
. 0

The 0
radiotherapy 0
was 0
performed 0
in 0
the 0
same 0
way 0
in 0
all 0
patients 0
with 0
irradiations 0
of 0
the 0
thoracic 0
wall 0
and 0
the 0
regional 0
lymph 0
nodes 0
. 0

Two 0
groups 0
were 0
built 0
by 0
randomization 0
. 0

The 0
study 0
group 0
received 0
an 0
additional 0
treatment 0
with 0
Esberitox 0
, 0
the 0
control 0
group 0
did 0
not 0
receive 0
an 0
additional 0
treatment 0
. 0

3 0
. 0

As 0
a 0
result 0
, 0
no 0
protective 0
influence 0
of 0
Esberitox 0
could 0
be 0
demonstrated 0
. 0

The 0
parameters 0
investigated 0
were 0
the 0
peripheral B-PHYSICAL
blood I-PHYSICAL
count I-PHYSICAL
( 0
leucocytes B-PHYSICAL
, 0
granulocytes B-PHYSICAL
, 0
lymphocytes B-PHYSICAL
, 0
monocytes B-PHYSICAL
, 0
thrombocytes B-PHYSICAL
, 0
hemoglobin B-PHYSICAL
, 0
hematocrit B-PHYSICAL
) 0
and B-PHYSICAL
the I-PHYSICAL
incidence 0

[ 0
Dexmedetomidine 0
use 0
for 0
postoperative B-PHYSICAL
adrenergic I-PHYSICAL
analgesia I-PHYSICAL
and I-PHYSICAL
sedation I-PHYSICAL
in 0
abdominal 0
surgery 0
] 0
. 0

Comparative 0
study 0
of 0
postoperative 0
analgesia 0
and 0
sedation 0
with 0
trimeperidine 0
and 0
dexmedetomidine 0
and 0
their 0
effects 0
on 0
haemodynamics 0
and 0
vegetative 0
nervous 0
system 0
was 0
performed 0
. 0

Assessment 0
of 0
analgesia 0
and 0
sedation 0
during 0
vagotonia 0
( 0
first 0
part 0
of 0
the 0
study 0
) 0
and 0
hypokinetic 0
type 0
of 0
haemodynamics 0
( 0
second 0
part 0
of 0
the 0
study 0
) 0
was 0
carried 0
out 0
with 0
visual 0
analogue 0
scale 0
( 0
VAS 0
) 0
and 0
Richmond B-PHYSICAL
scale I-PHYSICAL
. 0

Results 0
of 0
the 0
study 0
showed 0
that 0
dexmedetomidine 0
is 0
more 0
effective B-OTHER
and 0
safer B-OTHER
than 0
trimeperidine 0
for 0
analgesia B-PHYSICAL
and 0
sedation B-PHYSICAL
in 0
patients 0
with 0
spontaneous 0
breathing 0
after 0
abdominal 0
surgery 0
. 0

Dexmedetomidine 0
use 0
allows 0
keeping 0
optimal 0
type 0
of 0
haemodynamics 0
and 0
vegetative 0
nervous 0
system 0
parameters 0
on 0
first 0
day 0
of 0
postoperative 0
period 0
. 0

Daclizumab 0
high-yield 0
process 0
in 0
relapsing-remitting B-PHYSICAL
multiple I-PHYSICAL
sclerosis I-PHYSICAL
( 0
SELECT 0
) 0
: 0
a 0
randomised 0
, 0
double-blind 0
, 0
placebo-controlled 0
trial 0
. 0

BACKGROUND 0
Daclizumab 0
, 0
a 0
humanised 0
monoclonal 0
antibody 0
, 0
modulates 0
interleukin-2 0
signalling 0
by 0
blocking 0
the 0
? 0

subunit 0
( 0
CD25 0
) 0
of 0
the 0
interleukin-2 0
receptor 0
. 0

We 0
assessed 0
whether 0
daclizumab 0
high-yield 0
process 0
( 0
HYP 0
) 0
would 0
be 0
effective 0
when 0
given 0
as 0
monotherapy 0
for 0
a 0
1 0
year 0
treatment 0
period 0
in 0
patients 0
with 0
relapsing-remitting 0
multiple 0
sclerosis 0
. 0

METHODS 0
We 0
did 0
a 0
randomised 0
, 0
double-blind 0
, 0
placebo-controlled 0
trial 0
at 0
76 0
centres 0
in 0
the 0
Czech 0
Republic 0
, 0
Germany 0
, 0
Hungary 0
, 0
India 0
, 0
Poland 0
, 0
Russia 0
, 0
Ukraine 0
, 0
Turkey 0
, 0
and 0
the 0
UK 0
between 0
Feb 0
15 0
, 0
2008 0
, 0
and 0
May 0
14 0
, 0
2010 0
. 0

Patients 0
aged 0
18-55 0
years 0
with 0
relapsing-remitting 0
multiple 0
sclerosis 0
were 0
randomly 0
assigned 0
( 0
1:1:1 0
) 0
, 0
via 0
a 0
central 0
interactive 0
voice 0
response 0
system 0
, 0
to 0
subcutaneous 0
injections 0
of 0
daclizumab 0
HYP 0
150 0
mg 0
or 0
300 0
mg 0
, 0
or 0
placebo 0
, 0
every 0
4 0
weeks 0
for 0
52 0
weeks 0
. 0

Patients 0
and 0
study 0
personnel 0
were 0
masked 0
to 0
treatment 0
assignment 0
, 0
except 0
for 0
the 0
site 0
pharmacist 0
who 0
prepared 0
the 0
study 0
drug 0
for 0
injection 0
, 0
but 0
had 0
no 0
interaction 0
with 0
the 0
patient 0
. 0

The 0
primary 0
endpoint 0
was 0
annualised 0
relapse 0
rate 0
. 0

Analysis 0
was 0
by 0
intention 0
to 0
treat 0
. 0

The 0
trial 0
is 0
registered 0
with 0
ClinicalTrials.gov 0
, 0
number 0
NCT00390221 0
. 0

FINDINGS 0
204 0
patients 0
were 0
assigned 0
to 0
receive 0
placebo 0
, 0
208 0
to 0
daclizumab 0
HYP 0
150 0
mg 0
, 0
and 0
209 0
to 0
daclizumab 0
HYP 0
300 0
mg 0
, 0
of 0
whom 0
188 0
( 0
92 0
% 0
) 0
, 0
192 0
( 0
92 0
% 0
) 0
, 0
and 0
197 0
( 0
94 0
% 0
) 0
, 0
respectively 0
, 0
completed 0
follow-up 0
to 0
week 0
52 0
. 0

The 0
annualised 0
relapse 0
rate 0
was 0
lower 0
for 0
patients 0
given 0
daclizumab 0
HYP 0
150 0
mg 0
( 0
0?21 0
, 0
95 0
% 0
CI 0
0?16-0?29 0
; 0
54 0
% 0
reduction 0
, 0
95 0
% 0
CI 0
33-68 0
% 0
; 0
p 0
< 0
0?0001 0
) 0
or 0
300 0
mg 0
( 0
0?23 0
, 0
0?17-0?31 0
, 0
50 0
% 0
reduction 0
, 0
28-65 0
% 0
; 0
p=0?00015 0
) 0
than 0
for 0
those 0
given 0
placebo 0
( 0
0?46 0
, 0
0?37-0?57 0
) 0
. 0

More 0
patients 0
were 0
relapse 0
free 0
in 0
the 0
daclizumab 0
HYP 0
150 0
mg 0
( 0
81 0
% 0
) 0
and 0
300 0
mg 0
( 0
80 0
% 0
) 0
groups 0
than 0
in 0
the 0
placebo 0
group 0
( 0
64 0
% 0
; 0
p 0
< 0
0?0001 0
in 0
the 0
150 0
mg 0
group 0
and 0
p=0?0003 0
in 0
the 0
300 0
mg 0
group 0
) 0
. 0

12 0
( 0
6 0
% 0
) 0
patients 0
in 0
the 0
placebo 0
group 0
, 0
15 0
( 0
7 0
% 0
) 0
of 0
those 0
in 0
the 0
daclizumab 0
150 0
mg 0
group 0
, 0
and 0
19 0
( 0
9 0
% 0
) 0
in 0
the 0
300 0
mg 0
group 0
had 0
serious 0
adverse 0
events 0
excluding 0
multiple 0
sclerosis 0
relapse 0
. 0

One 0
patient 0
given 0
daclizumab 0
HYP 0
150 0
mg 0
who 0
was 0
recovering 0
from 0
a 0
serious 0
rash 0
died 0
because 0
of 0
local 0
complication 0
of 0
a 0
psoas 0
abscess 0
. 0

INTERPRETATION 0
Subcutaneous 0
daclizumab 0
HYP 0
administered 0
every 0
4 0
weeks 0
led 0
to 0
clinically 0
important 0
effects 0
on 0
multiple 0
sclerosis 0
disease 0
activity 0
during 0
1 0
year 0
of 0
treatment 0
. 0

Our 0
findings 0
support 0
the 0
potential 0
for 0
daclizumab 0
HYP 0
to 0
offer 0
an 0
additional 0
treatment 0
option 0
for 0
relapsing-remitting 0
disease 0
. 0

FUNDING 0
Biogen 0
Idec 0
and 0
AbbVie 0
Biotherapeutics 0
Inc 0
. 0

Efficacy 0
and 0
safety 0
of 0
mizolastine 0
10 0
mg 0
in 0
a 0
placebo-controlled 0
comparison 0
with 0
loratadine 0
in 0
chronic 0
idiopathic 0
urticaria 0
: 0
results 0
of 0
the 0
MILOR 0
Study 0
. 0

BACKGROUND 0
Mizolastine 0
is 0
a 0
novel 0
histamine 0
H1-antagonist 0
registered 0
in 0
Europe 0
for 0
the 0
management 0
of 0
allergic 0
rhinitis 0
and 0
urticaria 0
. 0

OBJECTIVES 0
To 0
compare 0
the 0
clinical 0
efficacy 0
and 0
safety 0
of 0
mizolastine 0
with 0
loratadine 0
and 0
placebo 0
in 0
patients 0
with 0
chronic 0
idiopathic 0
urticaria 0
( 0
CIU 0
) 0
. 0

METHODS 0
A 0
multicentre 0
, 0
double-blind 0
, 0
parallel 0
group 0
study 0
was 0
designed 0
in 0
which 0
247 0
patients 0
with 0
CIU 0
were 0
randomised 0
after 0
a 0
1-week 0
placebo 0
run-in 0
period 0
to 0
10 0
mg 0
daily 0
mizolastine 0
( 0
n 0
= 0
88 0
) 0
, 0
10 0
mg 0
daily 0
loratadine 0
( 0
n 0
= 0
79 0
) 0
, 0
or 0
placebo 0
( 0
n 0
= 0
80 0
) 0
for 0
a 0
4-week 0
treatment 0
period 0
. 0

RESULTS 0
Mizolastine 0
and 0
loratadine 0
both 0
relieved B-PHYSICAL
symptoms I-PHYSICAL
of I-PHYSICAL
CIU I-PHYSICAL
. 0

After 0
2 0
weeks 0
' 0
treatment 0
, 0
the 0
severity 0
of 0
pruritus B-PHYSICAL
( I-PHYSICAL
visual I-PHYSICAL
analogue I-PHYSICAL
score 0
( B-PHYSICAL
VAS 0
) B-PHYSICAL
assessed I-PHYSICAL
by I-PHYSICAL
patients B-PHYSICAL
) I-PHYSICAL
decreased 0
significantly 0
in 0
both 0
the 0
mizolastine 0
and 0
loratadine 0
groups 0
compared 0
with 0
placebo 0
( 0
mizolastine 0
: 0
-36.7 0
mm 0
, 0
P 0
= 0
0.0001 0
; 0
loratadine 0
: 0
-29.8 0
, 0
P 0
= 0
0.0071 0
; 0
placebo 0
: 0
-16.3 0
) 0
; 0
this 0
improvement 0
with 0
both 0
active 0
treatments 0
was 0
maintained 0
throughout 0
the 0
treatment 0
period 0
, 0
the 0
difference 0
being 0
significant 0
only 0
for 0
the 0
mizolastine 0
group 0
( 0
P 0
= 0
0.0090 0
) 0
. 0

Both 0
active 0
treatments 0
were 0
also 0
associated 0
with 0
reduced 0
weekly 0
episodes B-PHYSICAL
of B-PHYSICAL
urticaria I-PHYSICAL
compared 0
with 0
placebo 0
, 0
which 0
was 0
significant 0
after 0
2 0
weeks 0
' 0
treatment 0
( 0
mizolastine 0
: 0
7.9 0
episodes 0
, 0
P 0
= 0
0.0061 0
; 0
loratadine 0
: 0
8.3 0
, 0
P 0
= 0
0.0221 0
; 0
placebo 0
: 0
13.3 0
) 0
. 0

Angioedema B-PHYSICAL
was 0
improved 0
to 0
a 0
clinically 0
significant 0
extent 0
with 0
mizolastine 0
, 0
and 0
loratadine 0
compared 0
with 0
placebo 0
in 0
those 0
patients 0
who 0
had 0
this 0
symptom 0
before 0
treatment 0
. 0

Overall B-OTHER
tolerability I-OTHER
of 0
both 0
treatments 0
was 0
similar 0
to 0
placebo 0
, 0
and 0
there 0
were 0
no 0
clinically 0
relevant 0
effects 0
on 0
cardiac B-PHYSICAL
repolarisation I-PHYSICAL
with 0
either 0
mizolastine 0
or 0
loratadine 0
. 0

CONCLUSION 0
Mizolastine 0
( 0
10 0
mg 0
daily 0
) 0
is 0
confirmed 0
as 0
an 0

An 0
assessment 0
of 0
beta-adrenoceptor 0
blockade 0
in 0
man 0
by 0
prizidilol 0
hydrochloride 0
. 0

1 0
Prizidilol 0
hydrochloride 0
( 0
SK 0
& 0
F 0
92657 0
) 0
is 0
a 0
new 0
compound 0
which 0
causes 0
both 0
arteriolar 0
dilatation 0
and 0
beta-adrenoceptor B-PHYSICAL
blockade I-PHYSICAL
. 0

The 0
effect 0
of 0
a 0
single 0
oral 0
dose 0
on 0
the 0
responses 0
of 0
heart 0
rate 0
and 0
blood 0
pressure 0
to 0
isoprenaline 0
infusion 0
has 0
been 0
studied 0
in 0
healthy 0
volunteers 0
. 0

2 0
Isoprenaline 0
heart B-PHYSICAL
rate I-PHYSICAL
dose-response I-PHYSICAL
curves I-PHYSICAL
showed 0
parallel 0
shifts 0
to 0
the 0
right 0
after 0
oral 0
prizidilol 0
, 0
indicating 0
antagonism 0
by 0
this 0
compound 0
at 0
beta-adrenoceptors 0
in 0
the 0
heart 0
. 0

3 0
Isoprenaline 0
dose-response 0
curves 0
for 0
decreases 0
in 0
diastolic B-PHYSICAL
blood I-PHYSICAL
pressure I-PHYSICAL
also 0
showed 0
shifts 0
to 0
the 0
right 0
after 0
oral 0
prizidilol 0
, 0
providing 0
evidence 0
of 0
beta-adrenoceptor 0
antagonism 0
by 0
this 0
drug 0
in 0
peripheral 0
resistance 0
vessels 0
. 0

4 0
The 0
peak 0
effect 0
of 0
a 0
40 0
mg 0
dose 0
of 0
propranolol 0
was 0
greater 0
than 0
that 0
of 0
a 0
200 0
mg 0
dose 0
of 0
prizidilol 0
but 0
both 0
drugs 0
caused 0
persistent 0
beta-adrenoceptor B-PHYSICAL
blockade I-PHYSICAL
for 0
at 0
least 0
7 0
h 0
after 0
ingestion 0
. 0

Evaluation 0
of 0
postural B-OTHER
stability I-OTHER
by 0
computerised 0
posturography 0
following 0
outpatient 0
paediatric 0
anaesthesia 0
. 0

Comparison 0
of 0
propofol/alfentanil/N2O 0
anaesthesia 0
with 0
thiopentone/halothane/N2O 0
anaesthesia 0
. 0

Simple 0
clinical 0
tests 0
, 0
like 0
Romberg 0
's 0
test 0
or 0
a 0
walking 0
test 0
, 0
have 0
proved 0
to 0
be 0
inadequate 0
guidelines 0
for 0
safe B-OTHER
discharge I-OTHER
after 0
outpatient 0
anaesthesia 0
. 0

A 0
randomised 0
study 0
was 0
therefore 0
planned 0
to 0
compare 0
postural 0
stability 0
measured 0
by 0
computerised 0
posturography 0
in 0
31 0
oral 0
midazolam-atropine 0
premedicated 0
children 0
aged 0
6.9 0
( 0
s.e 0
. 0

0.4 0
) 0
years 0
who 0
had 0
been 0
anaesthetised 0
with 0
either 0
propofol/alfentanil/N2O 0
or 0
thiopentone/halothane/N2O 0
. 0

The 0
sway B-MENTAL
velocity I-MENTAL
of 0
the 0
children 0
was 0
measured 0
before 0
premedication 0
and 0
1 0
, 0
2 0
and 0
3 0
h 0
after 0
the 0
end 0
of 0
anaesthesia 0
. 0

Results 0
show 0
that 0
sway B-MENTAL
velocity I-MENTAL
had 0
returned 0
to 0
baseline 0
values 0
3 0
h 0
after 0
the 0
end 0
of 0
anaesthesia 0
in 0
all 0
children 0
who 0
had 0
received 0
propofol/alfentanil/N2O 0
and 0
in 0
12 0
of 0
the 0
15 0
children 0
who 0
had 0
received 0
thiopentone/halothane/N2O 0
. 0

The 0
quantified 0
version 0
of 0
the 0
Romberg B-OTHER
test I-OTHER
performed 0
with 0
eyes 0
open 0
or 0
closed 0
was 0
not 0
impaired 0
after 0
anaesthesia 0
, 0
compared 0
with 0
the 0
control 0
values 0
, 0
indicating 0
that 0
in 0
children 0
poor 0
equilibrium 0
is 0
not 0
compensated 0
by 0
vision 0
. 0

The 0
clinical 0
recovery 0
with 0
respect 0
to 0
the 0
times 0
to 0
eye B-PHYSICAL
opening I-PHYSICAL
, 0
to 0
responding 0
to 0
command 0
or 0
to 0
being 0
fully 0
awake 0
did 0
not 0
differ 0
between 0
the 0
two 0
anaesthesia 0
methods 0
. 0

On 0
the 0
basis 0
of 0
recovery 0
assessed 0
by 0
postural 0
stability 0
, 0
propofol/alfentanil/N2O 0
anaesthesia 0
was 0
not 0
preferable 0
to 0
thiopentone/halothane/N2O 0
anaesthesia 0
after 0
minor 0
paediatric 0
otolaryngological 0
surgery 0
. 0

Insular 0
and 0
anterior 0
cingulate 0
circuits 0
in 0
smokers 0
with 0
schizophrenia 0
. 0

Schizophrenia 0
( 0
SZ 0
) 0
is 0
associated 0
with 0
high 0
rates 0
of 0
smoking 0
. 0

We 0
previously 0
found 0
that 0
resting 0
state 0
functional 0
connectivity 0
( 0
rsFC 0
) 0
between 0
the 0
dorsal 0
anterior 0
cingulate 0
( 0
dACC 0
) 0
and 0
striatum 0
is 0
independently 0
associated 0
with 0
nicotine 0
addiction 0
and 0
psychiatric 0
illness 0
. 0

Since 0
the 0
insula 0
is 0
implicated 0
in 0
nicotine 0
dependence 0
, 0
we 0
hypothesized 0
that 0
SZ 0
smokers 0
will 0
have 0
greater 0
dysfunction 0
in 0
smoking-related 0
insular 0
and 0
dACC 0
circuits 0
than 0
normal 0
control 0
smokers 0
( 0
NC 0
) 0
independent 0
of 0
smoking 0
severity 0
, 0
consistent 0
with 0
an 0
inherent 0
disease-related 0
weakening 0
of 0
smoking-related 0
circuits 0
. 0

Nicotine 0
challenge 0
was 0
used 0
to 0
demonstrate 0
that 0
decreased 0
rsFC 0
in 0
identified 0
circuits 0
reflects 0
addiction 0
trait 0
and 0
is 0
not 0
affected 0
by 0
pharmacological 0
state 0
. 0

Twenty-four 0
NC 0
smokers 0
and 0
20 0
smokers 0
with 0
SZ 0
matched 0
on 0
nicotine 0
addiction 0
severity 0
participated 0
in 0
a 0
resting 0
state 0
fMRI 0
study 0
and 0
were 0
scanned 0
during 0
two 0
separate 0
sessions 0
while 0
receiving 0
a 0
placebo 0
or 0
nicotine 0
patch 0
, 0
in 0
a 0
randomized 0
, 0
cross-over 0
design 0
. 0

Using 0
individualized 0
, 0
anatomically 0
defined 0
anterior 0
and 0
posterior 0
insula 0
and 0
dACC 0
as 0
regions 0
of 0
interest 0
( 0
ROI 0
) 0
, 0
whole 0
brain 0
rsFC 0
was 0
performed 0
using 0
each 0
ROI 0
as 0
a 0
seed 0
. 0

Significant 0
negative 0
correlations 0
between 0
smoking B-MENTAL
severity I-MENTAL
and 0
rsFC B-PHYSICAL
between I-PHYSICAL
insula I-PHYSICAL
, 0
dACC 0
and 0
striatum 0
were 0
found 0
for 0
both 0
groups 0
. 0

Furthermore 0
, 0
smokers 0
with 0
SZ 0
demonstrated 0
additive 0
reductions 0
in 0
circuit 0
strength 0
between 0
the 0
dACC 0
and 0
insula 0
compared 0
to 0
NC 0
smokers 0
independent 0
of 0
smoking 0
severity 0
. 0

Nicotine B-OTHER
challenge I-OTHER
did 0
not 0
significantly 0
alter B-PHYSICAL
rsFC I-PHYSICAL
in I-PHYSICAL
insula-dACC-striatal I-PHYSICAL
circuits I-PHYSICAL
. 0

Reduced 0
rsFC B-PHYSICAL
strength I-PHYSICAL
between 0
the 0
insula 0
, 0
dACC 0
and 0
striatum 0
is 0
associated 0
with 0
nicotine 0
addiction 0
severity 0
in 0
both 0
non-psychiatrically 0
ill 0
and 0
in 0
SZ 0
smokers 0
. 0

Decreased 0
insula-dACC 0
rsFC 0
may 0
index 0
overlapping 0
circuitry 0
associated 0
with 0
smoking 0
and 0
SZ 0
. 0

Pharmacokinetics 0
and 0
pharmacodynamics 0
of 0
six 0
epoetin 0
alfa 0
dosing 0
regimens 0
in 0
anemic 0
critically 0
ill 0
patients 0
without 0
acute 0
blood 0
loss 0
. 0

OBJECTIVE 0
To 0
describe 0
the 0
pharmacokinetic 0
profiles 0
of 0
six 0
different 0
dosing 0
regimens 0
for 0
epoetin 0
alfa 0
, 0
and 0
whether 0
more 0
rapid 0
and 0
robust 0
reticulocytosis 0
can 0
be 0
elicited 0
with 0
more 0
frequent 0
administration 0
of 0
epoetin 0
alfa 0
in 0
anemic 0
critically 0
ill 0
patients 0
. 0

DESIGN 0
Randomized 0
, 0
open-label 0
, 0
multicenter 0
, 0
28-day 0
clinical 0
trial 0
. 0

SETTING 0
Ten 0
centers 0
in 0
the 0
United 0
States 0
. 0

PATIENTS 0
Adult 0
( 0
age 0
> 0
or=18 0
years 0
) 0
critically 0
ill 0
patients 0
with 0
hemoglobin 0
< 0
or=12 0
g/dL 0
, 0
expected 0
hospitalization 0
of 0
> 0
or=7 0
days 0
, 0
with 0
no 0
ongoing 0
acute 0
blood 0
loss 0
. 0

INTERVENTIONS 0
One 0
of 0
six 0
dosing 0
epoetin 0
alfa 0
regimens 0
for 0
15 0
days 0
, 0
as 0
follows 0
: 0
40,000 0
IU 0
once 0
weekly 0
, 0
subcutaneously 0
( 0
group 0
A 0
) 0
or 0
intravenously 0
( 0
IV 0
) 0
( 0
group 0
B 0
) 0
; 0
15,000 0
IU 0
every 0
other 0
day 0
, 0
subcutaneously 0
( 0
group 0
C 0
) 0
or 0
IV 0
( 0
group 0
D 0
) 0
; 0
or 0
40,000 0
IU 0
day 0
1 0
and 0
3 0
, 0
subcutaneously 0
( 0
group 0
E 0
) 0
or 0
IV 0
( 0
group 0
F 0
) 0
, 0
followed 0
by 0
15,000 0
IU 0
once 0
every 0
other 0
day 0
on 0
[ 0
corrected 0
] 0
days 0
5-15 0
[ 0
corrected 0
] 0
MEASUREMENTS 0
Serum B-PHYSICAL
erythropoietin I-PHYSICAL
concentration I-PHYSICAL
, 0
absolute B-PHYSICAL
reticulocyte I-PHYSICAL
count I-PHYSICAL
, 0
and 0
adverse B-ADVERSE-EFFECTS
events I-ADVERSE-EFFECTS
. 0

MAIN 0
RESULTS 0
Of 0
the 0
60 0
patients 0
who 0
were 0
enrolled 0
( 0
60 0
% 0
men 0
, 0
mean 0
age 0
53 0
years 0
, 0
mean 0
Acute 0
Physiology 0
and 0
Chronic 0
Health 0
Evaluation 0
II 0
score 0
, 0
19.5 0
) 0
, 0
30 0
were 0
evaluable 0
for 0
both 0
pharmacokinetics 0
and 0
pharmacodynamics 0
( 0
50 0
% 0
) 0
. 0

Erythropoietin B-PHYSICAL
exposure I-PHYSICAL
was 0
approximately 0
ten 0
times 0
greater 0
for 0
IV 0
dosing 0
than 0
for 0
subcutaneous 0
dosing 0
. 0

Mean 0
absolute B-PHYSICAL
reticulocyte I-PHYSICAL
count I-PHYSICAL
peaked 0
at 0
day 0
11 0
or 0
15 0
in 0
each 0
group 0
and 0
appeared 0
to 0
be 0
greater 0
for 0
subcutaneous 0
dosing 0
( 0
mean 0
peak 0
response 0
149-169 0
x 0
10 0
( 0
9 0
) 0
/L 0
) 0
compared 0
with 0
IV 0
dosing 0
( 0
mean 0
peak 0
response 0
138-147 0
x 0
10 0
( 0
9 0
) 0
/L 0
) 0
at 0
most 0
visits 0
. 0

The 0
most 0
frequently 0
reported 0
adverse B-ADVERSE-EFFECTS
events I-ADVERSE-EFFECTS
were 0
pyrexia B-ADVERSE-EFFECTS
( 0
18 0
% 0
) 0
, 0
hypokalemia B-ADVERSE-EFFECTS
( 0
15 0
% 0
) 0
, 0
and 0
hypophosphatemia B-ADVERSE-EFFECTS
( 0
15 0
% 0
) 0
. 0

CONCLUSIONS 0
In 0
this 0
study 0
of 0
anemic 0
critically 0
ill 0
patients 0
treated 0
with 0
epoetin 0
alfa 0
, 0
all 0
dosing 0
regimens 0
were 0
well 0
tolerated B-OTHER
and 0
appeared 0
to 0
effect 0
reticulocytosis B-PHYSICAL
, 0
with 0
a 0
peak 0
at 0
day 0
11 0
or 0
15 0
in 0
most 0
patients 0
. 0

The 0
pharmacokinetics 0
of 0
epoetin 0
alfa 0
did 0
not 0
predict 0
pharmacodynamic B-PHYSICAL
response I-PHYSICAL
in 0
anemic 0
critically 0
ill 0
patients 0
. 0

Combination 0
therapy 0
with 0
methotrexate 0
and 0
hydroxychloroquine 0
for 0
rheumatoid 0
arthritis 0
increases 0
exposure 0
to 0
methotrexate 0
. 0

OBJECTIVE 0
To 0
examine 0
the 0
bioavailability 0
of 0
methotrexate 0
( 0
MTX 0
) 0
in 0
the 0
presence 0
of 0
hydroxychloroquine 0
( 0
HCQ 0
) 0
, 0
and 0
vice 0
versa 0
, 0
to 0
determine 0
a 0
possible 0
pharmacokinetic 0
explanation 0
for 0
the 0
observation 0
that 0
combination 0
treatment 0
of 0
rheumatoid 0
arthritis 0
with 0
MTX 0
and 0
HCQ 0
has 0
been 0
shown 0
, 0
clinically 0
, 0
to 0
be 0
more 0
potent 0
than 0
MTX 0
used 0
alone 0
. 0

METHODS 0
In 0
a 0
randomized 0
crossover 0
study 0
, 0
10 0
healthy 0
subjects 0
received 0
, 0
on 0
each 0
of 0
5 0
dosing 0
occasions 0
, 0
MTX 0
alone 0
as 0
tablets 0
or 0
intravenous 0
solution 0
, 0
HCQ 0
alone 0
as 0
a 0
tablet 0
or 0
oral 0
solution 0
, 0
or 0
a 0
coadministered 0
dose 0
of 0
MTX 0
tablets 0
with 0
an 0
HCQ 0
tablet 0
. 0

The 0
area 0
under 0
the 0
concentration-time B-OTHER
curve 0
( B-OTHER
AUC I-OTHER
) B-OTHER
was 0
determined 0
for 0
each 0
subject 0
, 0
on 0
each 0
dosing 0
occasion 0
, 0
for 0
each 0
compound 0
. 0

RESULTS 0
The 0
mean 0
AUC B-OTHER
for I-OTHER
MTX I-OTHER
was 0
increased 0
( 0
p 0
= 0
0.005 0
) 0
and 0
the 0
maximum B-OTHER
MTX I-OTHER
concentration 0
( B-OTHER
Cmax I-OTHER
) I-OTHER
decreased 0
( 0
p 0
= 0
0.025 0
) 0
when 0
MTX 0
was 0
coadministered 0
with 0
HCQ 0
, 0
compared 0
to 0
MTX 0
administered 0
alone 0
. 0

The 0

Comparing 0
microvascular B-PHYSICAL
alterations I-PHYSICAL
during 0
minimal 0
extracorporeal 0
circulation 0
and 0
conventional 0
cardiopulmonary 0
bypass 0
in 0
coronary 0
artery 0
bypass 0
graft 0
surgery 0
: 0
a 0
prospective 0
, 0
randomized 0
study 0
. 0

OBJECTIVES 0
Minimal 0
extracorporeal 0
circulation 0
( 0
MECC 0
) 0
has 0
been 0
introduced 0
in 0
coronary 0
artery 0
bypass 0
graft 0
( 0
CABG 0
) 0
surgery 0
, 0
offering 0
clinical 0
benefits 0
owing 0
to 0
reduced 0
hemodilution 0
and 0
no 0
blood-air 0
interface 0
. 0

Yet 0
, 0
the 0
effects 0
of 0
MECC 0
on 0
the 0
intraoperative 0
microvascular 0
perfusion 0
in 0
comparison 0
with 0
conventional 0
extracorporeal 0
circulation 0
( 0
CECC 0
) 0
have 0
not 0
been 0
studied 0
so 0
far 0
. 0

METHODS 0
The 0
current 0
study 0
aimed 0
to 0
analyze 0
alterations 0
in 0
microvascular B-PHYSICAL
perfusion I-PHYSICAL
at 0
4 0
predefined 0
time 0
points 0
( 0
T1-T4 0
) 0
during 0
on-pump 0
CABG 0
using 0
orthogonal 0
polarization 0
spectral 0
imaging 0
. 0

Forty 0
patients 0
were 0
randomized 0
for 0
being 0
operated 0
on 0
with 0
either 0
MECC 0
or 0
CECC 0
. 0

Changes 0
in 0
functional B-PHYSICAL
capillary I-PHYSICAL
density I-PHYSICAL
( I-PHYSICAL
FCD I-PHYSICAL
) I-PHYSICAL
, 0
blood B-PHYSICAL
flow I-PHYSICAL
velocity I-PHYSICAL
, 0
and 0
vessel B-PHYSICAL
diameter I-PHYSICAL
were 0
analyzed 0
by 0
a 0
blinded 0
investigator 0
. 0

RESULTS 0
After 0
start 0
of 0
extracorporeal 0
circulation 0
( 0
ECC 0
) 0
and 0
aortic 0
crossclamping 0
( 0
T2 0
) 0
, 0
both 0
groups 0
showed 0
a 0
significant 0
drop 0
of 0
FCD B-PHYSICAL
, 0
with 0
a 0
significantly 0
higher 0
FCD B-PHYSICAL
in 0
the 0
MECC 0
group 0
( 0
206.8 0
? 0

33.6 0
cm/cm? 0
in 0
CECC 0
group 0
versus 0
217.8 0
? 0

35.3 0
cm/cm? 0
in 0
MECC 0
group 0
; 0
P 0
= 0
.034 0
) 0
. 0

In 0
the 0
late 0
phase 0
of 0
the 0
ECC 0
( 0
T3 0
) 0
, 0
FCD 0
in 0
the 0
MECC 0
group 0
was 0
already 0
recovered 0
, 0
whereas 0
FCD 0
in 0
the 0
CECC 0
group 0
was 0
still 0
significantly 0
depressed 0
( 0
223.1 0
? 0

35.6 0
cm/cm? 0
in 0
MECC 0
group 0
; 0
P 0
= 0
.100 0
vs 0
T1 0
; 0
211.1 0
? 0

36.9 0
cm/cm? 0
in 0
CECC 0
group 0
; 0
P 0
= 0
.017 0
vs 0
T1 0
) 0
. 0

After 0
termination 0
of 0
ECC 0
( 0
T4 0
) 0
, 0
FCD 0
recovered 0
in 0
both 0
groups 0
to 0
baseline 0
. 0

Blood 0
flow 0
velocity 0
tended 0
to 0
be 0
higher 0
in 0
the 0
MECC 0
group 0
, 0
with 0
a 0
significant 0
intergroup 0
difference 0
after 0
aortic 0
crossclamping 0
( 0
T2 0
) 0
. 0

CONCLUSIONS 0
Orthogonal 0
polarization 0
spectral 0
imaging 0
data 0
reveal 0
an 0
impairment 0
of 0
microvascular 0
perfusion 0
during 0
on-pump 0
CABG 0
. 0

Changes 0
in 0
FCD 0
indicate 0
a 0
faster 0
recovery 0
of 0
the 0
microvascular 0
perfusion 0
in 0
MECC 0
during 0
the 0
reperfusion 0
period 0
. 0

Beneficial 0
recovery 0
of 0
microvascular 0
organ 0
perfusion 0
could 0
partly 0
explain 0
the 0
perioperative 0
advantages 0
reported 0
for 0
MECC 0
. 0

Chlorthalidone 0
does 0
not 0
increase 0
the 0
hypotensive B-PHYSICAL
effect 0
of 0
nifedipine 0
in 0
essential 0
hypertensives 0
: 0
a 0
crossover 0
multicentre 0
study 0
. 0

To 0
determine 0
whether 0
the 0
combination 0
of 0
nifedipine 0
+ 0
chlorthalidone 0
exerts 0
an 0
additive B-PHYSICAL
antihypertensive I-PHYSICAL
effect 0
when 0
compared 0
with 0
single-drug 0
treatment 0
, 0
we 0
studied 0
66 0
uncomplicated 0
essential 0
hypertensives 0
, 0
with 0
diastolic 0
blood 0
pressure 0
of 0
greater 0
than 0
100 0
and 0
less 0
than 0
115 0
mmHg 0
. 0

At 0
the 0
end 0
of 0
a 0
1-month 0
washout 0
placebo 0
period 0
, 0
using 0
a 0
double-blind 0
crossover 0
design 0
, 0
the 0
patients 0
were 0
randomly 0
allocated 0
to 0
nifedipine 0
( 0
20 0
mg 0
twice 0
a 0
day 0
) 0
, 0
chlorthalidone 0
( 0
25 0
mg 0
once 0
a 0
day 0
) 0
, 0
the 0
two 0
drugs 0
combined 0
at 0
the 0
same 0
doses 0
and 0
the 0
corresponding 0
placebo 0
. 0

Compared 0
with 0
the 0
randomly 0
allocated 0
placebo 0
, 0
the 0
three 0
active 0
treatments 0
significantly 0
reduced 0
blood B-PHYSICAL
pressure I-PHYSICAL
without 0
changing 0
the 0
heart B-PHYSICAL
rate I-PHYSICAL
or 0
body B-PHYSICAL
weight 0
. 0

Both 0
the 0
absolute 0
and 0
percentage 0
decreases 0
in 0
mean 0
blood B-PHYSICAL
pressure I-PHYSICAL
induced 0
by 0
nifedipine 0
and 0
the 0
combination 0
compared 0
with 0
placebo 0
were 0
similar 0
and 0
significantly 0
greater 0
than 0
those 0
induced 0
by 0
chlorthalidone 0
. 0

Taken 0
together 0
, 0
these 0
data 0
show 0
that 0
the 0
combination 0
of 0
nifedipine 0
+ 0
chlorthalidone 0
does 0
not 0
exert 0
any 0
additive B-PHYSICAL
antihypertensive I-PHYSICAL
effect 0
compared 0
with 0
nifedipine 0
alone 0
. 0

This 0
finding 0
indicates 0
that 0
the 0
combination 0
of 0
a 0
dihydropyridine 0
calcium 0
antagonist 0
+ 0
a 0
thiazide 0
diuretic 0
is 0
probably 0
devoid 0
of 0
any 0
particular 0
clinical B-PHYSICAL
significance I-PHYSICAL
in 0
the 0
treatment 0
of 0
uncomplicated 0
essential 0
hypertensives 0
. 0

A 0
drug 0
interaction 0
study 0
between 0
ticlopidine 0
and 0
cyclosporin 0
in 0
heart 0
transplant 0
recipients 0
. 0

OBJECTIVES 0
Previous 0
uncontrolled 0
studies 0
have 0
suggested 0
an 0
interaction 0
between 0
ticlopidine 0
, 0
a 0
major 0
antiplatelet 0
agent 0
, 0
and 0
cyclosporin 0
in 0
heart- 0
and 0
kidney-transplant 0
recipients 0
. 0

The 0
aims 0
of 0
this 0
study 0
were 0
to 0
examine 0
in 0
a 0
randomised 0
, 0
double-blind 0
fashion 0
, 0
the 0
possible 0
interaction 0
between 0
cyclosporin 0
A 0
and 0
ticlopidine 0
( 0
250 0
mg 0
per 0
day 0
) 0
and 0
the 0
tolerability 0
of 0
this 0
combination 0
in 0
heart-transplant 0
recipients 0
. 0

METHODS 0
Twenty 0
heart-transplant 0
recipients 0
were 0
randomised 0
into 0
either 0
a 0
treated 0
or 0
a 0
placebo 0
group 0
. 0

Blood 0
samples 0
were 0
drawn 0
for 0
time-course 0
evaluation 0
of 0
cyclosporin 0
blood 0
levels 0
over 0
a 0
period 0
of 0
12 0
h 0
, 0
following 0
the 0
morning 0
intake 0
of 0
cyclosporin 0
and 0
, 0
for 0
platelet 0
aggregation 0
studies 0
, 0
before 0
and 0
after 0
14 0
days 0
of 0
ticlopidine 0
administration 0
. 0

Twenty 0
four-hour 0
urine 0
samples 0
were 0
collected 0
for 0
6-beta-hydroxycortisol 0
measurements 0
, 0
before 0
and 0
after 0
14 0
days 0
of 0
ticlopidine 0
. 0

RESULTS 0
Although 0
given 0
at 0
half 0
the 0
recommended 0
daily 0
dosage 0
, 0
ticlopidine 0
significantly 0
reduced 0
platelet B-PHYSICAL
aggregation 0
. 0

Pharmacokinetic 0
parameters 0
indicate 0
that 0
the 0
bioavailability B-OTHER
of I-OTHER
cyclosporin I-OTHER
A 0
was 0
not 0
significantly 0
modified 0
by 0
ticlopidine 0
. 0

However 0
, 0
one 0
patient 0
in 0
the 0
ticlopidine 0
group 0
was 0
withdrawn 0
because 0
of 0
a 0
major 0
fall B-OTHER
in I-OTHER
cyclosporin I-OTHER
blood I-OTHER
level I-OTHER
within 0
3 0
days 0
of 0
treatment 0
. 0

Urinary B-PHYSICAL
excretion I-PHYSICAL
of I-PHYSICAL
6-beta-hydroxycortisol I-PHYSICAL
was 0
augmented 0
after 0
treatment 0
in 0
the 0
ticlopidine 0
group 0
compared 0
with 0
the 0
placebo 0
group 0
, 0
suggesting 0
that 0
induction 0
of 0
drug 0
metabolism 0
might 0
have 0
occurred 0
. 0

Data 0
also 0
show 0
quite 0
a 0
large 0
intra-individual 0
variability 0
in 0
cyclosporin B-PHYSICAL
bioavailability I-PHYSICAL
in 0
the 0
placebo 0
group 0
, 0
suggesting 0
that 0
poor 0
absorption 0
of 0
the 0
drug 0
formulation 0
and/or 0
poor 0
compliance 0
might 0
have 0
contributed 0
to 0
the 0
decreased 0
cyclosporin B-PHYSICAL
blood I-PHYSICAL
levels I-PHYSICAL
in 0
the 0
patient 0
withdrawn 0
from 0
this 0
study 0
and 0
in 0
previous 0
uncontrolled 0
studies 0
. 0

CONCLUSION 0
Cyclosporin 0
bioavailability 0
was 0
not 0
clearly 0
modified 0
by 0
a 0
half 0
dosage 0
of 0
ticlopidine 0
in 0
this 0
study 0
. 0

We 0
, 0
however 0
, 0
recommend 0
closely 0
monitoring 0
cyclosporin 0
blood 0
levels 0
when 0
prescribing 0
ticlopidine 0
. 0

Further 0
studies 0
will 0
be 0
needed 0
with 0
new 0
formulations 0
of 0
cyclosporin 0
or 0
when 0
using 0
the 0
full 0
dosage 0
of 0
ticlopidine 0
. 0

Improving 0
the 0
immunogenicity B-PHYSICAL
of 0
pneumococcal 0
conjugate 0
vaccine 0
in 0
HIV-infected 0
adults 0
with 0
a 0
toll-like 0
receptor 0
9 0
agonist 0
adjuvant 0
: 0
a 0
randomized 0
, 0
controlled 0
trial 0
. 0

BACKGROUND 0
Persons 0
infected 0
with 0
human 0
immunodeficiency 0
virus 0
( 0
HIV 0
) 0
are 0
often 0
hyporesponsive 0
to 0
immunization 0
, 0
including 0
pneumococcal 0
vaccines 0
. 0

We 0
hypothesized 0
that 0
adding 0
CPG 0
7909 0
, 0
a 0
toll-like 0
receptor 0
9 0
( 0
TLR9 0
) 0
agonist 0
and 0
vaccine 0
adjuvant 0
, 0
to 0
7-valent 0
pneumococcal 0
conjugate 0
vaccine 0
( 0
7vPnC 0
) 0
would 0
increase 0
its 0
immunogenicity 0
in 0
HIV-infected 0
adults 0
. 0

METHODS 0
We 0
performed 0
a 0
double-blind 0
, 0
placebo-controlled 0
, 0
phase 0
1b/2a 0
trial 0
randomizing 0
HIV-positive 0
patients 0
to 0
receive 0
double 0
doses 0
of 0
7vPnC 0
( 0
Prevnar 0
) 0
at 0
0 0
and 0
3 0
months 0
and 0
1 0
dose 0
of 0
23-valent 0
pneumococcal 0
polysaccharide 0
vaccine 0
( 0
PPV-23 0
; 0
Pneumo 0
Novum 0
) 0
at 0
9 0
months 0
, 0
with 0
experimental 0
patients 0
receiving 0
1 0
mg 0
of 0
CPG 0
7909 0
added 0
to 0
each 0
of 0
their 0
3 0
vaccine 0
doses 0
; 0
control 0
patients 0
had 0
phosphate-buffered 0
saline 0
added 0
instead 0
. 0

Immunogenicity B-PHYSICAL
and 0
safety B-PHYSICAL
were 0
evaluated 0
for 0
up 0
to 0
10 0
months 0
. 0

The 0
primary 0
end 0
point 0
was 0
the 0
proportion 0
of 0
vaccine B-PHYSICAL
high I-PHYSICAL
responders I-PHYSICAL
at I-PHYSICAL
9 I-PHYSICAL
months I-PHYSICAL
, 0
defined 0
as 0
a 0
2-fold 0
increase 0
in 0
IgG 0
levels 0
to 0
> 0
or 0
= 0
1 0
microg/mL 0
for 0
at 0
least 0
5 0
of 0
7 0
of 0
the 0
7vPnC 0
serotypes 0
. 0

RESULTS 0
Ninety-seven 0
participants 0
were 0
included 0
in 0
the 0
study 0
. 0

The 0
proportion 0
of 0
vaccine B-PHYSICAL
high I-PHYSICAL
responders I-PHYSICAL
was 0
higher 0
in 0
the 0
experimental 0
group 0
( 0
n 0
= 0
48 0
) 0
than 0
among 0
controls 0
( 0
n 0
= 0
49 0
; 0
48.8 0
% 0
vs 0
25.0 0
% 0
; 0
P 0
= 0
.02 0
) 0
at 0
9 0
months 0
. 0

Greater 0
proportions 0
of 0
high B-PHYSICAL
responders I-PHYSICAL
were 0
also 0
observed 0
at 0
3 0
( 0
51.1 0
% 0
vs 0
39.6 0
% 0
; 0
P 0
= 0
.26 0
) 0
, 0
4 0
( 0
77.3 0
% 0
vs 0
56.3 0
% 0
; 0
P 0
= 0
.03 0
) 0
, 0
and 0
10 0
months 0
( 0
87.8 0
% 0
vs 0
51.1 0
% 0
; 0
P 0
< 0
.001 0
) 0
. 0

Mild B-PHYSICAL
systemic I-PHYSICAL
and I-PHYSICAL
injection I-PHYSICAL
site I-PHYSICAL
reactions I-PHYSICAL
to 0
7vPnC 0
were 0
more 0
common 0
in 0
the 0
experimental 0
group 0
than 0
the 0
control 0
group 0
( 0
100 0
% 0
vs 0
81.3 0
% 0
; 0
P 0
= 0
.002 0
) 0
. 0

CPG 0
7909 0
did 0
not 0
increase 0
non-7vPnC B-PHYSICAL
IgG I-PHYSICAL
levels I-PHYSICAL
after 0
PPV-23 0
immunization 0
. 0

No 0
adverse 0
effects 0
on 0
CD4 B-PHYSICAL
( I-PHYSICAL
+ I-PHYSICAL
) I-PHYSICAL
cell I-PHYSICAL
count I-PHYSICAL
or 0
organ B-PHYSICAL
functions I-PHYSICAL
occurred 0
in 0
either 0
group 0
. 0

CONCLUSIONS 0
The 0
addition 0
of 0
a 0
TLR9 0
agonist 0
to 0
7vPnC 0
significantly 0
enhanced 0
the 0
proportion 0
of 0
vaccine B-PHYSICAL
high I-PHYSICAL
responders I-PHYSICAL
. 0

TRIAL 0
REGISTRATION 0
ClinicalTrials.gov 0
identifier 0
: 0
NCT00562939 0
. 0

Intravenous 0
aflibercept 0
administered 0
in 0
combination 0
with 0
irinotecan 0
, 0
5-fluorouracil 0
and 0
leucovorin 0
in 0
patients 0
with 0
advanced 0
solid 0
tumours 0
: 0
results 0
from 0
the 0
expansion 0
cohort 0
of 0
a 0
phase 0
I 0
study 0
. 0

BACKGROUND 0
Following 0
the 0
dose-escalation 0
stage 0
, 0
this 0
double-blind 0
expansion 0
stage 0
of 0
the 0
phase 0
I 0
study 0
evaluated 0
the 0
safety 0
, 0
pharmacodynamics 0
, 0
pharmacokinetics 0
, 0
anti-vascular 0
effects 0
and 0
antitumour 0
activity 0
of 0
aflibercept 0
4 0
mg/kg 0
with 0
irinotecan 0
, 0
5-fluorouracil 0
and 0
leucovorin 0
( 0
LV5FU2 0
) 0
. 0

PATIENTS 0
AND 0
METHODS 0
Patients 0
with 0
advanced 0
solid 0
tumours 0
were 0
randomised 0
at 0
cycle-1 0
to 0
placebo 0
or 0
aflibercept 0
( 0
4 0
mg/kg 0
) 0
on 0
day 0
1 0
then 0
irinotecan-LV5FU2 0
on 0
days 0
1 0
and 0
2 0
. 0

Subsequently 0
, 0
all 0
patients 0
received 0
aflibercept 0
with 0
irinotecan-LV5FU2 0
every 0
2 0
weeks 0
. 0

Anti-vascular 0
effects 0
were 0
assessed 0
using 0
dynamic 0
contrast-enhanced 0
magnetic 0
resonance 0
imaging 0
( 0
DCE-MRI 0
) 0
. 0

RESULTS 0
Twenty-seven 0
patients 0
were 0
treated 0
; 0
14 0
received 0
placebo 0
in 0
cycle-1 0
followed 0
by 0
aflibercept 0
in 0
later 0
cycles 0
and 0
13 0
received 0
aflibercept 0
4 0
mg/kg 0
upfront 0
. 0

The 0
median 0
number 0
of 0
aflibercept B-PHYSICAL
cycles I-PHYSICAL
was 0
16 0
( 0
range 0
1-44 0
) 0
, 0
12 0
patients 0
received 0
?20 0
cycles 0
. 0

Most 0
frequent 0
grade 0
3/4 0
adverse 0
events 0
were 0
neutropenia 0
( 0
37 0
% 0
) 0
, 0
fatigue 0
( 0
33 0
% 0
) 0
and 0
hypertension 0
( 0
30 0
% 0
) 0
. 0

No 0
anti-aflibercept 0
antibodies 0
were 0
detected 0
. 0

Four 0
patients 0
achieved 0
partial 0
responses 0
and 0
17 0
had 0
stable 0
disease 0
, 0
lasting 0
> 0
3 0
months 0
in 0
14 0
patients 0
. 0

Plasma 0
levels 0
of 0
free 0
over 0
vascular 0
endothelial 0
growth 0
factor-bound 0
aflibercept 0
were 0
adequate 0
, 0
with 0
steady-state 0
achieved 0
from 0
cycle-3 0
. 0

Exploratory 0
DCE-MRI 0
showed 0
no 0
significant 0
perfusion 0
changes 0
with 0
aflibercept 0
. 0

CONCLUSION 0
Aflibercept 0
4 0
mg/kg 0
plus 0
irinotecan-LV5FU2 0
every 0
2 0
weeks 0
had 0
acceptable 0
toxicity 0
and 0
pharmacokinetics 0
, 0
and 0
showed 0
promising 0
antitumour 0
activity 0
. 0

Effects 0
of 0
maternal 0
glucose 0
infusion 0
on 0
fetal 0
acid-base 0
status 0
in 0
human 0
pregnancy 0
. 0

The 0
maternal 0
and 0
fetal 0
metabolic 0
effects 0
of 0
three 0
commonly 0
used 0
intravenous 0
fluids 0
administered 0
before 0
regional 0
anesthesia 0
were 0
studied 0
in 0
32 0
gravid 0
women 0
undergoing 0
elective 0
cesarean 0
section 0
at 0
term 0
. 0

Patients 0
were 0
randomized 0
into 0
one 0
of 0
three 0
groups 0
to 0
receive 0
1 0
L 0
of 0
either 0
5 0
% 0
dextrose 0
( 0
50 0
gm 0
of 0
glucose 0
) 0
or 0
Ringer 0
's 0
lactate 0
or 0
isotonic 0
saline 0
solution 0
before 0
epidural 0
anesthesia 0
. 0

Acute B-PHYSICAL
glucose I-PHYSICAL
infusion I-PHYSICAL
resulted 0
in 0
maternal B-ADVERSE-EFFECTS
hyperglycemia I-ADVERSE-EFFECTS
, 0
hyperinsulinemia B-PHYSICAL
, 0
and 0
an 0
increase 0
in 0
the B-PHYSICAL
blood I-PHYSICAL
lactate I-PHYSICAL
level I-PHYSICAL
. 0

Cord 0
blood 0
glucose 0
, 0
insulin 0
, 0
and 0
lactate 0
levels 0
were 0
also 0
increased 0
in 0
this 0
group 0
. 0

The 0
key 0
finding 0
of 0
this 0
study 0
was 0
the 0
significant B-PHYSICAL
lowering I-PHYSICAL
of I-PHYSICAL
pH I-PHYSICAL
in I-PHYSICAL
the I-PHYSICAL
umbilical I-PHYSICAL
cord I-PHYSICAL
vein I-PHYSICAL
( 0
7.31 0
+/- 0
0.04 0
) 0
and 0
artery B-PHYSICAL
( 0
7.21 0
+/- 0
0.06 0
) 0
in 0
the 0
glucose-infused 0
group 0
when 0
compared 0
with 0
the 0
non-glucose B-PHYSICAL
infusion I-PHYSICAL
groups 0
( 0
p 0
less 0
than 0
0.05 0
) 0
. 0

Confounding 0
perinatal 0
factors 0
such 0
as 0
maternal B-PHYSICAL
position 0
, 0
maternal B-PHYSICAL
hypotension I-PHYSICAL
, 0
and 0
prolonged 0
time 0
of 0
surgery 0
did 0
not 0
influence 0
the 0
fetal 0
acid-base 0
status 0
. 0

Thus 0
acute 0
maternal B-PHYSICAL
glucose I-PHYSICAL
infusion I-PHYSICAL
in 0
normal 0
patients 0
can 0
cause 0
fetal B-PHYSICAL
hyperglycemia I-PHYSICAL
, 0
metabolic B-PHYSICAL
acidosis I-PHYSICAL
, 0
and 0
neonatal B-PHYSICAL
hypoglycemia I-PHYSICAL
. 0

These 0
findings 0
may 0
be 0
of 0
particular 0
clinical 0
importance 0
when 0
fetal B-PHYSICAL
distress I-PHYSICAL
or 0
fetal B-PHYSICAL
hypoxemia I-PHYSICAL
is 0
due 0
to 0
other 0
perinatal 0
events 0
. 0

Under 0
these 0
circumstances 0
, 0
acute B-PHYSICAL
maternal I-PHYSICAL
glucose I-PHYSICAL
infusion I-PHYSICAL
may 0
further 0
contribute 0
to 0
fetal B-PHYSICAL
metabolic I-PHYSICAL
acidosis I-PHYSICAL
. 0

Rosiglitazone 0
and 0
cognitive 0
function 0
in 0
clozapine-treated 0
patients 0
with 0
schizophrenia 0
: 0
a 0
pilot 0
study 0
. 0

Studies 0
have 0
shown 0
that 0
insulin 0
resistance 0
is 0
associated 0
with 0
cognitive 0
impairment 0
. 0

Peroxisome 0
proliferator-activated 0
receptor-? 0
( 0
PPAR-? 0
) 0
agonists 0
improve 0
insulin 0
sensitivity 0
. 0

The 0
purpose 0
of 0
this 0
study 0
was 0
to 0
evaluate 0
the 0
effect 0
of 0
rosiglitazone 0
, 0
a 0
PPAR-? 0
agonist 0
, 0
on 0
cognition 0
in 0
clozapine-treated 0
patients 0
with 0
schizophrenia 0
. 0

In 0
an 0
eight-week 0
double-blind 0
, 0
placebo-controlled 0
pilot 0
trial 0
, 0
clozapine-treated 0
patients 0
with 0
schizophrenia 0
were 0
randomized 0
to 0
receive 0
rosiglitazone 0
( 0
4mg/day 0
) 0
or 0
placebo 0
. 0

A 0
neuropsychological 0
battery 0
including 0
the 0
Digit 0
Span 0
subtest 0
from 0
the 0
Wechsler 0
Adult 0
Intelligence 0
Scale-III 0
( 0
WAIS-III 0
) 0
, 0
the 0
verbal 0
fluency 0
test 0
, 0
the 0
Hopkins 0
Verbal 0
Learning 0
Test 0
( 0
HVLT 0
) 0
, 0
the 0
Trail-Making 0
Test 0
( 0
TMT 0
) 0
and 0
the 0
Wisconsin 0
Card 0
Sorting 0
Test 0
( 0
WCST 0
) 0
was 0
administered 0
at 0
baseline 0
and 0
week 0
eight 0
. 0

Nineteen 0
patients 0
completed 0
the 0
study 0
. 0

There 0
were 0
no 0
significant 0
differences 0
on 0
any 0
demographic 0
or 0
general 0
clinical 0
variables 0
between 0
the 0
rosiglitazone 0
group 0
( 0
n=9 0
) 0
and 0
the 0
placebo 0
group 0
( 0
n=10 0
) 0
. 0

When 0
baseline 0
scores 0
were 0
controlled 0
, 0
there 0
were 0
no 0
significant 0
differences 0
in 0
change 0
scores 0
of 0
cognitive B-MENTAL
performance I-MENTAL
over 0
eight 0
weeks 0
between 0
the 0
two 0
groups 0
. 0

In 0
this 0
pilot 0
study 0
, 0
rosiglitazone 0
had 0
no 0
cognitive B-MENTAL
benefit I-MENTAL
in 0
clozapine-treated 0
patients 0
with 0
schizophrenia 0
. 0

Future 0
studies 0
with 0
longer 0
treatment 0
duration 0
and 0
larger 0
sample 0
size 0
are 0
needed 0
to 0
further 0
explore 0
the 0
potential 0
role 0
of 0
rosiglitazone 0
in 0
improving 0
cognitive 0
function 0
in 0
patients 0
with 0
schizophrenia 0
. 0

Mecamylamine 0
reduces 0
some 0
EEG B-PHYSICAL
effects I-PHYSICAL
of 0
nicotine 0
chewing 0
gum 0
in 0
humans 0
. 0

Spontaneous B-PHYSICAL
EEG I-PHYSICAL
was 0
recorded 0
in 0
nine 0
cigarette 0
smokers 0
who 0
had 0
been 0
abstinent 0
from 0
tobacco 0
for 0
12 0
hr 0
. 0

Subjects 0
were 0
treated 0
with 0
a 0
capsule 0
containing 0
either 0
centrally 0
acting 0
nicotine 0
blocker 0
, 0
mecamylamine 0
( 0
10 0
mg 0
) 0
, 0
or 0
placebo 0
. 0

At 0
each 0
of 0
three 0
60-min 0
intervals 0
after 0
the 0
capsule 0
was 0
ingested 0
, 0
the 0
subjects 0
chewed 0
two 0
pieces 0
of 0
gum 0
containing 0
a 0
total 0
of 0
0 0
, 0
4 0
or 0
8 0
mg 0
of 0
nicotine 0
. 0

Nicotine 0
and 0
mecamylamine 0
dose 0
combinations 0
were 0
randomized 0
across 0
subjects 0
. 0

Two 0
three-minute 0
periods 0
of 0
spontaneous B-PHYSICAL
EEG I-PHYSICAL
were 0
recorded 0
before 0
the 0
capsule 0
and 0
before 0
and 0
after 0
gum 0
chewing 0
from 0
bipolar 0
electrode 0
montages 0
at 0
the 0
following 0
positions 0
: 0
Cz-T5 0
, 0
Cz-T6 0
, 0
Cz-F7 0
and 0
Cz-F8 0
. 0

During 0
one 0
period 0
the 0
subjects 0
relaxed 0
with 0
eyes 0
closed 0
, 0
in 0
the 0
other 0
period 0
they 0
performed 0
a 0
math 0
task 0
with 0
eyes 0
open 0
. 0

When 0
the 0
drugs 0
were 0
given 0
individually 0
, 0
mecamylamine 0
decreased 0
beta B-PHYSICAL
power I-PHYSICAL
and 0
nicotine 0
gum 0
( 0
4 0
and 0
8 0
mg 0
) 0
increased 0
alpha B-PHYSICAL
frequency 0
. 0

Mecamylamine 0
pretreatment 0
prevented 0
the 0
increase 0
in 0
alpha B-PHYSICAL
frequency I-PHYSICAL
caused 0
by 0
the 0
4 0
mg 0
gum 0
dose 0
but 0
not 0
the 0
8 0
mg 0
dose 0
. 0

Alpha B-OTHER
power I-OTHER
was 0
increased 0
by 0
the 0
8 0
mg 0
gum 0
dose 0
and 0
that 0
increase 0
was 0
prevented 0
by 0
mecamylamine 0
. 0

Self-reported 0
ratings 0
of 0
the 0
strength B-PHYSICAL
of 0
the 0
gum 0
were 0
significantly 0
diminished 0
by 0
mecamylamine 0
pretreatment 0
. 0

The 0
data 0
are 0
consistent 0
with 0
the 0
results 0
of 0
earlier 0
studies 0
which 0
indicate 0
that 0
the 0
effects 0
of 0
tobacco 0
administration 0
and 0
withdrawal 0
are 0
mediated 0
by 0
central 0
actions 0
of 0
nicotine 0
. 0

Racial 0
differences 0
in 0
primary 0
and 0
repeat 0
lower 0
extremity 0
amputation 0
: 0
results 0
from 0
a 0
multihospital 0
study 0
. 0

OBJECTIVE 0
African 0
Americans 0
have 0
a 0
much 0
higher 0
risk 0
of 0
major B-PHYSICAL
( 0
above- B-PHYSICAL
or 0
below-knee 0
) 0
lower 0
extremity 0
amputation 0
and 0
a 0
lower 0
rate 0
of 0
limb-preserving B-PHYSICAL
vascular I-PHYSICAL
surgery I-PHYSICAL
or 0
angioplasty 0
than 0
white 0
patients 0
. 0

This 0
article 0
analyzes 0
two 0
potential 0
pathways 0
for 0
racial 0
disparities 0
: 0
primary 0
amputation 0
, 0
defined 0
as 0
a 0
major 0
amputation 0
performed 0
without 0
any 0
prior 0
attempt 0
at 0
revascularization 0
, 0
and 0
repeat 0
amputation 0
, 0
defined 0
as 0
a 0
major 0
amputation 0
subsequent 0
to 0
a 0
previous 0
through-foot 0
or 0
major 0
amputation 0
. 0

METHODS 0
Randomly 0
selected 0
medical 0
records 0
were 0
reviewed 0
for 0
248 0
African 0
American 0
, 0
30 0
Hispanic 0
, 0
and 0
235 0
white 0
or 0
other-race 0
patients 0
undergoing 0
above- 0
or 0
below-knee 0
amputation 0
between 0
1995 0
and 0
2003 0
at 0
three 0
Chicago 0
teaching 0
hospitals 0
. 0

Chronic 0
disease 0
prevalence 0
and 0
severity 0
, 0
preadmission 0
functional 0
status 0
, 0
clinical 0
presentation 0
, 0
and 0
vascular 0
history 0
were 0
used 0
to 0
test 0
the 0
risk-adjusted 0
effect 0
of 0
race 0
and 0
ethnicity 0
on 0
rates 0
of 0
primary B-PHYSICAL
and 0
repeat B-PHYSICAL
amputation I-PHYSICAL
. 0

RESULTS 0
Controlling 0
for 0
demographic 0
, 0
functional 0
, 0
chronic 0
disease 0
, 0
and 0
clinical 0
characteristics 0
, 0
African 0
American 0
patients 0
were 0
1.7 0
times 0
more 0
likely 0
to 0
have 0
undergone 0
both 0
primary 0
( 0
P 0
= 0
.01 0
) 0
and 0
repeat 0
( 0
P 0
= 0
.03 0
) 0
amputation 0
than 0
white 0
or 0
other-race 0
amputees 0
. 0

Race 0
remained 0
a 0
significant 0
independent 0
risk 0
factor 0
even 0
after 0
controlling 0
for 0
the 0
higher 0
severity 0
of 0
illness 0
, 0
greater 0
disability 0
, 0
and 0
more 0
complex 0
presentation 0
of 0
African 0
American 0
amputees 0
. 0

CONCLUSIONS 0
Higher 0
rates 0
of 0
primary B-PHYSICAL
and I-PHYSICAL
repeat I-PHYSICAL
amputation I-PHYSICAL
for 0
African 0
American 0
patients 0
at 0
study 0
hospitals 0
, 0
which 0
all 0
have 0
significant 0
vascular 0
surgery 0
capacity 0
and 0
an 0
aggressive 0
policy 0
of 0
limb 0
salvage 0
, 0
suggest 0
that 0
these 0
rates 0
may 0
be 0
even 0
higher 0
at 0
less 0
well 0
equipped 0
institutions 0
. 0

Improving 0
access 0
to 0
primary 0
and 0
preventive 0
care 0
for 0
lower-income 0
patients 0
could 0
reduce 0
amputation B-PHYSICAL
rates I-PHYSICAL
among 0
African 0
Americans 0
. 0

Tegaserod 0
, 0
a 0
5-hydroxytryptamine 0
type 0
4 0
receptor 0
partial 0
agonist 0
, 0
is 0
devoid 0
of 0
electrocardiographic B-PHYSICAL
effects I-PHYSICAL
. 0

OBJECTIVES 0
Certain 0
GI 0
prokinetic 0
agents 0
have 0
been 0
shown 0
to 0
affect 0
cardiac 0
repolarization 0
, 0
which 0
may 0
be 0
associated 0
with 0
life-threatening 0
arrhythmias 0
. 0

The 0
selective 0
5-hydroxytryptamine 0
type 0
4 0
receptor 0
partial 0
agonist 0
tegaserod 0
is 0
a 0
novel 0
promotile 0
agent 0
developed 0
for 0
the 0
treatment 0
of 0
functional 0
motility 0
disorders 0
such 0
as 0
irritable 0
bowel 0
syndrome 0
( 0
IBS 0
) 0
. 0

The 0
aim 0
of 0
the 0
study 0
was 0
to 0
investigate 0
the 0
cardiac B-OTHER
safety I-OTHER
profile I-OTHER
of 0
tegaserod 0
through 0
analysis 0
of 0
electrocardiographic 0
data 0
from 0
clinical 0
studies 0
conducted 0
in 0
patients 0
with 0
IBS 0
and 0
a 0
study 0
conducted 0
in 0
healthy 0
male 0
subjects 0
. 0

METHODS 0
In 0
three 0
randomized 0
, 0
double 0
blind 0
, 0
placebo-controlled 0
, 0
parallel 0
group 0
clinical 0
studies 0
, 0
2516 0
IBS 0
patients 0
with 0
symptoms 0
of 0
abdominal 0
pain 0
and 0
constipation 0
received 0
tegaserod 0
2 0
or 0
6 0
mg 0
b.i.d 0
. 0
( 0

n 0
= 0
1679 0
) 0
or 0
placebo 0
( 0
n 0
= 0
837 0
) 0
for 0
12 0
wk 0
. 0

In 0
an 0
additional 0
study 0
, 0
36 0
healthy 0
male 0
subjects 0
received 0
iv 0
. 0

single 0
doses 0
of 0
tegaserod 0
( 0
0.8 0
mg 0
to 0
20 0
mg 0
) 0
or 0
placebo 0
. 0

Standard 0
12-lead 0
electrocardiograms 0
were 0
recorded 0
at 0
baseline 0
and 0
during 0
treatment 0
. 0

Baseline 0
values 0
were 0
compared 0
with 0
data 0
collected 0
during 0
the 0
treatment 0
period 0
. 0

RESULTS 0
The 0
proportion 0
of 0
patients 0
with 0
prolongation B-PHYSICAL
of I-PHYSICAL
the I-PHYSICAL
QTc I-PHYSICAL
interval I-PHYSICAL
was 0
the 0
same 0
for 0
placebo 0
and 0
tegaserod 0
, 0
as 0
was 0
the 0
frequency 0
of 0
overall B-PHYSICAL
electrocardiographic I-PHYSICAL
abnormalities I-PHYSICAL
. 0

No 0
ventricular B-PHYSICAL
or I-PHYSICAL
supraventricular I-PHYSICAL
tachycardia I-PHYSICAL
was 0
observed 0
. 0

Comparable 0
electrocardiographic B-PHYSICAL
results I-PHYSICAL
were 0
obtained 0
during 0
placebo 0
and 0
tegaserod 0
treatment 0
. 0

In 0
healthy 0
volunteers 0
, 0
tegaserod 0
at 0
i.v 0
. 0

doses 0
resulting 0
in 0
plasma B-PHYSICAL
concentrations I-PHYSICAL
up 0
to 0
100 0
times 0
those 0
measured 0
after 0
therapeutic 0
doses 0
( 0
6 0
mg 0
b.i.d 0
. 0
) 0

did 0
not 0
influence 0
electrocardiographic 0
parameters 0
. 0

CONCLUSIONS 0
Tegaserod 0
is 0
devoid 0
of 0
electrocardiographic B-PHYSICAL
effects I-PHYSICAL
and 0
is 0
not 0
expected 0
to 0
adversely 0
influence 0
cardiac B-PHYSICAL
function I-PHYSICAL
. 0

These 0
data 0
confirm 0
preclinical 0
findings 0
. 0

Oral 0
magnesium 0
supplementation 0
improves 0
the 0
metabolic B-PHYSICAL
profile I-PHYSICAL
of 0
metabolically 0
obese 0
, 0
normal-weight 0
individuals 0
: 0
a 0
randomized 0
double-blind 0
placebo-controlled 0
trial 0
. 0

BACKGROUND 0
AND 0
AIMS 0
We 0
undertook 0
this 0
study 0
to 0
determine 0
the 0
efficacy 0
of 0
oral 0
magnesium 0
supplementation 0
in 0
the 0
improvement 0
of 0
the 0
metabolic B-OTHER
profile I-OTHER
and 0
blood B-OTHER
pressure I-OTHER
in 0
metabolically 0
obese 0
, 0
normal-weight 0
( 0
MONW 0
) 0
individuals 0
. 0

METHODS 0
A 0
total 0
of 0
47 0
MONW 0
individuals 0
with 0
hypomagnesemia 0
were 0
enrolled 0
in 0
clinical 0
a 0
randomized 0
double-blind 0
placebo-controlled 0
trial 0
. 0

Individuals 0
in 0
the 0
intervention 0
group 0
received 0
30 0
mL 0
of 0
MgCl2 0
5 0
% 0
solution 0
( 0
equivalent 0
to 0
382 0
mg 0
of 0
magnesium 0
) 0
and 0
individuals 0
in 0
the 0
control 0
group 0
30 0
mL 0
of 0
placebo 0
solution 0
, 0
once 0
daily 0
during 0
4 0
months 0
. 0

In 0
the 0
absence 0
of 0
obesity 0
or 0
overweight 0
, 0
the 0
presence 0
of 0
fasting B-PHYSICAL
glucose I-PHYSICAL
levels I-PHYSICAL
?100 0
mg/dL 0
, 0
HOMA-IR 0
index 0
?3 0
, 0
triglyceride 0
levels 0
?150 0
mg/dL 0
and/or 0
systolic 0
and 0
diastolic 0
blood 0
pressure 0
?140 0
and 0
90 0
mmHg 0
defined 0
the 0
presence 0
of 0
the 0
MONW 0
phenotype 0
. 0

Hypomagnesemia 0
was 0
defined 0
by 0
serum 0
magnesium 0
concentration 0
?1.8 0
mg/dL 0
. 0

RESULTS 0
At 0
basal 0
conditions 0
there 0
were 0
no 0
significant 0
differences 0
between 0
groups 0
. 0

At 0
the 0
end 0
of 0
follow-up 0
, 0
changes 0
in 0
the 0
mean 0
of 0
systolic 0
( 0
-2.1 0
vs. 0
3.9 0
% 0
mmHg 0
, 0
p 0
< 0
0.05 0
) 0
and 0
diastolic 0
( 0
-3.8 0
vs. 0
7.5 0
% 0
mmHg 0
, 0
p 0
< 0
0.05 0
) 0
blood 0
pressures 0
, 0
HOMA-IR 0
index 0
( 0
-46.5 0
vs. 0
-5.4 0
% 0
, 0
p 0
< 0
0.0001 0
) 0
, 0
fasting 0
glucose 0
( 0
-12.3 0
vs. 0
-1.8 0
% 0
mg/dL 0
, 0
p 0
< 0
0.05 0
) 0
and 0
triglyceride 0
levels 0
( 0
-47.4 0
% 0
vs. 0
10.1 0
% 0
mg/dL 0
, 0
p 0
< 0
0.0001 0
) 0
were 0
significantly 0
lower 0
in 0
the 0
subjects 0
who 0
received 0
MgCl2 0
compared 0
with 0
individuals 0
in 0
the 0
control 0
group 0
. 0

CONCLUSIONS 0
Oral 0
magnesium 0
supplementation 0
improves 0
the 0
metabolic 0
profile 0
and 0
blood 0
pressure 0
of 0
MONW 0
individuals 0
. 0

Efficacy 0
of 0
nebulized 0
flunisolide 0
combined 0
with 0
salbutamol 0
and 0
ipratropium 0
bromide 0
in 0
stable 0
patients 0
with 0
moderate-to-severe 0
chronic 0
obstructive 0
pulmonary 0
disease 0
. 0

BACKGROUND 0
The 0
efficacy 0
of 0
nebulized 0
corticosteroids 0
in 0
the 0
prevention 0
of 0
exacerbation 0
of 0
chronic 0
obstructive 0
pulmonary 0
disease 0
( 0
COPD 0
) 0
has 0
been 0
poorly 0
studied 0
. 0

OBJECTIVE 0
To 0
evaluate 0
the 0
efficacy 0
and 0
tolerability B-OTHER
of 0
nebulized 0
flunisolide 0
( 0
1 0
mg 0
) 0
+ 0
salbutamol/ipratropium 0
bromide 0
( 0
1,875/375 0
microg 0
) 0
b.i.d 0
. 0

in 0
comparison 0
with 0
placebo 0
+ 0
salbutamol/ipratropium 0
bromide 0
. 0

METHODS 0
This 0
was 0
a 0
randomized 0
, 0
parallel-group 0
, 0
double-blind 0
study 0
on 0
114 0
patients 0
with 0
COPD 0
of 0
moderate-to-severe 0
degree 0
. 0

The 0
main 0
outcome 0
was 0
the 0
frequency 0
of 0
severe B-PHYSICAL
exacerbations I-PHYSICAL
over 0
a 0
6-month 0
period 0
. 0

Before 0
and 0
after 0
treatment 0
, 0
respiratory B-PHYSICAL
symptoms I-PHYSICAL
, I-PHYSICAL
forced I-PHYSICAL
expiratory I-PHYSICAL
volume I-PHYSICAL
in I-PHYSICAL
1 I-PHYSICAL
s I-PHYSICAL
( I-PHYSICAL
FEV I-PHYSICAL
( I-PHYSICAL
1 I-PHYSICAL
) I-PHYSICAL
) I-PHYSICAL
, I-PHYSICAL
shuttle I-PHYSICAL
walking I-PHYSICAL
test I-PHYSICAL
distance 0
and B-PHYSICAL
St. 0
George B-PHYSICAL
's 0
Respiratory B-PHYSICAL
Questionnaire 0
scores 0
were 0
evaluated 0
. 0

RESULTS 0
The 0
total 0
number B-PHYSICAL
of I-PHYSICAL
exacerbations I-PHYSICAL
was 0
slightly 0
lower 0
in 0
the 0
flunisolide 0
group 0
compared 0
to 0
the 0
placebo 0
group 0
( 0
19 0
vs. 0
34 0
, 0
p 0
= 0
0.054 0
) 0
; 0
the 0
number 0
of 0
patients B-PHYSICAL
experiencing I-PHYSICAL
at I-PHYSICAL
least B-PHYSICAL
one B-PHYSICAL
exacerbation B-PHYSICAL
during I-PHYSICAL
the B-PHYSICAL
study B-PHYSICAL
was 0
also 0
decreased 0
( 0
16 0
vs. 0
26 0
, 0
p 0
= 0
0.059 0
) 0
. 0

In 0
particular 0
, 0
type 0
3 0
Anthonisens B-PHYSICAL
's 0
exacerbations B-PHYSICAL
were 0
significantly 0
reduced 0
by 0
flunisolide 0
( 0
p 0
= 0
0.044 0
) 0
. 0

In 0
the 0
placebo 0
group 0
, 0
scores 0
were 0
higher 0
than 0
in 0
the 0
flunisolide 0
group 0
but 0
nonsignificant 0
for 0

Comparison 0
of 0
intravenous 0
and 0
intra-arterial 0
urokinase 0
thrombolysis 0
for 0
acute 0
ischaemic 0
stroke 0
. 0

Intravenous 0
fibrinolysis 0
( 0
IVF 0
) 0
with 0
rt-PA 0
( 0
alteplase 0
) 0
provides 0
significant 0
benefits 0
in 0
acute 0
ischaemic 0
stroke 0
when 0
it 0
is 0
given 0
within 0
the 0
first 0
three 0
hours 0
following 0
stroke 0
onset 0
. 0

Intra-arterial 0
fibrinolysis 0
( 0
IAF 0
) 0
with 0
pro-urokinase 0
in 0
PROACT 0
II 0
study 0
provides 0
quite 0
the 0
same 0
benefit 0
in 0
the 0
first 0
6 0
hours 0
. 0

IVF 0
and 0
IAF 0
have 0
never 0
been 0
compared 0
. 0

To 0
compare 0
the 0
efficacy 0
and 0
safety 0
of 0
IVF 0
and 0
IAF 0
with 0
urokinase 0
given 0
within 0
the 0
first 0
6 0
hours 0
of 0
acute 0
ischaemic 0
stroke 0
. 0

Patients 0
fulfilling 0
the 0
selection 0
criteria 0
were 0
randomly 0
assigned 0
to 0
receive 0
urokinase 0
900,000 0
units 0
via 0
intravenous 0
or 0
intra-arterial 0
routes 0
. 0

This 0
randomised 0
monocentre 0
study 0
was 0
done 0
between 0
December 0
1995 0
and 0
August 0
1997 0
. 0

The 0
primary 0
outcome 0
was 0
defined 0
as 0
the 0
number 0
of B-OTHER
patients I-OTHER
with I-OTHER
a I-OTHER
modified 0
Rankin B-OTHER
score 0

Evidence 0
for 0
poorer 0
outcome 0
in 0
patients 0
with 0
severe 0
negative 0
trauma-related 0
cognitions 0
receiving 0
prolonged 0
exposure 0
plus 0
cognitive 0
restructuring 0
: 0
implications 0
for 0
treatment 0
matching 0
in 0
posttraumatic 0
stress 0
disorder 0
. 0

In 0
the 0
current 0
article 0
, 0
we 0
address 0
the 0
existing 0
assumption 0
in 0
the 0
literature 0
on 0
cognitive 0
behavioral 0
treatment 0
of 0
PTSD 0
that 0
patients 0
with 0
severe 0
negative 0
trauma-related 0
cognitions 0
would 0
benefit 0
more 0
from 0
a 0
treatment 0
package 0
that 0
includes 0
exposure 0
and 0
cognitive 0
techniques 0
compared 0
with 0
a 0
treatment 0
that 0
includes 0
exposure 0
only 0
. 0

To 0
test 0
this 0
assumption 0
, 0
54 0
PTSD 0
patients 0
were 0
randomized 0
to 0
prolonged 0
exposure 0
therapy 0
or 0
prolonged 0
exposure 0
therapy 0
plus 0
cognitive 0
restructuring 0
. 0

Contrary 0
to 0
expectations 0
, 0
findings 0
revealed 0
that 0
patients 0
characterized 0
by 0
more 0
severe 0
pretreatment 0
trauma-related 0
cognitions 0
( 0
and 0
more 0
severe 0
pretreatment 0
PTSD 0
symptoms 0
) 0
fared 0
slightly 0
worse 0
in 0
treatment 0
combining 0
exposure 0
and 0
cognitive 0
restructuring 0
. 0

However 0
, 0
there 0
was 0
no 0
relationship 0
between 0
pre- 0
and 0
post-treatment B-MENTAL
measures I-MENTAL
of I-MENTAL
negative 0
cognitions B-MENTAL
and 0

Effect 0
of 0
total 0
androgen 0
ablation 0
on 0
pathologic B-PHYSICAL
stage I-PHYSICAL
and 0
resection B-PHYSICAL
limit I-PHYSICAL
status I-PHYSICAL
of I-PHYSICAL
prostate I-PHYSICAL
cancer I-PHYSICAL
. 0

Initial 0
results 0
of 0
the 0
Italian 0
PROSIT 0
study 0
. 0

The 0
likelihood 0
of 0
finding 0
organ-confined 0
untreated 0
prostate 0
cancer 0
( 0
PCa 0
) 0
by 0
pathological 0
examination 0
at 0
the 0
time 0
of 0
radical 0
prostatectomy 0
( 0
RP 0
) 0
is 0
only 0
50 0
% 0
in 0
patients 0
with 0
clinically 0
organ-confined 0
disease 0
. 0

In 0
addition 0
, 0
tumour 0
is 0
present 0
at 0
the 0
resection 0
margin 0
in 0
approximately 0
30 0
% 0
of 0
clinical 0
T2 0
( 0
clinical 0
stage 0
B 0
) 0
cases 0
. 0

The 0
issue 0
of 0
clinical 0
understaging 0
and 0
of 0
resection 0
limit 0
positivity 0
have 0
led 0
to 0
the 0
development 0
of 0
novel 0
management 0
practices 0
, 0
including 0
neoadjuvant 0
hormonal 0
therapy 0
( 0
NHT 0
) 0
. 0

The 0
optimal 0
duration 0
of 0
NHT 0
is 0
unknown 0
. 0

We 0
undertook 0
the 0
present 0
analysis 0
to 0
evaluate 0
the 0
effect 0
of B-PHYSICAL
NHT 0
on 0
pathologic B-PHYSICAL
stage B-PHYSICAL
of I-PHYSICAL
PCa I-PHYSICAL
and 0
resection B-PHYSICAL
limit I-PHYSICAL
status I-PHYSICAL
in 0
patients 0
with 0
prostate 0
cancer 0
and 0
treated 0
with 0
total 0
androgen 0
ablation 0
either 0
for 0
three 0
or 0
six 0
months 0
before 0
RP 0
. 0

Between 0
January 0
1996 0
and 0
February 0
1998 0
, 0
259 0
men 0
with 0
prostate 0
cancer 0
underwent 0
radical 0
retropubic 0
prostatectomy 0
and 0
bilateral 0
pelvic 0
node 0
dissection 0
in 0
the 0
26 0
centres 0
participating 0
in 0
the 0
Italian 0
randomised 0
prospective 0
PROSIT 0
study 0
. 0

Whole 0
mount 0
sectioning 0
of 0
the 0
complete 0
RP 0
specimens 0
was 0
adopted 0
in 0
each 0
centre 0
for 0
accurately 0
evaluating 0
the 0
pathologic B-PHYSICAL
stage I-PHYSICAL
and I-PHYSICAL
resection B-PHYSICAL
limit I-PHYSICAL
status I-PHYSICAL
. 0

By 0
February 0
1998 0
, 0
haematoxylin 0
and 0
eosin 0
stained 0
sections 0
from 0
155 0
RP 0
specimens 0
had 0
been 0
received 0
and 0
evaluated 0
by 0
the 0
reviewing 0
pathologist 0
( 0
RM 0
) 0
. 0

64 0
cases 0
had 0
not 0
been 0
treated 0
with 0
total 0
androgen 0
ablation 0
( 0
e.g 0
. 0

NHT 0
) 0
before 0
RP 0
was 0
performed 0
, 0
whereas 0
58 0
and 0
33 0
had 0
been 0
treated 0
for 0
three 0
and 0
six 0
months 0
, 0
respectively 0
. 0

114 0
patients 0
were 0
clinical 0
stage 0
B 0
whereas 0
41 0
were 0
clinical 0
stage 0
C. 0
After 0
three 0
months 0
of 0
total 0
androgen 0
ablation 0
, 0
pathological B-PHYSICAL
stage I-PHYSICAL
B I-PHYSICAL
was 0
more 0
prevalent 0
among 0
patients 0
with 0
clinical 0
B 0
tumours 0
, 0
compared 0
with 0
untreated 0
patients 0
( 0
57 0
% 0
in 0
treated 0
patients 0
vs. 0
36 0
% 0
in 0
untreated 0
) 0
. 0

The 0
percentage 0
of 0
cancers B-PHYSICAL
with B-PHYSICAL
negative 0
margins B-PHYSICAL
was 0
statistically 0
significantly 0
greater 0
in 0
patients 0
treated 0
with 0
neoadjuvant 0
therapy 0
than 0
those 0
treated 0
with 0
immediate 0
surgery 0
alone 0
( 0
69 0
% 0
vs. 0
42 0
% 0
, 0
respectively 0
) 0
. 0

After 0
six 0
months 0
of 0
NHT 0
therapy 0
the 0
proportion 0
of 0
patients B-PHYSICAL
with I-PHYSICAL
pathological B-PHYSICAL
stage I-PHYSICAL
B I-PHYSICAL
( 0
67 0
% 0
vs. 0
36 0
% 0
, 0
respectively 0
) 0
and 0
negative 0
margins B-PHYSICAL
was 0
greater 0
than 0
after 0
3 0
months 0
( 0
92 0
% 0
vs. 0
42 0
% 0
, 0
respectively 0
) 0
. 0

For 0
clinical 0
C 0
tumours 0
, 0
the 0
prevalence 0
of 0

Bupropion 0
SR 0
and 0
counseling 0
for 0
smoking 0
cessation 0
in 0
actual 0
practice 0
: 0
predictors 0
of 0
outcome 0
. 0

To 0
date 0
, 0
only 0
one 0
study 0
has 0
been 0
published 0
on 0
individual 0
characteristics 0
associated 0
with 0
outcome 0
following 0
standard 0
treatment 0
with 0
bupropion 0
SR 0
for 0
smoking 0
cessation 0
. 0

To 0
investigate 0
treatment 0
outcome 0
beyond 0
the 0
6-week 0
end-of-treatment 0
point 0
, 0
the 0
present 0
study 0
examined 0
characteristics 0
associated 0
with 0
more 0
clinically 0
relevant 0
smoking 0
endpoints 0
following 0
treatment 0
with 0
bupropion 0
SR 0
in 0
a 0
large 0
health 0
care 0
system 0
. 0

A 0
total 0
of 0
1,524 0
smokers 0
( 0
649 0
men 0
and 0
875 0
women 0
) 0
of 0
average 0
age 0
45.1 0
years 0
were 0
randomized 0
to 0
receive 0
one 0
of 0
four 0
combinations 0
of 0
bupropion 0
SR 0
( 0
150 0
or 0
300 0
mg 0
) 0
and 0
behavioral 0
counseling 0
( 0
tailored 0
mailings 0
or 0
proactive 0
telephone 0
counseling 0
) 0
and 0
assessed 0
for 0
point-prevalent 0
smoking 0
status 0
at 0
3 0
and 0
12 0
months 0
. 0

Multiple 0
logistic 0
regression 0
analyses 0
of 0
potential 0
risk 0
factors 0
for 0
12-month 0
point-prevalent 0
smoking 0
and 0
for 0
persistent 0
smoking 0
( 0
point-prevalent 0
smoking 0
at 0
both 0
follow-ups 0
) 0
following 0
treatment 0
were 0
conducted 0
for 0
men 0
and 0
women 0
combined 0
and 0
separately 0
. 0

Risk 0
factors 0
for 0
smoking 0
at 0
both 0
endpoints 0
in 0
the 0
combined 0
sample 0
included 0
treatment 0
with 0
tailored 0
mailings 0
, 0
female 0
gender 0
, 0
younger 0
age 0
, 0
higher 0
levels 0
of 0
tobacco 0
dependence 0
, 0
shorter 0
previous 0
quit 0
attempts 0
, 0
previous 0
use 0
of 0
nicotine 0
replacement 0
therapy 0
, 0
and 0
report 0
of 0
current 0
depressive 0
symptoms 0
or 0
lifetime 0
depression 0
. 0

Risk 0
factors 0
for 0
smoking 0
following 0
treatment 0
identified 0
in 0
women 0
only 0
included 0
treatment 0
with 0
the 0
lower 0
dose 0
of 0
bupropion 0
SR 0
, 0
younger 0
age 0
, 0
and 0
higher 0
perceived 0
stress 0
, 0
whereas 0
those 0
that 0
were 0
unique 0
to 0
men 0
included 0
the 0
presence 0
of 0
lifetime 0
depression 0
. 0

The 0
results 0
are 0
discussed 0
in 0
terms 0
of 0
their 0
implications 0
for 0
the 0
need 0
for 0
more B-OTHER
effective I-OTHER
treatments I-OTHER
in 0
general 0
, 0
and 0
the 0
role 0
of 0
individual 0
differences 0
in 0
the 0
likelihood 0
of 0
returning B-MENTAL
to I-MENTAL
smoking I-MENTAL
following I-MENTAL
treatment I-MENTAL
for 0
quitting 0
. 0

Social 0
stories 0
: 0
mechanisms 0
of 0
effectiveness 0
in 0
increasing 0
game 0
play 0
skills 0
in 0
children 0
diagnosed 0
with 0
autism 0
spectrum 0
disorder 0
using 0
a 0
pretest 0
posttest 0
repeated 0
measures 0
randomized 0
control 0
group 0
design 0
. 0

An 0
increasing 0
body 0
of 0
literature 0
has 0
indicated 0
that 0
social 0
stories 0
are 0
an 0
effective 0
way 0
to 0
teach 0
individuals 0
diagnosed 0
with 0
autism 0
appropriate 0
social 0
behavior 0
. 0

This 0
study 0
compared 0
two 0
formats 0
of 0
a 0
social 0
story 0
targeting 0
the 0
improvement 0
of 0
social B-MENTAL
skills I-MENTAL
during 0
game 0
play 0
using 0
a 0
pretest 0
posttest 0
repeated 0
measures 0
randomized 0
control 0
group 0
design 0
. 0

A 0
total 0
of 0
45 0
children 0
diagnosed 0
with 0
Autism 0
Spectrum 0
Disorder 0
( 0
ASD 0
) 0
ages 0
7-14 0
were 0
randomly 0
assigned 0
to 0
standard 0
, 0
directive 0
, 0
or 0
control 0
story 0
conditions 0
. 0

Results 0
demonstrated 0
that 0
the 0
standard 0
and 0
directive 0
story 0
formats 0
were 0
equally 0
as 0
effective 0
in 0
eliciting B-OTHER
, 0
generalizing B-OTHER
and 0
maintaining B-MENTAL
the I-MENTAL
targeted I-MENTAL
social I-MENTAL
skills I-MENTAL
in 0
participants 0
who 0
had 0
prior 0
game 0
play 0
experience 0
and 0
Verbal B-MENTAL
Comprehension I-MENTAL
Index 0
( B-MENTAL
VCI I-MENTAL
) I-MENTAL
scores I-MENTAL
from I-MENTAL
the I-MENTAL
WISC-IV I-MENTAL
intelligence I-MENTAL

A 0
randomized 0
comparison 0
of 0
the 0
effect 0
of 0
two 0
prelinguistic 0
communication 0
interventions 0
on 0
the 0
acquisition 0
of 0
spoken 0
communication 0
in 0
preschoolers 0
with 0
ASD 0
. 0

PURPOSE 0
This 0
randomized 0
group 0
experiment 0
compared 0
the 0
efficacy 0
of 0
2 0
communication 0
interventions 0
( 0
Responsive 0
Education 0
and 0
Prelinguistic 0
Milieu 0
Teaching 0
[ 0
RPMT 0
] 0
and 0
the 0
Picture 0
Exchange 0
Communication 0
System 0
[ 0
PECS 0
] 0
) 0
on 0
spoken 0
communication 0
in 0
36 0
preschoolers 0
with 0
autism 0
spectrum 0
disorders 0
( 0
ASD 0
) 0
. 0

METHOD 0
Each 0
treatment 0
was 0
delivered 0
to 0
children 0
for 0
a 0
maximum 0
total 0
of 0
24 0
hr 0
over 0
a 0
6-month 0
period 0
. 0

Spoken 0
communication 0
was 0
assessed 0
in 0
a 0
rigorous 0
test 0
of 0
generalization 0
at 0
pretreatment 0
, 0
posttreatment 0
, 0
and 0
6-month 0
follow-up 0
periods 0
. 0

RESULTS 0
PECS B-PHYSICAL
was I-PHYSICAL
more I-PHYSICAL
successful I-PHYSICAL
than I-PHYSICAL
RPMT I-PHYSICAL
in I-PHYSICAL
increasing 0
the 0
number 0
of 0
nonimitative B-MENTAL
spoken I-MENTAL
communication I-MENTAL
acts I-MENTAL
and 0
the B-PHYSICAL
number I-PHYSICAL
of I-PHYSICAL
different I-PHYSICAL
nonimitative I-PHYSICAL
words I-PHYSICAL
used I-PHYSICAL
at I-PHYSICAL
the I-PHYSICAL
posttreatment I-PHYSICAL
period 0
. 0

Considering 0
growth 0
over 0
all 0
3 0
measurement 0
periods 0
, 0
an 0
exploratory 0
analysis 0
showed 0
that 0
growth B-MENTAL
rate I-MENTAL
of I-MENTAL
the I-MENTAL
number I-MENTAL
of I-MENTAL
different I-MENTAL
nonimitative I-MENTAL
words I-MENTAL
was 0
faster B-PHYSICAL
in I-PHYSICAL
the I-PHYSICAL
PECS I-PHYSICAL
group 0
than 0
in 0
the 0
RPMT 0
group 0
for 0
children 0
who 0
began 0
treatment 0
with 0
relatively 0
high 0
object 0
exploration 0
. 0

In 0
contrast 0
, 0
analogous B-MENTAL
slopes I-MENTAL
were 0
steeper 0
in 0
the 0
RPMT 0
group 0
than 0
in 0
the 0
PECS 0
group 0
for 0
children 0
who 0
began 0
treatment 0
with 0
relatively 0
low 0
object 0
exploration 0
. 0

Rationale 0
and 0
design 0
of 0
a 0
randomized 0
trial 0
to 0
evaluate 0
an 0
evidence-based 0
prescription 0
drug 0
label 0
on 0
actual 0
medication 0
use 0
. 0

BACKGROUND 0
Medication 0
errors 0
are 0
an 0
important 0
public 0
health 0
concern 0
, 0
and 0
poor 0
understanding 0
of 0
medication 0
labels 0
are 0
a 0
root 0
cause 0
. 0

Research 0
shows 0
that 0
labels 0
are 0
variable 0
, 0
of 0
poor 0
quality 0
, 0
and 0
not 0
patient-centered 0
. 0

No 0
real-world 0
trials 0
have 0
evaluated 0
whether 0
improved 0
medication 0
labels 0
can 0
affect 0
appropriate 0
medication 0
use 0
, 0
adherence 0
or 0
health 0
outcomes 0
. 0

TRIAL 0
DESIGN 0
We 0
developed 0
an 0
evidence-based 0
prescription 0
label 0
that 0
addresses 0
both 0
content 0
and 0
format 0
. 0

The 0
enhanced 0
label 0
includes 0
a 0
universal 0
medication 0
schedule 0
( 0
UMS 0
) 0
that 0
standardizes 0
the 0
directions 0
for 0
use 0
incorporating 0
1 0
) 0
standard 0
time 0
periods 0
for 0
administration 0
( 0
morning 0
, 0
noon 0
, 0
evening 0
, 0
and 0
bedtime 0
) 0
, 0
2 0
) 0
numeric 0
vs. 0
alpha 0
characters 0
, 0
3 0
) 0
'carriage 0
returns 0
' 0
to 0
separate 0
daily 0
dose 0
and 0
4 0
) 0
a 0
graphic 0
aid 0
to 0
visually 0
depict 0
dose 0
and 0
frequency 0
. 0

We 0
will 0
evaluate 0
the 0
effect 0
of 0
providing 0
this 0
label 0
to 0
randomly 0
sampled 0
patients 0
who 0
receive 0
their 0
care 0
from 0
free 0
clinics 0
, 0
mobile 0
vans 0
and 0
federally 0
qualified 0
health 0
centers 0
( 0
FQHCs 0
) 0
in 0
Northern 0
Virginia 0
. 0

We 0
will 0
recruit 0
patients 0
with 0
diabetes 0
or 0
hypertension 0
; 0
these 0
patients 0
will 0
be 0
randomly 0
assigned 0
to 0
receive 0
all 0
of 0
their 0
medications 0
with 0
improved 0
labels 0
or 0
to 0
receive 0
prescriptions 0
with 0
standard 0
labels 0
. 0

The 0
primary 0
outcome 0
will 0
be 0
the 0
patient B-MENTAL
's 0
ability B-MENTAL
to I-MENTAL
correctly I-MENTAL
demonstrate I-MENTAL
dosing I-MENTAL
instructions I-MENTAL
. 0

Other 0
outcomes 0
include 0
adherence B-MENTAL
, 0
error 0
rates B-OTHER
and 0
health B-PHYSICAL
outcomes I-PHYSICAL
. 0

CONCLUSION 0
To 0
our 0
knowledge 0
, 0
this 0
trial 0
is 0
the 0
first 0
to 0
evaluate 0
the 0
effect 0
of 0
prescription 0
label 0
improvement 0
on 0
understanding B-MENTAL
, 0
medication B-MENTAL
use I-MENTAL
and 0
outcomes 0
in 0
a 0
clinical 0
setting 0
. 0

If 0
successful 0
, 0
these 0
findings 0
could 0
be 0
implemented 0
broadly 0
to 0
promote 0
safe 0
and 0
appropriate 0
medication 0
use 0
and 0
to 0
support 0
evidence-based 0
standards 0
in 0
the 0
development 0
of 0
labels 0
. 0

Effects 0
of 0
a 0
Chinese 0
medical 0
herbs 0
complex 0
on 0
cellular 0
immunity 0
and 0
toxicity-related 0
conditions 0
of 0
breast 0
cancer 0
patients 0
. 0

Rose 0
geranium 0
( 0
Pelargonium 0
graveolens 0
, 0
Geraniaceae 0
) 0
has 0
anti-cancer 0
and 0
anti-inflammatory 0
properties 0
, 0
and 0
promotes 0
wound 0
healing 0
. 0

Similarly 0
, 0
Ganoderma 0
tsugae 0
( 0
Ganodermataceae 0
) 0
, 0
Codonopsis 0
pilosula 0
( 0
Campanulaceae 0
) 0
and 0
Angelica 0
sinensis 0
( 0
Apiaceae 0
) 0
are 0
traditional 0
Chinese 0
herbs 0
associated 0
with 0
immunomodulatory 0
functions 0
. 0

In 0
the 0
present 0
study 0
, 0
a 0
randomised 0
, 0
double-blind 0
, 0
placebo-controlled 0
study 0
was 0
conducted 0
to 0
examine 0
whether 0
the 0
Chinese 0
medicinal 0
herb 0
complex 0
, 0
RG-CMH 0
, 0
which 0
represents 0
a 0
mixture 0
of 0
rose 0
geranium 0
and 0
extracts 0
of 0
G. 0
tsugae 0
, 0
C. 0
pilosula 0
and 0
A. 0
sinensis 0
, 0
can 0
improve 0
the 0
immune 0
cell 0
count 0
of 0
cancer 0
patients 0
receiving 0
chemotherapy 0
and/or 0
radiotherapy 0
to 0
prevent 0
leucopenia 0
and 0
immune 0
impairment 0
that 0
usually 0
occurs 0
during 0
cancer 0
therapy 0
. 0

A 0
total 0
of 0
fifty-eight 0
breast 0
cancer 0
patients 0
who 0
received 0
chemotherapy 0
or 0
radiotherapy 0
were 0
enrolled 0
. 0

Immune 0
cell 0
levels 0
in 0
patient 0
serum 0
were 0
determined 0
before 0
, 0
and 0
following 0
, 0
6 0
weeks 0
of 0
cancer 0
treatment 0
for 0
patients 0
receiving 0
either 0
an 0
RG-CMH 0
or 0
a 0
placebo 0
. 0

Administration 0
of 0
RG-CMH 0
was 0
associated 0
with 0
a 0
significant 0
reduction 0
in 0
levels B-PHYSICAL
of I-PHYSICAL
leucocytes I-PHYSICAL
from 0
31?5 0
% 0
for 0
the 0
placebo 0
group 0
to 0
13?4 0
% 0
for 0
the 0
RG-CMH 0
group 0
. 0

Similarly 0
, 0
levels 0
of 0
neutrophils 0
significantly 0
decreased 0
from 0
35?6 0
% 0
for 0
the 0
placebo 0
group 0
to 0
11?0 0
% 0
for 0
the 0
RG-CMH 0
group 0
. 0

RG-CMH 0
intervention 0
was 0
also 0
associated 0
with 0
a 0
decrease 0
in 0
levels 0
of 0
T 0
cells 0
, 0
helper 0
T 0
cells 0
, 0
cytotoxic 0
T 0
cells 0
and 0
natural 0
killer 0
cells 0
compared 0
with 0
the 0
placebo 0
group 0
. 0

However 0
, 0
these 0
differences 0
between 0
the 0
two 0
groups 0
were 0
not 0
statistically 0
significant 0
. 0

In 0
conclusion 0
, 0
administration 0
of 0
RG-CMH 0
to 0
patients 0
receiving 0
chemotherapy/radiotherapy 0
may 0
have 0
the 0
capacity 0
to 0
delay 0
, 0
or 0
ease 0
, 0
the 0
reduction 0
in 0
levels 0
of 0
leucocytes 0
and 0
neutrophils 0
that 0
are 0
experienced 0
by 0
patients 0
during 0
cancer 0
treatment 0
. 0

Immunoenhanced 0
enteral 0
nutrition 0
formulas 0
in 0
head 0
and 0
neck 0
cancer 0
surgery 0
: 0
a 0
prospective 0
, 0
randomized 0
clinical 0
trial 0
. 0

INTRODUCTION 0
Significant 0
malnutrition 0
exists 0
in 0
a 0
high 0
percentage 0
of 0
patients 0
with 0
head 0
and 0
neck 0
cancer 0
. 0

Malnutrition 0
is 0
associated 0
with 0
defects 0
in 0
immune 0
function 0
that 0
may 0
impair 0
the 0
host 0
response 0
to 0
malignancy 0
. 0

Malnutrition 0
and 0
immunosupression 0
make 0
patients 0
highly 0
susceptible 0
to 0
postoperative 0
infections 0
and 0
complications 0
. 0

OBJECTIVES 0
Compare 0
two 0
immunoenhanced 0
enteral 0
nutritions 0
with 0
a 0
control 0
diet 0
, 0
and 0
evaluate 0
the 0
effect 0
in 0
postoperative B-PHYSICAL
infections I-PHYSICAL
, 0
length B-PHYSICAL
of I-PHYSICAL
stay I-PHYSICAL
and 0
inflammatory B-PHYSICAL
markers I-PHYSICAL
. 0

PATIENTS 0
A 0
population 0
of 0
44 0
patients 0
with 0
oral 0
and 0
laryngeal 0
cancer 0
was 0
enrolled 0
in 0
a 0
randomized 0
trial 0
. 0

At 0
surgery 0
, 0
patients 0
were 0
randomly 0
allocated 0
to 0
three 0
groups 0
: 0
( 0
group 0
I 0
) 0
; 0
patients 0
receiving 0
an 0
arginine-enhanced 0
formula 0
( 0
group 0
II 0
) 0
; 0
patients 0
receiving 0
a 0
standard 0
polymeric 0
formula 0
, 0
and 0
( 0
group 0
III 0
) 0
patients 0
receiving 0
an 0
arginine 0
, 0
RNA 0
and 0
omega-3 0
fatty 0
acids 0
enhanced 0
formula 0
, 0
in 0
an 0
isonitrogenous 0
way 0
. 0

RESULTS 0
The 0
duration 0
of 0
enteral B-PHYSICAL
nutrition I-PHYSICAL
in 0
the 0
three 0
groups 0
was 0
similar 0
with 0
an 0
average 0
duration 0
of 0
14,5 0
+/- 0
8 0
days 0
. 0

The 0
length 0
of 0
postoperative B-PHYSICAL
stay I-PHYSICAL
was 0
similar 0
, 0
with 0
an 0
average 0
of 0
19,8 0
+/- 0
8,5 0
days 0
. 0

Wound B-PHYSICAL
infections I-PHYSICAL
and 0
general B-PHYSICAL
infections I-PHYSICAL
were 0
more 0
frequent 0
in 0
the 0
control 0
group 0
. 0

Fistula 0
rates 0
were 0
not 0
improved 0
in 0
the 0
enhanced 0
diet 0
groups 0
. 0

No 0
significant 0
intergroup 0
differences 0
in 0
the 0
trend 0
of 0
the 0
two 0
plasma 0
proteins 0
( 0
albumin 0
, 0
transferrin 0
) 0
, 0
lymphocytes 0
, 0
weight 0
, 0
IL-6 0
, 0
CPR 0
and 0
TNFalpha 0
were 0
detected 0
. 0

The 0
control 0
group 0
showed 0
the 0
highest 0
levels 0
of 0
TNFalpha B-OTHER
at 0
the 0
fourteenth 0
postoperative 0
day 0
. 0

Gastrointestinal 0
tolerance 0
and 0
diarrhoea 0
rate 0
were 0
similar 0
in 0
all 0
the 0
patients 0
. 0

CONCLUSIONS 0
Immunoenhanced 0
enteral 0
nutrition 0
formulas 0
improved 0
the 0
infection 0
rate 0
in 0
the 0
postoperative 0
of 0
head 0
and 0
neck 0
cancer 0
patients 0
. 0

In 0
the 0
fistula 0
rates 0
, 0
we 0
observed 0
that 0
technical 0
problems 0
and 0
nutritional 0
status 0
might 0
have 0
played 0
an 0
equally 0
important 0
role 0
, 0
and 0
therefore 0
the 0
positive 0
effect 0
of 0
immunonutrition 0
in 0
this 0
parameter 0
might 0
have 0
been 0
overestimated 0
. 0

Randomized 0
placebo 0
controlled 0
human 0
volunteer 0
trial 0
of 0
a 0
live 0
oral 0
cholera 0
vaccine 0
VA1.3 0
for 0
safety B-OTHER
and 0
immune 0
response 0
. 0

A 0
live 0
oral 0
cholera 0
vaccine 0
developed 0
from 0
a 0
non-toxigenic 0
Vibrio 0
cholerae 0
O1 0
El 0
Tor 0
strain 0
VA1.3 0
was 0
tested 0
in 0
a 0
double-blind 0
randomized 0
placebo 0
controlled 0
study 0
for 0
safety 0
and 0
immunogenicity 0
in 0
304 0
men 0
aged 0
between 0
16 0
and 0
50 0
years 0
from 0
Kolkata 0
, 0
India 0
. 0

A 0
dose 0
of 0
5 0
x 0
10 0
( 0
9 0
) 0
CFU 0
( 0
n=186 0
) 0
or 0
a 0
placebo 0
( 0
n=116 0
) 0
containing 0
the 0
diluent 0
buffer 0
was 0
administered 0
. 0

The 0
vaccine 0
did 0
not 0
elicit 0
adverse B-ADVERSE-EFFECTS
events I-ADVERSE-EFFECTS
except 0
in 0
two 0
vaccine 0
recipients 0
with 0
mild B-ADVERSE-EFFECTS
diarrhoea I-ADVERSE-EFFECTS
and 0
vomiting B-ADVERSE-EFFECTS
. 0

None 0
excreted 0
the 0
vaccine 0
strain 0
. 0

Vibriocidal B-PHYSICAL
antibody I-PHYSICAL
response I-PHYSICAL
developed 0
in 0
105/186 0
( 0
57 0
% 0
) 0
and 0
5/116 0
( 0
4 0
% 0
) 0
in 0
vaccine 0
and 0
placebo 0
recipients 0
, 0
respectively 0
. 0

In 0
a 0
subgroup 0
, 0
anti-CT B-PHYSICAL
antibody I-PHYSICAL
rose I-PHYSICAL
( 0
> 0
or 0
=2-folds 0
) 0
in 0
23/30 0
( 0
77 0
% 0
) 0
and 0
6/19 0
( 0
32 0
% 0
) 0
in 0
vaccine 0
and 0
placebo 0
recipients 0
, 0
respectively 0
. 0

These 0
studies 0
demonstrate 0
that 0
VA1.3 0
at 0
a 0
dose 0
of 0
5 0
x 0
10 0
( 0
9 0
) 0
is 0
safe B-OTHER
and 0
immunogenic B-OTHER
in 0
adults 0
from 0
a 0
cholera 0
endemic 0
region 0
. 0

A 0
stable 0
prostacyclin 0
analogue 0
( 0
iloprost 0
) 0
in 0
the 0
treatment 0
of 0
ischaemic 0
ulcers 0
of 0
the 0
lower 0
limb 0
. 0

A 0
Scandinavian-Polish 0
placebo 0
controlled 0
, 0
randomised 0
multicenter 0
study 0
. 0

The 0
clinical B-OTHER
efficacy I-OTHER
of 0
the 0
prostacyclin 0
analogue 0
iloprost 0
was 0
studied 0
during 0
a 0
2 0
week 0
treatment 0
and 0
6 0
month 0
follow-up 0
period 0
in 0
103 0
patients 0
with 0
ischaemic 0
ulcers 0
who 0
were 0
randomised 0
to 0
receive 0
active 0
treatment 0
or 0
placebo 0
. 0

Responders 0
were 0
defined 0
as 0
those 0
patients 0
who 0
achieved 0
healing 0
of 0
at 0
least 0
one 0
third 0
of 0
the 0
ulcer 0
area 0
during 0
the 0
study 0
period 0
. 0

The 0
overall 0
responder B-PHYSICAL
rate I-PHYSICAL
was 0
41.3 0
% 0
, 0
compared 0
with 0
25 0
% 0
for 0
the 0
control 0
group 0
( 0
P 0
= 0
0.086 0
) 0
. 0

Side 0
effects 0
including 0
flushing B-ADVERSE-EFFECTS
and 0
headache B-ADVERSE-EFFECTS
, 0
were 0
common 0
. 0

The 0
study 0
population 0
had 0
a 0
mortality B-MORTALITY
of 0
23 0
% 0
during 0
the 0
6 0
month 0
period 0
, 0
the 0
amputation B-PHYSICAL
rate I-PHYSICAL
was 0
43.5 0
% 0
for 0
iloprost 0
and 0
50 0
% 0
for 0
placebo 0
treated 0
patients 0
. 0

In 0
this 0
severely 0
diseased 0
population 0
of 0
patients 0
a 0
treatment 0
period 0
limited 0
to 0
2 0
weeks 0
did 0
not 0
sufficiently 0
improve 0
ulcer B-PHYSICAL
healing I-PHYSICAL
. 0

Cardiovascular 0
effects 0
of 0
non-depolarizing 0
neuromuscular 0
blockers 0
in 0
patients 0
with 0
aortic 0
valve 0
disease 0
. 0

To 0
compare 0
haemodynamic 0
responses 0
associated 0
with 0
equipotent 0
doses 0
of 0
neuromuscular 0
blockers 0
and 0
high-dose 0
fentanyl 0
( 0
50 0
micrograms.kg-1 0
) 0
, 0
40 0
patients 0
with 0
aortic 0
valve 0
stenosis 0
( 0
AS 0
) 0
and 0
20 0
patients 0
with 0
aortic 0
insufficiency 0
( 0
AI 0
) 0
were 0
randomized 0
to 0
four 0
study 0
groups 0
to 0
receive 0
the 0
following 0
: 0
( 0
1 0
) 0
pancuronium 0
0.12 0
mg.kg-1 0
, 0
( 0
2 0
) 0
vecuronium 0
0.12 0
mg.kg-1 0
, 0
( 0
3 0
) 0
atracurium 0
0.4 0
mg.kg-1 0
, 0
or 0
( 0
4 0
) 0
pancuronium-metocurine 0
mixture 0
( 0
0.4 0
mg 0
+ 0
1.6 0
mg/ml 0
) 0
: 0
1 0
ml/10 0
kg 0
) 0
. 0

Neuromuscular 0
blockers 0
were 0
injected 0
at 0
the 0
same 0
time 0
with 0
the 0
fentanyl 0
; 0
haemodynamics 0
were 0
recorded 0
with 0
the 0
patients 0
awake 0
( 0
baseline 0
) 0
, 0
at 0
two 0
minutes 0
post-induction 0
, 0
and 0
at 0
two 0
and 0
five 0
minutes 0
after 0
intubation 0
. 0

In 0
patients 0
with 0
AS 0
, 0
pancuronium 0
increased 0
heart B-PHYSICAL
rate I-PHYSICAL
more 0
than 0
vecuronium 0
or 0
atracurium 0
; 0
heart B-PHYSICAL
rates I-PHYSICAL
were 0
also 0
higher 0
with 0
the 0
pancuronium-metocurine 0
mixture 0
than 0
with 0
vecuronium 0
. 0

Although 0
there 0
were 0
no 0
ECG B-PHYSICAL
signs I-PHYSICAL
of I-PHYSICAL
ischaemia I-PHYSICAL
, 0
one 0
patient 0
given 0
pancuronium 0
developed 0
severe B-PHYSICAL
hypotension I-PHYSICAL
associated 0
with B-PHYSICAL
tachycardia B-PHYSICAL
. 0

Reductions 0
in 0
SVR B-PHYSICAL
after 0
atracurium 0
allowed 0
small 0
but 0
significant 0
( 0
p 0
less 0
than 0
0.01 0
) 0
decreases 0
in 0
MAP B-PHYSICAL
which 0
were 0
well B-OTHER
tolerated I-OTHER
; 0
one 0
patient 0
, 0
however 0
, 0
did 0
develop 0
severe B-PHYSICAL
hypotension B-PHYSICAL
. 0

Intubation 0
resulted 0
in 0
significant 0
( 0
p 0
less 0
than 0
0.01 0
) 0
increases 0
in 0
MAP B-PHYSICAL
in 0
the 0
pancuronium-metocurine 0
mixture 0
group 0
. 0

Vecuronium 0
permitted 0
the 0
most 0
stable 0
overall B-PHYSICAL
haemodynamic B-PHYSICAL
course B-PHYSICAL
at 0
all 0
measurement 0
times 0
. 0

In 0
contrast 0
, 0
patients 0
with 0
AI 0
showed 0
stable B-PHYSICAL
haemodynamics B-PHYSICAL
after 0
vecuronium 0
, 0
pancuronium 0
and 0
the 0
pancuronium-metocurine 0
mixture 0
; 0
one 0
patient 0
became 0
tachycardic B-PHYSICAL
following 0
vecuronium 0
. 0

Atracurium 0
caused 0
unexplained 0
elevations 0
in 0

[ 0
Clinical 0
study 0
on 0
retarding B-PHYSICAL
aging I-PHYSICAL
effect 0
of 0
tongbu 0
recipe 0
to 0
traditional 0
Chinese 0
medicine 0
] 0
. 0

OBJECTIVE 0
To 0
study 0
the 0
mechanism 0
of 0
Tongbu 0
No 0
. 0

1 0
( 0
TB1 0
, 0
a 0
prescription 0
for 0
reinforcing 0
Kidney 0
and 0
Spleen 0
, 0
clearing 0
up 0
the 0
bowel 0
viscera 0
to 0
send 0
Turbid 0
downward 0
and 0
regulating 0
Qi 0
and 0
blood 0
) 0
in 0
retarding B-PHYSICAL
aging I-PHYSICAL
. 0

METHODS 0
A 0
controlled 0
, 0
multiple 0
indexes 0
study 0
was 0
conducted 0
in 0
56 0
old 0
subjects 0
randomized 0
into 0
3 0
groups 0
. 0

RESULTS 0
TB1 0
( 0
containing 0
ginseng 0
leaf 0
, 0
cistanche 0
, 0
fleeceflower 0
root 0
, 0
immature 0
bitter 0
orange 0
, 0
rhubarb 0
, 0
etc 0
) 0
could 0
improve 0
various 0
symptoms B-PHYSICAL
of I-PHYSICAL
aging I-PHYSICAL
, 0
and 0
had 0
the 0
effect 0
in 0
regulating B-PHYSICAL
immune I-PHYSICAL
and 0
endocrinal B-PHYSICAL
function I-PHYSICAL
, 0
scavenging B-PHYSICAL
free I-PHYSICAL
radicals I-PHYSICAL
and 0
adjusting B-PHYSICAL
coli I-PHYSICAL
flora I-PHYSICAL
. 0

The 0
effects 0
of 0
TB1 0
and 0
TB2 0
( 0
containing 0
ginseng 0
leaf 0
, 0
cistanche 0
and 0
fleeceflower 0
root 0
) 0
were 0
different 0
significantly 0
( 0
P 0
< 0
0.05 0
, 0
P 0
< 0
0.01 0
) 0
. 0

CONCLUSION 0
TB1 0
has 0
a 0
good 0
comprehensive 0
effect 0
in 0
retarding B-PHYSICAL
aging I-PHYSICAL
. 0

Effect 0
of 0
age 0
and 0
radiation 0
dose 0
on 0
local B-PHYSICAL
control I-PHYSICAL
after 0
breast 0
conserving 0
treatment 0
: 0
EORTC 0
trial 0
22881-10882 0
. 0

PURPOSE 0
To 0
determine 0
whether 0
the 0
effect 0
of 0
an 0
additional 0
boost 0
radiation 0
after 0
breast 0
conservative 0
therapy 0
( 0
BCT 0
) 0
on 0
local 0
control 0
depends 0
on 0
age 0
and 0
evaluate 0
the 0
impact 0
of 0
a 0
treatment 0
policy 0
with 0
a 0
threshold 0
for 0
age 0
. 0

PATIENTS 0
AND 0
METHODS 0
We 0
used 0
data 0
from 0
EORTC 0
22881-10882 0
trial 0
, 0
with 0
median 0
follow-up 0
of 0
77.4 0
months 0
. 0

Patients 0
receiving 0
BCT 0
and 0
50Gy 0
whole 0
breast 0
irradiation 0
were 0
randomized 0
to 0
no 0
boost 0
and 0
16Gy 0
boost 0
( 0
N=5318 0
) 0
. 0

RESULTS 0
In 0
univariate 0
analysis 0
, 0
a 0
boost 0
reduced 0
local B-PHYSICAL
failure I-PHYSICAL
by 0
a 0
factor 0
of 0
2 0
( 0
P 0
< 0
0.0001 0
) 0
. 0

Multivariate 0
analysis 0
showed 0
local B-PHYSICAL
control I-PHYSICAL
increased 0
with 0
age 0
( 0
P=0.0003 0
) 0
. 0

There 0
was 0
no 0
evidence 0
that 0
the 0
relative 0
effect 0
of 0
a 0
boost 0
on 0
local B-PHYSICAL
control I-PHYSICAL
depends 0
on 0
age 0
( 0
P=0.97 0
) 0
However 0
in 0
younger 0
patients 0
the 0
5-year 0
local B-PHYSICAL
failure I-PHYSICAL
was 0
higher 0
, 0
therefore 0
the 0
absolute 0
reduction 0
was 0
greater 0
. 0

If 0
the 0
threshold-age 0
for 0
boost 0
treatment 0
were 0
set 0
at 0
40 0
years 0
, 0
8.4 0
% 0
of 0
the 0
study 0
population 0
would 0
receive 0
a 0
boost 0
, 0
resulting 0
in 0
a 0
5-year 0
local B-PHYSICAL
failure I-PHYSICAL
of 0
6.1 0
% 0
in 0
the 0
study 0
population 0
. 0

Changing 0
the 0
threshold-age 0
to 0
60 0
years 0
, 0
67 0
% 0
of 0
the 0
study 0
population 0
would 0
receive 0
a 0
boost 0
and 0
the 0
5-year 0
local B-PHYSICAL
failure I-PHYSICAL
would 0
be 0
reduced 0
to 0
4.4 0
% 0
. 0

CONCLUSIONS 0
In 0
younger 0
patients 0
a 0
boost 0
dose 0
resulted 0
in 0
a 0
greater 0
absolute 0
reduction 0
of 0
local B-PHYSICAL
failure I-PHYSICAL
. 0

The 0
relative 0
risk 0
reduction B-OTHER
was 0
however 0
similar 0
for 0
all 0
ages 0
. 0

Applying 0
a 0
treatment 0
policy 0
with 0
a 0
threshold-age 0
of 0
60 0
would 0
result 0
in 0
0.6 0
% 0
increase 0
in 0
local B-PHYSICAL
failure I-PHYSICAL
in 0
the 0
total 0
study 0
population 0
, 0
while 0
sparing 0
the 0
boost 0
to 0
1/3 0
of 0
the 0
patients 0
. 0

Two-year 0
prospective 0
clinical 0
comparison 0
of 0
immediate 0
replacement 0
vs. 0
immediate 0
restoration 0
of 0
single 0
tooth 0
in 0
the 0
esthetic 0
zone 0
. 0

AIM 0
To 0
compare 0
the 0
immediate 0
restoration 0
of 0
single 0
implants 0
in 0
the 0
esthetic 0
zones 0
performed 0
on 0
implants 0
placed 0
immediately 0
after 0
tooth 0
extraction 0
or 0
8 0
weeks 0
later 0
( 0
immediate 0
replacement 0
vs. 0
immediate 0
restoration 0
) 0
. 0

METHODS 0
Sixteen 0
patients 0
( 0
10 0
women 0
and 0
6 0
men 0
) 0
with 0
a 0
mean 0
age 0
of 0
35 0
years 0
( 0
ranging 0
from 0
21 0
to 0
49 0
years 0
old 0
) 0
were 0
treated 0
from 0
2004 0
to 0
2005 0
for 0
single-tooth 0
replacement 0
in 0
the 0
upper 0
arch 0
. 0

The 0
patients 0
were 0
randomly 0
divided 0
into 0
two 0
groups 0
: 0
in 0
the 0
test 0
group 0
patients 0
received 0
implants 0
placed 0
and 0
restored 0
( 0
non-occlusal 0
loading 0
) 0
at 0
the 0
time 0
of 0
tooth 0
extraction 0
; 0
in 0
the 0
control 0
group 0
implants 0
were 0
placed 0
8 0
weeks 0
after 0
tooth 0
extraction 0
and 0
immediately 0
restored 0
. 0

All 0
the 0
patients 0
received 0
tapered 0
effect 0
( 0
TE 0
) 0
implants 0
from 0
the 0
Straumann 0
Dental 0
Implant 0
System 0
. 0

The 0
following 0
parameters 0
were 0
evaluated 0
at 0
the 0
moment 0
of 0
provisional 0
restoration 0
( 0
within 0
48 0
h 0
after 0
implant 0
placement 0
) 0
and 0
at 0
the 0
2 0
years 0
follow-up 0
visit 0
: 0
marginal B-PHYSICAL
bone I-PHYSICAL
resorption I-PHYSICAL
, 0
papilla B-PHYSICAL
index 0
, 0
position 0
of B-PHYSICAL
the I-PHYSICAL
mucosal I-PHYSICAL
margin I-PHYSICAL
. 0

The 0
implant B-PHYSICAL
stability I-PHYSICAL
quotient I-PHYSICAL
was 0
measured 0
at 0
the 0
moment 0
of 0
implant 0
placement 0
and 0
at 0
the 0
moment 0
of 0
the 0
delivery 0
of 0
the 0
definitive 0
restoration 0
. 0

RESULTS 0
No 0
statistically 0
significant 0
differences 0
were 0
found 0
in 0
any 0
of 0
the 0
studied 0
parameters 0
between 0
the 0
test 0
and 0
the 0
control 0
groups 0
( 0
P 0
> 0
0.05 0
) 0
. 0

The 0
implant B-PHYSICAL
stability 0
quotient 0
values 0
between 0
the 0
test 0
and 0
control 0
groups 0
were 0
significant 0
( 0
P 0
< 0
0.05 0
) 0
at 0
the 0
moment 0
of 0
implant 0
placement 0
but 0
were 0
no 0
more 0
significant 0
at 0
the 0
loading 0
of 0
the 0
definitive 0
restoration 0
( 0
P 0
> 0
0.05 0
) 0
. 0

CONCLUSION 0
The 0
results 0
of 0
the 0
present 0
study 0
suggest 0
that 0
immediate 0
replacement 0
without 0
functional 0
loading 0
may 0
be 0
considered 0
a 0
valuable 0
therapeutic 0
option 0
for 0
selected 0
cases 0
of 0
single-tooth 0
replacement 0
in 0
the 0
esthetic 0
area 0
when 0
TE 0
implants 0
are 0
used 0
. 0

Implant B-PHYSICAL
stability I-PHYSICAL
at 0
the 0
moment 0
of 0
implant 0
placement 0
is 0
slightly 0
inferior 0
in 0
the 0
immediate 0
replacement 0
group 0
, 0
but 0
it 0
does 0
not 0
affect 0
the 0
treatment 0
result 0
. 0

Postoperative B-PAIN
pain I-PAIN
control I-PAIN
for 0
outpatient 0
oral 0
surgery 0
. 0

16 0
healthy 0
patients 0
requiring 0
removal 0
of 0
bilateral 0
symmetrically-impacted 0
mandibular 0
third 0
molars 0
participated 0
in 0
a 0
double-blind 0
randomised 0
crossover 0
trial 0
to 0
test 0
the 0
effectiveness 0
of 0
postoperative B-PAIN
pain I-PAIN
control I-PAIN
using 0
a 0
long-acting 0
anti-inflammatory 0
agent 0
( 0
diflunisal 0
) 0
in 0
combination 0
with 0
a 0
long-acting 0
local 0
anaesthetic 0
agent 0
( 0
bupivacaine 0
) 0
. 0

Results 0
were 0
compared 0
to 0
the 0
more 0
traditional 0
method 0
of 0
using 0
an 0
oral 0
analgesic 0
with 0
shorter 0
duration 0
of 0
action 0
( 0
paracetamol 0
with 0
codeine 0
) 0
with 0
lignocaine 0
as 0
the 0
local 0
anaesthetic 0
. 0

Using 0
a 0
visual B-PAIN
analogue I-PAIN
pain I-PAIN
scale 0
, 0
patients 0
reported 0
that 0
significantly 0
reduced 0
pain B-PAIN
was 0
experienced 0
over 0
the 0
first 0
4 0
days 0
postoperatively 0
with 0
the 0
diflunisal/bupivacaine 0
treatment 0
and 0
patient B-PAIN
preference I-PAIN
for 0
this 0
treatment 0
was 0
highly 0
significant 0
. 0

This 0
report 0
represents 0
the 0
first 0
such 0
study 0
of 0
diflunisal 0
used 0
for 0
an 0
extended 0
course 0
in 0
oral 0
surgery 0
with 0
pain B-PAIN
assessment 0
over 0
the 0
same 0
period 0
. 0

No 0
significant 0
side-effects B-ADVERSE-EFFECTS
or I-ADVERSE-EFFECTS
adverse I-ADVERSE-EFFECTS
reactions I-ADVERSE-EFFECTS
were 0
encountered 0
. 0

The 0
immunogenicity B-PHYSICAL
of 0
three 0
Haemophilus 0
influenzae 0
type 0
B 0
conjugate 0
vaccines 0
after 0
a 0
primary 0
vaccination 0
series 0
in 0
Philippine 0
infants 0
. 0

Serum B-PHYSICAL
antibody I-PHYSICAL
responses I-PHYSICAL
to 0
three 0
Haemophilus 0
influenzae 0
type 0
b 0
( 0
Hib 0
) 0
capsular 0
polysaccharide-protein 0
conjugate 0
vaccine 0
( 0
PRP-OMP 0
, 0
PRP-T 0
, 0
and 0
HbOC 0
) 0
were 0
evaluated 0
in 0
174 0
Philippine 0
infants 0
after 0
a 0
primary 0
vaccination 0
series 0
. 0

Children 0
were 0
randomized 0
to 0
receive 0
one 0
of 0
the 0
Hib 0
vaccines 0
( 0
Hib 0
groups 0
) 0
or 0
into 0
a 0
control 0
group 0
. 0

Vaccination 0
was 0
carried 0
out 0
at 0
six 0
, 0
10 0
and 0
14 0
weeks 0
of 0
age 0
based 0
on 0
the 0
local 0
Expanded 0
Program 0
of 0
Immunization 0
schedule 0
. 0

Sera 0
were 0
collected 0
at 0
six 0
weeks 0
of 0
age 0
for 0
the 0
Hib 0
groups 0
and 0
one 0
month 0
after 0
the 0
third 0
dose 0
for 0
all 0
subjects 0
. 0

Anti-Hib B-PHYSICAL
concentrations I-PHYSICAL
were 0
determined 0
by 0
the 0
Farr-type 0
radioimmunoassay 0
. 0

There 0
were 0
no 0
significant 0
differences 0
( 0
P 0
= 0
0.3626 0
) 0
in 0
the 0
prevaccination B-PHYSICAL
anti-Hib I-PHYSICAL
geometric 0
mean 0
concentration 0
( B-PHYSICAL
GMC B-PHYSICAL
) B-PHYSICAL
among 0
the 0
three 0
Hib 0
groups 0
. 0

Differences 0
in 0
the 0

Virtual 0
reality 0
for 0
acute 0
pain 0
reduction 0
in 0
adolescents 0
undergoing 0
burn 0
wound 0
care 0
: 0
a 0
prospective 0
randomized 0
controlled 0
trial 0
. 0

BACKGROUND 0
Effective 0
pain 0
management 0
remains 0
a 0
challenge 0
for 0
adolescents 0
during 0
conscious 0
burn 0
wound 0
care 0
procedures 0
. 0

Virtual 0
reality 0
( 0
VR 0
) 0
shows 0
promise 0
as 0
a 0
non-pharmacological 0
adjunct 0
in 0
reducing 0
pain 0
. 0

AIMS 0
This 0
study 0
assessed 0
off-the-shelf 0
VR 0
for 0
( 0
1 0
) 0
its 0
effect 0
on 0
reducing 0
acute 0
pain 0
intensity 0
during 0
adolescent 0
burn 0
wound 0
care 0
, 0
and 0
( 0
2 0
) 0
its 0
clinical 0
utility 0
in 0
a 0
busy 0
hospital 0
setting 0
. 0

METHODS 0
Forty-one 0
adolescents 0
( 0
11-17 0
years 0
) 0
participated 0
in 0
this 0
prospective 0
randomized 0
controlled 0
trial 0
. 0

Acute 0
pain 0
outcomes 0
including 0
adolescent 0
self-report 0
, 0
nursing 0
staff 0
behavioral 0
observation 0
, 0
caregiver 0
observation 0
and 0
physiological 0
measures 0
were 0
collected 0
. 0

Length 0
of 0
procedure 0
times 0
and 0
adolescent 0
reactions 0
were 0
also 0
recorded 0
to 0
inform 0
clinical 0
utility 0
. 0

RESULTS 0
Nursing 0
staff 0
reported 0
a 0
statistically 0
significant 0
reduction 0
in 0
pain B-PHYSICAL
scores I-PHYSICAL
during 0
dressing 0
removal 0
, 0
and 0
significantly 0
less 0
rescue B-PHYSICAL
doses I-PHYSICAL
of I-PHYSICAL
Entonox I-PHYSICAL
given 0
to 0
those 0
receiving 0
VR 0
, 0
compared 0
to 0
those 0
receiving 0
standard 0
distraction 0
. 0

For 0
all 0
other 0
pain 0
outcomes 0
and 0
length 0
of 0
treatment 0
, 0
there 0
was 0
a 0
trend 0
for 0
lower 0
pain B-OTHER
scores I-OTHER
and I-OTHER
treatment 0

Levobunolol 0
compared 0
with 0
timolol 0
: 0
a 0
four-year 0
study 0
. 0

Fifty-one 0
patients 0
with 0
raised 0
intraocular 0
pressure 0
( 0
IOP 0
) 0
were 0
treated 0
for 0
up 0
to 0
four 0
years 0
with 0
one 0
of 0
three 0
ophthalmic 0
solutions 0
: 0
0.5 0
% 0
levobunolol 0
, 0
1 0
% 0
levobunolol 0
, 0
or 0
0.5 0
% 0
timolol 0
. 0

The 0
study 0
was 0
conducted 0
as 0
a 0
double-masked 0
, 0
randomised 0
trial 0
in 0
which 0
medications 0
were 0
administered 0
twice 0
daily 0
to 0
both 0
eyes 0
. 0

Levobunolol 0
and 0
timolol 0
were 0
equally 0
effective 0
in 0
reducing 0
overall B-PHYSICAL
mean 0
IOP B-PHYSICAL
; 0
reductions 0
were 0
greater 0
than 0
8.8 0
mmHg 0
in 0
all 0
three 0
treatment 0
groups 0
. 0

The 0
study 0
showed 0
levobunolol 0
to 0
be 0
as 0
safe 0
and 0
effective 0
as 0
timolol 0
in 0
the 0
long-term 0
control 0
of 0
raised 0

Behavioral B-MENTAL
changes I-MENTAL
in 0
autistic 0
individuals 0
as 0
a 0
result 0
of 0
wearing 0
ambient 0
transitional 0
prism 0
lenses 0
. 0

A 0
double-blind 0
crossover 0
design 0
was 0
used 0
to 0
assess 0
the 0
efficacy 0
of 0
wearing 0
ambient 0
lenses 0
to 0
reduce 0
the 0
behavioral 0
symptoms 0
of 0
autism 0
. 0

Eighteen 0
autistic 0
individuals 0
, 0
ranging 0
in 0
age 0
from 0
7 0
to 0
18 0
years 0
, 0
participated 0
in 0
the 0
study 0
. 0

Behavior B-MENTAL
, 0
attention B-MENTAL
, 0
and 0
orientation B-MENTAL
were 0
evaluated 0
at 0
1 0
1/2 0
months 0
, 0
2 0
months 0
, 0
3 0
months 0
, 0
and 0
4 0
months 0
. 0

Compared 0
to 0
the 0
placebo 0
condition 0
, 0
the 0
results 0
showed 0
a 0
decrease 0
in 0
behavior B-MENTAL
problems I-MENTAL
at 0
the 0
1 0
1/2 0
and 0
2 0
month 0
assessment 0
periods 0
and 0
a 0
slight 0
loss 0
of 0
these 0
benefits 0
at 0
the 0
3 0
and 0
4 0
month 0
assessment 0
periods 0
. 0

These 0
findings 0
support 0
the 0
prediction 0
that 0
ambient 0
lenses 0
, 0
worn 0
without 0
engaging 0
in 0
visual-motor 0
exercises 0
, 0
have 0
positive 0
effects 0
on 0
autistic 0
individuals 0
. 0

Low-dose 0
mifepristone 0
for 0
uterine 0
leiomyomata 0
. 0

OBJECTIVE 0
To 0
compare 0
the 0
effect 0
of 0
5 0
and 0
10 0
mg 0
of 0
mifepristone 0
on 0
uterine B-PHYSICAL
leiomyoma I-PHYSICAL
size 0
and 0
symptoms B-PHYSICAL
, 0
and 0
to 0
measure 0
side 0
effects 0
. 0

METHODS 0
Forty 0
premenopausal 0
women 0
with 0
large 0
, 0
symptomatic 0
leiomyomata 0
were 0
randomized 0
to 0
receive 0
either 0
5 0
or 0
10 0
mg 0
of 0
mifepristone 0
daily 0
for 0
6 0
months 0
in 0
an 0
open-label 0
study 0
. 0

Uterine 0
volume 0
was 0
measured 0
at 0
bimonthly 0
intervals 0
by 0
sonography 0
. 0

Serum 0
concentrations 0
of 0
hemoglobin 0
levels 0
, 0
follicle-stimulating 0
hormone 0
, 0
and 0
liver 0
enzymes 0
were 0
obtained 0
, 0
and 0
endometrial 0
samples 0
, 0
symptoms 0
, 0
and 0
menstrual 0
bleeding 0
were 0
also 0
assessed 0
. 0

RESULTS 0
Nineteen 0
of 0
20 0
subjects 0
taking 0
5 0
mg 0
and 0
all 0
20 0
subjects 0
taking 0
10 0
mg 0
completed 0
all 0
6 0
months 0
of 0
the 0
study 0
. 0

Mean 0
uterine B-PHYSICAL
volume I-PHYSICAL
shrank I-PHYSICAL
by 0
48 0
% 0
( 0
P 0
< 0
.001 0
) 0
in 0
the 0
5-mg 0
group 0
and 0
49 0
% 0
( 0
P 0
< 0
.001 0
) 0
in 0
the 0
10-mg 0
group 0
, 0
a 0
nonsignificant 0
difference 0
. 0

Leiomyoma-related B-PHYSICAL
symptoms I-PHYSICAL
were 0
comparably 0
reduced 0
in 0
both 0
groups 0
. 0

Amenorrhea B-PHYSICAL
occurred 0
in 0
60-65 0
% 0
of 0
both 0
groups 0
. 0

Hemoglobin B-PHYSICAL
levels I-PHYSICAL
increased 0
by 0
2.5 0
g/dL 0
in 0
anemic 0
subjects 0
. 0

The 0
incidence 0
of 0
hot B-PHYSICAL
flashes I-PHYSICAL
increased 0
significantly 0
over 0
baseline 0
in 0
the 0
10-mg 0
group 0
but 0
not 0
in 0
the 0
5-mg 0
group 0
. 0

Simple B-PHYSICAL
endometrial I-PHYSICAL
hyperplasia I-PHYSICAL
occurred 0
in 0
28 0
% 0
of 0
all 0
subjects 0
, 0
with 0
no 0
difference 0
between 0
groups 0
. 0

No 0
atypical B-PHYSICAL
hyperplasia I-PHYSICAL
was 0
noted 0
. 0

CONCLUSION 0
Mifepristone 0
in 0
doses 0
of 0
5 0
mg 0
or 0
10 0
mg 0
results 0
in 0
comparable 0
leiomyoma B-PHYSICAL
regression I-PHYSICAL
, 0
improvement B-OTHER
in I-OTHER
symptoms I-OTHER
, 0
and 0
few 0
side B-ADVERSE-EFFECTS
effects I-ADVERSE-EFFECTS
. 0

Further 0
study 0
is 0
needed 0
to 0
assess 0
the 0
long-term 0
safety 0
and 0
efficacy 0
of 0
low-dose 0
mifepristone 0
. 0

Prevalence 0
and 0
treatment 0
outcome 0
of 0
cervicitis B-PHYSICAL
of 0
unknown 0
etiology 0
. 0

BACKGROUND 0
Mucopurulent 0
cervicitis 0
( 0
MPC 0
) 0
is 0
a 0
clinical 0
syndrome 0
characterized 0
by 0
mucopurulent 0
discharge 0
from 0
the 0
cervix 0
and 0
other 0
signs 0
of 0
inflammation 0
. 0

This 0
was 0
a 0
phase 0
III 0
, 0
multicenter 0
study 0
designed 0
to 0
evaluate 0
the 0
effectiveness 0
of 0
placebo 0
versus 0
empiric 0
antibiotic 0
treatment 0
for 0
clinical 0
cure 0
of 0
MPC B-PHYSICAL
of 0
unknown 0
etiology 0
at 0
2-month 0
follow-up 0
. 0

Unfortunately 0
, 0
enrollment 0
was 0
terminated 0
because 0
of 0
low 0
accrual 0
of 0
women 0
with 0
cervicitis 0
of 0
unknown 0
etiology 0
, 0
but 0
important 0
prevalence 0
and 0
outcome 0
data 0
were 0
obtained 0
. 0

METHODS 0
Five 0
hundred 0
seventy-seven 0
women 0
were 0
screened 0
for 0
MPC 0
. 0

Women 0
with 0
MPC 0
were 0
randomized 0
to 0
the 0
treatment 0
or 0
placebo 0
arm 0
of 0
the 0
study 0
, 0
and 0
the 0
2 0
arms 0
were 0
evaluated 0
based 0
on 0
the 0
etiology 0
, 0
clinical B-OTHER
cure I-OTHER
rates I-OTHER
, 0
adverse B-PHYSICAL
events I-PHYSICAL
( I-PHYSICAL
AEs I-PHYSICAL
) I-PHYSICAL
, 0
and 0
rates 0
of 0
pelvic B-PHYSICAL
inflammatory I-PHYSICAL
disease I-PHYSICAL
. 0

RESULTS 0
One 0
hundred 0
thirty-one 0
( 0
23 0
% 0
[ 0
131/577 0
] 0
) 0
screened 0
women 0
were 0
found 0
to 0
have 0
MPC 0
. 0

Eighty-seven 0
were 0
enrolled 0
and 0
randomized 0
. 0

After 0
excluding 0
women 0
with 0
sexually 0
transmitted 0
infections 0
and 0
other 0
exclusions 0
, 0
61 0
% 0
( 0
53/87 0
) 0
had 0
cervicitis B-PHYSICAL
of 0
unknown 0
etiology 0
. 0

The 0
overall B-OTHER
clinical I-OTHER
failure I-OTHER
rate I-OTHER
was 0
30 0
% 0
( 0
10/33 0
) 0
, 0
and 0
the 0
clinical B-OTHER
cure I-OTHER
rate I-OTHER
was 0
only 0
24 0
% 0
( 0
8/33 0
) 0
. 0

Rates 0
were 0
not 0
significantly 0
different 0
between 0
the 0
arms 0
. 0

There 0
were 0
24 0
gastrointestinal B-PHYSICAL
AEs I-PHYSICAL
in 0
the 0
treatment 0
arm 0
compared 0
with 0
1 0
AE 0
in 0
the 0
placebo 0
arm 0
. 0

CONCLUSIONS 0
More 0
than 0
half 0
of 0
the 0
cases 0
of 0
MPC 0
were 0
of 0
unknown 0
etiology 0
. 0

Clinical B-OTHER
cure I-OTHER
rates I-OTHER
for 0
the 0
placebo 0
and 0
treatment 0
arms 0
were 0
extremely 0
low 0
, 0
with 0
most 0
women 0
concluding 0
the 0
study 0
with 0
a 0
partial 0
response 0
. 0

Gastrointestinal B-PHYSICAL
AEs I-PHYSICAL
were 0
higher 0
in 0
the 0
treatment 0
arm 0
. 0

Effects 0
of 0
two 0
combined 0
oral 0
contraceptives 0
containing 0
ethinyl 0
estradiol 0
20 0
microg 0
combined 0
with 0
either 0
drospirenone 0
or 0
desogestrel 0
on 0
lipids 0
, 0
hemostatic 0
parameters 0
and 0
carbohydrate 0
metabolism 0
. 0

OBJECTIVE 0
To 0
compare 0
the 0
effect 0
of 0
ethinyl 0
estradiol 0
20 0
microg/drospirenone 0
3 0
mg 0
( 0
EE 0
20 0
microg/DRSP 0
3 0
mg 0
) 0
administered 0
according 0
to 0
a 0
24/4 0
regimen 0
with 0
ethinyl 0
estradiol 0
20 0
microg/desogestrel 0
150 0
microg 0
( 0
EE 0
20 0
microg/DSG 0
150 0
microg 0
) 0
administered 0
according 0
to 0
the 0
conventional 0
21/7 0
regimen 0
on 0
lipid 0
, 0
carbohydrate 0
and 0
hemostatic 0
parameters 0
. 0

STUDY 0
DESIGN 0
In 0
this 0
open-label 0
study 0
, 0
healthy 0
women 0
were 0
randomized 0
to 0
EE 0
20 0
microg/DRSP 0
3 0
mg 0
or 0
EE 0
20 0
microg/DSG 0
150 0
microg 0
for 0
seven 0
cycles 0
. 0

Mean 0
differences 0
in 0
high-density B-PHYSICAL
lipoprotein I-PHYSICAL
( I-PHYSICAL
HDL I-PHYSICAL
) I-PHYSICAL
- 0
and 0
low-density B-PHYSICAL
lipoprotein I-PHYSICAL
( I-PHYSICAL
LDL I-PHYSICAL
) I-PHYSICAL
-cholesterol I-PHYSICAL
levels I-PHYSICAL
at 0
cycle 0
7 0
compared 0
to 0
baseline 0
were 0
assessed 0
. 0

Secondary 0
variables 0
included 0
changes 0
in 0
other 0
lipid B-PHYSICAL
, 0
hemostatic B-PHYSICAL
and 0
carbohydrate B-PHYSICAL
parameters I-PHYSICAL
. 0

RESULTS 0
Both 0
treatments 0
increased 0
HDL-cholesterol B-PHYSICAL
, 0
but 0
decreased 0
LDL-cholesterol B-PHYSICAL
by 0
a 0
comparable 0
extent 0
. 0

Although 0
slightly 0
elevated 0
in 0
both 0
groups 0
, 0
blood B-PHYSICAL
glucose I-PHYSICAL
and I-PHYSICAL
C-peptide I-PHYSICAL
levels I-PHYSICAL
measured 0
during 0
oral 0
glucose 0
tolerance 0
tests 0
were 0
within 0
normal 0
reference 0
ranges 0
at 0
cycle 0
7 0
. 0

Overall 0
, 0
the 0
differences 0
in 0
lipid B-PHYSICAL
, 0
hemostatic B-PHYSICAL
or I-PHYSICAL
carbohydrate I-PHYSICAL
parameters I-PHYSICAL
were 0
not 0
significant 0
between 0
the 0
two 0
treatments 0
. 0

CONCLUSION 0
EE 0
20 0
microg/DRSP 0
3 0
mg 0
has 0
a 0
good 0
safety 0
profile 0
comparable 0
with 0
EE 0
20 0
microg/DSG 0
150 0
microg 0
. 0

Effect 0
of 0
ozone 0
application 0
on 0
the 0
resin-dentin B-OTHER
microtensile I-OTHER
bond I-OTHER
strength I-OTHER
. 0

When 0
ozone 0
is 0
used 0
during 0
caries 0
treatment 0
, 0
bond 0
strength 0
can 0
be 0
compromised 0
by 0
the 0
release 0
of 0
oxygen 0
. 0

The 0
use 0
of 0
antioxidant 0
agents 0
neutralizes 0
the 0
free 0
oxygen 0
. 0

The 0
aim 0
of 0
this 0
study 0
was 0
to 0
evaluate 0
the 0
effects 0
of 0
ozone 0
and 0
sodium 0
ascorbate 0
on 0
resin-dentin 0
microtensile 0
bond 0
strength 0
( 0
?TBS 0
) 0
. 0

Forty 0
human 0
third 0
molars 0
were 0
divided 0
into 0
four 0
groups 0
: 0
Group 0
1 0
, 0
not 0
treated 0
with 0
ozone 0
; 0
Group 0
2 0
, 0
ozone 0
application 0
followed 0
by 0
acid 0
etching 0
; 0
Group 0
3 0
, 0
acid 0
etching 0
followed 0
by 0
ozone 0
application 0
; 0
and 0
Group 0
4 0
, 0
ozone 0
and 0
application 0
of 0
sodium 0
ascorbate 0
. 0

Bonded 0
beams 0
( 0
1.0 0
mm 0
( 0
2 0
) 0
) 0
were 0
tested 0
under 0
tension 0
( 0
0.5 0
mm 0
min 0
( 0
-1 0
) 0
) 0
. 0

The 0
?TBS 0
values 0
were 0
analyzed 0
using 0
one-way 0
analysis 0
of 0
variance 0
( 0
ANOVA 0
) 0
and 0
the 0
Tukey 0
test 0
( 0
p=0.05 0
) 0
. 0

All 0
beams 0
that 0
fractured 0
were 0
analyzed 0
under 0
stereomicroscopy 0
( 0
40? 0
) 0
. 0

Group 0
1 0
had 0
significantly 0
higher 0
?TBS 0
values 0
than 0
Group 0
2 0
or 0
3 0
. 0

The 0
?TBS 0
values 0
of 0
Groups 0
1 0
and 0
4 0
were 0
similar 0
and 0
higher 0
than 0
those 0
of 0
Group 0
2 0
. 0

The 0
use 0
of 0
ozone 0
in 0
Group 0
2 0
resulted 0
in 0
lower 0
values 0
of 0
?TBS 0
in 0
all 0
conditions 0
evaluated 0
. 0

The 0
predominant 0
failure 0
mode 0
was 0
adhesive 0
. 0

The 0
application 0
of 0
ozone 0
decreased 0
the 0
?TBS 0
of 0
the 0
dentin-composite 0
resin 0
interface 0
. 0

These 0
values 0
were 0
reversed 0
when 0
compared 0
with 0
Groups 0
1 0
and 0
2 0
when 0
sodium 0
ascorbate 0
was 0
used 0
. 0

Differences 0
in 0
reach B-OTHER
and 0
attrition 0
between B-OTHER
Web-based I-OTHER
and 0
print-delivered B-OTHER
tailored I-OTHER
interventions I-OTHER
among 0
adults 0
over 0
50 0
years 0
of 0
age 0
: 0
clustered 0
randomized 0
trial 0
. 0

BACKGROUND 0
The 0
Internet 0
has 0
the 0
potential 0
to 0
provide 0
large 0
populations 0
with 0
individual 0
health 0
promotion 0
advice 0
at 0
a 0
relatively 0
low 0
cost 0
. 0

Despite 0
the 0
high 0
rates 0
of 0
Internet 0
access 0
, 0
actual 0
reach 0
by 0
Web-based 0
interventions 0
is 0
often 0
disappointingly 0
low 0
, 0
and 0
differences 0
in 0
use 0
between 0
demographic 0
subgroups 0
are 0
present 0
. 0

Furthermore 0
, 0
Web-based 0
interventions 0
often 0
have 0
to 0
deal 0
with 0
high 0
rates 0
of 0
attrition 0
. 0

OBJECTIVE 0
This 0
study 0
aims 0
to 0
assess 0
user B-OTHER
characteristics I-OTHER
related I-OTHER
to I-OTHER
participation I-OTHER
and I-OTHER
attrition I-OTHER
when 0
comparing 0
Web-based 0
and 0
print-delivered 0
tailored 0
interventions 0
containing 0
similar 0
content 0
and 0
thereby 0
to 0
provide 0
recommendations 0
in 0
choosing 0
the 0
appropriate 0
delivery 0
mode 0
for 0
a 0
particular 0
target 0
audience 0
. 0

METHODS 0
We 0
studied 0
the 0
distribution 0
of 0
a 0
Web-based 0
and 0
a 0
print-delivered 0
version 0
of 0
the 0
Active 0
Plus 0
intervention 0
in 0
a 0
clustered 0
randomized 0
controlled 0
trial 0
( 0
RCT 0
) 0
. 0

Participants 0
were 0
recruited 0
via 0
direct 0
mailing 0
within 0
the 0
participating 0
Municipal 0
Health 0
Council 0
regions 0
and 0
randomized 0
to 0
the 0
printed 0
or 0
Web-based 0
intervention 0
by 0
their 0
region 0
. 0

Based 0
on 0
the 0
answers 0
given 0
in 0
a 0
prior 0
assessment 0
, 0
participants 0
received 0
tailored 0
advice 0
on 0
3 0
occasions 0
: 0
( 0
1 0
) 0
within 0
2 0
weeks 0
after 0
the 0
baseline 0
, 0
( 0
2 0
) 0
2 0
months 0
after 0
the 0
baseline 0
, 0
and 0
( 0
3 0
) 0
within 0
4 0
months 0
after 0
the 0
baseline 0
( 0
based 0
on 0
a 0
second 0
assessment 0
at 0
3 0
months 0
) 0
. 0

The 0
baseline 0
( 0
printed 0
or 0
Web-based 0
) 0
results 0
were 0
analyzed 0
using 0
ANOVA 0
and 0
chi-square 0
tests 0
to 0
establish 0
the 0
differences 0
in 0
user 0
characteristics 0
between 0
both 0
intervention 0
groups 0
. 0

We 0
used 0
logistic 0
regression 0
analyses 0
to 0
study 0
the 0
interaction 0
between 0
the 0
user B-MENTAL
characteristics I-MENTAL
and 0
the 0
delivery 0
mode 0
in 0
the 0
prediction 0
of 0
dropout 0
rate B-OTHER
within 0
the 0
intervention 0
period 0
. 0

RESULTS 0
The 0
printed 0
intervention 0
resulted 0
in 0
a 0
higher B-MENTAL
participation I-MENTAL
rate I-MENTAL
( 0
19 0
% 0
) 0
than 0
the 0
Web-based 0
intervention 0
( 0
12 0
% 0
) 0
. 0

Participants 0
of 0
the 0
Web-based 0
intervention 0
were 0
significantly 0
younger 0
( 0
P 0
< 0
.001 0
) 0
, 0
more 0
often 0
men 0
( 0
P=.01 0
) 0
, 0
had 0
a 0
higher 0
body 0
mass 0
index 0
( 0
BMI 0
) 0
( 0
P=.001 0
) 0
and 0
a 0
lower 0
intention 0
to 0
be 0
physically 0
active 0
( 0
P=.03 0
) 0
than 0
participants 0
of 0
the 0
printed 0
intervention 0
. 0

The 0
dropout 0
rate B-OTHER
was 0
significantly 0
higher 0
in 0
the 0
Web-based 0
intervention 0
group 0
( 0
53 0
% 0
) 0
compared 0
to 0
the 0
print-delivered 0
intervention 0
( 0
39 0
% 0
, 0
P 0
< 0
.001 0
) 0
. 0

A 0
low 0
intention B-MENTAL
to I-MENTAL
be I-MENTAL
physically I-MENTAL
active I-MENTAL
was 0
a 0
strong 0
predictor 0
for 0
dropout 0
within 0
both 0
delivery 0
modes 0
( 0
P 0
< 0
.001 0
) 0
. 0

The 0
difference 0
in 0
dropout 0
rate 0
between 0
the 0
Web-based 0
and 0
the 0
printed 0
intervention 0
was 0
not 0
explained 0
by 0
user 0
characteristics 0
. 0

CONCLUSIONS 0
The 0
reach 0
of 0
the 0
same 0
tailored B-MENTAL
physical I-MENTAL
activity I-MENTAL
( 0
PA B-MENTAL
) 0
intervention 0
in 0
a 0
printed 0
or 0
Web-based 0
delivery 0
mode 0
differed 0
between 0
sociodemographic 0
subgroups 0
of 0
participants 0
over 0
50 0
years 0
of 0
age 0
. 0

Although 0
the 0
reach 0
of 0
the 0
Web-based 0
intervention 0
is 0
lower 0
, 0
Web-based 0
interventions 0
can 0
be 0
a 0
good 0
channel 0
to 0
reach 0
high-risk 0
populations 0
( 0
lower 0
PA 0
intention 0
and 0
higher 0
BMI 0
) 0
. 0

While 0
the 0
dropout 0
rate B-OTHER
was 0
significantly 0
higher 0
in 0
the 0
Web-based 0
intervention 0
group 0
, 0
no 0
specific 0
user 0
characteristics 0
explained 0
the 0
difference 0
in 0
dropout 0
rates B-OTHER
between 0
the 0
delivery 0
modes 0
. 0

More 0
research 0
is 0
needed 0
to 0
determine 0
what 0
caused 0
the 0
high 0
rate B-OTHER
of I-OTHER
dropout I-OTHER
in 0
the 0
Web-based 0
intervention 0
. 0

TRIAL 0
REGISTRATION 0
Dutch 0
Trial 0
Register 0
( 0
NTR 0
) 0
: 0
2297 0
: 0
http 0
: 0
//www.trialregister.nl/trialreg/admin/rctview.asp 0
? 0

TC=2297 0
( 0
Archived 0
by 0
WebCite 0
at 0
http 0
: 0
//www.webcitation.org/65TkwoESp 0
) 0
. 0

Human 0
motor 0
responses 0
to 0
simultaneous 0
aversive 0
stimulation 0
and 0
failure 0
on 0
a 0
valued 0
task 0
. 0

The 0
effects 0
of 0
presentation 0
of 0
an 0
aversive 0
stimulus 0
and 0
simultaneous 0
failure 0
on 0
a 0
bogus 0
intelligence 0
test 0
upon 0
a 0
subject 0
's 0
aggressive B-MENTAL
reactions I-MENTAL
were 0
studied 0
. 0

The 0
subject 0
's 0
fist B-MENTAL
clenching I-MENTAL
was 0
used 0
as 0
an 0
indicator B-MENTAL
of I-MENTAL
aggression I-MENTAL
. 0

Four 0
conditions 0
, 0
generated 0
by 0
the 0
combinations 0
of 0
two 0
kinds 0
of 0
stimulus 0
delivered 0
to 0
the 0
subjects 0
( 0
aversive 0
or 0
nonaversive 0
) 0
and 0
two 0
outcomes 0
of 0
the 0
task 0
( 0
failure 0
or 0
success 0
) 0
, 0
were 0
investigated 0
. 0

20 0
female 0
and 0
20 0
male 0
students 0
( 0
ages 0
: 0
17-34 0
years 0
) 0
were 0
instructed 0
, 0
upon 0
the 0
reception 0
of 0
an 0
aversive 0
or 0
nonaversive 0
acoustic 0
signal 0
, 0
to 0
press 0
with 0
the 0
right 0
hand 0
a 0
device 0
that 0
displayed 0
a 0
slide 0
. 0

Each 0
slide 0
presented 0
an 0
item 0
from 0
an 0
intelligence 0
test 0
, 0
to 0
which 0
the 0
subjects 0
were 0
either 0
allowed 0
to 0
answer 0
successfully 0
( 0
success 0
) 0
or 0
not 0
( 0
failure 0
) 0
. 0

Failure 0
increased 0
the 0
subject 0
's 0
autonomic B-MENTAL
arousal I-MENTAL
, 0
as 0
measured 0
by 0
photoplethysmographic 0
sensors 0
, 0
in 0
all 0
stimulation 0
conditions 0
, 0
but 0
only 0
the 0
condition 0
with 0
aversive 0
stimulation 0
increased 0
the 0
speed B-MENTAL
of I-MENTAL
clenching I-MENTAL
. 0

This 0
was 0
interpreted 0
as 0
indicating 0
subject 0
's 0
tendencies B-MENTAL
to I-MENTAL
aggression I-MENTAL
. 0

These 0
results 0
are 0
discussed 0
in 0
relation 0
to 0
the 0
effects 0
of 0
frustration 0
. 0

Pre-bent 0
instruments 0
used 0
in 0
single-port 0
laparoscopic 0
surgery 0
versus 0
conventional 0
laparoscopic 0
surgery 0
: 0
comparative 0
study 0
of 0
performance 0
in 0
a 0
dry 0
lab 0
. 0

BACKGROUND 0
Different 0
types 0
of 0
single-incision 0
laparoscopic 0
surgery 0
( 0
SILS 0
) 0
have 0
become 0
increasingly 0
popular 0
. 0

Although 0
SILS 0
is 0
technically 0
even 0
more 0
challenging 0
than 0
conventional 0
laparoscopy 0
, 0
published 0
data 0
of 0
first 0
clinical 0
series 0
seem 0
to 0
demonstrate 0
the 0
feasibility 0
of 0
these 0
approaches 0
. 0

Various 0
attempts 0
have 0
been 0
made 0
to 0
overcome 0
restrictions 0
due 0
to 0
loss 0
of 0
triangulation 0
in 0
SILS 0
by 0
specially 0
designed 0
SILS-specific 0
instruments 0
. 0

This 0
study 0
involving 0
novices 0
in 0
a 0
dry 0
lab 0
compared 0
task B-MENTAL
performances I-MENTAL
between 0
conventional 0
laparoscopic 0
surgery 0
( 0
CLS 0
) 0
and 0
single-port 0
laparoscopic 0
surgery 0
( 0
SPLS 0
) 0
using 0
newly 0
designed 0
pre-bent 0
instruments 0
. 0

METHODS 0
In 0
this 0
study 0
, 0
90 0
medical 0
students 0
without 0
previous 0
experience 0
in 0
laparoscopic 0
techniques 0
were 0
randomly 0
assigned 0
to 0
undergo 0
one 0
of 0
three 0
procedures 0
: 0
CLS 0
, 0
SPLS 0
using 0
two 0
pre-bent 0
instruments 0
( 0
SPLS-pp 0
) 0
, 0
or 0
SPLS 0
using 0
one 0
pre-bent 0
and 0
one 0
straight 0
laparoscopic 0
instrument 0
( 0
SPLS-ps 0
) 0
. 0

In 0
the 0
dry 0
lab 0
, 0
the 0
participants 0
performed 0
four 0
typical 0
laparoscopic 0
tasks 0
of 0
increasing 0
difficulty 0
. 0

Evaluation 0
included 0
performance B-MENTAL
times I-MENTAL
or 0
number 0
of 0
completed 0
tasks 0
within 0
a 0
given 0
time 0
frame 0
. 0

All 0
performances B-MENTAL
were 0
videotaped 0
and 0
evaluated 0
for 0
unsuccessful B-MENTAL
attempts I-MENTAL
and 0
unwanted B-MENTAL
interactions I-MENTAL
of I-MENTAL
instruments I-MENTAL
. 0

Using 0
subjective B-OTHER
questionnaires I-OTHER
, 0
the 0
participants 0
rated B-MENTAL
difficulties I-MENTAL
with I-MENTAL
two-dimensional I-MENTAL
vision I-MENTAL
and 0
coordination B-MENTAL
of I-MENTAL
instruments I-MENTAL
. 0

RESULTS 0
Task B-MENTAL
performances I-MENTAL
were 0
significantly 0
better 0
in 0
the 0
CLS 0
group 0
than 0
in 0
either 0
SPLS 0
group 0
. 0

The 0
SPLS-ps 0
group 0
showed 0
a 0
tendency 0
toward 0
better 0
performances B-OTHER
than 0
the 0
SPLS-pp 0
group 0
, 0
but 0
the 0
difference 0
was 0
not 0
significant 0
. 0

Video 0
sequences 0
and 0
participants` 0
questionnaires 0
showed 0
instrument B-MENTAL
interaction I-MENTAL
as 0
the 0
major B-ADVERSE-EFFECTS
problem I-ADVERSE-EFFECTS
in 0
the 0
single-incision 0
surgery 0
groups 0
. 0

CONCLUSIONS 0
Although 0
SILS 0
is 0
feasible 0
, 0
as 0
shown 0
in 0
clinical 0
series 0
published 0
by 0
laparoscopically 0
experienced 0
experts 0
, 0
SILS 0
techniques 0
are 0
demanding 0
due 0
to 0
restrictions 0
that 0
come 0
with 0
the 0
loss 0
of 0
triangulation 0
. 0

These 0
can 0
be 0
compensated 0
only 0
partially 0
by 0
currently 0
available 0
SILS-designed 0
instruments 0
. 0

The 0
future 0
of 0
SILS 0
depends 0
on 0
further 0
improvements 0
in 0
the 0
available 0
equipment 0
or 0
the 0
development 0
of 0
new 0
approaches 0
such 0
as 0
needlescopically 0
assisted 0
or 0
robotically 0
assisted 0
procedures 0
. 0

Markers 0
of 0
systemic B-PHYSICAL
inflammation I-PHYSICAL
predict 0
survival 0
in 0
patients 0
with 0
advanced 0
renal 0
cell 0
cancer 0
. 0

BACKGROUND 0
The 0
host 0
inflammatory 0
response 0
has 0
a 0
vital 0
role 0
in 0
carcinogenesis 0
and 0
tumour 0
progression 0
. 0

We 0
examined 0
the 0
prognostic 0
value 0
of 0
inflammatory 0
markers 0
( 0
albumin 0
, 0
white-cell 0
count 0
and 0
its 0
components 0
, 0
and 0
platelets 0
) 0
in 0
pre-treated 0
patients 0
with 0
advanced 0
renal 0
cell 0
carcinoma 0
( 0
RCC 0
) 0
. 0

METHODS 0
Using 0
data 0
from 0
a 0
randomised 0
trial 0
, 0
multivariable 0
proportional 0
hazards 0
models 0
were 0
generated 0
to 0
examine 0
the 0
impact 0
of 0
inflammatory B-PHYSICAL
markers I-PHYSICAL
and 0
established 0
prognostic B-PHYSICAL
factors I-PHYSICAL
( 0
performance 0
status 0
, 0
calcium 0
, 0
and 0
haemoglobin 0
) 0
on 0
overall B-MORTALITY
survival I-MORTALITY
( 0
OS 0
) 0
. 0

We 0
evaluated 0
a 0
new 0
prognostic 0
classification 0
incorporating 0
additional 0
information 0
from 0
inflammatory 0
markers 0
. 0

RESULTS 0
Of 0
the 0
416 0
patients 0
, 0
362 0
were 0
included 0
in 0
the 0
analysis 0
. 0

Elevated B-PHYSICAL
neutrophil I-PHYSICAL
counts I-PHYSICAL
, 0
elevated B-PHYSICAL
platelet I-PHYSICAL
counts I-PHYSICAL
, 0
and 0
a B-PHYSICAL
high I-PHYSICAL
neutrophil-lymphocyte I-PHYSICAL
ratio I-PHYSICAL
were 0
significant 0
independent 0
predictors 0
for 0
shorter 0
OS 0
in 0
a 0
model 0
with 0
established 0
prognostic 0
factors 0
. 0

The 0
addition 0
of 0
inflammatory 0
markers 0
improves 0
the 0
discriminatory 0
value 0
of 0
the 0
prognostic 0
classification 0
as 0
compared 0
with 0
established 0
factors 0
alone 0
( 0
C-statistic 0
0.673 0
vs 0
0.654 0
, 0
P=0.002 0
for 0
the 0
difference 0
) 0
, 0
with 0
25.8 0
% 0
( 0
P=0.004 0
) 0
of 0
patients 0
more 0
appropriately 0
classified 0
using 0
the 0
new 0
classification 0
. 0

CONCLUSION 0
Markers 0
of 0
systemic 0
inflammation 0
contribute 0
significantly 0
to 0
prognostic 0
classification 0
in 0
addition 0
to 0
established 0
factors 0
for 0
pre-treated 0
patients 0
with 0
advanced 0
RCC 0
. 0

Upon 0
validation 0
of 0
these 0
data 0
in 0
independent 0
studies 0
, 0
stratification 0
of 0
patients 0
using 0
these 0
markers 0
in 0
future 0
clinical 0
trials 0
is 0
recommended 0
. 0

Evaluating 0
online 0
continuing 0
medical 0
education 0
seminars 0
: 0
evidence 0
for 0
improving 0
clinical 0
practices 0
. 0

The 0
purpose 0
of 0
this 0
study 0
was 0
to 0
evaluate 0
the 0
potential 0
for 0
online 0
continuing 0
medical 0
education 0
( 0
CME 0
) 0
seminars 0
to 0
improve B-OTHER
quality I-OTHER
of I-OTHER
care I-OTHER
. 0

Primary 0
care 0
physicians 0
( 0
113 0
) 0
participated 0
in 0
a 0
randomized 0
controlled 0
trial 0
to 0
evaluate 0
an 0
online 0
CME 0
series 0
. 0

Physicians 0
were 0
randomized 0
to 0
view 0
either 0
a 0
seminar 0
about 0
type 0
2 0
diabetes 0
or 0
a 0
seminar 0
about 0
systolic 0
heart 0
failure 0
. 0

Following 0
the 0
seminar 0
, 0
physicians 0
were 0
presented 0
with 0
4 0
clinical 0
vignettes 0
and 0
asked 0
to 0
describe 0
what 0
tests 0
, 0
treatments 0
, 0
counseling 0
, 0
or 0
referrals 0
they 0
would 0
recommend 0
. 0

Physicians 0
who 0
viewed 0
the 0
seminars 0
were 0
significantly 0
more 0
likely 0
to 0
recommend B-MENTAL
guideline-consistent I-MENTAL
care I-MENTAL
to 0
patients 0
in 0
the 0
vignettes 0
. 0

For 0
example 0
, 0
physicians 0
who 0
viewed 0
the 0
diabetes 0
seminar 0
were 0
significantly 0
more 0
likely 0
to 0
order B-MENTAL
an I-MENTAL
eye I-MENTAL
exam I-MENTAL
for I-MENTAL
diabetes I-MENTAL
patients I-MENTAL
( 0
63 0
% 0
) 0
compared 0
with 0
physicians 0
in 0
the 0
control 0
group 0
( 0
27 0
% 0
) 0
. 0

For 0
some 0
guidelines 0
there 0
were 0
no 0
group 0
differences 0
. 0

These 0
results 0
provide 0
early 0
evidence 0
of 0
the 0
effectiveness 0
of 0
online 0
CME 0
programs 0
to 0
improve 0
physician B-OTHER
clinical I-OTHER
practice I-OTHER
. 0

Randomized 0
controlled 0
study 0
of 0
customized 0
preventive 0
medicine 0
reminder 0
letters 0
in 0
a 0
community 0
practice 0
. 0

OBJECTIVE 0
To 0
test 0
the 0
effectiveness 0
of 0
customized 0
, 0
family-oriented 0
reminder 0
letters 0
in 0
activating 0
patients 0
to 0
seek 0
appropriate 0
preventive 0
services 0
. 0

DESIGN 0
Randomized 0
clinical 0
trial 0
. 0

One 0
group 0
received 0
computer-generated 0
, 0
customized 0
letters 0
explaining 0
recommended 0
preventive 0
procedures 0
for 0
each 0
family 0
member 0
. 0

A 0
second 0
group 0
received 0
a 0
form 0
letter 0
listing 0
recommendations 0
for 0
all 0
preventive 0
procedures 0
for 0
all 0
age 0
and 0
sex 0
groups 0
. 0

A 0
third 0
group 0
( 0
control 0
group 0
) 0
received 0
no 0
letters 0
. 0

SETTING 0
A 0
private 0
medical 0
centre 0
, 0
without 0
university 0
affiliation 0
, 0
in 0
rural 0
Quebec 0
. 0

PARTICIPANTS 0
From 0
8770 0
patients 0
who 0
met 0
study 0
criteria 0
, 0
719 0
families 0
were 0
randomly 0
selected 0
. 0

Data 0
were 0
available 0
for 0
1971 0
of 0
1998 0
patients 0
in 0
these 0
families 0
. 0

MAIN 0
OUTCOME 0
MEASURES 0
The 0
Family B-PHYSICAL
Received I-PHYSICAL
Index I-PHYSICAL
is 0
the 0
proportion 0
of 0
all 0
procedures 0
for 0
which 0
a 0
family 0
was 0
overdue 0
that 0
they 0
received 0
. 0

The 0
Family B-PHYSICAL
End-of-study I-PHYSICAL
Up-to-date I-PHYSICAL
Index I-PHYSICAL
is 0
the 0
proportion 0
of 0
procedures 0
for 0
which 0
the 0
family 0
was 0
eligible 0
and 0
for 0
which 0
they 0
were 0
up-to-date 0
at 0
the 0
end 0
of 0
the 0
study 0
. 0

RESULTS 0
The 0
Family B-PHYSICAL
Received I-PHYSICAL
Index I-PHYSICAL
for 0
families 0
mailed 0
customized 0
letters 0
was 0
more 0
than 0
double 0
the 0
index 0
for 0
patients 0
not 0
mailed 0
letters 0
( 0
Kruskal-Wallis 0
P 0
= 0
.0139 0
) 0
. 0

Comparison 0
of 0
the 0
Family B-PHYSICAL
End-of-study I-PHYSICAL
Up-to-date I-PHYSICAL
indices I-PHYSICAL
also 0
demonstrated 0
that 0
families 0
of 0
patients 0
sent 0
customized 0
letters 0
were 0
more 0
likely 0
to 0
be 0
up-to-date 0
than 0
families 0
not 0
sent 0
letters 0
( 0
Kruskal-Wallis 0
P 0
= 0
.0054 0
) 0
. 0

No 0
statistically 0
significant 0
difference 0
appeared 0
between 0
the 0
number 0
of 0
preventive 0
measures 0
received 0
by 0
the 0
control 0
group 0
and 0
the 0
form-letter 0
group 0
. 0

CONCLUSIONS 0
This 0
study 0
demonstrates 0
a 0
clinically 0
small 0
but 0
statistically 0
significant 0
value 0
to 0
customizing 0
reminder 0
letters 0
. 0

Incidence 0
and 0
clinical 0
significance 0
of 0
false-negative 0
sextant 0
prostate 0
biopsies 0
. 0

PURPOSE 0
Since 0
most 0
patients 0
do 0
not 0
undergo 0
repeat 0
sextant 0
prostate 0
biopsies 0
after 0
a 0
biopsy 0
is 0
positive 0
for 0
prostate 0
cancer 0
, 0
the 0
true 0
incidence 0
of 0
false-negative 0
biopsies 0
is 0
not 0
well 0
defined 0
. 0

We 0
assess 0
the 0
incidence 0
and 0
clinical 0
significance 0
of 0
false-negative 0
sextant 0
prostate 0
biopsies 0
in 0
patients 0
undergoing 0
radical 0
prostatectomy 0
. 0

MATERIALS 0
AND 0
METHODS 0
A 0
total 0
of 0
118 0
patients 0
with 0
biopsy 0
proved 0
prostate 0
cancer 0
underwent 0
repeat 0
sextant 0
prostate 0
biopsy 0
before 0
enrollment 0
in 0
a 0
prospective 0
randomized 0
trial 0
of 0
radical 0
prostatectomy 0
with 0
or 0
without 0
neoadjuvant 0
hormonal 0
therapy 0
. 0

Clinical 0
parameters 0
were 0
assessed 0
to 0
determine 0
potential 0
sources 0
of 0
bias 0
. 0

Pathological 0
parameters 0
and 0
prostate B-ADVERSE-EFFECTS
specific I-ADVERSE-EFFECTS
antigen I-ADVERSE-EFFECTS
relapse-free I-ADVERSE-EFFECTS
survival I-ADVERSE-EFFECTS
rates I-ADVERSE-EFFECTS
were 0
compared 0
to 0
determine 0
the 0
clinical 0
significance 0
of 0
false-negative 0
biopsies 0
. 0

RESULTS 0
Of 0
the 0
118 0
patients 0
27 0
( 0
23 0
% 0
) 0
had 0
a 0
negative 0
repeat 0
sextant 0
biopsy 0
. 0

Except 0
for 0
initial 0
clinical 0
stage 0
, 0
no 0
differences 0
were 0
noted 0
in 0
the 0
clinical B-PHYSICAL
or I-PHYSICAL
pathological I-PHYSICAL
parameters I-PHYSICAL
, 0
or 0
prostate B-PHYSICAL
specific I-PHYSICAL
antigen I-PHYSICAL
relapse I-PHYSICAL
rates I-PHYSICAL
in 0
patients 0
with 0
negative 0
versus 0
positive 0
repeat 0
biopsies 0
. 0

CONCLUSIONS 0
Our 0
findings 0
suggest 0
that 0
this 0
23 0
% 0
incidence 0
of 0
false-negative 0
biopsies 0
represents 0
significant 0
cancer 0
. 0

This 0
relatively 0
high 0
incidence 0
is 0
important 0
to 0
consider 0
in 0
treatment 0
modalities 0
in 0
which 0
prostate 0
biopsy 0
may 0
be 0
performed 0
to 0
determine 0
response 0
to 0
therapy 0
. 0

Comparison 0
of 0
split-course 0
radiation 0
therapy 0
and 0
continuous 0
radiation 0
therapy 0
for 0
unresectable 0
bronchogenic 0
carcinoma 0
: 0
5 0
year 0
results 0
. 0

One 0
hundred 0
and 0
eighty-eight 0
patients 0
with 0
inoperable 0
or 0
unresectable 0
bronchogenic 0
carcinoma 0
were 0
stratified 0
by 0
cell 0
type 0
, 0
TNM 0
staging 0
, 0
and 0
prior 0
surgery 0
and 0
then 0
randomized 0
into 0
two 0
treatment 0
groups 0
: 0
continuous 0
radiation 0
therapy 0
and 0
split-course 0
radiation 0
therapy 0
. 0

There 0
was 0
no 0
difference 0
in 0
clinical 0
or 0
objective 0
improvement 0
in 0
the 0
two 0
groups 0
. 0

Survival B-MORTALITY
rates I-MORTALITY
for 0
cases 0
of 0
squamous 0
cell 0
carcinoma 0
, 0
small 0
cell 0
carcinoma 0
, 0
and 0
adrenocarcinoma 0
were 0
the 0
same 0
after 0
both 0
regimens 0
of 0
therapy 0
. 0

Split-course B-OTHER
therapy I-OTHER
resulted 0
in 0
a 0
significantly 0
better 0
survival 0
rate 0
in 0
cases 0
of 0
large 0
cell 0
carcinoma 0
but 0
the 0
number 0
of 0
cases 0
was 0
small 0
. 0

We 0
doubt 0
that 0
the 0
difference 0
is 0
clinically 0
significant 0
. 0

Objective B-PHYSICAL
roentgenographic I-PHYSICAL
response I-PHYSICAL
was 0
accompanied 0
by 0
improved B-MORTALITY
survival I-MORTALITY
in 0
squamous 0
cell 0
carcinoma 0
, 0
but 0
not 0
in 0
the 0
other 0
three 0
cell 0
types 0
. 0

Split-course 0
radiation 0
therapy 0
is 0
superior 0
to 0
continuous 0
radiation 0
therapy 0
because 0
it 0
is 0
better B-OTHER
tolerated I-OTHER
by 0
the 0
patient 0
and 0
because 0
re-examination 0
of 0
the 0
patient 0
prior 0
to 0
the 0
second 0
half 0
of 0
split-course 0
therapy 0
permits 0
the 0
detection 0
of 0
new 0
metastatic 0
disease 0
that 0
has 0
become 0
manifest 0
during 0
the 0
rest 0
period 0
and 0
spares 0
the 0
patient 0
the 0
futile 0
second 0
half 0
of 0
radiation 0
therapy 0
. 0

Sustained 0
benefit 0
of 0
continuous 0
glucose 0
monitoring 0
on 0
A1C 0
, 0
glucose 0
profiles 0
, 0
and 0
hypoglycemia 0
in 0
adults 0
with 0
type 0
1 0
diabetes 0
. 0

OBJECTIVE 0
To 0
evaluate 0
long-term 0
effects 0
of 0
continuous 0
glucose 0
monitoring 0
( 0
CGM 0
) 0
in 0
intensively 0
treated 0
adults 0
with 0
type 0
1 0
diabetes 0
. 0

RESEARCH 0
DESIGN 0
AND 0
METHODS 0
We 0
studied 0
83 0
of 0
86 0
individuals 0
> 0
or=25 0
years 0
of 0
age 0
with 0
type 0
1 0
diabetes 0
who 0
used 0
CGM 0
as 0
part 0
of 0
a 0
6-month 0
randomized 0
clinical 0
trial 0
in 0
a 0
subsequent 0
6-month 0
extension 0
study 0
. 0

RESULTS 0
After 0
12 0
months 0
, 0
median 0
CGM 0
use 0
was 0
6.8 0
days 0
per 0
week 0
. 0

Mean 0
change B-PHYSICAL
in I-PHYSICAL
A1C I-PHYSICAL
level I-PHYSICAL
from 0
baseline 0
to 0
12 0
months 0
was 0
-0.4 0
+/- 0
0.6 0
% 0
( 0
P 0
< 0
0.001 0
) 0
in 0
subjects 0
with 0
baseline 0
A1C 0
> 0
or=7.0 0
% 0
. 0

A1C B-PHYSICAL
remained 0
stable 0
at 0
6.4 0
% 0
in 0
those 0
with 0
baseline 0
A1C 0
< 0
7.0 0
% 0
. 0

The 0
incidence 0
rate 0
of 0
severe B-PHYSICAL
hypoglycemia I-PHYSICAL
was 0
21.8 0
and 0
7.1 0
events 0
per 0
100 0
person-years 0
in 0
the 0
first 0
and 0
last 0
6 0
months 0
, 0
respectively 0
. 0

Time B-PHYSICAL
per I-PHYSICAL
day I-PHYSICAL
with I-PHYSICAL
glucose I-PHYSICAL
levels I-PHYSICAL
in 0
the 0
range 0
of 0
71-180 0
mg/dl 0
increased 0
significantly 0
( 0
P 0
= 0
0.02 0
) 0
from 0
baseline 0
to 0
12 0
months 0
. 0

CONCLUSIONS 0
In 0
intensively 0
treated 0
adults 0
with 0
type 0
1 0
diabetes 0
, 0
CGM 0
use 0
and 0
benefit 0
can 0
be 0
sustained 0
for 0
12 0
months 0
. 0

Growth B-PHYSICAL
hormone I-PHYSICAL
( I-PHYSICAL
GH I-PHYSICAL
) I-PHYSICAL
responses I-PHYSICAL
to 0
GH-releasing 0
hormone 0
alone 0
or 0
combined 0
with 0
arginine 0
in 0
patients 0
with 0
adrenal 0
incidentaloma 0
: 0
evidence 0
for 0
enhanced 0
somatostatinergic 0
tone 0
. 0

Spontaneous 0
and 0
stimulated 0
GH 0
secretion 0
is 0
blunted 0
in 0
hypercortisolemic 0
states 0
due 0
to 0
increased 0
hypothalamic 0
somatostatinergic 0
tone 0
. 0

However 0
, 0
no 0
data 0
are 0
available 0
on 0
the 0
characteristics 0
of 0
GH 0
secretion 0
in 0
patients 0
with 0
incidentally 0
discovered 0
adrenal 0
adenomas 0
. 0

They 0
represent 0
an 0
interesting 0
model 0
for 0
studying 0
GH 0
secretion 0
, 0
as 0
a 0
slight 0
degree 0
of 0
cortisol 0
excess 0
may 0
frequently 0
be 0
observed 0
in 0
such 0
patients 0
who 0
do 0
not 0
present 0
with 0
any 0
clear 0
Cushingoid 0
sign 0
. 0

In 0
the 0
present 0
study 0
, 0
10 0
patients 0
( 0
3 0
men 0
and 0
7 0
women 0
, 0
aged 0
48-63 0
yr 0
) 0
with 0
an 0
adrenal 0
mass 0
discovered 0
serendipitously 0
underwent 0
, 0
on 0
separate 0
occasions 0
, 0
a 0
GHRH 0
injection 0
alone 0
or 0
combined 0
with 0
an 0
infusion 0
of 0
the 0
functional 0
somatostatin 0
antagonist 0
, 0
arginine 0
. 0

Thirteen 0
age-matched 0
healthy 0
volunteers 0
served 0
as 0
controls 0
. 0

Briefly 0
, 0
arginine 0
( 0
30 0
g 0
) 0
was 0
infused 0
from 0
-30 0
to 0
0 0
min 0
, 0
and 0
GHRH 0
( 0
100 0
microg 0
) 0
was 0
injected 0
as 0
a 0
bolus 0
at 0
0 0
min 0
, 0
with 0
measurement 0
of 0
serum 0
GH 0
[ 0
immunoradiometric 0
assay 0
( 0
IRMA 0
) 0
] 0
every 0
15 0
min 0
for 0
150 0
min 0
. 0

Plasma 0
IGF-I 0
( 0
RIA 0
after 0
acid-ethanol 0
extraction 0
) 0
was 0
measured 0
in 0
a 0
morning 0
sample 0
. 0

The 0
diagnosis 0
of 0
cortical 0
adenoma 0
was 0
based 0
on 0
computed 0
tomography 0
features 0
and 0
pattern 0
of 0
uptake 0
on 0
adrenal 0
scintigraphy 0
. 0

Patients 0
with 0
obesity 0
and/or 0
diabetes 0
were 0
excluded 0
. 0

The 0
study 0
design 0
included 0
also 0
an 0
endocrine 0
work-up 0
aimed 0
to 0
study 0
the 0
hypothalamic-pituitary-adrenal B-PHYSICAL
axis I-PHYSICAL
[ I-PHYSICAL
urinary I-PHYSICAL
free I-PHYSICAL
cortisol I-PHYSICAL
( I-PHYSICAL
UFC I-PHYSICAL
) I-PHYSICAL
excretion I-PHYSICAL
, 0
serum B-PHYSICAL
cortisol I-PHYSICAL
at I-PHYSICAL
0800 I-PHYSICAL
h I-PHYSICAL
, 0
plasma B-PHYSICAL
ACTH I-PHYSICAL
at I-PHYSICAL
0800 I-PHYSICAL
h I-PHYSICAL
, 0
morning B-PHYSICAL
cortisol I-PHYSICAL
after I-PHYSICAL
overnight I-PHYSICAL
1 I-PHYSICAL
mg I-PHYSICAL
dexamethasone I-PHYSICAL
] 0
. 0

Five 0
of 0
10 0
patients 0
showed 0
abnormalities 0
of 0
the 0
hypothalamic-pituitary-adrenal B-PHYSICAL
axis I-PHYSICAL
, 0
including 0
borderline B-PHYSICAL
or 0
increased 0
UFC B-PHYSICAL
excretion I-PHYSICAL
in 0
4 0
of 0
them 0
accompanied 0
by 0
blunted 0
ACTH 0
in 0
2 0
cases 0
and 0
failure 0
of 0
cortisol 0
to 0
suppress 0
after 0
dexamethasone 0
in 0
1 0
; 0
the 0
fifth 0
patient 0
displayed 0
low 0
ACTH 0
and 0
resistance 0
to 0
dexamethasone 0
suppression 0
. 0

However 0
, 0
all 0
patients 0
had 0
a 0
unilateral 0
uptake 0
of 0
the 0
tracer 0
on 0
the 0
side 0
of 0
the 0
mass 0
with 0
suppression 0
of 0
the 0
contralateral 0
normal 0
adrenal 0
gland 0
. 0

As 0
a 0
group 0
, 0
the 0
patients 0
displayed 0
greater 0
UFC B-PHYSICAL
excretion I-PHYSICAL
and 0
lower B-PHYSICAL
ACTH I-PHYSICAL
concentrations I-PHYSICAL
than 0
the 0
controls 0
. 0

GH B-PHYSICAL
release I-PHYSICAL
after I-PHYSICAL
GHRH I-PHYSICAL
treatment I-PHYSICAL
was 0
blunted 0
in 0
patients 0
bearing 0
adrenal 0
incidentaloma 0
compared 0
with 0
controls 0
( 0
GH 0
peak 0
, 0
5.7 0
+/- 0
5.2 0
vs. 0
18.0 0
+/- 0
7.0 0
microg/L 0
; 0
P 0
< 0
0.0001 0
) 0
, 0
whereas 0
GHRH 0
plus 0
arginine 0
was 0
able 0
to 0
elicit 0
a 0
comparable 0
response 0
in 0
the 0
2 0
groups 0
( 0
GH 0
peak 0
, 0
33.5 0
+/- 0
20.3 0
vs. 0
33.7 0
+/- 0
17.5 0
microg/L 0
; 0
P 0
= 0
NS 0
) 0
. 0

The 0
ratio 0
between 0
GH B-PHYSICAL
peaks I-PHYSICAL
after I-PHYSICAL
GHRH I-PHYSICAL
plus I-PHYSICAL
arginine I-PHYSICAL
and 0
after 0
GHRH B-PHYSICAL
plus 0
saline B-PHYSICAL
was 0
significantly 0
greater 0
in 0
patients 0
than 0
in 0
controls 0
( 0
751 0
+/- 0
531 0
% 0
vs. 0
81 0
+/- 0
45 0
% 0
; 0
P 0
= 0
0.0001 0
) 0
. 0

Similar 0
data 0
were 0
obtained 0
when 0
comparing 0
GH 0
area 0
under 0
the 0
curve 0
after 0
GHRH 0
plus 0
saline 0
or 0
GHRH 0
plus 0
arginine 0
between 0
the 0
2 0
groups 0
. 0

In 0
summary 0
, 0
the 0
present 0
data 0
suggest 0
that 0
in 0
patients 0
with 0
incidental 0
adrenal 0
adenomas 0
the 0
GH B-PHYSICAL
response I-PHYSICAL
to 0
GHRH 0
is 0
blunted 0
due 0
to 0
increased 0
somatostatinergic B-PHYSICAL
tone I-PHYSICAL
, 0
as 0
it 0
can 0
be 0
restored 0
to 0
normal 0
by 0
pretreatment 0
with 0
the 0
functional 0
somatostatin 0
antagonist 0
arginine 0
. 0

The 0
blunted 0
GH 0
release 0
to 0
GHRH 0
may 0
be 0
an 0
early 0
and 0
long 0
lasting 0
sign 0
of 0
autonomous 0
cortisol 0
secretion 0
by 0
the 0
adrenal 0
adenoma 0
. 0

Impact B-OTHER
of 0
a 0
fixed 0
combination 0
of 0
clindamycin 0
phosphate 0
1.2 0
% 0
-benzoyl 0
peroxide 0
2.5 0
% 0
aqueous 0
gel 0
on 0
health-related 0
quality 0
of 0
life 0
in 0
moderate 0
to 0
severe 0
acne 0
vulgaris 0
. 0

The 0
acne-specific 0
quality 0
of 0
life 0
( 0
Acne-QoL 0
) 0
questionnaire 0
was 0
developed 0
to 0
measure B-PHYSICAL
the I-PHYSICAL
impact I-PHYSICAL
of I-PHYSICAL
facial I-PHYSICAL
acne I-PHYSICAL
across 0
4 0
domains 0
( 0
acne 0
symptoms 0
, 0
role-emotional 0
, 0
self-perception 0
, 0
role-social 0
) 0
of 0
health-related B-PHYSICAL
quality 0
of 0
life 0
( B-PHYSICAL
HRQL B-PHYSICAL
) B-PHYSICAL
. 0

This 0
analysis 0
assessed 0
the 0
impact 0
of 0
clindamycin 0
phosphate 0
1.2 0
% 0
-benzoyl 0
peroxide 0
2.5 0
% 0
( 0
clindamycin-BPO 0
2.5 0
% 0
) 0
gel 0
on 0
HRQL 0
in 0
a 0
combined 0
study 0
population 0
( 0
N 0
= 0
2813 0
) 0
of 0
participants 0
with 0
moderate 0
to 0
severe 0
acne 0
vulgaris 0
. 0

Although 0
the 0
results 0
presented 0
within 0
do 0
not 0
include 0
factors 0
of 0
study 0
and 0
study-by-treatment 0
interaction 0
, 0
analyses 0
were 0
performed 0
to 0
confirm 0
that 0
the 0
results 0
were 0
consistent 0
across 0
the 0
2 0
identical 0
, 0
double-blind 0
, 0
randomized 0
studies 0
and 0
within 0
each 0
treatment 0
group 0
across 0
studies 0
to 0
justify 0
pooling 0
the 0
data 0
from 0
both 0
studies 0
. 0

The 0
Acne-QoL B-PHYSICAL
questionnaire 0
was 0
administered 0
at 0
baseline 0
and 0
at 0
the 0
end 0
of 0
treatment 0
( 0
week 0
12 0
) 0
. 0

Treatment 0
with 0
clindamycin-BPO 0
2.5 0
% 0
gel 0
significantly 0
improved 0
participant-reported 0

The 0
impact 0
of 0
patient 0
and 0
physician 0
computer 0
mediated 0
communication 0
skill 0
training 0
on 0
reported 0
communication 0
and 0
patient 0
satisfaction 0
. 0

OBJECTIVE 0
The 0
objective 0
was 0
to 0
evaluate 0
parallel B-MENTAL
patient I-MENTAL
and I-MENTAL
physician I-MENTAL
computer-mediated I-MENTAL
communication I-MENTAL
skill I-MENTAL
training I-MENTAL
on 0
participants 0
' 0
report 0
of 0
skill 0
use 0
and 0
patient 0
satisfaction 0
. 0

METHODS 0
Separate 0
patient 0
and 0
clinician 0
web-tools 0
comprised 0
of 0
over 0
500 0
, 0
10-s 0
video 0
clips 0
demonstrating 0
patient-centered B-MENTAL
skills I-MENTAL
in 0
various 0
ways 0
. 0

Four 0
clinician 0
members 0
of 0
the 0
American 0
Academy 0
of 0
Family 0
Physicians 0
National 0
Research 0
Network 0
participated 0
by 0
enrolling 0
194 0
patients 0
into 0
a 0
randomized 0
patient 0
trial 0
and 0
29 0
physicians 0
into 0
a 0
non-randomized 0
clinician 0
trial 0
of 0
respective 0
interventions 0
. 0

All 0
participants 0
completed 0
baseline 0
and 0
follow-up 0
self-report 0
measures 0
of 0
visit 0
communication B-OTHER
and 0
satisfaction B-OTHER
. 0

RESULTS 0
Intervention 0
patients 0
reported 0
using 0
more 0
skills B-MENTAL
than 0
controls 0
in 0
five 0
of 0
six 0
skill 0
areas 0
, 0
including 0
identification 0
of 0
problems/concerns B-MENTAL
, 0
information 0
exchange B-MENTAL
, 0
treatment 0
adherence B-MENTAL
, 0
shared 0
decision-making B-MENTAL
and 0
interpersonal B-MENTAL
rapport I-MENTAL
( 0
all 0
p 0
< 0
.05 0
) 0
; 0
post 0
intervention 0
, 0
physicians 0
reported 0
using 0
more 0
skills 0
in 0
the 0
same 0
5 0
areas 0
( 0
all 0
p 0
< 0
.01 0
) 0
. 0

Intervention 0
group 0
patients 0
reported 0
higher 0
levels 0
of 0
satisfaction 0
than 0
controls 0
in 0
five 0
of 0
six 0
domains 0
( 0
all 0
p 0
< 0
.05 0
) 0
. 0

CONCLUSION 0
Communication 0
skill 0
training 0
delivered 0
in 0
a 0
computer 0
mediated 0
format 0
had 0
a 0
positive 0
and 0
parallel B-OTHER
impact I-OTHER
on 0
both 0
patient 0
and 0
clinician 0
reported 0
use 0
of 0
patient-centered B-MENTAL
communication I-MENTAL
and 0
in 0
patient B-OTHER
satisfaction I-OTHER
. 0

PRACTICE 0
IMPLICATIONS 0
Computer-mediated 0
interventions 0
are 0
cost 0
and 0
time 0
effective 0
thereby 0
increasing 0
patient 0
and 0
clinician 0
willingness 0
to 0
undertake 0
training 0
. 0

Left 0
thoracoabdominal 0
approach 0
versus 0
abdominal-transhiatal 0
approach 0
for 0
gastric 0
cancer 0
of 0
the 0
cardia 0
or 0
subcardia 0
: 0
a 0
randomised 0
controlled 0
trial 0
. 0

BACKGROUND 0
Because 0
of 0
the 0
inaccessibility 0
of 0
mediastinal 0
nodal 0
metastases 0
, 0
the 0
left 0
thoracoabdominal 0
approach 0
( 0
LTA 0
) 0
has 0
often 0
been 0
used 0
to 0
treat 0
gastric 0
cancer 0
of 0
the 0
cardia 0
or 0
subcardia 0
. 0

In 0
a 0
randomised 0
phase 0
III 0
study 0
, 0
we 0
aimed 0
to 0
compare B-OTHER
LTA 0
with 0
the 0
abdominal-transhiatal 0
approach 0
( 0
TH 0
) 0
in 0
the 0
treatment 0
of 0
these 0
tumours 0
. 0

METHODS 0
Between 0
July 0
, 0
1995 0
, 0
and 0
December 0
, 0
2003 0
, 0
167 0
patients 0
were 0
enrolled 0
from 0
27 0
Japanese 0
hospitals 0
and 0
randomly 0
assigned 0
to 0
TH 0
( 0
n=82 0
) 0
or 0
LTA 0
( 0
n=85 0
) 0
. 0

The 0
primary 0
endpoint 0
was 0
overall B-MORTALITY
survival I-MORTALITY
, 0
and 0
secondary 0
endpoints 0
were 0
disease-free B-PHYSICAL
survival I-PHYSICAL
, 0
postoperative B-PHYSICAL
morbidity I-PHYSICAL
and 0
hospital B-MORTALITY
mortality I-MORTALITY
, 0
and 0
postoperative B-PHYSICAL
symptoms I-PHYSICAL
and 0
change 0
of 0
respiratory B-PHYSICAL
function I-PHYSICAL
. 0

The 0
projected 0
sample 0
size 0
was 0
302 0
. 0

After 0
the 0
first 0
interim 0
analysis 0
, 0
the 0
predicted 0
probability 0
of 0
LTA 0
having 0
a 0
significantly 0
better 0
overall 0
survival 0
than 0
TH 0
at 0
the 0
final 0
analysis 0
was 0
only 0
3.65 0
% 0
, 0
and 0
the 0
trial 0
was 0
closed 0
immediately 0
. 0

Analysis 0
was 0
by 0
intention 0
to 0
treat 0
. 0

This 0
study 0
is 0
registered 0
with 0
, 0
number 0
NCT00149266 0
. 0

FINDINGS 0
5-year B-MORTALITY
overall I-MORTALITY
survival I-MORTALITY
was 0
52.3 0
% 0
( 0
95 0
% 0
CI 0
40.4-64.1 0
) 0
in 0
the 0
TH 0
group 0
and 0
37.9 0
% 0
( 0
26.1-49.6 0
) 0
in 0
the 0
LTA 0
group 0
. 0

The 0
hazard 0
ratio 0
of 0
death B-MORTALITY
for 0
LTA B-PHYSICAL
compared 0
with 0
TH 0
was 0
1.36 0
( 0
0.89-2.08 0
, 0
p=0.92 0
) 0
. 0

Three 0
patients 0
died B-MORTALITY
in 0
hospital 0
after 0
LTA 0
but 0
none 0
after 0
TH 0
. 0

Morbidity B-PHYSICAL
was 0
worse 0
after 0
LTA 0
than 0
after 0
TH 0
. 0

INTERPRETATION 0
Because 0
LTA 0
does 0
not 0
improve 0
survival 0
after 0
TH 0
and 0
leads 0
to 0
increased 0
morbidity 0
in 0
patients 0
with 0
cancer 0
of 0
the 0
cardia 0
or 0
subcardia 0
, 0
LTA 0
can 0
not 0
be 0
justified 0
to 0
treat 0
these 0
tumours 0
. 0

Prevention 0
of 0
bone 0
loss 0
in 0
survivors 0
of 0
breast 0
cancer 0
: 0
A 0
randomized 0
, 0
double-blind 0
, 0
placebo-controlled 0
clinical 0
trial 0
. 0

BACKGROUND 0
Few 0
data 0
are 0
available 0
on 0
the 0
safety 0
and 0
efficacy 0
of 0
once-weekly 0
oral 0
bisphosphonate 0
therapy 0
in 0
breast 0
cancer 0
survivors 0
. 0

OBJECTIVE 0
Our 0
objective 0
was 0
to 0
determine 0
whether 0
risedronate 0
, 0
35 0
mg 0
weekly 0
, 0
is 0
efficacious 0
and 0
safe 0
in 0
preventing 0
bone 0
loss 0
associated 0
with 0
chemotherapy-induced 0
menopause 0
. 0

DESIGN 0
The 0
study 0
was 0
a 0
randomized 0
, 0
double-blind 0
, 0
placebo-controlled 0
clinical 0
trial 0
over 0
12 0
months 0
. 0

SETTING 0
AND 0
PARTICIPANTS 0
Participants 0
included 0
87 0
newly 0
postmenopausal 0
women 0
with 0
status 0
post 0
chemotherapy 0
, 0
recruited 0
from 0
a 0
breast 0
cancer 0
clinic 0
in 0
an 0
academic 0
medical 0
center 0
. 0

INTERVENTION 0
Participants 0
were 0
randomly 0
assigned 0
to 0
receive 0
risedronate 0
35 0
mg/wk 0
or 0
placebo 0
. 0

MAIN 0
OUTCOME 0
MEASURES 0
The 0
primary 0
outcomes 0
were 0
the 0
12-month B-PHYSICAL
changes I-PHYSICAL
in I-PHYSICAL
spine I-PHYSICAL
and 0
hip B-PHYSICAL
bone I-PHYSICAL
mineral I-PHYSICAL
density I-PHYSICAL
. 0

Secondary 0
outcomes 0
included 0
changes 0
in 0
markers B-PHYSICAL
of I-PHYSICAL
bone I-PHYSICAL
resorption I-PHYSICAL
( I-PHYSICAL
urine I-PHYSICAL
N-telopeptide I-PHYSICAL
cross-linked I-PHYSICAL
collagen I-PHYSICAL
type 0
I B-PHYSICAL
) B-PHYSICAL
and 0
formation B-PHYSICAL
( B-PHYSICAL
osteocalcin I-PHYSICAL
, 0
N-terminal B-PHYSICAL
propeptide I-PHYSICAL

Photodynamic 0
therapy 0
with 0
5-aminolaevulinic 0
acid 0
or 0
placebo 0
for 0
recalcitrant 0
foot B-PHYSICAL
and 0
hand B-PHYSICAL
warts I-PHYSICAL
: 0
randomised 0
double-blind 0
trial 0
. 0

BACKGROUND 0
Photodynamic 0
therapy 0
( 0
PDT 0
) 0
with 0
topical 0
5-aminolaevulinic 0
acid 0
( 0
ALA 0
) 0
followed 0
by 0
irradiation 0
with 0
incoherent 0
light 0
( 0
ALA-PDT 0
) 0
for 0
recalcitrant 0
warts 0
have 0
had 0
beneficial 0
results 0
. 0

Therefore 0
, 0
we 0
undertook 0
a 0
randomised 0
, 0
parallel 0
, 0
double-blind 0
clinical 0
trial 0
of 0
ALA-PDT 0
versus 0
placeboPDT 0
for 0
recalcitrant 0
foot 0
and 0
hand 0
warts 0
. 0

METHODS 0
Recalcitrant 0
foot 0
and 0
hand 0
warts 0
were 0
randomly 0
assigned 0
to 0
six 0
repetitive 0
ALA-PDT 0
or 0
placebo-PDT 0
interventions 0
combined 0
with 0
standard 0
treatment 0
encompassing 0
paring 0
followed 0
by 0
a 0
keratolytic 0
( 0
Verucid 0
) 0
. 0

Standardised 0
photographs 0
of 0
each 0
wart 0
were 0
taken 0
before 0
, 0
during 0
( 0
week 0
7 0
) 0
and 0
after 0
treatment 0
( 0
weeks 0
14 0
and 0
18 0
) 0
. 0

The 0
area 0
of 0
each 0
wart 0
compared 0
with 0
entry 0
area 0
was 0
the 0
primary 0
outcome 0
variable 0
, 0
measured 0
from 0
photographs 0
by 0
an 0
evaluator 0
unaware 0
of 0
treatment 0
allocation 0
for 0
intervention 0
. 0

Pain B-PAIN
intensity I-PAIN
immediately 0
and 0
24 0
h 0
after 0
each 0
intervention 0
was 0
assessed 0
by 0
a 0
five-point 0
scale 0
. 0

FINDINGS 0
A 0
total 0
of 0
232 0
foot 0
and 0
hand 0
warts 0
in 0
45 0
patients 0
were 0
entered 0
into 0
the 0
trial 0
: 0
117 0
warts 0
were 0
allocated 0
to 0
ALA-PDT 0
and 0
115 0
warts 0
to 0
placebo-PDT 0
. 0

In 0
week 0
14 0
, 0
the 0
median 0
relative B-PHYSICAL
reduction I-PHYSICAL
in I-PHYSICAL
wart I-PHYSICAL
area 0
was 0
98 0
% 0
in 0
the 0
ALA-PDT 0
group 0
( 0
interquartile 0
range 0
100 0
% 0
, 0
55 0
% 0
) 0
versus 0
52 0
% 0
( 0
100 0
% 0
, 0
0 0
) 0
in 0
the 0
placebo 0
group 0
( 0
p=0.0006 0
) 0
. 0

In 0
week 0
18 0
, 0
the 0
median 0
relative B-PHYSICAL
reduction I-PHYSICAL
in I-PHYSICAL
wart I-PHYSICAL
area 0
was 0
100 0
% 0
in 0
the 0
ALA-PDT 0
group 0
( 0
100 0
% 0
, 0
57 0
% 0
) 0
versus 0
71 0
% 0
( 0
100 0
% 0
, 0
0 0
) 0
in 0
the 0
placebo-PDT 0
arm 0
( 0
p=0.008 0
) 0
. 0

Both 0
the 0
number 0
of 0
vanishing B-OTHER
warts I-OTHER
and 0
the 0
difference 0
in 0
relative B-OTHER
wart I-OTHER
area 0
of B-OTHER
persisting I-OTHER
warts B-OTHER
at 0
week 0
14 0
and 0
18 0
were 0
significant 0
( 0
p 0
< 0
0.05 0
) 0
in 0
favour 0
of 0
ALA-PDT 0
. 0

Significantly 0
more 0
ALA-PDT 0
warts 0
were 0
graded 0
at 0
a 0
higher B-PAIN
pain I-PAIN

Can 0
patient 0
coaching 0
reduce 0
racial/ethnic 0
disparities 0
in 0
cancer 0
pain 0
control 0
? 0

Secondary 0
analysis 0
of 0
a 0
randomized 0
controlled 0
trial 0
. 0

PURPOSE 0
Minority 0
patients 0
with 0
cancer 0
experience 0
worse 0
control 0
of 0
their 0
pain 0
than 0
do 0
their 0
white 0
counterparts 0
. 0

This 0
disparity 0
may 0
, 0
in 0
part 0
, 0
reflect 0
more 0
miscommunication 0
between 0
minority 0
patients 0
and 0
their 0
physicians 0
. 0

Therefore 0
, 0
we 0
examined 0
whether 0
patient 0
coaching 0
could 0
reduce 0
disparities 0
in 0
pain B-PAIN
control I-PAIN
in 0
a 0
secondary 0
analysis 0
of 0
a 0
randomized 0
controlled 0
trial 0
. 0

METHODS 0
Sixty-seven 0
English-speaking 0
adult 0
cancer 0
outpatients 0
, 0
including 0
15 0
minorities 0
, 0
with 0
moderate 0
pain 0
over 0
the 0
prior 0
2 0
weeks 0
were 0
randomly 0
assigned 0
to 0
the 0
experimental 0
( 0
N 0
= 0
34 0
) 0
or 0
control 0
group 0
( 0
N 0
= 0
33 0
) 0
. 0

Experimental 0
patients 0
received 0
a 0
20-minute 0
individualized 0
education 0
and 0
coaching 0
session 0
to 0
increase 0
knowledge 0
of 0
pain 0
self-management 0
, 0
to 0
redress 0
personal 0
misconceptions 0
about 0
pain 0
treatment 0
, 0
and 0
to 0
rehearse 0
an 0
individually 0
scripted 0
patient-physician 0
dialog 0
about 0
pain B-PAIN
control I-PAIN
. 0

The 0
control 0
group 0
received 0
standardized 0
information 0
on 0
controlling 0
pain 0
. 0

Data 0
on 0
average 0
pain B-PAIN
( 0
0-10 0
scale 0
) 0
were 0
collected 0
at 0
enrollment 0
and 0
2-week 0
follow-up 0
. 0

RESULTS 0
At 0
enrollment 0
, 0
minority 0
patients 0
had 0
significantly 0
more 0
pain B-PAIN
than 0
their 0
white 0
counterparts 0
( 0
6.0 0
vs 0
5.0 0
, 0
P 0
= 0
0.05 0
) 0
. 0

At 0
follow-up 0
, 0
minorities 0
in 0
the 0
control 0
group 0
continued 0
to 0
have 0
more 0
pain B-PAIN
( 0
6.4 0
vs 0
4.7 0
, 0
P 0
= 0
0.01 0
) 0
, 0
whereas 0
in 0
the 0
experimental 0
group 0
, 0
disparities 0
were 0
eliminated 0
( 0
4.0 0
vs 0
4.3 0
, 0
P 0
= 0
0.71 0
) 0
. 0

The 0
effect 0
of 0
the 0
intervention 0
on 0
reducing 0
disparities 0
was 0
significant 0
( 0
P 0
= 0
0.04 0
) 0
. 0

CONCLUSIONS 0
Patient 0
coaching 0
offers 0
promise 0
as 0
a 0
means 0
of 0
reducing 0
racial/ethnic B-PAIN
disparities I-PAIN
in I-PAIN
pain I-PAIN
control I-PAIN
. 0

Larger 0
studies 0
are 0
needed 0
to 0
validate 0
these 0
findings 0
and 0
to 0
explore 0
possible 0
mechanisms 0
. 0

Methodological 0
issues 0
in 0
designing 0
a 0
multisite 0
trial 0
of 0
risperidone 0
in 0
children 0
and 0
adolescents 0
with 0
autism 0
. 0

OBJECTIVE 0
To 0
describe 0
the 0
methodological 0
challenges 0
and 0
decisions 0
made 0
in 0
developing 0
a 0
multisite 0
, 0
controlled 0
study 0
of 0
risperidone 0
in 0
children 0
and 0
adolescents 0
with 0
autism 0
. 0

METHODS 0
Review 0
the 0
design 0
considerations 0
for 0
clinical 0
trials 0
in 0
children 0
with 0
autistic 0
disorder 0
accompanied 0
by 0
severe 0
tantrums 0
, 0
aggressive 0
and/or 0
self-injurious 0
behaviors 0
. 0

These 0
design 0
considerations 0
include 0
the 0
definition 0
of 0
inclusion 0
criteria 0
that 0
are 0
relevant 0
to 0
clinical 0
practice 0
and 0
matching 0
study 0
design 0
to 0
the 0
goal 0
of 0
evaluating 0
short- 0
and 0
long-term 0
effects 0
. 0

Additional 0
ethical 0
and 0
scientific 0
issues 0
concern 0
the 0
length 0
of 0
trial 0
and 0
sample 0
size 0
. 0

RESULTS 0
We 0
undertook 0
a 0
short-term 0
, 0
placebo-controlled 0
study 0
to 0
evaluate 0
the 0
efficacy 0
and 0
safety B-OTHER
of 0
risperidone 0
in 0
children 0
and 0
adolescents 0
with 0
autistic 0
disorder 0
. 0

This 0
trial 0
design 0
was 0
followed 0
by 0
an 0
extended 0
open-label 0
maintenance 0
on 0
risperidone 0
to 0
confirm 0
durability B-OTHER
of 0
treatment 0
effects 0
and 0
to 0
monitor 0
safety B-OTHER
. 0

Finally 0
, 0
a 0
placebo-controlled 0
discontinuation 0
study 0
tested 0
the 0
need 0
for 0
continuous 0
treatment 0
. 0

CONCLUSIONS 0
In 0
the 0
absence 0
of 0
standard 0
pharmacological 0
treatment 0
for 0
children 0
with 0
autistic 0
disorder 0
, 0
a 0
placebo-controlled 0
study 0
remains 0
the 0
most 0
appropriate 0
method 0
of 0
testing 0
efficacy 0
and 0
safety 0
. 0

The 0
clinical 0
relevance 0
of 0
this 0
study 0
is 0
enhanced 0
by 0
the 0
addition 0
of 0
an 0
extended 0
maintenance 0
phase 0
followed 0
by 0
a 0
placebo 0
discontinuation 0
. 0

A 0
randomized 0
study 0
comparing 0
the 0
use 0
of 0
the 0
Ligaclip 0
with 0
bipolar 0
energy 0
to 0
prevent 0
lymphocele 0
during 0
laparoscopic 0
pelvic 0
lymphadenectomy 0
for 0
gynecologic 0
cancer 0
. 0

OBJECTIVE 0
This 0
prospective 0
randomized 0
pilot 0
study 0
compared 0
the 0
use 0
of 0
the 0
Ligaclip 0
( 0
Ethicon 0
Endo-Surgery 0
, 0
Cincinnati 0
, 0
OH 0
) 0
with 0
bipolar 0
coagulation 0
in 0
preventing 0
lymphoceles 0
after 0
laparoscopic 0
pelvic 0
lymphadenectomy 0
for 0
gynecologic 0
cancer 0
. 0

STUDY 0
DESIGN 0
Thirty 0
patients 0
with 0
gynecologic 0
malignancy 0
, 0
who 0
had 0
laparoscopic 0
pelvic 0
lymphadenectomy 0
were 0
randomly 0
assigned 0
for 0
lymphadenectomy 0
in 0
1 0
side 0
of 0
the 0
pelvis 0
using 0
the 0
Ligaclip 0
, 0
whereas 0
, 0
in 0
the 0
other 0
side 0
, 0
the 0
bipolar 0
coagulation 0
to 0
seal 0
lymphatic 0
vessels 0
was 0
used 0
. 0

RESULTS 0
At 0
ultrasound 0
examination 0
, 0
we 0
detected 0
lymphocele B-PHYSICAL
in 0
10 0
patients 0
( 0
33 0
% 0
) 0
. 0

Lymphocele B-PHYSICAL
developed 0
in 0
9 0
( 0
30 0
% 0
) 0
patients 0
on 0
the 0
side 0
where 0
laparoscopic 0
pelvic 0
lymphadenectomy 0
was 0
perfomed 0
using 0
bipolar 0
coagulation 0
, 0
and 0
in 0
1 0
( 0
3.3 0
% 0
) 0
patient 0
on 0
the 0
side 0
where 0
laparoscopic 0
pelvic 0
lymphadenectomy 0
was 0
performed 0
using 0
the 0
Ligaclip 0
. 0

Univariate 0
analysis 0
revealed 0
that 0
the 0
Ligaclip 0
's 0
use 0
compared 0
with 0
electrocoagulation 0
in 0
the 0
laparoscopic 0
pelvic 0
lymphadenectomy 0
is 0
an 0
independent 0
predictive 0
factor 0
for 0
development B-PHYSICAL
of I-PHYSICAL
lymphocele I-PHYSICAL
( 0
P 0
= 0
.006 0
) 0
. 0

CONCLUSION 0
This 0
study 0
demonstrates 0
that 0
the 0
use 0
of 0
the 0
Ligaclip 0
to 0
close 0
lymphatic 0
vessels 0
may 0
reduce 0
the 0
incidence 0
of 0
lymphoceles B-PHYSICAL
in 0
patients 0
undergoing 0
laparoscopic 0
pelvic 0
lymphadenectomy 0
. 0

Role 0
of 0
oxidized 0
regenerated 0
cellulose 0
in 0
preventing 0
infections 0
at 0
the 0
surgical 0
site 0
: 0
prospective 0
, 0
randomized 0
study 0
in 0
98 0
patients 0
affected 0
by 0
a 0
dirty 0
wound 0
. 0

AIM 0
The 0
aim 0
of 0
this 0
study 0
was 0
to 0
evaluate 0
whether 0
oxidized B-PHYSICAL
regenerated I-PHYSICAL
cellulose I-PHYSICAL
( 0
ORC B-PHYSICAL
) 0
, 0
applied 0
to 0
dirty 0
surgical 0
wounds 0
, 0
is 0
able 0
to 0
reduce 0
the 0
microbial 0
load 0
and 0
, 0
consequently 0
, 0
the 0
infection B-PHYSICAL
rate I-PHYSICAL
as 0
compared 0
to 0
conventional 0
local 0
wound 0
treatment 0
. 0

METHODS 0
The 0
study 0
included 0
98 0
patients 0
who 0
underwent 0
intestinal 0
recanalization 0
procedures 0
between 0
December 0
2003 0
and 0
December 0
2008 0
, 0
with 0
the 0
stoma 0
as 0
the 0
surgical 0
site 0
. 0

Authors 0
considered 0
several 0
risk 0
factors 0
for 0
SSI 0
. 0

The 0
patients 0
were 0
divided 0
into 0
two 0
groups 0
. 0

In 0
group 0
A 0
( 0
50 0
patients 0
) 0
, 0
the 0
surgical B-PHYSICAL
wound I-PHYSICAL
, 0
previous 0
site 0
of 0
the 0
stoma 0
, 0
was 0
packed 0
with 0
ORC 0
, 0
whereas 0
in 0
group 0
B 0
( 0
48 0
patients 0
) 0
gauze 0
soaked 0
in 0
iodine 0
was 0
used 0
. 0

Microbial B-PHYSICAL
contamination I-PHYSICAL
was 0
evaluated 0
with 0
three 0
swabs 0
( 0
in 0
subcutaneous 0
tissue 0
and 0
the 0
dermis 0
) 0
, 0
in 0
the 0
operating 0
room 0
before 0
wound 0
packing 0
and 0
on 0
the 0
2nd 0
and 0
3rd 0
postoperative 0
day 0
( 0
before 0
suturing 0
the 0
skin 0
) 0
. 0

RESULTS 0
There 0
were 0
no 0
cases 0
of 0
wound B-PHYSICAL
dehiscence I-PHYSICAL
and 0
no 0
clinically B-PHYSICAL
evident I-PHYSICAL
superficial I-PHYSICAL
or I-PHYSICAL
deep I-PHYSICAL
surgical I-PHYSICAL
site I-PHYSICAL
infections I-PHYSICAL
in 0
either 0
group 0
. 0

Analysis 0
of 0
all 0
data 0
revealed 0
that 0
there 0
was 0
no 0
or 0
reduced B-PHYSICAL
bacterial I-PHYSICAL
contamination I-PHYSICAL
in 0
the 0
second 0
and 0
third 0
swab 0
in 0
33 0
patients 0
( 0
66 0
% 0
) 0
of 0
Group 0
A 0
versus 0
12 0
patients 0
( 0
25 0
% 0
) 0
of 0
Group 0
B 0
. 0

CONCLUSION 0
Although 0
it 0
is 0
necessary 0
to 0
consider 0
all 0
factors 0
which 0
can 0
have 0
an 0
influence 0
on 0
SSI 0
and 0
use 0
all 0
the 0
means 0
shown 0
to 0
be 0
effective 0
to 0
reduce 0
the 0
risk 0
of 0
SSI 0
, 0
there 0
is 0
a 0
rationale 0
for 0
using 0
ORC 0
to 0
prevent 0
this 0
kind 0
of 0
infection 0
, 0
especially 0
in 0
patients 0
who 0
undergo 0
dirty 0
surgery 0
. 0

A 0
comparison 0
of 0
three 0
highly 0
active 0
antiretroviral 0
treatment 0
strategies 0
consisting 0
of 0
non-nucleoside 0
reverse 0
transcriptase 0
inhibitors 0
, 0
protease 0
inhibitors 0
, 0
or 0
both 0
in 0
the 0
presence 0
of 0
nucleoside 0
reverse 0
transcriptase 0
inhibitors 0
as 0
initial 0
therapy 0
( 0
CPCRA 0
058 0
FIRST 0
Study 0
) 0
: 0
a 0
long-term 0
randomised 0
trial 0
. 0

BACKGROUND 0
Long-term 0
data 0
from 0
randomised 0
trials 0
on 0
the 0
consequences 0
of 0
treatment 0
with 0
a 0
protease 0
inhibitor 0
( 0
PI 0
) 0
, 0
non-nucleoside 0
reverse 0
transcriptase 0
inhibitor 0
( 0
NNRTI 0
) 0
, 0
or 0
both 0
are 0
lacking 0
. 0

Here 0
, 0
we 0
report 0
results 0
from 0
the 0
FIRST 0
trial 0
, 0
which 0
compared 0
initial 0
treatment 0
strategies 0
for 0
clinical 0
, 0
immunological 0
, 0
and 0
virological 0
outcomes 0
. 0

METHODS 0
Between 0
1999 0
and 0
2002 0
, 0
1397 0
antiretroviral-treatment-naive 0
patients 0
, 0
presenting 0
at 0
18 0
clinical 0
trial 0
units 0
with 0
80 0
research 0
sites 0
in 0
the 0
USA 0
, 0
were 0
randomly 0
assigned 0
in 0
a 0
ratio 0
of 0
1:1:1 0
to 0
a 0
protease 0
inhibitor 0
( 0
PI 0
) 0
strategy 0
( 0
PI 0
plus 0
nucleoside 0
reverse 0
transcriptase 0
inhibitor 0
[ 0
NRTI 0
] 0
; 0
n=470 0
) 0
, 0
a 0
non-nucleoside 0
reverse 0
transcriptase 0
inhibitor 0
( 0
NNRTI 0
) 0
strategy 0
( 0
NNRTI 0
plus 0
NRTI 0
; 0
n=463 0
) 0
, 0
or 0
a 0
three-class 0
strategy 0
( 0
PI 0
plus 0
NNRTI 0
plus 0
NRTI 0
; 0
n=464 0
) 0
. 0

Primary 0
endpoints 0
were 0
a 0
composite 0
of 0
an 0
AIDS-defining B-PHYSICAL
event I-PHYSICAL
, 0
death B-MORTALITY
, 0
or 0
CD4 B-PHYSICAL
cell I-PHYSICAL
count I-PHYSICAL
decline I-PHYSICAL
to 0
less 0
than 0
200 0
cells 0
per 0
mm3 0
for 0
the 0
PI 0
versus 0
NNRTI 0
comparison 0
, 0
and 0
average 0
change 0
in 0
CD4 B-PHYSICAL
cell I-PHYSICAL
count I-PHYSICAL
at 0
or 0
after 0
32 0
months 0
for 0
the 0
three-class 0
versus 0
combined 0
two-class 0
comparison 0
. 0

Analyses 0
were 0
by 0
intention-to-treat 0
. 0

This 0
study 0
is 0
registered 0
ClinicalTrials.gov 0
, 0
number 0
NCT00000922 0
. 0

FINDINGS 0
1397 0
patients 0
were 0
assessed 0
for 0
the 0
composite 0
endpoint 0
. 0

A 0
total 0
of 0
388 0
participants 0
developed 0
the 0
composite B-OTHER
endpoint I-OTHER
, 0
302 0
developed 0
AIDS 0
or 0
died 0
, 0
and 0
188 0
died 0
. 0

NNRTI 0
versus 0
PI 0
hazard 0
ratios B-OTHER
( 0
HRs 0
) 0
for 0
the 0
composite 0
endpoint 0
, 0
for 0
AIDS B-MORTALITY
or 0
death B-MORTALITY
, 0
for 0
death B-MORTALITY
, 0
and 0
for 0
virological B-PHYSICAL
failure I-PHYSICAL
were 0
1.02 0
( 0
95 0
% 0
CI 0
0.79-1.31 0
) 0
, 0
1.07 0
( 0
0.80-1.41 0
) 0
, 0
0.95 0
( 0
0.66-1.37 0
) 0
, 0
and 0
0.66 0
( 0
0.56-0.78 0
) 0
, 0
respectively 0
. 0

1196 0
patients 0
were 0
assessed 0
for 0
the 0
three-class 0
versus 0
combined 0
two-class 0
primary 0
endpoint 0
. 0

Mean 0
change 0
in 0
CD4 B-PHYSICAL
cell I-PHYSICAL
count I-PHYSICAL
at 0
or 0
after 0
32 0
months 0
was 0
+234 0
cells 0
per 0
mm3 0
and 0
+227 0
cells 0
per 0
mm3 0
for 0
the 0
three-class 0
and 0
the 0
combined 0
two-class 0
strategies 0
( 0
p=0.62 0
) 0
, 0
respectively 0
. 0

HRs B-OTHER
( 0
three-class 0
vs 0
combined 0
two-class 0
) 0
for 0
AIDS B-MORTALITY
or 0
death B-MORTALITY
and 0
virological B-PHYSICAL
failure I-PHYSICAL
were 0
1.15 0
( 0
0.91-1.45 0
) 0
and 0
0.87 0
( 0
0.75-1.00 0
) 0
, 0
respectively 0
. 0

HRs B-OTHER
( 0
three-class 0
vs 0
combined 0
two-class 0
) 0
for 0
AIDS B-MORTALITY
or 0
death B-MORTALITY
were 0
similar 0
for 0
participants 0
with 0
baseline 0
CD4 0
cell 0
counts 0
of 0
200 0
cells 0
per 0
mm3 0
or 0
less 0
and 0
of 0
more 0
than 0
200 0
cells 0
per 0
mm3 0
( 0
p=0.38 0
for 0
interaction 0
) 0
, 0
and 0
for 0
participants 0
with 0
baseline 0
HIV 0
RNA 0
concentrations 0
less 0
than 0
100 0
000 0
copies 0
per 0
mL 0
and 0
100,000 0
copies 0
per 0
mL 0
or 0
more 0
( 0
p=0.26 0
for 0
interaction 0
) 0
. 0

Participants 0
assigned 0
the 0
three-class 0
strategy 0
were 0
significantly 0
more 0
likely 0
to 0
discontinue B-OTHER
treatment I-OTHER
because 0
of 0
toxic B-ADVERSE-EFFECTS
effects I-ADVERSE-EFFECTS
than 0
were 0
those 0
assigned 0
to 0
the 0
two-class 0
strategies 0
( 0
HR 0
1.58 0
; 0
p 0
< 0
0.0001 0
) 0
. 0

INTERPRETATION 0
Initial 0
treatment 0
with 0
either 0
an 0
NNRTI-based 0
regimen 0
or 0
a 0
PI-based 0
regimen 0
, 0
but 0
not 0
both 0
together 0
, 0
is 0
a 0
good 0
strategy 0
for 0
long-term 0
antiretroviral 0
management 0
in 0
treatment-naive 0
patients 0
with 0
HIV 0
. 0

The 0
overt 0
aggression 0
scale 0
for 0
rating 0
aggression 0
in 0
outpatient 0
youth 0
with 0
autistic 0
disorder 0
: 0
preliminary 0
findings 0
. 0

Aggression 0
is 0
a 0
common 0
and 0
costly 0
problem 0
in 0
youth 0
with 0
developmental 0
disabilities 0
. 0

Rating 0
scales 0
that 0
accurately 0
capture 0
and 0
measure 0
subtypes 0
of 0
aggression 0
phenomenology 0
, 0
frequency 0
and 0
severity 0
are 0
urgently 0
needed 0
, 0
in 0
both 0
clinical 0
practice 0
and 0
research 0
. 0

The 0
authors 0
studied 0
the 0
Overt 0
Aggression 0
Scale 0
( 0
OAS 0
) 0
in 0
a 0
preliminary 0
sample 0
of 0
eight 0
outpatients 0
who 0
participated 0
in 0
an 0
ongoing 0
placebo-controlled 0
study 0
of 0
valproate 0
for 0
aggression 0
in 0
autism 0
. 0

Subjects 0
' 0
OAS B-MENTAL
aggression I-MENTAL
scores I-MENTAL
showed 0
significant 0
correlation 0
with 0
the 0
already 0
validated 0
retrospectively 0
rated 0
Aberrant 0
Behavior 0
Checklist 0
Community 0
Scale 0
irritability 0
subscale 0
. 0

Further 0
study 0
of 0
the 0
OAS B-MENTAL
in 0
outpatients 0
with 0
aggression 0
and 0
developmental 0
disabilities 0
is 0
warranted 0
. 0

MRI B-PHYSICAL
signal I-PHYSICAL
hyperintensities I-PHYSICAL
and 0
failure B-PHYSICAL
to I-PHYSICAL
remit I-PHYSICAL
following 0
antidepressant 0
treatment 0
. 0

BACKGROUND 0
MRI 0
signal 0
hyperintensities 0
predict 0
poor 0
remission B-PHYSICAL
to 0
antidepressant 0
treatment 0
. 0

Previous 0
studies 0
using 0
volumetrics 0
in 0
outpatient 0
samples 0
have 0
relied 0
on 0
total 0
lesion B-PHYSICAL
volume I-PHYSICAL
. 0

The 0
purpose 0
of 0
this 0
study 0
was 0
to 0
test 0
whether 0
remission 0
from 0
geriatric 0
depression 0
depends 0
on 0
lesion B-PHYSICAL
volume I-PHYSICAL
by I-PHYSICAL
region I-PHYSICAL
of I-PHYSICAL
interest I-PHYSICAL
( I-PHYSICAL
ROI I-PHYSICAL
) I-PHYSICAL
. 0

METHOD 0
Thirty-eight 0
patients 0
received 0
baseline 0
MRIs 0
as 0
part 0
of 0
a 0
larger 0
12-week 0
, 0
randomized 0
clinical 0
trial 0
comparing 0
sertraline 0
and 0
nortriptyline 0
in 0
the 0
treatment 0
of 0
late-life 0
depression 0
. 0

MRIcro 0
was 0
used 0
to 0
quantify 0
MRI-hyperintensity 0
volume 0
into 0
total 0
hyperintensity 0
, 0
deep 0
white 0
matter 0
hyperintensity 0
( 0
DWMH 0
) 0
, 0
and 0
periventricular 0
hyperintensity 0
( 0
PVH 0
) 0
volumes 0
. 0

High 0
versus 0
low 0
total 0
, 0
DWMH B-PHYSICAL
, 0
and 0
PVH B-PHYSICAL
volumes I-PHYSICAL
were 0
defined 0
based 0
on 0
the 0
highest 0
quartile 0
of 0
their 0
respective 0
distributions 0
. 0

Remission B-MENTAL
from I-MENTAL
depression I-MENTAL
was 0
defined 0
as 0
a 0
24-item 0
Hamilton B-MENTAL
Rating I-MENTAL
Scale I-MENTAL
for I-MENTAL
Depression I-MENTAL
score 0
? 0

7 0
for 0
two 0
consecutive 0
weeks 0
. 0

RESULTS 0
Patients 0
classified 0
as 0
having 0
high 0
DWMH 0
were 0
7.14 0
times 0
more 0
likely 0
not 0
to 0
remit 0
following 0
antidepressant 0
treatment 0
compared 0
to 0
patients 0
classified 0
as 0
having 0
low 0
DWMH 0
( 0
p=0.02 0
) 0
. 0

Similar 0
odds 0
ratios 0
were 0
obtained 0
for 0
PVH 0
( 0
OR=4.17 0
, 0
p=0.16 0
) 0
and 0
total 0
volumes 0
( 0
OR=5.00 0
, 0
p=0.05 0
) 0
. 0

Importantly 0
, 0
adjusting 0
for 0
age 0
did 0
not 0
change 0
the 0
magnitude 0
of 0
these 0
effects 0
. 0

LIMITATIONS 0
A 0
small 0
and 0
predominantly 0
White 0
sample 0
. 0

CONCLUSIONS 0
This 0
is 0
the 0
first 0
study 0
to 0
test 0
whether 0
remission 0
from 0
geriatric 0
depression 0
depends 0
on 0
lesion 0
volume 0
by 0
ROI 0
in 0
an 0
outpatient 0
sample 0
. 0

The 0
pattern 0
of 0
remission 0
rates 0
and 0
odds 0
ratios 0
was 0
similar 0
when 0
patients 0
were 0
classified 0
as 0
having 0
high 0
DWMH 0
, 0
PVH 0
or 0
total 0
volume 0
suggesting 0
that 0
lesion 0
location 0
may 0
not 0
be 0
critical 0
. 0

Using 0
personalized 0
feedback 0
to 0
reduce 0
alcohol 0
use 0
among 0
hazardous 0
drinking 0
college 0
students 0
: 0
the 0
moderating 0
effect 0
of 0
alcohol-related 0
negative 0
consequences 0
. 0

UNLABELLED 0
Web-based 0
screening 0
and 0
brief 0
interventions 0
that 0
include 0
personalized 0
feedback 0
about 0
their 0
alcohol 0
use 0
have 0
proven 0
to 0
be 0
particularly 0
promising 0
for 0
reducing 0
hazardous 0
drinking 0
among 0
university 0
students 0
. 0

Despite 0
the 0
increasing 0
use 0
of 0
these 0
approaches 0
, 0
there 0
is 0
still 0
relatively 0
little 0
known 0
about 0
how 0
the 0
content 0
of 0
these 0
interventions 0
may 0
influence 0
outcomes 0
and 0
who 0
may 0
benefit 0
most 0
from 0
these 0
approaches 0
. 0

The 0
current 0
study 0
sought 0
to 0
address 0
these 0
issues 0
by 0
examining 0
how 0
individual 0
differences 0
in 0
alcohol 0
consequences 0
influence 0
outcomes 0
of 0
a 0
laboratory-based 0
computerized 0
intervention 0
. 0

METHODS 0
One-hundred 0
and 0
nineteen 0
introductory 0
psychology 0
students 0
who 0
either 0
had 0
two 0
episodes 0
of 0
heavy 0
episodic 0
drinking 0
in 0
the 0
past 0
month 0
or 0
scored 0
?8 0
on 0
the 0
AUDIT 0
participated 0
in 0
this 0
randomized 0
controlled 0
trial 0
for 0
course 0
credit 0
. 0

Participants 0
were 0
assigned 0
to 0
1 0
of 0
4 0
conditions 0
in 0
this 0
2 0
Intervention 0
( 0
Alcohol 0
Feedback 0
vs. 0
Control 0
) 0
?2 0
Assessment 0
( 0
Motivational 0
Assessment 0
vs. 0
No 0
Motivational 0
Assessment 0
) 0
between-subjects 0
design 0
. 0

Quantity 0
of 0
alcohol 0
consumed 0
per 0
week 0
and 0
heavy B-MENTAL
episodic I-MENTAL
drinking I-MENTAL
one I-MENTAL
month I-MENTAL
later I-MENTAL
were 0
the 0
primary 0
dependent 0
variables 0
. 0

RESULTS 0
Controlling 0
for 0
corresponding 0
baseline 0
alcohol 0
measures 0
, 0
hierarchical 0
linear 0
regression 0
analyses 0
showed 0
a 0
significant 0
interaction 0
between 0
intervention 0
condition 0
and 0
baseline 0
alcohol-related 0
consequences 0
. 0

For 0
those 0
who 0
reported 0
more 0
alcohol 0
consequences 0
at 0
baseline 0
, 0
the 0
alcohol 0
intervention 0
resulted 0
in 0
significantly 0
less 0
alcohol 0
use 0
and 0
fewer 0
heavy B-MENTAL
drinking I-MENTAL
episodes I-MENTAL
at 0
follow-up 0
, 0
while 0
no 0
difference 0
was 0
observed 0
between 0
intervention 0
conditions 0
for 0
those 0
with 0
few 0
baseline 0
consequences 0
. 0

Assessment 0
did 0
not 0
moderate 0
intervention 0
effects 0
. 0

DISCUSSION 0
These 0
findings 0
suggest 0
that 0
a 0
feedback-based 0
computerized 0
intervention 0
that 0
includes 0
normative 0
information 0
about 0
alcohol 0
use 0
and 0
consequences 0
may 0
be 0
more 0
effective 0
for 0
hazardous 0
drinking 0
students 0
who 0
are 0
experiencing 0
higher 0
levels 0
of 0
alcohol-related 0
consequences 0
. 0

[ 0
Comparison 0
of 0
three 0
analgesic 0
methods 0
for 0
postoperative 0
pain 0
relief 0
and 0
their 0
effects 0
on 0
plasma B-PHYSICAL
interleukin-6 I-PHYSICAL
concentration I-PHYSICAL
following 0
radical 0
surgery 0
for 0
gastric 0
carcinoma 0
] 0
. 0

OBJECTIVE 0
To 0
compare 0
the 0
efficacy 0
of 0
preemptive 0
epidural 0
analgesia 0
combined 0
with 0
postoperative 0
epidural 0
analgesia 0
, 0
postoperative 0
epidural 0
analgesia 0
alone 0
and 0
intravenous 0
analgesia 0
for 0
postoperative B-PAIN
pain I-PAIN
relief I-PAIN
and 0
their 0
effects 0
on 0
plasma B-PHYSICAL
interleukin-6 I-PHYSICAL
( I-PHYSICAL
IL-6 I-PHYSICAL
) I-PHYSICAL
concentration I-PHYSICAL
following 0
radical 0
surgery 0
for 0
gastric 0
carcinoma 0
. 0

METHODS 0
Sixty-six 0
patients 0
with 0
gastric 0
carcinoma 0
scheduled 0
for 0
gastrectomy 0
were 0
randomly 0
divided 0
into 0
3 0
groups 0
, 0
namely 0
group 0
P 0
( 0
n=22 0
) 0
, 0
group 0
E 0
( 0
n=22 0
) 0
and 0
group 0
V 0
( 0
n=22 0
) 0
, 0
to 0
receive 0
preemptive 0
epidural 0
analgesia 0
combined 0
with 0
postoperative 0
epidural 0
analgesia 0
, 0
exclusive 0
postoperative 0
epidural 0
analgesia 0
, 0
and 0
exclusive 0
postoperative 0
intravenous 0
analgesia 0
, 0
respectively 0
. 0

Hemodynamic B-PHYSICAL
data I-PHYSICAL
were 0
recorded 0
for 0
all 0
the 0
patients 0
during 0
the 0
operation 0
, 0
and 0
visual 0
analogue 0
scale 0
( 0
VAS 0
) 0
was 0
used 0
to 0
assess 0
the 0
pain B-PAIN
intensity I-PAIN
at 0
4 0
, 0
8 0
, 0
16 0
, 0
24 0
, 0
48 0
and 0
72 0
h 0
after 0
surgery 0
. 0

Plasma B-PHYSICAL
IL-6 I-PHYSICAL
concentration I-PHYSICAL
was 0
determined 0
before 0
surgery 0
and 0
at 0
24 0
, 0
48 0
, 0
72 0
h 0
after 0
surgery 0
. 0

RESULTS 0
No 0
significant 0
changes 0
occurred 0
in 0
the 0
hemodynamics 0
during 0
the 0
preoperative 0
periods 0
. 0

VAS 0
and 0
IL-6 B-PHYSICAL
were 0
lower 0
in 0
group 0
P 0
than 0
in 0
group 0
E 0
and 0
V 0
, 0
and 0
group 0
E 0
had 0
lower 0
measurement 0
than 0
group 0
V 0
( 0
P 0
< 0
0.05 0
) 0
. 0

CONCLUSION 0
Preemptive 0
epidural 0
analgesia 0
combined 0
with 0
postoperative 0
epidural 0
analgesia 0
provides 0
more 0
satisfactory 0
pain B-PAIN
relief I-PAIN
and 0
more 0
effectively 0
prevents 0
IL-6 B-PHYSICAL
increment I-PHYSICAL
than 0
exclusive 0
epidural 0
analgesia 0
or 0
intravenous 0
analgesia 0
after 0
gastrectomy 0
for 0
gastric 0
carcinoma 0
. 0

Nephrotoxicity 0
of 0
cyclosporin 0
A 0
in 0
patients 0
with 0
newly 0
diagnosed 0
type 0
1 0
diabetes 0
mellitus 0
. 0

Renal 0
function 0
was 0
studied 0
in 0
18 0
patients 0
with 0
Type 0
1 0
diabetes 0
mellitus 0
. 0

All 0
were 0
participating 0
in 0
the 0
Canadian-European 0
randomized 0
placebo-controlled 0
cyclosporin 0
trial 0
in 0
newly 0
diagnosed 0
Type 0
1 0
diabetic 0
patients 0
, 0
nine 0
being 0
randomized 0
to 0
placebo 0
, 0
and 0
nine 0
to 0
cyclosporin 0
A 0
. 0

During 0
treatment 0
for 0
12 0
to 0
18 0
months 0
, 0
cyclosporin 0
A 0
caused 0
significant 0
reductions 0
in 0
the 0
glomerular B-ADVERSE-EFFECTS
filtration I-ADVERSE-EFFECTS
rate I-ADVERSE-EFFECTS
( 0
before 0
drug 0
withdrawal 0
, 0
cyclosporin 0
97 0
+/- 0
18 0
vs 0
placebo 0
125 0
+/- 0
16 0
ml 0
min-1 0
1.73-m-2 0
, 0
p 0
less 0
than 0
0.05 0
) 0
, 0
renal B-ADVERSE-EFFECTS
plasma I-ADVERSE-EFFECTS
flow I-ADVERSE-EFFECTS
( 0
454 0
+/- 0
83 0
vs 0
536 0
+/- 0
70 0
ml 0
min-1 0
1.73-m-2 0
, 0
p 0
less 0
than 0
0.05 0
) 0
, 0
and 0
lithium B-PHYSICAL
clearance I-PHYSICAL
( 0
17 0
+/- 0
3 0
vs 0
28 0
+/- 0
5 0
ml 0
min-1 0
1.73-m-2 0
, 0
p 0
less 0
than 0
0.05 0
) 0
. 0

The 0
fractional B-PHYSICAL
proximal I-PHYSICAL
reabsorption I-PHYSICAL
was 0
increased 0
( 0
0.82 0
+/- 0
0.03 0
vs 0
0.78 0
+/- 0
0.03 0
, 0
p 0
less 0
than 0
0.05 0
) 0
, 0
and 0
the 0
fractional B-PHYSICAL
distal I-PHYSICAL
sodium I-PHYSICAL
reabsorption I-PHYSICAL
reduced 0
( 0
0.88 0
+/- 0
0.03 0
vs 0
0.94 0
+/- 0
0.02 0
, 0
p 0
less 0
than 0
0.05 0
) 0
. 0

These 0
results 0
are 0
in 0
accordance 0
with 0
the 0
hypothesis 0
that 0
the 0
nephrotoxic 0
effect 0
of 0
cyclosporin 0
A 0
results 0
from 0
a 0
preferential 0
constriction 0
of 0
afferent 0
glomerular 0
vessels 0
. 0

One 0
year 0
after 0
withdrawal 0
of 0
the 0
drug 0
, 0
all 0
variables 0
were 0
similar 0
in 0
the 0
two 0
groups 0
, 0
except 0
for 0
blood B-PHYSICAL
glucose I-PHYSICAL
control I-PHYSICAL
which 0
was 0
worse 0
in 0
the 0
cyclosporin 0
A 0
treated 0
group 0
. 0

When 0
corrected 0
for 0
differences 0
in 0
blood 0
glucose 0
control 0
it 0
appeared 0
that 0
in 0
three 0
out 0
of 0
nine 0
patients 0
glomerular B-PHYSICAL
filtration I-PHYSICAL
rate I-PHYSICAL
had 0
not 0
completely 0
returned 0
to 0
the 0
reference 0
range 0
of 0
the 0
placebo 0
group 0
. 0

We 0
conclude 0
that 0
the 0
nephrotoxic 0
side-effects 0
of 0
cyclosporin 0
A 0
treatment 0
for 0
1 0
year 0
are 0
reversible 0
. 0

There 0
are 0
, 0
however 0
, 0
signs 0
of 0
minor 0
and 0
perhaps 0
chronic 0
renal 0
injury 0
. 0

Sivelestat 0
sodium 0
hydrate 0
improves 0
septic 0
acute 0
lung 0
injury 0
by 0
reducing 0
alveolar 0
dysfunction 0
. 0

Sivelestat 0
sodium 0
hydrate 0
( 0
sivelestat 0
) 0
is 0
a 0
selective 0
inhibitor 0
of 0
polymorphonuclear 0
leukocyte 0
elastase 0
( 0
PMN-E 0
) 0
. 0

We 0
administered 0
sivelestat 0
to 0
patients 0
with 0
septic 0
acute 0
lung 0
injury 0
( 0
ALI 0
) 0
to 0
examine 0
its 0
usefulness 0
. 0

The 0
primary 0
endpoints 0
in 0
the 0
study 0
were 0
the 0
duration 0
of 0
artificial B-OTHER
ventilation I-OTHER
and 0
pulmonary B-PHYSICAL
oxygenation I-PHYSICAL
ability I-PHYSICAL
, 0
and 0
the 0
secondary 0
endpoints 0
were 0
mortality B-MORTALITY
and 0
the 0
concentrations 0
of 0
PMN-E 0
, B-MORTALITY
SP-D 0
, B-MORTALITY
TNF-alpha I-MORTALITY
and I-MORTALITY
IL-8 I-MORTALITY
in B-MORTALITY
blood I-MORTALITY
. 0

In 0
the 0
sivelestat 0
group 0
, 0
the 0
duration 0
of 0
artificial B-OTHER
ventilation I-OTHER
, 0
pulmonary 0
oxygenation 0
ability 0
, 0
and 0
the 0
blood B-PHYSICAL
PMN-E B-PHYSICAL
, 0
SP-D B-PHYSICAL
, 0
TNF-alpha B-PHYSICAL
and 0
IL-8 B-PHYSICAL
concentrations I-PHYSICAL
decreased 0
significantly 0
. 0

Administration 0
of 0
sivelestat 0
was 0
found 0
to 0
reduce 0

Preservative-free 0
ocular 0
hydrating 0
agents 0
in 0
symptomatic 0
contact 0
lens 0
wearers 0
: 0
saline 0
versus 0
PVP 0
solution 0
. 0

PURPOSE 0
To 0
compare 0
two 0
preservative-free 0
hydrating 0
agents 0
, 0
in 0
multidose 0
( 0
ABAK 0
) 0
bottles 0
, 0
in 0
contact 0
lens 0
wearers 0
experiencing 0
symptoms 0
of 0
ocular B-PHYSICAL
dryness I-PHYSICAL
. 0

METHODS 0
The 0
endpoint 0
of 0
this 0
4-week 0
multicenter 0
, 0
randomized 0
, 0
double-blind 0
, 0
parallel-group 0
study 0
comparing 0
a 0
2 0
% 0
polyvinylpyrrolidone 0
( 0
PVP 0
) 0
solution 0
with 0
a 0
0.9 0
% 0
NaCl 0
solution 0
was 0
to 0
assess 0
ocular 0
discomfort 0
using 0
a 0
visual 0
analog 0
scale 0
. 0

A 0
biomicroscopic 0
examination 0
and 0
a 0
test 0
of 0
tolerability 0
on 0
instillation 0
were 0
also 0
performed 0
, 0
and 0
adverse 0
events 0
were 0
recorded 0
. 0

RESULTS 0
Thirty-nine 0
subjects 0
were 0
enrolled 0
( 0
23 0
PVP 0
; 0
16 0
NaCl 0
) 0
. 0

The 0
average 0
age 0
was 0
30 0
; 0
subjects 0
were 0
predominantly 0
female 0
, 0
and 0
mostly 0
wore 0
frequent-replacement 0
contact 0
lenses 0
. 0

They 0
were 0
all 0
exposed 0
to 0
environmental 0
factors 0
such 0
as 0
routine 0
use 0
of 0
video 0
monitors 0
or 0
air 0
conditioning 0
. 0

The 0
two 0
groups 0
were 0
similar 0
at 0
baseline 0
( 0
D0 0
) 0
. 0

Both 0
PVP 0
and 0
NaCl 0
improved 0
the 0
comfort 0
of 0
contact B-OTHER
lens I-OTHER
wear I-OTHER
( 0
P 0
= 0
0.0003 0
) 0
, 0
with 0
no 0
difference 0
between 0
them 0
( 0
P 0
= 0
0.25 0
) 0
. 0

The 0
mean 0
daily 0
duration 0
of 0
lens 0
wear 0
and 0
the 0
daily 0
number 0
of 0
instillations 0
to 0
relieve 0
discomfort 0
( 0
4.2 0
+/- 0
2.0 0
for 0
PVP 0
ABAK 0
; 0
4.6 0
+/- 0
1.9 0
for 0
NaCl 0
ABAK 0
) 0
were 0
comparable 0
. 0

However 0
, 0
PVP 0
use 0
led 0
to 0
more 0
favorable 0
evolution 0
of 0
fluorescein-staining B-OTHER
corneal I-OTHER
punctuations I-OTHER
( 0
P 0
= 0
0.028 0
) 0
. 0

Safety B-OTHER
was 0
good 0
, 0
with 0
minimal 0
adverse B-ADVERSE-EFFECTS
events I-ADVERSE-EFFECTS
considered 0
unrelated 0
to 0
the 0
products 0
. 0

Lens B-OTHER
wettability I-OTHER
was 0
excellent 0
, 0
and 0
there 0
were 0
no 0
clinically 0
relevant 0
deposits 0
. 0

Most 0
subjects 0
also 0
found 0
the 0
ABAK 0
bottles 0
convenient 0
. 0

CONCLUSIONS 0
Ocular 0
hydration 0
improves 0
comfort B-OTHER
in 0
contact 0
lens 0
wearers 0
. 0

NaCl 0
is 0
an 0
appropriate 0
first-line 0
treatment 0
, 0
but 0
for 0
subjects 0
with 0
fluorescein-staining 0
punctuations 0
, 0
lubrication 0
with 0
PVP 0
is 0
preferable 0
. 0

Predictors 0
of 0
recruited 0
melanoma 0
families 0
into 0
a 0
behavioral 0
intervention 0
project 0
. 0

BACKGROUND 0
Examination 0
of 0
families 0
represents 0
an 0
important 0
priority 0
in 0
health 0
research 0
. 0

In 0
this 0
paper 0
we 0
report B-OTHER
on 0
individual B-MENTAL
and I-MENTAL
family-level I-MENTAL
factors I-MENTAL
associated 0
with 0
enrollment 0
in 0
a 0
cancer 0
prevention 0
research 0
project 0
. 0

We 0
approached 0
families 0
affected 0
by 0
melanoma 0
for 0
possible 0
participation 0
in 0
a 0
randomized 0
controlled 0
trial 0
of 0
a 0
web-based 0
communication 0
and 0
support 0
intervention 0
. 0

METHODS 0
We 0
recruited 0
three 0
family 0
members 0
per 0
family 0
for 0
assessment 0
- 0
the 0
melanoma 0
case 0
, 0
a 0
first-degree 0
relative 0
( 0
FDR 0
) 0
, 0
and 0
a 0
relative 0
who 0
is 0
a 0
parent 0
of 0
a 0
child 0
age 0
18 0
or 0
younger 0
. 0

Recruitment 0
involved 0
three 0
steps 0
: 0
requesting 0
the 0
physician 0
's 0
consent 0
to 0
approach 0
the 0
melanoma 0
case 0
, 0
approaching 0
the 0
case 0
to 0
request 0
their 0
participation 0
and 0
family 0
contact 0
information 0
, 0
and 0
they 0
approaching 0
the 0
FDRs 0
and 0
parents 0
. 0

RESULTS 0
Of 0
the 0
1380 0
families 0
approached 0
, 0
313 0
were 0
enrolled 0
, 0
263 0
were 0
excluded 0
because 0
we 0
could 0
not 0
find 0
or 0
contact 0
a 0
family 0
member 0
( 0
FDR 0
or 0
parent 0
) 0
, 0
331 0
did 0
not 0
have 0
eligible 0
family 0
members 0
, 0
and 0
473 0
refused 0
. 0

The 0
most 0
frequently 0
noted 0
reason 0
for 0
refusal B-OTHER
was 0
being 0
too 0
busy 0
or 0
having 0
no 0
time 0
. 0

The 0
primary 0
predictors 0
of 0
participation 0
for 0
cases 0
( 0
OR=1.6 0
; 0
CI=1.01-2.51 0
) 0
and 0
FDRs 0
( 0
OR=2.15 0
; 0
CI=1.11-4.13 0
) 0
included 0
higher B-MENTAL
educational I-MENTAL
attainment I-MENTAL
. 0

FDRs 0
were 0
more 0
likely 0
to 0
enroll 0
if 0
they 0
were 0
female 0
( 0
OR=1.77 0
; 0
CI=1.1-.85 0
) 0
and 0
parents 0
were 0
more 0
likely 0
to 0
enroll 0
if 0
the 0
case 0
had 0
been 0
diagnosed B-PHYSICAL
more I-PHYSICAL
recently I-PHYSICAL
( 0
OR=3.3 0
; 0
CI=1.9-5.93 0
) 0
, 0
if 0
the 0
parent B-OTHER
was I-OTHER
partnered I-OTHER
( 0
OR=4.37 0
; 0
CI=1.86-10.26 0
) 0
, 0
and 0
if 0
the 0
parent B-MENTAL
lived I-MENTAL
in I-MENTAL
the I-MENTAL
same I-MENTAL
city I-MENTAL
as I-MENTAL
the I-MENTAL
case I-MENTAL
( 0
OR=2.88 0
; 0
CI=1.08-7.68 0
) 0
. 0

CONCLUSIONS 0
The 0
results 0
can 0
provide 0
information 0
on 0
potential 0
directions 0
for 0
future 0
family 0
recruitment 0
. 0

Olanzapine 0
versus 0
haloperidol 0
in 0
children 0
with 0
autistic B-PHYSICAL
disorder I-PHYSICAL
: 0
an 0
open 0
pilot 0
study 0
. 0

OBJECTIVES 0
Conventional 0
neuroleptics 0
ameliorate 0
symptoms 0
in 0
children 0
with 0
autistic 0
disorder 0
; 0
however 0
, 0
they 0
are 0
known 0
to 0
cause 0
dyskinesias 0
. 0

Atypical 0
neuroleptics 0
, 0
including 0
olanzapine 0
, 0
may 0
have 0
less 0
risk 0
for 0
dyskinesia 0
, 0
but 0
their 0
efficacy 0
in 0
autistic 0
disorder 0
is 0
not 0
established 0
. 0

This 0
study 0
was 0
designed 0
to 0
investigate 0
the 0
safety 0
and 0
effectiveness 0
of 0
open-label 0
olanzapine 0
as 0
a 0
treatment 0
for 0
children 0
with 0
autistic 0
disorder 0
by 0
using 0
haloperidol 0
as 0
a 0
standard 0
comparator 0
treatment 0
. 0

METHOD 0
In 0
a 0
parallel 0
groups 0
design 0
, 0
12 0
children 0
with 0
DSM-IV 0
autistic 0
disorder 0
( 0
mean 0
age 0
7.8+/-2.1 0
years 0
) 0
were 0
randomized 0
to 0
6 0
weeks 0
of 0
open 0
treatment 0
with 0
olanzapine 0
or 0
haloperidol 0
. 0

Mean 0
final 0
dosages 0
were 0
7.9+/-2.5 0
mg/day 0
for 0
olanzapine 0
and 0
1.4+/-0.7 0
mg/day 0
for 0
haloperidol 0
. 0

Outcome 0
measures 0
included 0
the 0
Clinical B-MENTAL
Global I-MENTAL
Impressions I-MENTAL
( I-MENTAL
CGI I-MENTAL
) I-MENTAL
and 0
the 0
Children 0
's 0
Psychiatric 0
Rating 0
Scale 0
( 0
CPRS 0
) 0
. 0

RESULTS 0
Both 0
groups 0
had 0
symptom B-MENTAL
reduction I-MENTAL
. 0

Five 0
of 0
six 0
in 0
the 0
olanzapine 0
group 0
and 0
three 0
of 0
six 0
in 0
the 0
haloperidol 0
group 0
were 0
rated 0
as 0
responders 0
according 0
to 0
the 0
CGI B-MENTAL
Improvement 0
item 0
. 0

Subjects 0
showed 0
improvement 0
on 0
the 0
CPRS B-MENTAL
Autism I-MENTAL
Factor I-MENTAL
( 0
F1,9 0
= 0
24.4 0
, 0
p 0
= 0
.0008 0
) 0
. 0

Side 0
effects 0
included 0
drowsiness B-ADVERSE-EFFECTS
and 0
weight 0
gain B-ADVERSE-EFFECTS
. 0

CONCLUSIONS 0
The 0
findings 0
suggest 0
that 0
olanzapine 0
is 0
a 0
promising 0
treatment 0
for 0
children 0
with 0
autistic 0
disorder 0
. 0

Further 0
placebo-controlled 0
and 0
long-term 0
studies 0
of 0
olanzapine 0
in 0
autistic 0
disorder 0
are 0
required 0
. 0

Long-term 0
follow-up 0
of 0
cytostatic 0
intravesical 0
instillation 0
in 0
patients 0
with 0
superficial 0
bladder 0
carcinoma 0
. 0

Is 0
short-term 0
, 0
intensive 0
instillation 0
better 0
than 0
maintenance 0
therapy 0
? 0

OBJECTIVES 0
Comparisons 0
of 0
two 0
3-year 0
protocols 0
, 0
one 0
20-week 0
protocol 0
of 0
mitomycin 0
C 0
instillation 0
and 0
one 0
3-year 0
protocol 0
of 0
doxorubicin 0
instillation 0
for 0
the 0
prevention 0
of 0
recurrent B-PHYSICAL
tumors I-PHYSICAL
and 0
progression B-PHYSICAL
in 0
patients 0
whose 0
superficial 0
bladder 0
tumors 0
had 0
been 0
removed 0
by 0
transurethral 0
resection 0
. 0

METHODS 0
A 0
prospective 0
, 0
randomized 0
parallel 0
group 0
multicenter 0
trial 0
was 0
conducted 0
. 0

419 0
patients 0
were 0
evaluated 0
after 0
a 0
median 0
follow-up 0
of 0
57 0
months 0
. 0

Cox 0
proportional 0
hazards 0
analysis 0
was 0
performed 0
. 0

RESULTS 0
An 0
overall B-PHYSICAL
recurrence I-PHYSICAL
rate I-PHYSICAL
of 0
22.7 0
% 0
and 0
an 0
overall B-PHYSICAL
progression I-PHYSICAL
rate I-PHYSICAL
of 0
9.8 0
% 0
was 0
found 0
. 0

For 0
time 0
to 0
progression 0
a 0
significant 0
overall B-OTHER
treatment I-OTHER
effect 0
was 0
detected 0
dependent 0
on 0
the 0
recurrence 0
status 0
before 0
entry 0
into 0
the 0
study 0
( 0
p 0
= 0
0.0059 0
) 0
. 0

Pairwise 0
comparisons 0
showed 0
the 0
mitomycin 0
protocol 0
with 0
short-term 0
intensive 0
( 0
weekly 0
) 0
combined 0
with 0
long-term 0
maintenance 0
instillation 0
to 0
have 0
a 0
highly 0
beneficial B-OTHER
effect 0
compared 0
to 0
long-term 0
maintenance 0
instillation 0
only 0
especially 0
for 0
patients 0
entering 0
the 0
study 0
with 0
recurrent 0
tumors 0
( 0
RR 0
= 0
0.06 0
, 0
95 0
% 0
CI 0
: 0
[ 0
0.008 0
, 0
0.506 0
] 0
. 0

CONCLUSION 0
These 0
results 0
show 0
that 0
intensive B-PHYSICAL
therapeutic I-PHYSICAL
instillation I-PHYSICAL
may 0
have 0
an 0
advantage 0
over 0
less 0
intensive 0
, 0
prophylactic 0
regimens 0
. 0

A 0
double-blind 0
crossover 0
comparison 0
of 0
pindolol 0
, 0
metoprolol 0
, 0
atenolol 0
and 0
labetalol 0
in 0
mild 0
to 0
moderate 0
hypertension 0
. 0

1 0
This 0
study 0
was 0
designed 0
to 0
compare 0
in 0
a 0
double-blind 0
randomized 0
crossover 0
trial 0
, 0
atenolol 0
, 0
labetalol 0
, 0
metoprolol 0
and 0
pindolol 0
. 0

Considerable 0
differences 0
in 0
dose B-OTHER
( 0
atenolol 0
138 0
+/- 0
13 0
mg 0
daily 0
; 0
labetalol 0
308 0
+/- 0
34 0
mg 0
daily 0
; 0
metoprolol 0
234 0
+/- 0
22 0
mg 0
daily 0
; 0
and 0
pindolol 0
24 0
+/-2 0
mg 0
daily 0
were 0
required 0
to 0
produce 0
similar 0
antihypertensive B-PHYSICAL
effects I-PHYSICAL
. 0

3 0
The 0
overall 0
incidence 0
of 0
side-effects B-ADVERSE-EFFECTS
was 0
similar 0
with 0
atenolol 0
, 0
metoprolol 0
and 0
pindolol 0
but 0
was 0
slightly 0
less 0
with 0
labetalol 0
. 0

Sleep B-MENTAL
disturbances I-MENTAL
and 0
abnormal B-MENTAL
dreaming I-MENTAL
patterns I-MENTAL
were 0
most 0
frequent 0
with 0
pindolol 0
. 0

4 0
There 0
was 0
a 0
significantly B-PHYSICAL
greater 0
fall B-PHYSICAL
in I-PHYSICAL
pulse I-PHYSICAL

Effects 0
of 0
cuff 0
inflation 0
on 0
self-recorded B-PHYSICAL
blood I-PHYSICAL
pressure I-PHYSICAL
. 0

Changes 0
in 0
continuously 0
recorded 0
'Finapres 0
' 0
finger B-PHYSICAL
blood I-PHYSICAL
pressure I-PHYSICAL
in 0
ten 0
normotensive 0
and 0
seven 0
hypertensive 0
subjects 0
induced 0
by 0
self-inflation 0
of 0
the 0
cuff 0
or 0
just 0
wearing 0
the 0
inflated 0
cuff 0
were 0
studied 0
. 0

Inflating 0
the 0
cuff 0
caused 0
an 0
instantaneous 0
rise 0
in 0
systolic B-PHYSICAL
blood I-PHYSICAL
pressure I-PHYSICAL
of 0
13 0
and 0
12 0
mm 0
Hg 0
( 0
hypertensive 0
and 0
normotensive 0
subjects 0
, 0
respectively 0
) 0
. 0

Wearing 0
the 0
inflated 0
cuff 0
did 0
not 0
change 0
blood B-PHYSICAL
pressure I-PHYSICAL
. 0

Thus 0
the 0
rise 0
in 0
pressure B-PHYSICAL
was 0
related 0
to 0
the 0
muscular 0
activity 0
required 0
for 0
cuff 0
inflation 0
. 0

Systolic B-PHYSICAL
blood I-PHYSICAL
pressure I-PHYSICAL
took 0
on 0
average 0
7 0
s 0
and 0
at 0
most 0
21 0
s 0
to 0
return 0
to 0
baseline 0
level 0
after 0
stopping 0
cuff 0
inflation 0
. 0

Since 0
first 0
Korotkoff 0
sounds 0
may 0
already 0
be 0
heard 0
after 0
10-15 0
s 0
when 0
following 0
recommended 0
procedures 0
, 0
self-recorded B-PHYSICAL
systolic I-PHYSICAL
blood I-PHYSICAL
pressure I-PHYSICAL
may 0
be 0
recorded 0
as 0
too 0
high 0
when 0
subjects 0
inflate 0
their 0
cuff 0
at 0
too 0
low 0
a 0
pressure 0
or 0
deflate 0
it 0
too 0
fast 0
. 0

Clinical 0
trial 0
: 0
exposure 0
to 0
ribavirin 0
predicts 0
EVR 0
and 0
SVR 0
in 0
patients 0
with 0
HCV 0
genotype 0
1 0
infection 0
treated 0
with 0
peginterferon 0
alpha-2a 0
plus 0
ribavirin 0
. 0

BACKGROUND 0
The 0
impact 0
of 0
reduced 0
drug 0
exposure 0
on 0
outcomes 0
in 0
patients 0
with 0
chronic 0
hepatitis 0
C 0
has 0
not 0
been 0
determined 0
in 0
routine 0
clinical 0
practice 0
. 0

AIM 0
To 0
examine 0
the 0
impact 0
of 0
exposure 0
to 0
peginterferon 0
alpha-2a 0
and 0
ribavirin 0
on 0
early 0
virological 0
response 0
( 0
EVR 0
) 0
and 0
sustained 0
virological 0
response 0
( 0
SVR 0
) 0
in 0
treatment-naive 0
patients 0
with 0
HCV 0
genotype 0
1 0
infection 0
enrolled 0
in 0
a 0
large 0
expanded 0
access 0
programme 0
. 0

METHODS 0
Eight 0
hundred 0
and 0
ninety-one 0
patients 0
treated 0
for 0
48 0
weeks 0
with 0
an 0
initial 0
ribavirin 0
dose 0
of 0
800 0
or 0
1000/1200 0
mg/day 0
were 0
evaluated 0
. 0

Ribavirin 0
1000 0
mg/day 0
( 0
< 0
75 0
kg 0
) 0
or 0
1200 0
mg/day 0
( 0
> 0
or=75 0
kg 0
) 0
and 0
peginterferon 0
alpha-2a 0
180 0
microg/week 0
were 0
considered 0
optimal 0
. 0

The 0
impact 0
of 0
reduced B-PHYSICAL
drug I-PHYSICAL
exposure I-PHYSICAL
( 0
expressed 0
as 0
a 0
percentage 0
of 0
optimal 0
) 0
on 0
EVR B-PHYSICAL
and 0
SVR B-PHYSICAL
was 0
evaluated 0
. 0

RESULTS 0
Mean 0
ribavirin B-OTHER
exposure I-OTHER
in 0
week 0
0-12 0
was 0
70 0
% 0
and 0
96 0
% 0
in 0
patients 0
assigned 0
to 0
ribavirin 0
800 0
and 0
1000/1200 0
mg/day 0
, 0
respectively 0
. 0

EVR B-PHYSICAL
and 0
SVR B-PHYSICAL
rates I-PHYSICAL
were 0
lower 0
in 0
patients 0
assigned 0
to 0
ribavirin 0
800 0
than 0
1000/1200 0
mg/day 0
( 0
EVR 0
, 0
75 0
% 0
vs. 0
84 0
% 0
, 0
respectively 0
, 0
P 0
< 0
0.001 0
; 0
SVR 0
, 0
45 0
% 0
vs. 0
54 0
% 0
, 0
respectively 0
, 0
P 0
= 0
0.011 0
) 0
. 0

Furthermore 0
, 0
there 0
was 0
a 0
strong 0
correlation 0
between 0
achievement 0
of 0
EVR B-PHYSICAL
and 0
SVR B-PHYSICAL
and 0
ribavirin 0
dose 0
over 0
the 0
first 0
12 0
weeks 0
expressed 0
either 0
as 0
absolute 0
dose 0
or 0
proportion 0
of 0
optimal 0
dose 0
received 0
( 0
P 0
< 0
0.001 0
for 0
both 0
) 0
. 0

CONCLUSIONS 0
Ribavirin 0
exposure 0
to 0
week 0
12 0
is 0
significantly 0
associated 0
with 0
EVR 0
and 0
SVR 0
in 0
genotype 0
1 0
patients 0
. 0

Maintenance 0
of 0
an 0
optimal 0
ribavirin 0
dose 0
is 0
the 0
most 0
important 0
modifiable 0
factor 0
during 0
combination 0
therapy 0
for 0
chronic 0
hepatitis 0
C 0
. 0

A 0
randomized 0
, 0
phase 0
II 0
trial 0
of 0
two 0
dose 0
schedules 0
of 0
carboplatin/paclitaxel/cetuximab 0
in 0
stage 0
IIIB/IV 0
non-small-cell 0
lung 0
cancer 0
( 0
NSCLC 0
) 0
. 0

BACKGROUND 0
This 0
trial 0
investigated 0
the 0
efficacy 0
and 0
safety 0
of 0
weekly 0
cetuximab 0
combined 0
with 0
two 0
different 0
schedules 0
of 0
paclitaxel/carboplatin 0
for 0
stage 0
IIIB/IV 0
non-small-cell 0
lung 0
cancer 0
( 0
NSCLC 0
) 0
. 0

METHODS 0
A 0
total 0
of 0
168 0
patients 0
with 0
previously 0
untreated 0
stage 0
IIIB/IV 0
NSCLC 0
were 0
randomized 0
to 0
arm 0
A 0
, 0
cetuximab 0
( 0
400 0
mg/m 0
( 0
2 0
) 0
day 0
1 0
followed 0
by 0
weekly 0
250 0
mg/m 0
( 0
2 0
) 0
) 0
+ 0
paclitaxel 0
( 0
Taxol 0
) 0
( 0
225 0
mg/m 0
( 0
2 0
) 0
) 0
/carboplatin 0
( 0
AUC6 0
) 0
day 0
1 0
every 0
3 0
weeks 0
or 0
arm 0
B 0
, 0
same 0
cetuximab 0
regimen 0
plus 0
paclitaxel 0
( 0
100 0
mg/m 0
( 0
2 0
) 0
) 0
days 0
1 0
, 0
8 0
, 0
and 0
15 0
every 0
3 0
weeks 0
and 0
carboplatin 0
( 0
AUC6 0
) 0
day 0
1 0
every 0
4 0
weeks 0
. 0

Treatment 0
continued 0
for 0
a 0
four-cycle 0
maximum 0
. 0

Patients 0
with 0
a 0
complete 0
response 0
, 0
partial 0
response 0
, 0
or 0
stable 0
disease 0
after 0
four 0
cycles 0
could 0
receive 0
cetuximab 0
250 0
mg/m 0
( 0
2 0
) 0
/week 0
until 0
disease B-PHYSICAL
progression I-PHYSICAL
or I-PHYSICAL
unacceptable I-PHYSICAL
toxicity I-PHYSICAL
. 0

The 0
primary 0
end 0
point 0
was 0
to 0
evaluate 0
progression-free B-MORTALITY
survival I-MORTALITY
( I-MORTALITY
PFS I-MORTALITY
) I-MORTALITY
. 0

RESULTS 0
Median 0
PFS B-PHYSICAL
was 0
4.7 0
and 0
4.3 0
months 0
for 0
arms 0
A 0
and 0
B 0
, 0
respectively 0
( 0
6-month 0
PFS 0
, 0
27.3 0
% 0
versus 0
30.9 0
% 0
) 0
. 0

Median 0
overall B-MORTALITY
survival I-MORTALITY
was 0
11.4 0
versus 0
9.8 0
months 0
for 0
arms 0
A 0
and 0
B 0
, 0
respectively 0
; 0
estimated 0
1-year 0
survival 0
, 0
47.7 0
% 0
versus 0
39.3 0
% 0
; 0
and 0
objective 0
response 0
rate 0
, 0
29.6 0
% 0
versus 0
25 0
% 0
. 0

The 0
regimen 0
was 0
well 0
tolerated B-OTHER
with 0
rash B-PHYSICAL
and I-PHYSICAL
hematologic I-PHYSICAL
toxicity I-PHYSICAL
being 0
most 0
common 0
. 0

CONCLUSIONS 0
This 0
study 0
did 0
not 0
meet 0
the 0
prespecified 0
benchmark 0
of 0
35 0
% 0
6-month 0
PFS 0
rate 0
; 0
both 0
combination 0
schedules 0
of 0
cetuximab 0
plus 0
paclitaxel/carboplatin 0
were 0
feasible 0
and 0
equivalent 0
for 0
treating 0
advanced 0
NSCLC 0
. 0

A 0
randomized 0
trial 0
of 0
external 0
beam 0
radiotherapy 0
versus 0
cryoablation 0
in 0
patients 0
with 0
localized 0
prostate 0
cancer 0
: 0
quality 0
of 0
life 0
outcomes 0
. 0

BACKGROUND 0
A 0
recent 0
randomized 0
trial 0
to 0
compare 0
external 0
beam 0
radiation 0
therapy 0
( 0
EBRT 0
) 0
to 0
cryoablation 0
for 0
localized 0
disease 0
showed 0
cryoablation 0
to 0
be 0
noninferior 0
to 0
external 0
beam 0
EBRT 0
in 0
disease 0
progression 0
and 0
overall 0
and 0
disease-specific 0
survival 0
. 0

We 0
report 0
on 0
the 0
quality 0
of 0
life 0
( B-OTHER
QOL I-OTHER
) I-OTHER
outcomes 0
for 0
this 0
trial 0
. 0

METHODS 0
From 0
December 0
1997 0
through 0
February 0
2003 0
, 0
244 0
men 0
with 0
newly 0
diagnosed 0
localized 0
prostate 0
cancer 0
were 0
randomly 0
assigned 0
to 0
cryoablation 0
or 0
EBRT 0
( 0
median 0
dose 0
68 0
Gy 0
) 0
. 0

All 0
patients 0
received 0
neoadjuvant 0
antiandrogen 0
therapy 0
. 0

Patients 0
completed 0
the 0
EORTC 0
QLQ 0
C30 0
and 0
the 0
Prostate 0
Cancer 0
Index 0
( 0
PCI 0
) 0
before 0
treatment 0
and 0
at 0
1.5 0
, 0
3 0
, 0
6 0
, 0
12 0
, 0
18 0
, 0
24 0
, 0
and 0
36 0
months 0
post-treatment 0
. 0

RESULTS 0
Regardless 0
of 0
treatment 0
arm 0
, 0
participants 0
reported 0
high 0
levels 0
of 0
QOL B-OTHER
with 0
few 0
exceptions 0
. 0

cryoablation 0
was 0
associated 0
with 0
more 0
acute B-PHYSICAL
urinary I-PHYSICAL
dysfunction I-PHYSICAL
( 0
mean 0
PCI 0
urinary 0
function 0
cryoablation=69.4 0
; 0
mean 0
EBRT=90.7 0
; 0
P 0
< 0
.001 0
) 0
, 0
which 0
resolved 0
over 0
time 0
. 0

No 0
late B-OTHER
arising I-OTHER
QOL I-OTHER
issues I-OTHER
were 0
observed 0
. 0

Both 0
EBRT 0
and 0
cryoablation 0
participants 0
reported 0
decreases 0
in 0
sexual B-PHYSICAL
function I-PHYSICAL
at 0
3 0
months 0
with 0
the 0
cryoablation 0
patients 0
reporting 0
poorer 0
functioning 0
( 0
mean 0
cryoablation=7.2 0
: 0
mean 0
EBRT=32.9 0
; 0
P 0
< 0
.001 0
) 0
. 0

Mean 0
sexual B-PHYSICAL
function I-PHYSICAL
score I-PHYSICAL
was 0
15 0
points 0
lower 0
at 0
3 0
years 0
for 0
the 0
cryoablation 0
group 0
and 0
13 0
% 0
more 0
of 0
the 0
cryoablation 0
men 0
said 0
that 0
sexuality 0
was 0
a 0
moderate 0
or 0
big 0
problem 0
. 0

CONCLUSIONS 0
In 0
this 0
randomized 0
trial 0
, 0
no 0
long-term 0
QOL B-OTHER
advantage 0
for 0
either 0
treatment 0
was 0
apparent 0
with 0
the 0
exception 0
of 0
poorer 0
sexual B-MENTAL
function I-MENTAL
reported 0
by 0
those 0
treated 0
with 0
cryoablation 0
. 0

Men 0
who 0
wish 0
to 0
increase 0
their 0
odds 0
of 0
retaining 0
sexual B-MENTAL
function I-MENTAL
might 0
be 0
counseled 0
to 0
choose 0
EBRT 0
over 0
cryoablation 0
. 0

In-season 0
effect 0
of 0
short-term 0
sprint 0
and 0
power 0
training 0
programs 0
on 0
elite 0
junior 0
soccer 0
players 0
. 0

The 0
aim 0
of 0
this 0
study 0
was 0
to 0
examine 0
the 0
effects 0
of 0
2 0
in-season 0
short-term 0
sprint 0
and 0
power 0
training 0
protocols 0
on 0
vertical 0
countermovement 0
jump 0
height 0
( 0
with 0
or 0
without 0
arms 0
) 0
, 0
sprint 0
( 0
Sprint-15m 0
) 0
speed 0
, 0
and 0
agility 0
( 0
Agility-15m 0
) 0
speed 0
in 0
male 0
elite 0
junior 0
soccer 0
players 0
. 0

Twenty 0
highly 0
trained 0
soccer 0
players 0
( 0
age 0
18.3 0
+/- 0
0.6 0
years 0
, 0
height 0
177 0
+/- 0
4 0
cm 0
, 0
body 0
mass 0
71.4 0
+/- 0
6.9 0
kg 0
, 0
sum 0
skinfolds 0
48.1 0
+/- 0
11.4 0
mm 0
) 0
, 0
members 0
of 0
a 0
professional 0
soccer 0
academy 0
, 0
were 0
randomly 0
allocated 0
to 0
either 0
a 0
CONTRAST 0
( 0
n 0
= 0
10 0
) 0
or 0
SPRINT 0
( 0
n 0
= 0
10 0
) 0
group 0
. 0

The 0
training 0
intervention 0
consisted 0
of 0
6 0
supervised 0
training 0
sessions 0
over 0
7 0
weeks 0
, 0
targeting 0
the 0
improvement 0
of 0
the 0
players 0
' 0
speed B-MENTAL
and 0
power B-MENTAL
. 0

CONTRAST 0
protocol 0
consisted 0
of 0
alternating 0
heavy-light 0
resistance 0
( 0
15-50 0
% 0
body 0
mass 0
) 0
with 0
soccer-specific 0
drills 0
( 0
small-sided 0
games 0
or 0
technical 0
skills 0
) 0
. 0

SPRINT 0
training 0
protocol 0
used 0
line 0
30-m 0
sprints 0
( 0
2-4 0
sets 0
of 0
4 0
x 0
30 0
m 0
with 0
180 0
and 0
90 0
seconds 0
of 0
recovery 0
, 0
respectively 0
) 0
. 0

At 0
baseline 0
no 0
difference 0
between 0
physical B-PHYSICAL
test I-PHYSICAL
performance I-PHYSICAL
was 0
evident 0
between 0
the 0
2 0
groups 0
( 0
p 0
> 0
0.05 0
) 0
. 0

No 0
time 0
x 0
training 0
group 0
effect 0
was 0
found 0
for 0
any 0
of 0
the 0
vertical B-OTHER
jump I-OTHER
and I-OTHER
Agility-15m I-OTHER
variables I-OTHER
( 0
p B-PHYSICAL
> 0
0.05 0
) 0
. 0

A 0
time 0
x 0
training 0
group 0
effect 0
was 0
found 0
for 0
Sprint-15m 0
performance 0
with 0
the 0
CONTRAST 0
group 0
showing 0
significantly 0
better 0
scores 0
than 0
the 0
SPRINT 0
group 0
( 0
7.23 0
+/- 0
0.18 0
vs. 0
7.09 0
+/- 0
0.20 0
m.s 0
, 0
p 0
< 0
0.01 0
) 0
. 0

In 0
light 0
of 0
these 0
findings 0
CONTRAST 0
training 0
should 0
be 0
preferred 0
to 0
line 0
sprint 0
training 0
in 0
the 0
short 0
term 0
in 0
young 0
elite 0
soccer 0
players 0
when 0
the 0
aim 0
is 0
to 0
improve 0
soccer-specific B-MENTAL
sprint I-MENTAL
performance I-MENTAL
( 0
15 B-PHYSICAL
m I-PHYSICAL
) 0
during 0
the 0
competitive 0
season 0
. 0

Long-term 0
decrease 0
in 0
bladder B-PHYSICAL
cancer I-PHYSICAL
recurrence I-PHYSICAL
with 0
hexaminolevulinate 0
enabled 0
fluorescence 0
cystoscopy 0
. 0

PURPOSE 0
We 0
assessed 0
the 0
impact 0
of 0
hexaminolevulinate 0
fluorescence 0
cystoscopic 0
detection 0
of 0
papillary 0
, 0
nonmuscle 0
invasive 0
bladder 0
cancer 0
on 0
the 0
long-term B-PHYSICAL
recurrence I-PHYSICAL
rate I-PHYSICAL
. 0

MATERIALS 0
AND 0
METHODS 0
Long-term 0
followup 0
was 0
assessed 0
in 0
551 0
participants 0
enrolled 0
in 0
a 0
prospective 0
, 0
randomized 0
study 0
of 0
fluorescence 0
cystoscopy 0
for 0
Ta 0
or 0
T1 0
urothelial 0
bladder 0
cancer 0
. 0

In 0
the 0
original 0
study 0
280 0
patients 0
in 0
the 0
white 0
light 0
cystoscopy 0
group 0
and 0
271 0
in 0
the 0
fluorescence 0
cystoscopy 0
group 0
were 0
followed 0
with 0
cystoscopy 0
for 0
3 0
, 0
6 0
and 0
9 0
months 0
after 0
initial 0
resection 0
or 0
until 0
recurrence 0
. 0

A 0
study 0
extension 0
protocol 0
was 0
done 0
for 0
long-term 0
followup 0
of 0
these 0
patients 0
. 0

RESULTS 0
Followup 0
information 0
was 0
obtained 0
for 0
261 0
of 0
the 0
280 0
patients 0
( 0
93 0
% 0
) 0
in 0
the 0
white 0
light 0
group 0
and 0
255 0
of 0
the 0
271 0
( 0
94 0
% 0
) 0
in 0
the 0
fluorescence 0
group 0
. 0

Median 0
followup 0
in 0
the 0
white 0
light 0
and 0
fluorescence 0
groups 0
was 0
53.0 0
and 0
55.1 0
months 0
, 0
and 0
83 0
( 0
31.8 0
% 0
) 0
and 0
97 0
patients 0
( 0
38 0
% 0
) 0
remained 0
tumor 0
free 0
, 0
respectively 0
. 0

Median 0
time B-PHYSICAL
to I-PHYSICAL
recurrence I-PHYSICAL
was 0
9.4 0
months 0
in 0
the 0
white 0
light 0
group 0
and 0
16.4 0
months 0
in 0
the 0
fluorescence 0
group 0
( 0
p 0
= 0
0.04 0
) 0
. 0

The 0
intravesical B-OTHER
therapy I-OTHER
rate I-OTHER
was 0
similar 0
in 0
the 0
2 0
groups 0
( 0
46 0
% 0
and 0
45 0
% 0
, 0
respectively 0
) 0
. 0

Cystectomy 0
was 0
done 0
in 0
22 0
of 0
280 0
cases 0
( 0
7.9 0
% 0
) 0
in 0
the 0
white 0
light 0
group 0
and 0
in 0
13 0
of 0
the 0
271 0
( 0
4.8 0
% 0
) 0
in 0
the 0
fluorescence 0
group 0
( 0
p 0
= 0
0.16 0
) 0
. 0

CONCLUSIONS 0
Hexaminolevulinate 0
fluorescence 0
cystoscopy 0
significantly 0
improves 0
long-term 0
bladder 0
cancer 0
time 0
to 0
recurrence 0
with 0
a 0
trend 0
toward 0
improved 0
bladder 0
preservation 0
. 0

Cognitive 0
effects 0
of 0
lithium 0
carbonate 0
and 0
haloperidol 0
in 0
treatment-resistant 0
aggressive 0
children 0
. 0

The 0
effects 0
of 0
lithium 0
carbonate 0
and 0
haloperidol 0
on 0
cognition 0
were 0
examined 0
in 0
a 0
placebo-controlled 0
, 0
double-blind 0
study 0
of 0
61 0
treatment-resistant 0
, 0
hospitalized 0
school-aged 0
children 0
. 0

They 0
all 0
had 0
a 0
DSM-III 0
diagnosis 0
of 0
conduct 0
disorder 0
-- 0
undersocialized 0
, 0
aggressive 0
, 0
with 0
a 0
profile 0
of 0
highly 0
explosive 0
and 0
aggressive 0
behavior 0
. 0

Children 0
were 0
assessed 0
at 0
the 0
end 0
of 0
a 0
two-week 0
placebo-baseline 0
period 0
and 0
again 0
after 0
four 0
weeks 0
of 0
treatment 0
. 0

Drug 0
effects 0
on 0
cognition 0
were 0
mild 0
. 0

Haloperidol 0
( 0
mean 0
dose 0
, 0
2.95 0
mg/day 0
) 0
caused 0
significant 0
decreases 0
in 0
Porteus B-MENTAL
Maze I-MENTAL
test I-MENTAL
quotient I-MENTAL
scores 0
and 0
a 0
slowing 0
of 0
reaction 0
time 0
( 0
RT 0
) 0
on 0
a 0
simple 0
RT 0
task 0
. 0

Lithium 0
carbonate 0
( 0
mean 0
dose 0
, 0
1,166 0
mg/day 0
) 0
adversely 0
affected 0
qualitative B-MENTAL
scores I-MENTAL
on I-MENTAL
the I-MENTAL
Porteus I-MENTAL
Maze I-MENTAL
test I-MENTAL
. 0

No 0
significant 0
treatment 0
effects 0
were 0
found 0
for 0
the 0
Matching 0
Familiar 0
Figures 0
Test 0
, 0
short-term 0
recognition 0
memory 0
and 0
concept B-MENTAL
attainment I-MENTAL
tasks I-MENTAL
, 0
or 0
the 0
Stroop 0
Test 0
. 0

Just-in-time 0
evidence-based 0
e-mail 0
reminders 0
in 0
home 0
health 0
care 0
: 0
impact 0
on 0
nurse 0
practices 0
. 0

OBJECTIVE 0
To 0
test 0
the 0
effectiveness 0
of 0
two 0
interventions 0
designed 0
to 0
improve 0
the 0
adoption 0
of 0
evidence-based 0
practices 0
by 0
home 0
health 0
nurses 0
caring 0
for 0
heart 0
failure 0
( 0
HF 0
) 0
patients 0
. 0

DATA 0
SOURCES/STUDY 0
SETTING 0
Information 0
on 0
nurse 0
practices 0
was 0
abstracted 0
from 0
the 0
clinical 0
records 0
of 0
patients 0
admitted 0
between 0
June 0
2000 0
and 0
November 0
2001 0
to 0
the 0
care 0
of 0
354 0
study 0
nurses 0
at 0
a 0
large 0
, 0
urban 0
, 0
nonprofit 0
home 0
care 0
agency 0
. 0

STUDY 0
DESIGN 0
The 0
study 0
employed 0
a 0
randomized 0
design 0
with 0
nurses 0
assigned 0
to 0
usual 0
care 0
or 0
one 0
of 0
two 0
intervention 0
groups 0
upon 0
identification 0
of 0
an 0
eligible 0
patient 0
. 0

The 0
basic 0
intervention 0
was 0
a 0
one-time 0
e-mail 0
reminder 0
highlighting 0
six 0
HF-specific 0
clinical 0
recommendations 0
. 0

The 0
augmented 0
intervention 0
consisted 0
of 0
the 0
initial 0
e-mail 0
reminder 0
supplemented 0
by 0
provider 0
prompts 0
, 0
patient 0
education 0
material 0
, 0
and 0
clinical 0
nurse 0
specialist 0
outreach 0
. 0

DATA 0
COLLECTION 0
At 0
each 0
home 0
health 0
visit 0
provided 0
by 0
a 0
study 0
nurse 0
to 0
an 0
eligible 0
HF 0
patient 0
during 0
the 0
45-day 0
follow-up 0
period 0
, 0
a 0
structured 0
chart 0
abstraction 0
tool 0
was 0
used 0
to 0
collect 0
information 0
on 0
whether 0
the 0
nurse 0
provided 0
the 0
care 0
practices 0
highlighted 0
in 0
the 0
e-mail 0
reminder 0
. 0

PRINCIPAL 0
FINDINGS 0
Both 0
the 0
basic 0
and 0
the 0
augmented 0
interventions 0
greatly 0
increased 0
the 0
practice 0
of 0
evidence-based B-OTHER
care I-OTHER
, 0
according 0
to 0
patient 0
records 0
, 0
in 0
the 0
areas 0
of 0
patient 0
assessment 0
and 0
instructions 0
about 0
HF 0
disease 0
management 0
. 0

While 0
not 0
all 0
results 0
were 0
statistically 0
significant 0
at 0
conventional 0
levels 0
, 0
intervention B-OTHER
effects I-OTHER
were 0
positive 0
in 0
virtually 0
all 0
cases 0
and 0
effect 0
magnitudes B-OTHER
frequently I-OTHER
were 0
large 0
. 0

CONCLUSIONS 0
The 0
results 0
of 0
this 0
randomized 0
trial 0
strongly 0
support 0
the 0
efficacy 0
of 0
just-in-time B-OTHER
evidence-based I-OTHER
reminders I-OTHER
as 0
a 0
means 0
of 0
changing 0
clinical 0
practice 0
among 0
home 0
health 0
nurses 0
who 0
are 0
geographically 0
dispersed 0
and 0
spend 0
much 0
of 0
their 0
time 0
in 0
the 0
field 0
. 0

Physical 0
activity 0
for 0
patients 0
undergoing 0
an 0
allogeneic 0
hematopoietic 0
stem 0
cell 0
transplantation 0
: 0
benefits 0
of 0
a 0
moderate 0
exercise 0
intervention 0
. 0

UNLABELLED 0
An 0
allogeneic 0
hematopoietic 0
stem 0
cell 0
transplantation 0
( 0
HSCT 0
) 0
can 0
have 0
profound 0
and 0
lasting 0
adverse 0
effects 0
on 0
a 0
patient 0
's 0
physical 0
and 0
psychological 0
well-being 0
. 0

So 0
far 0
, 0
only 0
few 0
studies 0
have 0
investigated 0
the 0
effectiveness 0
of 0
physical 0
activity 0
over 0
the 0
entire 0
inpatient 0
phase 0
of 0
an 0
allogeneic 0
HSCT 0
. 0

PURPOSE 0
We 0
performed 0
a 0
randomized 0
controlled 0
study 0
to 0
examine 0
the 0
influence 0
of 0
a 0
controlled 0
moderate 0
exercise 0
program 0
starting 0
parallel 0
to 0
chemotherapeutic 0
conditioning 0
and 0
total 0
body 0
irradiation 0
on 0
the 0
patient 0
's 0
physical 0
and 0
psychological 0
constitution 0
. 0

PATIENTS 0
AND 0
METHODS 0
Forty-seven 0
patients 0
undergoing 0
an 0
allogeneic 0
HSCT 0
were 0
randomly 0
assigned 0
to 0
an 0
exercise 0
group 0
( 0
EG 0
) 0
or 0
a 0
control 0
group 0
( 0
CG 0
) 0
. 0

While 0
the 0
EG 0
took 0
part 0
in 0
an 0
endurance 0
and 0
activity 0
of 0
daily 0
living-training 0
twice 0
a 0
day 0
, 0
the 0
CG 0
received 0
the 0
clinic 0
's 0
standard 0
physiotherapy 0
program 0
once 0
a 0
day 0
. 0

RESULTS 0
Significant 0
differences 0
and/or 0
trends 0
in 0
favor 0
of 0
the 0
EG 0
were 0
observed 0
regarding 0
the 0
primary 0
endpoint 0
endurance B-PHYSICAL
performance I-PHYSICAL
( 0
P=0.002 0
) 0
, 0
muscular B-PHYSICAL
strength I-PHYSICAL
( 0
P=0.022 0
) 0
, 0
fatigue B-PHYSICAL
( 0
P=0.046 0
) 0
, 0
and 0
emotional B-PHYSICAL
state I-PHYSICAL
( 0
P=0.028 0
) 0
without 0
posing 0
an 0
additional 0
risk 0
for 0
the 0
individual 0
. 0

CONCLUSION 0
The 0
results 0
show 0
that 0
the 0
training 0
program 0
is 0
feasible 0
and 0
seems 0
to 0
have 0
positive 0
influences 0
on 0
physical B-PHYSICAL
performance I-PHYSICAL
and 0
quality B-PHYSICAL
of I-PHYSICAL
life I-PHYSICAL
in 0
patients 0
undergoing 0
an 0
allogeneic 0
HSCT 0
. 0

However 0
, 0
further 0
studies 0
are 0
necessary 0
to 0
confirm 0
these 0
results 0
. 0

Tomato 0
paste 0
rich 0
in 0
lycopene 0
protects 0
against 0
cutaneous B-PHYSICAL
photodamage I-PHYSICAL
in 0
humans 0
in 0
vivo 0
: 0
a 0
randomized 0
controlled 0
trial 0
. 0

BACKGROUND 0
Previous 0
epidemiological 0
, 0
animal 0
and 0
human 0
data 0
report 0
that 0
lycopene 0
has 0
a 0
protective 0
effect 0
against 0
ultraviolet B-PHYSICAL
radiation I-PHYSICAL
( 0
UVR B-PHYSICAL
) 0
-induced B-PHYSICAL
erythema B-PHYSICAL
. 0

OBJECTIVES 0
We 0
examined 0
whether 0
tomato 0
paste 0
-- 0
rich 0
in 0
lycopene 0
, 0
a 0
powerful 0
antioxidant 0
-- 0
can 0
protect 0
human 0
skin 0
against 0
UVR-induced 0
effects 0
partially 0
mediated 0
by 0
oxidative 0
stress 0
, 0
i.e 0
. 0

erythema 0
, 0
matrix 0
changes 0
and 0
mitochondrial 0
DNA 0
( 0
mtDNA 0
) 0
damage 0
. 0

METHODS 0
In 0
a 0
randomized 0
controlled 0
study 0
, 0
20 0
healthy 0
women 0
( 0
median 0
age 0
33 0
years 0
, 0
range 0
21-47 0
; 0
phototype 0
I/II 0
) 0
ingested 0
55 0
g 0
tomato 0
paste 0
( 0
16 0
mg 0
lycopene 0
) 0
in 0
olive 0
oil 0
, 0
or 0
olive 0
oil 0
alone 0
, 0
daily 0
for 0
12 0
weeks 0
. 0

Pre- 0
and 0
postsupplementation 0
, 0
UVR 0

Double-blind 0
, 0
randomized 0
, 0
placebo-controlled 0
clinical 0
trial 0
on 0
the 0
efficacy 0
and 0
tolerability B-OTHER
of I-OTHER
a I-OTHER
physostigmine I-OTHER
patch I-OTHER
in 0
patients 0
with 0
senile 0
dementia 0
of 0
the 0
Alzheimer 0
type 0
. 0

Owing 0
to 0
the 0
pharmacokinetic 0
properties 0
of 0
physostigmine 0
when 0
administered 0
by 0
conventional 0
routes 0
, 0
long-term 0
cholinergic 0
treatment 0
of 0
Alzheimer 0
's 0
disease 0
is 0
difficult 0
to 0
manage 0
. 0

In 0
order 0
to 0
overcome 0
the 0
problems 0
associated 0
with 0
the 0
oral 0
and 0
intravenous 0
application 0
of 0
physostigmine 0
, 0
and 0
to 0
improve 0
patients B-MENTAL
' 0
compliance B-MENTAL
, 0
a 0
transdermal 0
therapeutic 0
system 0
was 0
developed 0
. 0

The 0
efficacy 0
and 0
tolerability B-OTHER
of 0
this 0
system 0
were 0
evaluated 0
in 0
a 0
double-blind 0
, 0
randomized 0
, 0
multicenter 0
study 0
comparing 0
patches 0
containing 0
30 0
mg 0
and 0
60 0
mg 0
physostigmine 0
with 0
a 0
placebo 0
patch 0
. 0

The 0
clinical 0
trial 0
followed 0
the 0
basic 0
principles 0
of 0
the 0
various 0
guidelines 0
on 0
the 0
evaluation 0
of 0
anti-dementia 0
drugs 0
, 0
and 0
included 0
patients 0
with 0
mild 0
to 0
moderate 0
probable 0
Alzheimer 0
's 0
disease 0
. 0

A 0
total 0
of 0
204 0
patients 0
with 0
probable 0
Alzheimer 0
's 0
disease 0
were 0
included 0
in 0
the 0
study 0
. 0

Of 0
these 0
, 0
136 0
patients 0
were 0
eligible 0
for 0
the 0
according-to-protocol 0
analysis 0
of 0
efficacy 0
, 0
167 0
subjects 0
for 0
the 0
intention-to-treat 0
analysis 0
of 0
efficacy 0
, 0
and 0
181 0
patients 0
were 0
included 0
in 0
the 0
safety 0
analysis 0
. 0

In 0
contrast 0
to 0
the 0
hypothesis 0
to 0
be 0
tested 0
, 0
the 0
efficacy 0
of 0
physostigmine 0
was 0
not 0
superior 0
to 0
that 0
of 0
placebo 0
after 0
a 0
treatment 0
period 0
of 0
24 0
weeks 0
. 0

On 0
the 0
contrary 0
, 0
there 0
was 0
even 0
a 0
slight 0
, 0
but 0
not 0
statistically 0
significant 0
, 0
trend 0
toward 0
a 0
better 0
outcome 0
in 0
the 0
placebo 0
group 0
. 0

Median 0
physostigmine B-PHYSICAL
plasma I-PHYSICAL
concentrations I-PHYSICAL
of 0
approximately 0
100 0
pg/ml 0
were 0
measured 0
, 0
showing 0
a 0
high 0
degree 0
of 0
interindividual 0
variability 0
and 0
no 0
linear 0
dose 0
relationship 0
between 0
the 0
30 0
mg 0
and 0
60 0
mg 0
dosages 0
. 0

Plasma B-PHYSICAL
cholinesterase I-PHYSICAL
activity I-PHYSICAL
was 0
not 0
significantly 0
affected 0
by 0
physostigmine 0
. 0

The 0
physostigmine 0
patch 0
application 0
in 0
doses 0
of 0
30 0
mg 0
and 0
60 0
mg 0
apparently 0
did 0
not 0
lead 0
to 0
physostigmine B-PHYSICAL
plasma I-PHYSICAL
concentrations B-PHYSICAL
that 0
were 0
sufficient 0
to 0
compensate 0
for 0
cholinergic 0
deficiencies 0
in 0
affected 0
brain 0
areas 0
and 0
produce 0
clinical 0
benefits 0
. 0

Both 0
the 0
drug 0
and 0
the 0
transdermal 0
system 0
were 0
generally 0
well B-OTHER
tolerated I-OTHER
under 0
the 0
study 0
conditions 0
. 0

Modifications 0
of 0
the 0
patch 0
system 0
may 0
perhaps 0
make 0
it 0
possible 0
to 0
achieve 0
higher 0

[ 0
4 0
years 0
' 0
experience 0
with 0
a 0
balloon-expandable 0
endoprosthesis 0
. 0

Experimental 0
and 0
clinical 0
application 0
] 0
. 0

During 0
a 0
4-year 0
period 0
of 0
clinical 0
application 0
of 0
the 0
balloon-expandable 0
Palmaz 0
stent 0
, 0
a 0
randomized 0
trial 0
comparing 0
stent 0
implantation 0
and 0
traditional 0
balloon 0
angioplasty 0
of 0
iliac 0
arteries 0
in 0
arterial 0
occlusive 0
disease 0
was 0
started 0
. 0

The 0
first 0
long-term 0
results 0
, 0
recorded 0
after 0
2 0
years 0
, 0
indicate 0
statistically 0
significant 0
differences 0
in 0
the 0
complication B-ADVERSE-EFFECTS
rate I-ADVERSE-EFFECTS
( 0
after 0
stenting 0
2/62 0
and 0
after 0
angioplasty 0
5/69 0
) 0
and 0
patency B-OTHER
( 0
greater 0
than 0
or 0
equal 0
to 0
70 0
% 0
of 0
original 0
lumen 0
size 0
upon 0
stent 0
implantation 0
or 0
balloon 0
inflation 0
: 0
95 0
% 0
after 0
stenting 0
and 0
72 0
% 0
after 0
angioplasty 0
) 0
. 0

Clinical B-OTHER
improvement I-OTHER
after 0
2 0
years B-PHYSICAL
was 0
89 0
% 0
after 0
stenting 0
and 0
70 0
% 0
after 0
angioplasty 0
. 0

Parallel 0
to 0
the 0
clinical 0
trials 0
, 0
experimental 0
canine 0
artery 0
stenting 0
was 0
performed 0
to 0
evaluate 0
differences 0
in 0
the 0
long-term 0
patency 0
of 0
stents 0
exposed 0
to 0
restricted 0
flow 0
. 0

Significant 0
differences 0
in 0
neointimal B-PHYSICAL
healing I-PHYSICAL
were 0
found 0
between 0
normally 0
perfused 0
stents 0
and 0
stents 0
with 0
artificially 0
reduced 0
flow 0
: 0
during 0
the 0
total 0
observation 0
period 0
of 0
6 0
months 0
the 0
neointimal B-PHYSICAL
height I-PHYSICAL
was 0
up 0
to 0
200 0
% 0
higher 0
in 0
flow-restricted 0
stents 0
, 0
while 0
the 0
histological B-PHYSICAL
composition I-PHYSICAL
of I-PHYSICAL
the I-PHYSICAL
neointima I-PHYSICAL
was 0
the 0
same 0
as 0
with 0
normally 0
perfused 0
stents 0
. 0

[ 0
Comparative 0
effects 0
of 0
nebivolol 0
and 0
valsartan 0
on 0
atrial 0
electromechanical B-PHYSICAL
coupling I-PHYSICAL
in 0
newly 0
diagnosed 0
stage 0
1 0
hypertensive 0
patients 0
] 0
. 0

OBJECTIVES 0
Hypertension 0
is 0
an 0
important 0
cardiovascular 0
risk 0
factor 0
for 0
the 0
development 0
of 0
atrial 0
fibrillation B-PHYSICAL
( I-PHYSICAL
AF I-PHYSICAL
) I-PHYSICAL
. 0

Increased 0
atrial 0
electromechanical 0
coupling 0
time 0
interval 0
measured 0
by 0
tissue 0
Doppler 0
is 0
accepted 0
as 0
an 0
important 0
factor 0
for 0
prediction 0
of 0
AF B-PHYSICAL
development I-PHYSICAL
in 0
hypertensive 0
patients 0
. 0

The 0
aim 0
of 0
this 0
study 0
was 0
to 0
compare 0
the 0
effects 0
of 0
valsartan 0
, 0
an 0
angiotensin 0
receptor 0
blocker 0
, 0
and 0
nebivolol 0
, 0
a 0
beta-blocker 0
, 0
on 0
atrial 0
electromechanical 0
coupling 0
in 0
newly 0
diagnosed 0
stage 0
1 0
hypertensive 0
patients 0
. 0

STUDY 0
DESIGN 0
The 0
study 0
included 0
60 0
newly 0
diagnosed 0
stage 0
1 0
hypertensive 0
patients 0
with 0
no 0
other 0
systemic 0
disease 0
. 0

The 0
patients 0
were 0
randomized 0
to 0
receive 0
nebivolol 0
5 0
mg 0
( 0
30 0
patients 0
; 0
21 0
women 0
, 0
9 0
men 0
; 0
mean 0
age 0
48.4 0
? 0

11.4 0
years 0
) 0
and 0
valsartan 0
160 0
mg 0
( 0
30 0
patients 0
; 0
21 0
women 0
, 0
9 0
men 0
; 0
mean 0
age 0
49.8 0
? 0

11.3 0
years 0
) 0
. 0

All 0
the 0
patients 0
underwent 0
tissue 0
Doppler 0
echocardiographic 0
examination 0
before 0
and 0
three 0
months 0
after 0
treatment 0
to 0
compare 0
the 0
effects 0
of 0
the 0
two 0
drugs 0
on 0
atrial 0
electromechanical 0
coupling 0
. 0

RESULTS 0
Baseline 0
blood 0
pressures 0
, 0
electrocardiographic 0
and 0
echocardiographic 0
findings 0
, 0
and 0
atrial 0
electromechanical 0
coupling 0
were 0
similar 0
in 0
both 0
groups 0
( 0
p 0
> 0
0.05 0
) 0
. 0

Both 0
drugs 0
significantly 0
reduced 0
blood 0
pressure 0
after 0
treatment 0
, 0
with 0
similar 0
efficacy 0
( 0
p 0
> 0
0.05 0
) 0
. 0

Atrial 0
electromechanical 0
coupling 0
time 0
intervals 0
showed 0
significant 0
decreases 0
in 0
both 0
groups 0
. 0

CONCLUSION 0
Prolonged 0
interatrial 0
electromechanical 0
time 0
intervals 0
in 0
hypertensives 0
are 0
improved 0
with 0
antihypertensive 0
treatment 0
. 0

Amphotericin 0
versus 0
pentamidine 0
in 0
antimony-unresponsive 0
kala-azar 0
. 0

We 0
compared 0
the 0
efficacy 0
of 0
amphotericin 0
B 0
and 0
pentamidine 0
isethionate 0
in 0
a 0
prospective 0
randomised 0
trial 0
in 0
120 0
uncomplicated 0
and 0
parasitologically 0
confirmed 0
cases 0
of 0
antimony-unresponsive 0
kala-azar 0
. 0

Doses 0
were 0
twenty 0
intramuscular 0
injections 0
of 0
pentamidine 0
4 0
mg/kg 0
on 0
alternate 0
days 0
or 0
fourteen 0
definitive 0
doses 0
of 0
amphotericin 0
0.5 0
mg/kg 0
infused 0
in 0
5 0
% 0
dextrose 0
on 0
alternate 0
days 0
. 0

48 0
( 0
80 0
% 0
) 0
patients 0
given 0
pentamidine 0
showed 0
initial B-OTHER
cure I-OTHER
and 0
46 0
( 0
77 0
% 0
) 0
showed 0
definitive B-OTHER
cure I-OTHER
compared 0
with 0
60 0
( 0
100 0
% 0
) 0
and 0
59 0
( 0
98 0
% 0
) 0
cases 0
, 0
respectively 0
, 0
on 0
amphotericin 0
( 0
p 0
< 0
0.001 0
) 0
. 0

Amphotericin 0
also 0
brought 0
about 0
quicker 0
abatement B-PHYSICAL
of I-PHYSICAL
fever I-PHYSICAL
and 0
more 0
complete B-ADVERSE-EFFECTS
spleen I-ADVERSE-EFFECTS
regression I-ADVERSE-EFFECTS
. 0

Effects 0
of 0
intranasal 0
oxytocin 0
on 0
the 0
neural 0
basis 0
of 0
face 0
processing 0
in 0
autism 0
spectrum 0
disorder 0
. 0

BACKGROUND 0
Autism 0
spectrum 0
disorder 0
( 0
ASD 0
) 0
is 0
associated 0
with 0
altered 0
face 0
processing 0
and 0
decreased 0
activity 0
in 0
brain 0
regions 0
involved 0
in 0
face 0
processing 0
. 0

The 0
neuropeptide 0
oxytocin 0
has 0
been 0
shown 0
to 0
promote 0
face 0
processing 0
and 0
modulate 0
brain 0
activity 0
in 0
healthy 0
adults 0
. 0

The 0
present 0
study 0
examined 0
the 0
effects 0
of 0
oxytocin 0
on 0
the 0
neural 0
basis 0
of 0
face 0
processing 0
in 0
adults 0
with 0
Asperger 0
syndrome 0
( 0
AS 0
) 0
. 0

METHODS 0
A 0
group 0
of 0
14 0
individuals 0
with 0
AS 0
and 0
a 0
group 0
of 0
14 0
neurotypical 0
control 0
participants 0
performed 0
a 0
face-matching 0
and 0
a 0
house-matching 0
task 0
during 0
functional 0
magnetic 0
resonance 0
imaging 0
. 0

The 0
effects 0
of 0
a 0
single 0
dose 0
of 0
24 0
IU 0
intranasally 0
administered 0
oxytocin 0
were 0
tested 0
in 0
a 0
randomized 0
, 0
placebo-controlled 0
, 0
within-subject 0
, 0
cross-over 0
design 0
. 0

RESULTS 0
Under 0
placebo 0
, 0
the 0
AS 0
group 0
showed 0
decreased 0
activity 0
in 0
the B-PHYSICAL
right I-PHYSICAL
amygdala I-PHYSICAL
, I-PHYSICAL
fusiform I-PHYSICAL
gyrus I-PHYSICAL
, I-PHYSICAL
and I-PHYSICAL
inferior I-PHYSICAL
occipital I-PHYSICAL
gyrus I-PHYSICAL
compared 0
with 0
the 0
control 0
group 0
during 0
face 0
processing 0
. 0

After 0
oxytocin 0
treatment 0
, 0
right B-PHYSICAL
amygdala I-PHYSICAL
activity I-PHYSICAL
to I-PHYSICAL
facial I-PHYSICAL
stimuli I-PHYSICAL
increased 0
in 0
the 0
AS 0
group 0
. 0

CONCLUSIONS 0
These 0
findings 0
indicate 0
that 0
oxytocin 0
increases 0
the 0
saliency 0
of 0
social 0
stimuli 0
and 0
in 0
ASD 0
and 0
suggest 0
that 0
oxytocin 0
might 0
promote 0
face 0
processing 0
and 0
eye 0
contact 0
in 0
individuals 0
with 0
ASD 0
as 0
prerequisites 0
for 0
neurotypical 0
social 0
interaction 0
. 0

TENS 0
for 0
the 0
treatment 0
of 0
writer 0
's 0
cramp 0
dystonia 0
: 0
a 0
randomized 0
, 0
placebo-controlled 0
study 0
. 0

Manipulation 0
of 0
afferent 0
inputs 0
may 0
temporarily 0
modulate 0
dystonic 0
spasms 0
. 0

Ten 0
patients 0
with 0
writer 0
's 0
cramp 0
were 0
enrolled 0
in 0
a 0
double-blind 0
, 0
randomized 0
, 0
crossover 0
study 0
in 0
which 0
the 0
effects 0
of 0
transcutaneous 0
electrical 0
stimulation 0
( 0
TENS 0
) 0
and 0
placebo 0
treatment 0
were 0
compared 0
. 0

Patients 0
were 0
evaluated 0
using 0
four 0
measures 0
of 0
dystonic B-PHYSICAL
impairment I-PHYSICAL
. 0

The 0
TENS 0
group 0
showed 0
a 0
significant B-OTHER
improvement I-OTHER
that 0
persisted 0
for 0
3 0
weeks 0
in 0
three 0
of 0
the 0
four 0
measures 0
. 0

Predictive 0
validity 0
of 0
a 0
medication 0
adherence 0
measure 0
in 0
an 0
outpatient 0
setting 0
. 0

This 0
study 0
examines 0
the 0
psychometric 0
properties 0
and 0
tests 0
the 0
concurrent 0
and 0
predictive 0
validity 0
of 0
a 0
structured 0
, 0
self-reported 0
medication 0
adherence 0
measure 0
in 0
patients 0
with 0
hypertension 0
. 0

The 0
authors 0
also 0
assessed 0
various 0
psychosocial B-MENTAL
determinants I-MENTAL
of I-MENTAL
adherence I-MENTAL
, 0
such 0
as 0
knowledge B-MENTAL
, 0
social B-MENTAL
support I-MENTAL
, 0
satisfaction B-OTHER
with I-OTHER
care I-OTHER
, 0
and 0
complexity 0
of 0
the 0
medical B-OTHER
regimen I-OTHER
. 0

A 0
total 0
of 0
1367 0
patients 0
participated 0
in 0
the 0
study 0
; 0
mean 0
age 0
was 0
52.5 0
years 0
, 0
40.8 0
% 0
were 0
male 0
, 0
76.5 0
% 0
were 0
black 0
, 0
50.8 0
% 0
graduated 0
from 0
high 0
school 0
, 0
26 0
% 0
were 0
married 0
, 0
and 0
54.1 0
% 0
had 0
income 0
< 0
$ 0
5,000 0
. 0

The 0
8-item 0
medication 0
adherence 0
scale 0
was 0
reliable 0
( 0
alpha=.83 0
) 0
and 0
significantly 0
associated 0
with 0
blood B-PHYSICAL
pressure I-PHYSICAL
control I-PHYSICAL
( 0
P 0
< 0
.05 0
) 0
. 0

Using 0
a 0
cutpoint 0
of 0
< 0
6 0
, 0
the 0
sensitivity 0
of 0
the 0
measure 0
to 0
identify 0
patients 0
with 0
poor 0
blood B-PHYSICAL
pressure I-PHYSICAL
control I-PHYSICAL
was 0
estimated 0
to 0
be 0
93 0
% 0
, 0
and 0
the 0
specificity 0
was 0
53 0
% 0
. 0

The 0
medication 0
adherence 0
measure 0
proved 0
to 0
be 0
reliable 0
, 0
with 0
good 0
concurrent 0
and 0
predictive 0
validity 0
in 0
primarily 0
low-income 0
, 0
minority 0
patients 0
with 0
hypertension 0
and 0
might 0
function 0
as 0
a 0
screening 0
tool 0
in 0
outpatient 0
settings 0
with 0
other 0
patient 0
groups 0
. 0

Histopathologic B-PHYSICAL
changes I-PHYSICAL
of I-PHYSICAL
the I-PHYSICAL
eyelid I-PHYSICAL
skin I-PHYSICAL
following 0
trichloroacetic 0
acid 0
chemical 0
peel 0
. 0

The 0
use 0
of 0
trichloroacetic 0
acid 0
( 0
TCA 0
) 0
as 0
a 0
periorbital 0
and 0
eyelid 0
peel 0
for 0
skin 0
rejuvenation 0
is 0
gaining 0
significant 0
acceptance 0
among 0
oculoplastic 0
surgeons 0
, 0
dermatologists 0
, 0
and 0
other 0
surgery 0
groups 0
. 0

In 0
spite 0
of 0
the 0
current 0
enthusiasm 0
, 0
there 0
remain 0
potentially 0
serious 0
complications 0
resulting 0
from 0
any 0
periorbital 0
peel 0
. 0

Cases 0
of 0
cicatricial 0
ectropion 0
have 0
been 0
reported 0
in 0
phenol-peeled 0
patients 0
, 0
and 0
lower 0
eyelid 0
ectropion 0
has 0
reportedly 0
occurred 0
in 0
patients 0
undergoing 0
deep 0
eyelid 0
peel 0
in 0
conjunction 0
with 0
a 0
blepharoplasty 0
( 0
1,2 0
) 0
. 0

To 0
avoid 0
this 0
complication 0
, 0
it 0
is 0
necessary 0
to 0
better 0
understand 0
the 0
depth 0
of 0
the 0
wound 0
produced 0
by 0
different 0
strengths 0
and 0
combinations 0
of 0
peeling 0
agents 0
applied 0
to 0
living 0
eyelid 0
tissue 0
and 0
, 0
more 0
important 0
, 0
to 0
determine 0
the 0
concentrations 0
of 0
TCA 0
that 0
are 0
likely 0
to 0
lead 0
to 0
cicatricial 0
ectropion 0
when 0
applied 0
in 0
a 0
consistent 0
fashion 0
. 0

We 0
chose 0
upper-eyelid 0
skin 0
because 0
it 0
is 0
easier 0
to 0
obtain 0
for 0
histopathologic 0
study 0
than 0
lower-eyelid 0
skin 0
and 0
, 0
in 0
our 0
experience 0
, 0
is 0
more 0
sensitive 0
to 0
hypertrophic 0
changes 0
after 0
chemical 0
peeling 0
or 0
carbon 0
dioxide 0
laser 0
resurfacing 0
. 0

We 0
applied 0
TCA 0
to 0
the 0
preseptal 0
skin 0
of 0
10 0
patients 0
48 0
h 0
before 0
standard 0
upper-eyelid 0
blepharoplasty 0
. 0

The 0
acid 0
was 0
applied 0
to 0
produce 0
a 0
frost 0
, 0
using 0
varying 0
concentrations 0
of 0
acid 0
, 0
ranging 0
from 0
20 0
to 0
50 0
% 0
. 0

The 0
treated 0
skin 0
removed 0
at 0
the 0
time 0
of 0
blepharoplasty 0
was 0
reviewed 0
in 0
a 0
masked 0
fashion 0
by 0
a 0
dermatopathologist 0
to 0
determine 0
the 0
depth 0
of 0
necrosis 0
. 0

We 0
found 0
that 0
superficial B-PHYSICAL
peels I-PHYSICAL
with I-PHYSICAL
necrosis I-PHYSICAL
involving 0
30 0
% 0
of 0
the 0
epidermis 0
were 0
produced 0
by 0
the 0
lowest-concentration 0
combination 0
of 0
TCA 0
applied B-OTHER
( 0
20 0
% 0
followed 0
by 0
0 0
% 0
) 0
. 0

As 0
the 0
strength B-OTHER
increased 0
, 0
so 0
did 0
the 0
depth 0
of 0
peel 0
. 0

The 0
combination 0
of 0
50 0
% 0
followed 0
by 0
a 0
second 0
application 0
of 0
50 0
% 0
produced 0
the 0
deepest B-PHYSICAL
peel I-PHYSICAL
, 0
with 0
necrosis 0
into 0
the 0
papillary 0
dermis 0
. 0

This 0
finding 0
would 0
indicate 0
that 0
the 0
chance 0
of 0
developing 0
cicatricial 0
ectropion 0
with 0
any 0
of 0
the 0
tested 0
combinations 0
of 0
TCA 0
should 0
be 0
very 0
remote 0
. 0

Custom 0
tray 0
application 0
of 0
peroxide 0
gel 0
as 0
an 0
adjunct 0
to 0
scaling 0
and 0
root 0
planing 0
in 0
the 0
treatment 0
of 0
periodontitis 0
: 0
results 0
of 0
a 0
randomized 0
controlled 0
trial 0
after 0
six 0
months 0
. 0

OBJECTIVE 0
Scaling 0
and 0
root 0
planing 0
( 0
SRP 0
) 0
is 0
the 0
primary 0
non-surgical 0
treatment 0
for 0
periodontitis 0
, 0
but 0
its 0
effectiveness 0
is 0
limited 0
. 0

Consequently 0
, 0
various 0
adjunctive 0
therapies 0
have 0
been 0
investigated 0
to 0
improve 0
clinical 0
outcome 0
. 0

This 0
study 0
evaluated 0
the 0
clinical 0
effects 0
of 0
one 0
SRP 0
procedure 0
alone 0
or 0
combined 0
with 0
local 0
administration 0
of 0
hydrogen 0
peroxide 0
gel 0
using 0
customized 0
trays 0
for 0
the 0
treatment 0
of 0
subjects 0
with 0
chronic 0
periodontitis 0
over 0
a 0
period 0
of 0
six 0
months 0
. 0

METHODS 0
An 0
examiner-blind 0
clinical 0
trial 0
was 0
conducted 0
among 0
30 0
subjects 0
with 0
moderate 0
to 0
advanced 0
periodontitis 0
who 0
were 0
randomized 0
to 0
SRP 0
alone 0
or 0
SRP 0
combined 0
with 0
prescription 0
custom-tray 0
application 0
( 0
Perio 0
Tray 0
) 0
of 0
1.7 0
% 0
hydrogen 0
peroxide 0
gel 0
( 0
Perio 0
Gel 0
) 0
for 0
a 0
period 0
of 0
three 0
months 0
, 0
then 0
extended 0
to 0
six 0
months 0
. 0

Following 0
impressions 0
for 0
the 0
test 0
group 0
, 0
all 0
subjects 0
brushed 0
twice 0
daily 0
with 0
a 0
regular 0
dentifrice 0
and 0
toothbrush 0
for 0
a 0
four-week 0
acclimation 0
phase 0
to 0
standardize 0
oral 0
conditions 0
( 0
while 0
trays 0
were 0
fabricated 0
) 0
prior 0
to 0
initiating 0
the 0
treatment 0
phase 0
. 0

SRP 0
was 0
performed 0
three 0
weeks 0
after 0
baseline 0
, 0
and 0
clinical 0
assessments 0
, 0
i.e. 0
, 0
pocket B-PHYSICAL
probing I-PHYSICAL
depth I-PHYSICAL
( 0
PPD B-PHYSICAL
) 0
and B-PHYSICAL
bleeding I-PHYSICAL
index 0
( 0
BI B-PHYSICAL
) 0
, 0
were 0
conducted 0
at 0
baseline 0
and 0
after 0
two 0
, 0
five 0
, 0
13 0
, 0
and 0
26 0
weeks 0
of 0
peroxide 0
gel 0
applications 0
. 0

Clinical 0
variables 0
were 0
compared 0
by 0
ANCOVA 0
and 0
paired 0
t-tests 0
after 0
each 0
treatment 0
interval 0
. 0

RESULTS 0
A 0
total 0
of 0
13 0
test 0
and 0
15 0
control 0
subjects 0
completed 0
the 0
original 0
three-month 0
trial 0
, 0
of 0
whom 0
10 0
test 0
and 0
13 0
control 0
subjects 0
finished 0
the 0
three-month 0
extension 0
. 0

After 0
two 0
weeks 0
of 0
peroxide 0
gel 0
use 0
prior 0
to 0
SRP 0
, 0
mean 0
PPD B-PHYSICAL
for 0
the 0
test 0
group 0
significantly 0
decreased 0
from 0
baseline 0
by 0
0.21 0
mm 0
and 0
mean 0
BI B-PHYSICAL
significantly 0
dropped 0
by 0
0.14 0
; 0
clinical 0
parameters 0
for 0
the 0
control 0
group 0
were 0
unchanged 0
. 0

Two 0
weeks 0
following 0
SRP 0
, 0
mean 0
PPD B-PHYSICAL
significantly 0
decreased 0
from 0
baseline 0
by 0
0.65 0
mm 0
for 0
the 0
test 0
group 0
and 0
0.17 0
mm 0
for 0
the 0
control 0
; 0
mean 0
BI 0
significantly 0
dropped 0
by 0
0.17 0
for 0
the 0
test 0
group 0
and 0
0.05 0
for 0
the 0
control 0
. 0

Ten 0
weeks 0
following 0
SRP 0
, 0
mean 0
PPD B-PHYSICAL
decreases 0
were 0
0.77 0
mm 0
for 0
the 0
test 0
group 0
and 0
0.13 0
mm 0
for 0
the 0
control 0
, 0
and 0
mean 0
BI B-PHYSICAL
reductions 0
were 0
0.14 0
for 0
the 0
test 0
group 0
and 0
0.00 0
for 0
the 0
control 0
. 0

For 0
subjects 0
who 0
completed 0
the 0
three-month 0
extension 0
( 0
i.e. 0
, 0
23 0
weeks 0
post-SRP 0
) 0
, 0
mean 0
PPD B-PHYSICAL
decreases 0
were 0
0.72 0
mm 0
for 0
the 0
test 0
group 0
and 0
0.13 0
mm 0
for 0
the 0
control 0
, 0
and 0
mean 0
BI B-PHYSICAL
reductions 0
were 0
0.05 0
for 0
the 0
test 0
group 0
and 0
0.01 0
for 0
the 0
control 0
. 0

Analysis 0
of 0
deeper 0
pockets 0
( 0
i.e. 0
, 0
> 0
5 0
mm 0
at 0
baseline 0
) 0
showed 0
the 0
same 0
relationship 0
for 0
PPD 0
, 0
but 0
with 0
larger 0
differences 0
between 0
groups 0
. 0

For 0
example 0
, 0
after 0
two 0
weeks 0
of 0
peroxide 0
gel 0
use 0
prior 0
to 0
SRP 0
, 0
mean 0
PPD B-PHYSICAL
decreased 0
by 0
0.48 0
mm 0
for 0
the 0
test 0
group 0
compared 0
to 0
0.04 0
mm 0
for 0
the 0
control 0
. 0

Two 0
weeks 0
after 0
SRP 0
, 0
mean 0
PPD B-PHYSICAL
decreased 0
from 0
baseline 0
by 0
1.40 0
mm 0
for 0
the 0
test 0
group 0
and 0
0.60 0
mm 0
for 0
the 0
control 0
, 0
and 0
10 0
weeks 0
after 0
SRP 0
by 0
1.57 0
mm 0
for 0
the 0
test 0
group 0
and 0
0.58 0
mm 0
for 0
the 0
control 0
. 0

After 0
the 0
extension 0
( 0
i.e. 0
, 0
23 0
weeks 0
post-SRP 0
) 0
, 0
mean 0

A 0
comparison 0
of 0
sclerotherapy 0
with 0
staple 0
transection 0
of 0
the 0
esophagus 0
for 0
the 0
emergency 0
control 0
of 0
bleeding B-PHYSICAL
from 0
esophageal 0
varices 0
. 0

We 0
compared 0
two 0
procedures 0
for 0
the 0
emergency 0
treatment 0
of 0
bleeding B-PHYSICAL
esophageal 0
varices 0
in 0
patients 0
who 0
did 0
not 0
respond 0
to 0
blood 0
transfusion 0
and 0
vasoactive 0
drugs 0
. 0

We 0
randomly 0
assigned 0
101 0
patients 0
with 0
cirrhosis 0
of 0
the 0
liver 0
and 0
bleeding 0
esophageal 0
varices 0
to 0
undergo 0
either 0
emergency 0
sclerotherapy 0
( 0
n 0
= 0
50 0
) 0
or 0
staple 0
transection 0
of 0
the 0
esophagus 0
( 0
n 0
= 0
51 0
) 0
. 0

Four 0
patients 0
assigned 0
to 0
sclerotherapy 0
and 0
12 0
assigned 0
to 0
staple 0
transection 0
did 0
not 0
actually 0
undergo 0
those 0
procedures 0
, 0
but 0
all 0
analyses 0
were 0
made 0
on 0
an 0
intention-to-treat 0
basis 0
. 0

Total 0
mortality B-MORTALITY
did 0
not 0
differ 0
significantly 0
between 0
the 0
two 0
groups 0
; 0
the 0
relative 0
risk 0
of 0
death B-MORTALITY
for 0
staple 0
transection 0
as 0
compared 0
with 0
sclerotherapy 0
was 0
0.88 0
( 0
95 0
percent 0
confidence 0
interval 0
, 0
0.51 0
to 0
1.54 0
) 0
. 0

Mortality B-MORTALITY
at 0
six 0
weeks 0
was 0
44 0
percent 0
among 0
those 0
assigned 0
to 0
sclerotherapy 0
and 0
35 0
percent 0
among 0
those 0
assigned 0
to 0
staple 0
transection 0
. 0

Complication B-PHYSICAL
rates I-PHYSICAL
were 0
similar 0
for 0
the 0
two 0
groups 0
. 0

An 0
interval 0
of 0
five B-PHYSICAL
days I-PHYSICAL
without I-PHYSICAL
bleeding I-PHYSICAL
was 0
achieved 0
in 0
88 0
percent 0
of 0
those 0
assigned 0
to 0
staple 0
transection 0
and 0
in 0
62 0
percent 0
of 0
those 0
assigned 0
to 0
sclerotherapy 0
after 0
a 0
single 0
injection 0
( 0
P 0
less 0
than 0
0.01 0
) 0
and 0
82 0
percent 0
after 0
three 0
injections 0
. 0

In 0
only 0
2 0
of 0
the 0
11 0
patients 0
who 0
received 0
a 0
third 0
sclerotherapy 0
injection 0
was 0
bleeding B-PHYSICAL
controlled I-PHYSICAL
for 0
more 0
than 0
five 0
days 0
, 0
and 0
9 0
died 0
. 0

We 0
conclude 0
that 0
staple 0
transection 0
of 0
the 0
esophagus 0
is 0
as 0
safe B-OTHER
as I-OTHER
sclerotherapy I-OTHER
for 0
the 0
emergency B-PHYSICAL
treatment 0
of B-PHYSICAL

Serotonergic 0
control 0
of 0
TSH B-PHYSICAL
and 0
PRL B-PHYSICAL
secretion I-PHYSICAL
in 0
obese 0
men 0
. 0

To 0
evaluate 0
whether 0
the 0
inhibitory 0
control 0
of 0
TSH B-PHYSICAL
and 0
the 0
stimulatory B-PHYSICAL
control 0
of B-PHYSICAL
prolactin I-PHYSICAL
( I-PHYSICAL
PRL I-PHYSICAL
) I-PHYSICAL
secretion B-PHYSICAL
exerted 0
by 0
endogenous 0
serotonin 0
was 0
altered 0
in 0
obesity 0
, 0
22 0
obese 0
men 0
and 0
10 0
normal 0
controls 0
were 0
tested 0
with 0
TRH 0
( 0
200 0
micrograms 0
IV 0
bolus 0
) 0
in 0
the 0
presence 0
( 0
experimental 0
test 0
) 0
and 0
absence 0
( 0
control 0
test 0
) 0
of 0
the 0
serotonergic 0
agonist 0
fenfluramine 0
( 0
60 0
mg 0
PO 0
90 0
min 0
before 0
TRH 0
) 0
. 0

Control 0
and 0
experimental 0
tests 0
were 0
also 0
performed 0
in 0
seven 0
male 0
patients 0
with 0
subclinical 0
hypothyroidism 0
and 0
were 0
repeated 0
in 0
the 0
same 0
obese 0
subjects 0
after 0
substantial 0
weight 0
loss 0
. 0

Basal B-PHYSICAL
TSH I-PHYSICAL
levels I-PHYSICAL
were 0
similar 0
in 0
control 0
and 0
obese 0
men 0
. 0

Normal B-PHYSICAL
TSH I-PHYSICAL
responses I-PHYSICAL
to B-PHYSICAL
TRH I-PHYSICAL
( 0
peak 0
less 0
than 0
or 0
equal 0
to 0
14 0
mU/L 0
) 0
were 0
observed 0
in 0
all 0
normal 0
controls 0
( 0
mean 0
peak 0
+/- 0
SE 0
9.8 0
+/- 0
0.6 0
mU/L 0
) 0
. 0

In 0
contrast 0
, 0
obese 0
men 0
were 0
divided 0
into 0
two 0
groups 0
: 0
nine 0
in 0
whom 0
the 0
TRH-induced B-PHYSICAL
TSH I-PHYSICAL
rise I-PHYSICAL
was 0
higher 0
than 0
normal 0
( 0
group 0
I 0
: 0
mean 0
peak 0
= 0
16.5 0
+/- 0
0.5 0
mU/L 0
) 0
and 0
13 0
in 0
whom 0
it 0
was 0
normal 0
( 0
group 0
II 0
: 0
mean 0
peak 0
= 0
10.6 0
+/- 0
0.7 0
mU/L 0
) 0
. 0

The 0
hypothyroid 0
men 0
all 0
had 0
elevated 0

Low 0
protein 0
provision 0
during 0
the 0
first 0
year 0
of 0
life 0
, 0
but 0
not 0
during 0
foetal 0
life 0
, 0
affects 0
metabolic B-PHYSICAL
traits I-PHYSICAL
, 0
organ B-PHYSICAL
mass I-PHYSICAL
development I-PHYSICAL
and 0
growth B-PHYSICAL
in 0
male 0
mink 0
( 0
Neovison 0
vison 0
) 0
. 0

Low 0
protein 0
provision 0
in 0
utero 0
and 0
post-partum 0
may 0
induce 0
metabolic B-PHYSICAL
disorders I-PHYSICAL
in 0
adulthood 0
. 0

Studies 0
in 0
mink 0
have 0
mainly 0
focused 0
on 0
short-term 0
consequences 0
of 0
low 0
protein 0
provision 0
in 0
utero 0
whereas 0
the 0
long-term 0
responses 0
to 0
low 0
protein 0
( 0
LP 0
) 0
provision 0
in 0
metabolically 0
programmed 0
mink 0
are 0
unknown 0
. 0

We 0
investigated 0
whether 0
low 0
protein 0
provision 0
in 0
utero 0
affects 0
the 0
long-term 0
response 0
to 0
adequate 0
( 0
AP 0
) 0
or 0
LP 0
provision 0
after 0
weaning 0
in 0
male 0
mink 0
. 0

Eighty-six 0
male 0
mink 0
were 0
exposed 0
to 0
low 0
( 0
19 0
% 0
of 0
ME 0
from 0
CP 0
; 0
crude 0
protein 0
) 0
or 0
adequate 0
( 0
31 0
% 0
of 0
ME 0
from 0
CP 0
) 0
protein 0
provision 0
in 0
utero 0
, 0
and 0
to 0
LP 0
( 0
~20 0
% 0
of 0
ME 0
from 0
CP 0
) 0
or 0
AP 0
( 0
30-42 0
% 0
of 0
ME 0
from 0
CP 0
) 0
provision 0
post-weaning 0
. 0

Being 0
metabolically 0
programmed 0
by 0
low 0
protein 0
provision 0
in 0
utero 0
did 0
not 0
affect 0
the 0
response 0
to 0
post-weaning B-PHYSICAL
diets I-PHYSICAL
. 0

Dietary B-PHYSICAL
protein I-PHYSICAL
content I-PHYSICAL
in 0
the 0
LP 0
feed 0
after 0
weaning 0
was 0
below 0
requirements 0
; 0
evidenced 0
by 0
lower 0
nitrogen 0
retention 0
( 0
p 0
< 0
0.001 0
) 0
preventing 0
LP 0
mink 0
from 0
attaining 0
their 0
growth 0
potential 0
( 0
p 0
< 0
0.02 0
) 0
. 0

LP 0
mink 0
had 0
a 0
lower 0
liver B-PHYSICAL
, 0
pancreas B-PHYSICAL
and 0
kidney B-PHYSICAL
weight I-PHYSICAL
( 0
p 0
< 0
0.05 0
) 0
as 0
well 0
as 0
lower 0
plasma B-PHYSICAL
IGF-1 I-PHYSICAL
concentrations I-PHYSICAL
at 0
8 0
and 0
25 0
( 0
p 0
< 0
0.05 0
) 0
weeks 0
, 0
and 0
a 0
higher 0
incidence 0
of 0
hepatic B-PHYSICAL
lipidosis I-PHYSICAL
at 0
25 0
weeks 0
( 0
p 0
< 0
0.05 0
) 0
. 0

Furthermore 0
, 0
LP 0
mink 0
had 0
a 0
higher B-PHYSICAL
body I-PHYSICAL
fat I-PHYSICAL
( 0
p 0
< 0
0.05 0
) 0
and 0
lower 0
body B-PHYSICAL
CP I-PHYSICAL
content I-PHYSICAL
( 0
p 0
< 0
0.05 0
) 0
at 0
50 0
weeks 0
of 0
age 0
. 0

It 0
is 0
concluded 0
that 0
some 0
effects 0
of 0
low B-PHYSICAL
protein I-PHYSICAL
provision I-PHYSICAL
in 0
utero 0
can 0
be 0
alleviated 0
by 0
an 0
adequate 0
nutrient B-PHYSICAL
supply I-PHYSICAL
post-partum I-PHYSICAL
. 0

However 0
, 0
long-term 0
exposure 0
to 0
low 0
protein 0
provision 0
in 0
mink 0
reduces 0
their 0
growth B-PHYSICAL
potential I-PHYSICAL
and 0
induces B-PHYSICAL
transient I-PHYSICAL
hepatic I-PHYSICAL
lipidosis I-PHYSICAL
and 0
modified B-PHYSICAL
body I-PHYSICAL
composition I-PHYSICAL
. 0

Pulse 0
oximeter 0
perfusion 0
index 0
as 0
an 0
early 0
indicator 0
of 0
sympathectomy 0
after 0
epidural 0
anesthesia 0
. 0

BACKGROUND 0
The 0
pulse 0
oximeter 0
perfusion 0
index 0
( 0
PI 0
) 0
has 0
been 0
used 0
to 0
indicate 0
sympathectomy-induced 0
vasodilatation 0
. 0

We 0
hypothesized 0
that 0
pulse 0
oximeter 0
PI 0
provides 0
an 0
earlier 0
and 0
clearer 0
indication 0
of 0
sympathectomy 0
following 0
epidural 0
anesthesia 0
than 0
skin 0
temperature 0
and 0
arterial 0
pressure 0
. 0

METHODS 0
Forty 0
patients 0
received 0
lumbar 0
epidural 0
catheters 0
. 0

Patients 0
were 0
randomized 0
to 0
receive 0
either 0
10 0
ml 0
0.5 0
% 0
bupivacaine 0
or 0
10 0
ml 0
0.25 0
% 0
bupivacaine 0
. 0

PI 0
in 0
the 0
toe B-PHYSICAL
, 0
mean 0
arterial B-PHYSICAL
pressure I-PHYSICAL
( 0
MAP B-PHYSICAL
) 0
and 0
toe B-PHYSICAL
temperature I-PHYSICAL
were 0
all 0
assessed 0
at 0
baseline 0
and 0
at 0
5 0
, 0
10 0
and 0
20 0
min 0
following 0
epidural 0
anesthesia 0
. 0

The 0
effect 0
of 0
epidural 0
anesthesia 0
over 0
time 0
was 0
assessed 0
by 0
repeated 0
measures B-OTHER
analysis I-OTHER
of I-OTHER
variance I-OTHER
. 0

Additionally 0
, 0
we 0
defined 0
clinically B-PHYSICAL
evident I-PHYSICAL
sympathectomy I-PHYSICAL
criteria I-PHYSICAL
( I-PHYSICAL
a I-PHYSICAL
100 I-PHYSICAL
% I-PHYSICAL
increase I-PHYSICAL
in I-PHYSICAL
the I-PHYSICAL
PI I-PHYSICAL
, I-PHYSICAL
a I-PHYSICAL
15 I-PHYSICAL
% I-PHYSICAL
decrease I-PHYSICAL
in I-PHYSICAL
MAP I-PHYSICAL
and I-PHYSICAL
a I-PHYSICAL
1 I-PHYSICAL
degrees I-PHYSICAL
C I-PHYSICAL
increase I-PHYSICAL
in I-PHYSICAL
toe I-PHYSICAL
temperature B-PHYSICAL
) B-PHYSICAL
. 0

The 0
numbers 0
of 0
patients 0
demonstrating 0
these 0
changes B-PHYSICAL
for 0
each 0
test 0
were 0
compared 0
using 0
the 0
McNemar B-OTHER
test B-OTHER
for 0
each 0
time 0
point 0
. 0

RESULTS 0
Twenty-nine 0
subjects 0
had 0
photoplethysmography B-PHYSICAL
signals I-PHYSICAL
that 0
met 0
a 0
priori 0
signal 0
quality 0
criteria 0
for 0
analysis 0
. 0

By 0
20 0
min 0
, 0
PI B-PHYSICAL
increased 0
by 0
326 0
% 0
, 0
compared 0
with 0
a 0
10 0
% 0
decrease 0
and 0
a 0
3 0
% 0
increase 0
in 0
MAP B-PHYSICAL
and 0
toe B-PHYSICAL
temperature I-PHYSICAL
, 0
respectively 0
. 0

For 0
PI 0
15/29 0
, 0
26/29 0
and 0
29/29 0
of 0
the 0
subjects 0
met 0
the 0
sympathectomy B-PHYSICAL
criteria I-PHYSICAL
at 0
5 0
, 0
10 0
and 0
20 0
min 0
, 0
respectively 0
, 0
compared 0
with 0
4/29 0
, 0
6/29 0
and 0
18/29 0
for 0
MAP B-PHYSICAL
changes 0
and 0
3/29 0
, 0
8/29 0
and 0
14/29 0
for 0
toe 0

Ascorbic 0
acid 0
and 0
performance B-PHYSICAL
in 0
man 0
. 0

Effects 0
on 0
performance B-PHYSICAL
of 0
1 0
, 0
2 0
and 0
4 0
g 0
ascorbic 0
acid 0
were 0
studied 0
from 0
0.5-5.5 0
h 0
after 0
ingestion 0
in 0
six 0
healthy 0
females 0
. 0

Diazepam 0
( 0
5 0
mg 0
) 0
was 0
included 0
as 0
an 0
active 0
control 0
, 0
and 0
it 0
impaired 0
digit B-PHYSICAL
symbol I-PHYSICAL
substitution 0
, B-PHYSICAL
visuomotor I-PHYSICAL
coordination I-PHYSICAL
and I-PHYSICAL
complex I-PHYSICAL
reaction I-PHYSICAL
time B-PHYSICAL
. 0

There 0
were 0
no 0
effects 0
of 0
any 0
dose 0
of 0
ascorbic 0
acid 0
on 0

Neurophysiological 0
double-blind 0
trial 0
of 0
a 0
botulinum 0
neurotoxin 0
type 0
a 0
free 0
of 0
complexing 0
proteins 0
. 0

OBJECTIVE 0
Safety B-OTHER
and 0
efficacy 0
of 0
botulinum 0
neurotoxin 0
type 0
A 0
preparation 0
NT 0
201 0
( 0
Xeomin 0
, 0
Merz 0
Pharmaceuticals 0
GmbH 0
, 0
Frankfurt 0
am 0
Main 0
, 0
Germany 0
) 0
were 0
investigated 0
over 0
52 0
weeks 0
in 0
a 0
double-blind 0
, 0
randomized 0
trial 0
with 0
32 0
male 0
volunteers 0
. 0

METHODS 0
Electroneurographic B-OTHER
assessments B-PHYSICAL
with 0
surface 0
electrodes 0
were 0
performed 0
after 0
single 0
injections 0
of 0
NT 0
201 0
( 0
2 0
, 0
4 0
, 0
16 0
, 0
or 0
32 0
units 0
) 0
into 0
the 0
extensor 0
digitorum 0
brevis 0
( 0
EDB 0
) 0
muscle 0
and 0
the 0
same 0
dose 0
( 0
Botox 0
; 0
Allergan 0
Pharmaceuticals 0
( 0
Ireland 0
) 0
Ltd. 0
Westport 0
, 0
Ireland 0
) 0
into 0
the 0
contralateral 0
EDB 0
. 0

RESULTS 0
All 0
NT 0
201 0
and 0
BTXCo 0
doses 0
achieved 0
a 0
statistically 0
significant 0
reduction B-PHYSICAL
of I-PHYSICAL
the I-PHYSICAL
compound I-PHYSICAL
muscle I-PHYSICAL
action I-PHYSICAL
potential I-PHYSICAL
M-wave I-PHYSICAL
amplitude I-PHYSICAL
in 0
the 0
EDB 0
muscle 0
. 0

At 0
week 0
4 0
, 0
the 0
highest 0
dose 0
was 0
statistically 0
significantly 0
more 0
effective 0
than 0
the 0
lowest 0
dose 0
( 0
NT 0
201 0
, 0
P 0
= 0
0.019 0
; 0
95 0
% 0
confidence 0
interval 0
, 0
0.195-1.370 0
; 0
and 0
BTXCo 0
, 0
P 0
= 0
0.002 0
; 0
95 0
% 0
confidence 0
interval 0
, 0
0.309-1.167 0
) 0
. 0

Duration B-OTHER
of 0
effect 0
was 0
dose 0
dependent 0
. 0

The 0
mean 0
values 0
of 0
compound B-PHYSICAL
muscle I-PHYSICAL
action I-PHYSICAL
potential I-PHYSICAL
M-wave I-PHYSICAL
amplitudes I-PHYSICAL
in I-PHYSICAL
the I-PHYSICAL
adjacent I-PHYSICAL
muscles I-PHYSICAL
( 0
abductor 0
digiti 0
quinti 0
and 0
abductor 0
hallucis 0
) 0
were 0
above 0
the 0
predefined 0
threshold 0
of 0
effect 0
, 0
indicating 0
that 0
there 0
was 0
no 0
relevant 0
diffusion-induced 0
reduction 0
of 0
muscle B-PHYSICAL
activity I-PHYSICAL
. 0

NT 0
201 0
and 0
BTXCo 0
were 0
well 0
tolerated B-OTHER
. 0

CONCLUSIONS 0
NT 0
201 0
is 0
effective 0
and 0
safe 0
in 0
inducing 0
the 0
desired 0
paretic 0
effect 0
. 0

Residual 0
platelet 0
reactivity 0
, 0
bleedings 0
, 0
and 0
adherence 0
to 0
treatment 0
in 0
patients 0
having 0
coronary 0
stent 0
implantation 0
treated 0
with 0
prasugrel 0
. 0

Recent 0
guidelines 0
have 0
recommended 0
the 0
use 0
of 0
aspirin 0
and 0
prasugrel 0
in 0
patients 0
with 0
acute 0
coronary 0
syndromes 0
undergoing 0
percutaneous 0
coronary 0
intervention 0
. 0

However 0
, 0
prasugrel 0
use 0
has 0
been 0
evaluated 0
only 0
in 0
randomized 0
trials 0
. 0

This 0
study 0
sought 0
to 0
evaluate 0
bleeding B-PHYSICAL
rates I-PHYSICAL
and 0
adherence 0
to 0
treatment 0
in 0
real-world 0
patients 0
treated 0
with 0
prasugrel 0
. 0

In 0
total 0
298 0
consecutive 0
patients 0
68 0
? 0

10 0
years 0
old 0
( 0
31 0
% 0
> 0
75 0
years 0
old 0
) 0
underwent 0
stent 0
implantation 0
and 0
received 0
prasugrel 0
therapy 0
. 0

Indications 0
to 0
prasugrel 0
therapy 0
were 0
( 0
1 0
) 0
ST-elevation 0
acute 0
myocardial 0
infarction 0
( 0
41 0
% 0
) 0
, 0
( 0
2 0
) 0
drug-eluting 0
stent 0
implantation 0
in 0
diabetics 0
( 0
24 0
% 0
) 0
, 0
( 0
3 0
) 0
stent 0
thrombosis 0
( 0
3 0
% 0
) 0
, 0
( 0
4 0
) 0
left 0
main 0
coronary 0
artery 0
drug-eluting 0
stent 0
implantation 0
( 0
6 0
% 0
) 0
, 0
and 0
( 0
5 0
) 0
percutaneous 0
coronary 0
intervention 0
in 0
patients 0
with 0
high 0
residual 0
platelet 0
reactivity 0
on 0
clopidogrel 0
therapy 0
( 0
26 0
% 0
) 0
. 0

All 0
patients 0
received 0
a 0
loading 0
of 0
prasugrel 0
60 0
mg 0
. 0

Patients 0
?75 0
years 0
old 0
and 0
with 0
body 0
weight 0
?60 0
kg 0
received 0
a 0
maintenance 0
dose 0
of 0
5 0
mg/day 0
( 0
10 0
mg/day 0
for 0
all 0
the 0
other 0
patients 0
) 0
. 0

Follow-up 0
data 0
including 0
adherence 0
to 0
prasugrel 0
therapy 0
were 0
collected 0
by 0
telephone 0
interviews 0
or 0
outpatient 0
visits 0
. 0

Minimal 0
follow-up 0
length 0
was 0
6 0
months 0
( 0
mean 0
9 0
? 0

3 0
) 0
. 0

Major 0
, 0
minor 0
, 0
and 0
minimal 0
bleedings 0
( 0
Thrombolysis 0
In 0
Myocardial 0
Infarction 0
criteria 0
) 0
occurred 0
in 0
2.7 0
% 0
, 0
4.7 0
% 0
, 0
and 0
15.1 0
% 0
of 0
enrolled 0
patients 0
. 0

Low 0
residual 0
platelet 0
reactivity 0
( 0
p 0
= 0
0.001 0
) 0
and 0
female 0
gender 0
( 0
p 0
= 0
0.29 0
) 0
were 0
independent 0
predictors 0
of 0
bleeding 0
events 0
. 0

The 0
most 0
frequent 0
minimal 0
bleeding 0
event 0
was 0
epistaxis 0
. 0

Only 0
8 0
patients 0
( 0
2.7 0
% 0
) 0
permanently 0
discontinued 0
prasugrel 0
therapy 0
because 0
of 0
bleeding 0
events 0
( 0
n 0
= 0
4 0
) 0
, 0
possible 0
side 0
effects 0
( 0
n 0
= 0
2 0
) 0
, 0
or 0
medical 0
decisions 0
not 0
associated 0
with 0
bleeding 0
or 0
side 0
effects 0
( 0
n 0
= 0
2 0
) 0
. 0

Fourteen 0
patients 0
( 0
4.7 0
% 0
) 0
temporarily 0
discontinued 0
prasugrel 0
( 0
average 0
6.5 0
days 0
) 0
mainly 0
because 0
of 0
surgical 0
procedures 0
. 0

No 0
definite 0
or 0
probable 0
stent 0
thrombosis 0
occurred 0
, 0
although 0
3 0
patients 0
develop 0
de 0
novo 0
myocardial 0
infarction 0
and 0
1 0
an 0
ischemic 0
stroke 0
. 0

There 0
were 0
11 0
deaths 0
because 0
of 0
heart 0
failure 0
or 0
refractory 0
cardiogenic 0
shock 0
in 0
9 0
, 0
pulmonary 0
embolism 0
in 0
1 0
, 0
and 0
cancer 0
in 0
1 0
. 0

In 0
conclusion 0
, 0
in 0
clinical 0
practice 0
, 0
major 0
and 0
minor 0
bleeding 0
event 0
rates 0
associated 0
with 0
prasugrel 0
therapy 0
are 0
comparable 0
to 0
those 0
reported 0
in 0
controlled 0
randomized 0
trials 0
. 0

The 0
minimal 0
bleeding 0
event 0
rate 0
is 0
higher 0
than 0
reported 0
but 0
does 0
not 0
seem 0
to 0
affect 0
adherence 0
to 0
treatment 0
. 0

Evaluation 0
of 0
mood 0
profiles 0
during 0
malaria 0
chemoprophylaxis 0
: 0
a 0
randomized 0
, 0
double-blind 0
, 0
four-arm 0
study 0
. 0

BACKGROUND 0
To 0
objectively 0
compare 0
the 0
mood 0
profiles 0
of 0
users 0
of 0
malaria 0
chemoprophylaxis 0
regimens 0
( 0
atovaquone-proguanil 0
, 0
chloroquine-proguanil 0
, 0
doxycycline 0
, 0
or 0
mefloquine 0
) 0
in 0
a 0
group 0
of 0
nonimmune 0
tourists 0
to 0
sub-Saharan 0
Africa 0
. 0

METHODS 0
In 0
a 0
randomized 0
, 0
double-blind 0
, 0
four-arm 0
study 0
with 0
placebo 0
run-in 0
phase 0
conducted 0
at 0
travel 0
clinics 0
in 0
Switzerland 0
, 0
Germany 0
, 0
and 0
Israel 0
, 0
we 0
compared 0
moods 0
and 0
feelings 0
in 0
chemoprophylaxis 0
users 0
( 0
n= 0
547 0
) 0
by 0
administering 0
the 0
standardized 0
Profile 0
of 0
Mood 0
States 0
( 0
POMS 0
) 0
questionnaire 0
. 0

This 0
is 0
designed 0
to 0
provide 0
data 0
on 0
six 0
categories 0
of 0
feelings 0
: 0
tension 0
, 0
depression 0
, 0
anger 0
, 0
vigor 0
, 0
fatigue 0
, 0
and 0
confusion 0
. 0

The 0
questionnaire 0
was 0
administered 0
at 0
four 0
time 0
points 0
: 0
recruitment 0
( 0
T1 0
) 0
, 0
13 0
to 0
11 0
days 0
before 0
departure 0
( 0
T2 0
) 0
, 0
6 0
to 0
4 0
days 0
before 0
departure 0
( 0
T3 0
) 0
, 0
and 0
7 0
to 0
14 0
days 0
after 0
return 0
from 0
Africa 0
( 0
T4 0
) 0
. 0

RESULTS 0
There 0
were 0
no 0
significant 0
differences 0
with 0
respect 0
to 0
overall 0
mood B-MENTAL
impact 0
between 0
the 0
medication 0
arms 0
. 0

All 0
scores 0
were 0
in 0
the 0
normal 0
range 0
, 0
and 0
no 0
means 0
were 0
more 0
than 0
1 0
SD 0
from 0
the 0
norm 0
. 0

The 0
POMS 0
data 0
were 0
reanalyzed 0
with 0
respect 0
to 0
sex 0
, 0
age 0
, 0
medication 0
group 0
, 0
and 0
control 0
time 0
points 0
( 0
T1-T4 0
) 0
. 0

There 0
were 0
significant 0
interaction 0
effects 0
between 0
sex 0
and 0
medication 0
group 0
-- 0
women 0
in 0
the 0
mefloquine 0
group 0
showed 0
more 0
fatigue B-MENTAL
( 0
p= 0
.011 0
) 0
and 0
confusion B-MENTAL
( 0
p= 0
.011 0
) 0
than 0
men 0
. 0

Significant 0
effects 0
of 0
age 0
group 0
( 0
below 0
median 0
age 0
34 0
y 0
vs 0
median 0
age 0
and 0
above 0
) 0
were 0
noted 0
on 0
the 0
tension B-MENTAL
and 0
fatigue B-MENTAL
scales 0
in 0
that 0
less 0
tension B-MENTAL
( 0
p= 0
.045 0
) 0
and 0
less 0
fatigue B-MENTAL
( 0
p= 0
.000 0
) 0
were 0
noted 0
in 0
those 0
aged 0
34 0
years 0
and 0
older 0
. 0

Younger 0
participants 0
, 0
aged 0
< 0
34 0
years 0
, 0
reported 0
more 0
confusion B-MENTAL
( 0
p= 0
.013 0
) 0
at 0
T2 0
than 0
at 0
T1 0
and 0
T4 0
. 0

CONCLUSIONS 0
Although 0
the 0
overall 0
mood 0
profiles 0
were 0
similar 0
for 0
the 0
users 0
of 0
any 0
of 0
the 0
standard 0
malaria 0
chemoprophylaxis 0
regimens 0
, 0
we 0
found 0
that 0
women 0
using 0
mefloquine 0
showed 0
more 0
fatigue 0
and 0
confusion 0
than 0
men 0
and 0
that 0
younger 0
persons 0
aged 0
less 0
than 0
34 0
years 0
, 0
regardless 0
of 0
chemoprophylaxis 0
used 0
, 0
reported 0
more 0
tension 0
and 0
fatigue 0
than 0
their 0
older 0
counterparts 0
. 0

Gabapentin 0
for 0
the 0
prevention 0
of 0
postoperative B-PAIN
pain I-PAIN
after 0
vaginal 0
hysterectomy 0
. 0

Gabapentin 0
alleviates 0
and/or 0
prevents 0
acute B-PAIN
nociceptive I-PAIN
and I-PAIN
inflammatory I-PAIN
pain I-PAIN
both 0
in 0
animals 0
and 0
volunteers 0
, 0
especially 0
when 0
given 0
before 0
trauma 0
. 0

Gabapentin 0
might 0
also 0
reduce 0
postoperative B-PAIN
pain I-PAIN
. 0

To 0
test 0
the 0
hypothesis 0
that 0
gabapentin 0
reduces 0
the 0
postoperative B-PHYSICAL
need I-PHYSICAL
for I-PHYSICAL
additional I-PHYSICAL
pain I-PHYSICAL
treatment I-PHYSICAL
( 0
postoperative 0
opioid 0
sparing 0
effect 0
of 0
gabapentin 0
in 0
humans 0
) 0
, 0
we 0
gave 0
1200 0
mg 0
of 0
gabapentin 0
or 0
15 0
mg 0
of 0
oxazepam 0
( 0
active 0
placebo 0
) 0
2.5 0
h 0
prior 0
to 0
induction 0
of 0
anaesthesia 0
to 0
patients 0
undergoing 0
elective 0
vaginal 0
hysterectomy 0
in 0
an 0
active 0
placebo-controlled 0
, 0
double 0
blind 0
, 0
randomised 0
study 0
. 0

Gabapentin 0
reduced 0
the 0
need 0
for 0
additional 0
postoperative B-PAIN
pain I-PAIN
treatment I-PAIN
( 0
PCA 0
boluses 0
of 0
50 0
microg 0
of 0
fentanyl 0
) 0
by 0
40 0
% 0
during 0
the 0
first 0
20 0
postoperative 0
hours 0
. 0

During 0
the 0
first 0
2 0
postoperative 0
hours 0
pain 0
scores 0
at 0
rest 0
and 0
worst B-PAIN
pain I-PAIN
score I-PAIN
( 0
VAS 0
0-100 0
mm 0
) 0
were 0
significantly 0
higher 0
in 0
the 0
active 0
placebo 0
group 0
compared 0
to 0
the 0
gabapentin-treated 0
patients 0
. 0

Additionally 0
, 0
pretreatment 0
with 0
gabapentin 0
reduced 0
the 0
degree B-PHYSICAL
of I-PHYSICAL
postoperative I-PHYSICAL
nausea B-ADVERSE-EFFECTS
and 0
incidence 0
of B-ADVERSE-EFFECTS
vomiting/retching I-ADVERSE-EFFECTS
possibly 0
either 0
due 0
to 0
the 0
diminished 0
need 0
for 0
postoperative B-PAIN
pain I-PAIN
treatment 0
with 0
opioids 0
or 0
because 0
of 0
an 0
anti-emetic 0
effect 0
of 0
gabapentin 0
itself 0
. 0

No 0
preoperative 0
differences 0
between 0
the 0
two 0
groups 0
were 0
encountered 0
with 0
respect 0
to 0
the 0
side 0
effects 0
of 0
the 0
premedication 0
. 0

However 0
, 0
15 0
mg 0
oxazepam 0
was 0
more 0
effective 0
in 0
relieving 0
preoperative B-PHYSICAL
anxiety I-PHYSICAL
than 0
1200 0
mg 0
gabapentin 0
. 0

Influenza 0
and 0
pneumococcal 0
vaccination 0
as 0
a 0
model 0
to 0
assess 0
C-reactive 0
protein 0
response 0
to 0
mild 0
inflammation 0
. 0

This 0
study 0
was 0
set 0
up 0
to 0
examine 0
whether 0
an 0
influenza 0
vaccine 0
or 0
an 0
influenza 0
vaccine 0
in 0
combination 0
with 0
pneumococcal 0
vaccine 0
can 0
be 0
used 0
as 0
a 0
model 0
to 0
study 0
responses 0
to 0
mild 0
stimulation 0
of 0
the 0
inflammatory 0
system 0
. 0

In 0
this 0
study 0
, 0
19 0
subjects 0
received 0
the 0
influenza 0
vaccine 0
, 0
20 0
subjects 0
the 0
combination 0
of 0
influenza 0
and 0
pneumococcal 0
vaccine 0
. 0

CRP B-PHYSICAL
and 0
prothrombin B-PHYSICAL
fragment I-PHYSICAL
1 I-PHYSICAL
and I-PHYSICAL
2 I-PHYSICAL
( 0
F1+2 B-PHYSICAL
) 0
were 0
measured 0
at 0
baseline 0
, 0
and 0
two 0
times 0
after 0
vaccination 0
. 0

Influenza 0
vaccination 0
increased 0
CRP B-PHYSICAL
by 0
0.20 0
mg/L 0
, 0
and 0
influenza 0
in 0
combination 0
with 0
pneumococcal 0
vaccine 0
increased 0
CRP B-PHYSICAL
by 0
0.60 0
mg/L 0
. 0

F1+2 B-PHYSICAL
increased 0
0.15 0
nmol/L 0
after 0
the 0
combined 0
vaccination 0
; 0
an 0
increase 0
in 0
response 0
to 0
the 0
influenza B-PHYSICAL
vaccination I-PHYSICAL
was 0
not 0
statistically 0
significant 0
. 0

Our 0
findings 0
show 0
that 0
the 0
influenza 0
vaccine 0
alone 0
as 0
well 0
as 0
the 0
combination 0
of 0
the 0
influenza 0
and 0
pneumococcal 0
vaccine 0
increases 0
CRP-levels B-PHYSICAL
with 0
a 0
peak 0
2 0
days 0
after 0
vaccination 0
. 0

Superior 0
efficacy 0
of 0
clopidogrel 0
plus 0
acetylsalicylic 0
acid 0
compared 0
with 0
extended-release 0
dipyridamole 0
plus 0
acetylsalicylic 0
acid 0
in 0
preventing 0
arterial 0
thrombogenesis 0
in 0
healthy 0
volunteers 0
. 0

INTRODUCTION 0
Recent 0
ex 0
vivo 0
platelet 0
aggregometry 0
data 0
indicate 0
that 0
clopidogrel 0
75 0
mg/day 0
plus 0
acetylsalicylic 0
acid 0
( 0
ASA 0
) 0
75 0
mg/day 0
is 0
a 0
more 0
potent 0
antiplatelet 0
regimen 0
than 0
the 0
marketed 0
combination 0
of 0
dipyridamole+ASA 0
. 0

The 0
present 0
study 0
was 0
designed 0
to 0
assess 0
the 0
antithrombotic 0
effect 0
of 0
both 0
dual 0
antiplatelet 0
regimens 0
using 0
a 0
human 0
ex 0
vivo 0
model 0
of 0
arterial 0
thrombosis 0
. 0

MATERIALS 0
AND 0
METHODS 0
This 0
was 0
a 0
randomized 0
, 0
double-blind 0
, 0
placebo-controlled 0
, 0
crossover 0
study 0
. 0

During 0
two 0
10-day 0
treatment 0
periods 0
separated 0
by 0
a 0
14-day 0
washout 0
period 0
, 0
23 0
healthy 0
male 0
volunteers 0
received 0
once-daily 0
clopidogrel 0
75 0
mg 0
plus 0
acetylsalicylic 0
acid 0
75 0
mg 0
, 0
or 0
twice-daily 0
extended-release 0
dipyridamole 0
200 0
mg 0
plus 0
acetylsalicylic 0
acid 0
25 0
mg 0
. 0

Assessments 0
were 0
made 0
at 0
baseline 0
and 0
on 0
Day 0
10 0
of 0
each 0
period 0
. 0

Arterial 0
thrombus 0
formation 0
was 0
induced 0
ex 0
vivo 0
by 0
exposing 0
a 0
collagen-coated 0
surface 0
in 0
a 0
parallel-plate 0
perfusion 0
chamber 0
to 0
native 0
blood 0
for 0
3 0
min 0
( 0
arterial 0
wall 0
shear 0
rate 0
2600 0
s 0
( 0
-1 0
) 0
) 0
. 0

Total 0
platelet B-PHYSICAL
and 0
fibrin B-PHYSICAL
deposition I-PHYSICAL
was 0
determined 0
by 0
immunoenzymatic 0
methods 0
. 0

RESULTS 0
Compared 0
with 0
baseline 0
values 0
, 0
the 0
mean 0
inhibition 0
of 0
total 0
platelet B-PHYSICAL
deposition I-PHYSICAL
was 0
63.9+/-5.9 0
% 0
with 0
clopidogrel 0
plus 0
acetylsalicylic 0
acid 0
, 0
compared 0
with 0
18.4+/-5.6 0
% 0
for 0
extended-release 0
dipyridamole 0
plus 0
acetylsalicylic 0
acid 0
( 0
67 0
% 0
reduction 0
; 0
95 0
% 0
CI 0
, 0
49-79 0
% 0
; 0
p 0
< 0
0.0001 0
) 0
. 0

Corresponding 0
figures 0
for 0
fibrin B-PHYSICAL
deposition I-PHYSICAL
were 0
64.9+/-4.8 0
% 0
and 0
18.3+/-9.7 0
% 0
, 0
respectively 0
( 0
58 0
% 0
reduction 0
; 0
95 0
% 0
CI 0
, 0
45-67 0
% 0
; 0
p 0
< 0
0.0001 0
) 0
. 0

Both 0
treatments 0
were 0
well 0
tolerated B-OTHER
. 0

CONCLUSIONS 0
Clopidogrel 0
plus 0
acetylsalicylic 0
acid 0
showed 0
significantly 0
superior 0
antithrombotic 0
efficacy 0
compared 0
with 0
extended-release 0
dipyridamole 0
plus 0
acetylsalicylic 0
acid 0
in 0
preventing 0
arterial 0
thrombogenesis 0
in 0
humans 0
. 0

West 0
Midlands 0
Oncology 0
Association 0
trials 0
of 0
adjuvant 0
chemotherapy 0
in 0
operable 0
breast 0
cancer 0
: 0
results 0
after 0
a 0
median 0
follow-up 0
of 0
7 0
years 0
. 0

I 0
. 0

Patients 0
with 0
involved 0
axillary 0
lymph 0
nodes 0
. 0

The 0
aim 0
of 0
this 0
study 0
was 0
to 0
test 0
the 0
effectiveness 0
of 0
a 0
regimen 0
of 0
combination 0
chemotherapy 0
known 0
to 0
be 0
active 0
in 0
advanced 0
breast 0
cancer 0
when 0
given 0
as 0
an 0
adjuvant 0
treatment 0
after 0
mastectomy 0
. 0

A 0
total 0
of 0
569 0
patients 0
with 0
cancer 0
of 0
the 0
breast 0
and 0
involvement 0
of 0
axillary 0
lymph 0
nodes 0
were 0
randomised 0
, 0
after 0
simple 0
mastectomy 0
with 0
axillary 0
sampling 0
, 0
to 0
receive 0
either 0
no 0
adjuvant 0
treatment 0
or 0
intravenous 0
adriamycin 0
50 0
mg 0
, 0
vincristine 0
1 0
mg 0
, 0
cyclophosphamide 0
250 0
mg 0
, 0
methotrexate 0
150 0
mg 0
and 0
fluorouracil 0
250 0
mg 0
( 0
AVCMF 0
) 0
every 0
21 0
days 0
for 0
eight 0
cycles 0
. 0

Randomisation 0
was 0
stratified 0
according 0
to 0
menopausal 0
status 0
and 0
tumour 0
size 0
. 0

Treatment 0
was 0
started 0
within 0
14 0
days 0
of 0
surgery 0
in 0
94 0
% 0
of 0
patients 0
. 0

Eighty-eight 0
per 0
cent 0
of 0
patients 0
received 0
at 0
least 0
seven 0
cycles 0
of 0
chemotherapy 0
with 0
no 0
dose 0
reduction 0
. 0

The 0
median 0
relapse-free B-MORTALITY
survival I-MORTALITY
was 0
prolonged 0
by 0
14 0
months 0
in 0
patients 0
treated 0
with 0
AVCMF 0
( 0
chi2 0
1 0
= 0
11.7 0
; 0
P 0
= 0
0.0006 0
) 0
. 0

In 0
the 0
premenopausal 0
group 0
this 0
period 0
was 0
17 0
months 0
( 0
chi2 0
1 0
= 0
8.8 0
; 0
P 0
= 0
0.003 0
) 0
compared 0
with 0
8 0
months 0
in 0
the 0
post-menopausal 0
group 0
( 0
chi2 0
1 0
= 0
3.3 0
; 0
P 0
= 0
0.07 0
) 0
. 0

Neither 0
overall B-MORTALITY
survival I-MORTALITY
nor I-MORTALITY
survival I-MORTALITY
in 0
these 0
subgroups 0
was 0
significantly 0
influenced 0
by 0
treatment 0
. 0

[ 0
Study 0
on 0
classification 0
and 0
treatment 0
of 0
vulvovaginal 0
candidiasis 0
] 0
. 0

OBJECTIVE 0
To 0
determine 0
the 0
clinical 0
manifestations 0
of 0
vulvovaginal 0
candidiasis 0
( 0
VVC 0
) 0
and 0
to 0
study 0
the 0
mycologic B-PHYSICAL
eradication I-PHYSICAL
rate I-PHYSICAL
of 0
different 0
miconazole 0
treatment 0
courses 0
for 0
VVC 0
. 0

METHODS 0
Three 0
hundred 0
cases 0
of 0
VVC 0
were 0
recruited 0
. 0

The 0
Candidas 0
were 0
cultured 0
. 0

A 0
prospective 0
and 0
randomized 0
study 0
was 0
performed 0
to 0
compare 0
the 0
treatment 0
effect 0
of 0
3 0
day 0
miconazole 0
( 0
400 0
mg/d 0
) 0
, 0
6 0
day 0
miconazole 0
( 0
400 0
mg/d 0
) 0
, 0
and 0
7 0
day 0
miconazole 0
( 0
200 0
mg/d 0
) 0
for 0
uncomplicated 0
and 0
complicated 0
VVC 0
. 0

RESULTS 0
Among 0
300 0
cases 0
of 0
VVC 0
, 0
uncomplicated 0
, 0
complicated 0
and 0
recurrent 0
VVC 0
were 0
56.0 0
% 0
, 0
44.0 0
% 0
and 0
9.7 0
% 0
( 0
29/300 0
) 0
respectively 0
. 0

C. 0
albicans 0
was 0
isolated 0
most 0
frequently 0
90.3 0
% 0
( 0
271/300 0
) 0
, 0
followed 0
by 0
C. 0
glabrata 0
( 0
7.3 0
% 0
) 0
, 0
C. 0
tropicalis 0
( 0
1.3 0
% 0
) 0
, 0
C. 0
krusei 0
( 0
0.7 0
% 0
) 0
, 0
and 0
C. 0
parapsilosis 0
( 0
0.3 0
% 0
) 0
. 0

Mycologic B-PHYSICAL
eradication I-PHYSICAL
rate I-PHYSICAL
of 0
3 0
day 0
, 0
6 0
day 0
and 0
7 0
day 0
miconazole 0
courses 0
for 0
uncomplicated 0
VVC 0
at 0
day 0
14 0
was 0
96.0 0
% 0
, 0
93.5 0
% 0
and 0
98.0 0
% 0
, 0
respectively 0
( 0
P 0
> 0
0.05 0
) 0
. 0

Eradication B-PHYSICAL
rate I-PHYSICAL
of 0
3 0
day 0
, 0
6 0
day 0
and 0
7 0
day 0
miconazole 0
courses 0
for 0
complicated 0
VVC 0
at 0
day 0
14 0
was 0
86.7 0
% 0
, 0
92.5 0
% 0
, 0
and 0
86.4 0
% 0
, 0
respectively 0
( 0
P 0
> 0
0.05 0
) 0
. 0

Eradication B-PHYSICAL
rate I-PHYSICAL
of 0
3 0
day 0
, 0
6 0
day 0
and 0
7 0
day 0
miconazole 0
courses 0
for 0
uncomplicated 0
VVC 0
at 0
day 0
35 0
was 0
93.8 0
% 0
, 0
95.3 0
% 0
, 0
and 0
89.8 0
% 0
, 0
respectively 0
( 0
P 0
> 0
0.05 0
) 0
. 0

Eradication B-PHYSICAL
rate I-PHYSICAL
of 0
3 0
day 0
, 0
6 0
day 0
and 0
7 0
day 0
miconazole 0
courses 0
for 0
complicated 0
VVC 0
at 0
day 0
35 0
was 0
89.7 0
% 0
, 0
97.3 0
% 0
and 0
86.8 0
% 0
, 0
respectively 0
( 0
P 0
> 0
0.05 0
) 0
. 0

CONCLUSION 0
Treatment 0
of 0
VVC 0
should 0
be 0
individualized 0
, 0
and 0
women 0
with 0
complicated 0
VVC 0
achieve 0
superior 0
mycologic B-PHYSICAL
eradication I-PHYSICAL
by 0
a 0
6 0
day 0
miconazole 0
course 0
. 0

Visual 0
and 0
kinesthetic 0
locomotor 0
imagery 0
training 0
integrated 0
with 0
auditory 0
step 0
rhythm 0
for 0
walking 0
performance 0
of 0
patients 0
with 0
chronic 0
stroke 0
. 0

OBJECTIVE 0
To 0
compare 0
the 0
effect 0
of 0
visual 0
and 0
kinesthetic 0
locomotor 0
imagery 0
training 0
on 0
walking B-MENTAL
performance I-MENTAL
and 0
to 0
determine 0
the 0
clinical B-OTHER
feasibility I-OTHER
of 0
incorporating 0
auditory 0
step 0
rhythm 0
into 0
the 0
training 0
. 0

DESIGN 0
Randomized 0
crossover 0
trial 0
. 0

SETTING 0
Laboratory 0
of 0
a 0
Department 0
of 0
Physical 0
Therapy 0
. 0

SUBJECTS 0
Fifteen 0
subjects 0
with 0
post-stroke 0
hemiparesis 0
. 0

INTERVENTION 0
Four 0
locomotor 0
imagery 0
trainings 0
on 0
walking 0
performance 0
: 0
visual 0
locomotor 0
imagery 0
training 0
, 0
kinesthetic 0
locomotor 0
imagery 0
training 0
, 0
visual 0
locomotor 0
imagery 0
training 0
with 0
auditory 0
step 0
rhythm 0
and 0
kinesthetic 0
locomotor 0
imagery 0
training 0
with 0
auditory 0
step 0
rhythm 0
. 0

MAIN 0
OUTCOME 0
MEASURES 0
The 0
timed B-OTHER
up-and-go I-OTHER
test I-OTHER
and 0
electromyographic B-OTHER
and 0
kinematic B-OTHER
analyses I-OTHER
of I-OTHER
the I-OTHER
affected 0
lower 0
limb B-OTHER
during 0
one 0
gait B-PHYSICAL
cycle I-PHYSICAL
. 0

RESULTS 0
After 0
the 0
interventions 0
, 0
significant 0
differences 0
were 0
found 0
in 0
the 0

Predicting 0
the 0
effect 0
of 0
anthelmintic 0
treatment 0
on 0
milk B-PHYSICAL
production I-PHYSICAL
of I-PHYSICAL
dairy I-PHYSICAL
cattle I-PHYSICAL
in 0
Canada 0
using 0
an 0
Ostertagia 0
ostertagi 0
ELISA 0
from 0
individual 0
milk 0
samples 0
. 0

Gastrointestinal 0
nematodes 0
, 0
such 0
as 0
Ostertagia 0
ostertagi 0
and 0
several 0
species 0
of 0
Cooperia 0
, 0
are 0
ubiquitous 0
in 0
temperate 0
climates 0
and 0
have 0
been 0
shown 0
to 0
have 0
detrimental 0
effects 0
on 0
production 0
in 0
adult 0
dairy 0
cattle 0
. 0

A 0
published 0
meta-analysis 0
demonstrated 0
that 0
overall 0
, 0
producers 0
lose 0
approximately 0
0.35 0
kg 0
of 0
milk 0
per 0
parasitized 0
cow 0
per 0
day 0
. 0

Enzyme-linked 0
immunosorbent 0
assays 0
( 0
ELISAs 0
) 0
have 0
the 0
ability 0
to 0
quantify 0
nematode 0
infections 0
in 0
cattle 0
, 0
and 0
thus 0
, 0
could 0
be 0
used 0
to 0
estimate 0
the 0
amount 0
of 0
milk 0
production 0
loss 0
due 0
to 0
differing 0
levels 0
of 0
parasitism 0
at 0
the 0
individual 0
cow 0
level 0
. 0

ELISA 0
results 0
from 0
individual 0
cow 0
milk 0
samples 0
were 0
used 0
to 0
predict 0
milk 0
production 0
response 0
following 0
a 0
randomized 0
anthelmintic 0
treatment 0
in 0
a 0
large 0
field 0
trial 0
. 0

To 0
increase 0
statistical 0
power 0
, 0
the 0
data 0
collected 0
from 0
this 0
field 0
trial 0
was 0
pooled 0
with 0
data 0
from 0
two 0
other 0
published 0
field 0
trials 0
to 0
form 0
an 0
individual 0
patient 0
data 0
meta-analysis 0
( 0
IPDMA 0
) 0
. 0

The 0
ability 0
to 0
predict 0
the 0
effect 0
of 0
anthelmintic 0
treatment 0
on 0
milk 0
production 0
depends 0
on 0
the 0
level 0
of 0
parasitism 0
quantified 0
by 0
an 0
ELISA 0
measuring 0
milk B-PHYSICAL
antibodies I-PHYSICAL
against 0
O. 0
ostertagi 0
, 0
and 0
reported 0
as 0
optical B-OTHER
density I-OTHER
ratios I-OTHER
( I-OTHER
ODRs I-OTHER
) I-OTHER
. 0

Therefore 0
, 0
the 0
estimates 0
from 0
the 0
interaction 0
between 0
ODR 0
and 0
treatment 0
on 0
milk 0
production 0
were 0
used 0
to 0
determine 0
how 0
well 0
the 0
ODR 0
predicted 0
the 0
response 0
of 0
the 0
treatment 0
. 0

It 0
was 0
anticipated 0
that 0
the 0
relationship 0
between 0
milk B-PHYSICAL
production I-PHYSICAL
and 0
ODR B-OTHER
was 0
unlikely 0
to 0
be 0
linear 0
, 0
so 0
fractional 0
polynomials 0
were 0
applied 0
to 0
the 0
continuous 0
ODR B-PHYSICAL
values I-PHYSICAL
. 0

The 0
interaction 0
in 0
the 0
field 0
trial 0
showed 0
a 0
trend 0
( 0
p=0.138 0
) 0
toward 0
a 0
beneficial 0
treatment 0
effect 0
when 0
the 0
individual 0
ODR B-OTHER
values I-OTHER
, 0
measured 0
in 0
late 0
lactation 0
and 0
using 0
Svanovir 0
( 0
? 0
) 0
, 0

were 0
greater 0
than 0
0.12 0
. 0

When 0
individual 0
data 0
from 0
two 0
other 0
similar 0
studies 0
were 0
included 0
in 0
an 0
IPDMA 0
, 0
the 0
interaction 0
terms 0
became 0
statistically 0
significant 0
( 0
p=0.009 0
) 0
indicating 0
that 0
there 0
is 0
a 0
beneficial 0
treatment 0
effect 0
when 0
ODR 0
values 0
are 0
slightly 0
elevated 0
. 0

A 0
graph 0
was 0
used 0
to 0
demonstrate 0
the 0
treatment 0
effect 0
( 0
the 0
estimated 0
difference 0
of 0
kg/cow/day 0
of 0
milk 0
yield 0
between 0
the 0
treated 0
and 0
placebo 0
cows 0
) 0
, 0
with 0
95 0
% 0
confidence 0
intervals 0
, 0
as 0
the 0
ODR 0
values 0
increase 0
. 0

It 0
is 0
important 0
to 0
note 0
that 0
the 0
methods 0
of 0
quantifying 0
the 0
ODR 0
values 0
differed 0
between 0
the 0
three 0
studies 0
in 0
the 0
IPDMA 0
, 0
therefore 0
some 0
caution 0
should 0
be 0
used 0
when 0
using 0
these 0
final 0
estimated 0
values 0
. 0

However 0
, 0
the 0
shape 0
and 0
magnitude 0
of 0
the 0
treatment 0
effects 0
, 0
as 0
well 0
as 0
the 0
other 0
fixed 0
model 0
estimates 0
, 0
were 0
very 0
similar 0
between 0
the 0
field 0
trial 0
and 0
the 0
IPDMA 0
suggesting 0
that 0
any 0
bias 0
would 0
likely 0
be 0
minimal 0
. 0

Thromboprophylaxis 0
by 0
low-molecular-weight 0
heparin 0
in 0
elective 0
hip 0
surgery 0
. 0

A 0
placebo 0
controlled 0
study 0
. 0

In 0
a 0
double-blind 0
, 0
randomised 0
study 0
of 0
thromboprophylaxis 0
in 0
patients 0
undergoing 0
total 0
hip 0
replacement 0
, 0
we 0
compared 0
a 0
low-molecular-weight 0
heparin 0
with 0
a 0
placebo 0
. 0

Of 0
the 0
120 0
patients 0
enrolled 0
, 0
112 0
completed 0
the 0
trial 0
; 0
58 0
in 0
the 0
treatment 0
group 0
and 0
54 0
in 0
the 0
placebo 0
group 0
. 0

Nine 0
( 0
16 0
% 0
) 0
patients 0
in 0
the 0
treatment 0
group 0
and 0
19 0
( 0
35 0
% 0
) 0
in 0
the 0
placebo 0
group 0
developed 0
deep B-PHYSICAL
venous I-PHYSICAL
thrombosis I-PHYSICAL
, 0
diagnosed 0
by 0
the 0
125I-fibrinogen 0
uptake 0
test 0
( 0
p 0
< 0
0.02 0
) 0
. 0

Verification 0
was 0
obtained 0
by 0
phlebography 0
in 0
86 0
% 0
of 0
the 0
patients 0
. 0

Prolonged 0
surgery 0
increased 0
the 0
risk 0
of 0
thrombosis B-PHYSICAL
in 0
the 0
placebo 0
group 0
but 0
not 0
in 0
the 0
treatment 0
group 0
( 0
p 0
< 0
0.05 0
) 0
. 0

There 0
were 0
significantly 0
more 0
cases 0
of 0
deep B-PHYSICAL
venous I-PHYSICAL
thrombosis I-PHYSICAL
in 0
the 0
placebo 0
group 0
during 0
the 0
first 0
four 0
postoperative 0
days 0
( 0
p 0
< 0
0.02 0
) 0
. 0

The 0
groups 0
did 0
not 0
differ 0
with 0
respect 0
to 0
peroperative 0
and 0
postoperative B-PHYSICAL
bleeding I-PHYSICAL
. 0

Low-molecular-weight 0
heparin 0
offers 0
safe 0
and 0
easily 0
administered 0
thromboprophylaxis 0
in 0
total 0
hip 0
replacement 0
. 0

Predictors 0
of 0
stable 0
return-to-work 0
in 0
non-acute 0
, 0
non-specific 0
spinal 0
pain 0
: 0
low 0
total 0
prior 0
sick-listing 0
, 0
high 0
self 0
prediction 0
and 0
young 0
age 0
. 0

A 0
two-year 0
prospective 0
cohort 0
study 0
. 0

BACKGROUND 0
Non-specific 0
spinal 0
pain 0
( 0
NSP 0
) 0
, 0
comprising 0
back 0
and/or 0
neck 0
pain 0
, 0
is 0
one 0
of 0
the 0
leading 0
disorders 0
in 0
long-term 0
sick-listing 0
. 0

During 0
2000-2004 0
, 0
125 0
Swedish 0
primary-care 0
patients 0
with 0
non-acute 0
NSP 0
, 0
full-time 0
sick-listed 0
6 0
weeks-2 0
years 0
, 0
were 0
included 0
in 0
a 0
randomized 0
controlled 0
trial 0
to 0
compare 0
a 0
cognitive-behavioural 0
programme 0
with 0
traditional 0
primary 0
care 0
. 0

This 0
prospective 0
cohort 0
study 0
is 0
a 0
re-assessment 0
of 0
the 0
data 0
from 0
the 0
randomized 0
trial 0
with 0
the 0
2 0
treatment 0
groups 0
considered 0
as 0
a 0
single 0
cohort 0
. 0

The 0
aim 0
was 0
to 0
investigate 0
which 0
baseline 0
variables 0
predict 0
a 0
stable 0
return-to-work 0
during 0
a 0
2-year 0
period 0
after 0
baseline 0
: 0
objective 0
variables 0
from 0
function 0
tests 0
, 0
socioeconomic 0
, 0
subjective 0
and/or 0
treatment 0
variables 0
. 0

Stable 0
return-to-work 0
was 0
a 0
return-to-work 0
lasting 0
for 0
at 0
least 0
1 0
month 0
from 0
the 0
start 0
of 0
follow-up 0
. 0

METHODS 0
Stable 0
return-to-work 0
was 0
the 0
outcome 0
variable 0
, 0
the 0
above-mentioned 0
factors 0
were 0
the 0
predictive 0
variables 0
in 0
multiple-logistic 0
regression 0
models 0
, 0
one 0
per 0
follow-up 0
at 0
6 0
, 0
12 0
, 0
18 0
and 0
24 0
months 0
after 0
baseline 0
. 0

The 0
factors 0
from 0
univariate 0
analyzes 0
with 0
a 0
p-value 0
of 0
at 0
most 0
.10 0
were 0
included 0
. 0

The 0
non-significant 0
variables 0
were 0
excluded 0
stepwise 0
to 0
yield 0
models 0
comprising 0
only 0
significant 0
factors 0
( 0
p 0
< 0
.05 0
) 0
. 0

As 0
the 0
comparatively 0
few 0
cases 0
made 0
it 0
risky 0
to 0
associate 0
certain 0
predictors 0
with 0
certain 0
time-points 0
, 0
we 0
finally 0
considered 0
the 0
predictors 0
which 0
were 0
represented 0
in 0
at 0
least 0
3 0
follow-ups 0
. 0

They 0
are 0
presented 0
with 0
odds 0
ratios 0
( 0
OR 0
) 0
and 0
95 0
% 0
confidence 0
intervals 0
. 0

RESULTS 0
Three 0
variables 0
qualified 0
, 0
all 0
of 0
them 0
represented 0
in 0
3 0
follow-ups 0
: 0
Low B-OTHER
total 0
prior B-OTHER
sick-listing I-OTHER
( I-OTHER
including I-OTHER
all I-OTHER
diagnoses I-OTHER
) B-OTHER
was 0
the 0
strongest B-OTHER
predictor I-OTHER
in 0
2 0
follow-ups 0
, 0
18 0
and 0
24 0
months 0
, 0
OR 0
4.8 0
[ 0
1.9-12.3 0
] 0
and 0
3.8 0
[ 0
1.6-8.7 0
] 0
respectively 0
, 0
High B-OTHER

Secondary 0
prevention 0
of 0
macrovascular B-PHYSICAL
events I-PHYSICAL
in 0
patients 0
with 0
type 0
2 0
diabetes 0
in 0
the 0
PROactive 0
Study 0
( 0
PROspective 0
pioglitAzone 0
Clinical 0
Trial 0
In 0
macroVascular 0
Events 0
) 0
: 0
a 0
randomised 0
controlled 0
trial 0
. 0

BACKGROUND 0
Patients 0
with 0
type 0
2 0
diabetes 0
are 0
at 0
high 0
risk 0
of 0
fatal 0
and 0
non-fatal 0
myocardial B-PHYSICAL
infarction I-PHYSICAL
and 0
stroke B-PHYSICAL
. 0

There 0
is 0
indirect 0
evidence 0
that 0
agonists 0
of 0
peroxisome 0
proliferator-activated 0
receptor 0
gamma 0
( 0
PPAR 0
gamma 0
) 0
could 0
reduce 0
macrovascular B-PHYSICAL
complications I-PHYSICAL
. 0

Our 0
aim 0
, 0
therefore 0
, 0
was 0
to 0
ascertain 0
whether 0
pioglitazone 0
reduces 0
macrovascular B-PHYSICAL
morbidity I-PHYSICAL
and 0
mortality B-MORTALITY
in 0
high-risk 0
patients 0
with 0
type 0
2 0
diabetes 0
. 0

METHODS 0
We 0
did 0
a 0
prospective 0
, 0
randomised 0
controlled 0
trial 0
in 0
5238 0
patients 0
with 0
type 0
2 0
diabetes 0
who 0
had 0
evidence 0
of 0
macrovascular B-PHYSICAL
disease I-PHYSICAL
. 0

We 0
recruited 0
patients 0
from 0
primary-care 0
practices 0
and 0
hospitals 0
. 0

We 0
assigned 0
patients 0
to 0
oral 0
pioglitazone 0
titrated 0
from 0
15 0
mg 0
to 0
45 0
mg 0
( 0
n=2605 0
) 0
or 0
matching 0
placebo 0
( 0
n=2633 0
) 0
, 0
to 0
be 0
taken 0
in 0
addition 0
to 0
their 0
glucose-lowering 0
drugs 0
and 0
other 0
medications 0
. 0

Our 0
primary 0
endpoint 0
was 0
the 0
composite B-MORTALITY
of I-MORTALITY
all-cause I-MORTALITY
mortality I-MORTALITY
, 0
non B-PHYSICAL
fatal I-PHYSICAL
myocardial I-PHYSICAL
infarction I-PHYSICAL
( 0
including 0
silent B-PHYSICAL
myocardial I-PHYSICAL
infarction I-PHYSICAL
) 0
, 0
stroke B-PHYSICAL
, 0
acute B-PHYSICAL
coronary I-PHYSICAL
syndrome I-PHYSICAL
, 0
endovascular B-PHYSICAL
or 0
surgical B-PHYSICAL
intervention I-PHYSICAL
in I-PHYSICAL
the I-PHYSICAL
coronary I-PHYSICAL
or 0
leg B-PHYSICAL
arteries I-PHYSICAL
, 0
and 0
amputation B-PHYSICAL
above I-PHYSICAL
the I-PHYSICAL
ankle I-PHYSICAL
. 0

Analysis 0
was 0
by 0
intention 0
to 0
treat 0
. 0

This 0
study 0
is 0
registered 0
as 0
an 0
International 0
Standard 0
Randomised 0
Controlled 0
Trial 0
, 0
number 0
ISRCTN 0
NCT00174993 0
. 0

FINDINGS 0
Two 0
patients 0
were 0
lost 0
to 0
follow-up 0
, 0
but 0
were 0
included 0
in 0
analyses 0
. 0

The 0
average 0
time 0
of 0
observation 0
was 0
34.5 0
months 0
. 0

514 0
of 0
2605 0
patients 0
in 0
the 0
pioglitazone 0
group 0
and 0
572 0
of 0
2633 0
patients 0
in 0
the 0
placebo 0
group 0
had 0
at 0
least 0
one 0
event 0
in 0
the 0
primary B-PHYSICAL
composite I-PHYSICAL
endpoint I-PHYSICAL
( 0
HR 0
0.90 0
, 0
95 0
% 0
CI 0
0.80-1.02 0
, 0
p=0.095 0
) 0
. 0

The 0
main 0
secondary 0
endpoint 0
was 0
the 0
composite B-MORTALITY
of I-MORTALITY
all-cause I-MORTALITY
mortality I-MORTALITY
, 0
non-fatal B-PHYSICAL
myocardial I-PHYSICAL
infarction I-PHYSICAL
, 0
and 0

Learning 0
curve 0
in 0
multidetector 0
CT 0
coronary 0
angiography 0
( 0
MDCT-CA 0
) 0
. 0

PURPOSE 0
Coronary 0
angiography 0
using 0
multidetector 0
computed 0
tomography 0
( 0
MDCT-CA 0
) 0
is 0
a 0
recent 0
technique 0
for 0
the 0
nonivasive 0
study 0
of 0
coronary 0
arteries 0
. 0

This 0
study 0
assessed 0
the 0
diagnostic B-OTHER
accuracy 0
of B-OTHER
coronary I-OTHER
artery I-OTHER
stenosis I-OTHER
evaluation B-OTHER
obtained 0
by 0
three 0
readers 0
at 0
different 0
levels 0
of 0
training 0
or 0
at 0
different 0
points 0
of 0
the 0
learning 0
curve 0
proposed 0
by 0
the 0
international 0
guidelines 0
. 0

MATERIALS 0
AND 0
METHODS 0
Three 0
radiologists 0
in 0
training 0
with 0
different 0
levels 0
of 0
experience 0
in 0
MDCT-CA 0
scored 0
50 0
cases 0
at 0
various 0
time 0
points 0
of 0
the 0
learning 0
curve 0
: 0
baseline 0
, 0
4 0
weeks 0
, 0
8 0
weeks 0
and 0
6 0
months 0
. 0

The 0
trainee 0
radiologists 0
evaluated 0
the 0
degree 0
of 0
stenosis B-OTHER
on I-OTHER
each B-OTHER
coronary I-OTHER
segment I-OTHER
, 0
and 0
overall B-OTHER
accuracy B-OTHER
was 0
calculated 0
on 0
a 0
per-segment 0
, 0
pervessel 0
and 0
per-patient 0
basis 0
. 0

RESULTS 0
All 0
readers 0
improved B-OTHER
analysis I-OTHER
accuracy 0

Comparative 0
trial 0
of 0
carbenicillin 0
and 0
ampicillin 0
therapy 0
for 0
purulent 0
meningitis 0
. 0

A 0
randomized 0
therapeutic 0
trial 0
of 0
carbenicillin 0
( 0
CB 0
) 0
or 0
ampicillin 0
( 0
AMP 0
) 0
in 0
purulent 0
meningitis 0
was 0
performed 0
in 0
86 0
pediatric 0
and 0
adult 0
patients 0
( 0
41 0
Haemophilus 0
influenzae 0
, 0
22 0
Streptococcus 0
pneumoniae 0
, 0
13 0
Neisseria 0
meningitidis 0
, 0
and 0
10 0
of 0
unknown 0
etiology 0
) 0
. 0

All 0
isolates 0
, 0
incuding 0
H. 0
influenzae 0
, 0
were 0
susceptible 0
to 0
CB 0
and 0
AMP 0
. 0

Median 0
cerebrospinal B-PHYSICAL
fluid I-PHYSICAL
( I-PHYSICAL
CSF I-PHYSICAL
) I-PHYSICAL
antibiotic I-PHYSICAL
concentrations I-PHYSICAL
were 0
0.85 0
and 0
1.60 0
mug/ml 0
for 0
CB 0
and 0
AMP 0
, 0
respectively 0
, 0
during 0
administration 0
of 0
daily 0
doses 0
of 0
400 0
mg/kg 0
and 0
0.65 0
and 0
0.45 0
mug/ml 0
, 0
respectively 0
, 0
on 0
daily 0
doses 0
of 0
200 0
mg/kg 0
. 0

Higher B-PHYSICAL
CSF I-PHYSICAL
concentrations I-PHYSICAL
, 0
up 0
to 0
a 0
median 0
concentration 0
of 0
4.5 0
mug/ml 0
, 0
were 0
observed 0
in 0
patients 0
with 0
CSF 0
protein 0
concentrations 0
> 0
/=75 0
mg/100 0
ml 0
. 0

Clinical B-PHYSICAL
responses I-PHYSICAL
were 0
equivalent 0
on 0
either 0
antibiotic 0
regimen 0
. 0

Among 0
AMP 0
patients 0
( 0
45 0
) 0
, 0
8 0
had 0
significant B-ADVERSE-EFFECTS
residua I-ADVERSE-EFFECTS
and 0
3 0
died B-MORTALITY
; 0
among 0
CB 0
patients 0
( 0
41 0
) 0
, 0
5 0
had 0
residua 0
and 0
none 0
died 0
. 0

However 0
, 0
38 0
% 0
of 0
H. 0
influenzae 0
patients 0
treated 0
with 0
CB 0
had 0
positive 0
CSF B-PHYSICAL
cultures I-PHYSICAL
on 0
day 0
1 0
follow-up 0
lumbar 0
punctures 0
, 0
compared 0
with 0
only 0
5.8 0
% 0
of 0
AMP 0
patients 0
with 0
H. 0
influenzae 0
. 0

The 0
significance 0
of 0
a 0
delay 0
of 0
CSF B-PHYSICAL
sterilization I-PHYSICAL
among 0
CB-treated 0
patients 0
is 0
unknown 0
, 0
since 0
there 0
was 0
no 0
correlation 0
between 0
persistence 0
of 0
hemophilus 0
organisms 0
and 0
the 0
frequency 0
of 0
adverse 0
outcome 0
. 0

AMP 0
and 0
CB 0
are 0
equivalent 0
for 0
the 0
treatment 0
of 0
bacterial 0
meningitis 0
due 0
to 0
susceptible 0
organisms 0
. 0

Pentoxifylline 0
therapy 0
in 0
HIV 0
seropositive 0
subjects 0
with 0
elevated 0
TNF 0
. 0

Tumor 0
necrosis 0
factor-alpha 0
( 0
TNF-alpha 0
) 0
is 0
thought 0
to 0
induce 0
cachexia 0
in 0
subjects 0
infected 0
with 0
human 0
immunodeficiency 0
virus 0
( 0
HIV 0
) 0
, 0
and 0
it 0
has 0
been 0
suggested 0
that 0
HIV-seropositive 0
patients 0
would 0
benefit 0
from 0
treatment 0
with 0
pentoxifylline 0
, 0
a 0
known 0
suppressor 0
of 0
TNF-alpha 0
production 0
. 0

The 0
purpose 0
of 0
the 0
present 0
study 0
was 0
to 0
examine 0
how 0
pentoxifylline 0
at 0
a 0
dose 0
of 0
800 0
mg 0
thrice 0
daily 0
would 0
influence 0
the 0
cellular B-PHYSICAL
immune I-PHYSICAL
system I-PHYSICAL
in 0
HIV-seropositive 0
persons 0
with 0
elevated 0
TNF-alpha 0
. 0

Six 0
HIV-seropositive 0
subjects 0
with 0
elevated 0
amounts 0
of 0
TNF-alpha 0
in 0
plasma 0
at 0
least 0
at 0
two 0
occasions 0
were 0
included 0
in 0
an 0
open 0
, 0
controlled 0
, 0
randomized 0
, 0
cross-over 0
study 0
consisting 0
of 0
a 0
6 0
week 0
treatment 0
period 0
and 0
a 0
6 0
week 0
control 0
period 0
. 0

Blood 0
samples 0
were 0
collected 0
before 0
and 0
at 0
the 0
end 0
of 0
each 0
period 0
. 0

Pentoxifylline 0
treatment 0
did 0
not 0
influence 0
the 0
concentration 0
of B-PHYSICAL
plasma-TNF-alpha B-PHYSICAL
, 0
subpopulations B-PHYSICAL
of I-PHYSICAL
blood I-PHYSICAL
mononuclear B-PHYSICAL
cells I-PHYSICAL
, 0
the B-PHYSICAL
proliferative I-PHYSICAL
responses I-PHYSICAL
nor I-PHYSICAL
the I-PHYSICAL
natural I-PHYSICAL
killer B-PHYSICAL
( 0
NK B-PHYSICAL
) 0
, 0
and 0
lymphokine B-PHYSICAL
activated B-PHYSICAL
killer I-PHYSICAL
( 0
LAK B-PHYSICAL
) 0
cell B-PHYSICAL
activities I-PHYSICAL
. 0

Furthermore 0
, 0
pentoxifylline 0
treatment 0
did 0
not 0
influence 0
the 0
weight 0
, B-PHYSICAL
temperature I-PHYSICAL
, I-PHYSICAL
well B-PHYSICAL
being I-PHYSICAL
, I-PHYSICAL
or I-PHYSICAL
tiredness I-PHYSICAL
of I-PHYSICAL
the I-PHYSICAL
subjects I-PHYSICAL
. 0

However 0
, 0
the 0
patients 0
frequently 0
reported 0
gastrointestinal B-ADVERSE-EFFECTS
side B-ADVERSE-EFFECTS
effects I-ADVERSE-EFFECTS
. 0

In 0
vitro 0
, 0
however 0
, 0
pentoxifylline 0
at 0
suprapharmacological 0
concentrations 0
inhibited 0
the 0

[ 0
Clinical 0
observation 0
on 0
effect 0
of 0
fuzheng 0
yiliu 0
granule 0
on 0
cell 0
cycle 0
and 0
nuclear 0
transcription 0
factor-kappa 0
B 0
in 0
tissue 0
of 0
esophageal-gastric 0
carcinoma 0
] 0
. 0

OBJECTIVE 0
To 0
observe 0
the 0
effect 0
of 0
Fuzheng 0
Yiliu 0
Granule 0
( 0
FZYLG 0
) 0
on 0
cell 0
cycle 0
and 0
nuclear 0
transcription 0
factor-kappa 0
B 0
( 0
NF-kappa 0
B 0
) 0
in 0
tissue 0
of 0
esophageal-gastric 0
carcinoma 0
. 0

METHODS 0
Seventy-six 0
patients 0
with 0
esophageal 0
gastric 0
carcinoma 0
were 0
randomly 0
divided 0
into 0
two 0
groups 0
, 0
the 0
FZYLG 0
group 0
and 0
the 0
control 0
group 0
. 0

FZYLG 0
was 0
given 0
to 0
the 0
former 0
for 0
15 0
days 0
. 0

The 0
tumor 0
tissue 0
in 0
both 0
groups 0
was 0
resected 0
and 0
cell B-PHYSICAL
cycle I-PHYSICAL
and 0
apoptosis B-PHYSICAL
rate I-PHYSICAL
as 0
well 0
as 0
NF-kappa 0
B 0
were 0
determined 0
by 0
flowcytometry 0
. 0

RESULTS 0
Level B-PHYSICAL
of I-PHYSICAL
NF-kappa I-PHYSICAL
B I-PHYSICAL
in 0
the 0
treated 0
group 0
was 0
significantly 0
higher 0
than 0
that 0
in 0
the 0
control 0
group 0
( 0
P 0
< 0
0.05 0
) 0
. 0

In 0
the 0
treated 0
group 0
, 0
the 0
percentage 0
of 0
G0/G1 B-PHYSICAL
stage I-PHYSICAL
cells I-PHYSICAL
were 0
significantly 0
increased 0
and 0
that 0
of 0
S 0
stage B-PHYSICAL
significantly 0
decreased 0
( 0
both 0
P 0
< 0
0.05 0
) 0
. 0

At 0
the 0
same 0
time 0
, 0
obvious 0
cell B-PHYSICAL
apoptosis I-PHYSICAL
was 0
found 0
in 0
the 0
treated 0
group 0
, 0
the 0
apoptosis B-PHYSICAL
rate 0
of 0
which 0
was 0
significantly 0
higher 0
than 0
that 0
in 0
the 0
control 0
group 0
( 0
P 0
< 0
0.01 0
) 0
. 0

CONCLUSION 0
FZYLG 0
can 0
increase 0
the 0
NF-kappa 0
B 0
expression 0
, 0
block 0
the 0
proliferation 0
to 0
promote 0
the 0
apoptosis B-PHYSICAL
of 0
tumor 0
cells 0
. 0

Does 0
waiting 0
matter 0
? 0

A 0
randomized 0
controlled 0
trial 0
of 0
new 0
non-urgent 0
rheumatology 0
out-patient 0
referrals 0
. 0

OBJECTIVE 0
To 0
examine 0
the 0
effect 0
of 0
waiting 0
times 0
on 0
the 0
health 0
status 0
of 0
patients 0
referred 0
for 0
a 0
non-urgent 0
rheumatology 0
opinion 0
. 0

METHODS 0
The 0
study 0
was 0
a 0
randomized 0
controlled 0
clinical 0
study 0
evaluating 0
a 0
'fast 0
track 0
' 0
appointment 0
with 0
a 0
6-week 0
target 0
waiting 0
time 0
against 0
an 0
'ordinary 0
' 0
appointment 0
in 0
the 0
main 0
city 0
out-patient 0
clinic 0
of 0
the 0
rheumatology 0
service 0
for 0
the 0
Lothian 0
and 0
Borders 0
region 0
( 0
population 0
approximately 0
1 0
million 0
) 0
. 0

Health B-PHYSICAL
status I-PHYSICAL
was 0
measured 0
using 0
the 0
SF12 B-PHYSICAL
physical I-PHYSICAL
and I-PHYSICAL
mental I-PHYSICAL
summary I-PHYSICAL
component I-PHYSICAL
T-scores I-PHYSICAL
and 0
pain B-PAIN
was 0
measured 0
with 0
a 0
100 0
mm 0
visual B-OTHER
analogue I-OTHER
pain I-OTHER
scale 0
. 0

Secondary 0
outcomes 0
were 0
health B-PHYSICAL
utility I-PHYSICAL
and 0
perceived B-PHYSICAL
health I-PHYSICAL
both 0
measured 0
with 0
the 0
EuroQol 0
instrument 0
, 0
mental 0
health 0
measured 0
with 0
the 0
Hospital 0
Anxiety B-MENTAL
and I-MENTAL
Depression I-MENTAL
scale 0
, 0
disability B-PHYSICAL
with 0
the 0
modified 0
Health 0
Assessment 0
Questionnaire 0
and 0
economic 0
costs 0
measured 0
from 0
a 0
societal 0
perspective 0
. 0

RESULTS 0
Mean 0
waiting B-OTHER
times I-OTHER
were 0
43 0
days 0
( 0
sigma 0
= 0
+/-16 0
) 0
and 0
105 0
days 0
( 0
sigma 0
= 0
+/-51 0
) 0
for 0
'fast 0
track 0
' 0
and 0
'ordinary 0
' 0
appointments 0
, 0
respectively 0
. 0

Both 0
groups 0
showed 0
significant 0
improvements 0
in 0
mean 0
[ 0
95 0
% 0
confidence 0
interval 0
( 0
CI 0
) 0
] 0
scores 0
for 0
pain B-PAIN
: 0
11 0
( 0
7 0
, 0
16 0
) 0
( 0
P 0
< 0
0.001 0
) 0
; 0
physical B-PHYSICAL
health I-PHYSICAL
status I-PHYSICAL
: 0
4 0
( 0
2 0
, 0
5 0
) 0
( 0
P 0
< 0
0.001 0
) 0
; 0
mental B-MENTAL
health I-MENTAL
status I-MENTAL
: 0
2 0
( 0
0.1 0
, 0
4 0
) 0
( 0
P 0
< 0
0.02 0
) 0
; 0
and 0
health B-PHYSICAL
utility I-PHYSICAL
: 0
0.11 0
( 0
0.07 0
, 0
0.16 0
) 0
( 0
P 0
< 0
0.001 0
) 0
by 0
the 0
end 0
of 0
the 0
15-month 0
period 0
of 0
the 0
study 0
, 0
but 0
there 0
was 0
no 0
significant 0
difference 0
between 0
either 0
arm 0
of 0
the 0
study 0
. 0

CONCLUSIONS 0
Rationing 0
by 0
delay 0
was 0
not 0
detrimental 0
to 0
either 0
mental 0
or 0
physical 0
health 0
and 0
patients 0
in 0
both 0
arms 0
of 0
the 0
study 0
showed 0
significant 0
and 0
similar 0
improvement 0
in 0
health 0
by 0
15 0
months 0
. 0

Expenditure 0
of 0
resources 0
on 0
waiting 0
times 0
without 0
regard 0
to 0
clinical 0
outcomes 0
is 0
likely 0
to 0
be 0
wasteful 0
and 0
additional 0
resources 0
should 0
be 0
directed 0
at 0
achieving 0
the 0
greatest 0
clinical 0
benefit 0
. 0

More 0
research 0
into 0
effective 0
methods 0
of 0
controlling 0
demand 0
and 0
better 0
identification 0
of 0
those 0
who 0
would 0
benefit 0
from 0
access 0
to 0
specialist 0
care 0
is 0
needed 0
. 0

Heart 0
rate 0
variability 0
characteristics 0
in 0
sedentary 0
postmenopausal 0
women 0
following 0
six 0
months 0
of 0
exercise 0
training 0
: 0
the 0
DREW 0
study 0
. 0

BACKGROUND 0
Decreased 0
heart 0
rate 0
variability 0
( 0
HRV 0
) 0
is 0
associated 0
with 0
a 0
higher 0
risk 0
of 0
mortality 0
. 0

Overall 0
, 0
postmenopausal 0
women 0
have 0
lower 0
levels 0
of 0
HRV 0
than 0
premenopausal 0
women 0
, 0
which 0
may 0
be 0
additionally 0
complicated 0
by 0
lifestyle 0
related 0
behaviors 0
such 0
as 0
physical 0
inactivity 0
and 0
obesity 0
. 0

Though 0
cardiorespiratory 0
exercise 0
training 0
increases 0
HRV 0
, 0
little 0
is 0
known 0
regarding 0
the 0
exercise 0
dose 0
necessary 0
to 0
promote 0
this 0
improvement 0
. 0

METHODOLOGY/PRINCIPAL 0
FINDINGS 0
Our 0
primary 0
aim 0
was 0
to 0
measure 0
HRV 0
in 0
post-menopausal 0
women 0
following 0
6-months 0
of 0
exercise 0
training 0
. 0

We 0
examined 0
supine 0
resting 0
HRV 0
in 0
373 0
post-menopausal 0
women 0
( 0
45-75 0
y 0
) 0
after 0
6-months 0
of 0
randomly 0
assigned 0
and 0
double-blinded 0
administered 0
exercise 0
training 0
exercise 0
training 0
at 0
50 0
% 0
, 0
100 0
% 0
and 0
150 0
% 0
of 0
the 0
NIH 0
Consensus 0
Development 0
Panel 0
's 0
recommended 0
minimal 0
physical 0
activity 0
level 0
. 0

This 0
corresponded 0
to 0
4 0
, 0
8 0
, 0
or 0
12 0
kcal/kg 0
per 0
week 0
( 0
KKW 0
) 0
of 0
energy 0
expenditure 0
. 0

At 0
baseline 0
, 0
we 0
observed 0
no 0
significant 0
differences 0
in 0
HRV B-PHYSICAL
or 0
hormone B-PHYSICAL
replacement 0
use 0
between 0
treatment 0
groups 0
. 0

However 0
, 0
we 0
did 0
observe 0
that 0
Caucasian 0
women 0
and 0
those 0
taking 0
antidepressant 0
medications 0
had 0
lower 0
levels 0
of 0
baseline 0
HRV B-PHYSICAL
. 0

After 0
6-months 0
of 0
exercise 0
intervention 0
, 0
we 0
observed 0
a 0
dose 0
dependent 0
increase 0
in 0
all 0
parasympathetically 0
derived 0
time B-PHYSICAL
and I-PHYSICAL
frequency 0
domain B-PHYSICAL
measurements B-PHYSICAL
across 0
exercise 0
groups 0
after 0
adjustment 0
for 0
age 0
, 0
ethnicity 0
, 0
antidepressants B-PHYSICAL
, 0
and 0
baseline 0
rMSSD 0
( 0
all 0
, 0
P 0
< 0
0.001 0
) 0
. 0

For 0
example 0
, 0
the 0

Milk 0
protein 0
quantity 0
and 0
quality 0
in 0
low-birth-weight 0
infants 0
. 0

IV 0
. 0

Effects 0
on 0
tyrosine B-PHYSICAL
and 0
phenylalanine B-PHYSICAL
in 0
plasma 0
and 0
urine 0
. 0

Well 0
, 0
appropriate-for-gestational 0
age 0
, 0
low-birth-weight 0
infants 0
were 0
divided 0
into 0
three 0
gestational 0
age 0
groups 0
and 0
assigned 0
randomly 0
within 0
each 0
age 0
group 0
to 0
one 0
of 0
five 0
feeding 0
regimens 0
: 0
pooled 0
human 0
milk 0
( 0
BM 0
) 0
; 0
formula 0
1 0
( 0
F1 0
) 0
= 0
1.5 0
gm/dl 0
protein 0
, 0
60 0
parts 0
bovine 0
whey 0
proteins 0
: 0
40 0
parts 0
bovine 0
caseins 0
; 0
F2 0
= 0
3.0 0
gm/dl 0
, 0
60:40 0
; 0
F3 0
= 0
1.5 0
gm/dl 0
, 0
18:82 0
; 0
F4 0
= 0
3.0 0
gm/dl 0
, 0
18:82 0
. 0

Plasma 0
and 0
urine 0
concentrations 0
of 0
tyrosine B-PHYSICAL
and 0
phenylalanine B-PHYSICAL
were 0
far 0
higher 0
in 0
the 0
infants 0
fed 0
F1 0
to 0
F4 0
, 0
especially 0
F2 0
and 0
F4 0
, 0
than 0
in 0
the 0
infants 0
fed 0
BM 0
. 0

These 0
findings 0
offer 0
further 0
evidence 0
for 0
the 0
limited 0
capacity 0
of 0
the 0
low-birth-weight 0
infant 0
to 0
catabolize B-PHYSICAL
tyrosine I-PHYSICAL
. 0

Infants 0
fed 0
F3 0
had 0
significantly 0
higher 0
plasma B-PHYSICAL
tyrosine I-PHYSICAL
concentrations I-PHYSICAL
than 0
infants 0
fed 0
F1 0
, 0
and 0
those 0
fed 0
F4 0
had 0
higher 0
concentrations 0
than 0
those 0
fed 0
F2 0
. 0

Thus 0
, 0
increased 0
plasma B-PHYSICAL
tyrosine I-PHYSICAL
concentrations I-PHYSICAL
in 0
low-birth-weight 0
infants 0
are 0
related 0
directly 0
both 0
to 0
the 0
quantity 0
and 0
to 0
the 0
quality 0
of 0
the 0
protein 0
in 0
their 0
diets 0
. 0

Effect 0
of 0
acebutolol 0
on 0
left 0
ventricular 0
performance 0
. 0

The 0
effect 0
of 0
acebutolol 0
on 0
left 0
ventricular 0
performance 0
was 0
examined 0
by 0
various 0
noninvasive 0
means 0
in 0
three 0
studies 0
. 0

M-mode 0
echocardiographic 0
measurements 0
were 0
made 0
in 0
21 0
patients 0
with 0
coronary 0
artery 0
disease 0
who 0
were 0
receiving 0
placebo 0
, 0
acebutolol 0
, 0
and 0
propranolol 0
in 0
a 0
double-blind 0
, 0
randomized 0
, 0
crossover 0
study 0
. 0

In 0
these 0
patients 0
with 0
normal 0
or 0
near-normal 0
resting 0
left 0
ventricular 0
function 0
, 0
neither 0
drug 0
induced 0
depression 0
of 0
left 0
ventricular 0
function 0
. 0

In 0
26 0
patients 0
with 0
chronic 0
angina 0
pectoris 0
receiving 0
acebutolol 0
under 0
double-blind 0
, 0
placebo-controlled 0
conditions 0
, 0
gated 0
( 0
equilibrium 0
) 0
myocardial 0
blood 0
pool 0
imaging 0
using 0
red 0
blood 0
cells 0
labeled 0
with 0
technetium 0
99m 0
showed 0
acebutolol 0
to 0
have 0
no 0
clinically 0
significant 0
negative 0
effect 0
on 0
left 0
ventricular 0
performance 0
at 0
rest 0
or 0
during 0
supine 0
bicycle 0
exercise 0
. 0

Acebutolol 0
at 0
effective 0
antianginal 0
doses 0
modestly 0
improved 0
resting B-PHYSICAL
global I-PHYSICAL
and 0
regional B-PHYSICAL
myocardial I-PHYSICAL
function I-PHYSICAL
. 0

In 0
13 0
patients 0
with 0
stable 0
angina 0
pectoris 0
, 0
single-pass 0
studies 0
of 0
left 0
ventricular 0
function 0
with 0
indium 0
113 0
under 0
double-blind 0
, 0
placebo-controlled 0
conditions 0
similarly 0
showed 0
acebutolol 0
to 0
have 0
no 0
clinically 0
significant 0
negative 0
inotropic 0
effects 0
. 0

In 0
conclusion 0
, 0
acebutolol 0
is 0
safe 0
for 0
use 0
in 0
patients 0
with 0
coronary 0
disease 0
and 0
a 0
wide 0
range 0
of 0
ejection 0
fractions 0
but 0
, 0
as 0
with 0
all 0
beta 0
blockers 0
, 0
should 0
be 0
used 0
cautiously 0
in 0
patients 0
with 0
markedly 0
reduced 0
resting 0
left 0
ventricular 0
function 0
. 0

Risperidone 0
in 0
children 0
with 0
autism 0
and 0
serious 0
behavioral 0
problems 0
. 0

BACKGROUND 0
Atypical 0
antipsychotic 0
agents 0
, 0
which 0
block 0
postsynaptic 0
dopamine 0
and 0
serotonin 0
receptors 0
, 0
have 0
advantages 0
over 0
traditional 0
antipsychotic 0
medications 0
in 0
the 0
treatment 0
of 0
adults 0
with 0
schizophrenia 0
and 0
may 0
be 0
beneficial 0
in 0
children 0
with 0
autistic 0
disorder 0
who 0
have 0
serious 0
behavioral 0
disturbances 0
. 0

However 0
, 0
data 0
on 0
the 0
safety 0
and 0
efficacy 0
of 0
atypical 0
antipsychotic 0
agents 0
in 0
children 0
are 0
limited 0
. 0

METHODS 0
We 0
conducted 0
a 0
multisite 0
, 0
randomized 0
, 0
double-blind 0
trial 0
of 0
risperidone 0
as 0
compared 0
with 0
placebo 0
for 0
the 0
treatment 0
of 0
autistic 0
disorder 0
accompanied 0
by 0
severe 0
tantrums 0
, 0
aggression 0
, 0
or 0
self-injurious 0
behavior 0
in 0
children 0
5 0
to 0
17 0
years 0
old 0
. 0

The 0
primary 0
outcome 0
measures 0
were 0
the 0
score 0
on 0
the 0
Irritability 0
subscale 0
of 0
the 0
Aberrant 0
Behavior 0
Checklist 0
and 0
the 0
rating 0
on 0
the 0
Clinical 0
Global 0
Impressions 0
- 0
Improvement 0
( 0
CGI-I 0
) 0
scale 0
at 0
eight 0
weeks 0
. 0

RESULTS 0
A 0
total 0
of 0
101 0
children 0
( 0
82 0
boys 0
and 0
19 0
girls 0
; 0
mean 0
[ 0
+/-SD 0
] 0
age 0
, 0
8.8+/-2.7 0
years 0
) 0
were 0
randomly 0
assigned 0
to 0
receive 0
risperidone 0
( 0
49 0
children 0
) 0
or 0
placebo 0
( 0
52 0
) 0
. 0

Treatment 0
with 0
risperidone 0
for 0
eight 0
weeks 0
( 0
dose 0
range 0
, 0
0.5 0
to 0
3.5 0
mg 0
per 0
day 0
) 0
resulted 0
in 0
a 0
56.9 0
percent 0
reduction 0
in 0
the 0
Irritability B-MENTAL
score I-MENTAL
, 0
as 0
compared 0
with 0
a 0
14.1 0
percent 0
decrease 0
in 0
the 0
placebo 0
group 0
( 0
P 0
< 0
0.001 0
) 0
. 0

The 0
rate 0
of 0
a 0
positive 0
response 0
, 0
defined 0
as 0
at 0
least 0
a 0
25 0
percent 0
decrease 0
in 0
the 0
Irritability B-MENTAL
score I-MENTAL
and 0
a 0
rating 0
of 0
much 0
improved 0
or 0
very 0
much 0
improved 0
on 0
the 0
CGI-I B-MENTAL
scale I-MENTAL
, 0
was 0
69 0
percent 0
in 0
the 0
risperidone 0
group 0
( 0
34 0
of 0
49 0
children 0
had 0
a 0
positive 0
response 0
) 0
and 0
12 0
percent 0
in 0
the 0
placebo 0
group 0
( 0
6 0
of 0
52 0
, 0
P 0
< 0
0.001 0
) 0
. 0

Risperidone 0
therapy 0
was 0
associated 0
with 0
an 0
average 0
weight 0
gain B-PHYSICAL
of 0
2.7+/-2.9 0
kg 0
, 0
as 0
compared 0
with 0
0.8+/-2.2 0
kg 0
with 0
placebo 0
( 0
P 0
< 0
0.001 0
) 0
. 0

Increased 0
appetite B-PHYSICAL
, 0
fatigue B-ADVERSE-EFFECTS
, 0
drowsiness B-ADVERSE-EFFECTS
, 0
dizziness B-ADVERSE-EFFECTS
, 0
and 0
drooling B-ADVERSE-EFFECTS
were 0
more 0
common 0
in 0
the 0
risperidone 0
group 0
than 0
in 0
the 0
placebo 0
group 0
( 0
P 0
< 0
0.05 0
for 0
each 0
comparison 0
) 0
. 0

In 0
two 0
thirds 0
of 0
the 0
children 0
with 0
a 0
positive 0
response 0
to 0
risperidone 0
at 0
eight 0
weeks 0
( 0
23 0
of 0
34 0
) 0
, 0
the 0
benefit 0
was 0
maintained 0
at 0
six 0
months 0
. 0

CONCLUSIONS 0
Risperidone 0
was 0
effective 0
and 0
well 0
tolerated 0
for 0
the 0
treatment 0
of 0
tantrums 0
, 0
aggression 0
, 0
or 0
self-injurious 0
behavior 0
in 0
children 0
with 0
autistic 0
disorder 0
. 0

The 0
short 0
period 0
of 0
this 0
trial 0
limits 0
inferences 0
about 0
adverse 0
effects 0
such 0
as 0
tardive 0
dyskinesia 0
. 0

Efficacy 0
of 0
outpatient 0
induction 0
with 0
low-dose 0
intravaginal 0
prostaglandin 0
E2 0
: 0
a 0
randomized 0
, 0
double-blind 0
, 0
placebo-controlled 0
trial 0
. 0

OBJECTIVE 0
Our 0
purpose 0
was 0
to 0
determine 0
whether 0
a 0
protocol 0
for 0
outpatient 0
induction 0
is 0
safe B-PHYSICAL
and 0
effective 0
for 0
initiating 0
labor 0
. 0

STUDY 0
DESIGN 0
A 0
randomized 0
, 0
double-blind 0
, 0
placebo-controlled 0
trial 0
was 0
performed 0
with 0
100 0
low-risk 0
patients 0
having 0
well-dated 0
pregnancies 0
. 0

Women 0
with 0
a 0
Bishop 0
score 0
< 0
or 0
= 0
6 0
at 0
38 0
to 0
40 0
weeks 0
' 0
gestation 0
were 0
administered 0
either 0
2 0
mg 0
of 0
intravaginal 0
prostaglandin 0
E2 0
gel 0
or 0
placebo 0
for 0
5 0
consecutive 0
days 0
as 0
outpatients 0
while 0
undergoing 0
fetal 0
monitoring 0
. 0

RESULTS 0
The 0
median 0
interval 0
from 0
randomization 0
to B-PHYSICAL
delivery I-PHYSICAL
was 0
4 0
days 0
in 0
the 0
prostaglandin 0
E2 0
group 0
( 0
range 0
0 0
to 0
28 0
days 0
) 0
versus 0
10 0
days 0
in 0
the 0
placebo 0
group 0
( 0
range 0
0 0
to 0
26 0
days 0
, 0
p 0
= 0
0.002 0
) 0
. 0

Twenty-seven 0
of 0
50 0
patients 0
( 0
54 0
% 0
) 0
in 0
the 0
prostaglandin 0
E2 0
group 0
were 0
admitted 0
for 0
labor 0
during 0
the 0
dosing 0
interval 0
compared 0
with 0
10 0
placebo-treated 0
patients 0
( 0
20 0
% 0
, 0
p 0
= 0
0.001 0
) 0
. 0

The 0
mean 0
gestational B-PHYSICAL
age 0
at B-PHYSICAL
delivery B-PHYSICAL
was 0
significantly 0
reduced 0
in 0
the 0
treatment 0
group 0
( 0
39.9 0
+/- 0
1.0 0
weeks 0
vs 0
40.5 0
+/- 0
0.99 0
weeks 0
, 0
p 0
= 0
0.003 0
) 0
as 0
was 0
the 0
incidence 0
of 0
postdates B-MENTAL

Walking 0
trials 0
in 0
postmenopausal 0
women 0
: 0
effect 0
of 0
one 0
vs 0
two 0
daily 0
bouts 0
on 0
aerobic B-PHYSICAL
fitness I-PHYSICAL
. 0

We 0
compared 0
the 0
effects 0
of 0
one 0
vs 0
two 0
daily 0
bouts 0
of 0
walking 0
on 0
aerobic B-PHYSICAL
fitness I-PHYSICAL
and 0
body B-PHYSICAL
composition I-PHYSICAL
in 0
postmenopausal 0
women 0
. 0

One 0
hundred 0
and 0
thirty-four 0
subjects 0
were 0
randomized 0
into 0
exercise 0
groups 0
or 0
a 0
control 0
group 0
and 0
130 0
completed 0
the 0
study 0
. 0

The 0
subjects 0
walked 0
5 0
d/week 0
for 0
15 0
weeks 0
at 0
65 0
% 0
of 0
their 0
maximal 0
aerobic 0
power 0
expending 0
300 0
kcal 0
( 0
1255 0
kJ 0
) 0
in 0
exercise 0
in 0
one 0
( 0
Group 0
S1 0
) 0
or 0
two 0
daily 0
sessions 0
( 0
Group 0
S2 0
) 0
. 0

VO B-PHYSICAL
( I-PHYSICAL
2max I-PHYSICAL
) I-PHYSICAL
was 0
measured 0
in 0
a 0
direct 0
maximal 0
treadmill 0
test 0
. 0

Body 0
mass 0
index 0
( 0
BMI 0
) 0
was 0
calculated 0
and 0
the 0
percentage 0
of 0
body 0
fat 0
( 0
fat 0
% 0
) 0
estimated 0
using 0
skinfold 0
measurements 0
. 0

The 0
net 0
change 0
in 0
the 0
VO B-PHYSICAL
( I-PHYSICAL
2max I-PHYSICAL
) I-PHYSICAL
was 0
2.5 0
mL 0
min/kg 0
( 0
95 0
% 0
CI 0
1.5 0
, 0
3.5 0
) 0
( 0
8.7 0
% 0
) 0
in 0
Group 0
S1 0
and 0
2.5 0
mL 0
min/kg 0
( 0
95 0
% 0
CI 0
1.5 0
, 0
3.5 0
) 0
( 0
8.8 0
% 0
) 0
in 0
Group 0
S2 0
. 0

The 0
net B-PHYSICAL
change I-PHYSICAL
in I-PHYSICAL
body I-PHYSICAL
mass I-PHYSICAL
was 0
-1.2 0
kg 0
( 0
95 0
% 0
CI-1.9 0
, 0
-0.5 0
) 0
in 0
Group 0
S1 0
and 0
-1.1 0
kg 0
( 0
95 0
% 0
CI 0
-1.8 0
, 0
-0.4 0
) 0
in 0
Group 0
S2 0
. 0

The 0
net B-PHYSICAL
fat I-PHYSICAL
% I-PHYSICAL
change I-PHYSICAL
was 0
-2.1 0
% 0
( 0
95 0
% 0
CI-2.7 0
, 0
-1.4 0
) 0
in 0
Group 0
S1 0
and 0
-1.7 0
% 0
( 0
95 0
% 0
CI-2.3 0
, 0
-1.0 0
) 0
in 0
Group 0
S2 0
. 0

Exercise 0
improved 0
the 0
maximal 0
aerobic 0
power 0
and 0
body 0
composition 0
equally 0
when 0
walking 0
was 0
performed 0
in 0
one 0
or 0
two 0
daily 0
bouts 0
. 0

Epileptogenic 0
activity 0
of 0
folic 0
acid 0
after 0
drug 0
induces 0
SLE 0
( 0
folic 0
acid 0
and 0
epilepsy 0
) 0
OBJECTIVE 0
To 0
study 0
the 0
effect 0
of 0
folic 0
acid-containing 0
multivitamin 0
supplementation 0
in 0
epileptic 0
women 0
before 0
and 0
during 0
pregnancy 0
in 0
order 0
to 0
determine 0
the 0
rate 0
of 0
structural 0
birth 0
defects 0
and 0
epilepsy-related 0
side 0
effects 0
. 0

STUDY 0
DESIGN 0
First 0
a 0
randomised 0
trial 0
, 0
later 0
periconception 0
care 0
including 0
in 0
total 0
12225 0
females 0
. 0

RESULTS 0
Of 0
60 0
epileptic 0
women 0
with 0
periconceptional 0
folic 0
acid 0
( 0
0.8 0
mg 0
) 0
-containing 0
multivitamin 0
supplementation 0
, 0
no 0
one 0
developed 0
epilepsy-related 0
side 0
effects 0
during 0
the 0
periconception 0
period 0
. 0

One 0
epileptic 0
woman 0
delivered 0
a 0
newborn 0
with 0
cleft 0
lip 0
and 0
palate 0
. 0

Another 0
patient 0
exhibited 0
with 0
a 0
cluster 0
of 0
seizures B-ADVERSE-EFFECTS
after 0
the 0
periconception 0
period 0
using 0
another 0
multivitamin 0
. 0

This 0
22-year-old 0
epileptic 0
woman 0
was 0
treated 0
continuously 0
by 0
carbamazepine 0
and 0
a 0
folic 0
acid 0
( 0
1 0
mg 0
) 0
-containing 0
multivitamin 0
from 0
the 0
20th 0
week 0
of 0
gestation 0
. 0

She 0
developed 0
status B-ADVERSE-EFFECTS
epilepticus I-ADVERSE-EFFECTS
and 0
later 0
symptoms 0
of 0
systemic B-ADVERSE-EFFECTS
lupus I-ADVERSE-EFFECTS
erythematodes I-ADVERSE-EFFECTS
. 0

Her 0
pregnancy 0
ended 0
with 0
stillbirth B-MORTALITY
. 0

CONCLUSIONS 0
The 0
epileptic 0
pregnant 0
patient 0
's 0
autoimmune 0
disease 0
( 0
probably 0
drug-induced 0
lupus 0
) 0
could 0
damage 0
the 0
blood-brain 0
barrier 0
, 0
therefore 0
the 0
therapeutic 0
dose 0
( 0
> 0
or 0
=1 0
mg 0
) 0
of 0
folic 0
acid 0
triggered 0
a 0
cluster 0
of 0
seizures B-ADVERSE-EFFECTS
. 0

Physiological 0
dose 0
( 0
< 0
1 0
mg 0
) 0
of 0
folic 0
acid 0
both 0
in 0
healthy 0
and 0
60 0
epileptic 0
women 0
, 0
all 0
without 0
any 0
autoimmune 0
disease 0
, 0
did 0
not 0
increase 0
the 0
risk 0
for 0
epileptic B-PHYSICAL
seizures I-PHYSICAL
. 0

Impact 0
of 0
an 0
Asha 0
intervention 0
on 0
depressive B-PHYSICAL
symptoms I-PHYSICAL
among 0
rural 0
women 0
living 0
with 0
AIDS 0
in 0
India 0
: 0
comparison 0
of 0
the 0
Asha-Life 0
and 0
Usual 0
Care 0
program 0
. 0

The 0
purpose 0
of 0
this 0
randomized 0
pilot 0
study 0
is 0
to 0
conduct 0
an 0
intervention 0
with 0
68 0
rural 0
women 0
living 0
with 0
AIDS 0
to 0
compare 0
the 0
effectiveness 0
of 0
two 0
different 0
programs 0
on 0
depressive 0
symptoms 0
. 0

The 0
trial 0
was 0
designed 0
to 0
assess 0
the 0
impact 0
of 0
the 0
Asha-Life 0
intervention 0
engaging 0
with 0
an 0
HIV-trained 0
village 0
woman 0
, 0
Asha 0
( 0
Accredited 0
Social 0
Health 0
Activist 0
) 0
, 0
to 0
participate 0
in 0
the 0
care 0
of 0
women 0
living 0
with 0
AIDS 0
( 0
WLA 0
) 0
, 0
along 0
with 0
other 0
health 0
care 0
providers 0
compared 0
to 0
a 0
Usual 0
Care 0
group 0
. 0

Two 0
high 0
prevalence 0
HIV/AIDS 0
villages 0
in 0
rural 0
Andhra 0
Pradesh 0
, 0
which 0
were 0
demographically 0
alike 0
and 0
served 0
by 0
distinct 0
Public 0
Health 0
Centers 0
, 0
were 0
selected 0
randomly 0
from 0
a 0
total 0
of 0
16 0
villages 0
. 0

The 0
findings 0
of 0
this 0
study 0
demonstrated 0
that 0
the 0
Asha-Life 0
participants 0
significantly B-PHYSICAL
reduced I-PHYSICAL
their 0
depressive B-PHYSICAL
symptom I-PHYSICAL
scores I-PHYSICAL
compared 0
to 0
the 0
Usual 0
Care 0
participants 0
. 0

Moreover 0
, 0
women 0
living 0
with 0
AIDS 0
who 0
demonstrated 0
higher 0
depressive B-PHYSICAL
symptom I-PHYSICAL
scores I-PHYSICAL
at 0
baseline 0
had 0
greater 0
reduction 0
in 0
their 0
depressive B-PHYSICAL
symptoms I-PHYSICAL
than 0
women 0
with 0
lower 0
scores 0
. 0

Prophylactic B-PHYSICAL
effect 0
of 0
phenytoin 0
in 0
bipolar 0
disorder 0
: 0
a 0
controlled 0
study 0
. 0

OBJECTIVE 0
Phenytoin 0
is 0
an 0
effective 0
anticonvulsant 0
that 0
has 0
not 0
previously 0
been 0
studied 0
prophylactically 0
in 0
bipolar 0
( 0
BP 0
) 0
patients 0
. 0

Thus 0
a 0
study 0
of 0
phenytoin 0
prophylaxis 0
was 0
undertaken 0
and 0
is 0
herein 0
reported 0
. 0

METHOD 0
Bipolar 0
patients 0
were 0
studied 0
who 0
had 0
at 0
least 0
one 0
episode 0
per 0
year 0
in 0
the 0
previous 0
2 0
years 0
despite 0
ongoing 0
prophylaxis 0
. 0

Patients 0
were 0
stable 0
for 0
a 0
mean 0
of 0
4 0
months 0
( 0
range 0
1-13 0
) 0
before 0
entering 0
the 0
study 0
. 0

Phenytoin 0
or 0
placebo 0
was 0
added 0
to 0
their 0
current 0
therapy 0
in 0
a 0
double-blind 0
cross-over 0
design 0
for 0
6 0
months 0
in 0
each 0
phase 0
. 0

Thirty 0
observation 0
periods 0
of 0
6 0
months 0
each 0
were 0
studied 0
for 0
23 0
patients 0
. 0

RESULTS 0
Three 0
patients 0
had 0
relapse B-PHYSICAL
on 0
phenytoin 0
and 0
nine 0
had 0
relapse 0
on 0
placebo 0
. 0

There 0
was 0
a 0
significant 0
prophylactic B-PHYSICAL
effect 0
of 0
phenytoin 0
in 0
BP 0
disorder 0
[ 0
Cox B-PHYSICAL
's 0
F-test B-PHYSICAL
for 0
comparing 0
survival B-MORTALITY
in 0
two 0
groups 0
: 0
F 0
( 0
6 0
, 0
18 0
) 0
= 0
3.44 0
, 0
p 0
= 0
0.02 0
] 0
. 0

CONCLUSIONS 0
This 0
study 0
suggests 0
prophylactic B-PHYSICAL
effects I-PHYSICAL
of 0
add-on 0
phenytoin 0
in 0
BP 0
illness 0
. 0

However 0
, 0
the 0
number 0
of 0
patients 0
was 0
small 0
and 0
confirmation 0
is 0
necessary 0
. 0

Laparoscopic 0
vs 0
open 0
appendectomy 0
in 0
overweight 0
patients 0
. 0

BACKGROUND 0
Laparoscopic 0
appendectomy 0
( 0
LA 0
) 0
has 0
been 0
associated 0
with 0
a 0
faster 0
recovery 0
and 0
less 0
postoperative 0
pain 0
than 0
the 0
open 0
technique 0
. 0

However 0
, 0
few 0
data 0
are 0
available 0
on 0
the 0
clinical 0
outcome 0
of 0
LA 0
in 0
overweight 0
patients 0
. 0

METHODS 0
A 0
group 0
of 0
106 0
patients 0
with 0
a 0
body 0
mass 0
index 0
( 0
BMI 0
) 0
> 0
26.4 0
, 0
representing 0
the 0
upper 0
quintile 0
of 0
500 0
prospectively 0
randomized 0
patients 0
, 0
were 0
included 0
in 0
the 0
study 0
. 0

They 0
were 0
randomized 0
to 0
undergo 0
either 0
laparoscopic 0
or 0
open 0
appendectomy 0
( 0
OA 0
) 0
. 0

Operating B-OTHER
and I-OTHER
anesthesia I-OTHER
times I-OTHER
, 0
postoperative B-PAIN
pain I-PAIN
, 0
complications B-ADVERSE-EFFECTS
, 0
hospital B-OTHER
stay I-OTHER
, 0
functional B-PHYSICAL
index I-PHYSICAL
( 0
1 0
week 0
postoperatively 0
) 0
, 0
sick B-OTHER
leave I-OTHER
, 0
and 0
time B-OTHER
to I-OTHER
full I-OTHER
recovery I-OTHER
were 0
documented 0
. 0

RESULTS 0
In 0
OA 0
, 0
the 0
operating B-OTHER
time I-OTHER
for 0
overweight 0
patients 0
was 0
significantly 0
longer 0
than 0
that 0
for 0
patients 0
in 0
the 0
normal 0
weight 0
range 0
( 0
40 0
vs 0
35 0
min 0
, 0
p 0
< 0
0.05 0
) 0
. 0

In 0
LA 0
, 0
there 0
was 0
no 0
difference 0
in 0
operating B-OTHER
time I-OTHER
between 0
the 0
normal 0
and 0
overweight 0
patients 0
. 0

Overweight 0
patients 0
who 0
underwent 0
LA 0
had 0
longer 0
operating B-OTHER
and I-OTHER
anesthesia I-OTHER
times I-OTHER
than 0
their 0
OA 0
counterparts 0
( 0
55 0
vs 0
40 0
min 0
, 0
p 0
< 0
0.001 0
; 0
and 0
125 0
vs 0
100 0
min 0
, 0
p 0
< 0
0.001 0
, 0
respectively 0
) 0
. 0

Postoperative B-PAIN
pain I-PAIN
was 0
significantly 0
greater 0
in 0
overweight 0
patients 0
who 0
underwent 0
OA 0
than 0
in 0
those 0
treated 0
with 0
the 0
laparoscopic 0
technique 0
. 0

Postoperative B-PAIN
pain I-PAIN
was 0
also 0
significantly 0
greater 0
in 0
overweight 0
patients 0
subjected 0
to 0
OA 0
than 0
in 0
patients 0
of 0
normal 0
weight 0
after 0
4 0
weeks 0
; 0
the 0
clinical 0
significance 0
may 0
, 0
however 0
, 0
be 0
of 0
less 0
importance 0
since 0
the 0
values 0
are 0
low 0
( 0
0.26 0
vs 0
0.09 0
, 0
p 0
< 0
0.05 0
) 0
. 0

There 0
were 0
no 0
significant 0
differences 0
between 0
the 0
two 0
operating 0
techniques 0
in 0
terms 0
of 0
complications 0
. 0

Hospital B-OTHER
stay I-OTHER
was 0
longer 0
for 0
overweight 0
patients 0
than 0
for 0
normal-weight 0
patients 0
undergoing 0
OA 0
( 0
3.0 0
vs 0
2.0 0
, 0
p 0
< 0
0.01 0
) 0
. 0

The 0
functional 0
index 0
did 0
not 0
differ 0
between 0
any 0
group 0
of 0
patients 0
. 0

Sick B-OTHER
leave I-OTHER
was 0
longer 0
for 0
overweight 0
patients 0
who 0
underwent 0
OA 0
than 0
for 0
normal-weight 0
patients 0
treated 0
with 0
the 0
same 0
technique 0
( 0
17 0
vs 0
13 0
days 0
, 0
p 0
< 0
0.01 0
) 0
. 0

In 0
the 0
laparoscopic 0
group 0
, 0
however 0
, 0
there 0
were 0
no 0
differences 0
between 0
the 0
overweight 0
and 0
normal-weight 0
patients 0
. 0

Time B-OTHER
to I-OTHER
full I-OTHER
recovery I-OTHER
was 0
greater 0
in 0
overweight 0
patients 0
subjected 0
to 0
OA 0
than 0
in 0
the 0
overweight 0
patients 0
in 0
the 0
LA 0
group 0
( 0
22 0
vs 0
15 0
days 0
, 0
p 0
< 0
0.001 0
) 0
. 0

CONCLUSION 0
In 0
this 0
study 0
, 0
overweight 0
patients 0
who 0
were 0
submitted 0
to 0
LA 0
had 0
less 0
postoperative B-PAIN
pain I-PAIN
and 0
a 0
faster 0
postoperative B-OTHER
recovery I-OTHER
than 0
overweight 0
patients 0
who 0
had 0
OA 0
. 0

LA 0
also 0
abolished 0
some 0
of 0
the 0
negative 0
effects 0
that 0
overweight 0
had 0
on 0
operating B-OTHER
time I-OTHER
, 0
hospital B-OTHER
stay I-OTHER
, 0
and 0
sick B-OTHER
leave I-OTHER
with 0
the 0
open 0
technique 0
. 0

However 0
, 0
anesthesia 0
and 0
operating 0
times 0
were 0
significantly 0
longer 0
in 0
LA 0
for 0
both 0
overweight 0
patients 0
and 0
those 0
with 0
a 0
normal 0
BMI 0
. 0

Do 0
colonic 0
short-chain 0
fatty 0
acids 0
contribute 0
to 0
the 0
long-term B-PHYSICAL
adaptation I-PHYSICAL
of I-PHYSICAL
blood I-PHYSICAL
lipids I-PHYSICAL
in 0
subjects 0
with 0
type 0
2 0
diabetes 0
consuming 0
a 0
high-fiber 0
diet 0
? 0

BACKGROUND 0
We 0
recently 0
obtained 0
evidence 0
of 0
long-term B-PHYSICAL
adaptation I-PHYSICAL
of I-PHYSICAL
blood I-PHYSICAL
lipids I-PHYSICAL
to 0
changes 0
in 0
intakes 0
of 0
carbohydrate 0
and 0
fiber 0
in 0
subjects 0
with 0
type 0
2 0
diabetes 0
. 0

OBJECTIVE 0
We 0
determined 0
the 0
effect 0
of 0
increased 0
carbohydrate 0
and 0
fiber 0
intakes 0
on 0
serum B-PHYSICAL
short-chain I-PHYSICAL
fatty I-PHYSICAL
acids I-PHYSICAL
( I-PHYSICAL
SCFAs I-PHYSICAL
) I-PHYSICAL
and 0
the 0
relation 0
between 0
changes B-PHYSICAL
in I-PHYSICAL
serum I-PHYSICAL
acetate I-PHYSICAL
and 0
changes B-PHYSICAL
in I-PHYSICAL
blood I-PHYSICAL
lipids I-PHYSICAL
. 0

DESIGN 0
Subjects 0
with 0
type 0
2 0
diabetes 0
( 0
n 0
= 0
62 0
) 0
were 0
randomly 0
assigned 0
to 0
receive 0
approximately 0
10 0
% 0
of 0
energy 0
from 0
low-fiber 0
breakfast 0
cereal 0
( 0
LF 0
diet 0
) 0
, 0
high-fiber 0
breakfast 0
cereal 0
( 0
HF 0
diet 0
) 0
, 0
or 0
monounsaturated 0
fatty 0
acids 0
( 0
MUFA 0
diet 0
) 0
for 0
6 0
mo 0
. 0

RESULTS 0
Carbohydrate B-PHYSICAL
intakes I-PHYSICAL
were 0
higher 0
in 0
the 0
LF 0
and 0
HF 0
groups 0
than 0
in 0
the 0
MUFA 0
group 0
( 0
54 0
% 0
compared 0
with 0
43 0
% 0
) 0
, 0
and 0
more 0
fiber 0
was 0
consumed 0
by 0
the 0
HF 0
group 0
( 0
approximately 0
50 0
g/d 0
) 0
than 0
by 0
the 0
LF 0
or 0
MUFA 0
group 0
( 0
approximately 0
23 0
g/d 0
) 0
. 0

Fasting B-PHYSICAL
serum I-PHYSICAL
SCFAs I-PHYSICAL
did 0
not 0
change 0
significantly 0
over 0
the 0
first 0
3 0
mo 0
. 0

Between 0
3 0
and 0
6 0
mo 0
, 0
serum B-PHYSICAL
acetate I-PHYSICAL
tended 0
( 0
NS 0
) 0
to 0
decrease 0
in 0
the 0
LF 0
group 0
( 0
from 0
69 0
+/- 0
4 0
to 0
59 0
+/- 0
5 0
micromol/L 0
) 0
and 0
increase 0
in 0
the 0
HF 0
group 0
( 0
from 0
100 0
+/- 0
18 0
to 0
107 0
+/- 0
17 0
micromol/L 0
) 0
, 0
with 0
no 0
significant 0
change 0
in 0
the 0
MUFA 0
group 0
. 0

Serum B-PHYSICAL
butyrate I-PHYSICAL
did 0
not 0
change 0
significantly 0
in 0
the 0
LF 0
or 0
MUFA 0
group 0
but 0
increased 0
in 0
the 0
HF 0
group 0
( 0
from 0
2.5 0
+/- 0
0.5 0
to 0
3.1 0
+/- 0
0.6 0
micromol/L 0
; 0
P 0
< 0
0.001 0
) 0
. 0

Changes 0
in 0
serum B-PHYSICAL
acetate I-PHYSICAL
from 0
0 0
to 0
3 0
mo 0
were 0
not 0
related 0
to 0
changes B-PHYSICAL
in I-PHYSICAL
lipids I-PHYSICAL
. 0

However 0
, 0
changes 0
in 0
serum B-PHYSICAL
acetate I-PHYSICAL
from 0
3 0
to 0
6 0
mo 0
were 0
positively 0
related 0
to 0
changes 0
in 0
the 0
ratio 0
of B-PHYSICAL
total 0
to B-PHYSICAL
HDL I-PHYSICAL
cholesterol B-PHYSICAL
( 0
P 0
= 0
0.041 0
) 0
and 0
in 0
fasting 0
( 0
P 0
= 0
0.013 0
) 0
and 0
postprandial B-PHYSICAL
( 0
P B-PHYSICAL
= B-PHYSICAL
0.016 0
) 0
triacylglycerols B-PHYSICAL
. 0

CONCLUSIONS 0
In 0
subjects 0
with 0
type 0
2 0
diabetes 0
, 0
changes 0
in 0
serum B-PHYSICAL
SCFAs I-PHYSICAL
in 0
response 0
to 0
changes 0
in 0

Effects 0
of 0
misoprostol B-PHYSICAL
on 0
human 0
circulation 0
. 0

Prostaglandins 0
( 0
PGs 0
) 0
of 0
the 0
E-type 0
are 0
potent 0
vasodilators 0
in 0
most 0
species 0
and 0
in 0
most 0
vascular 0
beds 0
. 0

However 0
, 0
vasoconstrictor 0
effects 0
of 0
PGEs 0
have 0
also 0
been 0
noted 0
at 0
selected 0
sites 0
. 0

This 0
study 0
examined 0
the 0
effects 0
of 0
misoprostol B-PHYSICAL
, 0
a 0
PGE1 0
analog 0
with 0
antiulcer 0
activity 0
, 0
on 0
the 0
human 0
cardiovascular 0
system 0
. 0

Twenty 0
healthy 0
subjects 0
participated 0
in 0
this 0
double-blind 0
, 0
placebo-controlled 0
, 0
parallel 0
group 0
study 0
. 0

Following 0
a 0
12 0
hour 0
fast 0
, 0
heart 0
rate 0
, 0
arterial 0
blood 0
pressure 0
, 0
light 0
reflex 0
plethysmography 0
of 0
the 0
finger 0
, 0
resting 0
blood 0
flow 0
volume 0
in 0
the 0
lower 0
arm 0
and 0
leg 0
and 0
peripheral B-PHYSICAL
vascular I-PHYSICAL
resistance I-PHYSICAL
were 0
measured 0
at 0
10 0
min 0
. 0

intervals 0
for 0
1 0
hour 0
prior 0
to 0
drug 0
administration 0
, 0
to 0
permit 0
calculating 0
baseline 0
values 0
. 0

Misoprostol 0
( 0
400 0
mcg 0
) 0
or 0
its 0
matching 0
placebo 0
were 0
administered 0
orally 0
, 0
and 0
the 0
measurements 0
were 0
repeated 0
at 0
10 0
min 0
. 0

intervals 0
over 0
the 0
next 0
2 0
hours 0
. 0

A 0
decrease 0
in 0
leg B-PHYSICAL
blood I-PHYSICAL
flow I-PHYSICAL
volume I-PHYSICAL
and 0
a 0
corresponding 0
increase 0
in 0
leg B-PHYSICAL
peripheral I-PHYSICAL
vascular I-PHYSICAL
resistance I-PHYSICAL
were 0
noted 0
in 0
the 0
misoprostol 0
group 0
. 0

A 0
statistically 0
significant 0
decrease 0
in 0
heart B-PHYSICAL
rate I-PHYSICAL
between 0
the 0
two 0
treatment 0
groups 0
was 0
also 0
noted 0
. 0

These 0
small 0
changes 0
were 0
not 0
considered 0
to 0
be 0
of 0
clinical 0
importance 0
. 0

No 0
adverse B-PHYSICAL
experiences I-PHYSICAL
were 0
reported 0
. 0

In 0
conclusion 0
, 0
a 0
single 0
dose 0
of 0
misoprostol 0
( 0
400 0
mcg 0
) 0
has 0
no 0
clinically 0
significant 0
vasoconstrictive B-PHYSICAL
or 0
vasodilative B-PHYSICAL
properties 0
in 0
man 0
. 0

Secondary 0
caries 0
formation 0
in 0
vitro 0
around 0
glass 0
ionomer-lined 0
amalgam 0
and 0
composite 0
restorations 0
. 0

The 0
aim 0
of 0
this 0
in 0
vitro 0
secondary 0
caries 0
study 0
was 0
to 0
examine 0
the 0
glass-ionomer 0
liner 0
's 0
effect 0
on 0
wall-lesion 0
inhibition 0
when 0
a 0
conventional 0
and 0
a 0
light-cured 0
glass 0
ionomer 0
liner 0
was 0
placed 0
under 0
amalgam 0
and 0
composite 0
resin 0
restorations 0
. 0

Class 0
V 0
preparations 0
in 0
extracted 0
upper 0
premolars 0
were 0
used 0
and 0
ten 0
restorations 0
were 0
used 0
for 0
each 0
of 0
the 0
following 0
groups 0
: 0
( 0
i 0
) 0
two 0
layers 0
of 0
copal 0
varnish 0
and 0
amalgam 0
; 0
( 0
ii 0
) 0
conventional 0
glass-ionomer 0
and 0
amalgam 0
; 0
( 0
iii 0
) 0
light-cured 0
glass-ionomer 0
and 0
amalgam 0
; 0
( 0
iv 0
) 0
bonding 0
agent 0
and 0
light-cured 0
composite 0
resin 0
; 0
( 0
v 0
) 0
conventional 0
glass-ionomer 0
, 0
bonding 0
agent 0
and 0
light-cured 0
composite 0
resin 0
; 0
( 0
vi 0
) 0
light-cured 0
glass-ionomer 0
, 0
extended 0
0.3 0
mm 0
short 0
of 0
the 0
enamel 0
margin 0
bonding 0
agent 0
and 0
light-cured 0
composite 0
resin 0
; 0
and 0
( 0
vii 0
) 0
light-cured 0
glass-ionomer 0
, 0
extended 0
1 0
mm 0
short 0
of 0
the 0
enamel 0
margin 0
, 0
bonding 0
agent 0
and 0
light-cured 0
composite 0
resin 0
. 0

The 0
teeth 0
were 0
thermocycled 0
and 0
artificial 0
caries 0
were 0
created 0
using 0
an 0
acid-gel 0
. 0

The 0
results 0
of 0
this 0
study 0
showed 0
that 0
artificial B-PHYSICAL
recurrent I-PHYSICAL
caries I-PHYSICAL
can 0
be 0
reduced 0
significantly 0
( 0
P 0
< 0
0.05 0
) 0
with 0
a 0
glass-ionomer 0
liner 0
under 0
amalgam 0
restorations 0
. 0

The 0
results 0
also 0
showed 0
that 0
when 0
the 0
light-cured 0
glass-ionomer 0
liner 0
was 0
placed 0
0.3 0
mm 0
from 0
the 0
cavosurface 0
margin 0
under 0
composite 0
resin 0
restoration 0
, 0
the 0
artificial B-PHYSICAL
recurrent I-PHYSICAL
caries I-PHYSICAL
reduced I-PHYSICAL
significantly 0
( 0
P 0
< 0
0.05 0
) 0
. 0

A 0
workplace 0
intervention 0
for 0
increasing 0
outdoor 0
workers 0
' 0
use 0
of 0
solar 0
protection 0
. 0

OBJECTIVES 0
Outdoor 0
workers 0
are 0
at 0
high 0
risk 0
of 0
developing 0
skin 0
cancer 0
. 0

Primary 0
prevention 0
in 0
this 0
group 0
can 0
potentially 0
reduce 0
the 0
incidence 0
of 0
skin 0
cancer 0
, 0
and 0
also 0
potentiates 0
the 0
spontaneous 0
remission 0
of 0
existing 0
solar 0
keratoses 0
. 0

A 0
randomized 0
controlled 0
trial 0
was 0
conducted 0
to 0
evaluate 0
a 0
solar 0
protection 0
intervention 0
targeting 0
outdoor 0
workers 0
. 0

METHODS 0
Outdoor 0
workers 0
were 0
randomly 0
allocated 0
to 0
an 0
intervention 0
( 0
n 0
= 0
65 0
) 0
or 0
control 0
group 0
( 0
n 0
= 0
77 0
) 0
. 0

The 0
intervention 0
group 0
received 0
individual 0
skin 0
screening 0
by 0
a 0
dermatologist 0
and 0
participated 0
in 0
an 0
education 0
session 0
. 0

Pre- 0
and 0
posttest 0
outcome 0
measures 0
included 0
solar B-MENTAL
protection I-MENTAL
behavior I-MENTAL
( 0
assessed 0
using 0
a 0
validated 0
diary 0
) 0
, 0
knowledge B-MENTAL
, 0
and 0
attitudes B-MENTAL
. 0

RESULTS 0
There 0
was 0
a 0
significant B-OTHER
increase 0
( 0
16 0
% 0
) 0
in 0
the 0
percentage 0
of 0
outdoor 0
workers 0
who 0
were 0
using 0
a 0
high 0
level 0
of 0
solar 0
protection 0
at 0
posttest 0
compared 0
to 0
pretest 0
in 0
the 0
intervention 0
group 0
, 0
but 0
there 0
was 0
no 0
change B-OTHER
in 0
the 0
control 0
group 0
. 0

Although 0
both 0
groups 0
improved B-OTHER
in 0
their 0
knowledge B-MENTAL
score I-MENTAL
, 0
the 0
intervention B-OTHER
group 0
showed B-OTHER
a I-OTHER
significantly I-OTHER
greater 0
improvement B-OTHER
at 0
posttest 0
. 0

No 0
changes B-OTHER
in I-OTHER

Anatomical 0
benefit 0
from 0
ranibizumab 0
treatment 0
of 0
predominantly 0
classic 0
neovascular 0
age-related 0
macular 0
degeneration 0
in 0
the 0
2-year 0
anchor 0
study 0
. 0

PURPOSE 0
To 0
compare 0
lesion 0
anatomical 0
responses 0
to 0
ranibizumab 0
versus 0
verteporfin 0
photodynamic 0
therapy 0
( 0
PDT 0
) 0
in 0
the 0
ANCHOR 0
( 0
Anti-VEGF 0
Antibody 0
for 0
the 0
Treatment 0
of 0
Predominantly 0
Classic 0
Choroidal 0
Neovascularization 0
[ 0
CNV 0
] 0
in 0
Age-Related 0
Macular 0
Degeneration 0
) 0
study 0
. 0

METHODS 0
In 0
this 0
2-year 0
, 0
Phase 0
III 0
, 0
randomized 0
, 0
multicenter 0
, 0
double-masked 0
trial 0
, 0
423 0
patients 0
received 0
ranibizumab 0
( 0
0.3 0
or 0
0.5 0
mg 0
) 0
monthly 0
+ 0
sham 0
PDT 0
or 0
PDT 0
+ 0
monthly 0
sham 0
injection 0
. 0

Photodynamic 0
therapy 0
( 0
or 0
sham 0
PDT 0
) 0
was 0
administered 0
at 0
Day 0
0 0
and 0
then 0
quarterly 0
as 0
needed 0
. 0

A 0
central 0
reading 0
center 0
assessed 0
fundus 0
photography 0
and 0
fluorescein 0
angiography 0
images 0
. 0

A 0
subset 0
( 0
n 0
= 0
61 0
) 0
had 0
optical 0
coherence 0
tomography 0
assessments 0
. 0

Main 0
outcome 0
measures 0
included 0
mean 0
change 0
from 0
baseline 0
at 0
Months 0
12 0
and 0
24 0
for 0
area 0
of 0
classic 0
CNV 0
and 0
total 0
area 0
of 0
leakage 0
from 0
CNV 0
. 0

RESULTS 0
At 0
Months 0
12 0
and 0
24 0
, 0
ranibizumab 0
was 0
superior 0
to 0
PDT 0
( 0
P 0
< 0
0.0001 0
) 0
for 0
mean 0
changes 0
from 0
baseline 0
in 0
total B-PHYSICAL
area 0
of 0
lesion B-PHYSICAL
, 0
CNV B-PHYSICAL
area 0
, 0
and 0
total B-PHYSICAL
area 0
CNV B-PHYSICAL

Effect 0
of 0
mild 0
endurance 0
exercise 0
training 0
and 0
pravastatin 0
on 0
peripheral 0
vasodilatation 0
of 0
forearm 0
resistance 0
vessels 0
in 0
patients 0
with 0
coronary 0
artery 0
disease 0
. 0

BACKGROUND 0
Improved 0
endothelial 0
function 0
may 0
contribute 0
to 0
the 0
beneficial 0
effects 0
of 0
cholesterol 0
lowering 0
therapy 0
in 0
patients 0
with 0
coronary 0
artery 0
disease 0
( 0
CAD 0
) 0
, 0
but 0
results 0
of 0
the 0
effect 0
of 0
statin 0
therapy 0
on 0
endothelial 0
function 0
are 0
disparate 0
in 0
these 0
patients 0
. 0

Exercise 0
training 0
has 0
been 0
reported 0
to 0
improve 0
endothelial 0
function 0
of 0
patients 0
at 0
risk 0
of 0
or 0
with 0
established 0
CAD 0
. 0

The 0
goal 0
of 0
the 0
study 0
was 0
to 0
compare 0
the 0
effect 0
of 0
mild 0
exercise 0
training 0
or 0
statin 0
therapy 0
on 0
forearm 0
endothelial 0
function 0
in 0
CAD 0
patients 0
with 0
average 0
cholesterol 0
levels 0
. 0

DESIGN 0
AND 0
METHODS 0
Twenty-eight 0
sedentary 0
male 0
patients 0
with 0
angiographically 0
documented 0
CAD 0
and 0
average 0
pretreatment 0
total 0
plasma 0
cholesterol 0
levels 0
( 0
5.1+/-0.9 0
mmol/l 0
) 0
aged 0
42-75 0
years 0
were 0
included 0
. 0

They 0
were 0
randomly 0
assigned 0
in 0
a 0
2 0
: 0
1 0
order 0
to 0
either 0
statin 0
therapy 0
( 0
pravastatin 0
, 0
40 0
mg 0
daily 0
) 0
or 0
exercise 0
training 0
therapy 0
( 0
mild 0
endurance 0
exercise 0
three 0
or 0
more 0
times 0
a 0
week 0
) 0
. 0

The 0
effects 0
of 0
10 0
weeks 0
of 0
either 0
treatment 0
on 0
endothelium-dependent 0
and 0
independent 0
vasodilation 0
of 0
forearm 0
resistance 0
vessels 0
was 0
assessed 0
by 0
plethysmography 0
. 0

Cardiopulmonary 0
exercise 0
testing 0
was 0
performed 0
at 0
baseline 0
and 0
after 0
10 0
weeks 0
. 0

RESULTS 0
Ten 0
weeks 0
of 0
pravastatin 0
therapy 0
significantly 0
reduced 0
low-density B-PHYSICAL
lipoprotein I-PHYSICAL
cholesterol I-PHYSICAL
( 0
from 0
3.8+/-0.6 0
to 0
3.1+/-0.6 0
mmol/l 0
at 0
study 0
end 0
, 0
P=0.04 0
) 0
and 0
the 0
ratio 0
of 0
total 0
to 0
high-density B-PHYSICAL
lipoprotein I-PHYSICAL
cholesterol I-PHYSICAL
( 0
from 0
4.9+/-0.8 0
to 0
3.7+/-0.7 0
mmol/l 0
, 0
P=0.002 0
) 0
. 0

Exercise 0
training 0
did 0
not 0
significantly 0
modify 0
the 0
lipid B-PHYSICAL
profile I-PHYSICAL
. 0

Peak 0
oxygen B-PHYSICAL
consumption I-PHYSICAL
, 0
maximal B-PHYSICAL
achieved 0
workload B-PHYSICAL
and 0
exercise B-MENTAL
duration B-MENTAL
tended 0
to 0
improve 0
in 0
the 0
exercise 0
training 0
group 0
but 0
remained 0
unchanged 0
in 0
the 0
pravastatin-treated 0
group 0
. 0

Neither 0
10 0
weeks 0
of 0
pravastatin 0
nor 0
mild 0
endurance 0
exercise 0
training 0
improved 0

Are 0
back 0
supports 0
plus 0
education 0
more 0
effective 0
than 0
education 0
alone 0
in 0
promoting 0
recovery 0
from 0
low 0
back 0
pain 0
? 0
: 0

Results 0
from 0
a 0
randomized 0
clinical 0
trial 0
. 0

STUDY 0
DESIGN 0
Randomized 0
clinical 0
trial 0
. 0

OBJECTIVES 0
To 0
evaluate 0
the 0
effectiveness 0
of 0
a 0
back 0
support 0
plus 0
education 0
versus 0
education 0
alone 0
in 0
promoting 0
recovery 0
from 0
a 0
work-related 0
low 0
back 0
disorder 0
( 0
WR-LBD 0
) 0
while 0
simultaneously 0
considering 0
personal 0
, 0
health 0
, 0
and 0
occupational 0
factors 0
and 0
the 0
impact 0
of 0
occupational 0
factors 0
on 0
recovery 0
. 0

SUMMARY 0
OF 0
BACKGROUND 0
DATA 0
No 0
randomized 0
studies 0
of 0
active 0
industrial 0
workers 0
with 0
low 0
back 0
disorders 0
exist 0
regarding 0
the 0
effectiveness 0
of 0
back 0
supports 0
plus 0
education 0
. 0

METHODS 0
A 0
total 0
of 0
433 0
actively 0
employed 0
hourly 0
union 0
workers 0
who 0
had 0
a 0
recent 0
diagnosis 0
of 0
a 0
WR-LBD 0
: 0
1 0
) 0
those 0
who 0
wore 0
a 0
specially 0
designed 0
back 0
support 0
plus 0
received 0
education 0
on 0
back 0
health 0
; 0
and 0
2 0
) 0
those 0
who 0
received 0
education 0
on 0
back 0
health 0
only 0
. 0

Demographic 0
, 0
health 0
, 0
medical 0
, 0
and 0
occupational 0
factors 0
were 0
obtained 0
through 0
interview 0
or 0
abstraction 0
of 0
computer 0
files 0
; 0
individual 0
ergonomic 0
exposures 0
were 0
measured 0
with 0
a 0
lumbar 0
motion 0
monitor 0
. 0

Outcomes 0
evaluated 0
over 0
a 0
12-month 0
period 0
included 0
: 0
self-reported B-PAIN
measures I-PAIN
of I-PAIN
back I-PAIN
pain I-PAIN
, 0
back 0
pain 0
disability 0
level 0
, 0
physical 0
health 0
, 0
mental B-MENTAL
health I-MENTAL
, 0
and 0
administrative 0
measures 0
of 0
recurrence 0
, 0
lost 0
work 0
time 0
, 0
and 0
medical 0
care 0
utilization 0
. 0

RESULTS 0
There 0
was 0
no 0
difference 0
between 0
the 0
study 0
groups 0
with 0
respect 0
to 0
mental 0
or 0
physical 0
health 0
, 0
low B-PAIN
back I-PAIN
pain I-PAIN
, 0
back 0
pain 0
disability 0
, 0
neurogenic B-MENTAL
symptoms I-MENTAL
, 0
lost 0
work 0
time 0
, 0
likelihood 0
of B-PHYSICAL
recurrence 0
of B-PHYSICAL
an I-PHYSICAL
episode I-PHYSICAL
of I-PHYSICAL
a B-PHYSICAL
back I-PHYSICAL

Double 0
hearing 0
protection 0
and 0
speech 0
intelligibility-room 0
for 0
improvement 0
. 0

INTRODUCTION 0
Double 0
hearing 0
protection 0
is 0
used 0
in 0
many 0
air 0
forces 0
around 0
the 0
world 0
for 0
protection 0
in 0
noisy 0
aircraft 0
environments 0
, 0
particularly 0
in 0
helicopters 0
. 0

The 0
usual 0
combination 0
is 0
foam 0
ear 0
plugs 0
under 0
headset 0
or 0
helmet 0
muffs 0
. 0

Much 0
of 0
the 0
research 0
that 0
spurred 0
the 0
introduction 0
of 0
foam 0
earplugs 0
indicated 0
little 0
change 0
in 0
speech 0
intelligibility 0
in 0
persons 0
with 0
normal 0
hearing 0
. 0

However 0
, 0
aircrew 0
often 0
complain 0
about 0
having 0
to 0
maximize 0
intercom 0
volume 0
for 0
speech 0
understanding 0
, 0
causing 0
a 0
situation 0
with 0
no 0
reserve 0
volume 0
and 0
bad 0
sound 0
quality 0
. 0

In 0
recent 0
years 0
, 0
further 0
developments 0
have 0
included 0
so-called 0
hi-fi 0
plugs 0
and 0
custom 0
made 0
ear 0
plugs 0
which 0
are 0
claimed 0
to 0
improve 0
speech 0
communication 0
. 0

The 0
aim 0
of 0
the 0
present 0
project 0
was 0
to 0
investigate 0
different 0
types 0
of 0
ear 0
plugs 0
and 0
their 0
effect 0
on 0
speech 0
intelligibility 0
in 0
helicopter 0
noise 0
. 0

METHODS 0
Each 0
of 0
nine 0
normal-hearing 0
pilot 0
subjects 0
were 0
placed 0
in 0
an 0
environment 0
of 0
recorded 0
helicopter 0
noise 0
from 0
a 0
BO-105 0
helicopter 0
. 0

Speech 0
audiometry 0
was 0
performed 0
under 0
four 0
different 0
conditions 0
: 0
headset 0
only 0
, 0
and 0
three 0
different 0
ear 0
plugs 0
worn 0
under 0
the 0
headset 0
. 0

Fitting 0
of 0
the 0
ear 0
plugs 0
was 0
performed 0
by 0
an 0
ear 0
, 0
nose 0
and 0
throat 0
specialist 0
to 0
ensure 0
similar 0
conditions 0
. 0

The 0
sequence 0
of 0
test 0
conditions 0
was 0
randomized 0
and 0
double-blind 0
. 0

In 0
addition 0
, 0
a 0
subjective B-OTHER
rating I-OTHER
scale I-OTHER
was 0
used 0
. 0

RESULTS 0
Wearing 0
foam 0
ear 0
plugs 0
under 0
the 0
headset 0
decreased 0
speech B-MENTAL
intelligibility I-MENTAL
dramatically 0
. 0

The 0
hi-fi 0
plug 0
was 0
somewhat 0
better 0
than 0
foam 0
plugs 0
, 0
and 0
the 0
custom 0
made 0
ear 0
plug 0
provided 0
a 0
speech B-MENTAL
intelligibility I-MENTAL
close 0
to 0
the 0
headset-only 0
situation 0
. 0

Subjective B-OTHER
rating I-OTHER
scores I-OTHER
coincided 0
with 0
these 0
findings 0
. 0

DISCUSSION 0
In 0
helicopter 0
noise 0
, 0
custom 0
made 0
ear 0
plugs 0
may 0
provide 0
a 0
much 0
improved 0
speech B-MENTAL
intelligibility I-MENTAL
over 0
conventional 0
plugs 0
when 0
worn 0
under 0
a 0
headset 0
, 0
while 0
maintaining 0
improved 0
noise 0
protection B-MENTAL
over 0
the 0
headset-alone 0
situation 0
. 0

Custom 0
made 0
ear 0
plugs 0
might 0
therefore 0
be 0
a 0
good 0
alternative 0
to 0
other 0
forms 0
of 0
enhanced B-OTHER
noise 0

Does 0
tetanus 0
immune 0
globulin 0
interfere 0
with 0
the 0
immune B-PHYSICAL
response I-PHYSICAL
to 0
simultaneous 0
administration 0
of 0
tetanus-diphtheria 0
vaccine 0
? 0

A 0
comparative 0
clinical 0
trial 0
in 0
adults 0
. 0

In 0
the 0
management 0
of 0
wounds 0
, 0
sometimes 0
it 0
is 0
recommended 0
to 0
give 0
an 0
adult-type 0
tetanus-diphtheria 0
( 0
Td 0
) 0
vaccine 0
dose 0
plus 0
tetanus 0
immune 0
globulin 0
( 0
TIG 0
) 0
. 0

Sixty 0
and 0
59 0
healthy 0
young 0
adults 0
previously 0
immunized 0
against 0
tetanus 0
( 0
T 0
) 0
and 0
diphtheria 0
( 0
D 0
) 0
were 0
randomized 0
to 0
receive 0
intramuscularly 0
either 0
Td 0
vaccine 0
alone 0
( 0
group 0
1 0
) 0
or 0
Td 0
vaccine 0
plus 0
500 0
IU 0
of 0
TIG 0
( 0
group 0
2 0
) 0
simultaneously 0
. 0

Antitoxin B-PHYSICAL
response I-PHYSICAL
was 0
assessed 0
after 0
4 0
weeks 0
and 0
4 0
months 0
. 0

Circulating B-PHYSICAL
antibodies I-PHYSICAL
were I-PHYSICAL
measured I-PHYSICAL
by I-PHYSICAL
enzyme-linked I-PHYSICAL
immunosorbent I-PHYSICAL
assay 0
( 0
ELISA B-PHYSICAL
) 0
. 0

The 0
cutoff 0
of 0
these 0
tests 0
was 0
0.1 0
IU/mL 0
. 0

Titers 0
of 0
0.1 0
IU/mL 0
or 0
greater 0
were 0
considered 0
protective 0
. 0

For 0
geometric 0
mean 0
titers 0
( 0
GMT 0
) 0
, 0
antibody B-PHYSICAL
titers I-PHYSICAL
below 0
the 0
cutoff 0
of 0
the 0
assay 0
were 0
given 0
, 0
arbitrarily 0
, 0
0.05 0
IU/mL 0
. 0

At 0
4 0
weeks 0
, 0
98 0
% 0
or 0
more 0
of 0
the 0
subjects 0
in 0
group 0
1 0
had 0
circulating B-PHYSICAL
T I-PHYSICAL
and B-PHYSICAL
D I-PHYSICAL

Pre-treatment 0
proliferation 0
and 0
the 0
outcome 0
of 0
conventional 0
and 0
accelerated 0
radiotherapy 0
. 0

This 0
study 0
investigated 0
the 0
influence 0
of 0
pre-treatment 0
proliferation 0
characteristics 0
, 0
assessed 0
by 0
Ki-67 0
staining 0
, 0
in 0
patients 0
treated 0
in 0
the 0
CHART 0
trial 0
of 0
accelerated 0
radiotherapy 0
in 0
head 0
and 0
neck 0
cancer 0
. 0

Histological 0
material 0
from 0
402 0
patients 0
was 0
collected 0
and 0
stained 0
for 0
the 0
presence 0
and 0
pattern 0
of 0
Ki-67 0
staining 0
. 0

Locoregional B-PHYSICAL
control I-PHYSICAL
and 0
overall 0
survival 0
were 0
the 0
main 0
clinical 0
endpoints 0
. 0

Increasing 0
Ki-67 0
positivity 0
was 0
associated 0
with 0
decreasing 0
differentiation 0
( 0
P 0
< 0
0.001 0
) 0
and 0
increasing 0
N-stage 0
( 0
P 0
< 0
0.004 0
) 0
. 0

Increasing 0
N-stage 0
was 0
also 0
associated 0
with 0
the 0
progression 0
of 0
proliferation 0
pattern 0
from 0
marginal 0
to 0
random 0
( 0
P 0
< 0
0.001 0
) 0
. 0

Using 0
a 0
multivariate 0
model 0
, 0
a 0
trend 0
was 0
seen 0
towards 0
a 0
greater 0
benefit 0
from 0
CHART 0
in 0
the 0
lower 0
Ki-67 0
tumours 0
( 0
P 0
= 0
0.08 0
) 0
; 0
this 0
became 0
significant 0
by 0
pooling 0
the 0
low 0
and 0
intermediate 0
Ki-67 0
groups 0
in 0
comparison 0
with 0
the 0
high 0
Ki-67 0
group 0
( 0
P 0
= 0
0.032 0
) 0
. 0

Tumours 0
with 0
marginal 0
proliferation 0
pattern 0
showed 0
a 0
lower 0
hazard 0
ratio 0
with 0
CHART 0
versus 0
conventional 0
for 0
locoregional 0
control 0
( 0
P 0
= 0
0.005 0
) 0
. 0

The 0
data 0
presented 0
in 0
this 0
study 0
do 0
not 0
support 0
that 0
a 0
high 0
pre-treatment 0
Ki-67 0
is 0
associated 0
with 0
a 0
therapeutic B-OTHER
benefit I-OTHER
from 0
accelerated 0
radiotherapy 0
. 0

Comparison 0
of 0
sedative 0
drugs 0
under 0
peribulbar 0
or 0
topical 0
anesthesia 0
during 0
phacoemulsification 0
. 0

BACKGROUND 0
AND 0
OBJECTIVE 0
To 0
compare 0
dexmedetomidine 0
and 0
midazolam+fentanyl 0
sedation 0
primarily 0
based 0
on 0
patient 0
satisfaction 0
during 0
phacoemulsification 0
under 0
topical 0
and 0
peribulbar 0
anesthesia 0
. 0

PATIENTS 0
AND 0
METHODS 0
Prospective 0
, 0
randomized 0
, 0
and 0
double-blind 0
study 0
of 0
80 0
American 0
Society 0
of 0
Anesthesiology 0
grade 0
I-II 0
patients 0
who 0
underwent 0
phacoemulsification 0
with 0
local 0
anesthesia 0
under 0
sedation 0
. 0

Patients 0
were 0
divided 0
into 0
four 0
groups 0
( 0
20 0
patients 0
for 0
each 0
) 0
: 0
dexmedetomidine 0
and 0
topical 0
anesthesia 0
, 0
dexmedetomidine 0
and 0
peribulbar 0
anesthesia 0
, 0
midazolam+fentanyl 0
and 0
topical 0
anesthesia 0
, 0
and 0
midazolam+fentanyl 0
and 0
peribulbar 0
anesthesia 0
. 0

Patient 0
and 0
surgeon 0
satisfaction 0
were 0
determined 0
on 0
a 0
5-point 0
scale 0
. 0

The 0
pain 0
was 0
determined 0
by 0
verbal 0
pain 0
scale 0
intraoperatively 0
and 0
postoperatively 0
. 0

Drugs 0
were 0
given 0
to 0
a 0
Ramsay 0
sedation 0
scale 0
of 0
3 0
. 0

Topical 0
and 0
peribulbar 0
anesthesia 0
were 0
performed 0
by 0
an 0
ophthalmologist 0
. 0

Hemodynamic 0
, 0
respiratory 0
, 0
and 0
intraocular 0
pressure 0
monitoring 0
was 0
done 0
. 0

Operative 0
and 0
recovery 0
times 0
were 0
recorded 0
. 0

RESULTS 0
In 0
the 0
midazolam+fentanyl 0
groups 0
, 0
better 0
patient B-OTHER
and I-OTHER
surgeon I-OTHER
satisfaction I-OTHER
scores 0
were 0
obtained 0
( 0
P 0
< 0
.005 0
) 0
, 0
verbal B-PAIN
pain I-PAIN
scale I-PAIN
scores 0
were 0
significantly 0
lower 0
( 0
P 0
< 0
.001 0
) 0
, 0
and 0
patients 0
needed 0
less 0
postoperative B-OTHER
analgesia I-OTHER
. 0

Ramsay B-OTHER
sedation I-OTHER
scale I-OTHER
scores 0
were 0
between 0
3 0
and 0
4 0
in 0
all 0
patients 0
and 0
there 0
were 0
no 0
significant 0
differences 0
. 0

Intraocular B-PHYSICAL
pressure I-PHYSICAL
alterations I-PHYSICAL
were 0
similar 0
between 0
groups 0
. 0

Recovery B-OTHER
time I-OTHER
was 0
longer 0
in 0
the 0
dexmedetomidine 0
groups 0
( 0
P 0
< 0
.05 0
) 0
. 0

CONCLUSION 0
The 0
study 0
demonstrated 0
that 0
the 0
midazolam+fentanyl 0
combination 0
provided 0
high-level 0
patient B-OTHER
satisfaction I-OTHER
scores I-OTHER
, 0
low-level 0
pain B-PAIN
scores I-PAIN
, 0
and 0
shorter 0
recovery B-OTHER
time I-OTHER
. 0

Also 0
, 0
both 0
of 0
the 0
peribulbar 0
and 0
topical 0
anesthesia 0
procedures 0
showed 0
similar 0
efficiency 0
. 0

[ 0
Administration 0
of 0
tobramycin 0
aerosols 0
in 0
patients 0
with 0
nosocomial 0
pneumonia 0
: 0
a 0
preliminary 0
study 0
] 0
. 0

OBJECTIVE 0
The 0
aim 0
of 0
this 0
study 0
was 0
to 0
assess 0
renal B-PHYSICAL
and I-PHYSICAL
respiratory I-PHYSICAL
tolerance I-PHYSICAL
of 0
aerosolized 0
tobramycin 0
in 0
intubated 0
and 0
mechanically 0
ventilated 0
patients 0
with 0
nosocomial 0
pneumonia 0
. 0

PATIENTS 0
AND 0
METHODS 0
This 0
was 0
a 0
multicenter 0
, 0
randomized 0
, 0
double-blind 0
, 0
placebo 0
controlled 0
study 0
. 0

Thirty-eight 0
mechanically 0
ventilated 0
patients 0
with 0
documented 0
nosocomial 0
pneumonia 0
were 0
included 0
. 0

Patients 0
treated 0
with 0
intravenous 0
betalactam 0
and 0
tobramycin 0
were 0
randomly 0
allocated 0
to 0
receive 0
aerosolized 0
tobramycin 0
( 0
6 0
mg/kg/day 0
, 0
n 0
= 0
21 0
) 0
or 0
placebo 0
( 0
n 0
= 0
17 0
) 0
. 0

The 0
aerosol 0
was 0
administered 0
via 0
a 0
pneumatic 0
nebulizer 0
once 0
a 0
day 0
for 0
5 0
days 0
. 0

RESULTS 0
Respiratory B-PHYSICAL
tolerance I-PHYSICAL
was 0
good 0
in 0
all 0
but 0
two 0
patients 0
. 0

No 0
acute B-PHYSICAL
renal I-PHYSICAL
failure I-PHYSICAL
occurred 0
. 0

By 0
day 0
10 0
, 0
7 0
patients 0
in 0
the 0
tobramycin 0
group 0
( 0
35 0
% 0
) 0
had 0
been 0
extubated B-PHYSICAL
versus 0
3 0
in 0
the 0
placebo 0
group 0
( 0
18.5 0
% 0
, 0
p 0
= 0
0.18 0
) 0
. 0

By 0
day 0
28 0
, 0
6 0
patients 0
had 0
died B-MORTALITY
( 0
2 0
in 0
the 0
tobramycin 0
group 0
and 0
4 0
in 0
the 0
placebo 0
group 0
, 0
p 0
= 0
0.23 0
) 0
. 0

CONCLUSION 0
Aerosolized 0
tobramycin 0
was 0
well 0
tolerated 0
in 0
ventilated 0
patients 0
with 0
documented 0
nosocomial 0
pneumonia 0
. 0

[ 0
Cardiac 0
protection 0
is 0
a 0
clinical 0
evidence 0
] 0
. 0

AIM 0
Anaesthetics 0
may 0
have 0
protective 0
effect 0
against 0
myocardial 0
ischemia 0
. 0

We 0
aimed 0
to 0
investigate 0
if 0
sevoflurane 0
administration 0
could 0
exert 0
myocardial B-PHYSICAL
protection I-PHYSICAL
during 0
following 0
coronary 0
occlusion 0
in 0
patients 0
with 0
coronary 0
artery 0
disease 0
. 0

METHODS 0
a 0
) 0
. 0

EXPERIMENTAL 0
DESIGN 0
prospective 0
, 0
randomized 0
study 0
. 0

b 0
) 0
. 0

SETTING 0
University 0
Hospital 0
, 0
cardiac 0
surgical 0
operative 0
theatre 0
. 0

c 0
) 0
. 0

PATIENTS 0
42 0
patients 0
with 0
coronary 0
artery 0
disease 0
, 0
scheduled 0
to 0
undergo 0
coronary 0
surgery 0
. 0

INCLUSION 0
CRITERIA 0
severe 0
coronary 0
stenosis 0
of 0
anterior 0
descending 0
coronary 0
artery 0
; 0
no 0
collateral 0
flow 0
on 0
angiography 0
; 0
at 0
least 0
two 0
normokinetic 0
segments 0
in 0
the 0
myocardial 0
region 0
supplied 0
by 0
the 0
vessel 0
being 0
bypassed 0
. 0

PATIENTS 0
were 0
randomized 0
to 0
receive 0
( 0
group 0
S 0
) 0
or 0
not 0
( 0
group 0
C 0
) 0
sevoflurane 0
administration 0
for 0
15 0
min 0
just 0
before 0
coronary 0
occlusion 0
. 0

d 0
) 0
. 0

INTERVENTIONS 0
Transoesophageal 0
Tissue 0
Doppler 0
echocardiographic 0
examination 0
of 0
myocardial 0
systolic 0
and 0
early 0
diastolic 0
velocities 0
in 0
both 0
groups 0
basally 0
and 0
60 0
s 0
after 0
coronary 0
occlusion 0
by 0
the 0
surgeon 0
. 0

e 0
) 0
. 0

MEASURES 0
systolic B-PHYSICAL
and I-PHYSICAL
early I-PHYSICAL
diastolic I-PHYSICAL
velocities I-PHYSICAL
were 0
registered 0
by 0
Tissue 0
Doppler 0
from 0
a 0
long-axis 0
view 0
of 0
the 0
interventricular 0
septum 0
or 0
the 0
anterior 0
wall 0
of 0
the 0
left 0
ventricle 0
. 0

RESULTS 0
In 0
group 0
C 0
a 0
significant 0
reduction 0
of 0
systolic B-PHYSICAL
and I-PHYSICAL
diastolic I-PHYSICAL
intramyocardial I-PHYSICAL
velocities I-PHYSICAL
was 0
found 0
during 0
myocardial 0
ischemia 0
due 0
to 0
coronary 0
occlusion 0
. 0

CONCLUSION 0
Treatment 0
with 0
sevoflurane 0
before 0
coronary 0
occlusion 0
seem 0
effective 0
in 0
reducing 0
functional B-PHYSICAL
myocardial I-PHYSICAL
impairment I-PHYSICAL
due 0
to 0
ischemia 0
. 0

Modified 0
constraint-induced 0
movement 0
therapy 0
improved 0
upper 0
limb 0
function 0
in 0
subacute 0
poststroke 0
patients 0
: 0
a 0
small-scale 0
clinical 0
trial 0
. 0

BACKGROUND 0
Constraint-induced 0
movement 0
therapy 0
( 0
CIMT 0
) 0
has 0
been 0
advocated 0
as 0
a 0
means 0
of 0
facilitating 0
motor 0
function 0
in 0
poststroke 0
patients 0
; 0
however 0
, 0
the 0
evidence 0
for 0
its 0
efficacy 0
is 0
controversial 0
. 0

OBJECTIVE 0
To 0
evaluate 0
the 0
effect 0
of 0
modified 0
CIMT 0
on 0
improving 0
paretic 0
arm 0
function 0
in 0
poststroke 0
patients 0
during 0
a 0
subacute 0
rehabilitation 0
period 0
. 0

METHODS 0
A 0
single-blinded 0
randomized 0
controlled 0
trial 0
was 0
conducted 0
at 0
the 0
Loewenstein 0
Rehabilitation 0
Hospital 0
, 0
Israel 0
. 0

Twenty-eight 0
subacute 0
stroke 0
patients 0
with 0
arm 0
paresis 0
after 0
a 0
first 0
ischemic 0
stroke 0
in 0
the 0
middle 0
cerebral 0
artery 0
area 0
were 0
randomized 0
into 0
a 0
modified 0
CIMT 0
or 0
control 0
group 0
by 0
a 0
1:2 0
ratio 0
. 0

The 0
modified 0
CIMT 0
group 0
received 0
1-hour 0
daily 0
physical 0
rehabilitation 0
sessions 0
for 0
2 0
weeks 0
. 0

The 0
unaffected 0
arm 0
was 0
restrained 0
during 0
the 0
sessions 0
. 0

Subjects 0
were 0
encouraged 0
to 0
wear 0
a 0
restrictive 0
mitten 0
up 0
to 0
4 0
hours 0
a 0
day 0
. 0

The 0
control 0
group 0
received 0
similar 0
intensive 0
regular 0
rehabilitation 0
. 0

Three 0
upper 0
limb 0
function 0
tests 0
, 0
developed 0
for 0
this 0
study 0
, 0
were 0
used 0
as 0
outcome 0
measures 0
. 0

The 0
subjects 0
were 0
asked 0
to 0
perform 0
the 0
following 0
tasks 0
, 0
with 0
the 0
affected 0
hand 0
for 0
30 0
seconds 0
: 0
( 0
1 0
) 0
transfer 0
pegs 0
from 0
a 0
saucer 0
to 0
a 0
pegboard 0
; 0
( 0
2 0
) 0
grasp 0
, 0
carry 0
, 0
and 0
release 0
a 0
hard 0
rubber 0
ball 0
; 0
and 0
( 0
3 0
) 0
eating 0
, 0
using 0
a 0
spoon 0
to 0
remove 0
the 0
jelly 0
from 0
the 0
plate 0
, 0
bring 0
it 0
towards 0
the 0
mouth 0
, 0
and 0
then 0
place 0
it 0
on 0
another 0
plate 0
. 0

The 0
number B-OTHER
of I-OTHER
repetitions I-OTHER
in I-OTHER
each I-OTHER
test I-OTHER
was 0
recorded 0
as 0
an 0
outcome 0
. 0

RESULTS 0
The 0
modified 0
CIMT 0
group 0
showed 0
significantly 0
higher 0
changes 0
in 0
all 0
3 0
tests 0
compared 0
to 0
the 0
standard 0
rehabilitation 0
group 0
. 0

CONCLUSION 0
Our 0
study 0
provides 0
additional 0
support 0
for 0
the 0
use 0
of 0
modified 0
CIMT 0
during 0
a 0
subacute 0
rehabilitation 0
period 0
of 0
poststroke 0
patients 0
. 0

CIMT 0
may 0
facilitate 0
functional 0
improvement 0
of 0
a 0
plegic 0
hand 0
. 0

[ 0
A 0
multicenter 0
, 0
randomized 0
clinical 0
trial 0
of 0
intravenous 0
diltiazem 0
in 0
treatment 0
of 0
unstable 0
angina 0
] 0
. 0

OBJECTIVE 0
To 0
investigate 0
the 0
clinical 0
efficacy 0
and 0
safety 0
of 0
intravenous 0
diltiazem 0
compared 0
with 0
nitroglycerin 0
in 0
the 0
patients 0
with 0
unstable 0
angina 0
pectoris 0
. 0

METHODS 0
A 0
multicenter 0
, 0
randomized 0
, 0
open-label 0
, 0
parallel 0
group 0
trial 0
was 0
conducted 0
. 0

A 0
total 0
of 0
213 0
eligible 0
patients 0
were 0
enrolled 0
. 0

They 0
were 0
randomized 0
either 0
to 0
diltiazem 0
or 0
nitroglycerin 0
treatment 0
. 0

The 0
diltiazem 0
was 0
administered 0
from 0
100 0
microg/min 0
at 0
the 0
initiation 0
of 0
treatment 0
, 0
the 0
largest 0
dosage 0
was 0
200 0
- 0
300 0
microg/min 0
; 0
the 0
nitroglycerin 0
was 0
administered 0
from 0
20 0
microg/min 0
at 0
the 0
initiation 0
of 0
treatment 0
. 0

The 0
largest 0
dosage 0
was 0
80 0
- 0
100 0
microg/min 0
. 0

Intravenous 0
infusion 0
was 0
kept 0
over 0
48 0
hours 0
. 0

The 0
endpoints 0
included 0
refractory B-PHYSICAL
angina I-PHYSICAL
pectoris I-PHYSICAL
, 0
acute B-PHYSICAL
myocardial I-PHYSICAL
infarction I-PHYSICAL
, 0
death B-MORTALITY
, 0
emergency B-PHYSICAL
PTCA I-PHYSICAL
and 0
CABG B-PHYSICAL
. 0

RESULTS 0
( 0
1 0
) 0
Intravenous 0
diltiazem 0
was 0
effective 0
on 0
the 0
improvement 0
of 0
symptom B-PHYSICAL
and 0
electrocardiogram B-PHYSICAL
, 0
and 0
its 0
effects 0
were 0
similar 0
to 0
intravenous 0
nitroglycerin 0
. 0
( 0

2 0
) 0
Compared 0
with 0
nitroglycerin 0
, 0
intravenous 0
diltiazem 0
lowered B-PHYSICAL
heart I-PHYSICAL
rate I-PHYSICAL
and 0
myocardial B-OTHER
oxygen I-OTHER
consumption I-OTHER
index I-OTHER
( 0
systolic 0
pressure 0
x 0
heart 0
rate 0
) 0
to 0
more 0
extent 0
significantly 0
. 0
( 0

3 0
) 0
After 0
treatment 0
, 0
the 0
onsets 0
of 0
refractory B-PHYSICAL
angina I-PHYSICAL
pectoris I-PHYSICAL
were 0
reduced B-OTHER
more I-OTHER
significantly I-OTHER
in 0
the 0
diltiazem 0
group 0
than 0
in 0
nitroglycerin 0
group 0
[ 0
4 0
( 0
3.8 0
% 0
) 0
vs 0
13 0
( 0
11.9 0
% 0
) 0
, 0
RR 0
0.32 0
( 0
95 0
% 0
CI 0
0.11 0
- 0
0.96 0
) 0
, 0
P 0
< 0
0.05 0
] 0
. 0
( 0

4 0
) 0
The 0
patients 0
whose 0
heart B-PHYSICAL
rate I-PHYSICAL
were 0
reduced B-OTHER
significantly I-OTHER
( 0
< 0
or= 0
50 0
beats 0
per 0
minute 0
) 0
in 0
the 0
diltiazem 0
group 0
were 0
more 0
than 0
in 0
the 0
nitroglycerin 0
group 0
[ 0
8 0
( 0
7.7 0
% 0
) 0
vs 0
0 0
( 0
0 0
% 0
) 0
, 0
P 0
< 0
0.01 0
] 0
. 0

But 0
these 0
patients 0
could 0
tolerate 0
the 0
lower 0
heart B-PHYSICAL
rate I-PHYSICAL
very 0
well 0
in 0
the 0
diltiazem 0
group 0
. 0
( 0

5 0
) 0
The 0
needs 0
of 0
beta 0
receptor 0
blocker 0
or 0
calcium 0
antagonists 0
were 0
reduced 0
more 0
significantly 0
in 0
the 0
diltiazem 0
group 0
compared 0
with 0
those 0
in 0
the 0
nitroglycerin 0
group 0
[ 0
2 0
( 0
1.9 0
% 0
) 0
vs 0
13 0
( 0
11.9 0
% 0
) 0
, 0
P 0
< 0
0.01 0
] 0
. 0

CONCLUSION 0
Intravenous 0
diltiazem 0
therapy 0
is 0
effective 0
and 0
safe 0
for 0
patients 0
with 0
unstable 0
angina 0
pectoris 0
. 0

It 0
may 0
significantly 0
lower 0
the 0
risk 0
of 0
refractory 0
angina 0
pectoris 0
compared 0
with 0
intravenous 0
nitroglycerin 0
. 0

Is 0
psychotherapy 0
more 0
effective 0
when 0
therapists 0
disclose 0
information 0
about 0
themselves 0
? 0

Theorists 0
have 0
long 0
debated 0
the 0
wisdom 0
of 0
therapists 0
disclosing B-OTHER
personal I-OTHER
information I-OTHER
during 0
psychotherapy 0
. 0

Some 0
observers 0
have 0
argued 0
that 0
such 0
therapist 0
self-disclosure 0
impedes 0
treatment 0
, 0
whereas 0
others 0
have 0
suggested 0
that 0
it 0
enhances 0
the 0
effectiveness 0
of 0
therapy B-OTHER
. 0

To 0
test 0
these 0
competing 0
positions 0
, 0
therapists 0
at 0
a 0
university 0
counseling 0
center 0
were 0
instructed 0
to 0
increase 0
the 0
number 0
of 0
self-disclosures 0
they 0
made 0
during 0
treatment 0
of 0
one 0
client 0
and 0
refrain 0
from 0
making 0
self-disclosures 0
during 0
treatment 0
of 0
another 0
client 0
. 0

Analyses 0
revealed 0
that 0
clients 0
receiving 0
psychotherapy 0
under 0
conditions 0
of 0
heightened 0
therapist 0
disclosure 0
not 0
only 0
reported 0
lower 0
levels 0
of 0
symptom 0
distress 0
but 0
also 0
liked B-OTHER
their I-OTHER
therapist I-OTHER
more 0
. 0

Such 0
findings 0
suggest 0
that 0
self-disclosure 0
by 0
the 0
therapist 0
may 0
improve 0
both 0
the 0
quality 0
of 0
the 0
therapeutic B-OTHER
relationship I-OTHER
and 0
the 0
outcome 0
of 0
treatment B-MENTAL
. 0

Treatment 0
of 0
acute 0
asthma 0
. 0

Lack 0
of 0
therapeutic B-PHYSICAL
benefit I-PHYSICAL
and 0
increase 0
of 0
the 0
toxicity B-ADVERSE-EFFECTS
from 0
aminophylline 0
given 0
in 0
addition 0
to 0
high 0
doses 0
of 0
salbutamol 0
delivered 0
by 0
metered-dose 0
inhaler 0
with 0
a 0
spacer 0
. 0

We 0
conducted 0
a 0
randomized 0
, 0
double-blind 0
, 0
placebo-controlled 0
study 0
to 0
determine 0
if 0
intravenous 0
aminophylline 0
adds 0
any 0
benefit 0
to 0
high 0
doses 0
of 0
inhaled 0
salbutamol 0
in 0
patients 0
who 0
presented 0
for 0
treatment 0
of 0
acute 0
asthma 0
. 0

We 0
studied 0
94 0
patients 0
( 0
mean 0
age 0
, 0
35.6 0
+/- 0
11.2 0
years 0
) 0
with 0
moderate 0
to 0
severe 0
acute 0
asthma 0
. 0

All 0
patients 0
received 0
therapy 0
with 0
salbutamol 0
delivered 0
with 0
metered-dose 0
inhaler 0
( 0
MDI 0
) 0
into 0
a 0
spacer 0
device 0
( 0
Volumatic 0
) 0
in 0
four 0
puffs 0
( 0
400 0
micrograms 0
) 0
at 0
10-min 0
interval 0
, 0
and 0
intravenous 0
hydrocortisone 0
( 0
500 0
mg 0
) 0
. 0

Patients 0
were 0
randomly 0
assigned 0
to 0
receive 0
either 0
a 0
loading 0
dose 0
of 0
intravenous 0
aminophylline 0
followed 0
by 0
a 0
routine 0
infusion 0
( 0
n 0
= 0
45 0
) 0
or 0
an 0
equal 0
volume 0
of 0
placebo 0
as 0
a 0
loading 0
dose 0
and 0
infusion 0
( 0
n 0
= 0
49 0
) 0
. 0

The 0
two 0
groups 0
showed 0
no 0
differences 0
in 0
measurements 0
of 0
peak 0
expiratory B-PHYSICAL
flow I-PHYSICAL
, 0
FEV1 B-PHYSICAL
, 0
and 0
FVC B-PHYSICAL
at 0
baseline 0
and 0
at 0
the 0
end 0
of 0
treatment 0
. 0

However 0
, 0
the 0
patients 0
treated 0
with 0
aminophylline 0
had 0
significantly 0
more 0
adverse B-ADVERSE-EFFECTS
effects I-ADVERSE-EFFECTS
( 0
p 0
< 0
0.05 0
) 0
. 0

There 0
were 0
no 0
differences 0
in 0
the 0
final 0
mean 0
dose 0
of 0
salbutamol 0
( 0
6.3 0
+/- 0
44.5 0
mg 0
for 0
the 0
placebo 0
group 0
and 0
5.8 0
+/- 0
4.2 0
mg 0
for 0
the 0
aminophylline 0
group 0
) 0
, 0
hospital 0
admission 0
rate 0
( 0
10.2 0
percent 0
for 0
the 0
placebo 0
group 0
and 0
9.0 0
percent 0
for 0
the 0
aminophylline 0
group 0
) 0
, 0
and 0
mean 0
duration 0
of 0
Emergency 0
Department 0
treatment 0
( 0
2.5 0
+/- 0
1.83 0
h 0
for 0
the 0
placebo 0
group 0
and 0
2.37 0
+/- 0
1.75 0
h 0
for 0
the 0
aminophylline 0
group 0
) 0
. 0

The 0
results 0
were 0
similar 0
when 0
the 0
patients 0
were 0
divided 0
in 0
accord 0
with 0
the 0
degree 0
of 0
respiratory B-PHYSICAL
obstruction I-PHYSICAL
( 0
baseline 0
FEV1 0
< 0
30 0
percent 0
of 0
predicted 0
) 0
and 0
theophylline B-PHYSICAL
level I-PHYSICAL
at 0
30 0
min 0
of 0
treatment 0
( 0
placebo 0
group 0
patients 0
with 0
theophylline 0
level 0
< 0
10 0
mg/L 0
vs 0
aminophylline 0
group 0
patients 0
with 0
theophylline 0
level 0
> 0
or 0
= 0
10 0
mg/L 0
) 0
. 0

We 0
conclude 0
that 0
intravenous 0
aminophylline 0
adds 0
to 0
the 0
toxicity B-ADVERSE-EFFECTS
but 0
not 0
the 0
efficacy 0
of 0
inhaled 0
salbutamol 0
in 0
the 0
treatment 0
of 0
acute 0
exacerbations 0
of 0
asthma 0
. 0

There 0
are 0
some 0
benefits 0
for 0
eradicating 0
Helicobacter 0
pylori 0
in 0
patients 0
with 0
non-ulcer 0
dyspepsia 0
. 0

BACKGROUND 0
The 0
relationship 0
between 0
Helicobacter 0
pylori 0
infection 0
and 0
non-ulcer 0
dyspepsia 0
is 0
not 0
established 0
. 0

AIM 0
To 0
determine 0
whether 0
eradication 0
of 0
H. 0
pylori 0
might 0
be 0
of 0
benefit 0
in 0
non-ulcer 0
dyspepsia 0
patients 0
. 0

METHODS 0
We 0
randomly 0
assigned 0
129 0
H. 0
pylori 0
infected 0
patients 0
with 0
severe 0
epigastric 0
pain 0
, 0
without 0
gastro-oesophageal 0
reflux 0
symptoms 0
, 0
to 0
receive 0
twice 0
daily 0
treatment 0
with 0
300 0
mg 0
of 0
ranitidine 0
, 0
1000 0
mg 0
of 0
amoxicillin 0
, 0
and 0
500 0
mg 0
of 0
clarithromycin 0
for 0
7 0
days 0
and 0
124 0
such 0
patients 0
to 0
receive 0
identical-appearing 0
placebos 0
. 0

RESULTS 0
Treatment 0
was 0
successful 0
( 0
decrease 0
of 0
symptoms 0
at 0
12 0
months 0
) 0
in 0
62 0
% 0
of 0
patients 0
in 0
the 0
active-treatment 0
group 0
and 0
in 0
60 0
% 0
of 0
the 0
placebo 0
group 0
( 0
N.S. 0
) 0
. 0

At 0
12 0
months 0
, 0
the 0
rate 0
of B-PHYSICAL
eradication I-PHYSICAL
of I-PHYSICAL
H. 0
pylori B-PHYSICAL
was 0
69 0
% 0
in 0
the 0
active-treatment 0
group 0
and 0
18 0
% 0
in 0
the 0
placebo 0
group 0
( 0
P 0
< 0
0.001 0
) 0
. 0

Complete B-OTHER
relief I-OTHER

A 0
comparison 0
of 0
a 0
short 0
nurse-based 0
and 0
a 0
long 0
multidisciplinary 0
version 0
of 0
structured 0
patient 0
education 0
in 0
irritable 0
bowel 0
syndrome 0
. 0

OBJECTIVE 0
Structured 0
multidisciplinary 0
patient 0
group 0
education 0
has 0
positive 0
effects 0
on 0
symptoms 0
, 0
health-related 0
quality 0
of 0
life 0
, 0
and 0
disease-related 0
knowledge 0
in 0
patients 0
with 0
irritable 0
bowel 0
syndrome 0
( 0
IBS 0
) 0
, 0
but 0
few 0
studies 0
comparing 0
different 0
forms 0
of 0
educational 0
interventions 0
are 0
available 0
. 0

Our 0
aim 0
was 0
to 0
compare 0
the 0
effects 0
of 0
long 0
multidisciplinary 0
group 0
education 0
with 0
a 0
short 0
nurse-based 0
group 0
education 0
with 0
regard 0
to 0
symptoms 0
, 0
knowledge 0
, 0
quality 0
of 0
life 0
, 0
and 0
satisfaction 0
with 0
the 0
intervention 0
in 0
IBS 0
patients 0
. 0

METHODS 0
Patients 0
with 0
IBS 0
according 0
to 0
the 0
Rome 0
II 0
criteria 0
were 0
randomized 0
to 0
either 0
short 0
nurse-based 0
or 0
a 0
long 0
multidisciplinary-based 0
education 0
. 0

The 0
effects 0
were 0
evaluated 0
by 0
self-administered 0
questionnaires 0
at 0
3 0
, 0
6 0
, 0
and 0
12 0
months 0
after 0
baseline 0
, 0
and 0
compared 0
between 0
the 0
groups 0
. 0

RESULTS 0
No 0
differences 0
in 0
effects 0
were 0
detected 0
in 0
the 0
between-group 0
comparisons 0
at 0
any 0
of 0
the 0
follow-up 0
assessments 0
. 0

However 0
, 0
positive 0
effects 0
on 0
symptoms B-PHYSICAL
, 0
knowledge B-MENTAL
, 0
quality 0
of 0
life 0
, 0
and 0
satisfaction B-OTHER
with 0
the 0
intervention 0
were 0
found 0
in 0
both 0
the 0
short 0
and 0
the 0
long 0
version 0
. 0

CONCLUSION 0
A 0
short 0
, 0
nurse-based 0
educational 0
intervention 0
seems 0
to 0
be 0
as 0
efficacious 0
as 0
a 0
longer 0
multidisciplinary 0
version 0
. 0

In 0
both 0
groups 0
, 0
positive 0
effects 0
on 0
patients 0
' 0
well-being 0
were 0
found 0
to 0
a 0
similar 0
extent 0
. 0

This 0
is 0
an 0
important 0
finding 0
that 0
, 0
from 0
a 0
cost-effective 0
perspective 0
, 0
could 0
contribute 0
toward 0
an 0
optimized 0
management 0
of 0
patients 0
with 0
IBS 0
. 0

Effect 0
of 0
motivational 0
music 0
on 0
lactate B-PHYSICAL
levels I-PHYSICAL
during 0
recovery 0
from 0
intense 0
exercise 0
. 0

The 0
effects 0
of 0
music 0
played 0
during 0
an 0
exercise 0
task 0
on 0
athletic 0
performance 0
have 0
been 0
previously 0
studied 0
. 0

Yet 0
, 0
these 0
results 0
are 0
not 0
applicable 0
for 0
competitive 0
athletes 0
, 0
who 0
can 0
use 0
music 0
only 0
during 0
warm-up 0
or 0
recovery 0
from 0
exercise 0
. 0

Therefore 0
, 0
the 0
aim 0
of 0
this 0
study 0
was 0
to 0
determine 0
the 0
effect 0
of 0
motivational 0
music 0
( 0
music 0
that 0
stimulates 0
or 0
inspires 0
physical 0
activity 0
) 0
during 0
recovery 0
from 0
intense B-PHYSICAL
exercise I-PHYSICAL
, 0
on 0
activity B-PHYSICAL
pattern I-PHYSICAL
, 0
rate 0
of 0
perceived B-PHYSICAL
exertion I-PHYSICAL
( 0
RPE B-PHYSICAL
) 0
, 0
and 0
blood B-PHYSICAL
lactate I-PHYSICAL
concentration 0
. 0

Twenty 0
young 0
, 0
active 0
men 0
( 0
mean 0
age 0
26.2 0
? 0

2.1 0
years 0
) 0
performed 0
a 0
6-minute 0
run 0
at 0
peak 0
oxygen 0
consumption 0
speed 0
( 0
predetermined 0
from 0
the 0
VO 0
( 0
2 0
) 0
max 0
test 0
) 0
. 0

The 0
mean 0
heart 0
rate 0
( 0
HR 0
) 0
, 0
RPE 0
, 0
number 0
of 0
steps 0
( 0
determined 0
by 0
step 0
counter 0
) 0
, 0
and 0
blood 0
lactate 0
concentrations 0
were 0
determined 0
at 0
3 0
, 0
6 0
, 0
9 0
, 0
12 0
, 0
and 0
15 0
minutes 0
during 0
the 0
recovery 0
from 0
the 0
exercise 0
, 0
with 0
and 0
without 0
motivational 0
music 0
( 0
2 0
separate 0
sessions 0
, 0
at 0
random 0
order 0
) 0
. 0

There 0
was 0
no 0
difference 0
in 0
the 0
mean 0
HR 0
during 0
the 0
recovery 0
with 0
and 0
without 0
music 0
. 0

Listening 0
to 0
motivational 0
music 0
during 0
the 0
recovery 0
was 0
associated 0
with 0
increased 0
voluntary 0
activity 0
of 0
the 0
participants 0
, 0
determined 0
by 0
increased 0
number 0
of 0
steps 0
( 0
499.4 0
? 0

220.1 0
vs. 0
413.2 0
? 0

150.6 0
steps 0
, 0
with 0
and 0
without 0
music 0
, 0
respectively 0
; 0
p 0
? 0

0.05 0
) 0
. 0

The 0
increased 0
number 0
of 0
steps 0
during 0
the 0
recovery 0
was 0
accompanied 0
by 0
a 0
significantly 0
greater 0
decrease 0
in 0
blood 0
lactate 0
concentration 0
percentage 0
( 0
28.1 0
? 0

12.2 0
vs. 0
22.8 0
? 0

10.9 0
% 0
, 0
with 0
and 0
without 0
music 0
, 0
respectively 0
, 0
p 0
? 0

0.05 0
) 0
. 0

This 0
was 0
associated 0
with 0
a 0
greater 0
decrease 0
in 0
RPE 0
( 0
77.7 0
? 0

14.4 0
vs. 0
73.1 0
? 0

14.7 0
% 0
with 0
and 0
without 0
music 0
, 0
respectively 0
; 0
p 0
? 0

0.05 0
) 0
. 0

Our 0
results 0
suggest 0
that 0
listening 0
to 0
motivational 0
music 0
during 0
nonstructured 0
recovery 0
from 0
intense 0
exercise 0
leads 0
to 0
increased 0
activity 0
, 0
faster 0
lactate 0
clearance 0
, 0
and 0
reduced 0
RPE 0
and 0
therefore 0
may 0
be 0
used 0
by 0
athletes 0
in 0
their 0
effort 0
to 0
enhance 0
recovery 0
. 0

An 0
open-label 0
extension 0
study 0
of 0
the 0
safety 0
and 0
efficacy 0
of 0
risperidone 0
in 0
children 0
and 0
adolescents 0
with 0
autistic 0
disorder 0
. 0

OBJECTIVE 0
The 0
purpose 0
of 0
this 0
study 0
was 0
to 0
evaluate 0
the 0
long-term 0
safety 0
and 0
efficacy 0
of 0
risperidone 0
in 0
treating 0
irritability B-PHYSICAL
and 0
related 0
behaviors 0
in 0
children 0
and 0
adolescents 0
with 0
autistic 0
disorders 0
. 0

METHODS 0
In 0
this 0
6 0
month 0
( 0
26 0
week 0
) 0
open-label 0
extension 0
( 0
OLE 0
) 0
study 0
, 0
patients 0
( 0
5-17 0
years 0
of 0
age 0
, 0
who 0
completed 0
the 0
previous 0
fixed-dose 0
, 0
6 0
week 0
, 0
double-blind 0
[ 0
DB 0
] 0
phase 0
) 0
were 0
flexibly 0
dosed 0
with 0
risperidone 0
based 0
on 0
body 0
weight 0
. 0

The 0
maximum 0
allowed 0
dose 0
was 0
1.25 0
mg/day 0
for 0
those 0
weighing 0
20 0
to 0
< 0
45 0
kg 0
, 0
and 0
1.75 0
mg/day 0
for 0
those 0
weighing 0
? 0

45 0
kg 0
. 0

The 0
study 0
primarily 0
assessed 0
risperidone 0
's 0
safety 0
; 0
efficacy 0
was 0
assessed 0
as 0
a 0
secondary 0
end-point 0
. 0

RESULTS 0
Fifty-six 0
( 0
71 0
% 0
) 0
out 0
of 0
79 0
enrolled 0
patients 0
completed 0
the 0
OLE 0
; 0
the 0
most 0
common 0
discontinuations 0
were 0
for 0
insufficient 0
response 0
( 0
7 0
[ 0
9 0
% 0
] 0
) 0
or 0
adverse 0
events 0
( 0
AE 0
) 0
( 0
5 0
[ 0
6 0
% 0
] 0
) 0
. 0

The 0
most 0
common 0
( 0
? 0

5 0
% 0
frequency 0
in 0
the 0
total 0
group 0
) 0
AEs 0
were 0
increased 0
appetite 0
( 0
11 0
% 0
[ 0
n=9 0
] 0
) 0
; 0
increased 0
weight 0
and 0
vomiting 0
( 0
9 0
% 0
[ 0
n=7 0
] 0
each 0
) 0
; 0
sedation 0
, 0
pyrexia 0
, 0
and 0
upper 0
respiratory 0
tract 0
infection 0
( 0
8 0
% 0
[ 0
n=6 0
] 0
each 0
) 0
; 0
nasopharyngitis 0
( 0
6 0
% 0
[ 0
n=5 0
] 0
) 0
; 0
and 0
somnolence 0
and 0
fatigue 0
( 0
5 0
% 0
[ 0
n=4 0
] 0
each 0
) 0
. 0

Extrapyramidal 0
AEs 0
were 0
reported 0
in 0
6 0
( 0
8 0
% 0
) 0
patients 0
. 0

Increase 0
in 0
mean 0
weight 0
( 0
11-15 0
% 0
) 0
and 0
body 0
mass 0
index 0
( 0
5-10 0
% 0
) 0
occurred 0
; 0
one 0
patient 0
discontinued 0
because 0
of 0
weight 0
increase 0
. 0

One 0
potentially 0
prolactin-related 0
AE 0
( 0
irregular 0
menstruation 0
) 0
was 0
reported 0
. 0

The 0
risperidone 0
high-dose 0
group 0
had 0
the 0
greatest 0
mean 0
improvement 0
in 0
sleep 0
visual 0
analog 0
scale 0
( 0
24.6 0
) 0
. 0

All 0
groups 0
showed 0
additional 0
improvement 0
in 0
efficacy 0
scale 0
scores 0
during 0
the 0
OLE 0
. 0

CONCLUSIONS 0
During 0
this 0
OLE 0
, 0
safety 0
findings 0
with 0
risperidone 0
treatment 0
( 0
maximum 0
weight-based 0
dose 0
of 0
1.25 0
mg/day 0
or 0
1.75 0
mg/day 0
) 0
were 0
consistent 0
with 0
those 0
observed 0
in 0
the 0
DB 0
phase 0
, 0
and 0
with 0
the 0
current 0
safety 0
information 0
for 0
risperidone 0
in 0
autistic 0
, 0
psychiatric 0
, 0
and 0
behavioral 0
disorders 0
. 0

Patients 0
experienced 0
some 0
additional 0
improvement 0
in 0
irritability 0
and 0
related 0
behaviors 0
. 0

CLINICAL 0
TRIALS 0
REGISTRY 0
This 0
phase-4 0
study 0
is 0
registered 0
at 0
ClinicalTrials.gov 0
( 0
NCT00576732 0
) 0
. 0

The 0
effects 0
of 0
encoding 0
in 0
hypnosis 0
and 0
post-hypnotic 0
suggestion 0
on 0
academic 0
performance 0
. 0

This 0
study 0
examined 0
the 0
relationship 0
between 0
proactive 0
learning 0
in 0
hypnosis 0
, 0
post-hypnotic 0
suggestion 0
, 0
and 0
academic 0
performance 0
. 0

Participants 0
( 0
N 0
= 0
56 0
) 0
were 0
randomly 0
assigned 0
to 0
a 0
control 0
group 0
or 0
a 0
treatment 0
group 0
. 0

The 0
treatment 0
group 0
was 0
hypnotized 0
and 0
read 0
a 0
passage 0
while 0
in 0
hypnosis 0
. 0

Concurrently 0
, 0
they 0
were 0
given 0
a 0
post-hypnotic 0
suggestion 0
, 0
which 0
attempted 0
to 0
aid 0
recognition 0
and 0
performance 0
on 0
a 0
test 0
immediately 0
following 0
the 0
hypnosis 0
session 0
. 0

Both 0
groups 0
completed 0
a 0
multiple-choice 0
test 0
based 0
on 0
the 0
aforementioned 0
passage 0
. 0

An 0
analysis 0
of 0
covariance 0
discerned 0
the 0
effect 0
of 0
proactive B-MENTAL
learning I-MENTAL
and 0
post-hypnotic B-MENTAL
suggestion I-MENTAL
on 0
test B-MENTAL
performance I-MENTAL
, 0
while 0
controlling 0
for 0
the 0
variance 0
introduced 0
by 0
scholastic B-OTHER
aptitude I-OTHER
as 0
measured 0
by 0
the 0
ACT 0
. 0

Results 0
indicated 0
that 0
the 0
hypnosis 0
sessions 0
predicted 0
significantly 0
impaired B-MENTAL
test I-MENTAL
performance I-MENTAL
. 0

Albumin-glutaraldehyde 0
bioadhesive 0
( 0
Bioglue 0
) 0
for 0
prevention 0
of 0
postoperative B-ADVERSE-EFFECTS
complications I-ADVERSE-EFFECTS
after 0
stapled 0
hemorrhoidopexy 0
: 0
A 0
randomized 0
controlled 0
trial 0
. 0

BACKGROUND 0
Hemorrhoidopexy 0
using 0
the 0
circumferential 0
stapler 0
is 0
an 0
established 0
method 0
for 0
surgical 0
treatment 0
of 0
patients 0
with 0
prolapsing 0
hemorrhoids 0
. 0

Despite 0
its 0
advantages 0
, 0
complications 0
such 0
as 0
anal 0
canal 0
stenosis 0
, 0
hemorrhage 0
and 0
anastomosis 0
leak 0
with 0
eventual 0
intrapelvic 0
sepsis 0
can 0
cause 0
serious 0
postoperative 0
problems 0
. 0

The 0
aim 0
of 0
this 0
study 0
was 0
to 0
evaluate 0
the 0
utility 0
of 0
a 0
surgical 0
adhesive 0
, 0
the 0
biological 0
albumin-glutaraldehyde 0
glue 0
Bioglue 0
, 0
in 0
reduction 0
of 0
these 0
postoperative 0
complications 0
. 0

PATIENTS 0
AND 0
METHODS 0
Between 0
January 0
2002 0
and 0
November 0
2004 0
, 0
200 0
patients 0
undergoing 0
stapled 0
hemorrhoidopexy 0
were 0
enrolled 0
in 0
a 0
prospective 0
, 0
randomized 0
clinical 0
trial 0
. 0

One 0
hundred 0
patients 0
were 0
randomly 0
assigned 0
to 0
the 0
control 0
group 0
; 0
the 0
study 0
group 0
consisted 0
of 0
100 0
patients 0
who 0
received 0
Bioglue 0
in 0
the 0
mucosa 0
anastomosis 0
area 0
. 0

All 0
patients 0
received 0
standardized 0
postoperative 0
analgesic 0
, 0
laxative 0
and 0
antibiotic 0
treatment 0
. 0

We 0
then 0
evaluated 0
the 0
two 0
groups 0
for 0
postoperative B-ADVERSE-EFFECTS
complications I-ADVERSE-EFFECTS
( 0
after 0
surgery 0
and 0
6 0
months 0
postoperatively 0
) 0
. 0

RESULTS 0
From 0
the 0
control 0
group 0
( 0
no 0
Bioglue 0
application 0
) 0
, 0
two 0
patients 0
presented 0
with 0
anal B-ADVERSE-EFFECTS
stenosis I-ADVERSE-EFFECTS
, 0
two 0
with 0
hemorrhage B-ADVERSE-EFFECTS
, 0
three 0
had 0
anastomosis B-ADVERSE-EFFECTS
leak I-ADVERSE-EFFECTS
and 0
one 0
had 0
thrombosis B-ADVERSE-EFFECTS
, 0
whereas 0
none 0
of 0
the 0
patients 0
from 0
the 0
Bioglue 0
group 0
had 0
any 0
of 0
these 0
complications B-ADVERSE-EFFECTS
. 0

Both 0
groups 0
had 0
patients 0
with 0
severe B-ADVERSE-EFFECTS
postoperative I-ADVERSE-EFFECTS
pain I-ADVERSE-EFFECTS
( 0
3 0
each 0
) 0
and 0
fecal B-ADVERSE-EFFECTS
incontinence I-ADVERSE-EFFECTS
( 0
1 0
patient 0
each 0
) 0
. 0

The 0
overall B-OTHER
difference I-OTHER
in 0
the 0
number B-ADVERSE-EFFECTS
of I-ADVERSE-EFFECTS
complications I-ADVERSE-EFFECTS
in 0
the 0
two 0
groups 0
was 0
statistically 0
significant 0
( 0
p 0
< 0
0.05 0
) 0
. 0

CONCLUSION 0
In 0
this 0
first 0
study 0
using 0
Bioglue 0
in 0
patients 0
undergoing 0
circumferential 0
stapled 0
hemorrhoidopexy 0
we 0
have 0
shown 0
that 0
application 0
of 0
the 0
glue 0
is 0
effective 0
in 0
reducing B-ADVERSE-EFFECTS
postoperative I-ADVERSE-EFFECTS
complications I-ADVERSE-EFFECTS
. 0

Hemostasis 0
by 0
bipolar 0
coagulation 0
versus 0
suture 0
after 0
surgical 0
stripping 0
of 0
bilateral 0
ovarian 0
endometriomas 0
: 0
a 0
randomized 0
controlled 0
trial 0
. 0

STUDY 0
OBJECTIVE 0
To 0
estimate 0
whether 0
the 0
suture 0
of 0
the 0
ovary 0
is 0
superior 0
to 0
bipolar 0
coagulation 0
in 0
preserving 0
ovarian 0
reserve 0
in 0
infertile 0
women 0
undergoing 0
laparoscopic 0
stripping 0
of 0
bilateral 0
endometriomas 0
. 0

DESIGN 0
Randomized 0
controlled 0
trial 0
( 0
Canadian 0
Task 0
Force 0
classification 0
I 0
) 0
. 0

SETTING 0
University 0
teaching 0
hospital 0
. 0

PATIENTS 0
100 0
patients 0
with 0
bilateral 0
endometriomas 0
. 0

INTERVENTIONS 0
Patients 0
underwent 0
stripping 0
of 0
bilateral 0
endometriomas 0
and 0
were 0
randomized 0
to 0
undergo 0
hemostasis 0
by 0
use 0
of 0
either 0
laparoscopic 0
suturing 0
( 0
LS 0
group 0
) 0
or 0
bipolar 0
coagulation 0
( 0
BC 0
group 0
) 0
. 0

Changes 0
in 0
ovarian B-PHYSICAL
reserve I-PHYSICAL
were 0
investigated 0
by 0
measuring 0
the 0
levels 0
of 0
anti-Mullerian B-PHYSICAL
hormone I-PHYSICAL
( I-PHYSICAL
AMH I-PHYSICAL
) I-PHYSICAL
and 0
basal B-PHYSICAL
follicle-stimulating I-PHYSICAL
hormone I-PHYSICAL
( I-PHYSICAL
FSH I-PHYSICAL
) I-PHYSICAL
before 0
surgery 0
and 0
at 0
3 0
, 0
6 0
and 0
12 0
months 0
from 0
surgery 0
. 0

MEASUREMENTS 0
AND 0
MAIN 0
RESULTS 0
At 0
3-month 0
, 0
6-month 0
, 0
and 0
12-month 0
follow-up 0
, 0
in 0
both 0
study 0
groups 0
, 0
postsurgical B-PHYSICAL
AMH I-PHYSICAL
levels I-PHYSICAL
were 0
significantly 0
lower 0
and 0
basal B-PHYSICAL
FSH I-PHYSICAL
levels I-PHYSICAL
were 0
significantly 0
higher 0
than 0
before 0
surgery 0
. 0

There 0
was 0
no 0
significant 0
difference 0
in 0
the 0
mean 0
percentage 0
decrease 0
of 0
AMH B-PHYSICAL
levels I-PHYSICAL
in 0
the 0
BC 0
group 0
and 0
LS 0
group 0
at 0
3- 0
, 0
6- 0
, 0
and 0
12-month 0
follow-up 0
. 0

The 0
mean 0
percentage 0
increase 0
in 0
basal B-PHYSICAL
FSH I-PHYSICAL
was 0
higher 0
in 0
the 0
BC 0
group 0
than 0
in 0
the 0
LS 0
group 0
at 0
both 0
3-month 0
( 0
p 0
= 0
.023 0
) 0
and 0
6-month 0
follow-up 0
( 0
p 0
= 0
.029 0
) 0
, 0
but 0
not 0
at 0
12-month 0
follow-up 0
. 0

Pregnancy 0
rate 0
, 0
time 0
to 0
conception 0
, 0
and 0
rate 0
of 0
endometrioma 0
recurrence 0
was 0
similar 0
in 0
the 0
2 0
study 0
groups 0
. 0

CONCLUSION 0
Laparoscopic 0
stripping 0
of 0
ovarian 0
endometriotic 0
cyst 0
significantly 0
decreases 0
serum B-PHYSICAL
AMH I-PHYSICAL
levels I-PHYSICAL
and 0
increases 0
basal B-PHYSICAL
FSH I-PHYSICAL
levels I-PHYSICAL
independent 0
from 0
the 0
method 0
used 0
to 0
obtain 0
hemostasis 0
on 0
the 0
ovarian 0
tissue 0
. 0

Effects 0
of 0
nutritional 0
supplementation 0
on 0
IQ B-MENTAL
and 0
certain 0
other 0
variables 0
associated 0
with 0
Down 0
syndrome 0
. 0

In 0
a 0
double-blind 0
study 0
, 0
24 0
Down 0
syndrome 0
children 0
, 0
ages 0
6 0
to 0
17 0
years 0
living 0
at 0
home 0
, 0
were 0
given 0
a 0
megadose 0
multi-vitamin/mineral 0
supplement 0
for 0
4 0
months 0
. 0

A 0
matched 0
group 0
of 0
23 0
children 0
received 0
a 0
placebo 0
in 0
identical 0
form 0
. 0

The 0
children B-MENTAL
's 0
IQ B-MENTAL
, 0

The 0
effect 0
of 0
levetiracetam 0
on 0
essential B-PHYSICAL
tremor I-PHYSICAL
. 0

The 0
effect 0
of 0
a 0
single 0
dose 0
of 0
1,000 0
mg 0
of 0
levetiracetam 0
on 0
essential 0
tremor 0
was 0
investigated 0
in 0
24 0
patients 0
in 0
a 0
double-blind 0
, 0
placebo-controlled 0
trial 0
. 0

There 0
was 0
a 0
significant 0
reduction 0
of 0
hand B-PHYSICAL
tremor I-PHYSICAL
for 0
at 0
least 0
2 0
hours 0
as 0
measured 0
by 0
accelerometry 0
and 0
functional 0
tests 0
. 0

Children 0
with 0
autism 0
's 0
response 0
to 0
novel B-PHYSICAL
stimuli I-PHYSICAL
while 0
participating 0
in 0
interventions 0
targeting 0
joint 0
attention 0
or 0
symbolic 0
play 0
skills 0
. 0

Thirty-five 0
children 0
diagnosed 0
with 0
autism 0
were 0
randomly 0
assigned 0
to 0
either 0
a 0
joint 0
attention 0
or 0
a 0
symbolic 0
play 0
intervention 0
. 0

During 0
the 0
5-8 0
week 0
treatment 0
, 0
three 0
novel 0
probes 0
were 0
administered 0
to 0
determine 0
mastery 0
of 0
joint B-MENTAL
attention I-MENTAL
skills I-MENTAL
. 0

The 0
probes 0
consisted 0
of 0
auditory 0
and 0
visual 0
stimuli 0
, 0
such 0
as 0
a 0
loud 0
spider 0
crawling 0
or 0
a 0
musical 0
ball 0
bouncing 0
. 0

The 0
current 0
study 0
examined 0
affect 0
, 0
gaze 0
, 0
joint 0
attention 0
behaviors 0
, 0
and 0
verbalizations B-MENTAL
at 0
three 0
different 0
time 0
points 0
of 0
intervention 0
. 0

Results 0
revealed 0
that 0
children 0
randomized 0
to 0
the 0
joint 0
attention 0
group 0
were 0
more 0
likely 0
to 0
acknowledge 0
the 0
probe B-MENTAL
and I-MENTAL
engage I-MENTAL
in I-MENTAL
shared I-MENTAL
interactions I-MENTAL
between 0
intervener 0
and 0
probe 0
upon 0
termination 0
of 0
intervention 0
. 0

Additionally 0
, 0
the 0
joint 0
attention 0
group 0
improved 0
in 0
the 0
proportion 0
of 0
time 0
spent 0
sharing 0
coordinated 0
joint 0
looks 0
between 0
intervener 0
and 0
probe 0
. 0

These 0
results 0
suggest 0
that 0
generalization 0
of 0
joint 0
attention 0
skills 0
to 0
a 0
novel 0
probe 0
did 0
occur 0
for 0
the 0
group 0
targeting 0
joint 0
attention 0
and 0
provides 0
further 0
evidence 0
of 0
the 0
effectiveness 0
of 0
the 0
joint 0
attention 0
intervention 0
. 0

Interactions 0
of 0
morphine 0
and 0
methotrimeprazine 0
in 0
mouse 0
and 0
man 0
with 0
respect 0
to 0
analgesia B-PHYSICAL
, 0
respiration B-PHYSICAL
and 0
sedation B-PHYSICAL
. 0

Interactions 0
between 0
morphine 0
and 0
methotrimeprazine 0
have 0
been 0
studied 0
in 0
mice 0
and 0
man 0
with 0
respect 0
to 0
analgesia B-PHYSICAL
or I-PHYSICAL
antinociceptive I-PHYSICAL
activity I-PHYSICAL
, 0
respiratory B-PHYSICAL
effects I-PHYSICAL
and 0
sedation B-PHYSICAL
. 0

The 0
volunteer 0
study 0
was 0
a 0
double-blind 0
cross-over 0
trial 0
with 0
10 0
volunteers 0
. 0

In 0
mice 0
, 0
methotrimeprazine 0
only 0
possessed 0
antinociceptive B-PHYSICAL
activity I-PHYSICAL
in 0
doses 0
which 0
caused 0
marked B-PHYSICAL
sedation I-PHYSICAL
. 0

However 0
, 0
small 0
non-sedative 0
doses 0
of 0
methotrimeprazine 0
potentiated 0
the 0
analgesic B-PAIN
action I-PAIN
of I-PAIN
morphine I-PAIN
. 0

The 0
volunteer 0
study 0
did 0
not 0
confirm 0
this 0
finding 0
in 0
man 0
. 0

Methotrimeprazine 0
7.5 0
mg 0
i.m 0
. 0

caused 0
significant B-PHYSICAL
sedation I-PHYSICAL
, 0
but 0
did 0
not 0
alter 0
the 0
effects 0
of 0
morphine 0
5 0
mg 0
on 0
pain B-PAIN
threshold I-PAIN
or 0
ventilatory B-PHYSICAL
response I-PHYSICAL
to 0
carbon 0
dioxide 0
. 0

Effect 0
of 0
postural 0
supports 0
on 0
neuromotor B-PHYSICAL
function I-PHYSICAL
in 0
very 0
preterm 0
infants 0
to 0
term 0
equivalent 0
age 0
. 0

OBJECTIVE 0
To 0
determine 0
the 0
effect 0
of 0
a 0
postural 0
support 0
nappy 0
and/or 0
a 0
postural 0
support 0
roll 0
on 0
neuromotor B-PHYSICAL
function I-PHYSICAL
in 0
very 0
preterm 0
infants 0
when 0
nursed 0
prone 0
to 0
term 0
equivalent 0
age 0
. 0

METHODS 0
A 0
randomized 0
observer 0
blind 0
controlled 0
trial 0
of 0
123 0
very 0
preterm 0
infants 0
was 0
conducted 0
in 0
the 0
neonatal 0
intensive 0
care 0
unit 0
of 0
the 0
sole 0
tertiary 0
referral 0
centre 0
in 0
Western 0
Australia 0
. 0

Infants 0
were 0
stratified 0
by 0
gestational 0
age 0
( 0
< 0
29 0
weeks 0
or 0
29-30 0
weeks 0
) 0
, 0
then 0
randomized 0
into 0
one 0
of 0
three 0
intervention 0
groups 0
: 0
postural 0
support 0
nappy 0
, 0
postural 0
support 0
nappy 0
and 0
postural 0
support 0
roll 0
, 0
or 0
disposable 0
nappy 0
and 0
postural 0
support 0
roll 0
. 0

Interventions 0
started 0
when 0
infants 0
were 0
stable 0
and 0
ceased 0
when 0
routine 0
side-lying 0
commenced 0
. 0

Measurements 0
of 0
shoulder B-PHYSICAL
and 0
hip B-PHYSICAL
posture I-PHYSICAL
were 0
performed 0
pre-intervention 0
, 0
5 0
weeks 0
post-intervention 0
and 0
term 0
postmenstrual 0
age 0
. 0

RESULTS 0
Infants 0
nursed 0
with 0
a 0
postural 0
support 0
roll 0
and 0
a 0
postural 0
support 0
nappy 0
demonstrated 0
improved 0
hip B-PHYSICAL
posture I-PHYSICAL
to 0
term 0
equivalent 0
age 0
compared 0
with 0
infants 0
nursed 0
with 0
either 0
a 0
postural 0
support 0
roll 0
only 0
, 0
or 0
a 0
postural 0
support 0
nappy 0
only 0
. 0

Infants 0
nursed 0
with 0
a 0
postural 0
support 0
roll 0
either 0
with 0
or 0
without 0
a 0
postural 0
support 0
nappy 0
demonstrated 0
improved 0
shoulder B-PHYSICAL
posture I-PHYSICAL
to 0
term 0
equivalent 0
age 0
. 0

CONCLUSIONS 0
Combined 0
use 0
of 0
a 0
postural 0
support 0
roll 0
and 0
a 0
postural 0
support 0
nappy 0
while 0
very 0
preterm 0
infants 0
are 0
nursed 0
prone 0
improves 0
hip B-PHYSICAL
posture I-PHYSICAL
up 0
to 0
term 0
postmenstrual 0
age 0
. 0

Use 0
of 0
a 0
postural 0
support 0
roll 0
improves 0
shoulder B-PHYSICAL
posture I-PHYSICAL
up 0
to 0
term 0
equivalent 0
age 0
. 0

Sialyl 0
Lewisa 0
expression 0
as 0
a 0
predictor 0
of 0
the 0
prognosis 0
of 0
colon 0
carcinoma 0
patients 0
in 0
a 0
prospective 0
randomized 0
clinical 0
trial 0
. 0

BACKGROUND 0
The 0
metastatic 0
potential 0
of 0
tumors 0
is 0
dependent 0
on 0
the 0
cell 0
to 0
cell 0
adhesion 0
by 0
cell 0
surface 0
carbohydrate 0
antigens 0
. 0

Thus 0
, 0
expression 0
of 0
sialyl 0
Lewis 0
( 0
a 0
) 0
, 0
which 0
is 0
one 0
of 0
the 0
important 0
molecules 0
of 0
cell 0
surface 0
carbohydrates 0
, 0
may 0
serve 0
as 0
a 0
prognostic 0
marker 0
of 0
aggressive 0
and 0
metastasizing 0
tumor 0
growth 0
. 0

However 0
, 0
the 0
prognostic 0
value 0
of 0
sialyl 0
Lewis 0
( 0
a 0
) 0
expression 0
in 0
colon 0
cancer 0
is 0
still 0
controversial 0
. 0

METHODS 0
In 0
this 0
study 0
, 0
we 0
investigated 0
the 0
expression 0
of 0
sialyl 0
Lewis 0
( 0
a 0
) 0
antigen 0
in 0
233 0
colon 0
cancer 0
specimens 0
from 0
patients 0
who 0
were 0
registered 0
in 0
a 0
prospective 0
adjuvant 0
immunochemotherapy 0
clinical 0
trial 0
. 0

The 0
clinical 0
course 0
and 0
the 0
prognosis 0
of 0
the 0
patients 0
were 0
evaluated 0
after 0
all 0
the 0
immunohistochemical 0
analyses 0
had 0
been 0
performed 0
. 0

RESULTS 0
Sialyl 0
Lewis 0
( 0
a 0
) 0
expression 0
levels 0
were 0
correlated 0
with 0
both 0
overall B-MORTALITY
survival I-MORTALITY
( 0
P 0
= 0
0.0006 0
) 0
and 0
disease-free B-MORTALITY
survival I-MORTALITY
( 0
P 0
= 0
0.004 0
) 0
in 0
all 0
patients 0
with 0
the 0
log-rank 0
test 0
. 0

This 0
result 0
could 0
be 0
assumed 0
to 0
have 0
been 0
influenced 0
by 0
the 0
difference 0
in 0
the 0
metastatic 0
preponderance 0
in 0
a 0
high 0
versus 0
low 0
sialyl 0
Lewis 0
( 0
a 0
) 0
expression 0
in 0
the 0
tumor 0
cells 0
. 0

CONCLUSION 0
This 0
prospective 0
study 0
in 0
a 0
randomized 0
controlled 0
trial 0
suggests 0
that 0
sialyl 0
Lewis 0
( 0
a 0
) 0
expression 0
levels 0
may 0
serve 0
as 0
an 0
indicator 0
of 0
the 0
metastatic 0
potential 0
of 0
colon 0
cancer 0
cells 0
, 0
which 0
would 0
strongly 0
predict 0
the 0
prognosis 0
. 0

Diet 0
and 0
vitamin 0
D 0
status 0
among 0
pregnant 0
Pakistani 0
women 0
in 0
Oslo 0
. 0

OBJECTIVES 0
In 0
the 0
present 0
study 0
the 0
diet 0
and 0
the 0
nutritional 0
status 0
of 0
pregnant 0
Pakistani 0
immigrant 0
women 0
have 0
been 0
compared 0
with 0
a 0
group 0
of 0
Norwegian 0
women 0
. 0

DESIGN 0
A 0
cross-sectional 0
survey 0
of 0
women 0
in 0
the 0
18th 0
week 0
of 0
pregnancy 0
. 0

SETTING 0
Women 0
referred 0
to 0
routine 0
ultrasound 0
examination 0
at 0
Aker 0
and 0
Ullev?l 0
Hospitals 0
in 0
Norway 0
. 0

SUBJECTS 0
All 0
( 0
58 0
) 0
healthy 0
women 0
of 0
Pakistani 0
origin 0
referred 0
from 0
October 0
of 0
1991 0
to 0
January 0
of 0
1992 0
were 0
included 0
, 0
of 0
whom 0
38 0
( 0
66 0
% 0
) 0
participated 0
. 0

Forty-five 0
Norwegian 0
women 0
were 0
randomly 0
included 0
in 0
the 0
same 0
period 0
and 0
38 0
( 0
84 0
% 0
) 0
of 0
these 0
women 0
participated 0
. 0

RESULTS 0
The 0
serum 0
levels 0
of 0
25-hydroxyvitamin 0
D3 0
were 0
significantly 0
lower 0
in 0
the 0
Pakistanis 0
compared 0
with 0
the 0
Norwegians 0
( 0
median 0
19 0
nmol/l 0
vs 0
55 0
nmol/l 0
, 0
P 0
< 0
0.001 0
) 0
and 0
83 0
% 0
of 0
the 0
Pakistani 0
women 0
had 0
25-hydroxyvitamin B-PHYSICAL
D3 I-PHYSICAL
levels I-PHYSICAL
below 0
the 0
reference 0
value 0
( 0
< 0
30 0
nmol/l 0
) 0
. 0

The 0
Pakistanis 0
had 0
higher 0
levels 0
of 0
serum B-PHYSICAL
parathyroid I-PHYSICAL
hormone I-PHYSICAL
( 0
median 0
2.6 0
vs 0
1.6 0
pmol/l 0
, 0
P 0
< 0
0.001 0
) 0
. 0

The 0
Pakistanis 0
also 0
had 0
a 0
lower 0
dietary B-PHYSICAL
intake I-PHYSICAL
of I-PHYSICAL
vitamin I-PHYSICAL
D 0
than 0
that 0
of 0
the 0
Norwegians 0
( 0
median 0
2.2 0
vs 0
3.3 0
micrograms/day 0
, 0
P 0
< 0
0.05 0
) 0
, 0
and 0
a 0
lower 0
total 0
intake 0
, 0
including 0
supplements 0
( 0
median 0
2.9 0
vs 0
7.0 0
micrograms/day 0
, 0
P 0
< 0
0.001 0
) 0
. 0

Among 0
the 0
Pakistanis 0
a 0
correlation 0
was 0
found 0
between 0
the 0
dietary 0
intake 0
of 0
margarine 0
, 0
the 0
main 0
source 0
of 0
vitamin 0
D 0
in 0
the 0
diet 0
, 0
and 0
the 0
concentration 0
of 0
25-hydroxyvitamin 0
D3 0
in 0
serum 0
, 0
r 0
= 0
0.48 0
( 0
P 0
= 0
0.01 0
) 0
. 0

In 0
general 0
, 0
the 0
Pakistanis 0
avoided 0
any 0
direct 0
sunshine 0
exposure 0
, 0
and 0
no 0
relation 0
between 0
outdoor 0
activity 0
and 0
serum 0
level 0
of 0
25-hydroxyvitamin 0
D3 0
was 0
found 0
. 0

The 0
Pakistani 0
women 0
had 0
a 0
lower 0
intake 0
of 0
calcium 0
than 0
the 0
Norwegians 0
( 0
median 0
793 0
vs 0
1134 0
mg/day 0
, 0
P 0
< 0
0.001 0
) 0
. 0

CONCLUSION 0
This 0
study 0
has 0
shown 0
that 0
Pakistani 0
women 0
living 0
in 0
Oslo 0
are 0
at 0
great 0
risk 0
of 0
developing 0
vitamin 0
D 0
deficiency 0
during 0
pregnancy 0
. 0

The 0
main 0
reasons 0
for 0
this 0
are 0
avoidance 0
of 0
sun 0
exposure 0
, 0
a 0
low 0
dietary 0
intake 0
of 0
vitamin 0
D 0
, 0
and 0
no 0
or 0
little 0
use 0
of 0
supplementation 0
. 0

A 0
randomised 0
trial 0
comparing 0
holmium 0
laser 0
enucleation 0
versus 0
transurethral 0
resection 0
in 0
the 0
treatment 0
of 0
prostates 0
larger 0
than 0
40 0
grams 0
: 0
results 0
at 0
2 0
years 0
. 0

OBJECTIVE 0
To 0
compare 0
holmium 0
laser 0
enucleation 0
of 0
the 0
prostate 0
( 0
HoLEP 0
) 0
with 0
transurethral 0
resection 0
of 0
the 0
prostate 0
( 0
TURP 0
) 0
for 0
treatment 0
of 0
men 0
with 0
bladder 0
outflow 0
obstruction 0
( 0
BOO 0
) 0
secondary 0
to 0
benign 0
prostatic 0
hyperplasia 0
with 0
a 0
minimum 0
of 0
24-month 0
follow-up 0
. 0

PATIENTS 0
AND 0
METHODS 0
Sixty-one 0
patients 0
were 0
randomised 0
to 0
either 0
HoLEP 0
or 0
TURP 0
. 0

All 0
patients 0
had 0
BOO 0
proven 0
on 0
urodynamic 0
studies 0
pre-operatively 0
( 0
prostate 0
size 0
40-200 0
g 0
) 0
. 0

One 0
patient 0
died 0
before 0
treatment 0
, 0
which 0
left 0
30 0
patients 0
in 0
each 0
group 0
. 0

Perioperative 0
data 0
, 0
as 0
well 0
as 0
symptom 0
scores 0
, 0
Quality 0
of 0
Life 0
( 0
QoL 0
) 0
scores 0
, 0
and 0
maximum 0
urinary 0
flow 0
rates 0
( 0
Qmax 0
) 0
were 0
obtained 0
at 0
one 0
, 0
three 0
, 0
six,12 0
, 0
and 0
24 0
months 0
. 0

Post-void B-PHYSICAL
residual 0
volumes B-PHYSICAL
, 0
transrectal B-PHYSICAL
ultrasound B-PHYSICAL
( 0

Outpatient 0
management 0
of 0
asthma 0
with 0
regular 0
nebulized 0
beta 0
agonists 0
: 0
comparison 0
of 0
bitolterol 0
mesylate 0
and 0
isoproterenol 0
. 0

Nebulized 0
bitolterol 0
solution 0
and 0
isoproterenol 0
solution 0
were 0
compared 0
when 0
used 0
on 0
a 0
regular 0
basis 0
, 0
2.5 0
mg 0
three 0
times 0
a 0
day 0
for 0
1 0
month 0
by 0
patients 0
with 0
chronic 0
asthma 0
. 0

In 0
this 0
multicenter 0
, 0
double-blind 0
trial 0
; 0
130 0
nonsteroid-dependent 0
patients 0
were 0
randomized 0
to 0
receive 0
one 0
of 0
the 0
two 0
treatments 0
concomitantly 0
with 0
their 0
regular 0
asthma 0
medications 0
. 0

On 0
study 0
days 0
, 0
at 0
the 0
beginning 0
of 0
the 0
study 0
and 0
after 0
2 0
and 0
4 0
weeks 0
, 0
treatments 0
were 0
given 0
in 0
the 0
office 0
or 0
laboratory 0
and 0
patients 0
were 0
monitored 0
with 0
pulmonary B-OTHER
function I-OTHER
tests I-OTHER
for 0
eight 0
hours 0
. 0

Both 0
medications 0
induced 0
rapid B-PHYSICAL
bronchodilation I-PHYSICAL
that 0
had 0
a 0
longer 0
duration B-OTHER
after 0
bitolterol 0
. 0

The 0
incidence 0
of 0
tremor B-PHYSICAL
was 0
similar 0
with 0
the 0
two 0
medications 0
. 0

Tachycardia B-PHYSICAL
and 0
palpitations B-PHYSICAL
were 0
more 0
frequent 0
following 0
isoproterenol 0
. 0

Bitolterol 0
has 0
a 0
much 0
longer 0
duration B-OTHER
of I-OTHER
action I-OTHER
and 0
should 0
be 0
considered 0
as 0
a 0
suitable 0
bronchodilator 0
for 0
regular 0
nebulizer 0
treatment 0
of 0
chronic 0
asthma 0
. 0

Randomized 0
controlled 0
trial 0
of 0
education 0
and 0
feedback 0
for 0
implementation 0
of 0
guidelines 0
for 0
acute 0
low 0
back 0
pain 0
. 0

OBJECTIVE 0
The 0
effect 0
of 0
clinical 0
guidelines 0
on 0
resource 0
utilization 0
for 0
complex 0
conditions 0
with 0
substantial 0
barriers 0
to 0
clinician 0
behavior 0
change 0
has 0
not 0
been 0
well 0
studied 0
. 0

We 0
report 0
the 0
impact 0
of 0
a 0
multifaceted 0
guideline 0
implementation 0
intervention 0
on 0
primary 0
care 0
clinician 0
utilization 0
of 0
radiologic 0
and 0
specialty 0
services 0
for 0
the 0
care 0
of 0
acute 0
low 0
back 0
pain 0
. 0

DESIGN 0
Physician 0
groups 0
were 0
randomized 0
to 0
receive 0
guideline 0
education 0
and 0
individual 0
feedback 0
, 0
supporting 0
patient 0
education 0
materials 0
, 0
both 0
, 0
or 0
neither 0
. 0

The 0
impact 0
on 0
guideline 0
adherence 0
and 0
resource 0
utilization 0
was 0
evaluated 0
during 0
the 0
12-month 0
period 0
before 0
and 0
after 0
implementation 0
. 0

PARTICIPANTS 0
Fourteen 0
physician 0
groups 0
with 0
120 0
primary 0
care 0
physician 0
and 0
associate 0
practitioners 0
from 0
2 0
group 0
model 0
HMO 0
practices 0
. 0

INTERVENTIONS 0
Guideline 0
implementation 0
utilized 0
an 0
education/audit/feedback 0
model 0
with 0
local 0
peer 0
opinion 0
leaders 0
. 0

The 0
patient 0
education 0
component 0
included 0
written 0
and 0
videotaped 0
materials 0
on 0
the 0
care 0
of 0
low 0
back 0
pain 0
. 0

MAIN 0
RESULTS 0
The 0
clinician 0
intervention 0
was 0
associated 0
with 0
an 0
absolute 0
increase 0
in 0
guideline-consistent B-MENTAL
behavior I-MENTAL
of 0
5.4 0
% 0
in 0
the 0
intervention 0
group 0
versus 0
a 0
decline 0
of 0
2.7 0
% 0
in 0
the 0
control 0
group 0
( 0
P 0
=.04 0
) 0
. 0

The 0
patient 0
education 0
intervention 0
produced 0
no 0
significant 0
change 0
in 0
guideline-consistent B-PHYSICAL
behavior I-PHYSICAL
, 0
but 0
was 0
poorly 0
adopted 0
. 0

Patient 0
characteristics 0
including 0
duration B-PAIN
of I-PAIN
pain I-PAIN
, 0
prior B-PAIN
history I-PAIN
of I-PAIN
low I-PAIN
back I-PAIN
pain I-PAIN
, 0
and 0
number B-PAIN
of I-PAIN
visits I-PAIN
during 0
the 0
illness 0
episode 0
were 0
strong 0
predictors 0
of 0
service 0
utilization 0
and 0
guideline-consistent 0
behavior 0
. 0

CONCLUSIONS 0
Implementation 0
of 0
an 0
education 0
and 0
feedback-supported 0
acute 0
low 0
back 0
pain 0
care 0
guideline 0
for 0
primary 0
care 0
clinicians 0
was 0
associated 0
with 0
an 0
increase 0
in 0
guideline-consistent 0
behavior 0
. 0

Patient 0
education 0
materials 0
did 0
not 0
enhance 0
guideline 0
effectiveness 0
. 0

Implementation 0
barriers 0
could 0
limit 0
the 0
utility 0
of 0
this 0
approach 0
in 0
usual 0
care 0
settings 0
. 0

Effects 0
of 0
alcohol 0
on 0
the 0
pharmacokinetics B-OTHER
of 0
morphine 0
sulfate 0
and 0
naltrexone 0
hydrochloride 0
extended 0
release 0
capsules 0
. 0

Although 0
contraindicated 0
, 0
coingestion 0
of 0
alcohol 0
and 0
opioids 0
by 0
patients 0
or 0
drug 0
abusers 0
is 0
a 0
major 0
health 0
concern 0
because 0
of 0
dangerous 0
additive 0
and 0
potentially 0
life-threatening 0
sedative 0
and 0
respiratory 0
effects 0
. 0

In 0
addition 0
, 0
alcohol 0
has 0
been 0
shown 0
to 0
disrupt 0
the 0
extended-release 0
characteristics 0
of 0
certain 0
extended-release 0
opioid 0
formulations 0
, 0
releasing 0
a 0
hazardous 0
amount 0
of 0
opioid 0
over 0
a 0
short 0
time 0
period 0
. 0

Morphine 0
sulfate 0
and 0
naltrexone 0
hydrochloride 0
extended 0
release 0
capsules 0
( 0
MS-sNT 0
) 0
, 0
which 0
contain 0
naltrexone 0
sequestered 0
in 0
each 0
pellet 0
core 0
, 0
are 0
indicated 0
for 0
management 0
of 0
chronic 0
, 0
moderate 0
to 0
severe 0
pain 0
. 0

Sequestered 0
naltrexone 0
is 0
designed 0
for 0
release 0
upon 0
product 0
tampering 0
( 0
crushing 0
) 0
to 0
potentially 0
mitigate 0
morphine-induced 0
subjective 0
effects 0
. 0

This 0
open-label 0
, 0
single-dose 0
, 0
4-way 0
crossover 0
, 0
pharmacokinetic 0
drug 0
interaction 0
study 0
compared 0
the 0
relative B-OTHER
bioavailability I-OTHER
of 0
morphine B-PHYSICAL
and 0
naltrexone B-PHYSICAL
when 0
MS-sNT 0
is 0
administered 0
( 0
under 0
fasting 0
conditions 0
) 0
with 0
increasing 0
doses B-PHYSICAL
of I-PHYSICAL
alcohol I-PHYSICAL
. 0

Thirty-two 0
healthy 0
, 0
opioid-naive 0
adults 0
were 0
randomized 0
to 0
MS-sNT 0
administered 0
with 0
240 0
mL 0
of 0
4 0
% 0
, 0
20 0
% 0
, 0
or 0
40 0
% 0
alcohol 0
or 0
water 0
. 0

No 0
drug B-PHYSICAL
interaction I-PHYSICAL
was 0
found 0
between 0
morphine 0
in 0
MS-sNT 0
and 0
4 0
% 0
or 0
20 0
% 0
alcohol 0
. 0

Administration 0
with 0
40 0
% 0
alcohol 0
did 0
not 0
affect 0
overall B-OTHER
morphine I-OTHER
exposure I-OTHER
but 0
was 0
associated 0
with 0
a 0
2-fold 0
increase 0
in 0
C B-OTHER
( I-OTHER
max I-OTHER
) I-OTHER
and 0
reduction 0
of 0
t 0
( B-OTHER
max I-OTHER
) I-OTHER
from 0
9 0
to 0
4 0
hours 0
versus 0
MS-sNT 0
taken 0
with 0
water 0
. 0

Naltrexone B-OTHER
sequestering I-OTHER
was I-OTHER
successful I-OTHER
in 0
all 0
treatment 0
arms 0
and 0
not 0
affected 0
by 0
coadministration 0
with 0
alcohol 0
over 0
the 0
dose 0
range 0
tested 0
. 0

RCT 0
of 0
a 0
manualized 0
social 0
treatment 0
for 0
high-functioning 0
autism 0
spectrum 0
disorders 0
. 0

This 0
RCT 0
examined 0
the 0
efficacy 0
of 0
a 0
manualized 0
social 0
intervention 0
for 0
children 0
with 0
HFASDs 0
. 0

Participants 0
were 0
randomly 0
assigned 0
to 0
treatment 0
or 0
wait-list 0
conditions 0
. 0

Treatment 0
included 0
instruction 0
and 0
therapeutic 0
activities 0
targeting 0
social 0
skills 0
, 0
face-emotion 0
recognition 0
, 0
interest 0
expansion 0
, 0
and 0
interpretation 0
of 0
non-literal 0
language 0
. 0

A 0
response-cost 0
program 0
was 0
applied 0
to 0
reduce 0
problem 0
behaviors 0
and 0
foster 0
skills 0
acquisition 0
. 0

Significant 0
treatment 0
effects 0
were 0
found 0
for 0
five 0
of 0
seven 0
primary 0
outcome 0
measures 0
( 0
parent B-MENTAL
ratings I-MENTAL
and 0
direct 0
child 0
measures 0
) 0
. 0

Secondary 0
measures 0
based 0
on 0
staff B-OTHER
ratings I-OTHER
( 0
treatment 0
group 0
only 0
) 0
corroborated 0
gains 0
reported 0
by 0
parents 0
. 0

High 0
levels 0
of 0
parent B-OTHER
, 0
child B-OTHER
and 0
staff B-OTHER
satisfaction I-OTHER
were 0
reported 0
, 0
along 0
with 0
high 0
levels 0
of 0
treatment 0
fidelity B-MENTAL
. 0

Standardized 0
effect 0
size 0
estimates 0
were 0
primarily 0
in 0
the 0
medium 0
and 0
large 0
ranges 0
and 0
favored 0
the 0
treatment 0
group 0
. 0

Primary 0
capsulectomy 0
, 0
anterior 0
vitrectomy 0
, 0
lensectomy 0
, 0
and 0
posterior 0
chamber 0
lens 0
implantation 0
in 0
children 0
: 0
limbal 0
versus 0
pars 0
plana 0
. 0

PURPOSE 0
To 0
compare 0
the 0
results 0
of 0
a 0
limbal 0
versus 0
a 0
pars 0
plana 0
approach 0
for 0
primary 0
posterior 0
capsulectomy 0
and 0
anterior 0
vitrectomy 0
in 0
the 0
management 0
of 0
childhood B-PHYSICAL
cataract I-PHYSICAL
. 0

SETTING 0
Department 0
of 0
Ophthalmology 0
, 0
Labbafinejad 0
Medical 0
Center 0
, 0
Tehran 0
, 0
Iran 0
. 0

METHODS 0
A 0
randomized 0
, 0
controlled 0
, 0
double-masked 0
clinical 0
trial 0
of 0
45 0
eyes 0
was 0
conducted 0
. 0

After 0
being 0
matched 0
, 0
38 0
eyes 0
were 0
included 0
in 0
the 0
study 0
and 0
were 0
divided 0
into 0
2 0
equal 0
groups 0
for 0
data 0
analysis 0
. 0

All 0
eyes 0
had 0
lensectomy 0
and 0
posterior 0
chamber 0
intraocular 0
lens 0
( 0
PC 0
IOL 0
) 0
implantation 0
. 0

Primary 0
posterior 0
capsulectomy 0
and 0
anterior 0
vitrectomy 0
were 0
performed 0
through 0
the 0
limbus 0
in 0
half 0
of 0
the 0
eyes 0
and 0
the 0
pars 0
plana 0
in 0
the 0
other 0
half 0
. 0

Main 0
outcome 0
measures 0
included 0
visual B-PHYSICAL
acuity I-PHYSICAL
, 0
estimated 0
red B-PHYSICAL
reflex I-PHYSICAL
, 0
postsurgical B-PHYSICAL
inflammatory I-PHYSICAL
reaction I-PHYSICAL
, 0
corneal B-PHYSICAL
clarity I-PHYSICAL
, 0
posterior B-PHYSICAL
synechias I-PHYSICAL
, 0
iris B-PHYSICAL
capture I-PHYSICAL
, 0
IOL B-PHYSICAL
position 0
, 0
capsulectomy B-PHYSICAL
size 0
, 0
glaucoma B-PHYSICAL
, 0
cystoid B-PHYSICAL
macular I-PHYSICAL
edema I-PHYSICAL
, 0
retinal B-PHYSICAL
tear 0
, 0
and 0

Training 0
referential 0
communicative 0
skills 0
to 0
individuals 0
with 0
autism 0
spectrum 0
disorder 0
: 0
a 0
pilot 0
study 0
. 0

The 0
present 0
study 0
reports 0
the 0
effects 0
of 0
referential 0
communication 0
training 0
in 0
individuals 0
formally 0
diagnosed 0
with 0
autism 0
spectrum 0
disorder 0
( 0
ASD 0
) 0
. 0

Participants 0
were 0
20 0
children 0
with 0
ASD 0
( 0
M 0
age 0
= 0
14.3 0
yr. 0
, 0
SD 0
= 0
4.2 0
; 0
6 0
girls 0
, 0
14 0
boys 0
) 0
in 0
the 0
role 0
of 0
speakers 0
and 0
20 0
control 0
children 0
, 0
who 0
acted 0
as 0
listeners 0
. 0

They 0
were 0
all 0
enrolled 0
in 0
mainstream 0
compulsory 0
education 0
. 0

Inclusion/exclusion 0
criteria 0
were 0
defined 0
according 0
to 0
the 0
clinical 0
diagnosis 0
of 0
ASD 0
, 0
the 0
presence 0
or 0
absence 0
of 0
additional 0
or 0
associated 0
disability 0
, 0
previous 0
training 0
in 0
referential 0
communication 0
, 0
and 0
any 0
drug 0
treatment 0
. 0

Speakers 0
were 0
randomly 0
assigned 0
to 0
one 0
of 0
two 0
groups 0
( 0
trained 0
vs 0
untrained 0
) 0
. 0

Linguistic B-PHYSICAL
age 0
, 0
cognitive 0
level 0
and 0
autistic 0
symptoms 0
were 0
analyzed 0
, 0
respectively 0
, 0
with 0
the 0
Peabody 0
Picture 0
Vocabulary 0
Test 0
( 0
PPVT 0
) 0
, 0
the 0
Wechsler 0
Intelligence 0
Scale 0
( 0
WISC-R 0
or 0
WAIS-III 0
) 0
, 0
and 0
the 0
Autistic 0
Behavior 0
Checklist 0
( 0
ABC 0
) 0
. 0

Communicative 0
abilities 0
were 0
analyzed 0
through 0
two 0
indexes 0
related 0
to 0
message 0
complexity 0
and 0
self-regulation 0
. 0

The 0
trained 0
group 0
was 0
trained 0
in 0
referential 0
communication 0
tasks 0
( 0
task 0
analysis 0
, 0
role 0
taking 0
, 0
and 0
task 0
evaluation 0
) 0
, 0
while 0
the 0
untrained 0
group 0
took 0
part 0
in 0
a 0
communicative 0
game 0
but 0
without 0
any 0
specific 0
communicative 0
training 0
. 0

The 0
results 0
showed 0
that 0
the 0
complexity 0
of 0
emitted B-PHYSICAL
messages I-PHYSICAL
had 0
improved 0
statistically 0
significantly 0
in 0
the 0
trained 0
group 0
as 0
an 0
effect 0
of 0
training 0
. 0

Ecological 0
referential 0
communication 0
is 0
shown 0
to 0
be 0
an 0
appropriate 0
paradigm 0
for 0
studying 0
the 0
communicative 0
process 0
and 0
its 0
products 0
and 0
could 0
be 0
used 0
to 0
develop 0
and 0
implement 0
a 0
training 0
program 0
focused 0
on 0
those 0
skills 0
in 0
which 0
individuals 0
with 0
ASD 0
are 0
most 0
deficient 0
. 0

Antioxidant 0
supplementation 0
and 0
exercise-induced 0
oxidative 0
stress 0
in 0
the 0
60-year-old 0
as 0
measured 0
by 0
antipyrine 0
hydroxylates 0
. 0

The 0
effects 0
of 0
12 0
weeks 0
of 0
antioxidant 0
supplementation 0
on 0
exercise-induced 0
oxidative 0
stress 0
were 0
investigated 0
in 0
older 0
adults 0
( 0
60 0
( 0
SE 0
1 0
) 0
years 0
; 0
BMI 0
26 0
( 0
SE 0
1 0
) 0
kg/m 0
( 0
2 0
) 0
) 0
. 0

Subjects 0
were 0
randomly 0
divided 0
in 0
two 0
groups 0
: 0
supplementation 0
( 0
n 0
11 0
) 0
with 0
100 0
mg 0
dl-alpha-tocopheryl 0
acetate 0
, 0
200 0
mg 0
ascorbic 0
acid 0
, 0
and 0
2 0
mg 0
beta-carotene 0
, 0
and 0
placebo 0
( 0
n 0
9 0
) 0
. 0

Before 0
and 0
after 0
the 0
12 0
week 0
supplementation 0
period 0
, 0
subjects 0
cycled 0
for 0
45 0
min 0
at 0
submaximal 0
intensity 0
( 0
50 0
% 0
maximal 0
workload 0
capacity 0
) 0
. 0

Antipyrine 0
was 0
used 0
as 0
marker 0
for 0
oxidative 0
stress 0
. 0

Antipyrine 0
reacts 0
quickly 0
with 0
hydroxyl 0
radicals 0
to 0
form 0
para- 0
and 0
ortho-hydroxyantipyrine 0
. 0

The 0
latter 0
metabolite 0
is 0
not 0
formed 0
in 0
man 0
through 0
the 0
mono-oxygenase 0
pathway 0
of 0
cytochrome 0
P450 0
. 0

Daily 0
supplementation 0
significantly 0
increased 0
plasma B-PHYSICAL
concentrations I-PHYSICAL
of I-PHYSICAL
alpha-tocopherol I-PHYSICAL
and I-PHYSICAL
beta-carotene I-PHYSICAL
in 0
the 0
supplemented 0
group 0
( 0
Delta 0
14.4 0
( 0
SE 0
3.2 0
) 0
and 0
0.4 0
( 0
se 0
0.1 0
) 0
micromol/l 0
; 0
P 0
< 0
0.001 0
and 0
P 0
< 0
0.01 0
) 0
. 0

No 0
significant 0
differences 0
, 0
within 0
and 0
between 0
groups 0
, 0
were 0
observed 0
in 0
the 0
exercise-induced B-PHYSICAL
increase 0
in B-PHYSICAL
the I-PHYSICAL
ratios I-PHYSICAL
para- I-PHYSICAL
and I-PHYSICAL
ortho-hydroxyantipyrine I-PHYSICAL
to I-PHYSICAL
antipyrine B-PHYSICAL
. 0

In 0
addition 0
, 0
supplementation 0
did 0
not 0
affect 0
the 0
exercise-induced B-PHYSICAL
increase 0
in B-PHYSICAL
thiobarbituric I-PHYSICAL
acid I-PHYSICAL
reactive I-PHYSICAL
substances I-PHYSICAL
in B-PHYSICAL
plasma I-PHYSICAL
. 0

In 0
conclusion 0
, 0
in 0
60-year-old 0
subjects 0
antioxidant 0
supplementation 0
had 0

A 0
controlled 0
study 0
of 0
the 0
effect 0
of 0
indomethacin 0
in 0
uremic B-PHYSICAL
pericarditis I-PHYSICAL
. 0

To 0
determine 0
the 0
impact 0
of 0
indomethacin 0
on 0
the 0
course 0
of 0
uremic 0
pericarditis 0
we 0
performed 0
a 0
prospective 0
, 0
double 0
blind 0
study 0
in 0
which 0
24 0
patients 0
with 0
endstage 0
chronic 0
renal 0
failure 0
and 0
pericarditis 0
randomly 0
received 0
indomethacin 0
, 0
25 0
mg 0
four 0
times 0
daily 0
, 0
( 0
11 0
patients 0
) 0
or 0
a 0
placebo 0
( 0
13 0
patients 0
) 0
for 0
a 0
3-week 0
period 0
. 0

All 0
patients 0
received 0
peritoneal 0
or 0
hemodialysis 0
treatment 0
concurrently 0
with 0
the 0
study 0
drug 0
. 0

In 0
contrast 0
to 0
the 0
placebo 0
, 0
indomethacin 0
produced 0
an 0
immediate 0
and 0
sustained 0
reduction B-PHYSICAL
of I-PHYSICAL
fever I-PHYSICAL
in 0
all 0
but 0
one 0
patient 0
. 0

On 0
the 0
other 0
hand 0
, 0
indomethacin 0
had 0
no 0
effect 0
on 0
the 0
duration 0
of 0
chest B-PAIN
pain I-PAIN
( 0
mean 0
days 0
+/- 0
SE 0
: 0
placebo 0
1.4 0
+/- 0
0.6 0
, 0
indomethacin 0
5.5 0
+/- 0
3.3 0
) 0
, 0
duration 0
of 0
pericardial B-PHYSICAL
friction I-PHYSICAL
rub I-PHYSICAL
( 0
placebo 0
10.3 0
+/- 0
1.7 0
, 0
indomethacin 0
16.0 0
+/- 0
3.8 0
) 0
, 0
or 0
on 0
the 0
amount 0
of 0
pericardial B-PHYSICAL
effusion I-PHYSICAL
. 0

Further 0
, 0
indomethacin 0
did 0
not 0
diminish 0
the 0
need 0
for 0
invasive B-PHYSICAL
surgical I-PHYSICAL
procedures I-PHYSICAL
for 0
relief 0
of 0
tamponade B-PHYSICAL
( 0
three 0
of 0
13 0
placebo 0
patients 0
, 0
two 0
of 0
11 0
indomethacin 0
patients 0
) 0
or 0
result 0
in 0
decreased 0
mortality B-MORTALITY
rate I-MORTALITY
. 0

Death B-MORTALITY
( 0
not 0
due 0
to 0
pericarditis 0
) 0
occurred 0
in 0
two 0
patients 0
treated 0
with 0
indomethacin 0
and 0
one 0
patient 0
who 0
received 0
the 0
placebo 0
. 0

In 0
our 0
patients 0
pericarditis 0
encompassed 0
a 0
wide 0
spectrum 0
ranging 0
from 0
a 0
mild B-PHYSICAL
illness I-PHYSICAL
of I-PHYSICAL
several I-PHYSICAL
days B-PHYSICAL
duration I-PHYSICAL
to 0
a 0
painful 0
and 0
debilitating B-PHYSICAL

Clinic 0
visit 0
and 0
waiting 0
: 0
patient B-MENTAL
education I-MENTAL
and 0
satisfaction B-OTHER
. 0

Patients 0
who 0
were 0
taught 0
about 0
their 0
health 0
problems 0
while 0
waiting 0
in 0
the 0
clinic 0
( 0
n 0
= 0
104 0
) 0
were 0
significantly 0
more 0
satisfied B-OTHER
with I-OTHER
the I-OTHER
education I-OTHER
received 0
during 0
that 0
visit 0
than 0
the 0
control 0
group 0
( 0
n 0
= 0
101 0
) 0
. 0

The 0
longer 0
patients 0
waited 0
in 0
the 0
clinic 0
to 0
see 0
their 0
providers 0
, 0
the 0
less 0
satisfied B-OTHER
they 0
were 0
with 0
the 0
clinic 0
visit 0
. 0

Longterm B-OTHER
safety I-OTHER
, 0
efficacy 0
, 0
and 0

The 0
dud 0
effect 0
: 0
adding 0
highly 0
dissimilar 0
fillers 0
increases 0
confidence 0
in 0
lineup 0
identifications 0
. 0

Recent 0
research 0
in 0
decision-making 0
has 0
demonstrated 0
the 0
dud-alternative 0
effect 0
-- 0
the 0
tendency 0
to 0
become 0
more 0
confident 0
that 0
a 0
chosen 0
response 0
option 0
is 0
correct 0
if 0
it 0
is 0
surrounded 0
by 0
implausible 0
response 0
options 0
( 0
Windschitl 0
& 0
Chambers 0
, 0
J 0
Exp 0
Psychol 0
30:198-215 0
, 0
2004 0
) 0
. 0

This 0
finding 0
may 0
be 0
applicable 0
to 0
a 0
lineup 0
task 0
: 0
The 0
presence 0
of 0
duds 0
( 0
i.e. 0
, 0
highly 0
dissimilar 0
fillers 0
) 0
may 0
increase 0
a 0
witness B-MENTAL
's 0
confidence B-MENTAL
that 0
an 0
identified 0
( 0
non-dud 0
) 0
lineup 0
member 0
is 0
the 0
criminal 0
. 0

Four 0
studies 0
( 0
N 0
= 0
665 0
) 0
demonstrate 0
that 0
the 0
mere 0
presence 0
of 0
highly 0
dissimilar 0
fillers 0
inflates 0
witnesses B-OTHER
' 0
confidence B-OTHER
in 0
a 0
mistaken 0
identification 0
( 0
Studies 0
1-4 0
) 0
, 0
provides 0
evidence 0
that 0
this 0

Effect 0
of 0
food 0
on 0
the 0
antiviral B-OTHER
activity I-OTHER
of 0
didanosine 0
enteric-coated 0
capsules 0
: 0
a 0
pilot 0
comparative 0
study 0
. 0

OBJECTIVES 0
To 0
determine 0
the 0
effect 0
of 0
food 0
on 0
the 0
antiviral 0
activity 0
of 0
enteric-coated 0
( 0
EC 0
) 0
capsules 0
of 0
didanosine 0
( 0
ddI 0
) 0
. 0

METHODS 0
We 0
conducted 0
a 0
pilot 0
, 0
randomized 0
, 0
open-label 0
study 0
of 0
28-day 0
ddI-EC 0
capsules 0
monotherapy-administered 0
in 0
a 0
fasted 0
state 0
( 0
group 0
1 0
, 0
n=11 0
) 0
or 0
with 0
food 0
( 0
group 0
2 0
, 0
n=10 0
) 0
to 0
treatment-na?ve 0
chronically 0
HIV-1-infected 0
individuals 0
. 0

To 0
assess 0
the 0
antiviral 0
efficacy 0
, 0
HIV-1 0
RNA 0
was 0
determined 0
at 0
baseline 0
, 0
day 0
3 0
, 0
day 0
7 0
and 0
weekly 0
thereafter 0
. 0

The 0
area 0
under 0
the 0
HIV-1 0
RNA 0
curve 0
minus 0
baseline 0
weighted 0
by 0
time 0
( 0
AUCMB/day 0
) 0
was 0
calculated 0
. 0

RESULTS 0
Mean 0
baseline 0
HIV-1 0
RNA 0
was 0
4.2 0
log 0
( 0
10 0
) 0
copies/mL 0
in 0
group 0
1 0
and 0
3.8 0
log 0
( 0
10 0
) 0
copies/mL 0
in 0
group 0
2 0
. 0

After 0
28 0
days 0
, 0
the 0
mean 0
HIV-1 0
RNA 0
reduction 0
was 0
0.99 0
log 0
( 0
10 0
) 0
copies/mL 0
[ 0
95 0
% 0
confidence 0
interval 0
( 0
CI 0
) 0
0.45-1.53 0
] 0
for 0
group 0
1 0
and 0
0.89 0
log 0
( 0
10 0
) 0
copies/mL 0
( 0
95 0
% 0
CI 0
0.38-1.40 0
) 0
for 0
group 0
2 0
. 0

AUCMB/day 0
values 0
were 0
0.775 0
log 0
( 0
10 0
) 0
copies/mL 0
( 0
95 0
% 0
CI 0
0.33-1.22 0
) 0
and 0
0.774 0
log 0
( 0
10 0
) 0
copies/mL 0
( 0
95 0
% 0
CI 0
0.48-1.07 0
) 0
, 0
respectively 0
, 0
showing 0
no 0
difference 0
in 0
the 0
rate 0
of 0
decrease 0
of 0
HIV-1 0
RNA 0
( 0
P=0.995 0
) 0
. 0

Mean 0
ddI 0
plasma 0
levels 0
at 0
day 0
28 0
were 0
0.0234 0
mg/L 0
for 0
group 0
1 0
and 0
0.0227 0
mg/L 0
for 0
group 0
2 0
( 0
P=0.96 0
) 0
. 0

CONCLUSIONS 0
In 0
this 0
pilot 0
study 0
, 0
the 0
administration 0
of 0
food 0
did 0
not 0
have 0
any 0
significant 0
effect 0
on 0
the 0
antiviral 0
activity 0
of 0
ddI-EC 0
capsules 0
. 0

Overexpression 0
of 0
vascular 0
endothelial 0
growth 0
factor 0
( 0
VEGF 0
) 0
and 0
its 0
cellular 0
receptor 0
KDR 0
( 0
VEGFR-2 0
) 0
in 0
the 0
bone 0
marrow 0
of 0
patients 0
with 0
acute 0
myeloid 0
leukemia 0
. 0

Vascular 0
endothelial 0
growth 0
factor 0
( 0
VEGF 0
) 0
and 0
its 0
cellular 0
receptor 0
VEGFR-2 0
have 0
been 0
implicated 0
as 0
the 0
main 0
endothelial 0
pathway 0
required 0
for 0
tumor 0
neovascularization 0
. 0

However 0
, 0
the 0
importance 0
of 0
the 0
VEGF/VEGFR-2 0
system 0
for 0
angiogenesis 0
in 0
hematologic 0
malignancies 0
such 0
as 0
AML 0
remains 0
to 0
be 0
elucidated 0
. 0

In 0
32 0
patients 0
with 0
newly 0
diagnosed 0
untreated 0
AML 0
, 0
we 0
observed 0
by 0
immunohistochemical 0
analysis 0
of 0
bone 0
marrow 0
biopsies 0
significantly 0
higher 0
levels 0
of 0
VEGF 0
and 0
VEGFR-2 0
expression 0
than 0
in 0
10 0
control 0
patients 0
( 0
P 0
< 0
0.001 0
) 0
. 0

In 0
contrast 0
, 0
VEGFR-1 0
staining 0
levels 0
in 0
AML 0
patients 0
were 0
in 0
the 0
same 0
range 0
as 0
in 0
the 0
controls 0
. 0

Expression 0
of 0
VEGF B-PHYSICAL
and 0
VEGFR-2 B-PHYSICAL
was 0
significantly 0
higher 0
in 0
patients 0
with 0
a 0
high 0
degree 0
of 0
microvessel 0
density 0
compared 0
to 0
those 0
with 0
a 0
low 0
degree 0
( 0
VEGF 0
: 0
P 0
=0.024 0
; 0
VEGFR-2 0
: 0
P 0
=0.040 0
) 0
and 0
correlated 0
well 0
with 0
bone 0
marrow 0
microvessel 0
density 0
( 0
r 0
( 0
s 0
) 0
=0.566 0
and 0
0.609 0
, 0
respectively 0
; 0
P 0
< 0
0.001 0
) 0
. 0

Furthermore 0
, 0
in 0
patients 0
who 0
achieved 0
a 0
complete 0
remission B-PHYSICAL
following 0
induction 0
chemotherapy 0
VEGFR-2 B-PHYSICAL
staining I-PHYSICAL
levels I-PHYSICAL
decreased 0
into 0
the 0
normal 0
range 0
. 0

In 0
conclusion 0
, 0
our 0
results 0
provide 0
evidence 0
for 0
increased 0
expression 0
of 0
VEGF/VEGFR-2 0
of 0
leukemic B-PHYSICAL
blasts I-PHYSICAL
and 0
correlation 0
with 0
angiogenesis 0
in 0
the 0
bone 0
marrow 0
of 0
AML 0
patients 0
. 0

Thus 0
, 0
VEGF/VEGFR-2 0
might 0
constitute 0
promising 0
targets 0
for 0
antiangiogenic 0
and 0
antileukemic 0
treatment 0
strategies 0
in 0
AML 0
. 0

Gene 0
expression 0
of 0
endothelin-1 0
and 0
its 0
receptors 0
in 0
the 0
heart 0
of 0
broiler 0
chickens 0
with 0
T 0
( 0
3 0
) 0
-induced 0
pulmonary 0
hypertension 0
. 0

To 0
investigate 0
the 0
effect 0
of 0
T 0
( 0
3 0
) 0
-induced 0
pulmonary 0
hypertension 0
on 0
endothelin 0
( 0
ET 0
) 0
production 0
and 0
genes B-PHYSICAL
expression I-PHYSICAL
of I-PHYSICAL
ET-1 I-PHYSICAL
, 0
ET B-PHYSICAL
( 0
A B-PHYSICAL
) 0
and B-PHYSICAL
ET I-PHYSICAL
( 0
B B-PHYSICAL
) 0
receptors B-PHYSICAL
( 0
ET B-PHYSICAL
( 0
A B-PHYSICAL
) 0
R 0
and B-PHYSICAL
ET I-PHYSICAL
( 0
B B-PHYSICAL
) 0
R 0
) 0
during 0
rearing 0
, 0
semiquantitative 0
RT-PCR 0
and 0
enzyme 0
immunometric 0
assay 0
were 0
performed 0
in 0
the 0
heart 0
ventricles 0
and 0
serum 0
, 0
respectively 0
. 0

The 0
ET-1 B-PHYSICAL
and I-PHYSICAL
its I-PHYSICAL
receptor I-PHYSICAL
genes I-PHYSICAL
were 0
expressed 0
in 0
the 0
right 0
and 0
left 0
ventricles 0
of 0
control 0
and 0
T 0
( 0
3 0
) 0
-treated 0
broilers 0
at 0
12 0
, 0
28 0
and 0
49 0
days 0
of 0
age 0
. 0

There 0
were 0
significant 0
( 0
P 0
< 0
0.05 0
) 0
reductions 0
of B-PHYSICAL
the I-PHYSICAL
relative I-PHYSICAL
amounts I-PHYSICAL
of I-PHYSICAL
ET-1 I-PHYSICAL
( I-PHYSICAL
in I-PHYSICAL
both B-PHYSICAL
ventricles B-PHYSICAL
) I-PHYSICAL
and I-PHYSICAL
ET I-PHYSICAL
( I-PHYSICAL
A I-PHYSICAL
) I-PHYSICAL
R 0

[ 0
Postoperative 0
analgesia 0
: 0
peridural 0
morphine 0
versus 0
sublingual 0
buprenorphine 0
. 0

Comparative 0
clinical 0
study 0
] 0
. 0

The 0
authors 0
herein 0
present 0
their 0
personal 0
series 0
on 0
the 0
clinical 0
evaluation 0
of 0
the 0
analgesic 0
efficacy 0
of 0
2 0
opiodes 0
, 0
peridural 0
morphine 0
hydrochloride 0
( 0
0.5 0
mg/kg 0
) 0
administered 0
to 0
group 0
A 0
patients 0
, 0
and 0
sublingual 0
buprenorphine 0
( 0
0.4 0
mg 0
) 0
administered 0
to 0
group 0
B 0
patients 0
in 0
the 0
management 0
of 0
post-operative 0
pain 0
in 0
major 0
abdominal 0
surgery 0
. 0

The 0
study 0
was 0
conducted 0
on 0
44 0
patients 0
, 0
both 0
male 0
and 0
female 0
, 0
classified 0
as 0
ASA 0
II 0
and 0
III 0
. 0

Statistical 0
analysis 0
of 0
cardiovascular B-PHYSICAL
parameters I-PHYSICAL
( I-PHYSICAL
BP I-PHYSICAL
and 0
cardiac B-PHYSICAL
frequency 0
) B-PHYSICAL
, 0
respiratory B-PHYSICAL
frequency I-PHYSICAL
and 0
pain B-PAIN
score I-PAIN
showed 0
an 0
overlapping 0
progression 0
among 0
the 0
two 0
groups 0
. 0

Triple 0
antiretroviral 0
compared 0
with 0
zidovudine 0
and 0
single-dose 0
nevirapine 0
prophylaxis 0
during 0
pregnancy 0
and 0
breastfeeding 0
for 0
prevention 0
of 0
mother-to-child 0
transmission 0
of 0
HIV-1 0
( 0
Kesho 0
Bora 0
study 0
) 0
: 0
a 0
randomised 0
controlled 0
trial 0
. 0

BACKGROUND 0
Breastfeeding 0
is 0
essential 0
for 0
child 0
health 0
and 0
development 0
in 0
low-resource 0
settings 0
but 0
carries 0
a 0
significant 0
risk 0
of 0
transmission 0
of 0
HIV-1 0
, 0
especially 0
in 0
late 0
stages 0
of 0
maternal 0
disease 0
. 0

We 0
aimed 0
to 0
assess 0
the 0
efficacy 0
and 0
safety B-OTHER
of 0
triple 0
antiretroviral 0
compared 0
with 0
zidovudine 0
and 0
single-dose 0
nevirapine 0
prophylaxis 0
in 0
pregnant 0
women 0
infected 0
with 0
HIV 0
. 0

METHODS 0
Pregnant 0
women 0
with 0
WHO 0
stage 0
1 0
, 0
2 0
, 0
or 0
3 0
HIV-1 0
infection 0
who 0
had 0
CD4 0
cell 0
counts 0
of 0
200-500 0
cells 0
per 0
?L 0
were 0
enrolled 0
at 0
five 0
study 0
sites 0
in 0
Burkina 0
Faso 0
, 0
Kenya 0
, 0
and 0
South 0
Africa 0
to 0
start 0
study 0
treatment 0
at 0
28-36 0
weeks 0
' 0
gestation 0
. 0

Women 0
were 0
randomly 0
assigned 0
( 0
1:1 0
) 0
by 0
a 0
computer 0
generated 0
random 0
sequence 0
to 0
either 0
triple 0
antiretroviral 0
prophylaxis 0
( 0
a 0
combination 0
of 0
300 0
mg 0
zidovudine 0
, 0
150 0
mg 0
lamivudine 0
, 0
and 0
400 0
mg 0
lopinavir 0
plus 0
100 0
mg 0
ritonavir 0
twice 0
daily 0
until 0
cessation 0
of 0
breastfeeding 0
to 0
a 0
maximum 0
of 0
6?5 0
months 0
post 0
partum 0
) 0
or 0
zidovudine 0
and 0
single-dose 0
nevirapine 0
( 0
300 0
mg 0
zidovudine 0
twice 0
daily 0
until 0
delivery 0
and 0
a 0
dose 0
of 0
600 0
mg 0
zidovudine 0
plus 0
200 0
mg 0
nevirapine 0
at 0
the 0
onset 0
of 0
labour 0
and 0
, 0
after 0
a 0
protocol 0
amendment 0
in 0
December 0
, 0
2006 0
, 0
1 0
week 0
post-partum 0
zidovudine 0
300 0
mg 0
twice 0
daily 0
and 0
lamivudine 0
150 0
mg 0
twice 0
daily 0
) 0
. 0

All 0
infants 0
received 0
a 0
0?6 0
mL 0
dose 0
of 0
nevirapine 0
at 0
birth 0
and 0
, 0
from 0
December 0
, 0
2006 0
, 0
4 0
mg/kg 0
twice 0
daily 0
of 0
zidovudine 0
for 0
1 0
week 0
after 0
birth 0
. 0

Patients 0
and 0
investigators 0
were 0
not 0
masked 0
to 0
treatment 0
. 0

The 0
primary 0
endpoints 0
were 0
HIV-free 0
infant 0
survival 0
at 0
6 0
weeks 0
and 0
12 0
months 0
; 0
HIV-free 0
survival 0
at 0
12 0
months 0
in 0
infants 0
who 0
were 0
ever 0
breastfed 0
; 0
AIDS-free 0
survival 0
in 0
mothers 0
at 0
18 0
months 0
; 0
and 0
serious 0
adverse 0
events 0
in 0
mothers 0
and 0
babies 0
. 0

Analysis 0
was 0
by 0
intention 0
to 0
treat 0
. 0

This 0
trial 0
is 0
registered 0
with 0
Current 0
Controlled 0
Trials 0
, 0
ISRCTN71468401 0
. 0

FINDINGS 0
From 0
June 0
, 0
2005 0
, 0
to 0
August 0
, 0
2008 0
, 0
882 0
women 0
were 0
enrolled 0
, 0
824 0
of 0
whom 0
were 0
randomised 0
and 0
gave 0
birth 0
to 0
805 0
singleton 0
or 0
first 0
, 0
liveborn 0
infants 0
. 0

The 0
cumulative 0
rate 0
of 0
HIV 0
transmission 0
at 0
6 0
weeks 0
was 0
3?3 0
% 0
( 0
95 0
% 0
CI 0
1?9-5?6 0
% 0
) 0
in 0
the 0
triple 0
antiretroviral 0
group 0
compared 0
with 0
5?0 0
% 0
( 0
3?3-7?7 0
% 0
) 0
in 0
the 0
zidovudine 0
and 0
single-dose 0
nevirapine 0
group 0
, 0
and 0
at 0
12 0
months 0
was 0
5?4 0
% 0
( 0
3?6-8?1 0
% 0
) 0
in 0
the 0
triple 0
antiretroviral 0
group 0
compared 0
with 0
9?5 0
% 0
( 0
7?0-12?9 0
% 0
) 0
in 0
the 0
zidovudine 0
and 0
single-dose 0
nevirapine 0
group 0
( 0
p=0?029 0
) 0
. 0

The 0
cumulative 0
rate 0
of 0
HIV 0
transmission 0
or 0
death 0
at 0
12 0
months 0
was 0
10?2 0
% 0
( 0
95 0
% 0
CI 0
7?6-13?6 0
% 0
) 0
in 0
the 0
triple 0
antiretroviral 0
group 0
compared 0
with 0
16?0 0
% 0
( 0
12?7-20?0 0
% 0
) 0
in 0
the 0
zidovudine 0
and 0
single-dose 0
nevirapine 0
group 0
( 0
p=0?017 0
) 0
. 0

In 0
infants 0
whose 0
mothers 0
declared 0
they 0
intended 0
to 0
breastfeed 0
, 0
the 0
cumulative 0
rate 0
of 0
HIV 0
transmission 0
at 0
12 0
months 0
was 0
5?6 0
% 0
( 0
95 0
% 0
CI 0
3?4-8?9 0
% 0
) 0
in 0
the 0
triple 0
antiretroviral 0
group 0
compared 0
with 0
10?7 0
% 0
( 0
7?6-14?8 0
% 0
) 0
in 0
the 0
zidovudine 0
and 0
single-dose 0
nevirapine 0
group 0
( 0
p=0?02 0
) 0
. 0

AIDS-free 0
survival 0
in 0
mothers 0
at 0
18 0
months 0
will 0
be 0
reported 0
in 0
a 0
different 0
publication 0
. 0

The 0
incidence 0
of 0
laboratory 0
and 0
clinical 0
serious 0
adverse 0
events 0
in 0
both 0
mothers 0
and 0
their 0
babies 0
was 0
similar 0
between 0
groups 0
. 0

INTERPRETATION 0
Triple 0
antiretroviral 0
prophylaxis 0
during 0
pregnancy 0
and 0
breastfeeding 0
is 0
safe 0
and 0
reduces 0
the 0
risk 0
of 0
HIV 0
transmission 0
to 0
infants 0
. 0

Revised 0
WHO 0
guidelines 0
now 0
recommend 0
antiretroviral 0
prophylaxis 0
( 0
either 0
to 0
the 0
mother 0
or 0
to 0
the 0
baby 0
) 0
during 0
breastfeeding 0
if 0
the 0
mother 0
is 0
not 0
already 0
receiving 0
antiretroviral 0
treatment 0
for 0
her 0
own 0
health 0
. 0

FUNDING 0
Agence 0
nationale 0
de 0
recherches 0
sur 0
le 0
sida 0
et 0
les 0
h?patites 0
virales 0
, 0
Department 0
for 0
International 0
Development 0
, 0
European 0
and 0
Developing 0
Countries 0
Clinical 0
Trials 0
Partnership 0
, 0
Thrasher 0
Research 0
Fund 0
, 0
Belgian 0
Directorate 0
General 0
for 0
International 0
Cooperation 0
, 0
Centers 0
for 0
Disease 0
Control 0
and 0
Prevention 0
, 0
Eunice 0
Kennedy 0
Shriver 0
National 0
Institute 0
of 0
Child 0
Health 0
and 0
Human 0
Development 0
, 0
and 0
UNDP/UNFPA/World 0
Bank/WHO 0
Special 0
Programme 0
of 0
Research 0
, 0
Development 0
and 0
Research 0
Training 0
in 0
Human 0
Reproduction 0
. 0

Effects 0
of 0
a 0
common 0
variant 0
in 0
the 0
CD38 0
gene 0
on 0
social B-MENTAL
processing I-MENTAL
in 0
an 0
oxytocin 0
challenge 0
study 0
: 0
possible 0
links 0
to 0
autism 0
. 0

The 0
intranasal 0
application 0
of 0
oxytocin 0
( 0
OT 0
) 0
has 0
been 0
shown 0
to 0
influence 0
behavioral B-MENTAL
and 0
neural B-MENTAL
correlates I-MENTAL
of I-MENTAL
social I-MENTAL
processing I-MENTAL
. 0

These 0
effects 0
are 0
probably 0
mediated 0
by 0
genetic 0
variations 0
within 0
the 0
OT 0
system 0
. 0

One 0
potential 0
candidate 0
could 0
be 0
the 0
CD38 0
gene 0
, 0
which 0
codes 0
for 0
a 0
transmembrane 0
protein 0
engaged 0
in 0
OT 0
secretion 0
processes 0
. 0

A 0
common 0
variation 0
in 0
this 0
gene 0
( 0
rs3796863 0
) 0
was 0
recently 0
found 0
to 0
be 0
associated 0
with 0
autism 0
spectrum 0
disorders 0
( 0
ASD 0
) 0
. 0

Using 0
an 0
imaging 0
genetics 0
approach 0
, 0
we 0
studied 0
differential 0
effects 0
of 0
an 0
intranasal 0
OT 0
application 0
on 0
neural B-MENTAL
processing I-MENTAL
of I-MENTAL
social I-MENTAL
stimuli I-MENTAL
in 0
55 0
healthy 0
young 0
men 0
depending 0
on 0
their 0
CD38 0
gene 0
variant 0
in 0
a 0
double-blind 0
placebo-controlled 0
crossover 0
design 0
. 0

Genotype 0
had 0
a 0
significant 0
influence 0
on 0
both 0
behavioral B-MENTAL
and 0
neuronal B-MENTAL
measures I-MENTAL
of I-MENTAL
social I-MENTAL
processing I-MENTAL
. 0

Homozygotic 0
risk 0
allele 0
carriers 0
showed 0
slower 0
reaction 0
times 0
( 0
RT 0
) 0
and 0
higher 0
activation 0
of 0
left B-MENTAL
fusiform I-MENTAL
gyrus I-MENTAL
during 0
visual 0
processing 0
of 0
social B-MENTAL
stimuli I-MENTAL
. 0

Under 0
OT 0
activation B-MENTAL
differences I-MENTAL
between 0
genotypes 0
were 0
more 0
evident 0
( 0
though 0
not 0
statistically 0
significantly 0
increased 0
) 0
and 0
RT 0
were 0
accelerated 0
in 0
homozygotic 0
risk 0
allele 0
carriers 0
. 0

According 0
to 0
our 0
data 0
, 0
rs3796863 B-MENTAL
mainly I-MENTAL
influences I-MENTAL
fusiform I-MENTAL
gyrus I-MENTAL
activation I-MENTAL
, 0
an 0
area 0
which 0
has 0
been 0
widely 0
discussed 0
in 0
ASD 0
research 0
. 0

OT 0
seems 0
to 0
modulate 0
this 0
effect 0
by 0
enhancing 0
activation B-MENTAL
differences I-MENTAL
between 0
allele 0
groups 0
, 0
which 0
suggests 0
an 0
interaction 0
between 0
genetic B-PHYSICAL
makeup I-PHYSICAL
and 0
OT B-PHYSICAL
availability I-PHYSICAL
on 0
fusiform B-MENTAL
gyrus I-MENTAL
activation I-MENTAL
. 0

These 0
results 0
support 0
recent 0
approaches 0
to 0
apply 0
OT 0
as 0
a 0
pharmacological 0
treatment 0
of 0
ASD 0
symptoms 0
. 0

Pharmacokinetic-pharmacodynamic B-OTHER
modelling I-OTHER
of 0
the 0
antihistaminic 0
( 0
H1 0
) 0
effect 0
of 0
bilastine 0
. 0

OBJECTIVE 0
To 0
model 0
the 0
pharmacokinetic B-PHYSICAL
and 0
pharmacodynamic B-PHYSICAL
relationship 0
of 0
bilastine 0
, 0
a 0
new 0
histamine 0
H 0
( 0
1 0
) 0
receptor 0
antagonist 0
, 0
from 0
single- 0
and 0
multiple-dose 0
studies 0
in 0
healthy 0
adult 0
subjects 0
. 0

METHODS 0
The 0
pharmacokinetic 0
model 0
was 0
developed 0
from 0
different 0
single-dose 0
and 0
multiple-dose 0
studies 0
. 0

In 0
the 0
single-dose 0
studies 0
, 0
a 0
total 0
of 0
183 0
subjects 0
received 0
oral 0
doses 0
of 0
bilastine 0
2.5 0
, 0
5 0
, 0
10 0
, 0
20 0
, 0
50 0
, 0
100 0
, 0
120 0
, 0
160 0
, 0
200 0
and 0
220 0
mg 0
. 0

In 0
the 0
multiple-dose 0
studies 0
, 0
127 0
healthy 0
subjects 0
received 0
bilastine 0
10 0
, 0
20 0
, 0
40 0
, 0
50 0
, 0
80 0
, 0
100 0
, 0
140 0
or 0
200 0
mg/day 0
as 0
multiple 0
doses 0
during 0
a 0
4- 0
, 0
7- 0
or 0
14-day 0
period 0
. 0

The 0
pharmacokinetic B-OTHER
profile I-OTHER
of 0
bilastine 0
was 0
investigated 0
using 0
a 0
simultaneous 0
analysis 0
of 0
all 0
concentration-time B-OTHER
data I-OTHER
by 0
means 0
of 0
nonlinear 0
mixed-effects 0
modelling 0
population 0
pharmacokinetic 0
software 0
NONMEM 0
version 0
6.1 0
. 0

Plasma B-PHYSICAL
concentrations I-PHYSICAL
were 0
modelled 0
according 0
to 0
a 0
two-compartment 0
open 0
model 0
with 0
first-order 0
absorption 0
and 0
elimination 0
. 0

For 0
the 0
pharmacodynamic 0
analysis 0
, 0
the 0
inhibitory 0
effect 0
of 0
bilastine 0
( 0
inhibition 0
of 0
histamine-induced 0
wheal 0
and 0
flare 0
) 0
was 0
assessed 0
on 0
a 0
preselected 0
time 0
schedule 0
, 0
and 0
the 0
predicted 0
typical B-OTHER
pharmacokinetic I-OTHER
profile I-OTHER
( 0
based 0
on 0
the 0
pharmacokinetic 0
model 0
previously 0
developed 0
) 0
was 0
used 0
. 0

An 0
indirect 0
response 0
model 0
was 0
developed 0
to 0
describe 0
the 0
pharmacodynamic B-OTHER
relationships I-OTHER
between 0
flare 0
or 0
wheal 0
areas 0
and 0
bilastine 0
plasma 0
concentrations 0
. 0

Finally 0
, 0
once 0
values 0
of 0
the 0
concentration 0
that 0
produced B-OTHER
50 I-OTHER
% I-OTHER
inhibition I-OTHER
( 0
IC B-OTHER
( 0
50 B-OTHER
) 0
) 0
had 0
been 0
estimated 0
for 0
wheal 0
and 0
flare 0
effects 0
, 0
simulations 0
were 0
carried 0
out 0
to 0
predict 0
plasma B-PHYSICAL
concentrations I-PHYSICAL
for 0
the 0
doses 0
of 0
bilastine 0
5 0
, 0
10 0
and 0
20 0
mg 0
at 0
steady 0
state 0
( 0
72-96 0
hours 0
) 0
. 0

RESULTS 0
A 0
non-compartmental 0
analysis 0
resulted 0
in 0
linear 0
kinetics 0
of 0
bilastine 0
in 0
the 0
dose 0
range 0
studied 0
. 0

Bilastine 0
was 0
characterized 0
by 0
two-compartmental 0
kinetics 0
with 0
a 0
rapid-absorption 0
phase 0
( 0
first-order 0
absorption 0
rate 0
constant 0
= 0
1.50 0
h 0
( 0
-1 0
) 0
) 0
, 0
plasma B-PHYSICAL
peak 0
concentrations B-PHYSICAL
were 0
observed 0
at 0
1 0
hour 0
following 0
administration 0
and 0
the 0
maximal B-OTHER
response I-OTHER
was 0
observed 0
at 0
approximately 0
4 0
hours 0
or 0
later 0
. 0

Concerning 0
the 0
selected 0
pharmacodynamic 0
model 0
to 0
fit 0
the 0
data 0
( 0
type 0
I 0
indirect 0
response 0
model 0
) 0
, 0
this 0
selection 0
is 0
attributable 0
to 0
the 0
presence 0
of 0
inhibitory 0
bilastine 0
plasma 0
concentrations 0
that 0
decrease 0
the 0
input B-OTHER
response 0
function B-OTHER
, 0
i.e 0
. 0

the 0
production 0
of 0
the 0
skin 0
reaction 0
. 0

This 0
model 0
resulted 0
in 0
the 0
best 0
fit 0
of 0
wheal 0
and 0
flare 0
data 0
. 0

The 0
estimates 0
( 0
with 0
relative 0
standard 0
errors 0
expressed 0
in 0
percentages 0
in 0
parentheses 0
) 0
of 0
the 0
apparent B-PHYSICAL
zero-order I-PHYSICAL
rate I-PHYSICAL
constant B-PHYSICAL
for I-PHYSICAL
flare I-PHYSICAL
or 0
wheal B-PHYSICAL
spontaneous B-PHYSICAL
appearance I-PHYSICAL
( 0
k 0
( 0
in 0
) 0
) 0
, 0
the 0
first-order B-PHYSICAL
rate I-PHYSICAL
constant B-PHYSICAL
for I-PHYSICAL
flare I-PHYSICAL
or 0
wheal B-PHYSICAL
disappearance I-PHYSICAL
( 0
k 0
( 0
out 0
) 0
) 0
and 0

The 0
effect 0
of 0
prophylactic 0
calcium 0
and 0
magnesium 0
infusions 0
on 0
the 0
incidence 0
of 0
neurotoxicity 0
and 0
clinical 0
outcome 0
of 0
oxaliplatin-based 0
systemic 0
treatment 0
in 0
advanced 0
colorectal 0
cancer 0
patients 0
. 0

BACKGROUND 0
Peripheral 0
sensory 0
neurotoxicity 0
is 0
a 0
frequent 0
and 0
potentially 0
debilitating 0
side 0
effect 0
of 0
oxaliplatin 0
treatment 0
. 0

Calcium 0
and 0
magnesium 0
( 0
Ca/Mg 0
) 0
infusions 0
are 0
frequently 0
used 0
to 0
prevent 0
this 0
toxicity 0
. 0

However 0
, 0
concerns 0
about 0
a 0
negative 0
impact 0
of 0
Ca/Mg 0
infusions 0
on 0
outcome 0
have 0
been 0
raised 0
. 0

We 0
retrospectively 0
assessed 0
the 0
effect 0
of 0
Ca/Mg 0
infusions 0
on 0
the 0
incidence 0
of 0
neurotoxicity B-PHYSICAL
and 0
on 0
clinical B-PHYSICAL
outcome I-PHYSICAL
in 0
advanced 0
colorectal 0
cancer 0
( 0
ACC 0
) 0
patients 0
treated 0
in 0
the 0
phase 0
III 0
CAIRO2 0
study 0
. 0

MATERIALS 0
AND 0
METHODS 0
Seven 0
hundred 0
and 0
fifty 0
five 0
previously 0
untreated 0
ACC 0
patients 0
were 0
randomised 0
between 0
treatment 0
with 0
capecitabine 0
, 0
oxaliplatin 0
and 0
bevacizumab 0
or 0
the 0
same 0
combination 0
with 0
the 0
addition 0
of 0
cetuximab 0
. 0

Patients 0
were 0
retrospectively 0
divided 0
into 0
two 0
groups 0
: 0
patients 0
in 0
the 0
Ca/Mg 0
( 0
+ 0
) 0
group 0
received 0
Ca/Mg 0
at 0
least 0
during 0
their 0
first 0
treatment 0
cycle 0
, 0
and 0
patients 0
in 0
the 0
Ca/Mg 0
( 0
- 0
) 0
group 0
did 0
not 0
. 0

RESULTS 0
Seven 0
hundred 0
and 0
thirty 0
two 0
patients 0
were 0
evaluable 0
for 0
this 0
analysis 0
. 0

The 0
Ca/Mg 0
( 0
+ 0
) 0
group 0
consisted 0
of 0
551 0
patients 0
, 0
the 0
Ca/Mg 0
( 0
- 0
) 0
group 0
consisted 0
of 0
181 0
patients 0
. 0

The 0
incidence 0
of 0
all 0
grade 0
neurotoxicity B-PHYSICAL
in 0
the 0
Ca/Mg 0
( 0
+ 0
) 0
group 0
and 0
the 0
Ca/Mg 0
( 0
- 0
) 0
group 0
was 0
85 0
% 0
and 0
92 0
% 0
, 0
respectively 0
( 0
p 0
= 0
0.02 0
) 0
, 0
and 0
the 0
incidence 0
of 0
grade 0
? 0

2 0
neurotoxicity 0
was 0
40 0
% 0
and 0
45 0
% 0
, 0
respectively 0
( 0
p 0
= 0
0.22 0
) 0
. 0

The 0
median 0
PFS 0
in 0
the 0
Ca/Mg 0
( 0
+ 0
) 0
versus 0
Ca/Mg 0
( 0
- 0
) 0
group 0
was 0
10.1 0
versus 0
10.7 0
months 0
( 0
p 0
= 0
0.92 0
) 0
, 0
the 0
median 0
OS 0
was 0
19.8 0
versus 0
20.7 0
months 0
( 0
p 0
= 0
0.10 0
) 0
, 0
and 0
the 0
response 0
rate 0
was 0
43.1 0
% 0
versus 0
50 0
% 0
( 0
p 0
= 0
0.11 0
) 0
, 0
respectively 0
. 0

CONCLUSIONS 0
In 0
this 0
largest 0
retrospective 0
analysis 0
to 0
date 0
we 0
observed 0
that 0
Ca/Mg 0
infusions 0
significantly 0
reduced 0
all 0
grade 0
oxaliplatin-related 0
neurotoxicity 0
. 0

Ca/Mg 0
infusions 0
did 0
not 0
affect 0
the 0
clinical 0
efficacy 0
of 0
treatment 0
. 0

The 0
effect 0
of 0
splinting 0
of 0
teeth 0
in 0
combination 0
with 0
reconstructive 0
periodontal 0
surgery 0
in 0
humans 0
. 0

The 0
purpose 0
of 0
this 0
study 0
was 0
to 0
evaluate 0
the 0
effect 0
of 0
splinting 0
teeth 0
on 0
the 0
results 0
of 0
periodontal 0
reconstructive 0
surgery 0
using 0
a 0
specific 0
carbonate 0
bone 0
replacement 0
graft 0
( 0
BRG 0
) 0
material 0
. 0

Forty-five 0
patients 0
were 0
randomly 0
treated 0
with 0
a 0
periodontal 0
surgery 0
approach 0
. 0

Natural 0
coral 0
calcium 0
BRG 0
was 0
utilised 0
in 0
33 0
patients 0
. 0

This 0
33-patient 0
group 0
was 0
divided 0
into 0
three 0
equal 0
groups 0
. 0

In 0
the 0
presplint 0
group 0
, 0
teeth 0
were 0
splinted 0
to 0
at 0
least 0
two 0
rigid 0
teeth 0
before 0
surgery 0
, 0
in 0
the 0
postsplint 0
group 0
, 0
teeth 0
were 0
splinted 0
at 0
suture 0
removal 0
, 0
and 0
in 0
the 0
nonsplint 0
group 0
, 0
the 0
treated 0
teeth 0
were 0
not 0
splinted 0
at 0
all 0
. 0

In 0
12 0
patients 0
, 0
teeth 0
were 0
treated 0
with 0
surgical 0
debridement 0
( 0
DEBR 0
) 0
alone 0
and 0
not 0
splinted 0
. 0

Periodontal 0
probing 0
depth 0
( 0
PPD 0
) 0
, 0
clinical 0
probing 0
attachment 0
level 0
( 0
CPAL 0
) 0
, 0
and 0
tooth 0
mobility 0
were 0
measured 0
using 0
desmodontometry 0
( 0
DDM 0
) 0
and 0
periotest 0
( 0
PTV 0
) 0
with 0
reproducible 0
methods 0
before 0
surgery 0
and 0
at 0
various 0
periods 0
up 0
to 0
1 0
year 0
afterwards 0
. 0

A 0
decrease 0
in 0
PPD B-OTHER
( 0
5.4 0
mm 0
, 0
SD 0
1.4 0
mm 0
) 0
and 0
tooth B-PHYSICAL
mobility I-PHYSICAL
( 0
DDM-horizontal 0
257 0
microns 0
, 0
SD 0
60 0
microns 0
) 0
and 0
a 0
gain B-OTHER
of I-OTHER
CPAL I-OTHER
( 0
5.1 0
mm 0
, 0
SD 0
1.4 0
mm 0
) 0
were 0
seen 0
following 0
the 0
use 0
of 0
BRG 0
in 0
presplint 0
teeth 0
. 0

In 0
the 0
same 0
group 0
, 0
PPD B-OTHER
and 0
tooth B-PHYSICAL
mobility I-PHYSICAL
were 0
significantly 0
reduced 0
compared 0
to 0
nonsplint 0
teeth 0
. 0

DEBR 0
alone 0
showed 0
reductions 0
in 0
tooth B-PHYSICAL
mobility I-PHYSICAL
and 0
PPD B-OTHER
and 0
a 0
significantly 0
smaller 0
gain 0
in 0
CPAL B-OTHER
than 0
in 0
presplint 0
teeth 0
treated 0
with 0
BRG 0
. 0

The 0
less 0
favourable 0
improvement 0
in 0
periodontal 0
function 0
of 0
postsplint 0
or 0
nonsplint 0
teeth 0
seemed 0
to 0
be 0
due 0
to 0
the 0
loss 0
of 0
BRG B-PHYSICAL
material I-PHYSICAL
caused 0
by 0
tooth B-PHYSICAL
mobility I-PHYSICAL
. 0

These 0
results 0
indicate 0
that 0
an 0
undisturbed 0
wound 0
healing 0
process 0
using 0
BRG 0
together 0
with 0
tooth 0
stability 0
is 0
beneficial 0
to 0
overall B-PHYSICAL
clinical I-PHYSICAL
success I-PHYSICAL
. 0

Stability 0
, 0
tipping 0
and 0
relapse 0
of 0
bone-borne 0
versus 0
tooth-borne 0
surgically 0
assisted 0
rapid 0
maxillary 0
expansion 0
; 0
a 0
prospective 0
randomized 0
patient 0
trial 0
. 0

This 0
study 0
evaluated 0
stability 0
, 0
tipping 0
and 0
relapse 0
after 0
surgically 0
assisted 0
rapid 0
maxillary 0
expansion 0
( 0
SARME 0
) 0
, 0
comparing 0
bone-borne 0
and 0
tooth-borne 0
devices 0
, 0
in 0
skeletally 0
matured 0
non-syndromal 0
patients 0
with 0
transverse 0
maxillary 0
hypoplasia 0
. 0

The 0
study 0
is 0
a 0
randomized 0
, 0
open-label 0
, 0
clinical 0
trial 0
. 0

Patients 0
were 0
randomized 0
to 0
bone-borne 0
( 0
n=25 0
) 0
and 0
tooth-borne 0
( 0
n=21 0
) 0
groups 0
. 0

The 0
surgical 0
technique 0
for 0
corticotomy 0
was 0
the 0
same 0
in 0
both 0
groups 0
. 0

Expansion 0
was 0
performed 0
using 0
a 0
bone-borne 0
or 0
tooth-borne 0
device 0
. 0

Dental 0
study 0
casts 0
, 0
lateral 0
and 0
postero-anterior 0
cephalograms 0
were 0
taken 0
before 0
treatment 0
, 0
after 0
the 0
distraction 0
phase 0
and 0
at 0
12-month 0
follow 0
up 0
. 0

Stability B-PHYSICAL
, 0
segmental B-PHYSICAL
maxillary I-PHYSICAL
tipping I-PHYSICAL
and 0
relapse B-PHYSICAL
were 0
studied 0
. 0

23 0
bone-borne 0
and 0
19 0
tooth-borne 0
patients 0
were 0
analyzed 0
. 0

There 0
were 0
no 0
significant 0
differences 0
between 0
the 0
two 0
groups 0
. 0

Widening B-PHYSICAL
was 0
comparable 0
at 0
canine 0
, 0
premolar 0
and 0
molar 0
level 0
. 0

Relapse B-PHYSICAL
was 0
not 0
significant 0
and 0
at 0
follow 0
up 0
the 0
significant 0
increase 0
in 0
distance 0
was 0
sustained 0
. 0

A 0
significant 0
increase 0
in 0
palatal B-PHYSICAL
width I-PHYSICAL
, I-PHYSICAL
at I-PHYSICAL
premolar I-PHYSICAL
and I-PHYSICAL
molar I-PHYSICAL
level I-PHYSICAL
, 0
occurred 0
in 0
both 0
groups 0
. 0

The 0
maxilla 0
moves 0
slightly 0
downward 0
in 0
SARME 0
. 0

Segmental B-PHYSICAL
maxillary I-PHYSICAL
tipping I-PHYSICAL
occurred 0
in 0
both 0
groups 0
and 0
did 0
not 0
affect 0
relapse B-PHYSICAL
. 0

There 0
is 0
no 0
significant 0
difference 0
between 0
the 0
two 0
groups 0
. 0

In 0
SARME 0
, 0
the 0
widening 0
achieved 0
at 0
dental 0
level 0
is 0
stable 0
after 0
12 0
months 0
. 0

Over-correction 0
is 0
not 0
necessary 0
. 0

Tipping 0
of 0
the 0
maxillary 0
segments 0
and 0
increases 0
in 0
the 0
retention B-PHYSICAL
period I-PHYSICAL
are 0
equal 0
in 0
both 0
groups 0
. 0

Divalproex 0
sodium 0
vs 0
placebo 0
for 0
the 0
treatment 0
of 0
irritability B-MENTAL
in 0
children 0
and 0
adolescents 0
with 0
autism 0
spectrum 0
disorders 0
. 0

Autism 0
spectrum 0
disorders 0
( 0
ASDs 0
) 0
are 0
neurodevelopmental 0
disorders 0
characterized 0
by 0
social 0
and 0
language 0
deficits 0
and 0
by 0
repetitive 0
behaviors 0
and 0
interests 0
. 0

Irritability/aggression 0
is 0
a 0
significant 0
comorbid 0
symptom 0
in 0
this 0
population 0
, 0
which 0
greatly 0
impacts 0
burden 0
of 0
care 0
. 0

This 0
study 0
examined 0
the 0
effect 0
of 0
divalproex 0
sodium 0
for 0
irritability/aggression 0
in 0
children 0
and 0
adolescents 0
with 0
ASD 0
. 0

This 0
was 0
a 0
12-week 0
randomized 0
, 0
double-blind 0
, 0
placebo-controlled 0
trial 0
. 0

All 0
efficacy 0
measures 0
were 0
obtained 0
by 0
an 0
independent 0
evaluator 0
blinded 0
to 0
randomization 0
condition 0
and 0
side 0
effects 0
. 0

A 0
total 0
of 0
55 0
subjects 0
gavetheir 0
consent 0
and 0
27 0
were 0
randomized 0
in 0
a 0
1 0
: 0
1 0
manner 0
( 0
mean 0
age 0
9.46+/-2.46 0
, 0
mean 0
nonverbal 0
IQ 0
63.3+/-23.9 0
) 0
. 0

Two 0
subjects 0
from 0
the 0
active 0
group 0
and 0
one 0
subject 0
from 0
the 0
placebo 0
group 0
discontinued 0
the 0
study 0
because 0
of 0
either 0
a 0
lack 0
of 0
efficacy 0
or 0
side 0
effects 0
( 0
increased 0
irritability 0
) 0
. 0

Primary 0
outcome 0
measures 0
were 0
Aberrant B-MENTAL
Behavior I-MENTAL
Checklist-Irritability I-MENTAL
subscale I-MENTAL
and I-MENTAL
Clinical I-MENTAL
Global I-MENTAL
Impression-Improvement I-MENTAL
, 0
which 0
focused 0
on 0
irritability 0
. 0

Overall 0
, 0
62.5 0
% 0
of 0
divalproex 0
subjects 0
vs 0
9 0
% 0
of 0
placebo 0
subjects 0
were 0
responders B-MENTAL
( 0
CGI-irritability 0
OR 0
: 0
16.7 0
, 0
Fisher 0
's 0
exact 0
p=0.008 0
) 0
. 0

A 0
statistically 0
significant 0
improvement 0
was 0
also 0
noted 0
on 0
the 0
ABC-Irritability B-MENTAL
subscale I-MENTAL
( 0
p=0.048 0
) 0
. 0

There 0
was 0
a 0
trend 0
for 0
responders 0
to 0
have 0
higher 0
valproate B-PHYSICAL
blood I-PHYSICAL
levels I-PHYSICAL
compared 0
with 0
nonresponders 0
. 0

This 0
study 0
suggests 0
the 0
efficacy 0
of 0
divalproex 0
for 0
the 0
treatment 0
of 0
irritability B-MENTAL
in 0
children 0
and 0
adolescents 0
with 0
ASD 0
. 0

Larger 0
sample 0
follow-up 0
studies 0
are 0
warranted 0
. 0

The 0
role 0
of 0
the 0
MA-sensitive 0
leukocyte 0
chemotaxis 0
in 0
rheumatoid 0
arthritis 0
. 0

A 0
randomized 0
double-blind 0
clinical 0
trial 0
of 0
griseofulvin 0
treatment 0
. 0

Polymorphonuclear 0
leukocyte 0
( 0
PMN 0
) 0
chemotaxis 0
is 0
thought 0
to 0
play 0
an 0
essential 0
role 0
in 0
the 0
pathogenesis 0
of 0
rheumatoid 0
arthritis 0
. 0

PMN 0
chemotaxis 0
is 0
in 0
part 0
sensitive 0
to 0
microtubule 0
antagonists 0
( 0
MAs 0
) 0
, 0
e.g 0
. 0

colchicine 0
. 0

The 0
antimycotic 0
antibiotic 0
griseofulvin 0
inhibits 0
the 0
MA-sensitive 0
PMN 0
chemotaxis 0
in 0
vitro 0
in 0
concentrations 0
far 0
below 0
those 0
obtained 0
in 0
serum 0
during 0
antimycotic 0
therapy 0
. 0

The 0
role 0
of 0
the 0
MA-sensitive 0
chemotaxis 0
in 0
rheumatoid 0
arthritis 0
could 0
thus 0
be 0
elucidated 0
by 0
a 0
clinical 0
trial 0
of 0
griseofulvin 0
treatment 0
. 0

Griseofulvin 0
( 0
n 0
= 0
20 0
) 0
was 0
tested 0
in 0
a 0
randomized 0
double-blind 0
study 0
versus 0
placebo 0
( 0
m 0
= 0
19 0
) 0
during 0
one 0
year 0
in 0
patients 0
with 0
rheumatoid 0
arthritis 0
of 0
mild-moderate 0
activity 0
. 0

No 0
beneficial B-OTHER
effect 0
of 0
griseofulvin 0
treatment 0
was 0
noted 0
on 0
clinical B-PHYSICAL
symptoms I-PHYSICAL
or I-PHYSICAL
laboratory I-PHYSICAL
parameters I-PHYSICAL
of 0
rheumatoid 0
arthritis 0
. 0

Moreover 0
, 0
the 0
placebo-treated 0
patients 0
showed 0
more 0
improvement B-OTHER
than 0
the 0
griseofulvin-treated 0
patients 0
. 0

It 0
is 0
therefore 0
suggested 0
that 0
the 0
MA-sensitive 0
chemotaxis 0
plays 0
a 0
reparative 0
role 0
in 0
the 0
inflammatory 0
lesions 0
of 0
rheumatoid 0
arthritis 0
. 0

What 0
is 0
the 0
optimum 0
maximal 0
gonadotropin 0
dosage 0
used 0
in 0
microdose 0
flare-up 0
cycles 0
in 0
poor 0
responders 0
? 0

OBJECTIVE 0
To 0
find 0
out 0
the 0
optimum 0
maximal 0
dosage 0
of 0
recombinant 0
follicle 0
stimulating 0
hormone 0
( 0
rFSH 0
) 0
in 0
microdose 0
gonadotropin-releasing 0
hormone 0
analog 0
( 0
GnRH-a 0
) 0
flare 0
cycles 0
in 0
poor 0
responders 0
. 0

DESIGN 0
Prospective 0
randomized 0
study 0
. 0

SETTING 0
Private 0
infertility 0
clinic 0
. 0

PATIENT 0
( 0
S 0
) 0
A 0
total 0
of 0
119 0
women 0
were 0
taken 0
into 0
the 0
study 0
. 0

INTERVENTION 0
( 0
S 0
) 0
The 0
study 0
group 0
underwent 0
a 0
microdose 0
protocol 0
with 0
a 0
GnRH-agonist 0
followed 0
by 0
rFSH 0
administration 0
. 0

On 0
the 0
third 0
day 0
of 0
GnRH-a 0
administration 0
, 0
119 0
patients 0
were 0
randomized 0
in 0
three 0
groups 0
to 0
receive 0
daily 0
fixed 0
doses 0
of 0
300 0
IU 0
of 0
rFSH 0
( 0
group 0
A 0
, 0
n 0
= 0
38 0
) 0
, 0
or 0
450 0
IU 0
of 0
rFSH 0
( 0
group 0
B 0
, 0
n 0
= 0
39 0
) 0
, 0
or 0
600 0
IU 0
of 0
rFSH 0
( 0
group 0
C 0
, 0
n 0
= 0
42 0
) 0
. 0

MAIN 0
OUTCOME 0
MEASURE 0
( 0
S 0
) 0
Peak 0
E 0
( 0
2 0
) 0
levels 0
, 0
days 0
of B-ADVERSE-EFFECTS
stimulation 0
with 0
rFSH 0
, 0
total 0
rFSH 0
dosage 0
, 0
total 0
number B-ADVERSE-EFFECTS
of I-ADVERSE-EFFECTS
oocytes I-ADVERSE-EFFECTS
retrieved B-ADVERSE-EFFECTS
, 0
M2 0
oocytes B-ADVERSE-EFFECTS
retrieved I-ADVERSE-EFFECTS
, 0
total 0
number B-ADVERSE-EFFECTS
of I-ADVERSE-EFFECTS
embryos I-ADVERSE-EFFECTS
, 0
number B-ADVERSE-EFFECTS
of B-ADVERSE-EFFECTS
embryos I-ADVERSE-EFFECTS
transferred 0
, 0
number B-ADVERSE-EFFECTS
of I-ADVERSE-EFFECTS
Grade-1 0
embryos B-ADVERSE-EFFECTS
transferred 0
, 0
clinical 0
pregnancy 0
rate 0
( 0
positive 0
fetal 0
cardiac 0
activity 0
) 0
, 0
and 0
cancellation 0
rates 0
of B-ADVERSE-EFFECTS
stimulation 0
and 0
embryo 0
transfer 0
. 0

RESULT 0
( 0
S 0
) 0

Parietal B-PHYSICAL
cell I-PHYSICAL
density I-PHYSICAL
in 0
duodenal 0
ulcer 0
patients 0
after 0
short-term 0
treatment 0
with 0
cimetidine 0
and 0
antacids 0
. 0

In 0
a 0
prospective 0
study 0
, 0
20 0
patients 0
with 0
endoscopically 0
proven 0
duodenal 0
ulcers 0
were 0
randomised 0
to 0
be 0
treated 0
with 0
cimetidine 0
1 0
g 0
daily 0
or 0
with 0
antacids 0
350 0
mmol 0
daily 0
. 0

The 0
duration 0
of 0
treatment 0
was 0
30 0
days 0
, 0
but 0
this 0
was 0
extended 0
to 0
three 0
months 0
in 0
3 0
patients 0
in 0
the 0
cimetidine 0
group 0
and 0
4 0
patients 0
in 0
the 0
antacid 0
group 0
. 0

A 0
morphological 0
study 0
of 0
biopsies 0
taken 0
via 0
a 0
gastroscope 0
from 0
the 0
corpus 0
mucosa 0
showed 0
no 0
change 0
in 0
mucosal B-PHYSICAL
height I-PHYSICAL
, 0
parietal B-PHYSICAL
cell I-PHYSICAL
density I-PHYSICAL
per I-PHYSICAL
unit I-PHYSICAL
volume I-PHYSICAL
or 0
changes 0
in 0
cellular B-PHYSICAL
infiltration I-PHYSICAL
after 0
30 0
and 0
90 0
days 0
treatment 0
in 0
the 0
two 0
groups 0
. 0

Neither 0
H-2 0
receptor 0
blockers 0
nor 0
antacids 0
alter 0
mucosal B-PHYSICAL
height I-PHYSICAL
or 0
parietal B-PHYSICAL
cell I-PHYSICAL
density I-PHYSICAL
. 0

Treatment 0
was 0
not 0
found 0
to 0
induce 0
gastritic B-PHYSICAL
changes I-PHYSICAL
in 0
the 0
mucosa 0
. 0

Effect 0
of 0
granulocyte/colony-stimulating 0
factor 0
on 0
the 0
onset 0
of 0
the 0
adult 0
respiratory 0
distress 0
syndrome 0
. 0

To 0
evaluate 0
the 0
effect 0
of 0
granulocyte/colony-stimulating 0
factor 0
( 0
G-CSF 0
) 0
on 0
the 0
onset 0
of 0
the 0
adult 0
respiratory 0
distress 0
syndrome 0
( 0
ARDS 0
) 0
, 0
we 0
investigated 0
whether 0
the 0
incidence 0
of 0
ARDS 0
due 0
to 0
pulmonary 0
infection 0
differed 0
between 0
the 0
G-CSF 0
group 0
which 0
received 0
chemotherapy 0
with 0
G-CSF 0
and 0
historical 0
controls 0
without 0
G-CSF 0
. 0

We 0
evaluated 0
132 0
patients 0
with 0
hematological 0
malignancy 0
in 0
complete 0
remission 0
without 0
any 0
main 0
organ 0
dysfunction 0
who 0
had 0
been 0
treated 0
between 0
April 0
1983 0
and 0
December 0
1997 0
. 0

We 0
compared 0
the 0
incidence 0
of 0
ARDS 0
due 0
to 0
pulmonary 0
infection 0
between 0
those 0
who 0
received 0
G-CSF 0
and 0
those 0
who 0
did 0
not 0
. 0

There 0
was 0
no 0
remarkable 0
difference 0
in 0
the 0
number 0
of 0
patients 0
, 0
gender 0
, 0
age 0
, 0
or 0
distribution 0
of 0
primary 0
diseases 0
between 0
the 0
two 0
groups 0
. 0

The 0
intensity 0
of 0
chemotherapy B-OTHER
was 0
not 0
considered 0
to 0
significantly 0
differ 0
between 0
the 0
two 0
groups 0
, 0
though 0
the 0
chemotherapy 0
regimens 0
administered 0
differed 0
slightly 0
. 0

In 0
the 0
G-CSF 0
group 0
, 0
the 0
duration B-PHYSICAL
of I-PHYSICAL
neutropenia I-PHYSICAL
was 0
significantly 0
shorter 0
and 0
the 0
frequency 0
of 0
documented 0
infection 0
was 0
significantly 0
decreased 0
. 0

We 0
could 0
not 0
find 0
any 0
relationship 0
between 0
ARDS 0
due 0
to 0
pulmonary B-PHYSICAL
infection I-PHYSICAL
and 0
any 0
anticancer 0
agent 0
or 0
antibiotics 0
. 0

There 0
was 0
no 0
relationship 0
between 0
the 0
kind 0
of 0
G-CSF 0
and 0
the 0
incidence 0
of 0
ARDS 0
due 0
to 0
pulmonary B-PHYSICAL
infection I-PHYSICAL
( 0
per 0
chemotherapy 0
session 0
; 0
p 0
> 0
0.10 0
, 0
per 0
case 0
; 0
p 0
> 0
0.30 0
, 0
chi2 0
test 0
) 0
. 0

The 0
incidence 0
of 0
ARDS B-PHYSICAL
due I-PHYSICAL
to I-PHYSICAL
pulmonary I-PHYSICAL
infection I-PHYSICAL
per I-PHYSICAL
chemotherapy I-PHYSICAL
session I-PHYSICAL
was 0
4.21 0
% 0
, 0
and 0
showed 0
a 0
higher 0
tendency 0
in 0
the 0
G-CSF 0
group 0
( 0
p 0
< 0
0.100 0
, 0
chi2 0
test 0
) 0
. 0

The 0
incidence 0
of 0
ARDS 0
due 0
to 0
pulmonary 0
infection 0
per 0
case 0
was 0
25.4 0
% 0
and 0
was 0
significantly 0
higher 0
in 0
the 0
G-CSF 0
group 0
( 0
p 0
< 0
0.025 0
, 0
chi2 0
test 0
) 0
. 0

The 0
incidence 0
of 0
ARDS B-PHYSICAL
due I-PHYSICAL
to I-PHYSICAL
pulmonary I-PHYSICAL
infection I-PHYSICAL
was I-PHYSICAL
higher 0
in B-PHYSICAL
the I-PHYSICAL
G-CSF I-PHYSICAL

Twenty-four 0
vs. 0
forty-eight 0
weeks 0
of 0
re-therapy 0
with 0
interferon 0
alpha 0
2b 0
and 0
ribavirin 0
in 0
interferon 0
alpha 0
monotherapy 0
relapsers 0
with 0
chronic 0
hepatitis 0
C. 0
BACKGROUND/AIM 0
Roughly 0
50 0
% 0
of 0
patients 0
with 0
chronic 0
hepatitis 0
C 0
, 0
who 0
relapsed 0
after 0
a 0
previous 0
monotherapy 0
with 0
interferon 0
alpha 0
, 0
will 0
respond 0
in 0
a 0
sustained 0
fashion 0
to 0
24 0
weeks 0
of 0
re-therapy 0
with 0
the 0
combination 0
of 0
interferon 0
alpha 0
plus 0
ribavirin 0
. 0

Whether 0
prolonging 0
treatment 0
duration 0
to 0
48 0
weeks 0
will 0
further 0
increase 0
sustained 0
response 0
rates 0
remains 0
ill 0
defined 0
. 0

In 0
this 0
randomised 0
controlled 0
pilot 0
trial 0
we 0
compared 0
the 0
efficacy 0
and 0
tolerability B-OTHER
of 0
a 0
24 0
week 0
with 0
that 0
of 0
a 0
48 0
week 0
course 0
of 0
combination 0
therapy 0
with 0
interferon 0
alpha 0
and 0
ribavirin 0
in 0
interferon 0
monotherapy 0
relapsers 0
with 0
chronic 0
hepatitis 0
C. 0
METHODS 0
Interferon 0
alpha 0
monotherapy 0
relapsers 0
with 0
chronic 0
hepatitis 0
C 0
were 0
randomised 0
to 0
receive 0
interferon 0
alpha 0
2b 0
( 0
3 0
x 0
3 0
MIU 0
sc 0
weekly 0
) 0
and 0
oral 0
ribavirin 0
( 0
1000/1200 0
mg 0
po 0
daily 0
) 0
for 0
either 0
24 0
weeks 0
or 0
48 0
weeks 0
. 0

Virological 0
response 0
was 0
evaluated 0
by 0
HCV 0
RNA 0
PCR 0
at 0
week 0
10 0
( 0
initial 0
response 0
) 0
, 0
at 0
the 0
end 0
of 0
treatment 0
( 0
end 0
of- 0
treatment 0
response 0
) 0
and 0
at 0
the 0
end 0
of 0
24 0
weeks 0
follow-up 0
( 0
sustained 0
response 0
) 0
. 0

Only 0
patients 0
with 0
negative 0
HCV 0
RNA 0
at 0
week 0
10 0
continued 0
treatment 0
. 0

Adverse B-ADVERSE-EFFECTS
events I-ADVERSE-EFFECTS
were 0
recorded 0
at 0
regular 0
intervals 0
. 0

RESULTS 0
Thirty-seven 0
patients 0
were 0
enrolled 0
, 0
19 0
( 0
6 0
females 0
, 0
median 0
age 0
43 0
) 0
in 0
the 0
24 0
week 0
and 0
18 0
( 0
5 0
females 0
, 0
median 0
age 0
40 0
) 0
in 0
the 0
48 0
week 0
treatment 0
arm 0
. 0

Baseline 0
characteristics 0
were 0
similar 0
in 0
both 0
groups 0
. 0

At 0
treatment 0
week 0
10 0
, 0
12/19 0
( 0
63 0
% 0
) 0
in 0
the 0
24 0
week 0
group 0
and 0
14/18 0
( 0
78 0
% 0
) 0
patients 0
in 0
the 0
48 0
week 0
group 0
had 0
lost B-PHYSICAL
HCV I-PHYSICAL
RNA I-PHYSICAL
in I-PHYSICAL
serum I-PHYSICAL
( 0
p 0
= 0
0.33 0
) 0
. 0

All 0
initial 0
responders 0
remained 0
HCV B-PHYSICAL
RNA I-PHYSICAL
negative 0
throughout 0
the 0
treatment 0
period 0
. 0

Sustained B-OTHER
response 0
rates B-OTHER
were 0
10/19 0
( 0
53 0
% 0
) 0
in 0
the 0
24 0
week 0
group 0
and 0
13/18 0
( 0
72 0
% 0
) 0
in 0
the 0
48 0
week 0
group 0
( 0
p 0
= 0
0.31 0
) 0
. 0

Three 0
patients 0
discontinued 0
treatment 0
early 0
( 0
two 0
due 0
to 0
moderate B-ADVERSE-EFFECTS
adverse B-ADVERSE-EFFECTS
events B-ADVERSE-EFFECTS
, 0
one 0
due 0
to 0
non-compliance 0
) 0
. 0

Dose 0
modifications 0
were 0
necessary 0
in 0
9 0
patients 0
, 0
4 0
in 0
the 0
24 0
week 0
and 0
5 0
in 0
the 0
48 0
week 0
group 0
for 0
anaemia B-PHYSICAL
, 0
neutropenia B-PHYSICAL
, 0

A 0
double-blind 0
placebo 0
controlled 0
trial 0
of 0
Ginkgo 0
biloba 0
added 0
to 0
risperidone 0
in 0
patients 0
with 0
autistic 0
disorders 0
. 0

Ginkgo 0
biloba 0
has 0
been 0
reported 0
to 0
affect 0
the 0
neurotransmitter 0
system 0
and 0
to 0
have 0
antioxidant 0
properties 0
that 0
could 0
impact 0
the 0
pathogenesis 0
of 0
Autism 0
Spectrum 0
Disorder 0
. 0

Based 0
on 0
these 0
studies 0
, 0
we 0
decided 0
to 0
assess 0
the 0
effectiveness 0
of 0
Ginkgo 0
biloba 0
extract 0
( 0
Ginko 0
T.D. 0
, 0
Tolidaru 0
, 0
Iran 0
) 0
as 0
an 0
adjunctive 0
agent 0
to 0
risperidone 0
in 0
the 0
treatment 0
of 0
autism 0
. 0

Forty-seven 0
outpatients 0
with 0
a 0
DSM-IV-TR 0
diagnosis 0
of 0
autism 0
ages 0
between 0
4 0
and 0
12 0
years 0
were 0
assigned 0
to 0
this 0
double 0
blinded 0
clinical 0
trial 0
and 0
were 0
randomly 0
divided 0
into 0
two 0
groups 0
. 0

One 0
group 0
received 0
risperidone 0
plus 0
Ginko 0
T.D 0
and 0
the 0
other 0
received 0
risperidone 0
plus 0
placebo 0
. 0

The 0
dose 0
of 0
risperidone 0
was 0
1-3 0
mg/day 0
and 0
the 0
dose 0
of 0
Ginko 0
T.D 0
. 0

was 0
80 0
mg/day 0
for 0
patients 0
under 0
30 0
kg 0
and 0
120 0
mg/day 0
for 0
patients 0
above 0
30 0
kg 0
. 0

Patients 0
were 0
assessed 0
using 0
Aberrant B-MENTAL
Behavior I-MENTAL
Checklist-Community I-MENTAL
( I-MENTAL
ABC-C I-MENTAL
) I-MENTAL
rating I-MENTAL
scale 0
and 0
the 0
side B-MENTAL
effect 0
check B-MENTAL
list B-MENTAL
every 0
2 0
weeks 0
until 0
the 0
endpoint 0
. 0

None 0
of 0
the 0
5 0
subscales 0
of 0
ABC-C B-MENTAL
rating I-MENTAL

Symptomatic 0
and 0
functional 0
improvement 0
in 0
employed 0
depressed 0
patients 0
: 0
a 0
double-blind 0
clinical 0
trial 0
of 0
desvenlafaxine 0
versus 0
placebo 0
. 0

OBJECTIVE 0
This 0
is 0
the 0
first 0
study 0
to 0
assess 0
the 0
efficacy 0
of 0
desvenlafaxine 0
( 0
administered 0
as 0
desvenlafaxine 0
succinate 0
) 0
for 0
improving 0
depressive B-MENTAL
symptoms I-MENTAL
and 0
functioning B-MENTAL
exclusively 0
in 0
employed 0
patients 0
with 0
major 0
depressive 0
disorder 0
( 0
MDD 0
) 0
. 0

METHODS 0
Gainfully 0
employed 0
( 0
?20 0
h/wk 0
) 0
male 0
and 0
female 0
outpatients 0
with 0
MDD 0
were 0
randomly 0
assigned 0
( 0
2:1 0
ratio 0
) 0
to 0
12 0
weeks 0
of 0
double-blind 0
treatment 0
with 0
desvenlafaxine 0
50 0
mg/d 0
or 0
placebo 0
. 0

Analysis 0
of 0
covariance 0
was 0
used 0
to 0
compare 0
differences 0
in 0
week 0
12 0
adjusted 0
mean 0
changes 0
from 0
baseline 0
on 0
the 0
17-item 0
Hamilton 0
Depression 0
Rating 0
Scale 0
( 0
HAM-D?? 0
) 0
( 0
primary 0
outcome 0
) 0
and 0
Sheehan 0
Disability 0
Scale 0
( 0
SDS 0
) 0
( 0
key 0
secondary 0
outcome 0
) 0
in 0
the 0
intent-to-treat 0
( 0
ITT 0
) 0
population 0
. 0

A 0
predefined 0
, 0
modified 0
ITT 0
population 0
( 0
ie 0
, 0
those 0
in 0
the 0
ITT 0
population 0
with 0
baseline 0
HAM-D?? 0
?20 0
) 0
was 0
also 0
analyzed 0
. 0

Tolerability 0
was 0
assessed 0
by 0
recording 0
adverse 0
events 0
and 0
change 0
on 0
the 0
Arizona 0
Sexual 0
Experience 0
Scale 0
. 0

RESULTS 0
Baseline 0
HAM-D?? 0
scores 0
for 0
desvenlafaxine 0
( 0
n 0
= 0
285 0
) 0
and 0
placebo 0
( 0
n 0
= 0
142 0
) 0
were 0
22.0 0
and 0
21.8 0
, 0
whereas 0
baseline 0
SDS 0
scores 0
were 0
19.8 0
and 0
20.4 0
. 0

Adjusted 0
mean 0
differences 0
between 0
desvenlafaxine 0
and 0
placebo 0
were 0
2.1 0
( 0
95 0
% 0
confidence 0
interval 0
[ 0
CI 0
] 0
, 0
0.78-3.46 0
; 0
P 0
= 0
0.002 0
) 0
on 0
the 0
HAM-D?? 0
and 0
1.3 0
( 0
95 0
% 0
CI 0
, 0
-0.09 0
to 0
2.76 0
; 0
P 0
= 0
0.067 0
) 0
on 0
the 0
SDS 0
. 0

For 0
the 0
modified 0
ITT 0
sample 0
, 0
desvenlafaxine 0
( 0
n 0
= 0
208 0
) 0
and 0
placebo 0
( 0
n 0
= 0
102 0
) 0
, 0
baseline 0
HAM-D?? 0
scores 0
were 0
23.8 0
and 0
23.9 0
; 0
the 0
SDS 0
baseline 0
scores 0
were 0
20.1 0
and 0
20.8 0
. 0

Mean 0
differences 0
were 0
2.6 0
( 0
95 0
% 0
CI 0
, 0
0.93-4.22 0
; 0
P 0
= 0
0.002 0
) 0
on 0
the 0
HAM-D?? 0
and 0
2.1 0
( 0
95 0
% 0
CI 0
, 0
0.36-3.76 0
; 0
P 0
= 0
0.017 0
) 0
on 0
the 0
SDS 0
. 0

Adverse 0
events 0
and 0
Arizona 0
Sexual 0
Experience 0
Scale 0
scores 0
were 0
comparable 0
between 0
groups 0
. 0

CONCLUSIONS 0
Desvenlafaxine 0
50 0
mg/d 0
was 0
efficacious 0
for 0
treating 0
MDD 0
in 0
gainfully 0
employed 0
adults 0
. 0

Between-group 0
differences 0
on 0
the 0
SDS 0
narrowly 0
missed 0
statistical 0
significance 0
in 0
the 0
ITT 0
population 0
alone 0
, 0
but 0
the 0
totality 0
of 0
data 0
suggests 0
functional 0
improvements 0
with 0
active 0
treatment 0
. 0

Clonidine 0
premedication 0
improves 0
metabolic B-PHYSICAL
control 0
in B-PHYSICAL
type 0
2 B-PHYSICAL
diabetic B-PHYSICAL
patients I-PHYSICAL
during 0
ophthalmic 0
surgery 0
. 0

BACKGROUND 0
In 0
stressful 0
conditions 0
, 0
increasing 0
blood 0
glucose 0
concentrations 0
are 0
closely 0
related 0
to 0
an 0
increase 0
in 0
catecholamines 0
and 0
cortisol 0
release 0
. 0

Clonidine 0
, 0
a 0
centrally 0
acting 0
alpha 0
( 0
2 0
) 0
-adrenoceptor 0
agonist 0
, 0
has 0
neuroendocrine 0
effects 0
, 0
including 0
inhibition 0
of 0
sympathoadrenal 0
activity 0
. 0

We 0
therefore 0
evaluated 0
the 0
effect 0
of 0
clonidine 0
on 0
blood B-PHYSICAL
glucose I-PHYSICAL
control B-PHYSICAL
and 0
insulin B-PHYSICAL
requirements B-PHYSICAL
during 0
ophthalmic 0
surgery 0
when 0
given 0
as 0
premedication 0
in 0
type 0
2 0
diabetic 0
patients 0
. 0

METHODS 0
After 0
randomization 0
, 0
patients 0
were 0
premedicated 0
with 0
clonidine 0
or 0
flunitrazepam 0
( 0
control 0
) 0
. 0

Patients 0
were 0
given 0
insulin 0
by 0
continuous 0
i.v 0
. 0

infusion 0
to 0
maintain 0
blood 0
glucose 0
in 0
the 0
range 0
5.5-11.1 0
mmol 0
litre 0
( 0
-1 0
) 0
. 0

Blood B-PHYSICAL
glucose B-PHYSICAL
concentrations I-PHYSICAL
were 0
measured 0
every 0
15 0
min 0
during 0
surgery 0
, 0
and 0
hourly 0
for 0
6 0
h 0
after 0
surgery 0
. 0

Plasma B-PHYSICAL
C-peptide I-PHYSICAL
and I-PHYSICAL
counter-regulatory B-PHYSICAL
hormones I-PHYSICAL
were 0
also 0
measured 0
. 0

RESULTS 0
Glycaemia B-PHYSICAL
was 0
significantly 0
lower 0
in 0
the 0
clonidine 0
group 0
( 0
P 0
< 0
0.01 0
) 0
and 0
the 0
median 0
amount 0
of 0

Levamisole 0
versus 0
placebo 0
as 0
an 0
adjunct 0
to 0
primary 0
therapy 0
of 0
laryngopharyngeal 0
epidermoid 0
carcinoma 0
. 0

Evaluation 0
of 0
the 0
immune 0
status 0
. 0

Twenty-four 0
patients 0
, 0
with 0
a 0
biopsy-proven 0
laryngeal 0
or 0
hypopharyngeal 0
carcinoma 0
, 0
received 0
as 0
an 0
adjunct 0
to 0
their 0
primary 0
treatment 0
( 0
surgery 0
and/or 0
radiotherapy 0
) 0
, 0
levamisole 0
( 0
150 0
mg 0
daily 0
during 0
three 0
consecutive 0
days 0
, 0
every 0
fortnight 0
) 0
or 0
placebo 0
, 0
following 0
a 0
single-blind 0
, 0
but 0
randomized 0
method 0
. 0

At 0
the 0
end 0
of 0
the 0
follow-up 0
, 0
an 0
investigation 0
of 0
the 0
immune B-PHYSICAL
status 0
was 0
done 0
, 0
and 0
compared 0
with 0
that 0
of 0
a 0
healthy 0
control-group 0
. 0

It 0
is 0
concluded 0
that 0
the 0
immunity B-PHYSICAL
is 0
disturbed 0
in 0
patients 0
with 0
laryngo-pharyngeal 0
cancer 0
, 0
but 0
that 0
this 0
disturbance 0
does 0
not 0
clearly 0
correlate 0
with 0
the 0
clinical 0
state 0
of 0
the 0
disease 0
. 0

Also 0
, 0
the 0
immunological 0
measures 0
did 0
not 0
appear 0
relevant 0
to 0
the 0
significantly 0
favourable 0
effect 0
of 0
levamisole 0
on 0
the 0
prognosis 0
. 0

Ganitumab 0
with 0
either 0
exemestane 0
or 0
fulvestrant 0
for 0
postmenopausal 0
women 0
with 0
advanced 0
, 0
hormone-receptor-positive 0
breast 0
cancer 0
: 0
a 0
randomised 0
, 0
controlled 0
, 0
double-blind 0
, 0
phase 0
2 0
trial 0
. 0

BACKGROUND 0
Insulin-like 0
growth 0
factors 0
( 0
IGF-1 0
and 0
IGF-2 0
) 0
bind 0
to 0
the 0
IGF-1 0
receptor 0
( 0
IGF-1R 0
) 0
, 0
increasing 0
cell B-PHYSICAL
proliferation I-PHYSICAL
and 0
survival B-MORTALITY
. 0

Ganitumab 0
is 0
a 0
monoclonal 0
IgG1 0
antibody 0
that 0
blocks 0
IGF-1R 0
. 0

We 0
tested 0
the 0
efficacy 0
and 0
safety B-OTHER
of 0
adding 0
ganitumab 0
to 0
endocrine 0
treatment 0
for 0
patients 0
with 0
hormone-receptor-positive 0
breast 0
cancer 0
. 0

METHODS 0
We 0
did 0
this 0
phase 0
2 0
trial 0
in 0
outpatient 0
clinics 0
and 0
hospitals 0
. 0

We 0
enrolled 0
postmenopausal 0
women 0
with 0
hormone-receptor-positive 0
, 0
locally 0
advanced 0
or 0
metastatic 0
breast 0
cancer 0
previously 0
treated 0
with 0
endocrine 0
treatment 0
. 0

They 0
were 0
randomly 0
assigned 0
( 0
2:1 0
) 0
with 0
a 0
central 0
randomisation 0
schedule 0
to 0
receive 0
intravenous 0
ganitumab 0
12 0
mg 0
per 0
kg 0
bodyweight 0
or 0
placebo 0
in 0
combination 0
with 0
open-label 0
intramuscular 0
fulvestrant 0
( 0
500 0
mg 0
on 0
day 0
1 0
, 0
then 0
250 0
mg 0
on 0
days 0
15 0
, 0
29 0
, 0
and 0
every 0
28 0
days 0
) 0
or 0
oral 0
exemestane 0
( 0
25 0
mg 0
once 0
daily 0
) 0
on 0
a 0
28-day 0
cycle 0
. 0

Patients 0
, 0
investigators 0
, 0
study 0
monitors 0
, 0
and 0
the 0
sponsor 0
staff 0
were 0
masked 0
to 0
treatment 0
allocation 0
. 0

Response 0
was 0
assessed 0
every 0
8 0
weeks 0
. 0

The 0
primary 0
endpoint 0
was 0
median 0
progression-free B-MORTALITY
survival I-MORTALITY
in 0
the 0
intention-to-treat 0
population 0
. 0

We 0
analysed 0
overall B-MORTALITY
survival I-MORTALITY
as 0
one 0
of 0
our 0
secondary 0
endpoints 0
. 0

The 0
study 0
is 0
registered 0
at 0
ClinicalTrials.gov 0
, 0
number 0
NCT00626106 0
. 0

FINDINGS 0
We 0
screened 0
189 0
patients 0
and 0
enrolled 0
156 0
( 0
106 0
in 0
the 0
ganitumab 0
group 0
and 0
50 0
in 0
the 0
placebo 0
group 0
) 0
. 0

Median 0
progression-free B-MORTALITY
survival I-MORTALITY
did 0
not 0
differ 0
significantly 0
between 0
the 0
ganitumab 0
and 0
placebo 0
groups 0
( 0
3?9 0
months 0
, 0
80 0
% 0
CI 0
3?6-5?3 0
vs 0
5?7 0
months 0
, 0
4?4-7?4 0
; 0
hazard 0
ratio 0
[ 0
HR 0
] 0
1?17 0
, 0
80 0
% 0
CI 0
0?91-1?50 0
; 0
p=0?44 0
) 0
. 0

However 0
, 0
overall 0
survival 0
was 0
worse 0
in 0
the 0
the 0
ganitumab 0
group 0
than 0
in 0
the 0
placebo 0
group 0
( 0
HR 0
1?78 0
, 0
80 0
% 0
CI 0
1?27-2?50 0
; 0
p=0?025 0
) 0
. 0

With 0
the 0
exception 0
of 0
hyperglycaemia 0
, 0
adverse 0
events 0
were 0
generally 0
similar 0
between 0
groups 0
. 0

The 0
most 0
common 0
grade 0
3 0
or 0
higher 0
adverse 0
event 0
was 0
neutropenia-reported 0
by 0
six 0
of 0
106 0
( 0
6 0
% 0
) 0
patients 0
in 0
the 0
ganitumab 0
group 0
and 0
one 0
of 0
49 0
( 0
2 0
% 0
) 0
in 0
the 0
placebo 0
group 0
. 0

Hyperglycaemia 0
was 0
reported 0
by 0
12 0
of 0
106 0
( 0
11 0
% 0
) 0
patients 0
in 0
the 0
ganitumab 0
group 0
( 0
with 0
six 0
patients 0
having 0
grade 0
3 0
or 0
4 0
hyperglycaemia 0
) 0
and 0
none 0
of 0
49 0
in 0
the 0
placebo 0
group 0
. 0

Serious 0
adverse 0
events 0
were 0
reported 0
by 0
27 0
of 0
106 0
( 0
25 0
% 0
) 0
patients 0
in 0
the 0
ganitumab 0
group 0
and 0
nine 0
of 0
49 0
( 0
18 0
% 0
) 0
patients 0
in 0
the 0
placebo 0
group 0
. 0

INTERPRETATION 0
Addition 0
of 0
ganitumab 0
to 0
endocrine 0
treatment 0
in 0
women 0
with 0
previously 0
treated 0
hormone-receptor-positive 0
locally 0
advanced 0
or 0
metastatic 0
breast 0
cancer 0
did 0
not 0
improve 0
outcomes 0
. 0

Our 0
results 0
do 0
not 0
support 0
further 0
study 0
of 0
ganitumab 0
in 0
this 0
subgroup 0
of 0
patients 0
. 0

FUNDING 0
Amgen 0
. 0

Efficacy 0
and 0
safety 0
of 0
routine 0
blood B-PHYSICAL
pressure I-PHYSICAL
lowering I-PHYSICAL
in 0
older 0
patients 0
with 0
diabetes 0
: 0
results 0
from 0
the 0
ADVANCE 0
trial 0
. 0

OBJECTIVE 0
The 0
efficacy 0
and 0
safety 0
of 0
blood B-PHYSICAL
pressure I-PHYSICAL
lowering I-PHYSICAL
in 0
elderly 0
patients 0
have 0
not 0
been 0
sufficiently 0
investigated 0
in 0
patients 0
with 0
diabetes 0
. 0

Using 0
data 0
from 0
the 0
Action 0
in 0
Diabetes 0
and 0
Vascular 0
disease 0
: 0
preterAx 0
and 0
diamicroN-MR 0
Controlled 0
Evaluation 0
study 0
, 0
we 0
assessed 0
the 0
efficacy 0
and 0
safety 0
of 0
routine 0
blood B-PHYSICAL
pressure I-PHYSICAL
lowering I-PHYSICAL
to 0
prevent 0
major 0
clinical 0
outcomes 0
in 0
elderly 0
patients 0
with 0
type 0
2 0
diabetes 0
. 0

METHODS 0
Eleven 0
thousand 0
one 0
hundred 0
and 0
forty 0
patients 0
aged 0
at 0
least 0
55 0
years 0
with 0
type 0
2 0
diabetes 0
( 0
mean 0
66+/-6 0
years 0
) 0
were 0
randomly 0
assigned 0
to 0
perindopril-indapamide 0
or 0
placebo 0
. 0

The 0
primary 0
endpoint 0
was 0
a 0
composite B-PHYSICAL
of I-PHYSICAL
major I-PHYSICAL
macrovascular I-PHYSICAL
and 0
microvascular B-PHYSICAL
disease I-PHYSICAL
. 0

The 0
effects 0
of 0
active 0
treatment 0
on 0
outcomes 0
were 0
estimated 0
in 0
subgroups 0
according 0
to 0
age 0
: 0
below 0
65 0
, 0
65-74 0
and 0
at 0
least 0
75 0
years 0
. 0

RESULTS 0
During 0
a 0
mean 0
4.3-year 0
follow-up 0
, 0
1799 0
( 0
16.1 0
% 0
) 0
patients 0
experienced 0
a 0
major 0
event 0
. 0

Active 0
treatment 0
produced 0
similar 0
relative 0
risk 0
reductions B-PHYSICAL
for 0
the 0
primary 0
outcome 0
, 0
major B-PHYSICAL
macrovascular I-PHYSICAL
disease I-PHYSICAL
, 0
death B-PHYSICAL
and 0
renal B-PHYSICAL
events I-PHYSICAL
across 0
age 0
groups 0
( 0
all 0
P 0
heterogeneity 0
> 0
0.3 0
) 0
. 0

Over 0
5 0
years 0
, 0
active 0
treatment 0
was 0
estimated 0
to 0
prevent 0
one 0
primary 0
outcome 0
in 0
every 0
21 0
, 0
71 0
and 0
118 0
patients 0
of 0
at 0
least 0
75 0
, 0
65-74 0
and 0
below 0
65 0
years 0
, 0
respectively 0
. 0

Similar 0
patterns 0
of 0
benefits 0
were 0
observed 0
for 0
secondary 0
outcomes 0
. 0

There 0
were 0
no 0
differences 0
in 0
the 0
tolerability B-OTHER
between 0
randomized 0
allocations 0
across 0
age 0
groups 0
( 0
all 0
P 0
heterogeneity 0
> 0
0.6 0
) 0
CONCLUSION 0
Routine 0
administration 0
of 0
perindopril-indapamide 0
lowers 0
blood B-PHYSICAL
pressure I-PHYSICAL
safely 0
and 0
reduces 0
the 0
risk 0
of 0
major 0
clinical 0
outcomes 0
in 0
patients 0
of 0
at 0
least 0
75 0
years 0
with 0
type 0
2 0
diabetes 0
. 0

The 0
greater 0
absolute 0
benefits 0
in 0
older 0
patients 0
in 0
this 0
age 0
group 0
were 0
not 0
offset 0
by 0
an 0
increased 0
risk 0
of 0
side 0
effects 0
. 0

Benzodiazepine 0
and 0
opioid 0
sedation 0
attenuate 0
the 0
sympathetic 0
response 0
to 0
fiberoptic B-OTHER
bronchoscopy I-OTHER
. 0

Prophylactic 0
labetalol 0
gave 0
no 0
additional 0
benefit 0
. 0

Results 0
of 0
a 0
randomized 0
double-blind 0
placebo-controlled 0
study 0
. 0

BACKGROUND 0
Hypertension 0
and 0
tachycardia 0
are 0
common 0
during 0
fiber-optic 0
bronchoscopy 0
( 0
FOB 0
) 0
, 0
and 0
this 0
may 0
lead 0
to 0
cardiac 0
ischemia 0
. 0

The 0
prophylactic 0
addition 0
of 0
a 0
beta-adrenergic 0
anatagonist 0
might 0
mask 0
this 0
response 0
and 0
prevent 0
the 0
deleterious 0
cardiovascular B-PHYSICAL
effects I-PHYSICAL
of I-PHYSICAL
FOB I-PHYSICAL
. 0

METHODS 0
We 0
performed 0
a 0
randomized 0
double-blind 0
placebo-controlled 0
trial 0
of 0
labetalol 0
10mg 0
iv 0
given 0
with 0
midazolam-alfentanil 0
sedation 0
. 0

We 0
monitored 0
heart B-PHYSICAL
rate I-PHYSICAL
( I-PHYSICAL
HR I-PHYSICAL
) I-PHYSICAL
and 0
systolic/diastolic B-PHYSICAL
blood I-PHYSICAL
pressure I-PHYSICAL
( I-PHYSICAL
SBP/DBP I-PHYSICAL
) I-PHYSICAL
throughout 0
the 0
bronchoscopy 0
and 0
calculated 0
the 0
rate-pressure 0
product 0
( 0
RPP= 0
( 0
HRxSBP 0
) 0
/100 0
) 0
. 0

One-hundred 0
twenty 0
patients 0
were 0
enrolled 0
. 0

RESULTS 0
In 0
the 0
placebo 0
group 0
, 0
there 0
was 0
no 0
rise 0
in 0
HR B-PHYSICAL
, 0
SBP B-PHYSICAL
, 0
DBP B-PHYSICAL
or 0
RPP B-PHYSICAL
, 0
and 0
there 0
was 0
no 0
difference 0
between 0
the 0
placebo 0
and 0
labetalol 0
groups 0
. 0

Adverse B-ADVERSE-EFFECTS
events I-ADVERSE-EFFECTS
during I-ADVERSE-EFFECTS
bronchoscopy I-ADVERSE-EFFECTS
were 0
similar 0
in 0
both 0
groups 0
. 0

In 0
a 0
subgroup 0
of 0
patients 0
undergoing 0
interventional 0
bronchoscopy 0
, 0
there 0
was 0
a 0
trend 0
towards 0
lower 0
SBP B-PHYSICAL
( 0
p=0.06 0
) 0
. 0

CONCLUSIONS 0
Patients 0
undergoing 0
FOB 0
under 0
adequate 0
midazolam-alfentanil 0
sedation 0
do 0
not 0
develop 0
excessive 0
sympathetic 0
drive 0
that 0
may 0
lead 0
to 0
cardiac 0
stress 0
. 0

The 0
addition 0
of 0
labetalol 0
did 0
not 0
confer 0
additional 0
benefit 0
or 0
risk 0
to 0
the 0
patients 0
. 0
( 0

ClinicalTrials.gov 0
number 0
, 0
NCT00394537 0
) 0
. 0

Sodium-potassium 0
pump 0
activity 0
in 0
white 0
blood 0
cells 0
from 0
children 0
with 0
an 0
increased 0
risk 0
of 0
developing 0
hypertension 0
-- 0
The 0
Odense 0
Schoolchild 0
Study 0
. 0

We 0
have 0
measured 0
the 0
capacity 0
of 0
the 0
sodium-potassium 0
pump 0
, 0
as 0
assessed 0
by 0
86rubidium 0
uptake 0
and 0
the 0
number 0
of 0
[ 0
3H 0
] 0
-ouabain 0
binding 0
sites 0
on 0
white 0
blood 0
cells 0
, 0
in 0
children 0
aged 0
9-11 0
years 0
, 0
partly 0
cross-sectionally 0
and 0
partly 0
longitudinally 0
after 0
a 0
physical 0
training 0
programme 0
. 0

Children 0
from 0
a 0
hypertensive 0
subgroup 0
comprising 0
the 0
upper 0
5 0
% 0
of 0
the 0
blood 0
pressure 0
distribution 0
and 0
children 0
from 0
a 0
randomly 0
selected 0
normotensive 0
subgroup 0
were 0
eligible 0
for 0
the 0
study 0
. 0

In 0
the 0
cross-sectional 0
study 0
40 0
children 0
from 0
the 0
hypertensive 0
subgroup 0
and 0
40 0
children 0
from 0
the 0
normotensive 0
subgroup 0
were 0
evaluated 0
. 0

A 0
significant 0
increase 0
in 0
86rubidium B-PHYSICAL
uptake I-PHYSICAL
was 0
present 0
in 0
boys 0
as 0
compared 0
to 0
girls 0
. 0

After 0
adjustment 0
for 0
differences 0
in 0
sexual 0
maturation 0
the 0
observed 0
significant 0
difference 0
disappeared 0
. 0

Important 0
correlates 0
of 0
pump 0
activity 0
were 0
height 0
, 0
plasma 0
glucose 0
, 0
and 0
physical 0
fitness 0
. 0

In 0
the 0
training 0
study 0
10 0
boys 0
from 0
the 0
hypertensive 0
subgroup 0
and 0
10 0
boys 0
from 0
the 0
normotensive 0
subgroup 0
were 0
also 0
evaluated 0
after 0
eight 0
months 0
of 0
physical 0
training 0
. 0

A 0
significant 0
fall 0
in 0
86rubidium B-PHYSICAL
uptake I-PHYSICAL
was 0
observed 0
. 0

No 0
control 0
group 0
was 0
examined 0
and 0
probably 0
the 0
changes 0
reflect 0
some 0
effects 0
of 0
sexual B-PHYSICAL
maturation I-PHYSICAL
on I-PHYSICAL
cation I-PHYSICAL
handling I-PHYSICAL
of I-PHYSICAL
cells I-PHYSICAL
. 0

These 0
results 0
indicate 0
a 0
significant 0
effect 0
of 0
sexual B-PHYSICAL
maturation I-PHYSICAL
in I-PHYSICAL
capacity I-PHYSICAL
of I-PHYSICAL
sodium-potassium I-PHYSICAL
pump I-PHYSICAL
in 0
children 0
. 0

Perioperative 0
immunotherapy 0
with 0
recombinant 0
interleukin 0
2 0
in 0
patients 0
undergoing 0
surgery 0
for 0
colorectal 0
cancer 0
. 0

Major 0
surgery 0
impairs 0
the 0
cellular 0
immune 0
response 0
. 0

We 0
have 0
therefore 0
studied 0
the 0
immunological 0
effects 0
of 0
low-dose 0
recombinant 0
interleukin 0
2 0
given 0
to 0
patients 0
undergoing 0
surgery 0
for 0
colorectal 0
cancer 0
to 0
determine 0
whether 0
this 0
agent 0
has 0
potential 0
in 0
perioperative 0
adjuvant 0
immunotherapy 0
. 0

Patients 0
were 0
randomly 0
allocated 0
to 0
control 0
( 0
n 0
= 0
13 0
) 0
or 0
treatment 0
groups 0
( 0
n 0
= 0
12 0
) 0
. 0

Immunological 0
studies 0
of 0
both 0
lymphocyte B-PHYSICAL
function I-PHYSICAL
and 0
subset 0
number 0
were 0
performed 0
preoperatively 0
and 0
on 0
Days 0
1 0
, 0
4 0
, 0
7 0
, 0
and 0
10 0
. 0

Treatment 0
with 0
recombinant 0
interleukin 0
2 0
prevented 0
the 0
postoperative 0
fall 0
in 0
both 0
natural B-PHYSICAL
killer I-PHYSICAL
and 0
lymphokine-activated B-PHYSICAL
killer I-PHYSICAL
cell I-PHYSICAL
cytotoxicity I-PHYSICAL
, 0
clearly 0
demonstrated 0
in 0
the 0
control 0
group 0
. 0

The 0
treatment 0
group 0
also 0
showed 0
in 0
vivo B-PHYSICAL
T-cell I-PHYSICAL
activation I-PHYSICAL
with 0
an 0
initial 0
lymphopenia 0
followed 0
by 0
a 0
rebound B-PHYSICAL
lymphocytosis I-PHYSICAL
and 0
upregulation 0
of 0
the 0
subset B-PHYSICAL
markers I-PHYSICAL
CD25 I-PHYSICAL
( 0
interleukin B-PHYSICAL
2 I-PHYSICAL
receptor I-PHYSICAL
) 0
and 0
CD45RO B-PHYSICAL
( I-PHYSICAL
T-memory I-PHYSICAL
cells I-PHYSICAL
) I-PHYSICAL
. 0

These 0
combined 0
effects 0
may 0
have 0
important 0
consequences 0
in 0
controlling 0
metastatic 0
dissemination 0
of 0
tumor 0
during 0
the 0
vulnerable 0
perioperative 0
period 0
. 0

Atypical 0
recruitment 0
of 0
medial 0
prefrontal 0
cortex 0
in 0
autism 0
spectrum 0
disorders 0
: 0
an 0
fMRI 0
study 0
of 0
two 0
executive 0
function 0
tasks 0
. 0

Recent 0
studies 0
have 0
suggested 0
an 0
uneven 0
profile 0
of 0
executive 0
dysfunction 0
in 0
autism 0
spectrum 0
disorders 0
( 0
ASD 0
) 0
. 0

For 0
example 0
, 0
some 0
authors 0
have 0
reported 0
deficits 0
on 0
newly 0
developed 0
tests 0
of 0
executive 0
function 0
sensitive 0
to 0
rostral 0
prefrontal 0
function 0
, 0
despite 0
spared 0
, 0
or 0
even 0
superior 0
, 0
performance 0
on 0
other 0
tests 0
. 0

We 0
investigated 0
the 0
performance 0
of 0
a 0
group 0
of 0
high-functioning 0
participants 0
with 0
ASD 0
( 0
N=15 0
) 0
and 0
an 0
age- 0
and 0
IQ-matched 0
control 0
group 0
( 0
N=18 0
) 0
on 0
two 0
executive 0
function 0
tests 0
, 0
whilst 0
undergoing 0
functional 0
magnetic 0
resonance 0
imaging 0
( 0
fMRI 0
) 0
. 0

Behaviourally 0
, 0
there 0
were 0
no 0
significant 0
differences 0
between 0
the 0
two 0
groups 0
. 0

In 0
a 0
classical 0
test 0
of 0
executive 0
function 0
( 0
random 0
response 0
generation 0
) 0
, 0
BOLD B-PHYSICAL
signal I-PHYSICAL
differed 0
between 0
the 0
groups 0
in 0
the 0
cerebellum 0
but 0
not 0
in 0
the 0
frontal 0
lobes 0
. 0

However 0
, 0
on 0
a 0
new 0
test 0
of 0
executive 0
function 0
( 0
selection 0
between 0
stimulus-oriented 0
and 0
stimulus-independent 0
thought 0
) 0
, 0
the 0
ASD 0
group 0
exhibited 0
significantly 0
greater 0
signal-change 0
in 0
medial B-PHYSICAL
rostral I-PHYSICAL
prefrontal I-PHYSICAL
cortex I-PHYSICAL
( I-PHYSICAL
especially I-PHYSICAL
Brodmann I-PHYSICAL
Area 0
10 B-PHYSICAL
) B-PHYSICAL
in 0
the 0
comparison 0
of 0
stimulus-oriented 0
versus 0
stimulus-independent 0
attention 0
. 0

In 0
addition 0
, 0
the 0
new 0
test 0
( 0
but 0
not 0
the 0
classical 0
test 0
) 0
provided 0
evidence 0
for 0

Effects 0
of 0
losartan 0
and 0
enalapril 0
on 0
high-sensitivity 0
C-reactive 0
protein 0
and 0
total 0
antioxidant 0
in 0
renal 0
transplant 0
recipients 0
with 0
Renin-Angiotensin 0
system 0
polymorphisms 0
. 0

BACKGROUND 0
As 0
renin-angiotensin 0
system 0
( 0
RAS 0
) 0
activity 0
may 0
affect 0
the 0
severity 0
of 0
oxidative 0
stress 0
and 0
inflammatory 0
markers 0
, 0
we 0
assessed 0
the 0
effects 0
of 0
enalapril 0
( 0
E 0
) 0
and/or 0
losartan 0
( 0
L 0
) 0
on 0
these 0
markers 0
in 0
renal 0
transplant 0
recipients 0
with 0
RAS 0
polymorphisms 0
. 0

PATIENTS 0
AND 0
METHODS 0
After 0
determination 0
by 0
PCR 0
of 0
RAS 0
genotypes 0
, 0
consisting 0
of 0
the 0
angiotensin-converting 0
enzymes 0
( 0
ACE 0
I/D 0
) 0
, 0
angiotensinogens 0
( 0
AGT 0
M235T 0
) 0
and 0
angiotensin 0
II 0
type 0
1 0
receptors 0
( 0
ATR1 0
A1166C 0
) 0
, 0
76 0
recipients 0
were 0
recruited 0
randomly 0
and 0
assigned 0
4 0
groups 0
. 0

The 0
first 0
( 0
n 0
= 0
17 0
) 0
and 0
second 0
( 0
n 0
= 0
24 0
) 0
groups 0
were 0
treated 0
with 0
E 0
( 0
E 0
( 0
+ 0
) 0
: 0
10 0
mg/d 0
) 0
and 0
L 0
( 0
L 0
( 0
+ 0
) 0
: 0
50 0
mg/d 0
) 0
alone 0
, 0
respectively 0
. 0

The 0
third 0
positive 0
control 0
group 0
( 0
n 0
= 0
17 0
) 0
received 0
E 0
+ 0
L 0
( 0
E 0
( 0
+ 0
) 0
L 0
( 0
+ 0
) 0
: 0
10 0
mg/d 0
+ 0
50 0
mg/d 0
) 0
and 0
the 0
fourth 0
negative 0
control 0
group 0
( 0
n 0
= 0
18 0
) 0
received 0
no 0
medication 0
( 0
E 0
( 0
- 0
) 0
: 0
L 0
( 0
- 0
) 0
) 0
. 0

High-sensitivity 0
C-reactive 0
protein 0
( 0
hs-CRP 0
) 0
and 0
total 0
antioxidant 0
( 0
TA 0
) 0
inflammatory 0
and 0
antioxidative 0
markers 0
were 0
measured 0
after 0
2 0
months 0
. 0

After 0
a 0
2-week 0
washout 0
period 0
, 0
the 0
E 0
( 0
+ 0
) 0
group 0
was 0
changed 0
to 0
L 0
( 0
+ 0
) 0
and 0
vice 0
versa 0
in 0
a 0
crossover 0
design 0
. 0

They 0
were 0
followed 0
for 0
another 0
8 0
weeks 0
before 0
retesting 0
hs-CRP 0
and 0
TA 0
. 0

A 0
value 0
of 0
P 0
< 0
or 0
= 0
.05 0
was 0
considered 0
significant 0
. 0

RESULTS 0
After 0
2 0
and 0
4 0
months 0
of 0
treatment 0
with 0
the 0
drug 0
regimen 0
, 0
hs-CRP B-PHYSICAL
and I-PHYSICAL
TA I-PHYSICAL
levels I-PHYSICAL
were 0
significantly 0
decreased 0
and 0
consequently 0
increased 0
among 0
the 0
E 0
( 0
+ 0
) 0
L 0
( 0
+ 0
) 0
, 0
L 0
( 0
+ 0
) 0
and 0
E 0
( 0
+ 0
) 0
groups 0
( 0
P 0
< 0
.05 0
) 0
. 0

On 0
analyzing 0
the 0
relationship 0
between 0
RAS 0
polymorphisms 0
and 0
baseline 0
hs-CRP 0
or 0
TA 0
levels 0
, 0
CC 0
genotype 0
of 0
ATR1 0
showed 0
lower 0
hs-CRP B-PHYSICAL
levels I-PHYSICAL
( 0
P 0
= 0
.04 0
) 0
. 0

However 0
, 0
none 0
of 0
the 0
RAS 0
polymorphisms 0
predicted 0
the 0
antioxidant B-PHYSICAL
and 0
anti-inflammatory B-PHYSICAL
response 0
rates 0
to 0
the 0
drugs 0
( 0
P 0
> 0
.05 0
) 0
. 0

CONCLUSION 0
Although 0
hs-CRP B-PHYSICAL
was 0
lower 0
in 0
the 0
CC 0
genotype 0
patients 0
of 0
ATR1 0
polymorphisms 0
E 0
and/or 0
L 0
reduced 0
hs-CRP 0
and 0
increased 0
TA 0
regardless 0
of 0
the 0
RAS 0
genotype 0
. 0

Prazosin 0
versus 0
captopril 0
as 0
initial 0
therapy 0
. 0

Effect 0
on 0
hypertension B-PHYSICAL
and I-PHYSICAL
lipid I-PHYSICAL
levels I-PHYSICAL
. 0

A 0
randomized 0
, 0
parallel 0
group 0
study 0
evaluated 0
the 0
safety B-OTHER
, I-OTHER
efficacy 0
, B-OTHER
and 0
effect 0
of 0
the 0
alpha 0
blocking 0
agent 0
prazosin 0
and 0
the 0
angiotensin 0
converting 0
enzyme 0
inhibitor 0
captopril 0
on 0
serum 0
lipid 0
levels 0
in 0
patients 0
with 0
mild 0
to 0
moderate 0
hypertension 0
. 0

Baseline 0
evaluations 0
were 0
performed 0
on 0
31 0
patients 0
after 0
a 0
four-week 0
placebo 0
washout 0
period 0
. 0

Patients 0
were 0
randomly 0
assigned 0
to 0
receive 0
either 0
prazosin 0
( 0
n 0
= 0
15 0
) 0
or 0
captopril 0
( 0
n 0
= 0
16 0
) 0
. 0

Daily 0
doses 0
were 0
titrated 0
as 0
follows 0
: 0
for 0
prazosin 0
, 0
1 0
mg 0
two 0
times 0
daily 0
to 0
maximum 0
of 0
20 0
mg 0
per 0
day 0
; 0
for 0
captopril 0
, 0
25 0
mg 0
three 0
times 0
daily 0
to 0
a 0
maximum 0
of 0
450 0
mg 0
per 0
day 0
. 0

If 0
diastolic B-PHYSICAL
blood I-PHYSICAL
pressure I-PHYSICAL
was 0
not 0
adequately 0
controlled 0
( 0
less 0
than 0
85 0
mm 0
Hg 0
) 0
after 0
four 0
weeks 0
of 0
monotherapy 0
, 0
1 0
mg 0
of 0
polythiazide 0
was 0
added 0
to 0
the 0
daily 0
regimen 0
. 0

There 0
were 0
no 0
statistically 0
significant 0
differences 0
between 0
the 0
drug 0
groups 0
for 0
the 0
measured 0
variables 0
in 0
either 0
the 0
parallel 0
or 0
crossover 0
phase 0
of 0
the 0
study 0
. 0

Five 0
of 0
15 0
prazosin-treated 0
patients 0
and 0
six 0
of 0
16 0
captopril-treated 0
patients 0
required 0
the 0
addition 0
of 0
thiazide 0
to 0
achieve 0

The 0
benefits 0
of 0
including 0
clinical 0
factors 0
in 0
rectal 0
normal 0
tissue 0
complication 0
probability 0
modeling 0
after 0
radiotherapy 0
for 0
prostate 0
cancer 0
. 0

PURPOSE 0
To 0
study 0
the 0
impact 0
of 0
clinical 0
predisposing 0
factors 0
on 0
rectal 0
normal 0
tissue 0
complication 0
probability 0
modeling 0
using 0
the 0
updated 0
results 0
of 0
the 0
Dutch 0
prostate 0
dose-escalation 0
trial 0
. 0

METHODS 0
AND 0
MATERIALS 0
Toxicity 0
data 0
of 0
512 0
patients 0
( 0
conformally 0
treated 0
to 0
68 0
Gy 0
[ 0
n 0
= 0
284 0
] 0
and 0
78 0
Gy 0
[ 0
n 0
= 0
228 0
] 0
) 0
with 0
complete 0
follow-up 0
at 0
3 0
years 0
after 0
radiotherapy 0
were 0
studied 0
. 0

Scored 0
end 0
points 0
were 0
rectal 0
bleeding 0
, 0
high 0
stool 0
frequency 0
, 0
and 0
fecal 0
incontinence 0
. 0

Two 0
traditional 0
dose-based 0
models 0
( 0
Lyman-Kutcher-Burman 0
( 0
LKB 0
) 0
and 0
Relative 0
Seriality 0
( 0
RS 0
) 0
and 0
a 0
logistic 0
model 0
were 0
fitted 0
using 0
a 0
maximum 0
likelihood 0
approach 0
. 0

Furthermore 0
, 0
these 0
model 0
fits 0
were 0
improved 0
by 0
including 0
the 0
most 0
significant 0
clinical 0
factors 0
. 0

The 0
area 0
under 0
the 0
receiver 0
operating 0
characteristic 0
curve 0
( 0
AUC 0
) 0
was 0
used 0
to 0
compare 0
the 0
discriminating 0
ability 0
of 0
all 0
fits 0
. 0

RESULTS 0
Including 0
clinical 0
factors 0
significantly 0
increased 0
the 0
predictive 0
power 0
of 0
the 0
models 0
for 0
all 0
end 0
points 0
. 0

In 0
the 0
optimal 0
LKB 0
, 0
RS 0
, 0
and 0
logistic 0
models 0
for 0
rectal 0
bleeding 0
and 0
fecal 0
incontinence 0
, 0
the 0
first 0
significant 0
( 0
p 0
= 0
0.011-0.013 0
) 0
clinical 0
factor 0
was 0
previous 0
abdominal 0
surgery 0
. 0

As 0
second 0
significant 0
( 0
p 0
= 0
0.012-0.016 0
) 0
factor 0
, 0
cardiac 0
history 0
was 0
included 0
in 0
all 0
three 0
rectal 0
bleeding 0
fits 0
, 0
whereas 0
including 0
diabetes 0
was 0
significant 0
( 0
p 0
= 0
0.039-0.048 0
) 0
in 0
fecal 0
incontinence 0
modeling 0
but 0
only 0
in 0
the 0
LKB 0
and 0
logistic 0
models 0
. 0

High B-PHYSICAL
stool I-PHYSICAL
frequency I-PHYSICAL
fits 0
only 0
benefitted 0
significantly 0
( 0
p 0
= 0
0.003-0.006 0
) 0
from 0
the 0
inclusion 0
of 0
the 0
baseline 0
toxicity 0
score 0
. 0

For 0
all 0
models 0
rectal 0
bleeding 0
fits 0
had 0
the 0
highest 0
AUC 0
( 0
0.77 0
) 0
where 0
it 0
was 0
0.63 0
and 0
0.68 0
for 0
high 0
stool 0
frequency 0
and 0
fecal 0
incontinence 0
, 0
respectively 0
. 0

LKB 0
and 0
logistic 0
model 0
fits 0
resulted 0
in 0
similar 0
values 0
for 0
the 0
volume 0
parameter 0
. 0

The 0
steepness 0
parameter 0
was 0
somewhat 0
higher 0
in 0
the 0
logistic 0
model 0
, 0
also 0
resulting 0
in 0
a 0
slightly 0
lower 0
D 0
( 0
50 0
) 0
. 0

Anal 0
wall 0
DVHs 0
were 0
used 0
for 0
fecal 0
incontinence 0
, 0
whereas 0
anorectal 0
wall 0
dose 0
best 0
described 0
the 0
other 0
two 0
endpoints 0
. 0

CONCLUSIONS 0
Comparable 0
prediction 0
models 0
were 0
obtained 0
with 0
LKB 0
, 0
RS 0
, 0
and 0
logistic 0
NTCP 0
models 0
. 0

Including 0
clinical 0
factors 0
improved 0
the 0
predictive 0
power 0
of 0
all 0
models 0
significantly 0
. 0

A 0
randomized 0
multicenter 0
trial 0
comparing 0
resection 0
and 0
radiochemotherapy 0
for 0
resectable 0
locally 0
invasive 0
pancreatic 0
cancer 0
. 0

BACKGROUND 0
Though 0
the 0
outcome 0
of 0
resection 0
for 0
locally 0
invasive 0
pancreatic 0
cancer 0
is 0
still 0
poor 0
, 0
it 0
has 0
gradually 0
improved 0
in 0
Japan 0
, 0
and 0
the 0
5-year B-MORTALITY
survival I-MORTALITY
is 0
now 0
about 0
10 0
% 0
. 0

However 0
, 0
the 0
advantage 0
of 0
resection 0
over 0
radiochemotherapy 0
has 0
not 0
yet 0
been 0
confirmed 0
by 0
a 0
randomized 0
trial 0
. 0

We 0
conducted 0
this 0
study 0
to 0
compare 0
surgical 0
resection 0
alone 0
versus 0
radiochemotherapy 0
without 0
resection 0
for 0
locally 0
invasive 0
pancreatic 0
cancer 0
using 0
a 0
multicenter 0
randomized 0
design 0
. 0

METHODS 0
Patients 0
with 0
pancreatic 0
cancer 0
who 0
met 0
our 0
preoperative 0
criteria 0
for 0
inclusion 0
( 0
pancreatic 0
cancer 0
invading 0
the 0
pancreatic 0
capsule 0
without 0
involvement 0
of 0
the 0
superior 0
mesenteric 0
artery 0
or 0
the 0
common 0
hepatic 0
artery 0
, 0
or 0
without 0
distant 0
metastasis 0
) 0
underwent 0
laparotomy 0
. 0

Patients 0
with 0
operative 0
findings 0
consistent 0
with 0
our 0
criteria 0
were 0
randomized 0
into 0
a 0
radical 0
resection 0
group 0
and 0
a 0
radiochemotherapy 0
group 0
( 0
200 0
mg/m 0
( 0
2 0
) 0
/day 0
of 0
intravenous 0
5-fluorouracil 0
and 0
5040 0
cGy 0
of 0
radiotherapy 0
) 0
without 0
resection 0
. 0

The 0
2 0
groups 0
were 0
compared 0
for 0
mean 0
survival B-MORTALITY
, 0
hazard 0
ratio 0
, 0
1-year B-MORTALITY
survival I-MORTALITY
, 0
quality 0
of 0
life 0
scores B-MORTALITY
, 0
and 0
hematologic B-PHYSICAL
and I-PHYSICAL
blood I-PHYSICAL
chemical I-PHYSICAL
data I-PHYSICAL
. 0

RESULTS 0
Twenty 0
patients 0
were 0
assigned 0
to 0
the 0
resection 0
group 0
and 0
22 0
to 0
the 0
radiochemotherapy 0
group 0
. 0

There 0
was 0
1 0
operative B-MORTALITY
death I-MORTALITY
. 0

The 0
surgical 0
resection 0
group 0
had 0
better 0
results 0
than 0
the 0
radiochemotherapy 0
group 0
as 0
measured 0
by 0
1-year B-MORTALITY
survival I-MORTALITY
( 0
62 0
% 0
vs 0
32 0
% 0
, 0
P=.05 0
) 0
, 0
mean 0
survival B-MORTALITY
time I-MORTALITY
( 0
> 0
17 0
vs 0
11 0
months 0
, 0
P 0
< 0
.03 0
) 0
, 0
and 0
hazard 0
ratio 0
( 0
0.46 0
, 0
P=.04 0
) 0
. 0

There 0
were 0
no 0
differences 0
in 0
the 0
quality 0
of 0
life 0
score 0
or 0
laboratory B-PHYSICAL
data I-PHYSICAL
apart 0
from 0
increased 0
diarrhea B-PHYSICAL
after 0
surgical 0
resection 0
. 0

CONCLUSIONS 0
Locally 0
invasive 0
pancreatic 0
cancer 0
without 0
distant 0
metastases 0
and 0
major 0
arterial 0
invasion 0
appears 0
to 0
be 0
best 0
treated 0
by 0
surgical 0
resection 0
. 0

A 0
double-blind 0
, 0
placebo-controlled 0
trial 0
of 0
intravenous 0
immunoglobulin 0
therapy 0
in 0
patients 0
with 0
chronic 0
fatigue 0
syndrome 0
. 0

PURPOSE 0
The 0
chronic 0
fatigue 0
syndrome 0
( 0
CFS 0
) 0
is 0
characterized 0
by 0
profound 0
fatigue 0
, 0
neuropsychiatric 0
dysfunction 0
, 0
and 0
frequent 0
abnormalities 0
in 0
cell-mediated 0
immunity 0
. 0

No 0
effective 0
therapy 0
is 0
known 0
. 0

PATIENTS 0
AND 0
METHODS 0
Forty-nine 0
patients 0
( 0
40 0
with 0
abnormal 0
cell-mediated 0
immunity 0
) 0
participated 0
in 0
a 0
randomized 0
, 0
double-blind 0
, 0
placebo-controlled 0
trial 0
to 0
determine 0
the 0
effectiveness 0
of 0
high-dose 0
intravenously 0
administered 0
immunoglobulin 0
G. 0
The 0
patients 0
received 0
three 0
intravenous 0
infusions 0
of 0
a 0
placebo 0
solution 0
or 0
immunoglobulin 0
at 0
a 0
dose 0
of 0
2 0
g/kg/month 0
. 0

Assessment 0
of 0
the 0
severity 0
of 0
symptoms 0
and 0
associated 0
disability 0
, 0
both 0
before 0
and 0
after 0
treatment 0
, 0
was 0
completed 0
at 0
detailed 0
interviews 0
by 0
a 0
physician 0
and 0
psychiatrist 0
, 0
who 0
were 0
unaware 0
of 0
the 0
treatment 0
status 0
. 0

In 0
addition 0
, 0
any 0
change 0
in 0
physical 0
symptoms 0
and 0
functional 0
capacity 0
was 0
recorded 0
using 0
visual 0
analogue 0
scales 0
, 0
while 0
changes 0
in 0
psychologic 0
morbidity 0
were 0
assessed 0
using 0
patient-rated 0
indices 0
of 0
depression 0
. 0

Cell-mediated 0
immunity 0
was 0
evaluated 0
by 0
T-cell 0
subset 0
analysis 0
, 0
delayed-type 0
hypersensitivity 0
skin 0
testing 0
, 0
and 0
lymphocyte 0
transformation 0
with 0
phytohemagglutinin 0
. 0

RESULTS 0
At 0
the 0
interview 0
conducted 0
by 0
the 0
physician 0
3 0
months 0
after 0
the 0
final 0
infusion 0
, 0
10 0
of 0
23 0
( 0
43 0
% 0
) 0
immunoglobulin 0
recipients 0
and 0
three 0
of 0
the 0
26 0
( 0
12 0
% 0
) 0
placebo 0
recipients 0
were 0
assessed 0
as 0
having 0
responded 0
with 0
a 0
substantial B-OTHER
reduction I-OTHER
in I-OTHER
their I-OTHER
symptoms I-OTHER
and 0
recommencement B-OTHER
of I-OTHER
work I-OTHER
, 0
leisure B-OTHER
, 0
and 0
social B-MENTAL
activities I-MENTAL
. 0

The 0
patients 0
designated 0
as 0
having 0
responded 0
had 0
improvement 0
in 0
physical 0
, 0
psychologic 0
, 0
and 0
immunologic 0
measures 0
( 0
p 0
less 0
than 0
0.01 0
for 0
each 0
) 0
. 0

CONCLUSION 0
Immunomodulatory 0
treatment 0
with 0
immunoglobulin 0
is 0
effective 0
in 0
a 0
significant 0
number 0
of 0
patients 0
with 0
CFS 0
, 0
a 0
finding 0
that 0
supports 0
the 0
concept 0
that 0
an 0
immunologic 0
disturbance 0
may 0
be 0
important 0
in 0
the 0
pathogenesis 0
of 0
this 0
disorder 0
. 0

[ 0
Mitomycin 0
C 0
plus 0
HCFU 0
adjuvant 0
chemotherapy 0
for 0
noncuratively 0
resected 0
cases 0
of 0
colorectal 0
carcinoma 0
. 0
( 0

Second 0
report 0
) 0
: 0
5-year 0
survival 0
rate 0
. 0

Cooperative 0
Study 0
Group 0
of 0
Kyushu 0
and 0
Chugoku 0
for 0
HCFU 0
Adjuvant 0
Chemotherapy 0
] 0
. 0

In 0
order 0
to 0
examine 0
the 0
efficacy 0
of 0
adjuvant 0
chemotherapy 0
employing 0
mitomycin 0
C 0
( 0
MMC 0
) 0
and 0
carmofur 0
( 0
HCFU 0
) 0
for 0
patients 0
with 0
noncuratively 0
resected 0
colorectal 0
carcinoma 0
, 0
a 0
cooperative 0
study 0
was 0
performed 0
by 0
54 0
institutions 0
in 0
the 0
Kyushu 0
and 0
Chugoku 0
areas 0
of 0
Japan 0
. 0

The 0
criteria 0
for 0
patient 0
selection 0
were 0
as 0
follows 0
: 0
1 0
) 0
Age 0
of 0
75 0
years 0
or 0
less 0
and 0
not 0
accompanied 0
by 0
any 0
serious 0
disease 0
. 0

2 0
) 0
Macroscopic 0
diagnosis 0
as 0
being 0
noncuratively 0
resected 0
on 0
completion 0
of 0
the 0
surgical 0
procedure 0
. 0

3 0
) 0
Definitive 0
diagnosis 0
of 0
colorectal 0
carcinomas 0
, 0
histologically 0
. 0

4 0
) 0
No 0
synchronous 0
or 0
metachronous 0
double 0
cancer 0
. 0

The 0
prospective 0
randomized 0
controlled 0
study 0
consisted 0
of 0
two 0
groups 0
. 0

In 0
Group 0
A 0
, 0
the 0
MMC 0
group 0
received 0
bolus 0
intravenous 0
injections 0
of 0
20 0
mg 0
MMC 0
on 0
the 0
day 0
of 0
operation 0
and 0
10 0
mg 0
the 0
next 0
day 0
, 0
followed 0
by 0
10 0
mg 0
every 0
4 0
weeks 0
until 0
a 0
total 0
of 0
100 0
mg 0
had 0
been 0
administered 0
. 0

In 0
Group 0
B 0
, 0
the 0
MMC 0
+ 0
HCFU 0
group 0
received 0
the 0
same 0
treatment 0
in 0
Group 0
A 0
, 0
but 0
with 0
the 0
addition 0
of 0
600 0
mg/day 0
of 0
HCFU 0
from 0
the 0
second 0
week 0
, 0
orally 0
for 0
at 0
least 0
one 0
year 0
. 0

Concerning 0
the 0
69-month B-MORTALITY
survival I-MORTALITY
rate I-MORTALITY
, 0
a 0
better 0
result 0
was 0
observed 0
in 0
the 0
MMC 0
+ 0
HCFU 0
group 0
than 0
in 0
the 0
MMC 0
only 0
group 0
( 0
generalized 0
Wilcoxon 0
test 0
: 0
p 0
less 0
than 0
0.05 0
) 0
. 0

Significantly 0
better 0
survival B-MORTALITY
rates I-MORTALITY
were 0
obtained 0
in 0
those 0
cases 0
with 0
disseminating 0
peritoneal 0
metastasis 0
, 0
hepatic 0
metastasis 0
and 0
stage 0
V 0
cancer 0
in 0
the 0
MMC 0
+ 0
HCFU 0
group 0
as 0
when 0
compared 0
with 0
the 0
MMC 0
only 0
group 0
. 0

No 0
significant B-ADVERSE-EFFECTS
side I-ADVERSE-EFFECTS
effects I-ADVERSE-EFFECTS
due 0
to 0
the 0
combined 0
administration 0
of 0
HCFU 0
were 0
recognized 0
. 0

The 0
combined 0
administration 0
of 0
MMC 0
and 0
HCFU 0
was 0
suggested 0
to 0
be 0
a 0
safe 0
and 0
effective 0
adjuvant 0
chemotherapy 0
for 0
noncuratively 0
resected 0
cases 0
of 0
colorectal 0
carcinoma 0
. 0

The 0
biological 0
factors 0
in 0
the 0
etiopathogenesis 0
and 0
management 0
of 0
cervical 0
spondylosis 0
. 0

Two 0
hundred 0
cases 0
of 0
cervical 0
spondylosis 0
were 0
studied 0
for 0
1 0
to 0
4 0
average 0
( 0
2 0
1/2 0
) 0
years 0
. 0

No 0
co-relation 0
could 0
be 0
established 0
between 0
the 0
clinical 0
features 0
and 0
the 0
radiological 0
findings 0
in 0
these 0
cases 0
. 0

It 0
was 0
found 0
that 0
parasites B-OTHER
play I-OTHER
an I-OTHER
important I-OTHER
role I-OTHER
in I-OTHER
the I-OTHER
multifactorial I-OTHER
etiology I-OTHER
of I-OTHER
this I-OTHER
condition I-OTHER
and I-OTHER
their I-OTHER
eradication I-OTHER
by I-OTHER
deworming I-OTHER
drugs I-OTHER
gives I-OTHER
better I-OTHER
results I-OTHER
than I-OTHER
the I-OTHER
traditional I-OTHER
therapies I-OTHER
. 0

Many 0
new 0
hypotheses 0
are 0
proposed 0
to 0
explain 0
the 0
same 0
. 0

Safety B-OTHER
and 0
efficacy 0
of 0
a 0
low 0
molecular 0
weight 0
heparin 0
( 0
Logiparin 0
) 0
versus 0
dextran 0
as 0
prophylaxis 0
against 0
thrombosis 0
after 0
total 0
hip 0
replacement 0
. 0

In 0
order 0
to 0
study 0
the 0
plasma 0
levels 0
of 0
factor 0
XaI 0
and 0
IIaI 0
activity 0
an 0
enzymatically 0
depolymerized 0
low 0
molecular 0
weight 0
heparin 0
( 0
LMW-heparin 0
; 0
Logiparin 0
) 0
was 0
given 0
s.c. 0
in 0
a 0
dose 0
of 0
35 0
XaI 0
mu/kg 0
b.w 0
. 0

once 0
daily 0
for 0
7 0
days 0
to 0
10 0
patients 0
undergoing 0
total 0
hip 0
replacement 0
( 0
THR 0
) 0
in 0
a 0
pilot 0
study 0
. 0

The 0
XaI 0
activity 0
was 0
less 0
than 0
or 0
equal 0
to 0
0.24 0
XaI 0
units/ml 0
and 0
the 0
IIaI 0
activity 0
less 0
than 0
or 0
equal 0
to 0
0.043 0
IIaI 0
mu/ml 0
. 0

No 0
accumulation 0
of 0
the 0
activities 0
were 0
seen 0
. 0

No 0
phlebographically B-PHYSICAL
verified I-PHYSICAL
thrombi I-PHYSICAL
or 0
any 0
bleeding B-PHYSICAL
complications I-PHYSICAL
were 0
registered 0
. 0

From 0
this 0
study 0
it 0
was 0
concluded 0
that 0
the 0
given 0
dose 0
of 0
Logiparin 0
was 0
safe 0
with 0
regard 0
to 0
bleeding 0
complications 0
. 0

Based 0
on 0
these 0
data 0
, 0
an 0
open 0
, 0
randomized 0
controlled 0
trial 0
was 0
started 0
. 0

In 0
this 0
main 0
study 0
the 0
thromboprophylactic B-PHYSICAL
effect 0
of 0
the 0
LMW-heparin 0
( 0
Logiparin 0
) 0
in 0
a 0
dose 0
of 0
35 0
XaI 0
mu/kg 0
b.w 0
. 0

once 0
daily 0
was 0
compared 0
with 0
that 0
of 0
dextran 0
70 0
in 0
patients 0
undergoing 0
THR 0
. 0

100 0
patients 0
were 0
randomized 0
. 0

The 0
over-all B-OTHER
thrombosis I-OTHER
rate I-OTHER
was 0
28 0
% 0
in 0
patients 0
treated 0
with 0
LMW-heparin 0
and 0
39 0
% 0
in 0
those 0
given 0
dextran 0
, 0
a 0
non-significant 0
difference 0
. 0

No 0
bleeding B-ADVERSE-EFFECTS
complications I-ADVERSE-EFFECTS
, 0
deaths B-MORTALITY
or 0
pulmonary B-PHYSICAL
embolism I-PHYSICAL
were 0
recorded 0
in 0
either 0
group 0
. 0

Peroperative B-PHYSICAL
blood I-PHYSICAL
loss I-PHYSICAL
and I-PHYSICAL
transfusion I-PHYSICAL
requirements I-PHYSICAL
were 0
similar 0
in 0
the 0
two 0
groups 0
. 0

In 0
conclusion 0
, 0
the 0
investigated 0
LMW-heparin 0
( 0
Logiparin 0
) 0
is 0
safe 0
and 0
effective 0
in 0
preventing 0
postoperative 0
thromboembolism 0
in 0
patients 0
undergoing 0
total 0
hip 0
replacement 0
, 0
but 0
the 0
dosage 0
can 0
probably 0
be 0
optimized 0
. 0

Losartan 0
vs. 0
amlodipine 0
treatment 0
in 0
elderly 0
oncologic 0
hypertensive 0
patients 0
: 0
a 0
randomized 0
clinical 0
trial 0
. 0

Elderly 0
neoplastic 0
patients 0
frequently 0
may 0
show 0
hypertension 0
and 0
hyperuricemia 0
, 0
before 0
and 0
after 0
chemotherapeutic 0
treatments 0
. 0

The 0
purpose 0
of 0
this 0
study 0
was 0
to 0
evaluate 0
the 0
efficacy 0
of 0
losartan 0
which 0
is 0
an 0
antihypertensive 0
drug 0
with 0
uricosuric 0
properties 0
vs. 0
amlodipine 0
in 0
hypertensive 0
neoplastic 0
elderly 0
patients 0
. 0

This 0
was 0
an 0
open-labeled 0
, 0
randomized 0
, 0
comparative 0
trial 0
. 0

The 0
study 0
was 0
performed 0
as 0
a 0
30-day 0
study 0
. 0

Seventy 0
patients 0
with 0
cancer 0
were 0
randomly 0
assigned 0
to 0
receive 0
losartan 0
or 0
amlodipine 0
. 0

Blood 0
pressure 0
( 0
BP 0
) 0
, 0
blood 0
urea 0
nitrogen 0
( 0
BUN 0
) 0
levels 0
, 0
creatinine 0
, 0
serum 0
and 0
urinary 0
uric 0
acid 0
, 0
creatinine 0
and 0
uric 0
acid 0
clearance 0
were 0
determined 0
before 0
and 0
after 0
chemotherapy 0
. 0

One 0
day 0
after 0
chemotherapy 0
in 0
losartan 0
group 0
vs. 0
amlodipine 0
group 0
we 0
observed 0
a 0
significant 0
difference 0
in 0
urinary B-PHYSICAL
uric I-PHYSICAL
acid I-PHYSICAL
( 0
p 0
< 0
0.001 0
) 0
of 0
18 0
mg/24 0
h 0
vs. 0
40 0
mg/24 0
h. 0
Thirty 0
days 0
after 0
chemotherapy 0
we 0
observed 0
a 0
significant 0
difference 0
in 0
azotemia B-PHYSICAL
of 0
0.0 0
mg/dl 0
vs. 0
3.8 0
mg/dl 0
( 0
p 0
< 0
0.001 0
) 0
, 0
serum B-PHYSICAL
uric I-PHYSICAL
acid I-PHYSICAL
of 0
0.05 0
mg/dl 0
vs. 0
0.49 0
mg/dl 0
( 0
p 0
< 0
0.001 0
) 0
, 0
urinary B-PHYSICAL
uric I-PHYSICAL
acid I-PHYSICAL
( 0
p 0
< 0
0.001 0
) 0
of 0
23 0
mg/24 0
h 0
vs. 0
0.0 0
mg/24 0
h 0
, 0
GFR 0
of 0
2 0
ml/min/1.73 0
m 0
( 0
2 0
) 0
vs. 0
-8 0
ml/min/1.73 0
m 0
( 0
2 0
) 0
( 0
p 0
< 0
0.05 0
) 0
and 0
systolic B-PHYSICAL
BP I-PHYSICAL
( 0
SBP 0
) 0
of 0
3.6 0
mmHg 0
vs. 0
0.8 0
mmHg 0
( 0
p 0
< 0
0.05 0
) 0
. 0

The 0
findings 0
of 0
the 0
present 0
study 0
support 0
the 0
effective 0
role 0
of 0
losartan 0
compared 0
to 0
amlodipine 0
in 0
treating 0
hypertension 0
and 0
hyperuricemia 0
in 0
elderly 0
patients 0
under 0
chemotherapeutic 0
treatment 0
. 0

Biochemical 0
and 0
functional 0
effects 0
of 0
creatine 0
phosphate 0
in 0
cardioplegic 0
solution 0
during 0
aortic 0
valve 0
surgery 0
-- 0
a 0
clinical 0
study 0
. 0

During 0
myocardial 0
ischemia 0
there 0
is 0
a 0
drop 0
in 0
high-energy B-PHYSICAL
phosphates I-PHYSICAL
in 0
the 0
myocardium 0
. 0

Cold 0
potassium 0
cardioplegia 0
decreases 0
but 0
does 0
not 0
altogether 0
prevent 0
this 0
reduction 0
. 0

Supplementation 0
of 0
cardioplegic 0
solutions 0
with 0
the 0
high-energy 0
compound 0
creatine 0
phosphate 0
( 0
10 0
mmol/L 0
) 0
compared 0
to 0
plain 0
cardioplegic 0
solutions 0
was 0
investigated 0
in 0
this 0
study 0
. 0

Thirty 0
patients 0
scheduled 0
for 0
aortic 0
valve 0
replacement 0
were 0
included 0
. 0

The 0
patients 0
were 0
randomized 0
to 0
group 0
I 0
( 0
creatine 0
phosphate 0
) 0
or 0
group 0
II 0
( 0
control 0
) 0
. 0

Postoperative 0
hemodynamic B-PHYSICAL
evaluation I-PHYSICAL
revealed 0
no 0
significant 0
differences 0
between 0
the 0
groups 0
. 0

However 0
, 0
group 0
I 0
exhibited 0
a 0
tendency 0
toward 0
a 0
better 0
stroke-work B-PHYSICAL
index I-PHYSICAL
( 0
135 0
+/- 0
18 0
% 0
vs. 0
102 0
+/- 0
5 0
% 0
recovery 0
15 0
minutes 0
after 0
bypass 0
and 0
145 0
+/- 0
16 0
% 0
vs. 0
119 0
+/- 0
11 0
% 0
recovery 0
105 0
min 0
after 0
bypass 0
) 0
. 0

There 0
were 0
fewer 0
patients 0
in 0
group 0
I 0
( 0
5/15 0
) 0
needing B-PHYSICAL
inotropic I-PHYSICAL
support I-PHYSICAL
compared 0
to 0
group 0
II 0
( 0
9/14 0
) 0
. 0

The 0
myocardial B-PHYSICAL
content I-PHYSICAL
of I-PHYSICAL
ATP I-PHYSICAL
and 0
creatine B-PHYSICAL
phosphate I-PHYSICAL
showed 0
no 0
significant 0
differences 0
during 0
ischemia 0
and 0
reperfusion 0
. 0

It 0
is 0
concluded 0
that 0
the 0
myocardial 0
protection 0
during 0
ischemia 0
was 0
sufficient 0
to 0
prevent 0
significant 0
reductions 0
of 0
myocardial B-PHYSICAL
ATP I-PHYSICAL
and I-PHYSICAL
creatine I-PHYSICAL
phosphate I-PHYSICAL
irrespective 0
of 0
supplementation 0
with 0
CP 0
. 0

Controlled 0
, 0
prospective 0
, 0
randomized 0
, 0
clinical 0
evaluation 0
of 0
partial 0
ceramic 0
crowns 0
inserted 0
with 0
RelyX 0
Unicem 0
with 0
or 0
without 0
selective 0
enamel 0
etching 0
. 0

1-year 0
results 0
. 0

PURPOSE 0
To 0
compare 0
the 0
performance 0
of 0
partial B-OTHER
ceramic I-OTHER
crowns I-OTHER
( I-OTHER
PCCs I-OTHER
) I-OTHER
inserted 0
with 0
RelyX 0
Unicem 0
( 0
RXU 0
) 0
either 0
with 0
( 0
RXU+E 0
) 0
or 0
without 0
( 0
RXU 0
) 0
selective 0
enamel 0
etching 0
. 0

METHODS 0
34 0
patients 0
( 0
15 0
male 0
, 0
19 0
female 0
) 0
participated 0
in 0
the 0
investigation 0
, 0
with 0
a 0
total 0
of 0
68 0
PCC 0
restorations 0
. 0

In 0
each 0
patient 0
, 0
one 0
PCC 0
was 0
randomly 0
assigned 0
to 0
insertion 0
with 0
RXU 0
, 0
the 0
second 0
PCC 0
was 0
assigned 0
to 0
insertion 0
with 0
RXU+E 0
. 0

The 0
PCCs 0
were 0
CAD/CAM 0
fabricated 0
using 0
the 0
Cerec 0
3 0
system 0
. 0

RXU 0
: 0
25 0
PCCs 0
were 0
placed 0
in 0
molars 0
, 0
nine 0
in 0
premolars 0
. 0

RXU+E 0
: 0
26 0
PCCs 0
were 0
placed 0
in 0
molars 0
, 0
eight 0
in 0
premolars 0
. 0

The 0
restorations 0
were 0
clinically 0
rated 0
using 0
modified 0
United 0
States 0
Public 0
Health 0
Service 0
( 0
USPHS 0
) 0
criteria 0
at 0
baseline 0
, 0
6 0
and 0
12 0
months 0
after 0
placement 0
. 0

The 0
median 0
patient 0
age 0
was 0
41 0
years 0
( 0
24-59 0
years 0
) 0
. 0

The 0
median 0
( 0
25-75 0
% 0
) 0
PBI 0
was 0
6 0
% 0
( 0
3-9 0
% 0
) 0
. 0

RESULTS 0
All 0
patients 0
were 0
available 0
for 0
the 0
three 0
recall 0
appointments 0
. 0

One 0
PCC 0
( 0
RXU 0
) 0
debonded B-PHYSICAL
after 0
11 0
months 0
in 0
situ 0
, 0
one 0
PCC 0
( 0
RXU+E 0
) 0
fractured B-PHYSICAL
after 0
12 0
months 0
in 0
situ 0
. 0

Both 0
restorations B-OTHER
had 0
to 0
be 0
replaced B-OTHER
. 0

At 0
the 0
12 0
months 0
recall 0
, 0
66 0
of 0
68 0
controlled 0
restorations 0
were 0
functional B-OTHER
without 0
need 0
of 0
replacement 0
. 0

The 0
evaluation 0
using 0
USHPS 0
criteria 0
revealed 0
a 0
significant 0
decrease 0
of 0
alfa 0
ratings B-PHYSICAL
over I-PHYSICAL
time I-PHYSICAL
with 0
respect B-OTHER
to I-OTHER
criteria I-OTHER
marginal I-OTHER
adaptation I-OTHER
and I-OTHER
marginal I-OTHER
discoloration I-OTHER
. 0

No 0
statistically 0
significant 0
differences 0
between 0
the 0
two 0
luting 0
techniques 0
, 0
RXU 0
and 0
RXU+E 0
, 0
we 0
reobserved 0
during 0
the 0
observation 0
period 0
of 0
1 0
year 0
. 0

Within 0
the 0
limitations 0
of 0
the 0
present 0
study 0
, 0
adhesive 0
luting 0
with 0
RXU 0
with 0
or 0
without 0
selective 0
enamel 0
etching 0
can 0
be 0
recommended 0
. 0

Efficacy 0
, 0
tolerability B-OTHER
and 0
pharmacokinetics B-OTHER
of 0
two 0
nelfinavir-based 0
regimens 0
in 0
human 0
immunodeficiency 0
virus-infected 0
children 0
and 0
adolescents 0
: 0
pediatric 0
AIDS 0
clinical 0
trials 0
group 0
protocol 0
403 0
. 0

INTRODUCTION 0
Few 0
combinations 0
of 0
highly 0
active 0
antiretrovirals 0
have 0
been 0
studied 0
in 0
nucleoside 0
reverse 0
transcription 0
inhibitor 0
( 0
NRTI 0
) 0
-experienced 0
, 0
human 0
immunodeficiency 0
virus 0
( 0
HIV 0
) 0
-infected 0
children 0
. 0

We 0
tested 0
the 0
efficacy 0
, 0
tolerability 0
and 0
pharmacokinetics 0
of 0
2 0
combination 0
therapies 0
containing 0
an 0
NRTI 0
, 0
protease 0
inhibitors 0
+/- 0
a 0
nonnucleoside 0
reverse 0
transcription 0
inhibitor 0
( 0
NNRTI 0
) 0
. 0

METHODS 0
This 0
was 0
a 0
phase 0
II 0
, 0
randomized 0
, 0
multicenter 0
study 0
. 0

Forty-one 0
children 0
and 0
youths 0
between 0
5 0
months 0
and 0
21 0
years 0
with 0
prior 0
NRTI 0
and 0
no 0
prior 0
NNRTI 0
or 0
protease 0
inhibitor 0
experience 0
received 0
either 0
nelfinavir 0
( 0
NFV 0
) 0
30 0
mg/kg 0
twice 0
daily 0
( 0
bid 0
) 0
, 0
ritonavir 0
( 0
RTV 0
) 0
400 0
mg/m 0
bid 0
and 0
buffered 0
didanosine 0
( 0
ddI 0
) 0
240 0
mg/m 0
daily 0
( 0
arm 0
A 0
) 0
or 0
NFV 0
50-55 0
mg/kg 0
bid 0
, 0
nevirapine 0
( 0
NVP 0
) 0
120 0
mg/m 0
bid 0
and 0
stavudine 0
( 0
d4T 0
) 0
1 0
mg/kg 0
bid 0
( 0
arm 0
B 0
) 0
. 0

Patients 0
were 0
evaluated 0
clinically 0
for 0
48 0
weeks 0
after 0
initiation 0
of 0
therapy 0
. 0

Intensive 0
pharmacokinetic 0
sampling 0
occurred 0
after 0
4 0
weeks 0
of 0
therapy 0
. 0

RESULTS 0
: 0
The 0
proportion 0
of 0
children 0
with 0
HIV-1 0
RNA 0
< 0
or 0
=400 0
copies/mL 0
and 0
on 0
randomized 0
treatment 0
at 0
48 0
weeks 0
was 0
65 0
% 0
among 0
children 0
assigned 0
NFV 0
+ 0
RTV 0
+ 0
ddI 0
versus 0
28 0
% 0
among 0
those 0
assigned 0
NFV 0
+ 0
NVP 0
+ 0
d4T 0
( 0
P 0
= 0
0.039 0
) 0
. 0

No 0
significant 0
difference 0
in 0
median 0
CD4 B-PHYSICAL
% I-PHYSICAL
change I-PHYSICAL
from 0
baseline 0
to 0
week 0
48 0
was 0
found 0
( 0
3 0
% 0
versus 0
1 0
% 0
) 0
. 0

No 0
significant 0
differences 0
in 0
safety B-OTHER
or 0
tolerability B-OTHER
between 0
children 0
randomized 0
to 0
NFV 0
+ 0
RTV 0
+ 0
ddI 0
versus 0
NFV 0
+ 0
NVP 0
+ 0
d4T 0
were 0
identified 0
. 0

However 0
, 0
a 0
trend 0
toward 0
a 0
higher 0
rate 0
of 0
permanent B-OTHER
discontinuation I-OTHER
of I-OTHER
study I-OTHER
treatment I-OTHER
was 0
noted 0
among 0
children 0
assigned 0
to 0
NFV 0
+ 0
NVP 0
+ 0
d4T 0
compared 0
with 0
NFV 0
+ 0
RTV 0
+ 0
ddI 0
[ 0
7 0
of 0
20 0
( 0
35 0
% 0
) 0
versus 0
2 0
of 0
21 0
( 0
10 0
% 0
) 0
; 0
P 0
= 0
0.12 0
] 0
. 0

NFV 0
pharmacokinetic 0
measurements 0
were 0
not 0
statistically 0
different 0
between 0
the 0
treatment 0
groups 0
, 0
yet 0
exposure 0
to 0
the 0
NFV 0
metabolite 0
, 0
M8 0
, 0
was 0
significantly 0
higher 0
in 0
subjects 0
receiving 0
RTV 0
. 0

The 0
pharmacokinetics 0
for 0
NVP 0
, 0
RTV 0
and 0
d4T 0
were 0
similar 0
to 0
those 0
of 0
previously 0
reported 0
data 0
. 0

CONCLUSION 0
: 0
Combination 0
therapy 0
containing 0
NFV 0
+ 0
RTV 0
+ 0
ddI 0
appears 0
more 0
efficacious 0
in 0
NRTI-experienced 0
children 0
than 0
a 0
regimen 0
containing 0
NFV 0
+ 0
NVP 0
+ 0
d4T 0
. 0

Differences 0
in 0
tolerability 0
between 0
the 0
2 0
treatment 0
groups 0
were 0
not 0
identified 0
. 0

Systemic 0
exposure 0
of 0
these 0
drugs 0
was 0
similar 0
to 0
that 0
reported 0
in 0
other 0
HIV-infected 0
children 0
and 0
adults 0
. 0

Combination 0
chemotherapy 0
and 0
ALVAC-CEA/B7.1 0
vaccine 0
in 0
patients 0
with 0
metastatic 0
colorectal 0
cancer 0
. 0

PURPOSE 0
The 0
combination 0
of 0
vaccines 0
and 0
chemotherapy 0
holds 0
promise 0
for 0
cancer 0
therapy 0
, 0
but 0
the 0
effect 0
of 0
cytotoxic 0
chemotherapy 0
on 0
vaccine-induced 0
antitumor 0
immunity 0
is 0
unknown 0
. 0

This 0
study 0
was 0
conducted 0
to 0
assess 0
the 0
effects 0
of 0
systemic 0
chemotherapy 0
on 0
ALVAC-CEA/B7.1-induced 0
T-cell 0
immunity 0
in 0
patients 0
with 0
metastatic 0
colorectal 0
cancer 0
. 0

EXPERIMENTAL 0
DESIGN 0
Patients 0
with 0
metastatic 0
colorectal 0
cancer 0
were 0
treated 0
with 0
fluorouracil 0
, 0
leucovorin 0
, 0
and 0
irinotecan 0
and 0
were 0
also 0
given 0
ALVAC-CEA/B7.1 0
vaccine 0
with 0
or 0
without 0
tetanus 0
toxoid 0
adjuvant 0
. 0

Eligible 0
patients 0
were 0
randomized 0
to 0
ALVAC 0
followed 0
by 0
chemotherapy 0
and 0
booster 0
vaccination 0
( 0
group 0
1 0
) 0
, 0
ALVAC 0
and 0
tetanus 0
toxoid 0
followed 0
by 0
chemotherapy 0
( 0
group 0
2 0
) 0
, 0
or 0
chemotherapy 0
alone 0
followed 0
by 0
ALVAC 0
in 0
patients 0
without 0
disease 0
progression 0
( 0
group 0
3 0
) 0
. 0

Humoral 0
immune 0
responses 0
were 0
measured 0
by 0
standard 0
ELISA 0
assay 0
, 0
and 0
carcinoembryonic 0
antigen 0
( 0
CEA 0
) 0
-specific 0
T-cell 0
responses 0
were 0
measured 0
by 0
IFN-gamma 0
enzyme-linked 0
immunospot 0
assay 0
. 0

RESULTS 0
One 0
hundred 0
eighteen 0
patients 0
were 0
randomized 0
to 0
receive 0
either 0
ALVAC 0
before 0
and 0
concomitantly 0
with 0
chemotherapy 0
( 0
n 0
= 0
39 0
) 0
, 0
ALVAC 0
with 0
tetanus 0
adjuvant 0
before 0
and 0
concomitantly 0
with 0
chemotherapy 0
( 0
n 0
= 0
40 0
) 0
, 0
or 0
chemotherapy 0
followed 0
by 0
ALVAC 0
( 0
n 0
= 0
39 0
) 0
. 0

Serious B-ADVERSE-EFFECTS
adverse I-ADVERSE-EFFECTS
events I-ADVERSE-EFFECTS
were 0
largely 0
gastrointestinal B-ADVERSE-EFFECTS
( 0
n 0
= 0
30 0
) 0
and 0
hematologic B-ADVERSE-EFFECTS
( 0
n 0
= 0
24 0
) 0
. 0

Overall 0
, 0
42 0
patients 0
( 0
40.4 0
% 0
) 0
showed 0
objective 0
clinical 0
responses 0
. 0

All 0
patients 0
developed 0
antibody B-PHYSICAL
responses I-PHYSICAL
against I-PHYSICAL
ALVAC I-PHYSICAL
, 0
but 0
increased 0
anti-CEA B-PHYSICAL
antibody I-PHYSICAL
titers I-PHYSICAL
were 0
detected 0
in 0
only 0
three 0
patients 0
. 0

Increases 0
in 0
CEA-specific B-PHYSICAL
T I-PHYSICAL
cells I-PHYSICAL
were 0
detected 0
in 0
50 0
% 0
, 0
37 0
% 0
, 0
and 0
30 0
% 0
of 0
patients 0
in 0
groups 0
1 0
, 0
2 0
, 0
and 0
3 0
, 0
respectively 0
. 0

There 0
were 0
no 0
differences 0
in 0
clinical 0
or 0
immune 0
responses 0
between 0
the 0
treatment 0
groups 0
. 0

CONCLUSION 0
The 0
combination 0
of 0
ALVAC-CEA/B7.1 0
vaccine 0
and 0
systemic 0
chemotherapy 0
has 0
an 0
acceptable 0
safety 0
profile 0
in 0
patients 0
with 0
metastatic 0
colorectal 0
cancer 0
. 0

Systemic 0
chemotherapy 0
did 0
not 0
affect 0
the 0
generation 0
of 0
CEA-specific B-PHYSICAL
T-cell I-PHYSICAL
responses I-PHYSICAL
following 0
vaccination 0
. 0

Comparison 0
of 0
fluid 0
types 0
for 0
resuscitation 0
after 0
acute B-PHYSICAL
blood I-PHYSICAL
loss I-PHYSICAL
in 0
mallard 0
ducks 0
( 0
Anas 0
platyrhynchos 0
) 0
. 0

OBJECTIVE 0
The 0
purpose 0
of 0
this 0
study 0
was 0
to 0
determine 0
the 0
LD 0
( 0
50 0
) 0
for 0
acute 0
blood 0
loss 0
in 0
mallard 0
ducks 0
( 0
Anas 0
platyrhynchos 0
) 0
, 0
compare 0
the 0
mortality 0
rate 0
among 0
3 0
fluid 0
resuscitation 0
groups 0
, 0
and 0
determine 0
the 0
time 0
required 0
for 0
a 0
regenerative 0
RBC 0
response 0
. 0

DESIGN 0
Prospective 0
study 0
. 0

SETTING 0
Medical 0
College 0
of 0
Wisconsin 0
Research 0
facility 0
. 0

ANIMALS 0
Eighteen 0
mallard 0
ducks 0
were 0
included 0
for 0
the 0
LD 0
( 0
50 0
) 0
study 0
and 0
28 0
for 0
the 0
fluid 0
resuscitation 0
study 0
. 0

INTERVENTIONS 0
Phlebotomy 0
was 0
performed 0
during 0
both 0
the 0
LD 0
( 0
50 0
) 0
and 0
fluid 0
resuscitation 0
studies 0
. 0

Ducks 0
in 0
the 0
fluid 0
resuscitation 0
study 0
received 0
a 0
5 0
mL/kg 0
intravenous 0
bolus 0
of 0
crystalloids 0
, 0
hetastarch 0
( 0
HES 0
) 0
, 0
or 0
a 0
hemoglobin-based 0
oxygen-carrying 0
solution 0
( 0
HBOCS 0
) 0
. 0

MEASUREMENTS 0
AND 0
MAIN 0
RESULTS 0
The 0
LD 0
( 0
50 0
) 0
for 0
acute B-PHYSICAL
blood I-PHYSICAL
loss I-PHYSICAL
was 0
60 0
% 0
of 0
total 0
blood B-PHYSICAL
volume I-PHYSICAL
. 0

This 0
blood 0
volume 0
was 0
removed 0
in 0
the 0
fluid 0
resuscitation 0
study 0
to 0
create 0
a 0
model 0
of 0
acute 0
blood 0
loss 0
. 0

Following 0
fluid 0
administration 0
, 0
6 0
birds 0
in 0
the 0
crystalloid 0
group 0
( 0
66 0
% 0
) 0
, 0
4 0
birds 0
in 0
the 0
HES 0
group 0
( 0
40 0
% 0
) 0
, 0
and 0
2 0
birds 0
in 0
the 0
HBOCS 0
group 0
( 0
20 0
% 0
) 0
died 0
. 0

No 0
statistical 0
difference 0
in 0
mortality B-MORTALITY
rate I-MORTALITY
was 0
seen 0
among 0
the 0
3 0
fluid 0
resuscitation 0
groups 0
. 0

Relative 0
polychromasia 0
evaluated 0
post-phlebotomy 0
demonstrated 0
regeneration 0
starting 0
at 0
24 0
hours 0
and 0
continuing 0
through 0
48 0
hours 0
. 0

CONCLUSIONS 0
The 0
LD 0
( 0
50 0
) 0
for 0
acute B-PHYSICAL
blood I-PHYSICAL
loss I-PHYSICAL
in 0
mallard 0
ducks 0
was 0
60 0
% 0
of 0
their 0
total 0
blood 0
volume 0
. 0

Although 0
no 0
statistical 0
difference 0
in 0
mortality B-MORTALITY
rate I-MORTALITY
was 0
appreciated 0
among 0
the 0
3 0
fluid 0
resuscitation 0
groups 0
, 0
a 0
trend 0
of 0
decreased 0
mortality B-MORTALITY
rate I-MORTALITY
was 0
observed 0
in 0
the 0
HBOCS 0
group 0
. 0

An 0
early 0
regenerative 0
response 0
was 0
apparent 0
following 0
acute B-PHYSICAL
blood I-PHYSICAL
loss I-PHYSICAL
. 0

The 0
experience 0
of 0
pleasure 0
before 0
and 0
after 0
hearing 0
rehabilitation 0
. 0

Hearing 0
loss 0
may 0
lead 0
to 0
major 0
changes 0
in 0
the 0
social 0
and 0
emotional 0
aspects 0
of 0
daily 0
life 0
. 0

This 0
follow-up 0
study 0
investigated 0
the 0
effect 0
of 0
hearing-aid 0
use 0
on 0
emotional 0
experience 0
in 0
adults 0
with 0
hearing 0
impairment 0
. 0

Thirteen 0
individuals 0
with 0
impaired 0
hearing 0
were 0
tested 0
before 0
and 0
after 0
6 0
months 0
of 0
hearing-aid 0
use 0
, 0
and 0
were 0
compared 0
with 0
19 0
individuals 0
who 0
had 0
worn 0
hearing 0
aids 0
for 0
many 0
years 0
. 0

The 0
participants 0
reported 0
their 0
daily B-MENTAL
emotional I-MENTAL
experiences I-MENTAL
, 0
by 0
completing 0
questionnaires B-MENTAL
relating I-MENTAL
to I-MENTAL
sensory I-MENTAL
and I-MENTAL
social I-MENTAL
pleasure I-MENTAL
. 0

After 0
6 0
months 0
of 0
hearing-aid 0
use 0
, 0
individuals 0
experienced 0
more 0
physical B-MENTAL
and I-MENTAL
social I-MENTAL
pleasure I-MENTAL
, 0
whereas 0
individuals 0
using 0
hearing 0
aids 0
for 0
long 0
periods 0
of 0
time 0
reported 0
similar 0
levels 0
of 0
pleasure 0
at 0
the 0
beginning 0
and 0
at 0
the 0
end 0
of 0
a 0
6-month 0
interval 0
. 0

The 0
participants 0
also 0
performed 0
a 0
visual 0
task 0
, 0
in 0
which 0
they 0
rated 0
the 0
intensity 0
of 0
pleasure B-MENTAL
they I-MENTAL
experienced I-MENTAL
in I-MENTAL
response 0
to B-MENTAL
emotionally I-MENTAL
positive 0
and B-MENTAL
neutral I-MENTAL
pictures I-MENTAL
differing I-MENTAL
in I-MENTAL
luminance B-MENTAL
contrast I-MENTAL
. 0

In 0
this 0
task 0
, 0
pleasure 0
typically 0
decreases 0
with 0
decreasing 0
contrast 0
of 0
the 0
positive 0
images 0
displayed 0
. 0

Once 0
they 0
had 0
been 0
fitted 0
with 0
hearing 0
aids 0
, 0
the 0
participants 0
reported 0
lower 0
levels B-MENTAL
of I-MENTAL

Utilization 0
patterns 0
of 0
conventional 0
and 0
complementary/alternative 0
treatments 0
in 0
children 0
with 0
autism 0
spectrum 0
disorders 0
and 0
developmental 0
disabilities 0
in 0
a 0
population-based 0
study 0
. 0

OBJECTIVE 0
To 0
compare 0
the 0
utilization 0
of 0
conventional 0
treatments 0
and 0
utilization 0
of 0
complementary 0
and 0
alternative 0
medicine 0
in 0
preschoolers 0
with 0
autism 0
spectrum 0
disorders 0
( 0
ASD 0
) 0
and 0
other 0
developmental 0
disabilities 0
( 0
DD 0
) 0
. 0

METHODS 0
Participants 0
were 0
578 0
children 0
who 0
were 0
part 0
of 0
an 0
ongoing 0
population-based 0
, 0
case-control 0
study 0
of 0
2- 0
to 0
5-year 0
olds 0
with 0
ASD 0
, 0
DD 0
, 0
and 0
the 0
general 0
population 0
. 0

Parents 0
completed 0
an 0
interview 0
on 0
past 0
and 0
current 0
services 0
. 0

RESULTS 0
Four 0
hundred 0
fifty-three 0
children 0
with 0
ASD 0
and 0
125 0
DD 0
children 0
were 0
included 0
. 0

ASD 0
families 0
received 0
more 0
hours 0
of 0
conventional B-OTHER
services I-OTHER
compared 0
with 0
DD 0
families 0
( 0
17.8 0
vs 0
11 0
; 0
p 0
< 0
.001 0
) 0
. 0

The 0
use 0
of 0
psychotropic 0
medications 0
was 0
low 0
in 0
both 0
groups 0
( 0
approximately 0
3 0
% 0
) 0
. 0

Overall 0
, 0
complementary B-OTHER
and 0
alternative B-OTHER
medicine I-OTHER
( I-OTHER
CAM I-OTHER
) I-OTHER
use 0
was 0
not 0
significantly 0
different 0
in 0
ASD 0
( 0
39 0
% 0
) 0
versus 0
DD 0
( 0
30 0
% 0
) 0
. 0

Hispanic 0
families 0
in 0
both 0
groups 0
used 0
CAM B-OTHER
less 0
often 0
than 0
non-Hispanic 0
families 0
. 0

Variables 0
such 0
as 0
level B-PHYSICAL
of I-PHYSICAL
function I-PHYSICAL
, I-PHYSICAL
immunization I-PHYSICAL
status I-PHYSICAL
, I-PHYSICAL
and I-PHYSICAL
the I-PHYSICAL
presence I-PHYSICAL
of I-PHYSICAL
an I-PHYSICAL
identified I-PHYSICAL
neurogenetic I-PHYSICAL
disorder I-PHYSICAL
were 0
not 0
predictive 0
of 0
CAM 0
use 0
. 0

A 0
higher 0
level B-OTHER
of I-OTHER
parental I-OTHER
education I-OTHER
was 0
associated 0
with 0
an 0
increased 0
CAM B-OTHER
use 0
in 0
ASD 0
and 0
DD 0
. 0

Families 0
who 0
used 0
> 0
20 0
hours 0
per 0
week 0
of 0
conventional 0
services 0
were 0
more 0
likely 0
to 0
use 0
CAM 0
, 0
including 0
potentially 0
unsafe 0
or 0
disproven 0
CAM 0
. 0

Underimmunized 0
children 0
were 0
marginally 0
more 0
likely 0
to 0
use 0
CAM 0
but 0
not 0
more 0
likely 0
to 0
have 0
received 0
potentially 0
unsafe 0
or 0
disproven 0
CAM 0
. 0

CONCLUSION 0
Use 0
of 0
CAM 0
is 0
common 0
in 0
families 0
of 0
young 0
children 0
with 0
neurodevelopmental 0
disorders 0
, 0
and 0
it 0
is 0
predicted 0
by 0
higher 0
parental 0
education 0
and 0
non-Hispanic 0
ethnicity 0
but 0
not 0
developmental 0
characteristics 0
. 0

Further 0
research 0
should 0
address 0
how 0
health 0
care 0
providers 0
can 0
support 0
families 0
in 0
making 0
decisions 0
about 0
CAM 0
use 0
. 0

Development 0
of 0
renal 0
disease 0
in 0
people 0
at 0
high 0
cardiovascular 0
risk 0
: 0
results 0
of 0
the 0
HOPE 0
randomized 0
study 0
. 0

In 0
people 0
with 0
diabetes 0
, 0
renal 0
disease 0
tends 0
to 0
progress 0
from 0
microalbuminuria 0
to 0
clinical 0
proteinuria 0
to 0
renal 0
insufficiency 0
. 0

Little 0
evidence 0
has 0
been 0
published 0
for 0
the 0
nondiabetic 0
population 0
. 0

This 0
study 0
retrospectively 0
analyzed 0
changes 0
of 0
proteinuria 0
over 0
4.5 0
yr 0
in 0
the 0
HOPE 0
( 0
Heart 0
Outcomes 0
and 0
Prevention 0
Evaluation 0
) 0
study 0
, 0
which 0
compared 0
ramipril 0
's 0
effects 0
to 0
placebo 0
in 0
9297 0
participants 0
, 0
including 0
3577 0
with 0
diabetes 0
and 0
1956 0
with 0
microalbuminuria 0
. 0

This 0
report 0
is 0
restricted 0
to 0
7674 0
participants 0
with 0
albuminuria 0
data 0
at 0
baseline 0
and 0
at 0
follow-up 0
. 0

Inclusion 0
criteria 0
were 0
known 0
vascular 0
disease 0
or 0
diabetes 0
plus 0
one 0
other 0
cardiovascular 0
risk 0
factor 0
, 0
exclusion 0
criteria 0
included 0
heart 0
failure 0
or 0
known 0
impaired 0
left 0
ventricular 0
function 0
, 0
dipstick-positive 0
proteinuria 0
( 0
> 0
1+ 0
) 0
, 0
and 0
serum 0
creatinine 0
> 0
2.3 0
mg/dl 0
( 0
200 0
microM 0
) 0
. 0

Baseline 0
microalbuminuria 0
predicted 0
subsequent 0
clinical B-PHYSICAL
proteinuria I-PHYSICAL
for 0
the 0
study 0
participants 0
overall 0
( 0
adjusted 0
odds 0
ratio 0
[ 0
OR 0
] 0
, 0
17.5 0
; 0
95 0
% 0
confidence 0
interval 0
[ 0
CI 0
] 0
, 0
12.6 0
to 0
24.4 0
) 0
, 0
in 0
participants 0
without 0
diabetes 0
( 0
OR 0
, 0
16.7 0
; 0
95 0
% 0
CI 0
, 0
8.6 0
to 0
32.4 0
) 0
, 0
and 0
in 0
participants 0
with 0
diabetes 0
( 0
OR 0
, 0
18.2 0
; 0
95 0
% 0
CI 0
, 0
12.4 0
to 0
26.7 0
) 0
. 0

Any 0
progression B-PHYSICAL
of I-PHYSICAL
albuminuria I-PHYSICAL
( 0
defined 0
as 0
new 0
microalbuminuria 0
or 0
new 0
clinical 0
proteinuria 0
) 0
occurred 0
in 0
1859 0
participants 0
; 0
1542 0
developed 0
new 0
microalbuminuria B-PHYSICAL
, 0
and 0
317 0
participants 0
developed 0
clinical B-PHYSICAL
proteinuria I-PHYSICAL
. 0

Ramipril 0
reduced 0
the 0
risk 0
for 0
any 0
progression B-PHYSICAL
( 0
OR 0
, 0
0.87 0
; 0
95 0
% 0
CI 0
, 0
0.78 0
to 0
0.97 0
; 0
P 0
= 0
0.0146 0
) 0
. 0

People 0
without 0
and 0
with 0
diabetes 0
who 0
are 0
at 0
high B-PHYSICAL
risk 0
for B-PHYSICAL
cardiovascular I-PHYSICAL
disease B-PHYSICAL
are 0
also 0
at 0
risk 0
for 0
a 0
progressive 0
rise 0
in 0
albuminuria B-PHYSICAL
. 0

Microalbuminuria B-PHYSICAL
itself 0
predicts 0
clinical 0
proteinuria 0
in 0
nondiabetic 0
and 0
in 0
diabetic 0
people 0
. 0

Ramipril 0
prevents 0
or 0
delays 0
the 0

Pars 0
plana 0
vitrectomy 0
for 0
diabetic 0
macular 0
edema 0
. 0

Internal 0
limiting 0
membrane 0
delamination 0
vs 0
posterior 0
hyaloid 0
removal 0
. 0

A 0
prospective 0
randomized 0
trial 0
. 0

BACKGROUND 0
Diabetes 0
mellitus 0
, 0
as 0
well 0
as 0
subsequent 0
ocular 0
complications 0
such 0
as 0
cystoid 0
macular 0
edema 0
( 0
CME 0
) 0
, 0
are 0
of 0
fundametal 0
socio-economic 0
relevance 0
. 0

Therefore 0
, 0
we 0
evaluated 0
the 0
influence 0
of 0
internal 0
limiting 0
membrane 0
( 0
ILM 0
) 0
removal 0
on 0
longterm 0
morphological 0
and 0
functional 0
outcome 0
in 0
patients 0
with 0
diabetes 0
mellitus 0
( 0
DM 0
) 0
type 0
2 0
and 0
chronic 0
CME 0
without 0
evident 0
vitreomacular 0
traction 0
. 0

METHOD 0
Forty 0
eyes 0
with 0
attached 0
posterior 0
hyaloid 0
were 0
included 0
in 0
this 0
prospective 0
trial 0
and 0
randomized 0
intraoperatively 0
. 0

Prior 0
focal 0
( 0
n 0
= 0
31 0
) 0
or 0
panretinal 0
( 0
n 0
= 0
25 0
) 0
laser 0
coagulation 0
was 0
permitted 0
. 0

Group 0
I 0
( 0
n 0
= 0
19 0
patients 0
) 0
underwent 0
surgical 0
induction 0
of 0
posterior 0
vitreous 0
detachment 0
( 0
PVD 0
) 0
, 0
group 0
II 0
( 0
n 0
= 0
20 0
patients 0
) 0
PVD 0
and 0
removal 0
of 0
the 0
ILM 0
. 0

Eleven 0
patients 0
with 0
detached 0
posterior 0
hyaloid 0
( 0
group 0
III 0
) 0
were 0
not 0
randomized 0
, 0
and 0
ILM 0
removal 0
was 0
performed 0
. 0

One 0
eye 0
had 0
to 0
be 0
excluded 0
from 0
further 0
analysis 0
. 0

Examinations 0
included 0
ETDRS B-PHYSICAL
best-corrected I-PHYSICAL
visual I-PHYSICAL
acuity I-PHYSICAL
( I-PHYSICAL
BCVA I-PHYSICAL
) I-PHYSICAL
, 0
fluorescein 0
angiography 0
( 0
FLA 0
) 0
and 0
OCT 0
at 0
baseline 0
, 0
3 0
and 0
6 0
months 0
postoperatively 0
. 0

Main 0
outcome 0
measure 0
was 0
BCVA 0
at 0
6 0
months 0
, 0
secondary 0
was 0
foveal B-PHYSICAL
thickness I-PHYSICAL
. 0

RESULTS 0
Mean 0
BCVA B-PHYSICAL
over 0
6 0
months 0
remained 0
unchanged 0
in 0
85 0
% 0
of 0
patients 0
of 0
group 0
II 0
, 0
and 0
decreased 0
in 0
53 0
% 0
of 0
patients 0
of 0
group 0
I 0
. 0

Results 0
were 0
not 0
statistically 0
significant 0
different 0
[ 0
group 0
I 0
: 0
mean 0
decrease 0
log 0
MAR 0
95 0
% 0
CI 0
( 0
0.06 0
; 0
0.32 0
) 0
, 0
group 0
II 0
: 0
( 0
-0.02 0
; 0
0.11 0
) 0
] 0
. 0

OCT 0
revealed 0
a 0
significantly 0
greater 0
reduction 0
of 0
foveal B-PHYSICAL
thickness I-PHYSICAL
following 0
PVD 0
with 0
ILM 0
removal 0
[ 0
group 0
I 0
: 0
mean 0
change 0
: 0
95 0
% 0
CI 0
( 0
-208.95 0
?m 0
; 0
-78.05 0
?m 0
) 0
, 0
group 0
II 0
: 0
( 0
-80.90 0
?m 0
: 0
+59.17 0
?m 0
) 0
] 0
. 0

CONCLUSION 0
Vitrectomy 0
, 0
PVD 0
with 0
or 0
without 0
ILM 0
removal 0
does 0
not 0
improve 0
vision 0
in 0
patients 0
with 0
DM 0
type 0
2 0
and 0
cystoid 0
diabetic 0
macular 0
edema 0
without 0
evident 0
vitreoretinal 0
traction 0
. 0

ILM 0
delamination 0
shows 0
improved 0
morphological 0
results 0
, 0
and 0
appears 0
to 0
be 0
beneficial 0
in 0
eyes 0
with 0
preexisting 0
PVD 0
. 0

Predictive 0
and 0
prognostic 0
roles 0
of 0
BRAF 0
mutation 0
in 0
stage 0
III 0
colon 0
cancer 0
: 0
results 0
from 0
intergroup 0
trial 0
CALGB 0
89803 0
. 0

PURPOSE 0
Alterations 0
in 0
the 0
RAS-RAF-MAP2K 0
( 0
MEK 0
) 0
-MAPK 0
signaling 0
pathway 0
are 0
major 0
drivers 0
in 0
colorectal 0
carcinogenesis 0
. 0

In 0
colorectal 0
cancer 0
, 0
BRAF 0
mutation 0
is 0
associated 0
with 0
microsatellite 0
instability 0
( 0
MSI 0
) 0
, 0
and 0
typically 0
predicts 0
inferior 0
prognosis 0
. 0

We 0
examined 0
the 0
effect 0
of 0
BRAF 0
mutation 0
on 0
survival 0
and 0
treatment 0
efficacy 0
in 0
patients 0
with 0
stage 0
III 0
colon 0
cancer 0
. 0

METHODS 0
We 0
assessed 0
status 0
of 0
BRAF 0
c.1799T 0
> 0
A 0
( 0
p.V600E 0
) 0
mutation 0
and 0
MSI 0
in 0
506 0
stage 0
III 0
colon 0
cancer 0
patients 0
enrolled 0
in 0
a 0
randomized 0
adjuvant 0
chemotherapy 0
trial 0
[ 0
5-fluorouracil 0
and 0
leucovorin 0
( 0
FU/LV 0
) 0
vs. 0
irinotecan 0
( 0
CPT11 0
) 0
, 0
FU 0
and 0
LV 0
( 0
IFL 0
) 0
; 0
CALGB 0
89803 0
] 0
. 0

Cox 0
proportional 0
hazards 0
model 0
was 0
used 0
to 0
assess 0
the 0
prognostic 0
role 0
of 0
BRAF 0
mutation 0
, 0
adjusting 0
for 0
clinical 0
features 0
, 0
adjuvant 0
chemotherapy 0
arm 0
, 0
and 0
MSI 0
status 0
. 0

RESULTS 0
Compared 0
with 0
431 0
BRAF 0
wild-type 0
patients 0
, 0
75 0
BRAF-mutated 0
patients 0
experienced 0
significantly 0
worse 0
overall B-MORTALITY
survival I-MORTALITY
[ I-MORTALITY
OS I-MORTALITY
; 0
log-rank 0
P 0
= 0
0.015 0
; 0
multivariate 0
HR 0
= 0
1.66 0
; 0
95 0
% 0
CI 0
: 0
1.05-2.63 0
] 0
. 0

By 0
assessing 0
combined 0
status 0
of 0
BRAF 0
and 0
MSI 0
, 0
it 0
seemed 0
that 0
BRAF-mutated 0
MSS 0
( 0
microsatellite 0
stable 0
) 0
tumor 0
was 0
an 0
unfavorable 0
subtype 0
, 0
whereas 0
BRAF 0
wild-type 0
MSI-high 0
tumor 0
was 0
a 0
favorable 0
subtype 0
, 0
and 0
BRAF-mutated 0
MSI-high 0
tumor 0
and 0
BRAF 0
wild-type 0
MSS 0
tumor 0
were 0
intermediate 0
subtypes 0
. 0

Among 0
patients 0
with 0
BRAF-mutated 0
tumors 0
, 0
a 0
nonsignificant 0
trend 0
toward 0
improved 0
OS B-PHYSICAL
was 0
observed 0
for 0
IFL 0
versus 0
FU/LV 0
arm 0
( 0
multivariate 0
HR 0
= 0
0.52 0
; 0
95 0
% 0
CI 0
: 0
0.25-1.10 0
) 0
. 0

Among 0
patients 0
with 0
BRAF 0
wild-type 0
cancer 0
, 0
IFL 0
conferred 0
no 0
suggestion 0
of 0
benefit 0
beyond 0
FU/LV 0
alone 0
( 0
multivariate 0
HR 0
= 0
1.02 0
; 0
95 0
% 0
CI 0
: 0
0.72-1.46 0
) 0
. 0

CONCLUSIONS 0
BRAF 0
mutation 0
is 0
associated 0
with 0
inferior 0
survival B-MORTALITY
in 0
stage 0
III 0
colon 0
cancer 0
. 0

Additional 0
studies 0
are 0
necessary 0
to 0
assess 0
whether 0
there 0
is 0
any 0
predictive 0
role 0
of 0
BRAF 0
mutation 0
for 0
irinotecan-based 0
therapy 0
. 0

Oral 0
sildenafil 0
to 0
control 0
pulmonary B-PHYSICAL
hypertension I-PHYSICAL
after 0
congenital 0
heart 0
surgery 0
. 0

This 0
study 0
investigates 0
the 0
role 0
of 0
oral 0
sildenafil 0
in 0
decreasing 0
pulmonary B-PHYSICAL
pressure I-PHYSICAL
after 0
congenital 0
heart 0
surgery 0
. 0

Between 0
September 0
2002 0
and 0
September 0
2004 0
, 0
among 0
a 0
group 0
of 0
postoperative 0
children 0
with 0
large 0
septal 0
defects 0
, 0
moderate 0
to 0
severe 0
pulmonary 0
hypertension 0
[ 0
pulmonary 0
artery 0
( 0
PA 0
) 0
to 0
aortic 0
( 0
Ao 0
) 0
pressure 0
ratio 0
of 0
0.76 0
+/- 0
0.17 0
] 0
and 0
systemic 0
desaturation 0
( 0
Ao 0
Sat 0
= 0
0.89 0
+/- 0
0.11 0
) 0
, 0
oral 0
sildenafil 0
( 0
0.3 0
mg 0
x 0
kg 0
( 0
-1 0
) 0
, 0
every 0
3 0
hours 0
) 0
was 0
administered 0
for 0
a 0
period 0
of 0
24-48 0
hours 0
( 0
sildenafil 0
group 0
) 0
. 0

These 0
patients 0
were 0
compared 0
to 0
a 0
group 0
of 0
22 0
children 0
with 0
similar 0
pathologies 0
who 0
did 0
not 0
receive 0
sildenafil 0
( 0
control 0
group 0
) 0
. 0

Postoperative B-PHYSICAL
PA I-PHYSICAL
pressure I-PHYSICAL
( 0
28.61 0
+/- 0
7.80 0
vs 0
39.40 0
+/- 0
10.80 0
mm 0
Hg 0
) 0
and 0
PA/Ao B-PHYSICAL
pressure I-PHYSICAL
( 0
0.28 0
+/- 0
0.08 0
vs 0
0.41 0
+/- 0
0.11 0
) 0
were 0
significantly 0
lower 0
in 0
the 0
sildenafil 0
group 0
( 0
p 0
= 0
0.001 0
and 0
0.001 0
respectively 0
) 0
. 0

Pulmonary B-PHYSICAL
hypertensive I-PHYSICAL
crisis I-PHYSICAL
was 0
detected 0
in 0
4 0
patients 0
in 0
the 0
control 0
group 0
, 0
but 0
none 0
in 0
the 0
sildenafil 0
group 0
( 0
p 0
= 0
0.02 0
) 0
. 0

There 0
was 0
no 0
significant 0
rise 0
in 0
PA 0
pressure 0
following 0
discontinuation 0
of 0
the 0
drug 0
( 0
26.30 0
+/- 0
6.66 0
vs 0
28.49 0
+/- 0
10.93 0
mm 0
Hg 0
, 0
p 0
= 0
0.366 0
) 0
. 0

No 0
significant 0
complications B-PHYSICAL
were 0
noticed 0
regarding 0
sildenafil 0
use 0
. 0

Low 0
doses 0
of 0
oral 0
sildenafil 0
appear 0
to 0
be 0
effective 0
and 0
safe 0
to 0
control 0
postoperative 0
PA 0
pressure 0
in 0
children 0
. 0

Absence 0
of 0
rebound 0
pulmonary B-PHYSICAL
hypertension I-PHYSICAL
, 0
availability 0
, 0
and 0
low 0
cost 0
of 0
the 0
drug 0
are 0
considered 0
as 0
its 0
major 0
advantages 0
. 0

Botulinum 0
toxin 0
a 0
has 0
antinociceptive B-PHYSICAL
effects I-PHYSICAL
in 0
treating 0
interstitial 0
cystitis 0
. 0

OBJECTIVES 0
To 0
present 0
clinical 0
evidence 0
with 0
botulinum 0
toxin 0
A 0
( 0
BTX-A 0
) 0
suggesting 0
an 0
antinociceptive B-PAIN
role I-PAIN
in 0
patients 0
with 0
interstitial 0
cystitis 0
( 0
IC 0
) 0
. 0

Intriguing 0
evidence 0
in 0
a 0
somatic 0
pain 0
model 0
has 0
suggested 0
that 0
BTX-A 0
injection 0
may 0
have 0
an 0
antinociceptive 0
effect 0
on 0
both 0
acute 0
and 0
chronic 0
( 0
inflammatory 0
) 0
pain 0
. 0

METHODS 0
Thirteen 0
female 0
patients 0
( 0
6 0
in 0
the 0
United 0
States 0
and 0
7 0
in 0
Poland 0
) 0
with 0
IC 0
according 0
to 0
the 0
criteria 0
of 0
the 0
National 0
Institute 0
of 0
Diabetes 0
, 0
Digestive 0
and 0
Kidney 0
Disease 0
were 0
included 0
. 0

Under 0
short 0
general 0
anesthesia 0
or 0
sedation 0
, 0
100 0
to 0
200 0
U 0
of 0
Dysport 0
( 0
Polish 0
patients 0
) 0
or 0
Botox 0
( 0
U.S. 0
patients 0
) 0
was 0
injected 0
through 0
a 0
cystoscope 0
into 0
20 0
to 0
30 0
sites 0
submucosally 0
in 0
the 0
trigone 0
and 0
floor 0
of 0
the 0
bladder 0
. 0

Patients 0
were 0
evaluated 0
with 0
the 0
O'Leary-Sant 0
validated B-PHYSICAL
IC I-PHYSICAL
questionnaire 0
or 0
with B-PHYSICAL
voiding I-PHYSICAL
charts I-PHYSICAL
and 0
a 0
visual 0
analog 0
pain 0
scale 0
1 0
month 0
postoperatively 0
and 0
at 0
subsequent 0
3-month 0
intervals 0
. 0

The 0
Polish 0
patients 0
also 0
underwent 0
pretreatment 0
and 0
post-treatment 0
urodynamic B-PHYSICAL
evaluations I-PHYSICAL
. 0

RESULTS 0
Overall 0
, 0
9 0
( 0
69 0
% 0
) 0
of 0
13 0
patients 0
noted 0
subjective B-OTHER
improvement I-OTHER
after 0
BTX-A 0
treatment 0
. 0

The 0
Interstitial B-PHYSICAL
Cystitis I-PHYSICAL
Symptom I-PHYSICAL
Index 0
and B-PHYSICAL
Interstitial I-PHYSICAL
Cystitis I-PHYSICAL
Problem B-PHYSICAL
Index 0
mean 0
scores 0
improved 0
by 0
71 0
% 0
and 0
69 0
% 0
, 0
respectively 0
( 0
P 0
< 0
0.05 0
) 0
. 0

Daytime B-PAIN
frequency 0
, 0

An 0
exploratory 0
, 0
pragmatic 0
, 0
cluster 0
randomised 0
trial 0
of 0
practice 0
nurse 0
training 0
in 0
the 0
use 0
of 0
asthma 0
action 0
plans 0
. 0

INTRODUCTION 0
To 0
investigate 0
the 0
feasibility B-OTHER
of 0
improving 0
asthma 0
management 0
- 0
in 0
particular 0
, 0
the 0
implementation 0
of 0
individualised 0
asthma 0
action 0
plans 0
( 0
AAPs 0
) 0
for 0
poorly-controlled 0
adult 0
asthma 0
patients 0
- 0
by 0
providing 0
training 0
in 0
asthma-focused 0
clinical 0
and 0
communication 0
skills 0
for 0
practice 0
nurses 0
who 0
deliver 0
asthma 0
clinics 0
. 0

METHODS 0
A 0
pragmatic 0
, 0
cluster 0
randomised 0
trial 0
with 0
an 0
intervention 0
( 0
an 0
interactive 0
seminar 0
) 0
delivered 0
at 0
practice 0
level 0
( 0
n=13 0
practices 0
; 0
6=intervention 0
, 0
7=control 0
) 0
. 0

The 0
impact 0
of 0
the 0
intervention 0
was 0
assessed 0
against 0
patient B-PHYSICAL
outcomes I-PHYSICAL
: 0
routinely B-PHYSICAL
available I-PHYSICAL
asthma I-PHYSICAL
outcome 0
measures B-PHYSICAL
( I-PHYSICAL
beta2-agonist B-OTHER
prescription B-OTHER
rate I-OTHER
and 0
number 0
of 0
oral B-OTHER
steroid I-OTHER
courses I-OTHER
) 0
for 0
asthma 0
patients 0
identified 0
as 0
being 0
poorly-controlled 0
from 0
practice 0
records 0
; 0
and 0
questionnaire 0
data 0
- B-PHYSICAL
Mini I-PHYSICAL

Analgesic 0
efficacy 0
of 0
low-dose 0
diclofenac 0
versus 0
paracetamol 0
and 0
placebo 0
in 0
postoperative 0
dental 0
pain 0
. 0

AIMS 0
To 0
compare 0
the 0
efficacy 0
and 0
safety 0
of 0
diclofenac-K 0
( 0
12.5 0
mg 0
) 0
vs 0
paracetamol 0
( 0
500 0
mg 0
) 0
and 0
placebo 0
given 0
in 0
a 0
flexible 0
dosage 0
regimen 0
to 0
treat 0
pain 0
resulting 0
from 0
extraction 0
of 0
impacted 0
third 0
molar 0
teeth 0
. 0

METHODS 0
This 0
was 0
a 0
2-day 0
, 0
double-blind 0
, 0
double-dummy 0
, 0
randomized 0
, 0
parallel-group 0
, 0
placebo-controlled 0
study 0
of 0
diclofenac-K 0
( 0
12.5 0
mg 0
) 0
tablets 0
vs 0
paracetamol 0
( 0
500 0
mg 0
) 0
tablets 0
and 0
placebo 0
in 0
patients 0
with 0
moderate 0
or 0
severe 0
pain 0
within 0
8 0
hours 0
of 0
extraction 0
of 0
impacted 0
third 0
molars 0
. 0

RESULTS 0
After 0
the 0
first 0
2-tablet 0
dose 0
, 0
patients 0
took 0
on 0
average 0
2.5 0
additional 0
tablets 0
of 0
diclofenac-K 0
or 0
2.4 0
tablets 0
of 0
paracetamol 0
, 0
almost 0
all 0
as 0
1-tablet 0
doses 0
. 0

Most 0
placebo 0
patients 0
discontinued 0
by 0
taking 0
rescue B-PHYSICAL
medication I-PHYSICAL
( 0
ibuprofen 0
200 0
mg 0
) 0
on 0
the 0
first 0
day 0
. 0

Pain B-PAIN
relief I-PAIN
after 0
the 0
initial 0
dose 0
of 0
diclofenac-K 0
( 0
2 0
x 0
12.5 0
mg 0
) 0
was 0
superior 0
to 0
placebo 0
( 0
P 0
< 0
.01 0
for 0
all 0
efficacy 0
outcomes 0
) 0
and 0
comparable 0
to 0
paracetamol 0
( 0
2 0
x 0
500 0
mg 0
) 0
. 0

About 0
30 0
% 0
of 0
patients 0
in 0
each 0
active 0
treatment 0
group 0
took 0
rescue B-PHYSICAL
medication I-PHYSICAL
during 0
the 0
study 0
, 0
compared 0
to 0
78 0
% 0
on 0
placebo 0
. 0

About 0
70 0
% 0
in 0
each 0
active 0
treatment 0
group 0
considered 0
the 0
overall B-PAIN
pain I-PAIN
relief I-PAIN
to 0
be 0
some 0
, 0
a 0
lot 0
, 0
or 0
complete 0
compared 0
to 0
only 0
15 0
% 0
on 0
placebo 0
. 0

The 0
incidence 0
of 0
adverse B-ADVERSE-EFFECTS
events I-ADVERSE-EFFECTS
in 0
each 0
active 0
treatment 0
group 0
was 0
low 0
and 0
comparable 0
between 0
the 0
treatments 0
. 0

CONCLUSION 0
An 0
initial 0
double-dose 0
of 0
diclofenac-K 0
( 0
2 0
x 0
12.5 0
mg 0
) 0
or 0
paracetamol 0
( 0
2 0
x 0
500 0
mg 0
) 0
adequately 0
relieved 0
the 0
most 0
intense 0
postoperative B-PAIN
pain I-PAIN
, 0
and 0
the 0
flexible 0
multiple 0
dose 0
regimen 0
( 0
1 0
or 0
2 0
tablets 0
) 0
maintained 0
adequate 0
pain B-PAIN
relief I-PAIN
thereafter 0
. 0

Most 0
patients 0
needed 0
only 0
1-tablet 0
doses 0
following 0
the 0
initial 0
2-tablet 0
dose 0
. 0

Which 0
socio-demographic 0
factors 0
are 0
associated 0
with 0
participation 0
in 0
oral 0
cancer 0
screening 0
in 0
the 0
developing 0
world 0
? 0

Results 0
from 0
a 0
population-based 0
screening 0
project 0
in 0
India 0
. 0

BACKGROUND 0
This 0
study 0
examines 0
socio-demographic 0
determinants 0
of 0
participation 0
in 0
a 0
population-based 0
randomized 0
controlled 0
trial 0
that 0
proved 0
that 0
oral 0
visual 0
inspection 0
was 0
effective 0
in 0
reducing 0
oral B-MORTALITY
cancer I-MORTALITY
mortality I-MORTALITY
in 0
high-risk 0
individuals 0
in 0
India 0
. 0

METHODS 0
Multivariate 0
logistic 0
regression 0
was 0
used 0
to 0
establish 0
socio-demographic 0
characteristics 0
of 0
participants 0
versus 0
non-participants 0
in 0
the 0
intervention 0
arm 0
. 0

Compliance B-MENTAL
with I-MENTAL
referral I-MENTAL
was 0
analysed 0
according 0
to 0
the 0
socio-demographic 0
characteristics 0
of 0
screen-positives 0
. 0

RESULTS 0
Of 0
96,517 0
eligible 0
subjects 0
, 0
87,655 0
were 0
screened 0
, 0
8688 0
individuals 0
never 0
received 0
the 0
invitation 0
and 0
174 0
refused 0
screening 0
. 0

Compared 0
to 0
the 0
non-screened 0
, 0
a 0
higher 0
proportion 0
of 0
screened B-OTHER
individuals 0
were 0
women 0
( 0
OR=4.51 0
; 0
CI 0
: 0
4.28-4.75 0
) 0
, 0
lived 0
in 0
better 0
housing 0
( 0
OR=1.35 0
; 0
CI 0
: 0
1.25-1.41 0
) 0
, 0
had 0
television/radio 0
( 0
OR=1.50 0
; 0
CI 0
: 0
1.43-1.58 0
) 0
and 0
were 0
tobacco 0
and 0
alcohol 0
users 0
( 0
OR=2.75 0
; 0
CI 0
: 0
2.57-2.95 0
) 0
. 0

Being 0
65 0
and 0
older 0
decreased 0
the 0
chances B-OTHER
of I-OTHER
screening I-OTHER
( 0
OR=0.39 0
; 0
CI 0
: 0
0.37-0.42 0
) 0
, 0
as 0
well 0
as 0
living 0
in 0
high-size B-OTHER
households I-OTHER
( 0
OR=0.73 0
; 0
CI 0
: 0
0.68-0.78 0
) 0
. 0

Sixty-three 0
percent 0
of 0
5143 0
screen-positives 0
complied 0
with 0
referral B-OTHER
. 0

Controlling 0
for 0
all 0
other 0
factors 0
, 0
individuals 0
older 0
than 0
44 0
, 0
and 0
those 0
with 0
more 0
advanced 0
lesions 0
were 0
more 0
likely 0
to 0
comply 0
with 0
referral B-OTHER
( 0
p 0
< 0
0.001 0
) 0
. 0

Individuals 0
living 0
in 0
better 0
housing 0
were 0
less 0
likely 0
to 0
comply B-OTHER
with I-OTHER
referral I-OTHER
( 0
OR=0.79 0
; 0
CI 0
: 0
0.65-0.95 0
) 0
. 0

CONCLUSIONS 0
In 0
summary 0
, 0
adequate 0
coverage 0
can 0
be 0
obtained 0
in 0
population-based 0
oral 0
screening 0
in 0
developing 0
countries 0
. 0

The 0
study 0
underscores 0
the 0
important 0
role 0
of 0
patient-provider 0
communication 0
in 0
assuring 0
high 0
compliance 0
with 0
referral 0
. 0

A 0
randomized 0
, 0
controlled 0
trial 0
of 0
a 0
home-based 0
intervention 0
program 0
for 0
children 0
with 0
autism 0
and 0
developmental 0
delay 0
. 0

OBJECTIVE 0
This 0
study 0
aimed 0
to 0
( 0
1 0
) 0
investigate 0
whether 0
provision 0
of 0
a 0
home-based 0
program 0
in 0
addition 0
to 0
a 0
center-based 0
program 0
improves 0
development 0
in 0
young 0
children 0
with 0
disabilities 0
and 0
coping 0
abilities 0
of 0
their 0
families 0
and 0
( 0
2 0
) 0
describe 0
the 0
characteristics 0
of 0
children 0
and 0
families 0
who 0
benefit 0
most 0
from 0
the 0
intervention 0
. 0

METHODS 0
Fifty-nine 0
children 0
, 0
aged 0
3-5 0
years 0
, 0
with 0
no 0
cerebral 0
palsy 0
, 0
participated 0
in 0
the 0
study 0
. 0

Half 0
of 0
the 0
group 0
was 0
randomized 0
to 0
receive 0
an 0
additional 0
program 0
in 0
their 0
homes 0
. 0

A 0
special 0
education 0
teacher 0
provided 0
40 0
visits 0
over 0
12 0
months 0
working 0
with 0
the 0
families 0
to 0
help 0
generalize 0
skills 0
to 0
the 0
home 0
environment 0
and 0
assist 0
with 0
their 0
concerns 0
. 0

All 0
children 0
were 0
assessed 0
before 0
and 0
after 0
the 0
intervention 0
, 0
and 0
families 0
completed 0
questionnaires 0
assessing 0
family B-MENTAL
stress 0
, 0
support 0
, 0
and 0

Risperidone 0
dosing 0
in 0
children 0
and 0
adolescents 0
with 0
autistic 0
disorder 0
: 0
a 0
double-blind 0
, 0
placebo-controlled 0
study 0
. 0

Efficacy 0
and 0
safety B-OTHER
of 0
2 0
risperidone 0
doses 0
were 0
evaluated 0
in 0
children 0
and 0
adolescents 0
with 0
autism 0
. 0

Patients 0
( 0
N 0
= 0
96 0
; 0
5-17 0
years 0
) 0
, 0
received 0
risperidone 0
( 0
low-dose 0
: 0
0.125 0
mg/day 0
[ 0
20 0
to 0
< 0
45 0
kg 0
] 0
, 0
0.175 0
mg/day 0
[ 0
> 0
45 0
kg 0
] 0
or 0
high-dose 0
: 0
1.25 0
mg/day 0
[ 0
20 0
to 0
< 0
45 0
kg 0
] 0
, 0
1.75 0
mg/day 0
[ 0
> 0
45 0
kg 0
] 0
) 0
or 0
placebo 0
. 0

Mean 0
baseline 0
( 0
range 0
27-29 0
) 0
to 0
endpoint 0
change 0
in 0
Aberrant 0
Behavior 0
Checklist-Irritability 0
( 0
primary 0
endpoint 0
) 0
was 0
significantly 0
greater 0
in 0
the 0
high-dose- 0
( 0
-12.4 0
[ 0
6.5 0
] 0
; 0
p 0
< 0
0.001 0
) 0
, 0
but 0
not 0
low-dose 0
( 0
-7.4 0
[ 0
8.1 0
] 0
; 0
p 0
= 0
0.164 0
) 0
group 0
, 0
versus 0
placebo 0
( 0
-3.5 0
[ 0
10.7 0
] 0
) 0
. 0

Clinical 0
Global 0
Impressions-Severity 0
and 0
Children 0
's 0
Yale-Brown 0
Obsessive 0
Compulsive 0
Scale 0
scores 0
improved 0
significantly 0
only 0
in 0
the 0
high-dose 0
group 0
, 0
consistent 0
with 0
ABC-I 0
results 0
. 0

Somnolence 0
, 0
sedation 0
and 0
increased 0
appetite 0
occurred 0
more 0
frequently 0
in 0
high-versus 0
low-dose 0
groups 0
. 0

Overall 0
, 0
increased 0
appetite 0
occurred 0
most 0
frequently 0
. 0

Preoperative 0
small-dose 0
ketamine 0
has 0
no 0
preemptive 0
analgesic 0
effect 0
in 0
patients 0
undergoing 0
total 0
mastectomy 0
. 0

UNLABELLED 0
We 0
evaluated 0
the 0
preemptive 0
analgesic 0
effect 0
of 0
a 0
small 0
dose 0
of 0
ketamine 0
given 0
before 0
or 0
immediately 0
after 0
surgery 0
in 0
a 0
randomized 0
, 0
double-blinded 0
study 0
performed 0
in 0
128 0
women 0
undergoing 0
total 0
mastectomy 0
. 0

Group 0
1 0
patients 0
received 0
ketamine 0
0.15 0
mg/kg 0
as 0
a 0
5-mL 0
i.v 0
. 0

injection 0
5 0
min 0
before 0
surgery 0
and 0
isotonic 0
saline 0
5 0
mL 0
i.v 0
. 0

at 0
the 0
time 0
of 0
skin 0
closure 0
. 0

Group 0
2 0
received 0
5 0
mL 0
i.v 0
. 0

of 0
isotonic 0
saline 0
, 0
then 0
0.15 0
mg/kg 0
i.v 0
. 0

ketamine 0
. 0

A 0
standard 0
general 0
anesthesia 0
procedure 0
including 0
sufentanil 0
was 0
used 0
. 0

In 0
the 0
recovery 0
room 0
, 0
patient-controlled 0
analgesia 0
i.v 0
. 0

morphine 0
was 0
used 0
for 0
postoperative 0
analgesia 0
. 0

Postoperative 0
pain 0
was 0
assessed 0
by 0
measuring 0
morphine B-PAIN
consumption I-PAIN
and I-PAIN
visual 0
analog 0
scale 0

Effects 0
of 0
resistance 0
versus 0
endurance 0
training 0
on 0
serum B-PHYSICAL
adiponectin I-PHYSICAL
and 0
insulin B-PHYSICAL
resistance I-PHYSICAL
index 0
. 0

PURPOSE 0
The 0
purpose 0
of 0
the 0
present 0
study 0
was 0
to 0
investigate 0
the 0
effects 0
of 0
resistance 0
and 0
endurance 0
training 0
on 0
serum 0
adiponectin 0
and 0
insulin 0
resistance 0
index 0
( 0
SI 0
) 0
in 0
healthy 0
men 0
. 0

METHODS 0
Twenty-four 0
healthy 0
males 0
( 0
age 0
, 0
35-48 0
years 0
) 0
participated 0
in 0
the 0
study 0
. 0

The 0
subjects 0
were 0
randomly 0
assigned 0
to 0
one 0
of 0
three 0
groups 0
: 0
endurance 0
training 0
group 0
( 0
n=8 0
) 0
, 0
resistance 0
training 0
group 0
( 0
n=8 0
) 0
and 0
control 0
group 0
( 0
n=8 0
) 0
. 0

Blood B-PHYSICAL
samples I-PHYSICAL
were 0
taken 0
in 0
fasting 0
state 0
from 0
all 0
subjects 0
. 0

The 0
experimental 0
groups 0
performed 0
either 0
endurance 0
or 0
resistance 0
training 0
3 0
days 0
a 0
week 0
for 0
12 0
weeks 0
. 0

The 0
endurance 0
training 0
programme 0
included 0
continuous 0
running 0
at 0
an 0
intensity 0
corresponding 0
to 0
75-85 0
% 0
of 0
maximal 0
heart 0
rate 0
, 0
while 0
resistance 0
training 0
consisted 0
of 0
four 0
sets 0
of 0
circuit 0
weight 0
training 0
for 0
11 0
stations 0
and 0
at 0
an 0
intensity 0
corresponding 0
to 0
50-60 0
% 0
of 0
one-repetition 0
maximum 0
. 0

The 0
maximum 0
numbers 0
of 0
repetitions 0
in 0
each 0
station 0
was 0
12 0
. 0

RESULTS 0
There 0
were 0
significant 0
negative 0
correlations 0
between 0
serum B-PHYSICAL
adiponectin I-PHYSICAL
and 0
body B-PHYSICAL
fat I-PHYSICAL
percentage I-PHYSICAL
, 0
waist-to-hip B-PHYSICAL
ratio 0
, 0
body B-PHYSICAL
mass 0
index 0
and 0
the B-PHYSICAL
insulin B-PHYSICAL
resistance B-PHYSICAL
index 0

Complementary 0
feeding 0
with 0
fortified 0
spread 0
and 0
incidence 0
of 0
severe B-PHYSICAL
stunting I-PHYSICAL
in 0
6- 0
to 0
18-month-old 0
rural 0
Malawians 0
. 0

OBJECTIVE 0
To 0
compare 0
growth B-OTHER
and 0
incidence 0
of 0
malnutrition B-PHYSICAL
in 0
infants 0
receiving 0
long-term 0
dietary 0
supplementation 0
with 0
ready-to-use 0
fortified 0
spread 0
( 0
FS 0
) 0
or 0
micronutrient-fortified 0
maize-soy 0
flour 0
( 0
likuni 0
phala 0
[ 0
LP 0
] 0
) 0
. 0

DESIGN 0
Randomized 0
, 0
controlled 0
, 0
single-blind 0
trial 0
. 0

SETTING 0
Rural 0
Malawi 0
. 0

PARTICIPANTS 0
A 0
total 0
of 0
182 0
six-month-old 0
infants 0
. 0

INTERVENTION 0
Participants 0
were 0
randomized 0
to 0
receive 0
1 0
year 0
of 0
daily 0
supplementation 0
with 0
71 0
g 0
of 0
LP 0
( 0
282 0
kcal 0
) 0
, 0
50 0
g 0
of 0
FS 0
( 0
FS50 0
) 0
( 0
256 0
kcal 0
) 0
, 0
or 0
25 0
g 0
of 0
FS 0
( 0
FS25 0
) 0
( 0
130 0
[ 0
corrected 0
] 0
kcal 0
) 0
. 0

OUTCOME 0
MEASURES 0
Weight 0
and 0
length B-PHYSICAL
gains I-PHYSICAL
and 0
the 0
incidences 0
of 0
severe B-PHYSICAL
stunting I-PHYSICAL
, 0
underweight B-PHYSICAL
, 0
and 0
wasting B-PHYSICAL
. 0

RESULTS 0
Mean 0
weight 0
and 0
length B-PHYSICAL
gains I-PHYSICAL
in 0
the 0
LP 0
, 0
FS50 0
, 0
and 0
FS25 0
groups 0
were 0
2.37 0
, 0
2.47 0
, 0
and 0
2.37 0
kg 0
( 0
P 0
= 0
.66 0
) 0
and 0
12.7 0
, 0
13.5 0
, 0
and 0
13.2 0
cm 0
( 0
P 0
= 0
.23 0
) 0
, 0
respectively 0
. 0

In 0
the 0
same 0
groups 0
, 0
the 0
cumulative 0
12-month 0
incidence 0
of 0
severe B-PHYSICAL
stunting I-PHYSICAL
was 0
13.3 0
% 0
, 0
0.0 0
% 0
, 0
and 0
3.5 0
% 0
( 0
P 0
= 0
.01 0
) 0
, 0
of 0
severe 0
underweight B-PHYSICAL
was 0
15.0 0
% 0
, 0
22.5 0
% 0
, 0
and 0
16.9 0
% 0
( 0
P 0
= 0
.71 0
) 0
, 0
and 0
of 0
severe B-PHYSICAL
wasting I-PHYSICAL
was 0
1.8 0
% 0
, 0
1.9 0
% 0
, 0
and 0
1.8 0
% 0
( 0
P 0
> 0
.99 0
) 0
. 0

Compared 0
with 0
LP-supplemented 0
infants 0
, 0
those 0
given 0
FS50 0
gained 0
a 0
mean 0
of 0
100 0
g 0
more 0
weight 0
and 0
0.8 0
cm 0
more 0
length B-PHYSICAL
. 0

There 0
was 0
a 0
significant 0
interaction 0
between 0
baseline 0
length 0
and 0
intervention 0
( 0
P 0
= 0
.04 0
) 0
; 0
in 0
children 0
with 0
below-median 0
length 0
at 0
enrollment 0
, 0
those 0
given 0
FS50 0
gained 0
a 0
mean 0
of 0
1.9 0
cm 0
more 0
than 0
individuals 0
receiving 0
LP 0
. 0

CONCLUSION 0
One-year-long 0
complementary 0
feeding 0
with 0
FS 0
does 0
not 0
have 0
a 0
significantly 0
larger 0
effect 0
than 0
LP 0
on 0
mean 0
weight 0
gain B-PHYSICAL
in 0
all 0
infants 0
, 0
but 0
it 0
is 0
likely 0
to 0
boost 0
linear B-PHYSICAL
growth I-PHYSICAL
in 0
the 0
most 0
disadvantaged 0
individuals 0
and 0
, 0
hence 0
, 0
decrease 0
the 0
incidence 0
of 0
severe B-PHYSICAL
stunting I-PHYSICAL
. 0

Double-blind 0
, 0
placebo-controlled 0
trial 0
of 0
risperidone 0
plus 0
topiramate 0
in 0
children 0
with 0
autistic 0
disorder 0
. 0

BACKGROUND 0
Autism 0
is 0
a 0
complex 0
neurodevelopmental 0
disorder 0
that 0
forms 0
part 0
of 0
a 0
spectrum 0
of 0
related 0
disorders 0
referred 0
to 0
as 0
Autism 0
Spectrum 0
Disorders 0
. 0

The 0
present 0
study 0
assessed 0
the 0
effects 0
of 0
topiramate 0
plus 0
risperidone 0
in 0
the 0
treatment 0
of 0
autistic 0
disorder 0
. 0

METHOD 0
Forty 0
children 0
between 0
the 0
ages 0
of 0
4 0
and 0
12 0
years 0
with 0
a 0
DSM 0
IV 0
clinical 0
diagnosis 0
of 0
autism 0
who 0
were 0
outpatients 0
from 0
a 0
specialty 0
clinic 0
for 0
children 0
were 0
recruited 0
. 0

The 0
children 0
presented 0
with 0
a 0
chief 0
complaint 0
of 0
severely 0
disruptive 0
symptoms 0
related 0
to 0
autistic 0
disorder 0
. 0

Patients 0
were 0
randomly 0
allocated 0
to 0
topiramate+risperidone 0
( 0
Group 0
A 0
) 0
or 0
placebo+risperidone 0
( 0
Group 0
B 0
) 0
for 0
an 0
8-week 0
, 0
double-blind 0
, 0
placebo-controlled 0
study 0
. 0

The 0
dose 0
of 0
risperidone 0
was 0
titrated 0
up 0
to 0
2 0
mg/day 0
for 0
children 0
between 0
10 0
and 0
40 0
kg 0
and 0
3 0
mg/day 0
for 0
children 0
weighting 0
above 0
40 0
kg 0
. 0

The 0
dose 0
of 0
topiramate 0
was 0
titrated 0
up 0
to 0
200 0
mg/day 0
depending 0
on 0
weight 0
( 0
100 0
mg/day 0
for 0
< 0
30 0
kg 0
and 0
200 0
mg/day 0
for 0
> 0
30 0
kg 0
) 0
. 0

Patients 0
were 0
assessed 0
at 0
baseline 0
and 0
after 0
2 0
, 0
4 0
, 0
6 0
and 0
8 0
weeks 0
after 0
starting 0
medication 0
. 0

Measure 0
of 0
outcome 0
was 0
the 0
Aberrant B-OTHER
Behavior I-OTHER
Checklist-Community I-OTHER
( I-OTHER
ABC-C I-OTHER
) I-OTHER
Rating I-OTHER
Scale 0
. 0

RESULTS 0
Difference 0
between 0
the 0
two 0
protocols 0
was 0
significant 0
as 0
the 0
group 0
that 0
received 0
topiramate 0
had 0
a 0
greater 0
reduction 0
in 0
ABC-C 0
subscale 0
scores 0
for 0
irritability 0
, 0
stereotypic B-PHYSICAL
behavior I-PHYSICAL
and 0
hyperactivity/noncompliance B-MENTAL
. 0

CONCLUSION 0
The 0
results 0
suggest 0
that 0
the 0
combination 0
of 0
topiramate 0
with 0
risperidone 0
may 0
be 0
superior 0
to 0
risperidone 0
monotherapy 0
for 0
children 0
with 0
autistic 0
disorder 0
. 0

However 0
the 0
results 0
need 0
to 0
be 0
further 0
confirmed 0
by 0
a 0
larger 0
randomized 0
controlled 0
trial 0
. 0

Pimecrolimus 0
cream 0
and 0
Tacrolimus 0
ointment 0
in 0
the 0
treatment 0
of 0
atopic B-PHYSICAL
dermatitis I-PHYSICAL
: 0
a 0
pilot 0
study 0
on 0
patient 0
preference 0
. 0

BACKGROUND 0
Pimecrolimus 0
cream 0
1 0
% 0
is 0
approved 0
for 0
mild 0
to 0
moderate 0
atopic 0
dermatitis 0
in 0
children 0
older 0
than 0
two 0
years 0
of 0
age 0
and 0
adults 0
. 0

Tacrolimus 0
ointment 0
0.03 0
% 0
is 0
approved 0
for 0
moderate 0
to 0
severe 0
atopic 0
dermatitis 0
in 0
the 0
patient 0
population 0
between 0
two 0
to 0
seventeen 0
years 0
of 0
age 0
and 0
Tacrolimus 0
0.1 0
% 0
ointment 0
for 0
moderate 0
to 0
severe 0
atopic 0
dermatitis 0
in 0
patients 0
18 0
years 0
of 0
age 0
and 0
older 0
. 0

However 0
, 0
beyond 0
safety 0
and 0
efficacy 0
, 0
the 0
delivery 0
system 0
or 0
vehicle 0
used 0
in 0
topical 0
treatment 0
formulations 0
is 0
equally 0
important 0
in 0
affecting 0
patient B-OTHER
satisfaction I-OTHER
, 0
tolerability B-OTHER
, 0
and 0

[ 0
Evaluating 0
an 0
interactive 0
, 0
multi-media 0
learning 0
system 0
for 0
the 0
study 0
of 0
primary 0
open 0
angle 0
glaucoma 0
] 0
. 0

Using 0
the 0
interactive 0
multimedia 0
learning 0
system 0
for 0
studying 0
open-angle 0
glaucoma 0
[ 0
3 0
] 0
a 0
prospective 0
, 0
randomized 0
, 0
case-controlled 0
study 0
was 0
carried 0
out 0
to 0
determine 0
the 0
value 0
of 0
this 0
new 0
form 0
of 0
learning 0
in 0
terms 0
of 0
acceptance B-MENTAL
and I-MENTAL
the I-MENTAL
imparting I-MENTAL
of I-MENTAL
knowledge I-MENTAL
. 0

This 0
article 0
describes 0
details 0
of 0
the 0
study 0
and 0
presents 0
their 0
results 0
. 0

Results 0
were 0
established 0
on 0
the 0
basis 0
of 0
targeted 0
questions 0
asked 0
prior 0
to 0
and 0
after 0
the 0
learning 0
phase 0
, 0
followed 0
by 0
an 0
analysis 0
of 0
frequencies 0
and 0
significance 0
testing 0
by 0
the 0
Chi 0
squared 0
method 0
. 0

It 0
was 0
shown 0
that 0
the 0
imparting B-MENTAL
of I-MENTAL
knowledge I-MENTAL
is 0
significantly 0
improved 0
when 0
this 0
learning 0
system 0
is 0
employed 0
. 0

In 0
addition 0
, 0
after 0
its 0
first 0
use 0
, 0
acceptance 0
of 0
this 0
new B-MENTAL
medium I-MENTAL
rose 0
dramatically 0
. 0

A 0
randomized 0
controlled 0
trial 0
of 0
COMPASS 0
web-based 0
and 0
face-to-face 0
teacher 0
coaching 0
in 0
autism 0
. 0

OBJECTIVE 0
Most 0
children 0
with 0
autism 0
rely 0
on 0
schools 0
as 0
their 0
primary 0
source 0
of 0
intervention 0
, 0
yet 0
research 0
has 0
suggested 0
that 0
teachers 0
rarely 0
use 0
evidence-based 0
practices 0
. 0

To 0
address 0
the 0
need 0
for 0
improved 0
educational 0
outcomes 0
, 0
a 0
previously 0
tested 0
consultation 0
intervention 0
called 0
the 0
Collaborative 0
Model 0
for 0
Promoting 0
Competence 0
and 0
Success 0
( 0
COMPASS 0
; 0
Ruble 0
, 0
Dalrymple 0
, 0
& 0
McGrew 0
, 0
2010 0
; 0
Ruble 0
, 0
Dalrymple 0
, 0
& 0
McGrew 0
, 0
2012 0
) 0
was 0
evaluated 0
in 0
a 0
2nd 0
randomized 0
controlled 0
trial 0
, 0
with 0
the 0
addition 0
of 0
a 0
web-based 0
group 0
. 0

METHOD 0
Forty-nine 0
teacher-child 0
dyads 0
were 0
randomized 0
into 0
1 0
of 0
3 0
groups 0
: 0
( 0
1 0
) 0
a 0
placebo 0
control 0
( 0
PBO 0
) 0
group 0
, 0
( 0
2 0
) 0
COMPASS 0
followed 0
by 0
face-to-face 0
( 0
FF 0
) 0
coaching 0
sessions 0
, 0
and 0
( 0
3 0
) 0
COMPASS 0
followed 0
by 0
web-based 0
( 0
WEB 0
) 0
coaching 0
sessions 0
. 0

Three 0
individualized 0
goals 0
( 0
social 0
, 0
communication 0
, 0
and 0
independence 0
skills 0
) 0
were 0
selected 0
for 0
intervention 0
for 0
each 0
child 0
. 0

The 0
primary 0
outcome 0
of 0
independent B-PHYSICAL
ratings I-PHYSICAL
of I-PHYSICAL
child I-PHYSICAL
goal I-PHYSICAL
attainment I-PHYSICAL
and I-PHYSICAL
several I-PHYSICAL
process I-PHYSICAL
measures I-PHYSICAL
( 0
e.g. 0
, 0
consultant 0
and 0
teacher 0
fidelity 0
) 0
were 0
evaluated 0
. 0

RESULTS 0
Using 0
an 0
intent-to-treat 0
approach 0
, 0
findings 0
replicated 0
earlier 0
results 0
with 0
a 0
very 0
large 0
effect 0
size 0
( 0
d 0
= 0
1.41 0
) 0
for 0
the 0
FF 0
group 0
and 0
a 0
large 0
effect 0
size 0
( 0
d 0
= 0
1.12 0
) 0
for 0
the 0
WEB 0
group 0
relative 0
to 0
the 0
PBO 0
group 0
. 0

There 0
were 0
no 0
differences 0
in 0
overall 0
change 0
across 0
goal 0
domains 0
between 0
the 0
FF 0
and 0
WEB 0
groups 0
, 0
suggesting 0
the 0
efficacy 0
of 0
videoconferencing 0
technology 0
. 0

CONCLUSIONS 0
COMPASS 0
is 0
effective 0
and 0
results 0
in 0
improved 0
educational 0
outcomes 0
for 0
young 0
children 0
with 0
autism 0
. 0

Videoconferencing 0
technology 0
, 0
as 0
a 0
scalable 0
tool 0
, 0
has 0
promise 0
for 0
facilitating 0
access 0
to 0
autism 0
specialists 0
and 0
bridging 0
the 0
research-to-practice 0
gap 0
. 0

Marginal 0
benefit/disadvantage B-OTHER
of 0
granulocyte 0
colony-stimulating 0
factor 0
therapy 0
after 0
autologous 0
blood 0
stem 0
cell 0
transplantation 0
in 0
children 0
: 0
results 0
of 0
a 0
prospective 0
randomized 0
trial 0
. 0

The 0
Japanese 0
Cooperative 0
Study 0
Group 0
of 0
PBSCT 0
. 0

In 0
this 0
prospective 0
trial 0
, 0
a 0
total 0
of 0
74 0
children 0
who 0
were 0
scheduled 0
to 0
undergo 0
high-dose 0
chemotherapy 0
followed 0
by 0
autologous 0
peripheral 0
blood 0
stem 0
cell 0
transplantation 0
( 0
PBSCT 0
) 0
were 0
prospectively 0
randomized 0
at 0
diagnosis 0
to 0
evaluate 0
the 0
effectiveness 0
of 0
exogenous 0
granulocyte 0
colony-stimulating 0
factor 0
( 0
G-CSF 0
) 0
treatment 0
in 0
accelerating 0
hematopoietic B-PHYSICAL
recovery I-PHYSICAL
after 0
PBSCT 0
. 0

The 0
diagnosis 0
included 0
acute 0
lymphoblastic 0
leukemia 0
( 0
ALL 0
) 0
( 0
n 0
= 0
27 0
) 0
, 0
neuroblastoma 0
( 0
n 0
= 0
29 0
) 0
, 0
and 0
miscellaneous 0
solid 0
tumors 0
( 0
n 0
= 0
18 0
) 0
. 0

Eligibility 0
criteria 0
included 0
( 0
1 0
) 0
primary 0
PBSCT 0
, 0
( 0
2 0
) 0
chemotherapy-responsive 0
disease 0
, 0
and 0
( 0
3 0
) 0
collected 0
cell 0
number 0
> 0
1 0
x 0
10 0
( 0
5 0
) 0
colony-forming 0
unit-granulocyte-macrophage 0
( 0
CFU-GM 0
) 0
/kg 0
and 0
> 0
1 0
x 0
10 0
( 0
6 0
) 0
CD34 0
( 0
+ 0
) 0
cells/kg 0
patient 0
's 0
body 0
weight 0
. 0

After 0
applying 0
the 0
above 0
criteria 0
, 0
11 0
patients 0
were 0
excluded 0
due 0
to 0
disease 0
progression 0
before 0
PBSCT 0
( 0
n 0
= 0
6 0
) 0
or 0
a 0
low 0
number 0
of 0
harvested 0
cells 0
( 0
n 0
= 0
5 0
) 0
, 0
leaving 0
63 0
patients 0
for 0
analysis 0
; 0
32 0
patients 0
in 0
the 0
treatment 0
group 0
( 0
300 0
microg/m2 0
of 0
G-CSF 0
intravenously 0
over 0
1 0
hour 0
from 0
day 0
1 0
of 0
PBSCT 0
) 0
and 0
31 0
in 0
the 0
control 0
group 0
without 0
treatment 0
. 0

Two 0
distinct 0
disease-oriented 0
high-dose 0
regimens 0
without 0
total 0
body 0
irradiation 0
consisted 0
of 0
the 0
MCVAC 0
regimen 0
using 0
ranimustine 0
( 0
MCNU 0
, 0
450 0
mg/m2 0
) 0
, 0
cytosine 0
arabinoside 0
( 0
16 0
g/m2 0
) 0
, 0
etoposide 0
( 0
1.6 0
g/m2 0
) 0
, 0
and 0
cyclophosphamide 0
( 0
100 0
mg/kg 0
) 0
for 0
patients 0
with 0
ALL 0
, 0
and 0
the 0
Hi-MEC 0
regimen 0
using 0
melphalan 0
( 0
180 0
mg/m2 0
) 0
, 0
etoposide 0
( 0
1.6 0
g/m2 0
) 0
, 0
and 0
carboplatinum 0
( 0
1.6 0
g/m2 0
) 0
for 0
those 0
with 0
solid 0
tumors 0
. 0

Five 0
patients 0
( 0
two 0
in 0
the 0
treatment 0
group 0
and 0
three 0
in 0
the 0
control 0
group 0
) 0
were 0
subsequently 0
removed 0
due 0
to 0
protocol 0
violations 0
. 0

All 0
patients 0
survived B-MORTALITY
PBSCT 0
. 0

The 0
median 0
numbers B-PHYSICAL
of I-PHYSICAL
transfused I-PHYSICAL
mononuclear I-PHYSICAL
cells I-PHYSICAL
( I-PHYSICAL
MNC I-PHYSICAL
) I-PHYSICAL
, I-PHYSICAL
CD34 I-PHYSICAL
( I-PHYSICAL
+ I-PHYSICAL
) I-PHYSICAL
cells I-PHYSICAL
, I-PHYSICAL
and I-PHYSICAL
CFU-GM I-PHYSICAL
were 0
, 0
respectively 0
, 0
4.5 0
( 0
range 0
, 0
1 0
to 0
19 0
) 0
x 0
10 0
( 0
8 0
) 0
/kg 0
, 0
8.0 0
( 0
1.1 0
to 0
25 0
) 0
x 0
10 0
( 0
6 0
) 0
/kg 0
, 0
and 0
3.7 0
( 0
1.2 0
to 0
23 0
) 0
x 0
10 0
( 0
5 0
) 0
/kg 0
in 0
the 0
treatment 0
group 0
( 0
n 0
= 0
30 0
) 0
and 0
2.9 0
( 0
0.8 0
to 0
21 0
) 0
x 0
10 0
( 0
8 0
) 0
/kg 0
, 0
6.3 0
( 0
1.1 0
to 0
34 0
) 0
x 0
10 0
( 0
6 0
) 0
/kg 0
, 0
and 0
5.5 0
( 0
1.3 0
to 0
37 0
) 0
x 0
10 0
( 0
5 0
) 0
/kg 0
, 0
respectively 0
, 0
in 0
the 0
control 0
group 0
( 0
n 0
= 0
28 0
) 0
, 0
with 0
no 0
significant 0
difference 0
. 0

After 0
PBSCT 0
, 0
the 0
time B-OTHER
to I-OTHER
achieve I-OTHER
an I-OTHER
absolute I-OTHER
neutrophil I-OTHER
count I-OTHER
( I-OTHER
ANC I-OTHER
) I-OTHER
of I-OTHER
> I-OTHER
0.5 0
x B-OTHER
10 I-OTHER
( I-OTHER
9 I-OTHER
) I-OTHER
/L I-OTHER
in 0
the 0
treatment 0
group 0
was 0
less 0
than 0
that 0
in 0
the 0
control 0
group 0
( 0
median 0
, 0
11 0
v 0
12 0
days 0
; 0
the 0
log-rank 0
test 0
, 0
P 0
=.046 0
) 0
, 0
although 0
the 0
last 0
day 0
of 0
red 0
blood 0
cell 0
( 0
RBC 0
) 0
transfusion 0
( 0
day 0
11 0
v 0
day 0
10 0
) 0
and 0
the 0
duration 0
of 0
febrile B-OTHER
days I-OTHER
( 0
> 0
38 0
degrees 0
C 0
) 0
after 0
PBSCT 0
( 0
4 0
v 0
4 0
days 0
) 0
were 0
identical 0
in 0
both 0
groups 0
. 0

However 0
, 0
platelet B-OTHER
recovery I-OTHER
to I-OTHER
> 0
20 B-OTHER
x I-OTHER
10 B-OTHER
( 0
9 B-OTHER
) 0
/L 0
was 0
significantly 0
longer 0
in 0
treatment 0
group 0
than 0
control 0
group 0
( 0
26 0
v 0
16 0
days 0
; 0
P 0
=.009 0
) 0
and 0
> 0
50 0
x 0
10 0
( 0
9 0
) 0
/L 0
tended 0
to 0
take 0
longer 0
in 0
the 0
treatment 0
group 0
( 0
29 0
v 0
26 0
days 0
; 0
P 0
=.126 0
) 0
, 0
with 0
significantly 0
more 0
platelet B-OTHER
transfusion-dependent I-OTHER
days B-OTHER
( 0
27 0
v 0
13 0
days 0
; 0
t-test 0
, 0
P 0
=.037 0
) 0
. 0

When 0
patients 0
were 0
divided 0
into 0
two 0
different 0
disease 0
cohorts 0
, 0
ALL 0
patients 0
showed 0
no 0
difference 0
in 0
engraftment B-PHYSICAL
kinetics I-PHYSICAL
between 0
the 0
G-CSF 0
treatment 0
and 0
control 0
groups 0
, 0
while 0
differences 0
were 0
seen 0
in 0
those 0
with 0
solid 0
tumors 0
. 0

We 0
concluded 0
that 0
the 0
marginal 0
clinical 0
benefit 0
of 0
1 0
day 0
earlier 0

Comparative 0
efficacy 0
and 0
safety 0
of 0
calcium 0
carbasalate 0
plus 0
metoclopramide 0
versus 0
ergotamine 0
tartrate 0
plus 0
caffeine 0
in 0
the 0
treatment 0
of 0
acute 0
migraine 0
attacks 0
. 0

This 0
randomized 0
, 0
double-blind 0
, 0
double-dummy 0
, 0
multicenter 0
, 0
parallel-group 0
study 0
aimed 0
at 0
comparing 0
the 0
efficacy 0
and 0
safety 0
of 0
calcium 0
carbasalate 0
( 0
equivalent 0
to 0
900 0
mg 0
aspirin 0
) 0
plus 0
metoclopramide 0
10 0
mg 0
( 0
CM 0
) 0
with 0
ergotamine 0
tartrate 0
1 0
mg 0
plus 0
caffeine 0
100 0
mg 0
( 0
EC 0
) 0
administered 0
in 0
the 0
treatment 0
of 0
2 0
acute 0
migraine 0
attacks 0
. 0

A 0
total 0
of 0
296 0
patients 0
fulfilling 0
the 0
International 0
Headache 0
Society 0
diagnostic 0
criteria 0
for 0
migraine 0
were 0
enrolled 0
. 0

In 0
total 0
, 0
one 0
or 0
two 0
migraine 0
attacks 0
were 0
treated 0
in 0
268 0
and 0
235 0
patients 0
, 0
respectively 0
. 0

The 0
primary 0
endpoint 0
for 0
the 0
first 0
treated 0
attack 0
was 0
headache 0
relief 0
, 0
with 0
intensity 0
decreasing 0
from 0
moderate 0
or 0
severe 0
to 0
mild 0
or 0
absent 0
2 0
h 0
after 0
drug 0
intake 0
. 0

Usual 0
secondary 0
efficacy 0
endpoints 0
were 0
assessed 0
. 0

A 0
superiority 0
of 0
CM 0
over 0
EC 0
was 0
observed 0
for 0
both 0
treated 0
attacks 0
for 0
the 0
main 0
endpoint 0
: 0
success 0
in 0
54 0
versus 0
36 0
% 0
, 0
p 0
= 0
0.003 0
for 0
the 0
first 0
attack 0
and 0
60 0
versus 0
44 0
% 0
, 0
p 0
= 0
0.02 0
for 0
the 0
second 0
attack 0
. 0

CM 0
was 0
also 0
significantly 0
superior 0
to 0
EC 0
during 0
the 0
first 0
attack 0
for 0
complete B-PHYSICAL
headache I-PHYSICAL
relief I-PHYSICAL
( 0
20 0
vs. 0
8 0
% 0
, 0
p 0
= 0
0.006 0
) 0
, 0
nausea B-ADVERSE-EFFECTS
( 0
42 0
vs. 0
63 0
% 0
, 0
p 0
= 0
0 0
. 0

007 0
) 0
and 0
willingness B-MENTAL
to I-MENTAL
take I-MENTAL
the I-MENTAL
drug I-MENTAL
again 0
( 0
90 0
vs. 0
80 0
% 0
, 0
p 0
= 0
0.043 0
) 0
. 0

The 0
global B-OTHER
efficacy 0
evaluation B-OTHER
, 0
rated B-OTHER
by I-OTHER
the B-OTHER
investigators I-OTHER
, 0
was 0
significantly 0
more 0
favorable 0
to 0
CM 0
for 0
both 0
attacks 0
( 0
p 0
= 0
0.001 0
for 0
the 0
first 0
attack 0
and 0
p 0
= 0
0.02 0
for 0
the 0
second 0
) 0
. 0

The 0
patients B-OTHER
' 0
evaluation B-OTHER
was I-OTHER
significant B-OTHER
for I-OTHER
the I-OTHER
first B-OTHER
attack I-OTHER
( I-OTHER
p I-OTHER
= I-OTHER
0.002 0
) B-OTHER
. 0

The 0
global B-ADVERSE-EFFECTS
incidence 0
of B-ADVERSE-EFFECTS
adverse I-ADVERSE-EFFECTS
events I-ADVERSE-EFFECTS
was 0
45 0
% 0
higher 0
with 0
EC 0
, 0
though 0
not 0
significant 0
( 0
32 0
vs. 0
22 0
% 0
, 0
p 0
= 0
0.075 0
) 0
. 0

They 0
were 0
most 0
often 0
unspecific 0
and 0
mild 0
to 0
moderate 0
in 0
intensity 0
. 0

The 0
Tiotropium 0
Safety B-OTHER
and 0
Performance B-OTHER
in 0
Respimat 0
Trial 0
( 0
TIOSPIR 0
) 0
, 0
a 0
large 0
scale 0
, 0
randomized 0
, 0
controlled 0
, 0
parallel-group 0
trial-design 0
and 0
rationale 0
. 0

BACKGROUND 0
Tiotropium 0
bromide 0
is 0
an 0
effective 0
therapy 0
for 0
COPD 0
patients 0
. 0

Comparing 0
across 0
programs 0
tiotropium 0
Respimat 0
Soft 0
Mist 0
inhaler 0
was 0
at 0
least 0
as 0
efficacious 0
as 0
tiotropium 0
HandiHaler 0
, 0
however 0
, 0
concerns 0
have 0
been 0
raised 0
about 0
tiotropium 0
's 0
safety 0
when 0
given 0
via 0
Respimat 0
. 0

METHODS 0
The 0
TIOSPIR 0
trial 0
( 0
NCT01126437 0
) 0
compares 0
the 0
safety B-OTHER
and 0
efficacy 0
of 0
tiotropium 0
Respimat 0
5 0
?g 0
once 0
daily 0
( 0
marketed 0
) 0
and 0
2.5 0
?g 0
once 0
daily 0
( 0
investigational 0
) 0
with 0
tiotropium 0
HandiHaler 0
18 0
? 0

once 0
daily 0
( 0
marketed 0
) 0
. 0

The 0
hypotheses 0
to 0
be 0
tested 0
are 0
1 0
) 0
. 0

that 0
tiotropium 0
Respimat 0
5 0
?g 0
once 0
daily 0
and 0
Respimat 0
2.5 0
?g 0
once 0
daily 0
are 0
non-inferior 0
to 0
HandiHaler 0
in 0
terms 0
of 0
all-cause 0
mortality 0
, 0
and 0
2 0
) 0
. 0

that 0
tiotropium 0
Respimat 0
5 0
?g 0
once 0
daily 0
is 0
superior 0
to 0
HandiHaler 0
in 0
terms 0
of 0
time 0
to 0
first 0
exacerbation 0
. 0

A 0
spirometry 0
substudy 0
evaluates 0
the 0
bronchodilator 0
efficacy 0
. 0

The 0
trial 0
is 0
a 0
randomized 0
, 0
double-blind 0
, 0
double 0
dummy 0
, 0
event-driven 0
, 0
parallel 0
group 0
study 0
. 0

Participants 0
can 0
use 0
any 0
background 0
treatment 0
for 0
COPD 0
except 0
inhaled 0
anticholinergic 0
agents 0
. 0

The 0
study 0
encompasses 0
a 0
wide 0
range 0
of 0
COPD 0
patients 0
, 0
e.g 0
. 0

patients 0
with 0
stable 0
cardiac 0
diseases 0
including 0
arrhythmia 0
can 0
be 0
included 0
. 0

Clinical 0
sites 0
are 0
international 0
and 0
include 0
both 0
primary 0
care 0
as 0
well 0
as 0
specialists 0
. 0

RESULTS 0
To 0
date 0
, 0
over 0
17,000 0
participants 0
have 0
been 0
randomized 0
from 0
over 0
1200 0
sites 0
in 0
50 0
countries 0
with 0
an 0
anticipated 0
treatment 0
duration 0
of 0
2-3 0
years 0
. 0

CONCLUSION 0
TIOSPIR 0
will 0
provide 0
precise 0
estimates 0
of 0
the 0
relative 0
safety 0
and 0
efficacy 0
of 0
the 0
Respimat 0
and 0
HandiHaler 0
formulations 0
of 0
tiotropium 0
, 0
assess 0
potential 0
dose-dependence 0
of 0
important 0
outcomes 0
and 0
provide 0
information 0
on 0
the 0
clinical 0
epidemiology 0
of 0
COPD 0
in 0
a 0
large 0
international 0
patient 0
cohort 0
. 0

Comparison 0
of 0
dual-axis 0
rotational 0
coronary 0
angiography 0
( 0
XPERSWING 0
) 0
versus 0
conventional 0
technique 0
in 0
routine 0
practice 0
. 0

INTRODUCTION 0
AND 0
OBJECTIVES 0
Coronary 0
angiography 0
is 0
the 0
gold 0
standard 0
for 0
the 0
study 0
of 0
coronary 0
artery 0
disease 0
. 0

This 0
technique 0
requires 0
several 0
orthogonal 0
projections 0
. 0

Rotational 0
angiography 0
is 0
a 0
new 0
technique 0
which 0
involves 0
pre-set 0
rotation 0
of 0
the 0
X-ray 0
tube 0
around 0
the 0
patient 0
and 0
allows 0
visualization 0
of 0
each 0
coronary 0
artery 0
in 0
different 0
views 0
, 0
using 0
a 0
single 0
contrast 0
injection 0
. 0

The 0
purpose 0
of 0
this 0
study 0
was 0
to 0
compare 0
conventional 0
coronary 0
angiography 0
( 0
A 0
) 0
vs 0
rotational 0
angiography 0
( 0
B 0
) 0
, 0
focusing 0
on 0
radiation 0
dose 0
, 0
amount 0
of 0
contrast 0
administered 0
, 0
and 0
total 0
procedure 0
time 0
for 0
both 0
diagnostic 0
and 0
therapeutic 0
percutaneous 0
coronary 0
interventions 0
. 0

METHODS 0
Prospective 0
study 0
of 0
104 0
consecutive 0
patients 0
undergoing 0
coronary 0
angiography 0
who 0
were 0
randomized 0
to 0
one 0
of 0
these 0
techniques 0
. 0

RESULTS 0
We 0
found 0
a 0
significant 0
reduction 0
in 0
the 0
amount B-OTHER
of I-OTHER
contrast 0
administered B-OTHER
( 0
A 0
vs 0
B 0
, 0
93.1 0
[ 0
41.7 0
] 0
vs 0
50.9 0
[ 0
14.7 0
] 0
mL 0
; 0
P 0
< 0
.0001 0
) 0
and 0
radiation B-OTHER
exposure I-OTHER
( 0
27.6 0
[ 0
11.5 0
] 0
vs 0
18 0
[ 0
6.4 0
] 0
mGycm 0
( 0
2 0
) 0
; 0
P 0
< 0
.0001 0
) 0
. 0

A 0
significant 0
increase 0
in 0
total 0
procedure B-OTHER
time I-OTHER
was 0
noted 0
in 0
the 0
rotational 0
angiography 0
arm 0
. 0

However 0
, 0
when 0
only 0
the 0
last 0
50 0
patients 0
were 0
analyzed 0
, 0
we 0
found 0
no 0
difference 0
in 0
procedure B-OTHER
time B-OTHER
between 0
the 0
groups 0
, 0
probably 0
related 0
to 0
the 0
learning 0
curve 0
of 0
the 0
operators 0
. 0

Angioplasty B-PHYSICAL
was 0
performed 0
in 0
29 0
patients 0
in 0
group 0
A 0
and 0
28 0
patients 0
in 0
group 0
B 0
. 0

Contrast 0
reduction B-OTHER
was 0
maintained 0
in 0
the 0
rotational 0
angiography 0
group 0
compared 0
to 0
the 0
conventional 0
technique 0
( 0
A 0
vs 0
B 0
, 0
335.1 0
[ 0
192.1 0
] 0
vs 0
238.5 0
[ 0
114.4 0
] 0
mL 0
; 0
P=.02 0
) 0
. 0

CONCLUSIONS 0
The 0
rotational 0
angiography 0
technique 0
leads 0
to 0
a 0
significant 0
decrease 0
in 0

Depressive 0
mood 0
symptoms 0
associated 0
with 0
ovarian 0
suppression 0
. 0

OBJECTIVE 0
To 0
determine 0
if 0
sertraline 0
is 0
helpful 0
in 0
the 0
management 0
of 0
depressive 0
symptoms 0
associated 0
with 0
ovarian 0
suppression 0
during 0
GnRH 0
agonist 0
therapy 0
as 0
compared 0
with 0
a 0
placebo-controlled 0
group 0
. 0

DESIGN 0
Double-blind 0
placebo-controlled 0
prospective 0
study 0
design 0
. 0

SETTING 0
An 0
obstetrics/gynecological 0
office 0
specializing 0
in 0
infertility 0
in 0
an 0
academic 0
environment 0
. 0

PATIENT 0
( 0
S 0
) 0
Premenstrual 0
women 0
with 0
laparoscopically 0
diagnosed 0
endometriosis 0
who 0
required 0
GnRH 0
agonist 0
therapy 0
for 0
treatment 0
and 0
did 0
not 0
have 0
significant 0
depressive 0
or 0
premenstrual 0
mood 0
symptoms 0
at 0
baseline 0
. 0

INTERVENTION 0
( 0
S 0
) 0
Participants 0
were 0
randomly 0
assigned 0
to 0
either 0
the 0
sertraline 0
treatment 0
group 0
or 0
to 0
the 0
placebo 0
group 0
for 0
the 0
3-month 0
duration 0
of 0
the 0
GnRH 0
agonist 0
therapy 0
. 0

MAIN 0
OUTCOME 0
MEASURE 0
( 0
S 0
) 0
The 0
21-item 0
Hamilton 0
Rating 0
Scale 0
for 0
Depression 0
( 0
HRSD 0
) 0
, 0
which 0
is 0
an 0
instrument 0
designed 0
to 0
assess 0
depressive 0
symptomatology 0
. 0

RESULT 0
( 0
S 0
) 0
A 0
Hotellings 0
T 0
( 0
2 0
) 0
test 0
for 0
repeated 0
measure 0
analysis 0
indicated 0
a 0
statistically 0
significant 0
( 0
P 0
< 0
.05 0
) 0
between-group 0
difference 0
across 0
time 0
for 0
the 0
HRSD 0
( 0
T 0
( 0
2 0
) 0
= 0
13.3 0
; 0
F 0
[ 0
3 0
, 0
28 0
] 0
= 0
4.1 0
; 0
P=.02 0
) 0
with 0
the 0
sertraline 0
treatment 0
group 0
manifesting 0
significantly 0
fewer 0
depressive B-MENTAL
symptoms I-MENTAL
than 0
the 0
control 0
group 0
. 0

CONCLUSION 0
( 0
S 0
) 0
The 0
results 0
indicate 0
that 0
sertraline 0
is 0
an 0
effective 0
option 0
in 0
the 0
management 0
of 0
depressive 0
mood 0
symptoms 0
associated 0
with 0
ovarian 0
suppression 0
during 0
GnRH 0
agonist 0
therapy 0
. 0

Predictors 0
of 0
smoking 0
cessation 0
among 0
cancer 0
patients 0
enrolled 0
in 0
a 0
smoking 0
cessation 0
program 0
. 0

UNLABELLED 0
Many 0
cancer 0
patients 0
continue 0
to 0
smoke 0
postdiagnosis 0
, 0
which 0
is 0
associated 0
with 0
poorer 0
clinical 0
outcomes 0
. 0

Identifying 0
prospective 0
predictors 0
of 0
smoking 0
cessation 0
among 0
patients 0
currently 0
receiving 0
smoking 0
cessation 0
treatment 0
can 0
help 0
guide 0
the 0
development 0
and 0
implementation 0
of 0
smoking 0
cessation 0
programs 0
with 0
this 0
population 0
. 0

MATERIAL 0
AND 0
METHODS 0
Data 0
from 0
246 0
cancer 0
patients 0
participating 0
in 0
a 0
randomized 0
placebo-controlled 0
smoking 0
cessation 0
clinical 0
trial 0
were 0
used 0
to 0
examine 0
baseline 0
predictors 0
of 0
end-of-treatment 0
and 0
six-month 0
postbaseline 0
smoking 0
cessation 0
outcomes 0
. 0

Baseline 0
demographic 0
, 0
smoking-related 0
, 0
disease-related 0
, 0
and 0
psychological 0
variables 0
were 0
examined 0
as 0
predictors 0
of 0
biochemically-confirmed 0
point-prevalence 0
abstinence 0
. 0

RESULTS 0
Multivariate B-OTHER
analysis 0
indicated 0
that 0
, 0
for 0
end-of-treatment B-MENTAL
abstinence I-MENTAL
, 0
patients 0
were 0
significantly 0
more 0
likely 0
to 0
have 0
quit B-MENTAL
smoking I-MENTAL
if 0
they 0
were 0
older 0
( 0
OR 0
= 0
1.06 0
, 0
95 0
% 0
CI 0
: 0
1.03-1.10 0
, 0
p 0
< 0
0.05 0
) 0
and 0
were 0
diagnosed 0
with 0
a 0
non-tobacco 0
related 0
cancer 0
( 0
OR 0
= 0
2.54 0
, 0
95 0
% 0
CI 0
: 0
1.24-5.20 0
, 0
p 0
< 0
0.05 0
) 0
. 0

Likewise 0
, 0
for 0
six-month B-MENTAL
abstinence I-MENTAL
, 0
patients 0
were 0
significantly 0
more 0
likely 0
to 0
have 0
quit B-MENTAL
smoking I-MENTAL
if 0
they 0
were 0
older 0
( 0
OR 0
= 0
1.04 0
, 0
95 0
% 0
CI 0
: 0
1.01-1.08 0
, 0
p 0
< 0
0.05 0
) 0
and 0
were 0
significantly 0
less 0
likely 0
to 0
have 0
quit 0
smoking 0
if 0
they 0
were 0
female 0
( 0
OR 0
= 0
0.47 0
, 0
95 0
% 0
CI 0
: 0
0.22-0.97 0
, 0
p 0
< 0
0.05 0
) 0
. 0

Patients 0
with 0
tobacco-related 0
cancers 0
and 0
female 0
patients 0
reported 0
significantly 0
higher 0
levels B-MENTAL
of I-MENTAL
depression I-MENTAL
symptoms I-MENTAL
( 0
p 0
< 0
0.05 0
) 0
, 0
which 0
proved 0
predictive B-MENTAL
of I-MENTAL
smoking I-MENTAL
relapse I-MENTAL
. 0

CONCLUSIONS 0
Patient 0
age 0
, 0
gender 0
, 0
and 0
cancer-type 0
may 0
be 0
important 0
factors 0
to 0
consider 0
when 0
developing 0
and 0
implementing 0
smoking 0
cessation 0
interventions 0
for 0
cancer 0
patients 0
. 0

A 0
placebo-controlled 0
, 0
randomized 0
clinical 0
trial 0
using 0
testosterone 0
undecanoate 0
with 0
injectable 0
norethisterone 0
enanthate 0
: 0
effect 0
on 0
anthropometric 0
, 0
metabolic 0
and 0
biochemical 0
parameters 0
. 0

Testosterone 0
administered 0
alone 0
or 0
in 0
combination 0
with 0
progestogens 0
in 0
male 0
contraception 0
induces 0
reversible 0
oligo-azoospermia 0
, 0
but 0
its 0
effects 0
on 0
body 0
composition 0
and 0
metabolism 0
are 0
less 0
known 0
. 0

We 0
analysed 0
anthropometric 0
and 0
metabolic 0
parameters 0
in 0
five 0
groups 0
of 0
10 0
males 0
: 0
four 0
receiving 0
testosterone 0
undecanoate 0
( 0
TU 0
: 0
1000 0
mg 0
) 0
plus 0
norethisterone 0
enanthate 0
( 0
NETE 0
: 0
200 0
mg 0
) 0
at 0
different 0
intervals 0
( 0
every 0
8 0
weeks 0
: 0
NETE-8 0
; 0
every 0
12 0
weeks 0
: 0
NETE-12 0
; 0
every 0
6 0
weeks 0
for 0
12 0
weeks 0
and 0
then 0
every 0
12 0
weeks 0
: 0
NETE-6/12 0
; 0
every 0
6 0
weeks 0
for 0
12 0
weeks 0
and 0
then 0
TU 0
plus 0
placebo 0
every 0
12 0
weeks 0
: 0
NETE-6/12/0 0
) 0
and 0
one 0
placebo 0
( 0
NETE-0/0 0
) 0
for 0
a 0
total 0
of 0
48 0
weeks 0
. 0

Body 0
mass 0
index 0
( B-PHYSICAL
BMI 0
) B-PHYSICAL
and I-PHYSICAL
waist I-PHYSICAL
circumference I-PHYSICAL
did I-PHYSICAL
not I-PHYSICAL
change B-PHYSICAL
in 0
any 0
groups 0
except 0
for 0
the 0
NETE-8 0
in 0
which 0
BMI 0
increased 0
significantly B-PHYSICAL
( 0
p 0
= 0
0.02 0
) 0
at 0
the 0
end 0
of 0
the 0
treatment 0
period 0
. 0

Lean B-PHYSICAL
body I-PHYSICAL
mass I-PHYSICAL
( I-PHYSICAL
MAMC I-PHYSICAL
or B-PHYSICAL
AMA I-PHYSICAL
) B-PHYSICAL
increased 0
significantly B-PHYSICAL
in 0
the 0
highest 0
hormonal 0
dose 0
groups 0
( 0
p 0
= 0
0.04 0
, 0
NETE-6/12 0
; 0
p 0
= 0
0.004 0
, 0
NETE-8 0
) 0
. 0

No 0
differences 0
were 0
observed 0
in 0
glucose 0
levels 0
, 0
insulin 0
sensitivity 0
index 0
and 0
lipid 0
profile 0
as 0
well 0
as 0
in 0

Scent 0
and 0
mood 0
state 0
following 0
an 0
anxiety-provoking 0
task 0
. 0

The 0
purpose 0
of 0
this 0
study 0
was 0
to 0
assess 0
the 0
effects 0
of 0
water 0
, 0
lavender 0
, 0
or 0
rosemary 0
scent 0
on 0
physiology B-MENTAL
and 0
mood B-MENTAL
state I-MENTAL
following 0
an 0
anxiety-provoking 0
task 0
. 0

The 0
nonsmoking 0
participants 0
, 0
ages 0
18-30 0
years 0
, 0
included 0
42 0
women 0
and 0
31 0
men 0
who 0
reported 0
demographic 0
information 0
and 0
measures 0
of 0
external 0
temperature 0
and 0
heart 0
rate 0
were 0
taken 0
prior 0
to 0
introduction 0
of 0
an 0
anxiety-eliciting 0
task 0
and 0
exposure 0
to 0
lavender 0
, 0
rosemary 0
, 0
or 0
water 0
scents 0
. 0

Following 0
the 0
task 0
, 0
participants 0
completed 0
the 0
Profile 0
of 0
Mood 0
States 0
to 0
assess 0
mood B-MENTAL
, 0
and 0
temperature B-PHYSICAL
and 0
heart B-PHYSICAL
rate I-PHYSICAL
were 0
reassessed 0
. 0

Participants 0
rated 0
the 0
pleasantness 0
of 0
the 0
scent 0
received 0
. 0

When 0
pleasantness 0
ratings 0
of 0
scent 0
were 0
covaried 0
, 0
physiological B-PHYSICAL
changes I-PHYSICAL
in I-PHYSICAL
temperature I-PHYSICAL
and 0
heart B-PHYSICAL
rate I-PHYSICAL
did 0
not 0
differ 0
based 0
on 0
scent 0
exposure 0
, 0
but 0
mood B-MENTAL
ratings I-MENTAL
differed 0
by 0
scent 0
condition 0
. 0

Participants 0
in 0
the 0
rosemary 0
condition 0
scored 0
higher 0
on 0
measures 0
of 0
tension-anxiety B-MENTAL
and 0
confusion-bewilderment B-MENTAL
relative 0
to 0
the 0
lavender 0
and 0
control 0
conditions 0
. 0

The 0
lavender 0
and 0
control 0
conditions 0
showed 0
higher 0
mean 0
vigor-activity B-MENTAL
ratings I-MENTAL
relative 0
to 0
the 0
rosemary 0
group 0
, 0
while 0
both 0
rosemary 0
and 0
lavender 0
scents 0
were 0
associated 0
with 0
lower 0
mean 0
ratings B-MENTAL
on I-MENTAL
the I-MENTAL
fatigue-inertia I-MENTAL
subscale I-MENTAL
, 0
relative 0
to 0
the 0
control 0
group 0
. 0

These 0
results 0
suggest 0
that 0
, 0
when 0
individual 0
perception 0
of 0
scent 0
pleasantness 0
is 0
controlled 0
, 0
scent 0
has 0
the 0
potential 0
to 0
moderate 0
different 0
aspects 0
of 0
mood 0
following 0
an 0
anxiety-provoking 0
task 0
. 0

Effect 0
of 0
prophylactic 0
amiodarone 0
in 0
patients 0
with 0
rheumatic 0
valve 0
disease 0
undergoing 0
valve 0
replacement 0
surgery 0
. 0

The 0
study 0
was 0
carried 0
out 0
to 0
evaluate 0
the 0
effect 0
of 0
prophylactic 0
single-dose 0
intravenous 0
amiodarone 0
in 0
patients 0
undergoing 0
valve 0
replacement 0
surgery 0
. 0

Maintenance 0
of 0
sinus 0
rhythm 0
is 0
better 0
than 0
maintenance 0
of 0
fixed 0
ventricular 0
rate 0
in 0
atrial 0
fibrillation 0
( 0
AF 0
) 0
especially 0
in 0
the 0
presence 0
of 0
irritable 0
left 0
or 0
right 0
atrium 0
because 0
of 0
enlargement 0
. 0

Fifty-six 0
patients 0
with 0
valvular 0
heart 0
disease 0
with 0
or 0
without 0
AF 0
were 0
randomly 0
divided 0
into 0
two 0
groups 0
. 0

Group 0
I 0
or 0
the 0
amiodarone 0
group 0
( 0
n=28 0
) 0
received 0
amiodarone 0
( 0
3 0
mg/kg 0
in 0
100 0
ml 0
normal 0
saline 0
) 0
and 0
group 0
II 0
or 0
the 0
control 0
group 0
received 0
same 0
volume 0
of 0
normal 0
saline 0
. 0

The 0
standardized 0
protocol 0
for 0
cardiopulmonary 0
bypass 0
was 0
maintained 0
for 0
all 0
the 0
patients 0
. 0

AF B-PHYSICAL
occurred 0
in 0
7.14 0
% 0
patients 0
in 0
group 0
I 0
, 0
and 0
in 0
group 0
II 0
, 0
28.57 0
% 0
( 0
P=0.035 0
) 0
; 0
ventricular B-PHYSICAL
tachycardia/fibrillation I-PHYSICAL
was 0
observed 0
in 0
21.43 0
% 0
patients 0
in 0
group 0
I 0
and 0
46.43 0
% 0
patients 0
in 0
group 0
II 0
( 0
P=0.089 0
) 0
after 0
release 0
of 0
aortic 0
clamp 0
. 0

Most 0
of 0
the 0
patients 0
in 0
group 0
I 0
( 0
92.86 0
% 0
) 0
maintained 0
sinus B-PHYSICAL
rhythm I-PHYSICAL
without I-PHYSICAL
cardioversion I-PHYSICAL
or I-PHYSICAL
defibrillation I-PHYSICAL
after 0
release 0
of 0
aortic 0
cross 0
clamp 0
( 0
P=0.002 0
) 0
. 0

Defibrillation B-PHYSICAL
or 0
cardio B-PHYSICAL
version I-PHYSICAL
was 0
needed 0
in 0
7.14 0
% 0
patients 0
in 0
group 0
I 0
and 0
28.57 0
% 0
patients 0
in 0
group 0
II 0
( 0
P=0.078 0
) 0
. 0

A 0
single 0
prophylactic 0
intraoperative 0
dose 0
of 0
intravenous 0
amiodarone 0
decreased 0
post B-PHYSICAL
bypass I-PHYSICAL
arrhythmia I-PHYSICAL
in 0
this 0
study 0
in 0
comparison 0
to 0
the 0
control 0
group 0
. 0

Single 0
dose 0
of 0
intraoperative 0
amiodarone 0
may 0
be 0
used 0
to 0
decrease 0
postoperative 0
arrhythmia 0
in 0
open 0
heart 0
surgery 0
. 0

Evaluation 0
of 0
a 0
new 0
wound 0
closure 0
device 0
for 0
linear 0
surgical 0
incisions 0
: 0
3M 0
Steri-Strip 0
S 0
Surgical 0
Skin 0
Closure 0
versus 0
subcuticular 0
closure 0
. 0

BACKGROUND 0
Technological 0
innovations 0
are 0
often 0
adopted 0
before 0
scientific 0
comparison 0
to 0
an 0
accepted 0
standard 0
. 0

The 0
authors 0
' 0
study 0
compared 0
suture 0
with 0
a 0
new 0
coaptive 0
film 0
device 0
, 0
3M 0
Steri-Strip 0
S 0
Surgical 0
Skin 0
Closure 0
, 0
on 0
linear 0
incisions 0
. 0

METHODS 0
Patients 0
undergoing 0
Wise-pattern 0
breast 0
reduction 0
or 0
abdominal 0
procedures 0
had 0
paired 0
incisions 0
randomly 0
assigned 0
to 0
Steri-Strip 0
S 0
or 0
suture 0
closure 0
. 0

Key 0
outcome 0
measures 0
were 0
closure B-OTHER
time I-OTHER
, 0
patient B-OTHER
comfort I-OTHER
, 0
and 0
scar B-OTHER
quality I-OTHER
at 0
6 0
months 0
by 0
patients 0
and 0
surgeons 0
using 0
a 0
new 0
scar 0
evaluation 0
tool 0
, 0
visual 0
assessment 0
of 0
linear 0
scars 0
. 0

Statistical 0
differences 0
between 0
the 0
two 0
closure 0
techniques 0
were 0
assessed 0
by 0
Wilcoxon 0
signed 0
rank 0
test 0
. 0

RESULTS 0
Of 0
59 0
patients 0
, 0
eight 0
were 0
excluded 0
from 0
randomization 0
( 0
a 0
surgeon 0
judged 0
Steri-Strip 0
S 0
to 0
be 0
a 0
nonviable 0
closure 0
technique 0
for 0
mismatched 0
wound 0
edges 0
) 0
. 0

Fifty-one 0
patients 0
( 0
breast 0
, 0
n 0
= 0
24 0
; 0
abdomen 0
, 0
n 0
= 0
27 0
) 0
were 0
randomized 0
. 0

Operative B-OTHER
time I-OTHER
with 0
Steri-Strip 0
S 0
for 0
breast 0
was 0
2.0 0
minutes 0
( 0
SD 0
= 0
1.1 0
) 0
versus 0
suture 0
closure 0
at 0
4.6 0
minutes 0
( 0
SD 0
= 0
1.5 0
; 0
p 0
< 0
0.001 0
) 0
. 0

Similarly 0
, 0
Steri-Strip 0
S 0
versus 0
suture 0
for 0
the 0
abdomen 0
was 0
faster 0
( 0
p 0
< 0
0.001 0
; 0
4.9 0
minutes 0
, 0
SD 0
= 0
2.3 0
versus 0
10.1 0
minutes 0
, 0
SD 0
= 0
3.4 0
) 0
. 0

Comfort 0
scores 0
did 0
not 0
differ 0
between 0
closures 0
[ 0
5.8 0
( 0
SD 0
= 0
2.7 0
) 0
versus 0
6.9 0
( 0
SD 0
= 0
2.0 0
) 0
, 0
respectively 0
, 0
on 0
breast 0
( 0
p 0
= 0
0.142 0
) 0
and 0
7.7 0
( 0
SD 0
= 0
1.8 0
) 0
versus 0
7.7 0
( 0
SD 0
= 0
2.3 0
) 0
on 0
abdomen 0
( 0
p 0
= 0
0.903 0
) 0
] 0
. 0

Complication B-ADVERSE-EFFECTS
rates I-ADVERSE-EFFECTS
did 0
not 0
differ 0
between 0
closure 0
types 0
. 0

Patients B-OTHER
' 0
visual B-OTHER
assessment I-OTHER
of I-OTHER
linear I-OTHER
scars I-OTHER
rating I-OTHER
of I-OTHER
breasts B-OTHER
was 0
3.8 0
( 0
SD 0
= 0
2.9 0
) 0
for 0
Steri-Strip 0
S 0
and 0
better 0
at 0
2.6 0
( 0
SD 0
= 0
2.9 0
) 0
for 0
suture 0
( 0
p 0
= 0
0.008 0
) 0
. 0

One 0
surgeon 0
rated 0
breast 0
Steri-Strip 0
S 0
scars 0
worse 0
than 0
suture 0
scars 0
( 0
4.3 0
versus 0
3.7 0
; 0
p 0
= 0
0.014 0
) 0
. 0

For 0
abdominal 0
scars 0
, 0
there 0
was 0
no 0
difference 0
in 0
the 0
patient 0
or 0
surgeon 0
ratings 0
. 0

CONCLUSIONS 0
Steri-Strip 0
S 0
permits 0
faster 0
wound B-PHYSICAL
closure B-PHYSICAL
than 0
suture 0
. 0

On 0
the 0
basis 0
of 0
patient 0
reports 0
of 0
comfort B-OTHER
and 0

Erythema 0
migrans 0
: 0
comparison 0
of 0
treatment 0
with 0
azithromycin 0
, 0
doxycycline 0
and 0
phenoxymethylpenicillin 0
. 0

Azithromycin 0
, 0
doxycycline 0
and 0
phenoxymethylpenicillin 0
were 0
compared 0
in 0
a 0
prospective 0
, 0
randomized 0
study 0
of 0
64 0
patients 0
with 0
typical 0
erythema 0
migrans 0
. 0

Twenty 0
patients 0
were 0
treated 0
with 0
oral 0
azithromycin 0
, 0
250 0
mg 0
bd 0
for 0
two 0
days 0
followed 0
by 0
250 0
mg 0
od 0
for 0
eight 0
days 0
, 0
21 0
patients 0
were 0
given 0
phenoxymethylpenicillin 0
1 0
million 0
IU 0
tds 0
for 0
14 0
days 0
and 0
23 0
patients 0
received 0
doxycycline 0
, 0
100 0
mg 0
bd 0
for 0
14 0
days 0
. 0

All 0
patients 0
were 0
followed 0
up 0
for 0
24 0
months 0
. 0

There 0
were 0
no 0
significant 0
differences 0
between 0
the 0
groups 0
with 0
respect 0
to 0
the 0
persistence 0
of 0
cutaneous B-PHYSICAL
lesions I-PHYSICAL
after 0
starting 0
treatment 0
; 0
the 0
mean 0
durations B-OTHER
were 0
10.5 0
days 0
in 0
the 0
penicillin 0
group 0
, 0
8.8 0
days 0
in 0
the 0
doxycycline 0
group 0
and 0
8.6 0
days 0
in 0
the 0
azithromycin 0
group 0
. 0

There 0
were 0
statistically 0
significant 0
differences 0
in 0
terms 0
of 0
the 0
resolution B-PHYSICAL
of I-PHYSICAL
associated I-PHYSICAL
local I-PHYSICAL
and/or I-PHYSICAL
systemic I-PHYSICAL
symptoms I-PHYSICAL
. 0

The 0
response 0
time 0
was 0
shortest 0
in 0
patients 0
treated 0
with 0
azithromycin 0
. 0

Two 0
patients 0
who 0
received 0
phenoxymethylpenicillin 0
and 0
two 0
given 0
doxycycline 0
subsequently 0
developed 0
major 0
manifestations 0
of 0
Lyme B-PHYSICAL
borreliosis I-PHYSICAL
; 0
these 0
did 0
not 0
occur 0
in 0
patients 0
receiving 0
azithromycin 0
. 0

Although 0
azithromycin 0
has 0
been 0
shown 0
to 0
be 0
effective 0
in 0
the 0
treatment 0
of 0
erythema 0
migrans 0
, 0
further 0
studies 0
will 0
be 0
needed 0
to 0
determine 0
the 0
optimal 0
dosage 0
and 0
duration 0
of 0
therapy 0
. 0

Naltrexone 0
in 0
young 0
autistic 0
children 0
: 0
a 0
double-blind 0
, 0
placebo-controlled 0
crossover 0
study 0
. 0

OBJECTIVE 0
This 0
study 0
evaluated 0
the 0
efficacy 0
and 0
safety 0
of 0
naltrexone 0
, 0
an 0
opiate 0
blocker 0
, 0
in 0
the 0
treatment 0
of 0
autism 0
. 0

METHOD 0
Thirteen 0
children 0
with 0
autistic 0
disorder 0
, 0
aged 0
3.4 0
to 0
8.3 0
years 0
( 0
mean 0
5.4 0
) 0
, 0
were 0
studied 0
in 0
home 0
, 0
school 0
, 0
and 0
outpatient 0
laboratory 0
. 0

Naltrexone 0
, 0
1.0 0
mg/kg 0
, 0
was 0
given 0
daily 0
in 0
a 0
randomized 0
, 0
double-blind 0
, 0
placebo-controlled 0
crossover 0
design 0
. 0

Dependent 0
measures 0
included 0
parent 0
and 0
teacher 0
Clinical B-MENTAL
Global I-MENTAL
Impressions I-MENTAL
( I-MENTAL
CGI I-MENTAL
) I-MENTAL
, 0
Conners B-MENTAL
Rating I-MENTAL
Scales I-MENTAL
, 0
and 0
Naltrexone B-OTHER
Side-Effects I-OTHER
( I-OTHER
SE I-OTHER
) I-OTHER
Rating I-OTHER
Scale 0
; 0
laboratory B-MENTAL
CGI I-MENTAL
, 0
movement B-MENTAL
actometer I-MENTAL
readings I-MENTAL
, 0
and 0
a 0
10-second B-MENTAL
interval I-MENTAL
recording I-MENTAL
system I-MENTAL
analysis I-MENTAL
of I-MENTAL
on-task I-MENTAL
, 0
communication B-MENTAL
initiations I-MENTAL
, 0
disruptive B-MENTAL
behavior I-MENTAL
, 0
and 0
self-stimulation B-MENTAL
. 0

RESULTS 0
Eight 0
of 0
13 0
subjects 0
improved 0
in 0
two 0
or 0
more 0
settings 0
. 0

Changes 0
in 0
parent B-MENTAL
measures I-MENTAL
( I-MENTAL
CGI I-MENTAL
, 0
Conners B-MENTAL
Impulsivity-Hyperactivity I-MENTAL
Factor I-MENTAL
, 0
and 0
SE-Restlessness B-MENTAL
) 0
and 0
Teacher B-MENTAL
CGI I-MENTAL
achieved 0
statistical 0
significance 0
. 0

Teacher B-MENTAL
SE-Restlessness I-MENTAL
and 0
initiation B-MENTAL
of I-MENTAL
communication I-MENTAL
in 0
the 0
clinic 0
showed 0
a 0
trend 0
toward 0
improvement 0
. 0

Actometer B-PHYSICAL
readings I-PHYSICAL
improved 0
in 0
two 0
children 0
who 0
were 0
very 0
active 0
at 0
baseline 0
. 0

Adverse B-ADVERSE-EFFECTS
side I-ADVERSE-EFFECTS
effects I-ADVERSE-EFFECTS
were 0
behavioral 0
, 0
mild 0
, 0
and 0
transient 0
. 0

Administering 0
the 0
bitter 0
tablet 0
was 0
a 0
challenge 0
. 0

CONCLUSIONS 0
Naltrexone 0
offers 0
promise 0
as 0
an 0
agent 0
for 0
modest 0
improvement 0
of 0
behavior 0
and 0
social B-MENTAL
communication I-MENTAL
in 0
young 0
children 0
with 0
autism 0
. 0

Parent 0
and 0
teacher 0
measures 0
can 0
be 0
useful 0
in 0
outpatient 0
trials 0
to 0
evaluate 0
change 0
. 0

Changes 0
of 0
activated 0
circulating 0
endothelial 0
cells 0
and 0
survivin 0
in 0
patients 0
with 0
non-small 0
cell 0
lung 0
cancer 0
after 0
antiangiogenesis 0
therapy 0
. 0

BACKGROUND 0
Although 0
antiangiogenesis 0
therapy 0
plays 0
an 0
important 0
role 0
in 0
anti-neoplastic 0
treatment 0
with 0
its 0
recognized 0
efficacy 0
and 0
slight 0
adverse 0
effect 0
, 0
there 0
is 0
no 0
prospective 0
clinical 0
trial 0
to 0
define 0
ideal 0
markers 0
for 0
predicting 0
efficacy 0
of 0
antiangiogenic 0
therapy 0
. 0

This 0
study 0
was 0
undertaken 0
to 0
investigate 0
the 0
changes 0
of 0
activated 0
circulating 0
endothelial 0
cells 0
( 0
aCECs 0
) 0
and 0
survivin 0
after 0
anti-angiogenesis 0
therapy 0
and 0
their 0
significance 0
in 0
predicting 0
the 0
efficacy 0
of 0
the 0
therapy 0
. 0

METHODS 0
Patients 0
of 0
non-small 0
cell 0
lung 0
cancer 0
( 0
NSCLC 0
) 0
treated 0
with 0
chemotherapy 0
with 0
or 0
without 0
Endostar 0
were 0
observed 0
. 0

The 0
amount 0
of 0
activated 0
CECs 0
was 0
detected 0
by 0
flow 0
cytometry 0
, 0
and 0
the 0
expression 0
of 0
survivin 0
mRNA 0
was 0
determined 0
by 0
real-time 0
polymerase 0
chain 0
reaction 0
( 0
PCR 0
) 0
. 0

RESULTS 0
After 0
treatment 0
, 0
the 0
amount 0
of 0
activated B-PHYSICAL
CECs I-PHYSICAL
decreased 0
significantly 0
in 0
clinical 0
benefit 0
cases 0
( 0
P 0
= 0
0.021 0
in 0
chemotherapy 0
alone 0
, 0
P 0
= 0
0.001 0
in 0
chemotherapy 0
plus 0
Endostar 0
) 0
, 0
increased 0
in 0
disease B-PHYSICAL
progressive I-PHYSICAL
cases I-PHYSICAL
( 0
P 0
= 0
0.015 0
in 0
chemotherapy 0
alone 0
, 0
but 0
P 0
= 0
0.293 0
in 0
chemotherapy 0
with 0
Endotatar 0
) 0
. 0

After 0
therapy 0
, 0
the 0
expression 0
of 0
survivin B-PHYSICAL
mRNA I-PHYSICAL
decreased 0
in 0
clinical 0
benefit 0
cases 0
( 0
P 0
= 0
0.001 0
) 0
and 0
increased 0
in 0
disease B-PHYSICAL
progressive I-PHYSICAL
cases I-PHYSICAL
( 0
P 0
= 0
0.018 0
) 0
. 0

A 0
positive 0
correlation 0
was 0
found 0
between 0
activated B-PHYSICAL
CECs I-PHYSICAL
and 0
survivin 0
in 0
the 0
chemotherapy 0
group 0
pre- 0
and 0
post-therapy 0
( 0
P 0
= 0
0.001 0
and 0
0.021 0
, 0
respectively 0
) 0
, 0
but 0
only 0
in 0
the 0
chemotherapy 0
with 0
Endostar 0
group 0
pre-therapy 0
( 0
P 0
= 0
0.030 0
) 0
rather 0
than 0
post-therapy 0
. 0

A 0
positive 0
correlation 0
was 0
found 0
between 0
the 0
decreased 0
activated B-PHYSICAL
CECs I-PHYSICAL
after 0
therapy 0
and 0
time B-PHYSICAL
to I-PHYSICAL
progression I-PHYSICAL
( I-PHYSICAL
TTP I-PHYSICAL
) I-PHYSICAL
( 0
r 0
= 0
0.322 0
, 0
P 0
= 0
0.012 0
) 0
; 0
a 0
negative 0
correlation 0
was 0
found 0
between 0
the 0
amount 0
of 0
survivin B-PHYSICAL
mRNA I-PHYSICAL
in I-PHYSICAL
serum I-PHYSICAL
post-therapy I-PHYSICAL
and 0
TTP B-PHYSICAL
( 0
r 0
= 0
-0.291 0
, 0
P 0
= 0
0.048 0
) 0
. 0

CONCLUSIONS 0
Activated 0
CECs 0
and 0
survivin 0
may 0
be 0
ideal 0
markers 0
forecasting 0
efficacy 0
and 0
prognosis 0
of 0
NSCLC 0
. 0

The 0
former 0
can 0
reflect 0
more 0
sensitively 0
antiangiogenic 0
efficacy 0
and 0
the 0
latter 0
is 0
more 0
sensitive 0
to 0
shrinkage 0
or 0
swelling 0
of 0
tumors 0
. 0

Their 0
combination 0
can 0
evaluate 0
more 0
accurately 0
the 0
efficacy 0
of 0
antiangiogenic 0
therapy 0
of 0
NSCLC 0
. 0

Allopurinol 0
improves 0
endothelial 0
function 0
and 0
reduces 0
oxidant-inflammatory 0
enzyme 0
of 0
myeloperoxidase 0
in 0
metabolic 0
syndrome 0
. 0

OBJECTIVE 0
In 0
this 0
study 0
, 0
we 0
tested 0
in 0
patients 0
with 0
metabolic 0
syndrome 0
whether 0
allopurinol 0
through 0
decreasing 0
oxidative 0
stress 0
improves 0
endothelial 0
function 0
, 0
and 0
ameliorates 0
inflammatory 0
state 0
represented 0
by 0
markers 0
of 0
myeloperoxidase 0
, 0
C-reactive 0
protein 0
( 0
CRP 0
) 0
and 0
fibrinogen 0
. 0

METHODS 0
In 0
a 0
randomized 0
, 0
double-blind 0
fashion 0
; 0
subjects 0
with 0
metabolic 0
syndrome 0
were 0
treated 0
with 0
allopurinol 0
( 0
n 0
= 0
28 0
) 0
or 0
placebo 0
( 0
n 0
= 0
22 0
) 0
for 0
one 0
month 0
. 0

Before 0
and 0
after 0
treatment 0
, 0
blood 0
samples 0
were 0
collected 0
and 0
the 0
flow-mediated B-PHYSICAL
dilation I-PHYSICAL
( I-PHYSICAL
FMD I-PHYSICAL
) I-PHYSICAL
and 0
isosorbide B-PHYSICAL
dinitrate I-PHYSICAL
( 0
ISDN B-PHYSICAL
) 0
-mediated B-PHYSICAL
dilation B-PHYSICAL
of 0
the 0
brachial 0
artery 0
were 0
performed 0
. 0

RESULTS 0
Baseline 0
clinical 0
characteristics 0
of 0
the 0
allopurinol 0
and 0
placebo 0
groups 0
demonstrated 0
no 0
differences 0
in 0
terms 0
of 0
clinical B-OTHER
characteristics I-OTHER
, 0
endothelial B-PHYSICAL
function I-PHYSICAL
and 0
inflammatory B-PHYSICAL
markers B-PHYSICAL
. 0

After 0
the 0
treatment 0
with 0
allopurinol 0
, 0
FMD B-PHYSICAL
was 0
increased 0
from 0
8.0 0
+/- 0
0.5 0
% 0
to 0
11.8 0
+/- 0
0.6 0
% 0
( 0
P 0
< 0
0.01 0
) 0
, 0
but 0
there 0
were 0
no 0
change 0
in 0
the 0
placebo 0
group 0
. 0

In 0
both 0
groups 0
, 0
ISDN-mediated B-PHYSICAL
dilation I-PHYSICAL
is 0
unaffected 0
by 0
the 0
treatment 0
. 0

As 0
a 0
marker 0
of 0
oxidative 0
stress 0
, 0
allopurinol 0
significantly 0
reduced B-PHYSICAL
malondialdehyde I-PHYSICAL
. 0

Moreover 0
, 0
myeloperoxidase B-PHYSICAL
levels I-PHYSICAL
were 0
reduced 0
by 0
the 0
treatment 0
with 0
allopurinol 0
( 0
56.1 0
+/- 0
3.4 0
ng/ml 0
vs. 0
44.4 0
+/- 0
2.4 0
ng/ml 0
, 0
P 0
< 0
0.05 0
) 0
but 0
there 0
were 0
no 0
change 0
in 0
the 0
placebo 0
group 0
. 0

Surprisingly 0
, 0
neither 0

Topical 0
administration 0
of 0
diclofenac 0
( 0
1 0
% 0
) 0
in 0
the 0
prevention 0
of 0
miosis B-PHYSICAL
during 0
vitrectomy 0
. 0

PURPOSE 0
A 0
prospective 0
, 0
randomized 0
clinical 0
trial 0
was 0
conducted 0
to 0
assess 0
the 0
usefulness 0
of 0
preoperative 0
diclofenac 0
eye 0
drops 0
in 0
maintaining 0
mydriasis B-PHYSICAL
during 0
vitrectomy 0
and 0
in 0
reducing 0
postoperative B-PHYSICAL
inflammation I-PHYSICAL
. 0

METHODS 0
Fifty 0
consecutive 0
patients 0
undergoing 0
vitrectomy 0
were 0
randomly 0
assigned 0
to 0
diclofenac 0
( 0
n 0
= 0
24 0
) 0
or 0
control 0
( 0
n 0
= 0
26 0
) 0
groups 0
. 0

All 0
patients 0
received 0
a 0
standard 0
preoperative 0
regimen 0
of 0
cyclopentolate 0
( 0
2 0
% 0
) 0
and 0
phenylephrine 0
hydrochloride 0
( 0
2.5 0
% 0
) 0
. 0

The 0
diclofenac 0
group 0
also 0
received 0
diclofenac 0
( 0
1 0
% 0
) 0
preoperatively 0
. 0

Pupillary B-PHYSICAL
diameter I-PHYSICAL
was 0
recorded 0
at 0
four 0
time 0
points 0
during 0
surgery 0
. 0

Inflammatory B-PHYSICAL
indices I-PHYSICAL
were 0
measured 0
postoperatively 0
using 0
slit-lamp 0
examination 0
. 0

RESULTS 0
After 0
induction 0
of 0
anesthesia 0
, 0
the 0
decrease 0
in 0
pupil B-PHYSICAL
size I-PHYSICAL
was 0
not 0
significantly 0
different 0
between 0
the 0
two 0
groups 0
( 0
P 0
= 0
0.112 0
) 0
, 0
but 0
for 0
the 0
next 0
two 0
stages 0
, 0
it 0
was 0
significantly 0
less 0
in 0
the 0
diclofenac 0
group 0
( 0
P 0
= 0
0.012 0
and 0
P 0
= 0
0.003 0
, 0
respectively 0
) 0
. 0

No 0
significant 0
differences 0
were 0
found 0
between 0
the 0
two 0
groups 0
for 0
anterior B-PHYSICAL
chamber I-PHYSICAL
cells I-PHYSICAL
and 0
redness B-PHYSICAL
in I-PHYSICAL
the I-PHYSICAL
eye I-PHYSICAL
postoperatively 0
( 0
P 0
= 0
0.609 0
and 0
P 0
= 0
0.123 0
, 0
respectively 0
) 0
. 0

However 0
, 0
anterior B-PHYSICAL
chamber I-PHYSICAL
flare I-PHYSICAL
was 0
significantly 0
greater 0
in 0
the 0
control 0
group 0
( 0
P 0
= 0
0.035 0
) 0
, 0
and 0
patients 0
felt 0
significantly 0
more 0
pain B-PAIN
in 0
this 0
group 0
( 0
P 0
= 0
0.001 0
) 0
. 0

CONCLUSIONS 0
Topical 0
administration 0
of 0
diclofenac 0
was 0
effective 0
in 0
maintaining B-PHYSICAL
mydriasis I-PHYSICAL
during 0
vitrectomy 0
and 0
in 0
reducing 0
postoperative B-PAIN
pain I-PAIN
and 0
anterior B-PHYSICAL
chamber I-PHYSICAL
flare I-PHYSICAL
as 0
determined 0
by 0
slit-lamp 0
evaluations 0
. 0

Promoting 0
health 0
in 0
schools 0
through 0
a 0
board 0
game 0
. 0

Primary 0
prevention 0
and 0
health 0
promotion 0
have 0
become 0
salient 0
topics 0
in 0
Canadian 0
society 0
and 0
in 0
nursing 0
during 0
the 0
past 0
two 0
decades 0
. 0

The 0
noncommunicable 0
chronic 0
diseases 0
, 0
such 0
as 0
heart 0
disease 0
and 0
cancer 0
, 0
have 0
been 0
linked 0
to 0
specific 0
lifestyle B-MENTAL
behaviors I-MENTAL
or 0
habits 0
, 0
which 0
often 0
develop 0
early 0
in 0
life 0
. 0

The 0
success 0
of 0
public 0
health 0
efforts 0
to 0
improve 0
the 0
health 0
status 0
of 0
all 0
Canadians 0
depends 0
substantially 0
on 0
the 0
success 0
of 0
educational 0
programs 0
directed 0
toward 0
children 0
. 0

Effective 0
teaching 0
strategies 0
that 0
seek 0
to 0
promote 0
health 0
and 0
wellness 0
in 0
children 0
need 0
to 0
be 0
developed 0
and 0
empirically 0
evaluated 0
. 0

Educational 0
games 0
may 0
provide 0
an 0
efficient 0
vehicle 0
for 0
carrying 0
out 0
developmentally 0
specific 0
nursing 0
interventions 0
in 0
school 0
settings 0
. 0

This 0
article 0
begins 0
with 0
a 0
brief 0
overview 0
of 0
the 0
historical 0
origins 0
of 0
games 0
, 0
along 0
with 0
their 0
advantages 0
and 0
disadvantages 0
as 0
educational 0
strategies 0
. 0

The 0
results 0
of 0
a 0
pretest-posttest 0
control 0
group 0
design 0
study 0
that 0
evaluated 0
the 0
effectiveness 0
of 0
a 0
board 0
game 0
as 0
a 0
primary 0
prevention 0
teaching 0
strategy 0
with 0
23 0
sixth 0
grade 0
children 0
in 0
Winnipeg 0
, 0
Manitoba 0
are 0
presented 0
. 0

The 0
experimental 0
group 0
had 0
significant 0
gains 0
in 0
knowledge B-MENTAL
related I-MENTAL
to I-MENTAL
anatomy I-MENTAL
and I-MENTAL
physiology I-MENTAL
, 0
diet B-MENTAL
, 0
and B-MENTAL
lifestyle I-MENTAL
risk 0
factors B-MENTAL
associated I-MENTAL
with I-MENTAL
the I-MENTAL
development I-MENTAL
of I-MENTAL
heart I-MENTAL
disease I-MENTAL

Comparative 0
clinical 0
and 0
microbiological 0
effects 0
of 0
subgingival 0
metronidazole 0
application 0
in 0
adult 0
periodontitis 0
; 0
12-months 0
results 0
. 0

The 0
aim 0
of 0
the 0
present 0
study 0
was 0
to 0
evaluate 0
the 0
clinical 0
and 0
microbiological 0
effects 0
of 0
subgingival 0
application 0
of 0
25 0
% 0
metronidazole 0
dental 0
gel 0
as 0
an 0
adjunct 0
to 0
scaling 0
and 0
root 0
planing 0
( 0
SRP 0
) 0
in 0
the 0
treatment 0
of 0
adult 0
periodontitis 0
. 0

Eighty 0
teeth 0
in 0
18 0
patients 0
were 0
evaluated 0
using 0
a 0
split 0
mouth 0
design 0
. 0

The 0
test 0
teeth 0
received 0
SRP 0
and 0
a 0
25 0
% 0
metronidazole 0
gel 0
applied 0
subgingivally 0
on 0
days 0
0 0
and 0
7 0
. 0

The 0
control 0
teeth 0
received 0
SRP 0
only 0
. 0

Clinical 0
and 0
microbiological 0
examinations 0
were 0
carried 0
out 0
before 0
treatment 0
and 0
on 0
weeks 0
1 0
, 0
3 0
, 0
7 0
, 0
13 0
, 0
26 0
, 0
38 0
and 0
52 0
of 0
the 0
experimental 0
period 0
. 0

Colony 0
forming 0
units 0
of 0
Porphyromonas 0
gingivalis 0
and 0
Prevotella 0
intermedia 0
/ 0
Prevotella 0
nigrescens 0
were 0
determined 0
. 0

Both 0
treatments 0
provided 0
significant 0
improvements 0
in 0
all 0
the 0
clinical B-PHYSICAL
and I-PHYSICAL
microbiological I-PHYSICAL
parameters I-PHYSICAL
( 0
P 0
< 0
0.05 0
) 0
. 0

However 0
, 0
none 0
of 0
the 0
differences 0
between 0
the 0
study 0
groups 0
were 0
statistically 0
significant 0
( 0
P 0
> 0
0.05 0
) 0
. 0

As 0
a 0
conclusion 0
, 0
the 0
present 0
study 0
does 0
not 0
provide 0
evidence 0
in 0
favour B-OTHER
of I-OTHER
the I-OTHER
routine I-OTHER
use I-OTHER
of I-OTHER
adjunctive I-OTHER
metronidazole I-OTHER
dental I-OTHER
gel I-OTHER
in 0
the 0
treatment 0
of 0
adult B-PHYSICAL
periodontitis I-PHYSICAL
. 0

The 0
effects 0
of 0
prophylactic 0
management 0
and 0
therapeutics 0
on 0
hypertensive B-PHYSICAL
disease I-PHYSICAL
in 0
pregnancy 0
: 0
preliminary 0
studies 0
. 0

A 0
controlled 0
prospective 0
evaluation 0
of 0
pregnancy 0
complicated 0
by 0
chronic 0
hypertension 0
is 0
proposed 0
and 0
preliminary 0
data 0
on 0
population 0
selection B-OTHER
and 0
pregnancy B-PHYSICAL
outcome I-PHYSICAL
are 0
presented 0
. 0

Sixty-three 0
women 0
with 0
evidence 0
of 0
underlying 0
hypertensive 0
disease 0
were 0
followed 0
prospectively 0
throughout 0
pregnancy 0
. 0

Twenty-three 0
patients 0
were 0
followed 0
in 0
a 0
protocol 0
of 0
intensified 0
prenatal 0
care 0
and 0
randomized 0
assignment 0
of 0
antihypertensive 0
agents 0
: 0
placebo 0
, 0
hydralazine 0
, 0
or 0
methyldopa 0
. 0

Forty 0
patients 0
were 0
followed 0
in 0
the 0
high-risk 0
pregnancy 0
clinics 0
at 0
Duke 0
University 0
. 0

The 0
incidence 0
of 0
preeclampsia B-PHYSICAL
in 0
the 0
randomized 0
prophylactic 0
antihypertensive 0
group 0
was 0
statistically 0
lower 0
than 0
that 0
in 0
the 0
nonrandomized 0
group 0
( 0
8.7 0
versus 0
32.5 0
% 0
; 0
P 0
less 0
than 0
.01 0
) 0
. 0

There 0
were 0
no 0
other 0
statistically 0
significant 0
differences B-OTHER
between 0
the 0
groups 0
. 0

The 0
63 0
hypertensive 0
women 0
had 0
a 0
high 0
incidence 0
of 0
diabetes B-PHYSICAL
mellitus I-PHYSICAL
diagnosed 0
during 0
pregnancy 0
( 0
49.2 0
% 0
) 0
as 0
compared 0
to 0
the 0
authors 0
' 0
general 0
obstetric 0
population 0
( 0
8.1 0
% 0
) 0
. 0

The 0
efficacy 0
of 0
audiotapes 0
in 0
promoting B-MENTAL
psychological I-MENTAL
well-being I-MENTAL
in 0
cancer 0
patients 0
: 0
a 0
randomised 0
, 0
controlled 0
trial 0
. 0

Open 0
or 0
uncontrolled 0
studies 0
have 0
suggested 0
that 0
providing 0
cancer 0
patients 0
with 0
audiotapes 0
of 0
their 0
clinical 0
interviews 0
can 0
improve 0
information 0
recall B-MENTAL
and 0
reduce 0
psychological B-MENTAL
distress I-MENTAL
. 0

We 0
tested 0
these 0
hypotheses 0
in 0
a 0
'clinician-blind 0
' 0
, 0
prospective 0
, 0
randomised 0
controlled 0
trial 0
. 0

A 0
total 0
of 0
117 0
patients 0
newly 0
referred 0
to 0
a 0
medical 0
oncology 0
clinic 0
who 0
were 0
to 0
be 0
given 0
'bad 0
news 0
' 0
had 0
their 0
consultations 0
audiotaped 0
. 0

Blind 0
to 0
the 0
clinician 0
, 0
patients 0
were 0
randomly 0
allocated 0
to 0
receive 0
a 0
copy 0
of 0
the 0
tape 0
to 0
play 0
at 0
home 0
or 0
not 0
( 0
control 0
group 0
) 0
. 0

At 0
6 0
months 0
follow-up 0
, 0
tape 0
group 0
patients 0
reported 0
positive 0
attitudes B-MENTAL
to 0
the 0
audiotape 0
and 0
were 0
shown 0
to 0
recall B-MENTAL
significantly I-MENTAL
more I-MENTAL
information 0
about B-MENTAL
their I-MENTAL
illness B-MENTAL
than 0
did 0
controls 0
. 0

Overall 0
improvement 0
in 0
psychological B-MENTAL
distress I-MENTAL
at 0
1 0
and 0
6 0
months 0
follow-up 0
, 0
as 0
measured 0
with 0
the 0
30-item B-MENTAL
General I-MENTAL
Health B-MENTAL
Questionnaire 0
and B-MENTAL
the I-MENTAL

Efficacy 0
of 0
topical 0
azithromycin 0
ophthalmic 0
solution 0
1 0
% 0
in 0
the 0
treatment 0
of 0
posterior 0
blepharitis 0
. 0

INTRODUCTION 0
Azithromycin 0
, 0
a 0
broad-spectrum 0
antibiotic 0
with 0
potent 0
anti-inflammatory 0
activities 0
, 0
has 0
the 0
potential 0
to 0
effectively 0
treat 0
blepharitis B-PHYSICAL
, 0
an 0
inflammatory 0
disease 0
of 0
the 0
eyelid 0
with 0
abnormal 0
eyelid 0
flora 0
as 0
an 0
etiologic 0
determinant 0
. 0

The 0
present 0
study 0
compared 0
the 0
efficacy 0
of 0
topical 0
azithromycin 0
ophthalmic 0
solution 0
1 0
% 0
( 0
AzaSite 0
; 0
Inspire 0
Pharmaceuticals 0
, 0
Inc 0
, 0
NC 0
, 0
USA 0
) 0
combined 0
with 0
warm 0
compresses 0
( 0
azithromycin 0
group 0
) 0
to 0
warm 0
compresses 0
alone 0
( 0
compress 0
group 0
) 0
in 0
patients 0
with 0
posterior 0
blepharitis 0
. 0

METHODS 0
Twenty-one 0
patients 0
diagnosed 0
with 0
posterior 0
blepharitis 0
were 0
randomized 0
in 0
an 0
open-label 0
study 0
to 0
receive 0
either 0
azithromycin 0
plus 0
warm 0
compresses 0
( 0
10 0
patients 0
) 0
, 0
or 0
compresses 0
alone 0
( 0
11 0
patients 0
) 0
. 0

All 0
patients 0
were 0
instructed 0
to 0
apply 0
compresses 0
to 0
each 0
eye 0
for 0
5-10 0
minutes 0
twice 0
daily 0
for 0
14 0
days 0
. 0

Each 0
eye 0
in 0
the 0
azithromycin 0
group 0
also 0
received 0
azithromycin 0
solution 0
( 0
1 0
drop 0
) 0
twice 0
daily 0
for 0
the 0
first 0
2 0
days 0
followed 0
by 0
once 0
daily 0
for 0
the 0
next 0
12 0
days 0
. 0

Patients 0
were 0
evaluated 0
at 0
study 0
initiation 0
( 0
visit 0
1 0
) 0
and 0
at 0
end 0
of 0
treatment 0
( 0
visit 0
2 0
) 0
for 0
the 0
severity 0
of 0
five 0
clinical 0
signs 0
: 0
eyelid B-PHYSICAL
debris I-PHYSICAL
, 0
eyelid B-PHYSICAL
redness I-PHYSICAL
, 0
eyelid B-PHYSICAL
swelling I-PHYSICAL
, 0
meibomian B-PHYSICAL
gland I-PHYSICAL
( 0
MG B-PHYSICAL
) 0
plugging B-PHYSICAL
, 0
and 0
the 0
quality 0
of 0
MG B-PHYSICAL
secretion I-PHYSICAL
. 0

At 0
visit 0
2 0
, 0
patients 0
also 0
rated 0
their 0
degree 0
of 0
overall B-OTHER
symptomatic I-OTHER
relief B-OTHER
. 0

RESULTS 0
Twenty 0
patients 0
completed 0
the 0
study 0
. 0

At 0
visit 0
2 0
, 0
patients 0
in 0
the 0
azithromycin 0
group 0
demonstrated 0
significant B-MENTAL
improvements I-MENTAL
in 0
MG B-PHYSICAL
plugging I-PHYSICAL
, 0
MG B-PHYSICAL
secretions I-PHYSICAL
, 0
and 0
eyelid B-PHYSICAL
redness I-PHYSICAL
as 0
compared 0
with 0
the 0
compress 0
group 0
. 0

In 0
the 0
azithromycin 0
group 0
, 0
MG B-PHYSICAL
plugging I-PHYSICAL
resolved 0
completely 0
in 0
three 0
patients 0
and 0
MG B-PHYSICAL
secretion I-PHYSICAL
returned I-PHYSICAL
to I-PHYSICAL
normal I-PHYSICAL
in 0
two 0
patients 0
; 0
no 0
such 0
results 0
were 0
seen 0
in 0
the 0
compress 0
group 0
. 0

Furthermore 0
, 0
a 0
higher 0
percentage 0
of 0
patients 0
in 0
the 0
azithromycin 0
group 0
rated 0
overall B-PHYSICAL
symptomatic I-PHYSICAL
relief I-PHYSICAL
as 0
excellent 0
or 0
good 0
. 0

Visual B-OTHER
acuity I-OTHER
measurements I-OTHER

Naltrexone 0
in 0
autistic 0
children 0
: 0
a 0
double-blind 0
and 0
placebo-controlled 0
study 0
. 0

A 0
double-blind 0
, 0
placebo-controlled 0
study 0
was 0
designed 0
to 0
assess 0
critically 0
the 0
effects 0
of 0
naltrexone 0
on 0
behavioral B-MENTAL
symptoms I-MENTAL
and 0
learning B-MENTAL
in 0
autistic 0
children 0
, 0
and 0
its 0
safety 0
. 0

This 0
is 0
a 0
preliminary 0
report 0
on 0
18 0
children 0
, 0
ages 0
3.08 0
to 0
7.99 0
years 0
, 0
who 0
completed 0
this 0
ongoing 0
study 0
. 0

Subjects 0
were 0
randomly 0
assigned 0
to 0
naltrexone 0
or 0
placebo 0
and 0
received 0
daily 0
doses 0
over 0
a 0
period 0
of 0
21 0
days 0
. 0

Naltrexone 0
was 0
superior 0
to 0
placebo 0
according 0
to 0
blind 0
Clinical B-MENTAL
Global I-MENTAL
Consensus I-MENTAL
Ratings I-MENTAL
( 0
unpublished 0
scale 0
) 0
. 0

However 0
, 0
other 0
behavioral 0
rating 0
measures 0
did 0
not 0
confirm 0
this 0
result 0
. 0

There 0
was 0
only 0
a 0
suggestion 0
that 0
naltrexone 0
reduced 0
fidgety B-MENTAL
and I-MENTAL
hyperactive I-MENTAL
behavior I-MENTAL
and 0
tended 0
to 0
alleviate 0
overall B-MENTAL
symptomatology I-MENTAL
in 0
older 0
children 0
. 0

Naltrexone 0
did 0
not 0
appear 0
to 0
affect 0
discrimination B-MENTAL
learning I-MENTAL
. 0

Results 0
are 0
preliminary 0
and 0
, 0
owing 0
to 0
the 0
small 0
sample 0
size 0
, 0
can 0
be 0
considered 0
only 0
suggestive 0
until 0
this 0
study 0
is 0
completed 0
or 0
replication 0
is 0
obtained 0
from 0
independent 0
research 0
. 0

[ 0
How 0
to 0
treat 0
the 0
relapse B-PHYSICAL
of I-PHYSICAL
NSCLC I-PHYSICAL
after 0
surgery 0
and 0
chemotherapy 0
? 0

IFTC 0
0702 0
randomized 0
phase 0
III 0
study 0
] 0
. 0

BACKGROUND 0
As 0
chemotherapy 0
gains 0
wider 0
acceptance 0
for 0
the 0
treatment 0
of 0
earlier 0
stages 0
of 0
NSCLC 0
, 0
particularly 0
in 0
the 0
adjuvant 0
and 0
neoadjuvant 0
setting 0
, 0
physicians 0
face 0
a 0
growing 0
population 0
of 0
high 0
performance 0
status 0
patients 0
who 0
have 0
relapsed 0
after 0
their 0
first-line 0
chemotherapy 0
. 0

The 0
type 0
of 0
second-line 0
chemotherapy 0
after 0
initial 0
adjuvant 0
or 0
neoadjuvant 0
treatment 0
with 0
a 0
platinum-based 0
regimen 0
remains 0
largely 0
undefined 0
. 0

The 0
current 0
study 0
has 0
been 0
designed 0
to 0
compare 0
the 0
classical 0
mono 0
chemotherapy 0
docetaxel 0
with 0
a 0
docetaxel 0
cisplatin 0
doublet 0
. 0

METHODS 0
Patients 0
will 0
be 0
randomized 0
in 0
2 0
arms 0
. 0

Arm 0
: 0
docetaxel 0
cisplatin 0
( 0
cycles 0
repeated 0
every 0
21 0
days 0
) 0
, 0
4 0
cycles 0
followed 0
by 0
2 0
cycles 0
of 0
docetaxel 0
alone 0
in 0
case 0
of 0
objective B-PHYSICAL
response I-PHYSICAL
or 0
stabilisation 0
. 0

Arm 0
B 0
: 0
docetaxel 0
alone 0
( 0
cycles 0
repeated 0
every 0
21 0
days 0
) 0
, 0
4 0
cycles 0
followed 0
by 0
2 0
cycles 0
of 0
docetaxel 0
alone 0
in 0
case 0
of 0
objective 0
response 0
or 0
stabilisation 0
. 0

EXPECTED 0
RESULTS 0
300 0
patients 0
will 0
be 0
randomized 0
with 0
a 0
statistical 0
hypothesis 0
of 0
a 0
progression B-MORTALITY
free I-MORTALITY
survival I-MORTALITY
of 0
3 0
months 0
in 0
the 0
control 0
arm 0
and 0
of 0
4.5 0
months 0
in 0
the 0
experimental 0
arm 0
. 0

National 0
Surgical 0
Adjuvant 0
Breast 0
and 0
Bowel 0
Project 0
's 0
Breast 0
Cancer 0
Prevention 0
Trial 0
. 0

The 0
Breast 0
Cancer 0
Prevention 0
Trial 0
is 0
the 0
largest 0
breast 0
cancer 0
prevention 0
study 0
ever 0
undertaken 0
. 0

Administered 0
by 0
the 0
National 0
Surgical 0
Adjuvant 0
Breast 0
and 0
Bowel 0
Project 0
, 0
it 0
is 0
the 0
first 0
trial 0
seeking 0
to 0
demonstrate 0
whether 0
a 0
drug 0
, 0
tamoxifen 0
, 0
can 0
prevent 0
breast 0
cancer 0
in 0
high-risk 0
women 0
. 0

The 0
objectives 0
of 0
this 0
trial 0
are 0
to 0
determine 0
whether 0
tamoxifen 0
is 0
effective 0
in 0
1 0
) 0
reducing B-PHYSICAL
the I-PHYSICAL
incidence 0
of B-PHYSICAL
invasive I-PHYSICAL
breast I-PHYSICAL
cancer B-PHYSICAL
, 0
2 0
) 0
reducing 0
breast B-MORTALITY
cancer I-MORTALITY
mortality I-MORTALITY
, 0
3 0
) 0
reducing B-MORTALITY
deaths I-MORTALITY
from I-MORTALITY
cardiovascular B-MORTALITY

Tinidazole 0
and 0
metronidazole 0
in 0
hepatic 0
amoebiasis 0
. 0

The 0
efficacy 0
of 0
metronidazole 0
and 0
tinidazole 0
has 0
been 0
compared 0
in 0
31 0
patients 0
with 0
hepatic 0
amoebiasis 0
. 0

Only 0
those 0
with 0
unequivocal 0
clinical 0
, 0
radiological 0
and 0
laboratory 0
evidence 0
of 0
hepatic 0
amoebiasis 0
were 0
included 0
; 0
diagnostic 0
and 0
therapeutic 0
aspiration 0
was 0
performed 0
where 0
necessary 0
. 0

15 0
patients 0
received 0
metronidazole 0
and 0
16 0
tinidazole 0
, 0
in 0
random 0
order 0
. 0

The 0
2 0
groups 0
were 0
comparable 0
. 0

Both 0
drugs 0
were 0
given 0
orally 0
in 0
a 0
single 0
daily 0
dose 0
of 0
2g 0
for 0
a 0
minimum 0
of 0
3 0
days 0
, 0
with 0
treatment 0
extended 0
if 0
considered 0
clinically 0
advisable 0
. 0

12 0
of 0
15 0
patients 0
( 0
80 0
% 0
) 0
were 0
cured B-PHYSICAL
with 0
metronidazole 0
given 0
for 0
an 0
average 0
period 0
of 0
7 0
days 0
( 0
range 0
4 0
to 0
14 0
days 0
) 0
. 0

15 0
of 0
16 0
patients 0
( 0
93.8 0
% 0
) 0
given 0
tinidazole 0
were 0
cured B-PHYSICAL
and 0
the 0
mean 0
duration B-OTHER
of I-OTHER
treatment I-OTHER
was 0
4 0
days 0
( 0
range 0
3 0
to 0
6 0
days 0
) 0
. 0

There 0
were 0
fewer B-ADVERSE-EFFECTS
side-effects I-ADVERSE-EFFECTS
with 0
tinidazole 0
. 0

In 0
this 0
study 0
of 0
hepatic 0
amoebiasis 0
in 0
Bangladesh 0
, 0
tinidazole 0
was 0
found 0
to 0
be 0
superior 0
to 0
metronidazole 0
in 0
overall B-OTHER
efficacy I-OTHER
because 0
a 0
shorter 0
course 0
of 0
treatment 0
was 0
necessary 0
and 0
it 0
caused 0
fewer 0
side-effects B-ADVERSE-EFFECTS
. 0

Lung 0
function 0
and 0
respiratory 0
symptoms 0
in 0
a 0
1-year 0
randomized 0
smoking 0
cessation 0
trial 0
of 0
varenicline 0
in 0
COPD 0
patients 0
. 0

UNLABELLED 0
There 0
are 0
few 0
data 0
concerning 0
changes 0
in 0
lung 0
function 0
and 0
respiratory 0
symptoms 0
in 0
smokers 0
with 0
chronic 0
obstructive 0
pulmonary 0
disease 0
( 0
COPD 0
) 0
weeks 0
to 0
months 0
after 0
quitting 0
smoking 0
. 0

We 0
examined 0
serial 0
changes 0
in 0
spirometry 0
and 0
Clinical 0
COPD 0
Questionnaire 0
( 0
CCQ 0
) 0
scores 0
( 0
measuring 0
respiratory 0
symptoms 0
and 0
health-related 0
quality 0
of 0
life 0
) 0
in 0
COPD 0
participants 0
by 0
smoking 0
status 0
during 0
a 0
smoking 0
cessation 0
trial 0
. 0

In 0
this 0
randomized 0
, 0
double-blind 0
trial 0
, 0
smokers 0
with 0
mild-to-moderate 0
COPD 0
were 0
treated 0
with 0
varenicline 0
1 0
mg 0
b.i.d 0
. 0

or 0
placebo 0
for 0
12 0
weeks 0
and 0
followed 0
to 0
Week 0
52 0
. 0

Primary 0
endpoints 0
of 0
abstinence B-MENTAL
were 0
previously 0
reported 0
. 0

Secondary 0
endpoints 0
were 0
mean 0
changes B-OTHER
from I-OTHER
baseline I-OTHER
in 0
post-bronchodilator B-PHYSICAL
forced I-PHYSICAL
expired I-PHYSICAL
volume I-PHYSICAL
in I-PHYSICAL
1 I-PHYSICAL
s I-PHYSICAL
( 0
FEV B-PHYSICAL
( 0
1 B-PHYSICAL
) 0
) 0
and 0
CCQ B-PHYSICAL
scores I-PHYSICAL
. 0

Change B-OTHER
from I-OTHER
baseline I-OTHER
in 0
post-bronchodilator 0
FEV B-PHYSICAL
( I-PHYSICAL
1 I-PHYSICAL
) 0
was 0
significantly 0
improved 0
in 0
continuous 0
abstainers 0
( 0
121.8 0
mL 0
) 0
vs. 0
continuous 0
smokers 0
( 0
37.9 0
mL 0
) 0
at 0
Week 0
12 0
( 0
P 0
= 0
0.0069 0
) 0
, 0
but 0
not 0
at 0
Weeks 0
24 0
or 0
52 0
. 0

Mean 0
change 0
from 0
baseline 0
at B-OTHER
Week I-OTHER
12 I-OTHER
in 0
CCQ B-PHYSICAL
Total 0
Score B-PHYSICAL
was 0
significantly 0
better 0
in 0
continuous 0
abstainers 0
( 0
-1.04 0
) 0
vs. 0
continuous 0
smokers 0
( 0
-0.53 0
; 0
P 0
< 0
0.0001 0
) 0
: 0
this 0
improvement 0
was 0
sustained 0
at 0
Weeks 0
24 0
and 0
52 0
. 0

In 0
a 0
1-year 0
cessation 0
trial 0
of 0
smokers 0
with 0
COPD 0
, 0
continuous B-MENTAL
abstinence B-MENTAL
compared 0
with 0
continuous 0
smoking 0
significantly 0
improved 0

[ 0
Prevention 0
of 0
migraine B-MENTAL
with 0
flunarizine 0
and 0
acetylsalicylic 0
acid 0
. 0

A 0
double-blind 0
study 0
] 0
. 0

UNLABELLED 0
30 0
children 0
between 0
7 0
and 0
17 0
years 0
suffering 0
from 0
at 0
least 0
2 0
attacks/month 0
of 0
common 0
or 0
classical 0
migraine 0
since 0
more 0
than 0
1 0
year 0
were 0
studied 0
. 0

After 0
clinical 0
exclusion 0
of 0
symptomatic 0
headache 0
4 0
weeks 0
were 0
documented 0
by 0
means 0
of 0
a 0
migraine 0
diary 0
. 0

Prophylaxis 0
with 0
Calcium 0
entry 0
blocker 0
Flunarizine 0
( 0
Sibelium 0
) 0
or 0
Thromboxane 0
A 0
inhibitor 0
Acetylsalicylic 0
acid 0
( 0
ASS 0
) 0
was 0
carried 0
out 0
in 0
a 0
double 0
blind 0
design 0
for 0
3 0
months 0
. 0

Medication 0
was 0
given 0
as 0
one 0
dosage 0
in 0
the 0
evening 0
: 0
2-5 0
mg/kg 0
KG 0
ASS 0
or 0
5-10 0
mg 0
Flunarizine 0
. 0

Documented 0
attack B-PHYSICAL
frequency 0
and 0
duration B-PHYSICAL
were 0
controlled 0
at 0
monthly 0
physical 0
examinations 0
. 0

Final 0
results 0
showed 0
no 0
differences 0
in 0
significant 0
reduction 0
of 0
attack B-PHYSICAL
frequency 0
or 0
symptoms B-PHYSICAL
between 0
both 0
different 0
therapeutic 0
principals 0
. 0

72.4 0
% 0
( 0
ASS 0
73.3 0
% 0
; 0
Flunarizine 0
71.4 0
% 0
) 0
of 0
patients 0
were 0
attack-free 0
or 0
had 0
at 0
least 0
a 0
50 0
% 0
reduction 0
. 0

Migraine B-PHYSICAL
frequency I-PHYSICAL
of 0
initially 0
7-8 0
was 0
reduced 0
to 0
1-2 0
attacks/month 0
. 0

Duration B-PHYSICAL
remained 0
constant 0
in 0
both 0
groups 0
( 0
1-3 0
h 0
) 0
. 0

Side 0
effects 0
were 0
slight B-ADVERSE-EFFECTS
body I-ADVERSE-EFFECTS
weight 0
gain B-ADVERSE-EFFECTS
or 0

The 0
incidence 0
of 0
first-dose 0
hypotension 0
with 0
quinapril 0
in 0
patients 0
with 0
mild 0
to 0
moderate 0
hypertension 0
. 0

A 0
total 0
of 0
2242 0
patients 0
with 0
mild 0
to 0
moderate 0
hypertension 0
( 0
diastolic 0
pressure 0
95-120 0
mmHg 0
) 0
were 0
randomised 0
on 0
a 0
double-blind 0
basis 0
to 0
receive 0
a 0
single 0
dose 0
of 0
placebo 0
, 0
5 0
mg 0
quinapril 0
or 0
10 0
mg 0
quinapril 0
. 0

Patients 0
were 0
identified 0
who 0
: 0
( 0
a 0
) 0
met 0
the 0
blood B-PHYSICAL
pressure I-PHYSICAL
( 0
BP 0
) 0
criteria 0
for 0
first-dose 0
hypotension 0
( 0
sitting 0
or 0
standing 0
systolic 0
BP 0
< 0
100 0
mmHg 0
, 0
or 0
a 0
fall 0
in 0
systolic 0
BP 0
> 0
or 0
= 0
20 0
mmHg 0
on 0
standing 0
) 0
; 0
( 0
b 0
) 0
had 0
symptoms 0
suggestive 0
of 0
hypotension 0
; 0
and 0
( 0
c 0
) 0
met 0
the 0
BP 0
criteria 0
and 0
had 0
symptoms 0
. 0

In 0
all 0
three 0
classifications 0
there 0
were 0
no 0
statistically 0
significant 0
differences 0
between 0
the 0
incidences 0
in 0
placebo 0
and 0
combined 0
active 0
treatment 0
groups 0
, 0
or 0
between 0
those 0
in 0
the 0
two 0
quinapril 0
groups 0
. 0

No 0
associated 0
serious B-ADVERSE-EFFECTS
adverse I-ADVERSE-EFFECTS
events I-ADVERSE-EFFECTS
were 0
reported 0
. 0

In 0
the 0
low-risk 0
population 0
studied 0
, 0
it 0
would 0
appear 0
that 0
the 0
incidence 0
of 0
first-dose 0
hypotension 0
with 0
quinapril 0
is 0
similar 0
to 0
placebo 0
and 0
is 0
not 0
dose-related 0
. 0

Rapid-sequence 0
intubation 0
of 0
head 0
trauma 0
patients 0
: 0
prevention 0
of 0
fasciculations B-PHYSICAL
with 0
pancuronium 0
versus 0
minidose 0
succinylcholine 0
. 0

INTRODUCTION 0
Fasciculations B-PHYSICAL
during 0
rapid-sequence 0
intubation 0
may 0
lead 0
to 0
increased 0
intracranial 0
pressure 0
and 0
emesis B-PHYSICAL
with 0
aspiration 0
. 0

Standard 0
rapid-sequence 0
intubation 0
requires 0
a 0
nondepolarizing 0
blocking 0
agent 0
before 0
succinylcholine 0
administration 0
. 0

HYPOTHESIS 0
Prevention 0
of 0
fasciculations B-PHYSICAL
during 0
rapid-sequence 0
intubation 0
of 0
head 0
trauma 0
patients 0
can 0
be 0
accomplished 0
as 0
safely 0
and 0
effectively 0
with 0
minidose 0
succinylcholine 0
as 0
with 0
a 0
defasciculating 0
dose 0
of 0
pancuronium 0
. 0

DESIGN 0
A 0
prospective 0
, 0
randomized 0
, 0
double-blind 0
study 0
. 0

SETTING 0
An 0
inner-city 0
county 0
trauma 0
center 0
with 0
70,000 0
patient 0
visits 0
per 0
year 0
. 0

PARTICIPANTS 0
Sequential 0
adult 0
head 0
trauma 0
patients 0
requiring 0
rapid-sequence 0
intubation 0
who 0
had 0
no 0
contraindications 0
to 0
succinylcholine 0
or 0
pancuronium 0
. 0

INTERVENTIONS 0
Each 0
head 0
trauma 0
patient 0
requiring 0
rapid-sequence 0
intubation 0
who 0
met 0
the 0
inclusion 0
criteria 0
received 0
standard 0
rapid-sequence 0
intubation 0
maneuvers 0
and 0
lidocaine 0
( 0
1 0
mg/kg 0
) 0
IV 0
. 0

Patients 0
were 0
randomized 0
to 0
receive 0
either 0
minidose 0
succinylcholine 0
( 0
0.1 0
mg/kg 0
) 0
or 0
pancuronium 0
( 0
0.03 0
mg/kg 0
) 0
IV 0
one 0
minute 0
prior 0
to 0
the 0
full 0
paralytic 0
dose 0
of 0
succinylcholine 0
( 0
1.5 0
mg/kg 0
) 0
IV 0
. 0

Fasciculations B-PHYSICAL
were 0
recorded 0
using 0
a 0
graded B-OTHER
visual I-OTHER
scale I-OTHER
. 0

RESULTS 0
Of 0
46 0
patients 0
, 0
eight 0
of 0
19 0
( 0
42 0
% 0
) 0
in 0
the 0
pancuronium 0
group 0
and 0
six 0
of 0
27 0
( 0
22 0
% 0
) 0
in 0
the 0
succinylcholine 0
group 0
experienced 0
fasciculations B-PHYSICAL
. 0

No 0
statistically 0
significant 0
difference 0
in 0
fasciculations B-PHYSICAL
was 0
detected 0
between 0
the 0
two 0
groups 0
using 0
chi 0
2 0
analysis 0
. 0

Complete B-PHYSICAL
relaxation I-PHYSICAL
of I-PHYSICAL
the I-PHYSICAL
cords I-PHYSICAL
was 0
present 0
in 0
all 0
but 0
two 0
patients 0
, 0
one 0
in 0
each 0
group 0
. 0

No 0
patient 0
in 0
either 0
group 0
experienced 0
emesis B-PHYSICAL
or 0
significant B-PHYSICAL
dysrhythmias I-PHYSICAL
. 0

CONCLUSION 0
Pretreatment 0
with 0
minidose 0
succinylcholine 0
causes 0
no 0
greater 0
incidence 0
of 0
fasciculations B-PHYSICAL
than 0
pancuronium 0
in 0
rapid-sequence 0
intubation 0
of 0
head 0
trauma 0
patients 0
in 0
an 0
ED 0
setting 0
. 0

Thus 0
succinylcholine 0
may 0
be 0
used 0
as 0
the 0
sole 0
paralytic 0
agent 0
in 0
rapid-sequence 0
intubation 0
of 0
head 0
trauma 0
patients 0
. 0

In 0
vitro 0
determination 0
of 0
the 0
chromatic B-OTHER
effect 0
of 0
a 0
silver 0
nanoparticles 0
solution 0
linked 0
to 0
the 0
gantrez 0
S-97 0
copolymer 0
on 0
tooth 0
enamel 0
. 0

Silver 0
nanoparticles 0
( 0
NNPs 0
) 0
, 0
alone 0
or 0
in 0
combination 0
with 0
the 0
bioadhesive 0
Gantrez 0
S-97 0
, 0
have 0
demonstrated 0
their 0
efficacy 0
against 0
Streptococcus 0
mutans 0
; 0
however 0
, 0
it 0
is 0
not 0
known 0
if 0
this 0
combination 0
changes 0
the 0
color B-OTHER
of I-OTHER
teeth I-OTHER
. 0

The 0
aim 0
of 0
this 0
work 0
was 0
to 0
measure 0
the 0
color B-OTHER
changes I-OTHER
occurring 0
after 0
the 0
use 0
of 0
a 0
Gantrez-NNP 0
combination 0
on 0
enamel 0
tooth 0
blocks 0
. 0

Two 0
study 0
groups 0
were 0
randomly 0
formed 0
: 0
enamel 0
blocks 0
brushed 0
with 0
( 0
a 0
) 0
the 0
Gantrez-NNP 0
combination 0
and 0
( 0
b 0
) 0
conventional 0
toothpaste 0
, 0
for 0
1 0
minute 0
once 0
daily 0
for 0
4 0
weeks 0
, 0
then 0
rinsed 0
with 0
distilled 0
water 0
and 0
placed 0
in 0
thymol 0
solution 0
. 0

Color B-OTHER
changes I-OTHER
in I-OTHER
the I-OTHER
enamel I-OTHER
blocks I-OTHER
were 0
measured 0
using 0
a 0
Minolta B-OTHER
colorimeter I-OTHER
CR300 I-OTHER
. 0

Analysis 0
of 0
mixed 0
models 0
was 0
performed 0
with 0
R 0
2.10.1 0
at 0
a 0
95 0
% 0
confidence 0
level 0
, 0
using 0
the 0
nonlinear 0
mixed 0
effects 0
( 0
NLME 0
) 0
package 0
. 0

The 0
results 0
showed 0
that 0
there 0
were 0
no 0
color B-OTHER
changes I-OTHER
over I-OTHER
time I-OTHER
, 0
only 0
a 0
high B-PHYSICAL
luminosity I-PHYSICAL
equal I-PHYSICAL
in 0
both 0
groups 0
. 0

Our 0
study 0
showed 0
that 0
the 0
use 0
of 0
the 0
Gantrez-NNP 0
combination 0
is 0
safe B-OTHER
with 0
respect 0
to 0
dental B-OTHER
esthetics I-OTHER
in 0
the 0
control 0
of 0
S. 0
mutans B-OTHER
. 0

Central 0
nervous 0
system 0
serotonin 0
function 0
and 0
cardiovascular B-PHYSICAL
responses I-PHYSICAL
to 0
stress 0
. 0

OBJECTIVE 0
The 0
objective 0
of 0
this 0
study 0
was 0
to 0
evaluate 0
the 0
impact 0
of 0
indices 0
of 0
central 0
nervous 0
system 0
( 0
CNS 0
) 0
serotonin 0
function 0
on 0
cardiovascular B-PHYSICAL
reactivity I-PHYSICAL
to 0
mental 0
stress 0
. 0

METHODS 0
Lumbar 0
puncture 0
was 0
performed 0
on 0
54 0
healthy 0
volunteers 0
to 0
obtain 0
cerebrospinal 0
fluid 0
( 0
CSF 0
) 0
for 0
determination 0
of 0
5-hydroxyindoleacetic 0
acid 0
( 0
5HIAA 0
) 0
levels 0
. 0

Genotypes 0
were 0
determined 0
with 0
respect 0
to 0
a 0
functional 0
polymorphism 0
of 0
the 0
serotonin 0
transporter 0
gene 0
promoter 0
region 0
( 0
5HTTLPR 0
) 0
. 0

Subjects 0
then 0
underwent 0
mental 0
stress 0
testing 0
. 0

RESULTS 0
Persons 0
with 0
one 0
or 0
two 0
long 0
( 0
l 0
) 0
5HTTLPR 0
alleles 0
had 0
CSF B-PHYSICAL
levels I-PHYSICAL
of 0
the 0
major 0
serotonin 0
metabolite 0
, 0
5HIAA 0
, 0
that 0
were 0
50 0
% 0
higher 0
than 0
those 0
of 0
persons 0
with 0
the 0
s/s 0
5HTTLPR 0
genotype 0
. 0

Persons 0
with 0
one 0
or 0
two 0
l 0
alleles 0
or 0
higher 0
CSF B-PHYSICAL
5HIAA I-PHYSICAL
levels I-PHYSICAL
also 0
exhibited 0
greater 0
blood B-PHYSICAL
pressure I-PHYSICAL
and 0
heart B-PHYSICAL
rate I-PHYSICAL
responses I-PHYSICAL
to 0
a 0
mental 0
stress 0
protocol 0
. 0

CONCLUSIONS 0
These 0
findings 0
suggest 0
the 0
5HTTLPR 0
polymorphism 0
affects 0
CNS 0
serotonin 0
function 0
, 0
and 0
they 0
are 0
consistent 0
with 0
the 0
general 0
hypothesis 0
that 0
CNS 0
serotonin 0
function 0
is 0
involved 0
in 0
the 0
regulation 0
of 0
potentially 0
health-damaging 0
biobehavioral 0
characteristics 0
. 0

In 0
particular 0
, 0
the 0
l 0
allele 0
could 0
contribute 0
, 0
through 0
its 0
association 0
with 0
increased 0
cardiovascular B-PHYSICAL
reactivity I-PHYSICAL
to 0
stress 0
, 0
to 0
increased 0
risk 0
of 0
cardiovascular 0
disease 0
. 0

[ 0
Mitoxantrone 0
( 0
MTX 0
) 0
versus 0
mitomycin 0
C 0
( 0
MMC 0
) 0
in 0
the 0
ablative 0
treatment 0
of 0
Ta 0
, 0
T1 0
superficial 0
bladder 0
tumors 0
. 0

Phase 0
III 0
, 0
randomized 0
prospective 0
study 0
] 0
. 0

A 0
prospective 0
randomized 0
study 0
was 0
conducted 0
to 0
determine 0
the 0
ablation B-PHYSICAL
capacity I-PHYSICAL
of 0
mitoxantrone 0
in 0
Ta-T1 0
superficial 0
bladder 0
tumors 0
versus 0
mitomycin 0
C 0
, 0
a 0
drug 0
whose 0
intravesical 0
ablation 0
properties 0
are 0
well-known 0
. 0

Fifty-seven 0
patients 0
comprised 0
the 0
study 0
. 0

The 0
tumor 0
was 0
not 0
completely 0
resected 0
when 0
the 0
patient 0
underwent 0
TUR 0
. 0

This 0
residual 0
tumor 0
was 0
used 0
as 0
control 0
. 0

The 0
patients 0
were 0
treated 0
with 0
either 0
20 0
mg 0
Mitoxantrone 0
or 0
40 0
mg 0
mitomycin 0
C 0
weekly 0
for 0
8 0
weeks 0
and 0
two 0
other 0
instillations 0
every 0
15 0
days 0
in 0
50 0
ml 0
saline 0
solution 0
. 0

Response 0
to 0
therapy B-OTHER
was 0
evaluated 0
between 0
the 0
4th 0
and 0
8th 0
week 0
and 0
classified 0
as 0
complete B-OTHER
response 0
( B-OTHER
CR I-OTHER
) B-OTHER
, 0
defined 0
as 0
no 0
gross B-PHYSICAL
and 0
microscopic B-PHYSICAL
evidence I-PHYSICAL
of B-PHYSICAL
residual 0
tumor B-PHYSICAL
, 0
or 0
no 0
response 0
( B-OTHER
NR I-OTHER

The 0
influence 0
of 0
sequential 0
annual 0
vaccination 0
and 0
of 0
DHEA 0
administration 0
on 0
the 0
efficacy 0
of 0
the 0
immune 0
response 0
to 0
influenza 0
vaccine 0
in 0
the 0
elderly 0
. 0

The 0
present 0
study 0
examined 0
the 0
effect 0
of 0
repeated 0
vaccination 0
and 0
of 0
dehydroepiandrosterone 0
( 0
DHEA 0
) 0
treatment 0
on 0
the 0
immune 0
response 0
to 0
influenza 0
vaccine 0
in 0
elderly 0
subjects 0
. 0

Seventy-one 0
elderly 0
volunteers 0
, 0
aged 0
61-89 0
years 0
, 0
enrolled 0
in 0
a 0
prospective 0
randomized 0
, 0
double-blind 0
study 0
to 0
receive 0
either 0
DHEA 0
( 0
50 0
mg 0
qd 0
p.o 0
. 0

for 0
4 0
consecutive 0
days 0
starting 0
2 0
days 0
before 0
immunization 0
) 0
or 0
placebo 0
. 0

Antibody 0
response 0
against 0
the 0
three 0
strains 0
of 0
vaccine 0
was 0
measured 0
before 0
and 0
28 0
days 0
after 0
vaccination 0
, 0
and 0
compared 0
between 0
previously 0
vaccinated 0
and 0
non-vaccinated 0
subjects 0
. 0

DHEA 0
treatment 0
did 0
not 0
enhance 0
established B-PHYSICAL
immunity I-PHYSICAL
. 0

A 0
significant 0
decrease 0
in 0
attainment 0
of 0
protective B-OTHER
antibody I-OTHER
titer I-OTHER
( 0
titer 0
of 0
1:40 0
or 0
greater 0
) 0
against 0
A/Texas 0
in 0
subjects 0
with 0
non-protective 0
baseline 0
antibody 0
titer 0
was 0
recorded 0
following 0
DHEA 0
treatment 0
compared 0
to 0
placebo 0
( 0
52 0
vs. 0
84 0
% 0
, 0
P 0
< 0
0.05 0
) 0
. 0

Post-immunization B-OTHER
titers I-OTHER
against 0
influenza 0
A 0
strains 0
were 0
significantly 0
higher 0
in 0
those 0
subjects 0
who 0
were 0
never 0
immunized 0
before 0
. 0

Additionally 0
, 0
post-vaccination B-OTHER
protective I-OTHER
titers I-OTHER
against 0
the 0
A/Johannesburg 0
strain 0
were 0
more 0
prevalent 0
in 0
those 0
subjects 0
who 0
were 0
never 0
vaccinated 0
before 0
. 0

The 0
results 0
were 0
not 0
the 0
same 0
for 0
anti-B/Harbin 0
antibodies-repeated 0
vaccination 0
caused 0
a 0
non-significant 0
increase 0
in 0
HI 0
titer 0
in 0
previously 0
vaccinated 0
subjects 0
. 0

Levosulpiride 0
in 0
functional 0
dyspepsia 0
: 0
a 0
multicentric 0
, 0
double-blind 0
, 0
controlled 0
trial 0
. 0

Abnormalities 0
in 0
gastrointestinal 0
motility 0
have 0
been 0
reported 0
in 0
a 0
substantial 0
proportion 0
of 0
patients 0
with 0
functional 0
dyspepsia 0
, 0
supporting 0
the 0
use 0
of 0
prokinetic 0
drugs 0
for 0
treatment 0
of 0
dyspeptic 0
symptoms 0
. 0

To 0
evaluate 0
efficacy 0
and 0
safety 0
of 0
levosulpiride 0
in 0
short-term 0
treatment 0
, 0
1298 0
patients 0
were 0
enrolled 0
in 0
a 0
double-blind 0
multicentric 0
study 0
carried 0
out 0
in 0
45 0
Italian 0
Gastroenterology 0
Departments 0
. 0

Patients 0
were 0
randomly 0
assigned 0
to 0
either 0
levosulpiride 0
( 0
25 0
mg 0
tid 0
) 0
, 0
domperidone 0
( 0
10 0
mg 0
tid 0
) 0
, 0
metoclopramide 0
( 0
10 0
mg 0
tid 0
) 0
or 0
placebo 0
( 0
1 0
tablet 0
tid 0
) 0
for 0
4 0
weeks 0
. 0

Patients 0
were 0
selected 0
on 0
the 0
basis 0
of 0
: 0
a 0
) 0
occurrence 0
in 0
the 0
last 0
4 0
weeks 0
of 0
at 0
least 0
5/10 0
selected 0
symptoms 0
( 0
anorexia B-PHYSICAL
, I-PHYSICAL
nausea I-PHYSICAL
, I-PHYSICAL
vomiting I-PHYSICAL
, I-PHYSICAL
upper I-PHYSICAL
abdominal I-PHYSICAL
pain I-PHYSICAL
, I-PHYSICAL
postprandial I-PHYSICAL
bloating I-PHYSICAL
, I-PHYSICAL
abdominal I-PHYSICAL
fullness I-PHYSICAL
, I-PHYSICAL
early I-PHYSICAL
satiety I-PHYSICAL
, I-PHYSICAL
belching I-PHYSICAL
, I-PHYSICAL
heartburn I-PHYSICAL
, I-PHYSICAL
regurgitation I-PHYSICAL
) 0
, 0
severity 0
of 0
which 0
should 0
reach/exceed 0
a 0
total 0
score 0
of 0
8 0
, 0
as 0
assessed 0
by 0
a 0
specific 0
scale 0
ranging 0
from 0
0 0
( 0
absent 0
) 0
to 0
3 0
( 0
severe 0
) 0
; 0
b 0
) 0
normal 0
results 0
of 0
routine 0
biochemical 0
, 0
ultrasound 0
and 0
endoscopic 0
examinations 0
. 0

In 0
addition 0
, 0
each 0
patient 0
subjectively 0
evaluated 0
efficacy 0
of 0
treatment 0
by 0
a 0
visual 0
analogue 0
scale 0
. 0

Significant 0
improvement 0
was 0
recorded 0
for 0
all 0
symptoms 0
at 0
days 0
10 0
and 0
28 0
in 0
all 0
groups 0
( 0
p 0
< 0
0.001 0
) 0
, 0
but 0
levosulpiride 0
was 0
significantly 0
( 0
p 0
< 0
0.01 0
) 0
superior 0
to 0
domperidone 0
, 0
metoclopramide 0
and 0
placebo 0
both 0
in 0
the 0
overall 0
clinical 0
improvement 0
scale 0
as 0
well 0
as 0
in 0
a 0
subgroup 0
of 0
symptoms 0
( 0
postprandial B-PHYSICAL
bloating I-PHYSICAL
, 0
epigastric B-PAIN
pain I-PAIN
, 0
heartburn B-PHYSICAL
) 0
. 0

Active 0
treatments 0
and 0
placebo 0
were 0
comparable 0
as 0
far 0
as 0
concerns 0
occurrence 0
of 0
side-effects 0
( 0
12-20 0
% 0
) 0
including 0
galactorrhoea B-PHYSICAL
, 0
breast B-PHYSICAL
tenderness I-PHYSICAL
and 0
menstrual B-PHYSICAL
changes I-PHYSICAL
. 0

Testing 0
three 0
different 0
cancer 0
genetics 0
registry 0
recruitment 0
methods 0
with 0
Hispanic 0
cancer 0
patients 0
and 0
their 0
family 0
members 0
previously 0
registered 0
in 0
local 0
cancer 0
registries 0
in 0
Texas 0
. 0

OBJECTIVE 0
To 0
increase 0
accrual 0
among 0
Hispanics 0
to 0
the 0
Cancer 0
Genetics 0
Network 0
national 0
cancer 0
genetics 0
registry 0
. 0

METHODS 0
Drawing 0
from 0
South 0
Texas 0
cancer 0
registries 0
, 0
444 0
Hispanic 0
men 0
and 0
women 0
were 0
randomly 0
assigned 0
to 0
one 0
of 0
three 0
experimental 0
conditions 0
: 0
standard 0
direct-mailed 0
procedures 0
( 0
X1 0
) 0
, 0
X1 0
plus 0
culturally 0
tailored 0
materials 0
( 0
X2 0
) 0
, 0
and 0
X2 0
plus 0
interpersonal 0
phone 0
contact 0
( 0
X3 0
) 0
. 0

Participants 0
were 0
also 0
surveyed 0
about 0
the 0
effectiveness 0
of 0
the 0
education 0
materials 0
and 0
the 0
phone 0
contact 0
. 0

A 0
refusal 0
survey 0
was 0
provided 0
for 0
those 0
who 0
declined 0
to 0
join 0
the 0
study 0
. 0

RESULTS 0
A 0
total 0
of 0
154 0
individuals 0
joined 0
the 0
Cancer 0
Genetics 0
Network 0
. 0

The 0
X3 B-OTHER
condition I-OTHER
yielded I-OTHER
the I-OTHER
greatest I-OTHER
accrual I-OTHER
( 0
43.2 0
% 0
) 0
compared 0
to 0
X1 0
( 0
30.9 0
% 0
) 0
and 0
X2 0
( 0
29.9 0
% 0
; 0
p 0
< 0
0.05 0
) 0
. 0

Tailored 0
materials 0
appeared 0
to 0
have 0
no 0
effect 0
but 0
were 0
highly 0
regarded 0
. 0

The 0
main 0
reasons 0
for 0
not 0
participating 0
were 0
a 0
lack 0
of 0
interest 0
and 0
time 0
requirements 0
. 0

CONCLUSION 0
Interpersonal 0
communication 0
can 0
have 0
a 0
powerful 0
effect 0
on 0
recruitment 0
. 0

However 0
, 0
more 0
research 0
is 0
needed 0
to 0
determine 0
the 0
cost-efficacy 0
of 0
more 0
labor-intensive 0
approaches 0
to 0
registry 0
accrual 0
. 0

Dynamic 0
surface B-PHYSICAL
electromyographic I-PHYSICAL
responses I-PHYSICAL
in 0
chronic 0
low 0
back 0
pain 0
treated 0
by 0
traditional 0
bone 0
setting 0
and 0
conventional 0
physical 0
therapy 0
. 0

OBJECTIVE 0
This 0
study 0
compared 0
the 0
dynamic B-PHYSICAL
surface I-PHYSICAL
electromyographic I-PHYSICAL
( I-PHYSICAL
EMG I-PHYSICAL
) I-PHYSICAL
activities I-PHYSICAL
of 0
back 0
muscles 0
and 0
pain 0
before 0
and 0
after 0
traditional 0
bone 0
setting 0
and 0
physical 0
therapy 0
. 0

METHODS 0
This 0
study 0
was 0
a 0
prospective 0
clinical 0
trial 0
that 0
compared 0
surface B-PHYSICAL
EMG I-PHYSICAL
dynamic I-PHYSICAL
activities I-PHYSICAL
after 0
traditional 0
bone 0
setting 0
and 0
physical 0
therapy 0
. 0

Sixty-one 0
patients 0
( 0
mean 0
age 0
, 0
41 0
years 0
) 0
with 0
nonspecific 0
low 0
back 0
pain 0
were 0
randomized 0
into 0
two 0
subgroups 0
by 0
treatment 0
. 0

The 0
patients 0
underwent 0
a 0
dynamic B-PHYSICAL
EMG I-PHYSICAL
evaluation I-PHYSICAL
for 0
which 0
they 0
were 0
asked 0
to 0
stand 0
and 0
then 0
bend 0
forward 0
as 0
far 0
as 0
possible 0
, 0
stay 0
fully 0
flexed 0
, 0
and 0
return 0
to 0
standing 0
. 0

A 0
flexion-relaxation B-PHYSICAL
ratio I-PHYSICAL
was 0
calculated 0
by 0
comparing 0
maximal B-PHYSICAL
EMG I-PHYSICAL
activity I-PHYSICAL
while 0
flexing 0
with 0
the 0
average 0
EMG 0
activity 0
in 0
full 0
flexion 0
. 0

Concentric 0
( 0
maximal 0
EMG 0
activity 0
during 0
extension 0
) 0
and 0
eccentric 0
( 0
maximal 0
EMG 0
activity 0
during 0
flexion 0
) 0
ratios 0
were 0
also 0
used 0
in 0
the 0
analyses 0
. 0

RESULTS 0
Disability B-PHYSICAL
, 0
depression B-PHYSICAL
, 0
and 0
visual 0
analog 0
scale 0
scores 0
decreased 0
significantly 0
after 0
both 0
treatments 0
. 0

The 0
concentric B-PHYSICAL
ratio I-PHYSICAL
increased 0
statistically 0
in 0
both 0
groups 0
after 0
the 0
treatments 0
. 0

The 0
study 0
failed 0
to 0
show 0
a 0
significant 0
association 0
between 0
experienced 0
back 0
pain 0
and 0
EMG B-PHYSICAL
parameters I-PHYSICAL
. 0

CONCLUSIONS 0
Both 0
treatments 0
seem 0
to 0
have 0
a 0
positive 0
influence 0
on 0
back 0
muscle 0
function 0
by 0
improving 0
muscle B-PHYSICAL
symmetry 0
; 0
however 0
, 0
the 0
treatments 0
had 0
no 0
effect 0
on 0
the 0
flexion-relaxation B-PHYSICAL
phenomenon I-PHYSICAL
after 0
1 0
month 0
. 0

Active 0
back 0
exercise 0
at 0
home 0
together 0
with 0
rehabilitation 0
treatments 0
might 0
be 0
effective 0
and 0
improve 0
function 0
for 0
patients 0
with 0
chronic 0
low 0
back 0
pain 0
. 0

Use 0
of 0
an 0
Internet 0
portal 0
to 0
improve 0
community-based 0
pediatric 0
ADHD 0
care 0
: 0
a 0
cluster 0
randomized 0
trial 0
. 0

OBJECTIVE 0
To 0
determine 0
the 0
effectiveness 0
of 0
a 0
quality 0
improvement 0
program 0
to 0
improve 0
pediatricians 0
' 0
adherence 0
to 0
existing 0
, 0
evidence-based 0
, 0
attention-deficit/hyperactivity 0
disorder 0
( 0
ADHD 0
) 0
practice 0
guidelines 0
. 0

METHODS 0
Forty-nine 0
community-based 0
pediatricians 0
at 0
8 0
practices 0
participated 0
in 0
a 0
cluster-randomized 0
trial 0
. 0

Practices 0
were 0
matched 0
according 0
to 0
the 0
numbers 0
of 0
pediatricians 0
and 0
the 0
proportions 0
of 0
patients 0
receiving 0
Medicaid 0
. 0

The 0
medical 0
charts 0
for 0
a 0
random 0
sample 0
of 0
patients 0
with 0
ADHD 0
for 0
each 0
of 0
the 0
participating 0
pediatricians 0
were 0
examined 0
at 0
baseline 0
and 0
6 0
months 0
. 0

All 0
practices 0
participated 0
in 0
4 0
sessions 0
of 0
training 0
, 0
including 0
didactic 0
lectures 0
and 0
office 0
flow 0
modification 0
workshops 0
. 0

Practices 0
were 0
then 0
given 0
access 0
to 0
an 0
ADHD 0
Internet 0
portal 0
that 0
allowed 0
parents 0
, 0
teachers 0
, 0
and 0
pediatricians 0
to 0
input 0
information 0
( 0
eg 0
, 0
rating 0
scales 0
) 0
about 0
patients 0
, 0
after 0
which 0
information 0
was 0
scored 0
, 0
interpreted 0
, 0
and 0
formatted 0
in 0
a 0
report 0
style 0
that 0
was 0
helpful 0
for 0
assessment 0
and 0
treatment 0
of 0
patients 0
with 0
ADHD 0
. 0

Physicians 0
evaluated 0
their 0
practice B-MENTAL
behaviors I-MENTAL
quarterly 0
and 0
addressed 0
underperforming B-MENTAL
areas I-MENTAL
. 0

RESULTS 0
Pediatricians 0
in 0
the 0
intervention 0
group 0
, 0
compared 0
with 0
those 0
in 0
the 0
control 0
group 0
, 0
demonstrated 0
significantly 0
higher 0
rates 0
of 0
many 0
American 0
Academy 0
of 0
Pediatrics-recommended 0
ADHD 0
care 0
practices 0
, 0
including 0
collection B-MENTAL
of I-MENTAL
parent I-MENTAL
( 0
Cohen 0
's 0
d 0
= 0
0.69 0
) 0
and 0
teacher B-MENTAL
( 0
d 0
= 0
0.68 0
) 0
rating B-MENTAL
scales I-MENTAL
for 0
assessment 0
of 0
children 0
with 0
ADHD 0
, 0
use 0
of 0
Diagnostic 0
and 0
Statistical B-MENTAL
Manual I-MENTAL
of I-MENTAL
Mental I-MENTAL
Disorders I-MENTAL
, 0
Fourth 0
Edition 0
, 0
criteria 0
( 0
d 0
= 0
0.85 0
) 0
, 0
and 0
use 0
of 0
teacher B-MENTAL
rating I-MENTAL
scales I-MENTAL
to 0
monitor 0
treatment 0
responses 0
( 0
d 0
= 0
1.01 0
) 0
. 0

CONCLUSION 0
A 0
quality 0
improvement 0
intervention 0
that 0
can 0
be 0
widely 0
disseminated 0
by 0
using 0
Internet-based 0
information 0
technology 0
significantly 0
improved 0
the 0
quality 0
of 0
ADHD 0
care 0
in 0
community-based 0
pediatric 0
settings 0
. 0

Transcutaneous 0
electrical 0
nerve 0
stimulation 0
in 0
the 0
treatment 0
of 0
myofascial 0
pain 0
dysfunction 0
. 0

The 0
effect 0
of 0
transcutaneous 0
electrical 0
nerve 0
stimulation 0
( 0
TENS 0
) 0
plus 0
conservative 0
therapy 0
( 0
ibuprofen 0
, 0
bite 0
plate 0
, 0
self-physiotherapy 0
) 0
on 0
myofascial 0
pain 0
dysfunction 0
( 0
MPD 0
) 0
was 0
determined 0
. 0

A 0
single-blind 0
trial 0
as 0
done 0
in 0
10 0
patients 0
with 0
MPD 0
with 0
subthreshold 0
TENS 0
( 0
frequency 0
35 0
Hz 0
, 0
pulse 0
width 0
100 0
milliseconds 0
, 0
modulation 0
50 0
% 0
) 0
compared 0
with 0
sham 0
TENS 0
at 0
8 0
visits 0
over 0
14 0
weeks 0
. 0

Pain B-PAIN
was 0
assessed 0
on 0
a 0
visual 0
analogue 0
scale 0
before 0
and 0
after 0
TENS 0
at 0
each 0
visit 0
and 0
the 0
data 0
were 0
analysed 0
with 0
the 0
analysis 0
of 0
variance 0
( 0
ANOVA 0
) 0
for 0
repeated 0
measures 0
. 0

A 0
highly 0
significant 0
effect 0
was 0
seen 0
for 0
time 0
( 0
F 0
= 0
4.80 0
, 0
P 0
= 0
0.0003 0
) 0
but 0
not 0
for 0
TENS 0
. 0

Subthreshold 0
TENS 0
did 0
not 0
increase 0
the 0
symptom 0
relief 0
produced 0
by 0
conservative 0
treatment 0
with 0
the 0
protocol 0
used 0
. 0

Adenosinergic 0
mechanisms 0
contribute 0
to 0
individual 0
differences 0
in 0
sleep 0
deprivation-induced 0
changes 0
in 0
neurobehavioral 0
function 0
and 0
brain 0
rhythmic 0
activity 0
. 0

Large 0
individual 0
differences 0
characterize 0
the 0
changes 0
induced 0
by 0
sleep 0
deprivation 0
on 0
neurobehavioral 0
functions 0
and 0
rhythmic 0
brain 0
activity 0
. 0

To 0
investigate 0
adenosinergic 0
mechanisms 0
in 0
these 0
differences 0
, 0
we 0
studied 0
the 0
effects 0
of 0
prolonged 0
waking 0
and 0
the 0
adenosine 0
receptor 0
antagonist 0
caffeine 0
on 0
sustained 0
vigilant 0
attention 0
and 0
regional 0
electroencephalogram 0
( 0
EEG 0
) 0
power 0
in 0
the 0
ranges 0
of 0
theta 0
activity 0
( 0
6.25-8.25 0
Hz 0
) 0
in 0
waking 0
and 0
the 0
slow 0
oscillation 0
( 0
< 0
1 0
Hz 0
) 0
in 0
sleep 0
. 0

Activity 0
in 0
these 0
frequencies 0
is 0
functionally 0
related 0
to 0
sleep 0
deprivation 0
. 0

In 0
12 0
subjectively 0
caffeine-sensitive 0
and 0
10 0
-insensitive 0
young 0
men 0
, 0
psychomotor 0
vigilance 0
task 0
( 0
PVT 0
) 0
performance 0
and 0
EEG 0
were 0
assessed 0
at 0
3 0
h 0
intervals 0
before 0
, 0
during 0
, 0
and 0
after 0
one 0
night 0
without 0
sleep 0
. 0

After 0
11 0
and 0
23 0
h 0
waking 0
, 0
subjects 0
received 0
200 0
mg 0
caffeine 0
and 0
placebo 0
in 0
double-blind 0
, 0
cross-over 0
manner 0
. 0

In 0
the 0
placebo 0
condition 0
, 0
sleep 0
deprivation 0
impaired 0
PVT 0
speed 0
more 0
in 0
caffeine-sensitive 0
than 0
in 0
caffeine-insensitive 0
men 0
. 0

This 0
difference 0
was 0
counteracted 0
by 0
caffeine 0
. 0

Theta B-PHYSICAL
power 0
in B-PHYSICAL
waking B-PHYSICAL
increased 0
more 0
in 0
a 0
frontal 0
EEG 0
derivation 0
than 0
in 0
a 0
posterior 0
derivation 0
. 0

Caffeine 0
attenuated 0
this 0
power 0
gradient 0
in 0
caffeine 0
sensitive 0
subjects 0
. 0

Sleep B-PHYSICAL
loss I-PHYSICAL
also 0
differently 0
affected 0
the 0
power 0
distribution 0
< 0
1 0
Hz 0
in 0
non-rapid B-PHYSICAL
eye I-PHYSICAL
movement B-PHYSICAL
sleep B-PHYSICAL
between 0
caffeine 0
sensitive 0
and 0
insensitive 0
subjects 0
. 0

Also 0
, 0
this 0
difference 0
was 0
mirrored 0
by 0
the 0
action 0
of 0
caffeine 0
. 0

The 0
effects 0
of 0
sleep B-PHYSICAL
deprivation I-PHYSICAL
and 0
caffeine 0
on 0
sustained 0
attention 0
and 0
regional 0
EEG 0
power 0
in 0

Delayed B-PHYSICAL
alloimmunization I-PHYSICAL
using 0
random 0
single 0
donor 0
platelet 0
transfusions 0
: 0
a 0
prospective 0
study 0
in 0
thrombocytopenic 0
patients 0
with 0
acute 0
leukemia 0
. 0

A 0
randomized 0
study 0
was 0
performed 0
in 0
54 0
thrombocytopenic 0
patients 0
with 0
acute 0
leukemia 0
. 0

Alloimmunization 0
of 0
recipients 0
of 0
random 0
multiple-donor 0
platelet 0
concentrates 0
( 0
MD 0
group 0
) 0
was 0
compared 0
to 0
that 0
of 0
patients 0
receiving 0
random 0
single-donor 0
platelets 0
( 0
SD 0
group 0
) 0
. 0

In 0
the 0
SD 0
patients 0
, 0
formation 0
of 0
alloantibodies B-PHYSICAL
( I-PHYSICAL
mostly I-PHYSICAL
anti-HLA I-PHYSICAL
) I-PHYSICAL
occurred 0
less 0
frequently 0
( 0
p 0
less 0
than 0
0.002 0
) 0
, 0
after 0
a 0
longer 0
time 0
period 0
( 0
p 0
less 0
than 0
0.002 0
) 0
, 0
and 0
after 0
a 0
higher 0
number 0
of 0
transfusions 0
( 0
p 0
less 0
than 0
0.005 0
) 0
as 0
compared 0
to 0
MD 0
patients 0
. 0

SD 0
patients 0
also 0
became 0
refractory 0
to 0
random 0
platelets 0
less 0
frequently 0
( 0
p 0
less 0
than 0
0.005 0
) 0
, 0
after 0
a 0
longer 0
time 0
period 0
, 0
and 0
after 0
a 0
higher 0
number 0
of 0
transfusions B-OTHER
( 0
p 0
less 0
than 0
0.02 0
) 0
. 0

In 0
SD 0
patients 0
, 0
the 0
increments B-OTHER
after 0
the 0
first B-PHYSICAL
and I-PHYSICAL
the I-PHYSICAL
last I-PHYSICAL
transfusion I-PHYSICAL
were 0
in 0
the 0
same 0
range 0
, 0
whereas 0
in 0
MD 0
patients 0
, 0
the 0
1-hr 0
( 0
p 0
less 0
than 0
0.001 0
) 0
and 0
the 0
24-hr 0
( 0
p 0
less 0
than 0
0.025 0
) 0
increments B-OTHER
decreased 0
from 0
the 0
first 0
to 0
the 0
last 0
transfusion 0
. 0

Thus 0
, 0
the 0
use 0
of 0
random 0
SD 0
platelet 0
transfusions 0
postponed 0
alloimmunization 0
. 0

Linguistic B-MENTAL
alignment I-MENTAL
in 0
adults 0
with 0
and 0
without 0
Asperger 0
's 0
syndrome 0
. 0

Individuals 0
with 0
Asperger 0
's 0
syndrome 0
( 0
AS 0
) 0
often 0
have 0
difficulties 0
with 0
social 0
interactions 0
and 0
conversations 0
. 0

We 0
investigated 0
if 0
these 0
difficulties 0
could 0
be 0
attributable 0
to 0
a 0
deficit 0
in 0
the 0
ability 0
to 0
linguistically 0
converge 0
with 0
an 0
interlocutor 0
, 0
which 0
is 0
posited 0
to 0
be 0
important 0
for 0
successful 0
communication 0
. 0

To 0
that 0
end 0
, 0
participants 0
completed 0
two 0
cooperative 0
tasks 0
with 0
a 0
confederate 0
, 0
which 0
allowed 0
us 0
to 0
measure 0
linguistic B-MENTAL
alignment I-MENTAL
with I-MENTAL
the I-MENTAL
confederate I-MENTAL
in 0
terms 0
of 0
lexical B-MENTAL
choice I-MENTAL
, 0
syntactic B-MENTAL
structure 0
and 0
spatial B-MENTAL
frame 0
of B-MENTAL
reference B-MENTAL
. 0

There 0
was 0
no 0
difference 0
in 0
the 0
performance 0
of 0
individuals 0
with 0
AS 0
and 0
matched 0
controls 0
and 0
both 0
groups 0
showed 0
significant 0
alignment 0
with 0
the 0
confederate 0
at 0
all 0
three 0
levels 0
. 0

We 0
conclude 0
that 0

Effectiveness 0
and 0
safety 0
of 0
inhaled 0
treprostinil 0
for 0
the 0
treatment 0
of 0
pulmonary 0
arterial 0
hypertension 0
in 0
children 0
. 0

The 0
introduction 0
of 0
prostanoid 0
therapy 0
has 0
revolutionized 0
the 0
treatment 0
of 0
pulmonary 0
arterial 0
hypertension 0
( 0
PAH 0
) 0
. 0

However 0
, 0
continuous 0
intravenous 0
prostacyclin 0
infusion 0
poses 0
significant 0
risks 0
and 0
challenges 0
, 0
particularly 0
in 0
children 0
. 0

Inhaled 0
treprostinil 0
has 0
been 0
shown 0
to 0
be 0
safe 0
and 0
efficacious 0
in 0
adults 0
. 0

This 0
study 0
describes 0
the 0
safety 0
and 0
efficacy 0
of 0
inhaled 0
treprostinil 0
in 0
children 0
with 0
PAH 0
. 0

A 0
retrospective 0
analysis 0
of 0
29 0
children 0
treated 0
with 0
inhaled 0
treprostinil 0
for 0
?6 0
weeks 0
was 0
performed 0
. 0

Effects 0
of 0
inhaled 0
treprostinil 0
on 0
exercise 0
capacity 0
, 0
functional 0
class 0
, 0
and 0
echocardiographic 0
and 0
hemodynamic 0
data 0
were 0
evaluated 0
. 0

Adverse 0
events 0
were 0
documented 0
. 0

Patients 0
received 0
3 0
to 0
9 0
breaths 0
( 0
6 0
?g/breath 0
) 0
of 0
inhaled 0
treprostinil 0
4 0
times/day 0
. 0

All 0
were 0
receiving 0
background 0
PAH 0
therapy 0
; 0
12 0
had 0
previously 0
received 0
parenteral 0
prostanoid 0
. 0

Inhaled 0
treprostinil 0
was 0
discontinued 0
in 0
4 0
patients 0
because 0
of 0
symptoms 0
including 0
cough B-ADVERSE-EFFECTS
and 0
bronchospasm B-ADVERSE-EFFECTS
( 0
n 0
= 0
3 0
) 0
and 0
progression 0
of 0
PAH 0
( 0
n 0
= 0
1 0
) 0
. 0

Mild 0
side 0
effects 0
including 0
cough 0
( 0
n 0
= 0
9 0
) 0
and 0
sore 0
throat 0
( 0
n 0
= 0
6 0
) 0
did 0
not 0
require 0
discontinuation 0
of 0
therapy 0
. 0

World 0
Health 0
Organization 0
functional 0
class 0
improved 0
in 0
19 0
and 0
was 0
unchanged 0
in 0
10 0
; 0
exercise B-PHYSICAL
capacity I-PHYSICAL
significantly 0
improved 0
with 0
the 0
6-minute 0
walk 0
distance 0
, 0
improving 0
on 0
follow-up 0
from 0
455.7 0
? 0

71.5 0
to 0
498 0
? 0

70 0
m 0
( 0
p 0
= 0
0.01 0
) 0
and 0
peak 0
oxygen B-PHYSICAL
consumption I-PHYSICAL
increasing 0
from 0
25.5 0
? 0

10.2 0
to 0
27.4 0
? 0

10 0
( 0
p 0
= 0
0.04 0
) 0
. 0

In 0
conclusion 0
, 0
inhaled 0
treprostinil 0
was 0
associated 0
with 0
improvement 0
in 0
exercise 0
capacity 0
and 0
World 0
Health 0
Organization 0
functional 0
class 0
when 0
added 0
to 0
background 0
targeted 0
PAH 0
therapy 0
in 0
children 0
and 0
had 0
an 0
acceptable 0
safety 0
profile 0
. 0

Based 0
on 0
these 0
early 0
data 0
, 0
further 0
study 0
of 0
inhaled 0
treprostinil 0
appears 0
warranted 0
in 0
pediatric 0
patients 0
with 0
PAH 0
. 0

Why 0
distinctive 0
information 0
reduces 0
false B-PHYSICAL
memories I-PHYSICAL
: 0
evidence 0
for 0
both 0
impoverished 0
relational-encoding 0
and 0
distinctiveness 0
heuristic 0
accounts 0
. 0

Two 0
accounts 0
explain 0
why 0
studying 0
pictures 0
reduces 0
false B-PHYSICAL
memories I-PHYSICAL
within 0
the 0
Deese-Roediger-McDermott 0
paradigm 0
( 0
J. 0
Deese 0
, 0
1959 0
; 0
H. 0
L. 0
Roediger 0
& 0
K. 0
B. 0
McDermott 0
, 0
1995 0
) 0
. 0

The 0
impoverished 0
relational-encoding 0
account 0
suggests 0
that 0
studying B-PHYSICAL
pictures I-PHYSICAL
interferes 0
with 0
the 0
encoding 0
of 0
relational 0
information 0
, 0
which 0
is 0
the 0
primary 0
basis 0
for 0
false 0
memories 0
in 0
this 0
paradigm 0
. 0

Alternatively 0
, 0
the 0
distinctiveness 0
heuristic 0
assumes 0
that 0
critical B-PHYSICAL
lures I-PHYSICAL
are 0
actively 0
withheld 0
by 0
the 0
use 0
of 0
a 0
retrieval 0
strategy 0
. 0

When 0
participants 0
were 0
given 0
inclusion 0
recall 0
instructions 0
to 0
report 0
studied 0
items 0
as 0
well 0
as 0
related 0
items 0
, 0
they 0
still 0
reported B-PHYSICAL
critical I-PHYSICAL
lures I-PHYSICAL
less 0
often 0
after 0
picture 0
encoding 0
than 0
they 0
did 0
after 0
word 0
encoding 0
. 0

As 0
the 0
impoverished 0
relational-encoding 0
account 0
suggests 0
, 0
critical B-PHYSICAL
lures I-PHYSICAL
appear 0
less 0
likely 0
to 0
come 0
to 0
mind 0
after 0
picture 0
encoding 0
than 0
they 0
do 0
after 0
word 0
encoding 0
. 0

However 0
, 0
the 0
results 0
from 0
a 0
postrecall B-PHYSICAL
recognition I-PHYSICAL
test 0
provide 0
evidence 0
in 0
favor 0
of 0
the 0
distinctiveness 0
heuristic 0
. 0

Pharmacokinetic B-OTHER
and 0
safety B-OTHER
assessments B-PHYSICAL
of 0
galantamine 0
and 0
risperidone 0
after 0
the 0
two 0
drugs 0
are 0
administered 0
alone 0
and 0
together 0
. 0

To 0
explore 0
the 0
steady-state 0
pharmacokinetic 0
profile 0
after 0
coadministration 0
of 0
galantamine 0
and 0
risperidone 0
, 0
an 0
open-label 0
, 0
randomized 0
, 0
single-center 0
, 0
two-way 0
crossover 0
drug-drug 0
interaction 0
study 0
was 0
conducted 0
in 0
16 0
healthy 0
elderly 0
subjects 0
, 0
ages 0
60 0
years 0
and 0
older 0
. 0

The 0
results 0
showed 0
that 0
risperidone 0
, 0
when 0
administered 0
with 0
galantamine 0
, 0
did 0
not 0
change 0
the 0
bioavailability B-OTHER
of 0
galantamine 0
at 0
steady 0
state 0
. 0

In 0
addition 0
, 0
systemic 0
exposure 0
of 0
risperidone 0
active 0
moiety 0
( 0
risperidone 0
plus 0
9-hydroxyrisperidone 0
) 0
, 0
the 0
most 0
clinically 0
relevant 0
component 0
of 0
risperidone 0
treatment 0
, 0
was 0
not 0
affected 0
by 0
galantamine 0
coadministration 0
, 0
while 0
systemic B-OTHER
exposure I-OTHER
was 0
increased 0
by 0
approximately 0
10 0
% 0
for 0
risperidone 0
and 0
decreased 0
by 0
about 0
10 0
% 0
for 0
9-hydroxyrisperidone 0
( 0
active 0
metabolite 0
of 0
risperidone 0
) 0
. 0

Galantamine 0
and 0
risperidone 0
were 0
both 0
safe B-OTHER
and I-OTHER
well I-OTHER
tolerated I-OTHER
administered 0
either 0
alone 0
or 0
together 0
. 0

Thus 0
, 0
no 0
dose 0
adjustment 0
for 0
either 0
risperidone 0
orgalantamine 0
is 0
necessary 0
when 0
these 0
two 0
drugs 0
are 0
administered 0
together 0
in 0
the 0
dose 0
range 0
evaluated 0
. 0

A 0
carbohydrate 0
meal 0
attenuates 0
the 0
forearm 0
vasoconstrictor 0
response 0
to 0
lower 0
body 0
subatmospheric 0
pressure 0
in 0
healthy 0
young 0
adults 0
. 0

The 0
cardiovascular 0
( 0
CV 0
) 0
responses 0
to 0
meal 0
ingestion 0
and 0
orthostasis 0
are 0
well 0
established 0
. 0

The 0
effect 0
of 0
meal 0
ingestion 0
and 0
meal 0
composition 0
on 0
the 0
CV 0
responses 0
to 0
orthostasis 0
are 0
unknown 0
. 0

The 0
effect 0
of 0
high 0
carbohydrate 0
( 0
HC 0
) 0
and 0
high 0
fat 0
( 0
HF 0
) 0
meal 0
ingestion 0
on 0
the 0
CV 0
responses 0
to 0
simulated 0
orthostatic 0
stress 0
( 0
using 0
graded 0
lower 0
body 0
subatmospheric 0
pressure 0
( 0
LBSP 0
) 0
) 0
was 0
assessed 0
in 0
nine 0
healthy 0
young 0
volunteers 0
. 0

Cardiac B-PHYSICAL
output I-PHYSICAL
( 0
CO B-PHYSICAL
) 0
, 0

Single-use 0
plaque 0
removal 0
efficacy 0
of 0
three 0
power 0
toothbrushes 0
. 0

OBJECTIVES 0
To 0
compare 0
the 0
safety B-OTHER
and 0
plaque B-OTHER
removal I-OTHER
efficacy I-OTHER
of 0
two 0
oscillating/rotating/pulsating 0
toothbrushes 0
( 0
Oral-B 0
ProfessionalCare 0
7000 0
[ 0
PC 0
7000 0
] 0
and 0
Oral-B 0
3D 0
Excel 0
[ 0
3DE 0
] 0
) 0
and 0
a 0
high-frequency 0
toothbrush 0
( 0
Sonicare 0
Advance 0
, 0
Philips 0
Oral 0
Healthcare 0
; 0
SA 0
) 0
in 0
a 0
single-use 0
, 0
examiner-blind 0
, 0
three 0
period 0
crossover 0
study 0
. 0

METHODS 0
After 0
refraining 0
from 0
all 0
oral 0
hygiene 0
procedures 0
for 0
23-25 0
hours 0
, 0
subjects 0
received 0
an 0
oral 0
tissue 0
examination 0
and 0
those 0
with 0
pre-brushing 0
whole 0
mouth 0
mean 0
plaque 0
scores 0
> 0
or 0
= 0
0.6 0
based 0
on 0
the 0
Rustogi 0
et 0
al 0
. 0

Modified 0
Navy 0
Plaque 0
Index 0
were 0
randomly 0
assigned 0
to 0
treatment 0
sequence 0
. 0

After 0
brushing 0
with 0
the 0
assigned 0
toothbrush 0
and 0
a 0
commercially 0
available 0
dentifrice 0
for 0
2 0
minutes 0
, 0
oral 0
tissues 0
were 0
then 0
re-examined 0
and 0
post-brushing 0
plaque 0
scores 0
recorded 0
. 0

Following 0
a 0
brief 0
washout 0
period 0
between 0
two 0
additional 0
visits 0
, 0
the 0
above 0
procedures 0
were 0
repeated 0
with 0
the 0
two 0
alternate 0
toothbrushes 0
. 0

One 0
examiner 0
, 0
blinded 0
to 0
the 0
treatment 0
sequence 0
, 0
performed 0
all 0
clinical 0
measurements 0
. 0

RESULTS 0
A 0
total 0
of 0
79 0
subjects 0
( 0
28 0
males 0
and 0
51 0
females 0
) 0
were 0
enrolled 0
and 0
completed 0
the 0
study 0
. 0

Each 0
toothbrush 0
was 0
found 0
to 0
be 0
safe B-OTHER
and 0
significantly 0
reduced 0
plaque B-OTHER
levels I-OTHER
after 0
a 0
single 0
brushing 0
. 0

The 0
PC 0
7000 0
and 0
3DE 0
were 0
equally 0
more 0
effective 0
in 0
plaque B-PHYSICAL
removal I-PHYSICAL
than 0
the 0
SA 0
, 0
at 0
all 0
tooth 0
areas 0
, 0
reducing 0
plaque B-PHYSICAL
by 0
59.0 0
% 0
, 0
59.7 0
% 0
and 0
51.8 0
% 0
, 0
respectively 0
on 0
whole 0
mouth 0
surfaces 0
, 0
and 0
by 0
67.5 0
% 0
, 0
67.8 0
% 0
and 0
59.4 0
% 0
, 0
respectively 0
on 0
approximal 0
surfaces 0
. 0

CONCLUSIONS 0
The 0
action 0
of 0
the 0
oscillating/rotating/pulsating 0
toothbrushes 0
( 0
Oral-B 0
ProfessionalCare 0
7000 0
and 0
Oral-B 0
3D 0
Excel 0
) 0
was 0
more 0
effective 0
in 0
plaque 0
removal 0
than 0
the 0
high-frequency 0
toothbrush 0
( 0
Sonicare 0
Advance 0
) 0
. 0

The 0
efficacy 0
of 0
melatonin 0
for 0
sleep 0
problems 0
in 0
children 0
with 0
autism 0
, 0
fragile 0
X 0
syndrome 0
, 0
or 0
autism 0
and 0
fragile 0
X 0
syndrome 0
. 0

STUDY 0
OBJECTIVE 0
To 0
determine 0
the 0
efficacy 0
of 0
melatonin 0
on 0
sleep 0
problems 0
in 0
children 0
with 0
autistic 0
spectrum 0
disorder 0
( 0
ASD 0
) 0
and 0
fragile 0
X 0
syndrome 0
( 0
FXS 0
) 0
. 0

METHODS 0
A 0
4-week 0
, 0
randomized 0
, 0
double 0
blind 0
, 0
placebo-controlled 0
, 0
crossover 0
design 0
was 0
conducted 0
following 0
a 0
1-week 0
baseline 0
period 0
. 0

Either 0
melatonin 0
, 0
3 0
mg 0
, 0
or 0
placebo 0
was 0
given 0
to 0
participants 0
for 0
2 0
weeks 0
and 0
then 0
alternated 0
for 0
another 0
2 0
weeks 0
. 0

Sleep B-PHYSICAL
variables I-PHYSICAL
, 0
including 0
sleep 0
duration 0
, 0
sleep-onset 0
time 0
, 0
sleep-onset 0
latency 0
time 0
, 0
and 0
the 0
number 0
of 0
night 0
awakenings 0
, 0
were 0
recorded 0
using 0
an 0
Actiwatch 0
and 0
from 0
sleep 0
diaries 0
completed 0
by 0
parents 0
. 0

All 0
participants 0
had 0
been 0
thoroughly 0
assessed 0
for 0
ASD 0
and 0
also 0
had 0
DNA 0
testing 0
for 0
the 0
diagnosis 0
of 0
FXS 0
. 0

RESULTS 0
Data 0
were 0
successfully 0
obtained 0
from 0
the 0
12 0
of 0
18 0
subjects 0
who 0
completed 0
the 0
study 0
( 0
11 0
males 0
, 0
age 0
range 0
2 0
to 0
15.25 0
years 0
, 0
mean 0
5.47 0
, 0
SD 0
3.6 0
) 0
. 0

Five 0
participants 0
met 0
diagnostic 0
criteria 0
for 0
ASD 0
, 0
3 0
for 0
FXS 0
alone 0
, 0
3 0
for 0
FXS 0
and 0
ASD 0
, 0
and 0
1 0
for 0
fragile 0
X 0
premutation 0
. 0

Eight 0
out 0
of 0
12 0
had 0
melatonin 0
first 0
. 0

The 0
conclusions 0
from 0
a 0
nonparametric 0
repeated-measures 0
technique 0
indicate 0
that 0
mean 0
night B-OTHER
sleep I-OTHER
duration I-OTHER
was 0
longer 0
on 0
melatonin 0
than 0
placebo 0
by 0
21 0
minutes 0
( 0
p 0
= 0
.02 0
) 0
, 0
mean 0
sleep-onset B-OTHER
latency I-OTHER
was 0
shorter 0
by 0
28 0
minutes 0
( 0
p 0
= 0
.0001 0
) 0
, 0
and 0
mean 0
sleep-onset B-OTHER
time I-OTHER
was 0
earlier 0
by 0
42 0
minutes 0
( 0
p 0
= 0
.02 0
) 0
. 0

CONCLUSION 0
The 0
results 0
of 0
this 0
study 0
support 0
the 0
efficacy 0
and 0
tolerability 0
of 0
melatonin 0
treatment 0
for 0
sleep 0
problems 0
in 0
children 0
with 0
ASD 0
and 0
FXS 0
. 0

[ 0
The 0
chemotherapy 0
of 0
advanced 0
breast 0
cancer 0
. 0

A 0
report 0
on 0
the 0
first 0
600 0
cases 0
in 0
a 0
cooperative 0
programme 0
to 0
carry 0
out 0
a 0
systematic 0
study 0
( 0
1974-1977 0
) 0
( 0
author 0
's 0
transl 0
) 0
] 0
. 0

The 0
authors 0
explain 0
the 0
objectives 0
and 0
the 0
structure 0
of 0
a 0
programme 0
evolved 0
for 0
the 0
methodic 0
study 0
of 0
advanced 0
breast 0
cancers 0
which 0
they 0
have 0
worked 0
out 0
and 0
carried 0
out 0
in 0
cooperation 0
with 0
the 0
departments 0
of 0
medicine 0
in 0
eight 0
French 0
anticancer 0
centres 0
. 0

They 0
analyse 0
the 0
initial 0
phases 0
, 0
which 0
correspond 0
to 0
the 0
three 0
first 0
years 0
of 0
work 0
. 0

They 0
give 0
the 0
state 0
of 0
the 0
results 0
that 0
have 0
been 0
obtained 0
in 0
603 0
patients 0
using 0
three 0
protocols 0
for 0
treatment 0
. 0

These 0
consisted 0
of 0
the 0
administration 0
in 0
interrupted 0
doses 0
of 0
chemotherapy 0
which 0
consisted 0
of 0
vincristine 0
associated 0
for 0
the 0
one 0
part 0
with 0
cyclophosphamide 0
and 0
5-fluoro-uracil 0
and 0
on 0
the 0
other 0
hand 0
with 0
doxorubicine 0
or/and 0
with 0
methotrexate 0
. 0

From 0
this 0
study 0
there 0
emerged 0
the 0
value 0
of 0
combined 0
therapy 0
using 0
doxorubicine 0
as 0
much 0
because 0
of 0
the 0
frequency 0
with 0
which B-PHYSICAL
results I-PHYSICAL
better I-PHYSICAL
than 0
50 0
% 0
were 0
obtained 0
( 0
in 0
a 0
randomised 0
trial 0
) 0
as 0
by 0
their 0
quality B-OTHER
, 0
which 0
was 0
made 0
clear 0
in 0
an 0
important 0
series 0
of 0
240 0
cases 0
. 0

They 0
point 0
out 0
the 0
conditions 0
required 0
to 0
initiate 0
the 0
place 0
of 0
such 0
a 0
scheme 0
in 0
all 0
complex 0
therapy 0
which 0
aims 0
as 0
much 0
at 0
palliation 0
as 0
at 0
cure 0
, 0
and 0
point 0
out 0
how 0
important 0
it 0
is 0
to 0
be 0
methodical 0
in 0
the 0
application 0
of 0
chemotherapy 0
in 0
order 0
to 0
ensure 0
its 0
development 0
as 0
an 0
anticancer 0
therapy 0
. 0

Circadian 0
changes 0
in 0
the 0
pharmacokinetics B-PHYSICAL
of 0
oral 0
ketoprofen 0
. 0

Several 0
investigations 0
which 0
have 0
taken 0
treatment 0
time 0
into 0
account 0
have 0
shown 0
that 0
the 0
pharmacokinetic 0
parameters 0
, 0
the 0
therapeutic B-OTHER
efficacy I-OTHER
and 0
even 0
the 0
toxicity B-PHYSICAL
of 0
a 0
large 0
number 0
of 0
products 0
may 0
vary 0
according 0
to 0
the 0
administration 0
schedule 0
. 0

The 0
present 0
study 0
was 0
carried 0
out 0
in 0
order 0
to 0
evaluate 0
any 0
circadian 0
changes 0
in 0
pharmacokinetic 0
parameters 0
of 0
ketoprofen 0
, 0
a 0
new 0
non-steroidal 0
anti-inflammatory 0
drug 0
( 0
NSAID 0
) 0
. 0

This 0
randomised 0
crossover 0
study 0
consisted 0
of 0
a 0
single 0
oral 0
dose 0
of 0
ketoprofen 0
100mg 0
administered 0
to 0
8 0
healthy 0
male 0
volunteers 0
, 0
mean 0
age 0
27.2 0
years 0
, 0
at 0
07.00 0
hours 0
, 0
13.00 0
hours 0
, 0
19.00 0
hours 0
or 0
01.00 0
hours 0
in 0
4 0
study 0
periods 0
during 0
the 0
first 0
3 0
months 0
of 0
the 0
year 0
. 0

The 0
order 0
of 0
administration 0
was 0
randomised 0
, 0
with 0
each 0
subject 0
acting 0
as 0
his 0
own 0
control 0
. 0

A 0
total 0
of 0
14 0
blood 0
and 0
4 0
urine 0
samples 0
were 0
taken 0
over 0
a 0
12-hour 0
period 0
. 0

The 0
peak 0
plasma B-PHYSICAL
concentration I-PHYSICAL
was 0
twice 0
as 0
high 0
after 0
drug 0
administration 0
at 0
07.00 0
hours 0
( 0
13.4 0
+/- 0
1 0
mg/L 0
) 0
than 0
after 0
other 0
administration 0
times 0
( 0
13.00 0
hours 0
: 0
6.9 0
+/- 0
1 0
; 0
19.00 0
hours 0
: 0
7.2 0
+/- 0
0.7 0
; 0
01.00 0
hours 0
: 0
6.3 0
+/- 0
0.5 0
mg/L 0
) 0
[ 0
p 0
less 0
than 0
0.001 0
] 0
. 0

The 0
time B-PHYSICAL
to I-PHYSICAL
reach I-PHYSICAL
peak 0
concentration B-PHYSICAL
was 0
much 0
longer 0
after 0
drug 0
administration 0
at 0
01.00 0
hours 0
( 0
135 0
+/- 0
16.7 0
min 0
) 0
than 0
at 0
07.00 0
( 0
73.1 0
+/- 0
14.1 0
min 0
) 0
, 0
13.00 0
( 0
75 0
+/- 0
16.5 0
min 0
) 0
or 0
19.00 0
hours 0
( 0
82.5 0
+/- 0
12.7 0
min 0
) 0
[ 0
p 0
less 0
than 0
0.05 0
] 0
. 0

The 0
lag 0
time 0
was 0
significantly 0
longer 0
at 0
01.00 0
hours 0
than 0
at 0
13.00 0
hours 0
( 0
p 0
less 0
than 0
0.01 0
) 0
. 0

The 0
absorption B-PHYSICAL
rate I-PHYSICAL
constant 0
after 0
treatment 0
at 0
01.00 0
hours 0
was 0
less 0
than 0
at 0
the 0
other 0
times 0
of 0
administration 0
( 0
p 0
less 0
than 0
0.05 0
) 0
. 0

The 0
bodyweight-corrected B-PHYSICAL
area 0
under B-PHYSICAL
the B-PHYSICAL
curve 0
( 0

Does 0
aerobic 0
training 0
lead 0
to 0
a 0
more 0
active B-MENTAL
lifestyle I-MENTAL
and 0
improved B-OTHER
quality I-OTHER
of I-OTHER
life I-OTHER
in 0
patients 0
with 0
chronic 0
heart 0
failure 0
? 0

BACKGROUND 0
Due 0
to 0
dyspnea 0
and 0
fatigue 0
, 0
patients 0
with 0
chronic 0
heart 0
failure 0
( 0
CHF 0
) 0
are 0
often 0
restricted 0
in 0
the 0
performance 0
of 0
everyday 0
activities 0
, 0
which 0
gradually 0
may 0
lead 0
to 0
hypoactivity 0
. 0

AIMS 0
To 0
assess 0
whether 0
aerobic 0
training 0
leads 0
to 0
a 0
more 0
active B-MENTAL
lifestyle I-MENTAL
and 0
improved 0
quality 0
of 0
life 0
( B-PHYSICAL
QoL I-PHYSICAL
) I-PHYSICAL
in 0
patients 0
with 0
CHF 0
. 0

METHODS 0
Patients 0
with 0
stable 0
CHF 0
( 0
NYHA 0
II/III 0
; 0
59 0
( 0
11 0
) 0
years 0
) 0
were 0
randomly 0
assigned 0
to 0
a 0
training 0
group 0
( 0
n=18 0
; 0
3-month 0
aerobic 0
program 0
above 0
standard 0
treatment 0
) 0
or 0
control 0
group 0
( 0
n=16 0
; 0
standard 0
treatment 0
without 0
special 0
advice 0
for 0
exercise 0
) 0
. 0

Measurements 0
were 0
performed 0
on 0
level 0
of 0
everyday B-MENTAL
physical I-MENTAL
activity I-MENTAL
( 0
PA B-MENTAL
, 0
novel B-MENTAL
accelerometry-based I-MENTAL
activity I-MENTAL
monitor I-MENTAL
) 0
and 0

Human 0
achaete-scute 0
homologue 0
( 0
hASH1 0
) 0
mRNA 0
level 0
as 0
a 0
diagnostic 0
marker 0
to 0
distinguish 0
esthesioneuroblastoma 0
from 0
poorly 0
differentiated 0
tumors 0
arising 0
in 0
the 0
sinonasal 0
tract 0
. 0

Distinction 0
of 0
high-grade 0
esthesioneuroblastomas 0
from 0
other 0
poorly 0
differentiated 0
tumors 0
arising 0
in 0
the 0
nasal 0
cavity 0
is 0
an 0
important 0
diagnostic 0
challenge 0
because 0
it 0
determines 0
patient 0
management 0
and 0
prognosis 0
. 0

The 0
human 0
achaete-scute 0
homologue 0
( 0
hASH1 0
) 0
gene 0
is 0
critical 0
in 0
olfactory 0
neuronal 0
differentiation 0
and 0
is 0
expressed 0
in 0
immature 0
olfactory 0
cells 0
; 0
therefore 0
, 0
it 0
could 0
have 0
potential 0
use 0
as 0
a 0
diagnostic 0
marker 0
The 0
aim 0
of 0
the 0
present 0
study 0
was 0
to 0
determine 0
the 0
value 0
of 0
hASH1 0
messenger 0
RNA 0
( 0
mRNA 0
) 0
levels 0
in 0
differentiating 0
esthesioneuroblastoma 0
from 0
other 0
poorly 0
differentiated 0
tumors 0
. 0

A 0
real-time 0
polymerase 0
chain 0
reaction 0
assay 0
was 0
developed 0
, 0
permitting 0
the 0
comparative 0
determination 0
of 0
hASH1 B-PHYSICAL
mRNA I-PHYSICAL
levels I-PHYSICAL
in 0
triplicate 0
in 0
a 0
double-blind 0
pilot 0
study 0
including 0
24 0
frozen 0
cases 0
of 0
esthesioneuroblastoma 0
and 0
poorly 0
differentiated 0
tumors 0
. 0

All 0
4 0
positive 0
cases 0
were 0
esthesioneuroblastomas B-PHYSICAL
, 0
and 0
all 0
19 0
poorly 0
differentiated 0
tumors 0
were 0
negative 0
. 0

In 0
addition 0
, 0
there 0
was 0
an 0
inverse 0
association 0
between 0
the 0
grade 0
of 0
esthesioneuroblastomas B-PHYSICAL
and 0
hASH1 0
mRNA 0
levels 0
. 0

The 0
hASH1 0
mRNA 0
level 0
might 0
represent 0
a 0
useful 0
tool 0
for 0
distinguishing 0
esthesioneuroblastoma 0
from 0
poorly 0
differentiated 0
tumors 0
of 0
the 0
sinonasal 0
region 0
. 0

Lack 0
of 0
benefit 0
of 0
an 0
active 0
pectoral 0
pulse 0
generator 0
on 0
atrial 0
defibrillation 0
thresholds 0
. 0

INTRODUCTION 0
Atrial 0
defibrillation 0
can 0
be 0
achieved 0
with 0
standard 0
implantable 0
cardioverter 0
defibrillator 0
leads 0
, 0
which 0
has 0
led 0
to 0
the 0
development 0
of 0
combined 0
atrial 0
and 0
ventricular 0
devices 0
. 0

For 0
ventricular 0
defibrillation 0
, 0
use 0
of 0
an 0
active 0
pectoral 0
electrode 0
( 0
active 0
can 0
) 0
in 0
the 0
shocking 0
pathway 0
markedly 0
reduces 0
defibrillation 0
thresholds 0
( 0
DFTs 0
) 0
. 0

However 0
, 0
the 0
effect 0
of 0
an 0
active 0
pectoral 0
can 0
on 0
atrial 0
defibrillation 0
is 0
unknown 0
. 0

METHODS 0
AND 0
RESULTS 0
This 0
study 0
was 0
a 0
prospective 0
, 0
randomized 0
, 0
paired 0
comparison 0
of 0
two 0
shock 0
configurations 0
on 0
atrial 0
DFTs 0
in 0
33 0
patients 0
. 0

The 0
lead 0
system 0
evaluated 0
was 0
a 0
dual-coil 0
transvenous 0
defibrillation 0
lead 0
with 0
a 0
left 0
pectoral 0
pulse 0
generator 0
emulator 0
. 0

Shocks 0
were 0
delivered 0
either 0
between 0
the 0
right 0
ventricular 0
coil 0
and 0
proximal 0
atrial 0
coil 0
( 0
lead 0
) 0
or 0
between 0
the 0
right 0
ventricular 0
coil 0
and 0
an 0
active 0
can 0
in 0
common 0
with 0
the 0
atrial 0
coil 0
( 0
active 0
can 0
) 0
. 0

Delivered B-PHYSICAL
energy I-PHYSICAL
at I-PHYSICAL
DFT I-PHYSICAL
was 0
4.2 0
+/- 0
4.1 0
J 0
in 0
the 0
lead 0
configuration 0
and 0
5.0 0
+/- 0
3.7 0
J 0
in 0
the 0
active 0
can 0
configuration 0
( 0
P 0
= 0
NS 0
) 0
. 0

Peak 0
current B-PHYSICAL
was 0
32 0
% 0
higher 0
with 0
an 0
active 0
can 0
( 0
P 0
< 0
0.01 0
) 0
, 0
whereas 0
shock B-PHYSICAL
impedance I-PHYSICAL
was 0
18 0
% 0
lower 0
( 0
P 0
< 0
0.001 0
) 0
. 0

Moreover 0
, 0
a 0
low B-PHYSICAL
threshold I-PHYSICAL
( 0
< 0
or 0
= 0
3 0
J 0
) 0
was 0
observed 0
in 0
61 0
% 0
of 0
subjects 0
in 0
the 0
lead 0
configuration 0
but 0
in 0
only 0
36 0
% 0
in 0
the 0
active 0
can 0
configuration 0
( 0
P 0
< 0
0.05 0
) 0
. 0

There 0
were 0
no 0
clinical B-PHYSICAL
predictors I-PHYSICAL
of 0
the 0
atrial 0
DFT 0
. 0

CONCLUSION 0
These 0
results 0
indicate 0
that 0
low 0
atrial 0
DFTs 0
can 0
be 0
achieved 0
using 0
a 0
transvenous 0
ventricular 0
defibrillation 0
lead 0
. 0

Because 0
no 0
benefit 0
was 0
observed 0
with 0
the 0
use 0
of 0
an 0
active 0
pectoral 0
electrode 0
for 0
atrial 0
defibrillation 0
, 0
programmable 0
shock 0
vectors 0
may 0
be 0
useful 0
for 0
dual-chamber 0
implantable 0
cardioverter 0
defibrillators 0
. 0

Testosterone 0
and 0
gonadotropins 0
but 0
not 0
estrogen 0
associated 0
with 0
spatial B-MENTAL
ability I-MENTAL
in 0
women 0
suffering 0
from 0
schizophrenia 0
: 0
a 0
double-blind 0
, 0
placebo-controlled 0
study 0
. 0

The 0
aim 0
of 0
this 0
study 0
was 0
to 0
investigate 0
the 0
association 0
between 0
estrogen B-PHYSICAL
and 0
spatial B-MENTAL
ability I-MENTAL
tasks 0
in 0
women 0
suffering 0
from 0
schizophrenia 0
. 0

For 0
this 0
purpose 0
, 0
a 0
placebo-controlled 0
, 0
double-blind 0
, 0
three-time 0
cross-over 0
study 0
using 0
17beta-estradiol 0
combined 0
with 0
norethisterone 0
acetate 0
for 0
replacement 0
therapy 0
and 0
as 0
an 0
adjunct 0
to 0
a 0
naturalistic 0
maintenance 0
antipsychotic 0
treatment 0
was 0
carried 0
out 0
over 0
a 0
period 0
of 0
8 0
months 0
. 0

Nineteen 0
women 0
( 0
mean 0
age=38.0 0
years 0
, 0
SD=9.9 0
years 0
) 0
with 0
schizophrenia 0
hospitalized 0
for 0
the 0
first 0
time 0
or 0
repeatedly 0
were 0
included 0
in 0
the 0
study 0
. 0

Sex B-PHYSICAL
hormones I-PHYSICAL
- I-PHYSICAL
17beta-estradiol I-PHYSICAL
, 0
luteinizing B-PHYSICAL
hormone I-PHYSICAL
( 0
LH B-PHYSICAL
) 0
, 0
follicle-stimulating B-PHYSICAL
hormone I-PHYSICAL
( 0
FSH B-PHYSICAL
) 0
, 0
prolactin B-PHYSICAL
, 0
testosterone B-PHYSICAL
, 0
and 0
dehydroepiandrosterone B-PHYSICAL
sulfate I-PHYSICAL
- 0
were 0
measured 0
and 0
the 0
patients 0
completed 0
a 0
neuropsychological 0
test 0
in 0
the 0
last 0
two 0
active 0
drug 0
and/or 0
placebo 0
phases 0
. 0

Three 0
different 0
spatial 0
ability 0
tasks 0
- 0
spatial B-MENTAL
orientation I-MENTAL
, 0
spatial B-MENTAL
visualization I-MENTAL
, 0
and 0
flexibility B-MENTAL
of I-MENTAL
closure I-MENTAL
- 0
were 0
measured 0
by 0
a 0
paper-and-pencil 0
test 0
. 0

No 0
association 0
between 0
estrogen B-PHYSICAL
and 0
spatial B-MENTAL
ability I-MENTAL
was 0
found 0
; 0
however 0
, 0
in 0
an 0
additional 0
exploratory 0
data 0
analysis 0
, 0
high 0
levels 0
of 0
testosterone 0
, 0
LH B-PHYSICAL
, 0
and 0
FSH B-PHYSICAL
correlated 0
significantly 0
with 0
performance 0
in 0
the 0
flexibility B-PHYSICAL
of I-PHYSICAL
closure I-PHYSICAL
task 0
. 0

This 0
is 0
the 0
very 0
first 0
study 0
, 0
based 0
on 0
estrogen 0
intervention 0
instead 0
of 0
physiological 0
hormone 0
changes 0
, 0
to 0
examine 0
the 0
association 0
between 0
estrogen B-PHYSICAL
and 0
spatial B-PHYSICAL
ability I-PHYSICAL
in 0
women 0
with 0
schizophrenia 0
. 0

Treatment 0
of 0
hypertensive 0
and 0
hypercholesterolaemic 0
patients 0
in 0
general 0
practice 0
. 0

The 0
effect 0
of 0
captopril 0
, 0
atenolol 0
and 0
pravastatin 0
combined 0
with 0
life 0
style 0
intervention 0
. 0

OBJECTIVE 0
To 0
elucidate 0
the 0
effect 0
on 0
blood 0
pressure 0
and 0
blood 0
lipids 0
of 0
an 0
angiotensin 0
converting 0
enzyme 0
inhibitor 0
( 0
captopril 0
) 0
, 0
and 0
a 0
beta-receptor 0
blocking 0
agent 0
( 0
atenolol 0
) 0
, 0
given 0
alone 0
or 0
in 0
combination 0
with 0
a 0
cholesterol 0
reducing 0
drug 0
, 0
the 0
beta-hydroxy-methylglutaryl-coenzyme 0
A 0
reductase 0
inhibitor 0
pravastatin 0
, 0
in 0
patients 0
who 0
were 0
also 0
encouraged 0
to 0
improve 0
their 0
lifestyle 0
. 0

DESIGN 0
A 0
longitudinal 0
study 0
consisting 0
of 0
three 0
phases 0
. 0

I 0
: 0
Lifestyle 0
intervention 0
alone 0
. 0

II 0
: 0
Continued 0
lifestyle 0
intervention 0
combined 0
with 0
captopril 0
or 0
atenolol 0
. 0

III 0
: 0
Continued 0
lifestyle 0
intervention 0
combined 0
with 0
the 0
same 0
drugs 0
as 0
in 0
phase 0
II 0
and 0
in 0
addition 0
pravastatin 0
or 0
placebo 0
. 0

SETTING 0
Fifty-four 0
general 0
practice 0
surgeries 0
in 0
Norway 0
. 0

PARTICIPANTS 0
Hypertensive 0
patients 0
, 0
210 0
females 0
and 0
160 0
males 0
, 0
treated 0
or 0
untreated 0
with 0
antihypertensive 0
drugs 0
with 0
a 0
sitting 0
diastolic 0
blood 0
pressure 0
between 0
95 0
and 0
115 0
mmHg 0
and 0
a 0
serum 0
total 0
cholesterol 0
between 0
6.5 0
mmol/l 0
( 0
7.0 0
for 0
those 0
age 0
60-67 0
years 0
) 0
and 0
9.0 0
mmol/l 0
. 0

RESULTS 0
The 0
antihypertensive 0
effect 0
of 0
captopril 0
and 0
atenolol 0
was 0
not 0
influenced 0
by 0
concurrent 0
administration 0
of 0
pravastatin 0
. 0

The 0
effect 0
of 0
pravastatin 0
was 0
not 0
limited 0
by 0
concurrent 0
medication 0
with 0
captopril 0
or 0
atenolol 0
. 0

Improvement B-MENTAL
in I-MENTAL
lifestyle I-MENTAL
seemed 0
to 0
reduce 0
the 0
need 0
for 0
supplementary B-PHYSICAL
treatment 0
with B-PHYSICAL

Long-term 0
survival 0
in 0
a 0
phase 0
III 0
, 0
randomised 0
study 0
of 0
topotecan 0
versus 0
paclitaxel 0
in 0
advanced 0
epithelial 0
ovarian 0
carcinoma 0
. 0

BACKGROUND 0
We 0
have 0
continued 0
to 0
monitor 0
the 0
survival 0
of 0
patients 0
randomised 0
in 0
a 0
previously 0
reported 0
multicentre 0
phase 0
III 0
study 0
of 0
topotecan 0
versus 0
paclitaxel 0
in 0
patients 0
with 0
advanced 0
epithelial 0
ovarian 0
cancer 0
who 0
had 0
failed 0
one 0
prior 0
platinum-based 0
regimen 0
. 0

PATIENTS 0
AND 0
METHODS 0
Patients 0
with 0
bidimensionally 0
measurable 0
disease 0
were 0
randomised 0
to 0
topotecan 0
( 0
1.5 0
mg/m 0
( 0
2 0
) 0
/day 0
for 0
5 0
days 0
) 0
or 0
paclitaxel 0
( 0
175 0
mg/m 0
( 0
2 0
) 0
/day 0
as 0
a 0
3-h 0
infusion 0
) 0
every 0
21 0
days 0
. 0

Patients 0
were 0
eligible 0
for 0
treatment 0
with 0
the 0
alternate 0
therapy 0
at 0
third 0
line 0
. 0

The 0
European B-OTHER
Organisation I-OTHER
for I-OTHER
Research I-OTHER
and I-OTHER
Treatment 0
of B-OTHER
Cancer I-OTHER
Quality 0
of B-OTHER
Life 0
( 0
EORTC B-OTHER
QOL B-OTHER
) 0
-C30 B-OTHER
questionnaire 0
was 0
also 0
used 0
to 0
measure 0
eight 0
symptoms 0
at 0
baseline 0
and 0
during 0
each 0
course 0
( 0
pain B-PAIN
, 0
anorexia B-PHYSICAL
, 0
diarrhoea B-PHYSICAL
, 0
fatigue B-PHYSICAL
, 0
nausea B-PHYSICAL
and 0
vomiting B-PHYSICAL
, 0
dyspnea B-PHYSICAL
, 0
constipation B-PHYSICAL
and 0
insomnia B-PHYSICAL
) 0
. 0

RESULTS 0
A 0
total 0
of 0
226 0
patients 0
were 0
evaluable 0
for 0
response 0
. 0

Demographic 0
characteristics 0
were 0
similar 0
in 0
both 0
treatment 0
groups 0
, 0
as 0
were 0
results 0
of 0
the 0
EORTC 0
QOL-30 0
questionnaire 0
. 0

For 0
the 0
topotecan 0
group 0
, 0
median 0
time B-PHYSICAL
to B-PHYSICAL
progression I-PHYSICAL
was 0
18.9 0
weeks 0
( 0
range 0
< 0
1 0
to 0
92.6+ 0
weeks 0
; 0
25 0
% 0
censored 0
) 0
, 0
and 0
, 0
for 0
paclitaxel 0
, 0
14.7 0
weeks 0
( 0
range 0
< 0
1 0
to 0
137.3+ 0
weeks 0
; 0
12.3 0
% 0
censored 0
) 0
; 0
P 0
= 0
0.076 0
. 0

At 0
4 0
years 0
post-randomisation 0
, 0
median 0
survival B-MORTALITY
in 0
the 0
topotecan 0
group 0
was 0
63.0 0
weeks 0
( 0
range 0
< 0
1 0
to 0
238.4+ 0
weeks 0
; 0
20.5 0
% 0
censored 0
) 0
and 0
, 0
for 0
paclitaxel 0
, 0
53.0 0
weeks 0
( 0
range 0
< 0
1 0
to 0
226.3+ 0
weeks 0
; 0
12.3 0
% 0
censored 0
) 0
; 0
P 0
= 0
0.44 0
. 0

CONCLUSION 0
Topotecan 0
continues 0
to 0
demonstrate 0
comparable 0
efficacy 0
and 0

[ 0
Efficacy 0
and 0
safety B-PHYSICAL
of 0
extended-release 0
niacin 0
alone 0
or 0
with 0
atorvastatin 0
for 0
lipid 0
profile 0
modification 0
] 0
. 0

OBJECTIVE 0
To 0
evaluate 0
the 0
efficacy 0
and 0
safety B-PHYSICAL
of 0
extended-release 0
niacin 0
( 0
niacin 0
ER 0
) 0
either 0
alone 0
or 0
in 0
combination 0
with 0
atorvastatin 0
for 0
the 0
lipid 0
profile 0
modification 0
in 0
the 0
patients 0
with 0
coronary 0
heart 0
disease 0
( 0
CHD 0
) 0
and 0
its 0
equivalents 0
. 0

METHODS 0
One 0
hundred 0
and 0
ten 0
patients 0
with 0
CHD 0
and 0
its 0
equivalents 0
with 0
serum 0
total 0
cholesterol 0
( 0
TC 0
) 0
> 0
or 0
= 0
3.5 0
mmol/L 0
were 0
randomly 0
assigned 0
into 0
three 0
treatment 0
groups 0
: 0
( 0
1 0
) 0
atorvastatin 0
group 0
( 0
n 0
= 0
38 0
) 0
, 0
receiving 0
atorvastatin 0
10 0
mg/d 0
for 0
8 0
weeks 0
; 0
( 0
2 0
) 0
niacin 0
ER 0
group 0
( 0
n 0
= 0
38 0
) 0
, 0
given 0
niacin 0
ER 0
500 0
mg/d 0
for 0
4 0
weeks 0
and 0
then 0
1000 0
mg/d 0
for 0
4 0
weeks 0
; 0
( 0
3 0
) 0
combination 0
treatment 0
group 0
( 0
n 0
= 0
34 0
) 0
, 0
treated 0
with 0
atorvastatin 0
( 0
10 0
mg/d 0
) 0
plus 0
niacin 0
ER 0
, 0
with 0
the 0
dose 0
initiating 0
from 0
500 0
mg/d 0
, 0
and 0
increasing 0
to 0
1000 0
mg/d 0
after 0
4 0
weeks 0
, 0
for 0
8 0
weeks 0
. 0

The 0
serums B-PHYSICAL
lipid I-PHYSICAL
profiles I-PHYSICAL
and 0
adverse B-ADVERSE-EFFECTS
effects I-ADVERSE-EFFECTS
were 0
assessed 0
in 0
all 0
the 0
patients 0
before 0
treatment 0
, 0
and 0
4 0
and 0
8 0
weeks 0
after 0
treatment 0
. 0

RESULTS 0
( 0
1 0
) 0
After 0
8 0
weeks 0
of 0
treatment 0
, 0
the 0
serum 0
level 0
of 0
triglyceride 0
( 0
TG 0
) 0
and 0
high-density B-PHYSICAL
lipoprotein I-PHYSICAL
cholesterol I-PHYSICAL
( I-PHYSICAL
HDL-C I-PHYSICAL
) I-PHYSICAL
were 0
reduced 0
by 0
30 0
% 0
and 0
16 0
% 0
respectively 0
in 0
the 0
niacin 0
ER 0
group 0
compared 0
with 0
the 0
baseline 0
values 0
( 0
both 0
P 0
< 0
0.05 0
) 0
. 0

After 0
8 0
weeks 0
, 0
the 0
TC B-PHYSICAL
, 0
low-density B-PHYSICAL
lipoprotein I-PHYSICAL
cholesterol I-PHYSICAL
( I-PHYSICAL
LDL-C I-PHYSICAL
) I-PHYSICAL
, 0
and 0
TG B-PHYSICAL
in 0
the 0
atorvastatin B-PHYSICAL
group 0
decreased 0
by 0
19 0
% 0
, 0
26 0
% 0
, 0
and 0
17 0
% 0
respectively 0
compared 0
with 0
the 0
baseline 0
values 0
( 0
all 0
P 0
< 0
0.05 0
) 0
. 0

Combination 0
treatment 0
decreased 0
the 0
TC B-PHYSICAL
, 0
LDL-C B-PHYSICAL
, 0
and 0
TG B-PHYSICAL
levels I-PHYSICAL
by 0
28 0
% 0
, 0
38 0
% 0
, 0
and 0
39 0
% 0
respectively 0
, 0
and 0
increased 0
the 0
HDL-C B-PHYSICAL
level I-PHYSICAL
by 0
23 0
% 0
( 0
all 0
P 0
< 0
0.05 0
) 0
. 0

The 0
improvement 0
in 0
TC B-PHYSICAL
and 0
LDL-C B-PHYSICAL
achieved 0
by 0
combination 0
treatment 0
was 0
superior 0
to 0
treatment 0
of 0
atorvastatin 0
alone 0
and 0
treatment 0
of 0
niacin 0
ER 0
alone 0
( 0
all 0
P 0
< 0
0.05 0
) 0
. 0
( 0

2 0
) 0
The 0
rate 0
of 0
achieving 0
the 0
LDL-C B-PHYSICAL
goal 0
of 0
The 0
National 0
Cholesterol 0
Education 0
Program 0
( 0
NCEP 0
) 0
in 0
Adult 0
Treatment 0
Panel 0
III 0
( 0
ATP 0
III 0
) 0
in 0
the 0
combination 0
therapy 0
group 0
was 0
73.5 0
% 0
, 0
significantly 0
higher 0
than 0
those 0
of 0
the 0
atorvastatin 0
and 0
niacin 0
groups 0
( 0
47.7 0
% 0
and 0
42.1 0
% 0
respectively 0
, 0
both 0
P 0
< 0
0.05 0
) 0
. 0
( 0

3 0
) 0
Adverse 0
effect 0
, 0
such 0
as 0
flushing B-ADVERSE-EFFECTS
( 0
15.8 0
% 0
) 0
and 0
gastrointestinal B-ADVERSE-EFFECTS
symptoms I-ADVERSE-EFFECTS
( 0
23.7 0
% 0
) 0
were 0
found 0
in 0
the 0
niacin 0
ER 0
group 0
, 0
however 0
, 0
no 0
more 0
adverse 0
effects 0
were 0
found 0
in 0
the 0
combination 0
therapy 0
group 0
. 0

There 0
were 0
no 0
serious 0
adverse 0
events 0
in 0
all 0
groups 0
. 0

CONCLUSION 0
Niacin 0
ER 0
has 0
a 0
favorable 0
effect 0
in 0
modulating 0
the 0
blood 0
lipid 0
profile 0
, 0
especially 0
in 0
reducing B-OTHER
TG B-PHYSICAL
and 0
elevating B-OTHER
HDL-C B-PHYSICAL
. 0

Combined 0
statin 0
with 0
niacin 0
may 0
produce 0
a 0
more 0
global B-PHYSICAL
and I-PHYSICAL
effective I-PHYSICAL
improvement I-PHYSICAL
in I-PHYSICAL
lipid I-PHYSICAL
blood I-PHYSICAL
levels I-PHYSICAL
than 0
monotherapy 0
and 0
is 0
generally 0
safe B-PHYSICAL
and 0
well B-PHYSICAL
tolerable I-PHYSICAL
. 0

[ 0
Local 0
therapy 0
of 0
grade 0
1 0
and 0
2 0
hemorrhoids 0
. 0

Effectiveness 0
of 0
a 0
combination 0
preparation 0
with 0
standardized 0
blood 0
leech 0
extract 0
] 0
. 0

AIMS 0
Testing 0
the 0
effectiveness 0
of 0
a 0
topical 0
combination 0
preparation 0
containing 0
standardized 0
leech 0
extract 0
, 0
polidocanol 0
and 0
allantoin 0
. 0

STUDY 0
DESIGN 0
Placebo-controlled 0
, 0
double-blind 0
study 0
in 0
80 0
patients 0
with 0
first 0
and 0
second 0
degree 0
hemorrhoids 0
; 0
duration 0
of 0
treatment 0
one 0
week 0
; 0
examinations 0
performed 0
on 0
admission 0
and 0
on 0
days 0
3 0
, 0
4 0
, 0
5 0
and 0
8 0
. 0

RESULTS 0
Both 0
the 0
subjective B-PHYSICAL
and I-PHYSICAL
objective I-PHYSICAL
symptoms I-PHYSICAL
and I-PHYSICAL
signs I-PHYSICAL
improved 0
during 0
the 0
one 0
week 0
of 0
treatment 0
statistically 0
significantly 0
more 0
rapidly 0
under 0
the 0
test 0
preparation 0
as 0
compared 0
with 0
placebo 0
. 0

Histologically 0
demonstrable 0
signs 0
of 0
inflammation B-PHYSICAL
were 0
more 0
clearly 0
improved 0
in 0
the 0
preparation 0
group 0
than 0
in 0
the 0
placebo 0
group 0
. 0

No 0
side 0
effects 0
were 0
observed 0
. 0

CONCLUSIONS 0
The 0
good 0
efficacy 0
and 0
tolerability 0
of 0
a 0
topical 0
therapeutic 0
preparation 0
in 0
first 0
and 0
second 0
degree 0
hemorrhoids 0
have 0
been 0
convincingly 0
demonstrated 0
. 0

Green 0
banana-supplemented 0
diet 0
in 0
the 0
home 0
management 0
of 0
acute B-PHYSICAL
and 0
prolonged B-PHYSICAL
diarrhoea I-PHYSICAL
in I-PHYSICAL
children I-PHYSICAL
: 0
a 0
community-based 0
trial 0
in 0
rural 0
Bangladesh 0
. 0

SUMMARY 0
OBJECTIVE 0
To 0
determine 0
the 0
effectiveness 0
of 0
green 0
banana 0
in 0
the 0
home 0
management 0
of 0
acute B-OTHER
( 0
< 0
7 0
days 0
) 0
or 0
prolonged B-MORTALITY
( 0
? 0

7 0
days 0
) 0
diarrhoea 0
at 0
the 0
community 0
level 0
. 0

METHODS 0
A 0
cluster 0
randomized 0
field 0
trial 0
was 0
conducted 0
among 0
2968 0
Bangladeshi 0
rural 0
children 0
6-36 0
months 0
old 0
. 0

Wards 0
( 0
villages 0
) 0
were 0
randomly 0
assigned 0
to 0
either 0
a 0
standard 0
care 0
group 0
or 0
a 0
standard 0
care 0
plus 0
green 0
banana 0
group 0
where 0
mothers 0
were 0
instructed 0
to 0
add 0
cooked 0
green 0
banana 0
to 0
the 0
diets 0
of 0
diarrhoeal 0
children 0
. 0

Through 0
a 0
village-based 0
surveillance 0
system 0
, 0
diarrhoeal 0
morbidity 0
data 0
( 0
severity 0
, 0
duration 0
, 0
compliance 0
) 0
were 0
collected 0
for 0
14 0
days 0
. 0

Treatment 0
effects 0
were 0
determined 0
by 0
analysing 0
cumulative 0
probability 0
of 0
cure 0
by 0
testing 0
Cox 0
proportional 0
hazards 0
models 0
and 0
relative 0
risk 0
( 0
RR 0
) 0
. 0

RESULTS 0
The 0
cumulative 0
probability 0
of 0
cure 0
was 0
significantly 0
( 0
P 0
< 0
0.001 0
) 0
different 0
in 0
children 0
receiving 0
GB 0
for 0
both 0
acute 0
[ 0
hazard 0
ratio 0
( 0
HR 0
) 0
= 0
0.63 0
( 0
95 0
% 0
CI 0
: 0
0.56-0.67 0
) 0
] 0
and 0
prolonged 0
diarrhoea 0
[ 0
HR 0
= 0
0.38 0
( 0
95 0
% 0
CI 0
: 0
0.26-0.59 0
) 0
] 0
. 0

The 0
recovery 0
rates 0
of 0
children 0
with 0
acute 0
diarrhoea 0
receiving 0
GB 0
( 0
vs. 0
control 0
) 0
were 0
significantly 0
more 0
by 0
day 0
3 0
: 0
79.9 0
% 0
vs 0
. 0

53.3 0
% 0
[ 0
( 0
RR 0
) 0
= 0
0.47 0
, 0
95 0
% 0
CI 0
: 0
0.41-0.55 0
] 0
, 0
( 0
P 0
< 0
0.001 0
) 0
and 0
day 0
7 0
: 0
96.6 0
% 0
vs 0
. 0

89.1 0
% 0
( 0
RR 0
= 0
0.32 0
; 0
0.22-0.46 0
) 0
, 0
( 0
P 0
< 0
0.001 0
) 0
. 0

Children 0
with 0
prolonged 0
diarrhoea 0
receiving 0
green 0
banana 0
had 0
significantly 0
higher 0
recovery 0
rates 0
by 0
day 0
10 0
: 0
79.8 0
% 0
vs 0
. 0

51.9 0
% 0
( 0
RR 0
= 0
0.42 0
; 0
0.23-0.73 0
) 0
, 0
( 0
P 0
< 0
0.001 0
) 0
and 0
day 0
14 0
: 0
93.6 0
% 0
vs 0
. 0

67.2 0
% 0
( 0
RR 0
= 0
0.22 0
; 0
0.08-0.54 0
) 0
, 0
( 0
P 0
< 0
0.001 0
) 0
. 0

CONCLUSION 0
A 0
green 0
banana-supplemented 0
diet 0
hastened 0
recovery 0
of 0
acute 0
and 0
prolonged 0
childhood 0
diarrhoea 0
managed 0
at 0
home 0
in 0
rural 0
Bangladesh 0
. 0

Effects 0
of 0
glucocorticoids 0
on 0
energy B-PHYSICAL
metabolism I-PHYSICAL
and 0
food B-MENTAL
intake I-MENTAL
in 0
humans 0
. 0

The 0
effect 0
of 0
glucocorticoid 0
administration 0
on 0
energy B-PHYSICAL
metabolism I-PHYSICAL
and 0
food B-MENTAL
intake I-MENTAL
was 0
studied 0
in 0
20 0
healthy 0
, 0
nondiabetic 0
Caucasian 0
male 0
volunteers 0
[ 0
27 0
+/- 0
5 0
( 0
SD 0
) 0
yr 0
, 0
72 0
+/- 0
9 0
kg 0
, 0
20 0
+/- 0
7 0
% 0
body 0
fat 0
] 0
randomly 0
and 0
blindly 0
assigned 0
to 0
glucocorticoid 0
( 0
methylprednisolone 0
, 0
METH 0
; 0
n 0
= 0
10 0
) 0
or 0
placebo 0
( 0
PLAC 0
; 0
n 0
= 0
10 0
) 0
treatment 0
. 0

Each 0
subject 0
was 0
studied 0
twice 0
: 0
during 0
a 0
weight 0
maintenance 0
diet 0
and 0
during 0
ad 0
libitum 0
food 0
intake 0
. 0

Energy B-PHYSICAL
metabolism I-PHYSICAL
was 0
measured 0
by 0
indirect 0
calorimetry 0
and 0
food B-MENTAL
intake I-MENTAL
by 0
an 0
automated 0
food-selection 0
system 0
. 0

Twenty-four-hour 0
urinary B-PHYSICAL
norepinephrine I-PHYSICAL
excretion I-PHYSICAL
( 0
24-h 0
NE 0
) 0
was 0
used 0
as 0
an 0
estimate 0
of 0
sympathetic B-PHYSICAL
nervous I-PHYSICAL
system I-PHYSICAL
activity I-PHYSICAL
. 0

During 0
weight 0
maintenance 0
, 0
METH 0
intravenous 0
infusion 0
( 0
125 0
mg/30 0
min 0
) 0
increased 0
energy B-PHYSICAL
expenditure I-PHYSICAL
compared 0
with 0
PLAC 0
, 0
and 0
after 0
4 0
days 0
of 0
oral 0
therapy 0
, 0
METH 0
( 0
40 0
mg/day 0
) 0
decreased 0
24-h B-PHYSICAL
NE I-PHYSICAL
and 0
increased 0
energy B-PHYSICAL
expenditure I-PHYSICAL
compared 0
with 0
PLAC 0
. 0

During 0
ad 0
libitum 0
food 0
intake 0
, 0
after 0
4 0
days 0
of 0
METH 0
( 0
40 0
mg/day 0
) 0
or 0
PLAC 0
oral 0
therapy 0
, 0
both 0
groups 0
increased 0
their 0
energy B-PHYSICAL
intake I-PHYSICAL
over 0
weight 0
maintenance 0
, 0
but 0
the 0
increase 0
was 0
significantly 0
larger 0
in 0
the 0
METH 0
group 0
compared 0
with 0
the 0
PLAC 0
group 0
( 0
4,554 0
+/- 0
1,857 0
vs. 0
2,867 0
+/- 0
846 0
kcal/day 0
; 0
P 0
= 0
0.04 0
) 0
. 0

Our 0
data 0
suggest 0
that 0
therapeutic 0
doses 0
of 0
glucocorticoids 0
induce 0
obesity 0
mostly 0
by 0
increasing 0
energy B-PHYSICAL
intake I-PHYSICAL
, 0
an 0
effect 0
which 0
may 0
be 0
related 0
to 0
the 0
ability 0
of 0
glucocorticoids 0
to 0
act 0
directly 0
or 0
indirectly 0
on 0
the 0
central 0
regulation 0
of 0
appetite 0
. 0

Preventing 0
disability B-PHYSICAL
and 0
managing B-PHYSICAL
chronic I-PHYSICAL
illness I-PHYSICAL
in 0
frail 0
older 0
adults 0
: 0
a 0
randomized 0
trial 0
of 0
a 0
community-based 0
partnership 0
with 0
primary 0
care 0
. 0

BACKGROUND 0
Effective 0
new 0
strategies 0
that 0
complement 0
primary 0
care 0
are 0
needed 0
to 0
reduce 0
disability 0
risks 0
and 0
improve 0
self-management 0
of 0
chronic B-PHYSICAL
illness I-PHYSICAL
in 0
frail 0
older 0
people 0
living 0
in 0
the 0
community 0
. 0

OBJECTIVE 0
To 0
evaluate 0
the 0
impact 0
of 0
a 0
1-year 0
, 0
senior 0
center-based 0
chronic B-PHYSICAL
illness I-PHYSICAL
self-management 0
and 0
disability 0
prevention 0
program 0
on 0
health 0
, 0
functioning 0
, 0
and 0
healthcare B-PHYSICAL
utilization I-PHYSICAL
in 0
frail 0
older 0
adults 0
. 0

DESIGN 0
A 0
randomized 0
controlled 0
trial 0
. 0

SETTING 0
A 0
large 0
senior 0
center 0
located 0
in 0
a 0
northeast 0
Seattle 0
suburb 0
. 0

The 0
trial 0
was 0
conducted 0
in 0
collaboration 0
with 0
primary 0
care 0
providers 0
of 0
two 0
large 0
managed 0
care 0
organizations 0
. 0

PARTICIPANTS 0
A 0
total 0
of 0
201 0
chronically 0
ill 0
older 0
adults 0
seniors 0
aged 0
70 0
and 0
older 0
recruited 0
through 0
medical 0
practices 0
. 0

INTERVENTION 0
A 0
targeted 0
, 0
multi-component 0
disability 0
prevention 0
and 0
disease 0
self-management 0
program 0
led 0
by 0
a 0
geriatric 0
nurse 0
practitioner 0
( 0
GNP 0
) 0
. 0

MEASUREMENTS 0
Self-reported 0
Physical 0
function 0
, 0
physical 0
performance 0
tests 0
, 0
health B-PHYSICAL
care I-PHYSICAL
utilization I-PHYSICAL
, 0
and 0
health 0
behaviors 0
. 0

RESULTS 0
Each 0
of 0
101 0
intervention 0
participants 0
met 0
with 0
the 0
GNP 0
from 0
1 0
to 0
8 0
times 0
( 0
median 0
= 0
3 0
) 0
during 0
the 0
study 0
year 0
. 0

The 0
intervention 0
group 0
showed 0
less 0
decline 0
in 0
function B-PHYSICAL
, 0
as 0
measured 0
by 0
disability 0
days 0
and 0
lower 0
scores 0
on 0
the 0
Health B-PHYSICAL
Assessment I-PHYSICAL
Questionnaire 0
. 0

Other 0
measures 0
of 0
function 0
, 0
including 0
the 0
SF-36 B-PHYSICAL
and 0
a 0
battery 0
of 0
physical 0
performance 0
tests 0
, 0
did 0
not 0
change 0
with 0
the 0
intervention 0
. 0

The 0
number 0
of 0
hospitalized B-OTHER
participants I-OTHER
increased 0
by 0
69 0
% 0
among 0
the 0
controls 0
and 0
decreased 0
by 0
38 0
% 0
in 0
the 0
intervention 0
group 0
( 0
P 0
= 0
.083 0
) 0
. 0

The 0
total 0
number 0
of 0
inpatient B-OTHER
hospital I-OTHER
days I-OTHER
during 0
the 0
study 0
year 0
was 0
significantly 0
less 0
in 0
the 0
intervention 0
group 0
compared 0
with 0
controls 0
( 0
total 0
days 0
= 0
33 0
vs 0
116 0
, 0
P 0
= 0
.049 0
) 0
. 0

The 0
intervention 0
led 0
to 0
significantly 0
higher 0
levels 0
of 0
physical B-PHYSICAL
activity I-PHYSICAL
and 0
senior B-MENTAL
center I-MENTAL
participation I-MENTAL
and 0
significant 0
reductions 0
in 0
the 0
use 0
of 0
psychoactive B-PHYSICAL
medications I-PHYSICAL
. 0

CONCLUSIONS 0
This 0
project 0
provides 0
evidence 0
that 0
a 0
community-based 0
collaboration 0
with 0
primary 0
care 0
providers 0
can 0
improve 0
function B-PHYSICAL
and 0
reduce 0
inpatient B-OTHER
utilization I-OTHER
in 0
chronically 0
ill 0
older 0
adults 0
. 0

Linking 0
organized 0
medical 0
care 0
with 0
complementary 0
community-based 0
interventions 0
may 0
be 0
a 0
promising 0
direction 0
for 0
research 0
and 0
practice 0
. 0

Results 0
of 0
a 0
phase 0
I/II 0
trial 0
of 0
recombinant 0
human 0
granulocyte-macrophage 0
colony-stimulating 0
factor 0
in 0
very 0
low 0
birthweight 0
neonates 0
: 0
significant 0
induction 0
of 0
circulatory 0
neutrophils 0
, 0
monocytes 0
, 0
platelets 0
, 0
and 0
bone 0
marrow 0
neutrophils 0
. 0

Neonates 0
, 0
especially 0
those 0
of 0
very 0
low 0
birthweight 0
( 0
VLBW 0
) 0
, 0
have 0
an 0
increased 0
risk 0
of 0
nosocomial 0
infections 0
secondary 0
to 0
deficiencies 0
in 0
development 0
. 0

We 0
previously 0
demonstrated 0
that 0
granulocyte-macrophage 0
colony-stimulating 0
factor 0
( 0
GM-CSF 0
) 0
production 0
and 0
mRNA 0
expression 0
from 0
stimulated 0
neonatal 0
mononuclear 0
cells 0
are 0
significantly 0
less 0
than 0
that 0
from 0
adult 0
cells 0
. 0

Recombinant 0
murine 0
GM-CSF 0
administration 0
to 0
neonatal 0
rats 0
has 0
resulted 0
in 0
neutrophilia 0
, 0
increased 0
neutrophil 0
production 0
, 0
and 0
increased 0
survival 0
of 0
pups 0
during 0
experimental 0
Staphylococcus 0
aureus 0
sepsis 0
. 0

In 0
the 0
present 0
study 0
, 0
we 0
sought 0
to 0
determine 0
the 0
safety 0
and 0
biologic 0
response 0
of 0
recombinant 0
human 0
( 0
rhu 0
) 0
GM-CSF 0
in 0
VLBW 0
neonates 0
. 0

Twenty 0
VLBW 0
neonates 0
( 0
500 0
to 0
1,500 0
g 0
) 0
, 0
aged 0
< 0
72 0
hours 0
, 0
were 0
randomized 0
to 0
receive 0
either 0
placebo 0
( 0
n 0
= 0
5 0
) 0
or 0
rhuGM-CSF 0
at 0
5.0 0
micrograms/kg 0
once 0
per 0
day 0
( 0
n 0
= 0
5 0
) 0
, 0
5.0 0
micrograms/kg 0
twice 0
per 0
day 0
( 0
n 0
= 0
5 0
) 0
, 0
or 0
10 0
micrograms/kg 0
once 0
per 0
day 0
( 0
n 0
= 0
5 0
) 0
given 0
via 0
2-hour 0
intravenous 0
infusion 0
for 0
7 0
days 0
. 0

Complete 0
blood 0
counts 0
, 0
differential 0
, 0
and 0
platelet 0
counts 0
were 0
obtained 0
, 0
and 0
tibial 0
bone 0
marrow 0
aspirate 0
was 0
performed 0
on 0
day 0
8 0
. 0

Neutrophil 0
C3bi 0
receptor 0
expression 0
was 0
measured 0
at 0
0 0
and 0
24 0
hours 0
. 0

GM-CSF B-PHYSICAL
levels I-PHYSICAL
were 0
measured 0
by 0
a 0
sandwich 0
enzyme-linked 0
immunosorbent 0
assay 0
at 0
2 0
, 0
4 0
, 0
6 0
, 0
12 0
, 0
and 0
24 0
hours 0
after 0
the 0
first 0
dose 0
of 0
rhuGM-CSF 0
. 0

At 0
all 0
doses 0
, 0
rhuGM-CSF 0
was 0
well 0
tolerated 0
, 0
and 0
there 0
was 0
no 0
evidence 0
of 0
grade 0
III B-PHYSICAL
or 0
IV B-PHYSICAL
toxicity I-PHYSICAL
. 0

Within 0
48 0
hours 0
of 0
administration 0
, 0
there 0
was 0
a 0
significant 0
increase 0
in 0
the 0
circulating B-PHYSICAL
absolute I-PHYSICAL
neutrophil I-PHYSICAL
count I-PHYSICAL
( 0
ANC B-PHYSICAL
) 0
at 0
5.0 0
micrograms/kg 0
twice 0
per 0
day 0
and 0
10.0 0
micrograms/kg 0
once 0
per 0
day 0
, 0
which 0
continued 0
for 0
at 0
least 0
24 0
hours 0
after 0
discontinuation 0
of 0
rhuGM-CSF 0
. 0

When 0
the 0
ANC 0
was 0
normalized 0
for 0
each 0
patient 0
's 0
first 0
ANC 0
, 0
there 0
was 0
a 0
significant 0
increase 0
in 0
the 0
ANC B-PHYSICAL
on 0
days 0
6 0
and 0
7 0
at 0
each 0
dose 0
level 0
. 0

By 0
day 0
7 0
, 0
all 0
tested 0
doses 0
of 0
rhuGM-CSF 0
resulted 0
in 0
an 0
increase 0
in 0
the 0
absolute B-PHYSICAL
monocyte I-PHYSICAL
count I-PHYSICAL
( I-PHYSICAL
AMC I-PHYSICAL
) I-PHYSICAL
compared 0
with 0
placebo-treated 0
neonates 0
. 0

In 0
those 0
receiving 0
rhuGM-CSF 0
5.0 0
micrograms/kg 0
twice 0
per 0
day 0
, 0
there 0
was 0
additionally 0
a 0
significant 0
increase 0
in 0
the 0
day B-PHYSICAL
7 I-PHYSICAL
and 0
8 B-PHYSICAL
platelet I-PHYSICAL
count I-PHYSICAL
. 0

Tibial 0
bone 0
marrow 0
aspirates 0
demonstrated 0
a 0
significant 0
increase 0
in 0
the 0
bone B-PHYSICAL
marrow I-PHYSICAL
neutrophil I-PHYSICAL
storage I-PHYSICAL
pool I-PHYSICAL
( I-PHYSICAL
BM I-PHYSICAL
NSP I-PHYSICAL
) I-PHYSICAL
at 0
5.0 0
micrograms/kg 0
twice 0
per 0
day 0
and 0
10.0 0
micrograms/kg 0
once 0
per 0
day 0
. 0

Neutrophil B-PHYSICAL
C3bi I-PHYSICAL
receptor I-PHYSICAL
expression I-PHYSICAL
was 0
significantly 0
increased 0
24 0
hours 0
after 0
the 0
first 0
dose 0
of 0
rhuGM-CSF 0
at 0
5.0 0
micrograms/kg 0
once 0
per 0
day 0
. 0

The 0
elimination 0
half-life 0
( 0
T1/2 0
) 0
of 0
rhuGM-CSF 0
was 0
1.4 0
+/- 0
0.8 0
to 0
3.9 0
+/- 0
2.8 0
hours 0
. 0
( 0

ABSTRACT 0
TRUNCATED 0
AT 0
400 0
WORDS 0
) 0

Patterns 0
of 0
management 0
of 0
atrial 0
fibrillation 0
complicating 0
coronary 0
artery 0
bypass 0
grafting 0
: 0
Results 0
from 0
the 0
PRoject 0
of 0
Ex-vivo 0
Vein 0
graft 0
ENgineering 0
via 0
Transfection 0
IV 0
( 0
PREVENT-IV 0
) 0
Trial 0
. 0

BACKGROUND 0
Current 0
practice 0
related 0
to 0
the 0
management 0
of 0
atrial 0
fibrillation B-PHYSICAL
( I-PHYSICAL
AF I-PHYSICAL
) I-PHYSICAL
complicating 0
coronary 0
artery 0
bypass 0
grafting 0
( 0
CABG 0
) 0
is 0
uncertain 0
. 0

METHODS 0
We 0
examined 0
management 0
of 0
post-CABG 0
AF 0
in 0
the 0
PREVENT-IV 0
trial 0
, 0
and 0
we 0
explored 0
patterns 0
of 0
use 0
of 0
postoperative 0
rhythm 0
versus 0
rate 0
control 0
and 0
anticoagulation 0
for 0
AF B-PHYSICAL
by 0
geographic 0
region 0
and 0
type 0
of 0
site 0
. 0

We 0
also 0
compared 0
outcomes 0
of 0
patients 0
who 0
developed 0
post-CABG 0
AF 0
( 0
663 0
) 0
with 0
those 0
who 0
did 0
not 0
( 0
2,131 0
) 0
. 0

RESULTS 0
The 0
incidence 0
of 0
AF B-PHYSICAL
was 0
24 0
% 0
. 0

Post-CABG B-PHYSICAL
AF I-PHYSICAL
was 0
treated 0
with 0
a 0
rhythm 0
control 0
strategy 0
in 0
81 0
% 0
of 0
patients 0
and 0
with 0
warfarin 0
in 0
23 0
% 0
of 0
patients 0
. 0

Although 0
there 0
were 0
significant 0
variations 0
across 0
sites 0
in 0
the 0
management 0
of 0
post-CABG B-PHYSICAL
AF I-PHYSICAL
, 0
patterns 0
of 0
use 0
of 0
postoperative 0
rhythm 0
versus 0
rate 0
control 0
and 0
anticoagulation 0
did 0
not 0
differ 0
by 0
geographic 0
region 0
or 0
by 0
whether 0
or 0
not 0
the 0
enrolling 0
site 0
was 0
an 0
academic 0
institution 0
. 0

Mortality B-MORTALITY
was 0
higher 0
in 0
patients 0
with 0
post-CABG 0
AF 0
than 0
patients 0
without 0
AF 0
at 0
30 0
days 0
( 0
1.5 0
% 0
vs 0
0.7 0
% 0
, 0
P 0
= 0
.01 0
) 0
but 0
not 0
at 0
3 0
years 0
( 0
6.9 0
% 0
vs 0
4.9 0
% 0
, 0
P 0
= 0
.41 0
) 0
. 0

There 0
was 0
a 0
trend 0
toward 0
a 0
higher 0
risk 0
of 0
mortality B-MORTALITY
or 0
stroke B-PHYSICAL
at 0
30 0
days 0
in 0
patients 0
with 0
AF 0
( 0
2.4 0
% 0
vs 0
1.9 0
% 0
, 0
P 0
= 0
.08 0
) 0
. 0

CONCLUSION 0
Although 0
a 0
rhythm 0
control 0
strategy 0
was 0
used 0
in 0
most 0
of 0
the 0
patients 0
in 0
this 0
trial 0
and 0
the 0
overall 0
rate 0
of 0
use 0
of 0
warfarin 0
was 0
low 0
, 0
the 0
significance 0
of 0
these 0
findings 0
is 0
uncertain 0
because 0
of 0
the 0
lack 0
of 0
data 0
from 0
randomized 0
clinical 0
trials 0
. 0

The 0
substantial 0
variations 0
in 0
the 0
management 0
of 0
post-CABG 0
AF 0
across 0
sites 0
are 0
likely 0
because 0
of 0
definitive 0
data 0
on 0
the 0
most 0
effective 0
therapies 0
, 0
highlighting 0
the 0
need 0
for 0
clinical 0
trials 0
on 0
rate 0
versus 0
rhythm 0
control 0
and 0
on 0
anticoagulation 0
for 0
AF 0
in 0
this 0
setting 0
. 0

Effects 0
of 0
clonidine 0
on 0
postoperative 0
nausea 0
and 0
vomiting 0
in 0
breast 0
cancer 0
surgery 0
. 0

BACKGROUND 0
Postoperative 0
nausea 0
and 0
vomiting 0
( 0
PONV 0
) 0
is 0
still 0
common 0
, 0
especially 0
among 0
female 0
patients 0
. 0

Our 0
hypothesis 0
is 0
that 0
coinduction 0
with 0
clonidine 0
reduces 0
the 0
incidence 0
of 0
PONV 0
in 0
adult 0
patients 0
undergoing 0
breast 0
cancer 0
surgery 0
. 0

METHODS 0
Sixty-eight 0
women 0
premedicated 0
with 0
midazolam 0
were 0
randomly 0
allocated 0
to 0
coinduction 0
with 0
intravenous 0
clonidine 0
( 0
group 0
C 0
) 0
or 0
placebo 0
( 0
group 0
P 0
) 0
in 0
this 0
prospective 0
, 0
double-blind 0
study 0
. 0

Anesthesia 0
was 0
standardized 0
( 0
laryngeal 0
mask 0
airway 0
, 0
fentanyl 0
, 0
propofol 0
, 0
sevoflurane 0
, 0
nitrous 0
oxide 0
, 0
and 0
oxygen 0
) 0
. 0

Hemodynamic 0
parameters 0
and 0
the 0
requirements 0
for 0
propofol 0
, 0
sevoflurane 0
, 0
and 0
the 0
postoperative 0
need 0
for 0
ketobemidone 0
were 0
noted 0
. 0

The 0
primary 0
endpoints 0
studied 0
were 0
the 0
number 0
of 0
PONV-free B-PHYSICAL
patients I-PHYSICAL
and 0
patient B-MENTAL
satisfaction I-MENTAL
with I-MENTAL
respect I-MENTAL
to I-MENTAL
PONV I-MENTAL
. 0

RESULTS 0
Patients 0
in 0
group 0
C 0
had 0
a 0
significantly 0
reduced B-OTHER
need I-OTHER
for I-OTHER
propofol I-OTHER
( 0
P 0
< 0
0.04 0
) 0
and 0
sevoflurane 0
( 0
P 0
< 0
0.01 0
) 0
and 0
a 0
reduced 0
early B-OTHER
need I-OTHER
for I-OTHER
ketobemidone I-OTHER
( 0
P 0
< 0
0.04 0
) 0
. 0

There 0
were 0
significantly 0
more 0
PONV-free B-PHYSICAL
patients I-PHYSICAL
in 0
group 0
C 0
compared 0
with 0
group 0
P 0
( 0
20 0
and 0
11 0
of 0
30 0
, 0
respectively 0
; 0
P 0
< 0
0.04 0
) 0
. 0

The 0
number 0
needed 0
to 0
treat 0
was 0
3.3 0
( 0
95 0
% 0
confidence 0
interval 0
, 0
1.8 0
, 0
16.9 0
) 0
. 0

Intraoperative B-PHYSICAL
blood I-PHYSICAL
pressure I-PHYSICAL
, 0
postoperative B-PHYSICAL
heart I-PHYSICAL
rate I-PHYSICAL
, 0
and 0

Phase 0
III 0
trial 0
of 0
induction 0
gemcitabine 0
or 0
paclitaxel 0
plus 0
carboplatin 0
followed 0
by 0
paclitaxel 0
consolidation 0
in 0
ovarian 0
cancer 0
. 0

OBJECTIVE 0
The 0
safety 0
and 0
efficacy 0
of 0
gemcitabine 0
plus 0
carboplatin 0
( 0
GC 0
) 0
or 0
paclitaxel 0
plus 0
carboplatin 0
( 0
TC 0
) 0
induction 0
regimens 0
with 0
or 0
without 0
paclitaxel 0
consolidation 0
therapy 0
were 0
assessed 0
in 0
ovarian 0
cancer 0
( 0
OC 0
) 0
. 0

METHODS 0
Patients 0
with 0
stage 0
IC-IV 0
OC 0
were 0
randomized 0
to 0
either 0
GC 0
( 0
gemcitabine 0
1,000 0
mg/m 0
( 0
2 0
) 0
, 0
days 0
1 0
and 0
8 0
, 0
plus 0
carboplatin 0
area 0
under 0
the 0
curve 0
[ 0
AUC 0
] 0
5 0
, 0
day 0
1 0
) 0
or 0
TC 0
( 0
paclitaxel 0
175 0
mg/m 0
( 0
2 0
) 0
plus 0
carboplatin 0
AUC 0
6 0
, 0
day 0
1 0
) 0
every 0
21 0
days 0
for 0
up 0
to 0
six 0
cycles 0
. 0

Patients 0
with 0
complete B-PHYSICAL
response 0
( B-PHYSICAL
CR I-PHYSICAL

Nebulized 0
racemic 0
epinephrine 0
by 0
IPPB 0
for 0
the 0
treatment 0
of 0
croup 0
: 0
a 0
double-blind 0
study 0
. 0

Racemic 0
epinephrine 0
has 0
been 0
advocated 0
for 0
the 0
treatment 0
of 0
croup 0
, 0
but 0
controlled 0
studies 0
have 0
not 0
proved 0
it 0
more 0
effective 0
than 0
saline 0
. 0

Twenty 0
patients 0
( 0
aged 0
4 0
months 0
to 0
5 0
years 0
) 0
hospitalized 0
with 0
acute 0
croup 0
and 0
persistent 0
inspiratory 0
stridor 0
at 0
rest 0
were 0
randomly 0
assigned 0
to 0
one 0
of 0
two 0
treatment 0
groups 0
: 0
saline 0
or 0
racemic 0
epinephrine 0
, 0
both 0
nebulized 0
and 0
delivered 0
by 0
intermittent 0
positive 0
pressure 0
breathing 0
. 0

Clinical B-PHYSICAL
scores I-PHYSICAL
were 0
significantly 0
improved 0
( 0
P 0
less 0
than 0
.01 0
) 0
at 0
ten 0
and 0
30 0
minutes 0
following 0
the 0
treatment 0
with 0
racemic 0
epinephrine 0
but 0
not 0
at 0
120 0
minutes 0
. 0

Racemic 0
epinephrine 0
was 0
significantly 0
more 0
effective 0
than 0
saline 0
at 0
10 0
( 0
P 0
less 0
than 0
.01 0
) 0
and 0
30 0
minutes 0
( 0
P 0
less 0
than 0
.05 0
) 0
but 0
not 0
at 0
120 0
minutes 0
after 0
the 0
treatment 0
. 0

We 0
conclude 0
that 0
nebulized 0
racemic 0
epinephrine 0
is 0
effective 0
treatment 0
for 0
the 0
acute 0
signs 0
of 0
croup 0
. 0

An 0
exploratory 0
study 0
: 0
the 0
use 0
of 0
paroxetine 0
for 0
methamphetamine B-PHYSICAL
craving I-PHYSICAL
. 0

Methamphetamine 0
abuse 0
and 0
dependence 0
are 0
growing 0
problems 0
nationally 0
and 0
worldwide 0
. 0

There 0
are 0
currently 0
no 0
effective 0
pharmocologic 0
treatments 0
. 0

Animal 0
studies 0
with 0
SSRI 0
's 0
suggest 0
that 0
serotonergic 0
modulation 0
alters 0
methamphetamine 0
's 0
behavioral B-MENTAL
effects I-MENTAL
. 0

This 0
exploratory 0
study 0
is 0
a 0
trial 0
of 0
the 0
effects 0
of 0
the 0
SSRI 0
paroxetine 0
versus 0
placebo 0
( 0
in 0
a 0
double 0
blind 0
design 0
) 0
on 0
craving 0
and 0
use 0
in 0
a 0
population 0
of 0
methamphetamine 0
users 0
. 0

Many 0
subjects 0
dropped 0
out 0
of 0
the 0
study 0
, 0
but 0
those 0
in 0
active 0
treatment 0
who 0
completed 0
the 0
eight 0
week 0
trial 0
had 0
a 0
decrease 0
in 0
methamphetamine B-PHYSICAL
craving I-PHYSICAL
compared 0
to 0
the 0
placebo 0
treatment 0
as 0
measured 0
by 0
the 0
OCDS 0
modified 0
for 0
use 0
in 0
this 0
population 0
. 0

Statistical 0
analyses 0
were 0
not 0
performed 0
due 0
to 0
the 0
low 0
number 0
of 0
subjects 0
. 0

The 0
preliminary 0
data 0
suggest 0
that 0
serotonergic 0
agents 0
may 0
play 0
a 0
role 0
in 0
the 0
effective 0
treatment 0
of 0
methamphetamine B-PHYSICAL
abuse I-PHYSICAL
and 0
dependence B-PHYSICAL
within 0
the 0
context 0
of 0
other 0
effective 0
behavioral 0
interventions 0
. 0

A 0
prospective 0
randomized 0
trial 0
of 0
Duraflo 0
II 0
heparin-coated 0
circuits 0
in 0
cardiac 0
reoperations 0
. 0

BACKGROUND 0
Heparin-coated 0
circuits 0
in 0
cardiopulmonary 0
bypass 0
have 0
been 0
shown 0
to 0
decrease 0
the 0
systemic 0
inflammatory 0
responses 0
associated 0
with 0
cardiopulmonary 0
bypass 0
. 0

Previous 0
clinical 0
studies 0
on 0
low-risk 0
patients 0
who 0
had 0
coronary 0
artery 0
bypass 0
grafting 0
( 0
CABG 0
) 0
and 0
received 0
full-dose 0
systemic 0
heparin 0
did 0
not 0
have 0
clearly 0
improved 0
clinical 0
outcomes 0
. 0

We 0
hypothesized 0
that 0
the 0
beneficial 0
effects 0
of 0
heparin-coated 0
circuits 0
might 0
be 0
seen 0
in 0
patients 0
who 0
had 0
cardiac 0
reoperations 0
. 0

METHODS 0
Three 0
hundred 0
fifty 0
patients 0
who 0
had 0
reoperation 0
with 0
CABG 0
only 0
( 0
58 0
% 0
) 0
, 0
or 0
with 0
valve 0
operations 0
( 0
42 0
% 0
) 0
were 0
randomly 0
assigned 0
to 0
receive 0
either 0
a 0
heparin-coated 0
( 0
Duraflo 0
II 0
; 0
study 0
group 0
) 0
or 0
uncoated 0
( 0
control 0
group 0
) 0
circuit 0
. 0

Clinical 0
outcomes 0
were 0
compared 0
and 0
the 0
variables 0
were 0
analyzed 0
using 0
the 0
following 0
three 0
groups 0
: 0
entire 0
populations 0
of 0
study 0
group 0
and 0
control 0
group 0
, 0
subgroup 0
of 0
patients 0
who 0
had 0
CABG 0
reoperation 0
only 0
, 0
and 0
a 0
subgroup 0
who 0
had 0
valve 0
reoperation 0
or 0
combined 0
valve 0
and 0
CABG 0
reoperation 0
. 0

RESULTS 0
Preoperative 0
variables 0
were 0
the 0
same 0
in 0
both 0
groups 0
. 0

No 0
difference 0
in 0
clinical 0
outcomes 0
could 0
be 0
demonstrated 0
except 0
that 0
the 0
percentage 0
of 0
patients B-ADVERSE-EFFECTS
with I-ADVERSE-EFFECTS
major I-ADVERSE-EFFECTS
bleeding I-ADVERSE-EFFECTS
episodes I-ADVERSE-EFFECTS
was 0
significantly 0
lower 0
in 0
the 0
study 0
group 0
( 0
1.2 0
% 0
versus 0
5.4 0
% 0
, 0
p 0
= 0
0.035 0
) 0
. 0

In 0
the 0
subgroup 0
analysis 0
of 0
patients 0
who 0
had 0
valve B-PHYSICAL
reoperations I-PHYSICAL
, 0
lower 0
blood B-PHYSICAL
transfusion I-PHYSICAL
requirements I-PHYSICAL
in 0
the 0
intensive 0
care 0
unit 0
( 0
p 0
= 0
0.013 0
) 0
were 0
found 0
in 0
the 0
study 0
group 0
. 0

When 0
the 0
subgroup 0
of 0
patients 0
who 0
had 0
CABG 0
reoperations 0
was 0
analyzed 0
separately 0
, 0
there 0
was 0
a 0
trend 0
toward 0
less 0
reoperation B-PHYSICAL
for I-PHYSICAL
bleeding I-PHYSICAL
in 0
the 0
study 0
group 0
( 0
0 0
% 0
versus 0
4.0 0
% 0
, 0
p 0
= 0
0.058 0
) 0
. 0

CONCLUSIONS 0
We 0
conclude 0
that 0
the 0
use 0
of 0
heparin-coated 0
circuits 0
was 0
safe 0
and 0
imparted 0
protection 0
from 0
reoperations 0
for 0
bleeding 0
and 0
major 0
bleeding 0
episodes 0
. 0

Material-independent 0
blood 0
activation 0
( 0
eg 0
, 0
blood-air 0
interface 0
and 0
cardiotomy 0
suction 0
) 0
blunted 0
the 0
total 0
effect 0
of 0
the 0
heparin-coated 0
surface 0
. 0

Deliberate 0
mild 0
intraoperative 0
hypothermia 0
for 0
craniotomy 0
. 0

BACKGROUND 0
Despite 0
enthusiasm 0
for 0
the 0
use 0
of 0
mild 0
hypothermia 0
during 0
neurosurgical 0
procedures 0
, 0
this 0
therapy 0
has 0
not 0
been 0
evaluated 0
systematically 0
. 0

This 0
study 0
examined 0
the 0
feasibility 0
and 0
safety 0
of 0
deliberate 0
mild 0
hypothermia 0
and 0
rewarming 0
. 0

METHODS 0
Thirty 0
patients 0
scheduled 0
for 0
craniotomy 0
were 0
assigned 0
to 0
either 0
a 0
normothermic 0
or 0
mildly 0
hypothermic 0
group 0
. 0

Tympanic 0
membrane 0
temperature 0
was 0
monitored 0
at 0
anesthetic 0
induction 0
, 0
throughout 0
the 0
isoflurane-fentanyl-N2O-O2 0
anesthetic 0
, 0
and 0
for 0
18 0
h 0
postoperatively 0
. 0

Normothermic 0
patients 0
were 0
warmed 0
to 0
36.5-37.0 0
degrees 0
C 0
after 0
an 0
initial 0
temperature 0
decrease 0
, 0
and 0
hypothermic 0
patients 0
were 0
cooled 0
to 0
35 0
degrees 0
C. 0
In 0
the 0
hypothermic 0
group 0
temperatures 0
were 0
allowed 0
to 0
drift 0
to 0
34.5 0
degrees 0
C 0
before 0
rewarming 0
was 0
initiated 0
. 0

Water 0
blankets 0
and 0
convective 0
heating 0
devices 0
were 0
used 0
to 0
cool 0
and 0
rewarm 0
. 0

RESULTS 0
The 0
minimum B-PHYSICAL
temperature I-PHYSICAL
achieved 0
by 0
the 0
hypothermic 0
group 0
was 0
34.3 0
+/- 0
0.4 0
degrees 0
C. 0
Cooling B-PHYSICAL
occurred 0
at 0
a 0
rate 0
of 0
1.0 0
+/- 0
0.4 0
degrees 0
C/h 0
. 0

Rewarming B-OTHER
took 0
place 0
at 0
a 0
rate 0
of 0
0.7 0
+/- 0
0.6 0
degrees 0
C/h 0
( 0
range 0
0.1-1.8 0
) 0
in 0
the 0
hypothermic 0
group 0
. 0

Hypothermia B-OTHER
did 0
not 0
delay 0
emergence 0
from 0
anesthesia B-PHYSICAL
( 0
20 0
+/- 0
15 0
min 0
) 0
compared 0
with 0
normothermia 0
( 0
15 0
+/- 0
15 0
min 0
, 0
P 0
= 0
.45 0
) 0
. 0

Mean 0
temperature 0
upon 0
intensive B-OTHER
care I-OTHER
unit I-OTHER
admission I-OTHER
was 0
35.8 0
+/- 0
1.0 0
degrees 0
C 0
for 0
the 0
hypothermic 0
group 0
and 0
37.1 0
+/- 0
0.5 0
degrees 0
C 0
for 0
the 0
normothermic 0
group 0
( 0
P 0
< 0
0.0001 0
) 0
. 0

The 0
hypothermic 0
patients 0
had 0
more 0
postoperative B-OTHER
shivering I-OTHER
. 0

From 0
8 0
to 0
18 0
h 0
postoperatively 0
the 0
temperatures B-PHYSICAL
of 0
the 0
two 0
groups 0
were 0
similar 0
except 0
for 0
a 0
slightly 0
greater 0
temperature B-OTHER
in 0
the 0
hypothermic 0
patients 0
at 0
12 0
h 0
( 0
37.6 0
+/- 0
0.5 0
vs. 0
37.3 0
+/- 0
0.4 0
degrees 0
C 0
, 0
P 0
= 0
.029 0
) 0
. 0

CONCLUSIONS 0
Although 0
deliberate 0
mild 0
hypothermia 0
is 0
easily 0
achieved 0
intraoperatively 0
, 0
complete 0
rewarming 0
may 0
be 0
difficult 0
to 0
attain 0
during 0
craniotomy 0
with 0
current 0
methods 0
. 0

In 0
addition 0
to 0
the 0
need 0
for 0
determining 0
whether 0
deliberate 0
mild 0
hypothermia 0
confers 0
cerebral 0
protection 0
in 0
humans 0
, 0
the 0
potential 0
risks 0
of 0
the 0
therapy 0
need 0
to 0
be 0
further 0
characterized 0
. 0

Benefits B-OTHER
, 0
morbidity B-PHYSICAL
, 0
and 0
mortality B-MORTALITY
associated 0
with 0
long-term 0
administration 0
of 0
oral 0
anticoagulant 0
therapy 0
to 0
patients 0
with 0
peripheral 0
arterial 0
bypass 0
procedures 0
: 0
a 0
prospective 0
randomized 0
study 0
. 0

BACKGROUND 0
The 0
benefits 0
of 0
the 0
long-term 0
administration 0
of 0
oral 0
anticoagulant 0
therapy 0
remain 0
unclear 0
in 0
patients 0
with 0
lower 0
extremity 0
arterial 0
bypass 0
surgery 0
. 0

We 0
studied 0
the 0
effect 0
of 0
warfarin 0
plus 0
aspirin 0
therapy 0
( 0
WASA 0
) 0
versus 0
aspirin 0
therapy 0
alone 0
( 0
ASA 0
) 0
on 0
patient B-MORTALITY
mortality I-MORTALITY
, 0
morbidity B-PHYSICAL
and 0
bypass B-PHYSICAL
patency I-PHYSICAL
rates I-PHYSICAL
in 0
a 0
randomized 0
clinical 0
trial 0
. 0

METHODS 0
In 0
a 0
multicenter 0
, 0
prospective 0
, 0
nonmasked 0
clinical 0
trial 0
, 0
831 0
patients 0
who 0
underwent 0
peripheral 0
arterial 0
bypass 0
surgery 0
were 0
compared 0
in 0
a 0
long-term 0
treatment 0
program 0
of 0
WASA 0
( 0
target 0
international 0
normalized 0
ratio 0
of 0
1.4 0
to 0
2.8 0
; 0
325 0
mg/day 0
) 0
with 0
ASA 0
( 0
325 0
mg/day 0
) 0
. 0

The 0
primary 0
end 0
point 0
was 0
bypass B-PHYSICAL
patency I-PHYSICAL
, 0
and 0
mortality B-MORTALITY
and 0
morbidity B-PHYSICAL
were 0
the 0
secondary 0
endpoints 0
. 0

RESULTS 0
There 0
were 0
133 0
deaths B-MORTALITY
in 0
the 0
WASA 0
group 0
( 0
31.8 0
% 0
) 0
and 0
95 0
deaths B-MORTALITY
in 0
the 0
ASA 0
group 0
( 0
23.0 0
% 0
; 0
risk 0
ratio 0
, 0
1.41 0
; 0
95 0
% 0
confidence 0
interval 0
, 0
1.09 0
to 0
1.84 0
; 0
P 0
=.0001 0
) 0
. 0

Major B-PHYSICAL
hemorrhagic I-PHYSICAL
events I-PHYSICAL
occurred 0
more 0
frequently 0
in 0
the 0
WASA 0
group 0
( 0
WASA 0
, 0
n 0
= 0
35 0
; 0
ASA 0
, 0
n 0
= 0
15 0
; 0
P 0
=.02 0
) 0
. 0

In 0
the 0
prosthetic 0
bypass 0
group 0
, 0
there 0
was 0
no 0
significant 0
difference 0
in 0
patency B-OTHER
rate I-OTHER
in 0
the 0
8-mm 0
bypass 0
subgroup 0
, 0
but 0
there 0
was 0
a 0
significant 0
difference 0
in 0
patency B-OTHER
rate I-OTHER
in 0
the 0
6-mm 0
bypass 0
subgroup 0
( 0
femoral-popliteal 0
; 0
71.4 0
% 0
in 0
the 0
WASA 0
group 0
versus 0
57.9 0
% 0
in 0
the 0
ASA 0
group 0
; 0
P 0
=.02 0
) 0
. 0

In 0
the 0
vein 0
bypass 0
group 0
, 0
patency B-OTHER
rate I-OTHER
was 0
unaffected 0
( 0
75.3 0
% 0
in 0
the 0
WASA 0
group 0
versus 0
74.9 0
% 0
in 0
the 0
ASA 0
group 0
) 0
. 0

CONCLUSION 0
The 0
long-term 0
administration 0
of 0
warfarin 0
therapy 0
when 0
combined 0
with 0
aspirin 0
therapy 0
has 0
only 0
a 0
few 0
selected 0
indications 0
for 0
improvement 0
of 0
bypass B-OTHER
patency I-OTHER
and 0
is 0
associated 0
with 0
an 0
increased 0
risk 0
of 0
morbidity B-PHYSICAL
and 0
mortality B-MORTALITY
. 0

A 0
comparison 0
of 0
seven 0
antiarrhythmic 0
drugs 0
in 0
patients 0
with 0
ventricular 0
tachyarrhythmias 0
. 0

Electrophysiologic 0
Study 0
versus 0
Electrocardiographic 0
Monitoring 0
Investigators 0
. 0

BACKGROUND 0
The 0
relative 0
efficacies 0
of 0
various 0
antiarrhythmic 0
drugs 0
in 0
the 0
treatment 0
of 0
ventricular 0
tachyarrhythmias 0
are 0
not 0
well 0
known 0
. 0

This 0
study 0
examined 0
the 0
effectiveness 0
of 0
imipramine 0
, 0
mexiletine 0
, 0
pirmenol 0
, 0
procainamide 0
, 0
propafenone 0
, 0
quinidine 0
, 0
and 0
sotalol 0
in 0
patients 0
with 0
ventricular 0
tachyarrhythmias 0
who 0
were 0
enrolled 0
in 0
the 0
Electrophysiologic 0
Study 0
versus 0
Electrocardiographic 0
Monitoring 0
trial 0
. 0

METHODS 0
Patients 0
were 0
randomly 0
assigned 0
to 0
undergo 0
serial 0
testing 0
of 0
the 0
efficacy 0
of 0
the 0
seven 0
antiarrhythmic 0
drugs 0
by 0
one 0
of 0
two 0
strategies 0
: 0
electrophysiologic 0
study 0
or 0
Holter 0
monitoring 0
together 0
with 0
exercise 0
testing 0
. 0

The 0
seven 0
drugs 0
were 0
then 0
tested 0
for 0
efficacy 0
in 0
random 0
order 0
in 0
patients 0
who 0
were 0
eligible 0
to 0
receive 0
them 0
. 0

The 0
frequencies 0
of 0
predictions 0
of 0
drug 0
efficacy 0
and 0
of 0
adverse 0
drug 0
effects 0
during 0
the 0
initial 0
drug 0
titration 0
were 0
tabulated 0
for 0
all 0
486 0
randomized 0
subjects 0
. 0

Patients 0
received 0
long-term 0
treatment 0
with 0
the 0
first 0
antiarrhythmic 0
drug 0
that 0
was 0
predicted 0
to 0
be 0
effective 0
on 0
the 0
basis 0
of 0
drug 0
testing 0
. 0

Recurrences 0
of 0
arrhythmia 0
, 0
deaths 0
, 0
and 0
adverse 0
drug 0
effects 0
during 0
long-term 0
follow-up 0
were 0
recorded 0
for 0
the 0
296 0
patients 0
in 0
whom 0
an 0
antiarrhythmic 0
drug 0
was 0
predicted 0
to 0
be 0
effective 0
. 0

RESULTS 0
In 0
the 0
electrophysiologic-study 0
group 0
, 0
the 0
percentage 0
of 0
patients 0
who 0
had 0
predictions 0
of 0
drug B-MENTAL
efficacy I-MENTAL
was 0
higher B-MENTAL
with 0
sotalol 0
( 0
35 0
percent 0
) 0
than 0
with 0
the 0
other 0
drugs 0
( 0
16 0
percent 0
, 0
P 0
< 0
0.001 0
) 0
. 0

There 0
was 0
no 0
significant B-MENTAL
difference I-MENTAL
among 0
the 0
drugs 0
in 0
the 0
Holter-monitoring 0
group 0
. 0

The 0
percentage 0
of 0
patients 0
with 0
adverse B-MENTAL
drug I-MENTAL
effects I-MENTAL
was 0
lowest B-MENTAL
among 0
those 0
receiving 0
sotalol 0
. 0

The 0
actuarial B-MENTAL
probability 0
of B-MENTAL
a I-MENTAL
recurrence I-MENTAL
of I-MENTAL
arrhythmia B-MENTAL
after 0
a 0
prediction 0
of 0
drug 0
efficacy 0
by 0
either 0
strategy 0
was 0
significantly B-OTHER
lower B-OTHER
for 0
patients 0
treated 0
with 0
sotalol 0
than 0
for 0
patients 0
treated 0
with 0
the 0
other 0
drugs 0
( 0
risk 0
ratio 0
, 0
0.43 0
; 0
95 0
percent 0
confidence 0
interval 0
, 0
0.29 0
to 0
0.62 0
; 0
P 0
< 0
0.001 0
) 0
. 0

With 0
sotalol 0
, 0
as 0
compared 0
with 0
the 0
other 0
drugs 0
combined 0
, 0
there 0
were 0
lower 0
risks 0
of 0

A 0
double-blind 0
placebo-controlled 0
trial 0
of 0
zonisamide 0
( 0
zonegran 0
) 0
in 0
the 0
treatment 0
of 0
essential B-PHYSICAL
tremor I-PHYSICAL
. 0

Medical 0
therapy 0
for 0
essential B-PHYSICAL
tremor I-PHYSICAL
( I-PHYSICAL
ET I-PHYSICAL
) I-PHYSICAL
, 0
a 0
common 0
movement 0
disorder 0
, 0
is 0
often 0
inadequate 0
. 0

We 0
performed 0
a 0
double-blind 0
placebo-controlled 0
randomized 0
trial 0
to 0
evaluate 0
the 0
efficacy 0
and 0
tolerability B-OTHER
of 0
zonisamide 0
( 0
ZNS 0
) 0
, 0
an 0
antiepileptic 0
agent 0
, 0
in 0
treating 0
ET B-PHYSICAL
. 0

Twenty 0
patients 0
( 0
mean 0
age 0
, 0
60 0
+/- 0
15 0
years 0
) 0
with 0
ET B-PHYSICAL
were 0
randomized 0
to 0
receive 0
ZNS 0
or 0
placebo 0
. 0

ZNS 0
was 0
initiated 0
at 0
a 0
dosage 0
of 0
100 0
mg/day 0
and 0
escalated 0
to 0
200 0
mg/day 0
at 0
day 0
14 0
. 0

Patients 0
were 0
evaluated 0
by 0
accelerometry 0
and 0
the 0
Fahn-Tolosa-Marin B-OTHER
( I-OTHER
FTM I-OTHER
) I-OTHER
rating I-OTHER
scale 0
at 0
baseline 0
and 0
days 0
14 0
and 0
28 0
, 0
as 0
well 0
as 0
the 0
Clinical B-OTHER
Global I-OTHER
Impression I-OTHER
( I-OTHER
CGI-C I-OTHER
) I-OTHER
scale 0
at 0
day 0
28 0
. 0

At 0
endpoint 0
, 0
subjects 0
assigned 0
to 0
ZNS 0
were 0
taking 0
a 0
mean 0
dosage 0
of 0
160 0
+/- 0
50 0
mg/day 0
. 0

There 0
were 0
no 0
significant 0
improvements 0
in 0
the 0
FTM B-OTHER
total 0
score 0
or B-OTHER
its B-OTHER
subsections I-OTHER
. 0

Tremor B-PHYSICAL
amplitude B-PHYSICAL
as 0
assessed 0
by 0
accelerometry 0
significantly 0
improved 0
in 0
the 0
ZNS 0
group 0
compared 0
to 0
the 0
placebo 0
group 0
at 0
endpoint 0
relative 0
to 0
baseline 0
( 0
-0.50 0
+/- 0
0.72 0
vs. 0
0.30 0
+/- 0
0.79 0
m/s 0
( 0
2 0
) 0
; 0
P 0
= 0
0.03 0
) 0
. 0

On 0
the 0
CGI-C 0
, 0
60 0
% 0
( 0
n 0
= 0
6 0
) 0
of 0
patients 0
in 0
the 0
ZNS 0
group 0
felt 0
that 0
their 0
tremor B-PHYSICAL
was 0
unchanged 0
, 0
while 0
the 0
remaining 0
patients 0
felt 0
that 0
their 0
tremor B-PHYSICAL
was 0
minimally 0
improved 0
. 0

Thirty 0
percent 0
( 0
n 0
= 0
3 0
) 0
of 0
patients 0
taking 0
ZNS 0
discontinued 0
the 0
study 0
due 0
to 0
side 0
effects 0
( 0
fatigue B-ADVERSE-EFFECTS
, 0
headache B-ADVERSE-EFFECTS
, 0
paresthesias B-ADVERSE-EFFECTS
) 0
while 0
taking 0
100 0
mg 0
per 0
day 0
. 0

ZNS 0
did 0
not 0
provide 0
significant 0
improvements 0
in 0
clinical B-OTHER
rating B-OTHER
scales I-OTHER
at 0
study 0
endpoint 0
compared 0
to 0
placebo 0
and 0
was 0
only 0
modestly 0
well 0

A 0
randomized 0
, 0
prospective 0
trial 0
of 0
adjuvant 0
chemotherapy 0
in 0
adults 0
with 0
soft 0
tissue 0
sarcomas 0
of 0
the 0
head 0
and 0
neck 0
, 0
breast 0
, 0
and 0
trunk 0
. 0

Since 0
1977 0
, 0
31 0
patients 0
were 0
entered 0
in 0
a 0
randomized 0
, 0
prospective 0
study 0
testing 0
the 0
efficacy 0
of 0
adjuvant 0
chemotherapy 0
after 0
aggressive 0
local 0
treatment 0
of 0
high-grade 0
sarcomas 0
of 0
the 0
head 0
, 0
neck 0
, 0
breast 0
, 0
and 0
trunk 0
( 0
excluding 0
retroperitoneal 0
sarcomas 0
) 0
. 0

All 0
patients 0
had 0
complete 0
resection 0
of 0
gross 0
tumor 0
and 0
underwent 0
postoperative 0
radiotherapy 0
( 0
6000-6300 0
rads 0
over 0
7-8 0
weeks 0
) 0
. 0

Seventeen 0
patients 0
received 0
adjuvant 0
chemotherapy 0
consisting 0
of 0
doxorubicin 0
( 0
less 0
than 0
or 0
equal 0
to 0
550 0
mg/m2 0
) 0
, 0
cyclophosphamide 0
( 0
less 0
than 0
or 0
equal 0
to 0
5500 0
mg/m2 0
) 0
, 0
and 0
methotrexate 0
( 0
less 0
than 0
or 0
equal 0
to 0
1000 0
mg/kg 0
) 0
. 0

Three-year 0
actuarial B-MORTALITY
disease-free I-MORTALITY
survival I-MORTALITY
in 0
the 0
chemotherapy 0
arm 0
was 0
77 0
% 0
, 0
compared 0
to 0
49 0
% 0
in 0
the 0
no-chemotherapy 0
arm 0
( 0
P 0
= 0
0.075 0
) 0
. 0

Three-year 0
overall B-MORTALITY
actuarial I-MORTALITY
survivals I-MORTALITY
in 0
the 0
two 0
treatment 0
arms 0
, 0
however 0
, 0
were 0
68 0
% 0
and 0
58 0
% 0
, 0
respectively 0
( 0
P 0
= 0
0.38 0
) 0
. 0

Considering 0
only 0
patients 0
with 0
tumors 0
of 0
the 0
trunk 0
( 0
22 0
patients 0
) 0
, 0
3-year 0
actuarial 0
disease-free 0
survival 0
in 0
the 0
chemotherapy 0
arm 0
was 0
92 0
% 0
, 0
compared 0
to 0
47 0
% 0
in 0
the 0
no-chemotherapy 0
arm 0
( 0
P 0
= 0
0.006 0
) 0
. 0

Actuarial 0
3-year 0
overall 0
survival 0
in 0
the 0
chemotherapy 0
arm 0
was 0
82 0
% 0
, 0
compared 0
to 0
61 0
% 0
in 0
the 0
no-chemotherapy 0
arm 0
( 0
P 0
= 0
0.18 0
) 0
. 0

An 0
additional 0
26 0
patients 0
were 0
treated 0
in 0
an 0
identical 0
fashion 0
, 0
but 0
were 0
not 0
part 0
of 0
the 0
randomized 0
trial 0
because 0
of 0
contraindications 0
to 0
chemotherapy 0
, 0
refusal 0
to 0
enter 0
the 0
randomized 0
trial 0
, 0
or 0
because 0
they 0
were 0
treated 0
before 0
1977 0
in 0
a 0
trial 0
in 0
which 0
all 0
patients 0
received 0
chemotherapy 0
. 0

Considering 0
the 0
entire 0
group 0
of 0
57 0
patients 0
, 0
follow-up 0
ranged 0
from 0
10 0
to 0
86 0
months 0
( 0
median 0
, 0
35 0
months 0
) 0
. 0

Local B-OTHER
control I-OTHER
was 0
achieved 0
in 0
46 0
patients 0
( 0
81 0
% 0
) 0
; 0
3-year 0
actuarial B-MORTALITY
disease-free I-MORTALITY
and I-MORTALITY
overall I-MORTALITY
survivals I-MORTALITY
were 0
67 0
% 0
and 0
77 0
% 0
, 0
respectively 0
. 0

A 0
tendency 0
toward 0
improved 0
disease-free B-MORTALITY
survival I-MORTALITY
was 0
apparent 0
among 0
patients 0
treated 0
with 0
chemotherapy 0
( 0
P 0
= 0
0.018 0
) 0
, 0
but 0
there 0
was 0
no 0
statistically 0
significant 0
improvement 0
in 0
overall B-MORTALITY
actuarial I-MORTALITY
survival I-MORTALITY
( 0
P 0
= 0
0.46 0
) 0
. 0

The 0
subgroup 0
of 0
patients 0
with 0
sarcomas 0
of 0
the 0
trunk 0
( 0
39 0
patients 0
) 0
demonstrated 0
the 0
greatest 0
benefit 0
from 0
chemotherapy 0
, 0
with 0
regard 0
to 0
disease-free B-MORTALITY
survival I-MORTALITY
( 0
P 0
less 0
than 0
or 0
equal 0
to 0
0.001 0
) 0
. 0

The 0
most 0
significant 0
toxicity B-PHYSICAL
associated 0
with 0
chemotherapy 0
was 0
doxorubicin-induced B-ADVERSE-EFFECTS
cardiomyopathy I-ADVERSE-EFFECTS
, 0
which 0
resulted 0
in 0
clinically 0
apparent 0
congestive B-PHYSICAL
heart I-PHYSICAL
failure I-PHYSICAL
in 0
five 0
patients 0
. 0

Thus 0
, 0
the 0
use 0
of 0
chemotherapy 0
when 0
combined 0
with 0
aggressive 0
local 0
measures 0
appears 0
to 0
improve 0
disease-free B-MORTALITY
survival I-MORTALITY
, 0
but 0
additional 0
patients 0
and 0
longer 0
follow-up 0
are 0
necessary 0
to 0
determine 0
if 0
improved 0
overall B-MORTALITY
survival I-MORTALITY
will 0
result 0
. 0

Changing 0
sodium 0
intake 0
in 0
children 0
. 0

The 0
Minneapolis 0
Children 0
's 0
Blood 0
Pressure 0
Study 0
. 0

To 0
assess 0
the 0
effects 0
of 0
modifying 0
dietary 0
sodium 0
intake 0
, 0
80 0
school 0
children 0
with 0
blood 0
pressures 0
above 0
the 0
95th 0
percentile 0
for 0
age 0
and 0
sex 0
but 0
below 0
130/90 0
mm 0
Hg 0
at 0
school 0
screening 0
were 0
randomized 0
to 0
a 0
family 0
intervention 0
program 0
or 0
a 0
control 0
group 0
. 0

Twenty 0
children 0
aged 0
6 0
to 0
9 0
years 0
and 0
their 0
families 0
began 0
a 0
program 0
to 0
modify 0
the 0
family 0
diet 0
toward 0
a 0
goal 0
of 0
70 0
mEq 0
sodium 0
per 0
person 0
per 0
day 0
. 0

Adherence B-MENTAL
was 0
assessed 0
by 0
3-day B-OTHER
food I-OTHER
records I-OTHER
and 0
urine B-OTHER
collections I-OTHER
in I-OTHER
children I-OTHER
and 0
adults B-OTHER
. 0

The 0
sodium B-MENTAL
intakes I-MENTAL
and 0
blood B-PHYSICAL
pressures I-PHYSICAL
of 0
the 0
intervention 0
and 0
control 0
group 0
were 0
compared 0
1 0
year 0
after 0
randomization 0
. 0

Sodium B-MENTAL
intake I-MENTAL
was 0
significantly 0
lower 0
in 0
the 0
intervention 0
group 0
only 0
in 0
the 0
active 0
participants 0
as 0
compared 0
to 0
dropouts 0
and 0
controls 0
( 0
87 0
vs 0
130 0
and 0
133 0
mmoles/24 0
hr 0
) 0
. 0

There 0
were 0
no 0
significant 0
differences 0
between 0
the 0
groups 0
in 0
height B-PHYSICAL
, 0
weight 0
, 0
or 0
blood B-PHYSICAL
pressure I-PHYSICAL
. 0

Blood 0
pressure 0
control 0
during 0
weight 0
reduction 0
in 0
obese 0
hypertensive 0
men 0
: 0
separate 0
effects 0
of 0
sodium 0
and 0
energy 0
restriction 0
. 0

The 0
separate 0
and 0
combined 0
effects 0
of 0
dietary 0
energy 0
and 0
sodium 0
restriction 0
on 0
regulation 0
of 0
blood B-PHYSICAL
pressure I-PHYSICAL
were 0
investigated 0
in 0
30 0
middle 0
aged 0
obese 0
men 0
with 0
essential 0
hypertension 0
attending 0
the 0
outpatient 0
department 0
. 0

In 0
group 0
1 0
( 0
n 0
= 0
15 0
) 0
a 0
basal 0
period 0
with 0
no 0
dietary 0
restriction 0
was 0
followed 0
by 0
a 0
period 0
taking 0
an 0
energy 0
reduced 0
diet 0
( 0
5.1 0
MJ 0
; 0
1230 0
kcal 0
) 0
, 0
the 0
sodium 0
intake 0
being 0
supplemented 0
and 0
hence 0
unchanged 0
( 0
1 0
: 0
ErSn 0
) 0
. 0

In 0
group 0
2 0
( 0
n 0
= 0
15 0
) 0
the 0
basal 0
period 0
preceded 0
a 0
control 0
period 0
with 0
no 0
intervention 0
, 0
which 0
was 0
followed 0
by 0
taking 0
a 0
diet 0
restricted 0
in 0
energy 0
( 0
5.1 0
MJ 0
; 0
1220 0
kcal 0
) 0
and 0
sodium 0
( 0
2 0
: 0
ErSr 0
) 0
. 0

During 0
period 0
1 0
: 0
ErSn 0
there 0
were 0
reductions 0
in 0
heart B-PHYSICAL
rate I-PHYSICAL
and 0
urinary B-PHYSICAL
noradrenaline I-PHYSICAL
output I-PHYSICAL
but 0
not 0
in 0
systolic B-PHYSICAL
or I-PHYSICAL
diastolic I-PHYSICAL
blood I-PHYSICAL
pressure I-PHYSICAL
. 0

Body B-PHYSICAL
weight I-PHYSICAL
decreased 0
by 0
4.9-11.7 0
kg 0
and 0
urinary B-PHYSICAL
sodium I-PHYSICAL
excretion I-PHYSICAL
did 0
not 0
change 0
. 0

In 0
period 0
2 0
: 0
ErSr 0
urinary B-PHYSICAL
sodium I-PHYSICAL
output I-PHYSICAL
was 0
reduced 0
by 0
81.4 0
( 0
SEM 0
17.8 0
) 0
mmol 0
( 0
mEq 0
) 0
/24 0
h 0
and 0
there 0
was 0
a 0
weight 0
loss B-PHYSICAL
of 0
8.2 0
( 0
SEM 0
0.7 0
) 0
kg 0
. 0

Systolic B-PHYSICAL
and I-PHYSICAL
diastolic I-PHYSICAL
blood I-PHYSICAL
pressures I-PHYSICAL
fell 0
significantly 0
, 0
as 0
did 0
the 0
heart B-PHYSICAL
rate I-PHYSICAL
and 0
urinary B-PHYSICAL
noradrenaline I-PHYSICAL
excretion I-PHYSICAL
. 0

These 0
results 0
show 0
that 0
in 0
hypertensive 0
obese 0
men 0
a 0
moderate 0
weight 0
reducing 0
diet 0
decreases 0
indices 0
of 0
sympathetic B-PHYSICAL
nervous I-PHYSICAL
system I-PHYSICAL
activity I-PHYSICAL
. 0

Reduction 0
of 0
blood B-PHYSICAL
pressure I-PHYSICAL
to 0
the 0
normotensive 0
range 0
was 0
observed 0
only 0
when 0
there 0
was 0
a 0
concomitant 0
restriction 0
of 0
sodium 0
intake 0
. 0

Effects 0
of 0
irrigation 0
fluid 0
temperature 0
on 0
core 0
body 0
temperature 0
during 0
transurethral 0
resection 0
of 0
the 0
prostate 0
. 0

OBJECTIVES 0
To 0
determine 0
the 0
effect 0
irrigation 0
fluid 0
temperature 0
has 0
on 0
core 0
body 0
temperature 0
changes 0
in 0
patients 0
undergoing 0
transurethral 0
resection 0
of 0
the 0
prostate 0
( 0
TURP 0
) 0
. 0

METHODS 0
Fifty-six 0
male 0
patients 0
( 0
mean 0
age 0
71.2 0
+/- 0
8.2 0
years 0
) 0
scheduled 0
for 0
TURP 0
were 0
enrolled 0
in 0
the 0
study 0
. 0

Patients 0
were 0
randomized 0
to 0
one 0
of 0
two 0
groups 0
. 0

Group 0
1 0
consisted 0
of 0
27 0
patients 0
who 0
received 0
room 0
temperature 0
irrigation 0
fluid 0
( 0
70 0
degrees 0
F 0
) 0
throughout 0
TURP 0
; 0
group 0
2 0
consisted 0
of 0
29 0
patients 0
whose 0
procedure 0
was 0
performed 0
with 0
warmed 0
irrigation 0
fluid 0
( 0
91.5 0
degrees 0
F 0
) 0
. 0

The 0
irrigation 0
fluid 0
used 0
for 0
both 0
groups 0
was 0
glycine 0
. 0

The 0
baseline 0
temperature 0
, 0
final 0
temperature 0
, 0
total 0
time 0
in 0
the 0
operating 0
room 0
, 0
and 0
amount 0
of 0
irrigation 0
fluid 0
used 0
during 0
the 0
procedure 0
were 0
recorded 0
for 0
each 0
patient 0
. 0

RESULTS 0
No 0
significant 0
difference 0
in 0
the 0
average 0
time B-OTHER
spent I-OTHER
in I-OTHER
the I-OTHER
operating I-OTHER
room I-OTHER
or 0
in 0
the 0
total 0
irrigation B-OTHER
fluid I-OTHER
used 0
between 0
the 0
two 0
groups 0
was 0
observed 0
. 0

Of 0
the 0
27 0
patients 0
who 0
received 0
room B-PHYSICAL
temperature I-PHYSICAL
irrigation I-PHYSICAL
fluid I-PHYSICAL
, 0
15 0
( 0
55.6 0
% 0
) 0
had 0
a 0
decrease 0
in 0
body B-PHYSICAL
temperature I-PHYSICAL
. 0

A 0
decrease 0
in 0
temperature B-PHYSICAL
was 0
observed 0
in 0
21 0
( 0
72.4 0
% 0
) 0
of 0
the 0
29 0
patients 0
who 0
received 0
warm 0
irrigation B-OTHER
fluid I-OTHER
. 0

Groups 0
1 0
and 0
2 0
had 0
12 0
( 0
44.4 0
% 0
) 0
of 0
27 0
and 0
8 0
( 0
27.6 0
% 0
) 0
of 0
29 0
patients 0
, 0
respectively 0
, 0
who 0
demonstrated 0
an 0
elevation 0
in 0
their 0
core B-PHYSICAL
body I-PHYSICAL
temperature I-PHYSICAL
. 0

CONCLUSIONS 0
The 0
results 0
of 0
our 0
study 0
suggest 0
that 0
irrigation 0
fluid 0
temperature 0
is 0
not 0
a 0
factor 0
responsible 0
for 0
altering 0
the 0
core 0
body B-PHYSICAL
temperature I-PHYSICAL
in 0
patients 0
undergoing 0
TURP 0
. 0

The 0
effect 0
of 0
case 0
management 0
on 0
the 0
costs 0
of 0
health B-OTHER
care I-OTHER
for 0
enrollees 0
in 0
Medicare 0
Plus 0
Choice 0
plans 0
: 0
a 0
randomized 0
trial 0
. 0

OBJECTIVE 0
To 0
measure 0
the 0
effects 0
of 0
case 0
management 0
on 0
an 0
older 0
population 0
's 0
costs 0
of 0
health B-OTHER
care I-OTHER
. 0

DESIGN 0
A 0
1-year 0
randomized 0
controlled 0
trial 0
. 0

SETTING 0
Multiple 0
sites 0
of 0
care 0
in 0
San 0
Francisco 0
, 0
California 0
. 0

PARTICIPANTS 0
Patients 0
aged 0
65 0
or 0
older 0
of 0
primary 0
care 0
physicians 0
in 0
a 0
large 0
provider 0
organization 0
bearing 0
financial 0
risk 0
for 0
their 0
care 0
( 0
n 0
= 0
6409 0
) 0
. 0

INTERVENTION 0
Screening 0
for 0
high 0
risk 0
and 0
provision 0
of 0
social 0
work-based 0
case 0
management 0
. 0

OUTCOME 0
MEASURES 0
Volume B-OTHER
and 0
cost B-OTHER
of I-OTHER
hospital I-OTHER
, 0
physician B-OTHER
, 0
case B-OTHER
management I-OTHER
, 0
and 0

Untreated 0
silicone 0
breast 0
implant 0
rupture 0
. 0

Implant 0
rupture 0
is 0
a 0
well-known 0
complication 0
of 0
breast 0
implant 0
surgery 0
that 0
can 0
pass 0
unnoticed 0
by 0
both 0
patient 0
and 0
physician 0
. 0

To 0
date 0
, 0
no 0
prospective 0
study 0
has 0
addressed 0
the 0
possible 0
health 0
implications 0
of 0
silicone 0
breast 0
implant 0
rupture 0
. 0

The 0
aim 0
of 0
the 0
present 0
study 0
was 0
to 0
evaluate 0
whether 0
untreated 0
ruptures 0
are 0
associated 0
with 0
changes 0
over 0
time 0
in 0
magnetic 0
resonance 0
imaging 0
findings 0
, 0
serologic 0
markers 0
, 0
or 0
self-reported 0
breast 0
symptoms 0
. 0

A 0
baseline 0
magnetic 0
resonance 0
imaging 0
examination 0
was 0
performed 0
in 0
1999 0
on 0
271 0
women 0
who 0
were 0
randomly 0
chosen 0
from 0
a 0
larger 0
cohort 0
of 0
women 0
having 0
cosmetic 0
breast 0
implants 0
for 0
a 0
median 0
period 0
of 0
12 0
years 0
( 0
range 0
, 0
3 0
to 0
25 0
years 0
) 0
. 0

A 0
follow-up 0
magnetic 0
resonance 0
imaging 0
examination 0
was 0
carried 0
out 0
in 0
2001 0
, 0
excluding 0
women 0
who 0
underwent 0
explantation 0
in 0
the 0
period 0
between 0
the 0
two 0
magnetic 0
resonance 0
imaging 0
examinations 0
( 0
n 0
= 0
44 0
) 0
. 0

On 0
the 0
basis 0
of 0
these 0
examinations 0
, 0
the 0
authors 0
identified 0
64 0
women 0
who 0
had 0
at 0
least 0
one 0
ruptured 0
implant 0
at 0
the 0
first 0
magnetic 0
resonance 0
imaging 0
examination 0
and 0
, 0
for 0
comparison 0
, 0
all 0
women 0
who 0
had 0
intact 0
implants 0
at 0
both 0
examinations 0
( 0
n 0
= 0
98 0
) 0
. 0

Magnetic 0
resonance 0
images 0
from 0
the 0
two 0
examinations 0
were 0
compared 0
and 0
changes 0
in 0
rupture 0
configuration 0
were 0
evaluated 0
. 0

Comparisons 0
were 0
also 0
made 0
for 0
self-reported 0
breast 0
symptoms 0
occurring 0
during 0
the 0
study 0
period 0
and 0
for 0
changes 0
in 0
serum 0
values 0
of 0
antinuclear 0
antibodies 0
, 0
rheumatoid 0
factor 0
, 0
and 0
cardiolipin 0
antibodies 0
immunoglobulin 0
G 0
and 0
immunoglobulin 0
M. 0
The 0
majority 0
of 0
the 0
women 0
with 0
implant 0
rupture 0
had 0
no 0
visible 0
magnetic B-PHYSICAL
resonance I-PHYSICAL
imaging I-PHYSICAL
changes I-PHYSICAL
of 0
their 0
ruptured 0
implants 0
. 0

For 0
11 0
implants 0
( 0
11 0
percent 0
) 0
in 0
10 0
women 0
, 0
the 0
authors 0
observed 0
progression 0
of 0
silicone B-PHYSICAL
seepage I-PHYSICAL
, 0
either 0
as 0
a 0
conversion 0
from 0
intracapsular 0
into 0
extracapsular 0
rupture 0
( 0
n 0
= 0
7 0
) 0
, 0
as 0
progression 0
of 0
extra-capsular 0
silicone 0
( 0
n 0
= 0
3 0
) 0
, 0
or 0
as 0
increasing 0
herniation 0
of 0
the 0
silicone 0
within 0
the 0
fibrous 0
capsule 0
( 0
n 0
= 0
1 0
) 0
; 0
however 0
, 0
in 0
most 0
cases 0
, 0
these 0
changes 0
were 0
minor 0
. 0

Some 0
changes 0
could 0
be 0
ascribed 0
to 0
trauma 0
, 0
but 0
others 0
seemed 0
spontaneous 0
. 0

There 0
was 0
no 0
increase 0
in 0
levels B-PHYSICAL
of I-PHYSICAL
autoantibodies I-PHYSICAL
during 0
the 0
study 0
period 0
in 0
either 0
study 0
group 0
. 0

Women 0
with 0
untreated 0
implant 0
ruptures 0
reported 0
a 0
significant 0
increase 0
in 0
nonspecific B-PHYSICAL
breast I-PHYSICAL
changes I-PHYSICAL
( 0
odds 0
ratio 0
, 0
2.1 0
; 0
95 0
percent 0
confidence 0
interval 0
, 0
1.2 0
to 0
3.8 0
) 0
compared 0
with 0
women 0
without 0
ruptures 0
. 0

On 0
the 0
basis 0
of 0
this 0
first 0
study 0
of 0
women 0
with 0
untreated 0
silicone 0
breast 0
implant 0
rupture 0
, 0
the 0
authors 0
conclude 0
that 0
implant 0
rupture 0
is 0
a 0
relatively 0
harmless 0
condition 0
, 0
which 0
only 0
rarely 0
progresses 0
and 0
gives 0
rise 0
to 0
notable 0
symptoms 0
. 0

Even 0
so 0
, 0
because 0
of 0
a 0
small 0
risk 0
of 0
silicone 0
spread 0
, 0
the 0
authors 0
suggest 0
that 0
women 0
with 0
implant 0
ruptures 0
be 0
followed 0
clinically 0
, 0
if 0
not 0
operated 0
on 0
. 0

Because 0
implant 0
ruptures 0
often 0
occur 0
asymptomatically 0
, 0
any 0
woman 0
with 0
silicone 0
implants 0
, 0
regardless 0
of 0
rupture 0
status 0
, 0
should 0
be 0
evaluated 0
at 0
regular 0
intervals 0
. 0

Effects 0
of 0
atropine 0
and 0
scopolamine 0
on 0
bradycardia B-PHYSICAL
and 0
emetic B-PHYSICAL
symptoms I-PHYSICAL
in 0
otoplasty 0
. 0

OBJECTIVE 0
To 0
assess 0
the 0
effects 0
of 0
unilateral 0
or 0
bilateral 0
otoplasty 0
on 0
bradycardia B-PHYSICAL
and 0
postoperative B-PHYSICAL
nausea I-PHYSICAL
and I-PHYSICAL
vomiting I-PHYSICAL
( 0
PONV B-PHYSICAL
) 0
and 0
the 0
efficiency 0
of 0
transdermal 0
scopolamine 0
in 0
the 0
prophylaxis B-PHYSICAL
of I-PHYSICAL
PONV I-PHYSICAL
. 0

STUDY 0
DESIGN 0
Post 0
hoc 0
assessment 0
of 0
the 0
data 0
from 0
a 0
double-blind 0
, 0
randomized 0
study 0
. 0

METHODS 0
Fifty 0
otoplasty 0
patients 0
were 0
studied 0
; 0
half 0
of 0
them 0
received 0
randomly 0
and 0
in 0
double-blind 0
fashion 0
a 0
transdermal 0
therapeutic 0
system 0
( 0
patch 0
) 0
of 0
scopolamine 0
( 0
TTS-scopolamine 0
) 0
as 0
prophylaxis 0
against 0
PONV 0
before 0
general 0
anesthesia 0
. 0

The 0
placebo 0
group 0
received 0
atropine 0
10 0
microg 0
x 0
kg 0
( 0
-1 0
) 0
intravenously 0
during 0
induction 0
. 0

RESULTS 0
The 0
scopolamine-treated 0
patients 0
suffered 0
more 0
from 0
moderate B-PHYSICAL
peroperative I-PHYSICAL
bradycardia I-PHYSICAL
( 0
8/25 0
; 0
P 0
< 0
.05 0
) 0
than 0
the 0
atropine-treated 0
patients 0
( 0
1/25 0
) 0
. 0

Two 0
patients 0
wearing 0
a 0
half 0
of 0
the 0
TTS-scopolamine 0
patch 0
needed 0
intravenous B-PHYSICAL
atropine I-PHYSICAL
. 0

After 0
unilateral 0
otoplasty 0
, 0
none 0
of 0
the 0
TTS-scopolamine-treated 0
patients 0
and 0
50 0
% 0
of 0
the 0
atropine-treated 0
patients 0
suffered 0
from 0
PONV B-PHYSICAL
. 0

After 0
bilateral 0
operation 0
, 0
the 0
respective 0
incidences 0
were 0
39 0
% 0
and 0
81 0
% 0
( 0
P 0
< 0
.01 0
) 0
. 0

After 0
unilateral 0
otoplasty 0
no 0
patient 0
needed 0
droperidol B-OTHER
, 0
but 0
after 0
bilateral 0
otoplasty 0
, 0
12 0
of 0
19 0
of 0
the 0
atropine-treated 0
and 0
4 0
of 0
18 0
( 0
P 0
< 0
.05 0
) 0
of 0
the 0
scopolamine-treated 0
patients 0
needed 0
droperidol 0
. 0

The 0
mean 0
numbers 0
of B-OTHER
doses I-OTHER
of I-OTHER
droperidol B-OTHER
were 0
0.8+/-0.9 0
and 0
0.3+/-0.6 0
( 0
P 0
< 0
.05 0
) 0
, 0
respectively 0
. 0

Two 0
additional 0
patients 0
, 0
wearing 0
half 0
of 0
the 0
TTS-scopolamine 0
patch 0
, 0
suffered 0
from 0
mild B-ADVERSE-EFFECTS
central B-ADVERSE-EFFECTS
anticholinergic I-ADVERSE-EFFECTS
syndrome I-ADVERSE-EFFECTS
. 0

CONCLUSION 0
TTS-scopolamine 0
offers 0
effective 0
prophylaxis B-OTHER
against 0
PONV B-PHYSICAL
( I-PHYSICAL
auriculoemetic I-PHYSICAL

Randomized 0
trial 0
of 0
angiotensin 0
II-receptor 0
blocker 0
vs. 0
dihydropiridine 0
calcium 0
channel 0
blocker 0
in 0
the 0
treatment 0
of 0
paroxysmal 0
atrial 0
fibrillation 0
with 0
hypertension 0
( 0
J-RHYTHM 0
II 0
study 0
) 0
. 0

AIMS 0
Atrial 0
fibrillation 0
( 0
AF 0
) 0
is 0
a 0
common 0
arrhythmia 0
frequently 0
associated 0
with 0
hypertension 0
. 0

This 0
study 0
was 0
designed 0
to 0
test 0
the 0
hypothesis 0
that 0
lowering 0
blood 0
pressure 0
by 0
angiotensin 0
II-receptor 0
blockers 0
( 0
ARB 0
) 0
has 0
more 0
beneficial 0
effects 0
than 0
by 0
conventional 0
calcium 0
channel 0
blockers 0
( 0
CCB 0
) 0
on 0
the 0
frequency 0
of 0
paroxysmal 0
AF 0
with 0
hypertension 0
. 0

METHODS 0
AND 0
RESULTS 0
The 0
Japanese 0
Rhythm 0
Management 0
Trial 0
II 0
for 0
Atrial 0
Fibrillation 0
( 0
J-RHYTHM 0
II 0
study 0
) 0
is 0
an 0
open-label 0
randomized 0
comparison 0
between 0
an 0
ARB 0
( 0
candesartan 0
) 0
and 0
a 0
CCB 0
( 0
amlodipine 0
) 0
in 0
the 0
treatment 0
of 0
paroxysmal 0
AF 0
associated 0
with 0
hypertension 0
. 0

Using 0
daily 0
transtelephonic 0
monitoring 0
, 0
we 0
examined 0
asymptomatic 0
and 0
symptomatic 0
paroxysmal B-PHYSICAL
AF I-PHYSICAL
episodes 0
during 0
a 0
maximum 0
1 0
year 0
treatment 0
. 0

The 0
primary 0
endpoint 0
was 0
the 0
difference 0
in 0
AF B-OTHER
frequency I-OTHER
between 0
the 0
pre-treatment 0
period 0
and 0
the 0
final 0
month 0
of 0
the 0
follow-up 0
. 0

The 0
secondary 0
endpoints 0
included 0
cardiovascular B-PHYSICAL
events I-PHYSICAL
, 0
development 0
of 0
persistent B-PHYSICAL
AF I-PHYSICAL
, 0
left B-PHYSICAL
atrial I-PHYSICAL
dimension I-PHYSICAL
, 0
and 0
quality-of-life B-MENTAL
( I-MENTAL
QOL I-MENTAL
) I-MENTAL
. 0

The 0
study 0
enrolled 0
318 0
patients 0
( 0
66 0
years 0
, 0
male/female 0
219/99 0
, 0
158 0
in 0
the 0
ARB 0
group 0
and 0
160 0
in 0
the 0
CCB 0
group 0
) 0
treated 0
at 0
48 0
sites 0
throughout 0
Japan 0
. 0

At 0
baseline 0
, 0
the 0
frequency 0
of 0
AF B-PHYSICAL
episodes I-PHYSICAL
( 0
days/month 0
) 0
was 0
3.8 0
? 0

5.0 0
in 0
the 0
ARB 0
group 0
vs. 0
4.8 0
? 0

6.3 0
in 0
the 0
CCB 0
group 0
( 0
not 0
significant 0
) 0
. 0

During 0
the 0
follow-up 0
, 0
blood 0
pressure 0
was 0
significantly 0
lower 0
in 0
the 0
CCB 0
group 0
than 0
in 0
the 0
ARB 0
group 0
( 0
P 0
< 0
0.001 0
) 0
. 0

The 0
AF 0
frequency 0
decreased 0
similarly 0
in 0
both 0
groups 0
, 0
and 0
there 0
was 0
no 0
significant 0
difference 0
in 0
the 0
primary 0
endpoint 0
between 0
the 0
two 0
groups 0
. 0

There 0
were 0
no 0
significant 0
differences 0
between 0
the 0
two 0
groups 0
in 0
the 0
development 0
of 0
persistent 0
AF 0
, 0
changes 0
in 0
left 0
atrial 0
dimension 0
, 0
occurrence 0
of 0
cardiovascular 0
events 0
, 0
or 0
changes 0
in 0
QOL 0
. 0

CONCLUSIONS 0
In 0
patients 0
with 0
paroxysmal 0
AF 0
and 0
hypertension 0
, 0
treatment 0
of 0
hypertension 0
by 0
candesartan 0
did 0
not 0
have 0
an 0
advantage 0
over 0
amlodipine 0
in 0
the 0
reduction 0
in 0
the 0
frequency 0
of 0
paroxysmal 0
AF 0
( 0
umin 0
CTR 0
C000000427 0
) 0
. 0

The 0
benefit 0
of 0
low-dose 0
dopamine 0
during 0
vigorous 0
diuresis 0
for 0
congestive 0
heart 0
failure 0
associated 0
with 0
renal 0
insufficiency 0
: 0
does 0
it 0
protect 0
renal 0
function 0
? 0

BACKGROUND 0
Low-dose 0
dopamine 0
, 0
a 0
renal 0
vasodilator 0
, 0
has 0
been 0
used 0
empirically 0
to 0
improve 0
renal 0
function 0
or 0
outcome 0
in 0
critically 0
ill 0
patients 0
with 0
oliguria 0
or 0
acute 0
renal 0
failure 0
. 0

HYPOTHESIS 0
This 0
study 0
was 0
designed 0
to 0
investigate 0
the 0
efficacy 0
of 0
low-dose 0
dopamine 0
( 0
2 0
micrograms/kg/min 0
) 0
as 0
a 0
renal-protective 0
agent 0
during 0
vigorous 0
diuresis 0
for 0
congestive 0
heart 0
failure 0
( 0
CHF 0
) 0
associated 0
with 0
mild 0
or 0
moderate 0
renal 0
insufficiency 0
. 0

METHODS 0
Of 0
20 0
study 0
patients 0
( 0
mean 0
age 0
74.3 0
+/- 0
15 0
years 0
) 0
with 0
severe 0
CHF 0
, 0
10 0
( 0
Group 0
A 0
) 0
were 0
randomized 0
to 0
a 0
treatment 0
strategy 0
of 0
intravenous 0
bumetanide 0
( 0
1 0
mg 0
b.i.d 0
. 0
) 0

alone 0
and 0
another 0
10 0
( 0
Group 0
B 0
) 0
to 0
low-dose 0
dopamine 0
and 0
a 0
similar 0
diuretic 0
regimen 0
for 0
a 0
duration 0
of 0
5 0
days 0
or 0
less 0
if 0
clinical 0
edema 0
remitted 0
. 0

RESULTS 0
Group 0
B 0
patients 0
showed 0
a 0
significant 0
improvement 0
in 0
renal B-PHYSICAL
function I-PHYSICAL
and I-PHYSICAL
urinary I-PHYSICAL
output I-PHYSICAL
: 0
serum B-PHYSICAL
blood I-PHYSICAL
urea I-PHYSICAL
nitrogen B-PHYSICAL
48.9 0
+/- 0
10.3 0
to 0
32.1 0
+/- 0
14.4 0
mg/dl 0
( 0
p 0
< 0
0.05 0
) 0
; 0
serum B-PHYSICAL
creatinine I-PHYSICAL
1.97 0
+/- 0
0.24 0
to 0
1.49 0
+/- 0
0.39 0
mg/dl 0
( 0
p 0
< 0
0.05 0
) 0
; 0
creatinine B-PHYSICAL
clearance I-PHYSICAL
35.6 0
+/- 0
11.6 0
to 0
48.8 0
+/- 0
12.3 0
ml/min 0
( 0
p 0
< 0
0.05 0
) 0
; 0
and 0
indexed B-PHYSICAL
urinary I-PHYSICAL
output I-PHYSICAL
0.56 0
+/- 0
0.16 0
to 0
2.02 0
+/- 0
0.72 0
ml/kg/h 0
( 0
p 0
< 0
0.05 0
) 0
. 0

Group 0
A 0
patients 0
showed 0
a 0
significant 0
increase 0
in 0

Short- 0
and 0
long-term 0
results 0
after 0
thrombolytic 0
treatment 0
of 0
deep 0
venous 0
thrombosis 0
. 0

OBJECTIVES 0
The 0
goal 0
of 0
this 0
study 0
was 0
to 0
assess 0
the 0
short- 0
and 0
long-term 0
efficacy 0
of 0
different 0
thrombolytic 0
therapy 0
regimens 0
in 0
patients 0
with 0
leg 0
or 0
pelvic 0
deep 0
venous 0
thrombosis 0
( 0
DVT 0
) 0
. 0

BACKGROUND 0
It 0
is 0
unclear 0
whether 0
locoregional 0
or 0
systemic 0
thrombolysis 0
is 0
superior 0
in 0
treating 0
acute 0
leg 0
DVT 0
or 0
even 0
whether 0
lysis 0
is 0
more 0
effective 0
than 0
anticoagulation 0
therapy 0
in 0
preventing 0
postthrombotic 0
syndrome 0
. 0

METHODS 0
A 0
total 0
of 0
250 0
patients 0
averaging 0
40 0
years 0
of 0
age 0
with 0
acute 0
DVT 0
were 0
randomized 0
into 0
five 0
groups 0
to 0
receive 0
full 0
heparinization 0
( 0
1,000 0
IU/h 0
) 0
and 0
compression 0
treatment 0
, 0
with 0
four 0
groups 0
also 0
administered 0
locoregional 0
tissue 0
plasminogen 0
activator 0
( 0
20 0
mg/day 0
) 0
or 0
urokinase 0
( 0
100,000 0
IU/day 0
) 0
or 0
systemic 0
streptokinase 0
( 0
3,000,000 0
IU 0
daily 0
) 0
or 0
urokinase 0
( 0
5,000,000 0
IU 0
daily 0
) 0
. 0

All 0
groups 0
then 0
received 0
anticoagulation 0
and 0
compression 0
treatment 0
for 0
one 0
year 0
. 0

Primary 0
efficacy 0
criteria 0
included 0
the 0
change 0
after 0
one 0
year 0
in 0
the 0
number 0
of 0
closed B-PHYSICAL
vein I-PHYSICAL
segments I-PHYSICAL
and 0
the 0
occurrence 0
of 0
postthrombotic 0
syndrome 0
. 0

RESULTS 0
Systemic 0
thrombolytic 0
therapy 0
significantly 0
reduced 0
the 0
number 0
of 0
closed B-PHYSICAL
vein I-PHYSICAL
segments I-PHYSICAL
after 0
12 0
months 0
in 0
patients 0
with 0
acute 0
DVT 0
compared 0
with 0
conventional 0
treatment 0
( 0
p 0
< 0
0.05 0
) 0
. 0

Postthrombotic B-PHYSICAL
syndrome I-PHYSICAL
also 0
occurred 0
with 0
less 0
frequency 0
in 0
systemically 0
treated 0
patients 0
versus 0
controls 0
( 0
p 0
< 0
0.001 0
) 0
. 0

High-dose 0
thrombolysis 0
led 0
to 0
better 0
rates 0
of 0
complete B-PHYSICAL
recanalization I-PHYSICAL
after 0
seven 0
days 0
( 0
p 0
< 0
0.01 0
) 0
than 0
locoregional 0
lysis 0
. 0

However 0
, 0
12 0
patients 0
receiving 0
thrombolysis 0
( 0
9 0
systemic 0
, 0
3 0
local 0
) 0
suffered 0
major B-PHYSICAL
bleeding I-PHYSICAL
complications I-PHYSICAL
; 0
9 0
patients 0
on 0
systemic 0
treatment 0
developed 0
pulmonary B-ADVERSE-EFFECTS
emboli I-ADVERSE-EFFECTS
. 0

CONCLUSIONS 0
Systemic 0
thrombolytic 0
treatment 0
for 0
acute 0
DVT 0
achieved 0
a 0
significantly 0
better 0
short- 0
and 0
long-term 0
clinical 0
outcome 0
than 0
conventional 0
heparin/anticoagulation 0
therapy 0
but 0
at 0
the 0
expense 0
of 0
a 0
serious 0
increase 0
in 0
major 0
bleeding 0
and 0
pulmonary 0
emboli 0
. 0

Given 0
the 0
inherent 0
risks 0
for 0
such 0
serious 0
complications 0
, 0
systemic 0
thrombolysis 0
, 0
although 0
effective 0
, 0
should 0
be 0
used 0
selectively 0
in 0
limb-threatening 0
thrombotic 0
situations 0
. 0

A 0
comparison 0
of 0
the 0
recovery B-OTHER
times I-OTHER
of 0
desflurane 0
and 0
isoflurane 0
in 0
outpatient 0
anesthesia 0
. 0

The 0
low 0
solubility 0
of 0
desflurane 0
has 0
been 0
shown 0
to 0
contribute 0
to 0
faster 0
awakening 0
from 0
anesthesia 0
when 0
compared 0
with 0
other 0
anesthetics 0
in 0
common 0
use 0
. 0

However 0
, 0
research 0
has 0
failed 0
to 0
consistently 0
demonstrate 0
faster 0
discharge 0
times 0
from 0
the 0
postanesthesia 0
care 0
unit 0
following 0
the 0
use 0
of 0
desflurane 0
. 0

This 0
study 0
was 0
undertaken 0
to 0
compare 0
the 0
recovery B-OTHER
and I-OTHER
discharge I-OTHER
times I-OTHER
of 0
outpatients 0
undergoing 0
procedures 0
greater 0
than 0
2 0
hours 0
in 0
length 0
. 0

Thirty-three 0
patients 0
aged 0
18 0
to 0
70 0
years 0
were 0
randomized 0
to 0
receive 0
either 0
desflurane 0
or 0
isoflurane 0
following 0
a 0
standard 0
intravenous 0
induction 0
with 0
propofol 0
. 0

Patients 0
received 0
premedication 0
and 0
opioids 0
consistent 0
with 0
institutional 0
practice 0
, 0
and 0
inhalation 0
agents 0
were 0
titrated 0
to 0
effect 0
during 0
anesthetic 0
maintenance 0
. 0

Following 0
surgery 0
, 0
patients 0
were 0
evaluated 0
for 0
time B-OTHER
to I-OTHER
emergence I-OTHER
and I-OTHER
time I-OTHER
to I-OTHER
meeting I-OTHER
discharge I-OTHER
criteria I-OTHER
. 0

The 0
results 0
demonstrated 0
no 0
differences 0
between 0
the 0
emergence 0
or 0
discharge 0
times 0
following 0
desflurane 0
or 0
isoflurane 0
. 0

In 0
addition 0
, 0
measured 0
parameters 0
, 0
such 0
as 0
intraoperative B-PHYSICAL
vital I-PHYSICAL
signs I-PHYSICAL
and I-PHYSICAL
postoperative I-PHYSICAL
emesis I-PHYSICAL
and I-PHYSICAL
opioid I-PHYSICAL
requirements I-PHYSICAL
, 0
were 0
not 0
different 0
between 0
the 0
groups 0
. 0

The 0
use 0
of 0
desflurane 0
as 0
part 0
of 0
a 0
balanced 0
anesthetic 0
technique 0
did 0
not 0
speed 0
the 0
emergence 0
or 0
discharge B-OTHER
time I-OTHER
when 0
compared 0
with 0
isoflurane 0
. 0

Acute 0
and 0
subchronic 0
effects 0
of 0
levocetirizine 0
and 0
diphenhydramine 0
on 0
memory 0
functioning 0
, 0
psychomotor 0
performance 0
, 0
and 0
mood B-MENTAL
. 0

BACKGROUND 0
Central 0
nervous 0
system 0
adverse 0
effects 0
, 0
such 0
as 0
sedation B-PHYSICAL
, 0
often 0
accompany 0
the 0
use 0
of 0
first-generation 0
antihistamines 0
. 0

These 0
effects 0
might 0
interfere 0
with 0
memory 0
functioning 0
and 0
psychomotor 0
performance 0
. 0

Levocetirizine 0
was 0
recently 0
introduced 0
as 0
a 0
new 0
antihistamine 0
said 0
to 0
be 0
free 0
from 0
sedative 0
effects 0
. 0

OBJECTIVE 0
We 0
sought 0
to 0
investigate 0
the 0
effects 0
of 0
levocetirizine 0
( 0
5 0
mg 0
) 0
, 0
diphenhydramine 0
( 0
50 0
mg 0
) 0
, 0
and 0
placebo 0
on 0
memory B-MENTAL
and 0
psychomotor B-MENTAL
performance I-MENTAL
after 0
acute 0
( 0
day 0
1 0
) 0
and 0
subchronic 0
( 0
day 0
4 0
) 0
daily 0
administration 0
in 0
48 0
healthy 0
volunteers 0
( 0
24 0
men 0
and 0
24 0
women 0
) 0
. 0

METHODS 0
This 0
study 0
was 0
a 0
double-blind 0
, 0
placebo-controlled 0
, 0
randomized 0
clinical 0
trial 0
. 0

Treatments 0
were 0
administrated 0
on 0
days 0
1 0
, 0
2 0
, 0
3 0
, 0
and 0
4 0
, 0
3 0
hours 0
before 0
the 0
start 0
of 0
the 0
laboratory 0
test 0
battery 0
( 0
performed 0
on 0
days 0
1 0
and 0
4 0
) 0
, 0
comprising 0
a 0
word-learning 0
test 0
, 0
the 0
Sternberg 0
Memory 0
Scanning 0
Test 0
, 0
a 0
tracking 0
test 0
( 0
easy 0
and 0
hard 0
version 0
) 0
, 0
and 0
a 0
divided 0
attention 0
test 0
( 0
tracking 0
and 0
memory 0
scanning 0
simultaneously 0
) 0
. 0

Statistical 0
analyses 0
were 0
performed 0
separately 0
for 0
days 0
1 0
and 0
4 0
by 0
using 0
analysis 0
of 0
variance 0
. 0

RESULTS 0
On 0
day 0
1 0
, 0
diphenhydramine 0
significantly 0
impaired 0
tracking B-MENTAL
performance I-MENTAL
( 0
easy 0
: 0
F 0
( 0
1,90 0
) 0
= 0
25.9 0
, 0
P 0
< 0
.0001 0
; 0
hard 0
: 0
F 0
( 0
1,90 0
) 0
= 0
20.5 0
, 0
P 0
< 0
.0001 0
) 0
and 0
divided B-PHYSICAL
attention I-PHYSICAL
( 0
tracking 0
: 0
F 0
( 0
1,90 0
) 0
= 0
23.8 0
, 0
P 0
< 0
.0001 0
; 0
memory B-PHYSICAL
scanning I-PHYSICAL
: 0
F 0
( 0
1,90 0
) 0
= 0
22.0 0
, 0
P 0
< 0
.0001 0
) 0
. 0

Results 0
on 0
word-learning B-MENTAL
tests I-MENTAL
and 0
Sternberg B-MENTAL
Memory I-MENTAL
Scanning I-MENTAL
Tests I-MENTAL
were 0
not 0
significantly 0
impaired 0
. 0

On 0
day 0
4 0
, 0
the 0
effects 0
of 0
diphenhydramine 0
did 0
not 0
reach 0
significance 0
. 0

In 0
contrast 0
, 0
on 0
both 0
days 0
1 0
and 0
4 0
, 0
levocetirizine 0
did 0
not 0
significantly 0
impair 0
laboratory B-OTHER
test I-OTHER
performance I-OTHER
. 0

CONCLUSION 0
The 0
results 0
show 0
that 0
memory B-MENTAL
, 0
attention B-MENTAL
, 0
and 0
tracking B-MENTAL
performance I-MENTAL
are 0
unaffected 0
after 0
acute 0
and 0
subchronic 0
administration 0
of 0
levocetirizine 0
( 0
5 0
mg 0
) 0
, 0
whereas 0
diphenhydramine 0
( 0
50 0
mg 0
) 0
significantly 0
affected 0
divided B-MENTAL
attention I-MENTAL
and 0
tracking B-MENTAL
after 0
acute 0
administration 0
. 0

Trial 0
design 0
challenges 0
when 0
combining 0
medication 0
and 0
parent 0
training 0
in 0
children 0
with 0
pervasive 0
developmental 0
disorders 0
. 0

This 0
paper 0
presents 0
the 0
rationale 0
for 0
a 0
24-week 0
, 0
randomized 0
trial 0
designed 0
to 0
test 0
whether 0
risperidone 0
plus 0
structured 0
parent 0
training 0
would 0
be 0
superior 0
to 0
risperidone 0
only 0
on 0
measures 0
of 0
noncompliance B-MENTAL
, 0
irritability B-MENTAL
and 0
adaptive B-MENTAL
functioning I-MENTAL
. 0

In 0
this 0
model 0
, 0
medication 0
reduces 0
tantrums B-MENTAL
, 0
aggression B-MENTAL
and 0
self-injury B-MENTAL
; 0
parent 0
training 0
promotes 0
improvement 0
in 0
noncompliance B-MENTAL
and 0
adaptive B-MENTAL
functioning I-MENTAL
. 0

Thus 0
, 0
medication 0
and 0
parent 0
training 0
target 0
related 0
, 0
but 0
separate 0
, 0
outcomes 0
. 0

At 0
week 0
24 0
, 0
the 0
medication 0
was 0
gradually 0
withdrawn 0
to 0
determine 0
whether 0
subjects 0
in 0
the 0
combined 0
treatment 0
group 0
could 0
be 0
managed 0
on 0
a 0
lower 0
dose 0
or 0
off 0
medication 0
without 0
relapse 0
. 0

Both 0
symptom B-OTHER
reduction I-OTHER
and 0
functional B-OTHER
improvement I-OTHER
are 0
important 0
clinical 0
treatment 0
targets 0
. 0

Thus 0
, 0
experimental 0
evidence 0
on 0
the 0
beneficial 0
effects 0
of 0
combining 0
pharmacotherapy 0
and 0
exportable 0
behavioral 0
interventions 0
is 0
needed 0
to 0
guide 0
clinical 0
practice 0
. 0

Bacterial 0
ribosomal 0
immunostimulants 0
prime 0
alveolar 0
macrophages 0
in 0
vivo 0
to 0
produce 0
interleukin 0
1 0
in 0
vitro 0
. 0

Alveolar 0
macrophages 0
( 0
AMs 0
) 0
may 0
play 0
a 0
key 0
role 0
in 0
human 0
respiratory 0
immune 0
defenses 0
, 0
partially 0
by 0
synthesizing 0
and 0
releasing 0
interleukin 0
1 0
( 0
IL 0
= 0
1 0
) 0
. 0

D53 0
( 0
Ribomunyl 0
) 0
, 0
a 0
composite 0
bacterial 0
ribosomal 0
immunostimulant 0
, 0
has 0
been 0
recognized 0
as 0
an 0
efficient 0
prevention 0
of 0
respiratory B-PHYSICAL
tract I-PHYSICAL
infections I-PHYSICAL
. 0

In 0
vitro 0
, 0
D53 0
enhances 0
the 0
IL-1 B-PHYSICAL
production I-PHYSICAL
by 0
mouse 0
spleen 0
adherent 0
cells 0
. 0

A 0
thymocyte 0
proliferative 0
response 0
assay 0
was 0
used 0
to 0
evaluate 0
the 0
in 0
vitro B-PHYSICAL
IL-1 I-PHYSICAL
production I-PHYSICAL
by 0
AMs 0
in 0
healthy 0
subjects 0
who 0
received 0
D53 0
immunostimulant 0
. 0

Twelve 0
nonsmoking 0
healthy 0
subjects 0
took 0
part 0
in 0
a 0
prospective 0
double-blind 0
placebo 0
control 0
study 0
. 0

On 0
day 0
1 0
, 0
a 0
first 0
bronchoalveolar 0
lavage 0
( 0
BAL 0
) 0
was 0
performed 0
to 0
assess 0
IL-1 B-PHYSICAL
production I-PHYSICAL
by 0
unstimulated 0
and 0
lipopolysaccharide 0
( 0
LPS 0
) 0
stimulated 0
AM 0
. 0

Then 0
, 0
subjects 0
were 0
randomized 0
to 0
receive 0
D53 0
( 0
n 0
= 0
6 0
) 0
or 0
its 0
placebo 0
( 0
n 0
= 0
6 0
) 0
by 0
both 0
oral 0
and 0
subcutaneous 0
injection 0
routes 0
from 0
day 0
1 0
to 0
day 0
15 0
. 0

On 0
day 0
15 0
, 0
a 0
second 0
BAL 0
was 0
done 0
and 0
AM 0
IL-1 B-PHYSICAL
production I-PHYSICAL
was 0
again 0
tested 0
. 0

IL-1 B-PHYSICAL
production I-PHYSICAL
on 0
day 0
15 0
did 0
not 0
significantly 0
differ 0
from 0
day 0
1 0
in 0
both 0
D53-treated 0
and 0
placebo 0
groups 0
either 0
when 0
AMs 0
were 0
unstimulated 0
or 0
were 0
stimulated 0
with 0
concentrations 0
of 0
LPS 0
resulting 0
in 0
maximal 0
IL-1 B-PHYSICAL
production I-PHYSICAL
. 0

However 0
, 0
in 0
the 0
D53-treated 0
group 0
, 0
but 0
not 0
in 0
the 0
placebo 0
group 0
, 0
IL-1 B-PHYSICAL
production I-PHYSICAL
induced 0
by 0
low 0
LPS B-PHYSICAL
concentration I-PHYSICAL
( 0
5 0
mg/L 0
) 0
was 0
significantly 0
higher 0
( 0
mean 0
+/- 0
SEM 0
: 0
1,238 0
+/- 0
287 0
U/10 0
( 0
6 0
) 0
AM 0
) 0
on 0
day 0
15 0
in 0
comparison 0
with 0
day 0
1 0
( 0
577 0
+/- 0
113 0
U/10 0
( 0
6 0
) 0
AM 0
; 0
p 0
less 0
than 0
0.05 0
, 0
Wilcoxon 0
W 0
test 0
) 0
and 0
in 0
comparison 0
with 0
the 0
control 0
group 0
( 0
day 0
15 0
IL-1 B-PHYSICAL
production 0
induced 0
by 0
5 0
mg/L 0
LPS 0
, 0
758 0
+/- 0
175 0
U/10 0
( 0
6 0
) 0
AM 0
; 0
p 0
less 0
than 0
0.05 0
, 0
Mann-Whitney 0
U 0
test 0
) 0
. 0

Moreover 0
, 0
in 0
the 0
D53-treated 0
group 0
, 0
the 0
optimal B-PHYSICAL
LPS I-PHYSICAL
concentration I-PHYSICAL
( 0
ie 0
, 0
LPS 0
concentration 0
that 0
induced 0
maximal 0
IL-1 0
production 0
) 0
was 0
significantly 0
lower 0
on 0
day 0
15 0
( 0
mean 0
+/- 0
SD 0
: 0
11 0
+/- 0
7 0
mg/L 0
) 0
than 0
on 0
day 0
1 0
( 0
16 0
+/- 0
7 0
mg/L 0
; 0
p 0
less 0
than 0
0.05 0
Wilcoxon 0
W 0
test 0
) 0
. 0

We 0
conclude 0
that 0
D53 0
immunostimulant 0
in 0
vivo 0
primes 0
AM 0
to 0
produce 0
IL-1 B-PHYSICAL
following 0
low B-PHYSICAL
LPS I-PHYSICAL
concentration I-PHYSICAL
stimulation 0
. 0

This 0
may 0
partially 0
explain 0
the 0
protective 0
effect 0
of 0
D53 0
immunostimulant 0
against 0
respiratory B-PHYSICAL
tract I-PHYSICAL
infection I-PHYSICAL
. 0

Post 0
hoc 0
analysis 0
of 0
a 0
single 0
IV 0
infusion 0
of 0
zoledronic 0
acid 0
versus 0
daily 0
oral 0
risedronate 0
on 0
lumbar 0
spine 0
bone 0
mineral 0
density 0
in 0
different 0
subgroups 0
with 0
glucocorticoid-induced 0
osteoporosis 0
. 0

This 0
study 0
summarizes 0
the 0
treatment 0
effect 0
of 0
zoledronic 0
acid 0
infusion 0
on 0
lumbar B-PHYSICAL
spine I-PHYSICAL
bone I-PHYSICAL
mineral I-PHYSICAL
density I-PHYSICAL
in 0
different 0
subgroups 0
with 0
glucocorticoid-induced 0
osteoporosis 0
. 0

Zoledronic 0
acid 0
is 0
significantly 0
more 0
effective 0
than 0
risedronate 0
in 0
increasing 0
lumbar B-PHYSICAL
spine I-PHYSICAL
( I-PHYSICAL
LS I-PHYSICAL
) I-PHYSICAL
bone I-PHYSICAL
mineral I-PHYSICAL
density I-PHYSICAL
( I-PHYSICAL
BMD I-PHYSICAL
) I-PHYSICAL
in 0
both 0
prevention 0
and 0
treatment 0
of 0
glucocorticoid-induced 0
osteoporosis 0
. 0

Introduction 0
In 0
patients 0
on 0
glucocorticoids 0
, 0
a 0
single 0
zoledronic 0
acid 0
infusion 0
significantly 0
increased 0
BMD B-PHYSICAL
versus 0
daily 0
oral 0
risedronate 0
. 0

We 0
assessed 0
treatment 0
effect 0
on 0
LS B-PHYSICAL
BMD I-PHYSICAL
in 0
different 0
patient 0
subgroups 0
at 0
month 0
12 0
that 0
contributed 0
to 0
the 0
risk 0
of 0
osteoporosis 0
in 0
addition 0
to 0
glucocorticoids 0
. 0

Methods 0
Patients 0
randomized 0
to 0
a 0
single 0
IV 0
infusion 0
of 0
zoledronic 0
acid 0
5 0
mg 0
or 0
risedronate 0
( 0
5 0
mg/day 0
) 0
and 0
stratified 0
based 0
on 0
glucocorticoids 0
duration 0
[ 0
treatment 0
( 0
> 0
3 0
months 0
) 0
and 0
prevention 0
( 0
? 0

3 0
months 0
) 0
subpopulations 0
] 0
were 0
subgrouped 0
by 0
age 0
; 0
gender 0
; 0
menopausal 0
status 0
in 0
women 0
; 0
dose 0
and 0
duration 0
of 0
prednisone 0
during 0
the 0
trial 0
; 0
and 0
baseline 0
serum 0
25-OH 0
vitamin 0
D 0
, 0
LS 0
BMD 0
T-score 0
, 0
creatinine 0
clearance 0
, 0
and 0
concomitant 0
medication 0
use 0
. 0

Results 0
At 0
month 0
12 0
, 0
zoledronic 0
acid 0
significantly 0
increased 0
LS 0
BMD 0
versus 0
risedronate 0
in 0
patients 0
? 0

74 0
years 0
( 0
P 0
< 0
0.05 0
) 0
in 0
the 0
treatment 0
and 0
65-74 0
years 0
( 0
P 0
= 0
0.0008 0
) 0
in 0
the 0
prevention 0
subpopulation 0
. 0

At 0
month 0
12 0
, 0
zoledronic 0
acid 0
significantly 0
increased 0
LS 0
BMD 0
versus 0
risedronate 0
in 0
both 0
subpopulations 0
irrespective 0
of 0
gender 0
( 0
all 0
P 0
< 0
0.05 0
) 0
, 0
cumulative 0
prednisone 0
dose 0
( 0
all 0
P 0
< 0
0.01 0
) 0
, 0
and 0
postmenopausal 0
status 0
( 0
all 0
P 0
< 0
0.05 0
) 0
. 0

In 0
premenopausal 0
women 0
, 0
in 0
both 0
subpopulations 0
, 0
zoledronic 0
acid 0
significantly 0
increased 0
total 0
hip 0
BMD 0
( 0
all 0
P 0
< 0
0.05 0
) 0
versus 0
risedronate 0
at 0
month 0
12 0
but 0
not 0
LS 0
BMD 0
. 0

Osteoporotic 0
patients 0
in 0
the 0
prevention 0
( 0
P=0.0189 0
) 0
and 0
osteopenic 0
patients 0
in 0
the 0
treatment 0
subpopulation 0
( 0
P=0.0305 0
) 0
showed 0
significant 0
LS 0
BMD 0
increases 0
with 0
zoledronic 0
acid 0
versus 0
risedronate 0
at 0
month 0
12 0
. 0

Conclusions 0
This 0
post 0
hoc 0
analysis 0
suggests 0
that 0
zoledronic 0
acid 0
is 0
significantly 0
more 0
effective 0
than 0
risedronate 0
in 0
increasing 0
LS 0
BMD 0
in 0
prevention 0
and 0
treatment 0
of 0
glucocorticoid-induced 0
osteoporosis 0
across 0
a 0
wide 0
range 0
of 0
patients 0
. 0

Comparison 0
of 0
inhaled 0
albuterol 0
powder 0
and 0
aerosol 0
in 0
asthma 0
. 0

In 0
this 0
multicenter 0
, 0
randomized 0
, 0
double-blind 0
study 0
comparing 0
the 0
efficacy 0
and 0
safety 0
of 0
aerosolized 0
albuterol 0
with 0
the 0
dry 0
powder 0
formulation 0
, 0
231 0
patients 0
with 0
chronic 0
reversible 0
obstructive 0
airway 0
disease 0
were 0
randomly 0
allocated 0
to 0
receive 0
either 0
placebo 0
albuterol 0
aerosol 0
followed 0
immediately 0
by 0
active 0
albuterol 0
powder 0
( 0
200 0
micrograms 0
) 0
or 0
active 0
albuterol 0
aerosol 0
( 0
two 0
puffs 0
, 0
180 0
micrograms 0
) 0
followed 0
immediately 0
by 0
placebo 0
lactose 0
powder 0
four 0
times 0
a 0
day 0
for 0
a 0
period 0
of 0
12 0
weeks 0
. 0

No 0
statistically 0
significant 0
differences 0
were 0
found 0
between 0
the 0
powder 0
and 0
aerosol 0
formulations 0
with 0
respect 0
to 0
pulmonary B-PHYSICAL
function I-PHYSICAL
, 0
length 0
of 0
time 0
mean 0
FEV1 0
remained 0
greater 0
than 0
or 0
equal 0
to 0
15 0
% 0
above 0
baseline 0
, 0
physicians B-PHYSICAL
' 0
assessments B-PHYSICAL
of I-PHYSICAL
patients I-PHYSICAL
' 0
clinical B-PHYSICAL
response I-PHYSICAL
, 0
or 0
patients B-OTHER
' 0
subjective B-OTHER
symptom I-OTHER
scores 0
. 0

There 0
were 0
also 0
no 0
significant 0
differences 0
between 0
treatment 0
groups 0
in 0
cardiovascular B-PHYSICAL
effects I-PHYSICAL
, 0
laboratory B-PHYSICAL
values I-PHYSICAL
, 0
or 0
adverse B-ADVERSE-EFFECTS

Granulocyte-macrophage 0
colony-stimulating 0
factor 0
( 0
GM-CSF 0
) 0
as 0
adjunct 0
therapy 0
in 0
relapsed 0
Hodgkin 0
disease 0
. 0

OBJECTIVE 0
To 0
determine 0
the 0
clinical 0
and 0
economic 0
effects 0
of 0
granulocyte 0
macrophage 0
colony-stimulating 0
factor 0
( 0
GM-CSF 0
) 0
as 0
adjunct 0
therapy 0
in 0
relapsed 0
or 0
refractory 0
Hodgkin 0
disease 0
. 0

DESIGN 0
A 0
randomized 0
, 0
double-blind 0
, 0
phase 0
III 0
clinical 0
trial 0
. 0

SETTING 0
A 0
tertiary 0
referral 0
center 0
. 0

PATIENTS 0
Twenty-four 0
patients 0
( 0
twelve 0
of 0
whom 0
were 0
controls 0
) 0
treated 0
with 0
high-dose 0
chemotherapy 0
and 0
autologous 0
bone 0
marrow 0
transplantation 0
. 0

MAIN 0
RESULTS 0
The 0
12 0
patients 0
treated 0
with 0
GM-CSF 0
, 0
when 0
compared 0
with 0
placebo 0
recipients 0
, 0
had 0
shorter 0
periods B-PHYSICAL
of I-PHYSICAL
neutropenia I-PHYSICAL
( 0
median 0
duration 0
of 0
an 0
absolute 0
neutrophil 0
count 0
of 0
less 0
than 0
1000 0
cells/mm3 0
, 0
16 0
days 0
compared 0
with 0
27 0
days 0
; 0
P 0
= 0
0.02 0
) 0
, 0
shorter 0
periods 0
of 0
platelet-transfusion B-PHYSICAL
dependency I-PHYSICAL
( 0
median 0
duration 0
, 0
13.5 0
days 0
compared 0
with 0
21 0
days 0
; 0
P 0
= 0
0.03 0
) 0
, 0
and 0
shorter B-OTHER
hospitalizations I-OTHER
( 0
median 0
hospital 0
stay 0
, 0
32 0
days 0
compared 0
with 0
40.5 0
days 0
; 0
P 0
= 0
0.004 0
) 0
. 0

Other 0
clinical 0
outcomes 0
, 0
such 0
as 0
frequency 0
and 0
severity B-PHYSICAL
of I-PHYSICAL
toxicities I-PHYSICAL
, 0
development 0
of 0
pneumonia B-PHYSICAL
or 0
infection B-PHYSICAL
, 0
in-hospital B-MORTALITY
death I-MORTALITY
, 0
and 0
response 0
rate B-MENTAL
were 0
similar 0
in 0
the 0
two 0
groups 0
. 0

Actuarial 0
long-term B-MORTALITY
disease-free I-MORTALITY
survival I-MORTALITY
was 0
64 0
% 0
for 0
patients 0
treated 0
with 0
GM-CSF 0
and 0
58 0
% 0
for 0
patients 0
who 0
received 0
placebo 0
after 0
32 0
months 0
of 0
follow-up 0
( 0
P 0
= 0
0.15 0
) 0
. 0

The 0
group 0
treated 0
with 0
GM-CSF 0
had 0
lower 0
total 0
charges 0
after 0
infusion B-PHYSICAL
of I-PHYSICAL
autologous I-PHYSICAL
marrow I-PHYSICAL
than 0
the 0
placebo 0
group 0
( 0
median 0
in-hospital 0
charges 0
, 0
$ 0
39,800 0
compared 0
with 0
$ 0
62,500 0
; 0
P 0
= 0
0.005 0
) 0
because 0
of 0
lower B-PHYSICAL
post-infusion I-PHYSICAL
charges I-PHYSICAL
for 0
room 0
and 0
board 0
, 0
antibiotic 0
therapy 0
, 0
transfusions 0
, 0
laboratory 0
tests 0
, 0
and 0
physical 0
therapy 0
visits 0
. 0

CONCLUSIONS 0
Administration 0
of 0
GM-CSF 0
was 0
associated 0
with 0
acceleration 0
of 0
myeloid B-PHYSICAL
and 0
platelet B-PHYSICAL
recovery I-PHYSICAL
and 0
was 0
cost B-OTHER
effective I-OTHER
in 0
the 0
treatment 0
of 0
patients 0
with 0
relapsed 0
Hodgkin 0
disease 0
who 0
received 0
intensive 0
chemotherapy 0
. 0

Prognostic 0
value 0
of 0
postoperative 0
CEA 0
clearance 0
in 0
rectal 0
cancer 0
patients 0
with 0
high 0
preoperative 0
CEA 0
levels 0
. 0

PURPOSE 0
We 0
determined 0
the 0
prognostic 0
value 0
of 0
carcinoembryonic 0
antigen 0
( 0
CEA 0
) 0
clearance 0
after 0
tumor 0
resection 0
with 0
serial 0
evaluation 0
of 0
postoperative 0
CEA 0
levels 0
in 0
rectal 0
cancer 0
. 0

METHODS 0
Between 0
1994 0
and 0
2004 0
, 0
we 0
retrospectively 0
reviewed 0
122 0
patients 0
with 0
rectal 0
cancer 0
whose 0
serum B-PHYSICAL
CEA I-PHYSICAL
levels I-PHYSICAL
were 0
measured 0
on 0
the 0
preoperative 0
day 0
and 0
postoperative 0
days 0
7 0
and 0
30 0
. 0

Patients 0
with 0
preoperative 0
CEA 0
levels 0
< 0
5.0 0
ng/ml 0
were 0
excluded 0
. 0

An 0
exponential 0
trend 0
line 0
was 0
drawn 0
using 0
the 0
three 0
CEA 0
values 0
. 0

Patients 0
were 0
categorized 0
into 0
three 0
groups 0
based 0
on 0
R 0
( 0
2 0
) 0
values 0
calculated 0
through 0
trend 0
line 0
, 0
which 0
indicates 0
the 0
correlation 0
coefficient 0
between 0
exponential 0
graph 0
and 0
measured 0
CEA B-PHYSICAL
values I-PHYSICAL
: 0
exponential 0
decrease 0
group 0
( 0
group 0
1 0
: 0
0.9 0
< 0
R 0
( 0
2 0
) 0
< 0
or 0
= 0
1.0 0
) 0
, 0
nearly 0
exponential 0
decrease 0
group 0
( 0
group 0
2 0
: 0
0.5 0
< 0
R 0
( 0
2 0
) 0
< 0
or 0
= 0
0.9 0
) 0
, 0
and 0
randomized 0
clearance 0
group 0
( 0
group 0
3 0
: 0
0.5 0
< 0
or 0
= 0
R 0
( 0
2 0
) 0
) 0
. 0

We 0
then 0
analyzed 0
the 0
CEA 0
clearance 0
pattern 0
as 0
a 0
prognostic 0
indicator 0
. 0

RESULTS 0
With 0
a 0
median 0
follow-up 0
of 0
57 0
months 0
, 0
the 0
5-year B-MORTALITY
overall I-MORTALITY
survival I-MORTALITY
was 0
62.3 0
% 0
vs. 0
48.1 0
% 0
vs. 0
25 0
% 0
and 0
the 0
5-year B-MORTALITY
disease-free I-MORTALITY
survival I-MORTALITY
was 0
58.6 0
% 0
vs. 0
52.7 0
% 0
vs. 0
25 0
% 0
among 0
groups 0
1 0
, 0
2 0
, 0
and 0
3 0
( 0
P 0
= 0
0.014 0
, 0
P 0
= 0
0.027 0
, 0
respectively 0
) 0
in 0
patients 0
with 0
stage 0
III 0
rectal 0
cancer 0
. 0

For 0
those 0
with 0
stage 0
II 0
rectal 0
cancer 0
, 0
the 0
5-year B-MORTALITY
overall I-MORTALITY
survival I-MORTALITY
rate I-MORTALITY
of 0
group 0
1 0
was 0
significantly 0
better 0
than 0
groups 0
2 0
and 0
3 0
( 0
88.8 0
% 0
vs. 0
74.1 0
% 0
, 0
respectively 0
, 0
P 0
= 0
0.021 0
) 0
. 0

CONCLUSIONS 0
The 0
postoperative 0
pattern 0
of 0
CEA 0
clearance 0
is 0
a 0
useful 0
prognostic 0
determinant 0
in 0
patients 0
with 0
rectal 0
cancer 0
. 0

Patients 0
with 0
a 0
randomized 0
pattern 0
of 0
CEA B-PHYSICAL
clearance I-PHYSICAL
after 0
tumor 0
resection 0
should 0
be 0
regarded 0
as 0
having 0
the 0
possibility 0
of 0
a 0
persistent 0
CEA 0
source 0
and 0
may 0
require 0
consideration 0
of 0
intensive 0
follow-up 0
or 0
adjuvant 0
therapy 0
. 0

Clinical 0
efficacy 0
of 0
antazoline 0
in 0
rapid B-PHYSICAL
cardioversion I-PHYSICAL
of I-PHYSICAL
paroxysmal I-PHYSICAL
atrial I-PHYSICAL
fibrillation I-PHYSICAL
-- I-PHYSICAL
a 0
protocol 0
of 0
a 0
single 0
center 0
, 0
randomized 0
, 0
double-blind 0
, 0
placebo-controlled 0
study 0
( 0
the 0
AnPAF 0
Study 0
) 0
. 0

BACKGROUND 0
Rapid B-PHYSICAL
conversion I-PHYSICAL
of I-PHYSICAL
atrial I-PHYSICAL
fibrillation I-PHYSICAL
( 0
AF B-PHYSICAL
) 0
to B-PHYSICAL
sinus I-PHYSICAL
rhythm B-PHYSICAL
may 0
be 0
achieved 0
by 0
the 0
administration 0
of 0
class 0
IA 0
, 0
IC 0
and 0
III 0
antiarrhythmic 0
drugs 0
or 0
vernakalant 0
hydrochloride 0
. 0

However 0
, 0
that 0
treatment 0
may 0
be 0
related 0
to 0
potential 0
pro-arrhythmia 0
, 0
lack 0
of 0
efficacy 0
or 0
the 0
exceptionally 0
high 0
cost 0
of 0
a 0
compound 0
used 0
. 0

Antazoline 0
is 0
a 0
first 0
generation 0
antihistaminic 0
agent 0
with 0
chinidin-like 0
properties 0
. 0

When 0
administered 0
intravenously 0
, 0
antazoline 0
exerts 0
a 0
strong B-PHYSICAL
antiarrhythmic I-PHYSICAL
effect 0
on 0
supraventricular B-PHYSICAL
arrhythmia B-PHYSICAL
, 0
especially 0
on 0
AF B-PHYSICAL
, 0
facilitating 0
rapid B-PHYSICAL
conversion I-PHYSICAL
to B-PHYSICAL
sinus I-PHYSICAL
rhythm I-PHYSICAL
. 0

Despite 0
a 0
relative 0
lack 0
of 0
published 0
data 0
antazoline 0
has 0
been 0
marketed 0
in 0
Poland 0
and 0
widely 0
used 0
in 0
cardiology 0
wards 0
and 0
emergency 0
rooms 0
for 0
many 0
years 0
due 0
to 0
its 0
efficacy 0
, 0
safety 0
and 0
rapid 0
onset 0
of 0
action 0
within 0
minutes 0
of 0
administration 0
. 0

METHODS/DESIGN 0
A 0
randomized 0
, 0
double 0
blind 0
, 0
placebo-controlled 0
, 0
superiority 0
clinical 0
trial 0
was 0
designed 0
to 0
assess 0
clinical B-OTHER
efficacy I-OTHER
of 0
antazoline 0
in 0
rapid 0
conversion 0
of 0
AF 0
to 0
sinus 0
rhythm 0
. 0

Eligible 0
patients 0
will 0
present 0
AF 0
lasting 0
less 0
than 0
43 0
hours 0
, 0
will 0
be 0
in 0
stable 0
cardio-pulmonary 0
condition 0
and 0
will 0
have 0
no 0
prior 0
history 0
of 0
advanced 0
heart 0
failure 0
or 0
significant 0
valvular 0
disease 0
. 0

Long-term 0
antiarrhythmic 0
therapy 0
is 0
not 0
considered 0
an 0
exclusion 0
criterion 0
. 0

Subjects 0
who 0
fulfill 0
selection 0
criteria 0
will 0
be 0
randomly 0
assigned 0
to 0
receive 0
intravenously 0
either 0
antazoline 0
or 0
placebo 0
in 0
divided 0
doses 0
and 0
observed 0
for 0
1.5 0
hours 0
after 0
conversion 0
to 0
sinus 0
rhythm 0
or 0
after 0
the 0
last 0
i.v 0
. 0

bolus 0
. 0

Primary 0
end 0
point 0
will 0
be 0
the 0
conversion 0
of 0

Helicobacter 0
pylori 0
and 0
gastric 0
cancer 0
: 0
current 0
status 0
of 0
the 0
Austrain 0
Czech 0
German 0
gastric 0
cancer 0
prevention 0
trial 0
( 0
PRISMA 0
Study 0
) 0
. 0

AIM 0
To 0
test 0
the 0
hypothesis 0
that 0
Helicobacter 0
pylori 0
eradication 0
alone 0
can 0
reduce 0
the 0
incidence 0
of 0
gastric B-PHYSICAL
cancer I-PHYSICAL
in 0
a 0
subgroup 0
of 0
individuals 0
with 0
an 0
increased 0
risk 0
for 0
this 0
fatal 0
disease 0
. 0

METHODS 0
It 0
is 0
a 0
prospective 0
, 0
randomized 0
, 0
double 0
blind 0
, 0
placebo 0
controlled 0
multinational 0
multicenter 0
trial 0
. 0

Men 0
between 0
55 0
and 0
65 0
years 0
of 0
age 0
with 0
a 0
gastric 0
cancer 0
phenotype 0
of 0
Helicobacter 0
pylori 0
gastritis 0
are 0
randomized 0
to 0
receive 0
a 0
7 0
day 0
course 0
of 0
omeprazole 0
2 0
X 0
20mg 0
, 0
clarithromycin 0
2 0
X 0
500mg 0
, 0
and 0
amoxicillin 0
2 0
X 0
1g 0
for 0
7 0
days 0
, 0
or 0
omeprazole 0
2 0
X 0
20mg 0
plus 0
placebo 0
. 0

Follow-up 0
endoscopy 0
is 0
scheduled 0
3 0
months 0
after 0
therapy 0
, 0
and 0
thereafter 0
in 0
one-year 0
intervals 0
. 0

Predefined 0
study 0
endpoints 0
are 0
gastric B-PHYSICAL
cancer I-PHYSICAL
, 0
precancerous B-PHYSICAL
lesions I-PHYSICAL
( 0
dysplasia B-PHYSICAL
, 0
adenoma B-PHYSICAL
) 0
, 0

Potential 0
effect 0
of 0
the 0
risk 0
of 0
ovarian 0
cancer 0
algorithm 0
( 0
ROCA 0
) 0
on 0
the 0
mortality B-MORTALITY
outcome I-MORTALITY
of 0
the 0
Prostate 0
, 0
Lung 0
, 0
Colorectal 0
and 0
Ovarian 0
( 0
PLCO 0
) 0
trial 0
. 0

Recently 0
, 0
the 0
Prostate 0
, 0
Lung 0
, 0
Colorectal 0
and 0
Ovarian 0
( 0
PLCO 0
) 0
Trial 0
reported 0
no 0
mortality 0
benefit 0
for 0
annual 0
screening 0
with 0
CA-125 0
and 0
transvaginal 0
ultrasound 0
( 0
TVU 0
) 0
. 0

Currently 0
ongoing 0
is 0
the 0
UK 0
Collaborative 0
Trial 0
of 0
Ovarian 0
Cancer 0
Screening 0
( 0
UKCTOCS 0
) 0
, 0
which 0
utilizes 0
the 0
risk 0
of 0
ovarian 0
cancer 0
algorithm 0
( 0
ROCA 0
) 0
, 0
a 0
statistical 0
tool 0
that 0
considers 0
current 0
and 0
past 0
CA125 0
values 0
to 0
determine 0
ovarian 0
cancer 0
risk 0
. 0

In 0
contrast 0
, 0
PLCO 0
used 0
a 0
single 0
cutoff 0
for 0
CA125 0
, 0
based 0
on 0
current 0
levels 0
alone 0
. 0

We 0
investigated 0
whether 0
having 0
had 0
used 0
ROCA 0
in 0
PLCO 0
could 0
have 0
, 0
under 0
optimal 0
assumptions 0
, 0
resulted 0
in 0
a 0
significant B-MORTALITY
mortality I-MORTALITY
benefit I-MORTALITY
by 0
applying 0
ROCA 0
to 0
PLCO 0
CA125 0
screening 0
values 0
. 0

A 0
best-case 0
scenario 0
assumed 0
that 0
all 0
cancers 0
showing 0
a 0
positive 0
screen 0
result 0
earlier 0
with 0
ROCA 0
than 0
under 0
the 0
PLCO 0
protocol 0
would 0
have 0
avoided 0
mortality B-MORTALITY
; 0
under 0
a 0
stage-shift 0
scenario 0
, 0
such 0
women 0
were 0
assigned 0
survival 0
equivalent 0
to 0
Stage 0
I/II 0
screen-detected 0
cases 0
. 0

Updated 0
PLCO 0
data 0
show 0
132 0
intervention 0
arm 0
ovarian 0
cancer 0
deaths 0
versus 0
119 0
in 0
usual 0
care 0
( 0
relative 0
risk 0
, 0
RR 0
= 0
1.11 0
) 0
. 0

Forty-three 0
ovarian 0
cancer 0
cases 0
, 0
25 0
fatal 0
, 0
would 0
have 0
been 0
detected 0
earlier 0
with 0
ROCA 0
, 0
with 0
a 0
median 0
( 0
minimum 0
) 0
advance 0
time 0
for 0
fatal B-MORTALITY
cases I-MORTALITY
of 0
344 0
( 0
147 0
) 0
days 0
. 0

Best-case 0
and 0
stage-shift 0
scenarios 0
gave 0
25 0
and 0
19 0
deaths B-MORTALITY
prevented 0
with 0
ROCA 0
, 0
for 0
RRs 0
of 0
0.90 0
( 0
95 0
% 0
CI 0
: 0
0.69-1.17 0
) 0
and 0
0.95 0
( 0
95 0
% 0
CI 0
: 0
0.74-1.23 0
) 0
, 0
respectively 0
. 0

Having 0
utilized 0
ROCA 0
in 0
PLCO 0
would 0
not 0
have 0
led 0
to 0
a 0
significant 0
mortality B-MORTALITY
benefit I-MORTALITY
of 0
screening 0
. 0

However 0
, 0
ROCA 0
could 0
still 0
show 0
a 0
significant 0
effect 0
in 0
other 0
screening 0
trials 0
, 0
including 0
UKCTOCS 0
. 0

Effect 0
of 0
extradural 0
analgesia 0
on 0
stress 0
responses B-PHYSICAL
to 0
abdominal 0
surgery 0
in 0
infants 0
. 0

We 0
studied 0
40 0
children 0
younger 0
than 0
4 0
yr 0
having 0
elective 0
abdominal 0
surgery 0
under 0
general 0
anaesthesia 0
supplemented 0
with 0
either 0
systemic 0
opioids 0
or 0
extradural 0
bupivacaine 0
. 0

Venous B-PHYSICAL
blood I-PHYSICAL
samples I-PHYSICAL
were 0
obtained 0
before 0
tracheal 0
intubation 0
to 0
measure 0
baseline 0
concentrations B-PHYSICAL
of I-PHYSICAL
adrenaline I-PHYSICAL
, 0
noradrenaline B-PHYSICAL
, 0
glucose B-PHYSICAL
, 0
ACTH B-PHYSICAL
and 0
cortisol B-PHYSICAL
. 0

Additional 0
samples 0
were 0
obtained 0
45 0
min 0
after 0
the 0
start 0
of 0
surgery 0
, 0
at 0
the 0
end 0
of 0
surgery 0
, 0
1 0
h 0
and 0
24 0
h 0
after 0
the 0
end 0
of 0
surgery 0
. 0

Plasma B-OTHER
concentrations I-OTHER
of I-OTHER
bupivacaine I-OTHER
were 0
measured 0
also 0
in 0
the 0
extradural 0
group 0
at 0
each 0
sampling 0
time 0
. 0

Both 0
techniques 0
provided 0
acceptable 0
analgesia 0
, 0
but 0
the 0
perioperative B-PHYSICAL
increases 0
in B-PHYSICAL
adrenaline B-PHYSICAL
, 0
glucose B-PHYSICAL
and 0
ACTH B-PHYSICAL
were 0
significantly 0
greater 0
in 0
the 0
opioid 0
group 0
. 0

Noradrenaline B-PHYSICAL
concentrations I-PHYSICAL
decreased 0
to 0
less 0
than 0
baseline 0
values 0
in 0
the 0
extradural 0
group 0
and 0
were 0
significantly 0
less 0
than 0
in 0
the 0
opioid 0
group 0
. 0

The 0
perioperative B-PHYSICAL
increase 0
in B-PHYSICAL
cortisol B-PHYSICAL
was 0
similar 0
in 0
the 0
two 0
groups 0
, 0
despite 0
the 0
differences 0
in 0
ACTH 0
responses 0
. 0

Most 0
responses 0
returned 0
to 0
the 0
baseline 0
values 0
within 0
24 0
h. 0

Contribution 0
of 0
endogenous 0
bradykinin 0
to 0
fibrinolysis B-PHYSICAL
, 0
inflammation B-PHYSICAL
, 0
and 0
blood B-PHYSICAL
product I-PHYSICAL
transfusion I-PHYSICAL
following 0
cardiac 0
surgery 0
: 0
a 0
randomized 0
clinical 0
trial 0
. 0

Bradykinin 0
increases 0
during 0
cardiopulmonary 0
bypass 0
( 0
CPB 0
) 0
and 0
stimulates 0
the 0
release 0
of 0
nitric B-PHYSICAL
oxide I-PHYSICAL
, 0
inflammatory 0
cytokines 0
, 0
and 0
tissue-type 0
plasminogen 0

Clobazam 0
in 0
catamenial 0
epilepsy 0
. 0

A 0
model 0
for 0
evaluating 0
anticonvulsants 0
. 0

The 0
cyclical 0
exacerbations 0
of 0
epilepsy 0
( 0
catamenial 0
epilepsy 0
) 0
were 0
used 0
to 0
assess 0
the 0
antiepileptic 0
effect 0
of 0
a 0
benzodiazepine 0
, 0
clobazam 0
. 0

Doses 0
of 0
20 0
mg 0
, 0
and 0
in 0
some 0
cases 0
30 0
mg 0
, 0
per 0
day 0
were 0
compared 0
with 0
placebo 0
over 0
predetermined 0
ten-day 0
periods 0
in 0
a 0
double-blind 0
cross-over 0
study 0
. 0

The 0
results 0
were 0
evaluated 0
by 0
preference 0
in 0
a 0
sequential 0
procedure 0
. 0

In 0
14 0
of 0
18 0
patients 0
who 0
received 0
both 0
treatments 0
clobazam 0
was 0
superior 0
to 0
placebo 0
, 0
and 0
in 0
4 0
patients 0
no 0
preference 0
was 0
established 0
. 0

Clobazam 0
completely 0
prevented 0
seizures B-PHYSICAL
in 0
most 0
of 0
the 0
patients 0
, 0
and 0
toxic 0
effects 0
were 0
of 0
low 0
frequency 0
and 0
severity B-OTHER
. 0

Diclofenac 0
, 0
a 0
nonsteroidal 0
anti-inflammatory 0
drug 0
, 0
decreases 0
proteinuria 0
in 0
some 0
glomerular 0
diseases 0
: 0
a 0
controlled 0
study 0
. 0

Treatment 0
with 0
nonsteroidal 0
anti-inflammatory 0
drugs 0
( 0
NSAIDs 0
) 0
was 0
first 0
used 0
in 0
glomerulonephritis 0
( 0
GN 0
) 0
in 0
1966 0
but 0
its 0
efficiency 0
is 0
still 0
debated 0
. 0

We 0
studied 0
the 0
antiproteinuric B-PHYSICAL
effect 0
of 0
such 0
a 0
treatment 0
in 0
a 0
double-blind 0
study 0
. 0

29 0
GN 0
patients 0
with 0
normal 0
renal 0
function 0
( 0
17 0
membranoproliferative 0
GN 0
, 0
12 0
IgA 0
GN 0
) 0
were 0
randomly 0
assigned 0
to 0
receive 0
100 0
mg/day 0
of 0
diclofenac 0
or 0
placebo 0
for 0
at 0
least 0
2 0
months 0
. 0

There 0
was 0
a 0
significant 0
antiproteinuric B-PHYSICAL
effect 0
of 0
diclofenac 0
versus 0
placebo 0
with 0
a 0
fall 0
of 0
70 0
% 0
in 0
the 0
diclofenac 0
group 0
versus 0
6 0
% 0
in 0
the 0
placebo 0
group 0
( 0
p 0
less 0
than 0
0.001 0
with 0
the 0
Mann-Whitney 0
test 0
) 0
. 0

The 0
median 0
was 0
3 0
mg/min 0
at 0
onset 0
and 0
2.45 0
mg/min 0
after 0
2 0
months 0
treatment 0
with 0
the 0
placebo 0
. 0

In 0
the 0
diclofenac 0
group 0
, 0
it 0
was 0
2.2 0
and 0
0.95 0
mg/min 0
, 0
respectively 0
( 0
p 0
less 0
than 0
0.01 0
) 0
. 0

Diclofenac 0
did 0
not 0
significantly 0
increase 0
creatinine B-PHYSICAL
levels I-PHYSICAL
. 0

Gastric B-PHYSICAL
irritation I-PHYSICAL
was 0
noted 0
only 0
once 0
. 0

This 0
study 0
establishes 0
the 0
short-term B-PHYSICAL
antiproteinuric I-PHYSICAL
action I-PHYSICAL
of 0
diclofenac 0
. 0

Whether 0
this 0
action 0
affects 0
the 0
final 0
outcome 0
is 0
not 0
yet 0
determined 0
. 0

Benefit 0
of 0
FSH 0
priming 0
of 0
women 0
with 0
PCOS 0
to 0
the 0
in 0
vitro 0
maturation 0
procedure 0
and 0
the 0
outcome 0
: 0
a 0
randomized 0
prospective 0
study 0
. 0

The 0
aim 0
of 0
this 0
study 0
was 0
to 0
determine 0
whether 0
the 0
rates B-PHYSICAL
of I-PHYSICAL
in I-PHYSICAL
vitro I-PHYSICAL
oocyte I-PHYSICAL
maturation I-PHYSICAL
, 0
fertilization B-PHYSICAL
and 0
cleavage B-PHYSICAL
, 0
as 0
well 0
as 0
implantation B-PHYSICAL
rate I-PHYSICAL
and 0
pregnancy B-PHYSICAL
rate I-PHYSICAL
, 0
could 0
be 0
improved 0
by 0
low-dose 0
priming 0
with 0
FSH 0
in 0
vivo 0
before 0
retrieval 0
of 0
immature 0
oocytes 0
in 0
patients 0
with 0
polycystic 0
ovary 0
syndrome 0
( 0
PCOS 0
) 0
. 0

From 0
March 0
1998 0
to 0
June 0
2000 0
, 0
a 0
total 0
of 0
28 0
women 0
underwent 0
36 0
completed 0
treatment 0
cycles 0
, 0
randomized 0
sequentially 0
in 0
one 0
of 0
two 0
groups 0
. 0

Women 0
in 0
group 0
1 0
( 0
n 0
= 0
12 0
cycles 0
) 0
received 0
no 0
stimulation 0
and 0
women 0
in 0
group 0
2 0
( 0
n 0
= 0
24 0
cycles 0
) 0
received 0
150 0
iu 0
recombinant 0
FSH 0
day 0
( 0
-1 0
) 0
for 0
3 0
days 0
, 0
initiated 0
on 0
day 0
3 0
after 0
menstruation 0
. 0

Aspiration 0
was 0
performed 0
transvaginally 0
between 0
day 0
9 0
and 0
day 0
17 0
in 0
the 0
unstimulated 0
group 0
and 0
on 0
day 0
8 0
or 0
day 0
9 0
in 0
the 0
FSH-primed 0
group 0
after 0
FSH 0
deprivation 0
for 0
2 0
or 0
3 0
days 0
. 0

All 0
cumulus-enclosed 0
oocytes 0
of 0
healthy 0
appearance 0
were 0
matured 0
in 0
culture 0
medium 0
( 0
TCM-199 0
) 0
in 0
vitro 0
for 0
28-36 0
h 0
before 0
intracytoplasmic 0
sperm 0
injection 0
( 0
ICSI 0
) 0
. 0

After 0
oocyte 0
retrieval 0
the 0
women 0
were 0
given 0
oestradiol 0
( 0
6 0
mg 0
day 0
( 0
-1 0
) 0
) 0
and 0
progesterone 0
administration 0
( 0
300 0
mg 0
day 0
( 0
-1 0
) 0
) 0
was 0
initiated 0
2 0
days 0
later 0
. 0

Suitable 0
embryos 0
( 0
maximum 0
two 0
embryos 0
) 0
were 0
transferred 0
on 0
day 0
3 0
after 0
ICSI 0
. 0

The 0
percentage 0
of 0
oocytes B-OTHER
reaching I-OTHER
metaphase I-OTHER
II I-OTHER
was 0
significantly 0
higher 0
( 0
P 0
< 0
0.05 0
) 0
in 0
the 0
FSH-primed 0
group 0
( 0
59 0
% 0
, 0
92/156 0
) 0
compared 0
with 0
the 0
non-primed 0
group 0
( 0
44 0
% 0
, 0
36/81 0
) 0
. 0

There 0
were 0
no 0
significant 0
differences 0
in 0
the 0
rates 0
of 0
oocyte B-OTHER
fertilization I-OTHER
and 0
cleavage B-OTHER
between 0
these 0
groups 0
. 0

No 0
pregnancies B-PHYSICAL
were 0
obtained 0
in 0
group 0
1 0
( 0
0 0
% 0
, 0
0/12 0
) 0
, 0
whereas 0
seven 0
clinical B-OTHER
pregnancies I-OTHER
were 0
obtained 0
in 0
group 0
2 0
( 0
29 0
% 0
, 0
7/24 0
) 0
( 0
P 0
< 0
0.05 0
) 0
. 0

In 0
group 0
2 0
, 0
37 0
embryo 0
transfers 0
resulted 0
in 0
eight 0
implantations B-PHYSICAL
( 0
21.6 0
% 0
) 0
. 0

Three 0
healthy B-PHYSICAL
singleton I-PHYSICAL
children I-PHYSICAL
have 0
been 0
born B-PHYSICAL
at 0
term 0
; 0
the 0
remaining 0
pregnancies 0
ended 0
with 0
spontaneous B-ADVERSE-EFFECTS
abortions I-ADVERSE-EFFECTS
in 0
the 0
first 0
trimester 0
. 0

These 0
results 0
indicate 0
that 0
priming 0
with 0
recombinant 0
FSH 0
before 0
harvesting 0
of 0
immature 0
oocytes 0
from 0
patients 0
with 0
PCOS 0
may 0
improve 0
the 0
maturational B-OTHER
potential I-OTHER
of I-OTHER
the I-OTHER
oocytes I-OTHER
and I-OTHER
the I-OTHER
implantation I-OTHER
rate I-OTHER
of I-OTHER
the I-OTHER
cleaved I-OTHER
embryos I-OTHER
. 0

Pentoxifylline 0
to 0
treat 0
radiation 0
proctitis 0
: 0
a 0
small 0
and 0
inconclusive 0
randomised 0
trial 0
. 0

This 0
prospective 0
randomised 0
controlled 0
study 0
of 0
40 0
patients 0
could 0
not 0
show 0
a 0
statistically 0
significant 0
advantage 0
with 0
6 0
months 0
of 0
pentoxifylline 0
compared 0
with 0
standard 0
measures 0
for 0
late B-PHYSICAL
radiation-induced I-PHYSICAL
rectal I-PHYSICAL
bleeding I-PHYSICAL
. 0

However 0
, 0
a 0
modest 0
benefit 0
can 0
not 0
be 0
excluded 0
and 0
larger 0
randomised 0
placebo-controlled 0
trials 0
with 0
longer 0
durations 0
of 0
pentoxifylline B-OTHER
treatment I-OTHER
may 0
be 0
justified 0
. 0

Effectiveness 0
of 0
a 0
calculus 0
scaling 0
gel 0
. 0

This 0
study 0
evaluated 0
the 0
effect 0
of 0
a 0
calculus 0
scaling 0
gel 0
( 0
SofScale 0
) 0
on 0
time B-OTHER
and I-OTHER
ease I-OTHER
of I-OTHER
the I-OTHER
scaling I-OTHER
procedure I-OTHER
in 0
a 0
double-blind 0
, 0
split-mouth 0
clinical 0
study 0
of 0
32 0
subjects 0
. 0

The 0
Volpe-Manhold B-PHYSICAL
calculus I-PHYSICAL
index I-PHYSICAL
was 0
used 0
to 0
quantify 0
the 0
distribution 0
and 0
amount 0
of 0
calculus 0
deposition 0
on 0
the 0
lingual 0
aspect 0
of 0
the 0
mandibular 0
6 0
anterior 0
teeth 0
at 0
baseline 0
. 0

The 0
gel 0
was 0
applied 0
directly 0
to 0
the 0
calculus 0
and 0
subgingivally 0
to 0
the 0
area 0
to 0
be 0
scaled 0
. 0

Pre- 0
and 0
post-treatment 0
gingival 0
and 0
stain 0
indices 0
were 0
taken 0
. 0

Operator B-OTHER
and 0
subject B-OTHER
questionnaires I-OTHER
were 0
completed 0
immediately 0
after 0
treatment 0
to 0
determine 0
ease 0
of 0
the 0
scaling 0
procedure 0
. 0

Results 0
were 0
analyzed 0
with 0
paired 0
t-tests 0
. 0

The 0
time B-OTHER
difference I-OTHER
in I-OTHER
scaling I-OTHER
between 0
the 0
product 0
and 0
placebo 0
side 0
was 0
not 0
significant 0
. 0

This 0
study 0
found 0
that 0
SofScale 0
is 0
safe 0
to 0
gingival B-PHYSICAL
tissues I-PHYSICAL
and 0
does 0
not 0
promote 0
tooth B-PHYSICAL
sensitivity I-PHYSICAL
. 0

However 0
, 0
this 0
study 0
did 0
not 0
find 0
significant 0
differences 0
in 0
scaling 0
time 0
between 0
product 0
and 0
placebo 0
when 0
using 0
a 0
2-minute 0
gel 0
contact 0
time 0
. 0

Acute 0
pressor 0
and 0
hormonal 0
effects 0
of 0
beta-endorphin 0
at 0
high 0
doses 0
in 0
healthy 0
and 0
hypertensive 0
subjects 0
: 0
role 0
of 0
opioid 0
receptor 0
agonism 0
. 0

CONTEXT 0
The 0
opioid 0
system 0
is 0
involved 0
in 0
blood 0
pressure 0
regulation 0
in 0
both 0
normal 0
humans 0
and 0
patients 0
with 0
essential 0
hypertension 0
. 0

OBJECTIVE 0
The 0
objective 0
of 0
the 0
study 0
was 0
to 0
investigate 0
the 0
effects 0
of 0
a 0
high-dose 0
infusion 0
of 0
beta-endorphin 0
, 0
an 0
opioid 0
peptide 0
, 0
on 0
blood 0
pressure 0
and 0
on 0
the 0
hormonal 0
profile 0
in 0
healthy 0
subjects 0
and 0
in 0
hypertensive 0
patients 0
and 0
the 0
mediation 0
played 0
by 0
opioid 0
receptor 0
agonism 0
. 0

DESIGN 0
, 0
SETTING 0
, 0
AND 0
PARTICIPANTS 0
According 0
to 0
a 0
randomized 0
double-blind 0
design 0
, 0
11 0
healthy 0
subjects 0
( 0
controls 0
) 0
and 0
12 0
hypertensive 0
inpatients 0
( 0
mean 0
age 0
, 0
38.9 0
and 0
40.4 0
yr 0
, 0
respectively 0
) 0
received 0
1-h 0
iv 0
infusion 0
of 0
beta-endorphin 0
( 0
250 0
mug/h 0
) 0
and 0
, 0
on 0
another 0
occasion 0
, 0
the 0
same 0
infusion 0
protocol 0
preceded 0
by 0
the 0
opioid 0
antagonist 0
naloxone 0
( 0
8 0
mg 0
) 0
. 0

MAIN 0
OUTCOME 0
MEASURES 0
Hemodynamic B-PHYSICAL
and I-PHYSICAL
hormonal I-PHYSICAL
measurements I-PHYSICAL
were 0
performed 0
at 0
established 0
times 0
during 0
the 0
infusion 0
protocols 0
. 0

RESULTS 0
At 0
baseline 0
, 0
circulating 0
beta-endorphin 0
, 0
norepinephrine 0
, 0
and 0
endothelin-1 0
in 0
hypertensive 0
patients 0
were 0
significantly 0
( 0
P 0
< 0
0.05 0
) 0
higher 0
than 0
in 0
controls 0
. 0

In 0
controls 0
, 0
beta-endorphin 0
reduced 0
blood B-PHYSICAL
pressure I-PHYSICAL
( 0
P 0
< 0
0.01 0
) 0
and 0
circulating B-PHYSICAL
norepinephrine I-PHYSICAL
( 0
P 0
< 0
0.02 0
) 0
and 0
increased 0
plasma 0
atrial 0
natriuretic B-PHYSICAL
factor I-PHYSICAL
( 0
P 0
< 0
0.003 0
) 0
and 0
GH 0
( 0
P 0
< 0
0.0001 0
) 0
. 0

In 0
hypertensive 0
patients 0
, 0
beta-endorphin 0
decreased 0
systemic B-PHYSICAL
vascular I-PHYSICAL
resistance I-PHYSICAL
( 0
P 0
< 0
0.0001 0
) 0
, 0
blood B-PHYSICAL
pressure I-PHYSICAL
( 0
P 0
< 0
0.0001 0
) 0
, 0
and 0
plasma B-PHYSICAL
norepinephrine I-PHYSICAL
( 0
P 0
< 0
0.0001 0
) 0
and 0
endothelin-1 B-PHYSICAL
( 0
P 0
< 0
0.0001 0
) 0
and 0
raised 0
circulating 0
atrial 0
natriuretic B-PHYSICAL
factor I-PHYSICAL
( 0
P 0
< 0
0.0001 0
) 0
, 0
GH B-PHYSICAL
( 0
P 0
< 0
0.0001 0
) 0
, 0
and 0
IGF-I B-PHYSICAL
( 0
P 0
< 0
0.0001 0
) 0
. 0

These 0
hemodynamic B-PHYSICAL
and I-PHYSICAL
hormonal I-PHYSICAL
responses I-PHYSICAL
to 0
beta-endorphin 0
in 0
hypertensive 0
patients 0
were 0
significantly 0
( 0
P 0
< 0
0.0001 0
) 0
greater 0
than 0
in 0
controls 0
but 0
were 0
annulled 0
in 0
all 0
individuals 0
when 0
naloxone 0
preceded 0
beta-endorphin 0
infusion 0
. 0

CONCLUSIONS 0
High 0
doses 0
of 0
beta-endorphin 0
induce 0
hypotensive 0
and 0
beneficial 0
hormonal 0
effects 0
in 0
humans 0
, 0
which 0
are 0
enhanced 0
in 0
essential 0
hypertension 0
and 0
are 0
mediated 0
by 0
opioid 0
receptors 0
. 0

Effect 0
of 0
pravastatin 0
on 0
kidney B-PHYSICAL
function I-PHYSICAL
and I-PHYSICAL
urinary I-PHYSICAL
protein I-PHYSICAL
excretion I-PHYSICAL
in 0
autosomal 0
dominant 0
polycystic 0
kidney 0
disease 0
. 0

OBJECTIVE 0
Autosomal 0
dominant 0
polycystic 0
kidney 0
disease 0
( 0
ADPKD 0
) 0
is 0
progressive 0
, 0
resulting 0
in 0
end-stage 0
kidney 0
failure 0
in 0
most 0
patients 0
. 0

Experimental 0
and 0
clinical 0
studies 0
have 0
suggested 0
that 0
statins 0
may 0
slow 0
the 0
progression 0
of 0
chronic B-PHYSICAL
kidney I-PHYSICAL
disease I-PHYSICAL
in 0
general 0
and 0
ADPKD 0
specifically 0
. 0

MATERIAL 0
AND 0
METHODS 0
This 0
randomized 0
open-label 0
clinical 0
trial 0
was 0
conducted 0
to 0
assess 0
the 0
effect 0
of 0
pravastatin 0
20 0
mg 0
on 0
kidney 0
function 0
and 0
urinary 0
protein 0
excretion 0
in 0
patients 0
with 0
ADPKD 0
. 0

Sixty 0
patients 0
were 0
initially 0
recruited 0
but 0
49 0
of 0
these 0
received 0
either 0
pravastatin 0
20 0
mg 0
or 0
no 0
treatment 0
for 0
2 0
years 0
. 0

Trial 0
visits 0
were 0
conducted 0
every 0
3 0
months 0
, 0
assessing 0
kidney B-PHYSICAL
function I-PHYSICAL
by 0
estimated 0
glomerular B-OTHER
filtration I-OTHER
rate I-OTHER
and 0
24 0
h B-OTHER
urine I-OTHER
creatinine I-OTHER
clearance I-OTHER
and 0
urinary B-OTHER
protein I-OTHER
excretion I-OTHER
. 0

RESULTS 0
There 0
were 0
no 0
significant 0
( 0
p 0
> 0
0.05 0
) 0
changes B-OTHER
in 0
markers 0
of 0
kidney B-PHYSICAL
function I-PHYSICAL
or 0
urinary B-PHYSICAL
protein I-PHYSICAL
excretion I-PHYSICAL
between 0
groups 0
over 0
the 0
2 0
years 0
despite 0
a 0
significant 0
fall 0
in 0
total 0
serum B-PHYSICAL
cholesterol I-PHYSICAL
in 0
pravastatin-treated 0
patients 0
( 0
p 0
= 0
0.029 0
) 0
. 0

CONCLUSION 0
This 0
trial 0
found 0
that 0
taking 0
20 0
mg 0
pravastatin 0
for 0
2 0
years 0
had 0
no 0
significant 0
effect 0
on 0
kidney B-PHYSICAL
function I-PHYSICAL
or I-PHYSICAL
urinary I-PHYSICAL
protein I-PHYSICAL
excretion I-PHYSICAL
in 0
patients 0
with 0
ADPKD 0
. 0

The 0
lack 0
of 0
statistical 0
power 0
limits 0
the 0
external 0
validity 0
of 0
these 0
findings 0
. 0

A 0
larger 0
, 0
longer 0
duration 0
study 0
using 0
a 0
higher 0
dose 0
of 0
a 0
more 0
potent 0
statin 0
is 0
required 0
. 0

Are 0
tyrosine 0
kinase 0
inhibitors 0
still 0
active 0
in 0
patients 0
with 0
metastatic 0
renal 0
cell 0
carcinoma 0
previously 0
treated 0
with 0
a 0
tyrosine 0
kinase 0
inhibitor 0
and 0
everolimus 0
? 0

Experience 0
of 0
36 0
patients 0
treated 0
in 0
France 0
in 0
the 0
RECORD-1 0
Trial 0
. 0

BACKGROUND 0
Because 0
the 0
response 0
to 0
treatment 0
is 0
limited 0
, 0
patients 0
with 0
metastatic 0
renal 0
cell 0
carcinoma 0
( 0
mRCC 0
) 0
typically 0
receive 0
multiple 0
treatments 0
. 0

Guidelines 0
recommend 0
everolimus 0
for 0
patients 0
previously 0
treated 0
with 0
tyrosine 0
kinase 0
inhibitors 0
( 0
TKI 0
) 0
sunitinib 0
or 0
sorafenib 0
. 0

This 0
study 0
evaluated 0
the 0
efficacy 0
of 0
TKI 0
re-treatment 0
in 0
patients 0
with 0
disease 0
progression 0
after 0
a 0
TKI-everolimus 0
sequence 0
. 0

PATIENTS 0
AND 0
METHODS 0
Data 0
were 0
reviewed 0
for 0
patients 0
enrolled 0
in 0
RECORD-1 0
( 0
Renal 0
Cell 0
Cancer 0
Treatment 0
With 0
Oral 0
RAD001 0
Given 0
Daily 0
) 0
at 0
French 0
sites 0
. 0

Response 0
, B-MORTALITY
progression-free I-MORTALITY
survival I-MORTALITY
( I-MORTALITY
PFS I-MORTALITY
) I-MORTALITY
, I-MORTALITY
and I-MORTALITY
overall I-MORTALITY
survival B-MORTALITY
were 0
evaluated 0
in 0
patients 0
treated 0
with 0
a 0
TKI-everolimus-TKI 0
sequence 0
. 0

RESULTS 0
Thirty-six 0
patients 0
received 0
a 0
TKI 0
after 0
everolimus 0
: 0
sunitinib 0
in 0
17 0
patients 0
, 0
sorafenib 0
in 0
15 0
, 0
and 0
dovitinib 0
( 0
TKI258 0
) 0
in 0
4 0
. 0

The 0
response 0
rate B-PHYSICAL
with 0
TKI 0
re-treatment 0
was 0
8 0
% 0
, 0
and 0
the 0
disease-control B-PHYSICAL
rate B-PHYSICAL
( I-PHYSICAL
response 0
plus B-PHYSICAL
stable I-PHYSICAL

Effects 0
of 0
diet 0
and 0
Aspergillus 0
oryzae 0
extract 0
or 0
Saccharomyces 0
cervisiae 0
on 0
growth 0
and 0
carcass 0
characteristics 0
of 0
lambs 0
and 0
steers 0
fed 0
to 0
meet 0
requirements 0
of 0
natural 0
markets 0
. 0

Two 0
studies 0
were 0
conducted 0
to 0
determine 0
the 0
effects 0
of 0
diet 0
and 0
feed 0
additive 0
on 0
growth 0
and 0
carcass 0
characteristics 0
of 0
lambs 0
and 0
cattle 0
destined 0
for 0
all 0
natural 0
markets 0
. 0

In 0
Exp 0
. 0

1 0
, 0
48 0
Dorset 0
? 0

Hampshire 0
lambs 0
( 0
initial 0
BW 0
29.4 0
? 0

0.1 0
kg 0
) 0
were 0
used 0
in 0
a 0
randomized 0
complete 0
block 0
experiment 0
to 0
determine 0
the 0
effects 0
of 0
Aspergillus 0
oryzae 0
extract 0
, 0
Amaferm 0
( 0
AMF 0
) 0
supplementation 0
( 0
1 0
g/d 0
) 0
in 0
an 0
85 0
% 0
concentrate 0
diet 0
on 0
growth 0
and 0
carcass 0
characteristics 0
. 0

Lambs 0
were 0
allotted 0
to 0
12 0
pens 0
( 0
4 0
lambs 0
per 0
pen 0
) 0
, 0
and 0
blocked 0
by 0
sex 0
and 0
BW 0
. 0

Lambs 0
were 0
fed 0
until 0
the 0
average 0
BW 0
of 0
each 0
pen 0
reached 0
a 0
target 0
BW 0
( 0
55.4 0
kg 0
for 0
wethers 0
and 0
50.0 0
kg 0
for 0
ewes 0
) 0
, 0
at 0
which 0
time 0
the 0
entire 0
pen 0
of 0
lambs 0
was 0
slaughtered 0
. 0

Amaferm 0
resulted 0
in 0
a 0
greater 0
( 0
P=0.07 0
) 0
G 0
: 0
F. 0
In 0
Exp 0
. 0

2 0
, 0
168 0
crossbred 0
steers 0
( 0
initial 0
BW 0
300 0
? 0

0.7 0
kg 0
) 0
were 0
used 0
in 0
a 0
trial 0
with 0
a 0
3 0
? 0

2 0
factorial 0
arrangement 0
of 0
treatments 0
to 0
examine 0
the 0
effects 0
of 0
0.5 0
g/d 0
of 0
Saccaromyces 0
cervisiae 0
boulardii 0
CNCM 0
1079-Levucell 0
SB 0
( 0
LEV 0
) 0
, 0
or 0
3 0
g/d 0
of 0
AMF 0
with 0
2 0
corn 0
sources 0
, 0
dry 0
whole-shelled 0
corn 0
or 0
high 0
moisture 0
corn 0
, 0
on 0
growth 0
and 0
carcass 0
characteristics 0
. 0

Neither 0
LEV 0
nor 0
AMF 0
improved 0
( 0
P 0
> 0
0.10 0
) 0
carcass B-PHYSICAL
characteristics I-PHYSICAL
compared 0
with 0
control 0
or 0
non-feed-supplemented 0
steers 0
. 0

Addition 0
of 0
LEV 0
to 0
high-concentrate 0
, 0
corn-based 0
diets 0
did 0
not 0
improve 0
( 0
P 0
> 0
0.10 0
) 0
growth B-PHYSICAL
performance I-PHYSICAL
of 0
feedlot 0
steers 0
. 0

However 0
, 0
addition 0
of 0
AMF 0
to 0
a 0
diet 0
composed 0
of 0
dry 0
whole-shelled 0
corn 0
resulted 0
in 0
an 0
improvement 0
( 0
P 0
< 0
0.05 0
) 0
in 0
G B-PHYSICAL
: 0
F B-PHYSICAL
( 0
0.208 0
vs. 0
0.194 0
) 0
. 0

Results 0
indicate 0
that 0
at 0
the 0
amounts 0
fed 0
, 0
AMF 0
may 0
improve 0

Bridge 0
plate 0
osteosynthesis 0
using 0
dynamic 0
condylar 0
screw 0
( 0
DCS 0
) 0
or 0
retrograde 0
intramedullary 0
supracondylar 0
nail 0
( 0
RIMSN 0
) 0
in 0
the 0
treatment 0
of 0
distal 0
femoral 0
fractures 0
: 0
comparison 0
of 0
two 0
methods 0
in 0
a 0
prospective 0
randomized 0
study 0
. 0

BACKGROUND 0
The 0
treatment 0
of 0
distal 0
femoral 0
fractures 0
remains 0
a 0
significant 0
surgical 0
challenge 0
. 0

With 0
the 0
rigid 0
fixation 0
of 0
the 0
distal 0
femoral 0
fractures 0
, 0
bone 0
grafting 0
is 0
frequently 0
needed 0
. 0

Biological 0
osteosynthesis 0
using 0
dynamic 0
condylar 0
screw 0
( 0
DCS 0
) 0
and 0
retrograde 0
intramedullary 0
supracondylar 0
nail 0
( 0
RIMSN 0
) 0
preserve 0
the 0
blood 0
supply 0
and 0
limit 0
the 0
need 0
for 0
bone 0
grafting 0
. 0

METHODS 0
From 0
September 0
2002 0
to 0
December 0
2004 0
, 0
68 0
closed 0
fractures 0
of 0
the 0
distal 0
femur 0
were 0
treated 0
by 0
bridge 0
plate 0
osteosynthesis 0
using 0
DCS 0
in 0
31 0
and 0
RIMSN 0
in 0
37 0
. 0

The 0
patients 0
were 0
allocated 0
to 0
one 0
of 0
the 0
two 0
groups 0
randomly 0
and 0
followed 0
for 0
24-36 0
months 0
( 0
average 0
: 0
30 0
months 0
) 0
. 0

RESULTS 0
With 0
respect 0
to 0
operation 0
time 0
, 0
the 0
DCS 0
group 0
presented 0
significantly 0
better 0
results 0
than 0
the 0
RIMSN 0
group 0
( 0
p=0.000 0
) 0
. 0

However 0
, 0
the 0
blood B-PHYSICAL
loss I-PHYSICAL
was 0
significantly 0
more 0
in 0
the 0
DCS 0
group 0
( 0
p=0.000 0
) 0
. 0

There 0
were 0
no 0
significant 0
differences 0
in 0
terms 0
of 0
cumulative B-OTHER
rate I-OTHER
of I-OTHER
union I-OTHER
( 0
p=0.855 0
) 0
, 0
range 0
of B-PHYSICAL
motion I-PHYSICAL
of I-PHYSICAL
the I-PHYSICAL
knee B-PHYSICAL
( 0
p=0.727 0
) 0
, 0
overall B-PHYSICAL

Dysfunctional 0
attitudes 0
as 0
a 0
moderator 0
of 0
pharmacotherapy 0
and 0
psychotherapy 0
for 0
chronic 0
depression 0
. 0

OBJECTIVE 0
Individuals 0
with 0
chronic 0
depression 0
exhibit 0
heterogeneous 0
responses 0
to 0
treatment 0
. 0

Important 0
individual 0
differences 0
may 0
therefore 0
exist 0
within 0
this 0
particularly 0
difficult 0
to 0
treat 0
population 0
that 0
act 0
as 0
moderators 0
of 0
treatment 0
response 0
. 0

METHOD 0
The 0
present 0
study 0
examined 0
whether 0
pretreatment 0
levels 0
of 0
dysfunctional 0
attitudes 0
( 0
DA 0
) 0
moderated 0
treatment 0
response 0
in 0
a 0
large 0
sample 0
of 0
chronically 0
depressed 0
individuals 0
. 0

Data 0
were 0
taken 0
from 0
the 0
Research 0
Evaluating 0
the 0
Value 0
of 0
Augmenting 0
Medication 0
with 0
Psychotherapy 0
( 0
REVAMP 0
) 0
treatment 0
study 0
-- 0
a 0
multi-site 0
treatment 0
and 0
augmentation 0
study 0
of 0
808 0
chronically 0
depressed 0
individuals 0
. 0

REVAMP 0
comprised 0
two 0
phases 0
: 0
1 0
) 0
a 0
12-week 0
open-label 0
antidepressant 0
trial 0
and 0
2 0
) 0
, 0
a 0
subsequent 0
phase 0
, 0
in 0
which 0
phase 0
1 0
non-remitters 0
( 0
N 0
= 0
491 0
) 0
were 0
randomized 0
to 0
either 0
receive 0
an 0
ongoing 0
medication 0
algorithm 0
alone 0
, 0
medication 0
plus 0
cognitive 0
behavioral 0
analysis 0
system 0
of 0
psychotherapy 0
, 0
or 0
medication 0
plus 0
brief 0
supportive 0
psychotherapy 0
. 0

RESULT 0
In 0
phase 0
1 0
, 0
compared 0
to 0
the 0
pharmacotherapy B-PHYSICAL
response I-PHYSICAL
of 0
patients 0
with 0
lower 0
DA 0
scores 0
, 0
the 0
response 0
for 0
patients 0
with 0
higher 0
DA 0
scores 0
was 0
steeper 0
, 0
but 0
leveled 0
off 0
toward 0
the 0
end 0
of 0
the 0
phase 0
. 0

In 0
phase 0
2 0
, 0
DA 0
predicted 0
a 0
differential 0
response 0
in 0
the 0
medication 0
only 0
arm 0
, 0
but 0
not 0
in 0
the 0
two 0
psychotherapy 0
+ 0
medication 0
conditions 0
. 0

Specifically 0
, 0
in 0
the 0
phase 0
2 0
medication 0
only 0
condition 0
, 0
patients 0
with 0
higher 0
DA 0
improved B-OTHER
while 0
those 0
with 0
lower 0
DA 0
scores 0
did 0
not 0
. 0

CONCLUSION 0
These 0
results 0
indicate 0
that 0
the 0
relation 0
between 0
DA 0
and 0
treatment 0
response 0
in 0
chronic 0
depression 0
is 0
complex 0
, 0
but 0
suggest 0
that 0
greater 0
DA 0
may 0
be 0
associated 0
with 0
a 0
steeper 0
reduction 0
and/or 0
better 0
response 0
to 0
pharmacotherapy 0
. 0

Sleep B-PHYSICAL
patterns I-PHYSICAL
in 0
autistic 0
children 0
. 0

Sleep B-PHYSICAL
disturbances I-PHYSICAL
are 0
regarded 0
as 0
a 0
common 0
clinical 0
feature 0
in 0
autistic 0
children 0
. 0

This 0
concept 0
is 0
based 0
primarily 0
on 0
informal 0
observations 0
or 0
studies 0
conducted 0
with 0
questionnaires 0
. 0

In 0
this 0
study 0
we 0
compared 0
data 0
obtained 0
by 0
questionnaires 0
to 0
that 0
obtained 0
with 0
actigraphy 0
. 0

Among 0
22 0
autistic 0
children 0
, 0
12 0
were 0
reported 0
as 0
having 0
sleep 0
problems 0
and 0
8 0
patients 0
completed 0
72 0
hours 0
actigraphy 0
. 0

While 0
the 0
employment 0
of 0
questionnaires 0
disclosed 0
that 0
autistic 0
children 0
had 0
an 0
earlier B-PHYSICAL
morning I-PHYSICAL
awakening I-PHYSICAL
time I-PHYSICAL
and 0
multiple B-PHYSICAL
and I-PHYSICAL
early I-PHYSICAL
night I-PHYSICAL
arousals I-PHYSICAL
, 0
actigraphic 0
monitoring 0
showed 0
that 0
with 0
the 0
exception 0
of 0
an 0
earlier B-PHYSICAL
morning I-PHYSICAL
arousal I-PHYSICAL
time I-PHYSICAL
( 0
p 0
= 0
.045 0
) 0
, 0
sleep B-PHYSICAL
patterns I-PHYSICAL
of 0
autistic 0
children 0
were 0
similar 0
to 0
that 0
of 0
normal 0
children 0
. 0

Parental 0
oversensitivity 0
to 0
sleep B-PHYSICAL
disturbances I-PHYSICAL
of 0
the 0
autistic 0
children 0
may 0
explain 0
this 0
phenomenon 0
. 0

Exhaled 0
NO 0
during 0
graded 0
changes 0
in 0
inhaled 0
oxygen 0
in 0
man 0
. 0

BACKGROUND 0
Nitric 0
oxide 0
( 0
NO 0
) 0
is 0
present 0
in 0
the 0
exhaled 0
air 0
of 0
animals 0
and 0
humans 0
. 0

In 0
isolated 0
animal 0
lungs 0
the 0
amount 0
of 0
exhaled 0
NO 0
is 0
decreased 0
during 0
hypoxia 0
. 0

A 0
study 0
was 0
undertaken 0
to 0
determine 0
whether 0
changes 0
in 0
arterial 0
oxygen 0
tension 0
affect 0
levels 0
of 0
exhaled 0
NO 0
in 0
humans 0
. 0

METHODS 0
Sixteen 0
healthy 0
subjects 0
were 0
randomised 0
to 0
inhale 0
different 0
gas 0
mixtures 0
of 0
oxygen 0
and 0
nitrogen 0
in 0
a 0
double 0
blind 0
crossover 0
study 0
. 0

Eight 0
gas 0
mixtures 0
of 0
oxygen 0
and 0
nitrogen 0
( 0
fractional 0
inspired 0
oxygen 0
concentration 0
( 0
FiO2 0
) 0
0.1 0
to 0
1.0 0
) 0
were 0
administered 0
. 0

Exhaled B-PHYSICAL
NO 0
was 0
measured 0
with 0
a 0
chemiluminescence 0
detector 0
from 0
end 0
expiratory 0
single 0
breath 0
exhalation 0
. 0

RESULTS 0
A 0
dose-dependent 0
change 0
in 0
exhaled B-PHYSICAL
NO 0
during 0
graded B-PHYSICAL
oxygen I-PHYSICAL
breathing I-PHYSICAL
was 0
observed 0
( 0
p 0
= 0
0.0012 0
) 0
. 0

The 0
mean 0
( 0
SE B-PHYSICAL
) 0
exhaled B-PHYSICAL
NO I-PHYSICAL
concentration I-PHYSICAL
was 0
31 0
( 0
3 0
) 0
ppb 0
at 0
baseline 0
, 0
39 0
( 0
4 0
) 0
ppb 0
at 0
an 0
FiO2 0
of 0
1.0 0
, 0
and 0
26 0
( 0
3 0
) 0
ppb 0
at 0
an 0
FiO2 0
of 0
0.1 0
. 0

CONCLUSIONS 0
The 0
NO 0
concentration B-PHYSICAL
in 0
exhaled 0
air 0
in 0
healthy 0
humans 0
is 0
dependent 0
on 0
oxygen 0
tension 0
. 0

Hyperoxia 0
increases 0
the 0
level 0
of 0
exhaled 0
NO 0
, 0
which 0
indicates 0
increased 0
NO 0
production 0
. 0

The 0
mechanism 0
behind 0
this 0
phenomenon 0
remains 0
to 0
be 0
elucidated 0
. 0

Late 0
miscarriage 0
and 0
preterm 0
birth 0
after 0
treatment 0
with 0
clindamycin 0
: 0
a 0
randomised 0
consent 0
design 0
study 0
according 0
to 0
Zelen 0
. 0

OBJECTIVE 0
To 0
screen 0
for 0
bacterial 0
vaginosis 0
( 0
BV 0
) 0
and 0
to 0
investigate 0
the 0
effect 0
of 0
treatment 0
with 0
vaginal 0
clindamycin 0
in 0
order 0
to 0
observe 0
the 0
effect 0
on 0
late B-PHYSICAL
miscarriage I-PHYSICAL
and I-PHYSICAL
delivery I-PHYSICAL
prior I-PHYSICAL
to I-PHYSICAL
37 I-PHYSICAL
completed I-PHYSICAL
weeks I-PHYSICAL
( 0
primary 0
outcome 0
) 0
. 0

DESIGN 0
Randomised 0
consent 0
design 0
for 0
clinical 0
trials 0
according 0
to 0
Zelen 0
. 0

SETTING 0
Southeast 0
region 0
of 0
Sweden 0
. 0

POPULATION 0
A 0
total 0
of 0
9025 0
women 0
were 0
screened 0
in 0
early 0
pregnancy 0
. 0

METHODS 0
A 0
total 0
of 0
819 0
women 0
with 0
a 0
Nugent 0
score 0
of 0
6 0
and 0
above 0
were 0
considered 0
to 0
have 0
BV 0
and 0
treated 0
according 0
to 0
Zelen 0
allocation 0
. 0

The 0
incidence 0
of 0
late B-PHYSICAL
miscarriage I-PHYSICAL
and I-PHYSICAL
spontaneous I-PHYSICAL
( I-PHYSICAL
noniatrogenic I-PHYSICAL
) I-PHYSICAL
preterm I-PHYSICAL
birth I-PHYSICAL
was 0
assessed 0
. 0

MAIN 0
OUTCOME 0
MEASURES 0
Late B-PHYSICAL
miscarriage I-PHYSICAL
and I-PHYSICAL
spontaneous I-PHYSICAL
preterm I-PHYSICAL
delivery I-PHYSICAL
before I-PHYSICAL
37 I-PHYSICAL
weeks I-PHYSICAL
. 0

RESULTS 0
Therapy 0
with 0
vaginal 0
clindamycin 0
had 0
no 0
significant 0
impact 0
on 0
the 0
incidence 0
of 0
spontaneous B-PHYSICAL
preterm I-PHYSICAL
delivery I-PHYSICAL
prior 0
to 0
37 0
completed 0
weeks 0
; 0
OR 0
0.90 0
, 0
95 0
% 0
CI 0
0.40-2.02 0
( 0
primary 0
outcome 0
variable 0
) 0
. 0

However 0
, 0
only 0
1 0
of 0
11 0
women 0
in 0
the 0
treatment 0
group 0
versus 0
5 0
of 0
12 0
in 0
the 0
control 0
group 0
delivered 0
prior 0
to 0
33 0
completed 0
weeks 0
; 0
OR 0
0.14 0
, 0
95 0
% 0
CI 0
0.02-0.95 0
. 0

Treatment 0
was 0
associated 0
with 0
32 0
days 0
longer B-PHYSICAL
gestation I-PHYSICAL
for 0
the 0
23 0
participants 0
who 0
had 0
late B-PHYSICAL
miscarriage I-PHYSICAL
or I-PHYSICAL
spontaneous I-PHYSICAL
preterm I-PHYSICAL
birth I-PHYSICAL
( 0
P= 0
0.024 0
, 0
Mann-Whitney 0
U 0
test 0
) 0
and 0
significantly 0
fewer 0
infants 0
had 0
a 0
birthweight 0
below 0
2,500 0
g B-PHYSICAL
( 0
secondary 0
outcome 0
) 0
. 0

A 0
follow 0
up 0
of 0
infants 0
born 0
preterm 0
4 0
years 0
postnatally 0
indicated 0
that 0
extending 0
gestational 0
age 0
did 0
not 0
increase 0
the 0
number 0
of 0
sequelae 0
. 0

CONCLUSIONS 0
Clindamycin 0
vaginal 0
cream 0
therapy 0
was 0
associated 0
with 0
significantly 0
prolonged 0
gestation 0
and 0
reduced 0
cost 0
of 0
neonatal 0
care 0
in 0
women 0
with 0
BV 0
. 0

Early 0
screening 0
for 0
BV 0
and 0
treatment 0
with 0
clindamycin 0
saved 0
approximately 0
27 0
euro 0
per 0
woman 0
. 0

Double-blind 0
, 0
placebo-controlled 0
, 0
dose-ranging 0
study 0
of 0
new 0
recombinant 0
hypoallergenic 0
Bet 0
v 0
1 0
in 0
an 0
environmental 0
exposure 0
chamber 0
. 0

BACKGROUND 0
Recombinant 0
allergens 0
offer 0
a 0
tool 0
for 0
improving 0
specific 0
immunotherapy 0
( 0
SIT 0
) 0
. 0

OBJECTIVE 0
To 0
find 0
the 0
optimal 0
dose 0
of 0
a 0
new 0
hypoallergenic 0
folding 0
variant 0
of 0
recombinant 0
Bet 0
v 0
1 0
( 0
rBet 0
v 0
1-FV 0
) 0
as 0
SIT 0
for 0
patients 0
with 0
birch 0
pollen 0
allergy 0
. 0

METHODS 0
Before 0
SIT 0
, 0
thirty-seven 0
adult 0
patients 0
were 0
exposed 0
for 0
eight 0
hours 0
in 0
an 0
environmental 0
exposure 0
chamber 0
( 0
EEC 0
) 0
to 0
birch 0
pollen 0
at 0
an 0
average 0
concentration 0
of 0
3500 0
? 0

500 0
grains/m 0
( 0
3 0
) 0
, 0
then 0
randomized 0
to 0
four 0
maintenance 0
dose 0
groups 0
of 0
rBet 0
v 0
1-FV 0
and 0
one 0
placebo 0
group 0
: 0
20 0
?g 0
( 0
n 0
= 0
7 0
) 0
, 0
80 0
?g 0
( 0
n 0
= 0
8 0
) 0
, 0
160 0
?g 0
( 0
n 0
= 0
7 0
) 0
, 0
320 0
?g 0
( 0
n 0
= 0
8 0
) 0
, 0
and 0
placebo 0
( 0
n 0
= 0
7 0
) 0
. 0

Patients 0
were 0
treated 0
for 0
10 0
weeks 0
with 0
weekly 0
injections 0
and 0
then 0
re-exposed 0
in 0
the 0
EEC 0
. 0

The 0
optimal 0
dose 0
for 0
SIT 0
was 0
assessed 0
using 0
efficacy 0
results 0
from 0
the 0
EEC 0
, 0
IgG 0
responses 0
, 0
and 0
tolerability 0
. 0

RESULTS 0
Thirty-six 0
patients 0
were 0
evaluable 0
for 0
efficacy 0
assessment 0
. 0

The 0
total 0
symptom 0
score 0
significantly 0
decreased 0
in 0
all 0
active 0
groups 0
compared 0
with 0
placebo 0
( 0
-18.8 0
% 0
for 0
placebo 0
patients 0
; 0
-71.9 0
% 0
, 0
P 0
= 0
0.0022 0
for 0
20 0
?g 0
; 0
-75.6 0
% 0
, 0
P 0
= 0
0.0007 0
for 0
80 0
?g 0
; 0
-81.8 0
% 0
, 0
P 0
= 0
0.0009 0
for 0
160 0
?g 0
; 0
-78.3 0
% 0
, 0
P 0
= 0
0.0003 0
for 0
320 0
?g 0
) 0
. 0

IgG1 B-PHYSICAL
increased 0
significantly 0
in 0
all 0
active 0
groups 0
compared 0
to 0
placebo 0
. 0

All 0
four 0
active 0
doses 0
were 0
well 0
tolerated 0
, 0
no 0
serious 0
adverse 0
event 0
occurred 0
; 0
two 0
Grade 0
II B-ADVERSE-EFFECTS
reactions I-ADVERSE-EFFECTS
, 0
according 0
to 0
EAACI 0
classification 0
, 0
were 0
observed 0
, 0
one 0
in 0
each 0
of 0
the 0
160- 0
and 0
320-?g 0
groups 0
. 0

CONCLUSIONS 0
Considering 0
efficacy 0
, 0
immunological 0
response 0
, 0
and 0
tolerability 0
, 0
a 0
maintenance 0
dose 0
of 0
80 0
?g 0
of 0
rBet 0
v 0
1-FV 0
appears 0
to 0
be 0
the 0
ideal 0
dose 0
for 0
allergen 0
immunotherapy 0
in 0
birch 0
pollen 0
allergic 0
patients 0
. 0

Prophylaxis 0
with 0
meropenem 0
of 0
septic B-PHYSICAL
complications I-PHYSICAL
in 0
acute 0
pancreatitis 0
: 0
a 0
randomized 0
, 0
controlled 0
trial 0
versus 0
imipenem 0
. 0

OBJECTIVES 0
Prophylactic 0
antibiotics 0
are 0
helpful 0
in 0
decreasing 0
the 0
incidence 0
of 0
septic B-PHYSICAL
complications I-PHYSICAL
in 0
acute 0
pancreatitis 0
. 0

The 0
aim 0
of 0
this 0
study 0
was 0
to 0
compare 0
the 0
efficacy 0
of 0
meropenem 0
, 0
a 0
new 0
carbapenem 0
antibiotic 0
, 0
with 0
that 0
of 0
imipenem 0
, 0
which 0
is 0
the 0
standard 0
prophylactic 0
treatment 0
in 0
patients 0
with 0
severe 0
acute 0
pancreatitis 0
. 0

METHODS 0
One 0
hundred 0
seventy-six 0
patients 0
with 0
necrotizing 0
pancreatitis 0
were 0
prospectively 0
randomized 0
to 0
prophylactic 0
treatment 0
with 0
0.5 0
g 0
meropenem 0
t.i.d 0
. 0

intravenously 0
or 0
0.5 0
g 0
imipenem 0
q.i.d 0
. 0

intravenously 0
. 0

The 0
occurrence 0
of B-PHYSICAL
infection I-PHYSICAL
of I-PHYSICAL
pancreatic I-PHYSICAL
necrosis B-PHYSICAL
, 0
rate 0
of 0
extrapancreatic B-PHYSICAL
infections I-PHYSICAL
, 0
systemic B-ADVERSE-EFFECTS
and B-ADVERSE-EFFECTS
local I-ADVERSE-EFFECTS
complications I-ADVERSE-EFFECTS
, 0
need B-OTHER
for I-OTHER
surgery B-OTHER
, 0
mortality B-MORTALITY
rate B-MORTALITY
, 0
and 0
length B-OTHER
of I-OTHER
hospitalization B-OTHER
were 0
recorded 0
for 0
each 0
group 0
. 0

When 0
a 0
septic B-PHYSICAL
complication I-PHYSICAL
of 0
pancreatic 0
necrosis 0
was 0
suspected 0
, 0
fine 0
needle 0
aspiration 0
with 0
cultures 0
of 0
the 0
sample 0
was 0
performed 0
. 0

Surgery 0
was 0
performed 0
in 0
cases 0
of 0
verified 0
infected 0
necrosis 0
. 0

CONCLUSION 0
No 0
difference 0
was 0
observed 0
between 0
patients 0
treated 0
with 0
meropenem 0
and 0
those 0
treated 0
with 0
imipenem 0
in 0
terms 0
of 0
incidence 0
of 0
pancreatic B-PHYSICAL
infection I-PHYSICAL
( 0
11.4 0
% 0
versus 0
13.6 0
% 0
) 0
and 0

Effects 0
of 0
preoperative 0
intentional 0
hemodilution 0
on 0
the 0
extravasation B-PHYSICAL
rate I-PHYSICAL
of I-PHYSICAL
albumin I-PHYSICAL
and I-PHYSICAL
fluid I-PHYSICAL
. 0

OBJECTIVE 0
To 0
evaluate 0
the 0
effects 0
of 0
preoperative 0
intentional 0
hemodilution 0
with 0
4 0
% 0
albumin 0
solution 0
on 0
the 0
extravasation 0
rate 0
of 0
intravascular 0
albumin 0
and 0
fluid 0
in 0
surgical 0
patients 0
. 0

DESIGN 0
A 0
prospective 0
, 0
randomized 0
, 0
clinical 0
study 0
. 0

SETTING 0
University 0
teaching 0
hospital 0
. 0

PATIENTS 0
Two 0
groups 0
( 0
control 0
group 0
[ 0
group 0
1 0
] 0
and 0
hemodiluted 0
group 0
[ 0
group 0
2 0
] 0
) 0
of 0
13 0
healthy 0
patients 0
were 0
studied 0
during 0
a 0
long-term 0
( 0
> 0
4 0
hrs 0
) 0
surgical 0
procedure 0
. 0

INTERVENTIONS 0
Autologous 0
technetium-99m 0
( 0
99mTc 0
) 0
-labeled 0
red 0
blood 0
cells 0
and 0
indium-oxine 0
( 0
( 0
111 0
) 0
In 0
) 0
-labeled 0
human 0
serum 0
albumin 0
were 0
injected 0
intravenously 0
during 0
anesthesia 0
at 0
T 0
= 0
0 0
min 0
in 0
the 0
two 0
groups 0
for 0
the 0
determination 0
of 0
total 0
blood 0
volume 0
and 0
albumin 0
diffusion 0
space 0
, 0
respectively 0
. 0

In 0
addition 0
, 0
body 0
tetrapolar 0
electrical 0
impedance 0
was 0
used 0
to 0
assess 0
extracellular 0
fluid 0
volume 0
. 0

In 0
the 0
hemodiluted 0
group 0
( 0
group 0
2 0
) 0
, 0
15 0
mL/kg 0
of 0
blood 0
was 0
withdrawn 0
over 0
30 0
mins 0
( 0
T 0
= 0
20 0
mins 0
to 0
T 0
= 0
50 0
mins 0
) 0
and 0
simultaneously 0
replaced 0
by 0
an 0
equal 0
volume 0
of 0
4 0
% 0
albumin 0
solution 0
( 0
0.6 0
g/kg 0
) 0
. 0

MEASUREMENTS 0
AND 0
MAIN 0
RESULTS 0
The 0
albumin 0
diffusion 0
space 0
, 0
the 0
colloid 0
oncotic 0
pressure 0
, 0
the 0
plasma B-PHYSICAL
albumin I-PHYSICAL
concentration I-PHYSICAL
and 0
the 0
electrical B-PHYSICAL
impedance I-PHYSICAL
were 0
measured 0
before 0
( 0
T 0
= 0
10 0
mins 0
) 0
and 0
after 0
( 0
T 0
= 0
60 0
, 0
120 0
, 0
and 0
240 0
mins 0
) 0
hemodilution 0
. 0

Urine B-PHYSICAL
was 0
collected 0
from 0
T 0
= 0
10 0
mins 0
to 0
T 0
= 0
240 0
mins 0
. 0

The 0
total 0
blood B-PHYSICAL
volume I-PHYSICAL
was 0
calculated 0
at 0
T 0
= 0
10 0
mins 0
. 0

No 0
differences 0
in 0
the 0
initial 0
values 0
were 0
found 0
between 0
the 0
two 0
groups 0
. 0

In 0
group 0
2 0
, 0
hemodilution 0
( 0
hematocrit 0
30 0
+/- 0
3 0
% 0
) 0
resulted 0
in 0
a 0
steeper 0
increase 0
in 0
the 0
albumin B-PHYSICAL
diffusion I-PHYSICAL
space I-PHYSICAL
( 0
p 0
< 0
.05 0
) 0
and 0
a 0
progressive 0
decrease 0
in 0
the 0
body B-PHYSICAL
electrical I-PHYSICAL
impedance I-PHYSICAL
( 0
p 0
< 0
.05 0
) 0
. 0

The 0
extravasation B-PHYSICAL
rate I-PHYSICAL
of I-PHYSICAL
albumin I-PHYSICAL
was 0
0.052 0
+/- 0
0.007 0
mL/kg/min 0
in 0
group 0
2 0
vs. 0
0.038 0
+/- 0
0.020 0
mL/kg/min 0
in 0
group 0
1 0
( 0
p 0
< 0
.05 0
) 0
. 0

The 0
value B-PHYSICAL
of I-PHYSICAL
calculated I-PHYSICAL
plasma I-PHYSICAL
volume I-PHYSICAL
at 0
T 0
= 0
0 0
min 0
did 0
not 0
shown 0
any 0
difference 0
between 0
the 0
two 0
groups 0
. 0

This 0
value 0
was 0
then 0
lower 0
than 0
expected 0
in 0
group 0
2 0
, 0
corresponding 0
to 0
a 0
loss 0
of 0
plasma B-PHYSICAL
volume I-PHYSICAL
of 0
> 0
3 0
mL/kg 0
. 0

Urine B-PHYSICAL
output I-PHYSICAL
was 0
significantly 0
lower 0
in 0
group 0
2 0
than 0
in 0
group 0
1 0
( 0
0.7 0
+/- 0
0.4 0
vs. 0
1.4 0
+/- 0
1.0 0
mL/min 0
, 0
respectively 0
; 0
p 0
< 0
.05 0
) 0
. 0

A 0
comparable 0
decrease 0
in 0
colloid B-PHYSICAL
oncotic I-PHYSICAL
pressure I-PHYSICAL
and 0
in B-PHYSICAL
plasma I-PHYSICAL
albumin I-PHYSICAL
concentration I-PHYSICAL
was 0
observed 0
in 0
both 0
groups 0
. 0

CONCLUSIONS 0
These 0
results 0
suggest 0
that 0
preoperative 0
hemodilution 0
using 0
4 0
% 0
albumin 0
on 0
a 0
1:1 0
volume 0
basis 0
for 0
blood 0
substitution 0
during 0
a 0
prolonged 0
surgical 0
procedure 0
with 0
reduced 0
blood 0
losses 0
enhances 0
the 0
extravasation 0
rate 0
of 0
albumin 0
and 0
fluid 0
to 0
the 0
interstitial 0
tissues 0
, 0
impeding 0
the 0
maintenance 0
of 0
isovolemia 0
. 0

These 0
findings 0
support 0
the 0
use 0
of 0
a 0
volume 0
of 0
infused 0
colloid 0
solution 0
higher 0
than 0
that 0
of 0
withdrawn 0
blood 0
during 0
preoperative 0
hemodilution 0
. 0

Comparison 0
of 0
eltanolone 0
and 0
thiopental 0
in 0
anaesthesia B-PHYSICAL
for 0
termination 0
of 0
pregnancy 0
. 0

Eltanolone 0
, 0
a 0
new 0
steroid 0
hypnotic 0
, 0
was 0
compared 0
to 0
thiopental 0
in 0
short 0
anaesthesia 0
. 0

Sixty 0
unpremedicated 0
, 0
Asa 0
1-2 0
women 0
were 0
randomized 0
to 0
receive 0
eltanolone 0
0.6 0
( 0
group 0
E1 0
) 0
or 0
0.8 0
mg.kg-1 0
( 0
group 0
E2 0
) 0
or 0
thiopental 0
4 0
mg.kg-1 0
( 0
group 0
T 0
) 0
for 0
induction 0
of 0
anaesthesia 0
. 0

One 0
minute 0
before 0
induction 0
glycopyrrolate 0
0.2 0
mg 0
and 0
alfentanil 0
15 0
micrograms.kg-1 0
i.v 0
. 0

were 0
administered 0
. 0

If 0
induction 0
failed 0
, 0
additional 0
boluses 0
of 0
the 0
test 0
drug 0
were 0
given 0
. 0

Anaesthesia 0
was 0
maintained 0
with 0
67 0
% 0
nitrous 0
oxide 0
in 0
oxygen 0
, 0
and 0
additional 0
bolus 0
doses 0
of 0
the 0
test 0
drug 0
were 0
given 0
in 0
a 0
standardized 0
fashion 0
, 0
if 0
needed 0
. 0

Recovery B-MENTAL
was 0
assessed 0
by 0
a 0
research 0
nurse 0
blinded 0
to 0
the 0
agent 0
used 0
. 0

Mean 0
+/- B-PHYSICAL
s.d 0
. 0

induction 0
doss B-PHYSICAL
were 0
0.7 0
+/- 0
0.1 0
mg.kg-1 0
( 0
group 0
E1 0
) 0
, 0
0.8 0
+/- 0
0.1 0
mg.kg-1 0
( 0
group 0
E2 0
) 0
and 0
4.0 0
+/- 0
0.0 0
mg.kg-1 0
( 0
group 0
T 0
) 0
. 0

Induction 0
time 0
was 0
prolonged 0
in 0
the 0
group 0
E1 0
compared 0
to 0
the 0
other 0
two 0
groups 0
( 0
P 0
< 0
0.05 0
) 0
. 0

Side 0
effects 0
were 0
few 0
in 0
all 0
groups 0
, 0
but 0
involuntary B-PHYSICAL
muscle I-PHYSICAL
movements I-PHYSICAL
or I-PHYSICAL
hypertonus I-PHYSICAL
occurred 0
in 0
23 0
% 0
of 0
the 0
patients 0
in 0
the 0
eltanolone 0
and 0
in 0
3 0
% 0
in 0
the 0
thiopental 0
groups 0
( 0
n.s 0
) 0
. 0

A 0
comparison 0
of 0
recombinant 0
human 0
thyrotropin 0
and 0
thyroid 0
hormone 0
withdrawal 0
for 0
the 0
detection 0
of 0
thyroid 0
remnant 0
or 0
cancer 0
. 0

Recombinant 0
human 0
TSH 0
has 0
been 0
developed 0
to 0
facilitate 0
monitoring 0
for 0
thyroid 0
carcinoma 0
recurrence 0
or 0
persistence 0
without 0
the 0
attendant 0
morbidity 0
of 0
hypothyroidism 0
seen 0
after 0
thyroid 0
hormone 0
withdrawal 0
. 0

The 0
objectives 0
of 0
this 0
study 0
were 0
to 0
compare 0
the 0
effect 0
of 0
administered 0
recombinant 0
human 0
TSH 0
with 0
thyroid 0
hormone 0
withdrawal 0
on 0
the 0
results 0
of 0
radioiodine 0
whole 0
body 0
scanning 0
( 0
WBS 0
) 0
and 0
serum 0
thyroglobulin 0
( 0
Tg 0
) 0
levels 0
. 0

Two 0
hundred 0
and 0
twenty-nine 0
adult 0
patients 0
with 0
differentiated 0
thyroid 0
cancer 0
requiring 0
radioiodine 0
WBS 0
were 0
studied 0
. 0

Radioiodine 0
WBS 0
and 0
serum 0
Tg 0
measurements 0
were 0
performed 0
after 0
administration 0
of 0
recombinant 0
human 0
TSH 0
and 0
again 0
after 0
thyroid 0
hormone 0
withdrawal 0
in 0
each 0
patient 0
. 0

Radioiodine 0
whole 0
body 0
scans 0
were 0
concordant 0
between 0
the 0
recombinant B-PHYSICAL
TSH-stimulated I-PHYSICAL
and 0
thyroid B-PHYSICAL
hormone I-PHYSICAL
withdrawal I-PHYSICAL
phases I-PHYSICAL
in 0
195 0
of 0
220 0
( 0
89 0
% 0
) 0
patients 0
. 0

Of 0
the 0
discordant 0
scans 0
, 0
8 0
( 0
4 0
% 0
) 0
had 0
superior 0
scans 0
after 0
recombinant 0
human 0
TSH 0
administration 0
, 0
and 0
17 0
( 0
8 0
% 0
) 0
had 0
superior 0
scans 0
after 0
thyroid 0
hormone 0
withdrawal 0
( 0
P 0
= 0
0.108 0
) 0
. 0

Based 0
on 0
a 0
serum B-PHYSICAL
Tg I-PHYSICAL
level I-PHYSICAL
of 0
2 0
ng/mL 0
or 0
more 0
, 0
thyroid 0
tissue 0
or 0
cancer 0
was 0
detected 0
during 0
thyroid 0
hormone 0
therapy 0
in 0
22 0
% 0
, 0
after 0
recombinant 0
human 0
TSH 0
stimulation 0
in 0
52 0
% 0
, 0
and 0
after 0
thyroid 0
hormone 0
withdrawal 0
in 0
56 0
% 0
of 0
patients 0
with 0
disease 0
or 0
tissue 0
limited 0
to 0
the 0
thyroid 0
bed 0
and 0
in 0
80 0
% 0
, 0
100 0
% 0
, 0
and 0
100 0
% 0
of 0
patients 0
, 0
respectively 0
, 0
with 0
metastatic 0
disease 0
. 0

A 0
combination 0
of 0
radioiodine 0
WBS 0
and 0
serum 0
Tg 0
after 0
recombinant 0
human 0
TSH 0
stimulation 0
detected 0
thyroid B-PHYSICAL
tissue I-PHYSICAL
or 0
cancer B-PHYSICAL
in 0
93 0
% 0
of 0
patients 0
with 0
disease 0
or 0
tissue 0
limited 0
to 0
the 0
thyroid 0
bed 0
and 0
100 0
% 0
of 0
patients 0
with 0
metastatic 0
disease 0
. 0

In 0
conclusion 0
, 0
recombinant 0
human 0
TSH 0
administration 0
is 0
a 0
safe 0
and 0
effective 0
means 0
of 0
stimulating 0
radioiodine 0
uptake 0
and 0
serum 0
Tg 0
levels 0
in 0
patients 0
undergoing 0
evaluation 0
for 0
thyroid 0
cancer 0
persistence 0
and 0
recurrence 0
. 0

Prospective 0
randomized 0
evaluation 0
of 0
diode-laser 0
and 0
cryotherapy 0
in 0
prethreshold B-PHYSICAL
retinopathy I-PHYSICAL
of 0
prematurity 0
. 0

PURPOSE 0
To 0
study 0
the 0
efficacy 0
of 0
indirect 0
diode 0
laser 0
photocoagulation 0
and 0
cryotherapy 0
in 0
prethreshold B-PHYSICAL
retinopathy I-PHYSICAL
of I-PHYSICAL
prematurity I-PHYSICAL
( I-PHYSICAL
ROP I-PHYSICAL
) I-PHYSICAL
. 0

METHODS 0
Thirty-six 0
eyes 0
of 0
18 0
premature 0
infants 0
less 0
than 0
34 0
weeks 0
gestational 0
age 0
and/or 0
less 0
than 0
1600 0
g 0
birth 0
weight 0
with 0
prethreshold 0
ROP 0
were 0
prospectively 0
randomized 0
to 0
treatment 0
with 0
either 0
indirect 0
laser 0
photocoagulation 0
or 0
cryotherapy 0
. 0

Prethreshold 0
ROP 0
was 0
defined 0
as 0
any 0
stage 0
of 0
ROP 0
in 0
zone 0
I 0
with 0
plus 0
disease 0
; 0
or 0
stage 0
3 0
with 0
three 0
or 0
more 0
contiguous 0
clock 0
hours 0
or 0
five 0
or 0
more 0
total 0
clock 0
hours 0
of 0
involvement 0
of 0
retina 0
in 0
zone 0
II 0
with 0
plus 0
disease 0
but 0
less 0
than 0
threshold 0
disease 0
. 0

Regression 0
of 0
the 0
ROP B-PHYSICAL
was 0
assessed 0
for 0
a 0
minimum 0
period 0
of 0
6 0
months 0
. 0

RESULTS 0
Regression 0
of 0
ROP B-PHYSICAL
occurred 0
in 0
all 0
36 0
eyes 0
( 0
100 0
% 0
) 0
in 0
both 0
groups 0
. 0

CONCLUSIONS 0
Excellent 0
results 0
are 0
achieved 0
if 0
ROP B-OTHER
is 0
treated 0
at 0
the 0
prethreshold 0
stage 0
with 0
both 0
indirect 0
laser 0
photocoagulation 0
and 0
cryotherapy 0
. 0

Although 0
laser 0
has 0
definite 0
advantages 0
, 0
cryotherapy 0
can 0
be 0
considered 0
as 0
an 0
alternative 0
modality 0
of 0
treatment 0
in 0
developing 0
countries 0
due 0
to 0
economic 0
reasons 0
. 0

Association 0
of 0
efavirenz 0
hypersusceptibility 0
with 0
virologic 0
response 0
in 0
ACTG 0
368 0
, 0
a 0
randomized 0
trial 0
of 0
abacavir 0
( 0
ABC 0
) 0
in 0
combination 0
with 0
efavirenz 0
( 0
EFV 0
) 0
and 0
indinavir 0
( 0
IDV 0
) 0
in 0
HIV-infected 0
subjects 0
with 0
prior 0
nucleoside 0
analog 0
experience 0
. 0

PURPOSE 0
To 0
evaluate 0
the 0
association 0
of 0
efavirenz 0
hypersusceptibility 0
( 0
EFV-HS 0
) 0
with 0
clinical 0
outcome 0
in 0
a 0
double-blind 0
, 0
placebo-controlled 0
, 0
randomized 0
trial 0
of 0
EFV 0
plus 0
indinavir 0
( 0
EFV+IDV 0
) 0
vs. 0
EFV+IDV 0
plus 0
abacavir 0
( 0
ABC 0
) 0
in 0
283 0
nucleoside-experienced 0
HIV-infected 0
patients 0
. 0

METHOD 0
AND 0
RESULTS 0
Rates 0
of 0
virologic B-OTHER
failure I-OTHER
were 0
similar 0
in 0
the 0
2 0
arms 0
at 0
week 0
16 0
( 0
p 0
= 0
.509 0
) 0
. 0

Treatment 0
discontinuations B-OTHER
were 0
more 0
common 0
in 0
the 0
ABC 0
arm 0
( 0
p 0
= 0
.001 0
) 0
. 0

Using 0
logistic 0
regression 0
, 0
there 0
was 0
no 0
association 0
between 0
virologic B-OTHER
failure I-OTHER
and 0
either 0
baseline 0
ABC B-MENTAL
resistance I-MENTAL
or 0
regimen B-OTHER
sensitivity I-OTHER
score I-OTHER
. 0

Using 0
3 0
different 0
genotypic 0
scoring 0
systems 0
, 0
EFV-HS 0
was 0
significantly 0
associated 0
with 0
reduced 0
virologic 0
failure 0
at 0
week 0
16 0
, 0
independent 0
of 0
treatment 0
assignment 0
. 0

In 0
some 0
patients 0
on 0
the 0
nucleoside-sparing 0
arm 0
, 0
the 0
nucleoside-resistance 0
mutation 0
L74V 0
was 0
selected 0
for 0
in 0
combination 0
with 0
the 0
uncommonly 0
occurring 0
EFV-resistance 0
mutations 0
K103N+L100I 0
; 0
L74V 0
was 0
not 0
detected 0
as 0
a 0
minority 0
variant 0
, 0
using 0
clonal 0
sequence 0
analysis 0
, 0
when 0
the 0
nucleoside-sparing 0
regimen 0
was 0
initiated 0
. 0

CONCLUSION 0
Premature 0
treatment 0
discontinuations B-MENTAL
in 0
the 0
ABC 0
arm 0
and 0
the 0
presence 0
of 0
EFV-HS 0
HIV 0
variants 0
in 0
this 0
patient 0
population 0
likely 0
made 0
it 0
difficult 0
to 0
detect 0
a 0
benefit 0
of 0
adding B-OTHER
ABC I-OTHER
to I-OTHER
EFV+IDV I-OTHER
. 0

In 0
addition 0
, 0
L74V 0
, 0
when 0
combined 0
with 0
K103N+L100I 0
, 0
may 0
confer 0
a 0
selective 0
advantage 0
to 0
the 0
virus 0
that 0
is 0
independent 0
of 0
its 0
effects 0
on 0
nucleoside B-ADVERSE-EFFECTS
resistance I-ADVERSE-EFFECTS
. 0

The 0
effectiveness 0
of 0
single-dose 0
metronidazole 0
therapy 0
for 0
patients 0
and 0
their 0
partners 0
with 0
bacterial 0
vaginosis 0
. 0

A 0
randomized 0
, 0
placebo-controlled 0
, 0
double-blind 0
clinical 0
trial 0
was 0
performed 0
to 0
test 0
the 0
hypothesis 0
that 0
a 0
2-g 0
single 0
dose 0
of 0
metronidazole 0
for 0
male 0
partners 0
of 0
women 0
with 0
bacterial 0
vaginosis 0
was 0
more 0
effective 0
than 0
placebo 0
in 0
improving 0
cure 0
rate 0
and 0
decreasing 0
recurrence 0
rate 0
. 0

In 0
addition 0
, 0
the 0
effectiveness 0
of 0
a 0
2-g 0
single 0
dose 0
of 0
metronidazole 0
was 0
compared 0
with 0
a 0
seven-day 0
course 0
of 0
500 0
mg 0
of 0
metronidazole 0
twice 0
a 0
day 0
in 0
patients 0
with 0
bacterial 0
vaginosis 0
. 0

Statistically 0
significant 0
benefits 0
of 0
partner 0
treatment 0
were 0
noted 0
in 0
the 0
initial 0
cure 0
rate 0
by 0
Gram-stained 0
smear 0
criteria 0
( 0
P 0
less 0
than 0
.01 0
) 0
and 0
in 0
percentage 0
of 0
women 0
with 0
symptoms 0
eight 0
weeks 0
after 0
initiating 0
therapy 0
( 0
P 0
less 0
than 0
.05 0
) 0
. 0

The 0
seven-day 0
course 0
of 0
metronidazole 0
was 0
superior 0
to 0
the 0
single-dose 0
regimen 0
in 0
the 0
percentage 0
of 0
patients 0
with 0
clue 0
cells 0
and 0
the 0
percentage 0
of 0
patients 0
with 0
a 0
positive 0
sniff 0
test 0
at 0
the 0
first 0
follow-up 0
visit 0
; 0
however 0
, 0
differences 0
in 0
the 0
initial B-PHYSICAL
cure I-PHYSICAL
rate I-PHYSICAL
assessed I-PHYSICAL
by I-PHYSICAL
clinical I-PHYSICAL
criteria I-PHYSICAL
and 0
Gram-stained B-PHYSICAL
smear I-PHYSICAL
criteria I-PHYSICAL
were 0
not 0
statistically 0
significant 0
between 0
the 0
two 0
patient 0
treatment 0
regimens 0
. 0

Recurrence B-PHYSICAL
rates I-PHYSICAL
by I-PHYSICAL
Gram-stained I-PHYSICAL
smear I-PHYSICAL
criteria I-PHYSICAL
between 0
patient 0
and 0
partner 0
treatment 0
groups 0
at 0
five 0
and 0
eight 0
weeks 0
after 0
initiation 0
of 0
treatment 0
were 0
also 0
not 0
significantly 0
different 0
between 0
the 0
two 0
patient 0
regimens 0
. 0

Single-dose 0
metronidazole 0
treatment 0
of 0
the 0
sexual 0
partner 0
of 0
women 0
with 0
bacterial 0
vaginosis 0
improves 0
initial 0
bacterial B-PHYSICAL
vaginosis I-PHYSICAL
cure I-PHYSICAL
rates I-PHYSICAL
. 0

The 0
seven-day 0
course 0
of 0
metronidazole 0
was 0
not 0
found 0
by 0
statistical 0
analysis 0
to 0
be 0
significantly 0
superior 0
to 0
single-dose 0
therapy 0
when 0
considering 0
initial 0
cure 0
rates 0
by 0
clinical 0
or 0
Gram-stained 0
smear 0
criteria 0
or 0
recurrence 0
rates 0
. 0
( 0

ABSTRACT 0
TRUNCATED 0
AT 0
250 0
WORDS 0
) 0

Long-term 0
treatment 0
with 0
atomoxetine 0
for 0
attention-deficit/hyperactivity B-MENTAL
disorder I-MENTAL
symptoms I-MENTAL
in 0
children 0
and 0
adolescents 0
with 0
autism 0
spectrum 0
disorder 0
: 0
an 0
open-label 0
extension 0
study 0
. 0

OBJECTIVE 0
The 0
efficacy 0
and 0
tolerability B-OTHER
of 0
long-term 0
treatment 0
with 0
atomoxetine 0
for 0
symptoms 0
of 0
attention-deficit/hyperactivity B-MENTAL
disorder I-MENTAL
( I-MENTAL
ADHD I-MENTAL
) I-MENTAL
in 0
children 0
with 0
autism 0
spectrum 0
disorder 0
( 0
ASD 0
) 0
has 0
not 0
been 0
established 0
. 0

METHODS 0
In 0
this 0
study 0
, 0
88 0
patients 0
6-17 0
years 0
of 0
age 0
, 0
with 0
ADHD 0
and 0
ASD 0
, 0
were 0
treated 0
with 0
1.2 0
mg/kg/day 0
atomoxetine 0
for 0
20 0
weeks 0
as 0
follow-up 0
of 0
an 0
8 0
week 0
double-blind 0
placebo-controlled 0
period 0
. 0

Primary 0
endpoint 0
was 0
the 0
ADHD 0
Rating 0
Scale 0
( 0
ADHD-RS 0
) 0
. 0

RESULTS 0
After 0
8 0
weeks 0
of 0
initial 0
treatment 0
, 0
the 0
mean 0
total 0
, 0
inattention B-MENTAL
, 0
and 0
hyperactivity-impulsivity B-MENTAL
ADHD-RS I-MENTAL
further 0
decreased 0
significantly 0
from 0
34.9 0
to 0
27.0 0
for 0
the 0
total 0
ADHD-RS 0
, 0
from 0
18.3 0
to 0
14.5 0
for 0
the 0
ADHD-RS B-MENTAL
inattention I-MENTAL
subscale I-MENTAL
, 0
and 0
from 0
16.5 0
to 0
12.6 0
for 0
the 0
hyperactivity-impulsivity B-MENTAL
subscale I-MENTAL
. 0

Adverse B-ADVERSE-EFFECTS
events I-ADVERSE-EFFECTS
were 0
mild 0
and 0
tended 0
to 0
diminish 0
over 0
time 0
during 0
continued 0
treatment 0
, 0
especially 0
regarding 0
nausea B-ADVERSE-EFFECTS
and 0
fatigue B-ADVERSE-EFFECTS
. 0

There 0
were 0
no 0
serious B-ADVERSE-EFFECTS
adverse I-ADVERSE-EFFECTS
events I-ADVERSE-EFFECTS
. 0

CONCLUSIONS 0
The 0
results 0
of 0
the 0
present 0
analysis 0
suggest 0
that 0
continued 0
treatment 0
with 0
atomoxetine 0
up 0
to 0
28 0
weeks 0
further 0
improve B-MENTAL
ADHD I-MENTAL
symptoms I-MENTAL
in 0
children 0
and 0
adolescents 0
with 0
ASD 0
, 0
while 0
adverse B-ADVERSE-EFFECTS
events I-ADVERSE-EFFECTS
tend 0
to 0
subside 0
. 0

Future 0
studies 0
investigating 0
the 0
long-term 0
efficacy 0
of 0
atomoxetine 0
in 0
children 0
and 0
adolescents 0
with 0
ASD 0
should 0
be 0
randomized 0
and 0
placebo 0
controlled 0
. 0

This 0
study 0
has 0
been 0
registered 0
in 0
ClinicalTrials.gov 0
( 0
www.clinicaltrials.gov 0
) 0
under 0
registration 0
number 0
NCT00380692 0
. 0

Efficacy 0
and 0
safety B-OTHER
of 0
selamectin 0
against 0
fleas 0
and 0
heartworms 0
in 0
dogs 0
and 0
cats 0
presented 0
as 0
veterinary 0
patients 0
in 0
North 0
America 0
. 0

A 0
series 0
of 0
randomized 0
, 0
controlled 0
, 0
masked 0
field 0
studies 0
was 0
conducted 0
to 0
assess 0
the 0
efficacy 0
and 0
safety B-OTHER
of 0
selamectin 0
in 0
the 0
treatment 0
of 0
flea 0
infestations 0
on 0
dogs 0
and 0
cats 0
, 0
and 0
in 0
the 0
prevention 0
of 0
heartworm B-PHYSICAL
infection I-PHYSICAL
in 0
dogs 0
. 0

In 0
addition 0
, 0
observations 0
were 0
made 0
on 0
the 0
beneficial 0
effect 0
of 0
selamectin 0
treatment 0
on 0
dogs 0
and 0
cats 0
showing 0
signs 0
of 0
flea 0
allergy 0
dermatitis 0
( 0
FAD 0
) 0
. 0

In 0
all 0
studies 0
selamectin 0
was 0
applied 0
topically 0
, 0
once 0
per 0
month 0
, 0
in 0
unit 0
doses 0
providing 0
a 0
minimum 0
dosage 0
of 0
6mgkg 0
( 0
-1 0
) 0
. 0

Dogs 0
and 0
cats 0
with 0
naturally 0
occurring 0
flea 0
infestations 0
, 0
some 0
of 0
which 0
also 0
had 0
signs 0
associated 0
with 0
FAD 0
, 0
were 0
assigned 0
randomly 0
to 0
receive 0
three 0
months 0
of 0
topical 0
treatment 0
with 0
selamectin 0
( 0
220 0
dogs 0
, 0
189 0
cats 0
) 0
or 0
a 0
positive-control 0
product 0
( 0
dogs 0
: 0
fenthion 0
, 0
n=81 0
; 0
cats 0
: 0
pyrethrins 0
, 0
n=66 0
) 0
. 0

Selamectin 0
was 0
administered 0
on 0
days 0
0 0
, 0
30 0
, 0
and 0
60 0
. 0

Day 0
0 0
was 0
defined 0
as 0
the 0
day 0
that 0
the 0
animal 0
first 0
received 0
treatment 0
. 0

Flea B-PHYSICAL
burdens I-PHYSICAL
were 0
assessed 0
by 0
flea 0
comb 0
counts 0
and 0
clinical 0
evaluations 0
of 0
FAD 0
were 0
performed 0
before 0
treatment 0
, 0
and 0
on 0
days 0
14 0
, 0
30 0
, 0
60 0
, 0
and 0
90 0
. 0

On 0
days 0
30 0
, 0
60 0
, 0
and 0
90 0
, 0
mean 0
flea B-PHYSICAL
counts I-PHYSICAL
in 0
selamectin-treated 0
dogs 0
were 0
reduced 0
by 0
92.1 0
, 0
99.0 0
, 0
and 0
99.8 0
% 0
, 0
and 0
mean 0
flea B-PHYSICAL
counts I-PHYSICAL
in 0
fenthion-treated 0
dogs 0
were 0
reduced 0
by 0
81.5 0
, 0
86.8 0
, 0
and 0
86.1 0
% 0
, 0
respectively 0
, 0
compared 0
with 0
day 0
0 0
counts 0
. 0

Also 0
, 0
on 0
days 0
30 0
, 0
60 0
, 0
and 0
90 0
, 0
mean 0
flea B-PHYSICAL
counts I-PHYSICAL
in 0
selamectin-treated 0
cats 0
were 0
reduced 0
by 0
92.5 0
, 0
98.3 0
, 0
and 0
99.3 0
% 0
, 0
and 0
mean 0
flea B-PHYSICAL
counts I-PHYSICAL
in 0
pyrethrin-treated 0
cats 0
were 0
reduced 0
by 0
66.4 0
, 0
73.9 0
, 0
and 0
81.3 0
% 0
, 0
respectively 0
, 0
compared 0
with 0
day 0
0 0
counts 0
. 0

Selamectin 0
also 0
was 0
beneficial 0
in 0
alleviating 0
signs 0
in 0
dogs 0
and 0
cats 0
diagnosed 0
clinically 0
with 0
FAD 0
. 0

A 0
total 0
of 0
397 0
dogs 0
free 0
of 0
adult 0
heartworm 0
infection 0
from 0
four 0
heartworm-endemic 0
areas 0
of 0
the 0
USA 0
were 0
allocated 0
randomly 0
to 0
six 0
months 0
of 0
treatment 0
with 0
selamectin 0
( 0
n=298 0
) 0
or 0
ivermectin 0
( 0
n=99 0
) 0
. 0

Selamectin 0
achieved 0
a 0
heartworm B-PHYSICAL
prevention I-PHYSICAL
rate I-PHYSICAL
of 0
100 0
% 0
, 0
with 0
all 0
dogs 0
testing 0
negative 0
for 0
microfilariae 0
and 0
adult 0
heartworm 0
antigen 0
on 0
days 0
180 0
and 0
300 0
. 0

Selamectin 0
was 0
administered 0
to 0
a 0
total 0
of 0
673 0
dogs 0
and 0
347 0
cats 0
having 0
an 0
age 0
range 0
of 0
6 0
weeks 0
to 0
19 0
years 0
( 0
3954 0
doses 0
) 0
. 0

The 0
animals 0
included 0
19 0
purebred 0
or 0
crossbred 0
Collies 0
( 0
Bearded 0
, 0
Border 0
, 0
and 0
unspecified 0
) 0
. 0

There 0
were 0
no 0
serious B-ADVERSE-EFFECTS
adverse I-ADVERSE-EFFECTS
events I-ADVERSE-EFFECTS
. 0

Results 0
of 0
these 0
studies 0
indicated 0
that 0
selamectin 0
was 0
highly B-OTHER
effective I-OTHER
in 0
the 0
control 0
of 0
flea 0
infestations 0
in 0
dogs 0
and 0
cats 0
without 0
the 0
need 0
for 0
simultaneous 0
treatment 0
of 0
the 0
environment 0
or 0
of 0
in-contact 0
animals 0
and 0
also 0
was 0
beneficial 0
in 0
alleviating 0
signs 0
associated 0
with 0
FAD 0
. 0

Selamectin 0
also 0
was 0
100 0
% 0
effective 0
in 0
preventing 0
the 0
development 0
of 0
canine 0
heartworms 0
and 0
was 0
safe B-OTHER
for 0
topical 0
use 0
in 0
dogs 0
and 0
cats 0
. 0

Influence 0
of 0
sentinel 0
lymph 0
node 0
tumor 0
burden 0
on 0
survival 0
in 0
melanoma 0
. 0

BACKGROUND 0
Completion 0
lymph 0
node 0
dissection 0
( 0
CLND 0
) 0
is 0
the 0
standard 0
procedure 0
for 0
patients 0
with 0
positive 0
sentinel 0
lymph 0
nodes 0
( 0
SLN 0
) 0
. 0

With 0
extensive 0
pathological 0
workup 0
, 0
increased 0
numbers 0
of 0
small 0
metastatic 0
deposits 0
are 0
detected 0
in 0
SLN 0
. 0

This 0
study 0
evaluated 0
the 0
prognostic 0
significance 0
of 0
SLN 0
metastatic 0
deposits 0
< 0
or 0
= 0
0.2 0
mm 0
in 0
patients 0
treated 0
in 0
a 0
referral 0
cancer 0
center 0
in 0
Brazil 0
. 0

METHODS 0
Patients 0
with 0
stage 0
I/II 0
melanoma 0
, 0
consecutively 0
submitted 0
to 0
a 0
SLN 0
procedure 0
by 0
the 0
same 0
surgeon 0
from 0
2000 0
to 0
2006 0
, 0
were 0
evaluated 0
. 0

All 0
positive 0
SLN 0
and 0
randomly 0
selected 0
negative 0
cases 0
were 0
reviewed 0
by 0
two 0
pathologists 0
. 0

Different 0
prognostic 0
factors 0
and 0
SLN 0
tumor 0
burden 0
were 0
recorded 0
. 0

Additional 0
positive 0
non-SLN 0
after 0
CLND 0
, 0
and 0
disease 0
outcome 0
were 0
evaluated 0
. 0

RESULTS 0
Of 0
381 0
patients 0
who 0
underwent 0
SLN 0
biopsy 0
, 0
103 0
( 0
27 0
% 0
) 0
were 0
positive 0
. 0

The 0
mean/median 0
Breslow 0
tumor B-PHYSICAL
thickness I-PHYSICAL
in 0
the 0
overall 0
group 0
was 0
3.4/2.0 0
mm 0
and 0
in 0
the 0
SLN 0
positive 0
patients 0
was 0
5.72/4.0 0
mm 0
. 0

Among 0
these 0
patients 0
, 0
48 0
( 0
47 0
% 0
) 0
had 0
metastatic 0
deposits 0
> 0
2 0
mm 0
( 0
macrometastasis 0
) 0
, 0
49 0
( 0
47 0
% 0
) 0
had 0
metastatic 0
deposits 0
< 0
or 0
=2 0
mm 0
but 0
> 0
0.2 0
mm 0
( 0
micrometastasis 0
) 0
, 0
and 0
6 0
( 0
6 0
% 0
) 0
had 0
metastatic 0
deposits 0
< 0
or 0
=0.2 0
mm 0
( 0
submicrometastasis 0
) 0
. 0

Additional 0
positive 0
non-SLN 0
were 0
detected 0
in 0
29 0
% 0
of 0
patients 0
with 0
macrometastasis 0
, 0
in 0
25 0
% 0
of 0
patients 0
with 0
micrometastasis 0
, 0
and 0
in 0
0 0
% 0
of 0
patients 0
with 0
submicrometastases 0
. 0

At 0
median 0
follow-up 0
of 0
35 0
months 0
, 0
the 0
estimated 0
3-year 0
overall 0
survival 0
was 0
92 0
% 0
for 0
negative 0
SLN 0
, 0
64 0
% 0
for 0
micrometastases 0
, 0
53 0
% 0
for 0
macrometastases 0
, 0
and 0
100 0
% 0
for 0
submicrometastases 0
( 0
P 0
< 0
0.001 0
) 0
. 0

CONCLUSION 0
In 0
the 0
present 0
study 0
, 0
patients 0
with 0
SLN 0
metastatic 0
deposits 0
< 0
or 0
=0.2 0
mm 0
had 0
no 0
additional 0
positive 0
non-SLNs 0
, 0
and 0
no 0
recurrences 0
or 0
deaths 0
were 0
recorded 0
, 0
suggesting 0
that 0
their 0
prognosis 0
is 0
equivalent 0
to 0
that 0
of 0
patients 0
with 0
negative 0
SLN 0
. 0

Comparison 0
of 0
clinical B-OTHER
effectiveness I-OTHER
of 0
acupuncture 0
and 0
a 0
Western 0
drug 0
on 0
allergic 0
rhinitis 0
: 0
study 0
protocol 0
for 0
a 0
randomized 0
controlled 0
trial 0
. 0

OBJECTIVE 0
To 0
compare 0
the 0
efficacy 0
of 0
an 0
acupuncture 0
regimen 0
for 0
persistent 0
allergic 0
rhinitis 0
( 0
PER 0
) 0
, 0
aimed 0
at 0
improving 0
a 0
patient 0
's 0
mind 0
or 0
Shen 0
in 0
Traditional 0
Chinese 0
Medicine 0
, 0
to 0
that 0
of 0
a 0
second-generation 0
Hi-receptor 0
antagonist 0
, 0
cetirizine 0
hydrochloride 0
. 0

METHODS 0
This 0
multicenter 0
, 0
randomized 0
, 0
controlled 0
clinical 0
trial 0
on 0
PER 0
will 0
be 0
conducted 0
at 0
three 0
institutions 0
in 0
China 0
. 0

The 0
total 0
study 0
period 0
will 0
be 0
9 0
weeks 0
. 0

After 0
a 0
1-week 0
preparatory 0
screening 0
period 0
, 0
240 0
eligible 0
participants 0
with 0
PER 0
will 0
be 0
randomized 0
to 0
receive 0
acupuncture 0
or 0
pharmacotherapy 0
( 0
1:1 0
) 0
for 0
4 0
weeks 0
with 0
a 0
4-week 0
follow-up 0
. 0

The 0
primary 0
outcome 0
will 0
be 0
changes 0
in 0
7-day B-OTHER
average 0
total 0
nasal B-OTHER
symptom I-OTHER
score 0
. 0

Secondary 0
outcome 0
measures 0
include 0
rhinoconjunctivitis B-OTHER
quality 0
of 0
life 0
questionnaire 0

Phase 0
III 0
trial 0
of 0
satraplatin 0
, 0
an 0
oral 0
platinum 0
plus 0
prednisone 0
vs. 0
prednisone 0
alone 0
in 0
patients 0
with 0
hormone-refractory 0
prostate 0
cancer 0
. 0

Satraplatin 0
is 0
a 0
novel 0
oral 0
platinum 0
( 0
IV 0
) 0
complex 0
that 0
shows 0
activity 0
against 0
hormone-refractory 0
prostate 0
cancer 0
( 0
HRPC 0
) 0
in 0
cisplatin-resistant 0
human 0
tumor 0
lines 0
in 0
phase 0
I 0
and 0
phase 0
II 0
trials 0
. 0

A 0
randomized 0
multicenter 0
phase 0
III 0
trial 0
with 0
a 0
target 0
sample 0
size 0
of 0
380 0
patients 0
was 0
initiated 0
in 0
men 0
with 0
HRPC 0
. 0

After 0
50 0
randomized 0
patients 0
, 0
the 0
trial 0
was 0
closed 0
to 0
further 0
accrual 0
by 0
the 0
sponsoring 0
company 0
. 0

An 0
ad 0
hoc 0
analysis 0
of 0
all 0
available 0
data 0
is 0
reported 0
here 0
. 0

Eligibility 0
criteria 0
included 0
pathological 0
proof 0
of 0
prostate 0
cancer 0
, 0
documented 0
progression 0
despite 0
prior 0
hormonal 0
manipulation 0
, 0
WHO 0
PS 0
0-2 0
, 0
and 0
no 0
daily 0
intake 0
of 0
narcotic 0
analgesics 0
. 0

Patients 0
were 0
randomized 0
between 0
satraplatin 0
100 0
mg/m 0
( 0
2 0
) 0
for 0
5 0
days 0
plus 0
prednisone 0
10 0
mg 0
orally 0
BID 0
or 0
prednisone 0
alone 0
. 0

Compliance 0
was 0
excellent 0
. 0

48/50 0
patients 0
have 0
progressed B-PHYSICAL
and 0
42 0
have 0
died B-MORTALITY
, 0
mostly 0
due 0
to 0
prostate 0
cancer 0
. 0

Median 0
overall B-MORTALITY
survival I-MORTALITY
was 0
14.9 0
months 0
( 0
95 0
% 0
CI 0
: 0
13.7-28.4 0
) 0
on 0
the 0
satraplatin 0
plus 0
prednisone 0
arm 0
and 0
11.9 0
months 0
( 0
95 0
% 0
CI 0
: 0
8.4-23.1 0
) 0
on 0
prednisone 0
alone 0
( 0
hazard 0
ratio 0
, 0
HR 0
= 0
0.84 0
, 0
95 0
% 0
CI 0
: 0
0.46-1.55 0
) 0
. 0

A 0
> 0
50 0
% 0
decrease 0
in 0
prostrate B-PHYSICAL
specific I-PHYSICAL
antigen I-PHYSICAL
( 0
PSA 0
) 0
was 0
seen 0
in 0
9/27 0
( 0
33.3 0
% 0
) 0
in 0
the 0
satraplatin 0
plus 0
prednisone 0
arm 0
vs. 0
2/23 0
( 0
8.7 0
% 0
) 0
on 0
the 0
prednisone 0
alone 0
arm 0
. 0

Progression-free B-MORTALITY
survival I-MORTALITY
was 0
5.2 0
months 0
( 0
95 0
% 0
CI 0
: 0
2.8-13.7 0
) 0
on 0
the 0
satraplatin 0
plus 0
prednisone 0
arm 0
as 0
compared 0
to 0
2.5 0
months 0
( 0
95 0
% 0
CI 0
: 0
2.1- 0
4.7 0
) 0
on 0
the 0
prednisone 0
alone 0
arm 0
( 0
HR 0
= 0
0.50 0
, 0
95 0
% 0
CI 0
: 0
0.28-0.92 0
) 0
. 0

This 0
difference 0
is 0
statistically 0
significant 0
( 0
p 0
= 0
0.023 0
) 0
. 0

Toxicity B-PHYSICAL
was 0
generally 0
minimal 0
in 0
both 0
arms 0
. 0

This 0
randomized 0
comparison 0
of 0
a 0
combination 0
of 0
satraplatin 0
and 0
prednisone 0
versus 0
prednisone 0
alone 0
supports 0
the 0
antitumor 0
activity 0
of 0
the 0
combination 0
. 0

Its 0
role 0
in 0
the 0
treatment 0
of 0
HPRC 0
remains 0
to 0
be 0
elucidated 0
in 0
an 0
appropriate 0
phase 0
III 0
setting 0
. 0

Comparison 0
of 0
methods 0
for 0
intravenous 0
infusion 0
of 0
fat 0
emulsion 0
during 0
extracorporeal 0
membrane 0
oxygenation 0
. 0

STUDY 0
OBJECTIVES 0
To 0
characterize 0
the 0
effects 0
of 0
infusing 0
fat 0
emulsion 0
during 0
neonatal 0
extracorporeal 0
membrane 0
oxygenation 0
( 0
ECMO 0
) 0
by 0
comparing 0
results 0
from 0
patients 0
receiving 0
fat 0
emulsion 0
through 0
the 0
ECMO 0
circuit 0
with 0
those 0
receiving 0
fat 0
emulsion 0
through 0
separate 0
intravenous 0
access 0
. 0

A 0
second 0
goal 0
was 0
to 0
identify 0
the 0
optimal 0
route 0
for 0
administration 0
. 0

DESIGN 0
Prospective 0
, 0
randomized 0
, 0
open-label 0
trial 0
. 0

SETTING 0
Neonatal 0
intensive 0
care 0
unit 0
in 0
a 0
106-bed 0
quaternary 0
care 0
pediatric 0
hospital 0
. 0

SUBJECTS 0
Nine 0
neonates 0
receiving 0
ECMO 0
who 0
required 0
intravenous 0
nutrition 0
. 0

Intervention 0
. 0

Patients 0
received 0
1-3 0
g/kg/day 0
of 0
fat 0
emulsion 0
into 0
either 0
the 0
ecmo 0
circuit 0
or 0
separate 0
intravenous 0
access 0
. 0

MEASUREMENTS 0
AND 0
MAIN 0
RESULTS 0
The 0
ECMO 0
circuit 0
and 0
samples 0
of 0
blood 0
were 0
evaluated 0
hourly 0
for 0
phase 0
separation 0
, 0
layering 0
out 0
of 0
the 0
emulsion 0
from 0
blood 0
, 0
agglutination 0
, 0
and 0
blood 0
clots 0
. 0

After 0
completion 0
, 0
the 0
oxygenators 0
were 0
dissected 0
and 0
examined 0
. 0

Data 0
were 0
compared 0
with 0
an 0
unpaired 0
t 0
test 0
. 0

The 0
characteristics 0
of 0
the 0
groups 0
were 0
similar 0
, 0
except 0
for 0
a 0
higher 0
mean 0
weight 0
in 0
the 0
ECMO 0
circuit 0
group 0
( 0
3.6 0
+/- 0
0.3 0
kg 0
vs 0
2.8 0
+/- 0
0.4 0
kg 0
, 0
p=0.03 0
) 0
. 0

The 0
mean 0
+/- B-PHYSICAL
SD I-PHYSICAL
triglyceride I-PHYSICAL
level I-PHYSICAL
during 0
the 0
study 0
was 0
87 0
+/- 0
79 0
mg/dl 0
, 0
with 0
no 0
significant 0
difference 0
between 0
the 0
two 0
groups 0
. 0

Two 0
patients 0
in 0
each 0
group 0
had 0
elevated 0
triglyceride B-PHYSICAL
levels I-PHYSICAL
. 0

No 0
cases 0
of 0
phase 0
separation B-PHYSICAL
occurred 0
. 0

In 0
the 0
five 0
patients 0
who 0
received 0
fat 0
emulsion 0
into 0
the 0
ECMO 0
circuit 0
, 0
three 0
had 0
layering 0
out 0
of 0
the 0
emulsion 0
and 0
agglutination B-PHYSICAL
, 0
and 0
all 0
developed 0
clots B-PHYSICAL
in 0
the 0
circuit 0
despite 0
adequate 0
anticoagulation 0
. 0

Of 0
the 0
four 0
patients 0
in 0
the 0
intravenous-access 0
group 0
, 0
one 0
had 0
layering 0
and 0
agglutination 0
, 0
and 0
two 0
had 0
blood 0
clots 0
. 0

CONCLUSIONS 0
Although 0
both 0
methods 0
were 0
associated 0
with 0
layering B-PHYSICAL
out I-PHYSICAL
, 0
agglutination B-PHYSICAL
, 0
and 0

Cognitive 0
effects 0
of 0
risperidone 0
in 0
children 0
with 0
autism 0
and 0
irritable 0
behavior 0
. 0

OBJECTIVE 0
The 0
objective 0
of 0
this 0
research 0
was 0
to 0
explore 0
the 0
effects 0
of 0
risperidone 0
on 0
cognitive B-MENTAL
processes I-MENTAL
in 0
children 0
with 0
autism 0
and 0
irritable 0
behavior 0
. 0

METHOD 0
Thirty-eight 0
children 0
, 0
ages 0
5-17 0
years 0
with 0
autism 0
and 0
severe 0
behavioral 0
disturbance 0
, 0
were 0
randomly 0
assigned 0
to 0
risperidone 0
( 0
0.5 0
to 0
3.5 0
mg/day 0
) 0
or 0
placebo 0
for 0
8 0
weeks 0
. 0

This 0
sample 0
of 0
38 0
was 0
a 0
subset 0
of 0
101 0
subjects 0
who 0
participated 0
in 0
the 0
clinical 0
trial 0
; 0
63 0
were 0
unable 0
to 0
perform 0
the 0
cognitive 0
tasks 0
. 0

A 0
double-blind 0
placebo-controlled 0
parallel 0
groups 0
design 0
was 0
used 0
. 0

Dependent 0
measures 0
included 0
tests B-PHYSICAL
of I-PHYSICAL
sustained I-PHYSICAL
attention I-PHYSICAL
, 0
verbal B-PHYSICAL
learning I-PHYSICAL
, 0
hand-eye B-PHYSICAL
coordination I-PHYSICAL
, 0
and 0
spatial B-PHYSICAL
memory I-PHYSICAL
assessed I-PHYSICAL
before 0
, 0
during 0
, 0
and 0
after 0
the 0
8-week B-PHYSICAL
treatment I-PHYSICAL
. 0

Changes 0
in 0
performance 0
were 0
compared 0
by 0
repeated 0
measures 0
ANOVA 0
. 0

RESULTS 0
Twenty-nine 0
boys 0
and 0
9 0
girls 0
with 0
autism 0
and 0
severe 0
behavioral 0
disturbance 0
and 0
a 0
mental 0
age 0
> 0
or=18 0
months 0
completed 0
the 0
cognitive 0
part 0
of 0
the 0
study 0
. 0

No 0
decline 0
in 0
performance 0
occurred 0
with 0
risperidone 0
. 0

Performance 0
on 0
a 0
cancellation B-MENTAL
task I-MENTAL
( I-MENTAL
number I-MENTAL
of I-MENTAL
correct I-MENTAL
detections I-MENTAL
) 0
and 0
a 0
verbal B-MENTAL
learning I-MENTAL
task I-MENTAL
( 0
word B-MENTAL
recognition I-MENTAL
) 0
was 0
better 0
on 0
risperidone 0
than 0
on 0
placebo 0
( 0
without 0
correction 0
for 0
multiplicity 0
) 0
. 0

Equivocal B-PHYSICAL
improvement I-PHYSICAL
also 0
occurred 0
on 0
a 0
spatial B-MENTAL
memory I-MENTAL
task I-MENTAL
. 0

There 0
were 0
no 0
significant 0
differences 0
between 0
treatment 0
conditions 0
on 0
the 0
Purdue B-MENTAL
Pegboard I-MENTAL
( I-MENTAL
hand-eye I-MENTAL
coordination I-MENTAL
) I-MENTAL
task 0
or 0
the 0
Analog B-MENTAL
Classroom I-MENTAL
Task I-MENTAL
( I-MENTAL
timed I-MENTAL
math I-MENTAL
test I-MENTAL
) 0
. 0

CONCLUSION 0
Risperidone 0
given 0
to 0
children 0
with 0
autism 0
at 0
doses 0
up 0
to 0
3.5 0
mg 0
for 0
up 0
to 0
8 0
weeks 0
appears 0
to 0
have 0
no 0
detrimental 0
effect 0
on 0
cognitive B-MENTAL
performance I-MENTAL
. 0

Histamine 0
intolerance-like 0
symptoms 0
in 0
healthy 0
volunteers 0
after 0
oral 0
provocation 0
with 0
liquid 0
histamine 0
. 0

Histamine 0
in 0
food 0
at 0
non-toxic 0
doses 0
has 0
been 0
proposed 0
to 0
be 0
a 0
major 0
cause 0
of 0
food 0
intolerance 0
causing 0
symptoms 0
like 0
diarrhea 0
, 0
hypotension 0
, 0
headache 0
, 0
pruritus 0
and 0
flush 0
( 0
histamine 0
intolerance 0
) 0
. 0

Histamine-rich 0
foods 0
such 0
as 0
cheese 0
, 0
sausages 0
, 0
sauerkraut 0
, 0
tuna 0
, 0
tomatoes 0
, 0
and 0
alcoholic 0
beverages 0
may 0
contain 0
histamine 0
up 0
to 0
500 0
mg/kg 0
. 0

We 0
conducted 0
a 0
randomized 0
, 0
double-blind 0
, 0
placebo-controlled 0
cross-over 0
study 0
in 0
10 0
healthy 0
females 0
( 0
age 0
range 0
22-36 0
years 0
, 0
mean 0
29.1 0
+/- 0
5.4 0
) 0
who 0
were 0
hospitalized 0
and 0
challenged 0
on 0
two 0
consecutive 0
days 0
with 0
placebo 0
( 0
peppermint 0
tea 0
) 0
or 0
75 0
mg 0
of 0
pure 0
histamine 0
( 0
equaling 0
124 0
mg 0
histamine 0
dihydrochloride 0
, 0
dissolved 0
in 0
peppermint 0
tea 0
) 0
. 0

Objective 0
parameters 0
( 0
heart 0
rate 0
, 0
blood 0
pressure 0
, 0
skin 0
temperature 0
, 0
peak 0
flow 0
) 0
as 0
well 0
as 0
a 0
total 0
clinical 0
symptom 0
score 0
using 0
a 0
standardized 0
protocol 0
were 0
recorded 0
at 0
baseline 0
, 0
10 0
, 0
20 0
, 0
40 0
, 0
80 0
minutes 0
, 0
and 0
24 0
hours 0
. 0

The 0
subjects 0
received 0
a 0
histamine-free 0
diet 0
also 0
low 0
in 0
allergen 0
24 0
hours 0
before 0
hospitalization 0
and 0
over 0
the 0
whole 0
observation 0
period 0
. 0

Blood 0
samples 0
were 0
drawn 0
at 0
baseline 0
, 0
10 0
, 0
20 0
, 0
40 0
, 0
and 0
80 0
minutes 0
, 0
and 0
histamine 0
and 0
the 0
histamine-degrading 0
enzyme 0
diamine 0
oxidase 0
( 0
DAO 0
) 0
were 0
determined 0
. 0

After 0
histamine 0
challenge 0
, 0
5 0
of 0
10 0
subjects 0
showed 0
no 0
reaction B-PHYSICAL
. 0

One 0
individual 0
experienced 0
tachycardia B-PHYSICAL
, 0
mild B-PHYSICAL
hypotension I-PHYSICAL
after I-PHYSICAL
20 I-PHYSICAL
minutes I-PHYSICAL
, 0
sneezing B-PHYSICAL
, 0
itching 0
of 0
the 0
nose 0
, 0
and 0
rhinorrhea 0
after 0
60 B-PHYSICAL
minutes I-PHYSICAL
. 0

Four 0
subjects 0
experienced 0
delayed 0
symptoms 0
like 0
diarrhea B-PHYSICAL
( I-PHYSICAL
4x I-PHYSICAL
) I-PHYSICAL
, 0
flatulence B-PHYSICAL
( I-PHYSICAL
3x I-PHYSICAL
) I-PHYSICAL
, 0
headache B-PHYSICAL
( I-PHYSICAL
3x I-PHYSICAL
) I-PHYSICAL
, 0
pruritus B-PHYSICAL
( I-PHYSICAL
2x I-PHYSICAL
) I-PHYSICAL
and 0
ocular B-PHYSICAL
symptoms I-PHYSICAL
( 0
1x 0
) 0
starting 0
3 0
to 0
24 0
hours 0
after 0
provocation 0
. 0

No 0
subject 0
reacted 0
to 0
placebo 0
. 0

No 0
changes 0
were 0
observed 0
in 0
histamine B-PHYSICAL
and I-PHYSICAL
DAO I-PHYSICAL
levels I-PHYSICAL
within 0
the 0
first 0
80 0
minutes 0
in 0
non-reactors 0
as 0
well 0
as 0
reactors 0
. 0

There 0
was 0
no 0
difference 0
in 0
challenge 0
with 0
histamine 0
versus 0
challenge 0
with 0
placebo 0
. 0

We 0
conclude 0
that 0
75 0
mg 0
of 0
pure 0
liquid 0
oral 0
histamine 0
-- 0
a 0
dose 0
found 0
in 0
normal 0
meals 0
-- 0
can 0
provoke 0
immediate 0
as 0
well 0
as 0
delayed 0
symptoms 0
in 0
50 0
% 0
of 0
healthy 0
females 0
without 0
a 0
history 0
of 0
food 0
intolerance 0
. 0

Response 0
prediction 0
in 0
metastasised 0
colorectal 0
cancer 0
using 0
intratumoural 0
thymidylate 0
synthase 0
: 0
results 0
of 0
a 0
randomised 0
multicentre 0
trial 0
. 0

BACKGROUND 0
Molecular 0
markers 0
to 0
predict 0
response 0
to 0
5-fluorouracil 0
( 0
FU 0
) 0
-based 0
treatment 0
of 0
recurrent 0
or 0
metastasised 0
colorectal 0
cancer 0
( 0
mCRC 0
) 0
are 0
not 0
established 0
. 0

The 0
aim 0
of 0
this 0
trial 0
was 0
to 0
determine 0
the 0
value 0
of 0
thymidylate 0
synthase 0
( 0
TS 0
) 0
, 0
a 0
key 0
enzyme 0
of 0
DNA 0
synthesis 0
and 0
target 0
of 0
5-FU 0
, 0
to 0
predict B-PHYSICAL
response I-PHYSICAL
to 0
chemotherapy 0
of 0
mCRC 0
. 0

METHODS 0
Tumour 0
tissue 0
was 0
obtained 0
from 0
168 0
patients 0
with 0
mCRC 0
for 0
relative 0
thymidylate 0
synthase B-PHYSICAL
( I-PHYSICAL
TS I-PHYSICAL
) I-PHYSICAL
mRNA 0
quantitation 0
. 0

Patients 0
were 0
randomised 0
to 0
receive 0
either 0
5-FU/folinic 0
acid 0
( 0
FA 0
, 0
FUFA 0
) 0
alone 0
or 0
in 0
combination 0
with 0
irinotecan 0
5-fluorouracil/folinic 0
acid 0
and 0
irinotecan 0
( 0
FOLFIRI 0
) 0
stratified 0
by 0
TS 0
( 0
low 0
versus 0
high 0
) 0
. 0

Primary 0
end-point 0
was 0
overall B-PHYSICAL
response 0
to B-PHYSICAL
first-line I-PHYSICAL
treatment B-PHYSICAL
among 0
TS 0
high 0
patients 0
. 0

All 0
parties 0
, 0
except 0
for 0
the 0
randomisation 0
centre 0
, 0
were 0
blinded 0
for 0
TS 0
status 0
. 0

RESULTS 0
Biopsies 0
( 0
n=168 0
) 0
were 0
taken 0
without 0
complications 0
. 0

TS B-PHYSICAL
levels B-PHYSICAL
were 0
available 0
for 0
147 0
patients 0
( 0
87.5 0
% 0
) 0
. 0

Analysing 0
response 0
to 0

Effect 0
of 0
flurbiprofen 0
sodium 0
on 0
pupillary B-PHYSICAL
dilatation I-PHYSICAL
during 0
scleral 0
buckling 0
surgery 0
. 0

Maintenance 0
of 0
pupillary B-PHYSICAL
dilatation I-PHYSICAL
is 0
necessary 0
for 0
success 0
of 0
scleral 0
buckling 0
procedures 0
. 0

The 0
efficacy 0
of 0
0.03 0
% 0
flurbiprofen 0
in 0
preventing 0
intraoperative 0
miosis 0
was 0
evaluated 0
by 0
a 0
prospective 0
randomized 0
, 0
double-masked 0
controlled 0
trial 0
of 0
60 0
patients 0
. 0

Thirty 0
patients 0
received 0
0.03 0
% 0
flurbiprofen 0
6 0
times 0
at 0
15 0
minute 0
intervals 0
90 0
minutes 0
preoperatively 0
in 0
addition 0
to 0
the 0
routine 0
dilation 0
regimen 0
. 0

The 0
treated 0
group 0
had 0
a 0
mean 0
pupillary B-PHYSICAL
decrease 0
of 0
1.88 0
mm 0
and 0
the 0
control 0
group 0
had 0
a 0
decrease 0
of 0
1.57 0
mm 0
( 0
p 0
> 0
0.05 0
) 0
. 0

Flurbiprofen 0
did 0
not 0
affect 0
the 0
pupillary B-PHYSICAL
size I-PHYSICAL
at 0
any 0
step 0
of 0
the 0
surgery 0
. 0

Factors 0
such 0
as 0
age 0
of 0
the 0
patient B-MENTAL
, 0
lens B-PHYSICAL
status I-PHYSICAL
, 0
number 0
of 0
cryo B-PHYSICAL
applications I-PHYSICAL
, 0
duration B-OTHER
of I-OTHER
surgery I-OTHER
, 0
and 0
the 0
size 0
and 0
extent B-OTHER
of I-OTHER
buckle I-OTHER
were 0
assessed 0
. 0

The 0
use 0
of 0
flurbiprofen 0
did 0
not 0
affect 0
the 0
mean 0
pupillary B-PHYSICAL
change I-PHYSICAL
for 0
any 0
of 0
these 0
groups 0
. 0

Preoperative 0
use 0
of 0
flurbiprofen 0
does 0
not 0
significantly 0
decrease 0
intraoperative B-PHYSICAL
miosis I-PHYSICAL
during I-PHYSICAL
scleral I-PHYSICAL
buckling I-PHYSICAL
procedures I-PHYSICAL
. 0

The 0
effect 0
of 0
visual 0
supports 0
on 0
performance B-OTHER
of 0
the 0
TGMD-2 0
for 0
children 0
with 0
autism 0
spectrum 0
disorder 0
. 0

The 0
purpose 0
of 0
this 0
study 0
was 0
to 0
examine 0
the 0
effects 0
of 0
visual 0
supports 0
on 0
the 0
performance 0
of 0
the 0
Test 0
of 0
Gross 0
Motor 0
Development 0
( 0
TGMD-2 0
) 0
for 0
children 0
with 0
autism 0
spectrum 0
disorder 0
( 0
ASD 0
) 0
. 0

Participants 0
( 0
N 0
= 0
22 0
) 0
performed 0
the 0
TGMD-2 0
under 0
three 0
different 0
protocols 0
( 0
traditional 0
protocol 0
, 0
picture 0
task 0
card 0
protocol 0
, 0
and 0
picture 0
activity 0
schedule 0
protocol 0
) 0
. 0

Gross B-PHYSICAL
motor I-PHYSICAL
quotient I-PHYSICAL
scores 0
on 0
the 0
TGMD-2 0
were 0
measured 0
and 0
statistically 0
analyzed 0
using 0
a 0
within-subjects 0
repeated-measures 0
ANOVA 0
. 0

Results 0
indicated 0
statistically 0
significant 0
differences 0
between 0
protocols 0
, 0
while 0
post 0
hoc 0
tests 0
indicated 0
that 0
the 0
picture 0
task 0
card 0
condition 0
produced 0
significantly 0
higher 0
gross B-PHYSICAL
motor I-PHYSICAL
quotient I-PHYSICAL
scores 0
than 0
the 0
traditional 0
protocol 0
and 0
the 0
picture 0
activity 0
schedule 0
. 0

The 0
results 0
suggest 0
that 0
more 0
accurate 0
gross 0
motor 0
quotient 0
scores 0
on 0
the 0
TGMD-2 B-PHYSICAL
by 0
children 0
with 0
ASD 0
can 0
be 0
elicited 0
using 0
the 0
picture 0
task 0
card 0
protocol 0
. 0

Hysteroscopic 0
transcervical 0
endometrial 0
resection 0
versus 0
thermal 0
destruction 0
for 0
menorrhagia 0
: 0
a 0
prospective 0
randomized 0
trial 0
on 0
satisfaction 0
rate 0
. 0

OBJECTIVE 0
The 0
purpose 0
of 0
this 0
study 0
was 0
to 0
compare 0
the 0
satisfaction B-OTHER
rate I-OTHER
and 0
the 0
effectiveness 0
of 0
transcervical 0
hysteroscopic 0
endometrial 0
resection 0
and 0
thermal 0
destruction 0
of 0
the 0
endometrium 0
in 0
the 0
treatment 0
of 0
menorrhagia 0
. 0

STUDY 0
DESIGN 0
A 0
prospective 0
randomized 0
trial 0
with 0
2 0
years 0
of 0
follow-up 0
was 0
carried 0
out 0
in 0
the 0
Department 0
of 0
Gynecology 0
of 0
the 0
University 0
of 0
Naples 0
. 0

Eighty-two 0
patients 0
who 0
were 0
affected 0
by 0
menorrhagia 0
that 0
was 0
unresponsive 0
to 0
medical 0
treatment 0
were 0
respectively 0
randomized 0
to 0
transcervical 0
hysteroscopic 0
endometrial 0
resection 0
or 0
to 0
thermal 0
destruction 0
of 0
the 0
endometrium 0
. 0

Satisfaction B-OTHER
rate I-OTHER
, 0
operative B-OTHER
time I-OTHER
, 0
discharge B-OTHER
time I-OTHER
, 0
complication B-ADVERSE-EFFECTS
rate I-ADVERSE-EFFECTS
, 0
reintervention B-OTHER
rate I-OTHER
, 0
and 0
resumption 0
of 0
normal B-OTHER
activity I-OTHER
were 0
evaluated 0
in 0
each 0
group 0
. 0

RESULTS 0
The 0
satisfaction B-OTHER
rate I-OTHER
was 0
significantly 0
higher 0
in 0
the 0
thermal 0
destruction 0
group 0
. 0

Operative B-OTHER
time I-OTHER
was 0
significantly 0
shorter 0
in 0
the 0
thermal 0
destruction 0
group 0
( 0
24 0
+/- 0
4 0
minutes 0
vs 0
37 0
+/- 0
6 0
minutes 0
) 0
. 0

Intraoperative B-ADVERSE-EFFECTS
blood I-ADVERSE-EFFECTS
loss I-ADVERSE-EFFECTS
was 0
significantly 0
lower 0
in 0
the 0
thermal 0
destruction 0
group 0
( 0
7.2 0
+/- 0
2.8 0
mL 0
vs 0
89 0
+/- 0
38 0
mL 0
) 0
. 0

Reintervention B-OTHER
rates I-OTHER
were 0
higher 0
in 0
the 0
transcervical 0
hysteroscopic 0
endometrial 0
resection 0
group 0
, 0
although 0
postoperative 0
pain 0
was 0
not 0
significantly 0
different 0
between 0
the 0
two 0
groups 0
. 0

Discharge B-OTHER
time I-OTHER
, 0
complication B-ADVERSE-EFFECTS
rate I-ADVERSE-EFFECTS
, 0
and 0
resumption 0
of 0
normal B-OTHER
activity I-OTHER
were 0
not 0
significantly 0
different 0
between 0
the 0
two 0
groups 0
. 0

CONCLUSION 0
Thermal 0
destruction 0
of 0
the 0
endometrium 0
for 0
the 0
treatment 0
of 0
menorrhagia 0
should 0
be 0
considered 0
an 0
effective 0
therapeutic 0
option 0
because 0
of 0
its 0
acceptability B-OTHER
among 0
patients 0
, 0
shorter B-OTHER
operative I-OTHER
time I-OTHER
, 0
and 0
lower B-OTHER
blood I-OTHER
loss I-OTHER
. 0

Repeatability 0
and 0
protocol 0
comparability 0
of 0
presyncopal 0
symptom 0
limited 0
lower 0
body 0
negative 0
pressure 0
exposures 0
. 0

Data 0
on 0
repeatability 0
and 0
comparability 0
of 0
different 0
presyncopal 0
symptom-limited 0
lower 0
body 0
negative 0
pressure 0
( 0
PSL-LBNP 0
) 0
exposure 0
protocols 0
, 0
while 0
scarce 0
, 0
are 0
critical 0
to 0
the 0
interpretation 0
of 0
studies 0
using 0
PSL-LBNP 0
methods 0
. 0

To 0
investigate 0
if 0
PSL-LBNP 0
tolerance 0
, 0
heart 0
rate 0
, 0
and 0
blood 0
pressure 0
were 0
repeatable 0
, 0
11 0
subjects 0
were 0
exposed 0
to 0
4 0
PSL-LBNP 0
tests 0
; 0
each 0
test 0
occurring 0
at 0
the 0
same 0
time 0
of 0
day 0
, 0
separated 0
by 0
at 0
least 0
72 0
h 0
, 0
and 0
using 0
the 0
same 0
protocol 0
. 0

No 0
significant 0
differences 0
were 0
found 0
in 0
either 0
the 0
heart B-PHYSICAL
rate I-PHYSICAL
or 0
blood B-PHYSICAL
pressure I-PHYSICAL
responses I-PHYSICAL
to 0
the 0
PSL-LBNP 0
or 0
the 0
tolerance 0
indices B-OTHER
( 0
cumulative 0
stress 0
index 0
; 0
maximum 0
negative 0
pressure 0
tolerated 0
; 0
and 0
duration 0
of 0
negative 0
pressure 0
exposure 0
) 0
. 0

To 0
study 0
the 0
comparability 0
of 0
different 0
PSL-LBNP 0
protocols 0
, 0
nine 0
subjects 0
were 0
exposed 0
randomly 0
to 0
five 0
PSL-LBNP 0
tests 0
using 0
protocols 0
that 0
varied 0
in 0
stage 0
duration 0
but 0
not 0
pressure 0
profile 0
. 0

The 0
protocols 0
had 0
1- 0
, 0
3- 0
, 0
5- 0
, 0
7- 0
, 0
or 0
9-min 0
stage 0
durations 0
. 0

These 0
PSL-LBNP 0
exposures 0
were 0
conducted 0
at 0
the 0
same 0
time 0
of 0
day 0
and 0
separated 0
by 0
at 0
least 0
72 0
h. 0
While 0
no 0
differences 0
were 0
noted 0
in 0
either 0
the 0
response 0
pattern 0
or 0
magnitude 0
of 0
heart B-PHYSICAL
rate I-PHYSICAL
or 0
blood B-PHYSICAL
pressure I-PHYSICAL
to 0
the 0
differing 0
protocols 0
, 0
the 0
cumulative B-OTHER
stress 0
index B-OTHER
and 0
the B-PHYSICAL
duration I-PHYSICAL
of I-PHYSICAL
negative 0

Helicobacter B-PHYSICAL
pylori I-PHYSICAL
eradication I-PHYSICAL
in 0
children 0
and 0
adolescents 0
by 0
a 0
once 0
daily 0
6-day 0
treatment 0
with 0
or 0
without 0
a 0
proton 0
pump 0
inhibitor 0
in 0
a 0
double-blind 0
randomized 0
trial 0
. 0

AIM 0
To 0
evaluate 0
two 0
simplified 0
Helicobacter B-PHYSICAL
pylori I-PHYSICAL
eradication I-PHYSICAL
treatment 0
alternatives 0
for 0
children 0
and 0
adolescents 0
. 0

METHODS 0
Study 0
subjects 0
were 0
identified 0
by 0
enzyme-linked 0
immunosorbent 0
assay 0
and 0
immunoblot 0
in 0
a 0
family 0
screening 0
project 0
. 0

Helicobacter 0
pylori 0
infected 0
10-21 0
year 0
olds 0
were 0
offered 0
treatment 0
, 0
individuals 0
with 0
abdominal 0
pain 0
underwent 0
upper 0
endoscopy 0
and 0
those 0
with 0
peptic 0
ulcers 0
were 0
excluded 0
. 0

Participants 0
were 0
randomized 0
to 0
either 0
azithromycin 0
500 0
mg 0
daily 0
and 0
tinidazole 0
500 0
mg 0
two 0
tablets 0
daily 0
in 0
combination 0
with 0
lansoprasole 0
30 0
mg 0
daily 0
for 0
6 0
days 0
( 0
ATL-group 0
) 0
or 0
with 0
placebo 0
( 0
ATP-group 0
) 0
. 0

Urea 0
Breath 0
Test 0
was 0
performed 0
at 0
inclusion 0
and 0
after 0
a 0
minimum 0
of 0
6 0
weeks 0
after 0
end 0
of 0
therapy 0
. 0

RESULTS 0
In 0
total 0
, 0
131 0
individuals 0
were 0
randomized 0
, 0
of 0
whom 0
31 0
( 0
24 0
% 0
) 0
had 0
undergone 0
upper 0
endoscopy 0
. 0

Full B-MENTAL
compliance I-MENTAL
was 0
achieved 0
in 0
93 0
% 0
( 0
122 0
of 0
131 0
) 0
. 0

The 0
intention-to-treat B-OTHER
eradication I-OTHER
rate I-OTHER
was 0
67 0
% 0
( 0
44 0
of 0
66 0
) 0
and 0
58 0
% 0
( 0
38 0
of 0
65 0
) 0
for 0
the 0
ATL- 0
and 0
the 0
ATP-group 0
, 0
respectively 0
. 0

CONCLUSION 0
The 0
double-blind 0
randomized 0
clinical 0
trial 0
did 0
not 0
identify 0
a 0
simplified 0
, 0
successful 0
once 0
daily 0
H. 0
pylori 0
treatment 0
for 0
children 0
and 0
adolescents 0
. 0

Thus 0
, 0
twice 0
daily 0
proton 0
pump 0
inhibitor 0
( 0
PPI 0
) 0
-based 0
triple 0
therapies 0
for 0
7 0
days 0
remain 0
as 0
the 0
choice 0
of 0
treatment 0
in 0
children 0
. 0

Further 0
, 0
powerful 0
and 0
controlled 0
studies 0
are 0
needed 0
to 0
elucidate 0
the 0
best 0
treatment 0
strategies 0
for 0
H. 0
pylori 0
eradication 0
in 0
this 0
age 0
group 0
. 0

Randomised 0
controlled 0
trial 0
of 0
patient 0
triggered 0
and 0
conventional 0
fast 0
rate 0
ventilation 0
in 0
neonatal 0
respiratory 0
distress 0
syndrome 0
. 0

AIM 0
To 0
compare 0
patient 0
triggered 0
, 0
with 0
conventional 0
fast 0
rate 0
, 0
ventilation 0
in 0
a 0
randomised 0
controlled 0
trial 0
using 0
the 0
incidence 0
of 0
chronic B-PHYSICAL
lung I-PHYSICAL
disease I-PHYSICAL
as 0
the 0
primary 0
outcome 0
measure 0
. 0

METHODS 0
Three 0
hundred 0
and 0
eighty 0
six 0
preterm 0
infants 0
with 0
birthweights 0
from 0
1000 0
to 0
2000 0
g 0
, 0
and 0
requiring 0
ventilation 0
for 0
respiratory 0
distress 0
syndrome 0
within 0
24 0
hours 0
of 0
birth 0
, 0
were 0
randomised 0
to 0
receive 0
either 0
conventional 0
or 0
trigger 0
ventilation 0
with 0
the 0
SLE 0
2000 0
ventilator 0
. 0

RESULTS 0
There 0
were 0
no 0
significant 0
differences 0
in 0
the 0
incidence 0
of 0
chronic B-PHYSICAL
lung I-PHYSICAL
disease I-PHYSICAL
( 0
28 0
day 0
and 0
36 0
week 0
definitions 0
) 0
, 0
death B-MORTALITY
, 0
pneumothorax 0
, 0
intraventricular 0
haemorrhage 0
, 0
number B-OTHER
of I-OTHER
ventilator I-OTHER
days I-OTHER
, 0
or 0

Interventional 0
study 0
to 0
strengthen 0
the 0
health 0
promoting 0
behaviours 0
of 0
pregnant 0
women 0
to 0
prevent 0
anaemia 0
in 0
southern 0
India 0
. 0

OBJECTIVES 0
to 0
determine 0
the 0
effectiveness 0
of 0
a 0
health 0
information 0
package 0
in 0
terms 0
of 0
empowering 0
the 0
pregnant 0
women 0
to 0
modify 0
their 0
health-care 0
behaviour 0
and 0
take 0
appropriate 0
action 0
to 0
combat 0
anaemia 0
in 0
pregnancy 0
. 0

DESIGN 0
the 0
study 0
was 0
conceptualized 0
based 0
on 0
Rosenstock 0
and 0
Becker 0
's 0
health 0
belief 0
model 0
. 0

A 0
quasi-experimental 0
pretest-posttest 0
control 0
group 0
design 0
was 0
used 0
. 0

The 0
sample 0
consists 0
of 0
225 0
anaemic 0
pregnant 0
women 0
randomly 0
allocated 0
in 0
experimental 0
( 0
n=75 0
) 0
, 0
control 0
group 0
A 0
( 0
n=75 0
) 0
and 0
control 0
group 0
B 0
( 0
n=75 0
) 0
. 0

The 0
health 0
seeking 0
behaviour 0
outcome 0
measure 0
included 0
knowledge 0
regarding 0
anaemia 0
, 0
food 0
selection 0
ability 0
, 0
increase 0
in 0
haemoglobin 0
level 0
and 0
compliance 0
to 0
iron 0
supplementation 0
. 0

Intervention 0
was 0
a 0
validated 0
planned 0
educational 0
programme 0
with 0
visual 0
aids 0
and 0
iron 0
supplementation 0
. 0

FINDINGS 0
the 0
results 0
show 0
the 0
mean 0
gain B-OTHER
of I-OTHER
knowledge I-OTHER
scores 0
of 0
experimental 0
group 0
was 0
comparatively 0
higher 0
and 0
control 0
groups 0
A 0
and 0
B 0
showed 0
that 0
F 0
ratio 0
was 0
( 0
F 0
( 0
2,190 0
) 0
=11.910 0
, 0
p 0
< 0
0.01 0
) 0
indicating 0
that 0
the 0
pregnant 0
women 0
learned 0
more 0
about 0
anaemia 0
prevention 0
than 0
others 0
. 0

With 0
regard 0
to 0
food 0
selection 0
ability 0
scores 0
of 0
experimental 0
, 0
control 0
groups 0
A 0
and 0
B 0
the 0
F 0
ratio 0
was 0
also 0
significant 0
( 0
F 0
( 0
2,190 0
) 0
=20.92 0
, 0
p 0
< 0
0.01 0
) 0
. 0

Nearly 0
61.2 0
% 0
of 0
the 0
subjects 0
in 0
experimental 0
group 0
became 0
non-anaemic B-PHYSICAL
after 0
the 0
intervention 0
when 0
compared 0
to 0
control 0
group 0
A 0
. 0

This 0
indicated 0
that 0
inspite 0
of 0
iron 0
supplementation 0
received 0
by 0
the 0
three 0
groups 0
health 0
education 0
contributed 0
significantly 0
in 0
modifying 0
their 0
health 0
seeking 0
behaviour 0
and 0
their 0
perception 0
about 0
significance 0
of 0
anaemia 0
has 0
a 0
problem 0
. 0

CONCLUSION 0
developing 0
countries 0
still 0
face 0
the 0
critical 0
problem 0
of 0
anaemia 0
in 0
pregnancy 0
. 0

These 0
are 0
the 0
socio-cultural 0
priority 0
problems 0
that 0
demand 0
immediate 0
attention 0
by 0
the 0
policy 0
makers 0
and 0
health 0
professionals 0
. 0

The 0
national 0
anaemia 0
control 0
programme 0
focuses 0
on 0
iron 0
supplementation 0
, 0
but 0
nutritional 0
education 0
and 0
supervision 0
of 0
iron 0
supplementation 0
has 0
failed 0
in 0
different 0
regions 0
. 0

The 0
study 0
implies 0
that 0
economic 0
empowerment 0
; 0
strengthening 0
health 0
literacy 0
through 0
planned 0
educational 0
programs 0
will 0
definitely 0
improve 0
the 0
health 0
behaviour 0
of 0
individual 0
and 0
community 0
at 0
large 0
. 0

Effect 0
of 0
thermal 0
stress 0
, 0
restricted 0
feeding 0
and 0
combined 0
stresses 0
( 0
thermal 0
stress 0
and 0
restricted 0
feeding 0
) 0
on 0
growth 0
and 0
plasma 0
reproductive 0
hormone 0
levels 0
of 0
Malpura 0
ewes 0
under 0
semi-arid 0
tropical 0
environment 0
. 0

A 0
study 0
was 0
conducted 0
to 0
assess 0
the 0
effect 0
of 0
thermal 0
, 0
nutritional 0
and 0
combined 0
stresses 0
( 0
thermal 0
and 0
nutritional 0
) 0
on 0
the 0
growth 0
, 0
oestradiol 0
and 0
progesterone 0
levels 0
during 0
oestrus 0
cycles 0
in 0
Malpura 0
ewes 0
. 0

Twenty-eight 0
adult 0
Malpura 0
ewes 0
were 0
used 0
in 0
the 0
present 0
study 0
. 0

The 0
ewes 0
were 0
randomly 0
allocated 0
into 0
four 0
groups 0
, 0
viz. 0
, 0
GI 0
( 0
n=7 0
; 0
control 0
) 0
, 0
GII 0
( 0
n=7 0
; 0
thermal 0
stress 0
) 0
, 0
GIII 0
( 0
n=7 0
; 0
restricted 0
feeding 0
) 0
and 0
GIV 0
( 0
n=7 0
; 0
combined 0
stress 0
) 0
. 0

The 0
animals 0
were 0
stall 0
fed 0
with 0
a 0
diet 0
consisting 0
of 0
60 0
% 0
roughage 0
and 0
40 0
% 0
concentrate 0
. 0

GI 0
and 0
GII 0
ewes 0
were 0
provided 0
with 0
ad 0
libitum 0
feeding 0
while 0
GIII 0
and 0
GIV 0
ewes 0
were 0
provided 0
with 0
restricted 0
feed 0
( 0
30 0
% 0
intake 0
of 0
GI 0
and 0
GII 0
ewes 0
) 0
to 0
induce 0
nutritional 0
insufficiency 0
. 0

GII 0
and 0
GIV 0
ewes 0
were 0
kept 0
in 0
climatic 0
chamber 0
at 0
40?C 0
and 0
55 0
% 0
RH 0
for 0
6 0
h 0
a 0
day 0
between 0
10:00 0
and 0
16:00 0
hours 0
to 0
induce 0
thermal 0
stress 0
for 0
a 0
period 0
of 0
two 0
oestrous 0
cycles 0
. 0

Parameters 0
studied 0
were 0
body 0
weight 0
, 0
oestrus 0
incidences 0
, 0
plasma 0
oestradiol 0
17-? 0
, 0
plasma 0
progesterone 0
, 0
conception 0
rate 0
, 0
gestation 0
period 0
, 0
lambing 0
rate 0
, 0
and 0
birth 0
weight 0
of 0
lambs 0
. 0

The 0
results 0
indicate 0
that 0
combined 0
stress 0
significantly 0
( 0
p 0
< 0
0.05 0
) 0
reduced 0
body B-PHYSICAL
weight 0
, 0
oestrus B-PHYSICAL
duration I-PHYSICAL
, 0
birth B-PHYSICAL
weight 0
of B-PHYSICAL

Erythrocyte B-PHYSICAL
deformability I-PHYSICAL
, 0
endothelin B-PHYSICAL
levels I-PHYSICAL
, 0
and 0
renal B-PHYSICAL
function I-PHYSICAL
in 0
cyclosporin-treated 0
renal 0
transplant 0
recipients 0
: 0
effects 0
of 0
intervention 0
with 0
fish 0
oil 0
and 0
corn 0
oil 0
. 0

Twenty 0
nine 0
stable 0
renal 0
transplant 0
recipients 0
, 0
10 0
receiving 0
cyclosporin 0
, 0
10 0
cyclosporin-prednisolone 0
and 0
nine 0
azathioprine-prednisolone 0
were 0
supplemented 0
in 0
a 0
double 0
blind 0
randomization 0
cross-over 0
study 0
with 0
fish 0
oil 0
and 0
corn 0
oil 0
for 0
a 0
period 0
of 0
4 0
months 0
each 0
. 0

Erythrocyte B-PHYSICAL
deformability I-PHYSICAL
was 0
reduced 0
in 0
the 0
cyclosporin-treated 0
patients 0
and 0
returned 0
to 0
normal 0
values 0
after 0
supplementation 0
of 0
either 0
oil 0
. 0

The 0
oil 0
supplementation 0
resulted 0
in 0
an 0
increased 0
polyunsaturated B-PHYSICAL
fatty I-PHYSICAL
acid I-PHYSICAL
content I-PHYSICAL
in 0
the 0
plasma 0
phospholipids 0
. 0

An 0
increased 0
erythrocyte 0
membrane 0
polyunsaturated 0
fatty 0
acid 0
content 0
might 0
correct 0
the 0
lower 0
erythrocyte 0
deformability 0
in 0
cyclosporin 0
treated 0
patients 0
. 0

Therefore 0
, 0
it 0
is 0
probable 0
that 0
these 0
changes 0
are 0
membrane-related 0
. 0

The 0
oil 0
supplementation 0
had 0
no 0
effect 0
on 0
glomerular B-PHYSICAL
filtration I-PHYSICAL
rate I-PHYSICAL
, 0
effective B-PHYSICAL
renal I-PHYSICAL
plasma I-PHYSICAL
flow I-PHYSICAL
, 0
filtration B-PHYSICAL
fraction I-PHYSICAL
or 0
blood B-PHYSICAL
pressure I-PHYSICAL
, 0
which 0
does 0
not 0
exclude 0
effects 0
of 0
the 0
cyclosporin-induced 0
rigidified 0
erythrocytes 0
in 0
the 0
acute 0
phase 0
of 0
renal 0
transplantation 0
. 0

Decreased 0
erythrocyte B-PHYSICAL
deformability I-PHYSICAL
could 0
play 0
a 0
role 0
in 0
the 0
cyclosporin-induced 0
deterioration 0
of 0
renal 0
haemodynamics 0
. 0

This 0
may 0
enhance 0
the 0
effects 0
of 0
endothelin 0
, 0
as 0
these 0
patients 0
also 0
had 0
elevated 0
endothelin 0
levels 0
. 0

The 0
impact 0
of 0
fasting 0
and 0
treatment 0
omission 0
on 0
susceptibility B-PHYSICAL
to I-PHYSICAL
hypoglycaemia I-PHYSICAL
in 0
children 0
and 0
adolescents 0
with 0
GH 0
and 0
cortisol 0
insufficiency 0
. 0

OBJECTIVE 0
Hypoglycaemia 0
may 0
be 0
a 0
frequent 0
occurrence 0
in 0
young 0
GH 0
deficient 0
patients 0
and 0
so 0
we 0
studied 0
the 0
response 0
to 0
fasting 0
in 0
children 0
and 0
adolescents 0
with 0
GH 0
and/or 0
cortisol 0
deficiency 0
. 0

METHODS 0
A 0
total 0
of 0
20 0
patients 0
( 0
2-18 0
years 0
) 0
fasted 0
for 0
14 0
h 0
( 0
22.00-12.00 0
h 0
) 0
on 0
two 0
occasions 0
as 0
part 0
of 0
a 0
randomized 0
cross-over 0
study 0
. 0

Fourteen 0
had 0
pituitary 0
hormone 0
deficiency 0
( 0
PHD 0
) 0
including 0
GH 0
deficiency 0
( 0
GHD 0
) 0
. 0

Of 0
the 0
14 0
patients 0
, 0
seven 0
were 0
ACTH 0
sufficient 0
( 0
PHDC+ 0
) 0
and 0
seven 0
ACTH 0
deficient 0
( 0
PHDC- 0
) 0
. 0

Six 0
had 0
primary 0
adrenal 0
failure 0
( 0
PAF 0
) 0
. 0

Subjects 0
administered 0
or 0
omitted 0
their 0
normal 0
dose 0
of 0
evening 0
GH 0
and/or 0
morning 0
hydrocortisone 0
. 0

Glucose B-PHYSICAL
, 0
insulin B-PHYSICAL
, 0
GH B-PHYSICAL
, 0
cortisol B-PHYSICAL
, 0
ketones B-PHYSICAL
and 0
catecholamines B-PHYSICAL
were 0
measured 0
at 0
04.00 0
h 0
and 0
regularly 0
from 0
07.00 0
to 0
12.00 0
h. 0
Insulin B-PHYSICAL
sensitivity I-PHYSICAL
was 0
assessed 0
by 0
HOMA B-OTHER
and 0
hypoglycaemia B-PHYSICAL
defined 0
as 0
a 0
blood B-PHYSICAL
glucose I-PHYSICAL
( 0
BG 0
) 0
< 0
/= 0
3.3 0
mmol/l 0
. 0

RESULTS 0
BG 0
was 0
related 0
to 0
age 0
and 0
body B-PHYSICAL
mass I-PHYSICAL
index I-PHYSICAL
on 0
treatment 0
but 0
no 0
subject 0
became 0
hypoglycaemic 0
on 0
or 0
off 0
therapy 0
prior 0
to 0
07.00 0
h. 0
Five 0
children 0
( 0
aged 0
3 0
, 0
4 0
, 0
7 0
, 0
8 0
and 0
11 0
years 0
) 0
were 0
hypoglycaemic B-PHYSICAL
between 0
07.00 0
and 0
12.00 0
h 0
off 0
treatment 0
. 0

There 0
was 0
a 0
positive 0
relationship 0
between 0
GH B-PHYSICAL
AUC I-PHYSICAL
and 0
minimum B-PHYSICAL
BG I-PHYSICAL
in 0
patients 0
with 0
PHD 0
on 0
treatment 0
( 0
r 0
( 0
2 0
) 0
= 0
0.45 0
, 0
P 0
= 0
0.012 0
) 0
with 0
increased 0
insulin B-PHYSICAL
sensitivity I-PHYSICAL
off 0
treatment 0
. 0

Increased 0
cortisol B-PHYSICAL
levels I-PHYSICAL
were 0
seen 0
in 0
PHDC+ 0
patients 0
off 0
GH 0
( 0
P 0
< 0
0.001 0
) 0
. 0

A 0
negative 0
relationship 0
was 0
observed 0
between 0
minimum 0
BG B-PHYSICAL
and 0
adrenaline B-PHYSICAL
( 0
r 0
( 0
2 0
) 0
= 0
0.37 0
, 0
P 0
= 0
0.01 0
) 0
, 0
ketone B-PHYSICAL
bodies I-PHYSICAL
( 0
r 0
( 0
2 0
) 0
= 0
-0.20 0
, 0
P 0
= 0
0.05 0
) 0
and 0
NEFA B-PHYSICAL
( 0
r 0
( 0
2 0
) 0
= 0
-0.35 0
, 0
P 0
= 0
0.02 0
) 0
. 0

Noradrenaline B-PHYSICAL
levels I-PHYSICAL
were 0
reduced 0
in 0
patients 0
with 0
PHDC- 0
. 0

Low 0
BMI 0
( 0
on 0
treatment 0
) 0
and 0
young 0
age 0
( 0
off 0
treatment 0
) 0
were 0
determinants 0
of 0
low B-PHYSICAL
BG I-PHYSICAL
levels I-PHYSICAL
in 0
a 0
multiple 0
regression 0
model 0
. 0

CONCLUSIONS 0
Unrecognized 0
overnight 0
hypoglycaemia 0
in 0
children 0
and 0
adolescents 0
on 0
pituitary 0
hormone 0
replacement 0
is 0
uncommon 0
but 0
BG B-PHYSICAL
levels I-PHYSICAL
quickly 0
become 0
abnormal 0
when 0
treatment 0
and 0
meals 0
are 0
omitted 0
. 0

The 0
insulin B-PHYSICAL
antagonistic I-PHYSICAL
actions I-PHYSICAL
of I-PHYSICAL
GH I-PHYSICAL
are 0
important 0
in 0
preventing 0
hypoglycaemia 0
. 0

Patients 0
with 0
PHD 0
have 0
altered 0
sympathetic B-PHYSICAL
nerve I-PHYSICAL
activity I-PHYSICAL
. 0

Quantifications 0
of 0
the 0
major 0
urinary B-PHYSICAL
metabolite I-PHYSICAL
of I-PHYSICAL
the I-PHYSICAL
E I-PHYSICAL
prostaglandins I-PHYSICAL
by 0
mass 0
spectrometry 0
: 0
evaluation 0
of 0
the 0
method 0
's 0
application 0
to 0
clinical 0
studies 0
. 0

Measurement 0
of 0
7alpha-hydroxy-5,11-diketotetranoprostane-1,16-dioic 0
acid 0
, 0
( 0
PGE-M 0
) 0
, 0
the 0
major 0
urinary 0
metabolite 0
of 0
prostaglandin 0
E1 0
and 0
E2 0
in 0
man 0
provides 0
a 0
useful 0
indicator 0
to 0
monitor 0
prostaglandin 0
biosynthesis 0
. 0

For 0
quantitative 0
analysis 0
of 0
this 0
prostaglandin 0
metabolite 0
and 0
the 0
stable-isotope 0
dilution 0
techniqe 0
of 0
selected 0
ion 0
monitoring 0
( 0
SIM 0
) 0
is 0
employed 0
using 0
gas-liquid 0
chromatography-mass 0
spectrometry 0
. 0

The 0
preparation 0
of 0
the 0
bis 0
( 0
D3-methyloxime 0
) 0
, 0
bis-methyl 0
ester 0
of 0
PGE-M 0
containing 0
a 0
tritium 0
tracer 0
in 0
position 0
2 0
which 0
was 0
used 0
as 0
internal 0
standard 0
for 0
the 0
SIM 0
method 0
is 0
described 0
. 0

The 0
synthesis 0
of 0
this 0
internal 0
standard 0
includes 0
the 0
biosynthetic 0
conversion 0
of 0
11-hydroxy-9,15-diketoprostanoic 0
acid 0
to 0
PGE-M 0
by 0
the 0
rabbit 0
. 0

The 0
intra-assay 0
coefficient 0
of 0
variation 0
of 0
this 0
SIM 0
method 0
ranged 0
between 0
4.0 0
to 0
6.7 0
percent 0
. 0

The 0
recovery 0
of 0
authentic 0
, 0
underivatized 0
PGE-M 0
added 0
to 0
urine 0
was 0
93 0
+/- 0
3 0
% 0
( 0
mean 0
+/- 0
SEM 0
, 0
n=17 0
) 0
. 0

The 0
levels B-PHYSICAL
of I-PHYSICAL
PGE-M I-PHYSICAL
excreted I-PHYSICAL
in 0
urine 0
were 0
higher 0
( 0
p 0
less 0
than 0
0.001 0
) 0
in 0
males 0
than 0
in 0
females 0
( 0
15.2 0
+/- 0
1.9 0
mug/24 0
hours 0
( 0
n=24 0
) 0
and 0
3.3 0
+/- 0
0.3 0
mug/24 0
hours 0
( 0
n=17 0
) 0
, 0
respectively 0
. 0

These 0
levels 0
were 0
in 0
close 0
agreement 0
with 0
values 0
published 0
previously 0
. 0

No 0
significant 0
difference 0
in 0
excretion 0
of 0
PGE-M 0
between 0
the 0
sexes 0
was 0
observed 0
in 0
the 0
pre-pubertal 0
age-grou 0
( 0
male 0
: 0
2.9 0
+/- 0
0.8 0
mug/24 0
hours 0
, 0
n=5 0
; 0
female 0
: 0
3.1 0
+/- 0
0.9 0
mug/24 0
hours 0
, 0
n=5 0
) 0
or 0
in 0
the 0
age-group 0
of 0
45-80 0
years 0
( 0
male 0
: 0
9.3 0
+/- 0
1.1 0
mug/24 0
hours 0
, 0
n=21 0
; 0
female 0
: 0
7.3 0
+/- 0
0.9 0
mug/24 0
hours 0
, 0
n=12 0
) 0
. 0

The 0
amount 0
of 0
PGE-M 0
excreted 0
decreased 0
significantly 0
after 0
administration 0
of 0
indomethacin 0
or 0
acetyl 0
salicylic 0
acid 0
in 0
therapeutic 0
doses 0
. 0

The 0
concomitant 0
reduction 0
of 0
the 0
urinary 0
excretion 0
of 0
PGE-M 0
( 0
68 0
to 0
85 0
% 0
decrease 0
) 0
and 0
prostaglandin 0
E 0
( 0
73 0
to 0
100 0
% 0
decrease 0
) 0
after 0
indomethacin 0
treatment 0
in 0
each 0
case 0
( 0
n=8 0
) 0
is 0
evidence 0
that 0
a 0
diminished 0
urinary 0
PGE-M 0
output 0
reflects 0
a 0
decrease 0
in 0
prostaglandin 0
E 0
biosynthesis 0
. 0

Increasing 0
verbal 0
responsiveness 0
in 0
parents 0
of 0
children 0
with 0
autism 0
: 0
a 0
pilot 0
study 0
. 0

Correlational 0
studies 0
have 0
revealed 0
a 0
positive 0
relationship 0
between 0
parent 0
verbal 0
responsiveness 0
and 0
language 0
outcomes 0
in 0
children 0
with 0
autism 0
. 0

We 0
investigated 0
whether 0
parents 0
of 0
young 0
children 0
on 0
the 0
autism 0
spectrum 0
could 0
learn 0
and 0
implement 0
the 0
specific 0
categories 0
of 0
verbal 0
responsiveness 0
that 0
have 0
been 0
suggested 0
to 0
facilitate 0
language 0
development 0
. 0

Parents 0
were 0
taught 0
to 0
increase 0
their 0
verbal 0
responsiveness 0
in 0
the 0
context 0
of 0
a 0
short-term 0
language 0
intervention 0
that 0
included 0
group 0
parent 0
education 0
sessions 0
, 0
as 0
well 0
as 0
individual 0
and 0
small-group 0
coaching 0
sessions 0
of 0
parent-child 0
play 0
interactions 0
. 0

Parents 0
in 0
the 0
treatment 0
group 0
increased 0
their 0
use 0
of 0
comments 0
that 0
: 0
described 0
their 0
child B-MENTAL
's 0
focus B-MENTAL
of I-MENTAL
attention I-MENTAL
; 0
interpreted 0
or 0
expanded 0
child B-MENTAL
communication I-MENTAL
acts I-MENTAL
; 0
and 0
prompted 0
child B-MENTAL
communication I-MENTAL
. 0

Preliminary 0
treatment 0
effects 0
were 0
also 0
noted 0
in 0
children B-MENTAL
's 0
prompted B-MENTAL
and 0
spontaneous B-MENTAL
communication I-MENTAL
. 0

These 0
results 0
support 0
the 0
use 0
of 0
parent-mediated 0
interventions 0
targeting 0
verbal B-MENTAL
responsiveness I-MENTAL
to 0
facilitate 0
language B-MENTAL
development I-MENTAL
and 0
communication B-MENTAL
in 0
young 0
children 0
with 0
autism 0
. 0

Prospective 0
comparison 0
of 0
the 0
value 0
of 0
brushings 0
before 0
and 0
after 0
biopsy 0
in 0
the 0
endoscopic 0
diagnosis 0
of 0
gastroesophageal 0
malignancy 0
. 0

The 0
hypothesis 0
that 0
the 0
cytodiagnostic 0
results 0
on 0
endoscopic 0
brushings 0
obtained 0
before 0
biopsy 0
may 0
be 0
superior 0
to 0
those 0
brushings 0
obtained 0
after 0
biopsy 0
, 0
but 0
with 0
the 0
accuracy 0
of 0
the 0
subsequent 0
biopsy 0
reduced 0
, 0
was 0
examined 0
for 0
300 0
consecutive 0
patients 0
, 0
including 0
256 0
with 0
esophageal 0
or 0
gastric 0
carcinomas 0
. 0

Following 0
stratification 0
by 0
site 0
and 0
endoscopic 0
appearance 0
of 0
their 0
lesions 0
, 0
the 0
patients 0
were 0
randomized 0
to 0
undergo 0
brushing 0
either 0
before 0
or 0
after 0
forceps 0
biopsy 0
. 0

The 0
accuracy 0
of 0
brushing B-OTHER
cytology I-OTHER
in 0
patients 0
with 0
carcinoma B-PHYSICAL
was 0
significantly 0
higher 0
when 0
the 0
brushing B-OTHER
was 0
performed 0
before 0
biopsy 0
than 0
after 0
biopsy 0
( 0
93.5 0
% 0
versus 0
82.6 0
% 0
; 0
P 0
less 0
than 0
.01 0
) 0
. 0

The 0
diagnostic B-OTHER
yield I-OTHER
of 0
the 0
biopsy B-OTHER
was 0
not 0
significantly 0
different 0
whether 0
the 0
lesions 0
were 0
brushed 0
before 0
or 0
after 0
the 0
biopsy 0
( 0
92.7 0
% 0
versus 0
93.2 0
% 0
; 0
P 0
less 0
than 0
.5 0
) 0
. 0

The 0
diagnostic B-OTHER
superiority I-OTHER
of 0
brushings B-OTHER
obtained 0
before 0
biopsy 0
did 0
not 0
relate 0
to 0
the 0
site 0
or 0
endoscopic 0
appearance 0
of 0
the 0
tumor 0
. 0

There 0
were 0
no 0
false-positive B-OTHER
cytologic I-OTHER
or I-OTHER
histologic I-OTHER
reports I-OTHER
. 0

For 0
all 0
256 0
carcinomas 0
, 0
the 0
cumulative B-OTHER
accuracy I-OTHER
( 0
brushing B-OTHER
cytology I-OTHER
plus I-OTHER
biopsy I-OTHER
) 0
reached 0
98.8 0
% 0
and 0
was 0
significantly 0
better 0
( 0
P 0
less 0
than 0
.001 0
) 0
than 0
that 0
of 0
biopsy B-OTHER
alone 0
( 0
93.9 0
% 0
) 0
or 0
cytology B-OTHER
alone 0
( 0
87.9 0
% 0
) 0
. 0

Apart 0
from 0
reinforcing 0
the 0
belief 0
that 0
the 0
combined B-OTHER
application I-OTHER
of I-OTHER
brushing I-OTHER
and 0
biopsy B-OTHER
is 0
mandatory 0
for 0
achieving 0
optimal 0
results 0
, 0
this 0
study 0
indicated 0
that 0
the 0
brushing 0
should 0
be 0
performed 0
before 0
the 0
biopsy 0
. 0

A 0
placebo-controlled 0
trial 0
of 0
maintenance 0
therapy 0
with 0
fluconazole 0
after 0
treatment 0
of 0
cryptococcal 0
meningitis 0
in 0
the 0
acquired 0
immunodeficiency 0
syndrome 0
. 0

California 0
Collaborative 0
Treatment 0
Group 0
. 0

BACKGROUND 0
AND 0
METHODS 0
In 0
patients 0
with 0
the 0
acquired 0
immunodeficiency 0
syndrome 0
( 0
AIDS 0
) 0
, 0
the 0
rate 0
of 0
relapse 0
after 0
primary 0
treatment 0
for 0
cryptococcal 0
meningitis 0
remains 0
high 0
. 0

We 0
conducted 0
a 0
controlled 0
, 0
double-blind 0
trial 0
to 0
evaluate 0
the 0
efficacy 0
of 0
maintenance 0
therapy 0
with 0
fluconazole 0
. 0

At 0
entry 0
into 0
the 0
study 0
, 0
all 0
participants 0
had 0
sterile 0
cultures 0
of 0
cerebrospinal 0
fluid 0
, 0
blood 0
, 0
and 0
urine 0
after 0
following 0
a 0
standardized 0
course 0
of 0
therapy 0
for 0
culture-proved 0
cryptococcal 0
meningitis 0
. 0

The 0
patients 0
were 0
randomly 0
assigned 0
to 0
take 0
either 0
fluconazole 0
or 0
placebo 0
as 0
maintenance 0
therapy 0
. 0

The 0
dose 0
of 0
fluconazole 0
was 0
100 0
mg 0
daily 0
in 0
the 0
first 0
phase 0
of 0
study 0
and 0
200 0
mg 0
daily 0
in 0
the 0
second 0
phase 0
. 0

RESULTS 0
Of 0
84 0
patients 0
initially 0
enrolled 0
, 0
16 0
( 0
19 0
percent 0
) 0
were 0
found 0
to 0
have 0
silent 0
, 0
persistent 0
infection 0
on 0
the 0
basis 0
of 0
cultures 0
that 0
became 0
positive 0
after 0
entry 0
into 0
the 0
study 0
; 0
7 0
other 0
patients 0
were 0
lost 0
to 0
follow-up 0
shortly 0
after 0
entry 0
. 0

Of 0
the 0
remaining 0
61 0
patients 0
, 0
10 0
of 0
27 0
assigned 0
to 0
placebo 0
( 0
37 0
percent 0
) 0
and 0
1 0
of 0
34 0
assigned 0
to 0
fluconazole 0
( 0
3 0
percent 0
) 0
had 0
a 0
recurrence 0
of 0
cryptococcal B-PHYSICAL
infection I-PHYSICAL
at I-PHYSICAL
any I-PHYSICAL
site I-PHYSICAL
( 0
difference 0
in 0
risk 0
, 0
34 0
percent 0
; 0
95 0
percent 0
confidence 0
interval 0
, 0
15 0
to 0
53 0
) 0
. 0

Of 0
the 0
11 0
recurrent 0
infections 0
, 0
7 0
were 0
detected 0
in 0
urine 0
obtained 0
after 0
prostatic 0
massage 0
. 0

There 0
were 0
four 0
recurrent B-PHYSICAL
meningeal I-PHYSICAL
infections I-PHYSICAL
in 0
the 0
patients 0
taking 0
placebo 0
, 0
but 0
none 0
in 0
those 0
taking 0
fluconazole 0
( 0
mean 0
duration 0
of 0
follow-up 0
, 0
164 0
days 0
) 0
( 0
P 0
= 0
0.03 0
) 0
. 0

In 0
multivariate 0
analyses 0
, 0
the 0
best 0
predictors 0
of 0
recurrence-free B-MORTALITY
survival I-MORTALITY
were 0
fluconazole 0
treatment 0
( 0
P 0
= 0
0.02 0
; 0
relative 0
hazard 0
, 0
13.2 0
) 0
, 0
a 0
lower 0
serum 0
cryptococcal-antigen 0
titer 0
( 0
P 0
= 0
0.05 0
; 0
relative 0
hazard 0
, 0
1.2 0
) 0
, 0
and 0
more 0
prolonged 0
primary 0
therapy 0
with 0
flucytosine 0
( 0
P 0
= 0
0.09 0
; 0
relative 0
hazard 0
, 0
1.1 0
) 0
. 0

Survival B-MORTALITY
and 0
toxicity B-OTHER
were 0
similar 0
in 0
the 0
two 0
maintenance-treatment 0
groups 0
. 0

CONCLUSIONS 0
In 0
patients 0
with 0
AIDS 0
, 0
silent 0
persistent 0
infection 0
is 0
common 0
after 0
clinically 0
successful 0
treatment 0
for 0
cryptococcal 0
meningitis 0
. 0

Maintenance 0
therapy 0
with 0
fluconazole 0
is 0
highly 0
effective 0
in 0
preventing 0
recurrent 0
cryptococcal 0
infection 0
. 0

Efficacy 0
of 0
porcine 0
secretin 0
in 0
children 0
with 0
autism 0
and 0
pervasive 0
developmental 0
disorder 0
. 0

Secretin 0
, 0
a 0
gastrointestinal 0
( 0
GI 0
) 0
hormone 0
, 0
was 0
reported 0
in 0
a 0
preliminary 0
study 0
to 0
improve 0
language B-MENTAL
and 0
behavior B-MENTAL
in 0
children 0
with 0
autism/pervasive 0
developmental 0
disorder 0
( 0
PDD 0
) 0
and 0
chronic 0
diarrhea 0
. 0

To 0
determine 0
the 0
efficacy 0
of 0
secretin 0
, 0
we 0
completed 0
a 0
double-blind 0
, 0
placebo-controlled 0
, 0
crossover 0
( 0
3 0
weeks 0
) 0
study 0
in 0
children 0
with 0
autism/PDD 0
and 0
various 0
GI 0
conditions 0
using 0
a 0
single 0
dose 0
of 0
intravenous 0
porcine 0
secretin 0
. 0

Children 0
with 0
chronic 0
, 0
active 0
diarrhea 0
showed 0
a 0
reduction 0
in 0
aberrant B-MENTAL
behaviors I-MENTAL
when 0
treated 0
with 0
the 0
secretin 0
but 0
not 0
when 0
treated 0
with 0
the 0
placebo 0
. 0

Children 0
with 0
no 0
GI 0
problems 0
are 0
unaffected 0
by 0
either 0
secretin 0
or 0
placebo 0
. 0

The 0
improvement 0
seen 0
with 0
secretin 0
in 0
children 0
with 0
autism/PDD 0
and 0
chronic 0
diarrhea 0
suggests 0
that 0
there 0
may 0
be 0
a 0
subtype 0
of 0
children 0
with 0
autism/PDD 0
who 0
respond 0
to 0
secretin 0
. 0

A 0
randomized 0
, 0
double-blind 0
, 0
phase 0
II 0
study 0
of 0
two 0
doses 0
of 0
pemetrexed 0
as 0
first-line 0
chemotherapy 0
for 0
advanced 0
breast 0
cancer 0
. 0

PURPOSE 0
Pemetrexed 0
has 0
shown 0
varied 0
response 0
rates 0
in 0
advanced 0
breast 0
cancer 0
. 0

This 0
randomized 0
, 0
double-blind 0
, 0
phase 0
II 0
study 0
was 0
conducted 0
to 0
assess 0
the 0
efficacy 0
and 0
safety B-OTHER
of 0
two 0
doses 0
of 0
pemetrexed 0
in 0
a 0
homogeneous 0
population 0
. 0

A 0
secondary 0
objective 0
was 0
to 0
identify 0
molecular 0
biomarkers 0
correlating 0
with 0
response 0
and 0
toxicity B-ADVERSE-EFFECTS
. 0

EXPERIMENTAL 0
DESIGN 0
Patients 0
with 0
newly 0
diagnosed 0
metastatic 0
breast 0
cancer 0
or 0
locally 0
recurrent 0
breast 0
cancer 0
received 0
600 0
mg/m 0
( 0
2 0
) 0
( 0
P600 0
arm 0
) 0
or 0
900 0
mg/m 0
( 0
2 0
) 0
( 0
P900 0
arm 0
) 0
of 0
pemetrexed 0
on 0
day 0
1 0
of 0
a 0
21-day 0
cycle 0
. 0

All 0
patients 0
received 0
folic 0
acid 0
and 0
vitamin 0
B 0
( 0
12 0
) 0
supplementation 0
. 0

RESULTS 0
The 0
P600 0
( 0
47 0
patients 0
) 0
and 0
P900 0
( 0
45 0
patients 0
) 0
arms 0
had 0
response 0
rates B-OTHER
of 0
17.0 0
% 0
( 0
95 0
% 0
confidence 0
interval 0
, 0
7.7-30.8 0
% 0
) 0
and 0
15.6 0
% 0
( 0
95 0
% 0
confidence 0
interval 0
, 0
6.5-29.5 0
% 0
) 0
with 0
approximately 0
50 0
% 0
stable 0
disease 0
per 0
arm 0
, 0
median 0
progression-free B-MORTALITY
survival I-MORTALITY
of 0
4.2 0
and 0
4.1 0
months 0
, 0
and 0
median 0
times B-PHYSICAL
to I-PHYSICAL
tumor I-PHYSICAL
progression I-PHYSICAL
of 0
4.2 0
and 0
4.6 0
months 0
, 0
respectively 0
. 0

Both 0
arms 0
exhibited 0
minimal B-ADVERSE-EFFECTS
toxicity I-ADVERSE-EFFECTS
( 0
grade 0
3/4 0
neutropenia B-ADVERSE-EFFECTS
< 0
20 0
% 0
, 0
leukopenia B-ADVERSE-EFFECTS
< 0
9 0
% 0
, 0
and 0
other 0
toxicities B-ADVERSE-EFFECTS
< 0
5 0
% 0
) 0
. 0

Tumor 0
samples 0
from 0
49 0
patients 0
were 0
assessed 0
for 0
the 0
expression 0
levels 0
of 0
12 0
pemetrexed-related 0
genes 0
. 0

Folylpolyglutamate 0
synthetase 0
and 0
thymidine 0
phosphorylase 0
correlated 0
with 0
efficacy 0
. 0

Best B-OTHER
response 0
rates B-OTHER
and 0
median 0
time B-PHYSICAL
to B-PHYSICAL
tumor B-PHYSICAL
progression B-PHYSICAL
for 0
high 0
versus 0
low 0
thymidine 0
phosphorylase 0
expression 0
were 0
27.6 0
% 0
versus 0
6.3 0
% 0
( 0
P 0
= 0
0.023 0
) 0
and 0
5.4 0
versus 0
1.9 0
months 0
( 0
P 0
= 0
0.076 0
) 0
, 0
and 0
for 0
folylpolyglutamate 0
synthetase 0
were 0
37.5 0
% 0
versus 0
10.0 0
% 0
( 0
P 0
= 0
0.115 0
) 0
and 0
8.6 0
versus 0
3.0 0
months 0
( 0
P 0
= 0
0.019 0
) 0
, 0
respectively 0
. 0

gamma-Glutamyl 0
hydrolase 0
expression 0
correlated 0
with 0
grade 0
3/4 0

The 0
effect 0
of 0
acupressure 0
at 0
the 0
extra 0
1 0
point 0
on 0
subjective 0
and 0
autonomic B-MENTAL
responses I-MENTAL
to 0
needle 0
insertion 0
. 0

BACKGROUND 0
Premedication 0
with 0
sedatives 0
can 0
decrease 0
the 0
discomfort B-MENTAL
associated 0
with 0
invasive 0
anesthetic 0
procedures 0
. 0

Some 0
researchers 0
have 0
shown 0
that 0
acupressure 0
on 0
the 0
acupuncture 0
extra 0
1 0
point 0
is 0
effective 0
for 0
sedation 0
. 0

We 0
investigated 0
whether 0
acupressure 0
on 0
the 0
extra 0
1 0
point 0
could 0
alleviate 0
the 0
pain B-PAIN
of 0
needle 0
insertion 0
. 0

METHODS 0
We 0
investigated 0
the 0
effect 0
of 0
acupressure 0
at 0
the 0
extra 0
1 0
point 0
or 0
a 0
sham 0
point 0
on 0
needle 0
insertion 0
using 0
verbal B-PAIN
rating I-PAIN
scale I-PAIN
( I-PAIN
VRS I-PAIN
) I-PAIN
pain I-PAIN
scores 0
and 0
heart B-PHYSICAL
rate I-PHYSICAL
variability 0
( B-PHYSICAL
HRV I-PHYSICAL
) B-PHYSICAL
. 0

Twenty-two 0
healthy 0
female 0
volunteers 0
were 0
randomly 0
allocated 0
to 0
two 0
groups 0
: 0
the 0
extra 0
1 0
group 0
received 0
acupressure 0
at 0
the 0
extra 0
1 0
point 0
, 0
and 0
the 0
sham 0
group 0
received 0
acupressure 0
at 0
a 0
sham 0
point 0
. 0

After 0
starting 0
the 0
electrocardiogram 0
record 0
, 0
a 0
27-gauge 0
needle 0
was 0
inserted 0
into 0
the 0
skin 0
of 0
a 0
forearm 0
. 0

Thereafter 0
, 0
another 0
needle 0
was 0
inserted 0
into 0
the 0
skin 0
of 0
the 0
other 0
forearm 0
during 0
acupressure 0
. 0

RESULTS 0
Acupressure 0
at 0
the 0
extra 0
1 0
point 0
significantly 0
reduced 0
the 0
VRS B-OTHER
, 0
but 0
acupressure 0
at 0
the 0
sham 0
increased 0
the 0
VRS B-OTHER
. 0

Acupressure 0
at 0
the 0
extra 0
1 0
significantly 0
reduced 0
the 0
low B-PHYSICAL
frequency/high I-PHYSICAL
frequency 0
ratio 0
of B-PHYSICAL
HRV I-PHYSICAL
responding I-PHYSICAL
to I-PHYSICAL
needle B-PHYSICAL
insertion I-PHYSICAL
. 0

CONCLUSIONS 0
Acupressure 0
at 0
the 0
extra 0
1 0
point 0
significantly 0
reduced 0

Immunogenicity B-PHYSICAL
and 0
reactogenicity B-PHYSICAL
of 0
a 0
group 0
C 0
meningococcal 0
conjugate 0
vaccine 0
compared 0
with 0
a 0
group 0
A+C 0
meningococcal 0
polysaccharide 0
vaccine 0
in 0
adolescents 0
in 0
a 0
randomised 0
observer-blind 0
controlled 0
trial 0
. 0

This 0
study 0
evaluated 0
the 0
immunogenicity B-PHYSICAL
and 0
reactogenicity B-PHYSICAL
of 0
a 0
group 0
C 0
meningococcal 0
conjugate 0
vaccine 0
( 0
MenC 0
) 0
compared 0
with 0
a 0
group 0
A+C 0
meningococcal 0
polysaccharide 0
vaccine 0
( 0
MenPS 0
) 0
in 0
healthy 0
adolescents 0
. 0

Subjects 0
were 0
randomised 0
to 0
receive 0
one 0
dose 0
of 0
either 0
MenC 0
( 0
n=92 0
) 0
or 0
MenPS 0
( 0
n=90 0
) 0
. 0

Group 0
C 0
meningococcal B-PHYSICAL
IgG I-PHYSICAL
antibody I-PHYSICAL
concentrations I-PHYSICAL
and I-PHYSICAL
bactericidal I-PHYSICAL
titres I-PHYSICAL
were 0
higher 0
in 0
the 0
MenC 0
group 0
than 0
the 0
MenPS 0
group 0
at 0
1 0
month 0
( 0
22.8 0
U/ml 0
vs 0
4.0 0
U/ml 0
, 0
p 0
< 0
0.001 0
, 0
and 0
87 0
vs 0
20 0
, 0
p 0
< 0
0.001 0
, 0
respectively 0
) 0
and 0
12 0
months 0
( 0
6.1 0
U/ml 0
vs 0
3.0 0
U/ml 0
, 0
p 0
< 0
0.001 0
, 0
and 0
81.3 0
vs 0
20.2 0
, 0
p 0
< 0
0.001 0
, 0
respectively 0
) 0
. 0

No 0
differences 0
in 0
post B-PHYSICAL
immunisation I-PHYSICAL
reaction I-PHYSICAL
rates I-PHYSICAL
were 0
noted 0
between 0
the 0
two 0
vaccinated 0
groups 0
. 0

This 0
study 0
demonstrated 0
the 0
safety 0
and 0
enhanced 0
immunogenicity B-PHYSICAL
of 0
the 0
candidate 0
meningococcal 0
conjugate 0
vaccine 0
as 0
compared 0
with 0
the 0
licensed 0
polysaccharide 0
vaccine 0
in 0
adolescents 0
. 0

Clinical 0
pathway 0
for 0
fractured 0
neck 0
of 0
femur 0
: 0
a 0
prospective 0
, 0
controlled 0
study 0
. 0

OBJECTIVE 0
To 0
assess 0
outcomes 0
of 0
using 0
a 0
clinical 0
pathway 0
for 0
managing 0
patients 0
with 0
fractured 0
neck 0
of 0
femur 0
. 0

DESIGN 0
Prospective 0
, 0
pseudorandomised 0
, 0
controlled 0
trial 0
. 0

SETTING 0
St 0
Vincent 0
's 0
Hospital 0
, 0
Melbourne 0
, 0
Victoria 0
( 0
a 0
tertiary 0
referral 0
, 0
university 0
teaching 0
hospital 0
) 0
, 0
1 0
October 0
1997 0
to 0
30 0
November 0
1998 0
. 0

PARTICIPANTS 0
111 0
patients 0
( 0
80 0
women 0
and 0
31 0
men 0
; 0
mean 0
age 0
, 0
81 0
years 0
) 0
admitted 0
via 0
the 0
emergency 0
department 0
with 0
a 0
primary 0
diagnosis 0
of 0
fractured 0
neck 0
of 0
femur 0
. 0

INTERVENTIONS 0
Management 0
guided 0
by 0
a 0
clinical 0
pathway 0
( 0
55 0
patients 0
) 0
or 0
established 0
standard 0
of 0
care 0
( 0
control 0
group 0
, 0
56 0
patients 0
) 0
. 0

MAIN 0
OUTCOME 0
MEASURES 0
Timing B-OTHER
of I-OTHER
referrals I-OTHER
and I-OTHER
discharge I-OTHER
planning I-OTHER
; 0
total 0
length B-OTHER
of B-OTHER
stay B-OTHER
; 0
and 0
complication B-ADVERSE-EFFECTS
and 0
readmission B-OTHER
rates I-OTHER

Dose-response 0
characteristics 0
during 0
long-term 0
inhalation 0
of 0
nitric 0
oxide 0
in 0
patients 0
with 0
severe 0
acute 0
respiratory 0
distress 0
syndrome 0
: 0
a 0
prospective 0
, 0
randomized 0
, 0
controlled 0
study 0
. 0

Inhaled 0
nitric 0
oxide 0
( 0
NO 0
) 0
improves 0
systemic 0
oxygenation 0
( 0
PaO2/FIO2 0
) 0
in 0
adult 0
patients 0
with 0
acute 0
respiratory 0
distress 0
syndrome 0
( 0
ARDS 0
) 0
. 0

However 0
, 0
individual 0
response 0
varies 0
, 0
and 0
previous 0
trials 0
demonstrated 0
no 0
outcome 0
benefit 0
. 0

This 0
prospective 0
, 0
randomized 0
study 0
in 0
40 0
ARDS 0
patients 0
analyzed 0
dose-response B-PHYSICAL
( I-PHYSICAL
DR I-PHYSICAL
) I-PHYSICAL
characteristics I-PHYSICAL
during 0
long-term 0
inhaled 0
NO 0
. 0

Patients 0
were 0
randomized 0
for 0
conventional 0
therapy 0
( 0
control 0
) 0
or 0
continuous 0
treatment 0
with 0
10 0
parts 0
per 0
million 0
( 0
ppm 0
) 0
inhaled 0
NO 0
until 0
weaning 0
was 0
initiated 0
. 0

We 0
measured 0
DR B-OTHER
curves I-OTHER
of I-OTHER
PaO2/FIO2 I-OTHER
versus I-OTHER
the I-OTHER
inhaled I-OTHER
NO I-OTHER
dose I-OTHER
at 0
regular 0
intervals 0
. 0

Before 0
treatment 0
( 0
Day 0
0 0
) 0
, 0
peak 0
improvement 0
in 0
PaO2/FIO2 B-OTHER
was 0
achieved 0
at 0
10 0
ppm 0
for 0
both 0
control 0
and 0
NO-treated 0
patients 0
. 0

After 0
4 0
days 0
, 0
the 0
DR 0
curve 0
of 0
the 0
NO-treated B-OTHER
patients I-OTHER
was 0
left 0
shifted 0
with 0
a 0
peak 0
response 0
at 0
1 0
ppm 0
. 0

At 0
higher 0
doses 0
( 0
10 0
and 0
100 0
ppm 0
) 0
, 0
oxygenation B-PHYSICAL
deteriorated I-PHYSICAL
, 0
and 0
the 0
response 0
to 0
inhaled 0
NO 0
disappeared 0
in 0
several 0
patients 0
. 0

This 0
effect 0
was 0
not 0
observed 0
in 0
the 0
control 0
group 0
. 0

There 0
was 0
no 0
effect 0
of 0
inhaled 0
NO 0
on 0
duration 0
of 0
mechanical B-OTHER
ventilation I-OTHER
or 0
stay B-OTHER
at I-OTHER
the I-OTHER
intensive I-OTHER
care I-OTHER
unit I-OTHER
. 0

In 0
conclusion 0
, 0
long-term 0
inhaled 0
NO 0
with 0
constant 0
doses 0
of 0
10 0
ppm 0
leads 0
to 0
enhanced 0
sensitivity 0
after 0
several 0
days 0
and 0
does 0
do 0
not 0
allow 0
reduction 0
of 0
ventilation 0
parameters 0
. 0

Hence 0
, 0
previous 0
trials 0
on 0
therapy 0
with 0
inhaled 0
NO 0
in 0
ARDS 0
should 0
be 0
carefully 0
interpreted 0
, 0
as 0
they 0
used 0
constant 0
NO 0
concentrations 0
, 0
which 0
may 0
have 0
become 0
overdoses 0
leading 0
to 0
deterioration 0
of 0
oxygenation B-PHYSICAL
after 0
several 0
days 0
. 0

The 0
lunar 0
stent 0
characteristics 0
and 0
clinical 0
results 0
. 0

One 0
of 0
the 0
frequent 0
long-term 0
complications 0
after 0
stent 0
implantation 0
is 0
restenosis 0
due 0
to 0
the 0
building 0
up 0
of 0
a 0
neointima 0
within 0
the 0
artery 0
, 0
as 0
well 0
as 0
endovascular 0
hyperplasia 0
( 0
tissue 0
growth 0
) 0
. 0

The 0
interesting 0
feature 0
of 0
the 0
Lunar 0
stent 0
from 0
Inflow 0
Dynamics 0
is 0
that 0
it 0
is 0
coated 0
with 0
a 0
layer 0
of 0
iridium 0
oxide 0
. 0

The 0
iridium 0
oxide 0
coating 0
is 0
believed 0
to 0
reduce 0
restenosis B-PHYSICAL
by 0
decreasing 0
the 0
inflammatory B-PHYSICAL
response I-PHYSICAL
to 0
the 0
stent 0
via 0
its 0
antioxidant 0
action 0
. 0

The 0
MOONLIGHT 0
( 0
Multicenter 0
Objective 0
ObservatioNal 0
Lunar 0
Iridiumoxide 0
intimal 0
GrowtH 0
Trial 0
) 0
study 0
was 0
carried 0
out 0
to 0
evaluate 0
the 0
immediate 0
outcome 0
and 0
long-term 0
angiographic 0
success 0
after 0
implantation 0
of 0
Lunar 0
stents 0
. 0

Between 0
March 0
2001 0
and 0
November 0
2001 0
, 0
87 0
patients 0
with 0
99 0
lesions 0
were 0
enrolled 0
in 0
this 0
study 0
and 0
were 0
treated 0
with 0
12 0
and 0
16 0
mm 0
long 0
iridium-oxide 0
coated 0
Lunar 0
stents 0
. 0

Delivery 0
of 0
the 0
Lunar 0
stent 0
was 0
successful 0
in 0
most 0
lesions 0
and 0
the 0
optimal 0
radiopacity 0
facilitated 0
optimal 0
stent B-PHYSICAL
positioning 0
with 0
optimal 0
immediate 0
clinical 0
and 0
angiographic 0
results 0
is 0
an 0
unselected 0
patient 0
and 0
lesion 0
population 0
. 0

Preliminary 0
clinical 0
and 0
angiographic 0
follow-up 0
show 0
a 0
low 0
rate 0
of 0
cardiac B-PHYSICAL
events I-PHYSICAL
at 0
6 0
months 0
( 0
16.1 0
% 0
MACE 0
) 0
and 0
a 0
moderate 0
hyperplastic B-PHYSICAL
response 0
. 0

Noradrenergic 0
moderation B-OTHER
of 0
working 0
memory 0
impairments 0
in 0
adults 0
with 0
autism 0
spectrum 0
disorder 0
. 0

In 0
addition 0
to 0
having 0
difficulties 0
with 0
social 0
communications 0
, 0
individuals 0
with 0
an 0
autism 0
spectrum 0
disorder 0
( 0
ASD 0
) 0
often 0
also 0
experience 0
impairment 0
in 0
higher-order B-MENTAL
, I-MENTAL
executive I-MENTAL
skills I-MENTAL
. 0

The 0
present 0
study 0
examined 0
the 0
effects 0
of 0
pharmacological 0
modulation 0
of 0
the 0
norepinephrine 0
system 0
on 0
the 0
severity 0
of 0
such 0
impairments 0
. 0

A 0
sample 0
of 0
14 0
high-functioning 0
adults 0
with 0
ASD 0
and 0
a 0
demographically-matched 0
comparison 0
group 0
of 0
13 0
typically 0
developing 0
individuals 0
participated 0
. 0

An 0
AX 0
continuous 0
performance 0
test 0
( 0
AX-CPT 0
) 0
was 0
used 0
to 0
evaluate 0
working 0
memory 0
and 0
inhibitory 0
control 0
. 0

AX-CPT B-MENTAL
performance I-MENTAL
was 0
assessed 0
following 0
administration 0
of 0
a 0
single 0
dose 0
of 0
propranolol 0
( 0
a 0
beta 0
adrenergic 0
antagonist 0
) 0
and 0
following 0
placebo 0
( 0
sugar 0
pill 0
) 0
administration 0
. 0

Individuals 0
with 0
ASD 0
performed B-MENTAL
more 0
poorly 0
than 0
non-ASD 0
individuals 0
in 0
the 0
working 0
memory 0
condition 0
( 0
BX 0
trials 0
) 0
. 0

Importantly 0
, 0
administration 0
of 0
propranolol 0
attenuated B-MENTAL
this I-MENTAL
impairment I-MENTAL
, 0
with 0
the 0
ASD 0
group 0
performing B-MENTAL
significantly 0
better 0
in 0
the 0
propranolol 0
condition 0
than 0
the 0
placebo 0
condition 0
. 0

Working B-MENTAL
memory I-MENTAL
performance I-MENTAL
of 0
the 0
non-ASD 0
group 0
was 0
unaffected 0
by 0
propranolol/placebo 0
administration 0
. 0

No 0
group 0
or 0
medication 0
effects 0
were 0
observed 0
for 0
the 0
inhibition B-MENTAL
condition I-MENTAL
( 0
AY 0
trials 0
) 0
. 0

The 0
present 0
findings 0
suggest 0
that 0
norepinephrine 0
may 0
play 0
a 0
role 0
in 0
some 0
, 0
but 0
not 0
necessarily 0
all 0
, 0
cognitive B-MENTAL
impairments I-MENTAL
associated 0
with 0
ASD 0
. 0

Additional 0
research 0
is 0
needed 0
to 0
fully 0
understand 0
whether 0
this 0
role 0
is 0
primarily 0
causal 0
or 0
compensatory 0
in 0
nature 0
. 0

Exercise 0
for 0
methamphetamine 0
dependence 0
: 0
rationale 0
, 0
design 0
, 0
and 0
methodology 0
. 0

BACKGROUND 0
Effective 0
pharmacotherapies 0
to 0
treat 0
methamphetamine 0
( 0
MA 0
) 0
dependence 0
have 0
not 0
been 0
identified 0
, 0
and 0
behavioral 0
therapies 0
are 0
marginally 0
effective 0
. 0

Based 0
on 0
behavioral 0
studies 0
demonstrating 0
the 0
potential 0
efficacy 0
of 0
aerobic 0
exercise 0
for 0
improving 0
depressive B-MENTAL
symptoms I-MENTAL
, 0
anxiety B-MENTAL
, 0
cognitive B-MENTAL
deficits I-MENTAL
, 0
and 0

First-line 0
cisplatin 0
with 0
docetaxel 0
or 0
vinorelbine 0
in 0
patients 0
with 0
advanced 0
non-small-cell 0
lung 0
cancer 0
: 0
a 0
quality 0
of 0
life 0
directed 0
phase 0
II 0
randomized 0
trial 0
of 0
Gruppo 0
Oncologico 0
Italia 0
Meridionale 0
. 0

BACKGROUND 0
Quality 0
of 0
life 0
( B-MENTAL
QoL I-MENTAL
) I-MENTAL
has 0
gained 0
greater 0
importance 0
in 0
the 0
management 0
of 0
metastatic 0
non-small-cell 0
lung 0
cancer 0
due 0
to 0
the 0
palliative 0
nature 0
of 0
treatment 0
. 0

Docetaxel 0
( 0
DCT 0
) 0
and 0
cisplatin 0
( 0
CDDP 0
) 0
doublet 0
has 0
been 0
reported 0
to 0
be 0
associated 0
to 0
a 0
better 0
QoL 0
than 0
the 0
weekly 0
vinorelbine 0
( 0
VNR 0
) 0
and 0
CDDP 0
regimen 0
. 0

Recently 0
a 0
newer 0
more 0
tolerated 0
schedule 0
of 0
the 0
VNR/CDDP 0
regimen 0
has 0
been 0
published 0
and 0
is 0
widely 0
employed 0
in 0
medical 0
practice 0
. 0

The 0
impact 0
of 0
these 0
regimens 0
on 0
patients 0
' 0
QoL 0
as 0
well 0
as 0
symptoms B-PHYSICAL
control I-PHYSICAL
and 0
type 0
and 0
grading 0
chemo-related 0
side-effects B-PHYSICAL
has 0
been 0
compared 0
prospectically 0
. 0

METHODS 0
Patients 0
received 0
CDDP 0
75 0
mg/m 0
( 0
2 0
) 0
plus 0
DCT 0
75 0
mg/m 0
( 0
2 0
) 0
on 0
day 0
1 0
every 0
weeks 0
( 0
arm 0
A 0
) 0
or 0
CDDP 0
80 0
mg/m 0
( 0
2 0
) 0
on 0
day 0
1 0
plus 0
VNR 0
30 0
mg/m 0
( 0
2 0
) 0
day 0
1 0
and 0
8 0
every 0
3 0
weeks 0
( 0
arm 0
B 0
) 0
. 0

G-CSF 0
and/or 0
EPO 0
were 0
employed 0
as 0
needed 0
. 0

Health-related B-MENTAL
QoL I-MENTAL
was 0
assessed 0
at 0
entry 0
and 0
after 0
every 0
cycle 0
by 0
the 0
EORTC-QLQ-C30 0
and 0
LC13 B-MENTAL
questionnaires I-MENTAL
, 0
toxicity B-PHYSICAL
by 0
the 0
NCI-NCCN 0
CTC 0
vs 0
2 0
, 0
and 0
intent-to-treat 0
objective B-PHYSICAL
response I-PHYSICAL
by 0
the 0
Recist 0
criteria 0
. 0

RESULTS 0
The 0
QoL B-PHYSICAL
questionnaires I-PHYSICAL
were 0
completed 0
by 0
37 0
pts 0
( 0
88 0
% 0
) 0
in 0
the 0
DCT/CDDP 0
arm 0
and 0
39 0
pts 0
( 0
87 0
% 0
) 0
in 0
the 0
VNR/CDDP 0
one 0
. 0

Baseline 0
mean 0
scores 0
and 0
rates 0
at 0
which 0
pts 0
failed 0
to 0
complete 0
QoL 0
assessment 0
were 0
similar 0
in 0
the 0
two 0
arms 0
. 0

Global B-MENTAL
health I-MENTAL
status I-MENTAL
of 0
the 0
EORTC B-PHYSICAL
QLQ-C30 I-PHYSICAL
scale I-PHYSICAL
and 0
specific 0
symptoms 0
control 0
( 0
LC13 0
module 0
) 0
improved 0
during 0
treatment 0
without 0
any 0
statistically 0
significant 0
difference 0
between 0
the 0
two 0
arms 0
. 0

Emotional B-MENTAL
functioning I-MENTAL
remained 0
stable 0
in 0
both 0
groups 0
during 0
treatment 0
, 0
whereas 0
physical B-MENTAL
and 0
role B-MENTAL
improved 0
slightly 0
. 0

In 0
the 0
DCT/CDDP 0
arm 0
14 0
pts 0
( 0
33 0
% 0
; 0
95 0
% 0
CL 0
24-40 0
% 0
) 0
had 0
PR 0
, 0
and 0
10 0
( 0
24 0
% 0
) 0
SD 0
for 0
a 0
57 0
% 0
TGCR 0
. 0

In 0
the 0
VNR/CDDP 0
arm 0
12 0
pts 0
( 0
27 0
% 0
) 0
achieved 0
PR B-PHYSICAL
, 0
18 0
( 0
41 0
% 0
) 0
SD 0
a 0
68 0
% 0
TGCR 0
. 0

Differences 0
were 0
not 0
statistically 0
significant 0
. 0

Median 0
time-to-progression B-PHYSICAL
was 0
4.2 0
months 0
in 0
the 0
DCT/CDDP 0
arm 0
and 0
4.5 0
months 0
in 0
the 0
VNR/CDDP 0
one 0
, 0
and 0
median 0
overall B-MORTALITY
survival I-MORTALITY
was 0
12.1 0
( 0
range 0
1-26+ 0
months 0
) 0
and 0
12.5 0
months 0
( 0
range 0
1-28+ 0
months 0
) 0
for 0
DCT/CDDP 0
and 0
VNR/CDDP 0
arms 0
, 0
respectively 0
. 0

Febrile B-PHYSICAL
neutropenia I-PHYSICAL
rate I-PHYSICAL
was 0
higher 0
in 0
the 0
VNR/CDDP 0
arm 0
( 0
p=0.02 0
) 0
as 0
well 0
as 0
G3-4 0
anemia B-PHYSICAL
( 0
p=0.005 0
) 0
and 0
G-CSF/EPO 0
use 0
( 0
p=0.019 0
) 0
. 0

CONCLUSIONS 0
Global B-PHYSICAL
and I-PHYSICAL
specific I-PHYSICAL
health-related I-PHYSICAL
QoL I-PHYSICAL
data 0
similar 0
in 0
both 0
treatment 0
groups 0
with 0
no 0
statistically 0
significant 0
difference 0
. 0

Efficacy 0
measures B-OTHER
, 0
overall 0
response 0
rate B-PHYSICAL
, 0
time-to-progression B-PHYSICAL
and 0
overall B-MORTALITY
survival I-MORTALITY
were 0
equivalent 0
in 0
both 0
arms 0
. 0

However 0
, 0
severe B-PHYSICAL
anemia I-PHYSICAL
and 0
febrile B-PHYSICAL
neutropenia I-PHYSICAL
are 0
statistically 0
more 0
frequent 0
in 0
the 0
VNR/CDDP 0
arm 0
than 0
in 0
the 0
DCT/CDDP 0
one 0
. 0

These 0
data 0
should 0
be 0
considered 0
in 0
treatment 0
decision-making 0
for 0
pts 0
with 0
advanced 0
non-small-cell 0
lung 0
cancer 0
and 0
for 0
the 0
design 0
of 0
future 0
trials 0
with 0
chemotherapy 0
plus 0
biologics 0
. 0

Pharmacogenetic 0
interaction 0
analysis 0
for 0
the 0
efficacy 0
of 0
systemic 0
treatment 0
in 0
metastatic 0
colorectal 0
cancer 0
. 0

BACKGROUND 0
Pharmacogenetic 0
markers 0
related 0
to 0
drug 0
metabolism 0
and 0
mechanisms 0
of 0
action 0
could 0
help 0
to 0
better 0
select 0
patients 0
with 0
metastatic 0
colorectal 0
cancer 0
( 0
mCRC 0
) 0
for 0
treatment 0
. 0

Genetic 0
interaction 0
analysis 0
is 0
used 0
as 0
a 0
rational 0
tool 0
to 0
study 0
the 0
contribution 0
of 0
polygenic 0
variation 0
in 0
relation 0
to 0
drug 0
response 0
. 0

PATIENTS 0
AND 0
METHODS 0
A 0
selection 0
of 0
17 0
polymorphisms 0
in 0
genes 0
encoding 0
drug 0
targets 0
, 0
pathway B-PHYSICAL
molecules I-PHYSICAL
and 0
detoxification B-PHYSICAL
enzymes I-PHYSICAL
was 0
analyzed 0
in 0
279 0
previously 0
untreated 0
mCRC 0
patients 0
treated 0
with 0
capecitabine 0
, 0
oxaliplatin 0
and 0
bevacizumab 0
( 0
CAPOX-B 0
) 0
. 0

Multifactor 0
dimensionality 0
reduction 0
analysis 0
was 0
used 0
to 0
identify 0
a 0
genetic B-MORTALITY
interaction 0
profile B-MORTALITY
for I-MORTALITY
progression-free I-MORTALITY
survival I-MORTALITY
( I-MORTALITY
PFS I-MORTALITY
) B-MORTALITY
. 0

RESULTS 0
Median 0
PFS B-MORTALITY
was 0
10.9 0
[ 0
95 0
% 0
confidence 0
interval 0
( 0
CI 0
) 0
9.4-12.4 0
] 0
months 0
. 0

A 0
genetic B-PHYSICAL
interaction 0
profile B-PHYSICAL
consisting 0
of 0
the 0
TYMS 0
enhancer 0
region 0
and 0
VEGF 0
+405G 0
> 0
C 0
polymorphisms 0
was 0
significantly 0
associated 0
with 0
PFS 0
. 0

Median 0
PFS B-MORTALITY
was 0
13.3 0
( 0
95 0
% 0
CI 0
11.4-15.3 0
) 0
and 0
9.7 0
( 0
95 0
% 0
CI 0
7.6-11.8 0
) 0
months 0
for 0
the 0
beneficial 0
and 0
unfavorable 0
genetic B-PHYSICAL
profiles I-PHYSICAL
, 0
respectively 0
, 0
corresponding 0
to 0
a 0
hazards 0
ratio 0
for 0

Granulocyte-macrophage 0
colony-stimulating 0
factor 0
treatment 0
before 0
doxorubicin 0
and 0
cyclophosphamide 0
chemotherapy 0
priming 0
in 0
women 0
with 0
early-stage 0
breast 0
cancer 0
. 0

PURPOSE 0
To 0
determine 0
if 0
inhibition 0
of 0
stem-cell 0
activity 0
induced 0
by 0
granulocyte-macrophage 0
colony-stimulating 0
factor 0
( 0
[ 0
GM-CSF 0
] 0
; 0
Sargramostim 0
; 0
Immunex 0
Corporation 0
, 0
Seattle 0
, 0
WA 0
) 0
withdrawal 0
or 0
priming 0
protects 0
hematopoietic 0
stem 0
cells 0
from 0
the 0
cytotoxic 0
effects 0
of 0
adjuvant 0
chemotherapy 0
for 0
early-stage 0
breast 0
cancer 0
. 0

PATIENTS 0
AND 0
METHODS 0
Serial 0
blood 0
counts 0
were 0
performed 0
in 0
20 0
women 0
with 0
early-stage 0
breast 0
cancer 0
receiving 0
four 0
courses 0
of 0
cyclophosphamide 0
and 0
doxorubicin 0
chemotherapy 0
. 0

By 0
a 0
double-blind 0
, 0
placebo-controlled 0
, 0
balanced 0
randomization 0
, 0
subjects 0
received 0
GM-CSF 0
priming 0
on 0
days 0
5 0
to 0
1 0
for 0
courses 0
1 0
and 0
3 0
or 0
courses 0
2 0
and 0
4 0
. 0

RESULTS 0
Compared 0
with 0
before 0
priming 0
, 0
after 0
priming 0
the 0
times B-PHYSICAL
to I-PHYSICAL
neutrophil I-PHYSICAL
nadir I-PHYSICAL
( 0
12.8 0
+/- 0
2.5 0
days 0
v 0
14.8 0
+/- 0
1.5 0
days 0
, 0
respectively 0
; 0
P 0
=.0001 0
) 0
and 0
platelet B-PHYSICAL
nadir I-PHYSICAL
( 0
mean 0
+/- 0
SD 0
, 0
10.1 0
+/- 0
1.9 0
days 0
v 0
11.1 0
+/- 0
2.2 0
days 0
, 0
P 0
< 0
.05 0
) 0
were 0
shorter 0
, 0
indicating 0
a 0
shift 0
of 0
cytotoxicity 0
to 0
later 0
progenitors 0
. 0

The 0
neutrophil B-PHYSICAL
nadir I-PHYSICAL
was 0
similar 0
with 0
and 0
without 0
priming 0
( 0
mean 0
+/- 0
SD 0
, 0
490 0
+/- 0
310/microL 0
v 0
550 0
+/- 0
350/microL 0
, 0
respectively 0
; 0
P 0
=.2 0
) 0
; 0
however 0
, 0
on 0
day 0
16 0
the 0
mean 0
neutrophil B-PHYSICAL
count I-PHYSICAL
was 0
higher 0
( 0
mean 0
+/- 0
SD 0
, 0
1030 0
+/- 0
580/microL 0
v 0
690 0
+/- 0
370/microL 0
, 0
P 0
=.004 0
) 0
, 0
and 0
the 0
proportion 0
of 0
patients 0
with 0
a 0
neutrophil B-PHYSICAL
count I-PHYSICAL
less 0
than 0
500/microL 0
was 0
lower 0
after 0
priming 0
than 0
before 0
( 0
six 0
of 0
35 0
or 0
17 0
. 0

1 0
% 0
v 0
12 0
of 0
34 0
or 0
35.3 0
% 0
, 0
respectively 0
; 0
P 0
=.04 0
) 0
. 0

The 0
platelet B-PHYSICAL
nadir I-PHYSICAL
was 0
higher 0
( 0
mean 0
+/- 0
SD 0
, 0
166,000 0
+/- 0
51,000/microL 0
after 0
priming 0
v 0
151,000 0
+/- 0
45,000/microL 0
before 0
priming 0
, 0
P 0
=.007 0
) 0
, 0
and 0
the 0
duration B-PHYSICAL
of I-PHYSICAL
thrombocytopenia I-PHYSICAL
, 0
ie 0
, 0
a 0
platelet 0
count 0
less 0
than 0
150,000/microL 0
, 0
was 0
shorter 0
( 0
1.5 0
+/- 0
2.1 0
days 0
v 0
2.8 0
+/- 0
2.9 0
days 0
, 0
P 0
=.0025 0
) 0
after 0
priming 0
. 0

Episodes 0
of 0
fever B-ADVERSE-EFFECTS
and 0
neutropenia B-ADVERSE-EFFECTS
were 0
not 0
observed 0
. 0

CONCLUSIONS 0
GM-CSF 0
priming 0
from 0
days 0
5 0
to 0
1 0
before 0
doxorubicin 0
and 0
cyclophosphamide 0
chemotherapy 0
was 0
associated 0
with 0
an 0
earlier 0
neutrophil B-PHYSICAL
and 0
platelet B-PHYSICAL
nadir I-PHYSICAL
. 0

On 0
day 0
16 0
, 0
a 0
higher 0
mean 0
neutrophil B-PHYSICAL
count I-PHYSICAL
and 0
a 0
lower 0
proportion 0
of 0
patients 0
with 0
severe 0
( 0
< 0
500/microL 0
) 0
neutropenia B-ADVERSE-EFFECTS
were 0
observed 0
. 0

Beneficial 0
effects 0
on 0
the 0
severity 0
and 0
duration 0
of 0
thrombocytopenia B-PHYSICAL
were 0
also 0
noted 0
. 0

These 0
observations 0
support 0
the 0
hypothesis 0
that 0
GM-CSF 0
priming 0
protects 0
hematopoietic 0
progenitors 0
from 0
the 0
cytotoxic 0
effects 0
of 0
chemotherapy 0
. 0

Effects 0
of 0
ORG-2766 0
on 0
brain 0
event-related 0
potentials 0
of 0
autistic 0
children 0
. 0

A 0
double-blind 0
, 0
placebo-controlled 0
study 0
examined 0
the 0
effects 0
of 0
6 0
weeks 0
of 0
treatment 0
with 0
the 0
adrenocorticotropin4-9 0
analogue 0
ORG-2766 0
( 0
40 0
mg/day 0
) 0
on 0
brain 0
event-related 0
potentials 0
( 0
ERPs 0
) 0
of 0
autistic 0
children 0
. 0

In 0
visual 0
and 0
auditory 0
oddball 0
paradigms 0
( 0
with 0
task 0
and 0
nontask 0
conditions 0
) 0
, 0
standard 0
( 0
80 0
% 0
) 0
, 0
target 0
( 0
10 0
% 0
) 0
, 0
and 0
unexpected 0
novel 0
stimuli 0
( 0
10 0
% 0
) 0
were 0
presented 0
. 0

ORG-2766 0
( 0
a 0
) 0
increased 0
the B-PHYSICAL
occipital I-PHYSICAL
P3 I-PHYSICAL
component I-PHYSICAL
of I-PHYSICAL
the I-PHYSICAL
ERP I-PHYSICAL
to I-PHYSICAL
visual I-PHYSICAL
targets I-PHYSICAL
, 0
( 0
b B-PHYSICAL
) 0
decreased 0
the B-PHYSICAL
occipital I-PHYSICAL
P3 I-PHYSICAL
component I-PHYSICAL
of I-PHYSICAL
the I-PHYSICAL
ERP I-PHYSICAL
to I-PHYSICAL
auditory I-PHYSICAL
targets B-PHYSICAL
, 0
( B-PHYSICAL
c I-PHYSICAL
) I-PHYSICAL
did I-PHYSICAL
not I-PHYSICAL
affect I-PHYSICAL
visual I-PHYSICAL
and I-PHYSICAL
auditory I-PHYSICAL
parietal I-PHYSICAL
target I-PHYSICAL
P3 B-PHYSICAL
components I-PHYSICAL
, 0
and 0
( 0
d 0
) 0
also 0
did 0
not 0
affect 0
the 0
A/Pcz/300 0
to 0
auditory 0
novel 0
stimuli 0
. 0

In 0
addition 0
, 0
ORG-2766 0
treatment 0
increased 0

The 0
influence 0
of 0
epidermal 0
growth 0
factor 0
receptor 0
and 0
tumor 0
differentiation 0
on 0
the 0
response 0
to 0
accelerated 0
radiotherapy 0
of 0
squamous 0
cell 0
carcinomas 0
of 0
the 0
head 0
and 0
neck 0
in 0
the 0
randomized 0
DAHANCA 0
6 0
and 0
7 0
study 0
. 0

BACKGROUND 0
AND 0
PURPOSE 0
Reduction 0
of 0
the 0
overall 0
treatment 0
time 0
of 0
radiotherapy 0
has 0
increased 0
locoregional B-PHYSICAL
control I-PHYSICAL
and 0
disease B-PHYSICAL
specific I-PHYSICAL
survival I-PHYSICAL
in 0
squamous 0
cell 0
carcinomas 0
of 0
the 0
head 0
and 0
neck 0
( 0
HNSCC 0
) 0
, 0
but 0
the 0
response 0
is 0
heterogeneous 0
. 0

EGFr 0
is 0
often 0
overexpressed 0
in 0
HNSCC 0
and 0
has 0
been 0
related 0
to 0
the 0
repopulation 0
taking 0
place 0
during 0
radiotherapy 0
. 0

The 0
aim 0
of 0
the 0
current 0
study 0
was 0
to 0
address 0
the 0
influence 0
of 0
EGFr 0
and 0
histopathological B-PHYSICAL
differentiation I-PHYSICAL
when 0
the 0
overall 0
treatment 0
time 0
of 0
radiotherapy 0
was 0
moderately 0
reduced 0
. 0

PATIENTS 0
AND 0
METHODS 0
Eight 0
hundred 0
and 0
three 0
patients 0
with 0
representative 0
pretreatment 0
tissue 0
samples 0
from 0
the 0
randomized 0
DAHANCA 0
6 0
and 0
7 0
study 0
of 0
5 0
vs. 0
6 0
fx/wk 0
of 0
radiotherapy 0
. 0

EGFr 0
was 0
visualized 0
using 0
immunohistochemistry 0
and 0
separated 0
into 0
high 0
and 0
low 0
expression 0
before 0
correlation 0
with 0
clinical 0
data 0
. 0

RESULTS 0
Tumors 0
with 0
high 0
EGFr 0
( 0
84 0
% 0
) 0
responded 0
better 0
to 0
moderately 0
accelerated 0
radiotherapy 0
, 0
than 0
carcinomas 0
with 0
low 0
EGFr 0
, 0
using 0
locoregional 0
control 0
as 0
endpoint 0
and 0
a 0
similar 0
pattern 0
was 0
seen 0
, 0
stratifying 0
by 0
well/moderate 0
vs. 0
poor 0
tumor B-PHYSICAL
differentiation I-PHYSICAL
. 0

Therefore 0
, 0
a 0
combined 0
parameter 0
was 0
constructed 0
showing 0
a 0
more 0
prominent B-OTHER
separation I-OTHER
of I-OTHER
response I-OTHER
: 0
tumors 0
with 0
high 0
EGFr 0
and 0
well/moderate 0
differentiation 0
did 0
benefit 0
from 0
moderate 0
acceleration 0
of 0
treatment 0
regarding 0
locoregional 0
control 0
, 0
HR 0
0.54 0
( 0
0.37-0.78 0
) 0
, 0
whereas 0
such 0
an 0
effect 0
was 0
not 0
seen 0
in 0
tumors 0
with 0
low 0
EGFr 0
and/or 0
poor 0
differentiation 0
, 0
HR 0
0.8 0
( 0
0.51-1.25 0
) 0
. 0

These 0
results 0
reflected 0
the 0
disease B-MORTALITY
specific I-MORTALITY
survival I-MORTALITY
as 0
well 0
and 0
were 0
confirmed 0
in 0
multivariable 0
analyses 0
. 0

CONCLUSIONS 0
Moderately 0
accelerated 0
fractionation 0
is 0
superior 0
to 0
conventional 0
treatment 0
in 0
HNSCC 0
but 0
the 0
response 0
is 0
heterogeneous 0
and 0
may 0
be 0
predicted 0
by 0
high 0
expression B-PHYSICAL
of I-PHYSICAL
EGFr I-PHYSICAL
and 0
well/moderate 0
tumor B-PHYSICAL
differentiation I-PHYSICAL
. 0

Outcomes 0
in 0
a 0
nursing 0
home 0
transition 0
case-management 0
program 0
targeting 0
new 0
admissions 0
. 0

PURPOSE 0
The 0
Providing 0
Assistance 0
to 0
Caregivers 0
in 0
Transition 0
( 0
PACT 0
) 0
program 0
offers 0
nursing 0
home 0
discharge 0
planning 0
and 0
case 0
management 0
for 0
individuals 0
in 0
the 0
transitional 0
period 0
following 0
a 0
return 0
to 0
the 0
community 0
. 0

The 0
PACT 0
program 0
targeted 0
individuals 0
newly 0
admitted 0
to 0
nursing 0
homes 0
and 0
worked 0
with 0
a 0
family 0
caregiver 0
to 0
develop 0
and 0
implement 0
a 0
nursing 0
home 0
discharge 0
plan 0
. 0

DESIGN 0
AND 0
METHOD 0
Reported 0
are 0
the 0
results 0
of 0
a 0
randomized 0
control 0
design 0
evaluating 0
the 0
program 0
's 0
effectiveness 0
. 0

Those 0
individuals 0
randomly 0
assigned 0
to 0
the 0
intervention 0
group 0
( 0
n 0
= 0
33 0
) 0
received 0
PACT 0
case 0
management 0
in 0
addition 0
to 0
their 0
usual 0
medical 0
and 0
nursing 0
home 0
care 0
. 0

The 0
individuals 0
in 0
the 0
control 0
group 0
( 0
n 0
= 0
29 0
) 0
continued 0
their 0
usual 0
care 0
. 0

RESULT 0
There 0
were 0
no 0
statistical 0
differences B-OTHER
in I-OTHER
the I-OTHER
discharge I-OTHER
rate I-OTHER
( 0
84 0
% 0
treatment 0
vs 0
76 0
% 0
controls 0
) 0
or 0
in 0
the B-OTHER
median 0
length B-OTHER
of I-OTHER

Effects 0
of 0
soy 0
intake 0
on 0
sex B-PHYSICAL
hormone I-PHYSICAL
metabolism I-PHYSICAL
in 0
premenopausal 0
women 0
. 0

Studies 0
suggest 0
that 0
phytoestrogens 0
in 0
soy 0
products 0
may 0
impart 0
hormonal 0
effects 0
that 0
protect 0
women 0
against 0
breast 0
cancer 0
. 0

Limited 0
research 0
suggests 0
that 0
intake 0
of 0
soy 0
products 0
high 0
in 0
isoflavonoid 0
phytoestrogens 0
affects 0
sex B-PHYSICAL
hormone I-PHYSICAL
metabolism I-PHYSICAL
, 0
but 0
it 0
is 0
unknown 0
whether 0
phytoestrogens 0
in 0
soy 0
have 0
any 0
effect 0
on 0
menstrual 0
function 0
or 0
serum 0
sex 0
hormones 0
in 0
women 0
on 0
common 0
hormone 0
therapies 0
, 0
such 0
as 0
oral 0
contraceptives 0
( 0
OC 0
) 0
. 0

We 0
studied 0
the 0
effects 0
of 0
soy 0
in 0
36 0
premenopausal 0
women 0
, 0
20 0
of 0
whom 0
used 0
OC 0
. 0

Subjects 0
consumed 0
their 0
normal 0
diet 0
for 0
two 0
menstrual 0
cycles 0
and 0
added 0
a 0
soy 0
beverage 0
containing 0
20 0
g 0
of 0
protein 0
and 0
38 0
mg 0
of 0
total 0
isoflavones 0
to 0
their 0
usual 0
diet 0
for 0
another 0
two 0
menstrual 0
cycles 0
. 0

No 0
significant 0
differences 0
were 0
observed 0
in 0
serum B-PHYSICAL
estrone I-PHYSICAL
, 0
estradiol B-PHYSICAL
, 0
sex B-PHYSICAL
hormone-binding I-PHYSICAL
globulin I-PHYSICAL
, 0
dehydroepiandrosterone B-PHYSICAL
sulfate I-PHYSICAL
, 0
prolactin B-PHYSICAL
, 0
or 0
progesterone B-PHYSICAL
concentrations I-PHYSICAL
with 0
soy 0
feeding 0
in 0
the 0
non-OC 0
or 0
the 0
OC 0
group 0
. 0

No 0
changes 0
in 0
menstrual B-PHYSICAL
cycle 0
length B-PHYSICAL
or I-PHYSICAL
the I-PHYSICAL
urinary I-PHYSICAL
estrogen I-PHYSICAL
metabolite I-PHYSICAL
ratio 0
of B-PHYSICAL
2-hydroxyestrone I-PHYSICAL
to I-PHYSICAL
16 B-PHYSICAL
alpha-hydroxyestrone I-PHYSICAL
were 0
seen 0
with 0
soy 0
feeding 0
in 0
the 0
non-OC 0
or 0
the 0
OC 0
group 0
. 0

Levels B-PHYSICAL
of B-PHYSICAL
urinary I-PHYSICAL
estrogen I-PHYSICAL

Promoting 0
physical 0
activity 0
in 0
patients 0
with 0
colon 0
adenomas 0
: 0
a 0
randomized 0
pilot 0
intervention 0
trial 0
. 0

BACKGROUND 0
Physical 0
activity 0
decreases 0
risk 0
of 0
colon 0
polyps 0
and 0
colon 0
cancer 0
and 0
might 0
reduce 0
risk 0
of 0
colon 0
cancer 0
recurrence 0
. 0

Focusing 0
on 0
recent 0
calls 0
for 0
translation 0
of 0
epidemiologic 0
evidence 0
into 0
clinical 0
care 0
, 0
our 0
pilot 0
study 0
delivered 0
an 0
evidence-based 0
physical 0
activity 0
intervention 0
in 0
adults 0
with 0
polyps 0
, 0
who 0
are 0
thus 0
at 0
elevated 0
risk 0
of 0
developing 0
colon 0
cancer 0
. 0

The 0
objective 0
was 0
to 0
evaluate 0
change 0
in 0
physical 0
activity 0
, 0
measured 0
by 0
steps 0
per 0
day 0
and 0
minutes 0
of 0
moderate/vigorous B-MENTAL
physical 0
activity 0
. 0

METHODS 0
Sixteen 0
adults 0
with 0
adenomas 0
detected 0
and 0
removed 0
at 0
screening 0
colonoscopy 0
were 0
recruited 0
to 0
a 0
12-week 0
physical 0
activity 0
intervention 0
. 0

Participants 0
were 0
randomized 0
to 0
receive 0
a 0
standard 0
( 0
30 0
minutes/day 0
) 0
or 0
high 0
( 0
60 0
minutes/day 0
) 0
walking 0
program 0
. 0

Physical 0
activity 0
was 0
measured 0
via 0
blinded 0
pedometer 0
and 0
accelerometer 0
at 0
baseline 0
and 0
follow-up 0
. 0

Intervention 0
messages 0
focused 0
on 0
self-monitoring 0
using 0
pedometers 0
and 0
overcoming 0
barriers 0
to 0
engaging 0
in 0
physical 0
activity 0
. 0

RESULTS 0
Participants 0
in 0
both 0
arms 0
significantly 0
increased 0
objectively 0
measured 0
minutes B-MENTAL
of I-MENTAL
moderate/vigorous I-MENTAL
physical I-MENTAL
activity I-MENTAL
over 0
the 0
course 0
of 0
the 0
intervention 0
. 0

Both 0
arms 0
exceeded 0
the 0
intervention 0
goal 0
, 0
but 0
there 0
was 0
not 0
a 0
significant 0
difference 0
between 0
arms 0
at 0
follow-up 0
. 0

Results 0
were 0
similar 0
for 0
pedometer B-OTHER
measured I-OTHER
physical I-OTHER
activity I-OTHER
, 0
with 0
a 0
significant 0
overall 0
increase 0
in 0
steps/day B-MENTAL
from 0
baseline 0
to 0
follow-up 0
, 0
but 0
no 0
between 0
arm 0
difference 0
in 0
change 0
. 0

CONCLUSION 0
Simple 0
interventions 0
of 0
minimal 0
contact 0
time 0
focusing 0
on 0
walking 0
can 0
significantly 0
increase 0
physical 0
activity 0
in 0
individuals 0
at 0
increased 0
risk 0
of 0
developing 0
colon 0
cancer 0
. 0

TRIAL 0
REGISTRATION 0
ClinicalTrials.gov 0
NCT01476631 0
. 0

Measurement 0
of 0
health-related B-PHYSICAL
quality I-PHYSICAL
of I-PHYSICAL
life I-PHYSICAL
in 0
multiple 0
myeloma 0
. 0

Nordic 0
Myeloma 0
Study 0
Group 0
. 0

When 0
a 0
randomized 0
trial 0
( 0
NMSG 0
4/90 0
) 0
comparing 0
treatment 0
with 0
melphalan/prednisone 0
to 0
melphalan/ 0
prednisone 0
+ 0
interferon 0
alpha-2b 0
in 0
newly 0
diagnosed 0
multiple 0
myeloma 0
was 0
initiated 0
in 0
1990 0
, 0
a 0
quality-of-life B-OTHER
assessment B-PHYSICAL
was 0
integrated 0
into 0
the 0
study 0
. 0

We 0
used 0
the 0
questionnaire 0
( 0
QLQ-C30 0
) 0
developed 0
by 0
the 0
European 0
Organization 0
of 0
Research 0
and 0
Treatment 0
of 0
Cancer 0
( 0
EORTC 0
) 0
Study 0
Group 0
on 0
Quality 0
of 0
Life 0
. 0

The 0
QLQ-C30 0
incorporates 0
five 0
functional 0
scales 0
, 0
three 0
symptom 0
scales 0
, 0
a 0
global 0
health 0
and 0
quality-of B-OTHER
life I-OTHER
scale I-OTHER
and 0
some 0
single 0
symptom 0
measures 0
. 0

The 0
questionnaire 0
was 0
completed 0
prior 0
to 0
treatment 0
and 0
after 0
1 0
, 0
6 0
, 0
12 0
, 0
24 0
, 0
36 0
and 0
48 0
months 0
. 0

524 0
( 0
90.2 0
% 0
) 0
of 0
581 0
patients 0
enrolled 0
in 0
the 0
NMSG 0
4/90 0
completed 0
the 0
first 0
questionnaire 0
, 0
and 0
484 0
( 0
83.3 0
% 0
) 0
completed 0
all 0
questionnaires 0
given 0
to 0
them 0
. 0

All 0
but 0
one 0
of 0
the 0
scales 0
met 0
the 0
minimum 0
criteria 0
of 0
reliability 0
( 0
Cronbach 0
's 0
alpha 0
> 0
/ 0
0.70 0
) 0
. 0

Validity 0
was 0
shown 0
by 0
( 0
1 0
) 0
the 0
ability 0
of 0
the 0
scales 0
to 0
discriminate 0
clearly 0
between 0
patients 0
differing 0
in 0
clinical 0
status 0
as 0
defined 0
by 0
pretreatment 0
W.H.O 0
. 0

performance 0
index 0
and 0
Durie 0
& 0
Salmon 0
stage 0
, 0
and 0
( 0
2 0
) 0
the 0
sensitivity 0
to 0
changes 0
in 0
objective 0
disease 0
status 0
( 0
response 0
and 0
relapse 0
) 0
. 0

This 0
is 0
the 0
first 0
report 0
of 0
the 0
measurement 0
of 0
health-related B-OTHER
quality I-OTHER
of I-OTHER
life I-OTHER
in 0
a 0
prospective 0
clinical 0
trial 0
in 0
multiple 0
myeloma 0
. 0

The 0
results 0
demonstrate 0
that 0
the 0
QLQ-C30 B-OTHER
is 0
a 0
reliable 0
and 0
valid 0
instrument 0
for 0
the 0
measurement 0
of 0
quality 0
of 0
life 0
in 0
these 0
patients 0
. 0

The 0
data 0
will 0
be 0
used 0
for 0
a 0
cost-utility 0
analysis 0
of 0
the 0
results 0
of 0
the 0
NMSG 0
4/90 0
trial 0
. 0

Acute 0
cardiac 0
effects 0
of 0
nicotine 0
in 0
healthy 0
young 0
adults 0
. 0

BACKGROUND 0
Nicotine 0
is 0
known 0
to 0
have 0
many 0
physiologic 0
effects 0
. 0

The 0
influence 0
of 0
nicotine 0
delivered 0
in 0
chewing 0
gum 0
upon 0
cardiac 0
hemodynamics 0
and 0
conduction 0
has 0
not 0
been 0
well-characterized 0
. 0

METHODS 0
We 0
studied 0
the 0
effects 0
of 0
nicotine 0
in 0
nonsmoking 0
adults 0
( 0
6 0
male 0
, 0
5 0
female 0
; 0
ages 0
23-36 0
years 0
) 0
using 0
a 0
double-blind 0
, 0
randomized 0
, 0
cross-over 0
study 0
. 0

Subjects 0
chewed 0
nicotine 0
gum 0
( 0
4 0
mg 0
) 0
or 0
placebo 0
. 0

After 0
20 0
minutes 0
( 0
approximate 0
time 0
to 0
peak 0
nicotine 0
levels 0
) 0
, 0
echocardiograms 0
and 0
signal-averaged 0
electrocardiograms 0
( 0
SAECG 0
) 0
were 0
obtained 0
. 0

After 0
40 0
minutes 0
, 0
subjects 0
were 0
again 0
given 0
nicotine 0
gum 0
or 0
placebo 0
in 0
cross-over 0
fashion 0
. 0

Standard 0
echocardiographic 0
measurements 0
were 0
made 0
from 0
two-dimensional 0
images 0
. 0

We 0
then 0
calculated 0
end-systolic B-PHYSICAL
wall I-PHYSICAL
stress 0
( 0
ESWS B-PHYSICAL
) 0
, 0
shortening B-PHYSICAL
fraction B-PHYSICAL
( 0
SF B-PHYSICAL
) 0
, 0
systemic B-PHYSICAL
vascular I-PHYSICAL
resistance I-PHYSICAL
( 0
SVR B-PHYSICAL
) 0
, 0
velocity 0
for B-PHYSICAL
circumferential B-PHYSICAL
fiber I-PHYSICAL
shortening B-PHYSICAL
corrected I-PHYSICAL
for I-PHYSICAL
heart I-PHYSICAL
rate I-PHYSICAL
( 0
Vcfc B-PHYSICAL
) 0
, 0
stroke B-PHYSICAL
volume B-PHYSICAL
, 0
and B-PHYSICAL
cardiac I-PHYSICAL
output B-PHYSICAL
. 0

P B-PHYSICAL
wave I-PHYSICAL
and B-PHYSICAL
QRS I-PHYSICAL
duration I-PHYSICAL
were 0
measured 0
from 0
SAECG 0
. 0

RESULTS 0
Significant 0
differences 0
( 0
P 0
< 0
0.05 0
) 0
from 0
control 0
or 0
placebo 0
were 0
found 0
for 0
ESWS B-OTHER
, 0
mean 0
blood B-PHYSICAL
pressure I-PHYSICAL
, 0
cardiac B-OTHER
output B-OTHER
, 0
SVR B-OTHER
, 0
heart B-OTHER
rate I-OTHER
, 0
and 0
P B-OTHER
wave I-OTHER
duration B-OTHER
. 0

No 0
significant 0
changes 0
were 0
seen 0
in 0
left 0
ventricular 0
ejection 0
time 0
( 0
LVET 0
) 0
, 0
LV 0
dimensions 0
, 0

A 0
double 0
blind 0
randomized 0
study 0
of 0
oral 0
clodronate 0
in 0
the 0
treatment 0
of 0
bone 0
metastases 0
from 0
tumors 0
poorly 0
responsive 0
to 0
chemotherapy 0
. 0

Bisphosphonates 0
are 0
used 0
in 0
oncology 0
as 0
a 0
means 0
of 0
decreasing 0
complications 0
due 0
to 0
bone 0
metastases 0
, 0
in 0
association 0
with 0
anticancer 0
treatment 0
, 0
especially 0
in 0
patients 0
with 0
breast 0
cancer 0
, 0
prostate 0
cancer 0
and 0
myeloma 0
. 0

Little 0
is 0
known 0
about 0
the 0
effects 0
of 0
bisphosphonates 0
on 0
bone 0
metastases 0
from 0
other 0
tumors 0
and 0
in 0
particular 0
from 0
tumors 0
for 0
which 0
no 0
effective 0
treatment 0
is 0
available 0
. 0

We 0
conducted 0
a 0
randomized 0
, 0
double-blind 0
placebo-controlled 0
trial 0
of 0
oral 0
clodronate 0
in 0
patients 0
with 0
bone 0
metastases 0
from 0
tumors 0
poorly 0
responsive 0
to 0
chemotherapy 0
, 0
with 0
the 0
aims 0
of 0
evaluating 0
the 0
effects 0
of 0
this 0
drug B-PHYSICAL
on I-PHYSICAL
symptoms I-PHYSICAL
control 0
and 0
bone B-PHYSICAL
metastases I-PHYSICAL
evolution I-PHYSICAL
. 0

Sixty-six 0
patients 0
with 0
poorly 0
responsive 0
tumors 0
such 0
as 0
non-small 0
cell 0
lung 0
cancer 0
( 0
NSCLC 0
) 0
, 0
bladder 0
cancer 0
, 0
gastrointestinal 0
cancers 0
, 0
kidney 0
cancer 0
, 0
melanoma 0
and 0
metastatic 0
carcinoma 0
of 0
unknown 0
origin 0
entered 0
the 0
study 0
. 0

Patients 0
were 0
randomized 0
to 0
receive 0
either 0
clodronate 0
1,600 0
mg/day 0
for 0
one 0
year 0
or 0
identical 0
placebo-containing 0
tablets 0
. 0

Various 0
parameters 0
such 0
as 0
Karnofsky B-PHYSICAL
performance I-PHYSICAL
status I-PHYSICAL
, 0
pain 0
score 0
( 0
measured 0
by 0
a 0
visual-analogue 0
scale 0
) 0
and 0
analgesic B-PAIN
requirement B-PHYSICAL
were 0
recorded 0
at 0
monthly 0
intervals 0
. 0

Of 0
the 0
66 0
patients 0
enrolled 0
, 0
9 0
were 0
observed 0
for 0
one 0
month 0
or 0
less 0
; 0
7 0
were 0
followed 0
for 0
two 0
months 0
; 0
only 0
50 0
patients 0
were 0
followed 0
for 0
more 0
than 0
2 0
months 0
and 0
could 0
be 0
adequately 0
evaluated 0
. 0

At 0
3 0
months 0
both 0
clodronate 0
and 0
placebo-treated 0
patients 0
had 0
a 0
decrease 0
in 0
Karnofsky B-PHYSICAL
performance I-PHYSICAL
status I-PHYSICAL
, 0
with 0
the 0
decrease 0
being 0
more 0
evident 0
in 0
the 0
placebo 0
group 0
. 0

Mean 0
pain B-PAIN
scores I-PAIN
showed 0
an 0
increase 0
of 0
pain B-PAIN
in 0
patients 0
receiving 0
placebo 0
and 0
a 0
decrease 0
of 0
pain 0
in 0
patients 0
receiving 0
clodronate 0
, 0
although 0
the 0
difference 0
failed 0
to 0
be 0
statistically 0
significant 0
. 0

Analgesics B-PAIN
requirement I-PAIN
increased 0
in 0
both 0
groups 0
, 0
but 0
significantly 0
more 0
in 0
patients 0
receiving 0
placebo 0
( 0
p 0
= 0
0.042 0
) 0
, 0
in 0
whom 0
increase 0
in 0
opioid 0
requirements 0
was 0
particularly 0
evident 0
. 0

Toxicity B-ADVERSE-EFFECTS
was I-ADVERSE-EFFECTS
low I-ADVERSE-EFFECTS
, 0
with 0
occasional B-ADVERSE-EFFECTS
gastroenteric I-ADVERSE-EFFECTS
discomfort I-ADVERSE-EFFECTS
in 0
both 0
groups 0
. 0

The 0
main 0
problem 0
of 0
this 0
study 0
was 0
the 0
difficulty 0
in 0
recruiting 0
an 0
adequate 0
number 0
of 0
patients 0
and 0
following 0
them 0
for 0
a 0
sufficient 0
period 0
of 0
time 0
: 0
general 0
conditions 0
rapidly 0
deteriorated 0
in 0
many 0
patients 0
, 0
and 0
approximately 0
25 0
% 0
of 0
the 0
66 0
enrolled 0
were 0
not 0
considered 0
evaluable 0
; 0
few 0
patients 0
survived 0
for 0
the 0
length 0
of 0
the 0
study 0
, 0
one 0
year 0
. 0

This 0
might 0
partly 0
account 0
for 0
the 0
lack 0
of 0
significance 0
of 0
some 0
of 0
the 0
parameters 0
under 0
study 0
. 0

With 0
these 0
limits 0
, 0
oral 0
clodronate 0
demonstrated 0
some 0
efficacy 0
in 0
symptom 0
control 0
and 0
in 0
reducing 0
the 0
need 0
for 0
analgesics 0
. 0

Impact 0
of 0
interviewer 0
's 0
body 0
mass 0
index 0
on 0
underreporting 0
energy 0
intake 0
in 0
overweight 0
and 0
obese 0
women 0
. 0

OBJECTIVE 0
To 0
determine 0
if 0
overweight 0
and 0
obese 0
women 0
provide 0
more 0
accurate 0
reports 0
of 0
their 0
energy 0
intake 0
by 0
1 0
) 0
in-person 0
recall 0
with 0
an 0
obese 0
interviewer 0
, 0
2 0
) 0
in-person 0
recall 0
with 0
a 0
lean 0
interviewer 0
, 0
or 0
3 0
) 0
telephone 0
recall 0
with 0
an 0
unknown 0
interviewer 0
. 0

RESEARCH 0
METHODS 0
AND 0
PROCEDURES 0
Eighty-eight 0
overweight 0
and 0
obese 0
women 0
participated 0
in 0
this 0
study 0
. 0

Subjects 0
completed 0
one 0
telephone-administered 0
multiple-pass 0
24-hour 0
recall 0
( 0
MP24R 0
) 0
with 0
an 0
unknown 0
interviewer 0
and 0
were 0
then 0
randomly 0
assigned 0
to 0
an 0
in-person 0
MP24R 0
with 0
either 0
a 0
lean 0
or 0
obese 0
interviewer 0
to 0
gather 0
reported B-PHYSICAL
energy I-PHYSICAL
intake I-PHYSICAL
( 0
rEI B-PHYSICAL
) 0
. 0

Basal B-PHYSICAL
metabolic I-PHYSICAL
rate I-PHYSICAL
( I-PHYSICAL
BMR I-PHYSICAL
) I-PHYSICAL
was 0
measured 0
using 0
a 0
Deltrac 0
monitor 0
, 0
and 0
physical B-PHYSICAL
activity I-PHYSICAL
( I-PHYSICAL
EEPA I-PHYSICAL
) I-PHYSICAL
was 0
estimated 0
using 0
a 0
Caltrac 0
accelerometer 0
. 0

Therefore 0
, 0
estimated 0
energy 0
expenditure 0
was 0
determined 0
by 0
: 0
estTEE 0
= 0
( 0
BMR 0
+ 0
EEPA 0
) 0
x 0
1.10 0
. 0

RESULTS 0
No 0
significant 0
differences 0
were 0
found 0
between 0
the 0
two 0
in-person 0
interview 0
modes 0
for 0
subject 0
age 0
, 0
weight 0
, 0
body 0
mass 0
index 0
, 0
percentage 0
of 0
body 0
fat 0
, 0
total 0
energy 0
expenditure 0
, 0
rEI 0
, 0
and 0
misreporting 0
of 0
energy 0
intake 0
. 0

In-person 0
recall 0
data 0
were 0
combined 0
for 0
comparison 0
with 0
the 0
telephone 0
recalls 0
. 0

No 0
significant 0
difference 0
was 0
found 0
between 0
the 0
in-person 0
and 0
telephone 0
recalls 0
for 0
rEI B-PHYSICAL
and 0
misreporting B-OTHER
. 0

Mean 0
reported B-PHYSICAL
energy I-PHYSICAL
intake I-PHYSICAL
was 0
significantly 0
lower 0
than 0
estimated 0
total 0
energy B-PHYSICAL
expenditure I-PHYSICAL
for 0
the 0
telephone 0
recalls 0
and 0
combined 0
( 0
lean 0
and 0
obese 0
modes 0
) 0
in-person 0
recalls 0
. 0

CONCLUSIONS 0
This 0
study 0
found 0
that 0
interviewer 0
body 0
mass 0
index 0
had 0
no 0
impact 0
on 0
self-reported 0
energy 0
intake 0
during 0
an 0
in-person 0
MP24R 0
, 0
and 0
that 0
telephone 0
recall 0
data 0
were 0
comparable 0
with 0
in-person 0
recalls 0
. 0

Underreporting 0
was 0
a 0
widespread 0
problem 0
( 0
approximately 0
26 0
% 0
) 0
for 0
all 0
modes 0
in 0
this 0
sample 0
. 0

[ 0
Postural 0
biofeedback 0
and 0
locomotion 0
reeducation 0
in 0
stroke 0
patients 0
] 0
. 0

AIMS 0
To 0
compare 0
, 0
in 0
post-acute 0
hemiparetic 0
patients 0
, 0
gait B-OTHER
improvement I-OTHER
after 0
conventional 0
physical 0
therapy 0
alone 0
or 0
with 0
a 0
specialised 0
balance 0
retraining 0
program 0
. 0

PATIENTS 0
Twenty-six 0
patients 0
within 0
3 0
months 0
of 0
onset 0
of 0
stroke 0
were 0
randomised 0
to 0
receive 0
physical 0
therapy 0
( 0
control 0
group 0
) 0
or 0
therapy 0
and 0
retraining 0
( 0
experimental 0
group 0
) 0
, 0
most 0
of 0
the 0
patients 0
in 0
both 0
groups 0
with 0
left 0
hemiplegia 0
. 0

The 0
experimental 0
group 0
was 0
significantly 0
older 0
than 0
the 0
control 0
group 0
. 0

METHOD 0
Thirteen 0
patients 0
received 0
early 0
conventional 0
therapy 0
, 0
and 0
13 0
received 0
therapy 0
combined 0
with 0
standing 0
balance 0
training 0
by 0
biofeedback 0
( 0
BPM 0
Monitor 0
) 0
. 0

Clinical 0
measures 0
were 0
collected 0
at 0
entry 0
( 0
J0 0
) 0
, 0
once 0
when 0
subjects 0
began 0
to 0
walk B-PHYSICAL
( 0
JM 0
) 0
and 0
30 0
days 0
later 0
( 0
JM 0
+ 0
30 0
) 0
. 0

Gait B-OTHER
spatiotemporal I-OTHER
parameters I-OTHER
were 0
collected 0
by 0
use 0
of 0
the 0
Vicon B-OTHER
system I-OTHER
at 0
JM 0
and 0
JM 0
+ 0
30 0
. 0

RESULTS 0
Whatever 0
the 0
method 0
of 0
rehabilitation 0
, 0
the 0
clinical B-OTHER
scores I-OTHER
improved 0
significantly 0
between 0
J0 0
and 0
JM 0
+ 0
30 0
, 0
except 0
for 0
spasticity 0
. 0

The 0
time B-OTHER
between I-OTHER
stroke I-OTHER
and I-OTHER
the I-OTHER
beginning I-OTHER
of I-OTHER
walking I-OTHER
was 0
not 0
significantly 0
different 0
between 0
both 0
groups 0
. 0

Gait B-PHYSICAL
velocity I-PHYSICAL
increased 0
significantly 0
between 0
JM 0
and 0
JM 0
+ 0
30 0
in 0
both 0
groups 0
, 0
with 0
no 0
difference 0
between 0
groups 0
. 0

The 0
walking B-PHYSICAL
pattern I-PHYSICAL
was 0
improved 0
for 0
both 0
groups 0
, 0
with 0
a 0
significant 0
increase 0
of 0
the 0
duration 0
of 0
the 0
paretic B-OTHER
limb I-OTHER
single I-OTHER
stance I-OTHER
. 0

The 0
experimental 0
group 0
significantly 0
improved 0
the 0
duration 0
of 0
the B-OTHER
reception I-OTHER
double I-OTHER
stance I-OTHER
on I-OTHER
the I-OTHER
paretic I-OTHER
limb I-OTHER
between 0
JM 0
and 0
JM 0
+ 0
30 0
compared 0
with 0
the 0
control 0
group 0
( 0
P 0
= 0
0.03 0
) 0
. 0

CONCLUSION 0
Both 0
groups 0
demonstrated 0
improvement 0
in 0
the 0
rehabilitation 0
unit 0
. 0

The 0
benefits 0
of 0
visual 0
biofeedback 0
by 0
forceplate 0
system 0
training 0
suggest 0
particular 0
improvement 0
of 0
anticipation 0
equilibrium 0
with 0
conventional 0
therapy 0
. 0

Acute 0
effects 0
of 0
different 0
stretching 0
durations 0
on 0
passive B-PHYSICAL
torque I-PHYSICAL
, 0
mobility B-PHYSICAL
, 0
and 0

Safety B-OTHER
, 0
tolerability B-OTHER
, 0
and 0
changes 0
in 0
amyloid B-PHYSICAL
beta I-PHYSICAL
concentrations I-PHYSICAL
after 0
administration 0
of 0
a 0
gamma-secretase 0
inhibitor 0
in 0
volunteers 0
. 0

Amyloid 0
beta 0
( 0
Abeta 0
) 0
may 0
play 0
a 0
central 0
role 0
in 0
the 0
pathogenesis 0
of 0
Alzheimer 0
disease 0
. 0

A 0
functional 0
gamma-secretase 0
inhibitor 0
, 0
LY450139 0
, 0
was 0
developed 0
that 0
inhibits 0
Abeta 0
formation 0
in 0
whole 0
cell 0
assays 0
, 0
transgenic 0
mice 0
, 0
and 0
beagle 0
dogs 0
. 0

The 0
authors 0
wished 0
to 0
determine 0
the 0
safety 0
and 0
tolerability 0
of 0
this 0
drug 0
, 0
and 0
the 0
reduction 0
of 0
Abeta 0
in 0
plasma 0
and 0
cerebrospinal 0
fluid 0
( 0
CSF 0
) 0
after 0
multiple 0
doses 0
. 0

Volunteer 0
subjects 0
( 0
N 0
= 0
37 0
) 0
were 0
studied 0
using 0
doses 0
from 0
5 0
to 0
50 0
mg/day 0
given 0
for 0
14 0
days 0
. 0

Plasma B-PHYSICAL
and I-PHYSICAL
CSF I-PHYSICAL
concentrations I-PHYSICAL
of I-PHYSICAL
LY450139 I-PHYSICAL
, 0
Abeta B-PHYSICAL
( 0
1-40 B-PHYSICAL
) 0
and 0
Abeta B-PHYSICAL
( I-PHYSICAL
1-X I-PHYSICAL
) I-PHYSICAL
( I-PHYSICAL
Abeta I-PHYSICAL
( I-PHYSICAL
total 0
) B-PHYSICAL
) B-PHYSICAL
were 0
determined 0
, 0
and 0
safety 0
and 0
tolerability 0
were 0
assessed 0
. 0

The 0
plasma 0
half-life 0
of 0
LY450139 0
was 0
approximately 0
2.5 0
hours 0
. 0

Pharmacokinetic 0
analyses 0
showed 0
a 0
linear 0
relationship 0
between 0
dose 0
and 0
plasma 0
concentrations 0
, 0
with 0
a 0
Cmax 0
of 0
828 0
+/- 0
19.2 0
ng/mL 0
after 0
a 0
50-mg 0
dose 0
. 0

Plasma B-PHYSICAL
Abeta I-PHYSICAL
concentrations B-PHYSICAL
decreased 0
in 0
a 0
dose-dependent 0
manner 0
over 0
a 0
6-hour 0
interval 0
following 0
drug 0
administration 0
, 0
with 0
a 0
maximum 0
decrease 0
of 0
approximately 0
40 0
% 0
relative 0
to 0
baseline 0
. 0

After 0
returning 0
to 0
baseline 0
, 0
Abeta B-PHYSICAL
concentrations I-PHYSICAL
were 0
transiently 0
increased 0
. 0

CSF B-PHYSICAL
Abeta I-PHYSICAL
concentrations B-PHYSICAL
were 0
unchanged 0
. 0

Vitamin 0
D 0
supplementation 0
increases 0
calcium B-PHYSICAL
absorption I-PHYSICAL
without 0
a 0
threshold 0
effect 0
. 0

BACKGROUND 0
The 0
maximal 0
calcium 0
absorption 0
in 0
response 0
to 0
vitamin 0
D 0
has 0
been 0
proposed 0
as 0
a 0
biomarker 0
for 0
vitamin 0
D 0
sufficiency 0
. 0

OBJECTIVE 0
The 0
objective 0
was 0
to 0
determine 0
whether 0
there 0
is 0
a 0
threshold 0
beyond 0
which 0
increasing 0
doses 0
of 0
vitamin 0
D 0
, 0
or 0
concentrations 0
of 0
serum 0
25-hydroxyvitamin 0
D 0
[ 0
25 0
( 0
OH 0
) 0
D 0
] 0
, 0
no 0
longer 0
increase 0
calcium B-PHYSICAL
absorption I-PHYSICAL
. 0

DESIGN 0
This 0
was 0
a 0
placebo-controlled 0
, 0
dose-response 0
, 0
randomized 0
, 0
double-blind 0
study 0
of 0
the 0
effect 0
of 0
vitamin 0
D 0
on 0
calcium 0
absorption 0
in 0
healthy 0
postmenopausal 0
women 0
. 0

Seventy-six 0
healthy 0
postmenopausal 0
women 0
were 0
randomly 0
assigned 0
to 0
placebo 0
or 0
800 0
IU 0
( 0
20 0
?g 0
) 0
, 0
2000 0
IU 0
( 0
50 0
?g 0
) 0
, 0
or 0
4000 0
IU 0
( 0
100 0
?g 0
) 0
vitamin 0
D? 0
for 0
8 0
wk 0
. 0

The 0
technique 0
of 0
dual 0
isotopes 0
of 0
stable 0
calcium 0
was 0
used 0
with 0
a 0
calcium 0
carrier 0
to 0
measure 0
calcium 0
absorption 0
at 0
baseline 0
and 0
after 0
8 0
wk 0
. 0

RESULTS 0
Seventy-one 0
women 0
with 0
a 0
mean 0
? 0

SD 0
age 0
of 0
58.8 0
? 0

4.9 0
y 0
completed 0
the 0
study 0
. 0

The 0
mean 0
calcium 0
intake 0
was 0
1142 0
? 0

509 0
mg/d 0
and 0
serum 0
25 0
( 0
OH 0
) 0
D 0
was 0
63 0
? 0

14 0
nmol/L 0
at 0
baseline 0
. 0

A 0
statistically 0
significant 0
linear 0
trend 0
of 0
an 0
increase 0
in 0
calcium 0
absorption 0
adjusted 0
for 0
age 0
and 0
body 0
mass 0
index 0
with 0
increasing 0
vitamin 0
D? 0
dose 0
or 0
serum 0
25 0
( 0
OH 0
) 0
D 0
concentration 0
was 0
observed 0
. 0

A 0
6.7 0
% 0
absolute 0
increase 0
in 0
calcium 0
absorption 0
was 0
found 0
in 0
the 0
highest 0
vitamin 0
D? 0
group 0
( 0
100 0
?g 0
) 0
. 0

No 0
evidence 0
of 0
nonlinearity 0
was 0
observed 0
in 0
the 0
dose-response 0
curve 0
. 0

CONCLUSIONS 0
No 0
evidence 0
of 0
a 0
threshold 0
of 0
calcium 0
absorption 0
was 0
found 0
with 0
a 0
serum 0
25 0
( 0
OH 0
) 0
D 0
range 0
from 0
40 0
to 0
130 0
nmol/L 0
. 0

Calcium 0
absorption 0
in 0
this 0
range 0
is 0
not 0
a 0
useful 0
biomarker 0
to 0
determine 0
nutritional 0
recommendations 0
for 0
vitamin 0
D 0
. 0

Impact 0
of 0
a 0
16-community 0
trial 0
to 0
promote 0
judicious 0
antibiotic 0
use 0
in 0
Massachusetts 0
. 0

OBJECTIVES 0
Reducing 0
unnecessary 0
antibiotic 0
use 0
, 0
particularly 0
among 0
children 0
, 0
continues 0
to 0
be 0
a 0
public 0
health 0
priority 0
. 0

Previous 0
intervention 0
studies 0
have 0
been 0
limited 0
by 0
size 0
or 0
design 0
and 0
have 0
shown 0
mixed 0
results 0
. 0

The 0
objective 0
of 0
this 0
study 0
was 0
to 0
determine 0
the 0
impact 0
of 0
a 0
multifaceted 0
, 0
community-wide 0
intervention 0
on 0
overall 0
antibiotic 0
use 0
for 0
young 0
children 0
and 0
on 0
use 0
of 0
broad-spectrum 0
agents 0
. 0

In 0
addition 0
, 0
we 0
sought 0
to 0
compare 0
the 0
intervention 0
's 0
impact 0
on 0
commercially 0
and 0
Medicaid-insured 0
children 0
. 0

METHODS 0
We 0
conducted 0
a 0
controlled 0
, 0
community-level 0
, 0
cluster-randomized 0
trial 0
in 0
16 0
nonoverlapping 0
Massachusetts 0
communities 0
, 0
studied 0
from 0
1998 0
to 0
2003 0
. 0

During 0
3 0
years 0
, 0
we 0
implemented 0
a 0
physician 0
behavior-change 0
strategy 0
that 0
included 0
guideline 0
dissemination 0
, 0
small-group 0
education 0
, 0
frequent 0
updates 0
and 0
educational 0
materials 0
, 0
and 0
prescribing 0
feedback 0
. 0

Parents 0
received 0
educational 0
materials 0
by 0
mail 0
and 0
in 0
primary 0
care 0
practices 0
, 0
pharmacies 0
, 0
and 0
child 0
care 0
settings 0
. 0

Using 0
health-plan 0
data 0
, 0
we 0
measured 0
changes 0
in 0
antibiotics 0
dispensed 0
per 0
person-year 0
of 0
observation 0
among 0
children 0
who 0
were 0
aged 0
3 0
to 0
< 0
72 0
months 0
, 0
resided 0
in 0
study 0
communities 0
, 0
and 0
were 0
insured 0
by 0
a 0
participating 0
commercial 0
health 0
plan 0
or 0
Medicaid 0
. 0

RESULTS 0
The 0
data 0
include 0
223,135 0
person-years 0
of 0
observation 0
. 0

Antibiotic-use B-MENTAL
rates I-MENTAL
at 0
baseline 0
were 0
2.8 0
, 0
1.7 0
, 0
and 0
1.4 0
antibiotics 0
per 0
person-year 0
among 0
those 0
aged 0
3 0
to 0
< 0
24 0
, 0
24 0
to 0
< 0
48 0
, 0
and 0
48 0
to 0
< 0
72 0
months 0
, 0
respectively 0
. 0

We 0
observed 0
a 0
substantial 0
downward 0
trend 0
in 0
antibiotic B-MENTAL
prescribing I-MENTAL
, 0
even 0
in 0
the 0
absence 0
of 0
intervention 0
. 0

The 0
intervention 0
had 0
no 0
additional 0
effect 0
among 0
children 0
aged 0
3 0
to 0
< 0
24 0
months 0
but 0
was 0
responsible 0
for 0
a 0
4.2 0
% 0
decrease 0
among 0
those 0
aged 0
24 0
to 0
< 0
48 0
months 0
and 0
a 0
6.7 0
% 0
decrease 0
among 0
those 0
aged 0
48 0
to 0
< 0
72 0
months 0
. 0

The 0
intervention 0
effect 0
was 0
greater 0
among 0
Medicaid-insured 0
children 0
and 0
for 0
broad-spectrum 0
agents 0
. 0

CONCLUSIONS 0
A 0
sustained 0
, 0
multifaceted 0
, 0
community-level 0
intervention 0
was 0
only 0
modestly 0
successful 0
at 0
decreasing 0
overall B-MENTAL
antibiotic I-MENTAL
use I-MENTAL
beyond 0
substantial 0
secular 0
trends 0
. 0

The 0
more 0
robust 0
impact 0
among 0
Medicaid-insured 0
children 0
and 0
for 0
specific 0
medication 0
classes 0
provides 0
an 0
argument 0
for 0
specific 0
targeting 0
of 0
resources 0
for 0
patient 0
and 0
physician 0
behavior 0
change 0
. 0

Comparative B-OTHER
effectiveness I-OTHER
of 0
exercise 0
electrocardiography 0
with 0
or 0
without 0
myocardial 0
perfusion 0
single 0
photon 0
emission 0
computed 0
tomography 0
in 0
women 0
with 0
suspected 0
coronary 0
artery 0
disease 0
: 0
results 0
from 0
the 0
What 0
Is 0
the 0
Optimal 0
Method 0
for 0
Ischemia 0
Evaluation 0
in 0
Women 0
( 0
WOMEN 0
) 0
trial 0
. 0

BACKGROUND 0
There 0
is 0
a 0
paucity 0
of 0
randomized 0
trials 0
regarding 0
diagnostic 0
testing 0
in 0
women 0
with 0
suspected 0
coronary 0
artery 0
disease 0
( 0
CAD 0
) 0
. 0

It 0
remains 0
unclear 0
whether 0
the 0
addition 0
of 0
myocardial 0
perfusion 0
imaging 0
( 0
MPI 0
) 0
to 0
the 0
standard 0
ECG 0
exercise 0
treadmill 0
test 0
( 0
ETT 0
) 0
provides 0
incremental 0
information 0
to 0
improve 0
clinical 0
decision 0
making 0
in 0
women 0
with 0
suspected 0
CAD 0
. 0

METHODS 0
AND 0
RESULTS 0
We 0
randomized 0
symptomatic 0
women 0
with 0
suspected 0
CAD 0
, 0
an 0
interpretable 0
ECG 0
, 0
and 0
?5 0
metabolic 0
equivalents 0
on 0
the 0
Duke 0
Activity 0
Status 0
Index 0
to 0
1 0
of 0
2 0
diagnostic 0
strategies 0
: 0
ETT 0
or 0
exercise 0
MPI 0
. 0

The 0
primary 0
end 0
point 0
was 0
2-year 0
incidence 0
of 0
major 0
adverse 0
cardiac 0
events 0
, 0
defined 0
as 0
CAD 0
death 0
or 0
hospitalization 0
for 0
an 0
acute 0
coronary 0
syndrome 0
or 0
heart 0
failure 0
. 0

A 0
total 0
of 0
824 0
women 0
were 0
randomized 0
to 0
ETT 0
or 0
exercise 0
MPI 0
. 0

For 0
women 0
randomized 0
to 0
ETT 0
, 0
ECG 0
results 0
were 0
normal 0
in 0
64 0
% 0
, 0
indeterminate 0
in 0
16 0
% 0
, 0
and 0
abnormal 0
in 0
20 0
% 0
. 0

By 0
comparison 0
, 0
the 0
exercise 0
MPI 0
results 0
were 0
normal 0
in 0
91 0
% 0
, 0
mildly 0
abnormal 0
in 0
3 0
% 0
, 0
and 0
moderate 0
to 0
severely 0
abnormal 0
in 0
6 0
% 0
. 0

At 0
2 0
years 0
, 0
there 0
was 0
no 0
difference 0
in 0
major 0
adverse 0
cardiac 0
events 0
( 0
98.0 0
% 0
for 0
ETT 0
and 0
97.7 0
% 0
for 0
MPI 0
; 0
P=0.59 0
) 0
. 0

Compared 0
with 0
ETT 0
, 0
index 0
testing 0
costs 0
were 0
higher 0
for 0
exercise 0
MPI 0
( 0
P 0
< 0
0.001 0
) 0
, 0
whereas 0
downstream 0
procedural 0
costs 0
were 0
slightly 0
lower 0
( 0
P=0.0008 0
) 0
. 0

Overall 0
, 0
the 0
cumulative 0
diagnostic 0
cost 0
savings 0
was 0
48 0
% 0
for 0
ETT 0
compared 0
with 0
exercise 0
MPI 0
( 0
P 0
< 0
0.001 0
) 0
. 0

CONCLUSIONS 0
In 0
low-risk 0
, 0
exercising 0
women 0
, 0
a 0
diagnostic 0
strategy 0
that 0
uses 0
ETT 0
versus 0
exercise 0
MPI 0
yields 0
similar 0
2-year 0
posttest 0
outcomes 0
while 0
providing 0
significant 0
diagnostic 0
cost 0
savings 0
. 0

The 0
ETT 0
with 0
selective 0
follow-up 0
testing 0
should 0
be 0
considered 0
as 0
the 0
initial 0
diagnostic 0
strategy 0
in 0
symptomatic 0
women 0
with 0
suspected 0
CAD 0
. 0

CLINICAL 0
TRIAL 0
REGISTRATION 0
http 0
: 0
//www.clinicaltrials.gov 0
. 0

Unique 0
identifier 0
: 0
NCT00282711 0
. 0

A 0
comparison 0
of 0
lisinopril 0
and 0
nifedipine 0
in 0
the 0
treatment 0
of 0
mild 0
to 0
moderate 0
hypertension 0
. 0

A 0
multicentre 0
study 0
. 0

Lisinopril 0
has 0
been 0
compared 0
with 0
slow-release 0
nifedipine 0
in 0
a 0
16-week 0
double-blind 0
, 0
randomized 0
, 0
parallel-group 0
study 0
involving 0
102 0
patients 0
with 0
mild 0
to 0
moderate 0
hypertension 0
. 0

Sitting B-PHYSICAL
systolic I-PHYSICAL
and 0
diastolic B-PHYSICAL
blood I-PHYSICAL
pressures I-PHYSICAL
were 0
reduced 0
6 0
and 0
5 0
mmHg 0
more 0
by 0
lisinopril 0
than 0
by 0
nifedipine 0
over 0
12 0
weeks 0
monotherapy 0
. 0

After 0
12 0
weeks 0
a 0
greater 0
proportion 0
of 0
patients 0
taking 0
lisinopril 0
was 0
controlled 0
( 0
sitting 0
diastolic 0
blood 0
pressure 0
below 0
95 0
mm 0
Hg 0
) 0
than 0
in 0
those 0
taking 0
nifedipine 0
. 0

As 0
a 0
result 0
, 0
17 0
% 0
of 0
those 0
taking 0
lisinopril 0
and 0
38 0
% 0
of 0
those 0
taking 0
nifedipine 0
required 0
additional 0
therapy 0
with 0
hydrochlorothiazide B-PHYSICAL
. 0

The 0
addition 0
of 0
hydrochlorothiazide 0
resulted 0
in 0
similar B-OTHER
response 0
rates B-OTHER
in 0
the 0
lisinopril 0
and 0
nifedipine 0
groups 0
( 0
89 0
% 0
and 0
75 0
% 0
respectively 0
) 0
. 0

The 0
rate 0
of 0
reporting 0
of 0
adverse B-ADVERSE-EFFECTS
events B-ADVERSE-EFFECTS
considered 0
to 0
be 0
drug-related 0
and 0
the 0
rate 0
of 0
withdrawals 0
were 0
similar 0
for 0
both 0
treatments 0
. 0

Cough B-ADVERSE-EFFECTS
was 0
more 0
often 0
reported 0
with 0
lisinopril 0
and 0
headache B-ADVERSE-EFFECTS
, 0
sweating B-ADVERSE-EFFECTS
, 0
and 0

A 0
good 0
response 0
to 0
oil 0
with 0
medium- 0
and 0
long-chain 0
fatty 0
acids 0
in 0
body B-PHYSICAL
fat I-PHYSICAL
and 0
blood B-PHYSICAL
lipid I-PHYSICAL
profiles I-PHYSICAL
of 0
male 0
hypertriglyceridemic 0
subjects 0
. 0

A 0
double 0
blind 0
clinical 0
trial 0
was 0
carried 0
out 0
to 0
clarify 0
the 0
effects 0
of 0
oil 0
with 0
medium- 0
and 0
long-chain 0
triglyceride 0
( 0
MLCT 0
) 0
on 0
body B-PHYSICAL
fat I-PHYSICAL
and 0
blood B-PHYSICAL
lipid I-PHYSICAL
profiles I-PHYSICAL
in 0
hypertriglyceridemic 0
subjects 0
. 0

One-hundred-and-twelve 0
subjects 0
were 0
enrolled 0
and 0
divided 0
into 0
two 0
groups 0
; 0
those 0
that 0
consumed 0
MLCT 0
oil 0
and 0
those 0
that 0
consumed 0
long-chain 0
triglyceride 0
( 0
LCT 0
) 0
oil 0
for 0
8 0
weeks 0
. 0

All 0
subjects 0
were 0
requested 0
to 0
consume 0
25-30 0
g 0
of 0
the 0
oils 0
daily 0
and 0
maintain 0
a 0
fixed 0
level 0
of 0
energy 0
intake 0
and 0
exercise 0
. 0

Anthropometric B-PHYSICAL
and I-PHYSICAL
blood I-PHYSICAL
biochemical I-PHYSICAL
parameters I-PHYSICAL
were 0
measured 0
when 0
the 0
study 0
was 0
initiated 0
and 0
completed 0
. 0

The 0
LCT 0
group 0
consisted 0
of 0
50 0
subjects 0
( 0
34 0
men 0
and 0
16 0
women 0
) 0
, 0
while 0
the 0
MLCT 0
group 0
consisted 0
of 0
51 0
subjects 0
( 0
33 0
men 0
and 0
18 0
women 0
) 0
who 0
completed 0
the 0
study 0
. 0

Larger 0
decreases 0
in 0
body B-PHYSICAL
weight 0
, 0
body B-PHYSICAL
mass 0
index 0
, 0
waist 0
circumference 0
, 0
body B-PHYSICAL
fat 0
, 0
total 0
fat 0
area 0
and 0
subcutaneous 0
fat 0
area 0
in 0
the 0
abdomen 0
and 0
serum 0
triglycerides 0
, 0
low-density 0
lipoprotein 0
cholesterol 0
, 0
apolipoprotein 0
B 0
, 0
C2 0
, 0
C3 0
and 0
E 0
were 0
observed 0
in 0
male 0
subjects 0
in 0
the 0
MLCT 0
group 0
than 0
those 0
in 0
the 0
LCT 0
group 0
. 0

However 0
, 0
no 0
significant 0
differences 0
in 0
these 0
parameters B-OTHER
between 0
the 0
female 0
subjects 0
in 0
the 0
two 0
groups 0
were 0
observed 0
. 0

Data 0
from 0
this 0
study 0
indicate 0
that 0
consumption 0
of 0
medium-and 0
long-chain 0
triglycerides 0
can 0
reduce 0
body B-PHYSICAL
weight I-PHYSICAL
and 0
body B-PHYSICAL

Teaching 0
young 0
nonverbal 0
children 0
with 0
autism 0
useful 0
speech 0
: 0
a 0
pilot 0
study 0
of 0
the 0
Denver 0
Model 0
and 0
PROMPT 0
interventions 0
. 0

This 0
single 0
subject 0
design 0
study 0
examined 0
two 0
models 0
of 0
intervention 0
: 0
Denver 0
Model 0
( 0
which 0
merges 0
behavioral 0
, 0
developmental 0
, 0
and 0
relationship-oriented 0
intervention 0
) 0
, 0
and 0
PROMPT 0
( 0
a 0
neuro-developmental 0
approach 0
for 0
speech 0
production 0
disorders 0
) 0
. 0

Ten 0
young 0
, 0
nonverbal 0
children 0
with 0
autism 0
were 0
matched 0
in 0
pairs 0
and 0
randomized 0
to 0
treatment 0
. 0

They 0
received 0
12 0
1-h 0
weekly 0
sessions 0
of 0
therapy 0
and 0
daily 0
1-h 0
home 0
intervention 0
delivered 0
by 0
parents 0
. 0

Fidelity 0
criteria 0
were 0
maintained 0
throughout 0
. 0

Eight 0
of 0
the 0
ten 0
children 0
used 0
five 0
or 0
more 0
novel 0
, 0
functional B-MENTAL
words 0
spontaneously 0
and 0
spoke 0
multiple 0
times 0
per 0
hour 0
by 0
the 0
conclusion 0
of 0
treatment 0
. 0

There 0
were 0
no 0
differences 0
in 0
acquired B-MENTAL
language I-MENTAL
skills I-MENTAL
by 0
intervention 0
group 0
. 0

Initial 0
characteristics 0
of 0
the 0
best 0
responders 0
were 0
mild 0
to 0
moderate 0
symptoms 0
of 0
autism 0
, 0
better 0
motor 0
imitation 0
skills 0
, 0
and 0
emerging 0
joint 0
attention 0
skills 0
. 0

Clinical 0
evaluation 0
of 0
imidapril 0
in 0
congestive 0
heart 0
failure 0
in 0
dogs 0
: 0
results 0
of 0
the 0
EFFIC 0
study 0
. 0

OBJECTIVES 0
The 0
clinical 0
efficacy 0
and 0
safety 0
of 0
imidapril 0
were 0
evaluated 0
in 0
dogs 0
that 0
presented 0
with 0
mild 0
to 0
severe 0
congestive 0
heart 0
failure 0
( 0
New 0
York 0
Heart 0
Association 0
stage 0
II 0
to 0
IV 0
) 0
by 0
comparing 0
the 0
success 0
rate 0
of 0
imidapril 0
with 0
a 0
positive 0
control 0
by 0
a 0
non-inferiority 0
approach 0
. 0

METHODS 0
This 0
good 0
, 0
clinical 0
practice 0
compliant 0
, 0
multicentre 0
study 0
( 0
EFFIC 0
study 0
) 0
enrolled 0
142 0
client-owned 0
dogs 0
and 0
was 0
conducted 0
in 0
20 0
locations 0
in 0
France 0
, 0
Belgium 0
and 0
Germany 0
. 0

Dogs 0
of 0
various 0
breed 0
, 0
age 0
and 0
weight 0
were 0
included 0
in 0
the 0
study 0
. 0

These 0
dogs 0
were 0
randomised 0
into 0
two 0
groups 0
that 0
were 0
treated 0
for 0
84 0
days 0
with 0
either 0
the 0
test 0
product 0
, 0
imidapril 0
, 0
or 0
the 0
positive 0
control 0
, 0
benazepril 0
, 0
and 0
followed 0
up 0
in 0
parallel 0
over 0
this 0
period 0
. 0

Both 0
treatments 0
were 0
administered 0
at 0
a 0
dose 0
of 0
0.25 0
mg/kg 0
once 0
a 0
day 0
with 0
the 0
possibility 0
of 0
doubling 0
this 0
dose 0
to 0
0.5 0
mg/kg 0
if 0
considered 0
necessary 0
from 0
a 0
clinical 0
point 0
of 0
view 0
. 0

In 0
addition 0
, 0
concomitant 0
treatment 0
was 0
given 0
to 0
dogs 0
presenting 0
with 0
pulmonary 0
oedema 0
and/or 0
ascites 0
, 0
supraventricular 0
tachyarrhythmia 0
and/or 0
dilated 0
cardiomyopathy 0
. 0

The 0
evolution B-PHYSICAL
of I-PHYSICAL
the I-PHYSICAL
New I-PHYSICAL
York I-PHYSICAL
Heart I-PHYSICAL
Association 0
stage B-PHYSICAL
and 0
the 0
functional B-PHYSICAL
signs I-PHYSICAL
score B-PHYSICAL
were 0
evaluated 0
as 0
primary 0
efficacy 0
criteria 0
. 0

RESULTS 0
The 0
success B-OTHER
rate I-OTHER
in 0
the 0
imidapril 0
group 0
was 0
66 0
compared 0
with 0
68 0
per 0
cent 0
in 0
the 0
benazepril 0
group 0
. 0

Regarding 0
safety 0
, 0
35 0
dogs 0
in 0
each 0
group 0
experienced 0
at 0
least 0
one 0
adverse B-ADVERSE-EFFECTS
event 0
. 0

Nine 0
dogs 0
in 0
each 0
group 0
experienced 0
at 0
least 0
one 0
serious B-ADVERSE-EFFECTS

Breast 0
reduction 0
alleviates 0
depression B-MENTAL
and 0
anxiety B-MENTAL
and 0
restores 0
self-esteem B-MENTAL
: 0
a 0
prospective 0
randomised 0
clinical 0
trial 0
. 0

Of 0
women 0
who 0
seek 0
reduction 0
mammaplasty 0
, 0
up 0
to 0
a 0
third 0
have 0
pathological 0
degrees 0
of 0
anxiety B-MENTAL
or 0
depression B-MENTAL
, 0
or 0
both 0
. 0

The 0
psychological B-MENTAL
aspect I-MENTAL
of 0
reduction 0
mammaplasty 0
is 0
therefore 0
an 0
important 0
consideration 0
. 0

We 0
did 0
a 0
prospective 0
randomised 0
clinical 0
trial 0
to 0
see 0
how 0
reduction 0
mammaplasty 0
affected 0
macromastia 0
patients 0
' 0
depression B-MENTAL
, 0
anxiety B-MENTAL
, 0
and 0
self-esteem B-MENTAL
. 0

Eighty-two 0
patients 0
were 0
randomised 0
, 0
40 0
to 0
have 0
the 0
operation 0
, 0
and 0
42 0
patients 0
to 0
conservative 0
treatment 0
. 0

Both 0
groups 0
were 0
followed 0
for 0
six 0
months 0
. 0

The 0
patients 0
completed 0
the 0
RBDI B-MENTAL
questionnaire 0
( B-MENTAL
Raitasalo I-MENTAL
's 0
modification B-MENTAL
of I-MENTAL
the I-MENTAL
short I-MENTAL
form I-MENTAL
of I-MENTAL
the I-MENTAL
Beck I-MENTAL
Depression I-MENTAL
Inventory I-MENTAL
) B-MENTAL
. 0

Twenty-nine 0
patients 0
in 0
the 0
operated 0
group 0
and 0
35 0
patients 0
in 0
the 0
conservative 0
group 0
completed 0
the 0
study 0
. 0

At 0
the 0
second 0
examination 0
, 0
the 0
patients 0
who 0
had 0
been 0
operated 0
on 0
, 0
had 0
significantly 0
less 0
depression B-MENTAL
( 0
p 0
< 0
0.01 0
) 0
and 0
better B-MENTAL
self-esteem B-MENTAL
( 0
p=0.03 0
) 0
than 0
the 0
conservative 0
group 0
. 0

The 0
proportions 0
of 0
depressed B-MENTAL
( 0
p 0
< 0
0.01 0
) 0
and 0
anxious B-MENTAL
( 0
p=0.04 0
) 0
patients 0
were 0
also 0
smaller 0
in 0
the 0
group 0
who 0
were 0
operated 0
on 0
. 0

There 0
is 0
significantly 0
less 0
depression B-MENTAL
and 0

Comparison 0
of 0
ketoconazole 0
and 0
griseofulvin 0
in 0
the 0
treatment 0
of 0
tinea 0
pedis 0
. 0

Twenty-nine 0
patients 0
with 0
mycologically 0
proven 0
tinea 0
pedis 0
were 0
randomly 0
allocated 0
to 0
oral 0
treatment 0
with 0
either 0
ketoconazole 0
200 0
mg 0
daily 0
or 0
griseofulvin 0
1 0
g 0
daily 0
for 0
a 0
period 0
of 0
up 0
to 0
8 0
weeks 0
. 0

Mycological B-OTHER
cure I-OTHER
rate I-OTHER
at 0
4 0
weeks 0
was 0
33 0
% 0
for 0
ketoconazole 0
and 0
29 0
% 0
for 0
griseofulvin 0
, 0
and 0
at 0
8 0
weeks 0
was 0
53 0
% 0
and 0
57 0
% 0
respectively 0
. 0

The 0
efficacy 0
of 0
both 0
drugs 0
in 0
the 0
treatment 0
of 0
interdigital 0
tinea 0
pedis 0
is 0
similar 0
, 0
and 0
is 0
considerably 0
lower 0
than 0
that 0
found 0
with 0
topical 0
imidazole 0
preparations 0
where 0
cure B-OTHER
rates I-OTHER
of 0
over 0
70 0
% 0
are 0
generally 0
expected 0
. 0

Bizzy 0
Break 0
! 0

The 0
effect 0
of 0
a 0
classroom-based 0
activity 0
break 0
on 0
in-school B-MENTAL
physical I-MENTAL
activity I-MENTAL
levels I-MENTAL
of 0
primary 0
school 0
children 0
. 0

The 0
school 0
has 0
been 0
identified 0
as 0
a 0
key 0
setting 0
to 0
promote 0
physical 0
activity 0
. 0

The 0
purpose 0
of 0
this 0
study 0
was 0
to 0
evaluate 0
the 0
effect 0
of 0
a 0
classroom-based 0
activity 0
break 0
on 0
in-school B-MENTAL
step I-MENTAL
counts I-MENTAL
of 0
primary 0
school 0
children 0
. 0

Data 0
for 0
90 0
children 0
( 0
49 0
boys 0
, 0
41 0
girls 0
, 0
9.3 0
? 0

1.4 0
years 0
) 0
from 0
three 0
Irish 0
primary 0
schools 0
is 0
presented 0
. 0

In 0
each 0
school 0
one 0
class 0
was 0
randomly 0
assigned 0
as 0
the 0
intervention 0
group 0
and 0
another 0
as 0
controls 0
. 0

Children 0
's 0
step 0
counts 0
were 0
measured 0
for 0
five 0
consecutive 0
days 0
during 0
school 0
hours 0
at 0
baseline 0
and 0
follow-up 0
. 0

Teachers 0
of 0
the 0
intervention 0
classes 0
led 0
a 0
10 0
min 0
activity 0
break 0
in 0
the 0
classroom 0
each 0
day 0
( 0
Bizzy 0
Break 0
! 0
) 0
. 0

Mean 0
daily 0
in-school 0
steps 0
for 0
the 0
intervention 0
at 0
baseline 0
and 0
follow-up 0
were 0
5351 0
and 0
5054 0
. 0

Corresponding 0
values 0
for 0
the 0
control 0
group 0
were 0
5469 0
and 0
4246 0
. 0

There 0
was 0
a 0
significant 0
difference 0
in 0
the 0
change 0
in 0
daily 0
steps 0
from 0
baseline 0
to 0
follow-up 0
between 0
groups 0
( 0
p 0
< 0
.05 0
) 0
. 0

There 0
was 0
no 0
evidence 0
that 0
girls 0
and 0
boys 0
responded 0
differently 0
to 0
the 0
intervention 0
( 0
p 0
> 0
.05 0
) 0
. 0

Children 0
participating 0
in 0
a 0
daily 0
10 0
min 0
classroom-based 0
activity 0
break 0
undertake 0
more 0
physical 0
activity 0
during 0
school 0
hours 0
than 0
controls 0
. 0

Cost-effectiveness B-OTHER
of 0
collaborative 0
care 0
including 0
PST 0
and 0
an 0
antidepressant 0
treatment 0
algorithm 0
for 0
the 0
treatment 0
of 0
major 0
depressive 0
disorder 0
in 0
primary 0
care 0
; 0
a 0
randomised 0
clinical 0
trial 0
. 0

BACKGROUND 0
Depressive 0
disorder 0
is 0
currently 0
one 0
of 0
the 0
most 0
burdensome 0
disorders 0
worldwide 0
. 0

Evidence-based 0
treatments 0
for 0
depressive 0
disorder 0
are 0
already 0
available 0
, 0
but 0
these 0
are 0
used 0
insufficiently 0
, 0
and 0
with 0
less 0
positive 0
results 0
than 0
possible 0
. 0

Earlier 0
research 0
in 0
the 0
USA 0
has 0
shown 0
good 0
results 0
in 0
the 0
treatment 0
of 0
depressive 0
disorder 0
based 0
on 0
a 0
collaborative 0
care 0
approach 0
with 0
Problem B-PHYSICAL
Solving I-PHYSICAL
Treatment I-PHYSICAL
and 0
an 0
antidepressant 0
treatment 0
algorithm 0
, 0
and 0
research 0
in 0
the 0
UK 0
has 0
also 0
shown 0
good 0
results 0
with 0
Problem 0
Solving 0
Treatment 0
. 0

These 0
treatment 0
strategies 0
may 0
also 0
work 0
very 0
well 0
in 0
the 0
Netherlands 0
too 0
, 0
even 0
though 0
health 0
care 0
systems 0
differ 0
between 0
countries 0
. 0

METHODS/DESIGN 0
This 0
study 0
is 0
a 0
two-armed 0
randomised 0
clinical 0
trial 0
, 0
with 0
randomization 0
on 0
patient-level 0
. 0

The 0
aim 0
of 0
the 0
trial 0
is 0
to 0
evaluate 0
the 0
treatment 0
of 0
depressive 0
disorder 0
in 0
primary 0
care 0
in 0
the 0
Netherlands 0
by 0
means 0
of 0
an 0
adapted 0
collaborative 0
care 0
framework 0
, 0
including 0
contracting 0
and 0
adherence-improving 0
strategies 0
, 0
combined 0
with 0
Problem 0
Solving 0
Treatment 0
and 0
antidepressant 0
medication 0
according 0
to 0
a 0
treatment 0
algorithm 0
. 0

Forty 0
general 0
practices 0
will 0
be 0
randomised 0
to 0
either 0
the 0
intervention 0
group 0
or 0
the 0
control 0
group 0
. 0

Included 0
will 0
be 0
patients 0
who 0
are 0
diagnosed 0
with 0
moderate 0
to 0
severe 0
depression 0
, 0
based 0
on 0
DSM-IV 0
criteria 0
, 0
and 0
stratified 0
according 0
to 0
comorbid 0
chronic 0
physical 0
illness 0
. 0

Patients 0
in 0
the 0
intervention 0
group 0
will 0
receive 0
treatment 0
based 0
on 0
the 0
collaborative 0
care 0
approach 0
, 0
and 0
patients 0
in 0
the 0
control 0
group 0
will 0
receive 0
care 0
as 0
usual 0
. 0

Baseline 0
measurements 0
and 0
follow 0
up 0
measures 0
( 0
3 0
, 0
6 0
, 0
9 0
and 0
12 0
months 0
) 0
are 0
assessed 0
using 0
questionnaires 0
and 0
an 0
interview 0
. 0

The 0
primary 0
outcome 0
measure 0
is 0
severity 0
of 0
depressive B-MENTAL
symptoms I-MENTAL
, 0
according 0
to 0
the 0
PHQ9 B-PHYSICAL
. 0

Secondary 0
outcome 0
measures 0
are 0
remission B-PHYSICAL
as I-PHYSICAL
measured I-PHYSICAL
with I-PHYSICAL
the I-PHYSICAL
PHQ9 I-PHYSICAL
and I-PHYSICAL
the I-PHYSICAL
IDS-SR I-PHYSICAL
, I-PHYSICAL
and 0
cost-effectiveness B-OTHER
measured 0
with 0
the 0
TiC-P B-OTHER
, 0
the 0
EQ-5D B-OTHER
and 0
the 0
SF-36 B-OTHER
. 0

DISCUSSION 0
In 0
this 0
study 0
, 0
an 0
American 0
model 0
to 0
enhance 0
care 0
for 0
patients 0
with 0
a 0
depressive 0
disorder 0
, 0
the 0
collaborative 0
care 0
model 0
, 0
will 0
be 0
evaluated 0
for 0
effectiveness 0
in 0
the 0
primary 0
care 0
setting 0
. 0

If 0
effective 0
across 0
the 0
Atlantic 0
and 0
across 0
different 0
health 0
care 0
systems 0
, 0
it 0
is 0
also 0
likely 0
to 0
be 0
an 0
effective 0
strategy 0
to 0
implement 0
in 0
the 0
treatment 0
of 0
major 0
depressive 0
disorder 0
in 0
the 0
Netherlands 0
. 0

A 0
controlled 0
study 0
of 0
psychiatric 0
hospital 0
versus 0
community 0
treatment 0
- 0
the 0
effect 0
on 0
relatives B-MENTAL
. 0

One 0
hundred 0
and 0
twenty 0
patients 0
presenting 0
at 0
Macquarie 0
Hospital 0
for 0
admission 0
were 0
randomly 0
allocated 0
into 0
two 0
groups 0
. 0

The 0
control 0
group 0
patients 0
received 0
standard 0
hospital 0
care 0
and 0
follow-up 0
. 0

The 0
project 0
group 0
patients 0
were 0
not 0
admitted 0
if 0
this 0
could 0
be 0
avoided 0
; 0
instead 0
they 0
were 0
taken 0
back 0
to 0
the 0
community 0
by 0
the 0
project 0
team 0
who 0
provided 0
them 0
and 0
their 0
relatives 0
with 0
comprehensive 0
, 0
assertive 0
and 0
prolonged 0
follow-up 0
treatment 0
backed 0
by 0
a 0
24-hour 0
crisis 0
service 0
. 0

The 0
majority 0
( 0
63 0
% 0
) 0
of 0
the 0
project 0
group 0
had 0
no 0
admission 0
during 0
the 0
10 0
month 0
study 0
period 0
. 0

Initially 0
, 0
the 0
burden B-MENTAL
on I-MENTAL
the I-MENTAL
relatives I-MENTAL
of 0
the 0
project 0
group 0
was 0
higher 0
, 0
but 0
by 0
one 0
month 0
it 0
was 0
somewhat 0
lower 0
and 0
by 0
four 0
months 0
it 0
was 0
significantly 0
lower 0
than 0
the 0
burden 0
on 0
the 0
control 0
group 0
relatives 0
. 0

Relatives 0
of 0
the 0
project 0
group 0
patients 0
were 0
significantly 0
more 0
satisfied B-MENTAL
with I-MENTAL
the I-MENTAL
treatment I-MENTAL
than 0
control 0
group 0
relatives 0
. 0

It 0
is 0
clearly 0
feasible 0
to 0
treat 0
most 0
psychiatric 0
patients 0
in 0
the 0
community 0
without 0
increasing 0
the 0
burden B-MENTAL
on I-MENTAL
their I-MENTAL
relatives I-MENTAL
. 0

Tubeless 0
percutaneous 0
nephrolithotomy 0
: 0
safe 0
even 0
in 0
supracostal 0
access 0
. 0

PURPOSE 0
This 0
study 0
was 0
designed 0
to 0
determine 0
the 0
outcome 0
and 0
safety B-OTHER
of 0
tubeless 0
percutaneous 0
nephrolithotomy 0
( 0
PCNL 0
) 0
in 0
the 0
treatment 0
of 0
renal 0
calculi 0
. 0

PATIENTS 0
AND 0
METHODS 0
Between 0
November 0
2005 0
and 0
March 0
2006 0
, 0
48 0
patients 0
were 0
randomized 0
to 0
either 0
an 0
18F 0
Re-entry 0
nephrostomy 0
tube 0
( 0
group 0
1 0
) 0
or 0
a 0
6F 0
Double-J 0
stent 0
( 0
group 0
2 0
) 0
. 0

The 0
two 0
groups 0
were 0
well 0
matched 0
for 0
age 0
, 0
sex 0
, 0
stone 0
size 0
, 0
stone 0
laterality 0
, 0
and 0
number 0
of 0
previous 0
renal 0
procedures 0
. 0

All 0
PCNL 0
procedures 0
were 0
performed 0
by 0
the 0
same 0
surgeon 0
. 0

Postoperative B-PAIN
visual I-PAIN
analog I-PAIN
pain I-PAIN
scale I-PAIN
( I-PAIN
VAS 0
) B-PAIN
scores 0
at 0
8 0
and 0
24 0
hours 0
and 0
14 0
days 0
after 0
surgery 0
, 0
in-hospital B-OTHER
analgesic I-OTHER
use B-OTHER
, I-OTHER
length I-OTHER
of B-OTHER
hospital I-OTHER
stay B-OTHER
, 0
success B-OTHER
rate I-OTHER
, 0
blood B-OTHER
transfusion I-OTHER
rate B-OTHER
, 0
and 0
postoperative B-ADVERSE-EFFECTS
complications I-ADVERSE-EFFECTS
were 0
compared 0
for 0
the 0
two 0
groups 0
. 0

RESULTS 0
The 0
mean 0
hospital B-OTHER
stays I-OTHER
in 0
groups 0
1 0
and 0
2 0
were 0
3.1 0
and 0
1.6 0
days 0
, 0
respectively 0
( 0
P 0
= 0
0.003 0
) 0
. 0

The 0
mean 0
VAS 0
scores 0
8 0
and 0
24 0
hours 0
after 0
surgery 0
were 0
significantly 0
lower 0
in 0
group 0
2 0
than 0
in 0
group 0
1 0
( 0
P 0
= 0
0.001 0
) 0
. 0

The 0
postoperative B-PAIN
analgesic I-PAIN
requirement I-PAIN
( 0
diclofenac 0
sodium 0
) 0
was 0
significantly 0
higher 0
in 0
group 0
1 0
( 0
263 0
mg 0
) 0
than 0
in 0
group 0
2 0
( 0
120 0
mg 0
; 0
P 0
= 0
0.02 0
) 0
. 0

The 0
rate 0
of 0
blood B-PHYSICAL
transfusion I-PHYSICAL
in 0
the 0
two 0
groups 0
was 0
similar 0
( 0
P 0
= 0
NS 0
) 0
. 0

There 0
was 0
no 0
difference 0
between 0
the 0
groups 0
in 0
VAS 0
scores 0
on 0
postoperative 0
day 0
14 0
. 0

The 0
number 0
of 0
supracostal B-PHYSICAL
accesses I-PHYSICAL
was 0
significantly 0
higher 0
in 0
group 0
2 0
than 0
in 0
group 0
1 0
( 0
P 0
= 0
0.02 0
) 0
. 0

The 0

Enhancing 0
attitudes B-MENTAL
and 0
intentions B-MENTAL
in 0
prospective 0
blood 0
donors 0
: 0
evaluation 0
of 0
a 0
new 0
donor 0
recruitment 0
brochure 0
. 0

BACKGROUND 0
Although 0
little 0
empiric 0
evidence 0
has 0
been 0
published 0
concerning 0
the 0
efficacy 0
of 0
blood 0
donor 0
recruitment 0
materials 0
, 0
research 0
suggests 0
that 0
simple 0
attempts 0
to 0
enhance 0
knowledge 0
may 0
not 0
be 0
sufficient 0
to 0
motivate B-MENTAL
donation I-MENTAL
. 0

In 0
contrast 0
, 0
recent 0
donor 0
motivation 0
studies 0
highlight 0
the 0
importance 0
of 0
anxiety B-MENTAL
, 0
attitudes B-MENTAL
, 0
and 0
perceived B-MENTAL
ability I-MENTAL
to I-MENTAL
cope I-MENTAL
with I-MENTAL
donation I-MENTAL
( 0
i.e. 0
, 0
self-efficacy 0
) 0
as 0
crucial 0
determinants 0
of 0
donation 0
intention 0
. 0

Therefore 0
, 0
recruitment 0
materials 0
that 0
specifically 0
address 0
these 0
constructs 0
have 0
the 0
potential 0
to 0
outperform 0
traditional 0
educational 0
brochures 0
. 0

STUDY 0
DESIGN 0
AND 0
METHODS 0
Participants 0
were 0
randomly 0
assigned 0
to 0
read 0
one 0
of 0
three 0
brochures 0
: 0
1 0
) 0
a 0
new 0
brochure 0
addressing 0
common 0
donor 0
concerns 0
and 0
suggesting 0
specific 0
coping 0
strategies 0
, 0
2 0
) 0
a 0
standard 0
blood 0
center 0
brochure 0
, 0
or 0
3 0
) 0
a 0
control 0
brochure 0
on 0
healthy 0
eating 0
and 0
exercise 0
. 0

Standardized 0
questionnaires 0
were 0
completed 0
before 0
and 0
after 0
the 0
brochures 0
to 0
assess 0
change 0
in 0
blood B-MENTAL
donation I-MENTAL
anxiety I-MENTAL
, 0
attitude B-MENTAL
, 0
self-efficacy B-MENTAL
, 0
and 0
intention B-MENTAL
. 0

RESULTS 0
Although 0
no 0
significant 0
changes 0
were 0
noted 0
for 0
the 0
control 0
brochure 0
, 0
after 0
reading 0
the 0
new 0
brochure 0
participants 0
reported 0
significant 0
improvements 0
in 0
attitude B-MENTAL
, 0
anxiety B-MENTAL
, 0
self-efficacy B-MENTAL
, 0
and 0
donation B-MENTAL
intention I-MENTAL
. 0

The 0
standard 0
donation 0
brochure 0
had 0
an 0
intermediate 0
effect 0
. 0

CONCLUSION 0
Efforts 0
to 0
address 0
common 0
donor 0
fears 0
and 0
to 0
provide 0
useful 0
coping 0
suggestions 0
may 0
improve 0
the 0
effectiveness 0
of 0
blood B-MENTAL
donation I-MENTAL
recruitment I-MENTAL
materials I-MENTAL
. 0

Effect 0
of 0
cervical 0
spine 0
manipulative 0
therapy 0
on 0
judo 0
athletes 0
' 0
grip 0
strength 0
. 0

OBJECTIVE 0
The 0
objective 0
of 0
this 0
study 0
was 0
to 0
perform 0
an 0
investigation 0
evaluating 0
if 0
cervical 0
spinal 0
manipulative 0
therapy 0
( 0
SMT 0
) 0
can 0
increase 0
grip 0
strength 0
on 0
judo 0
athletes 0
in 0
a 0
top 0
10 0
national-ranked 0
team 0
. 0

METHODS 0
A 0
single-blinded 0
, 0
prospective 0
, 0
comparative 0
, 0
pilot 0
, 0
randomized 0
, 0
clinical 0
trial 0
was 0
performed 0
with 0
18 0
athletes 0
of 0
both 0
sexes 0
from 0
a 0
judo 0
team 0
currently 0
competing 0
on 0
a 0
national 0
level 0
. 0

The 0
athletes 0
were 0
randomly 0
assigned 0
to 0
2 0
groups 0
: 0
chiropractic 0
SMT 0
and 0
sham 0
. 0

Three 0
interventions 0
were 0
performed 0
on 0
each 0
of 0
the 0
athletes 0
at 0
different 0
time 0
points 0
. 0

Force 0
measurements 0
were 0
obtained 0
by 0
a 0
hydraulic 0
dynamometer 0
immediately 0
before 0
and 0
after 0
each 0
intervention 0
at 0
the 0
same 0
period 0
before 0
training 0
up 0
to 0
3 0
weeks 0
with 0
at 0
least 0
36 0
hours 0
between 0
interventions 0
. 0

RESULTS 0
Analysis 0
of 0
grip B-PHYSICAL
strength I-PHYSICAL
data 0
revealed 0
a 0
statistically 0
significant 0
increase 0
in 0
strength B-OTHER
within 0
the 0
treatment 0
group 0
after 0
the 0
first 0
intervention 0
( 0
6.95 0
% 0
right 0
, 0
12.61 0
% 0
left 0
) 0
as 0
compared 0
with 0
the 0
second 0
( 0
11.53 0
% 0
right 0
, 0
17.02 0
% 0
left 0
) 0
and 0
the 0
third 0
interventions 0
( 0
10.53 0
% 0
right 0
, 0
16.81 0
% 0
left 0
) 0
. 0

No 0
statistically 0
significant 0
differences 0
were 0
found 0
in 0
grip B-OTHER
strength I-OTHER
comparison I-OTHER
within 0
the 0
sham 0
group 0
. 0

Overall 0
differences B-OTHER
in 0
strength B-PHYSICAL
were 0
consistently 0
significant 0
between 0
the 0
study 0
groups 0
( 0
P 0
= 0
.0025 0
) 0
. 0

CONCLUSION 0
The 0
present 0
study 0
suggests 0
that 0
the 0
grip 0
strength 0
of 0
national 0
level 0
judo 0
athletes 0
receiving 0
chiropractic 0
SMT 0
improved 0
compared 0
to 0
those 0
receiving 0
sham 0
. 0

Fusidic 0
acid 0
prophylaxis 0
before 0
cataract 0
surgery 0
: 0
patient 0
self-administration 0
. 0

In 0
a 0
placebo-controlled 0
, 0
randomised 0
, 0
double-blind 0
clinical 0
trial 0
, 0
the 0
authors 0
evaluated 0
the 0
efficacy 0
of 0
patient-administered 0
1 0
% 0
fusidic 0
acid 0
viscous 0
eye 0
drops 0
in 0
clearing 0
the 0
commonest 0
organisms 0
causing 0
pseudophakic 0
endophthalmitis 0
( 0
Staphylococcus 0
epidermidis 0
and 0
aureus 0
) 0
from 0
the 0
lids 0
and 0
conjunctivae 0
of 0
79 0
patients 0
before 0
cataract 0
surgery 0
. 0

The 0
treatment 0
group 0
self-administered 0
fusidic 0
acid 0
viscous 0
eye 0
drops 0
four 0
times 0
daily 0
for 0
seven 0
days 0
before 0
surgery 0
; 0
the 0
placebo 0
group 0
received 0
inert 0
ophthalmic 0
drops 0
. 0

Fellow 0
eyes 0
of 0
both 0
groups 0
remained 0
untreated 0
as 0
a 0
natural 0
control 0
. 0

Lower 0
fornix 0
and 0
lid 0
margin 0
cultures 0
were 0
taken 0
from 0
both 0
eyes 0
before 0
and 0
after 0
treatment 0
. 0

Before 0
treatment 0
, 0
there 0
was 0
no 0
statistical 0
difference 0
in 0
organism B-PHYSICAL
counts I-PHYSICAL
between 0
the 0
groups 0
. 0

After 0
treatment 0
, 0
eyes 0
receiving 0
fusidic 0
acid 0
were 0
more 0
likely 0
to 0
be 0
free 0
of 0
clinically 0
relevant 0
Staphylococcus 0
spp 0
. 0

than 0
all 0
pre-treatment 0
eyes 0
( 0
for 0
lids 0
, 0
P 0
< 0
0.001 0
; 0
conjunctivae 0
, 0
P 0
= 0
0.02 0
) 0
. 0

A 0
highly 0
significant 0
( 0
P 0
< 0
0.001 0
) 0
number 0
of 0
lid B-PHYSICAL
margins I-PHYSICAL
were 0
rendered 0
'clinically 0
clean 0
' 0
( 0
i.e. 0
, 0
0-49 0
organisms/swab 0
) 0
by 0
fusidic 0
acid 0
when 0
compared 0
with 0
untreated 0
eyes 0
. 0

Treatment 0
also 0
effectively 0
( 0
P 0
< 0
0.05 0
) 0
reduced 0
the 0
numbers 0
of 0
bacteria B-PHYSICAL
isolated I-PHYSICAL
from I-PHYSICAL
conjunctivae I-PHYSICAL
. 0

This 0
study 0
indicates 0
that 0
there 0
is 0
a 0
highly 0
significant 0
reduction 0
of 0
Staphylococcus 0
spp 0
. 0
( 0

P 0
< 0
0.001 0
) 0
, 0
non-Staphylococcus 0
spp 0
. 0
( 0

P 0
< 0
0.001 0
) 0
and 0
attainment 0
of 0
sterile 0
eyes 0
( 0
P 0
< 0
0.001 0
) 0
at 0
operation 0
gained 0
by 0
patient 0
self-administration 0
of 0
1 0
% 0
fusidic 0
acid 0
four 0
times 0
daily 0
for 0
seven 0
days 0
before 0
surgery 0
. 0

Can 0
incentives 0
undermine 0
intrinsic B-MENTAL
motivation I-MENTAL
to 0
participate 0
in 0
epidemiologic 0
surveys 0
? 0

Response 0
rates 0
to 0
surveys 0
are 0
decreasing 0
. 0

The 0
purpose 0
of 0
this 0
study 0
was 0
to 0
evaluate 0
the 0
use 0
of 0
lottery 0
tickets 0
as 0
incentives 0
in 0
an 0
epidemiologic 0
control 0
group 0
. 0

A 0
self-administered 0
questionnaire 0
was 0
sent 0
to 0
parents 0
in 0
the 0
municipality 0
of 0
Stockholm 0
, 0
Sweden 0
, 0
who 0
were 0
to 0
be 0
used 0
as 0
a 0
control 0
group 0
in 0
a 0
study 0
addressing 0
stress 0
in 0
parents 0
of 0
children 0
with 0
cancer 0
. 0

A 0
stratified 0
random 0
sample 0
of 0
450 0
parents 0
were 0
randomized 0
into 0
three 0
incentive 0
groups 0
: 0
( 0
a 0
) 0
no 0
incentive 0
; 0
( 0
b 0
) 0
a 0
promised 0
incentive 0
of 0
one 0
lottery 0
ticket 0
to 0
be 0
received 0
upon 0
reply 0
; 0
( 0
c 0
) 0
a 0
promised 0
incentive 0
of 0
one 0
lottery 0
ticket 0
to 0
be 0
received 0
upon 0
reply 0
and 0
an 0
additional 0
lottery 0
ticket 0
upon 0
reply 0
within 0
1 0
week 0
. 0

The 0
overall 0
response 0
rate B-MENTAL
across 0
the 0
three 0
groups 0
was 0
65.3 0
% 0
. 0

The 0
response 0
rate B-MENTAL
was 0
highest 0
in 0
the 0
no 0
incentive 0
group 0
( 0
69.3 0
% 0
) 0
and 0
lowest 0
in 0
the 0
one 0
plus 0
one 0
lottery 0
ticket 0
group 0
( 0
62.0 0
% 0
) 0
. 0

In 0
a 0
survival 0
analysis 0
, 0
the 0
difference 0
between 0
the 0
two 0
response 0
curves 0
was 0
significant 0
by 0
the 0
log-rank 0
test 0
( 0
P 0
= 0
0.04 0
) 0
, 0
with 0
the 0
no 0
incentive 0
group 0
having 0
a 0
shorter 0
time 0
to 0
response 0
than 0
the 0
incentive 0
group 0
. 0

Our 0
findings 0
suggest 0
that 0
the 0
use 0
of 0
lottery 0
tickets 0
as 0
incentives 0
to 0
increase 0
participation B-MENTAL
in 0
a 0
mail B-OTHER
questionnaire 0
among 0
parents 0
may 0
be 0
less 0
valuable 0
or 0
even 0
harmful 0
. 0

Incentives 0
may 0
undermine 0
motivation B-MENTAL
in 0
studies 0
in 0
which 0
the 0
intrinsic 0
motivation 0
of 0
the 0
respondents 0
is 0
already 0
high 0
. 0

Mending 0
the 0
rhythm 0
does 0
not 0
improve 0
prognosis 0
in 0
patients 0
with 0
persistent 0
atrial 0
fibrillation 0
: 0
a 0
subanalysis 0
of 0
the 0
RACE 0
study 0
. 0

AIMS 0
To 0
compare 0
outcome 0
of 0
AF 0
patients 0
with 0
effective 0
rhythm 0
control 0
with 0
patients 0
treated 0
with 0
rate 0
control 0
. 0

METHODS 0
AND 0
RESULTS 0
Out 0
of 0
the 0
266 0
AF 0
patients 0
randomized 0
to 0
rhythm 0
control 0
in 0
the 0
RACE 0
study 0
, 0
49 0
patients 0
turned 0
to 0
long-term 0
sinus 0
rhythm 0
and 0
were 0
continuously 0
treated 0
with 0
oral 0
anticoagulation 0
. 0

The 0
incidence 0
of 0
the 0
primary 0
endpoint 0
in 0
these 0
patients 0
was 0
compared 0
to 0
that 0
in 0
178 0
patients 0
out 0
of 0
the 0
initial 0
256 0
rate-control 0
patients 0
of 0
RACE 0
who 0
were 0
in 0
AF 0
and 0
using 0
oral 0
anticoagulation 0
continuously 0
. 0

Baseline 0
characteristics 0
of 0
both 0
groups 0
were 0
not 0
different 0
. 0

After 0
a 0
mean 0
follow-up 0
of 0
2.3+/-0.6 0
years 0
, 0
the 0
primary 0
endpoint 0
( 0
a 0
composite B-PHYSICAL
of I-PHYSICAL
cardiovascular I-PHYSICAL
mortality I-PHYSICAL
, 0
heart B-PHYSICAL
failure I-PHYSICAL
, 0
thrombo-embolic B-PHYSICAL
complications I-PHYSICAL
( I-PHYSICAL
TECs I-PHYSICAL
) I-PHYSICAL
, 0
bleeding B-PHYSICAL
, 0
serious B-ADVERSE-EFFECTS
adverse I-ADVERSE-EFFECTS
effects I-ADVERSE-EFFECTS
of I-ADVERSE-EFFECTS
antiarrhythmic I-ADVERSE-EFFECTS
drugs I-ADVERSE-EFFECTS
and 0
pacemaker B-ADVERSE-EFFECTS
implants I-ADVERSE-EFFECTS
) 0
was 0
22.4 0
% 0
in 0
the 0
rhythm-control 0
group 0
vs. 0
15.2 0
% 0
in 0
the 0
rate-control 0
group 0
. 0

Multivariable 0
regression 0
analysis 0
indicated 0
coronary B-PHYSICAL
artery I-PHYSICAL
disease I-PHYSICAL
, 0
heart 0
failure 0
, 0
and 0
digitalis B-PHYSICAL
as 0
independent 0
risk 0
indicators 0
of 0
cardiovascular 0
morbidity 0
and 0
mortality 0
. 0

Chronic B-PHYSICAL
sinus I-PHYSICAL
rhythm I-PHYSICAL
did 0
not 0
matter 0
. 0

CONCLUSION 0
Among 0
patients 0
who 0
remained 0
on 0
warfarin 0
, 0
those 0
who 0
mostly 0
were 0
maintained 0
in 0
sinus 0
rhythm 0
under 0
a 0
rhythm-control 0
strategy 0
did 0
not 0
have 0
a 0
superior 0
prognosis 0
compared 0
to 0
those 0
who 0
remained 0
in 0
AF 0
under 0
a 0
rate-control 0
strategy 0
. 0

Total 0
anthelmintic 0
failure 0
to 0
control 0
nematode 0
parasites 0
of 0
small 0
ruminants 0
on 0
government 0
breeding 0
farms 0
in 0
Sabah 0
, 0
East 0
Malaysia 0
. 0

Government-owned 0
small-ruminant 0
breeding 0
farms 0
in 0
Malaysia 0
provide 0
the 0
source 0
of 0
sheep 0
and 0
goats 0
to 0
smallholder 0
farmers 0
in 0
the 0
country 0
. 0

In 0
the 0
eastern 0
Malaysian 0
state 0
of 0
Sabah 0
, 0
high-level 0
stock 0
losses 0
have 0
been 0
recorded 0
on 0
these 0
farms 0
for 0
several 0
years 0
, 0
frequently 0
accompanied 0
by 0
clinical 0
signs 0
indicating 0
pathogenic 0
levels 0
of 0
infections 0
with 0
the 0
nematode 0
parasite 0
Haemonchus 0
contortus 0
. 0

This 0
suggests 0
that 0
their 0
dependence 0
on 0
chemotherapy 0
to 0
control 0
parasite 0
infections 0
had 0
failed 0
. 0

Accordingly 0
, 0
tests 0
for 0
anthelmintic B-OTHER
efficacy I-OTHER
using 0
the 0
faecal 0
egg 0
count 0
reduction 0
test 0
( 0
FECRT 0
) 0
on 0
the 0
range 0
of 0
drugs 0
used 0
to 0
control 0
nematode 0
parasites 0
were 0
carried 0
out 0
on 0
the 0
five 0
government 0
small-ruminant 0
breeding 0
farms 0
in 0
Sabah 0
. 0

These 0
tests 0
showed 0
a 0
total 0
failure 0
of B-OTHER
the 0
benzimidazole B-OTHER
, 0
imidothiazole B-OTHER
, 0
macrocyclic B-OTHER
lactone I-OTHER
and 0
salicylanilide B-OTHER

Scaling 0
clinical 0
judgments 0
of 0
symptom 0
pathology 0
by 0
means 0
of 0
the 0
psychophysiological 0
method 0
of 0
magnitude 0
estimation 0
. 0

Summing 0
scores 0
across 0
heterogeneous 0
symptom 0
items 0
without 0
consideration 0
of 0
their 0
differing 0
psychopathological 0
significance 0
has 0
been 0
criticized 0
as 0
producing 0
an 0
inadequate 0
picture 0
of 0
an 0
individual 0
's 0
clinical 0
status 0
. 0

The 0
purpose 0
of 0
this 0
study 0
was 0
to 0
derive 0
symptom 0
item 0
weights 0
representing 0
clinically 0
judged 0
seriousness 0
of 0
each 0
symptom 0
through 0
the 0
application 0
of 0
Steven 0
's 0
psychophysical 0
method 0
of 0
magnitude 0
estimation 0
. 0

A 0
nationwide 0
sample 0
of 0
129 0
clinicians 0
rated 0
the 0
pathological 0
significance 0
of 0
221 0
symptom 0
items 0
in 0
a 0
design 0
such 0
that 0
every 0
rater 0
rated 0
121 0
items 0
, 0
21 0
of 0
which 0
were 0
rated 0
by 0
all 0
raters 0
and 0
100 0
of 0
which 0
were 0
rated 0
only 0
by 0
the 0
A 0
or 0
B 0
subgroup 0
to 0
which 0
each 0
rater 0
was 0
randomly 0
assigned 0
. 0

Each 0
item 0
was 0
rated 0
as 0
to 0
the 0
seriousness 0
of 0
the 0
pathology 0
it 0
would 0
represent 0
if 0
manifested 0
by 0
either 0
a 0
boy 0
child 0
, 0
girl 0
child 0
, 0
boy 0
adolescent 0
, 0
or 0
girl 0
adolescent 0
, 0
with 0
one-fourth 0
of 0
the 0
raters 0
assigned 0
to 0
each 0
condition 0
. 0

The 0
results 0
of 0
211 0
two-way 0
analyses 0
of 0
variance 0
revealed 0
that 0
age 0
and 0
age 0
and 0
sex B-MENTAL
in 0
interaction 0
, 0
but 0
not 0
sex 0
alone 0
, 0
significantly 0
influenced 0
the 0
clinical 0
ratings 0
. 0

The 0
resulting 0
magnitude B-MENTAL
estimation 0
ratings B-MENTAL
of I-MENTAL
symptom I-MENTAL

The 0
relationship 0
between 0
the 0
response 0
of 0
Plasmodium 0
falciparum 0
malaria 0
to 0
mefloquine 0
in 0
African 0
children 0
and 0
its 0
sensitivity 0
in 0
vitro 0
. 0

The 0
clinical 0
efficacy 0
of 0
two 0
doses 0
of 0
mefloquine 0
( 0
15 0
and 0
25 0
mg/kg 0
body 0
weight 0
) 0
was 0
evaluated 0
in 0
85 0
children 0
suffering 0
from 0
acute 0
symptomatic 0
falciparum 0
malaria 0
. 0

The 0
cure B-OTHER
rate I-OTHER
on 0
day 0
28 0
was 0
100 0
% 0
in 0
both 0
groups 0
. 0

There 0
was 0
no 0
significant 0
difference 0
( 0
P 0
> 0
0.05 0
) 0
in 0
the 0
mean 0
parasite B-PHYSICAL
and I-PHYSICAL
fever I-PHYSICAL
clearance I-PHYSICAL
times I-PHYSICAL
in 0
both 0
groups 0
( 0
48.5 0
+/- 0
14.6 0
and 0
32.0 0
+/- 0
12.7 0
h 0
respectively 0
for 0
the 0
25 0
mg/kg 0
group 0
and 0
49.0 0
+/- 0
15.1 0
and 0
30.0 0
+/- 0
13.3 0
h 0
respectively 0
for 0
the 0
15 0
mg/kg 0
group 0
) 0
. 0

There 0
was 0
also 0
no 0
significant 0
difference 0
( 0
P 0
> 0
0.05 0
) 0
in 0
these 0
values 0
between 0
children 0
with 0
hyperparasitaemia 0
( 0
53.6 0
+/- 0
11.1 0
and 0
36.0 0
+/- 0
17.0 0
h 0
respectively 0
) 0
and 0
those 0
without 0
hyperparasitaemia 0
( 0
49.1 0
+/- 0
13.6 0
and 0
31.8 0
+/- 0
14.6 0
h 0
respectively 0
) 0
. 0

Recurrence B-PHYSICAL
of I-PHYSICAL
parasitaemia I-PHYSICAL
was 0
observed 0
after 0
day 0
30 0
in 0
2 0
patients 0
in 0
the 0
15 0
mg/kg 0
group 0
and 0
in 0
1 0
patient 0
in 0
the 0
25 0
mg/kg 0
group 0
. 0

In 0
vitro 0
, 0
3 0
of 0
21 0
isolates 0
showed 0
reduced 0
susceptibility B-OTHER
to I-OTHER
mefloquine I-OTHER
, 0
with 0
minimum 0
inhibitory B-OTHER
concentrations I-OTHER
( 0
MIC 0
) 0
> 0
67 0
nM/litre 0
. 0

The 0
MIC 0
and 0
50 0
% 0
, 0
90 0
% 0
and 0
99 0
% 0
inhibitory 0
concentrations 0
were 0
200.8 0
, 0
6.27 0
, 0
31.7 0
and 0
119.6 0
nM/litre 0
respectively 0
. 0

Four 0
of 0
22 0
isolates 0
were 0
resistant B-OTHER
to 0
chloroquine 0
( 0
MIC 0
> 0
108 0
nM/litre 0
) 0
. 0

Isolates 0
that 0
showed 0
low 0
sensitivity B-OTHER
to 0
mefloquine 0
in 0
vitro 0
were 0
sensitive 0
to 0
chloroquine 0
in 0
vitro 0
, 0
and 0
the 0
4 0
that 0
were 0
resistant 0
to 0
chloroquine 0
were 0
sensitive 0
to 0
mefloquine 0
. 0

Irrespective 0
of 0
MIC 0
and 0
dose 0
of 0
mefloquine 0
, 0
parasitaemia 0
cleared 0
in 0
all 0
subjects 0
in 0
96 0
h 0
or 0
less 0
. 0
( 0

ABSTRACT 0
TRUNCATED 0
AT 0
250 0
WORDS 0
) 0

D-dimer 0
predicts 0
outcome 0
after 0
aneurysmal 0
subarachnoid 0
hemorrhage 0
: 0
no 0
effect 0
of 0
thromboprophylaxis 0
on 0
coagulation B-PHYSICAL
activity I-PHYSICAL
. 0

OBJECTIVE 0
Approximately 0
one-third 0
of 0
all 0
patients 0
with 0
acute 0
nontraumatic 0
subarachnoid 0
hemorrhage 0
( 0
SAH 0
) 0
experience 0
complications 0
owing 0
to 0
delayed 0
ischemic 0
deficit 0
. 0

We 0
reported 0
recently 0
that 0
enoxaparin 0
40 0
mg 0
once 0
daily 0
for 0
10 0
days 0
seems 0
safe 0
and 0
demonstrates 0
thromboprophylactic B-OTHER
efficacy I-OTHER
, 0
but 0
it 0
failed 0
to 0
improve 0
outcome 0
in 0
a 0
randomized 0
SAH 0
trial 0
. 0

In 0
the 0
present 0
study 0
, 0
we 0
assessed 0
hemostatic B-PHYSICAL
variables I-PHYSICAL
associated 0
with 0
clinical 0
status 0
and 0
outcome 0
of 0
SAH 0
. 0

We 0
also 0
monitored 0
the 0
effect 0
of 0
enoxaparin 0
on 0
activation 0
of 0
coagulation B-PHYSICAL
and 0
fibrinolysis B-PHYSICAL
after 0
closure 0
of 0
the 0
ruptured 0
aneurysm 0
. 0

METHODS 0
Blood B-OTHER
samples I-OTHER
to 0
measure 0
activation B-PHYSICAL
of I-PHYSICAL
coagulation I-PHYSICAL
and 0
fibrinolysis B-PHYSICAL
were 0
collected 0
from 0
42 0
patients 0
participating 0
in 0
the 0
enoxaparin 0
trial 0
for 0
acute 0
aneurysmal 0
SAH 0
at 0
four 0
time 0
points 0
: 0
1 0
) 0
at 0
hospital 0
admission 0
; 0
2 0
) 0
12 0
to 0
24 0
hours 0
after 0
aneurysm 0
surgery 0
but 0
before 0
initiation 0
of 0
enoxaparin 0
therapy 0
; 0
3 0
) 0
3 0
hours 0
after 0
the 0
first 0
dose 0
; 0
and 0
4 0
) 0
at 0
the 0
conclusion 0
of 0
treatment 0
. 0

RESULTS 0
At 0
admission 0
, 0
several 0
variables 0
of 0
coagulation B-PHYSICAL
and 0
fibrinolysis B-PHYSICAL
were 0
elevated 0
and 0
correlated 0
well 0
with 0
clinical 0
status 0
. 0

Specifically 0
, 0
D-dimer B-PHYSICAL
levels I-PHYSICAL
at 0
all 0
four 0
time 0
points 0
correlated 0
with 0
patients 0
' 0
long-term 0
outcomes 0
. 0

A 0
single 0
dose 0
of 0
enoxaparin 0
suppressed 0
early B-PHYSICAL
coagulation I-PHYSICAL
activity I-PHYSICAL
, 0
but 0
thrombin B-PHYSICAL
generation I-PHYSICAL
was 0
not 0
inhibited B-OTHER
during 0
thromboprophylaxis 0
. 0

However 0
, 0
PAI-1 B-PHYSICAL
activity I-PHYSICAL
was 0
suppressed 0
. 0

CONCLUSION 0
D-dimer 0
offers 0
a 0
useful 0
laboratory 0
tool 0
for 0
assessing 0
early 0
and 0
late 0
clinical 0
severity B-PHYSICAL
of I-PHYSICAL
SAH I-PHYSICAL
. 0

A 0
thromboprophylactic 0
dose 0
of 0
enoxaparin 0
inhibited 0
PAI-1 B-PHYSICAL
activity I-PHYSICAL
but 0
failed 0
to 0
down-regulate 0
coagulation B-PHYSICAL
activity I-PHYSICAL
and 0
D-dimer B-PHYSICAL
. 0

These 0
findings 0
are 0
compatible 0
with 0
the 0
lack 0
of 0
efficacy 0
of 0
enoxaparin 0
in 0
reducing 0
ischemic 0
deficit 0
after 0
SAH 0
. 0

A 0
plaque 0
index 0
for 0
occlusal 0
surfaces 0
and 0
fissures 0
. 0

Measurement 0
of 0
repeatability 0
and 0
plaque 0
removal 0
. 0

Plaque 0
indices 0
have 0
largely 0
been 0
developed 0
for 0
buccal 0
and 0
lingual 0
tooth 0
surfaces 0
. 0

There 0
has 0
been 0
minimal 0
interest 0
in 0
plaque 0
accumulation 0
on 0
occlusal 0
surfaces 0
despite 0
the 0
predilection 0
for 0
caries 0
at 0
these 0
sites 0
. 0

A 0
numerical 0
plaque 0
index 0
( 0
0-5 0
) 0
is 0
described 0
based 0
on 0
the 0
presence 0
and 0
distribution 0
of 0
plaque 0
in 0
the 0
fissures 0
and 0
over 0
the 0
occlusal 0
surfaces 0
of 0
permanent 0
molar 0
and 0
premolar 0
teeth 0
. 0

The 0
repeatability 0
of 0
a 0
single 0
examiner 0
in 0
scoring 0
the 0
index 0
was 0
performed 0
using 0
4 0
groups 0
of 0
10 0
subjects 0
. 0

Each 0
group 0
of 0
volunteers 0
suspended 0
tooth 0
cleaning 0
for 0
48 0
h 0
and 0
the 0
index 0
scored 0
after 0
disclosing 0
plaque 0
deposits 0
. 0

The 0
index 0
was 0
rescored 0
60-90 0
min 0
later 0
. 0

Plaque 0
area 0
was 0
also 0
determined 0
by 0
drawing 0
the 0
outline 0
of 0
plaque 0
onto 0
grids 0
. 0

Except 0
for 0
one 0
condition 0
of 0
repeatability 0
for 0
one 0
group 0
, 0
the 0
4 0
conditions 0
of 0
repeatability 0
in 0
scoring 0
the 0
index 0
were 0
met 0
for 0
all 0
4 0
groups 0
of 0
subjects 0
. 0

The 0
sensitivity 0
of 0
the 0
index 0
and 0
area 0
recordings B-OTHER
to 0
detect 0
plaque 0
removed 0
by 0
brushing 0
was 0
then 0
evaluated 0
. 0

A 0
group 0
of 0
10 0
subjects 0
had 0
plaque 0
scored 0
by 0
index 0
and 0
area 0
after 0
suspending 0
toothcleaning 0
for 0
48 0
h. 0
Subjects 0
were 0
then 0
randomly 0
allocated 0
to 0
brush 0
or 0
not 0
brush 0
their 0
teeth 0
and 0
plaque 0
rescored 0
. 0

The 0
experiment 0
was 0
then 0
repeated 0
and 0
brushing 0
or 0
not 0
brushing 0
crossed 0
over 0
. 0

Highly 0
significant 0
differences 0
between 0
brushing 0
and 0
no 0
brushing 0
plaque B-OTHER
indices I-OTHER
and 0
areas 0
were 0
determined 0
. 0

In 0
conclusion 0
, 0
the 0
occlusal B-OTHER
fissure I-OTHER
plaque I-OTHER
index I-OTHER
was 0
easy 0
to 0
apply 0
, 0
repeatable 0
and 0
sufficiently 0
sensitive 0
to 0
detect 0
plaque 0
removed 0
by 0
brushing 0
. 0

The 0
index 0
could 0
find 0
use 0
as 0
an 0
additional 0
measure 0
of 0
oral 0
hygiene 0
, 0
in 0
clinical 0
trials 0
on 0
plaque 0
control 0
and 0
possibly 0
epidemiological 0
studies 0
relating 0
to 0
caries 0
. 0

Quitting 0
a 0
weight 0
loss 0
program 0
is 0
associated 0
with 0
anhedonia 0
: 0
preliminary 0
findings 0
of 0
the 0
Lifestyle 0
Intervention 0
Treatment 0
Evaluation 0
Study 0
in 0
northern 0
Finland 0
. 0

OBJECTIVES 0
To 0
examine 0
whether 0
a 0
diagnosis 0
for 0
major 0
depression 0
, 0
chronic 0
depression 0
or 0
specific 0
symptoms 0
of 0
depression 0
is 0
associated 0
with 0
the 0
risk 0
of 0
quitting 0
a 0
weight 0
loss 0
program 0
. 0

STUDY 0
DESIGN 0
The 0
study 0
involved 0
82 0
overweight 0
adults 0
participating 0
in 0
the 0
Lifestyle 0
Intervention 0
Treatment 0
Evaluation 0
( 0
LITE 0
) 0
follow-up 0
study 0
at 0
Oulu 0
University 0
Hospital 0
in 0
northern 0
Finland 0
. 0

METHODS 0
Psychiatric B-MENTAL
diagnostic I-MENTAL
assessments I-MENTAL
were 0
based 0
on 0
the 0
Structured 0
Clinical 0
Interview 0
for 0
DSMIV B-PHYSICAL
disorders 0
( 0
SCID-I 0
) 0
conducted 0
by 0
a 0
clinical 0
psychiatrist 0
. 0

Anhedonia B-MENTAL
( I-MENTAL
lack I-MENTAL
of I-MENTAL
pleasure I-MENTAL
) I-MENTAL
was 0
assessed 0
as 0
one 0
of 0
the 0
core 0
symptoms 0
of 0
major 0
depression 0
and 0
chronic B-PHYSICAL
depression 0
( 0
dysthymia 0
) 0
. 0

Anhedonia B-MENTAL
was 0
defined 0
to 0
be 0
present 0
if 0
the 0
participants 0
reported 0
having 0
suffered 0
a 0
major 0
loss 0
of 0
interest 0
during 0
the 0
previous 0
month 0
. 0

RESULTS 0
Twenty 0
participants 0
( 0
24.4 0
% 0
) 0
quit 0
during 0
the 0
6-month 0
intervention 0
period 0
. 0

Anhedonia B-MENTAL
put 0
individuals 0
at 0
risk 0
of 0
quitting 0
the 0
weight 0
loss 0
program 0
( 0
bivariate 0
analysis 0
OR 0
3.1 0
, 0
95 0
% 0
CI 0
0.8-11.6 0
, 0
p=0.091 0
, 0
multivariate 0
analysis 0
OR 0
6.5 0
, 0
95 0
% 0
CI 0
1.1-38.2 0
, 0
p=0.038 0
) 0
. 0

However 0
, 0
a 0
diagnosis 0
for 0
major B-MENTAL
depression I-MENTAL
or 0
chronic B-MENTAL
depression I-MENTAL
did 0
not 0
predict 0
quitting 0
. 0

CONCLUSIONS 0
Individual 0
assessments 0
of 0
obesity 0
and 0
overweight 0
should 0
also 0
include 0
an 0
assessment 0
for 0
subthreshold 0
depression 0
, 0
mainly 0
anhedonia 0
. 0

The 0
Randomised 0
Intervention 0
Treatment 0
of 0
Angina 0
( 0
RITA 0
) 0
Trial 0
protocol 0
: 0
a 0
long 0
term 0
study 0
of 0
coronary 0
angioplasty 0
and 0
coronary 0
artery 0
bypass 0
surgery 0
in 0
patients 0
with 0
angina 0
. 0

The 0
Randomised 0
Intervention 0
Treatment 0
of 0
Angina 0
( 0
RITA 0
) 0
Trial 0
is 0
a 0
prospective 0
, 0
randomised 0
study 0
to 0
compare 0
the 0
short 0
term 0
and 0
long 0
term 0
effects 0
of 0
percutaneous 0
transluminal 0
coronary 0
angioplasty 0
and 0
coronary 0
artery 0
bypass 0
surgery 0
. 0

During 0
the 0
study 0
a 0
register 0
of 0
patients 0
undergoing 0
coronary 0
arteriography 0
at 0
the 0
fourteen 0
participating 0
centres 0
is 0
being 0
maintained 0
to 0
assess 0
the 0
overall 0
context 0
of 0
patient 0
recruitment 0
. 0

Patients 0
with 0
arteriographically 0
proven 0
coronary 0
artery 0
disease 0
are 0
considered 0
for 0
the 0
trial 0
if 0
the 0
participating 0
cardiologist 0
and 0
surgeon 0
agree 0
that 0
equivalent 0
revascularisation 0
could 0
be 0
achieved 0
by 0
either 0
treatment 0
method 0
. 0

Patients 0
who 0
satisfy 0
the 0
trial 0
entry 0
criteria 0
are 0
randomised 0
to 0
treatment 0
by 0
coronary 0
angioplasty 0
or 0
coronary 0
artery 0
bypass 0
surgery 0
, 0
with 0
prospective 0
stratification 0
into 0
groups 0
with 0
one 0
, 0
two 0
, 0
or 0
three 0
treatment 0
vessels 0
. 0

Randomisation 0
implies 0
an 0
intention 0
to 0
treat 0
the 0
patient 0
by 0
the 0
assigned 0
procedure 0
and 0
the 0
analysis 0
of 0
long 0
term 0
results 0
will 0
include 0
all 0
randomised 0
cases 0
. 0

The 0
trial 0
will 0
recruit 0
at 0
least 0
1000 0
patients 0
who 0
will 0
be 0
followed 0
for 0
five 0
years 0
. 0

The 0
major 0
trial 0
end 0
points 0
include 0
death B-MORTALITY
, 0
new B-PHYSICAL
myocardial I-PHYSICAL
infarction I-PHYSICAL
, 0
and 0
new B-PHYSICAL
coronary I-PHYSICAL
angioplasty I-PHYSICAL
or 0
coronary B-PHYSICAL
artery I-PHYSICAL
bypass I-PHYSICAL
procedures I-PHYSICAL
. 0

Other 0
outcome 0
measures 0
include 0
symptom B-OTHER
and 0
employment B-OTHER
status I-OTHER
, 0
quality 0
of 0
life 0
, 0
exercise B-PHYSICAL
tolerance I-PHYSICAL
, 0
and 0
left B-PHYSICAL
ventricular I-PHYSICAL
function I-PHYSICAL
. 0

Stapled B-OTHER
hemorrhoidopexy I-OTHER
versus 0
milligan-morgan B-OTHER
hemorrhoidectomy I-OTHER
: 0
a 0
prospective 0
, 0
randomized 0
, 0
multicenter 0
trial 0
with 0
2-year 0
postoperative 0
follow 0
up 0
. 0

PURPOSE 0
The 0
purpose 0
of 0
this 0
study 0
was 0
to 0
compare 0
the 0
outcome 0
of 0
stapled B-OTHER
hemorrhoidopexy I-OTHER
( 0
SH 0
group 0
) 0
performed 0
using 0
a 0
circular 0
stapler 0
with 0
that 0
of 0
the 0
Milligan-Morgan 0
technique 0
( 0
MM 0
group 0
) 0
. 0

The 0
goals 0
of 0
the 0
study 0
were 0
to 0
evaluate 0
the 0
efficacy 0
and 0
reproducibility B-OTHER
of 0
stapled 0
hemorrhoidopexy 0
and 0
define 0
its 0
place 0
among 0
conventional 0
techniques 0
. 0

METHODS 0
A 0
series 0
of 0
134 0
patients 0
were 0
included 0
at 0
7 0
hospital 0
centers 0
. 0

They 0
were 0
randomized 0
according 0
to 0
a 0
single-masked 0
design 0
and 0
stratified 0
by 0
center 0
( 0
with 0
balancing 0
every 0
4 0
patients 0
) 0
. 0

Patients 0
were 0
clinically 0
evaluated 0
preoperatively 0
and 0
at 0
6 0
weeks 0
, 0
1 0
year 0
, 0
and 0
a 0
minimum 0
of 0
2 0
years 0
after 0
treatment 0
. 0

Patients 0
completed 0
a 0
questionnaire 0
before 0
and 0
1 0
year 0
after 0
surgery 0
to 0
evaluate 0
symptoms 0
, 0
function 0
, 0
and 0
overall 0
satisfaction 0
. 0

RESULTS 0
The 0
mean 0
follow-up 0
period 0
was 0
2.21 0
years 0
+/- 0
0.26 0
( 0
1.89-3.07 0
) 0
. 0

Nine 0
patients 0
( 0
7 0
% 0
) 0
could 0
not 0
be 0
monitored 0
at 0
1 0
or 0
2 0
years 0
, 0
but 0
4 0
of 0
these 0
9 0
nevertheless 0
filled 0
in 0
the 0
1-year 0
questionnaire 0
. 0

The 0
patients 0
in 0
the 0
SH 0
group 0
experienced 0
less 0
postoperative B-PAIN
pain/discomfort I-PAIN
as 0
scored 0
by 0
pain 0
during 0
bowel B-PAIN
movement I-PAIN
( 0
P 0
< 0
0.001 0
) 0
, 0
total 0
analgesic B-OTHER
requirement I-OTHER
over I-OTHER
the I-OTHER
first I-OTHER
3 I-OTHER
days I-OTHER
( 0
according 0
to 0
the 0
World 0
Health 0
Organization 0
[ 0
WHO 0
] 0
class 0
II 0
analgesics 0
[ 0
P 0
= 0
0.002 0
] 0
; 0
class 0
III 0
[ 0
P 0
= 0
0.066 0
] 0
) 0
, 0
and 0
per-patient 0
consumption 0
frequency 0
of 0
class 0
III 0
analgesics 0
( 0
P 0
= 0
0.089 0
) 0
. 0

A 0
clear 0
difference 0
in 0
morphine B-OTHER
requirement I-OTHER
became 0
evident 0
after 0
24 0
hours 0
( 0
P 0
= 0
0.010 0
) 0
. 0

Hospital B-PHYSICAL
stay I-PHYSICAL
was 0
significantly 0
shorter 0
in 0
the 0
SH 0
group 0
( 0
SH 0
2.2 0
+/- 0
1.2 0
[ 0
0 0
; 0
5.0 0
] 0
versus 0
MM 0
3.1 0
+/- 0
1.7 0
[ 0
1 0
; 0
8.0 0
] 0
P 0
< 0
0.001 0
) 0
. 0

At 0
1 0
year 0
, 0
no 0
differences 0
in 0
the 0
resolution B-OTHER
of I-OTHER
symptoms I-OTHER
were 0
observed 0
between 0
the 0
2 0
groups 0
, 0
and 0
over 0
2 0
years 0
, 0
the 0
overall B-ADVERSE-EFFECTS
incidence 0
of B-ADVERSE-EFFECTS
complications B-ADVERSE-EFFECTS
was 0
the 0
same 0
, 0
specifically 0
fecaloma B-ADVERSE-EFFECTS
( 0
P 0
= 0
0.003 0
) 0
in 0
the 0
MM 0
group 0
and 0
external B-ADVERSE-EFFECTS
hemorrhoidal I-ADVERSE-EFFECTS
thrombosis I-ADVERSE-EFFECTS
( 0
P 0
= 0
0.006 0
) 0
in 0
the 0
SH 0
group 0
. 0

Impaired B-ADVERSE-EFFECTS
sphincter I-ADVERSE-EFFECTS
function B-ADVERSE-EFFECTS
was 0
observed 0
at 0
1 0
year 0
with 0
no 0
significant 0
difference 0
between 0
the 0
groups 0
for 0
urgency 0
( 0
12 0
% 0
) 0
, 0
continence 0
problems 0
( 0
10 0
% 0
) 0
, 0
or 0
tenesmus 0
( 0
3 0
% 0
) 0
. 0

No 0
patient 0
needed 0
a 0
second 0
procedure 0
for 0
recurrence 0
within 0
2 0
years 0
, 0
although 0
partial B-ADVERSE-EFFECTS
residual 0
prolapse B-ADVERSE-EFFECTS
was 0
detected 0
in 0
4 0
SH 0
patients 0
( 0
7.5 0
% 0
) 0
versus 0
1 0
MM 0
patient 0
( 0
1.8 0
% 0
) 0
( 0
P 0
= 0
0.194 0
) 0
. 0

CONCLUSION 0
Stapled 0
hemorrhoidopexy 0
causes 0
significantly 0
less 0

Assisted 0
exercise 0
and 0
bone 0
strength 0
in 0
preterm 0
infants 0
. 0

Studies 0
have 0
previously 0
demonstrated 0
that 0
brief 0
( 0
4 0
weeks 0
) 0
passive 0
range-of-motion 0
exercise 0
is 0
beneficial 0
for 0
bone 0
development 0
in 0
very 0
low 0
birth 0
weight 0
( 0
VLBW 0
) 0
preterm 0
infants 0
. 0

However 0
, 0
the 0
optimal 0
duration 0
of 0
exercise 0
for 0
bone 0
development 0
in 0
preterm 0
infants 0
is 0
yet 0
unknown 0
. 0

The 0
aim 0
of 0
the 0
present 0
study 0
was 0
to 0
examine 0
the 0
effect 0
of 0
8 0
weeks 0
of 0
assisted 0
exercise 0
on 0
bone 0
strength 0
and 0
metabolism 0
in 0
VLBW 0
premature 0
infants 0
. 0

Sixteen 0
infants 0
( 0
mean 0
+/- 0
standard 0
error 0
of 0
the 0
mean 0
birth 0
weight 0
1,009 0
+/- 0
55 0
g 0
and 0
gestational 0
age 0
27.3 0
+/- 0
0.3 0
weeks 0
) 0
were 0
randomly 0
assigned 0
into 0
exercise 0
( 0
n 0
= 0
8 0
) 0
and 0
control 0
( 0
n 0
= 0
8 0
) 0
groups 0
. 0

The 0
intervention 0
started 0
at 0
the 0
first 0
week 0
of 0
life 0
and 0
involved 0
8 0
weeks 0
of 0
daily 0
passive 0
extension 0
and 0
flexion 0
range-of-motion 0
exercise 0
of 0
the 0
upper 0
and 0
lower 0
extremities 0
. 0

Biochemical B-PHYSICAL
markers I-PHYSICAL
of I-PHYSICAL
bone I-PHYSICAL
turnover I-PHYSICAL
were 0
measured 0
at 0
enrollment 0
and 0
after 0
8 0
weeks 0
. 0

Bone B-PHYSICAL
strength I-PHYSICAL
was 0
measured 0
weekly 0
by 0
quantitative 0
ultrasound 0
measurement 0
of 0
tibial B-PHYSICAL
bone I-PHYSICAL
speed I-PHYSICAL
of I-PHYSICAL
sound I-PHYSICAL
( 0
SOS 0
) 0
. 0

Bone B-PHYSICAL
SOS I-PHYSICAL
decreased 0
significantly 0
in 0
the 0
control 0
group 0
( 0
-108.1 0
+/- 0
33.7 0
m/second 0
, 0
P 0
< 0
0.0001 0
) 0
during 0
the 0
study 0
period 0
, 0
while 0
remaining 0
stable 0
in 0
the 0
exercise 0
group 0
( 0
11.3 0
+/- 0
22.8 0
m/second 0
) 0
. 0

The 0
main B-PHYSICAL
beneficial I-PHYSICAL
effect 0
of B-PHYSICAL
exercise B-PHYSICAL
occurred 0
in 0
the 0
first 0
4 0
weeks 0
of 0
the 0
intervention 0
. 0

There 0
were 0
no 0
significant 0
differences 0
in 0
the 0
bone B-PHYSICAL
turnover I-PHYSICAL
marker I-PHYSICAL
changes I-PHYSICAL
between 0
the 0
groups 0
. 0

There 0
is 0
a 0
significant 0
postnatal B-PHYSICAL
decrease 0
in B-PHYSICAL

Investigations 0
into 0
the 0
potential 0
effects 0
of 0
multiple 0
dose 0
ketorolac 0
on 0
the 0
pharmacokinetics B-PHYSICAL
and 0
pharmacodynamics B-PHYSICAL
of I-PHYSICAL
racemic I-PHYSICAL
warfarin I-PHYSICAL
. 0

1 0
. 0

The 0
potential 0
interaction 0
between 0
racemic 0
warfarin 0
given 0
as 0
a 0
25 0
mg 0
single 0
oral 0
dose 0
and 0
chronically 0
administered 0
ketorolac 0
was 0
studied 0
in 0
12 0
young 0
healthy 0
male 0
volunteers 0
. 0

2 0
. 0

Ketorolac 0
produced 0
no 0
major B-PHYSICAL
change I-PHYSICAL
in I-PHYSICAL
the I-PHYSICAL
pharmacokinetics I-PHYSICAL
of I-PHYSICAL
( 0
R 0
) 0
- B-PHYSICAL
or I-PHYSICAL
( 0
S B-PHYSICAL
) 0
-warfarin B-PHYSICAL
. 0

3 0
. 0

Ketorolac 0
did 0
not B-PHYSICAL
alter I-PHYSICAL
the I-PHYSICAL

Patient-reported 0
outcomes 0
after 0
inguinal 0
herniorrhaphy 0
. 0

BACKGROUND 0
Patient-reported 0
outcomes 0
( 0
PRO 0
) 0
reflect 0
the 0
functional 0
outcomes 0
of 0
inguinal 0
herniorrhaphy 0
. 0

We 0
studied 0
the 0
effect 0
of 0
hernia 0
recurrence 0
and 0
complications 0
on 0
PRO 0
for 0
participants 0
in 0
the 0
Veterans 0
Affairs 0
trial 0
of 0
Open 0
or 0
Laparoscopic 0
Repair 0
of 0
Inguinal 0
Hernia 0
. 0

METHODS 0
Analyzed 0
PRO 0
included 0
( 0
1 0
) 0
the 0
Medical 0
Outcomes 0
Study 0
Short 0
Form 0
36 0
, 0
version 0
2 0
, 0
( 0
2 0
) 0
the 0
Surgical 0
Pain 0
Scale 0
, 0
( 0
3 0
) 0
the 0
Activities 0
Assessment 0
Scale 0
, 0
and 0
( 0
4 0
) 0
patient 0
satisfaction 0
. 0

Recurrences 0
and 0
complications 0
were 0
recorded 0
at 0
follow-up 0
visits 0
. 0

Complications 0
were 0
categorized 0
by 0
( 0
1 0
) 0
hematoma/seroma B-PHYSICAL
, 0
( 0
2 0
) 0
orchitis B-PHYSICAL
, 0
( 0
3 0
) 0
neuralgia B-PHYSICAL
, 0
and 0
( 0
4 0
) 0
other 0
. 0

Univariate 0
and 0
multivariable 0
regression 0
analyses 0
identified 0
variables 0
significantly 0
associated 0
with 0
postoperative 0
PRO 0
. 0

RESULTS 0
Of 0
the 0
1603 0
patients 0
with 0
PRO 0
data 0
, 0
105 0
had 0
a 0
recurrence 0
and 0
342 0
had 0
a 0
complication 0
at 0
2 0
years 0
. 0

Multivariable 0
analyses 0
showed 0
neuralgia B-PHYSICAL
( 0
P 0
< 0
.0005 0
) 0
adversely 0
affected 0
all 0
PRO 0
, 0
and 0
recurrence 0
( 0
P 0
< 0
.05 0
) 0
affected 0
patient-reported B-PAIN
pain I-PAIN
, 0
activity B-PHYSICAL
, 0
and 0
satisfaction B-OTHER
, 0
but 0
not 0
the 0
score 0
for 0
the 0
Medical B-OTHER
Outcomes I-OTHER
Study I-OTHER
Short I-OTHER
Form I-OTHER
3 I-OTHER
. 0

Patients 0
with 0
a 0
recurrence 0
after 0
open 0
repair 0
had 0
more 0
pain B-PAIN
than 0
those 0
with 0
a 0
recurrence 0
after 0
laparoscopic 0
repair 0
( 0
P 0
= 0
.0001 0
) 0
. 0

Patients 0
with 0
other 0
complications 0
after 0
laparoscopic 0
repair 0
reported 0
more 0
pain B-PAIN
and 0
less B-PHYSICAL
activity I-PHYSICAL
than 0
those 0
with 0
other 0
complications 0
after 0
open 0
repair 0
( 0
P 0
= 0
.003 0
and 0
P 0
= 0
.009 0
, 0
respectively 0
) 0
. 0

CONCLUSIONS 0
The 0
effectiveness 0
of 0
inguinal 0
herniorrhaphy 0
should 0
be 0
measured 0
by 0
the 0
rate 0
of 0
recurrence B-PHYSICAL
and 0
neuralgia B-PHYSICAL
. 0

Postoperative 0
neuralgias 0
have 0
a 0
deleterious 0
effect 0
on 0
all 0
patient-reported 0
outcomes 0
. 0

Reduced 0
cardiotoxicity 0
and 0
comparable 0
efficacy 0
in 0
a 0
phase 0
III 0
trial 0
of 0
pegylated 0
liposomal 0
doxorubicin 0
HCl 0
( 0
CAELYX/Doxil 0
) 0
versus 0
conventional 0
doxorubicin 0
for 0
first-line 0
treatment 0
of 0
metastatic 0
breast 0
cancer 0
. 0

BACKGROUND 0
This 0
study 0
was 0
designed 0
to 0
demonstrate 0
that 0
efficacy 0
[ 0
progression-free B-MORTALITY
survival I-MORTALITY
( I-MORTALITY
PFS I-MORTALITY
) I-MORTALITY
] 0
of 0
CAELYX 0
[ 0
pegylated 0
liposomal 0
doxorubicin 0
HCl 0
( 0
PLD 0
) 0
] 0
is 0
non-inferior 0
to 0
doxorubicin 0
with 0
significantly 0
less 0
cardiotoxicity 0
in 0
first-line 0
treatment 0
of 0
women 0
with 0
metastatic 0
breast 0
cancer 0
( 0
MBC 0
) 0
. 0

PATIENTS 0
AND 0
METHODS 0
Women 0
( 0
n=509 0
) 0
with 0
MBC 0
and 0
normal 0
cardiac 0
function 0
were 0
randomized 0
to 0
receive 0
either 0
PLD 0
50 0
mg/m2 0
( 0
every 0
4 0
weeks 0
) 0
or 0
doxorubicin 0
60 0
mg/m2 0
( 0
every 0
3 0
weeks 0
) 0
. 0

Cardiac B-ADVERSE-EFFECTS
event 0
rates B-ADVERSE-EFFECTS
were 0
based 0
on 0
reductions 0
in 0
left 0
ventricular 0
ejection 0
fraction 0
as 0
a 0
function 0
of 0
cumulative 0
anthracycline 0
dose 0
. 0

RESULTS 0
PLD 0
and 0
doxorubicin 0
were 0
comparable 0
with 0
respect 0
to 0
PFS B-MORTALITY
[ 0
6.9 0
versus 0
7.8 0
months 0
, 0
respectively 0
; 0
hazard 0
ratio 0
( 0
HR 0
) 0
=1.00 0
; 0
95 0
% 0
confidence 0
interval 0
( 0
CI 0
) 0
0.82-1.22 0
] 0
. 0

Subgroup 0
results 0
were 0
consistent 0
. 0

Overall B-ADVERSE-EFFECTS
risk 0
of B-ADVERSE-EFFECTS
cardiotoxicity B-ADVERSE-EFFECTS
was 0
significantly 0
higher 0
with 0
doxorubicin 0
than 0
PLD 0
( 0
HR=3.16 0
; 0
95 0
% 0
CI 0
1.58-6.31 0
; 0
P 0
< 0
0.001 0
) 0
. 0

Overall B-MORTALITY
survival B-MORTALITY
was 0
similar 0
( 0
21 0
and 0
22 0
months 0
for 0
PLD 0
and 0
doxorubicin 0
, 0
respectively 0
; 0
HR=0.94 0
; 0
95 0
% 0
CI 0
0.74-1.19 0
) 0
. 0

Alopecia B-ADVERSE-EFFECTS
( 0
overall 0
, 0
66 0
% 0
versus 0
20 0
% 0
; 0
pronounced 0
, 0
54 0
% 0
versus 0
7 0
% 0
) 0
, 0
nausea B-ADVERSE-EFFECTS
( 0
53 0
% 0
versus 0
37 0
% 0
) 0
, 0
vomiting B-ADVERSE-EFFECTS
( 0
31 0
% 0
versus 0
19 0
% 0
) 0
and 0
neutropenia B-ADVERSE-EFFECTS
( 0
10 0
% 0
versus 0
4 0
% 0
) 0
were 0
more 0
often 0
associated 0
with 0
doxorubicin 0
than 0
PLD 0
. 0

Palmar-plantar B-ADVERSE-EFFECTS
erythrodysesthesia B-ADVERSE-EFFECTS
( 0
48 0
% 0
versus 0
2 0
% 0
) 0
, 0
stomatitis B-ADVERSE-EFFECTS
( 0
22 0
% 0
versus 0
15 0
% 0
) 0
and 0

[ 0
Comparison 0
of 0
the 0
efficacy/tolerability 0
ratio 0
of 0
cibenzoline 0
and 0
propafenone 0
in 0
the 0
treatment 0
of 0
ventricular 0
arrhythmia 0
] 0
. 0

Cibenzoline 0
( 0
C 0
) 0
was 0
compared 0
with 0
propafenone 0
( 0
P 0
) 0
in 0
18 0
adult 0
patients 0
( 0
7 0
women 0
and 0
11 0
men 0
) 0
aged 0
50 0
+/- 0
7 0
in 0
double-blind 0
, 0
placebo-controlled 0
crossover 0
trial 0
. 0

After 0
a 0
therapeutic 0
wash-out 0
period 0
corresponding 0
to 0
5 0
times 0
the 0
half-life 0
of 0
previous 0
anti-arrhythmic 0
drugs 0
, 0
patients 0
with 0
more 0
than 0
100 0
premature 0
ventricular 0
contractions 0
( 0
PVC 0
) 0
per 0
hour 0
in 0
two 0
24 0
hour 0
Holter 0
records 0
obtained 0
at 0
an 0
interval 0
of 0
7 0
days 0
were 0
treated 0
in 0
succession 0
and 0
after 0
randomised 0
by 0
C 0
( 0
390 0
mg/day 0
in 0
3 0
divided 0
doses 0
) 0
and 0
P 0
( 0
900 0
mg/day 0
in 0
3 0
divided 0
doses 0
) 0
for 0
a 0
period 0
of 0
two 0
weeks 0
, 0
each 0
active 0
sequence 0
being 0
followed 0
by 0
a 0
two 0
week 0
wash-out 0
period 0
. 0

Efficacy 0
( 0
based 0
upon 0
the 0
decrease 0
in 0
PVC/hour 0
in 0
a 0
24 0
hour 0
Holter 0
) 0
and 0
tolerability 0
were 0
evaluated 0
at 0
the 0
end 0
of 0
each 0
sequence 0
, 0
with 0
samples 0
drawn 0
at 0
the 0
same 0
times 0
for 0
assay 0
of 0
the 0
study 0
drugs 0
. 0

Three 0
patients 0
dropped 0
out 0
of 0
the 0
trial 0
, 0
1 0
with 0
each 0
active 0
drug 0
( 0
for 0
epigastric B-PAIN
pain I-PAIN
) I-PAIN
and 0
1 0
with 0
dummy 0
. 0

No 0
significant 0
difference 0
was 0
seen 0
between 0
the 0
two 0
drugs 0
regarding 0
the 0
decrease 0
in 0
the 0
total 0
number B-OTHER
of I-OTHER
PVC/hour I-OTHER
in 0
the 0
15 0
patients 0
completing 0
the 0
cross-over 0
protocol 0
. 0

A 0
reduction B-OTHER
in I-OTHER
PVC/hour I-OTHER
of 0
more 0
than 0
70 0
per 0
cent 0
was 0
seen 0
in 0
7 0
patients 0
with 0
C 0
and 0
in 0
9 0
patients 0
with 0
P. 0
C B-OTHER
was I-OTHER
better I-OTHER
tolerated I-OTHER
than 0
P 0
on 0
the 0
basis B-PHYSICAL
of I-PHYSICAL
both I-PHYSICAL
clinical I-PHYSICAL
and 0
electrocardiographic B-PHYSICAL
parameters I-PHYSICAL
. 0

One 0
patient 0
developed 0
troublesome 0
adverse B-ADVERSE-EFFECTS
reactions I-ADVERSE-EFFECTS
with 0
C 0
as 0
compared 0
with 0
4 0
patients 0
in 0
the 0
case 0
of 0
P. 0
A 0
more 0
than 0
20 0
per B-PHYSICAL
cent I-PHYSICAL
increase 0
in B-PHYSICAL
QRS B-PHYSICAL
was 0
seen 0
in 0
7 0
patients 0
with 0
C 0
and 0
in 0
10 0
patients 0
with 0
P 0
, 0
the 0
figures 0
for 0
PR 0
being 0
2 0
and 0
6 0
patients 0
respectively 0
. 0

One 0
patient 0
showed 0
a 0
proarrhythmic 0
effect 0
with 0
P. 0
Plasma 0
levels 0
of 0
C 0
were 0
significantly 0
higher 0
in 0
responders 0
( 0
328 0
+/- 0
149 0
ng/ml 0
) 0
than 0
in 0
non-responders 0
( 0
137 0
+/- 0
41 0
ng/ml 0
, 0
p 0
less 0
than 0
0.05 0
) 0
. 0

No 0
significant 0
difference 0
was 0
found 0
concerning 0
plasma 0
levels 0
of 0
P 0
( 0
578 0
+/- 0
477 0
ng/ml 0
compared 0
with 0
646 0
+/- 0
457 0
ng/ml 0
, 0
p 0
greater 0
than 0
0.05 0
) 0
. 0

In 0
conclusion 0
, 0
the 0

Retrograde 0
tracing 0
and 0
electrophysiological 0
findings 0
of 0
collateral 0
sprouting 0
after 0
end-to-side 0
neurorrhaphy 0
. 0

The 0
aim 0
of 0
this 0
study 0
was 0
to 0
seek 0
more 0
potent 0
evidences 0
of 0
collateral 0
sprouting 0
for 0
both 0
motor 0
and 0
sensory 0
nerve 0
fibres 0
after 0
end-to-side 0
neurorrhaphy 0
using 0
a 0
modified 0
double-labelling 0
retrograde 0
tracing 0
method 0
and 0
to 0
investigate 0
the 0
function 0
of 0
regenerated 0
motor 0
axons 0
with 0
electrophysiological 0
evaluation 0
. 0

Four 0
groups 0
( 0
n=4 0
for 0
each 0
group 0
) 0
were 0
used 0
: 0
end-to-end 0
coaptation 0
( 0
six 0
months 0
postoperatively 0
) 0
, 0
end-to-side 0
coaptation 0
( 0
four 0
months 0
and 0
six 0
months 0
postoperatively 0
) 0
and 0
normal 0
control 0
. 0

Two 0
fluorescent 0
tracers 0
( 0
true 0
blue 0
and 0
diamidino 0
yellow 0
) 0
were 0
applied 0
to 0
the 0
proximal 0
ends 0
of 0
tibial 0
and 0
common 0
peroneal 0
nerves 0
, 0
respectively 0
after 0
four 0
or 0
six 0
months 0
of 0
nerve 0
coaptation 0
. 0

Five 0
days 0
later 0
, 0
we 0
only 0
found 0
single-labelled B-PHYSICAL
motor I-PHYSICAL
and I-PHYSICAL
sensory I-PHYSICAL
neurons I-PHYSICAL
in 0
the 0
normal 0
and 0
end-to-end 0
coaptation 0
groups 0
, 0
while 0
some 0
dual-labelled 0
neurons 0
can 0
be 0
identified 0
in 0
end-to-side 0
coaptation 0
groups 0
. 0

Four 0
months 0
after 0
surgery 0
, 0
the 0
motor B-PHYSICAL
nerve I-PHYSICAL
conduction I-PHYSICAL
velocity I-PHYSICAL
in I-PHYSICAL
end-to-side I-PHYSICAL
coaptation 0
was 0
significantly 0
slower 0
than 0
in 0
the 0
normal 0
control 0
. 0

But 0
no 0
difference 0
was 0
found 0
in 0
the 0
sixth 0
month 0
. 0

These 0
results 0
suggest 0
that 0
end-to-side 0
neurorrhaphy 0
can 0
induce 0
the 0
functional 0
collateral 0
sprouting 0
of 0
both 0
motor 0
and 0
sensory 0
axons 0
in 0
the 0
peripheral 0
nerve 0
. 0

The 0
impact 0
of 0
angiotensin 0
II 0
receptor 0
blockade 0
and 0
the 0
DASH 0
diet 0
on 0
markers B-PHYSICAL
of 0
endogenous 0
fibrinolysis 0
. 0

Hypertension 0
is 0
associated 0
with 0
impaired 0
fibrinolysis 0
. 0

Both 0
angiotensin 0
receptor 0
blockers 0
( 0
ARB 0
) 0
and 0
the 0
DASH 0
( 0
Dietary 0
Approaches 0
to 0
Stop 0
Hypertension 0
) 0
diet 0
effectively 0
lower 0
blood B-PHYSICAL
pressure I-PHYSICAL
in 0
hypertensive 0
patients 0
. 0

Some 0
evidence 0
suggests 0
that 0
treatment 0
with 0
ARBs 0
could 0
increase 0
fibrinolysis 0
, 0
however 0
, 0
data 0
is 0
conflicting 0
. 0

The 0
impact 0
of 0
the 0
DASH 0
diet 0
on 0
fibrinolytic B-PHYSICAL
parameters I-PHYSICAL
is 0
not 0
known 0
. 0

Fifty-five 0
hypertensive 0
participants 0
( 0
35 0
African-American 0
, 0
20 0
white 0
) 0
were 0
randomly 0
assigned 0
to 0
receive 0
8 0
weeks 0
of 0
either 0
a 0
control 0
diet 0
or 0
the 0
DASH 0
diet 0
. 0

The 0
diets 0
did 0
not 0
differ 0
in 0
sodium 0
content 0
( 0
approximately 0
3 0
g/day 0
) 0
. 0

Within 0
each 0
diet 0
, 0
individuals 0
were 0
randomly 0
assigned 0
to 0
receive 0
losartan 0
or 0
placebo 0
for 0
4 0
weeks 0
in 0
double-blind 0
, 0
cross-over 0
fashion 0
. 0

Tissue B-PHYSICAL
plasminogen I-PHYSICAL
activator I-PHYSICAL
( I-PHYSICAL
t-PA I-PHYSICAL
) I-PHYSICAL
antigen I-PHYSICAL
, 0
t-PA B-PHYSICAL
activity I-PHYSICAL
, 0
plasminogen B-PHYSICAL
activator I-PHYSICAL
inhibitor-1 I-PHYSICAL
( I-PHYSICAL
PAI-1 I-PHYSICAL
) I-PHYSICAL
activity I-PHYSICAL
and 0
plasma B-PHYSICAL
renin I-PHYSICAL
activity I-PHYSICAL
( I-PHYSICAL
PRA I-PHYSICAL
) I-PHYSICAL
were 0
measured 0
at 0
the 0
end 0
of 0
a 0
2-week 0
run-in 0
period 0
on 0
the 0
control 0
diet 0
and 0
after 0
each 0
treatment 0
period 0
. 0

The 0
DASH 0
diet 0
did 0
not 0
affect 0
markers 0
of 0
fibrinolysis 0
. 0

Losartan 0
significantly 0
lowered 0
t-PA B-PHYSICAL
antigen I-PHYSICAL
levels I-PHYSICAL
( 0
-1.8 0
ng/mL 0
, 0
P 0
= 0
0.045 0
) 0
, 0
but 0
had 0
no 0
effect 0
on 0
t-PA B-PHYSICAL
or 0
PAI-1 B-PHYSICAL
activities I-PHYSICAL
. 0

This 0
effect 0
was 0
more 0
pronounced 0
in 0
whites 0
( 0
-4.1 0
ng/mL 0
( 0
P 0
= 0
0.003 0
) 0
) 0
compared 0
with 0
African-Americans 0
( 0
-0.3 0
ng/mL 0
( 0
P 0
= 0
0.7 0
) 0
, 0
P-interaction 0
= 0
0.03 0
) 0
. 0

Results 0
were 0
not 0
materially 0
affected 0
by 0
adjustment 0
for 0
basline 0
values 0
or 0
changes 0
in 0
blood B-PHYSICAL
pressure I-PHYSICAL
. 0

This 0
study 0
demonstrates 0
that 0
losartan 0
reduces 0
t-PA B-PHYSICAL
antigen I-PHYSICAL
levels I-PHYSICAL
in 0
white 0
, 0
but 0
not 0
African-American 0
hypertensive 0
individuals 0
. 0

In 0
contrast 0
, 0
the 0
DASH 0
diet 0
had 0
no 0
significant 0
effect 0
on 0
markers B-PHYSICAL
of I-PHYSICAL
fibrinolysis I-PHYSICAL
in 0
whites 0
or 0
African-Americans 0
. 0

Influence 0
of 0
phase-related 0
variability 0
in 0
premenstrual B-PHYSICAL
symptomatology I-PHYSICAL
, 0
mood B-PHYSICAL
, 0
smoking B-PHYSICAL
withdrawal I-PHYSICAL
, 0
and 0

Randomized 0
clinical 0
trial 0
of 0
tamoxifen 0
plus 0
sequential 0
CMF 0
chemotherapy 0
versus 0
tamoxifen 0
alone 0
in 0
postmenopausal 0
women 0
with 0
advanced 0
breast 0
cancer 0
. 0

Eighty-eight 0
postmenopausal 0
women 0
with 0
metastatic 0
breast 0
cancer 0
, 0
in 0
whom 0
estrogen 0
receptors 0
( 0
ER 0
) 0
were 0
positive 0
or 0
unknown 0
, 0
were 0
treated 0
on 0
a 0
controlled 0
trial 0
to 0
determine 0
the 0
effectiveness 0
of 0
tamoxifen 0
and 0
to 0
assess 0
the 0
therapeutic B-OTHER
advantage I-OTHER
of 0
sequentially 0
adding 0
low-dose 0
cyclophosphamide-methotrexate-5-fluorouracil 0
( 0
CMF 0
) 0
chemotherapy 0
in 0
tamoxifen 0
responders 0
. 0

Patients 0
with 0
known 0
ER 0
negative 0
status 0
were 0
not 0
studied 0
. 0

After 0
the 0
initial 0
12-week 0
treatment 0
with 0
tamoxifen 0
alone 0
, 0
60 0
% 0
of 0
ER 0
positive 0
patients 0
achieved 0
complete B-OTHER
or I-OTHER
partial I-OTHER
response I-OTHER
as 0
did 0
35 0
% 0
in 0
whom 0
ER 0
were 0
unknown 0
. 0

Response 0
status 0
further 0
improved 0
in 0
18 0
% 0
randomized 0
to 0
continue 0
tamoxifen 0
alone 0
vs 0
31 0
% 0
in 0
whom 0
CMF 0
was 0
added 0
to 0
tamoxifen 0
. 0

There 0
were 0
no 0
statistically 0
significant 0
differences 0
in 0
time 0
to 0
the 0
development 0
of 0
progressive B-PHYSICAL
disease I-PHYSICAL
or 0
survival B-MORTALITY
between 0
the 0
ER 0
positive 0
and 0
ER 0
unknown 0
patients 0
or 0
between 0
the 0
tamoxifen 0
and 0
tamoxifen 0
plus 0
CMF 0
groups 0
. 0

We 0
conclude 0
that 0
inability 0
to 0
determine 0
ER 0
status 0
should 0
not 0
prejudice 0
against 0
the 0
use 0
of 0
tamoxifen 0
in 0
postmenopausal 0
patients 0
with 0
advanced 0
breast 0
cancer 0
. 0

No 0
benefit 0
has 0
been 0
demonstrated 0
from 0
the 0
addition 0
of 0
CMF 0
chemotherapy 0
in 0
tamoxifen 0
responders 0
. 0

A 0
randomized 0
surveillance 0
study 0
of 0
patients 0
with 0
pedunculated 0
and 0
small 0
sessile 0
tubular 0
and 0
tubulovillous 0
adenomas 0
. 0

The 0
Funen 0
Adenoma 0
Follow-up 0
Study 0
. 0

BACKGROUND 0
We 0
wanted 0
to 0
assess 0
the 0
influence 0
of 0
various 0
surveillance 0
intervals 0
on 0
the 0
risk 0
of 0
new B-PHYSICAL
neoplasia I-PHYSICAL
after 0
removal 0
of 0
pedunculated 0
and 0
small 0
sessile 0
tubular 0
and 0
tubulovillous 0
adenomas 0
. 0

METHODS 0
After 0
initial 0
colonoscopic 0
polypectomy 0
patients 0
were 0
randomized 0
to 0
surveillance 0
with 0
either 0
2 0
years 0
( 0
group 0
A 0
) 0
or 0
4 0
years 0
( 0
group 0
B 0
) 0
between 0
colorectal 0
examinations 0
. 0

RESULTS 0
The 0
cumulated 0
risk 0
of 0
a B-PHYSICAL
patient I-PHYSICAL
having I-PHYSICAL
new I-PHYSICAL
adenomas I-PHYSICAL
was 0
35.0 0
% 0
( 0
28.7-41.4 0
% 0
) 0
in 0
group 0
A 0
and 0
35.5 0
% 0
( 0
28.4-42.7 0
% 0
) 0
in 0
group 0
B 0
after 0
48 0
months 0
. 0

The 0
risk 0
increased 0
to 0
44.9 0
% 0
( 0
36.0-53.9 0
% 0
) 0
and 0
60.1 0
% 0
( 0
48.5-71.7 0
% 0
) 0
, 0
respectively 0
, 0
after 0
96 0
months 0
. 0

The 0
risk 0
of 0
significant B-PHYSICAL
neoplasia I-PHYSICAL
( 0
carcinoma B-PHYSICAL
or 0
adenoma B-PHYSICAL
with I-PHYSICAL
villous I-PHYSICAL
structure 0
, 0
severe B-PHYSICAL
dysplasia I-PHYSICAL
, 0
or 0
diameter 0
> 0
10 0
mm 0
) 0
was 0
5.2 0
% 0
( 0
2.3-8.1 0
% 0
) 0
and 0
8.6 0
% 0
( 0
3.8-13.3 0
% 0
) 0
after 0
48 0
months 0
and 0
8.6 0
% 0
( 0
4.2-13.0 0
% 0
) 0
and 0
17.4 0
% 0
( 0
7.6-27.2 0
% 0
) 0
after 0
96 0
months 0
. 0

More 0
than 0
one 0
adenoma 0
at 0
first 0
examination 0
was 0
associated 0
with 0
higher 0
risk 0

Cost-effectiveness 0
of 0
clopidogrel 0
in 0
acute 0
coronary 0
syndromes 0
in 0
Canada 0
: 0
a 0
long-term 0
analysis 0
based 0
on 0
the 0
CURE 0
trial 0
. 0

BACKGROUND 0
Cardiovascular 0
diseases 0
account 0
for 0
nearly 0
20 0
% 0
of 0
all 0
hospitalizations 0
in 0
Canada 0
and 0
consume 0
12 0
% 0
of 0
the 0
total 0
cost 0
of 0
all 0
illnesses 0
. 0

With 0
increasing 0
trends 0
of 0
cardiovascular 0
disease 0
and 0
increasing 0
costs 0
of 0
care 0
, 0
development 0
of 0
cost-effective 0
strategies 0
is 0
vital 0
. 0

The 0
Clopidogrel 0
in 0
Unstable 0
angina 0
to 0
prevent 0
Recurrent 0
Events 0
( 0
CURE 0
) 0
trial 0
demonstrated 0
the 0
effectiveness 0
of 0
clopidogrel 0
plus 0
acetylsalicylic 0
acid 0
( 0
ASA 0
) 0
compared 0
with 0
ASA 0
alone 0
in 0
reducing 0
cardiovascular 0
events 0
in 0
patients 0
with 0
acute 0
coronary 0
syndromes 0
and 0
, 0
in 0
addition 0
, 0
patients 0
undergoing 0
percutaneous 0
coronary 0
intervention 0
in 0
the 0
Percutaneous 0
Coronary 0
Intervention 0
in 0
CURE 0
( 0
PCI-CURE 0
) 0
trial 0
. 0

OBJECTIVE 0
To 0
assess 0
the 0
cost-effectiveness 0
of 0
clopidogrel 0
in 0
the 0
Canadian 0
health 0
care 0
system 0
. 0

METHODS 0
Estimates 0
of 0
hospitalization 0
costs 0
were 0
based 0
on 0
the 0
2003 0
cost 0
schedules 0
released 0
by 0
the 0
Health 0
Funding 0
and 0
Costing 0
Branch 0
of 0
the 0
Alberta 0
Health 0
and 0
Wellness 0
, 0
as 0
well 0
as 0
on 0
the 0
Case 0
Mix 0
Group 0
classification 0
system 0
. 0

Life 0
expectancy 0
beyond 0
the 0
trial 0
was 0
estimated 0
from 0
the 0
Saskatchewan 0
Health 0
Database 0
. 0

Cost-effectiveness 0
was 0
expressed 0
as 0
the 0
incremental 0
cost-effectiveness 0
ratio 0
, 0
and 0
bootstrap 0
methods 0
were 0
used 0
to 0
estimate 0
the 0
joint 0
distribution 0
of 0
costs 0
and 0
effectiveness 0
. 0

RESULTS 0
Clopidogrel 0
was 0
shown 0
to 0
be 0
cost-effective B-OTHER
, 0
with 0
incremental 0
cost-effectiveness B-OTHER
ratios I-OTHER
less 0
than 0
$ 0
10,000 0
per 0
event 0
prevented B-OTHER
and 0
less 0
than 0
$ 0
4,000 0
per 0
life-year 0
gained B-OTHER
. 0

The 0
probability 0
of 0
clopidogrel 0
resulting 0
in 0
cost 0
per 0
life-year B-OTHER
gained I-OTHER
of 0
less 0
than 0
$ 0
20,000 0
was 0
0.975 0
for 0
CURE 0
patients 0
and 0
0.904 0
for 0
PCI-CURE 0
patients 0
. 0

CONCLUSIONS 0
The 0
economic 0
analysis 0
demonstrated 0
that 0
clopidogrel 0
combination 0
therapy 0
is 0
not 0
only 0
cost-effective 0
as 0
antiplatelet 0
therapy 0
compared 0
with 0
ASA 0
alone 0
, 0
but 0
it 0
is 0
also 0
cost-effective 0
compared 0
with 0
other 0
commonly 0
used 0
and 0
openly 0
reimbursed 0
cardiovascular 0
therapies 0
in 0
the 0
Canadian 0
health 0
care 0
system 0
. 0

Strategies 0
for 0
dietary 0
and 0
anti-smoking 0
advice 0
. 0

Practical 0
experiences 0
from 0
the 0
Oslo 0
Study 0
. 0

One 0
of 0
the 0
2 0
controlled 0
preventive 0
trials 0
within 0
the 0
Oslo 0
Study 0
was 0
a 0
non-drug 0
trial 0
on 0
the 0
effect 0
of 0
diet B-OTHER
and 0
smoking B-OTHER
intervention I-OTHER
on 0
coronary 0
heart 0
disease 0
in 0
1232 0
middleaged 0
, 0
normotensive 0
, 0
healthy 0
men 0
. 0

All 0
had 0
elevated 0
serum 0
cholesterol 0
and 0
4 0
out 0
of 0
5 0
smoked 0
every 0
day 0
. 0

The 0
participants 0
in 0
the 0
intervention 0
group 0
met 0
every 0
6 0
months 0
during 0
the 0
5-year 0
study 0
for 0
clinical 0
examination 0
and 0
for 0
dietary 0
and 0
smoking B-OTHER
counselling I-OTHER
. 0

The 0
effect 0
on 0
serum B-PHYSICAL
cholesterol I-PHYSICAL
was 0
a 0
13 0
% 0
lowering 0
( 0
i.e 0
. 0

10 0
% 0
net 0
reduction 0
compared 0
with 0
control 0
group 0
) 0
, 0
and 0
about 0
a 0
50 0
% 0
reduction 0
in 0
cigarette B-MENTAL
consumption I-MENTAL
. 0

The 0
effect 0
on 0
coronary B-PHYSICAL
heart I-PHYSICAL
disease I-PHYSICAL
( 0
fatal 0
and 0
non-fatal 0
myocardial 0
infarction 0
or 0
sudden 0
death 0
) 0
was 0
a 0
47 0
% 0
lowering 0
of 0
the 0
5-year 0
incidence 0
in 0
the 0
intervention 0
group 0
compared 0
with 0
the 0
control 0
group 0
( 0
p 0
= 0
0.02 0
, 0
2-sided 0
) 0
. 0

The 0
main 0
intervention 0
strategies 0
were 0
: 0
information 0
about 0
the 0
risk 0
factor 0
concept 0
to 0
participant 0
and 0
spouse 0
( 0
in 0
groups 0
) 0
individual 0
diet 0
and 0
anti-smoking 0
counselling 0
after 0
finishing 0
an 0
extensive 0
clinical 0
and 0
electrocardiographic 0
examination 0
, 0
including 0
exercise-ECG 0
basis 0
and 0
background 0
for 0
the 0
counselling 0
strategy 0
: 0
the 0
total 0
situation 0
of 0
the 0
participant 0
. 0

Some 0
of 0
the 0
most 0
important 0
items 0
: 0
personality 0
, 0
motivation 0
, 0
diet 0
history 0
, 0
bodyweight 0
, 0
blood 0
lipids 0
and 0
blood 0
sugar 0
anti-smoking 0
advice 0
given 0
individually 0
to 0
all 0
smokers 0
in 0
the 0
intervention 0
group 0
advice 0
that 0
smoking 0
cessation 0
was 0
expected 0
to 0
be 0
of 0
special 0
importance 0
for 0
those 0
with 0
elevated 0
blood 0
lipids 0
. 0

Preventing 0
disability B-PHYSICAL
and 0
falls B-PHYSICAL
in I-PHYSICAL
older 0
adults B-PHYSICAL
: 0
a 0
population-based 0
randomized 0
trial 0
. 0

OBJECTIVES 0
Because 0
preventing 0
disability B-PHYSICAL
and 0
falls B-PHYSICAL
in B-PHYSICAL
older 0
adults B-PHYSICAL
is 0
a 0
national 0
priority 0
, 0
a 0
randomized 0
controlled 0
trial 0
was 0
conducted 0
to 0
test 0
a 0
multicomponent 0
intervention 0
program 0
. 0

METHODS 0
From 0
a 0
random 0
sample 0
of 0
health 0
maintenance 0
organization 0
( 0
HMO 0
) 0
enrollees 0
65 0
years 0
and 0
older 0
, 0
1559 0
ambulatory 0
seniors 0
were 0
randomized 0
to 0
one 0
of 0
three 0
groups 0
: 0
a 0
nurse 0
assessment 0
visit 0
and 0
follow-up 0
interventions 0
targeting 0
risk 0
factors 0
for 0
disability 0
and 0
falls 0
( 0
group 0
1 0
, 0
n 0
= 0
635 0
) 0
; 0
a 0
general 0
health 0
promotion 0
nurse 0
visit 0
( 0
group 0
2 0
, 0
n 0
= 0
317 0
) 0
; 0
and 0
usual 0
care 0
( 0
group 0
3 0
, 0
n 0
= 0
607 0
) 0
. 0

Data 0
collection 0
consisted 0
of 0
a 0
baseline 0
and 0
two 0
annual 0
follow-up 0
surveys 0
. 0

RESULTS 0
After 0
1 0
year 0
, 0
group 0
1 0
subjects 0
reported 0
a 0
significantly 0
lower 0
incidence 0
of 0
declining B-PHYSICAL
functional B-PHYSICAL
status I-PHYSICAL
and 0
a 0
significantly 0
lower 0
incidence 0
of 0
falls B-PHYSICAL
than 0
group 0
3 0
subjects 0
. 0

Group 0
2 0
subjects 0
had 0
intermediate 0
levels 0
of 0
most 0
outcomes 0
. 0

After 0
2 0
years 0
of 0
follow-up 0
, 0
the 0
differences 0
narrowed 0
. 0

CONCLUSIONS 0
The 0
results 0
suggest 0
that 0
a 0
modest 0
, 0
one-time 0
prevention 0
program 0
appeared 0
to 0
confer 0

A 0
comparative 0
trial 0
of 0
fixed 0
ratio 0
beta-adrenoceptor 0
blocker 0
and 0
diuretic 0
combination 0
products 0
in 0
moderate 0
hypertension 0
. 0

Two 0
fixed 0
ratio 0
combination 0
tablets 0
, 0
10 0
mg 0
pindolol 0
combined 0
with 0
5 0
mg 0
clopamide 0
and 0
100 0
mg 0
metoprolol 0
combined 0
with 0
12.5 0
mg 0
hydrochlorothiazide 0
, 0
were 0
compared 0
at 0
two 0
dose 0
levels 0
in 0
a 0
double-blind 0
crossover 0
trial 0
in 0
10 0
previously 0
untreated 0
hypertensive 0
patients 0
. 0

No 0
significant 0
difference 0
was 0
observed 0
between 0
resting B-PHYSICAL
blood I-PHYSICAL
pressure I-PHYSICAL
on 0
the 0
two 0
combinations 0
at 0
either 0
dose 0
level 0
. 0

Exercise B-PHYSICAL
systolic I-PHYSICAL
pressure I-PHYSICAL
was 0
lower 0
after 0
the 0
pindolol/clopamide 0
combination 0
at 0
low 0
dose 0
( 0
p 0
less 0
than 0
0.05 0
) 0
. 0

The 0
incidence 0
of 0
side-effects B-ADVERSE-EFFECTS
in 0
this 0
trial 0
was 0
high 0
but 0
proper 0
comparison 0
of 0
the 0
two 0
products 0
could 0
not 0
be 0
made 0
because 0
of 0
the 0
small 0
number 0
of 0
patients 0
. 0

It 0
is 0
suggested 0
that 0
combination 0
products 0
should 0
be 0
used 0
only 0
after 0
patients 0
have 0
failed 0
to 0
respond 0
adequately 0
to 0
a 0
single 0
agent 0
. 0

Elevated 0
concentration 0
of 0
placental 0
growth 0
factor 0
( 0
PlGF 0
) 0
and 0
long 0
term 0
risk 0
in 0
patients 0
with 0
acute 0
coronary 0
syndrome 0
in 0
the 0
PROVE 0
IT-TIMI 0
22 0
trial 0
. 0

Placental B-PHYSICAL
growth I-PHYSICAL
factor 0
( B-PHYSICAL
PlGF I-PHYSICAL
) B-PHYSICAL
, 0
a 0
member 0
of 0
the 0
vascular 0
endothelial 0
growth 0
factor 0
( 0
VEGF 0
) 0
family 0
, 0
acts 0
via 0
the 0
flt-1 0
receptor 0
and 0
promotes 0
endothelial 0
activation 0
and 0
macrophage 0
recruitment 0
into 0
atherosclerotic 0
lesions 0
. 0

We 0
investigated 0
the 0
relationship 0
of 0
PlGF 0
with 0
cardiovascular 0
outcomes 0
in 0
a 0
large 0
cohort 0
of 0
patients 0
presenting 0
across 0
the 0
spectrum 0
of 0
ACS 0
. 0

PlGF B-MENTAL
was 0
measured 0
at 0
baseline 0
( 0
n 0
= 0
3,761 0
) 0
and 0
at 0
four-months 0
( 0
n 0
= 0
3,369 0
) 0
in 0
patients 0
randomized 0
to 0
atorvastatin 0
80 0
mg 0
or 0
pravastatin 0
40 0
mg 0
after 0
ACS 0
in 0
the 0
PROVE 0
IT-TIMI 0
22 0
trial 0
. 0

The 0
primary 0
endpoint 0
was 0
death B-MORTALITY
, 0
myocardial B-PHYSICAL

EEG 0
mapping 0
and 0
psychopharmacological 0
studies 0
with 0
denbufylline 0
in 0
SDAT 0
and 0
MID 0
. 0

Computed 0
tomography 0
( 0
CT 0
) 0
, 0
electroencephalograms 0
( 0
EEG 0
) 0
, 0
clinical 0
and 0
psychometric 0
data 0
were 0
obtained 0
in 0
96 0
mildly 0
to 0
moderately 0
demented 0
patients 0
( 0
72 0
women 0
, 0
24 0
men 0
) 0
, 0
aged 0
61-96 0
years 0
( 0
mean 0
82 0
) 0
, 0
diagnosed 0
according 0
to 0
DSM-III 0
criteria 0
. 0

Patients 0
were 0
off 0
drugs 0
for 0
at 0
least 0
2 0
weeks 0
and 0
subdiagnosed 0
according 0
to 0
the 0
modified 0
Marshall-Hachinski 0
ischemic 0
score 0
and 0
CT 0
in 0
45 0
senile 0
dementia 0
of 0
the 0
Alzheimer 0
type 0
( 0
SDAT 0
) 0
and 0
51 0
multiinfarct 0
dementia 0
( 0
MID 0
) 0
patients 0
. 0

Evaluations 0
were 0
carried 0
out 0
before 0
and 0
12 0
weeks 0
after 0
treatment 0
with 0
either 0
100 0
mg 0
denbufylline 0
BID 0
or 0
placebo 0
and 0
included 0
EEG 0
mapping 0
, 0
the 0
Sandoz 0
Clinical 0
Assessment 0
Geriatric 0
( 0
SCAG 0
) 0
score/factors 0
, 0
the 0
Clinical 0
Global 0
Impression 0
( 0
CGI 0
) 0
, 0
the 0
Digit 0
Symbol 0
Substitution 0
Test 0
( 0
DSST 0
) 0
, 0
the 0
Trail-Making 0
Test 0
( 0
TMT 0
) 0
and 0
the 0
Digit 0
Span 0
Test 0
( 0
DS 0
) 0
. 0

Descriptive 0
data 0
analysis 0
including 0
confirmatory 0
statements 0
found 0
delta/theta B-PHYSICAL
activity I-PHYSICAL
enhanced 0
, 0
alpha B-PHYSICAL
and 0
beta B-PHYSICAL
activity I-PHYSICAL
reduced 0
, 0
total 0
power B-PHYSICAL
augmented 0
, 0
and 0
the 0
centroid B-PHYSICAL
slowed 0
down 0
over 0
various 0
brain 0
regions 0
in 0
patients 0
as 0
compared 0
with 0
controls 0
. 0

The 0
two 0
subtypes 0
of 0
dementia 0
could 0
be 0
differentiated 0
in 0
some 0
conventional 0
EEG 0
variables 0
but 0
mostly 0
by 0
means 0
of 0
power 0
asymmetry 0
indices 0
. 0

Denbufylline 0
induced 0
a 0
statistically 0
significant 0
and 0
clinically 0
relevant 0
improvement 0
in 0
both 0
SDAT B-OTHER
and 0
MID B-OTHER
patients 0
, 0
whereas 0
after 0
placebo 0
this 0
was 0
not 0
the 0
case 0
in 0
CGI 0
, 0
the 0
TMT 0
, 0
and 0
the 0
DS 0
, 0
with 0
interdrug 0
differences 0
being 0
significant 0
in 0
all 0
primary 0
target 0
variables 0
such 0
as 0
the 0
CGI 0
, 0
MMS 0
, 0
SCAG 0
, 0
and 0
DSST 0
. 0

Thus 0
, 0
both 0
the 0
degenerative 0
and 0
vascular 0
type 0
of 0
dementia 0
exhibited 0
a 0
therapeutic 0
benefit 0
that 0
could 0
be 0
objectified 0
at 0
the 0
neurophysiological 0
level 0
by 0
EEG 0
mapping 0
in 0
an 0
improvement 0
of 0
vigilance 0
. 0

Alendronate 0
daily 0
, 0
weekly 0
in 0
conventional 0
tablets 0
and 0
weekly 0
in 0
enteric 0
tablets 0
: 0
preliminary 0
study 0
on 0
the 0
effects 0
in 0
bone B-PHYSICAL
turnover I-PHYSICAL
markers I-PHYSICAL
and 0
incidence 0
of 0
side B-ADVERSE-EFFECTS
effects I-ADVERSE-EFFECTS
. 0

Bisphosphonates 0
are 0
now 0
in 0
the 0
vanguard 0
of 0
osteoporosis 0
treatment 0
. 0

Frequently 0
, 0
gastro-oesophageal 0
symptoms 0
are 0
associated 0
with 0
these 0
drugs 0
. 0

The 0
objective 0
of 0
this 0
study 0
was 0
to 0
compare 0
side 0
effects 0
and 0
bone 0
turnover 0
markers 0
in 0
postmenopausal 0
women 0
who 0
had 0
received 0
alendronate 0
daily 0
or 0
weekly 0
in 0
tablets 0
with 0
or 0
without 0
enteric 0
coating 0
. 0

We 0
conducted 0
a 0
randomised 0
, 0
double-blind 0
, 0
3-month 0
trial 0
. 0

The 0
trial 0
involved 0
75 0
volunteers 0
, 0
aged 0
45-58 0
with 0
moderate 0
to 0
severe 0
osteopenia 0
( 0
T-score 0
lower 0
than 0
-2 0
SD 0
) 0
assessed 0
by 0
quantitative 0
ultrasound 0
. 0

Women 0
were 0
assigned 0
randomly 0
to 0
receive 0
: 0
( 0
a 0
) 0
alendronate 0
10mg/day 0
: 0
( 0
b 0
) 0
alendronate 0
70 0
mg 0
once 0
a 0
week 0
: 0
or 0
( 0
c 0
) 0
enteric 0
alendronate 0
70 0
mg 0
per 0
week 0
. 0

We 0
recorded 0
side 0
effects 0
, 0
C-telopeptide B-PHYSICAL
, 0
osteocalcin B-PHYSICAL
and 0
urine B-PHYSICAL
hydroxyproline I-PHYSICAL
at 0
the 0
start 0
of 0
the 0
study 0
and 0
at 0
3 0
months 0
. 0

After 0
3 0
months 0
, 0
pyrosis B-PHYSICAL
( I-PHYSICAL
heartburn I-PHYSICAL
) I-PHYSICAL
was 0
noted 0
by 0
seven 0
women 0
in 0
group 0
A 0
( 0
28 0
% 0
) 0
, 0
three 0
in 0
group 0
B 0
( 0
12 0
% 0
) 0
and 0
two 0
in 0
group 0
C 0
( 0
8 0
% 0
) 0
; 0
nausea B-PHYSICAL
: 0
by 0
one 0
woman 0
in 0
group 0
B 0
; 0
and 0
headache B-PHYSICAL
by 0
one 0
patient 0
in 0
each 0
group 0
. 0

C-telopeptide B-PHYSICAL
( 0
A 0
: 0
40.7 0
% 0
; 0
B 0
: 0
34.1 0
% 0
and 0
C 0
: 0
38.5 0
% 0
) 0
; 0
hydroxyproline B-PHYSICAL
( 0
A 0
: 0
31.1 0
% 0
; 0
B 0
: 0
25.3 0
% 0
and 0
C 0
: 0
31.5 0
% 0
) 0
and 0
osteocalcin B-PHYSICAL
( 0
A 0
: 0
27.0 0
% 0
; 0
B 0
: 0
25.4 0
% 0
and 0
C 0
: 0
25.1 0
% 0
) 0
decreased 0
similarly 0
in 0
the 0
three 0
groups 0
. 0

Weekly 0
intake 0
of 0
alendronate 0
, 0
whether 0
conventional 0
or 0
enteric-coated 0
; 0
is 0
associated 0
with 0
less 0
heartburn B-PHYSICAL
and 0
nausea B-PHYSICAL
. 0

Enteric 0
alendronate 0
has 0
a 0
similar 0
action 0
to 0
the 0
conventional 0
tablets 0
on 0
biochemical B-PHYSICAL
markers I-PHYSICAL
. 0

Impact 0
of 0
different 0
platelet 0
glycoprotein 0
IIb/IIIa 0
receptor 0
inhibitors 0
among 0
diabetic 0
patients 0
undergoing 0
percutaneous 0
coronary 0
intervention 0
: 0
: 0
Do 0
Tirofiban 0
and 0
ReoPro 0
Give 0
Similar 0
Efficacy 0
Outcomes 0
Trial 0
( 0
TARGET 0
) 0
1-year 0
follow-up 0
. 0

BACKGROUND 0
The 0
platelet 0
glycoprotein 0
IIb/IIIa 0
receptor 0
inhibitor 0
abciximab 0
, 0
a 0
monoclonal 0
antibody 0
, 0
has 0
been 0
shown 0
to 0
improve 0
early 0
and 0
late 0
outcomes 0
among 0
diabetic 0
patients 0
undergoing 0
percutaneous 0
coronary 0
intervention 0
( 0
PCI 0
) 0
. 0

It 0
is 0
unknown 0
whether 0
small-molecule 0
agents 0
confer 0
similar 0
benefits 0
. 0

METHODS 0
AND 0
RESULTS 0
In 0
18 0
countries 0
, 0
4809 0
patients 0
undergoing 0
PCI 0
with 0
stent 0
implantation 0
were 0
randomized 0
to 0
tirofiban 0
or 0
abciximab 0
. 0

At 0
the 0
time 0
of 0
enrollment 0
, 0
patients 0
were 0
stratified 0
according 0
to 0
diabetes 0
status 0
. 0

As 0
compared 0
with 0
non-diabetic 0
patients 0
, 0
patients 0
with 0
diabetes 0
( 0
n=1117 0
) 0
showed 0
similar 0
30-day 0
ischemic 0
outcomes 0
, 0
an 0
increased 0
incidence 0
of 0
any B-PHYSICAL
target I-PHYSICAL
vessel I-PHYSICAL
revascularization I-PHYSICAL
( 0
TVR B-PHYSICAL
) 0
at 0
6 0
months 0
( 0
10.3 0
% 0
versus 0
7.8 0
% 0
; 0
P= 0
0.008 0
) 0
, 0
and 0
a 0
trend 0
toward 0
higher B-MORTALITY
1-year I-MORTALITY
mortality I-MORTALITY
( 0
2.5 0
% 0
versus 0
1.6 0
% 0
; 0
P=0.056 0
) 0
. 0

Among 0
diabetic 0
patients 0
randomized 0
to 0
tirofiban 0
( 0
n=560 0
) 0
, 0
the 0
incidence 0
of 0
death B-MORTALITY
, 0
myocardial B-PHYSICAL
infarction I-PHYSICAL
( 0
MI B-PHYSICAL
) 0
, 0
or 0

[ 0
Bupivacaine-CO2 0
and 0
bupivacaine-HCl 0
at 0
various 0
injection 0
temperatures 0
in 0
peridural 0
anesthesia 0
for 0
extracorporeal 0
shock 0
wave 0
lithotripsy 0
] 0
. 0

INTRODUCTION 0
The 0
effect 0
of 0
different 0
injection 0
temperatures 0
on 0
carbonated 0
anesthetics 0
has 0
been 0
controversial 0
since 0
1965 0
. 0

The 0
current 0
study 0
was 0
undertaken 0
to 0
determine 0
onset 0
times 0
of 0
sensory 0
and 0
motor 0
blockade 0
after 0
epidural 0
anesthesia 0
with 0
0.5 0
% 0
bupivacaine-CO2 0
and 0
0.5 0
% 0
bupivacaine-HCl 0
at 0
various 0
injection 0
temperatures 0
. 0

MATERIALS 0
AND 0
METHODS 0
The 0
study 0
was 0
performed 0
on 0
90 0
ASA 0
class 0
I-II 0
urologic 0
patients 0
during 0
extracorporeal 0
shock 0
wave 0
lithotripsy 0
. 0

The 0
patients 0
were 0
randomized 0
in 0
six 0
groups 0
to 0
receive 0
either 0
0.5 0
% 0
bupivacaine-CO2 0
or 0
0.5 0
% 0
bupivacaine-HCl 0
at 0
temperatures 0
of 0
4 0
degrees 0
, 0
20 0
degrees 0
, 0
or 0
36 0
degrees 0
C. 0
The 0
six 0
groups 0
were 0
comparable 0
in 0
age 0
, 0
height 0
, 0
and 0
weight 0
. 0

Epidural 0
anesthesia 0
was 0
performed 0
at 0
the 0
L2-3 0
interspace 0
with 0
an 0
18-gauge 0
Tuohy 0
needle 0
using 0
loss 0
of 0
resistance 0
. 0

A 0
catheter 0
was 0
advanced 0
4 0
cm 0
in 0
the 0
epidural 0
space 0
and 0
4 0
ml 0
0.5 0
% 0
bupivacaine 0
with 0
adrenaline 0
1:200,000 0
was 0
given 0
as 0
a 0
test 0
dose 0
. 0

After 0
4 0
min 0
the 0
full 0
anesthetic 0
dose 0
, 0
based 0
on 0
body 0
size 0
, 0
was 0
injected 0
with 0
the 0
patient 0
supine 0
. 0

Sensory B-OTHER
blockade I-OTHER
was 0
determined 0
by 0
the 0
pinprick 0
method 0
and 0
motor B-OTHER
blockade I-OTHER
by 0
the 0
Bromage 0
method 0
at 0
2-min 0
intervals 0
for 0
the 0
first 0
20 0
min 0
, 0
at 0
5-min 0
intervals 0
for 0
the 0
next 0
10 0
min 0
, 0
and 0
then 0
every 0
15 0
min 0
to 0
a 0
total 0
of 0
240 0
min 0
. 0

Statistical 0
analysis 0
was 0
done 0
by 0
the 0
Mann-Whitney 0
test 0
, 0
with 0
P 0
less 0
than 0
0.05 0
considered 0
significant 0
. 0

RESULTS 0
Spread 0
of 0
sensory B-OTHER
blockade I-OTHER
was 0
significantly 0
faster 0
with 0
bupivacaine-CO2 0
and 0
-HCl 0
at 0
a 0
temperature 0
of 0
36 0
degrees 0
C 0
as 0
compared 0
to 0
4 0
degrees 0
or 0
20 0
degrees 0
C 0
( 0
P 0
less 0
than 0
0.05 0
) 0
( 0
Figs 0
. 0

1 0
, 0
2 0
and 0
Table 0
2 0
) 0
. 0
( 0

ABSTRACT 0
TRUNCATED 0
AT 0
250 0
WORDS 0
) 0

Risk 0
of 0
infection 0
after 0
penetrating 0
abdominal 0
trauma 0
. 0

To 0
identify 0
the 0
risk 0
factors 0
for 0
the 0
development 0
of 0
postoperative 0
septic 0
complications 0
in 0
patients 0
with 0
intestinal 0
perforation 0
after 0
abdominal 0
trauma 0
, 0
and 0
to 0
compare 0
the 0
efficacies 0
of 0
single-drug 0
and 0
dual-drug 0
prophylactic 0
antibiotic 0
therapy 0
, 0
we 0
studied 0
145 0
patients 0
who 0
presented 0
with 0
abdominal 0
trauma 0
and 0
intestinal 0
perforation 0
at 0
two 0
hospitals 0
between 0
July 0
1979 0
and 0
June 0
1982 0
. 0

Logistic-regression 0
analysis 0
showed 0
that 0
a 0
higher 0
risk 0
of 0
infection 0
( 0
P 0
less 0
than 0
0.05 0
) 0
was 0
associated 0
with 0
increased 0
age 0
, 0
injury 0
to 0
the 0
left 0
colon 0
necessitating 0
colostomy 0
, 0
a 0
larger 0
number 0
of 0
units 0
of 0
blood 0
or 0
blood 0
products 0
administered 0
at 0
surgery 0
, 0
and 0
a 0
larger 0
number 0
of 0
injured 0
organs 0
. 0

The 0
presence 0
of 0
shock 0
on 0
arrival 0
, 0
which 0
was 0
found 0
to 0
increase 0
the 0
risk 0
of 0
infection B-PHYSICAL
when 0
this 0
factor 0
was 0
analyzed 0
individually 0
, 0
did 0
not 0
add 0
predictive 0
power 0
. 0

Patients 0
with 0
postoperative 0
sepsis 0
were 0
hospitalized B-OTHER
significantly I-OTHER
longer 0
than 0
were 0
patients 0
without 0
infection 0
( 0
13.8 0
vs. 0
7.7 0
days 0
, 0
P 0
less 0
than 0
0.0001 0
) 0
. 0

Both 0
treatment 0
regimens 0
-- 0
cefoxitin 0
given 0
alone 0
and 0
clindamycin 0
and 0
gentamicin 0
given 0
together 0
-- 0
resulted 0
in 0
similar 0
infection B-PHYSICAL
rates I-PHYSICAL
, 0
drug B-PHYSICAL
toxicity I-PHYSICAL
, 0
duration B-OTHER
of I-OTHER
hospitalization I-OTHER
, 0
and 0
costs 0
. 0

Immediately 0
restored 0
, 0
single-tapered 0
implants 0
in 0
the 0
anterior 0
maxilla 0
: 0
prosthodontic 0
and 0
aesthetic 0
outcomes 0
after 0
1 0
year 0
. 0

BACKGROUND 0
Conventional 0
implant 0
protocols 0
advocate 0
a 0
two-stage 0
technique 0
with 0
a 0
load-free 0
, 0
submerged 0
healing 0
period 0
. 0

Recent 0
studies 0
suggest 0
that 0
immediate 0
restoration 0
of 0
single 0
implants 0
may 0
be 0
a 0
viable 0
treatment 0
option 0
. 0

PURPOSE 0
The 0
purpose 0
of 0
this 0
study 0
was 0
to 0
evaluate 0
prosthodontic 0
and 0
aesthetic 0
peri-implant 0
mucosal 0
outcomes 0
of 0
immediately 0
restored 0
, 0
Southern 0
single-tapered 0
implants 0
in 0
the 0
anterior 0
maxilla 0
after 0
1 0
year 0
. 0

MATERIALS 0
AND 0
METHODS 0
Participants 0
( 0
mean 0
age 0
: 0
43.25 0
years 0
; 0
range 0
: 0
23-71 0
years 0
) 0
satisfying 0
specified 0
inclusion 0
criteria 0
were 0
randomly 0
allocated 0
to 0
conventional 0
two-stage 0
restoration 0
( 0
control 0
group 0
; 0
n=14 0
) 0
and 0
immediate 0
restoration 0
groups 0
( 0
test 0
group 0
; 0
n 0
=14 0
) 0
in 0
a 0
randomized 0
controlled 0
clinical 0
trial 0
. 0

Tapered 0
, 0
roughened-surface 0
Southern 0
implants 0
were 0
placed 0
using 0
a 0
standardized 0
technique 0
, 0
and 0
implant 0
level 0
bone 0
impressions 0
were 0
made 0
. 0

Provisional 0
screw-retained 0
crowns 0
, 0
out 0
of 0
occlusion 0
, 0
were 0
placed 0
at 0
second-stage 0
surgery 0
after 0
26 0
weeks 0
for 0
the 0
conventional 0
restoration 0
group 0
, 0
and 0
within 0
4 0
hours 0
of 0
implant 0
placement 0
for 0
the 0
immediate 0
restoration 0
group 0
. 0

Both 0
groups 0
had 0
definitive 0
screw-retained 0
metal-ceramic 0
crowns 0
placed 0
in 0
occlusion 0
8 0
weeks 0
later 0
. 0

Peri-implant B-PHYSICAL
mucosal I-PHYSICAL
response 0
and B-PHYSICAL
papilla I-PHYSICAL
index B-PHYSICAL
were 0
recorded 0
4 0
weeks 0
after 0
definitive 0
crown 0
placement 0
to 0
allow 0
for 0
mucosal 0
maturation 0
and 0
at 0
1 0
year 0
. 0

Prosthodontic B-PHYSICAL
and 0
aesthetic B-PHYSICAL
outcomes 0
were 0
assessed 0
using 0
established 0
criteria 0
. 0

RESULTS 0
There 0
were 0
no 0
significant 0
differences 0
within 0
, 0
or 0
between 0
, 0
the 0
control 0
and 0
test 0
groups 0
for 0
age 0
, 0
gender 0
, 0
bone B-OTHER
quality B-OTHER
or 0
quantity B-OTHER
, 0
implant 0
stability B-OTHER
measurements I-OTHER
at B-OTHER
surgery I-OTHER
, 0
or 0
implant B-OTHER
length I-OTHER
. 0

There 0
were 0
no 0
significant 0
differences 0
in 0
the 0
implant B-OTHER
success I-OTHER
rate B-OTHER
as 0
determined 0
by 0
radiographic 0

Nitrous 0
oxide 0
diffusion 0
into 0
tracheal 0
tube 0
cuffs B-PHYSICAL
-- 0
efficacy 0
of 0
a 0
new 0
prototype 0
cuff 0
pressure 0
release 0
valve 0
. 0

BACKGROUND 0
The 0
aim 0
of 0
this 0
study 0
was 0
to 0
evaluate 0
the 0
performance B-OTHER
of 0
a 0
new 0
cuff B-PHYSICAL
pressure I-PHYSICAL
release 0
valve 0
( 0
CPRV 0
) 0
, 0
in 0
which 0
the 0
release 0
pressure 0
can 0
be 0
adjusted 0
from 0
10 0
to 0
25 0
cmH2O 0
, 0
particularly 0
intended 0
to 0
control 0
pressure 0
in 0
paediatric 0
cuffed 0
tracheal 0
tubes 0
and 0
to 0
avoid 0
cuff 0
hyperinflation 0
caused 0
by 0
N2O 0
diffusion 0
. 0

METHODS 0
In 0
vitro 0
: 0
the 0
PRV 0
was 0
set 0
to 0
10 0
, 0
15 0
, 0
20 0
or 0
25 0
cmH2O 0
release 0
pressure 0
and 0
connected 0
to 0
a 0
cuffed 0
tube 0
placed 0
into 0
a 0
box 0
flushed 0
with 0
66 0
% 0
N2O 0
in 0
O2 0
. 0

The 0
cuff B-PHYSICAL
pressure I-PHYSICAL
was 0
monitored 0
with 0
and 0
without 0
CPRV 0
for 0
60 0
min 0
. 0

Experiments 0
were 0
performed 0
four 0
times 0
using 0
two 0
different 0
CPRVs 0
. 0

In 0
vivo 0
: 0
with 0
Institutional 0
Review 0
Board 0
approval 0
, 0
CPRV 0
was 0
studied 0
in 0
50 0
children 0
undergoing 0
general 0
anaesthesia 0
with 0
tracheal 0
intubation 0
and 0
standardized 0
anaesthesia 0
technique 0
( 0
including 0
66 0
% 0
N2O 0
in 0
O2 0
) 0
and 0
ventilator 0
settings 0
. 0

Patients 0
were 0
randomized 0
into 0
two 0
groups 0
( 0
with 0
and 0
without 0
CPRV 0
) 0
. 0

The 0
cuff B-PHYSICAL
pressure I-PHYSICAL
baseline 0
was 0
20 0
cmH2O 0
and 0
CPRV 0
was 0
set 0
to 0
25 0
cmH2O 0
. 0

If 0
the 0
cuff B-PHYSICAL
pressure I-PHYSICAL
exceeded 0
25 0
cmH2O 0
, 0
it 0
was 0
manually 0
released 0
to 0
20 0
cmH2O 0
. 0

The 0
numbers 0
of 0
deflations 0
in 0
both 0
groups 0
were 0
noted 0
and 0
compared 0
by 0
Mann-Whitney 0
U-test 0
( 0
P 0
< 0
0.05 0
) 0
. 0

RESULTS 0
In 0
vitro 0
: 0
the 0
cuff B-PHYSICAL
pressure I-PHYSICAL
exceeded 0
50 0
cmH2O 0
after 0
60 0
min 0
without 0
CPRV 0
, 0
but 0
did 0
not 0
exceed 0
the 0
settings 0
with 0
CPRV 0
. 0

In 0
vivo 0
: 0
there 0
was 0
no 0
need 0
to 0
manually 0
deflate 0
the 0
cuff 0
in 0
the 0
CPRV 0
group 0
but 0
, 0
in 0
every 0
patient 0
in 0
the 0
control 0
group 0
, 0
three 0
( 0
two 0
to 0
seven 0
) 0
deflating 0
manoeuvres 0
were 0
required 0
within 0
the 0
first 0
hour 0
of 0
anaesthesia 0
( 0
P 0
< 0
0.0001 0
) 0
. 0

CONCLUSION 0
The 0
CPRV 0
allows 0
reliable B-PHYSICAL
cuff I-PHYSICAL
pressure I-PHYSICAL
release I-PHYSICAL
at 0
various 0
pressure 0
levels 0
and 0
reliably 0
prevents 0
cuff B-PHYSICAL
pressure I-PHYSICAL
increases 0
caused 0
by 0
N2O 0
. 0

Cigarette 0
smoking 0
is 0
associated 0
with 0
increased 0
circulating 0
proinflammatory 0
and 0
procoagulant 0
markers 0
in 0
patients 0
with 0
chronic 0
coronary 0
artery 0
disease 0
: 0
effects 0
of 0
aspirin 0
treatment 0
. 0

BACKGROUND 0
Smoking 0
is 0
associated 0
with 0
endothelial 0
dysfunction 0
. 0

Cytokines 0
released 0
by 0
injured 0
endothelium 0
promote 0
vascular 0
interactions 0
with 0
leukocytes 0
and 0
platelets 0
. 0

We 0
investigated 0
whether 0
( 0
a 0
) 0
cigarette 0
smoking 0
is 0
linked 0
to 0
increased 0
cytokine 0
production 0
, 0
which 0
may 0
mediate 0
platelet 0
activation 0
and 0
thrombin 0
generation 0
in 0
chronic 0
coronary 0
artery 0
disease 0
( 0
CAD 0
) 0
, 0
and 0
( 0
b 0
) 0
aspirin 0
treatment 0
inhibits 0
smoking-related 0
changes 0
on 0
cytokines 0
, 0
platelets 0
, 0
and 0
thrombin 0
. 0

METHODS 0
AND 0
RESULTS 0
Plasma 0
macrophage-colony-stimulating 0
factor 0
( 0
M-CSF 0
) 0
and 0
C-reactive 0
protein 0
( 0
CRP 0
) 0
were 0
measured 0
in 0
100 0
patients 0
with 0
chronic 0
CAD 0
, 0
60 0
of 0
whom 0
were 0
chronic 0
smokers 0
. 0

Prothrombin 0
fragments 0
1+2 0
and 0
urinary 0
11-dehydro-thromboxane 0
B2 0
( 0
TXB2 0
) 0
were 0
additionally 0
measured 0
in 0
60 0
of 0
100 0
patients 0
( 0
30 0
of 0
whom 0
were 0
smokers 0
) 0
and 0
in 0
24 0
healthy 0
controls 0
. 0

Smokers 0
( 0
n 0
= 0
20 0
) 0
matched 0
for 0
age 0
, 0
myocardial 0
ischemia 0
, 0
and 0
other 0
risk 0
factors 0
with 0
20 0
nonsmokers 0
entered 0
a 0
double-blind 0
crossover 0
trial 0
of 0
aspirin 0
( 0
300 0
mg/d 0
for 0
3 0
weeks 0
) 0
versus 0
placebo 0
. 0

Blood 0
and 0
urine 0
measurements 0
were 0
repeated 0
after 0
each 0
treatment 0
. 0

Compared 0
with 0
nonsmokers 0
, 0
smokers 0
had 0
3-fold B-PHYSICAL
median 0
M-CSF B-PHYSICAL
( 0
1499 0
vs 0
476 0
pg/mL 0
) 0
, 0
2-fold B-PHYSICAL
CRP B-PHYSICAL
( 0
1.5 0
vs 0
0.8 0
mg/L 0
) 0
, 0
and 0
higher 0
11-dehydro-TXB B-PHYSICAL
2 0
( 0
3.6 0
vs 0
2.1 0
ng/mg 0
creatinine 0
, 0
P 0
< 0
.01 0
for 0
all 0
comparisons 0
) 0
. 0

After 0
aspirin 0
treatment 0
, 0
M-CSF B-PHYSICAL
, 0
CRP B-PHYSICAL
, 0
11-dehydro-TXB B-PHYSICAL
2 I-PHYSICAL
, 0
and 0

Conjugated 0
equine 0
estrogen 0
influence 0
on 0
mammographic B-PHYSICAL
density I-PHYSICAL
in 0
postmenopausal 0
women 0
in 0
a 0
substudy 0
of 0
the 0
women 0
's 0
health 0
initiative 0
randomized 0
trial 0
. 0

PURPOSE 0
Increased 0
mammographic B-PHYSICAL
density I-PHYSICAL
is 0
associated 0
with 0
increased 0
breast 0
cancer 0
risk 0
and 0
reduced 0
sensitivity 0
of 0
screening 0
mammography 0
and 0
is 0
related 0
to 0
hormone 0
exposure 0
. 0

However 0
, 0
the 0
effects 0
of 0
conjugated 0
equine 0
estrogens 0
( 0
CEEs 0
) 0
alone 0
on 0
mammographic B-PHYSICAL
density I-PHYSICAL
in 0
diverse 0
racial/ethnic 0
populations 0
are 0
not 0
established 0
. 0

We 0
examined 0
the 0
effect 0
of 0
CEE 0
alone 0
on 0
mammographic B-PHYSICAL
density I-PHYSICAL
in 0
a 0
subsample 0
of 0
the 0
Women 0
's 0
Health 0
Initiative 0
( 0
WHI 0
) 0
clinical 0
trial 0
participants 0
. 0

PATIENTS 0
AND 0
METHODS 0
In 0
the 0
WHI 0
trial 0
, 0
women 0
were 0
randomly 0
assigned 0
to 0
daily 0
CEE 0
0.625 0
mg 0
or 0
placebo 0
. 0

The 0
effect 0
of 0
CEE 0
on 0
mammographic B-PHYSICAL
percent I-PHYSICAL
density I-PHYSICAL
was 0
determined 0
over 0
1 0
and 0
2 0
years 0
in 0
a 0
stratified 0
random 0
sample 0
of 0
435 0
racially 0
and 0
ethnically 0
diverse 0
participants 0
from 0
15 0
of 0
40 0
WHI 0
clinics 0
. 0

RESULTS 0
Use 0
of 0
CEE 0
resulted 0
in 0
mean 0
increase 0
in 0
mammographic B-PHYSICAL
percent I-PHYSICAL
density I-PHYSICAL
of 0
1.6 0
percentage 0
points 0
( 0
95 0
% 0
CI 0
, 0
0.8 0
to 0
2.4 0
) 0
at 0
year 0
1 0
compared 0
with 0
a 0
mean 0
decrease 0
of 0
1.0 0
percentage 0
point 0
( 0
95 0
% 0
CI 0
, 0
-1.7 0
to 0
-0.4 0
) 0
in 0
the 0
placebo 0
group 0
( 0
P 0
< 0
.001 0
) 0
. 0

The 0
effect 0
persisted 0
for 0
2 0
years 0
, 0
with 0
a 0
mean 0
increase 0
of 0
1.7 0
percentage 0
points 0
( 0
95 0
% 0
CI 0
, 0
0.7 0
to 0
2.7 0
) 0
versus 0
a 0
mean 0
decrease 0
of 0
1.2 0
percentage 0
points 0
( 0
95 0
% 0
CI 0
, 0
-1.8 0
to 0
-0.5 0
; 0
P 0
< 0
.001 0
) 0
in 0
the 0
hormone 0
and 0
placebo 0
groups 0
, 0
respectively 0
. 0

These 0
effects 0
were 0
greater 0
in 0
women 0
age 0
60 0
to 0
79 0
years 0
( 0
P 0
= 0
.03 0
for 0
interaction 0
across 0
age 0
) 0
. 0

CONCLUSION 0
Use 0
of 0
CEE 0
results 0
in 0
a 0
modest 0
but 0
statistically 0
significant 0
increase 0
in 0
mammographic B-PHYSICAL
density I-PHYSICAL
that 0
is 0
sustained 0
over 0
at 0
least 0
a 0
2-year 0
period 0
. 0

The 0
clinical 0
significance 0
of 0
the 0
CEE 0
effect 0
on 0
mammographic B-PHYSICAL
density I-PHYSICAL
remains 0
to 0
be 0
determined 0
. 0

Low-dose 0
, 0
vaginally 0
administered 0
estrogens 0
may 0
enhance 0
local 0
benefits 0
of 0
systemic 0
therapy 0
in 0
the 0
treatment 0
of 0
urogenital 0
atrophy 0
in 0
postmenopausal 0
women 0
on 0
hormone 0
therapy 0
. 0

BACKGROUND 0
When 0
genital 0
atrophy 0
exists 0
, 0
systemic 0
hormone 0
therapy 0
( 0
HT 0
) 0
has 0
a 0
timing 0
until 0
to 0
induce 0
vaginal 0
proliferation 0
and 0
symptomatic 0
relieve 0
. 0

Thus 0
, 0
in 0
order 0
to 0
obtain 0
a 0
prompt 0
improvement 0
, 0
the 0
association 0
of 0
local 0
therapy 0
acting 0
on 0
the 0
genital 0
epithelium 0
to 0
the 0
systemic 0
treatment 0
should 0
be 0
considered 0
. 0

OBJECTIVE 0
To 0
evaluate 0
the 0
effects 0
of 0
a 0
combined 0
therapy 0
consisting 0
of 0
vaginal 0
estriol 0
with 0
transdermal 0
17-beta-estradiol 0
( 0
50 0
microg/day 0
) 0
plus 0
medroxyprogesterone 0
acetate 0
( 0
5 0
mg/day 0
) 0
per 0
os 0
in 0
shortening 0
the 0
period 0
of 0
uro-genital 0
symptoms 0
. 0

SUBJECTS 0
AND 0
METHODS 0
In 0
a 0
randomized 0
, 0
double 0
blind 0
, 0
controlled 0
with 0
placebo 0
study 0
, 0
27 0
women 0
with 0
climacteric 0
symptoms 0
and 0
atrophic 0
vaginitis 0
were 0
treated 0
for 0
4 0
months 0
with 0
HT 0
plus 0
vaginal 0
estriol 0
0.5 0
mg/day 0
( 0
group 0
E 0
) 0
or 0
placebo 0
( 0
group 0
P 0
) 0
. 0

Patients 0
use 0
the 0
local 0
medication 0
daily 0
for 0
the 0
first 0
3 0
weeks 0
and 0
twice-weekly 0
thereafter 0
. 0

Before 0
entering 0
in 0
the 0
study 0
, 0
patients 0
were 0
asked 0
about 0
HT 0
and 0
selected 0
for 0
inclusion 0
. 0

In 0
the 0
first 0
visit 0
, 0
electible 0
patients 0
after 0
written 0
informed 0
consent 0
were 0
randomized 0
to 0
receive 0
HT 0
plus 0
local 0
estriol 0
or 0
placebo 0
. 0

All 0
the 0
subjects 0
had 0
baseline 0
studies 0
, 0
including 0
medical 0
history 0
, 0
physical 0
examination 0
, 0
blood 0
and 0
urine 0
analysis 0
. 0

In 0
order 0
to 0
evaluate 0
the 0
effect 0
of 0
local 0
treatment 0
on 0
urinary 0
and 0
genital 0
symptoms 0
, 0
a 0
score 0
for 0
genital 0
, 0
urinary 0
and 0
colposcopic 0
complaints 0
( 0
0 0
minimum-100 0
maximum 0
) 0
was 0
developed 0
. 0

This 0
score 0
and 0
Blatt-Kuperman 0
were 0
recorded 0
and 0
performed 0
in 0
every 0
control 0
. 0

RESULTS 0
There 0
were 0
no 0
differences 0
on 0
climacteric B-OTHER
symptoms I-OTHER
relief I-OTHER
between I-OTHER
the I-OTHER
two I-OTHER
groups I-OTHER
. 0

Additionally 0
, 0
the 0
improvement 0
in 0
urinary B-OTHER
symptoms I-OTHER
at I-OTHER
the I-OTHER
end I-OTHER
of I-OTHER
the I-OTHER
study I-OTHER
was 0
similar 0
for 0
both 0
groups 0
( 0
from 0
16.5 0
+/- 0
6.1 0
to 0
8.5 0
+/- 0
2.4 0
for 0
E 0
group 0
and 0
from 0
15.8 0
+/- 0
7.8 0
to 0
8.8 0
+/- 0
2.7 0
for 0
P 0
group 0
; 0
P 0
< 0
0.01 0
versus 0
basal 0
) 0
; 0
however 0
, 0
those 0
women 0
in 0
group 0
E 0
reached 0
significant B-OTHER
improvement I-OTHER
on I-OTHER
urinary I-OTHER
complaints I-OTHER
since 0
the 0
first 0
month 0
of 0
treatment 0
. 0

Additionally 0
, 0
a 0
significant 0
difference 0
between 0
E 0
and 0
P 0
was 0
observed 0
at 0
months 0
2 0
and 0
3 0
, 0
although 0
no 0
differences 0
were 0
detected 0
at 0
the 0
end 0
of 0
the 0
study 0
. 0

Papanicolaou 0
smear 0
showed 0
reactive B-OTHER
or 0
reparative B-OTHER
changes I-OTHER
and 0
karyopyknotic B-OTHER
index 0
exhibited B-OTHER
a I-OTHER
significant B-OTHER
increase 0
in 0
superficial B-PHYSICAL
cells I-PHYSICAL
in 0
both B-OTHER
groups I-OTHER
and 0
at B-OTHER
the I-OTHER
end I-OTHER

Effect 0
of 0
ibuprofen 0
on 0
cyclooxygenase B-PHYSICAL
and 0
nitric B-PHYSICAL
oxide I-PHYSICAL
synthase I-PHYSICAL
of I-PHYSICAL
gastric I-PHYSICAL
mucosa I-PHYSICAL
: 0
correlation 0
with 0
endoscopic B-PHYSICAL
lesions I-PHYSICAL
and 0
adverse B-ADVERSE-EFFECTS
reactions I-ADVERSE-EFFECTS
. 0

The 0
aim 0
of 0
this 0
study 0
was 0
to 0
evaluate 0
the 0
effect 0
of 0
ibuprofen 0
on 0
gastric B-PHYSICAL
mucosa I-PHYSICAL
and 0
enzymes B-PHYSICAL
involved I-PHYSICAL
in I-PHYSICAL
gastroprotection I-PHYSICAL
in 0
healthy 0
volunteers 0
. 0

Twenty-four 0
Helicobacter 0
pylori-negative 0
subjects 0
were 0
randomized 0
to 0
treatment 0
with 0
ibuprofen 0
or 0
ibuprofen-arginate 0
( 0
each 0
600 0
mg/6 0
hr 0
during 0
3 0
days 0
) 0
. 0

Endoscopies 0
were 0
performed 0
1 0
week 0
before 0
and 0
after 0
treatment 0
. 0

Biopsies 0
were 0
taken 0
from 0
the 0
gastric 0
antrum 0
and 0
corpus 0
for 0
determination 0
of 0
prostaglandin 0
E2 0
( 0
PGE2 0
) 0
by 0
ELISA 0
and 0
cyclooxygenase 0
( 0
COX-1 0
and 0
COX-2 0
) 0
and 0
nitric 0
oxide 0
synthase 0
( 0
eNOS 0
and 0
iNOS 0
) 0
by 0
western 0
blot 0
. 0

All 0
subjects 0
had 0
at 0
least 0
one 0
gastric 0
lesion 0
except 0
for 0
two 0
individuals 0
taking 0
ibuprofen-arginate 0
. 0

Ibuprofen-arginate 0
caused 0
a 0
lower 0
rate 0
of 0
clinical B-PHYSICAL
adverse I-PHYSICAL
reactions I-PHYSICAL
than 0
ibuprofen 0
. 0

Subjects 0
with 0
gastric B-PHYSICAL
lesions I-PHYSICAL
or 0
adverse 0
reactions 0
had 0
lower 0
PGE2 0
levels 0
. 0

COX-1 B-PHYSICAL
, 0
COX-2 B-PHYSICAL
, 0
eNOS B-PHYSICAL
, 0
and 0
iNOS B-PHYSICAL
were 0
detectable 0
in 0
all 0
subjects 0
. 0

The 0
constitutive 0
enzymes 0
( 0
COX-1 0
and 0
eNOS 0
) 0
did 0
not 0
change 0
after 0
treatment 0
. 0

COX-2 0
was 0
higher 0
in 0
corpus 0
than 0
antrum 0
and 0
it 0
increased 0
after 0
ibuprofen 0
treatment 0
. 0

iNOS 0
tended 0
to 0
increase 0
mildly 0
in 0
the 0
corpus 0
in 0
subjects 0
with 0
adverse 0
reactions 0
or 0
endoscopic 0
lesions 0
. 0

There 0
were 0
no 0
significant 0
differences 0
between 0
ibuprofen 0
and 0
ibuprofen-arginate 0
in 0
PGE2 0
, 0
or 0
enzymes 0
. 0

The 0
patient 0
experience 0
of 0
community 0
hospital 0
-- 0
the 0
process 0
of 0
care 0
as 0
a 0
determinant 0
of 0
satisfaction 0
. 0

AIMS 0
AND 0
OBJECTIVES 0
We 0
report 0
findings 0
from 0
a 0
qualitative 0
study 0
to 0
identify 0
patient 0
views 0
of 0
community 0
hospital 0
care 0
. 0

We 0
consider 0
how 0
far 0
these 0
were 0
in 0
accord 0
with 0
the 0
hospital 0
staffs 0
' 0
views 0
. 0

This 0
constituted 0
part 0
of 0
a 0
wider 0
randomized 0
controlled 0
trial 0
( 0
RCT 0
) 0
. 0

The 0
methodological 0
challenges 0
in 0
seeking 0
to 0
identify 0
patient 0
satisfaction B-OTHER
and 0
in 0
linking 0
qualitative B-OTHER
findings I-OTHER
with 0
trial 0
results 0
are 0
explored 0
. 0

DESIGN 0
A 0
sample 0
of 0
13 0
patients 0
randomized 0
to 0
the 0
community 0
hospital 0
arm 0
of 0
the 0
RCT 0
joined 0
the 0
qualitative 0
study 0
. 0

Official 0
documentation 0
from 0
the 0
hospital 0
were 0
accessed 0
and 0
six 0
staff 0
interviewed 0
to 0
identify 0
assumptions 0
underlying 0
practice 0
. 0

RESULTS 0
Analysis 0
of 0
interviews 0
identified 0
a 0
complex 0
picture 0
concerning 0
expectations 0
These 0
could 0
be 0
classified 0
as 0
ideal 0
, 0
realistic 0
, 0
normative 0
and 0
unformed 0
. 0

The 0
hospital 0
philosophy 0
and 0
staff B-OTHER
views I-OTHER
about 0
service 0
delivery 0
were 0
closely 0
in 0
harmony 0
, 0
they 0
delivered 0
rehabilitation 0
in 0
a 0
home-based 0
atmosphere 0
. 0

The 0
formal B-MENTAL
, I-MENTAL
or I-MENTAL
'hard 0
' 0
, B-MENTAL
process I-MENTAL
of I-MENTAL

The 0
A-V 0
Impulse 0
System 0
reduces 0
deep-vein 0
thrombosis 0
and 0
swelling 0
after 0
hemiarthroplasty 0
for 0
hip 0
fracture 0
. 0

We 0
performed 0
a 0
prospective 0
randomised 0
controlled 0
trial 0
of 0
the 0
A-V 0
Impulse 0
System 0
in 0
82 0
patients 0
treated 0
by 0
hemiarthroplasty 0
for 0
subcapital 0
fracture 0
of 0
the 0
femoral 0
neck 0
. 0

The 0
incidence 0
of 0
proximal 0
deep-vein 0
thrombosis 0
as 0
assessed 0
by 0
Doppler 0
ultrasonography 0
was 0
23 0
% 0
in 0
the 0
control 0
group 0
and 0
0 0
% 0
in 0
those 0
using 0
the 0
device 0
( 0
p 0
less 0
than 0
0.01 0
) 0
. 0

Calf 0
and 0
thigh 0
circumferences 0
were 0
measured 0
in 0
both 0
groups 0
at 0
seven 0
to 0
ten 0
days 0
after 0
operation 0
. 0

In 0
the 0
treatment 0
group 0
there 0
was 0
a 0
mean 0
relative B-OTHER
reduction I-OTHER
of I-OTHER
postoperative I-OTHER
swelling I-OTHER
of I-OTHER
the I-OTHER
thigh I-OTHER
by 0
3.27 0
cm 0
( 0
p 0
less 0
than 0
0.001 0
) 0
and 0
of 0
the 0
calf 0
by 0
1.55 0
cm 0
( 0
p 0
less 0
than 0
0.001 0
) 0
. 0

The 0
A-V 0
Impulse 0
System 0
appears 0
to 0
be 0
a 0
safe B-OTHER
and 0
effective 0
method 0
of 0
reducing 0
the 0
incidence 0
of 0
proximal B-PHYSICAL
deep-vein I-PHYSICAL
thrombosis I-PHYSICAL
, 0
and 0
of 0
postoperative B-ADVERSE-EFFECTS
swelling I-ADVERSE-EFFECTS
. 0

Uterine 0
incision 0
closure 0
at 0
caesarean 0
section 0
: 0
a 0
randomised 0
comparative 0
study 0
of 0
intraperitoneal 0
closure 0
and 0
closure 0
after 0
temporary 0
exteriorisation 0
. 0

BACKGROUND 0
The 0
safety 0
of 0
the 0
technique 0
of 0
uterine 0
exteriorization 0
at 0
caesarean 0
section 0
though 0
popular 0
among 0
obstetricians 0
, 0
remains 0
controversial 0
. 0

OBJECTIVE 0
To 0
evaluate 0
the 0
influence 0
of 0
exteriorization 0
of 0
uterus 0
during 0
uterine 0
repair 0
on 0
caesarean 0
morbidity 0
. 0

METHODS 0
A 0
randomized 0
comparative 0
study 0
of 0
136 0
women 0
undergoing 0
primary 0
caesarean 0
delivery 0
at 0
Havana 0
Specialist 0
Hospital 0
Lagos 0
Nigeria 0
. 0

Data 0
on 0
operation 0
time 0
, 0
estimated 0
blood 0
loss 0
, 0
postoperative 0
morbidities 0
were 0
collected 0
and 0
analysed 0
with 0
comparison 0
between 0
the 0
two 0
groups 0
using 0
chi 0
square 0
, 0
Fischer 0
's 0
exact 0
test 0
and 0
t-test 0
as 0
appropriate 0
. 0

RESULTS 0
The 0
mean 0
operative B-OTHER
time I-OTHER
, 0
estimated B-PHYSICAL
blood I-PHYSICAL
loss I-PHYSICAL
, 0
transfusion B-PHYSICAL
rate I-PHYSICAL
and 0
postoperative B-PHYSICAL
anemia I-PHYSICAL
rate I-PHYSICAL
were 0
significantly 0
less 0
in 0
the 0
exteriorized 0
group 0
than 0
the 0
intraperitoneal 0
group 0
( 0
p 0
= 0
0.000 0
, 0
0.009,0.048 0
0.038 0
and 0
0.028 0
respectively 0
) 0
, 0
but 0
not 0
in 0
other 0
outcome 0
measures 0
. 0

CONCLUSION 0
With 0
shorter 0
operative 0
time 0
, 0
less 0
blood 0
loss 0
and 0
similar 0
morbidity 0
profile 0
exteriorization 0
of 0
uterus 0
during 0
caesarean 0
section 0
seems 0
to 0
be 0
preferred 0
except 0
where 0
it 0
is 0
not 0
possible 0
because 0
of 0
adhesions 0
and 0
surgeons 0
inexperience 0
. 0

Double-blind 0
placebo-controlled 0
administration 0
of 0
fluoxetine 0
in 0
restricting- 0
and 0
restricting-purging-type 0
anorexia 0
nervosa 0
. 0

BACKGROUND 0
Anorexia 0
nervosa 0
is 0
an 0
often 0
chronic 0
disorder 0
with 0
high 0
morbidity 0
and 0
mortality 0
. 0

Many 0
people 0
relapse 0
after 0
weight 0
restoration 0
. 0

This 0
study 0
was 0
designed 0
to 0
determine 0
whether 0
a 0
selective 0
serotonin 0
reuptake 0
inhibitor 0
would 0
improve 0
outcome 0
and 0
reduce 0
relapse 0
after 0
weight B-PHYSICAL
restoration I-PHYSICAL
by I-PHYSICAL
contributing I-PHYSICAL
to I-PHYSICAL
maintenance I-PHYSICAL
of I-PHYSICAL
a I-PHYSICAL
healthy I-PHYSICAL
normal I-PHYSICAL
weight I-PHYSICAL
and I-PHYSICAL
a I-PHYSICAL
reduction I-PHYSICAL
of I-PHYSICAL
symptoms B-PHYSICAL
. 0

METHODS 0
We 0
administered 0
a 0
double-blind 0
placebo-controlled 0
trial 0
of 0
fluoxetine 0
to 0
35 0
patients 0
with 0
restricting-type 0
anorexia 0
nervosa 0
. 0

Anorexics 0
were 0
randomly 0
assigned 0
to 0
fluoxetine 0
( 0
n 0
= 0
16 0
) 0
or 0
a 0
placebo 0
( 0
n 0
= 0
19 0
) 0
after 0
inpatient 0
weight 0
gain 0
and 0
then 0
were 0
observed 0
as 0
outpatients 0
for 0
1 0
year 0
. 0

RESULTS 0
Ten 0
of 0
16 0
( 0
63 0
% 0
) 0
subjects 0
remained 0
on 0
fluoxetine 0
for 0
a 0
year 0
, 0
whereas 0
only 0
three 0
of 0
19 0
( 0
16 0
% 0
) 0
remained 0
on 0
the 0
placebo 0
for 0
a 0
year 0
( 0
p 0
=.006 0
) 0
. 0

Those 0
subjects 0
remaining 0
on 0
fluoxetine 0
for 0
a 0
year 0
had 0
reduced B-MENTAL
relapse I-MENTAL
as 0
determined 0
by 0
a 0
significant B-PHYSICAL
increase 0
in B-PHYSICAL
weight 0
and 0
reduction B-PHYSICAL

Long-term 0
follow-up 0
of 0
the 0
Stockholm 0
randomized 0
trials 0
of 0
postoperative 0
radiation 0
therapy 0
versus 0
adjuvant 0
chemotherapy 0
among 0
'high 0
risk 0
' 0
pre- 0
and 0
postmenopausal 0
breast 0
cancer 0
patients 0
. 0

For 0
many 0
years 0
, 0
loco-regional 0
radiotherapy 0
was 0
the 0
standard 0
postoperative 0
treatment 0
for 0
node 0
positive 0
breast 0
cancer 0
patients 0
in 0
Sweden 0
. 0

Because 0
of 0
encouraging 0
results 0
from 0
trials 0
of 0
adjuvant 0
chemotherapy 0
in 0
the 0
mid 0
1970s 0
, 0
the 0
Stockholm 0
Breast 0
Cancer 0
Study 0
Group 0
decided 0
to 0
directly 0
compare 0
postoperative 0
radiation 0
( 0
RT 0
) 0
with 0
adjuvant 0
CMF-type 0
chemotherapy 0
( 0
CT 0
) 0
. 0

Long-term 0
results 0
are 0
presented 0
from 0
two 0
randomized 0
trials 0
of 0
RT 0
versus 0
CT 0
in 0
pre- 0
( 0
n 0
= 0
547 0
) 0
and 0
postmenopausal 0
( 0
n 0
= 0
679 0
) 0
patients 0
, 0
respectively 0
, 0
with 0
node 0
positive 0
disease 0
or 0
a 0
tumour 0
diameter 0
> 0
30 0
mm 0
. 0

RT 0
substantially 0
reduced 0
loco-regional B-PHYSICAL
recurrences I-PHYSICAL
among 0
both 0
pre- 0
and 0
postmenopausal 0
patients 0
( 0
relative 0
hazard 0
RT 0
versus 0
CT 0
: 0
0.67 0
and 0
0.43 0
, 0
respectively 0
) 0
. 0

Among 0
premenopausal 0
patients 0
distant B-PHYSICAL
metastases I-PHYSICAL
occurred 0
less 0
frequently 0
in 0
the 0
CT 0
group 0
( 0
relative 0
hazard 0
: 0
1.68 0
, 0
p 0
> 0
0.001 0
) 0
resulting 0
in 0
an 0
improved 0
recurrence-free B-MORTALITY
survival I-MORTALITY
( 0
p 0
= 0
0.04 0
) 0
. 0

Overall B-MORTALITY
survival I-MORTALITY
was 0
also 0
better 0
with 0
CT 0
( 0
cumulative 0
survival 0
at 0
15 0
years 0
: 0
50 0
% 0
and 0
44 0
% 0
in 0
the 0
CT 0
and 0
RT 0
groups 0
, 0
respectively 0
) 0
but 0
the 0
difference 0
was 0
not 0
statistically 0
significant 0
. 0

Among 0
the 0
postmenopausal 0
patients 0
there 0
were 0
no 0
substantial 0
differences 0
in 0
terms 0
of 0
recurrence-free B-MORTALITY
or I-MORTALITY
overall I-MORTALITY
survival I-MORTALITY
between 0
the 0
treatment 0
groups 0
. 0

The 0
risk 0
of 0
a 0
second 0
primary 0
malignancy 0
, 0
however 0
, 0
was 0
doubled 0
in 0
the 0
RT 0
group 0
( 0
p 0
> 0
0.01 0
) 0
. 0

The 0
most 0
pronounced 0
excess 0
concerned 0
second B-PHYSICAL
lung I-PHYSICAL
cancers I-PHYSICAL
occurring 0
after 0
10 0
years 0
. 0

The 0
cumulative B-PHYSICAL
incidence 0
at B-PHYSICAL
20 I-PHYSICAL
years B-PHYSICAL
was 0
estimated 0
at 0
0.3 0
% 0
and 0
3.7 0
% 0
in 0
the 0
CT 0
and 0
RT 0
groups 0
, 0
respectively 0
. 0

The 0
trials 0
illustrate 0
the 0
role 0
of 0
radiotherapy 0
in 0
preventing 0

Strength 0
of 0
vital 0
force 0
in 0
classical 0
homeopathy 0
: 0
bio-psycho-social-spiritual 0
correlates 0
within 0
a 0
complex 0
systems 0
context 0
. 0

OBJECTIVE 0
To 0
explore 0
associations 0
between 0
a 0
global 0
rating 0
for 0
the 0
classical 0
homeopathic 0
construct 0
of 0
vital 0
force 0
and 0
clinician 0
and 0
patient 0
ratings 0
on 0
previously 0
validated 0
bio-psycho-social-spiritual 0
questionnaires 0
. 0

METHODS 0
Sixty-two 0
( 0
62 0
) 0
community-recruited 0
patients 0
with 0
fibromyalgia 0
( 0
FM 0
) 0
were 0
assessed 0
at 0
baseline 0
prior 0
to 0
a 0
clinical 0
trial 0
of 0
individualized 0
homeopathy 0
. 0

Two 0
homeopaths 0
jointly 0
performed 0
case-taking 0
interviews 0
. 0

A 0
conventional 0
medical 0
provider 0
independently 0
evaluated 0
patients 0
with 0
a 0
standardized 0
history 0
and 0
physical 0
examination 0
. 0

Homeopaths 0
rated 0
each 0
patient 0
's 0
vital 0
force 0
( 0
five-point 0
Likert 0
scale 0
, 0
with 0
1 0
= 0
very 0
weak 0
to 0
5 0
= 0
very 0
strong 0
) 0
. 0

Homeopaths 0
and 0
the 0
conventional 0
medical 0
provider 0
rated 0
their 0
Clinical B-PHYSICAL
Global I-PHYSICAL
Impression I-PHYSICAL
( 0
CGI B-PHYSICAL
) 0
of B-PHYSICAL
the I-PHYSICAL
severity I-PHYSICAL
of I-PHYSICAL
illness B-PHYSICAL
( 0
1 0
= 0
normal 0
; 0
7 0
= 0
among 0
the 0
most 0
extremely 0
ill 0
) 0
. 0

Patients 0
completed 0
self-rating 0
scales 0
on 0
pain 0
, 0
global B-PHYSICAL
health B-PHYSICAL
, 0
mood B-MENTAL
, 0
quality 0
of 0
life 0
, 0
coping B-MENTAL
style I-MENTAL
, 0
health B-MENTAL
locus B-MENTAL
of I-MENTAL
control I-MENTAL
, 0
multidimensional B-MENTAL
well-being I-MENTAL
, 0
spirituality B-MENTAL
, 0
sense B-MENTAL
of I-MENTAL
coherence I-MENTAL
, 0
positive 0
states B-MENTAL
of I-MENTAL
mind B-MENTAL
, 0
and 0
social B-MENTAL
desirability B-MENTAL
. 0

RESULTS 0
Greater 0
vital B-PHYSICAL
force I-PHYSICAL
ratings B-PHYSICAL
( 0
mean 0
2.9 0
standard 0
deviation 0
[ 0
SD 0
] 0
0.6 0
) 0
correlated 0
moderately 0
( 0
p 0
< 0
or 0
= 0
0.005 0
) 0
with 0
less 0
severe 0
CGI B-PHYSICAL
illness I-PHYSICAL
ratings 0
by 0
the 0
homeopaths 0
( 0
r 0
=-0.59 0
) 0
, 0
decreased 0
patient-rated B-MENTAL
mental B-MENTAL
confusion I-MENTAL
( 0
r 0
=-0.43 0
) 0
, 0
higher 0
vigor B-MENTAL
( 0
r 0
= 0
0.38 0
) 0
, 0
and 0
greater 0
positive 0
states B-MENTAL
of I-MENTAL
mind I-MENTAL
( 0
r 0
= 0
0.36 0
) 0
. 0

Vital 0
force 0
also 0
showed 0
correlations 0
( 0
p 0
< 0
0.05 0
) 0
with 0
lower 0

Cyclosporine 0
inhibition 0
of 0
P-glycoprotein 0
in 0
chronic 0
myeloid 0
leukemia 0
blast 0
phase 0
. 0

Chronic 0
myeloid 0
leukemia 0
blast 0
phase 0
( 0
CML-BP 0
) 0
cells 0
commonly 0
express 0
the 0
multidrug 0
transporter 0
, 0
P-glycoprotein 0
( 0
Pgp 0
) 0
. 0

To 0
determine 0
whether 0
Pgp 0
inhibition 0
improves 0
treatment 0
outcome 0
in 0
CML-BP 0
, 0
the 0
Southwest 0
Oncology 0
Group 0
performed 0
a 0
randomized 0
, 0
controlled 0
trial 0
testing 0
the 0
benefit 0
of 0
the 0
Pgp 0
modulator 0
, 0
cyclosporin 0
A 0
( 0
CsA 0
) 0
. 0

Seventy-three 0
eligible 0
patients 0
were 0
assigned 0
to 0
treatment 0
with 0
cytarabine 0
and 0
infusional 0
daunorubicin 0
with 0
or 0
without 0
intravenous 0
CsA 0
. 0

Treatment 0
with 0
CsA 0
yielded 0
no 0
improvement B-OTHER
in 0
treatment 0
outcome 0
as 0
measured 0
by 0
the 0
frequency 0
of 0
induction 0
resistance B-PHYSICAL
( 0
68 0
% 0
vs 0
53 0
% 0
) 0
, 0
rate 0
of 0
complete B-PHYSICAL
remission I-PHYSICAL
or 0
restored B-PHYSICAL
chronic I-PHYSICAL
phase I-PHYSICAL
( 0
CR/CP 0
, 0
8 0
% 0
vs 0
30 0
% 0
) 0
, 0
and 0
survival B-MORTALITY
( 0
3 0
vs 0
5 0
months 0
) 0
. 0

Blast B-PHYSICAL
expression I-PHYSICAL
of I-PHYSICAL
Pgp I-PHYSICAL
( 0
63 0
% 0
) 0
and 0
LRP B-PHYSICAL
( 0
71 0
% 0
) 0
was 0
common 0
, 0
whereas 0
only 0
Pgp 0
adversely 0
impacted 0
the 0
rate B-PHYSICAL
of I-PHYSICAL
CR/CP I-PHYSICAL
( 0
P 0
=.025 0
) 0
. 0

We 0
conclude 0
that 0
Pgp 0
has 0
prognostic 0
relevance 0
in 0
CML-BP 0
but 0
that 0
the 0
modulation 0
of 0
Pgp 0
function 0
with 0
CsA 0
as 0
applied 0
in 0
this 0
trial 0
is 0
ineffective 0
. 0

Effects 0
of 0
halothane 0
and 0
isoflurane 0
on 0
transient B-PHYSICAL
renal I-PHYSICAL
dysfunction I-PHYSICAL
associated 0
with 0
infrarenal 0
aortic 0
cross-clamping 0
. 0

Aortic 0
cross-clamping 0
for 0
reconstructive 0
aortic 0
surgery 0
is 0
associated 0
with 0
impairment 0
of 0
renal B-PHYSICAL
function I-PHYSICAL
. 0

Halothane 0
or 0
isoflurane 0
was 0
used 0
to 0
assess 0
the 0
influence 0
of 0
volatile 0
anesthesia 0
on 0
renal B-PHYSICAL
hemodynamics I-PHYSICAL
during 0
aortic 0
surgery 0
. 0

Nineteen 0
patients 0
with 0
normal 0
preoperative 0
creatinine 0
clearances 0
who 0
were 0
scheduled 0
for 0
reconstructive 0
aortic 0
surgery 0
were 0
randomly 0
divided 0
into 0
two 0
groups 0
: 0
halothane 0
group 0
( 0
n 0
= 0
9 0
) 0
and 0
isoflurane 0
group 0
( 0
n 0
= 0
10 0
) 0
. 0

Induction 0
of 0
anesthesia 0
consisted 0
of 0
midazolam 0
, 0
fentanyl 0
, 0
and 0
pancuronium 0
. 0

Anesthesia 0
was 0
maintained 0
with 0
fentanyl 0
and 0
halothane 0
or 0
isoflurane 0
in 0
nitrous 0
oxide 0
and 0
oxygen 0
( 0
50/50 0
) 0
. 0

Systemic B-PHYSICAL
hemodynamics I-PHYSICAL
were 0
similar 0
in 0
both 0
groups 0
throughout 0
surgery 0
. 0

Before 0
aortic 0
cross-clamping 0
, 0
effective B-PHYSICAL
renal I-PHYSICAL
plasma I-PHYSICAL
flow I-PHYSICAL
( I-PHYSICAL
ERPF I-PHYSICAL
) I-PHYSICAL
( I-PHYSICAL
131I-hippuran I-PHYSICAL
clearance I-PHYSICAL
) I-PHYSICAL
and 0
glomerular B-PHYSICAL
filtration I-PHYSICAL
rate I-PHYSICAL
( I-PHYSICAL
GFR I-PHYSICAL
) I-PHYSICAL
( I-PHYSICAL
99Tc-DTPA I-PHYSICAL
clearance I-PHYSICAL
) I-PHYSICAL
were 0
significantly 0
lower 0
in 0
the 0
halothane 0
group 0
( 0
118.4 0
+/- 0
25.6 0
and 0
19.7 0
+/- 0
5.2 0
mL/min 0
, 0
respectively 0
) 0
than 0
in 0
the 0
isoflurane 0
group 0
( 0
253.4 0
+/- 0
51.5 0
and 0
44.9 0
+/- 0
8.4 0
mL/min 0
) 0
( 0
P 0
less 0
than 0
0.05 0
for 0
both 0
) 0
. 0

During 0
cross-clamping 0
, 0
the 0
renal B-PHYSICAL
variables I-PHYSICAL
were 0
not 0
markedly 0
affected 0
in 0
either 0
group 0
and 0
remained 0
higher 0
in 0
the 0
isoflurane-anesthetized 0
patients 0
( 0
232.9 0
+/- 0
47.1 0
and 0
49.5 0
+/- 0
1.2 0
mL/min 0
for 0
ERPF 0
and 0
GFR 0
, 0
respectively 0
) 0
than 0
in 0
the 0
halothane-anesthetized 0
patients 0
( 0
132.4 0
+/- 0
31.6 0
and 0
14.8 0
+/- 0
3.7 0
mL/min 0
, 0
respectively 0
) 0
( 0
P 0
less 0
than 0
0.05 0
) 0
. 0

After 0
aortic 0
unclamping 0
, 0
ERPF B-PHYSICAL
increased 0
markedly 0
in 0
both 0
groups 0
( 0
467.8 0
+/- 0
122 0
and 0
362.5 0
+/- 0
57.7 0
mL/min 0
in 0
the 0
halothane 0
and 0
isoflurane 0
groups 0
, 0
respectively 0
) 0
, 0
as 0
did 0
GFR B-PHYSICAL
( 0
74.8 0
+/- 0
22 0
and 0
71.8 0
+/- 0
13.1 0
mL/min 0
, 0
respectively 0
) 0
. 0

These 0
results 0
suggest 0
that 0
anesthesia 0
with 0
halothane 0
is 0
associated 0
with 0
transient B-PHYSICAL
renal I-PHYSICAL
vasoconstriction I-PHYSICAL
during 0
abdominal 0
surgery 0
. 0

In 0
contrast 0
, 0
aortic 0
cross-clamping 0
during 0
isoflurane 0
anesthesia 0
was 0
not 0
associated 0
with 0
renal B-PHYSICAL
hemodynamic I-PHYSICAL
impairment I-PHYSICAL
. 0

Lessons 0
learnt 0
in 0
conducting 0
a 0
clinical 0
drug 0
trial 0
in 0
children 0
with 0
Asperger 0
Syndrome 0
. 0

OBJECTIVE 0
To 0
describe 0
the 0
authors 0
' 0
experience 0
of 0
conducting 0
a 0
clinical 0
drug 0
trial 0
in 0
children 0
with 0
Asperger 0
Syndrome 0
, 0
including 0
the 0
pitfalls 0
encountered 0
and 0
lessons 0
learnt 0
. 0

CONCLUSIONS 0
The 0
main 0
barrier 0
encountered 0
was 0
in 0
the 0
recruitment B-OTHER
of I-OTHER
children I-OTHER
: 0
it 0
was 0
not 0
possible 0
to 0
recruit 0
the 0
target 0
of 0
60 0
patients 0
. 0

The 0
recruitment B-OTHER
of I-OTHER
children I-OTHER
is 0
often 0
the 0
major 0
barrier 0
to 0
the 0
progress 0
of 0
a 0
successful 0
clinical 0
trial 0
. 0

Conducting 0
the 0
clinical 0
drug 0
trial 0
was 0
greatly 0
facilitated 0
by 0
the 0
appropriate 0
setting 0
and 0
experienced 0
clinical 0
pharmacology 0
staff 0
. 0

The 0
tension-free 0
hernioplasty 0
in 0
a 0
randomized 0
trial 0
. 0

BACKGROUND 0
The 0
tension-free 0
hernioplasty 0
as 0
introduced 0
by 0
Lichtenstein 0
has 0
gained 0
increasing 0
acceptance 0
during 0
the 0
last 0
decade 0
although 0
the 0
technique 0
has 0
not 0
been 0
evaluated 0
in 0
a 0
randomized 0
trial 0
. 0

METHODS 0
This 0
randomized 0
study 0
compares 0
the 0
2-year 0
follow-up 0
results 0
after 0
102 0
tension-free 0
hernioplasties 0
with 0
implantation 0
of 0
a 0
prolene 0
mesh 0
in 0
all 0
groin 0
hernias 0
to 0
53 0
Cooper 0
ligament 0
repairs 0
in 0
direct 0
hernias 0
and 0
53 0
abdominal 0
ring 0
repairs 0
in 0
indirect 0
hernias 0
. 0

RESULTS 0
After 0
tension-free 0
repairs 0
five 0
hernias B-PHYSICAL
recurred I-PHYSICAL
( 0
5 0
% 0
) 0
, 0
and 0
after 0
either 0
Cooper 0
ligament 0
or 0
abdominal 0
ring 0
repair 0
, 0
16 0
recurrences B-PHYSICAL
were 0
found 0
( 0
15 0
% 0
) 0
( 0
P 0
= 0
0.025 0
) 0
. 0

No 0
indirect B-PHYSICAL
hernias I-PHYSICAL
recurred I-PHYSICAL
after 0
a 0
tension-free 0
repair 0
; 0
2 0
recurred 0
after 0
abdominal 0
ring 0
repair 0
( 0
4 0
% 0
; 0
NS 0
) 0
. 0

The 0
recurrence B-PHYSICAL
rate I-PHYSICAL
after I-PHYSICAL
tension-free I-PHYSICAL
repairs I-PHYSICAL
for I-PHYSICAL
primary I-PHYSICAL
direct I-PHYSICAL
inguinal I-PHYSICAL
hernias I-PHYSICAL
was 0
7 0
% 0
as 0
compared 0
with 0
30 0
% 0
after 0
Cooper 0
ligament 0
repair 0
( 0
P 0
= 0
0.0081 0
) 0
. 0

No 0
difference 0
in 0
complication B-ADVERSE-EFFECTS
rate I-ADVERSE-EFFECTS
between 0
the 0
tested 0
methods 0
was 0
found 0
. 0

CONCLUSION 0
Recurrence B-PHYSICAL
rate I-PHYSICAL
is 0
reduced 0
to 0
one-third 0
after 0
tension-free 0
herniotomies 0
as 0
compared 0
with 0
the 0
conventionel 0
herniotomies 0
without 0
increase 0
in 0
complication B-ADVERSE-EFFECTS
rate I-ADVERSE-EFFECTS
. 0

Comparing 0
the 0
effectiveness 0
of 0
copper 0
intrauterine 0
devices 0
available 0
in 0
Canada 0
. 0

Is 0
FlexiT 0
non-inferior 0
to 0
NovaT 0
when 0
inserted 0
immediately 0
after 0
first-trimester 0
abortion 0
? 0

Study 0
protocol 0
for 0
a 0
randomized 0
controlled 0
trial 0
. 0

BACKGROUND 0
We 0
describe 0
the 0
rationale 0
and 0
protocol 0
for 0
a 0
randomized 0
noninferiority 0
controlled 0
trial 0
( 0
RCT 0
) 0
to 0
determine 0
if 0
the 0
Flexi-T380 0
( 0
+ 0
) 0
copper 0
intrauterine 0
contraceptive 0
device 0
( 0
IUD 0
) 0
is 0
comparable 0
in 0
terms 0
of 0
effectiveness 0
and 0
expulsion 0
rates 0
to 0
the 0
most 0
common 0
Canadian 0
IUD 0
currently 0
in 0
use 0
, 0
NovaT-200 0
, 0
when 0
placed 0
immediately 0
after 0
a 0
first-trimester 0
abortion 0
. 0

METHODS/DESIGN 0
Consenting 0
women 0
choosing 0
to 0
use 0
an 0
IUD 0
after 0
an 0
abortion 0
for 0
a 0
pregnancy 0
of 0
less 0
than 0
12 0
weeks 0
of 0
gestation 0
will 0
be 0
randomized 0
to 0
device-type 0
groups 0
to 0
receive 0
immediate 0
post-abortion 0
placement 0
of 0
either 0
a 0
Flexi-T380 0
( 0
+ 0
) 0
IUD 0
, 0
a 0
device 0
for 0
which 0
no 0
current 0
evidence 0
on 0
expulsion 0
or 0
effectiveness 0
rates 0
is 0
available 0
, 0
or 0
the 0
Nova-T200 0
IUD 0
, 0
the 0
only 0
other 0
brand 0
of 0
copper 0
IUD 0
available 0
in 0
Canada 0
at 0
the 0
time 0
of 0
study 0
initiation 0
. 0

The 0
primary 0
outcome 0
measure 0
is 0
IUD B-MENTAL
expulsion I-MENTAL
rate I-MENTAL
at I-MENTAL
1 I-MENTAL
year I-MENTAL
. 0

Secondary 0
outcomes 0
include 0
: 0
pregnancy B-MENTAL
rate I-MENTAL
, 0
method B-MENTAL
continuation I-MENTAL
rate I-MENTAL
, 0
complication 0
rates 0
( 0
infection 0
, 0
perforation 0
) 0
, 0
and 0
satisfaction B-OTHER
with 0
contraceptive B-PHYSICAL
method I-PHYSICAL
. 0

A 0
non-intervention 0
group 0
of 0
consenting 0
women 0
choosing 0
a 0
range 0
of 0
other 0
post-abortion 0
contraception 0
methods 0
, 0
including 0
no 0
contraception 0
, 0
will 0
be 0
included 0
for 0
comparison 0
of 0
secondary 0
outcomes 0
. 0

Web-based 0
contraception 0
satisfaction 0
questionnaires 0
, 0
clinical 0
records 0
, 0
and 0
government-linked 0
health 0
administrative 0
databases 0
will 0
be 0
used 0
to 0
assess 0
primary 0
and 0
secondary 0
outcomes 0
. 0

DISCUSSION 0
The 0
RCT 0
design 0
, 0
combined 0
with 0
access 0
to 0
clinical 0
records 0
at 0
all 0
provincial 0
abortion 0
clinics 0
, 0
and 0
to 0
information 0
in 0
provincial 0
single-payer 0
linked 0
administrative 0
health 0
databases 0
, 0
birth 0
registry 0
, 0
and 0
hospital 0
records 0
, 0
offers 0
a 0
unique 0
opportunity 0
to 0
determine 0
if 0
a 0
novel 0
IUD 0
has 0
a 0
comparable 0
expulsion B-MENTAL
rate I-MENTAL
to 0
that 0
of 0
the 0
current 0
standard 0
IUD 0
in 0
Canada 0
, 0
in 0
addition 0
to 0
the 0
first 0
opportunity 0
to 0
determine 0
pregnancy B-OTHER
rate I-OTHER
and 0
method B-OTHER
satisfaction I-OTHER
at 0
1 0
year 0
post-abortion 0
for 0
women 0
choosing 0
a 0
range 0
of 0
post-abortion 0
contraceptive 0
options 0
. 0

We 0
highlight 0
considerations 0
of 0
design 0
, 0
implementation 0
, 0
and 0
evaluation 0
of 0
the 0
first 0
trial 0
to 0
provide 0
rigorous 0
evidence 0
for 0
the 0
effectiveness 0
of 0
current 0
Canadian 0
IUDs 0
when 0
inserted 0
after 0
first-trimester 0
abortion 0
. 0

TRIAL 0
REGISTRATION 0
ClinicalTrials.gov 0
Identifier 0
NCT01174225 0
. 0

Equivalence 0
study 0
of 0
a 0
topical 0
diclofenac 0
solution 0
( 0
pennsaid 0
) 0
compared 0
with 0
oral 0
diclofenac 0
in 0
symptomatic 0
treatment 0
of 0
osteoarthritis 0
of 0
the 0
knee 0
: 0
a 0
randomized 0
controlled 0
trial 0
. 0

OBJECTIVE 0
. 0

To 0
compare 0
the 0
safety 0
and 0
efficacy 0
of 0
a 0
topical 0
diclofenac 0
solution 0
versus 0
oral 0
diclofenac 0
in 0
relieving 0
the 0
symptoms 0
of 0
primary 0
osteoarthritis 0
( 0
OA 0
) 0
of 0
the 0
knee 0
, 0
in 0
a 0
randomized 0
, 0
double-blind 0
, 0
double-dummy 0
equivalence 0
trial 0
. 0

METHODS 0
A 0
total 0
of 0
622 0
men 0
and 0
women 0
with 0
radiological 0
evidence 0
of 0
primary 0
knee 0
OA 0
and 0
mild 0
to 0
severe 0
symptoms 0
were 0
randomly 0
assigned 0
to 0
treatment 0
with 0
a 0
topical 0
diclofenac 0
solution 0
plus 0
placebo 0
oral 0
capsules 0
, 0
or 0
placebo 0
topical 0
solution 0
plus 0
oral 0
diclofenac 0
( 0
50 0
mg 0
) 0
capsules 0
. 0

Patients 0
applied 0
50 0
drops 0
of 0
study 0
solution 0
and 0
took 0
1 0
study 0
capsule 0
3 0
times 0
daily 0
for 0
12 0
weeks 0
. 0

Efficacy 0
variables 0
were 0
pain 0
and 0
physical 0
function 0
, 0
measured 0
by 0
the 0
Western 0
Ontario 0
and 0
McMaster 0
Universities 0
( 0
WOMAC 0
) 0
VA 0
3.1 0
OA 0
Index 0
, 0
and 0
patient 0
global 0
assessment 0
( 0
PGA 0
) 0
. 0

Equivalence 0
in 0
the 0
per-protocol 0
group 0
was 0
based 0
on 0
previously 0
defined 0
ranges 0
of 0
clinically 0
significant 0
difference 0
. 0

Safety 0
was 0
assessed 0
by 0
evaluation 0
of 0
adverse 0
events 0
, 0
vital 0
signs 0
, 0
and 0
laboratory 0
data 0
. 0

RESULTS 0
The 0
difference 0
in 0
mean 0
( 0
95 0
% 0
CI 0
) 0
change 0
scores 0
( 0
final 0
minus 0
baseline 0
) 0
between 0
treatments 0
was 0
13.3 0
mm 0
( 0
-8.6 0
to 0
35.2 0
) 0
for 0
pain 0
( 0
total 0
scale 0
500 0
mm 0
) 0
, 0
71.0 0
mm 0
( 0
-2.4 0
to 0
144.5 0
) 0
for 0
physical 0
function 0
( 0
total 0
scale 0
1700 0
mm 0
) 0
, 0
and 0
4.3 0
mm 0
( 0
-1.2 0
to 0
9.8 0
) 0
for 0
PGA 0
( 0
total 0
scale 0
100 0
mm 0
) 0
. 0

The 0
CI 0
for 0
each 0
efficacy 0
variable 0
fell 0
within 0
the 0
predefined 0
equivalence 0
ranges 0
( 0
pain 0
, 0
+/- 0
75 0
mm 0
; 0
physical 0
function 0
, 0
+/- 0
255 0
mm 0
; 0
PGA 0
, 0
+/- 0
20 0
mm 0
) 0
, 0
indicating 0
that 0
no 0
clinically 0
relevant 0
difference 0
was 0
found 0
between 0
the 0
2 0
treatment 0
arms 0
. 0

Safety B-OTHER
analyses I-OTHER
of 0
patients 0
applying 0
topical 0
diclofenac 0
solution 0
revealed 0
some 0
minor B-ADVERSE-EFFECTS
skin I-ADVERSE-EFFECTS
irritation I-ADVERSE-EFFECTS
at I-ADVERSE-EFFECTS
the I-ADVERSE-EFFECTS
application I-ADVERSE-EFFECTS
site I-ADVERSE-EFFECTS
-- I-ADVERSE-EFFECTS
mostly I-ADVERSE-EFFECTS
skin 0
dryness 0
in 0
83/311 0
( 0
27 0
% 0
) 0
patients 0
-- 0
but 0
a 0
significantly 0
reduced 0
incidence 0
, 0
relative 0
to 0
oral 0
diclofenac 0
, 0
of 0
total 0
and 0
severe B-ADVERSE-EFFECTS
gastrointestinal I-ADVERSE-EFFECTS
( I-ADVERSE-EFFECTS
GI I-ADVERSE-EFFECTS
) I-ADVERSE-EFFECTS
adverse I-ADVERSE-EFFECTS
events I-ADVERSE-EFFECTS
, 0
including 0
dyspepsia B-ADVERSE-EFFECTS
, 0
abdominal B-PHYSICAL
pain I-PHYSICAL
, 0
diarrhea B-ADVERSE-EFFECTS
, 0
and 0
nausea B-ADVERSE-EFFECTS
. 0

The 0
number 0
of 0
patients 0
developing 0
abnormal 0
liver 0
function 0
tests 0
( 0
including 0
clinically 0
significant 0
elevation 0
) 0
, 0
hemoglobin 0
, 0
and 0
creatinine 0
clearance 0
was 0
significantly 0
higher 0
in 0
the 0
oral 0
diclofenac 0
group 0
. 0

CONCLUSION 0
Application 0
of 0
this 0
topical 0
diclofenac 0
solution 0
to 0
the 0
knee 0
of 0
patients 0
with 0
OA 0
produced 0
relief B-PHYSICAL
of I-PHYSICAL
symptoms I-PHYSICAL
equivalent 0
to 0
oral 0
diclofenac 0
, 0
with 0
minor 0
local 0
skin 0
irritation 0
, 0
but 0
significantly 0
reduced 0
incidence 0
of 0
diclofenac-related B-PHYSICAL
GI I-PHYSICAL
complaints I-PHYSICAL
and 0
abnormal B-PHYSICAL
laboratory I-PHYSICAL
values I-PHYSICAL
. 0

The 0
efficacy 0
of 0
sublingual 0
immunotherapy 0
for 0
respiratory 0
allergy 0
is 0
not 0
affected 0
by 0
different 0
dosage 0
regimens 0
in 0
the 0
induction 0
phase 0
. 0

BACKGROUND 0
Sublingual 0
administration 0
of 0
allergens 0
is 0
a 0
safe 0
and 0
effective 0
alternative 0
to 0
subcutaneous 0
immunotherapy 0
in 0
patients 0
with 0
respiratory 0
allergies 0
. 0

A 0
drawback 0
to 0
this 0
therapeutic 0
approach 0
is 0
the 0
relatively 0
long 0
and 0
complex 0
management 0
of 0
the 0
induction 0
phase 0
. 0

AIM 0
OF 0
THE 0
STUDY 0
To 0
determine 0
whether 0
different 0
induction 0
regimens 0
affect 0
the 0
outcome 0
of 0
sublingual 0
immunotherapy 0
. 0

METHODS 0
AND 0
RESULTS 0
Adult 0
and 0
pediatric 0
patients 0
with 0
allergic 0
rhinoconjunctivitis 0
and/or 0
asthma 0
were 0
included 0
in 0
the 0
study 0
. 0

Ten 0
subjects 0
served 0
as 0
controls 0
and 0
received 0
symptomatic 0
treatments 0
. 0

Forty-three 0
subjects 0
were 0
allocated 0
to 0
sublingual 0
immunotherapy 0
, 0
with 0
three 0
different 0
induction 0
protocols 0
( 0
8- 0
, 0
15- 0
and 0
20-day 0
, 0
respectively 0
) 0
. 0

Symptom B-PHYSICAL
and I-PHYSICAL
medication I-PHYSICAL
scores 0
, 0
skin B-PHYSICAL
test I-PHYSICAL
results I-PHYSICAL
and 0
( B-PHYSICAL
in I-PHYSICAL
asthmatic I-PHYSICAL
patients I-PHYSICAL
) 0
FEV1 0
values 0
were 0
monitored 0
for 0
two 0
years 0
. 0

Adverse B-ADVERSE-EFFECTS
effects I-ADVERSE-EFFECTS
were 0
recorded 0
. 0

All 0
induction 0
regimens 0
produced 0
a 0
significant B-PHYSICAL
improvement I-PHYSICAL
in I-PHYSICAL
symptom I-PHYSICAL
and 0
medication B-PHYSICAL
usage I-PHYSICAL
( 0
p 0
< 0
0.0001 0
) 0
; 0
skin B-PHYSICAL
test I-PHYSICAL
scores I-PHYSICAL
decreased 0
( 0
p 0
< 0
0.0001 0
) 0
and 0
FEV1 B-PHYSICAL
improved I-PHYSICAL
( 0
p 0
< 0
0.05 0
) 0
. 0

In 0
contrast 0
, 0
symptom 0
and 0
skin 0
test 0
scores 0
did 0
not 0
significantly 0
change B-OTHER
in 0
controls 0
. 0

No 0
relevant 0
adverse B-ADVERSE-EFFECTS
effects I-ADVERSE-EFFECTS
were 0
observed 0
with 0
any 0
of 0
the 0
induction 0
regimens 0
. 0

CONCLUSIONS 0
For 0
patients 0
with 0
respiratory 0
allergies 0
, 0
sublingual 0
immunotherapy 0
with 0
an 0
8-day 0
induction 0
protocol 0
is 0
safe 0
and 0
effective 0
. 0

Our 0
results 0
encourage 0
the 0
usage 0
of 0
shorter 0
induction 0
regimens 0
, 0
which 0
produce 0
better 0
compliance 0
with 0
this 0
therapy 0
. 0

A 0
randomised 0
comparison 0
of 0
three 0
drainage 0
systems 0
following 0
cholecystectomy 0
. 0

The 0
efficacy 0
of 0
low 0
pressure 0
, 0
high 0
pressure 0
and 0
passive 0
drainage 0
systems 0
have 0
been 0
compared 0
after 0
cholecystectomy 0
. 0

Symptoms B-PAIN
of I-PAIN
pain I-PAIN
, 0
discomfort B-ADVERSE-EFFECTS
and 0
nausea B-ADVERSE-EFFECTS
were 0
compared 0
using 0
linear 0
analogue 0
scales 0
and 0
spirometry 0
was 0
used 0
to 0
examine 0
pre-operative 0
and 0
postoperative 0
respiratory B-PHYSICAL
function I-PHYSICAL
. 0

The 0
low 0
pressure 0
suction 0
drain 0
removed 0
an 0
intraperitoneal 0
marker 0
, 0
gentamicin 0
, 0
more 0
effectively 0
than 0
the 0
high 0
pressure 0
suction 0
drain 0
, 0
but 0
not 0
more 0
effectively 0
than 0
the 0
passive 0
drain 0
. 0

There 0
were 0
no 0
differences 0
in 0
postoperative B-PHYSICAL
respiratory I-PHYSICAL
function I-PHYSICAL
nor 0
in 0
the 0
amount 0
of 0
pain B-PAIN
or 0
discomfort B-PAIN
between 0
the 0
groups 0
. 0

The 0
passive 0
drain 0
group 0
reported 0
less 0
nausea B-PHYSICAL
than 0
the 0
suction 0
drain 0
groups 0
. 0

If 0
a 0
negative 0
pressure 0
drainage 0
system 0
is 0
to 0
be 0
used 0
, 0
a 0
low 0
pressure 0
suction 0
drain 0
should 0
be 0
used 0
in 0
preference 0
to 0
a 0
high 0
pressure 0
system 0
. 0

[ 0
The 0
effect 0
of 0
losartan 0
versus 0
atenolol 0
on 0
cardiovascular B-MORTALITY
morbidity I-MORTALITY
and I-MORTALITY
mortality I-MORTALITY
in 0
patients 0
with 0
diabetes 0
mellitus 0
in 0
the 0
LIFE-study 0
] 0
. 0

INTRODUCTION 0
The 0
most 0
suitable 0
antihypertensive 0
drug 0
to 0
reduce 0
the 0
risk 0
of 0
cardiovascular 0
disease 0
in 0
patients 0
with 0
hypertension 0
and 0
diabetes 0
is 0
unclear 0
. 0

In 0
a 0
prespecified 0
analysis 0
of 0
the 0
LIFE-study 0
we 0
compared 0
the 0
effects 0
of 0
losartan 0
and 0
atenolol 0
on 0
cardiovascular B-PHYSICAL
morbidity I-PHYSICAL
and 0
mortality B-MORTALITY
in 0
diabetic 0
patients 0
. 0

MATERIAL 0
AND 0
METHODS 0
A 0
total 0
of 0
1195 0
patients 0
in 0
the 0
LIFE-study 0
had 0
diabetes 0
at 0
the 0
time 0
of 0
the 0
randomisation 0
. 0

The 0
patients 0
were 0
randomised 0
for 0
double-blind 0
treatment 0
with 0
losartan 0
versus 0
atenolol 0
. 0

The 0
patients 0
had 0
ECG-verified 0
left 0
ventricular 0
hypertrophy 0
, 0
mean 0
age 0
67 0
years 0
, 0
blood 0
pressure 0
177/96 0
mmHg 0
after 0
two 0
weeks 0
placebo 0
run-in 0
period 0
. 0

Patients 0
were 0
followed 0
for 0
at 0
least 0
four 0
years 0
( 0
mean 0
4.7 0
years 0
) 0
. 0

The 0
primary 0
composite 0
endpoint 0
was 0
cardiovascular B-PHYSICAL
death I-PHYSICAL
, 0
stroke B-PHYSICAL
or 0
myocardial B-PHYSICAL
infarction I-PHYSICAL
. 0

RESULTS 0
Blood B-PHYSICAL
pressure I-PHYSICAL
was 0
reduced 0
to 0
146/79 0
and 0
148/79 0
in 0
losartan-treated 0
patients 0
and 0
atenolol-treated 0
patients 0
, 0
respectively 0
. 0

The 0
primary 0
endpoint 0
occurred 0
in 0
103 0
patients 0
assigned 0
losartan 0
( 0
n 0
= 0
586 0
) 0
and 0
139 0
assigned 0
atenolol 0
( 0
n 0
= 0
609 0
) 0
. 0

Relative 0
risk 0
reduction B-PHYSICAL
24 0
% 0
( 0
p 0
< 0
0.031 0
) 0
. 0

Cardiovascular B-PHYSICAL
mortality I-PHYSICAL
was 0
reduced 0
by 0
37 0
% 0
in 0
favour 0
of 0
losartan 0
( 0
p 0
< 0
0.028 0
) 0
, 0
and 0
all 0
cause 0
mortality B-MORTALITY
by 0
39 0
% 0
( 0
p 0
< 0
0.002 0
) 0
. 0

DISCUSSION 0
Losartan 0
was 0
very 0
effective 0
in 0
reducing 0
cardiovascular B-PHYSICAL
morbidity I-PHYSICAL
and 0
mortality B-MORTALITY
as 0
compared 0
to 0
atenolol 0
. 0

These 0
results 0
will 0
have 0
a 0
major 0
impact 0
on 0
the 0
choice 0
of 0
anti-hypertensive 0
treatment 0
for 0
patients 0
with 0
hypertension 0
and 0
diabetes 0
. 0

The 0
effects 0
of 0
treatment 0
with 0
interleukin-1 0
receptor 0
antagonist 0
on 0
the 0
inflamed 0
synovial 0
membrane 0
in 0
rheumatoid 0
arthritis 0
. 0

OBJECTIVE 0
To 0
evaluate 0
the 0
effects 0
of 0
treatment 0
with 0
interleukin-1 0
receptor 0
antagonist 0
( 0
IL-1Ra 0
) 0
on 0
synovial 0
tissue 0
in 0
rheumatoid 0
arthritis 0
( 0
RA 0
) 0
. 0

METHODS 0
Twelve 0
patients 0
with 0
RA 0
entering 0
a 0
randomized 0
clinical 0
trial 0
of 0
human 0
recombinant 0
IL-1Ra 0
underwent 0
synovial 0
biopsies 0
before 0
and 0
after 0
treatment 0
. 0

Cellular B-PHYSICAL
infiltration I-PHYSICAL
and I-PHYSICAL
adhesion I-PHYSICAL
molecule I-PHYSICAL
expression I-PHYSICAL
were 0
evaluated 0
after 0
immunohistochemical 0
staining 0
. 0

RESULTS 0
There 0
was 0
a 0
notable 0
reduction 0
in 0
intimal B-PHYSICAL
layer I-PHYSICAL
macrophages I-PHYSICAL
and 0
subintimal B-PHYSICAL
macrophages I-PHYSICAL
and 0
lymphocytes B-PHYSICAL
after 0
treatment 0
with 0
IL-1Ra 0
at 0
150 0
mg/day 0
( 0
n=3 0
) 0
. 0

Increased 0
cellular B-PHYSICAL
infiltration I-PHYSICAL
was 0
observed 0
in 0
all 0
patients 0
receiving 0
placebo 0
( 0
n=3 0
) 0
; 0
variable 0
changes 0
were 0
observed 0
after 0
IL-1Ra 0
30 0
mg/day 0
( 0
n=6 0
) 0
. 0

In 0
a 0
limited 0
study 0
of 0
adhesion 0
molecule 0
expression 0
, 0
down-regulation 0
of 0
E-selectin B-PHYSICAL
and 0
vascular B-PHYSICAL
cell I-PHYSICAL
adhesion I-PHYSICAL
molecule-1 I-PHYSICAL
was 0
observed 0
after 0
treatment 0
with 0
IL-1Ra 0
150 0
mg/day 0
, 0
but 0
not 0
after 0
IL-1Ra 0
30 0
mg/day 0
or 0
placebo 0
. 0

The 0
apparent 0
arrest 0
of 0
progressive B-PHYSICAL
joint I-PHYSICAL
damage I-PHYSICAL
seen 0
in 0
four 0
patients 0
after 0
treatment 0
with 0
IL-1Ra 0
was 0
associated 0
with 0
reduced 0
intimal 0
layer 0
macrophage 0
accumulation 0
in 0
all 0
patients 0
. 0

CONCLUSION 0
Treatment 0
of 0
RA 0
with 0
IL-1Ra 0
resulted 0
in 0
reduced 0
mononuclear 0
cell 0
infiltration 0
of 0
synovial 0
membrane 0
, 0
which 0
may 0
represent 0
the 0
in 0
vivo 0
inhibition 0
of 0
biologically 0
relevant 0
IL-1ss-mediated 0
pathogenic 0
effects 0
. 0

Clinical 0
hypnosis 0
versus 0
cognitive 0
behavioral 0
training 0
for 0
pain B-PAIN
management I-PAIN
with 0
pediatric 0
cancer 0
patients 0
undergoing 0
bone 0
marrow 0
aspirations 0
. 0

A 0
randomized 0
controlled 0
trial 0
was 0
conducted 0
to 0
compare 0
the 0
efficacy 0
of 0
clinical 0
hypnosis 0
versus 0
cognitive 0
behavioral 0
( 0
CB 0
) 0
coping 0
skills 0
training 0
in 0
alleviating 0
the 0
pain B-PAIN
and 0
distress B-PAIN
of 0
30 0
pediatric 0
cancer 0
patients 0
( 0
age 0
5 0
to 0
15 0
years 0
) 0
undergoing 0
bone 0
marrow 0
aspirations 0
. 0

Patients 0
were 0
randomized 0
to 0
one 0
of 0
three 0
groups 0
: 0
hypnosis 0
, 0
a 0
package 0
of 0
CB 0
coping 0
skills 0
, 0
and 0
no 0
intervention 0
. 0

Patients 0
who 0
received 0
either 0
hypnosis 0
or 0
CB 0
reported 0
less 0
pain B-PAIN
and 0
pain-related B-MENTAL
anxiety I-MENTAL
than 0
did 0
control 0
patients 0
and 0
less 0
pain B-PAIN
and 0
anxiety B-MENTAL
than 0
at 0
their 0
own 0
baseline 0
. 0

Hypnosis 0
and 0
CB 0
were 0
similarly 0
effective 0
in 0
the 0
relief B-PHYSICAL
of I-PHYSICAL
pain I-PHYSICAL
. 0

Results 0
also 0
indicated 0
that 0
children 0
reported 0
more 0
anxiety B-MENTAL
and 0
exhibited 0
more 0
behavioral B-MENTAL
distress I-MENTAL
in 0
the 0
CB 0
group 0
than 0
in 0
the 0
hypnosis 0
group 0
. 0

It 0
is 0
concluded 0
that 0
hypnosis 0
and 0
CB 0
coping 0
skills 0
are 0
effective 0
in 0
preparing 0
pediatric 0
oncology 0
patients 0
for 0
bone 0
marrow 0
aspiration 0
. 0

Perioperative 0
blood 0
transfusions 0
, 0
with 0
or 0
without 0
allogeneic 0
leucocytes 0
, 0
relate 0
to 0
survival B-MORTALITY
, 0
not 0
to 0
cancer B-PHYSICAL
recurrence I-PHYSICAL
. 0

BACKGROUND 0
Perioperative 0
blood 0
transfusions 0
are 0
reported 0
to 0
be 0
related 0
to 0
cancer B-PHYSICAL
recurrence I-PHYSICAL
and 0
reduced B-MORTALITY
survival I-MORTALITY
. 0

Different 0
underlying 0
mechanisms 0
have 0
been 0
proposed 0
, 0
and 0
allogeneic 0
leucocytes 0
in 0
transfused 0
blood 0
have 0
been 0
suggested 0
to 0
contribute 0
to 0
this 0
phenomenon 0
. 0

METHODS 0
Packed 0
red 0
cells 0
without 0
buffy 0
coat 0
( 0
PC 0
group 0
) 0
were 0
compared 0
with 0
filtered 0
, 0
leucoreduced 0
, 0
red 0
cells 0
( 0
LD 0
group 0
) 0
in 0
a 0
randomized 0
trial 0
of 0
697 0
patients 0
with 0
colorectal 0
carcinoma 0
. 0

Five-year B-MORTALITY
survival I-MORTALITY
and 0
cancer B-PHYSICAL
recurrence I-PHYSICAL
rates I-PHYSICAL
were 0
determined 0
, 0
with 0
special 0
emphasis 0
on 0
the 0
location 0
of 0
recurrence B-PHYSICAL
. 0

RESULTS 0
The 0
intention-to-treat 0
analysis 0
showed 0
a 0
survival B-MORTALITY
rate I-MORTALITY
of 0
63.6 0
per 0
cent 0
in 0
the 0
PC 0
group 0
and 0
65.3 0
per 0
cent 0
in 0
the 0
LD 0
group 0
( 0
P 0
= 0
0.69 0
) 0
, 0
with 0
recurrence B-PHYSICAL
rates I-PHYSICAL
of 0
27.8 0
and 0
27.9 0
per 0
cent 0
respectively 0
. 0

The 0
observational 0
analysis 0
showed 0
a 0
significant 0
difference B-MORTALITY
in I-MORTALITY
survival I-MORTALITY
between 0
transfused 0
and 0
non-transfused 0
patients 0
( 0
59.6 0
versus 0
72.9 0
per 0
cent 0
; 0
P 0
< 0
0.001 0
) 0
. 0

The 0
difference 0
in 0
cancer B-PHYSICAL
recurrence I-PHYSICAL
rate I-PHYSICAL
between 0
transfused 0
and 0
non-transfused 0
patients 0
was 0
not 0
statistically 0
significant 0
( 0
29.8 0
versus 0
24.3 0
per 0
cent 0
; 0
P 0
= 0
0.13 0
) 0
. 0

Local B-PHYSICAL
recurrences I-PHYSICAL
were 0
more 0
frequent 0
in 0
transfused 0
than 0
non-transfused 0
patients 0
( 0
11.9 0
versus 0
7.6 0
per 0
cent 0
; 0
P 0
= 0
0.09 0
) 0
. 0

CONCLUSION 0
Leucocyte 0
depletion 0
of 0
perioperative 0
transfused 0
blood 0
has 0
no 0
effect 0
on 0
long-term B-MORTALITY
survival I-MORTALITY
and/or 0
cancer B-PHYSICAL
recurrence I-PHYSICAL
. 0

Perioperative 0
blood 0
transfusions 0
are 0
associated 0
with 0
impaired 0
survival 0
, 0
but 0
not 0
with 0
cancer 0
recurrence 0
. 0

The 0
slight 0
increase 0
in 0
local 0
recurrence B-PHYSICAL
rate I-PHYSICAL
in 0
transfused 0
patients 0
appears 0
to 0
be 0
related 0
to 0
complicated 0
, 0
in 0
particular 0
rectal 0
, 0
surgery 0
. 0

Controlled-release 0
melatonin 0
, 0
singly 0
and 0
combined 0
with 0
cognitive 0
behavioural 0
therapy 0
, 0
for 0
persistent 0
insomnia B-PHYSICAL
in 0
children 0
with 0
autism 0
spectrum 0
disorders 0
: 0
a 0
randomized 0
placebo-controlled 0
trial 0
. 0

Although 0
melatonin 0
and 0
cognitive-behavioural 0
therapy 0
have 0
shown 0
efficacy 0
in 0
treating 0
sleep 0
disorders 0
in 0
children 0
with 0
autism 0
spectrum 0
disorders 0
, 0
little 0
is 0
known 0
about 0
their 0
relative 0
or 0
combined 0
efficacy 0
. 0

One 0
hundred 0
and 0
sixty 0
children 0
with 0
autism 0
spectrum 0
disorders 0
, 0
aged 0
4-10 0
years 0
, 0
suffering 0
from 0
sleep 0
onset 0
insomnia 0
and 0
impaired 0
sleep 0
maintenance 0
, 0
were 0
assigned 0
randomly 0
to 0
either 0
( 0
1 0
) 0
combination 0
of 0
controlled-release 0
melatonin 0
and 0
cognitive-behavioural 0
therapy 0
; 0
( 0
2 0
) 0
controlled-release 0
melatonin 0
; 0
( 0
3 0
) 0
four 0
sessions 0
of 0
cognitive-behavioural 0
therapy 0
; 0
or 0
( 0
4 0
) 0
placebo 0
drug 0
treatment 0
condition 0
for 0
12 0
weeks 0
in 0
a 0
1 0
: 0
1 0
: 0
1 0
: 0
1 0
ratio 0
. 0

Children 0
were 0
studied 0
at 0
baseline 0
and 0
after 0
12 0
weeks 0
of 0
treatment 0
. 0

Treatment 0
response 0
was 0
assessed 0
with 0
1-week 0
actigraphic 0
monitoring 0
, 0
sleep 0
diary 0
and 0
sleep 0
questionnaire 0
. 0

Main 0
outcome 0
measures 0
, 0
derived 0
actigraphically 0
, 0
were 0
sleep 0
latency 0
, 0
total 0
sleep 0
time 0
, 0
wake 0
after 0
sleep 0
onset 0
and 0
number 0
of 0
awakenings 0
. 0

The 0
active 0
treatment 0
groups 0
all 0
resulted 0
in 0
improvements 0
across 0
all 0
outcome 0
measures 0
, 0
with 0
moderate-to-large 0
effect 0
sizes 0
from 0
baseline 0
to 0
a 0
12-week 0
assessment 0
. 0

Melatonin 0
treatment 0
was 0
mainly 0
effective 0
in 0
reducing 0
insomnia B-PHYSICAL
symptoms I-PHYSICAL
, 0
while 0
cognitive-behavioural 0
therapy 0
had 0
a 0
light 0
positive 0
impact 0
mainly 0
on 0
sleep B-PHYSICAL
latency I-PHYSICAL
, 0
suggesting 0
that 0
some 0
behavioural 0
aspects 0
might 0
play 0
a 0
role 0
in 0
determining 0
initial B-PHYSICAL
insomnia I-PHYSICAL
. 0

The 0
combination 0
treatment 0
group 0
showed 0
a 0
trend 0
to 0
outperform 0
other 0
active 0
treatment 0
groups 0
, 0
with 0
fewer 0
dropouts 0
and 0
a 0
greater 0
proportion 0
of 0
treatment 0
responders 0
achieving 0
clinically 0
significant 0
changes 0
( 0
63.38 0
% 0
normative 0
sleep 0
efficiency 0
criterion 0
of 0
> 0
85 0
% 0
and 0
84.62 0
% 0
, 0
sleep 0
onset 0
latency 0
< 0
30 0
min 0
) 0
. 0

This 0
study 0
demonstrates 0
that 0
adding 0
behavioural 0
intervention 0
to 0
melatonin 0
treatment 0
seems 0
to 0
result 0
in 0
a 0
better 0
treatment 0
response 0
, 0
at 0
least 0
in 0
the 0
short 0
term 0
. 0

Phase 0
II 0
trial 0
of 0
nab-paclitaxel 0
compared 0
with 0
docetaxel 0
as 0
first-line 0
chemotherapy 0
in 0
patients 0
with 0
metastatic 0
breast 0
cancer 0
: 0
final 0
analysis 0
of 0
overall 0
survival 0
. 0

BACKGROUND 0
A 0
randomized 0
phase 0
II 0
study 0
in 0
first-line 0
MBC 0
demonstrated 0
superior 0
efficacy 0
and 0
safety B-OTHER
of 0
weekly 0
nab-paclitaxel 0
compared 0
with 0
docetaxel 0
. 0

Final 0
survival B-MORTALITY
analyses 0
and 0
updated 0
safety B-OTHER
results 0
are 0
reported 0
. 0

PATIENTS 0
AND 0
METHODS 0
Three 0
hundred 0
two 0
patients 0
with 0
no 0
previous 0
chemotherapy 0
for 0
MBC 0
were 0
randomized 0
to 0
receive 0
nab-paclitaxel 0
300 0
mg/m 0
( 0
2 0
) 0
q3w 0
, 0
nab-paclitaxel 0
100 0
mg/m 0
( 0
2 0
) 0
or 0
150 0
mg/m 0
( 0
2 0
) 0
the 0
first 0
3 0
of 0
4 0
weeks 0
( 0
qw 0
3/4 0
) 0
, 0
or 0
docetaxel 0
100 0
mg/m 0
( 0
2 0
) 0
q3w 0
. 0

The 0
trial 0
was 0
powered 0
for 0
analyses 0
of 0
antitumor B-OTHER
activity I-OTHER
and 0
safety B-OTHER
. 0

RESULTS 0
Treatment 0
with 0
nab-paclitaxel 0
150 0
mg/m 0
( 0
2 0
) 0
qw 0
3/4 0
resulted 0
in 0
a 0
median 0
overall 0
survival B-MORTALITY
( 0
OS 0
) 0
of 0
33.8 0
months 0
compared 0
with 0
22.2 0
, 0
27.7 0
, 0
and 0
26.6 0
months 0
for 0
nab-paclitaxel 0
100 0
mg/m 0
( 0
2 0
) 0
qw 0
3/4 0
, 0
nab-paclitaxel 0
300 0
mg/m 0
( 0
2 0
) 0
q3w 0
, 0
and 0
docetaxel 0
, 0
respectively 0
( 0
overall 0
P 0
= 0
.047 0
) 0
. 0

Patients 0
receiving 0
150 0
mg/m 0
( 0
2 0
) 0
nab-paclitaxel 0
had 0
prolonged 0
median 0
OS B-MORTALITY
compared 0
with 0
those 0
in 0
the 0
100 0
mg/m 0
( 0
2 0
) 0
nab-paclitaxel 0
arm 0
( 0
hazard 0
ratio 0
, 0
0.575 0
; 0
P 0
= 0
.008 0
) 0
. 0

A 0
trend 0
toward 0
a 0
longer 0
OS B-MORTALITY
was 0
noted 0
in 0
the 0
150 0
mg/m 0
( 0
2 0
) 0
nab-paclitaxel 0
arm 0
versus 0
docetaxel 0
arm 0
( 0
hazard 0
ratio 0
, 0
0.688 0
) 0
. 0

Grade 0
3 0
or 0
4 B-PHYSICAL
fatigue I-PHYSICAL
, 0
neutropenia B-PHYSICAL
, 0
and 0
febrile B-PHYSICAL
neutropenia I-PHYSICAL
were 0
less 0
frequent 0
in 0
all 0
nab-paclitaxel 0
arms 0
compared 0
with 0
docetaxel 0
. 0

CONCLUSIONS 0
Consistent 0
with 0
previously 0
published 0
efficacy 0
results 0
, 0
these 0
data 0
suggest 0
that 0
150 0
mg/m 0
( 0
2 0
) 0
qw 0
3/4 0
may 0
represent 0
the 0
most 0
clinically 0
efficacious 0
nab-paclitaxel 0
dosing 0
regimen 0
for 0
patients 0
with 0
no 0
previous 0
chemotherapy 0
for 0
MBC 0
. 0

A 0
phase 0
III 0
trial 0
confirming 0
these 0
results 0
would 0
be 0
necessary 0
and 0
prudent 0
before 0
widespread 0
adoption 0
of 0
the 0
150 0
mg/m 0
( 0
2 0
) 0
dose 0
in 0
clinical 0
practice 0
. 0

Laser-aided 0
external 0
drainage 0
of 0
subretinal 0
fluid 0
: 0
prospective 0
randomized 0
comparison 0
with 0
needle 0
drainage 0
. 0

In 0
a 0
prospective 0
randomized 0
study 0
of 0
50 0
consecutive 0
eyes 0
, 0
we 0
compared 0
the 0
safety B-OTHER
and 0
efficacy 0
of 0
draining 0
subretinal 0
fluid 0
transchoroidally 0
in 0
primary 0
scleral 0
buckling 0
for 0
rhegmatogenous 0
retinal 0
detachment 0
using 0
a 0
needle 0
, 0
with 0
the 0
safety B-PHYSICAL
and 0
efficacy 0
of 0
the 0
same 0
procedure 0
using 0
an 0
angulated 0
endolaser 0
probe 0
set 0
at 0
1 0
W 0
for 0
0.2 0
seconds 0
, 0
using 0
an 0
average 0
of 0
2.4 0
laser 0
burns 0
. 0

There 0
were 0
no 0
significant 0
complications B-ADVERSE-EFFECTS
associated 0
with 0
the 0
laser-aided 0
drainage 0
procedures 0
( 0
25 0
eyes 0
) 0
. 0

In 0
the 0
transchoroidal 0
needle 0
drainage 0
procedures 0
( 0
25 0
eyes 0
) 0
, 0
subretinal B-PHYSICAL
hemorrhage I-PHYSICAL
occurred 0
in 0
three 0
eyes 0
and 0
retinal 0
incarceration 0
in 0
one 0
. 0

Thus 0
, 0
though 0
our 0
numbers 0
are 0
small 0
, 0
there 0
appears 0
to 0
be 0
some 0
advantage 0
of 0
laser-assisted 0
drainage 0
in 0
terms 0
of 0
a 0
lower 0
incidence 0
of 0
complications B-ADVERSE-EFFECTS
. 0

Effect 0
of 0
topical 0
anesthesia 0
and 0
age 0
on 0
pain B-PAIN
scores I-PAIN
during 0
retinopathy 0
of 0
prematurity 0
screening 0
. 0

OBJECTIVE 0
The 0
efficacy 0
of 0
topical 0
anesthesia 0
during 0
retinopathy 0
of 0
prematurity 0
( 0
ROP 0
) 0
screening 0
has 0
been 0
a 0
controversial 0
issue 0
. 0

To 0
determine 0
the 0
efficacy 0
of 0
proparacaine 0
eye 0
drops 0
( 0
0.5 0
% 0
) 0
, 0
we 0
compared 0
the 0
Premature B-PAIN
Infant I-PAIN
Pain I-PAIN
Profile I-PAIN
( 0
PIPP B-PAIN
) 0
scores 0
in 0
40 0
preterm 0
infants 0
undergoing 0
ROP 0
screening 0
. 0

STUDY 0
DESIGN 0
Prospective 0
randomized 0
double 0
masked 0
cross-over 0
clinical 0
trial 0
. 0

The 0
study 0
was 0
conducted 0
in 0
the 0
neonatal 0
intensive 0
units 0
for 0
infants 0
undergoing 0
routine 0
ROP 0
screening 0
exams 0
. 0

Baseline 0
PIPP B-PHYSICAL
scores I-PHYSICAL
and 0
post-examination B-PHYSICAL
PIPP I-PHYSICAL
scores I-PHYSICAL
at 0
1 0
and 0
5 0
min 0
were 0
compared 0
for 0
: 0
( 0
1 0
) 0
those 0
receiving 0
saline 0
vs 0
proparacaine 0
eye 0
drops 0
( 0
2 0
) 0
first 0
ROP 0
screening 0
vs 0
second 0
ROP 0
screening 0
, 0
regardless 0
of 0
the 0
type 0
of 0
eye 0
drops 0
used 0
. 0

Wilcoxon 0
signed-ranks 0
test 0
was 0
used 0
to 0
pair 0
pain 0
scores 0
. 0

RESULT 0
Forty 0
preterm 0
infants 0
were 0
included 0
in 0
the 0
study 0
. 0

Mean 0
gestational 0
age 0
( 0
GA 0
) 0
at 0
first 0
and 0
second 0
examinations 0
was 0
33.3 0
and 0
35.3 0
weeks 0
, 0
respectively 0
. 0

Proparacaine 0
use 0
significantly 0
lowered 0
mean 0
PIPP 0
scores 0
( 0
P=0.027 0
) 0
and 0
delta 0
scores 0
( 0
P=0.013 0
) 0
at 0
1 0
min 0
after 0
examination 0
, 0
but 0
there 0
was 0
no 0
difference 0
at 0
5 0
min 0
after 0
examination 0
. 0

Second 0
examinations 0
showed 0
significantly 0
lower 0
mean 0
PIPP 0
scores 0
after 0
examination 0
( 0
1 0
min 0
( 0
P=0.003 0
) 0
and 0
5 0
min 0
( 0
P=0.025 0
) 0
) 0
, 0
regardless 0
of 0
the 0
type 0
of 0
drop 0
used 0
. 0

CONCLUSION 0
Proparacaine 0
eye 0
drops 0
offer 0
significant 0
relief 0
of 0
pain 0
that 0
is 0
apparently 0
short 0
lived 0
. 0

Significantly 0
lower 0
PIPP 0
scores 0
at 0
second 0
ROP 0
examinations 0
suggested 0
that 0
infants 0
of 0
older 0
GA 0
may 0
have 0
a 0
greater 0
ability 0
to 0
tolerate 0
ROP 0
screening 0
. 0

We 0
recommend 0
the 0
use 0
of 0
proparacaine 0
eye 0
drops 0
for 0
the 0
short 0
term 0
, 0
immediate 0
relief 0
of 0
pain 0
during 0
ROP 0
screening 0
in 0
preterm 0
infants 0
of 0
lesser 0
GA 0
. 0

Iontophoretic 0
administration 0
of 0
dexamethasone 0
sodium 0
phosphate 0
for 0
acute 0
epicondylitis 0
. 0

A 0
randomized 0
, 0
double-blinded 0
, 0
placebo-controlled 0
study 0
. 0

BACKGROUND 0
A 0
better 0
treatment 0
modality 0
is 0
needed 0
to 0
control 0
the 0
pain B-PAIN
of 0
medial B-PHYSICAL
or 0
lateral B-PHYSICAL
epicondylitis I-PHYSICAL
( I-PHYSICAL
tennis I-PHYSICAL
elbow I-PHYSICAL
) I-PHYSICAL
. 0

HYPOTHESIS 0
Dermal 0
iontophoretic 0
administration 0
of 0
dexamethasone 0
sodium 0
phosphate 0
will 0
be 0
significantly 0
more 0
effective 0
in 0
controlling 0
pain B-PAIN
than 0
a 0
placebo 0
in 0
patients 0
with 0
medial 0
or 0
lateral 0
elbow 0
epicondylitis 0
. 0

STUDY 0
DESIGN 0
Randomized 0
, 0
double-blinded 0
, 0
placebo-controlled 0
study 0
. 0

METHODS 0
On 0
six 0
occasions 0
, 0
1 0
to 0
3 0
days 0
apart 0
within 0
15 0
days 0
, 0
199 0
patients 0
with 0
elbow 0
epicondylitis 0
received 0
40 0
mA-minutes 0
of 0
either 0
active 0
or 0
placebo 0
treatment 0
. 0

RESULTS 0
Dexamethasone 0
produced 0
a 0
significant 0
23-mm 0
improvement 0
on 0
the 0
100-mm B-PAIN
patient I-PAIN
visual 0
analog 0
scale 0
ratings B-PAIN
, 0
compared 0
with 0
14 0
mm 0
for 0
placebo 0
at 0
2 0
days 0
and 0
24 0
mm 0
compared 0
with 0
19 0
mm 0
at 0
1 0
month 0
. 0

More 0
patients 0
treated 0
with 0
dexamethasone 0
than 0
those 0
treated 0
with 0
placebo 0
scored 0
moderate 0
or 0
better 0
on 0
the 0
investigator B-PHYSICAL
's 0
global B-PHYSICAL
improvement I-PHYSICAL
scale 0
( 0
52 0
% 0
versus 0
33 0
% 0
) 0
at 0
2 0
days 0
, 0
but 0
the 0
difference 0
was 0
not 0
significant 0
at 0
1 0
month 0
( 0
54 0
% 0
versus 0
49 0
% 0
) 0
. 0

Investigator-rated B-PAIN
pain B-PAIN
and I-PAIN
tenderness I-PAIN
scores 0
favored 0
dexamethasone 0
over 0
placebo 0
at 0
2 0
days 0
. 0

Patients 0
completing 0
six 0
treatments 0
in 0
10 0
days 0
or 0
less 0
had 0
better 0
results 0
than 0
those 0
treated 0
over 0
a 0
longer 0
period 0
. 0

CONCLUSIONS 0
Iontophoresis 0
treatment 0
was 0
well 0

Long-term 0
retention 0
on 0
treatment 0
with 0
lumiracoxib 0
100 0
mg 0
once 0
or 0
twice 0
daily 0
compared 0
with 0
celecoxib 0
200 0
mg 0
once 0
daily 0
: 0
a 0
randomised 0
controlled 0
trial 0
in 0
patients 0
with 0
osteoarthritis 0
. 0

BACKGROUND 0
The 0
efficacy 0
, 0
safety 0
and 0
tolerability 0
of 0
lumiracoxib 0
, 0
a 0
novel 0
selective 0
cyclooxygenase-2 0
( 0
COX-2 0
) 0
inhibitor 0
, 0
has 0
been 0
demonstrated 0
in 0
previous 0
studies 0
of 0
patients 0
with 0
osteoarthritis 0
( 0
OA 0
) 0
. 0

As 0
it 0
is 0
important 0
to 0
establish 0
the 0
long-term 0
safety 0
and 0
efficacy 0
of 0
treatments 0
for 0
a 0
chronic 0
disease 0
such 0
as 0
OA 0
, 0
the 0
present 0
study 0
compared 0
the 0
effects 0
of 0
lumiracoxib 0
at 0
doses 0
of 0
100 0
mg 0
once 0
daily 0
( 0
o.d 0
. 0
) 0

and 0
100 0
mg 0
twice 0
daily 0
( 0
b.i.d 0
. 0
) 0

with 0
those 0
of 0
celecoxib 0
200 0
mg 0
o.d 0
. 0

on 0
retention 0
on 0
treatment 0
over 0
1 0
year 0
. 0

METHODS 0
In 0
this 0
52-week 0
, 0
multicentre 0
, 0
randomised 0
, 0
double-blind 0
, 0
parallel-group 0
study 0
, 0
male 0
and 0
female 0
patients 0
( 0
aged 0
at 0
least 0
40 0
years 0
) 0
with 0
symptomatic 0
primary 0
OA 0
of 0
the 0
hip 0
, 0
knee 0
, 0
hand 0
or 0
spine 0
were 0
randomised 0
( 0
1:2:1 0
) 0
to 0
lumiracoxib 0
100 0
mg 0
o.d 0
. 0
( 0

n 0
= 0
755 0
) 0
, 0
lumiracoxib 0
100 0
mg 0
b.i.d 0
. 0
( 0

n 0
= 0
1,519 0
) 0
or 0
celecoxib 0
200 0
mg 0
o.d 0
. 0
( 0

n 0
= 0
758 0
) 0
. 0

The 0
primary 0
objective 0
of 0
the 0
study 0
was 0
to 0
demonstrate 0
non-inferiority B-PHYSICAL
of I-PHYSICAL
lumiracoxib I-PHYSICAL
at 0
either 0
dose 0
compared 0
with 0
celecoxib 0
200 0
mg 0
o.d 0
. 0

with 0
respect 0
to 0
the 0
1-year B-MENTAL
retention I-MENTAL
on I-MENTAL
treatment 0
rate B-MENTAL
. 0

Secondary 0
outcome 0
variables 0
included 0
OA 0
pain 0
in 0
the 0
target 0
joint 0
, 0
patient 0
's 0
and 0
physician 0
's 0
global 0
assessments 0
of 0
disease 0
activity 0
, 0
Short 0
Arthritis 0
assessment 0
Scale 0
( 0
SAS 0
) 0
total 0
score 0
, 0
rescue 0
medication 0
use 0
, 0
and 0
safety 0
and 0
tolerability 0
. 0

RESULTS 0
Retention B-PHYSICAL
rates B-PHYSICAL
at 0
1 0
year 0
were 0
similar 0
for 0
the 0
lumiracoxib 0
100 0
mg 0
o.d. 0
, 0
lumiracoxib 0
100 0
mg 0
b.i.d 0
. 0

and 0
celecoxib 0
200 0
mg 0
o.d 0
. 0

groups 0
( 0
46.9 0
% 0
vs 0
47.5 0
% 0
vs 0
45.3 0
% 0
, 0
respectively 0
) 0
. 0

It 0
was 0
demonstrated 0
that 0
retention B-OTHER
on 0
treatment 0
with 0
lumiracoxib 0
at 0
either 0
dose 0
was 0
non-inferior 0
to 0
celecoxib 0
200 0
mg 0
o.d 0
. 0

Similarly 0
, 0
Kaplan-Meier 0
curves 0
for 0
the 0
probability 0
of 0
premature 0
discontinuation 0
from 0
the 0
study 0
for 0
any 0
reason 0
were 0
similar 0
across 0
the 0
treatment 0
groups 0
. 0

All 0
three 0
treatments 0
generally 0
yielded 0
comparable 0
results 0
for 0
the 0
secondary 0
efficacy 0
variables 0
and 0
all 0
treatments 0
were 0
well 0

The 0
effect 0
of 0
knee 0
position 0
on 0
blood B-PHYSICAL
loss I-PHYSICAL
and 0
range 0
of 0
motion B-PHYSICAL
following 0
total 0
knee 0
arthroplasty 0
. 0

PURPOSE 0
This 0
study 0
prospectively 0
assessed 0
the 0
effects 0
of 0
knee 0
position 0
on 0
blood B-PHYSICAL
loss I-PHYSICAL
and 0
range 0
of 0
motion B-PHYSICAL
after 0
primary 0
total 0
knee 0
arthroplasty 0
( 0
TKA 0
) 0
. 0

METHODS 0
One 0
hundred 0
and 0
ten 0
consecutive 0
TKA 0
patients 0
were 0
randomized 0
into 0
flexion 0
group 0
and 0
extension 0
group 0
. 0

Both 0
groups 0
had 0
the 0
leg 0
elevated 0
30? 0
at 0
the 0
hip 0
over 0
an 0
inactive 0
CPM 0
for 0
72 0
h 0
postoperatively 0
. 0

The 0
flexion 0
group 0
had 0
the 0
knee 0
flexed 0
to 0
30? 0
during 0
this 0
period 0
. 0

The 0
extension 0
group 0
had 0
the 0
knee 0
extended 0
fully 0
. 0

Perioperative 0
blood 0
loss 0
, 0
hidden 0
blood 0
loss 0
, 0
knee 0
swelling 0
, 0
ecchymosis 0
, 0
analgesia 0
requirements 0
, 0
range 0
of 0
motion 0
( 0
ROM 0
) 0
, 0
fixed 0
flexion 0
deformity 0
( 0
FFD 0
) 0
, 0
straight-leg 0
raising 0
action 0
, 0
and 0
postoperative 0
complications 0
within 0
6 0
weeks 0
of 0
surgery 0
were 0
measured 0
for 0
evaluation 0
and 0
comparison 0
. 0

RESULTS 0
The 0
postoperative 0
hidden 0
blood 0
loss 0
, 0
knee 0
swelling 0
, 0
and 0
scope 0
of 0
ecchymosis 0
were 0
significantly 0
lower 0
in 0
the 0
flexion 0
group 0
than 0
in 0
the 0
extension 0
group 0
, 0
and 0
ROM 0
and 0
straight-leg 0
raising 0
action 0
were 0
significantly 0
higher 0
during 0
the 0
early 0
period 0
after 0
operation 0
. 0

No 0
significant 0
difference 0
was 0
observed 0
in 0
perioperative 0
blood 0
loss 0
, 0
the 0
amount 0
of 0
morphine 0
used 0
, 0
or 0
FFD 0
in 0
the 0
early 0
postoperative 0
period 0
or 0
in 0
ROM 0
and 0
FFD 0
at 0
6 0
weeks 0
postoperatively 0
. 0

CONCLUSIONS 0
The 0
findings 0
of 0
this 0
study 0
indicate 0
that 0
flexion 0
of 0
the 0
knee 0
to 0
30? 0
with 0
the 0
leg 0
elevated 0
30? 0
at 0
the 0
hip 0
after 0
total 0
knee 0
arthroplasty 0
may 0
mitigate 0
knee 0
swelling 0
and 0
provide 0
other 0
beneficial 0
results 0
during 0
the 0
early 0
rehabilitation 0
following 0
TKA 0
. 0

LEVEL 0
OF 0
EVIDENCE 0
Prospective 0
comparative 0
study 0
, 0
Level 0
I 0
. 0

The 0
effects 0
of 0
aerobic 0
exercise 0
on 0
academic 0
engagement 0
in 0
young 0
children 0
with 0
autism 0
spectrum 0
disorder 0
. 0

PURPOSE 0
To 0
determine 0
whether 0
participation 0
in 0
aerobic 0
exercise 0
before 0
classroom 0
activities 0
improves 0
academic 0
engagement 0
and 0
reduces 0
stereotypic 0
behaviors 0
in 0
young 0
children 0
with 0
autism 0
spectrum 0
disorder 0
. 0

METHODS 0
This 0
study 0
employed 0
a 0
within-subjects 0
crossover 0
design 0
, 0
using 0
a 0
treatment 0
condition 0
( 0
aerobic 0
exercise 0
) 0
and 0
a 0
control 0
condition 0
, 0
across 0
4 0
classrooms 0
. 0

The 0
treatment 0
condition 0
included 0
15 0
minutes 0
of 0
running/jogging 0
followed 0
by 0
a 0
classroom 0
task 0
. 0

The 0
control 0
condition 0
included 0
a 0
classroom 0
task 0
not 0
preceded 0
by 0
exercise 0
. 0

The 0
number B-MENTAL
of I-MENTAL
stereotypic I-MENTAL
behaviors I-MENTAL
, 0
percentage B-MENTAL
of I-MENTAL
on-task I-MENTAL
behavior I-MENTAL
, 0
and 0

The 0
influence 0
of 0
pre- 0
and 0
intraoperative 0
positioning 0
of 0
the 0
condyle 0
in 0
the 0
centre 0
of 0
the 0
articular 0
fossa 0
on 0
the 0
position 0
of 0
the 0
disc 0
in 0
orthognathic 0
surgery 0
. 0

A 0
magnetic 0
resonance 0
study 0
. 0

OBJECTIVE 0
We 0
investigated 0
the 0
changes 0
in 0
the 0
temporomandibular 0
joint 0
( 0
TMJ 0
) 0
after 0
bilateral 0
sagittal 0
split 0
osteotomy 0
of 0
the 0
mandible 0
for 0
orthognathic 0
surgery 0
and 0
the 0
influence 0
of 0
positioning 0
of 0
the 0
condylar 0
process 0
in 0
the 0
centre 0
of 0
the 0
articular 0
fossa 0
before 0
and 0
during 0
the 0
operation 0
for 0
preventing 0
changes 0
in 0
the 0
TMJ 0
postoperatively 0
. 0

STUDY 0
DESIGN 0
A 0
total 0
of 0
28 0
patients 0
with 0
mandibular 0
retrognathism 0
had 0
bilateral 0
sagittal 0
split 0
osteotomies 0
for 0
mandibular 0
advancement 0
. 0

In 0
one 0
group 0
of 0
14 0
patients 0
( 0
28 0
TMJ 0
) 0
, 0
the 0
condyles 0
were 0
placed 0
in 0
the 0
centre 0
of 0
the 0
articular 0
fossa 0
before 0
and 0
during 0
the 0
operation 0
, 0
and 0
in 0
the 0
other 0
group 0
they 0
were 0
not 0
. 0

Differences B-OTHER
on I-OTHER
magnetic I-OTHER
resonance I-OTHER
imaging I-OTHER
( I-OTHER
MRI I-OTHER
) I-OTHER
were 0
calculated 0
and 0
the 0
results 0
were 0
evaluated 0
. 0

RESULTS 0
The 0
main 0
differences 0
were 0
found 0
at 0
maximal B-PHYSICAL
mouth I-PHYSICAL
opening I-PHYSICAL
. 0

15/28 0
TMJs 0
( 0
54 0
% 0
) 0
that 0
had 0
not 0
been 0
positioned 0
changed 0
the 0
position 0
of 0
the 0
disc 0
from 0
physiological 0
to 0
anterior 0
disc 0
derangement 0
with 0
and 0
without 0
reduction 0
postoperatively 0
. 0

In 0
the 0
28 0
that 0
had 0
been 0
positioned 0
, 0
changes 0
were 0
found 0
in 0
only 0
3 0
TMJs B-PHYSICAL
( 0
11 0
% 0
) 0
postoperatively 0
. 0

CONCLUSIONS 0
Fixing 0
the 0
condylar 0
process 0
in 0
the 0
centre 0
of 0
the 0
articular 0
fossa 0
intraoperatively 0
before 0
bilateral 0
sagittal 0
split 0
osteotomy 0
is 0
a 0
factor 0
in 0
preventing 0
postoperative 0
structural 0
changes 0
in 0
the 0
temporomandibular 0
joint 0
. 0

Recombinant 0
human 0
thyrotropin-stimulated 0
radioiodine 0
therapy 0
of 0
nodular 0
goiter 0
allows 0
major 0
reduction 0
of 0
the 0
radiation B-OTHER
burden I-OTHER
with 0
retained 0
efficacy 0
. 0

CONTEXT 0
AND 0
OBJECTIVE 0
Stimulation 0
with 0
recombinant 0
human 0
TSH 0
( 0
rhTSH 0
) 0
before 0
radioiodine 0
( 0
131I 0
) 0
therapy 0
augments 0
goiter B-PHYSICAL
volume I-PHYSICAL
reduction I-PHYSICAL
( I-PHYSICAL
GVR I-PHYSICAL
) I-PHYSICAL
. 0

Observations 0
indicate 0
that 0
rhTSH 0
has 0
a 0
preconditioning 0
effect 0
beyond 0
increasing 0
thyroid 0
( 0
131 0
) 0
I 0
uptake 0
. 0

We 0
test 0
the 0
hypothesis 0
that 0
an 0
equivalent 0
GVR 0
might 0
be 0
obtained 0
by 0
an 0
absorbed 0
thyroid 0
dose 0
well 0
below 0
what 0
has 0
been 0
used 0
previously 0
. 0

PATIENTS 0
AND 0
DESIGN 0
In 0
a 0
double-blinded 0
setup 0
, 0
90 0
patients 0
( 0
78 0
women 0
; 0
median 0
age 0
, 0
52 0
yr 0
; 0
range 0
, 0
22-83 0
) 0
with 0
a 0
nontoxic 0
nodular 0
goiter 0
( 0
median 0
size 0
, 0
63 0
ml 0
; 0
range 0
, 0
25-379 0
ml 0
) 0
were 0
randomized 0
to 0
either 0
0.1 0
mg 0
rhTSH 0
( 0
n=60 0
) 0
followed 0
by 0
a 0
thyroid 0
dose 0
of 0
50 0
Gy 0
or 0
placebo 0
followed 0
by 0
100 0
Gy 0
( 0
n=30 0
) 0
. 0

RESULTS 0
At 0
12 0
months 0
, 0
the 0
mean 0
relative B-PHYSICAL
GVR I-PHYSICAL
in 0
the 0
placebo 0
and 0
the 0
rhTSH 0
group 0
was 0
identical 0
( 0
35+/-3 0
% 0
; 0
P=0.81 0
) 0
. 0

The 0
median 0
administered 0
131I-activity B-PHYSICAL
was 0
170 0
MBq 0
( 0
45-1269 0
) 0
in 0
the 0
rhTSH 0
group 0
and 0
559 0
MBq 0
( 0
245-3530 0
) 0
in 0
the 0
placebo 0
group 0
( 0
70 0
% 0
reduction 0
, 0
P 0
< 0
0.0001 0
) 0
. 0

According 0
to 0
the 0
official 0
radiation 0
regulation 0
, 0
hospitalization B-OTHER
was 0
required 0
in 0
14 0
patients 0
in 0
the 0
placebo 0
group 0
vs. 0
one 0
patient 0
in 0
the 0
rhTSH 0
group 0
( 0
P 0
< 0
0.0001 0
) 0
. 0

In 0
both 0
groups 0
, 0
goiter-related B-PHYSICAL
symptoms I-PHYSICAL
were 0
effectively 0
relieved 0
in 0
the 0
majority 0
of 0
patients 0
. 0

The 0
prevalence 0
of 0
myxedema B-PHYSICAL
( 0
10 0
% 0
) 0
did 0
not 0
differ 0
among 0
groups 0
. 0

CONCLUSIONS 0
This 0
is 0
the 0
first 0
study 0
to 0
demonstrate 0
that 0
rhTSH 0
not 0
only 0
increases 0
the 0
thyroid B-PHYSICAL
131I I-PHYSICAL
uptake I-PHYSICAL
, 0
but 0
per 0
se 0
potentiates 0
the 0
effect 0
of 0
131I-therapy 0
, 0
allowing 0
a 0
major 0
reduction 0
of 0
the 0
131I-activity B-PHYSICAL
without 0
compromising 0
efficacy 0
. 0

This 0
approach 0
is 0
attractive 0
in 0
terms 0
of 0
minimizing 0
posttherapeutic B-OTHER
restrictions I-OTHER
and 0
in 0
reducing 0
the 0
potential 0
risk 0
of 0
radiation-induced B-PHYSICAL
malignancy I-PHYSICAL
. 0

Comparison 0
of 0
active-learning 0
strategies 0
for 0
motivational B-MENTAL
interviewing I-MENTAL
skills I-MENTAL
, 0
knowledge B-MENTAL
, 0
and 0

Intestinal 0
absorption 0
of 0
dietary 0
fat 0
in 0
patients 0
with 0
multiple 0
sclerosis 0
. 0

Fat B-PHYSICAL
absorption I-PHYSICAL
was 0
studied 0
in 0
24 0
patients 0
with 0
clinically 0
definite 0
multiple 0
sclerosis 0
and 0
in 0
36 0
healthy 0
control 0
subjects 0
. 0

Beta-carotene B-PHYSICAL
and I-PHYSICAL
vitamin I-PHYSICAL
A I-PHYSICAL
in I-PHYSICAL
their I-PHYSICAL
plasma I-PHYSICAL
were 0
also 0
measured 0
. 0

This 0
double-blind 0
and 0
randomized 0
study 0
showed 0
no 0
differences 0
between 0
these 0
two 0
populations 0
with 0
regard 0
to 0
the 0
three 0
parameters 0
. 0

We 0
did 0
not 0
find 0
evidence 0
for 0
fat 0
malabsorption 0
in 0
multiple 0
sclerosis 0
. 0

Low 0
power 0
Ga-Al-As 0
laser 0
treatment 0
of 0
painful B-PAIN
osteoarthritis I-PAIN
of 0
the 0
knee 0
. 0

A 0
double-blind 0
placebo-controlled 0
study 0
. 0

The 0
aim 0
of 0
this 0
double-blind 0
study 0
was 0
to 0
evaluate 0
the 0
effect 0
of 0
low 0
power 0
Ga-Al-As 0
laser 0
treatment 0
on 0
chronic B-PAIN
pain I-PAIN
related 0
to 0
osteoarthritis 0
of 0
the 0
knee 0
with 0
periarticular 0
tender 0
points 0
. 0

Twenty-nine 0
out-patients 0
with 0
uni- 0
or 0
bilateral 0
osteoarthritis 0
of 0
the 0
knee 0
were 0
included 0
and 0
randomly 0
assigned 0
to 0
treatment 0
with 0
either 0
laser 0
or 0
placebo 0
laser 0
. 0

Fourteen 0
patients 0
received 0
active 0
laser 0
treatment 0
and 0
all 0
patients 0
included 0
completed 0
the 0
study 0
. 0

The 0
effect 0
variables 0
were 0
daily 0
levels 0
of 0
pain 0
, 0
analgesic B-PAIN
requirements I-PAIN
, 0
palpation B-PHYSICAL
tenderness I-PHYSICAL
and I-PHYSICAL
isokinetic I-PHYSICAL
quadriceps I-PHYSICAL
strength I-PHYSICAL
. 0

Each 0
patient 0
participated 0
in 0
the 0
study 0
for 0
9 0
weeks 0
and 0
registered 0
daily 0
level 0
of 0
pain 0
and 0
consumption B-PHYSICAL
of I-PHYSICAL
analgesics I-PHYSICAL
. 0

In 0
weeks 0
4 0
, 0
5 0
and 0
6 0
the 0
patients 0
received 0
a 0
total 0
of 0
nine 0
treatments 0
, 0
each 0
of 0
15 0
min 0
and 0
administered 0
to 0
periarticular 0
tender 0
points 0
. 0

The 0
dose 0
per 0
treatment 0
was 0
22.5 0
joule 0
. 0

No 0
significant 0
differences 0
in 0
any 0
of 0
the 0
effect 0
variables 0
were 0
found 0
between 0
the 0
two 0
groups 0
before 0
, 0
during 0
or 0
after 0
treatment 0
. 0

With 0
regard 0
to 0
the 0
patients 0
' 0
overall 0
assessment 0
there 0
was 0
a 0
clearly 0
demonstrable 0
positive 0
effect 0
of 0
treatment 0
in 0
both 0
groups 0
. 0

This 0
is 0
likely 0
to 0
be 0
due 0
to 0
a 0
placebo 0
effect 0
. 0

Effects 0
of 0
pioglitazone 0
and 0
glimepiride 0
on 0
glycemic 0
control 0
and 0
insulin 0
sensitivity 0
in 0
Mexican 0
patients 0
with 0
type 0
2 0
diabetes 0
mellitus 0
: 0
A 0
multicenter 0
, 0
randomized 0
, 0
double-blind 0
, 0
parallel-group 0
trial 0
. 0

BACKGROUND 0
Pioglitazone 0
and 0
glimepiride 0
improve 0
glycemic 0
control 0
in 0
patients 0
with 0
type 0
2 0
diabetes 0
mellitus 0
by 0
different 0
mechanisms 0
. 0

Pioglitazone 0
is 0
a 0
thiazolidinedione 0
that 0
reduces 0
insulin 0
resistance 0
, 0
and 0
glimepiride 0
is 0
a 0
sulfonylurea 0
insulin 0
secretagogue 0
. 0

OBJECTIVE 0
The 0
goals 0
of 0
this 0
study 0
were 0
to 0
compare 0
changes 0
in 0
measures 0
of 0
glycemic 0
control 0
and 0
insulin 0
sensitivity 0
in 0
Mexican 0
patients 0
with 0
type 0
2 0
diabetes 0
who 0
received 0
pioglitazone 0
or 0
glimepiride 0
for 0
1 0
year 0
. 0

METHODS 0
This 0
was 0
a 0
multicenter 0
, 0
52-week 0
, 0
double-blind 0
, 0
parallel-group 0
trial 0
. 0

Patients 0
were 0
randomized 0
to 0
receive 0
monotherapy 0
with 0
either 0
glimepiride 0
( 0
2 0
mg 0
QD 0
initially 0
) 0
or 0
pioglitazone 0
( 0
15 0
mg 0
QD 0
initially 0
) 0
. 0

Doses 0
were 0
titrated 0
( 0
maximal 0
doses 0
: 0
pioglitazone 0
45 0
mg 0
, 0
glimepiride 0
8 0
mg 0
) 0
to 0
achieve 0
glycemic 0
targets 0
( 0
fasting 0
blood 0
glucose 0
< 0
or 0
=7 0
mmol/L 0
and 0
1-hour 0
postprandial 0
blood 0
glucose 0
< 0
or 0
=10 0
mmol/L 0
) 0
. 0

Insulin 0
sensitivity 0
( 0
primary 0
end 0
point 0
) 0
was 0
evaluated 0
in 0
terms 0
of 0
the 0
Homeostasis 0
Model 0
Assessment 0
for 0
Insulin 0
Sensitivity 0
( 0
HOMA-S 0
) 0
, 0
the 0
Quantitative 0
Insulin 0
Sensitivity 0
Check 0
Index 0
( 0
QUICKI 0
) 0
, 0
and 0
fasting 0
serum 0
insulin 0
( 0
FSI 0
) 0
concentrations 0
. 0

Glycemic 0
control 0
was 0
evaluated 0
in 0
terms 0
of 0
glycosylated 0
hemoglobin 0
( 0
HbA 0
( 0
1c 0
) 0
) 0
values 0
and 0
fasting 0
plasma 0
glucose 0
( 0
FPG 0
) 0
concentrations 0
. 0

Patients 0
were 0
encouraged 0
to 0
maintain 0
their 0
individual 0
diet 0
and 0
exercise 0
regimens 0
throughout 0
the 0
study 0
. 0

RESULTS 0
Two 0
hundred 0
forty-four 0
patients 0
( 0
125 0
women 0
, 0
119 0
men 0
; 0
all 0
but 0
1 0
Hispanic 0
) 0
were 0
randomized 0
to 0
receive 0
pioglitazone 0
( 0
n 0
= 0
121 0
) 0
or 0
glimepiride 0
( 0
n 0
= 0
123 0
) 0
. 0

In 0
the 0
intent-to-treat 0
sample 0
, 0
pioglitazone 0
and 0
glimepirede 0
produced 0
comparable 0
reductions 0
in 0
HbA B-PHYSICAL
( I-PHYSICAL
1c I-PHYSICAL
) I-PHYSICAL
from 0
baseline 0
to 0
the 0
end 0
of 0
the 0
study 0
( 0
-0.78 0
% 0
and 0
-0.68 0
% 0
, 0
respectively 0
) 0
. 0

The 0
pioglitazone 0
group 0
had 0
significantly 0
higher 0
HbA B-PHYSICAL
( I-PHYSICAL
1c I-PHYSICAL
) I-PHYSICAL
values 0
compared 0
with 0
the 0
glimepiride 0
group 0
after 0
12 0
weeks 0
of 0
therapy 0
( 0
8.66 0
% 0
vs 0
7.80 0
% 0
; 0
P 0
= 0
0.007 0
) 0
but 0
had 0
significantly 0
lower 0
values 0
after 0
52 0
weeks 0
( 0
7.46 0
% 0
vs 0
7.77 0
% 0
; 0
P 0
= 0
0.027 0
) 0
. 0

Pioglitazone 0
significantly 0
reduced 0
FPG B-PHYSICAL
compared 0
with 0
glimepiride 0
( 0
-0.6 0
vs 0
0.6 0
mmol/L 0
; 0
P 0
= 0
0.01 0
) 0
. 0

Pioglitazone 0
therapy 0
was 0
associated 0
with 0
significant 0
increases 0
in 0
insulin B-PHYSICAL
sensitivity I-PHYSICAL
( 0
reduced B-PHYSICAL
insulin I-PHYSICAL
resistance I-PHYSICAL
) 0
, 0
whereas 0
glimepiride 0
had 0
no 0
effect 0
. 0

HOMA-S B-PHYSICAL
values I-PHYSICAL
changed 0
18.0 0
% 0
for 0
pioglitazone 0
and 0
-7.9 0
% 0
for 0
glimepiride 0
( 0
P 0
< 0
0.001 0
) 0
, 0
QUICKI 0
values 0
changed 0
a 0
respective 0
0.013 0
and 0
-0.007 0
( 0
P 0
< 0
0.001 0
) 0
, 0
and 0
FSI 0
values 0
were 0
-21.1 0
and 0
15.1 0
pmol/L 0
( 0
P 0
< 0
0.001 0
) 0
. 0

Both 0
drugs 0
were 0
well 0
tolerated B-OTHER
, 0
with 0
pioglitazone 0
associated 0
with 0
more 0
peripheral B-PHYSICAL
edema I-PHYSICAL
( 0
number 0
of 0
treatment-emergent 0
cases 0
: 0
35/121 0
[ 0
28.9 0
% 0
] 0
vs 0
17/123 0
[ 0
13.8 0
% 0
] 0
; 0
P 0
= 0
0.005 0
) 0
and 0
fewer 0
hypoglycemic B-PHYSICAL
episodes I-PHYSICAL
( 0
19 0
[ 0
15.7 0
% 0
] 0
vs 0
38 0
[ 0
30.9 0
% 0
] 0
; 0
P 0
= 0
0.024 0
) 0
. 0

The 0
incidence 0
of 0
weight 0
gain B-PHYSICAL
was 0
not 0
significantly 0
different 0
between 0
treatment 0
groups 0
. 0

CONCLUSIONS 0
These 0
data 0
suggest 0
that 0
long-term 0
treatment 0
with 0
pioglitazone 0
enhances 0
insulin 0
sensitivity 0
relative 0
to 0
glimepiride 0
in 0
Mexican 0
patients 0
with 0
type 0
2 0
diabetes 0
and 0
that 0
pioglitazone 0
may 0
have 0
a 0
more 0
sustained 0
antihyperglycemic 0
effect 0
. 0

The 0
effect 0
of 0
Cys 0
LT1 0
receptor 0
blockade 0
on 0
airway 0
responses 0
to 0
allergen 0
. 0

STUDY 0
OBJECTIVE 0
To 0
evaluate 0
the 0
effect 0
of 0
a 0
potent 0
experimental 0
leukotriene 0
receptor 0
antagonist 0
, 0
MK-571 0
, 0
on 0
airway 0
responses 0
to 0
inhaled 0
allergen 0
. 0

DESIGN 0
Randomized 0
, 0
double-blind 0
, 0
placebo-controlled 0
, 0
crossover 0
trial 0
. 0

SETTING 0
Clinical 0
research 0
center 0
. 0

SUBJECTS 0
Eight 0
male 0
volunteers 0
with 0
allergic 0
asthma 0
. 0

INTERVENTIONS 0
An 0
intravenous 0
loading 0
dose 0
was 0
followed 0
by 0
an 0
8-hour 0
infusion 0
of 0
MK-571 0
or 0
placebo 0
, 0
with 0
a 0
7- 0
to 0
14-day 0
washout 0
between 0
treatments 0
. 0

Allergen 0
challenge 0
was 0
performed 0
after 0
the 0
loading 0
dose 0
and 0
a 0
histamine 0
challenge 0
was 0
performed 0
before 0
and 0
24 0
hours 0
after 0
allergen 0
. 0

MEASUREMENTS 0
AND 0
MAIN 0
RESULTS 0
Forced B-PHYSICAL
expiratory I-PHYSICAL
volume I-PHYSICAL
in 0
1 0
second 0
was 0
measured 0
serially 0
. 0

MK-571 0
provided 0
about 0
50 0
% 0
protection 0
during 0
maximum 0
early 0
and 0
late 0
responses 0
compared 0
with 0
placebo 0
( 0
p=0.005 0
) 0
, 0
but 0
airway B-PHYSICAL
obstruction I-PHYSICAL
persisted 0
8-24 0
hours 0
after 0
allergen 0
on 0
both 0
treatment 0
days 0
. 0

Airway B-OTHER
responsiveness I-OTHER
to 0
histamine B-OTHER
was 0
not 0
significantly 0
attenuated 0
at 0
24 0
hours 0
. 0

CONCLUSION 0
Blocking 0
Cys 0
LT1 0
receptors 0
for 0
8 0
hours 0
attenuated 0
the 0
early 0
and 0
late 0
responses 0
but 0
did 0
not 0
interrupt 0
the 0
cascade 0
of 0
events 0
leading 0
to 0
subsequent 0
allergen-induced 0
airway 0
obstruction 0
and 0
hyperreactivity 0
. 0

Rituximab 0
plus 0
concurrent 0
infusional 0
EPOCH 0
chemotherapy 0
is 0
highly 0
effective 0
in 0
HIV-associated 0
B-cell 0
non-Hodgkin 0
lymphoma 0
. 0

Rituximab 0
plus 0
intravenous 0
bolus 0
chemotherapy 0
is 0
a 0
standard 0
treatment 0
for 0
immunocompetent 0
patients 0
with 0
B-cell 0
non-Hodgkin 0
lymphoma 0
( 0
NHL 0
) 0
. 0

Some 0
studies 0
have 0
suggested 0
that 0
rituximab 0
is 0
associated 0
with 0
excessive B-PHYSICAL
toxicity I-PHYSICAL
in 0
HIV-associated 0
NHL 0
, 0
and 0
that 0
infusional 0
chemotherapy 0
may 0
be 0
more 0
effective 0
. 0

We 0
performed 0
a 0
randomized 0
phase 0
2 0
trial 0
of 0
rituximab 0
( 0
375 0
mg/m 0
( 0
2 0
) 0
) 0
given 0
either 0
concurrently 0
before 0
each 0
infusional 0
etoposide 0
, 0
vincristine 0
, 0
doxorubicin 0
, 0
cyclophosphamide 0
, 0
and 0
prednisone 0
( 0
EPOCH 0
) 0
chemotherapy 0
cycle 0
or 0
sequentially 0
( 0
weekly 0
for 0
6 0
weeks 0
) 0
after 0
completion 0
of 0
all 0
chemotherapy 0
in 0
HIV-associated 0
NHL 0
. 0

EPOCH 0
consisted 0
of 0
a 0
96-hour 0
intravenous 0
infusion 0
of 0
etoposide 0
, 0
doxorubicin 0
, 0
and 0
vincristine 0
plus 0
oral 0
prednisone 0
followed 0
by 0
intravenous 0
bolus 0
cyclophosphamide 0
given 0
every 0
21 0
days 0
for 0
4 0
to 0
6 0
cycles 0
. 0

In 0
the 0
concurrent 0
arm 0
, 0
35 0
of 0
48 0
evaluable 0
patients 0
( 0
73 0
% 0
; 0
95 0
% 0
confidence 0
interval 0
, 0
58 0
% 0
-85 0
% 0
) 0
had 0
a 0
complete B-OTHER
response I-OTHER
. 0

In 0
the 0
sequential 0
arm 0
, 0
29 0
of 0
53 0
evaluable 0
patients 0
( 0
55 0
% 0
; 0
95 0
% 0
confidence 0
interval 0
, 0
41 0
% 0
-68 0
% 0
) 0
had 0
a 0
complete 0
response 0
. 0

The 0
primary 0
efficacy 0
endpoint 0
was 0
met 0
for 0
the 0
concurrent 0
arm 0
only 0
. 0

Toxicity B-PHYSICAL
was 0
comparable 0
in 0
the 0
2 0
arms 0
, 0
although 0
patients 0
with 0
a 0
baseline 0
CD4 B-PHYSICAL
count 0
less 0
than 0
50/microL 0
had 0
a 0
high 0
infectious B-MORTALITY
death I-MORTALITY
rate I-MORTALITY
in 0
the 0
concurrent 0
arm 0
. 0

We 0
conclude 0
that 0
concurrent 0
rituximab 0
plus 0
infusional 0
EPOCH 0
is 0
an 0
effective 0
regimen 0
for 0
HIV-associated 0
lymphoma 0
. 0

Randomized 0
controlled 0
trial 0
: 0
Multimodal 0
Anxiety 0
and 0
Social 0
Skill 0
Intervention 0
for 0
adolescents 0
with 0
autism 0
spectrum 0
disorder 0
. 0

Anxiety 0
is 0
common 0
among 0
adolescents 0
with 0
autism 0
spectrum 0
disorders 0
( 0
ASD 0
) 0
and 0
may 0
amplify 0
the 0
core 0
social 0
disability 0
, 0
thus 0
necessitating 0
combined 0
treatment 0
approaches 0
. 0

This 0
pilot 0
, 0
randomized 0
controlled 0
trial 0
evaluated 0
the 0
feasibility B-OTHER
and 0
preliminary B-OTHER
outcomes I-OTHER
of 0
the 0
Multimodal 0
Anxiety 0
and 0
Social 0
Skills 0
Intervention 0
( 0
MASSI 0
) 0
program 0
in 0
a 0
sample 0
of 0
30 0
adolescents 0
with 0
ASD 0
and 0
anxiety 0
symptoms 0
of 0
moderate 0
or 0
greater 0
severity 0
. 0

The 0
treatment 0
was 0
acceptable 0
to 0
families 0
, 0
subject B-OTHER
adherence I-OTHER
was 0
high 0
, 0
and 0
therapist B-OTHER
fidelity I-OTHER
was 0
high 0
. 0

A 0
16 0
% 0
improvement 0
in 0
ASD B-MENTAL
social I-MENTAL
impairment I-MENTAL
( 0
within-group 0
effect 0
size 0
= 0
1.18 0
) 0
was 0
observed 0
on 0
a 0
parent-reported 0
scale 0
. 0

Although 0
anxiety B-MENTAL
symptoms I-MENTAL
declined 0
by 0
26 0
% 0
, 0
the 0
change 0
was 0
not 0
statistically 0
significant 0
. 0

These 0
findings 0
suggest 0
MASSI 0
is 0
a 0
feasible B-OTHER
treatment 0
program 0
and 0
further 0
evaluation 0
is 0
warranted 0
. 0

Treatment 0
of 0
anal 0
fissures 0
using 0
a 0
combination 0
of 0
minoxidil 0
and 0
lignocaine 0
: 0
a 0
randomized 0
, 0
double-blind 0
trial 0
. 0

AIM 0
Anal 0
fissures 0
are 0
associated 0
with 0
hypertonia 0
of 0
the 0
internal 0
anal 0
sphincter 0
and 0
pain 0
. 0

We 0
evaluated 0
the 0
efficacy 0
of 0
local 0
application 0
of 0
a 0
combination 0
of 0
minoxidil 0
and 0
lignocaine 0
in 0
healing 0
anal 0
fissures 0
. 0

METHODS 0
In 0
this 0
prospective 0
, 0
randomized 0
, 0
double-blind 0
study 0
, 0
90 0
patients 0
with 0
anal 0
fissure 0
were 0
recruited 0
. 0

Patients 0
received 0
local 0
applications 0
of 0
ointments 0
containing 0
5 0
% 0
lignocaine 0
( 0
n=28 0
) 0
, 0
0.5 0
% 0
minoxidil 0
( 0
n=36 0
) 0
, 0
or 0
both 0
( 0
n=26 0
) 0
. 0

Healing 0
of 0
anal B-PHYSICAL
fissure I-PHYSICAL
at 0
6 0
weeks 0
was 0
used 0
as 0
the 0
primary 0
end-point 0
. 0

RESULTS 0
Rates 0
of B-PHYSICAL
complete I-PHYSICAL
healing I-PHYSICAL
of I-PHYSICAL
fissure B-PHYSICAL
were 0
similar 0
in 0
the 0
three 0
groups 0
( 0
lignocaine 0
alone 0
8/27 0
, 0
minoxidil 0
alone 0
10/34 0
, 0
combination 0
7/22 0
; 0
p=ns 0
) 0
. 0

Mean 0
( 0
SD 0
) 0
time 0
taken 0
for 0
complete 0
healing 0
with 0
combination 0
treatment 0
[ 0
1.9 0
( 0
0.6 0
) 0
weeks 0
] 0
was 0
significantly 0
shorter 0
than 0
that 0
with 0
minoxidil 0
alone 0
( 0
3.1 0
[ 0
1.7 0
] 0
weeks 0
; 0
p=0.001 0
) 0
or 0
with 0
lignocaine 0
alone 0
( 0
3.3 0
[ 0
0.8 0
] 0
weeks 0
; 0
p=0.002 0
) 0
. 0

Rates B-PHYSICAL
of 0
pain B-PAIN
relief I-PAIN
were 0
similar 0
in 0
the 0
three 0
groups 0
. 0

Stoppage B-PHYSICAL
of I-PHYSICAL
bleeding I-PHYSICAL
occurred 0
more 0
often 0
with 0
combination 0
treatment 0
than 0
with 0
lignocaine 0
alone 0
. 0

No 0
patient 0
had 0

A 0
double-blind 0
comparison 0
of 0
oral 0
ketoprofen 0
'controlled 0
release 0
' 0
and 0
indomethacin 0
suppository 0
in 0
the 0
treatment 0
of 0
rheumatoid 0
arthritis 0
with 0
special 0
regard 0
to 0
morning 0
stiffness 0
and 0
pain 0
on 0
awakening 0
. 0

A 0
double-blind 0
, 0
double-dummy 0
, 0
crossover 0
study 0
was 0
carried 0
out 0
in 0
8 0
centres 0
to 0
compare 0
the 0
efficacy 0
and 0
tolerability 0
of 0
'controlled-release 0
' 0
ketoprofen 0
tablets 0
( 0
200 0
mg 0
) 0
with 0
that 0
of 0
indomethacin 0
suppositories 0
( 0
100 0
mg 0
) 0
in 0
out-patients 0
with 0
definite 0
or 0
classical 0
rheumatoid 0
arthritis 0
. 0

Patients 0
were 0
allocated 0
at 0
random 0
to 0
receive 0
a 0
daily 0
bedtime 0
dose 0
of 0
either 0
1 0
ketoprofen 0
tablet 0
or 0
1 0
indomethacin 0
suppository 0
plus 0
the 0
dummy 0
of 0
the 0
other 0
formulation 0
for 0
a 0
period 0
of 0
3 0
weeks 0
. 0

They 0
were 0
then 0
crossed 0
over 0
to 0
the 0
alternative 0
treatment 0
for 0
a 0
further 0
3 0
weeks 0
. 0

Daily 0
diary 0
records 0
were 0
kept 0
by 0
patients 0
of 0
the 0
number 0
of 0
night-time 0
awakenings 0
due 0
to 0
pain 0
, 0
pain 0
severity 0
at 0
awakening 0
in 0
the 0
morning 0
and 0
the 0
duration 0
of 0
early 0
morning 0
stiffness 0
. 0

Treatment 0
efficacy 0
was 0
also 0
assessed 0
at 0
the 0
end 0
of 0
each 0
trial 0
period 0
by 0
means 0
of 0
an 0
articular 0
index 0
and 0
by 0
physician 0
's 0
and 0
patient 0
's 0
overall 0
evaluation 0
of 0
response 0
. 0

Adverse 0
effects 0
spontaneously 0
mentioned 0
by 0
the 0
patients 0
or 0
elicited 0
by 0
direct 0
questioning 0
using 0
a 0
symptom 0
check-list 0
were 0
recorded 0
. 0

Statistical 0
analysis 0
of 0
the 0
results 0
from 0
83 0
evaluable 0
patients 0
showed 0
that 0
the 0
'controlled-release 0
' 0
tablet B-OTHER
formulation I-OTHER
of I-OTHER
200 I-OTHER
mg I-OTHER
ketoprofen 0
was 0
equally 0
as 0
effective 0
as 0
the 0
100 0
mg 0
indomethacin B-OTHER
suppository I-OTHER
in 0
the 0
treatment 0
of 0
rheumatoid 0
arthritis 0
, 0
especially 0
with 0
regard 0
to 0
pain B-PAIN
at I-PAIN
awakening I-PAIN
and 0
morning B-PAIN
stiffness I-PAIN
. 0

Side-effects 0
in 0
both 0
groups 0
were 0
those 0
commonly 0
seen 0
with 0
non-steroidal 0
anti-inflammatory 0
drugs 0
and 0
, 0
as 0
expected 0
, 0
gastro-intestinal B-ADVERSE-EFFECTS
and I-ADVERSE-EFFECTS
CNS I-ADVERSE-EFFECTS
disturbances I-ADVERSE-EFFECTS
predominated 0
. 0

Overall 0
, 0
side-effects B-ADVERSE-EFFECTS
were 0
fewer 0
with 0
ketoprofen B-OTHER
than 0
with 0
indomethacin B-OTHER
. 0

Genetic 0
polymorphisms 0
of 0
human 0
flavin 0
monooxygenase 0
3 0
in 0
sulindac-mediated 0
primary 0
chemoprevention 0
of 0
familial 0
adenomatous 0
polyposis 0
. 0

PURPOSE 0
Sulindac 0
is 0
a 0
nonsteroidal 0
anti-inflammatory 0
drug 0
( 0
NSAID 0
) 0
effective 0
in 0
regressing 0
adenomas 0
in 0
patients 0
with 0
familial 0
adenomatous 0
polyposis 0
( 0
FAP 0
) 0
. 0

However 0
, 0
a 0
recent 0
randomized 0
trial 0
showed 0
that 0
sulindac 0
, 0
when 0
compared 0
with 0
placebo 0
, 0
failed 0
to 0
prevent 0
the 0
development 0
of 0
adenomatous 0
polyps 0
in 0
genotypically 0
positive 0
but 0
phenotypically 0
negative 0
FAP 0
patients 0
. 0

The 0
present 0
study 0
determined 0
whether 0
polymorphisms 0
in 0
the 0
gene 0
encoding 0
flavin 0
monooxygenase 0
3 0
( 0
FMO3 0
) 0
, 0
a 0
hepatic 0
microsomal 0
enzyme 0
that 0
inactivates 0
sulindac 0
, 0
played 0
a 0
role 0
in 0
determining 0
the 0
efficacy 0
of 0
sulindac 0
in 0
preventing 0
polyposis 0
in 0
this 0
cohort 0
of 0
FAP 0
patients 0
. 0

EXPERIMENTAL 0
DESIGN 0
Genotyping 0
was 0
performed 0
on 0
seven 0
established 0
FMO3 0
polymorphisms 0
previously 0
shown 0
to 0
have 0
functional 0
relevance-M66I 0
, 0
P153L 0
, 0
E158K 0
, 0
V257M 0
, 0
E305X 0
, 0
E308G 0
, 0
and 0
R492W-in 0
21 0
and 0
20 0
FAP 0
patients 0
, 0
who 0
received 0
sulindac 0
and 0
placebo 0
, 0
respectively 0
. 0

RESULTS 0
None 0
of 0
the 0
41 0
patients 0
exhibited 0
heterozygous B-PHYSICAL
or 0
homozygous B-PHYSICAL
M66I I-PHYSICAL
and 0
R492W B-PHYSICAL
variant I-PHYSICAL
alleles I-PHYSICAL
, 0
or 0

Determinants 0
of 0
the 0
effect 0
of 0
estrogen 0
on 0
the 0
progression 0
of 0
subclinical B-PHYSICAL
atherosclerosis I-PHYSICAL
: 0
Estrogen 0
in 0
the 0
Prevention 0
of 0
Atherosclerosis 0
Trial 0
. 0

OBJECTIVE 0
To 0
determine 0
the 0
extent 0
to 0
which 0
the 0
estrogen-induced 0
changes 0
in 0
lipids 0
and 0
markers 0
of 0
carbohydrate 0
metabolism 0
explain 0
the 0
beneficial 0
effect 0
of 0
estrogen 0
therapy 0
on 0
the 0
progression 0
of 0
carotid B-PHYSICAL
artery I-PHYSICAL
intima-media I-PHYSICAL
thickness I-PHYSICAL
( I-PHYSICAL
IMT I-PHYSICAL
) I-PHYSICAL
in 0
postmenopausal 0
women 0
. 0

DESIGN 0
A 0
randomized 0
, 0
double-blind 0
, 0
placebo-controlled 0
, 0
single-center 0
trial 0
enrolling 0
222 0
postmenopausal 0
women 0
45 0
years 0
and 0
older 0
without 0
cardiovascular 0
disease 0
and 0
with 0
low-density 0
lipoprotein 0
( 0
LDL 0
) 0
cholesterol 0
levels 0
of 0
3.37 0
mmol/L 0
or 0
greater 0
( 0
> 0
or 0
= 0
130 0
mg/dL 0
) 0
. 0

Intervention 0
was 0
unopposed 0
micronized 0
17beta-estradiol 0
versus 0
placebo 0
. 0

Measurements 0
were 0
made 0
using 0
high-resolution 0
B-mode 0
ultrasonography 0
to 0
measure 0
carotid B-PHYSICAL
artery I-PHYSICAL
IMT I-PHYSICAL
at 0
baseline 0
and 0
every 0
6 0
months 0
on-trial 0
. 0

RESULTS 0
Progression 0
of 0
carotid B-PHYSICAL
IMT I-PHYSICAL
was 0
inversely 0
related 0
to 0
on-trial 0
high-density B-PHYSICAL
lipoprotein I-PHYSICAL
( I-PHYSICAL
HDL I-PHYSICAL
) I-PHYSICAL
cholesterol I-PHYSICAL
( 0
P 0
= 0
0.04 0
) 0
and 0
was 0
directly 0
related 0
to 0
on-trial 0
LDL-cholesterol 0
( 0
P 0
= 0
0.005 0
) 0
. 0

Compared 0
with 0
placebo 0
, 0
women 0
randomized 0
to 0
estradiol 0
showed 0
a 0
higher 0
mean 0
on-trial 0
HDL-cholesterol B-PHYSICAL
level I-PHYSICAL
and 0
a 0
lower 0
mean 0
on-trial 0
LDL-cholesterol B-PHYSICAL
level I-PHYSICAL
. 0

In 0
contrast 0
, 0
fasting B-PHYSICAL
glucose I-PHYSICAL
, 0
insulin B-PHYSICAL
, 0
and 0
hemoglobin B-PHYSICAL
A1C I-PHYSICAL
were 0
lowered 0
and 0
insulin 0
sensitivity 0
increased 0
with 0
estradiol 0
therapy 0
, 0
but 0
the 0
changes 0
were 0
not 0
related 0
to 0
carotid 0
IMT 0
progression 0
. 0

On-trial 0
HDL-cholesterol B-PHYSICAL
and 0
LDL-cholesterol B-PHYSICAL
were 0
significant 0
independent 0
determinants 0
of 0
carotid B-PHYSICAL
IMT I-PHYSICAL
progression 0
, 0
jointly 0
explaining 0
30 0
% 0
of 0
the 0
treatment 0
effect 0
of 0
unopposed 0
estrogen 0
on 0
the 0
progression 0
of 0
carotid B-PHYSICAL
IMT I-PHYSICAL
. 0

CONCLUSION 0
Unopposed 0
17beta-estradiol 0
reduced 0
carotid B-PHYSICAL
IMT I-PHYSICAL
progression 0
in 0
postmenopausal 0
women 0
in 0
part 0
by 0
increasing 0
HDL-cholesterol B-PHYSICAL
and 0
decreasing 0
LDL-cholesterol B-PHYSICAL
. 0

Although 0
women 0
randomized 0
to 0
estradiol 0
showed 0
improvement 0
in 0
all 0
the 0
markers 0
of 0
carbohydrate 0
metabolism 0
, 0
these 0
factors 0
did 0
not 0
play 0
a 0
significant 0
role 0
in 0
carotid B-PHYSICAL
IMT I-PHYSICAL
progression 0
. 0

Skin B-PHYSICAL
manifestations I-PHYSICAL
of I-PHYSICAL
inhaled I-PHYSICAL
corticosteroids I-PHYSICAL
in 0
COPD 0
patients 0
: 0
results 0
from 0
Lung 0
Health 0
Study 0
II 0
. 0

OBJECTIVE 0
To 0
define 0
the 0
relationship 0
between 0
skin B-ADVERSE-EFFECTS
bruising I-ADVERSE-EFFECTS
( B-PHYSICAL
as I-PHYSICAL
well I-PHYSICAL
as I-PHYSICAL
other 0
cutaneous B-ADVERSE-EFFECTS
manifestations I-ADVERSE-EFFECTS
) 0
and 0
inhaled 0
corticosteroid 0
( 0
ICS 0
) 0
therapy 0
vs 0
placebo 0
in 0
subjects 0
with 0
COPD 0
who 0
were 0
participating 0
in 0
a 0
clinical 0
trial 0
. 0

To 0
explore 0
the 0
relationship 0
between 0
easy B-PHYSICAL
skin I-PHYSICAL
bruising I-PHYSICAL
and 0
other 0
systemic B-PHYSICAL
effects I-PHYSICAL
of I-PHYSICAL
ICS I-PHYSICAL
therapy I-PHYSICAL
, 0
including 0
adrenal B-ADVERSE-EFFECTS
suppression I-ADVERSE-EFFECTS
and 0
loss 0
of 0
bone B-ADVERSE-EFFECTS
mineral I-ADVERSE-EFFECTS
density I-ADVERSE-EFFECTS
( I-ADVERSE-EFFECTS
BMD I-ADVERSE-EFFECTS
) 0
. 0

DESIGN 0
Double-blind 0
, 0
randomized 0
, 0
placebo-controlled 0
clinical 0
trial 0
of 0
triamcinolone 0
acetonide 0
( 0
1200 0
microg 0
daily 0
) 0
vs 0
placebo 0
in 0
participants 0
with 0
mild-to-moderate 0
COPD 0
. 0

SETTING 0
Lung 0
Health 0
Study 0
II 0
, 0
a 0
clinical 0
trial 0
to 0
assess 0
the 0
effect 0
of 0
ICS 0
compared 0
to 0
placebo 0
in 0
1,116 0
participants 0
in 0
10 0
centers 0
over 0
> 0
3.5 0
to 0
4.5 0
years 0
. 0

PARTICIPANTS 0
A 0
total 0
of 0
1,116 0
smokers 0
or 0
recent 0
ex-smokers 0
with 0
mild-to-moderate 0
COPD 0
( 0
age 0
range 0
, 0
40 0
to 0
69 0
years 0
; 0
mean 0
age 0
, 0
56.3 0
years 0
; 0
37.2 0
% 0
female 0
) 0
. 0

MEASUREMENTS 0
AND 0
RESULTS 0
Every 0
6 0
months 0
, 0
a 0
structured 0
questionnaire 0
was 0
administered 0
to 0
elicit 0
reports 0
of 0
any 0
bruising B-ADVERSE-EFFECTS
and/or I-ADVERSE-EFFECTS
skin I-ADVERSE-EFFECTS
rashes I-ADVERSE-EFFECTS
, 0
slow B-ADVERSE-EFFECTS
healing I-ADVERSE-EFFECTS
of I-ADVERSE-EFFECTS
cuts I-ADVERSE-EFFECTS
or 0
sores B-ADVERSE-EFFECTS
, 0
or B-PHYSICAL
other 0
skin B-ADVERSE-EFFECTS
changes I-ADVERSE-EFFECTS
. 0

Compliance 0
with 0
inhaler 0
use 0
was 0
assessed 0
by 0
canister 0
weighing 0
. 0

A 0
significantly 0
higher 0
proportion 0
of 0
ICS 0
than 0
placebo 0
participants 0
who 0
complied 0
with 0
using 0
their 0
inhaler 0
reported 0
easy B-ADVERSE-EFFECTS
bruising I-ADVERSE-EFFECTS
( 0
11.2 0
% 0
vs 0
3.5 0
% 0
, 0
respectively 0
) 0
and 0
the 0
slow B-ADVERSE-EFFECTS
healing I-ADVERSE-EFFECTS
of I-ADVERSE-EFFECTS
skin I-ADVERSE-EFFECTS
cuts I-ADVERSE-EFFECTS
or 0
sores B-ADVERSE-EFFECTS
( 0
2.4 0
% 0
vs 0
0.5 0
% 0
, 0
respectively 0
) 0
. 0

Older 0
men 0
in 0
the 0
ICS 0
group 0
with 0
good 0
inhaler 0
compliance 0
appeared 0
to 0
be 0
at 0
the 0
greatest 0
risk 0
of 0
bruising B-ADVERSE-EFFECTS
. 0

In 0
those 0
participants 0
undergoing 0
serial 0
measurements 0
of 0
adrenal 0
function 0
and 0
BMD 0
, 0
no 0
association 0
was 0
noted 0
between 0
skin B-ADVERSE-EFFECTS
bruising I-ADVERSE-EFFECTS
and 0
either 0
the 0
suppression 0
of 0
adrenal B-ADVERSE-EFFECTS
function I-ADVERSE-EFFECTS
or 0
the 0
loss B-ADVERSE-EFFECTS
of I-ADVERSE-EFFECTS
BMD I-ADVERSE-EFFECTS
as 0
systemic 0
complications 0
of 0
ICS 0
use 0
. 0

CONCLUSION 0
These 0
findings 0
indicate 0
that 0
moderate-to-high 0
doses 0
of 0
ICSs 0
result 0
in 0
an 0
increased 0
incidence 0
of 0
easy B-ADVERSE-EFFECTS
bruising I-ADVERSE-EFFECTS
and 0
impairment 0
in 0
skin B-ADVERSE-EFFECTS
healing I-ADVERSE-EFFECTS
in 0
middle-aged 0
to 0
elderly 0
persons 0
with 0
COPD 0
. 0

No 0
association 0
was 0
noted 0
between 0
skin B-ADVERSE-EFFECTS
bruising I-ADVERSE-EFFECTS
and 0
other 0
markers 0
of 0
systemic B-ADVERSE-EFFECTS
toxicity I-ADVERSE-EFFECTS
from 0
the 0
use 0
of 0
ICSs 0
. 0

A 0
phase 0
III 0
, 0
double-blind 0
, 0
placebo-controlled 0
, 0
multicenter 0
study 0
on 0
the 0
efficacy 0
of 0
recombinant 0
human 0
antithrombin 0
in 0
heparin-resistant 0
patients 0
scheduled 0
to 0
undergo 0
cardiac 0
surgery 0
necessitating 0
cardiopulmonary 0
bypass 0
. 0

BACKGROUND 0
The 0
study 0
evaluated 0
the 0
efficacy 0
of 0
recombinant 0
human 0
antithrombin 0
( 0
rhAT 0
) 0
for 0
restoring 0
heparin B-PHYSICAL
responsiveness I-PHYSICAL
in 0
heparin 0
resistant 0
patients 0
undergoing 0
cardiac 0
surgery 0
. 0

METHODS 0
This 0
was 0
a 0
multicenter 0
, 0
randomized 0
, 0
double-blind 0
, 0
placebo-controlled 0
study 0
in 0
heparin-resistant 0
patients 0
undergoing 0
cardiac 0
surgery 0
with 0
cardiopulmonary 0
bypass 0
. 0

Heparin 0
resistance 0
was 0
diagnosed 0
when 0
the 0
activated 0
clotting 0
time 0
was 0
less 0
than 0
480 0
s 0
after 0
400 0
U/kg 0
heparin 0
. 0

Fifty-four 0
heparin-resistant 0
patients 0
were 0
randomized 0
. 0

One 0
cohort 0
received 0
75 0
U/kg 0
rhAT 0
, 0
and 0
the 0
other 0
received 0
normal 0
saline 0
. 0

If 0
the 0
activated 0
clotting 0
time 0
remained 0
less 0
than 0
480 0
s 0
, 0
this 0
was 0
considered 0
treatment 0
failure 0
, 0
and 0
2 0
units 0
fresh 0
frozen 0
plasma 0
was 0
transfused 0
. 0

Patients 0
were 0
monitored 0
for 0
adverse 0
events 0
. 0

RESULTS 0
Only 0
19 0
% 0
of 0
patients 0
in 0
the 0
rhAT 0
group 0
received 0
fresh 0
frozen 0
plasma 0
, 0
compared 0
with 0
81 0
% 0
of 0
patients 0
in 0
the 0
placebo 0
group 0
( 0
P 0
< 0
0.001 0
) 0
. 0

During 0
their 0
hospitalization 0
, 0
48 0
% 0
of 0
patients 0
in 0
the 0
rhAT 0
group 0
received 0
fresh 0
frozen 0
plasma 0
, 0
compared 0
with 0
85 0
% 0
of 0
patients 0
in 0
the 0
placebo 0
group 0
( 0
P 0
= 0
0.009 0
) 0
. 0

Patients 0
in 0
the 0
placebo 0
group 0
required 0
higher 0
heparin 0
doses 0
( 0
P 0
< 0
0.005 0
) 0
for 0
anticoagulation 0
. 0

There 0
was 0
no 0
increase 0
in 0
serious 0
adverse 0
events 0
associated 0
with 0
rhAT 0
. 0

There 0
was 0
increased 0
blood B-PHYSICAL
loss I-PHYSICAL
12 0
h 0
postoperatively 0
( 0
P 0
= 0
0.05 0
) 0
with 0
a 0
trend 0
toward 0
increased 0
24-h B-PHYSICAL
bleeding I-PHYSICAL
in 0
the 0
rhAT 0
group 0
( 0
P 0
= 0
0.06 0
) 0
. 0

There 0
was 0
no 0
difference 0
between 0
the 0
groups 0
in 0
blood 0
and 0
platelet 0
transfusions 0
. 0

CONCLUSION 0
Treatment 0
with 0
75 0
U/kg 0
rhAT 0
is 0
effective B-PHYSICAL
in I-PHYSICAL
restoring I-PHYSICAL
heparin I-PHYSICAL
responsiveness I-PHYSICAL
and 0
promoting 0
therapeutic B-PHYSICAL
anticoagulation I-PHYSICAL
in 0
the 0
majority 0
of 0
heparin-resistant 0
patients 0
. 0

Treating 0
heparin-resistant 0
patients 0
with 0
rhAT 0
may 0
decrease 0
the B-PHYSICAL
requirement I-PHYSICAL
for I-PHYSICAL
heparin I-PHYSICAL
and 0
fresh 0
frozen 0
plasma 0
. 0

